Nucleobase editors and uses thereof

Description

BACKGROUND OF THE INVENTION

Targeted editing of nucleic acid sequences, for example, the targeted cleavage or the targeted introduction of a specific modification into genomic DNA, is a highly promising approach for the study of gene function and also has the potential to provide new therapies for human genetic diseases.¹An ideal nucleic acid editing technology possesses three characteristics: (1) high efficiency of installing the desired modification; (2) minimal off-target activity; and (3) the ability to be programmed to edit precisely any site in a given nucleic acid, e.g., any site within the human genome.²Current genome engineering tools, including engineered zinc finger nucleases (ZFNs),³transcription activator like effector nucleases (TALENs),⁴and most recently, the RNA-guided DNA endonuclease Cas9,⁵effect sequence-specific DNA cleavage in a genome. This programmable cleavage can result in mutation of the DNA at the cleavage site via non-homologous end joining (NHEJ) or replacement of the DNA surrounding the cleavage site via homology-directed repair (HDR).^6,7

One drawback to the current technologies is that both NHEJ and HDR are stochastic processes that typically result in modest gene editing efficiencies as well as unwanted gene alterations that can compete with the desired alteration.⁸Since many genetic diseases in principle can be treated by effecting a specific nucleotide change at a specific location in the genome (for example, a C to T change in a specific codon of a gene associated with a disease),⁹the development of a programmable way to achieve such precision gene editing would represent both a powerful new research tool, as well as a potential new approach to gene editing-based human therapeutics.

SUMMARY OF THE INVENTION

The clustered regularly interspaced short palindromic repeat (CRISPR) system is a recently discovered prokaryotic adaptive immune system¹⁰that has been modified to enable robust and general genome engineering in a variety of organisms and cell lines.¹¹CRISPR-Cas (CRISPR associated) systems are protein-RNA complexes that use an RNA molecule (sgRNA) as a guide to localize the complex to a target DNA sequence via base-pairing.¹²In the natural systems, a Cas protein then acts as an endonuclease to cleave the targeted DNA sequence.¹³The target DNA sequence must be both complementary to the sgRNA, and also contain a “protospacer-adjacent motif” (PAM) at the 3′-end of the complementary region in order for the system to function.¹⁴

Among the known Cas proteins, S. pyogenes Cas9 has been mostly widely used as a tool for genome engineering.¹⁵This Cas9 protein is a large, multi-domain protein containing two distinct nuclease domains. Point mutations can be introduced into Cas9 to abolish nuclease activity, resulting in a dead Cas9 (dCas9) that still retains its ability to bind DNA in a sgRNA-programmed manner.¹⁶In principle, when fused to another protein or domain, dCas9 can target that protein to virtually any DNA sequence simply by co-expression with an appropriate sgRNA.

The potential of the dCas9 complex for genome engineering purposes is immense. Its unique ability to bring proteins to specific sites in a genome programmed by the sgRNA in theory can be developed into a variety of site-specific genome engineering tools beyond nucleases, including transcriptional activators, transcriptional repressors, histone-modifying proteins, integrases, and recombinases.¹¹Some of these potential applications have recently been implemented through dCas9 fusions with transcriptional activators to afford RNA-guided transcriptional activators,^17,18transcriptional repressors,^16,19,20and chromatin modification enzymes.²¹Simple co-expression of these fusions with a variety of sgRNAs results in specific expression of the target genes. These seminal studies have paved the way for the design and construction of readily programmable sequence-specific effectors for the precise manipulation of genomes.

Significantly, 80-90% of protein mutations responsible for human disease arise from the substitution, deletion, or insertion of only a single nucleotide.⁶Most current strategies for single-base gene correction include engineered nucleases (which rely on the creation of double-strand breaks, DSBs, followed by stochastic, inefficient homology-directed repair, HDR), and DNA-RNA chimeric oligonucleotides.²²The latter strategy involves the design of a RNA/DNA sequence to base pair with a specific sequence in genomic DNA except at the nucleotide to be edited. The resulting mismatch is recognized by the cell's endogenous repair system and fixed, leading to a change in the sequence of either the chimera or the genome. Both of these strategies suffer from low gene editing efficiencies and unwanted gene alterations, as they are subject to both the stochasticity of HDR and the competition between HDR and non-homologous end-joining, NHEJ.^23-25HDR efficiencies vary according to the location of the target gene within the genome,²⁶the state of the cell cycle,²⁷and the type of cell/tissue.²⁸The development of a direct, programmable way to install a specific type of base modification at a precise location in genomic DNA with enzyme-like efficiency and no stochasticity therefore represents a powerful new approach to gene editing-based research tools and human therapeutics.

Some aspects of the disclosure are based on the recognition that certain configurations of a dCas9 domain, and a cytidine deaminase domain fused by a linker are useful for efficiently deaminating target cytidine residues. Other aspects of this disclosure relate to the recognition that a nucleobase editing fusion protein with a cytidine deaminase domain fused to the N-terminus of a nuclease inactive Cas9 (dCas9) via a linker was capable of efficiently deaminating target nucleic acids in a double stranded DNA target molecule. See for example, Examples 3 and 4 below, which demonstrate that the fusion proteins, which are also referred to herein as base editors, generate less indels and more efficiently deaminate target nucleic acids than other base editors, such as base editors without a UGI domain. In some embodiments, the fusion protein comprises a nuclease-inactive Cas9 (dCas9) domain and an apolipoprotein B mRNA-editing complex 1 (APOBEC1) deaminase domain, where the deaminase domain is fused to the N-terminus of the dCas9 domain via a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7). In some embodiments, the nuclease-inactive Cas9 (dCas9) domain of comprises the amino acid sequence set forth in SEQ ID NO: 263. In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1 (SEQ ID NO: 5738). In some embodiments, the deaminase is human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a human APOBEC3G variant of any one of (SEQ ID NOs: 5739-5741).

In some embodiments, the fusion protein comprises the amino acid residues 11-1629 of the amino acid sequence set forth in SEQ ID NO: 591. In some embodiments, the fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 591. In some embodiments, the fusion protein comprises the amino acid sequence of any one of SEQ ID NOs: 5737, 5743, 5745, and 5746.

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within a subject's genome, e.g., a human's genome. In some embodiments, fusion proteins of Cas9 (e.g., dCas9, nuclease active Cas9, or Cas9 nickase) and deaminases or deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and deaminases or deaminase domains, are provided.

Some aspects of this disclosure provide fusion proteins comprising a Cas9 protein as provided herein that is fused to a second protein (e.g., an enzymatic domain such as a cytidine deaminase domain), thus forming a fusion protein. In some embodiments, the second protein comprises an enzymatic domain, or a binding domain. In some embodiments, the enzymatic domain is a nuclease, a nickase, a recombinase, a deaminase, a methyltransferase, a methylase, an acetylase, an acetyltransferase, a transcriptional activator, or a transcriptional repressor domain. In some embodiments, the enzymatic domain is a nucleic acid editing domain. In some embodiments, the nucleic acid editing domain is a deaminase domain. In some embodiments, the deaminase is a cytosine deaminase or a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3A deaminase. In some embodiments, the deaminase is an APOBEC3B deaminase. In some embodiments, the deaminase is an APOBEC3C deaminase. In some embodiments, the deaminase is an APOBEC3D deaminase. In some embodiments, the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID). It should be appreciated that the deaminase may be from any suitable organism (e.g., a human or a rat). In some embodiments, the deaminase is from a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1.

Some aspects of this disclosure provide fusion proteins comprising: (i) a nuclease-inactive Cas9 (dCas9) domain comprising the amino acid sequence of SEQ ID NO: 263; and (ii) an apolipoprotein B mRNA-editing complex 1 (APOBEC1) deaminase domain, wherein the deaminase domain is fused to the N-terminus of the dCas9 domain via a linker comprising the amino acid sequence of SGSETPGTSESATPES (SEQ ID NO: 7). In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the fusion protein comprises the amino acid sequence of SEQ ID NO: 591. In some embodiments, the fusion protein comprises the amino acid sequence of SEQ ID NO: 5737. In some embodiments, the deaminase is pmCDA1 (SEQ ID NO: 5738). In some embodiments, the deaminase is human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a human APOBEC3G variant of any one of SEQ ID NOs: 5739-5741.

Some aspects of this disclosure provide fusion proteins comprising: (i) a Cas9 nickase domain and (ii) an apolipoprotein B mRNA-editing complex 1 (APOBEC1) deaminase domain, wherein the deaminase domain is fused to the N-terminus of the Cas9 nickase domain. In some embodiments, the Cas9 nickase domain comprises a D10X mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for D. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a histidine at amino acid position 840 of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding amino acid position in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises the amino acid sequence as set forth in SEQ ID NO: 267. In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1.

Other aspects of this disclosure relate to the recognition that fusion proteins comprising a deaminase domain, a dCas9 domain and a uracil glycosylase inhibitor (UGI) domain demonstrate improved efficiency for deaminating target nucleotides in a nucleic acid molecule. Without wishing to be bound by any particular theory, cellular DNA-repair response to the presence of U:G heteroduplex DNA may be responsible for a decrease in nucleobase editing efficiency in cells. Uracil DNA glycosylase (UDG) catalyzes removal of U from DNA in cells, which may initiate base excision repair, with reversion of the U:G pair to a C:G pair as the most common outcome. As demonstrated herein, Uracil DNA Glycosylase Inhibitor (UGI) may inhibit human UDG activity. Without wishing to be bound by any particular theory, base excision repair may be inhibited by molecules that bind the single strand, block the edited base, inhibit UGI, inhibit base excision repair, protect the edited base, and/or promote “fixing” of the non-edited strand, etc. Thus, this disclosure contemplates fusion proteins comprising a dCas9-cytidine deaminase domain that is fused to a UGI domain.

In some embodiments, the fusion protein comprises a nuclease-inactive Cas9 (dCas9) domain; a nucleic acid editing domain; and a uracil glycosylase inhibitor (UGI) domain. In some embodiments, the dCas9 domain comprises a D10X mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for D. In some embodiments, the amino acid sequence of the dCas9 domain comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the dCas9 domain comprises an H840X mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for H. In some embodiments, the amino acid sequence of the dCas9 domain comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the dCas9 domain comprises the amino acid sequence as set forth in SEQ ID NO: 263.

Further aspects of this disclosure relate to the recognition that fusion proteins using a Cas9 nickase as the Cas9 domain demonstrate improved efficiency for editing nucleic acids. For example, aspects of this disclosure relate to the recognition that fusion proteins comprising a Cas9 nickase, a deaminase domain and a UGI domain demonstrate improved efficiency for editing nucleic acids. For example, the improved efficiency for editing nucleotides is described below in the Examples section.

In some embodiments, a fusion protein comprises a Cas9 nickase domain, a nucleic acid editing domain; and a uracil glycosylase inhibitor (UGI) domain. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a D10X mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for D. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a histidine at amino acid position 840 of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding amino acid position in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises the amino acid sequence as set forth in SEQ ID NO: 267.

In some embodiments, the deaminase domain of the fusion protein is fused to the N-terminus of the dCas9 domain or the Cas9 nickase. In some embodiments, the UGI domain is fused to the C-terminus of the dCas9 domain or the Cas9 nickase. In some embodiments, the dCas9 domain or the Cas9 nickase and the nucleic acid editing domain are fused via a linker. In some embodiments, the dCas9 domain or the Cas9 nickase and the UGI domain are fused via a linker.

In certain embodiments, linkers may be used to link any of the peptides or peptide domains of the invention. The linker may be as simple as a covalent bond, or it may be a polymeric linker many atoms in length. In certain embodiments, the linker is a polpeptide or based on amino acids. In other embodiments, the linker is not peptide-like. In certain embodiments, the linker is a covalent bond (e.g., a carbon-carbon bond, disulfide bond, carbon-heteroatom bond, etc.). In certain embodiments, the linker is a carbon-nitrogen bond of an amide linkage. In certain embodiments, the linker is a cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic or heteroaliphatic linker. In certain embodiments, the linker is polymeric (e.g., polyethylene, polyethylene glycol, polyamide, polyester, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminoalkanoic acid. In certain embodiments, the linker comprises an aminoalkanoic acid (e.g., glycine, ethanoic acid, alanine, beta-alanine, 3-aminopropanoic acid, 4-aminobutanoic acid, 5-pentanoic acid, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminohexanoic acid (Ahx). In certain embodiments, the linker is based on a carbocyclic moiety (e.g., cyclopentane, cyclohexane). In other embodiments, the linker comprises a polyethylene glycol moiety (PEG). In other embodiments, the linker comprises amino acids. In certain embodiments, the linker comprises a peptide. In certain embodiments, the linker comprises an aryl or heteroaryl moiety. In certain embodiments, the linker is based on a phenyl ring. The linker may included functionalized moieties to facilitate attachment of a nucleophile (e.g., thiol, amino) from the peptide to the linker. Any electrophile may be used as part of the linker. Exemplary electrophiles include, but are not limited to, activated esters, activated amides, Michael acceptors, alkyl halides, aryl halides, acyl halides, and isothiocyanates.

In some embodiments, the linker comprises the amino acid sequence (GGGGS)_n(SEQ ID NO: 5), (G)_n, (EAAAK)_n(SEQ ID NO: 6), (GGS)_n, (SGGS)_n(SEQ ID NO: 4288), SGSETPGTSESATPES (SEQ ID NO: 7), (XP)_n, or any combination thereof, wherein n is independently an integer between 1 and 30, and wherein X is any amino acid. In some embodiments, the linker comprises the amino acid sequence (GGS)_n, wherein n is 1, 3, or 7. In some embodiments, the linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7).

In some embodiments, the fusion protein comprises the structure [nucleic acid editing domain]-[optional linker sequence]-[dCas9 or Cas9 nickase]-[optional linker sequence]-[UGI]. In some embodiments, the fusion protein comprises the structure [nucleic acid editing domain]-[optional linker sequence]-[UGI]-[optional linker sequence]-[dCas9 or Cas9 nickase]; [UGI]-[optional linker sequence]-[nucleic acid editing domain]-[optional linker sequence]-[dCas9 or Cas9 nickase]; [UGI]-[optional linker sequence]-[dCas9 or Cas9 nickase]-[optional linker sequence]-[nucleic acid editing domain]; [dCas9 or Cas9 nickase]-[optional linker sequence]-[UGI]-[optional linker sequence]-[nucleic acid editing domain]; or [dCas9 or Cas9 nickase]-[optional linker sequence]-[nucleic acid editing domain]-[optional linker sequence]-[UGI].

In some embodiments, the nucleic acid editing domain comprises a deaminase. In some embodiments, the nucleic acid editing domain comprises a deaminase. In some embodiments, the deaminase is a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase, an APOBEC2 deaminase, an APOBEC3A deaminase, an APOBEC3B deaminase, an APOBEC3C deaminase, an APOBEC3D deaminase, an APOBEC3F deaminase, an APOBEC3G deaminase, an APOBEC3H deaminase, or an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID). In some embodiments, the deaminase is a Lamprey CDA1 (pmCDA1) deaminase.

In some embodiments, the deaminase is from a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase is from a human. In some embodiments the deaminase is from a rat. In some embodiments, the deaminase is a rat APOBEC1 deaminase comprising the amino acid sequence set forth in (SEQ ID NO: 284). In some embodiments, the deaminase is a human APOBEC1 deaminase comprising the amino acid sequence set forth in (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1 (SEQ ID NO: 5738). In some embodiments, the deaminase is human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a human APOBEC3G variant of any one of (SEQ ID NOs: 5739-5741). In some embodiments, the deaminase is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 266-284 or 5725-5741.

In some embodiments, the UGI domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to SEQ ID NO: 600. In some embodiments, the UGI domain comprises the amino acid sequence as set forth in SEQ ID NO: 600.

Some aspects of this disclosure provide complexes comprising a Cas9 protein or a Cas9 fusion protein as provided herein, and a guide RNA bound to the Cas9 protein or the Cas9 fusion protein.

Some aspects of this disclosure provide kits comprising a nucleic acid construct, comprising (a) a nucleotide sequence encoding a Cas9 protein or a Cas9 fusion protein as provided herein; and (b) a heterologous promoter that drives expression of the sequence of (a). In some embodiments, the kit further comprises an expression construct encoding a guide RNA backbone, wherein the construct comprises a cloning site positioned to allow the cloning of a nucleic acid sequence identical or complementary to a target sequence into the guide RNA backbone.

Some aspects of this disclosure provide polynucleotides encoding a Cas9 protein of a fusion protein as provided herein. Some aspects of this disclosure provide vectors comprising such polynucleotides. In some embodiments, the vector comprises a heterologous promoter driving expression of polynucleotide.

Some aspects of this disclosure provide cells comprising a Cas9 protein, a fusion protein, a nucleic acid molecule, and/or a vector as provided herein.

The description of exemplary embodiments of the reporter systems above is provided for illustration purposes only and not meant to be limiting. Additional reporter systems, e.g., variations of the exemplary systems described in detail above, are also embraced by this disclosure.

The summary above is meant to illustrate, in a non-limiting manner, some of the embodiments, advantages, features, and uses of the technology disclosed herein. Other embodiments, advantages, features, and uses of the technology disclosed herein will be apparent from the Detailed Description, the Drawings, the Examples, and the Claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the deaminase activity of deaminases on single stranded DNA substrates. Single stranded DNA substrates using randomized PAM sequences (NNN PAM) were used as negative controls. Canonical PAM sequences used (NGG PAM)

FIG. 2 shows activity of Cas9:deaminase fusion proteins on single stranded DNA substrates.

FIG. 3 illustrates double stranded DNA substrate binding by Cas9:deaminase:sgRNA complexes.

FIG. 4 illustrates a double stranded DNA deamination assay.

FIG. 5 demonstrates that Cas9 fusions can target positions 3-11 of double-stranded DNA target sequences (numbered according to the schematic in FIG. 5). Upper Gel: 1 μM rAPOBEC1-GGS-dCas9, 125 nM dsDNA, 1 equivalent sgRNA. Mid Gel: 1 μM rAPOBEC1-(GGS)₃(SEQ ID NO: 596)-dCas9, 125 nM dsDNA, 1 equivalent sgRNA. Lower Gel: 1.85 μM rAPOBEC1-XTEN-dCas9, 125 nM dsDNA, 1 equivalent sgRNA.

FIG. 6 demonstrates that the correct guide RNA, e.g., the correct sgRNA, is required for deaminase activity.

FIG. 7 illustrates the mechanism of target DNA binding of in vivo target sequences by deaminase-dCas9:sgRNA complexes.

FIG. 8 shows successful deamination of exemplary disease-associated target sequences.

FIG. 9 shows in vitro C→T editing efficiencies using His6-rAPOBEC1-XTEN-dCas9.

FIG. 10 shows C→T editing efficiencies in HEK293T cells is greatly enhanced by fusion with UGI.

FIGS. 11A to 11C show NBE1 mediates specific, guide RNA-programmed C to U conversion in vitro. FIG. 11A: Nucleobase editing strategy. DNA with a target C (red) at a locus specified by a guide RNA (green) is bound by dCas9 (blue), which mediates the local denaturation of the DNA substrate. Cytidine deamination by a tethered APOBEC1 enzyme (orange) converts the target C to U. The resulting G:U heteroduplex can be permanently converted to an A:T base pair following DNA replication or repair. If the U is in the template DNA strand, it will also result in an RNA transcript containing a G to A mutation following transcription. FIG. 11B: Deamination assay showing an activity window of approximately five nucleotides. Following incubation of NBE1-sgRNA complexes with dsDNA substrates at 37° C. for 2 h, the 5′ fluorophore-labeled DNA was isolated and incubated with USER enzyme (uracil DNA glycosylase and endonuclease VIII) at 37° C. for 1 h to induce DNA cleavage at the site of any uracils. The resulting DNA was resolved on a denaturing polyacrylamide gel, and any fluorophore-linked strands were visualized. Each lane is labeled according to the position of the target C within the protospacer, or with “-” if no target C is present, counting the base distal from the PAM as position 1. FIG. 11C: Deaminase assay showing the sequence specificity and sgRNA-dependence of NBE1. The DNA substrate with a target C at position 7 was incubated with NBE1 as in FIG. 11B with either the correct sgRNA, a mismatched sgRNA, or no sgRNA. No C to U editing is observed with the mismatched sgRNA or with no sgRNA. The positive control sample contains a DNA sequence with a U synthetically incorporated at position 7.

FIGS. 12A to 12B show effects of sequence context and target C position on nucleobase editing efficiency in vitro. FIG. 12A: Effect of changing the sequence surrounding the target C on editing efficiency in vitro. The deamination yield of 80% of targeted strands (40% of total sequencing reads from both strands) for C₇in the protospacer sequence 5′-TTATTTCGTGGATTTATTTA-3′(SEQ ID NO: 264) was defined as 1.0, and the relative deamination efficiencies of substrates containing all possible single-base mutations at positions 1-6 and 8-13 are shown. Values and error bars reflect the mean and standard deviation of two or more independent biological replicates performed on different days. FIG. 12B: Positional effect of each NC motif on editing efficiency in vitro. Each NC target motif was varied from positions 1 to 8 within the protospacer as indicated in the sequences shown on the right (the PAM shown in red, the protospacer plus one base 5′ to the protospacer are also shown). The percentage of total sequence reads containing T at each of the numbered target C positions following incubation with NBE1 is shown in the graph. Note that the maximum possible deamination yield in vitro is 50% of total sequencing reads (100% of targeted strands). Values and error bars reflect the mean and standard deviation of two or three independent biological replicates performed on different days. FIG. 12B depicts SEQ ID NOs: 285 through 292 from top to bottom, respectively.

FIGS. 13A to 13C show nucleobase editing in human cells. FIG. 13A: Protospacer (black) and PAM (red) sequences of the six mammalian cell genomic loci targeted by nucleobase editors. Target Cs are indicated with subscripted numbers corresponding to their positions within the protospacer. FIG. 13A depicts SEQ ID NOs: 293 through 298 from top to bottom, respectively. FIG. 13B: HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and an appropriate sgRNA. Three days after transfection, genomic DNA was extracted and analyzed by high-throughput DNA sequencing at the six loci. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, are shown for NBE1, NBE2, and NBE3 at all six genomic loci, and for wt Cas9 with a donor HDR template at three of the six sites (EMX1, HEK293 site 3, and HEK293 site 4). Values and error bars reflect the mean and standard deviation of three independent biological replicates performed on different days. FIG. 13C: Frequency of indel formation, calculated as described in the Methods, is shown following treatment of HEK293T cells with NBE2 and NBE3 for all six genomic loci, or with wt Cas9 and a single-stranded DNA template for HDR at three of the six sites (EMX1, HEK293 site 3, and HEK293 site 4). Values reflect the mean of at least three independent biological replicates performed on different days.

FIGS. 14A to 14C show NBE2- and NBE3-mediated correction of three disease-relevant mutations in mammalian cells. For each site, the sequence of the protospacer is indicated to the right of the name of the mutation, with the PAM highlighted in green and the base responsible for the mutation indicated in bold with a subscripted number corresponding to its position within the protospacer. The amino acid sequence above each disease-associated allele is shown, together with the corrected amino acid sequence following nucleobase editing in red. Underneath each sequence are the percentages of total sequencing reads with the corresponding base. Cells were nucleofected with plasmids encoding NBE2 or NBE3 and an appropriate sgRNA. Two days after nucleofection, genomic DNA was extracted and analyzed by HTS to assess pathogenic mutation correction. FIG. 14A: The Alzheimer's disease-associated APOE4 allele is converted to APOE3′ in mouse astrocytes by NBE3 in 11% of total reads (44% of nucleofected astrocytes). Two nearby Cs are also converted to Ts, but with no change to the predicted sequence of the resulting protein (SEQ ID NO: 299). FIG. 14B The cancer-associated p53 N239D mutation is corrected by NBE2 in 11% of treated human lymphoma cells (12% of nucleofected cells) that are heterozygous for the mutation (SEQ ID NO: 300). FIG. 14C The p53 Y163C mutation is corrected by NBE3 in 7.6% of nucleofected human breast cancer cells (SEQ ID NO: 301).

FIGS. 15A to 15D show effects of deaminase-dCas9 linker length and composition on nucleobase editing. Gel-based deaminase assay showing the deamination window of nucleobase editors with deaminase-Cas9 linkers of GGS (FIG. 15A), (GGS)₃(SEQ ID NO: 596) (FIG. 15B), XTEN (FIG. 15C), or (GGS)₇(SEQ ID NO: 597) (FIG. 15D). Following incubation of 1.85 μM editor-sgRNA complexes with 125 nM dsDNA substrates at 37° C. for 2 h, the dye-conjugated DNA was isolated and incubated with USER enzyme (uracil DNA glycosylase and endonuclease VIII) at 37° C. for an additional hour to cleave the DNA backbone at the site of any uracils. The resulting DNA was resolved on a denaturing polyacrylamide gel, and the dye-conjugated strand was imaged. Each lane is numbered according to the position of the target C within the protospacer, or with—if no target C is present. 8U is a positive control sequence with a U synthetically incorporated at position 8.

FIGS. 16A to 16B show NBE1 is capable of correcting disease-relevant mutations in vitro. FIG. 16A: Protospacer and PAM sequences (red) of seven disease-relevant mutations. The disease-associated target C in each case is indicated with a subscripted number reflecting its position within the protospacer. For all mutations except both APOE4 SNPs, the target C resides in the template (non-coding) strand. FIG. 16A depicts SEQ ID NOs: 302 through 308 from top to bottom, respectively. FIG. 16B: Deaminase assay showing each dsDNA oligonucleotide before (−) and after (+) incubation with NBE1, DNA isolation, and incubation with USER enzymes to cleave DNA at positions containing U. Positive control lanes from incubation of synthetic oligonucleotides containing U at various positions within the protospacer with USER enzymes are shown with the corresponding number indicating the position of the U.

FIG. 17 shows processivity of NBE1. The protospacer and PAM (red) of a 60-mer DNA oligonucleotide containing eight consecutive Cs is shown at the top. The oligonucleotide (125 nM) was incubated with NBE1 (2 μM) for 2 h at 37° C. The DNA was isolated and analyzed by high-throughput sequencing. Shown are the percent of total reads for the most frequent nine sequences observed. The vast majority of edited strands (>93%) have more than one C converted to T. This figure depicts SEQ ID NO: 309.

FIGS. 18A to 18H show the effect of fusing UGI to NBE1 to generate NBE2. FIG. 18A: Protospacer and PAM (red) sequences of the six mammalian cell genomic loci targeted with nucleobase editors. Editable Cs are indicated with labels corresponding to their positions within the protospacer. FIG. 18A depicts SEQ ID NOs: 293 through 298 from top to bottom, respectively. FIGS. 18B to 18G: HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE1 and UGI, and an appropriate sgRNA. Three days after transfection, genomic DNA was extracted and analyzed by high-throughput DNA sequencing at the six loci. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, are shown for NBE1, NBE1 and UGI, and NBE2 at all six genomic loci. FIG. 18H: C to T mutation rates at 510 Cs surrounding the protospacers of interest for NBE1, NBE1 plus UGI on a separate plasmid, NBE2, and untreated cells are shown. The data show the results of 3,000,000 DNA sequencing reads from 1.5×106 cells. Values reflect the mean of at least two biological experiments conducted on different days.

FIG. 19 shows nucleobase editing efficiencies of NBE2 in U2OS and HEK293T cells. Cellular C to T conversion percentages by NBE2 are shown for each of the six targeted genomic loci in HEK293T cells and U2OS cells. HEK293T cells were transfected using lipofectamine 2000, and U2OS cells were nucleofected. U2OS nucleofection efficiency was 74%. Three days after plasmid delivery, genomic DNA was extracted and analyzed for nucleobase editing at the six genomic loci by HTS. Values and error bars reflect the mean and standard deviation of at least two biological experiments done on different days.

FIG. 20 shows nucleobase editing persists over multiple cell divisions. Cellular C to T conversion percentages by NBE2 are displayed at two genomic loci in HEK293T cells before and after passaging the cells. HEK293T cells were transfected using Lipofectamine 2000. Three days post transfection, the cells were harvested and split in half. One half was subjected to HTS analysis, and the other half was allowed to propagate for approximately five cell divisions, then harvested and subjected to HTS analysis.

FIG. 21 shows genetic variants from ClinVar that can be corrected in principle by nucleobase editing. The NCBI ClinVar database of human genetic variations and their corresponding phenotypes⁶⁸was searched for genetic diseases that can be corrected by current nucleobase editing technologies. The results were filtered by imposing the successive restrictions listed on the left. The x-axis shows the number of occurrences satisfying that restriction and all above restrictions on a logarithmic scale.

FIG. 22 shows in vitro identification of editable Cs in six genomic loci. Synthetic 80-mers with sequences matching six different genomic sites were incubated with NBE1 then analyzed for nucleobase editing via HTS. For each site, the sequence of the protospacer is indicated to the right of the name of the site, with the PAM highlighted in red. Underneath each sequence are the percentages of total DNA sequencing reads with the corresponding base. A target C was considered as “editable” if the in vitro conversion efficiency is >10%. Note that maximum yields are 50% of total DNA sequencing reads since the non-targeted strand is not a substrate for nucleobase editing. This figure depicts SEQ ID NOs: 293 through 298 from top to bottom, respectively.

FIG. 23 shows activities of NBE1, NBE2, and NBE3 at EMX1 off-targets. HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and a sgRNA matching the EMX1 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus the top ten known Cas9 off-target loci for the EMX1 sgRNA, as previously determined using the GUIDE-seq method⁵⁵. EMX1 off-target 5 locus did not amplify and is not shown. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for NBE1, NBE2, and NBE3. On the far right are displayed the total number of sequencing reads reported for each sequence. This figure depicts SEQ ID NOs: 293, and 310 through 318 from top to bottom, respectively.

FIG. 24 shows activities of NBE1, NBE2, and NBE3 at FANCF off-targets. HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and a sgRNA matching the FANCF sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus all of the known Cas9 off-target loci for the FANCF sgRNA, as previously determined using the GUIDE-seq method⁵⁵. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for NBE1, NBE2, and NBE3. On the far right are displayed the total number of sequencing reads reported for each sequence. This figure depicts SEQ ID NOs: 294 and 319 through 326 from top to bottom, respectively.

FIG. 25 shows activities of NBE1, NBE2, and NBE3 at HEK293 site 2 off-targets. HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and a sgRNA matching the HEK293 site 2 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus all of the known Cas9 off-target loci for the HEK293 site 2 sgRNA, as previously determined using the GUIDE-seq method⁵⁵. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for NBE1, NBE2, and NBE3. On the far right are displayed the total number of sequencing reads reported for each sequence. This figure depicts SEQ ID NOs: 295, 327, and 328 from top to bottom, respectively.

FIG. 26 shows activities of NBE1, NBE2, and NBE3 at HEK293 site 3 off-targets. HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and a sgRNA matching the HEK293 site 3 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus all of the known Cas9 off-target loci for the HEK293 site 3 sgRNA, as previously determined using the GUIDE-seq method⁵⁵. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for NBE1, NBE2, and NBE3. On the far right are displayed the total number of sequencing reads reported for each sequence. This figure depicts SEQ ID NOs: 296 and 659 through 663 from top to bottom, respectively.

FIG. 27 shows activities of NBE1, NBE2, and NBE3 at HEK293 site 4 off-targets. HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and a sgRNA matching the HEK293 site 4 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus the top ten known Cas9 off-target loci for the HEK293 site 4 sgRNA, as previously determined using the GUIDE-seq method⁵⁵. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for NBE1, NBE2, and NBE3. On the far right are displayed the total number of sequencing reads reported for each sequence. This figure depicts SEQ ID NOs: 297 and 664 through 673 from top to bottom, respectively.

FIG. 28 shows non-target C mutation rates. Shown here are the C to T mutation rates at 2,500 distinct cytosines surrounding the six on-target and 34 off-target loci tested, representing a total of 14,700,000 sequence reads derived from approximately 1.8×106 cells.

FIGS. 29A to 29C show base editing in human cells. FIG. 29A shows possible base editing outcomes in mammalian cells. Initial editing resulted in a U:G mismatch. Recognition and excision of the U by uracil DNA glycosylase (UDG) initiated base excision repair (BER), which lead to reversion to the C:G starting state. BER was impeded by BE2 and BE3, which inhibited UDG. The U:G mismatch was also processed by mismatch repair (MMR), which preferentially repaired the nicked strand of a mismatch. BE3 nicked the non-edited strand containing the G, favoring resolution of the U:G mismatch to the desired U:A or T:A outcome. FIG. 29B shows HEK293T cells treated as described in the Materials and Methods in the Examples below. The percentage of total DNA sequencing read with Ts at the target positions indicated show treatment with BE1, BE2, or BE3, or for treatment with wt Cas9 with a donor HDR template. FIG. 29C shows frequency of indel formation following the treatment in FIG. 29B. Values are listed in FIG. 34. For FIGS. 29B and 29C, values and error bars reflect the mean and s.d. of three independent biological replicates performed on different days.

FIGS. 30A to 30B show BE3-mediated correction of two disease-relevant mutations in mammalian cells. The sequence of the protospacer is shown to the right of the mutation, with the PAM in blue and the target base in red with a subscripted number indicating its position within the protospacer. Underneath each sequence are the percentages of total sequencing reads with the corresponding base. Cells were treated as described in the Materials and Methods. FIG. 30A shows the Alzheimer's disease-associated APOE4 allele converted to APOE3r in mouse astrocytes by BE3 in 74.9% of total reads. Two nearby Cs were also converted to Ts, but with no change to the predicted sequence of the resulting protein. Identical treatment of these cells with wt Cas9 and donor ssDNA results in only 0.3% correction, with 26.1% indel formation. FIG. 30B shows the cancer associated p53 Y163C mutation corrected by BE3 in 7.6% of nucleofected human breast cancer cells with 0.7% indel formation. Identical treatment of these cells with wt Cas9 and donor ssDNA results in no mutation correction with 6.1% indel formation. This figure depicts SEQ ID NOs: 675 to 680 from top to bottom, respectively.

FIG. 31 shows activities of BE1, BE2, and BE3 at HEK293 site 2 off-targets. HEK293T cells were transfected with plasmids expressing BE1, BE2, or BE3 and a sgRNA matching the HEK293 site 2 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus all of the known Cas9 and dCas9 off-target loci for the HEK293 site 2 sgRNA, as previously determined by Joung and coworkers using the GUIDE-seq method (63), and Adli and coworkers using chromatin immunoprecipitation high-throughput sequencing (ChIP-seq) experiments (18). Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for BE1, BE2, and BE3. On the far right are displayed the total number of sequencing reads reported, and the ChIP-seq signal intensity reported for each sequence. This figure depicts SEQ ID NOs: 681 to 688 from top to bottom, respectively.

FIG. 32 shows activities of BE1, BE2, and BE3 at HEK293 site 3 off-targets. HEK293T cells were transfected with plasmids expressing BE1, BE2, or BE3 and a sgRNA matching the HEK293 site 3 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus all of the known Cas9 off-target loci and the top five known dCas9 off-target loci for the HEK293 site 3 sgRNA, as previously determined by Joung and coworkers using the GUIDE-seq method⁵⁴, and using chromatin immunoprecipitation high-throughput sequencing (ChIP-seq) experiments⁶¹. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for BE1, BE2, and BE3. On the far right are displayed the total number of sequencing reads reported, and the ChIP-seq signal intensity reported for each sequence. This figure depicts SEQ ID NOs: 689 to 699 from top to bottom, respectively.

FIG. 33 shows activities of BE1, BE2, and BE3 at HEK293 site 4 off-targets. HEK293T cells were transfected with plasmids expressing BE1, BE2, or BE3 and a sgRNA matching the HEK293 site 4 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus the top ten known Cas9 off-target loci and the top five known dCas9 off-target loci for the HEK293 site 4 sgRNA, as previously determined using the GUIDE-seq method⁵⁴, and using chromatin immunoprecipitation high-throughput sequencing (ChIP-seq) experiments⁶¹. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for BE1, BE2, and BE3. On the far right are displayed the total number of sequencing reads reported, and the ChIP-seq signal intensity reported for each sequence. This figure depicts SEQ ID NOs: 700 to 712 from top to bottom, respectively.

FIG. 34 shows mutation rates of non-protospacer bases following BE3-mediated correction of the Alzheimer's disease-associated APOE4 allele to APOE3r in mouse astrocytes. The DNA sequence of the 50 bases on either side of the protospacer from FIG. 30A and FIG. 34B is shown with each base's position relative to the protospacer. The side of the protospacer distal to the PAM is designated with positive numbers, while the side that includes the PAM is designated with negative numbers, with the PAM shown in blue. Underneath each sequence are the percentages of total DNA sequencing reads with the corresponding base for untreated cells, for cells treated with BE3 and an sgRNA targeting the APOE4 C158R mutation, or for cells treated with BE3 and an sgRNA targeting the VEGFA locus. Neither BE3-treated sample resulted in mutation rates above those of untreated controls. This figure depicts SEQ ID NOs: 713 to 716 from top to bottom, respectively.

FIG. 35 shows mutation rates of non-protospacer bases following BE3-mediated correction of the cancer-associated p53 Y163C mutation in HCC1954 human cells. The DNA sequence of the 50 bases on either side of the protospacer from FIG. 30B and FIG. 39B is shown with each base's position relative to the protospacer. The side of the protospacer distal to the PAM is designated with positive numbers, while the side that includes the PAM is designated with negative numbers, with the PAM shown in blue. Underneath each sequence are the percentages of total sequencing reads with the corresponding base for untreated cells, for cells treated with BE3 and an sgRNA targeting the TP53 Y163C mutation, or for cells treated with BE3 and an sgRNA targeting the VEGFA locus. Neither BE3-treated sample resulted in mutational rates above those of untreated controls. This figure depicts SEQ ID NOs: 717 to 720 from top to bottom, respectively.

FIGS. 36A to 36F show the effects of deaminase, linker length, and linker composition on base editing. FIG. 36A shows a gel-based deaminase assay showing activity of rAPOBEC1, pmCDA1, hAID, hAPOBEC3G, rAPOBEC1-GGS-dCas9, rAPOBEC1-(GGS)₃(SEQ ID NO: 596)-dCas9, and dCas9-(GGS)₃(SEQ ID NO: 596)-rAPOBEC1 on ssDNA. Enzymes were expressed in a mammalian cell lysate-derived in vitro transcription-translation system and incubated with 1.8 μM dye-conjugated ssDNA and USER enzyme (uracil DNA glycosylase and endonuclease VIII) at 37° C. for 2 hours. The resulting DNA was resolved on a denaturing polyacrylamide gel and imaged. The positive control is a sequence with a U synthetically incorporated at the same position as the target C. FIG. 36B shows coomassie-stained denaturing PAGE gel of the expressed and purified proteins used in FIGS. 36C to 36F. FIGS. 36C to 36F show gel-based deaminase assay showing the deamination window of base editors with deaminase-Cas9 linkers of GGS (FIG. 36C), (GGS)₃(SEQ ID NO: 596) (FIG. 36D), XTEN (FIG. 36E), or (GGS)₇(SEQ ID NO: 597) (FIG. 36F). Following incubation of 1.85 μM deaminase-dCas9 fusions complexed with sgRNA with 125 nM dsDNA substrates at 37° C. for 2 hours, the dye-conjugated DNA was isolated and incubated with USER enzyme at 37° C. for 1 hour to cleave the DNA backbone at the site of any uracils. The resulting DNA was resolved on a denaturing polyacrylamide gel, and the dye-conjugated strand was imaged. Each lane is numbered according to the position of the target C within the protospacer, or with—if no target C is present. 8U is a positive control sequence with a U synthetically incorporated at position 8.

FIGS. 37A to 37C show BE1 base editing efficiencies are dramatically decreased in mammalian cells. FIG. 37A Protospacer (black and red) and PAM (blue) sequences of the six mammalian cell genomic loci targeted by base editors. Target Cs are indicated in red with subscripted numbers corresponding to their positions within the protospacer. FIG. 37B shows synthetic 80-mers with sequences matching six different genomic sites were incubated with BE1 then analyzed for base editing by HTS. For each site, the sequence of the protospacer is indicated to the right of the name of the site, with the PAM highlighted in blue. Underneath each sequence are the percentages of total DNA sequencing reads with the corresponding base. We considered a target C as “editable” if the in vitro conversion efficiency is >10%. Note that maximum yields are 50% of total DNA sequencing reads since the non-targeted strand is unaffected by BEL Values are shown from a single experiment. FIG. 37C shows HEK293T cells were transfected with plasmids expressing BE1 and an appropriate sgRNA. Three days after transfection, genomic DNA was extracted and analyzed by high-throughput DNA sequencing at the six loci. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, are shown for BE1 at all six genomic loci. Values and error bars of all data from HEK293T cells reflect the mean and standard deviation of three independent biological replicates performed on different days. FIG. 37A depicts SEQ ID NOs: 721 to 726 from top to bottom, respectively. FIG. 37B depicts SEQ ID NOs: 727 to 732 from top to bottom, respectively.

FIG. 38 shows base editing persists over multiple cell divisions. Cellular C to T conversion percentages by BE2 and BE3 are shown for HEK293 sites 3 and 4 in HEK293T cells before and after passaging the cells. HEK293T cells were nucleofected with plasmids expressing BE2 or BE3 and an sgRNA targeting HEK293 site 3 or 4. Three days after nucleofection, the cells were harvested and split in half. One half was subjected to HTS analysis, and the other half was allowed to propagate for approximately five cell divisions, then harvested and subjected to HTS analysis. Values and error bars reflect the mean and standard deviation of at least two biological experiments.

FIGS. 39A to 39C show non-target C/G mutation rates. Shown here are the C to T and G to A mutation rates at 2,500 distinct cytosines and guanines surrounding the six on-target and 34 off-target loci tested, representing a total of 14,700,000 sequence reads derived from approximately 1.8×10⁶cells. FIGS. 39A and 39B show cellular non-target C to T and G to A conversion percentages by BE1, BE2, and BE3 are plotted individually against their positions relative to a protospacer for all 2,500 cytosines/guanines. The side of the protospacer distal to the PAM is designated with positive numbers, while the side that includes the PAM is designated with negative numbers. FIG. 39C shows average non-target cellular C to T and G to A conversion percentages by BE1, BE2, and BE3 are shown, as well as the highest and lowest individual conversion percentages.

FIGS. 40A to 40B show additional data sets of BE3-mediated correction of two disease-relevant mutations in mammalian cells. For each site, the sequence of the protospacer is indicated to the right of the name of the mutation, with the PAM highlighted in blue and the base responsible for the mutation indicated in red bold with a subscripted number corresponding to its position within the protospacer. The amino acid sequence above each disease-associated allele is shown, together with the corrected amino acid sequence following base editing in green. Underneath each sequence are the percentages of total sequencing reads with the corresponding base. Cells were nucleofected with plasmids encoding BE3 and an appropriate sgRNA. Two days after nucleofection, genomic DNA was extracted from the nucleofected cells and analyzed by HTS to assess pathogenic mutation correction. FIG. 40A shows the Alzheimer's disease-associated APOE4 allele is converted to APOE3r in mouse astrocytes by BE3 in 58.3% of total reads only when treated with the correct sgRNA. Two nearby Cs are also converted to Ts, but with no change to the predicted sequence of the resulting protein. Identical treatment of these cells with wt Cas9 and donor ssDNA results in 0.2% correction, with 26.7% indel formation. FIG. 40B shows the cancer-associated p53 Y163C mutation is corrected by BE3 in 3.3% of nucleofected human breast cancer cells only when treated with the correct sgRNA. Identical treatment of these cells with wt Cas9 and donor ssDNA results in no detectable mutation correction with 8.0% indel formation. FIGS. 40A to 40B depict SEQ ID NOs: 733 to 740 from top to bottom, respectively.

FIG. 41 shows a schematic representation of an exemplary USER (Uracil-Specific Excision Reagent) Enzyme-based assay, which may be used to test the activity of various deaminases on single-stranded DNA (ssDNA) substrates.

FIG. 42 is a schematic of the pmCDA-nCas9-UGI-NLS construct and its activity at the HeK-3 site relative to the base editor (rAPOBEC1) and the negative control (untreated).

FIG. 43 is a schematic of the pmCDA1-XTEN-nCas9-UGI-NLS construct and its activity at the HeK-3 site relative to the base editor (rAPOBEC1) and the negative control (untreated).

FIG. 44 shows the percent of total sequencing reads with target C converted to T using cytidine deaminases (CDA) or APOBEC.

FIG. 45 shows the percent of total sequencing reads with target C converted to A using deaminases (CDA) or APOBEC.

FIG. 46 shows the percent of total sequencing reads with target C converted to G using deaminases (CDA) or APOBEC.

FIG. 47 is a schematic of the huAPOBEC3G-XTEN-nCas9-UGI-NLS construct and its activity at the HeK-2 site relative to a mutated form (huAPOBEC3G*(D316R_D317R)-XTEN-nCas9-UGI-NLS, the base editor (rAPOBEC1) and the negative control (untreated).

FIG. 48 shows the schematic of the LacZ construct used in the selection assay of Example 7.

FIG. 49 shows reversion data from different plasmids and constructs.

FIG. 50 shows the verification of lacZ reversion and the purification of reverted clones.

FIG. 51 is a schematic depicting a deamination selection plasmid used in Example 7.

FIG. 52 shows the results of a chloramphenicol reversion assay (pmCDA1 fusion).

FIGS. 53A to 53B demonstrated DNA correction induction of two constructs.

FIG. 54 shows the results of a chloramphenicol reversion assay (huAPOBEC3G fusion).

FIG. 55 shows the activities of BE3 and HF-BE3 at EMX1 off-targets. The sequences, from top to bottom, correspond to SEQ ID NOs: 286-292, 299-301.

FIG. 56 shows on-target base editing efficiencies of BE3 and HF-BE3.

FIG. 57 is a graph demonstrating that mutations affect cytidine deamination with varying degrees. Combinations of mutations that each slightly impairs catalysis allow selective deamination at one position over others. The FANCF site was

(SEQ ID NO: 303)

GGAATC₆C₇C₈TTC₁₁TGCAGCACCTGG.

FIG. 58 is a schematic depicting next generation base editors.

FIG. 59 is a schematic illustrating new base editors made from Cas9 variants.

FIG. 60 shows the base-edited percentage of different NGA PAM sites.

FIG. 61 shows the base-edited percentage of cytidines using NGCG PAM EMX (VRER BE3) and the C₁TC₃C₄C₅ATC₈AC₁₀ATCAACCGGT (SEQ ID NO: 304) spacer.

FIG. 62 shows the based-edited percentages resulting from different NNGRRT PAM sites.

FIG. 63 shows the based-edited percentages resulting from different NNHRRT PAM sites.

FIGS. 64A to 64C show the base-edited percentages resulting from different TTTN PAM sites using Cpf1 BE2. The spacers used were:

(FIG. 64A, SEQ ID NO: 305)

TTTCCTC₃C₄C₅C₆C₇C₈C₉AC₁₁AGGTAGAACAT,

(FIG. 64B, SEQ ID NO: 306)

TTTCC₁C₂TC₄TGTC₈C₉AC₁₁ACCCTCATCCTG,

and

(FIG. 64C, SEQ ID NO: 307)

TTTCC₁C₂C₃AGTC₇C₈TC₁₀C₁₁AC₁₃AC₁₅C₁₆C₁₇TGAAAC.

FIG. 65 is a schematic depicting selective deamination as achieved through kinetic modulation of cytidine deaminase point mutagenesis.

FIG. 66 is a graph showing the effect of various mutations on the deamination window probed in cell culture with multiple cytidines in the spacer. The spacer used was:

(SEQ ID NO: 308)

TGC₃C₄C₅C₆TC₈C₉C₁₀TC₁₂C₁₃C₁₄TGGCCC.

FIG. 67 is a graph showing the effect of various mutations on the deamination window probed in cell culture with multiple cytidines in the spacer. The spacer used was:

(SEQ ID NO: 309)

AGAGC₅C₆C₇C₈C₉C₁₀C₁₁TC₁₃AAAGAGA.

FIG. 68 is a graph showing the effect of various mutations on the FANCF site with a limited number of cytidines. The spacer used was: GGAATC₆C₇C₈TTC₁₁TGCAGCACCTGG (SEQ ID NO: 303). Note that the triple mutant (W90Y, R126E, R132E) preferentially edits the cytidine at the sixth position.

FIG. 69 is a graph showing the effect of various mutations on the HEK3 site with a limited number of cytidines. The spacer used was: GGCC₄C₅AGACTGAGCACGTGATGG (SEQ ID NO: 310). Note that the double and triple mutants preferentially edit the cytidine at the fifth position over the cytidine in the fourth position.

FIG. 70 is a graph showing the effect of various mutations on the EMX1 site with a limited number of cytidines. The spacer used was: GAGTC₅C₆GAGCAGAAGAAGAAGGG (SEQ ID NO: 311). Note that the triple mutant only edits the cytidine at the fifth position, not the sixth.

FIG. 71 is a graph showing the effect of various mutations on the HEK2 site with a limited number of cytidines. The spacer used was:

(SEQ ID NO: 312)

GAAC₄AC₆AAAGCATAGACTGCGGG.

FIG. 72 shows on-target base editing efficiencies of BE3 and BE3 comprising mutations W90Y R132E in immortalized astrocytes.

FIG. 73 depicts a schematic of three Cpf1 fusion constructs.

FIG. 74 shows a comparison of plasmid delivery of BE3 and HF-BE3 (EMX1, FANCF, and RNF2).

FIG. 75 shows a comparison of plasmid delivery of BE3 and HF-BE3 (HEK3 and HEK 4).

FIG. 76 shows off-target editing of EMX-1 at all 10 sites.

FIG. 77 shows deaminase protein lipofection to HEK cells using a GAGTCCGAGCAGAAGAAGAAG (SEQ ID NO: 313) spacer. The EMX-1 on-target and EMX-1 off target site 2 were examined.

FIG. 78 shows deaminase protein lipofection to HEK cells using a GGAATCCCTTCTGCAGCACCTGG (SEQ ID NO: 314) spacer. The FANCF on target and FANCF off target site 1 were examined.

FIG. 79 shows deaminase protein lipofection to HEK cells using a GGCCCAGACTGAGCACGTGA (SEQ ID NO: 315) spacer. The HEK-3 on target site was examined.

FIG. 80 shows deaminase protein lipofection to HEK cells using a GGCACTGCGGCTGGAGGTGGGGG (SEQ ID NO: 316) spacer. The HEK-4 on target, off target site 1, site 3, and site 4.

FIG. 81 shows the results of an in vitro assay for sgRNA activity for sgHR_13 (GTCAGGTCGAGGGTTCTGTC (SEQ ID NO: 317) spacer; C8 target: G51 to STOP), sgHR_14 (GGGCCGCAGTATCCTCACTC (SEQ ID NO: 318) spacer; C7 target; C7 target: Q68 to STOP), and sgHR_15 (CCGCCAGTCCCAGTACGGGA (SEQ ID NO: 319) spacer; C10 and C11 are targets: W239 or W237 to STOP).

FIG. 82 shows the results of an in vitro assay for sgHR_17 (CAACCACTGCTCAAAGATGC (SEQ ID NO: 320) spacer; C4 and C5 are targets: W410 to STOP), and sgHR_16 (CTTCCAGGATGAGAACACAG (SEQ ID NO: 321) spacer; C4 and C5 are targets: W273 to STOP).

FIG. 83 shows the direct injection of BE3 protein complexed with sgHR_13 in zebrafish embryos.

FIG. 84 shows the direct injection of BE3 protein complexed with sgHR_16 in zebrafish embryos.

FIG. 85 shows the direct injection of BE3 protein complexed with sgHR_17 in zebrafish embryos.

FIG. 86 shows exemplary nucleic acid changes that may be made using base editors that are capable of making a cytosine to thymine change.

FIG. 87 shows an illustration of apolipoprotein E (APOE) isoforms, demonstrating how a base editor (e.g., BE3) may be used to edit one APOE isoform (e.g., APOE4) into another APOE isoform (e.g., APOE3r) that is associated with a decreased risk of Alzheimer's disease.

FIG. 88 shows base editing of APOE4 to APOE3r in mouse astrocytes.

FIG. 89 shows base editing of PRNP to cause early truncation of the protein at arginine residue 37.

FIG. 90 shows that knocking out UDG (which UGI inhibits) dramatically improves the cleanliness of efficiency of C to T base editing.

FIG. 91 shows that use of a base editor with the nickase but without UGI leads to a mixture of outcomes, with very high indel rates.

FIGS. 92A to 92G show that SaBE3, SaKKH-BE3, VQR-BE3, EQR-BE3, and VRER-BE3 mediate efficient base editing at target sites containing non-NGG PAMs in human cells. FIG. 92A shows base editor architectures using S. pyogenes and S. aureus Cas9. FIG. 92B shows recently characterized Cas9 variants with alternate or relaxed PAM requirements. FIGS. 92C and 92D show HEK293T cells treated with the base editor variants shown as described in Example 12. The percentage of total DNA sequencing reads (with no enrichment for transfected cells) with C converted to T at the target positions indicated are shown. The PAM sequence of each target tested is shown below the X-axis. The charts show the results for SaBE3 and SaKKH-BE3 at genomic loci with NNGRRT PAMs (FIG. 92C), SaBE3 and SaKKH-BE3 at genomic loci with NNNRRT PAMs (FIG. 92D), VQR-BE3 and EQR-BE3 at genomic loci with NGAG PAMs (FIG. 92E), and with NGAH PAMs (FIG. 92F), and VRER-BE3 at genomic loci with NGCG PAMs (FIG. 92G). Values and error bars reflect the mean and standard deviation of at least two biological replicates.

FIGS. 93A to 93C demonstrate that base editors with mutations in the cytidine deaminase domain exhibit narrowed editing windows. FIGS. 93A to 93C show HEK293T cells transfected with plasmids expressing mutant base editors and an appropriate sgRNA. Three days after transfection, genomic DNA was extracted and analyzed by high-throughput DNA sequencing at the indicated loci. The percentage of total DNA sequencing reads (without enrichment for transfected cells) with C changed to T at the target positions indicated are shown for the EMX1 site, HEK293 site 3, FANCF site, HEK293 site 2, site A, and site B loci. FIG. 93A illustrates certain cytidine deaminase mutations which narrow the base editing window. See FIG. 98 for the characterization of additional mutations. FIG. 93B shows the effect of cytidine deaminase mutations which effect the editing window width on genomic loci. Combining beneficial mutations has an additive effect on narrowing the editing window. FIG. 93C shows that YE1-BE3, YE2-BE3, EE-BE3, and YEE-BE3 effect the product distribution of base editing, producing predominantly singly-modified products in contrast with BE3. Values and error bars reflect the mean and standard deviation of at least two biological replicates.

FIGS. 94A and 94B show genetic variants from ClinVar that in principle can be corrected by the base editors developed in this work. The NCBI ClinVar database of human genetic variations and their corresponding phenotypes was searched for genetic diseases that in theory can be corrected by base editing. FIG. 94A demonstrates improvement in base editing targeting scope among all pathogenic T→C mutations in the ClinVar database through the use of base editors with altered PAM specificities. The white fractions denote the proportion of pathogenic T→C mutations accessible on the basis of the PAM requirements of either BE3, or BE3 together with the five modified-PAM base editors developed in this work. FIG. 94B shows improvement in base editing targeting scope among all pathogenic T→C mutations in the ClinVar database through the use of base editors with narrowed activity windows. BE3 was assumed to edit Cs in positions 4-8 with comparable efficiency as shown in FIGS. 93A to 93C. YEE-BE3 was assumed to edit with C5>C6>C7>others preference within its activity window. The white fractions denote the proportion of pathogenic T→C mutations that can be edited BE3 without comparable editing of other Cs (left), or that can be edited BE3 or YEE-BE3 without comparable editing of other Cs (right).

FIGS. 95A and 95B show the effect of truncated guide RNAs on base editing window width. HEK293T cells were transfected with plasmids expressing BE3 and sgRNAs of different 5′ truncation lengths. The treated cells were analyzed as described in the Examples. FIG. 95A shows protospacer and PAM sequence (top, SEQ ID NO: 4270) and cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, at a site within the EMX1 genomic locus. At this site, the base editing window was altered through the use of a 17-nt truncated gRNA. FIG. 95B shows protospacer and PAM sequences (top, SEQ ID NO: 4270) and cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, at sites within the HEK site 3 and site 4 genomic loci. At these sites, no change in the base editing window was observed, but a linear decrease in editing efficiency for all substrate bases as the sgRNA is truncated was noted.

FIG. 96 shows the effect of APOBEC1-Cas9 linker lengths on base editing window width. HEK293T cells were transfected with plasmids expressing base editors with rAPOBEC1-Cas9 linkers of XTEN, GGS, (GGS)₃(SEQ ID NO: 596), (GGS)₅(SEQ ID NO: 4271), or (GGS)₇(SEQ ID NO: 597) and an sgRNA. The treated cells were analyzed as described in the Examples. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, are shown for the various base editors with different linkers.

FIGS. 97A to 97C show the effect of rAPOBEC mutations on base editing window width. FIG. 97C shows HEK293T cells transfected with plasmids expressing an sgRNA targeting either Site A or Site B and the BE3 point mutants indicated. The treated cells were analyzed as described in the Examples. All C's in the protospacer and within three basepairs of the protospacer are displayed and the cellular C to T conversion percentages are shown. The ‘editing window widths’, defined as the calculated number of nucleotides within which editing efficiency exceeds the half-maximal value, are displayed for all tested mutants.

FIG. 98 shows the effect of APOBEC1 mutation son product distributions of base editing in mammalian cells. HEK293T cells were transfected with plasmids expressing BE3 or its mutants and an appropriate sgRNAs. The treated cells were analyzed as described in the Examples. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, are shown (left). Percent of total sequencing reads containing the C to T conversion is shown on the right. The BE3 point mutants do not significantly affect base editing efficiencies at HEK site 4, a site with only one target cytidine.

FIG. 99 shows a comparison of on-target editing plasma delivery in BE3 and HF-BE3.

FIG. 100 shows a comparison of on-target editing in protein and plasma delivery of BE3.

FIG. 101 shows a comparison of on-target editing in protein and plasma delivery of HF-BE3.

FIG. 102 shows that both lipofection and installing HF mutations decrease off-target deamination events. The diamond indicates no off targets were detected and the specificity ratio was set to 100.

FIG. 103 shows in vitro C to T editing on a synthetic substrate with Cs placed at even positions in the protospacer (NNNNTC₂TC₄TC₆TC₈TC₁₀TC₁₂TC₁₄TC₁₆TC₁₈TC₂₀NGG, SEQ ID NO: 4272).

FIG. 104 shows in vitro C to T editing on a synthetic substrate with Cs placed at odd positions in the protospacer (NNNNTC₂TC₄TC₆TC₈TC₁₀TC₁₂TC₁₄TC₁₆TC₁₈TC₂₀NGG, SEQ ID NO: 4272).

FIG. 105 includes two graphs depicting the specificity ratio of base editing with plasmid vs. protein delivery.

FIGS. 106A to 106B shows BE3 activity on non-NGG PAM sites. HEK293T cells were transfected with plasmids expressing BE3 and appropriate sgRNA. The treated cells were analyzed as described in the Examples. FIG. 106A shows BE3 activity on sites can be efficiently targeted by SaBE3 or SaKKH-BE3. BE3 shows low but significant activity on the NAG PAM. FIG. 106B shows BE3 has significantly reduced editing at sites with NGA or NGCG PAMs, in contrast to VQR-BE3 or VRER-BE3.

FIGS. 107A to 107B show the effect of APOBEC1 mutations on VQR-BE3 and SaKKH-BE3. HEK293T cells were transfected with plasmids expressing VQR-BE3, SaKKH-BE3 or its mutants and an appropriate sgRNAs. The treated cells were analyzed as described in the Methods. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, are shown. FIG. 107A shows that the window-modulating mutations can be applied to VQR-BE3 to enable selective base editing at sites targetable by NGA PAM. FIG. 107B shows that, when applied to SaKKH-BE3, the mutations cause overall decrease in base editing efficiency without conferring base selectivity within the target window.

FIG. 108 shows a schematic representation of nucleotide editing. The following abbreviations are used: (MMR)—mismatch repair, (BE3 Nickase)—refers to base editor 3, which comprises a Cas9 nickase domain, (UGI)—uracil glycosylase inhibitor, UDG)—uracil DNA glycosylase, (APOBEC)—refers to an APOBEC cytidine deaminase.

DEFINITIONS

As used herein and in the claims, the singular forms “a,” “an,” and “the” include the singular and the plural reference unless the context clearly indicates otherwise. Thus, for example, a reference to “an agent” includes a single agent and a plurality of such agents.

The term “Cas9” or “Cas9 nuclease” refers to an RNA-guided nuclease comprising a Cas9 protein, or a fragment thereof (e.g., a protein comprising an active, inactive, or partially active DNA cleavage domain of Cas9, and/or the gRNA binding domain of Cas9). A Cas9 nuclease is also referred to sometimes as a casn1 nuclease or a CRISPR (clustered regularly interspaced short palindromic repeat)-associated nuclease. CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and a Cas9 protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently, Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer. The target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3′-5′ exonucleolytically. In nature, DNA-binding and cleavage typically requires protein and both RNAs. However, single guide RNAs (“sgRNA”, or simply “gNRA”) can be engineered so as to incorporate aspects of both the crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816-821 (2012), the entire contents of which is hereby incorporated by reference. Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus non-self. Cas9 nuclease sequences and structures are well known to those of skill in the art (see, e.g., “Complete genome sequence of an M1 strain of Streptococcus pyogenes.” Ferretti et al., J. J., McShan W. M., Ajdic D. J., Savic D. J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A. N., Kenton S., Lai H. S., Lin S. P., Qian Y., Jia H. G., Najar F. Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S. W., Roe B. A., McLaughlin R. E., Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663 (2001); “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E., Chylinski K., Sharma C. M., Gonzales K., Chao Y., Pirzada Z. A., Eckert M. R., Vogel J., Charpentier E., Nature 471:602-607 (2011); and “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816-821 (2012), the entire contents of each of which are incorporated herein by reference). Cas9 orthologs have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus. Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems” (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference. In some embodiments, a Cas9 nuclease has an inactive (e.g., an inactivated) DNA cleavage domain, that is, the Cas9 is a nickase.

A nuclease-inactivated Cas9 protein may interchangeably be referred to as a “dCas9” protein (for nuclease-“dead” Cas9). Methods for generating a Cas9 protein (or a fragment thereof) having an inactive DNA cleavage domain are known (See, e.g., Jinek et al., Science. 337:816-821 (2012); Qi et al., “Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression” (2013) Cell. 28; 152(5):1173-83, the entire contents of each of which are incorporated herein by reference). For example, the DNA cleavage domain of Cas9 is known to include two subdomains, the HNH nuclease subdomain and the RuvC1 subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, the mutations D10A and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al., Science. 337:816-821 (2012); Qi et al., Cell. 28; 152(5):1173-83 (2013)). In some embodiments, proteins comprising fragments of Cas9 are provided. For example, in some embodiments, a protein comprises one of two Cas9 domains: (1) the gRNA binding domain of Cas9; or (2) the DNA cleavage domain of Cas9. In some embodiments, proteins comprising Cas9 or fragments thereof are referred to as “Cas9 variants.” A Cas9 variant shares homology to Cas9, or a fragment thereof. For example a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to wild type Cas9. In some embodiments, the Cas9 variant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acid changes compared to wild type Cas9. In some embodiments, the Cas9 variant comprises a fragment of Cas9 (e.g., a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild type Cas9. In some embodiments, the fragment is is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of a corresponding wild type Cas9.

In some embodiments, the fragment is at least 100 amino acids in length. In some embodiments, the fragment is at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, or at least 1300 amino acids in length. In some embodiments, wild type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_017053.1, SEQ ID NO:1 (nucleotide); SEQ ID NO:2 (amino acid)).

(SEQ ID NO: 1)

ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAATAGCGTCGG

ATGGGCGGTGATCACTGATGATTATAAGGTTCCGTCTAAAAAGTTCAAGG

TTCTGGGAAATACAGACCGCCACAGTATCAAAAAAAATCTTATAGGGGCT

CTTTTATTTGGCAGTGGAGAGACAGCGGAAGCGACTCGTCTCAAACGGAC

AGCTCGTAGAAGGTATACACGTCGGAAGAATCGTATTTGTTATCTACAGG

AGATTTTTTCAAATGAGATGGCGAAAGTAGATGATAGTTTCTTTCATCGA

CTTGAAGAGTCTTTTTTGGTGGAAGAAGACAAGAAGCATGAACGTCATCC

TATTTTTGGAAATATAGTAGATGAAGTTGCTTATCATGAGAAATATCCAA

CTATCTATCATCTGCGAAAAAAATTGGCAGATTCTACTGATAAAGCGGAT

TTGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTCGTGGTCA

TTTTTTGATTGAGGGAGATTTAAATCCTGATAATAGTGATGTGGACAAAC

TATTTATCCAGTTGGTACAAATCTACAATCAATTATTTGAAGAAAACCCT

ATTAACGCAAGTAGAGTAGATGCTAAAGCGATTCTTTCTGCACGATTGAG

TAAATCAAGACGATTAGAAAATCTCATTGCTCAGCTCCCCGGTGAGAAGA

GAAATGGCTTGTTTGGGAATCTCATTGCTTTGTCATTGGGATTGACCCCT

AATTTTAAATCAAATTTTGATTTGGCAGAAGATGCTAAATTACAGCTTTC

AAAAGATACTTACGATGATGATTTAGATAATTTATTGGCGCAAATTGGAG

ATCAATATGCTGATTTGTTTTTGGCAGCTAAGAATTTATCAGATGCTATT

TTACTTTCAGATATCCTAAGAGTAAATAGTGAAATAACTAAGGCTCCCCT

ATCAGCTTCAATGATTAAGCGCTACGATGAACATCATCAAGACTTGACTC

TTTTAAAAGCTTTAGTTCGACAACAACTTCCAGAAAAGTATAAAGAAATC

TTTTTTGATCAATCAAAAAACGGATATGCAGGTTATATTGATGGGGGAGC

TAGCCAAGAAGAATTTTATAAATTTATCAAACCAATTTTAGAAAAAATGG

ATGGTACTGAGGAATTATTGGTGAAACTAAATCGTGAAGATTTGCTGCGC

AAGCAACGGACCTTTGACAACGGCTCTATTCCCCATCAAATTCACTTGGG

TGAGCTGCATGCTATTTTGAGAAGACAAGAAGACTTTTATCCATTTTTAA

AAGACAATCGTGAGAAGATTGAAAAAATCTTGACTTTTCGAATTCCTTAT

TATGTTGGTCCATTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCG

GAAGTCTGAAGAAACAATTACCCCATGGAATTTTGAAGAAGTTGTCGATA

AAGGTGCTTCAGCTCAATCATTTATTGAACGCATGACAAACTTTGATAAA

AATCTTCCAAATGAAAAAGTACTACCAAAACATAGTTTGCTTTATGAGTA

TTTTACGGTTTATAACGAATTGACAAAGGTCAAATATGTTACTGAGGGAA

TGCGAAAACCAGCATTTCTTTCAGGTGAACAGAAGAAAGCCATTGTTGAT

TTACTCTTCAAAACAAATCGAAAAGTAACCGTTAAGCAATTAAAAGAAGA

TTATTTCAAAAAAATAGAATGTTTTGATAGTGTTGAAATTTCAGGAGTTG

AAGATAGATTTAATGCTTCATTAGGCGCCTACCATGATTTGCTAAAAATT

ATTAAAGATAAAGATTTTTTGGATAATGAAGAAAATGAAGATATCTTAGA

GGATATTGTTTTAACATTGACCTTATTTGAAGATAGGGGGATGATTGAGG

AAAGACTTAAAACATATGCTCACCTCTTTGATGATAAGGTGATGAAACAG

CTTAAACGTCGCCGTTATACTGGTTGGGGACGTTTGTCTCGAAAATTGAT

TAATGGTATTAGGGATAAGCAATCTGGCAAAACAATATTAGATTTTTTGA

AATCAGATGGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATGAT

AGTTTGACATTTAAAGAAGATATTCAAAAAGCACAGGTGTCTGGACAAGG

CCATAGTTTACATGAACAGATTGCTAACTTAGCTGGCAGTCCTGCTATTA

AAAAAGGTATTTTACAGACTGTAAAAATTGTTGATGAACTGGTCAAAGTA

ATGGGGCATAAGCCAGAAAATATCGTTATTGAAATGGCACGTGAAAATCA

GACAACTCAAAAGGGCCAGAAAAATTCGCGAGAGCGTATGAAACGAATCG

AAGAAGGTATCAAAGAATTAGGAAGTCAGATTCTTAAAGAGCATCCTGTT

GAAAATACTCAATTGCAAAATGAAAAGCTCTATCTCTATTATCTACAAAA

TGGAAGAGACATGTATGTGGACCAAGAATTAGATATTAATCGTTTAAGTG

ATTATGATGTCGATCACATTGTTCCACAAAGTTTCATTAAAGACGATTCA

ATAGACAATAAGGTACTAACGCGTTCTGATAAAAATCGTGGTAAATCGGA

TAACGTTCCAAGTGAAGAAGTAGTCAAAAAGATGAAAAACTATTGGAGAC

AACTTCTAAACGCCAAGTTAATCACTCAACGTAAGTTTGATAATTTAACG

AAAGCTGAACGTGGAGGTTTGAGTGAACTTGATAAAGCTGGTTTTATCAA

ACGCCAATTGGTTGAAACTCGCCAAATCACTAAGCATGTGGCACAAATTT

TGGATAGTCGCATGAATACTAAATACGATGAAAATGATAAACTTATTCGA

GAGGTTAAAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTCCGAAA

AGATTTCCAATTCTATAAAGTACGTGAGATTAACAATTACCATCATGCCC

ATGATGCGTATCTAAATGCCGTCGTTGGAACTGCTTTGATTAAGAAATAT

CCAAAACTTGAATCGGAGTTTGTCTATGGTGATTATAAAGTTTATGATGT

TCGTAAAATGATTGCTAAGTCTGAGCAAGAAATAGGCAAAGCAACCGCAA

AATATTTCTTTTACTCTAATATCATGAACTTCTTCAAAACAGAAATTACA

CTTGCAAATGGAGAGATTCGCAAACGCCCTCTAATCGAAACTAATGGGGA

AACTGGAGAAATTGTCTGGGATAAAGGGCGAGATTTTGCCACAGTGCGCA

AAGTATTGTCCATGCCCCAAGTCAATATTGTCAAGAAAACAGAAGTACAG

ACAGGCGGATTCTCCAAGGAGTCAATTTTACCAAAAAGAAATTCGGACAA

GCTTATTGCTCGTAAAAAAGACTGGGATCCAAAAAAATATGGTGGTTTTG

ATAGTCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAAAAA

GGGAAATCGAAGAAGTTAAAATCCGTTAAAGAGTTACTAGGGATCACAAT

TATGGAAAGAAGTTCCTTTGAAAAAAATCCGATTGACTTTTTAGAAGCTA

AAGGATATAAGGAAGTTAAAAAAGACTTAATCATTAAACTACCTAAATAT

AGTCTTTTTGAGTTAGAAAACGGTCGTAAACGGATGCTGGCTAGTGCCGG

AGAATTACAAAAAGGAAATGAGCTGGCTCTGCCAAGCAAATATGTGAATT

TTTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAAGAT

AACGAACAAAAACAATTGTTTGTGGAGCAGCATAAGCATTATTTAGATGA

GATTATTGAGCAAATCAGTGAATTTTCTAAGCGTGTTATTTTAGCAGATG

CCAATTTAGATAAAGTTCTTAGTGCATATAACAAACATAGAGACAAACCA

ATACGTGAACAAGCAGAAAATATTATTCATTTATTTACGTTGACGAATCT

TGGAGCTCCCGCTGCTTTTAAATATTTTGATACAACAATTGATCGTAAAC

GATATACGTCTACAAAAGAAGTTTTAGATGCCACTCTTATCCATCAATCC

ATCACTGGTCTTTATGAAACACGCATTGATTTGAGTCAGCTAGGAGGTGA

CTGA

(SEQ ID NO: 2)

MDKKYSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGA

LLFGSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHR

LEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLADSTDKA

DLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQIYNQLFEE

NPINASRVDAKAILSARLSKSRRLENLIAQLPGEKRNGLFGNLIALSLG

LTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNL

SDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPE

KYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLN

REDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKI

LTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFI

ERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLS

GEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNAS

LGAYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDRGMIEERLKTY

AHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGF

ANRNFMQLIHDDSLTFKEDIQKAQVSGQGHSLHEQIANLAGSPAIKK

GILQTVKIVDELVK
VMGHKPENIVIEMARENQTTQKGQKNSRERMKRIE

EGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

DYDVDHIVPQSFIKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYW

RQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVA

QILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREI

NNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQ

EIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDK

GRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKD

WDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSF

EKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKG

NELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQ

ISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAP

AAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD

(single underline: HNH domain; double underline: RuvC domain)

In some embodiments, wild type Cas9 corresponds to, or comprises SEQ ID NO:3 (nucleotide) and/or SEQ ID NO: 4 (amino acid):

(SEQ ID NO: 3)

ATGGATAAAAAGTATTCTATTGGTTTAGACATCGGCACTAATTCCGTTGG

ATGGGCTGTCATAACCGATGAATACAAAGTACCTTCAAAGAAATTTAAGG

TGTTGGGGAACACAGACCGTCATTCGATTAAAAAGAATCTTATCGGTGCC

CTCCTATTCGATAGTGGCGAAACGGCAGAGGCGACTCGCCTGAAACGAAC

CGCTCGGAGAAGGTATACACGTCGCAAGAACCGAATATGTTACTTACAAG

AAATTTTTAGCAATGAGATGGCCAAAGTTGACGATTCTTTCTTTCACCGT

TTGGAAGAGTCCTTCCTTGTCGAAGAGGACAAGAAACATGAACGGCACCC

CATCTTTGGAAACATAGTAGATGAGGTGGCATATCATGAAAAGTACCCAA

CGATTTATCACCTCAGAAAAAAGCTAGTTGACTCAACTGATAAAGCGGAC

CTGAGGTTAATCTACTTGGCTCTTGCCCATATGATAAAGTTCCGTGGGCA

CTTTCTCATTGAGGGTGATCTAAATCCGGACAACTCGGATGTCGACAAAC

TGTTCATCCAGTTAGTACAAACCTATAATCAGTTGTTTGAAGAGAACCCT

ATAAATGCAAGTGGCGTGGATGCGAAGGCTATTCTTAGCGCCCGCCTCTC

TAAATCCCGACGGCTAGAAAACCTGATCGCACAATTACCCGGAGAGAAGA

AAAATGGGTTGTTCGGTAACCTTATAGCGCTCTCACTAGGCCTGACACCA

AATTTTAAGTCGAACTTCGACTTAGCTGAAGATGCCAAATTGCAGCTTAG

TAAGGACACGTACGATGACGATCTCGACAATCTACTGGCACAAATTGGAG

ATCAGTATGCGGACTTATTTTTGGCTGCCAAAAACCTTAGCGATGCAATC

CTCCTATCTGACATACTGAGAGTTAATACTGAGATTACCAAGGCGCCGTT

ATCCGCTTCAATGATCAAAAGGTACGATGAACATCACCAAGACTTGACAC

TTCTCAAGGCCCTAGTCCGTCAGCAACTGCCTGAGAAATATAAGGAAATA

TTCTTTGATCAGTCGAAAAACGGGTACGCAGGTTATATTGACGGCGGAGC

GAGTCAAGAGGAATTCTACAAGTTTATCAAACCCATATTAGAGAAGATGG

ATGGGACGGAAGAGTTGCTTGTAAAACTCAATCGCGAAGATCTACTGCGA

AAGCAGCGGACTTTCGACAACGGTAGCATTCCACATCAAATCCACTTAGG

CGAATTGCATGCTATACTTAGAAGGCAGGAGGATTTTTATCCGTTCCTCA

AAGACAATCGTGAAAAGATTGAGAAAATCCTAACCTTTCGCATACCTTAC

TATGTGGGACCCCTGGCCCGAGGGAACTCTCGGTTCGCATGGATGACAAG

AAAGTCCGAAGAAACGATTACTCCATGGAATTTTGAGGAAGTTGTCGATA

AAGGTGCGTCAGCTCAATCGTTCATCGAGAGGATGACCAACTTTGACAAG

AATTTACCGAACGAAAAAGTATTGCCTAAGCACAGTTTACTTTACGAGTA

TTTCACAGTGTACAATGAACTCACGAAAGTTAAGTATGTCACTGAGGGCA

TGCGTAAACCCGCCTTTCTAAGCGGAGAACAGAAGAAAGCAATAGTAGAT

CTGTTATTCAAGACCAACCGCAAAGTGACAGTTAAGCAATTGAAAGAGGA

CTACTTTAAGAAAATTGAATGCTTCGATTCTGTCGAGATCTCCGGGGTAG

AAGATCGATTTAATGCGTCACTTGGTACGTATCATGACCTCCTAAAGATA

ATTAAAGATAAGGACTTCCTGGATAACGAAGAGAATGAAGATATCTTAGA

AGATATAGTGTTGACTCTTACCCTCTTTGAAGATCGGGAAATGATTGAGG

AAAGACTAAAAACATACGCTCACCTGTTCGACGATAAGGTTATGAAACAG

TTAAAGAGGCGTCGCTATACGGGCTGGGGACGATTGTCGCGGAAACTTAT

CAACGGGATAAGAGACAAGCAAAGTGGTAAAACTATTCTCGATTTTCTAA

AGAGCGACGGCTTCGCCAATAGGAACTTTATGCAGCTGATCCATGATGAC

TCTTTAACCTTCAAAGAGGATATACAAAAGGCACAGGTTTCCGGACAAGG

GGACTCATTGCACGAACATATTGCGAATCTTGCTGGTTCGCCAGCCATCA

AAAAGGGCATACTCCAGACAGTCAAAGTAGTGGATGAGCTAGTTAAGGTC

ATGGGACGTCACAAACCGGAAAACATTGTAATCGAGATGGCACGCGAAAA

TCAAACGACTCAGAAGGGGCAAAAAAACAGTCGAGAGCGGATGAAGAGAA

TAGAAGAGGGTATTAAAGAACTGGGCAGCCAGATCTTAAAGGAGCATCCT

GTGGAAAATACCCAATTGCAGAACGAGAAACTTTACCTCTATTACCTACA

AAATGGAAGGGACATGTATGTTGATCAGGAACTGGACATAAACCGTTTAT

CTGATTACGACGTCGATCACATTGTACCCCAATCCTTTTTGAAGGACGAT

TCAATCGACAATAAAGTGCTTACACGCTCGGATAAGAACCGAGGGAAAAG

TGACAATGTTCCAAGCGAGGAAGTCGTAAAGAAAATGAAGAACTATTGGC

GGCAGCTCCTAAATGCGAAACTGATAACGCAAAGAAAGTTCGATAACTTA

ACTAAAGCTGAGAGGGGTGGCTTGTCTGAACTTGACAAGGCCGGATTTAT

TAAACGTCAGCTCGTGGAAACCCGCCAAATCACAAAGCATGTTGCACAGA

TACTAGATTCCCGAATGAATACGAAATACGACGAGAACGATAAGCTGATT

CGGGAAGTCAAAGTAATCACTTTAAAGTCAAAATTGGTGTCGGACTTCAG

AAAGGATTTTCAATTCTATAAAGTTAGGGAGATAAATAACTACCACCATG

CGCACGACGCTTATCTTAATGCCGTCGTAGGGACCGCACTCATTAAGAAA

TACCCGAAGCTAGAAAGTGAGTTTGTGTATGGTGATTACAAAGTTTATGA

CGTCCGTAAGATGATCGCGAAAAGCGAACAGGAGATAGGCAAGGCTACAG

CCAAATACTTCTTTTATTCTAACATTATGAATTTCTTTAAGACGGAAATC

ACTCTGGCAAACGGAGAGATACGCAAACGACCTTTAATTGAAACCAATGG

GGAGACAGGTGAAATCGTATGGGATAAGGGCCGGGACTTCGCGACGGTGA

GAAAAGTTTTGTCCATGCCCCAAGTCAACATAGTAAAGAAAACTGAGGTG

CAGACCGGAGGGTTTTCAAAGGAATCGATTCTTCCAAAAAGGAATAGTGA

TAAGCTCATCGCTCGTAAAAAGGACTGGGACCCGAAAAAGTACGGTGGCT

TCGATAGCCCTACAGTTGCCTATTCTGTCCTAGTAGTGGCAAAAGTTGAG

AAGGGAAAATCCAAGAAACTGAAGTCAGTCAAAGAATTATTGGGGATAAC

GATTATGGAGCGCTCGTCTTTTGAAAAGAACCCCATCGACTTCCTTGAGG

CGAAAGGTTACAAGGAAGTAAAAAAGGATCTCATAATTAAACTACCAAAG

TATAGTCTGTTTGAGTTAGAAAATGGCCGAAAACGGATGTTGGCTAGCGC

CGGAGAGCTTCAAAAGGGGAACGAACTCGCACTACCGTCTAAATACGTGA

ATTTCCTGTATTTAGCGTCCCATTACGAGAAGTTGAAAGGTTCACCTGAA

GATAACGAACAGAAGCAACTTTTTGTTGAGCAGCACAAACATTATCTCGA

CGAAATCATAGAGCAAATTTCGGAATTCAGTAAGAGAGTCATCCTAGCTG

ATGCCAATCTGGACAAAGTATTAAGCGCATACAACAAGCACAGGGATAAA

CCCATACGTGAGCAGGCGGAAAATATTATCCATTTGTTTACTCTTACCAA

CCTCGGCGCTCCAGCCGCATTCAAGTATTTTGACACAACGATAGATCGCA

AACGATACACTTCTACCAAGGAGGTGCTAGACGCGACACTGATTCACCAA

TCCATCACGGGATTATATGAAACTCGGATAGATTTGTCACAGCTTGGGGG

TGACGGATCCCCCAAGAAGAAGAGGAAAGTCTCGAGCGACTACAAAGACC

ATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGAC

AAGGCTGCAGGA

(SEQ ID NO: 4)

KKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL

LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHR

LEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKAD

LRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP

INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTP

NFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAI

LLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEI

FFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR

KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPY

YVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDK

NLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI

IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ

LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDD

SLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKV

MGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP

VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDD

SIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNL

TKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLI

REVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK

YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEI

TLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKT

EVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVA

KVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLII

KLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLK

GSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNK

HRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDAT

LIHQSITGLYETRIDLSQLGGD

(single underline: HNH domain; double underline: RuvC domain)

In some embodiments, wild type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_002737.2, SEQ ID NO: 8 (nucleotide); and Uniport Reference Sequence: Q99ZW2, SEQ ID NO: 10 (amino acid).

(SEQ ID NO: 8)

ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAATAGCGTCGGATGG

GCGGTGATCACTGATGAATATAAGGTTCCGTCTAAAAAGTTCAAGGTTCTGGGAA

ATACAGACCGCCACAGTATCAAAAAAAATCTTATAGGGGCTCTTTTATTTGACAG

TGGAGAGACAGCGGAAGCGACTCGTCTCAAACGGACAGCTCGTAGAAGGTATAC

ACGTCGGAAGAATCGTATTTGTTATCTACAGGAGATTTTTTCAAATGAGATGGCG

AAAGTAGATGATAGTTTCTTTCATCGACTTGAAGAGTCTTTTTTGGTGGAAGAAG

ACAAGAAGCATGAACGTCATCCTATTTTTGGAAATATAGTAGATGAAGTTGCTTA

TCATGAGAAATATCCAACTATCTATCATCTGCGAAAAAAATTGGTAGATTCTACT

GATAAAGCGGATTTGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTC

GTGGTCATTTTTTGATTGAGGGAGATTTAAATCCTGATAATAGTGATGTGGACAA

ACTATTTATCCAGTTGGTACAAACCTACAATCAATTATTTGAAGAAAACCCTATT

AACGCAAGTGGAGTAGATGCTAAAGCGATTCTTTCTGCACGATTGAGTAAATCA

AGACGATTAGAAAATCTCATTGCTCAGCTCCCCGGTGAGAAGAAAAATGGCTTA

TTTGGGAATCTCATTGCTTTGTCATTGGGTTTGACCCCTAATTTTAAATCAAATTT

TGATTTGGCAGAAGATGCTAAATTACAGCTTTCAAAAGATACTTACGATGATGAT

TTAGATAATTTATTGGCGCAAATTGGAGATCAATATGCTGATTTGTTTTTGGCAG

CTAAGAATTTATCAGATGCTATTTTACTTTCAGATATCCTAAGAGTAAATACTGA

AATAACTAAGGCTCCCCTATCAGCTTCAATGATTAAACGCTACGATGAACATCAT

CAAGACTTGACTCTTTTAAAAGCTTTAGTTCGACAACAACTTCCAGAAAAGTATA

AAGAAATCTTTTTTGATCAATCAAAAAACGGATATGCAGGTTATATTGATGGGGG

AGCTAGCCAAGAAGAATTTTATAAATTTATCAAACCAATTTTAGAAAAAATGGAT

GGTACTGAGGAATTATTGGTGAAACTAAATCGTGAAGATTTGCTGCGCAAGCAA

CGGACCTTTGACAACGGCTCTATTCCCCATCAAATTCACTTGGGTGAGCTGCATG

CTATTTTGAGAAGACAAGAAGACTTTTATCCATTTTTAAAAGACAATCGTGAGAA

GATTGAAAAAATCTTGACTTTTCGAATTCCTTATTATGTTGGTCCATTGGCGCGTG

GCAATAGTCGTTTTGCATGGATGACTCGGAAGTCTGAAGAAACAATTACCCCATG

GAATTTTGAAGAAGTTGTCGATAAAGGTGCTTCAGCTCAATCATTTATTGAACGC

ATGACAAACTTTGATAAAAATCTTCCAAATGAAAAAGTACTACCAAAACATAGT

TTGCTTTATGAGTATTTTACGGTTTATAACGAATTGACAAAGGTCAAATATGTTA

CTGAAGGAATGCGAAAACCAGCATTTCTTTCAGGTGAACAGAAGAAAGCCATTG

TTGATTTACTCTTCAAAACAAATCGAAAAGTAACCGTTAAGCAATTAAAAGAAG

ATTATTTCAAAAAAATAGAATGTTTTGATAGTGTTGAAATTTCAGGAGTTGAAGA

TAGATTTAATGCTTCATTAGGTACCTACCATGATTTGCTAAAAATTATTAAAGAT

AAAGATTTTTTGGATAATGAAGAAAATGAAGATATCTTAGAGGATATTGTTTTAA

CATTGACCTTATTTGAAGATAGGGAGATGATTGAGGAAAGACTTAAAACATATG

CTCACCTCTTTGATGATAAGGTGATGAAACAGCTTAAACGTCGCCGTTATACTGG

TTGGGGACGTTTGTCTCGAAAATTGATTAATGGTATTAGGGATAAGCAATCTGGC

AAAACAATATTAGATTTTTTGAAATCAGATGGTTTTGCCAATCGCAATTTTATGC

AGCTGATCCATGATGATAGTTTGACATTTAAAGAAGACATTCAAAAAGCACAAG

TGTCTGGACAAGGCGATAGTTTACATGAACATATTGCAAATTTAGCTGGTAGCCC

TGCTATTAAAAAAGGTATTTTACAGACTGTAAAAGTTGTTGATGAATTGGTCAAA

GTAATGGGGCGGCATAAGCCAGAAAATATCGTTATTGAAATGGCACGTGAAAAT

CAGACAACTCAAAAGGGCCAGAAAAATTCGCGAGAGCGTATGAAACGAATCGA

AGAAGGTATCAAAGAATTAGGAAGTCAGATTCTTAAAGAGCATCCTGTTGAAAA

TACTCAATTGCAAAATGAAAAGCTCTATCTCTATTATCTCCAAAATGGAAGAGAC

ATGTATGTGGACCAAGAATTAGATATTAATCGTTTAAGTGATTATGATGTCGATC

ACATTGTTCCACAAAGTTTCCTTAAAGACGATTCAATAGACAATAAGGTCTTAAC

GCGTTCTGATAAAAATCGTGGTAAATCGGATAACGTTCCAAGTGAAGAAGTAGT

CAAAAAGATGAAAAACTATTGGAGACAACTTCTAAACGCCAAGTTAATCACTCA

ACGTAAGTTTGATAATTTAACGAAAGCTGAACGTGGAGGTTTGAGTGAACTTGAT

AAAGCTGGTTTTATCAAACGCCAATTGGTTGAAACTCGCCAAATCACTAAGCATG

TGGCACAAATTTTGGATAGTCGCATGAATACTAAATACGATGAAAATGATAAAC

TTATTCGAGAGGTTAAAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTCCG

AAAAGATTTCCAATTCTATAAAGTACGTGAGATTAACAATTACCATCATGCCCAT

GATGCGTATCTAAATGCCGTCGTTGGAACTGCTTTGATTAAGAAATATCCAAAAC

TTGAATCGGAGTTTGTCTATGGTGATTATAAAGTTTATGATGTTCGTAAAATGATT

GCTAAGTCTGAGCAAGAAATAGGCAAAGCAACCGCAAAATATTTCTTTTACTCTA

ATATCATGAACTTCTTCAAAACAGAAATTACACTTGCAAATGGAGAGATTCGCAA

ACGCCCTCTAATCGAAACTAATGGGGAAACTGGAGAAATTGTCTGGGATAAAGG

GCGAGATTTTGCCACAGTGCGCAAAGTATTGTCCATGCCCCAAGTCAATATTGTC

AAGAAAACAGAAGTACAGACAGGCGGATTCTCCAAGGAGTCAATTTTACCAAAA

AGAAATTCGGACAAGCTTATTGCTCGTAAAAAAGACTGGGATCCAAAAAAATAT

GGTGGTTTTGATAGTCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGG

AAAAAGGGAAATCGAAGAAGTTAAAATCCGTTAAAGAGTTACTAGGGATCACAA

TTATGGAAAGAAGTTCCTTTGAAAAAAATCCGATTGACTTTTTAGAAGCTAAAGG

ATATAAGGAAGTTAAAAAAGACTTAATCATTAAACTACCTAAATATAGTCTTTTT

GAGTTAGAAAACGGTCGTAAACGGATGCTGGCTAGTGCCGGAGAATTACAAAAA

GGAAATGAGCTGGCTCTGCCAAGCAAATATGTGAATTTTTTATATTTAGCTAGTC

ATTATGAAAAGTTGAAGGGTAGTCCAGAAGATAACGAACAAAAACAATTGTTTG

TGGAGCAGCATAAGCATTATTTAGATGAGATTATTGAGCAAATCAGTGAATTTTC

TAAGCGTGTTATTTTAGCAGATGCCAATTTAGATAAAGTTCTTAGTGCATATAAC

AAACATAGAGACAAACCAATACGTGAACAAGCAGAAAATATTATTCATTTATTT

ACGTTGACGAATCTTGGAGCTCCCGCTGCTTTTAAATATTTTGATACAACAATTG

ATCGTAAACGATATACGTCTACAAAAGAAGTTTTAGATGCCACTCTTATCCATCA

ATCCATCACTGGTCTTTATGAAACACGCATTGATTTGAGTCAGCTAGGAGGTGAC

TGA

(SEQ ID NO: 10)

MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGE

TAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHE

RHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEG

DLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLP

GEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYA

DLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPE

KYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQR

TFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFA

WMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV

YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD

SVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERL

KTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

FMQLIHDDLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVK

VMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL

QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDK

NRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIK

RQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKV

REINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK

ATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSM

PQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVV

AKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFE

LENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQ

HKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA

PAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD

(single underline: HNH domain; double underline: RuvC domain)

In some embodiments, Cas9 refers to Cas9 from: Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquisI (NCBI Ref: NC_018721.1); Streptococcus thermophilus (NCBI Ref: YP_820832.1), Listeria innocua (NCBI Ref: NP_472073.1), Campylobacter jejuni (NCBI Ref: YP_002344900.1) or Neisseria meningitidis (NCBI Ref: YP_002342100.1) or to a Cas9 from any of the organisms listed in Example 5.

In some embodiments, dCas9 corresponds to, or comprises in part or in whole, a Cas9 amino acid sequence having one or more mutations that inactivate the Cas9 nuclease activity. For example, in some embodiments, a dCas9 domain comprises D10A and/or H840A mutation.

dCas9 (D10A and H840A):

(SEQ ID NO: 9)

MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDS

GET
AEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKK

HERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLI

EGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQ

LPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQ

YADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL

PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK

QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSR

FAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYF

TVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIEC

FDSVETSGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEE

RLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFAN

embedded image

NTOLONEKLYLYYLONGRDMYVDOELDINRLSDYDVDAIVPOSFLKDDSIDNKV

embedded image

TVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLI

IKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDN

EQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPlREQAENIIH

LFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD

(single underline: HNH domain; double underline: RuvC domain).

In some embodiments, the Cas9 domain comprises a D10A mutation, while the residue at position 840 remains a histidine in the amino acid sequence provided in SEQ ID NO: 10, or at corresponding positions in any of the amino acid sequences provided in SEQ ID NOs: 11-260. Without wishing to be bound by any particular theory, the presence of the catalytic residue H840 restores the activity of the Cas9 to cleave the non-edited (e.g., non-deaminated) strand containing a G opposite the targeted C. Restoration of H840 (e.g., from A840) does not result in the cleavage of the target strand containing the C. Such Cas9 variants are able to generate a single-strand DNA break (nick) at a specific location based on the gRNA-defined target sequence, leading to repair of the non-edited strand, ultimately resulting in a G to A change on the non-edited strand. A schematic representation of this process is shown in FIG. 108. Briefly, the C of a C-G basepair can be deaminated to a U by a deaminase, e.g., an APOBEC deamonase. Nicking the non-edited strand, having the G, facilitates removal of the G via mismatch repair mechanisms. UGI inhibits UDG, which prevents removal of the U.

In other embodiments, dCas9 variants having mutations other than D10A and H840A are provided, which, e.g., result in nuclease inactivated Cas9 (dCas9). Such mutations, by way of example, include other amino acid substitutions at D10 and H820, or other substitutions within the nuclease domains of Cas9 (e.g., substitutions in the HNH nuclease subdomain and/or the RuvC1 subdomain). In some embodiments, variants or homologues of dCas9 (e.g., variants of SEQ ID NO: 10) are provided which are at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to SEQ ID NO: 10. In some embodiments, variants of dCas9 (e.g., variants of SEQ ID NO: 10) are provided having amino acid sequences which are shorter, or longer than SEQ ID NO: 10, by about 5 amino acids, by about 10 amino acids, by about 15 amino acids, by about 20 amino acids, by about 25 amino acids, by about 30 amino acids, by about 40 amino acids, by about 50 amino acids, by about 75 amino acids, by about 100 amino acids or more.

In some embodiments, Cas9 fusion proteins as provided herein comprise the full-length amino acid sequence of a Cas9 protein, e.g., one of the Cas9 sequences provided herein. In other embodiments, however, fusion proteins as provided herein do not comprise a full-length Cas9 sequence, but only a fragment thereof. For example, in some embodiments, a Cas9 fusion protein provided herein comprises a Cas9 fragment, wherein the fragment binds crRNA and tracrRNA or sgRNA, but does not comprise a functional nuclease domain, e.g., in that it comprises only a truncated version of a nuclease domain or no nuclease domain at all. Exemplary amino acid sequences of suitable Cas9 domains and Cas9 fragments are provided herein, and additional suitable sequences of Cas9 domains and fragments will be apparent to those of skill in the art.

In some embodiments, Cas9 refers to Cas9 from: Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquisI (NCBI Ref: NC_018721.1); Streptococcus thermophilus (NCBI Ref: YP_820832.1); Listeria innocua (NCBI Ref: NP_472073.1); Campylobacter jejuni (NCBI Ref: YP_002344900.1); or Neisseria meningitidis (NCBI Ref: YP_002342100.1).

The term “deaminase” or “deaminase domain,” as used herein, refers to a protein or enzyme that catalyzes a deamination reaction. In some embodiments, the deaminase or deaminase domain is a cytidine deaminase, catalyzing the hydrolytic deamination of cytidine or deoxycytidine to uridine or deoxyuridine, respectively. In some embodiments, the deaminase or deaminase domain is a cytidine deaminase domain, catalyzing the hydrolytic deamination of cytosine to uracil. In some embodiments, the deaminase or deaminase domain is a naturally-occurring deaminase from an organism, such as a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase or deaminase domain is a variant of a naturally-occurring deaminase from an organism, that does not occur in nature. For example, in some embodiments, the deaminase or deaminase domain is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a naturally-occuring deaminase from an organism.

The term “effective amount,” as used herein, refers to an amount of a biologically active agent that is sufficient to elicit a desired biological response. For example, in some embodiments, an effective amount of a nuclease may refer to the amount of the nuclease that is sufficient to induce cleavage of a target site specifically bound and cleaved by the nuclease. In some embodiments, an effective amount of a fusion protein provided herein, e.g., of a fusion protein comprising a nuclease-inactive Cas9 domain and a nucleic acid editing domain (e.g., a deaminase domain) may refer to the amount of the fusion protein that is sufficient to induce editing of a target site specifically bound and edited by the fusion protein. As will be appreciated by the skilled artisan, the effective amount of an agent, e.g., a fusion protein, a nuclease, a deaminase, a recombinase, a hybrid protein, a protein dimer, a complex of a protein (or protein dimer) and a polynucleotide, or a polynucleotide, may vary depending on various factors as, for example, on the desired biological response, e.g., on the specific allele, genome, or target site to be edited, on the cell or tissue being targeted, and on the agent being used.

The term “linker,” as used herein, refers to a chemical group or a molecule linking two molecules or moieties, e.g., two domains of a fusion protein, such as, for example, a nuclease-inactive Cas9 domain and a nucleic acid editing domain (e.g., a deaminase domain). In some embodiments, a linker joins a gRNA binding domain of an RNA-programmable nuclease, including a Cas9 nuclease domain, and the catalytic domain of anucleic-acid editing protein. In some embodiments, a linker joins a dCas9 and a nucleic-acid editing protein. Typically, the linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond, thus connecting the two. In some embodiments, the linker is an amino acid or a plurality of amino acids (e.g., a peptide or protein). In some embodiments, the linker is an organic molecule, group, polymer, or chemical moiety. In some embodiments, the linker is 5-100 amino acids in length, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length. Longer or shorter linkers are also contemplated.

The term “mutation,” as used herein, refers to a substitution of a residue within a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or a deletion or insertion of one or more residues within a sequence. Mutations are typically described herein by identifying the original residue followed by the position of the residue within the sequence and by the identity of the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art, and are provided by, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual (4^thed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)).

The terms “nucleic acid” and “nucleic acid molecule,” as used herein, refer to a compound comprising a nucleobase and an acidic moiety, e.g., a nucleoside, a nucleotide, or a polymer of nucleotides. Typically, polymeric nucleic acids, e.g., nucleic acid molecules comprising three or more nucleotides are linear molecules, in which adjacent nucleotides are linked to each other via a phosphodiester linkage. In some embodiments, “nucleic acid” refers to individual nucleic acid residues (e.g. nucleotides and/or nucleosides). In some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used herein, the terms “oligonucleotide” and “polynucleotide” can be used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least three nucleotides). In some embodiments, “nucleic acid” encompasses RNA as well as single and/or double-stranded DNA. Nucleic acids may be naturally occurring, for example, in the context of a genome, a transcript, an mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule. On the other hand, a nucleic acid molecule may be a non-naturally occurring molecule, e.g., a recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragment thereof, or a synthetic DNA, RNA, DNA/RNA hybrid, or including non-naturally occurring nucleotides or nucleosides. Furthermore, the terms “nucleic acid,” “DNA,” “RNA,” and/or similar terms include nucleic acid analogs, e.g., analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications. A nucleic acid sequence is presented in the 5′ to 3′ direction unless otherwise indicated. In some embodiments, a nucleic acid is or comprises natural nucleosides (e.g. adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g., 2′-fluororibose, ribose, 2′-deoxyribose, arabinose, and hexose); and/or modified phosphate groups (e.g., phosphorothioates and 5′-N-phosphoramidite linkages).

The term “nucleic acid editing domain,” as used herein refers to a protein or enzyme capable of making one or more modifications (e.g., deamination of a cytidine residue) to a nucleic acid (e.g., DNA or RNA). Exemplary nucleic acid editing domains include, but are not limited to a deaminase, a nuclease, a nickase, a recombinase, a methyltransferase, a methylase, an acetylase, an acetyltransferase, a transcriptional activator, or a transcriptional repressor domain. In some embodiments the nucleic acid editing domain is a deaminase (e.g., a cytidine deaminase, such as an APOBEC or an AID deaminase).

The term “proliferative disease,” as used herein, refers to any disease in which cell or tissue homeostasis is disturbed in that a cell or cell population exhibits an abnormally elevated proliferation rate. Proliferative diseases include hyperproliferative diseases, such as pre-neoplastic hyperplastic conditions and neoplastic diseases. Neoplastic diseases are characterized by an abnormal proliferation of cells and include both benign and malignant neoplasias. Malignant neoplasia is also referred to as cancer.

The terms “protein,” “peptide,” and “polypeptide” are used interchangeably herein, and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. The terms refer to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids long. A protein, peptide, or polypeptide may refer to an individual protein or a collection of proteins. One or more of the amino acids in a protein, peptide, or polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. A protein, peptide, or polypeptide may also be a single molecule or may be a multi-molecular complex. A protein, peptide, or polypeptide may be just a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide may be naturally occurring, recombinant, or synthetic, or any combination thereof. The term “fusion protein” as used herein refers to a hybrid polypeptide which comprises protein domains from at least two different proteins. One protein may be located at the amino-terminal (N-terminal) portion of the fusion protein or at the carboxy-terminal (C-terminal) protein thus forming an “amino-terminal fusion protein” or a “carboxy-terminal fusion protein,” respectively. A protein may comprise different domains, for example, a nucleic acid binding domain (e.g., the gRNA binding domain of Cas9 that directs the binding of the protein to a target site) and a nucleic acid cleavage domain or a catalytic domain of a nucleic-acid editing protein. In some embodiments, a protein comprises a proteinaceous part, e.g., an amino acid sequence constituting a nucleic acid binding domain, and an organic compound, e.g., a compound that can act as a nucleic acid cleavage agent. In some embodiments, a protein is in a complex with, or is in association with, a nucleic acid, e.g., RNA. Any of the proteins provided herein may be produced by any method known in the art. For example, the proteins provided herein may be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker. Methods for recombinant protein expression and purification are well known, and include those described by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4^thed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)), the entire contents of which are incorporated herein by reference.

The term “RNA-programmable nuclease,” and “RNA-guided nuclease” are used interchangeably herein and refer to a nuclease that forms a complex with (e.g., binds or associates with) one or more RNA that is not a target for cleavage. In some embodiments, an RNA-programmable nuclease, when in a complex with an RNA, may be referred to as a nuclease:RNA complex. Typically, the bound RNA(s) is referred to as a guide RNA (gRNA). gRNAs can exist as a complex of two or more RNAs, or as a single RNA molecule. gRNAs that exist as a single RNA molecule may be referred to as single-guide RNAs (sgRNAs), though “gRNA” is used interchangeably to refer to guide RNAs that exist as either single molecules or as a complex of two or more molecules. Typically, gRNAs that exist as single RNA species comprise two domains: (1) a domain that shares homology to a target nucleic acid (e.g., and directs binding of a Cas9 complex to the target); and (2) a domain that binds a Cas9 protein. In some embodiments, domain (2) corresponds to a sequence known as a tracrRNA, and comprises a stem-loop structure. For example, in some embodiments, domain (2) is identical or homologous to a tracrRNA as provided in Jinek et al., Science 337:816-821 (2012), the entire contents of which is incorporated herein by reference. Other examples of gRNAs (e.g., those including domain 2) can be found in U.S. Provisional Patent Application, U.S. Ser. No. 61/874,682, filed Sep. 6, 2013, entitled “Switchable Cas9 Nucleases And Uses Thereof,” and U.S. Provisional Patent Application, U.S. Ser. No. 61/874,746, filed Sep. 6, 2013, entitled “Delivery System For Functional Nucleases,” the entire contents of each are hereby incorporated by reference in their entirety. In some embodiments, a gRNA comprises two or more of domains (1) and (2), and may be referred to as an “extended gRNA.” For example, an extended gRNA will, e.g., bind two or more Cas9 proteins and bind a target nucleic acid at two or more distinct regions, as described herein. The gRNA comprises a nucleotide sequence that complements a target site, which mediates binding of the nuclease/RNA complex to said target site, providing the sequence specificity of the nuclease:RNA complex. In some embodiments, the RNA-programmable nuclease is the (CRISPR-associated system) Cas9 endonuclease, for example Cas9 (Csn1) from Streptococcus pyogenes (see, e.g., “Complete genome sequence of an M1 strain of Streptococcus pyogenes.” Ferretti J. J., McShan W. M., Ajdic D. J., Savic D. J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A. N., Kenton S., Lai H. S., Lin S. P., Qian Y., Jia H. G., Najar F. Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S. W., Roe B. A., McLaughlin R. E., Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663 (2001); “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E., Chylinski K., Sharma C. M., Gonzales K., Chao Y., Pirzada Z. A., Eckert M. R., Vogel J., Charpentier E., Nature 471:602-607 (2011); and “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816-821 (2012), the entire contents of each of which are incorporated herein by reference.

Because RNA-programmable nucleases (e.g., Cas9) use RNA:DNA hybridization to target DNA cleavage sites, these proteins are able to be targeted, in principle, to any sequence specified by the guide RNA. Methods of using RNA-programmable nucleases, such as Cas9, for site-specific cleavage (e.g., to modify a genome) are known in the art (see e.g., Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013); Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013); Hwang, W. Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature biotechnology 31, 227-229 (2013); Jinek, M. et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013); Dicarlo, J. E. et al. Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic acids research (2013); Jiang, W. et al. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature biotechnology 31, 233-239 (2013); the entire contents of each of which are incorporated herein by reference).

The term “subject,” as used herein, refers to an individual organism, for example, an individual mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human mammal. In some embodiments, the subject is a non-human primate. In some embodiments, the subject is a rodent. In some embodiments, the subject is a sheep, a goat, a cattle, a cat, or a dog. In some embodiments, the subject is a vertebrate, an amphibian, a reptile, a fish, an insect, a fly, or a nematode. In some embodiments, the subject is a research animal. In some embodiments, the subject is genetically engineered, e.g., a genetically engineered non-human subject. The subject may be of either sex and at any stage of development.

The term “target site” refers to a sequence within a nucleic acid molecule that is deaminated by a deaminase or a fusion protein comprising a deaminase, (e.g., a dCas9-deaminase fusion protein provided herein).

The terms “treatment,” “treat,” and “treating,” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. As used herein, the terms “treatment,” “treat,” and “treating” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed and/or after a disease has been diagnosed. In other embodiments, treatment may be administered in the absence of symptoms, e.g., to prevent or delay onset of a symptom or inhibit onset or progression of a disease. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.

The term “recombinant” as used herein in the context of proteins or nucleic acids refers to proteins or nucleic acids that do not occur in nature, but are the product of human engineering. For example, in some embodiments, a recombinant protein or nucleic acid molecule comprises an amino acid or nucleotide sequence that comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations as compared to any naturally occurring sequence.

The term “nucleobase editors (NBEs)” or “base editors (BEs),” as used herein, refers to the Cas9 fusion proteins described herein. In some embodiments, the fusion protein comprises a nuclease-inactive Cas9 (dCas9) fused to a deaminase. In some embodiments, the fusion protein comprises a Cas9 nickase fused to a deaminase. In some embodiments, the fusion protein comprises a nuclease-inactive Cas9 fused to a deaminase and further fused to a UGI domain. In some embodiments, the fusion protein comprises a Cas9 nickase fused to a deaminase and further fused to a UGI domain. In some embodiments, the dCas9 of the fusion protein comprises a D10A and a H840A mutation of SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260, which inactivates nuclease activity of the Cas9 protein. In some embodiments, the fusion protein comprises a D10A mutation and comprises a histidine at residue 840 of SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260, which renders Cas9 capable of cleaving only one strand of a nucleic acid duplex. An example of a Cas9 nickase is shown below in SEQ ID NO: 674. The terms “nucleobase editors (NBEs)” and “base editors (BEs)” may be used interchangeably.

The term “uracil glycosylase inhibitor” or “UGI,” as used herein, refers to a protein that is capable of inhibiting a uracil-DNA glycosylase base-excision repair enzyme.

The term “Cas9 nickase,” as used herein, refers to a Cas9 protein that is capable of cleaving only one strand of a duplexed nucleic acid molecule (e.g., a duplexed DNA molecule). In some embodiments, a Cas9 nickase comprises a D10A mutation and has a histidine at position H840 of SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260. For example, a Cas9 nickase may comprise the amino acid sequence as set forth in SEQ ID NO: 674. Such a Cas9 nickase has an active HNH nuclease domain and is able to cleave the non-targeted strand of DNA, i.e., the strand bound by the gRNA. Further, such a Cas9 nickase has an inactive RuvC nuclease domain and is not able to cleave the targeted strand of the DNA, i.e., the strand where base editing is desired.

Exemplary Cas9 nickase (Cloning vector pPlatTET-gRNA2; Accession No. BAV54124).

(SEQ ID NO: 674)

MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIG

ALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFF

HRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTD

KADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF

EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALS

LGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAK

NLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL

PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVK

LNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIE

KILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQS

FIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAF

LSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFN

ASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK

TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSD

GFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKK

GILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRI

EEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRL

SDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNY

WRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHV

AQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINN

YHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEI

GKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR

DFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWD

PKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEK

NPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNE

LALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQIS

EFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAA

FKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

Some aspects of this disclosure provide fusion proteins that comprise a domain capable of binding to a nucleotide sequence (e.g., a Cas9, or a Cpf1 protein) and an enzyme domain, for example, a DNA-editing domain, such as, e.g., a deaminase domain. The deamination of a nucleobase by a deaminase can lead to a point mutation at the respective residue, which is referred to herein as nucleic acid editing. Fusion proteins comprising a Cas9 variant or domain and a DNA editing domain can thus be used for the targeted editing of nucleic acid sequences. Such fusion proteins are useful for targeted editing of DNA in vitro, e.g., for the generation of mutant cells or animals; for the introduction of targeted mutations, e.g., for the correction of genetic defects in cells ex vivo, e.g., in cells obtained from a subject that are subsequently re-introduced into the same or another subject; and for the introduction of targeted mutations, e.g., the correction of genetic defects or the introduction of deactivating mutations in disease-associated genes in a subject. Typically, the Cas9 domain of the fusion proteins described herein does not have any nuclease activity but instead is a Cas9 fragment or a dCas9 protein or domain. Methods for the use of Cas9 fusion proteins as described herein are also provided.

Cas9 Domains of Nucleobase Editors

Non-limiting, exemplary Cas9 domains are provided herein. The Cas9 domain may be a nuclease active Cas9 domain, a nuclease inactive Cas9 domain, or a Cas9 nickase. In some embodiments, the Cas9 domain is a nuclease active domain. For example, the Cas9 domain may be a Cas9 domain that cuts both strands of a duplexed nucleic acid (e.g., both strands of a duplexed DNA molecule). In some embodiments, the Cas9 domain comprises any one of the amino acid sequences as set forth in SEQ ID NOs: 10-263. In some embodiments the Cas9 domain comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 10-263. In some embodiments, the Cas9 domain comprises an amino acid sequence that has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more or more mutations compared to any one of the amino acid sequences set forth in SEQ ID NOs: 10-263. In some embodiments, the Cas9 domain comprises an amino acid sequence that has at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical contiguous amino acid residues as compared to any one of the amino acid sequences set forth in SEQ ID NOs: 10-263.

In some embodiments, the Cas9 domain is a nuclease-inactive Cas9 domain (dCas9). For example, the dCas9 domain may bind to a duplexed nucleic acid molecule (e.g., via a gRNA molecule) without cleaving either strand of the duplexed nucleic acid molecule. In some embodiments, the nuclease-inactive dCas9 domain comprises a D10X mutation and a H840X mutation of the amino acid sequence set forth in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid change. In some embodiments, the nuclease-inactive dCas9 domain comprises a D10A mutation and a H840A mutation of the amino acid sequence set forth in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. As one example, a nuclease-inactive Cas9 domain comprises the amino acid sequence set forth in SEQ ID NO: 263 (Cloning vector pPlatTET-gRNA2, Accession No. BAV54124).

(SEQ ID NO:

MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGA

LLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHR

LEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKAD

LRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP

INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTP

NFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAI

LLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEI

FFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR

KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPY

YVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDK

NLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI

IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ

LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDD

SLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKV

MGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP

VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDD

SIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNL

TKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLI

REVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK

YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEI

TLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV

QTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVE

KGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK

YSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPE

DNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDK

PIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQ

SITGLYETRIDLSQLGGD

263; see, e.g., Qi et al., Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013; 152(5):1173-83, the entire contents of which are incorporated herein by reference).

Additional suitable nuclease-inactive dCas9 domains will be apparent to those of skill in the art based on this disclosure and knowledge in the field, and are within the scope of this disclosure. Such additional exemplary suitable nuclease-inactive Cas9 domains include, but are not limited to, D10A/H840A, D10A/D839A/H840A, and D10A/D839A/H840A/N863A mutant domains (See, e.g., Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology. 2013; 31(9): 833-838, the entire contents of which are incorporated herein by reference). In some embodiments the dCas9 domain comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the dCas9 domains provided herein. In some embodiments, the Cas9 domain comprises an amino acid sequences that has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more or more mutations compared to any one of the amino acid sequences set forth in SEQ ID NOs: 10-263. In some embodiments, the Cas9 domain comprises an amino acid sequence that has at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical contiguous amino acid residues as compared to any one of the amino acid sequences set forth in SEQ ID NOs: 10-263.

In some embodiments, the Cas9 domain is a Cas9 nickase. The Cas9 nickase may be a Cas9 protein that is capable of cleaving only one strand of a duplexed nucleic acid molecule (e.g., a duplexed DNA molecule). In some embodiments the Cas9 nickase cleaves the target strand of a duplexed nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is base paired to (complementary to) a gRNA (e.g., an sgRNA) that is bound to the Cas9. In some embodiments, a Cas9 nickase comprises a D10A mutation and has a histidine at position 840 of SEQ ID NO: 10, or a mutation in any of SEQ ID NOs: 11-260. For example, a Cas9 nickase may comprise the amino acid sequence as set forth in SEQ ID NO: 674. In some embodiments the Cas9 nickase cleaves the non-target, non-base-edited strand of a duplexed nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is not base paired to a gRNA (e.g., an sgRNA) that is bound to the Cas9. In some embodiments, a Cas9 nickase comprises an H840A mutation and has an aspartic acid residue at position 10 of SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260. In some embodiments the Cas9 nickase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the Cas9 nickases provided herein. Additional suitable Cas9 nickases will be apparent to those of skill in the art based on this disclosure and knowledge in the field, and are within the scope of this disclosure.

Cas9 Domains with Reduced PAM Exclusivity

Some aspects of the disclosure provide Cas9 domains that have different PAM specificities. Typically, Cas9 proteins, such as Cas9 from S. pyogenes (spCas9), require a canonical NGG PAM sequence to bind a particular nucleic acid region. This may limit the ability to edit desired bases within a genome. In some embodiments, the base editing fusion proteins provided herein may need to be placed at a precise location, for example where a target base is placed within a 4 base region (e.g., a “deamination window”), which is approximately 15 bases upstream of the PAM. See Komor, A. C., et al., “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage” Nature 533, 420-424 (2016), the entire contents of which are hereby incorporated by reference. Accordingly, in some embodiments, any of the fusion proteins provided herein may contain a Cas9 domain that is capable of binding a nucleotide sequence that does not contain a canonical (e.g., NGG) PAM sequence. Cas9 domains that bind to non-canonical PAM sequences have been described in the art and would be apparent to the skilled artisan. For example, Cas9 domains that bind non-canonical PAM sequences have been described in Kleinstiver, B. P., et al., “Engineered CRISPR-Cas9 nucleases with altered PAM specificities” Nature 523, 481-485 (2015); and Kleinstiver, B. P., et al., “Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition” Nature Biotechnology 33, 1293-1298 (2015); the entire contents of each are hereby incorporated by reference.

In some embodiments, the Cas9 domain is a Cas9 domain from Staphylococcus aureus (SaCas9). In some embodiments, the SaCas9 domain is a nuclease active SaCas9, a nuclease inactive SaCas9 (SaCas9d), or a SaCas9 nickase (SaCas9n). In some embodiments, the SaCas9 comprises the amino acid sequence SEQ ID NO: 4273. In some embodiments, the SaCas9 comprises a N579X mutation of SEQ ID NO: 4273, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for N. In some embodiments, the SaCas9 comprises a N579A mutation of SEQ ID NO: 4273, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SaCas9 domain, the SaCas9d domain, or the SaCas9n domain can bind to a nucleic acid sequence having a non-canonical PAM. In some embodiments, the SaCas9 domain, the SaCas9d domain, or the SaCas9n domain can bind to a nucleic acid sequence having a NNGRRT PAM sequence. In some embodiments, the SaCas9 domain comprises one or more of a E781X, a N967X, and a R1014X mutation of SEQ ID NO: 4273, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid. In some embodiments, the SaCas9 domain comprises one or more of a E781K, a N967K, and a R1014H mutation of SEQ ID NO: 4273, or one or more corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SaCas9 domain comprises a E781K, a N967K, or a R1014H mutation of SEQ ID NO: 4273, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 11-260.

In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 4273-4275. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises the amino acid sequence of any one of SEQ ID NOs: 4273-4275. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein consists of the amino acid sequence of any one of SEQ ID NOs: 4273-4275.

Exemplary SaCas9 sequence

(SEQ ID NO: 4273)

KRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKR

GARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLS

EEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVA

ELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTY

IDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAY

NADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAK

EILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQI

AKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAIN

LILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVK

RSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQT

NERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPF

NYEVDHIIPRSVSFDNSFNNKVLVKQEENSKKGNRTPFQYLSSSDSKISY

ETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRY

ATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHH

AEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYK

EIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLI

VNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEK

NPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSR

NKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAK

KLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITY

REYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIK

KG

Residue N579 of SEQ ID NO: 4273, which is underlined and in bold, may be mutated (e.g., to a A579) to yield a SaCas9 nickase.

Exemplary SaCas9n sequence

(SEQ ID NO: 4274)

KRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKR

GARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLS

EEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVA

ELQLERLKKDGEVRGSINTRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDT

YIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYA

YNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIA

KEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQ

IAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAI

NLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVV

KRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQ

TNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNP

FNYEVDHIIPRSVSFDNSFNNKVLVKQEEASKKGNRTPFQYLSSSDSKIS

YETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTR

YATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKH

HAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEY

KEIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTL

IVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDE

KNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNS

RNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEA

KKLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDIT

YREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQII

KKG.

Residue A579 of SEQ ID NO: xx, which can be mutated from N579 of SEQ ID NO: 4274 to yield a SaCas9 nickase, is underlined and in bold.

Exemplary SaKKH Cas9

(SEQ ID NO: 4275)

KRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKR

GARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLS

EEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVA

ELQLERLKKDGEVRGSINTRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDT

YIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYA

YNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIA

KEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQ

IAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAI

NLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVV

KRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQ

TNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNP

FNYEVDHIIPRSVSFDNSFNNKVLVKQEEASKKGNRTPFQYLSSSDSKIS

YETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTR

YATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKH

HAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEY

KEIFITPHQIKHIKDFKDYKYSHRVDKKPNRKLINDTLYSTRKDDKGNTL

IVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDE

KNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNS

RNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEA

KKLKKISNQAEFIASFYKNDLIKINGELYRVIGVNNDLLNRIEVNMIDIT

YREYLENMNDKRPPHIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQII

KKG.

Residue A579 of SEQ ID NO: 4275, which can be mutated from N579 of SEQ ID NO: 4275 to yield a SaCas9 nickase, is underlined and in bold. Residues K781, K967, and H1014 of SEQ ID NO: 4275, which can be mutated from E781, N967, and R1014 of SEQ ID NO: 4275 to yield a SaKKH Cas9 are underlined and in italics.

In some embodiments, the Cas9 domain is a Cas9 domain from Streptococcus pyogenes (SpCas9). In some embodiments, the SpCas9 domain is a nuclease active SpCas9, a nuclease inactive SpCas9 (SpCas9d), or a SpCas9 nickase (SpCas9n). In some embodiments, the SpCas9 comprises the amino acid sequence SEQ ID NO: 4276. In some embodiments, the SpCas9 comprises a D9X mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for D. In some embodiments, the SpCas9 comprises a D9A mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain, the SpCas9d domain, or the SpCas9n domain can bind to a nucleic acid sequence having a non-canonical PAM. In some embodiments, the SpCas9 domain, the SpCas9d domain, or the SpCas9n domain can bind to a nucleic acid sequence having a NGG, a NGA, or a NGCG PAM sequence. In some embodiments, the SpCas9 domain comprises one or more of a D1134X, a R1334X, and a T1336X mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid. In some embodiments, the SpCas9 domain comprises one or more of a D1134E, R1334Q, and T1336R mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises a D1134E, a R1334Q, and a T1336R mutation of SEQ ID NO: 4276, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises one or more of a D1134X, a R1334X, and a T1336X mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid. In some embodiments, the SpCas9 domain comprises one or more of a D1134V, a R1334Q, and a T1336R mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises a D1134V, a R1334Q, and a T1336R mutation of SEQ ID NO: 4276, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises one or more of a D1134X, a G1217X, a R1334X, and a T1336X mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid. In some embodiments, the SpCas9 domain comprises one or more of a D1134V, a G1217R, a R1334Q, and a T1336R mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises a D1134V, a G1217R, a R1334Q, and a T1336R mutation of SEQ ID NO: 4276, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 11-260.

In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 4276-4280. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises the amino acid sequence of any one of SEQ ID NOs: 4276-4280. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein consists of the amino acid sequence of any one of SEQ ID NOs: 4276-4280.

Exemplary SpCas9

(SEQ ID NO: 4276)

DKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL

LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL

EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL

RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI

NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN

FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL

LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF

FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK

QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY

VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN

LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL

LFKTNRKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKII

KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL

KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS

LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM

GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV

ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS

IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT

KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR

EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY

PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT

LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ

TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEK

GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY

SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED

NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP

IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS

ITGLYETRIDLSQLGGD

Exemplary SpCas9n

(SEQ ID NO: 4277)

DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL

LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL

EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL

RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI

NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN

FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL

LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF

FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK

QQRTFDNGSIPHQIHLGELHAILRREDFYPFLKDNREKIEKILTFRIPYY

VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN

LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL

LFKTNRKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKII

KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL

KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS

LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM

GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV

ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS

IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT

KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR

EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY

PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT

LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ

TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEK

GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY

SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED

NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP

IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS

ITGLYETRIDLSQLGGD

Exemplary SpEQR Cas9

(SEQ ID NO: 4278)

DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL

LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL

EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL

RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI

NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN

FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL

LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF

FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK

QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY

VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN

LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL

LFKTNRKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKII

KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL

KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS

LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM

GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV

ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS

IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT

KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR

EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY

PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT

LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ

TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFESPTVAYSVLVVAKVEK

GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY

SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED

NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP

IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKQYRSTKEVLDATLIHQS

ITGLYETRIDLSQLGGD

Residues E1134, Q1334, and R1336 of SEQ ID NO: 4278, which can be mutated from D1134, R1334, and T1336 of SEQ ID NO: 4278 to yield a SpEQR Cas9, are underlined and in bold.

Exemplary SpVQR Cas9

(SEQ ID NO: 4279)

DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL

LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL

EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL

RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI

NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN

FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL

LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF

FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK

QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY

VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN

LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL

LFKTNRKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKII

KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL

KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS

LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM

GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV

ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS

IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT

KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR

EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY

PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT

LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ

TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFVSPTVAYSVLVVAKVEK

GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY

SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED

NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP

IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKQYRSTKEVLDATLIHQS

I
TGLYETRIDLSQLGGD

Residues V1134, Q1334, and R1336 of SEQ ID NO: 4279, which can be mutated from D1134, R1334, and T1336 of SEQ ID NO: 4279 to yield a SpVQR Cas9, are underlined and in bold.

Exemplary SpVRER Cas9

(SEQ ID NO: 4280)

DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL

LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL

EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL

RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI

NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN

FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL

LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF

FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK

QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY

VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN

LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL

LFKTNRKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKII

KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL

KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS

LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM

GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV

ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS

IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT

KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR

EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY

PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT

LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ

TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFVSPTVAYSVLVVAKVEK

GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY

SLFELENGRKRMLASARELQKGNELALPSKYVNFLYLASHYEKLKGSPED

NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP

IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKEYRSTKEVLDATLIHQS

ITGLYETRIDLSQLGGD

Residues V1134, R1217, Q1334, and R1336 of SEQ ID NO: 4280, which can be mutated from D1134, G1217, R1334, and T1336 of SEQ ID NO: 4280 to yield a SpVRER Cas9, are underlined and in bold.

The following are exemplary fusion proteins (e.g., base editing proteins) capable of binding to a nucleic acid sequence having a non-canonical (e.g., a non-NGG) PAM sequence:

Exemplary SaBE3 (rAPOBEC1-XTEN-SaCas9n-UGI-NLS)

(SEQ ID NO: 4281)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI

WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI

TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG

YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ

PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESKRNYI

LGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRL

KRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFS

AALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLE

RLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLE

TRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLY

NALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILVN

EEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILT

IYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDE

LWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQ

SIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIE

EIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVD

HIIPRSVSFDNSFNNKVLVKQEEASKKGNRTPFQYLSSSDSKISYETFKK

HILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGL

MNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDAL

IIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFIT

PHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLN

GLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYK

YYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVK

LSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKI

SNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLE

NMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKGSGG

STNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDES

TDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGGSPKKKRKV

Exemplary SaKKH-BE3 (rAPOBEC1-XTEN-SaCas9n-UGI-NLS)

(SEQ ID NO: 4282)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI

WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI

TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG

YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ

PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESKRNYI

LGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRL

KRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFS

AALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLE

RLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLE

TRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLY

NALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILVN

EEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILT

IYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDE

LWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQ

SIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIE

EIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVD

HIIPRSVSFDNSFNNKVLVKQEEASKKGNRTPFQYLSSSDSKISYETFKK

HILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGL

MNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDAL

IIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFIT

PHQIKHIKDFKDYKYSHRVDKKPNRKLINDTLYSTRKDDKGNTLIVNNLN

GLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYK

YYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVK

LSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKI

SNQAEFIASFYKNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLE

NMNDKRPPHIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKGSGG

STNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDES

TDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGGSPKKKRKV

Exemplary EQR-BE3 (rAPOBEC1-XTEN-Cas9n-UGI-NLS)

(SEQ ID NO: 4283)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI

WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI

TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG

YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ

PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESDKKYS

IGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG

ETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL

VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL

ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGV

DAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF

DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL

RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSK

NGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFD

NGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLA

RGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEK

VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN

RKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKIIKDKDF

LDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRY

TGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKE

DIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKP

ENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL

QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKV

LTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG

GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVI

TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLES

EFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGE

IRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFS

KESILPKRNSDKLIARKKDWDPKKYGGFESPTVAYSVLVVAKVEKGKSKK

LKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFEL

ENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ

LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA

ENIIHLFTLTNLGAPAAFKYFDTTIDRKQYRSTKEVLDATLIHQSITGLY

ETRIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGN

KPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLS

GGSPKKKRKV

VQR-BE3 (rAPOBEC1-XTEN-Cas9n-UGI-NLS)

(SEQ ID NO: 4284)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI

WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI

TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG

YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ

PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESDKKYS

IGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG

ETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL

VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL

ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGV

DAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF

DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL

RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSK

NGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFD

NGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLA

RGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEK

VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN

RKVTVKQLKDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKIIKDKDFL

DNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYT

GWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKED

IQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPE

NIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQ

NEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL

TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGG

LSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVIT

LKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESE

FVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEI

RKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSK

ESILPKRNSDKLIARKKDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKKL

KSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELE

NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQL

FVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAE

NIIHLFTLTNLGAPAAFKYFDTTIDRKQYRSTKEVLDATLIHQSITGLYE

TRIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNK

PESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSG

GSPKKKRKV

VRER-BE3 (rAPOBEC1-XTEN-Cas9n-UGI-NLS)

(SEQ ID NO: 4285)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI

WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI

TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG

YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ

PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESDKKYS

IGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG

ETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL

VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL

ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGV

DAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF

DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL

RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSK

NGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFD

NGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLA

RGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEK

VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN

RKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKIIKDKDF

LDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRY

TGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKE

DIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKP

ENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL

QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKV

LTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG

GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVI

TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLES

EFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGE

IRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFS

KESILPKRNSDKLIARKKDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKK

LKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFEL

ENGRKRMLASARELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ

LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA

ENIIHLFTLTNLGAPAAFKYFDTTIDRKEYRSTKEVLDATLIHQSITGLY

ETRIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGN

KPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLS

GGSPKKKRKV

High Fidelity Base Editors

Some aspects of the disclosure provide Cas9 fusion proteins (e.g., any of the fusion proteins provided herein) comprising a Cas9 domain that has high fidelity. Additional aspects of the disclosure provide Cas9 fusion proteins (e.g., any of the fusion proteins provided herein) comprising a Cas9 domain with decreased electrostatic interactions between the Cas9 domain and a sugar-phosphate backbone of a DNA, as compared to a wild-type Cas9 domain. In some embodiments, a Cas9 domain (e.g., a wild type Cas9 domain) comprises one or more mutations that decreases the association between the Cas9 domain and a sugar-phosphate backbone of a DNA. In some embodiments, any of the Cas9 fusion proteins provided herein comprise one or more of a N497X, a R661X, a Q695X, and/or a Q926X mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid. In some embodiments, any of the Cas9 fusion proteins provided herein comprise one or more of a N497A, a R661A, a Q695A, and/or a Q926A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the Cas9 domain comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the Cas9 domain (e.g., of any of the fusion proteins provided herein) comprises the amino acid sequence as set forth in SEQ ID NO: 325. In some embodiments, the fusion protein comprises the amino acid sequence as set forth in SEQ ID NO: 285. Cas9 domains with high fidelity are known in the art and would be apparent to the skilled artisan. For example, Cas9 domains with high fidelity have been described in Kleinstiver, B. P., et al. “High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.” Nature 529, 490-495 (2016); and Slaymaker, I. M., et al. “Rationally engineered Cas9 nucleases with improved specificity.” Science 351, 84-88 (2015); the entire contents of each are incorporated herein by reference.

It should be appreciated that the base editors provided herein, for example base editor 2 (BE2) or base editor 3 (BE3), may be converted into high fidelity base editors by modifying the Cas9 domain as described herein to generate high fidelity base editors, for example high fidelity base editor 2 (HF-BE2) or high fidelity base editor 3 (HF-BE3). In some embodiments, base editor 2 (BE2) comprises a deaminase domain, a dCas9, and a UGI domain. In some embodiments, base editor 3 (BE3) comprises a deaminase domain an nCas9 domain and a UGI domain.

Cas9 domain where mutations relative to Cas9 of

SEQ ID NO: 10 are shown in bold and underlines

(SEQ ID NO: 325)

DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL

LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL

EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL

RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI

NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN

FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL

LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF

FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK

QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY

VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTAFDKN

LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL

LFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKII

KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL

KRRRYTGWGALSRKLINGIRDKQSGKTILDFLKSDGFANRNFMALIHDDS

LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM

GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV

ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS

IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT

KAERGGLSELDKAGFIKRQLVETRAITKHVAQILDSRMNTKYDENDKLIR

EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY

PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT

LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ

TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEK

GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY

SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED

NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP

IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS

ITGLYETRIDLSQLGGD

HF-BE3

(SEQ ID NO: 285)

msSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI

WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI

TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG

YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ

PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESDKKYS

IGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG

ETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL

VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL

ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGV

DAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF

DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL

RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSK

NGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFD

NGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLA

RGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTAFDKNLPNEK

VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN

RKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDF

LDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRY

TGWGALSRKLINGIRDKQSGKTILDFLKSDGFANRNFMALIHDDSLTFKE

DIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKP

ENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL

QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKV

LTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG

GLSELDKAGFIKRQLVETRAITKHVAQILDSRMNTKYDENDKLIREVKVI

TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLES

EFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGE

IRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFS

KESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKK

LKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFEL

ENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ

LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA

ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLY

ETRIDLSQLGGD

Cas9 Fusion Proteins

Any of the Cas9 domains (e.g., a nuclease active Cas9 protein, a nuclease-inactive dCas9 protein, or a Cas9 nickase protein) disclosed herein may be fused to a second protein, thus fusion proteins provided herein comprise a Cas9 domain as provided herein and a second protein, or a “fusion partner”. In some embodiments, the second protein is fused to the N-terminus of the Cas9 domain. However, in other embodiments, the second protein is fused to the C-terminus of the Cas9 domain. In some embodiments, the second protein that is fused to the Cas9 domain is a nucleic acid editing domain. In some embodiments, the Cas9 domain and the nucleic acid editing domain are fused via a linker, while in other embodiments the Cas9 domain and the nucleic acid editing domain are fused directly to one another. In some embodiments, the linker comprises (GGGS)_n(SEQ ID NO: 265), (GGGGS)_n(SEQ ID NO: 5), (G)_n, (EAAAK)_n(SEQ ID NO: 6), (GGS)_n, (SGGS)_n(SEQ ID NO: 4288), SGSETPGTSESATPES (SEQ ID NO: 7), or (XP)_nmotif, or a combination of any of these, wherein n is independently an integer between 1 and 30, and wherein X is any amino acid. In some embodiments, the linker comprises a (GGS)_nmotif, wherein n is 1, 3, or 7. In some embodiments, the linker comprises a (GGS)_nmotif, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, the linker comprises an amino acid sequence of SGSETPGTSESATPES (SEQ ID NO: 7), also referred to as the XTEN linker in the Examples). The length of the linker can influence the base to be edited, as illustrated in the Examples. For example, a linker of 3-amino-acid long (e.g., (GGS)₁) may give a 2-5, 2-4, 2-3, 3-4 base editing window relative to the PAM sequence, while a 9-amino-acid linker (e.g., (GGS)₃(SEQ ID NO: 596)) may give a 2-6, 2-5, 2-4, 2-3, 3-6, 3-5, 3-4, 4-6, 4-5, 5-6 base editing window relative to the PAM sequence. A 16-amino-acid linker (e.g., the XTEN linker) may give a 2-7, 2-6, 2-5, 2-4, 2-3, 3-7, 3-6, 3-5, 3-4, 4-7, 4-6, 4-5, 5-7, 5-6, 6-7 base window relative to the PAM sequence with exceptionally strong activity, and a 21-amino-acid linker (e.g., (GGS)₇(SEQ ID NO: 597)) may give a 3-8, 3-7, 3-6, 3-5, 3-4, 4-8, 4-7, 4-6, 4-5, 5-8, 5-7, 5-6, 6-8, 6-7, 7-8 base editing window relative to the PAM sequence. The novel finding that varying linker length may allow the dCas9 fusion proteins of the disclosure to edit nucleobases different distances from the PAM sequence affords significant clinical importance, since a PAM sequence may be of varying distance to the disease-causing mutation to be corrected in a gene. It is to be understood that the linker lengths described as examples here are not meant to be limiting.

In some embodiments, the second protein comprises an enzymatic domain. In some embodiments, the enzymatic domain is a nucleic acid editing domain. Such a nucleic acid editing domain may be, without limitation, a nuclease, a nickase, a recombinase, a deaminase, a methyltransferase, a methylase, an acetylase, or an acetyltransferase. Non-limiting exemplary binding domains that may be used in accordance with this disclosure include transcriptional activator domains and transcriptional repressor domains.

Deaminase Domains

In some embodiments, second protein comprises a nucleic acid editing domain. In some embodiments, the nucleic acid editing domain can catalyze a C to U base change. In some embodiments, the nucleic acid editing domain is a deaminase domain. In some embodiments, the deaminase is a cytidine deaminase or a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3A deaminase. In some embodiments, the deaminase is an APOBEC3B deaminase. In some embodiments, the deaminase is an APOBEC3C deaminase. In some embodiments, the deaminase is an APOBEC3D deaminase. In some embodiments, the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID). In some embodiments, the deaminase is a vertebrate deaminase. In some embodiments, the deaminase is an invertebrate deaminase. In some embodiments, the deaminase is a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse deaminase. In some embodiments, the deaminase is a human deaminase. In some embodiments, the deaminase is a rat deaminase, e.g., rAPOBEC1. In some embodiments, the deaminase is a Petromyzon marinus cytidine deaminase 1 (pmCDA1). In some embodiments, the deminase is a human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a fragment of the human APOBEC3G (SEQ ID NO: 5740). In some embodiments, the deaminase is a human APOBEC3G variant comprising a D316R_D317R mutation (SEQ ID NO: 5739). In some embodiments, the deaminase is a frantment of the human APOBEC3G and comprising mutations corresponding to the D316R_D317R mutations in SEQ ID NO: 275 (SEQ ID NO: 5741).

In some embodiments, the nucleic acid editing domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the deaminase domain of any one of SEQ ID NOs: 266-284, 607-610, 5724-5736, or 5738-5741. In some embodiments, the nucleic acid editing domain comprises the amino acid sequence of any one of SEQ ID NOs: 266-284, 607-610, 5724-5736, or 5738-5741.

Deaminase Domains that Modulate the Editing Window of Base Editors

Some aspects of the disclosure are based on the recognition that modulating the deaminase domain catalytic activity of any of the fusion proteins provided herein, for example by making point mutations in the deaminase domain, affect the processivity of the fusion proteins (e.g., base editors). For example, mutations that reduce, but do not eliminate, the catalytic activity of a deaminase domain within a base editing fusion protein can make it less likely that the deaminase domain will catalyze the deamination of a residue adjacent to a target residue, thereby narrowing the deamination window. The ability to narrow the deaminataion window may prevent unwanted deamination of residues adjacent of specific target residues, which may decrease or prevent off-target effects.

In some embodiments, any of the fusion proteins provided herein comprise a deaminase domain (e.g., a cytidine deaminase domain) that has reduced catalytic deaminase activity. In some embodiments, any of the fusion proteins provided herein comprise a deaminase domain (e.g., a cytidine deaminase domain) that has a reduced catalytic deaminase activity as compared to an appropriate control. For example, the appropriate control may be the deaminase activity of the deaminase prior to introducing one or more mutations into the deaminase. In other embodiments, the appropriate control may be a wild-type deaminase. In some embodiments, the appropriate control is a wild-type apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the appropriate control is an APOBEC1 deaminase, an APOBEC2 deaminase, an APOBEC3A deaminase, an APOBEC3B deaminase, an APOBEC3C deaminase, an APOBEC3D deaminase, an APOBEC3F deaminase, an APOBEC3G deaminase, or an APOBEC3H deaminase. In some embodiments, the appropriate control is an activation induced deaminase (AID). In some embodiments, the appropriate control is a cytidine deaminase 1 from Petromyzon marinus (pmCDA1). In some embodiments, the deaminse domain may be a deaminase domain that has at least 1%, at least 5%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% less catalytic deaminase activity as compared to an appropriate control.

In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising one or more mutations selected from the group consisting of H121X, H122X, R126X, R126X, R118X, W90X, W90X, and R132X of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase, wherein X is any amino acid. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising one or more mutations selected from the group consisting of H121R, H122R, R126A, R126E, R118A, W90A, W90Y, and R132E of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase.

In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising one or more mutations selected from the group consisting of D316X, D317X, R320X, R320X, R313X, W285X, W285X, R326X of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase, wherein X is any amino acid. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising one or more mutations selected from the group consisting of D316R, D317R, R320A, R320E, R313A, W285A, W285Y, R326E of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase.

In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a H121R and a H122R mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R126A mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R126E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R118A mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W90A mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W90Y mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R132E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W90Y and a R126E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R126E and a R132E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W90Y and a R132E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W90Y, R126E, and R132E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase.

In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a D316R and a D317R mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R320A mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R320E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R313A mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W285A mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W285Y mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R326E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W285Y and a R320E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R320E and a R326E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W285Y and a R326E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W285Y, R320E, and R326E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase.

Some aspects of this disclosure provide fusion proteins comprising (i) a nuclease-inactive Cas9 domain; and (ii) a nucleic acid editing domain. In some embodiments, a nuclease-inactive Cas9 domain (dCas9), comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a Cas9 as provided by any one of SEQ ID NOs: 10-263, and comprises mutations that inactivate the nuclease activity of Cas9. Mutations that render the nuclease domains of Cas9 inactive are well-known in the art. For example, the DNA cleavage domain of Cas9 is known to include two subdomains, the HNH nuclease subdomain and the RuvC1 subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, the mutations D10A and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al., Science. 337:816-821 (2012); Qi et al., Cell. 28; 152(5):1173-83 (2013)). In some embodiments, the dCas9 of this disclosure comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the dCas9 of this disclosure comprises a H840A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the dCas9 of this disclosure comprises both D10A and H840A mutations of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the Cas9 further comprises a histidine residue at position 840 of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. The presence of the catalytic residue H840 restores the activity of the Cas9 to cleave the non-edited strand containing a G opposite the targeted C. Restoration of H840 does not result in the cleavage of the target strand containing the C. In some embodiments, the dCas9 comprises an amino acid sequence of SEQ ID NO: 263. It is to be understood that other mutations that inactivate the nuclease domains of Cas9 may also be included in the dCas9 of this disclosure.

The Cas9 or dCas9 domains comprising the mutations disclosed herein, may be a full-length Cas9, or a fragment thereof. In some embodiments, proteins comprising Cas9, or fragments thereof, are referred to as “Cas9 variants.” A Cas9 variant shares homology to Cas9, or a fragment thereof. For example a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to wild type Cas9. In some embodiments, the Cas9 variant comprises a fragment of Cas9 (e.g., a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild type Cas9, e.g., a Cas9 comprising the amino acid sequence of SEQ ID NO: 10.

Any of the Cas9 fusion proteins of this disclosure may further comprise a nucleic acid editing domain (e.g., an enzyme that is capable of modifying nucleic acid, such as a deaminase). In some embodiments, the nucleic acid editing domain is a DNA-editing domain. In some embodiments, the nucleic acid editing domain has deaminase activity. In some embodiments, the nucleic acid editing domain comprises or consists of a deaminase or deaminase domain. In some embodiments, the deaminase is a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 family deaminase. In some embodiments, the deaminase is an activation-induced cytidine deaminase (AID). Some nucleic-acid editing domains as well as Cas9 fusion proteins including such domains are described in detail herein. Additional suitable nucleic acid editing domains will be apparent to the skilled artisan based on this disclosure and knowledge in the field.

Some aspects of the disclosure provide a fusion protein comprising a Cas9 domain fused to a nucleic acid editing domain, wherein the nucleic acid editing domain is fused to the N-terminus of the Cas9 domain. In some embodiments, the Cas9 domain and the nucleic acid editing-editing domain are fused via a linker. In some embodiments, the linker comprises a (GGGS)_n(SEQ ID NO: 265), a (GGGGS)_n(SEQ ID NO: 5), a (G)_n, an (EAAAK)_n(SEQ ID NO: 6), a (GGS)_n, (SGGS)_n(SEQ ID NO: 4288), an SGSETPGTSESATPES (SEQ ID NO: 7) motif (see, e.g., Guilinger J P, Thompson D B, Liu D R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014; 32(6): 577-82; the entire contents are incorporated herein by reference), or an (XP)_nmotif, or a combination of any of these, wherein n is independently an integer between 1 and 30. In some embodiments, n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, or, if more than one linker or more than one linker motif is present, any combination thereof. In some embodiments, the linker comprises a (GGS)_nmotif, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15. In some embodiments, the linker comprises a (GGS)_nmotif, wherein n is 1, 3, or 7. In some embodiments, the linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7). Additional suitable linker motifs and linker configurations will be apparent to those of skill in the art. In some embodiments, suitable linker motifs and configurations include those described in Chen et al., Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013; 65(10):1357-69, the entire contents of which are incorporated herein by reference. Additional suitable linker sequences will be apparent to those of skill in the art based on the instant disclosure. In some embodiments, the general architecture of exemplary Cas9 fusion proteins provided herein comprises the structure:

- [NH₂]-[nucleic acid editing domain]-[Cas9]-[COOH] or
- [NH₂]-[nucleic acid editing domain]-[linker]-[Cas9]-[COOH],
  
  wherein NH₂is the N-terminus of the fusion protein, and COOH is the C-terminus of the fusion protein.

The fusion proteins of the present disclosure may comprise one or more additional features. For example, in some embodiments, the fusion protein comprises a nuclear localization sequence (NLS). In some embodiments, the NLS of the fusion protein is localized between the nucleic acid editing domain and the Cas9 domain. In some embodiments, the NLS of the fusion protein is localized C-terminal to the Cas9 domain.

Other exemplary features that may be present are localization sequences, such as cytoplasmic localization sequences, export sequences, such as nuclear export sequences, or other localization sequences, as well as sequence tags that are useful for solubilization, purification, or detection of the fusion proteins. Suitable protein tags provided herein include, but are not limited to, biotin carboxylase carrier protein (BCCP) tags, myc-tags, calmodulin-tags, FLAG-tags, hemagglutinin (HA)-tags, polyhistidine tags, also referred to as histidine tags or His-tags, maltose binding protein (MBP)-tags, nus-tags, glutathione-S-transferase (GST)-tags, green fluorescent protein (GFP)-tags, thioredoxin-tags, S-tags, Softags (e.g., Softag 1, Softag 3), strep-tags, biotin ligase tags, FlAsH tags, V5 tags, and SBP-tags. Additional suitable sequences will be apparent to those of skill in the art. In some embodiments, the fusion protein comprises one or more His tags.

In some embodiments, the nucleic acid editing domain is a deaminase. For example, in some embodiments, the general architecture of exemplary Cas9 fusion proteins with a deaminase domain comprises the structure:

- [NH₂]-[NLS]-[deaminase]-[Cas9]-[COOH],
- [NH₂]-[Cas9]-[deaminase]-[COOH],
- [NH₂]-[deaminase]-[Cas9]-[COOH], or
- [NH₂]-[deaminase]-[Cas9]-[NLS]-[COOH]
  
  wherein NLS is a nuclear localization sequence, NH₂is the N-terminus of the fusion protein, and COOH is the C-terminus of the fusion protein. Nuclear localization sequences are known in the art and would be apparent to the skilled artisan. For example, NLS sequences are described in Plank et al., PCT/EP2000/011690, the contents of which are incorporated herein by reference for their disclosure of exemplary nuclear localization sequences. In some embodiments, a NLS comprises the amino acid sequence PKKKRKV (SEQ ID NO: 741) or MDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 742). In some embodiments, a linker is inserted between the Cas9 and the deaminase. In some embodiments, the NLS is located C-terminal of the Cas9 domain. In some embodiments, the NLS is located N-terminal of the Cas9 domain. In some embodiments, the NLS is located between the deaminase and the Cas9 domain. In some embodiments, the NLS is located N-terminal of the deaminase domain. In some embodiments, the NLS is located C-terminal of the deaminase domain.

One exemplary suitable type of nucleic acid editing domain is a cytidine deaminase, for example, of the APOBEC family. The apolipoprotein B mRNA-editing complex (APOBEC) family of cytidine deaminase enzymes encompasses eleven proteins that serve to initiate mutagenesis in a controlled and beneficial manner.²⁹One family member, activation-induced cytidine deaminase (AID), is responsible for the maturation of antibodies by converting cytosines in ssDNA to uracils in a transcription-dependent, strand-biased fashion.³⁰The apolipoprotein B editing complex 3 (APOBEC3) enzyme provides protection to human cells against a certain HIV-1 strain via the deamination of cytosines in reverse-transcribed viral ssDNA.³¹These proteins all require a Zn²⁺-coordinating motif (His-X-Glu-X_23-26-Pro-Cys-X_2-4-Cys; SEQ ID NO: 598) and bound water molecule for catalytic activity. The Glu residue acts to activate the water molecule to a zinc hydroxide for nucleophilic attack in the deamination reaction. Each family member preferentially deaminates at its own particular “hotspot”, ranging from WRC (W is A or T, R is A or G) for hAID, to TTC for hAPOBEC3F.³²A recent crystal structure of the catalytic domain of APOBEC3G revealed a secondary structure comprised of a five-stranded β-sheet core flanked by six α-helices, which is believed to be conserved across the entire family.³³The active center loops have been shown to be responsible for both ssDNA binding and in determining “hotspot” identity.³⁴Overexpression of these enzymes has been linked to genomic instability and cancer, thus highlighting the importance of sequence-specific targeting.³⁵

Some aspects of this disclosure relate to the recognition that the activity of cytidine deaminase enzymes such as APOBEC enzymes can be directed to a specific site in genomic DNA. Without wishing to be bound by any particular theory, advantages of using Cas9 as a recognition agent include (1) the sequence specificity of Cas9 can be easily altered by simply changing the sgRNA sequence; and (2) Cas9 binds to its target sequence by denaturing the dsDNA, resulting in a stretch of DNA that is single-stranded and therefore a viable substrate for the deaminase. It should be understood that other catalytic domains, or catalytic domains from other deaminases, can also be used to generate fusion proteins with Cas9, and that the disclosure is not limited in this regard.

Some aspects of this disclosure are based on the recognition that Cas9:deaminase fusion proteins can efficiently deaminate nucleotides at positions 3-11 according to the numbering scheme in FIG. 3. In view of the results provided herein regarding the nucleotides that can be targeted by Cas9:deaminase fusion proteins, a person of skill in the art will be able to design suitable guide RNAs to target the fusion proteins to a target sequence that comprises a nucleotide to be deaminated.

In some embodiments, the deaminase domain and the Cas9 domain are fused to each other via a linker. Various linker lengths and flexibilities between the deaminase domain (e.g., AID) and the Cas9 domain can be employed (e.g., ranging from very flexible linkers of the form (GGGGS)_n(SEQ ID NO: 5), (GGS)_n, and (G)_nto more rigid linkers of the form (EAAAK)_n(SEQ ID NO: 6), (SGGS)_n(SEQ ID NO: 4288), SGSETPGTSESATPES (SEQ ID NO: 7) (see, e.g., Guilinger J P, Thompson D B, Liu D R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014; 32(6): 577-82; the entire contents are incorporated herein by reference) and (XP)_n)³⁶in order to achieve the optimal length for deaminase activity for the specific application. In some embodiments, the linker comprises a (GGS)_nmotif, wherein n is 1, 3, or 7. In some embodiments, the linker comprises a (an SGSETPGTSESATPES (SEQ ID NO: 7) motif.

Some exemplary suitable nucleic-acid editing domains, e.g., deaminases and deaminase domains, that can be fused to Cas9 domains according to aspects of this disclosure are provided below. It should be understood that, in some embodiments, the active domain of the respective sequence can be used, e.g., the domain without a localizing signal (nuclear localization sequence, without nuclear export signal, cytoplasmic localizing signal).

Human AID:

(SEQ ID NO: 266)

MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGYLRNKNGC

HVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTAR

LYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAWEGLHEN

SVRLSRQLRRILLPLYEVDDLRDAFRTLGL

(underline: nuclear localization sequence; double underline:

nuclear export signal)

Mouse AID:

(SEQ ID NO: 267)

MDSLLMKQKKFLYHFKNVRWAKGRHETYLCYVVKRRDSATSCSLDFGHLRNKSGC

HVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVAEFLRWNPNLSLRIFTAR

LYFCEDRKAEPEGLRRLHRAGVQIGIMTFKDYFYCWNTFVENRERTFKAWEGLHEN

SVRLTRQLRRILLPLYEVDDLRDAFRMLGF

(underline: nuclear localization sequence; double underline:

nuclear export signal)

Dog AID:

(SEQ ID NO: 268)

MDSLLMKQRKFLYHFKNVRWAKGRHETYLCYVVKRRDSATSFSLDFGHLRNKSGC

HVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGYPNLSLRIFAAR

LYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENREKTFKAWEGLHEN

SVRLSRQLRRILLPLYEVDDLRDAFRTLGL

(underline: nuclear localization sequence; double underline:

nuclear export signal)

Bovine AID:

(SEQ ID NO: 269)

MDSLLKKQRQFLYQFKNVRWAKGRHETYLCYVVKRRDSPTSFSLDFGHLRNKAGC

HVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGYPNLSLRIFTAR

LYFCDKERKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAWEGLHE

NSVRLSRQLRRILLPLYEVDDLRDAFRTLGL

(underline: nuclear localization sequence; double underline:

nuclear export signal)

Rat AID

(SEQ ID NO: 5725)

MAVGSKPKAALVGPHWERERIWCFLCSTGLGTQQTGQTSRWLRPAATQDPVSPPRS

LLMKQRKFLYHFKNVRWAKGRHETYLCYVVKRRDSATSFSLDFGYLRNKSGCHVE

LLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTARLTG

WGALPAGLMSPARPSDYFYCWNTFVENHERTFKAWEGLHENSVRLSRRLRRILLPL

YEVDDLRDAFRTLGL

(underline: nuclear localization sequence; double underline:

nuclear export signal)

Mouse APOBEC-3:

(SEQ ID NO: 270)

MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVS

LHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLA

THHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNG

GRRFRPWKRLLTNFRYQDSKLQEILRPCYIPVPSSSSSTLSNICLTKGLPETRFCVEGR

RMDPLSEEEFYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPLKGCLLSEKGKQ

HAEILFLDKIRSMELSQVTITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWK

RPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRLR

RIKESWGLQDLVNDFGNLQLGPPMS

(italic: nucleic acid editing domain)

Rat APOBEC-3:

(SEQ ID NO: 271)

MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLRYAIDRKDTFLCYEVTRKDCDSPVS

LHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQVLRFLA

THHNLSLDIFSSRLYNIRDPENQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNGG

RRFRPWKKLLTNFRYQDSKLQEILRPCYIPVPSSSSSTLSNICLTKGLPETRFCVERRR

VHLLSEEEFYSQFYNQRVKHLCYYHGVKPYLCYQLEQFNGQAPLKGCLLSEKGKQH

AEILFLDKIRSMELSQVIITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWKR

PFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRLHR

IKESWGLQDLVNDFGNLQLGPPMS

(italic: nucleic acid editing domain)

Rhesus macaque APOBEC-3G:

(SEQ ID NO: 272)

MVEPMDPRTFVSNFNNRPILSGLNTVWLCCEVKTKDPSGPPLDAKIFQGKVYSKAKY

HPEM
RFLRWFHKWRQLHHDQEYKVTWYVSWSPCTRCANSVATFLAKDPKVTLTIFVA

RLYYFWKPDYQQALRILCQKRGGPHATMKIMNYNEFQDCWNKFVDGRGKPFKPRN

NLPKHYTLLQATLGELLRHLMDPGTFTSNFNNKPWVSGQHETYLCYKVERLHNDT

WVPLNQHRGFLRNQAPNIHGFPKGRHAELCFLDLIPFWKLDGQQYRVTCFTSWSPCFS

CAQEMAKFISNNEHVSLCIFAARIYDDQGRYQEGLRALHRDGAKIAMMNYSEFEYC

WDTFVDRQGRPFQPWDGLDEHSQALSGRLRAI

(italic: nucleic acid editing domain; underline: cytoplasmic

localization signal)

Chimpanzee APOBEC-3G:

(SEQ ID NO: 273)

MKPHFRNPVERMYQDTFSDNFYNRPILSHRNTVWLCYEVKTKGPSRPPLDAKIFRGQ

VYSKLKYHPEMRFFHWFSKWRKLHRDQEYEVIWYISWSPCTKCTRDVATFLAEDPKV

TLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQHCWSKFVYSQRE

LFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTSNFNNELWVRGRHETYLCYEVERL

HNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLHQDYRVTCFTS

WSPCFSCAQEMAKFISNNKHVSLCIFAARIYDDQGRCQEGLRTLAKAGAKISIMTYSE

FKHCWDTFVDHQGCPFQPWDGLEEHSQALSGRLRAILQNQGN

(italic: nucleic acid editing domain; underline: cytoplasmic

localization signal)

Green monkey APOBEC-3G:

(SEQ ID NO: 274)

MNPQIRNMVEQMEPDIFVYYFNNRPILSGRNTVWLCYEVKTKDPSGPPLDANIFQGK

LYPEAKDHPEMKFLHWFRKWRQLHRDQEYEVTWYVSWSPCTRCANSVATFLAEDPKV

TLTIFVARLYYFWKPDYQQALRILCQERGGPHATMKIMNYNEFQHCWNEFVDGQG

KPFKPRKNLPKHYTLLHATLGELLRHVMDPGTFTSNFNNKPWVSGQRETYLCYKVE

RSHNDTWVLLNQHRGFLRNQAPDRHGFPKGRHAELCFLDLIPFWKLDDQQYRVTCFT

SWSPCFSCAQKMAKFISNNKHVSLCIFAARIYDDQGRCQEGLRTLHRDGAKIAVMNY

SEFEYCWDTFVDRQGRPFQPWDGLDEHSQALSGRLRAI

(italic: nucleic acid editing domain; underline: cytoplasmic

localization signal)

Human APOBEC-3G:

(SEQ ID NO: 275)

MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPPLDAKIFRGQ

VYSELKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKCTRDMATFLAEDPKV

TLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQHCWSKFVYSQRE

LFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTFNFNNEPWVRGRHETYLCYEVERM

HNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTS

WSPCFSCAQEMAKFISKNKHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISIMTYSE

FKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQNQEN

(italic: nucleic acid editing domain; underline: cytoplasmic

localization signal)

Human APOBEC-3F:

(SEQ ID NO: 276)

MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPRLDAKIFRGQ

VYSQPEHHAEMCFLSWFCGNQLPAYKCFQITWFVSWTPCPDCVAKLAEFLAEHPNVTL

TISAARLYYYWERDYRRALCRLSQAGARVKIMDDEEFAYCWENFVYSEGQPFMPW

YKFDDNYAFLHRTLKEILRNPMEAMYPHIFYFHFKNLRKAYGRNESWLCFTMEVVK

HHSPVSWKRGVFRNQVDPETHCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPECA

GEVAEFLARHSNVNLTIFTARLYYFWDTDYQEGLRSLSQEGASVEIMGYKDFKYCW

ENFVYNDDEPFKPWKGLKYNFLFLDSKLQEILE

(italic: nucleic acid editing domain)

Human APOBEC-3B:

(SEQ ID NO: 277)

MNPQRNPMERMYRDTFYDNFENEPILYGRSYTWLCYEVKIKRGRSNLLWDTGVFR

GQVYFKPQYHAEMCFLSWFCGNQLPAYKCFQITWFVSWTPCPDCVAKLAEFLSEHPN

VTLTISAARLYYYWERDYRRALCRLSQAGARVTIMDYEEFAYCWENFVYNEGQQF

MPWYKFDENYAFLHRTLKEILRYLMDPDTFTFNFNNDPLVLRRRQTYLCYEVERLD

NGTWVLMDQHMGFLCNEAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRWWFISWS

PCFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTY

DEFEYCWDTFVYRQGCPFQPWDGLEEHSQALSGRLRAILQNQGN

(italic: nucleic acid editing domain)

Rat APOBEC-3B:

(SEQ ID NO: 5729)

MQPQGLGPNAGMGPVCLGCSHRRPYSPIRNPLKKLYQQTFYFHFKNVRYAWGRKN

NFLCYEVNGMDCALPVPLRQGVFRKQGHIHAELCFIYWFHDKVLRVLSPMEEFKVT

WYMSWSPCSKCAEQVARFLAAHRNLSLAIFSSRLYYYLRNPNYQQKLCRLIQEGVH

VAAMDLPEFKKCWNKFVDNDGQPFRPWMRLRINFSFYDCKLQEIFSRMNLLREDVF

YLQFNNSHRVKPVQNRYYRRKSYLCYQLERANGQEPLKGYLLYKKGEQHVEILFLE

KMRSMELSQVRITCYLTWSPCPNCARQLAAFKKDHPDLILRIYTSRLYFYWRKKFQK

GLCTLWRSGIHVDVMDLPQFADCWTNFVNPQRPFRPWNELEKNSWRIQRRLRRIKE

SWGL

Bovine APOBEC-3B:

(SEQ ID NO: 5730)

DGWEVAFRSGTVLKAGVLGVSMTEGWAGSGHPGQGACVWTPGTRNTMNLLREVL

FKQQFGNQPRVPAPYYRRKTYLCYQLKQRNDLTLDRGCFRNKKQRHAEIRFIDKINS

LDLNPSQSYKIICYITWSPCPNCANELVNFITRNNHLKLEIFASRLYFHWIKSFKMGLQ

DLQNAGISVAVMTHTEFEDCWEQFVDNQSRPFQPWDKLEQYSASIRRRLQRILTAPI

Chimpanzee APOBEC-3B :

(SEQ ID NO: 5731)

MNPQIRNPMEWMYQRTFYYNFENEPILYGRSYTWLCYEVKIRRGHSNLLWDTGVFR

GQMYSQPEHHAEMCFLSWFCGNQLSAYKCFQITWFVSWTPCPDCVAKLAKFLAEHP

NVTLTISAARLYYYWERDYRRALCRLSQAGARVKIMDDEEFAYCWENFVYNEGQPF

MPWYKFDDNYAFLHRTLKEIIRHLMDPDTFTFNFNNDPLVLRRHQTYLCYEVERLD

NGTWVLMDQHMGFLCNEAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFIS

WSPCFSWGCAGQVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIM

TYDEFEYCWDTFVYRQGCPFQPWDGLEEHSQALSGRLRAILQVRASSLCMVPHRPPP

PPQSPGPCLPLCSEPPLGSLLPTGRPAPSLPFLLTASFSFPPPASLPPLPSLSLSPGHLPVP

SFHSLTSCSIQPPCSSRIRETEGWASVSKEGRDLG

Human APOBEC-3C:

(SEQ ID NO: 278)

MNPQIRNPMKAMYPGTFYFQFKNLWEANDRNETWLCFTVEGIKRRSVVSWKTGVF

RNQVDSETHCHAERCFLSWFCDDILSPNTKYQVIWYTSWSPCPDCAGEVAEFLARHSN

VNLTIFTARLYYFQYPCYQEGLRSLSQEGVAVEIMDYEDFKYCWENFVYNDNEPFKP

WKGLKTNFRLLKRRLRESLQ

(italic: nucleic acid editing domain)

Gorilla APOBEC3C

(SEQ ID NO: 5726)

MNPQIRNPMKAMYPGTFYFQFKNLWEANDRNETWLCFTVEGIKRRSVVSWKTGVF

RNQVDSETHCHAERCFLSWFCDDILSPNTNYQVTWYTSWSPCPECAGEVAEFLARHSN

VNLTIFTARLYYFQDTDYQEGLRSLSQEGVAVKIMDYKDFKYCWENFVYNDDEPFK

PWKGLKYNFRFLKRRLQEILE

(italic: nucleic acid editing domain)

Human APOBEC-3A:

(SEQ ID NO: 279)

MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLH

NQAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQ

ENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGC

PFQPWDGLDEHSQALSGRLRAILQNQGN

(italic: nucleic acid editing domain)

Rhesus macaque APOBEC-3A:

(SEQ ID NO: 5727)

MDGSPASRPRHLMDPNTFTFNFNNDLSVRGRHQTYLCYEVERLDNGTWVPMDERR

GFLCNKAKNVPCGDYGCHVELRFLCEVPSWQLDPAQTYRVTWFISWSPCFRRGCAGQ

VRVFLQENKHVRLRIFAARIYDYDPLYQEALRTLRDAGAQVSIMTYEEFKHCWDTF

VDRQGRPFQPWDGLDEHSQALSGRLRAILQNQGN

(italic: nucleic acid editing domain)

Bovine APOBEC-3A:

(SEQ ID NO: 5728)

MDEYTFTENFNNQGWPSKTYLCYEMERLDGDATIPLDEYKGFVRNKGLDQPEKPCH

AELYFLGKIHSWNLDRNQHYRLTCFISWSPCYDCAQKLTTFLKENHHISLHILASRIYTH

NRFGCHQSGLCELQAAGARITIMTFEDFKHCWETFVDHKGKPFQPWEGLNVKSQAL

CTELQAILKTQQN

(italic: nucleic acid editing domain)

Human APOBEC-3H:

(SEQ ID NO: 280)

MALLTAETFRLQFNNKRRLRRPYYPRKALLCYQLTPQNGSTPTRGYFENKKKCHAEI

CFINEIKSMGLDETQCYQVTCYLTWSPCSSCAWELVDFIKAHDHLNLGIFASRLYYHWC

KPQQKGLRLLCGSQVPVEVMGFPKFADCWENFVDHEKPLSFNPYKMLEELDKNSRA

IKRRLERIKIPGVRAQGRYMDILCDAEV

(italic: nucleic acid editing domain)

Rhesus macaque APOBEC-3H:

(SEQ ID NO: 5732)

MALLTAKTFSLQFNNKRRVNKPYYPRKALLCYQLTPQNGSTPTRGHLKNKKKDHAE

IRFINKIKSMGLDETQCYQVTCYLTWSPCPSCAGELVDFIKAHRHLNLRIFASRLYYH

WRPNYQEGLLLLCGSQVPVEVMGLPEFTDCWENFVDHKEPPSFNPSEKLEELDKNS

QAIKRRLERIKSRSVDVLENGLRSLQLGPVTPSSSIRNSR

Human APOBEC-3D:

(SEQ ID NO: 281)

MNPQIRNPMERMYRDTFYDNFENEPILYGRSYTWLCYEVKIKRGRSNLLWDTGVFR

GPVLPKRQSNHRQEVYFRFENHAEMCFLSWFCGNRLPANRRFQITWFVSWNPCLPCVV

KVTKFLAEHPNVTLTISAARLYYYRDRDWRWVLLRLHKAGARVKIMDYEDFAYCW

ENFVCNEGQPFMPWYKFDDNYASLHRTLKEILRNPMEAMYPHIFYFHFKNLLKACG

RNESWLCFTMEVTKHHSAVFRKRGVFRNQVDPETHCHAERCFLSWFCDDILSPNTNY

EVTWYTSWSPCPECAGEVAEFLARHSNVNLTIFTARLCYFWDTDYQEGLCSLSQEGAS

VKIMGYKDFVSCWKNFVYSDDEPFKPWKGLQTNFRLLKRRLREILQ

(italic: nucleic acid editing domain)

Human APOBEC-1:

(SEQ ID NO: 282)

MTSEKGPSTGDPTLRRRIEPWEFDVFYDPRELRKEACLLYEIKWGMSRKIWRSSGKN

TTNHVEVNFIKKFTSERDFHPSMSCSITWFLSWSPCWECSQAIREFLSRHPGVTLVIYV

ARLFWHMDQQNRQGLRDLVNSGVTIQIMRASEYYHCWRNFVNYPPGDEAHWPQYP

PLWMMLYALELHCIILSLPPCLKISRRWQNHLTFFRLHLQNCHYQTIPPHILLATGLIH

PSVAWR

Mouse APOBEC-1:

(SEQ ID NO: 283)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSVWRHTSQN

TSNHVEVNFLEKFTTERYFRPNTRCSITWFLSWSPCGECSRAITEFLSRHPYVTLFIYIA

RLYHHTDQRNRQGLRDLISSGVTIQIMTEQEYCYCWRNFVNYPPSNEAYWPRYPHL

WVKLYVLELYCIILGLPPCLKILRRKQPQLTFFTITLQTCHYQRIPPHLLWATGLK

Rat APOBEC-1:

(SEQ ID NO: 284)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNT

NKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIAR

LYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLW

VRLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK

Human APOBEC-2:

(SEQ ID NO: 5733)

MAQKEEAAVATEAASQNGEDLENLDDPEKLKELIELPPFEIVTGERLPANFFKFQFRN

VE

YSSGRNKTFLCYVVEAQGKGGQVQASRGYLEDEHAAAHAEEAFFNTILPAFDPALR

YNVTWYVSSSPCAACADRIIKTLSKTKNLRLLILVGRLFMWEEPEIQAALKKLKEAG

CKLRIMKPQDFEYVWQNFVEQEEGESKAFQPWEDIQENFLYYEEKLADILK

Mouse APOBEC-2:

(SEQ ID NO: 5734)

MAQKEEAAEAAAPASQNGDDLENLEDPEKLKELIDLPPFEIVTGVRLPVNFFKFQFR

NVEYSSGRNKTFLCYVVEVQSKGGQAQATQGYLEDEHAGAHAEEAFFNTILPAFDP

ALKYNVTWYVSSSPCAACADRILKTLSKTKNLRLLILVSRLFMWEEPEVQAALKKLK

EAGCKLRIMKPQDFEYIWQNFVEQEEGESKAFEPWEDIQENFLYYEEKLADILK

Rat APOBEC-2:

(SEQ ID NO: 5735)

MAQKEEAAEAAAPASQNGDDLENLEDPEKLKELIDLPPFEIVTGVRLPVNFFKFQFR

NVEYSSGRNKTFLCYVVEAQSKGGQVQATQGYLEDEHAGAHAEEAFFNTILPAFDP

ALKYNVTWYVSSSPCAACADRILKTLSKTKNLRLLILVSRLFMWEEPEVQAALKKLK

EAGCKLRIMKPQDFEYLWQNFVEQEEGESKAFEPWEDIQENFLYYEEKLADILK

Bovine APOBEC-2:

(SEQ ID NO: 5736)

MAQKEEAAAAAEPASQNGEEVENLEDPEKLKELIELPPFEIVTGERLPAHYFKFQFRN

VE

YSSGRNKTFLCYVVEAQSKGGQVQASRGYLEDEHATNHAEEAFFNSIMPTFDPALR

YMVTWYVSSSPCAACADRIVKTLNKTKNLRLLILVGRLFMWEEPEIQAALRKLKEA

GCRLRIMKPQDFEYIWQNFVEQEEGESKAFEPWEDIQENFLYYEEKLADILK

Petromyzon marinus CDA1 (pmCDA1)

(SEQ ID NO: 5738)

MTDAEYVRIHEKLDIYTFKKQFFNNKKSVSHRCYVLFELKRRGERRACFWGYAVNK

PQSGTERGIHAEIFSIRKVEEYLRDNPGQFTINWYSSWSPCADCAEKILEWYNQELRG

NGHTLKIWACKLYYEKNARNQIGLWNLRDNGVGLNVMVSEHYQCCRKIFIQSSHNQ

LNENRWLEKTLKRAEKRRSELSIMIQVKILHTTKSPAV

Human APOBEC3G D316R_D317R

(SEQ ID NO: 5739)

MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPPLDAKIFRGQ

VYSELKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKCTRDMATFLAEDP

KVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQHCWSKFVYSQ

RELFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTFNFNNEPWVRGRHETYLCYEVER

MHNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTC

FTSWSPCFSCAQEMAKFISKNKHVSLCIFTARIYRRQGRCQEGLRTLAEAGAKISIMT

YSEFKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQNQEN

Human APOBEC3G chain A

(SEQ ID NO: 5740)

MDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHG

FLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCI

FTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLD

EHSQDLSGRLRAILQ

Human APOBEC3G chain A D120R_D121R

(SEQ ID NO: 5741)

MDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHG

FLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCI

FTARIYRRQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLDE

HSQDLSGRLRAILQ

In some embodiments, fusion proteins as provided herein comprise the full-length amino acid of a nucleic acid editing enzyme, e.g., one of the sequences provided above. In other embodiments, however, fusion proteins as provided herein do not comprise a full-length sequence of a nucleic acid editing enzyme, but only a fragment thereof. For example, in some embodiments, a fusion protein provided herein comprises a Cas9 domain and a fragment of a nucleic acid editing enzyme, e.g., wherein the fragment comprises a nucleic acid editing domain. Exemplary amino acid sequences of nucleic acid editing domains are shown in the sequences above as italicized letters, and additional suitable sequences of such domains will be apparent to those of skill in the art.

Additional suitable nucleic-acid editing enzyme sequences, e.g., deaminase enzyme and domain sequences, that can be used according to aspects of this invention, e.g., that can be fused to a nuclease-inactive Cas9 domain, will be apparent to those of skill in the art based on this disclosure. In some embodiments, such additional enzyme sequences include deaminase enzyme or deaminase domain sequences that are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similar to the sequences provided herein. Additional suitable Cas9 domains, variants, and sequences will also be apparent to those of skill in the art. Examples of such additional suitable Cas9 domains include, but are not limited to, D10A, D10A/D839A/H840A, and D10A/D839A/H840A/N863A mutant domains (See, e.g., Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology. 2013; 31(9): 833-838 the entire contents of which are incorporated herein by reference). In some embodiments, the Cas9 comprises a histidine residue at position 840 of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. The presence of the catalytic residue H840 restores the activity of the Cas9 to cleave the non-edited strand containing a G opposite the targeted C. Restoration of H840 does not result in the cleavage of the target strand containing the C.

Additional suitable strategies for generating fusion proteins comprising a Cas9 domain and a deaminase domain will be apparent to those of skill in the art based on this disclosure in combination with the general knowledge in the art. Suitable strategies for generating fusion proteins according to aspects of this disclosure using linkers or without the use of linkers will also be apparent to those of skill in the art in view of the instant disclosure and the knowledge in the art. For example, Gilbert et al., CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013; 154(2):442-51, showed that C-terminal fusions of Cas9 with VP64 using 2 NLS's as a linker (SPKKKRKVEAS, SEQ ID NO: 599), can be employed for transcriptional activation. Mali et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013; 31(9):833-8, reported that C-terminal fusions with VP64 without linker can be employed for transcriptional activation. And Maeder et al., CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013; 10: 977-979, reported that C-terminal fusions with VP64 using a Gly₄Ser (SEQ ID NO: 5) linker can be used as transcriptional activators. Recently, dCas9-FokI nuclease fusions have successfully been generated and exhibit improved enzymatic specificity as compared to the parental Cas9 enzyme (In Guilinger J P, Thompson D B, Liu D R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014; 32(6): 577-82, and in Tsai S Q, Wyvekens N, Khayter C, Foden J A, Thapar V, Reyon D, Goodwin M J, Aryee M J, Joung J K. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol. 2014; 32(6):569-76. PMID: 24770325 a SGSETPGTSESATPES (SEQ ID NO: 7) or a GGGGS (SEQ ID NO: 5) linker was used in FokI-dCas9 fusion proteins, respectively).

Some aspects of this disclosure provide fusion proteins comprising (i) a Cas9 enzyme or domain (e.g., a first protein); and (ii) a nucleic acid-editing enzyme or domain (e.g., a second protein). In some aspects, the fusion proteins provided herein further include (iii) a programmable DNA-binding protein, for example, a zinc-finger domain, a TALE, or a second Cas9 protein (e.g., a third protein). Without wishing to be bound by any particular theory, fusing a programmable DNA-binding protein (e.g., a second Cas9 protein) to a fusion protein comprising (i) a Cas9 enzyme or domain (e.g., a first protein); and (ii) a nucleic acid-editing enzyme or domain (e.g., a second protein) may be useful for improving specificity of the fusion protein to a target nucleic acid sequence, or for improving specificity or binding affinity of the fusion protein to bind target nucleic acid sequence that does not contain a canonical PAM (NGG) sequence. In some embodiments, the third protein is a Cas9 protein (e.g., a second Cas9 protein). In some embodiments, the third protein is any of the Cas9 proteins provided herein. In some embodiments, the third protein is fused to the fusion protein N-terminal to the Cas9 protein (e.g., the first protein). In some embodiments, the third protein is fused to the fusion protein C-terminal to the Cas9 protein (e.g., the first protein). In some embodiments, the Cas9 domain (e.g., the first protein) and the third protein (e.g., a second Cas9 protein) are fused via a linker (e.g., a second linker). In some embodiments, the linker comprises a (GGGGS)n (SEQ ID NO: 5), a (G)n, an (EAAAK)n (SEQ ID NO: 6), a (GGS)n, (SGGS)_n(SEQ ID NO: 4288), an SGSETPGTSESATPES (SEQ ID NO: 7), or an (XP)n motif, or a combination of any of these, wherein n is independently an integer between 1 and 30. In some embodiments, the general architecture of exemplary Cas9 fusion proteins provided herein comprises the structure:

- [NH2]-[nucleic acid-editing enzyme or domain]-[Cas9]-[third protein]-[COOH];
- [NH2]-[third protein]-[Cas9]-[nucleic acid-editing enzyme or domain]-[COOH];
- [NH2]-[Cas9]-[nucleic acid-editing enzyme or domain]-[third protein]-[COOH];
- [NH2]-[third protein]-[nucleic acid-editing enzyme or domain]-[Cas9]-[COOH];
- [NH2]-[UGI]-[nucleic acid-editing enzyme or domain]-[Cas9]-[third protein]-[COOH];
- [NH2]-[UGI]-[third protein]-[Cas9]-[nucleic acid-editing enzyme or domain]-[COOH];
- [NH2]-[UGI]-[Cas9]-[nucleic acid-editing enzyme or domain]-[third protein]-[COOH];
- [NH2]-[UGI]-[third protein]-[nucleic acid-editing enzyme or domain]-[Cas9]-[COOH];
- [NH2]-[nucleic acid-editing enzyme or domain]-[Cas9]-[third protein]-[UGI]-[COOH];
- [NH2]-[third protein]-[Cas9]-[nucleic acid-editing enzyme or domain]-[UGI]-[COOH];
- [NH2]-[Cas9]-[nucleic acid-editing enzyme or domain]-[third protein]-[UGI]-[COOH]; or
- [NH2]-[third protein]-[nucleic acid-editing enzyme or domain]-[Cas9]-[UGI]-[COOH];
  
  wherein NH2 is the N-terminus of the fusion protein, and COOH is the C-terminus of the fusion protein. In some embodiments, the “]-[” used in the general architecture above indicates the presence of an optional linker sequence. In other examples, the general architecture of exemplary Cas9 fusion proteins provided herein comprises the structure:
- [NH2]-[nucleic acid-editing enzyme or domain]-[Cas9]-[second Cas9 protein]-[COOH];
- [NH2]-[second Cas9 protein]-[Cas9]-[nucleic acid-editing enzyme or domain]-[COOH];
- [NH2]-[Cas9]-[nucleic acid-editing enzyme or domain]-[second Cas9 protein]-[COOH];
- [NH2]-[second Cas9 protein]-[nucleic acid-editing enzyme or domain]-[Cas9]-[COOH];
- [NH2]-[UGI]-[nucleic acid-editing enzyme or domain]-[Cas9]-[second Cas9 protein]-[COOH],
- [NH2]-[UGI]-[second Cas9 protein]-[Cas9]-[nucleic acid-editing enzyme or domain]-[COOH];
- [NH2]-[UGI]-[Cas9]-[nucleic acid-editing enzyme or domain]-[second Cas9 protein]-[COOH];
- [NH2]-[UGI]-[second Cas9 protein]-[nucleic acid-editing enzyme or domain]-[Cas9]-[COOH];
- [NH2]-[nucleic acid-editing enzyme or domain]-[Cas9]-[second Cas9 protein]-[UGI]-[COOH];
- [NH2]-[second Cas9 protein]-[Cas9]-[nucleic acid-editing enzyme or domain]-[UGI]-[COOH];
- [NH2]-[Cas9]-[nucleic acid-editing enzyme or domain]-[second Cas9 protein]-[UGI]-[COOH]; or
- [NH2]-[second Cas9 protein]-[nucleic acid-editing enzyme or domain]-[Cas9]-[UGI]-[COOH];
  
  wherein NH₂is the N-terminus of the fusion protein, and COOH is the C-terminus of the fusion protein. In some embodiments, the “]-[” used in the general architecture above indicates the presence of an optional linker sequence. In some embodiments, the second Cas9 is a dCas9 protein. In some examples, the general architecture of exemplary Cas9 fusion proteins provided herein comprises a structure as shown in FIG. 3. It should be appreciated that any of the proteins provided in any of the general architectures of exemplary Cas9 fusion proteins may be connected by one or more of the linkers provided herein. In some embodiments, the linkers are the same. In some embodiments, the linkers are different. In some embodiments, one or more of the proteins provided in any of the general architectures of exemplary Cas9 fusion proteins are not fused via a linker. In some embodiments, the fusion proteins further comprise a nuclear targeting sequence, for example a nuclear localization sequence. In some embodiments, fusion proteins provided herein further comprise a nuclear localization sequence (NLS). In some embodiments, the NLS is fused to the N-terminus of the fusion protein. In some embodiments, the NLS is fused to the C-terminus of the fusion protein. In some embodiments, the NLS is fused to the N-terminus of the third protein. In some embodiments, the NLS is fused to the C-terminus of the third protein. In some embodiments, the NLS is fused to the N-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the C-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the N-terminus of the nucleic acid-editing enzyme or domain. In some embodiments, the NLS is fused to the C-terminus of the nucleic acid-editing enzyme or domain. In some embodiments, the NLS is fused to the N-terminus of the UGI protein. In some embodiments, the NLS is fused to the C-terminus of the UGI protein. In some embodiments, the NLS is fused to the fusion protein via one or more linkers. In some embodiments, the NLS is fused to the fusion protein without a linker
  
  Uracil Glycosylase Inhibitor Fusion Proteins

Some aspects of the disclosure relate to fusion proteins that comprise a uracil glycosylase inhibitor (UGI) domain. In some embodiments, any of the fusion proteins provided herein that comprise a Cas9 domain (e.g., a nuclease active Cas9 domain, a nuclease inactive dCas9 domain, or a Cas9 nickase) may be further fused to a UGI domain either directly or via a linker. Some aspects of this disclosure provide deaminase-dCas9 fusion proteins, deaminase-nuclease active Cas9 fusion proteins and deaminase-Cas9 nickase fusion proteins with increased nucleobase editing efficiency. Without wishing to be bound by any particular theory, cellular DNA-repair response to the presence of U:G heteroduplex DNA may be responsible for the decrease in nucleobase editing efficiency in cells. For example, uracil DNA glycosylase (UDG) catalyzes removal of U from DNA in cells, which may initiate base excision repair, with reversion of the U:G pair to a C:G pair as the most common outcome. As demonstrated in the Examples below, Uracil DNA Glycosylase Inhibitor (UGI) may inhibit human UDG activity. Thus, this disclosure contemplates a fusion protein comprising dCas9-nucleic acid editing domain further fused to a UGI domain. This disclosure also contemplates a fusion protein comprising a Cas9 nickase-nucleic acid editing domain further fused to a UGI domain. It should be understood that the use of a UGI domain may increase the editing efficiency of a nucleic acid editing domain that is capable of catalyzing a C to U change. For example, fusion proteins comprising a UGI domain may be more efficient in deaminating C residues. In some embodiments, the fusion protein comprises the structure:

[deaminase]-[optional linker sequence]-[dCas9]-[optional linker sequence]-[UGI];

[deaminase]-[optional linker sequence]-[UGI]-[optional linker sequence]-[dCas9];

[UGI]-[optional linker sequence]-[deaminase]-[optional linker sequence]-[dCas9];

[UGI]-[optional linker sequence]-[dCas9]-[optional linker sequence]-[deaminase];

[dCas9]-[optional linker sequence]-[deaminase]-[optional linker sequence]-[UGI]; or

[dCas9]-[optional linker sequence]-[UGI]-[optional linker sequence]-[deaminase].

In other embodiments, the fusion protein comprises the structure:

[deaminase]-[optional linker sequence]-[Cas9 nickase]-[optional linker sequence]-[UGI];

[deaminase]-[optional linker sequence]-[UGI]-[optional linker sequence]-[Cas9 nickase];

[UGI]-[optional linker sequence]-[deaminase]-[optional linker sequence]-[Cas9 nickase];

[UGI]-[optional linker sequence]-[Cas9 nickase]-[optional linker sequence]-[deaminase];

[Cas9 nickase]-[optional linker sequence]-[deaminase]-[optional linker sequence]-[UGI]; or

[Cas9 nickase]-[optional linker sequence]-[UGI]-[optional linker sequence]-[deaminase].

In some embodiments, the fusion proteins provided herein do not comprise a linker sequence. In some embodiments, one or both of the optional linker sequences are present.

In some embodiments, the “-” used in the general architecture above indicates the presence of an optional linker sequence. In some embodiments, the fusion proteins comprising a UGI further comprise a nuclear targeting sequence, for example a nuclear localization sequence. In some embodiments, fusion proteins provided herein further comprise a nuclear localization sequence (NLS). In some embodiments, the NLS is fused to the N-terminus of the fusion protein. In some embodiments, the NLS is fused to the C-terminus of the fusion protein. In some embodiments, the NLS is fused to the N-terminus of the UGI protein. In some embodiments, the NLS is fused to the C-terminus of the UGI protein. In some embodiments, the NLS is fused to the N-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the C-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the N-terminus of the deaminase. In some embodiments, the NLS is fused to the C-terminus of the deaminase. In some embodiments, the NLS is fused to the N-terminus of the second Cas9. In some embodiments, the NLS is fused to the C-terminus of the second Cas9. In some embodiments, the NLS is fused to the fusion protein via one or more linkers. In some embodiments, the NLS is fused to the fusion protein without a linker. In some embodiments, the NLS comprises an amino acid sequence of any one of the NLS sequences provided or referenced herein. In some embodiments, the NLS comprises an amino acid sequence as set forth in SEQ ID NO: 741 or SEQ ID NO: 742.

In some embodiments, a UGI domain comprises a wild-type UGI or a UGI as set forth in SEQ ID NO: 600. In some embodiments, the UGI proteins provided herein include fragments of UGI and proteins homologous to a UGI or a UGI fragment. For example, in some embodiments, a UGI domain comprises a fragment of the amino acid sequence set forth in SEQ ID NO: 600. In some embodiments, a UGI fragment comprises an amino acid sequence that comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid sequence as set forth in SEQ ID NO: 600. In some embodiments, a UGI comprises an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 600 or an amino acid sequence homologous to a fragment of the amino acid sequence set forth in SEQ ID NO: 600. In some embodiments, proteins comprising UGI or fragments of UGI or homologs of UGI or UGI fragments are referred to as “UGI variants.” A UGI variant shares homology to UGI, or a fragment thereof. For example a UGI variant is at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, at least 99.5% identical, or at least 99.9% identical to a wild type UGI or a UGI as set forth in SEQ ID NO: 600. In some embodiments, the UGI variant comprises a fragment of UGI, such that the fragment is at least 70% identical, at least 80% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, at least 99.5% identical, or at least 99.9% to the corresponding fragment of wild-type UGI or a UGI as set forth in SEQ ID NO: 600. In some embodiments, the UGI comprises the following amino acid sequence:

>sp|P14739|UNGI_BPPB2 Uracil-DNA glycosylase

inhibitor

(SEQ ID NO: 600)

MTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDES

TDENVMLLTSDAPEYKPWALVIQDSNGENKIKML

Suitable UGI protein and nucleotide sequences are provided herein and additional suitable UGI sequences are known to those in the art, and include, for example, those published in Wang et al., Uracil-DNA glycosylase inhibitor gene of bacteriophage PBS2 encodes a binding protein specific for uracil-DNA glycosylase. J. Biol. Chem. 264:1163-1171 (1989); Lundquist et al., Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein. Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase. J. Biol. Chem. 272:21408-21419 (1997); Ravishankar et al., X-ray analysis of a complex of Escherichia coli uracil DNA glycosylase (EcUDG) with a proteinaceous inhibitor. The structure elucidation of a prokaryotic UDG. Nucleic Acids Res. 26:4880-4887 (1998); and Putnam et al., Protein mimicry of DNA from crystal structures of the uracil-DNA glycosylase inhibitor protein and its complex with Escherichia coli uracil-DNA glycosylase. J. Mol. Biol. 287:331-346 (1999), the entire contents of each are incorporated herein by reference.

It should be appreciated that additional proteins may be uracil glycosylase inhibitors. For example, other proteins that are capable of inhibiting (e.g., sterically blocking) a uracil-DNA glycosylase base-excision repair enzyme are within the scope of this disclosure. Additionally, any proteins that block or inhibit base-excision repair as also within the scope of this disclosure. In some embodiments, a protein that binds DNA is used. In another embodiment, a substitute for UGI is used. In some embodiments, a uracil glycosylase inhibitor is a protein that binds single-stranded DNA. For example, a uracil glycosylase inhibitor may be a Erwinia tasmaniensis single-stranded binding protein. In some embodiments, the single-stranded binding protein comprises the amino acid sequence (SEQ ID NO: 322). In some embodiments, a uracil glycosylase inhibitor is a protein that binds uracil. In some embodiments, a uracil glycosylase inhibitor is a protein that binds uracil in DNA. In some embodiments, a uracil glycosylase inhibitor is a catalytically inactive uracil DNA-glycosylase protein. In some embodiments, a uracil glycosylase inhibitor is a catalytically inactive uracil DNA-glycosylase protein that does not excise uracil from the DNA. For example, a uracil glycosylase inhibitor is a UdgX. In some embodiments, the UdgX comprises the amino acid sequence (SEQ ID NO: 323). As another example, a uracil glycosylase inhibitor is a catalytically inactive UDG. In some embodiments, a catalytically inactive UDG comprises the amino acid sequence (SEQ ID NO: 324). It should be appreciated that other uracil glycosylase inhibitors would be apparent to the skilled artisan and are within the scope of this disclosure. In some embodiments, a uracil glycosylase inhibitor is a protein that is homologous to any one of SEQ ID NOs: 322-324. In some embodiments, a uracil glycosylase inhibitor is a protein that is at least 50% identical, at least 55% identical at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical at least 85% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical to any one of SEQ ID NOs: 322-324.

Erwinia tasmaniensis SSB (themostable single-

stranded DNA binding protein)

(SEQ ID NO: 322)

MASRGVNKVILVGNLGQDPEVRYMPNGGAVANITLATSESWRDKQTGETK

EKTEWHRVVLFGKLAEVAGEYLRKGSQVYIEGALQTRKWTDQAGVEKYTT

EVVVNVGGTMQMLGGRSQGGGASAGGQNGGSNNGWGQPQQPQGGNQFSGG

AQQQARPQQQPQQNNAPANNEPPIDFDDDIP

UdgX (binds to Uracil in DNA but does not excise)

(SEQ ID NO: 323)

MAGAQDFVPHTADLAELAAAAGECRGCGLYRDATQAVFGAGGRSARIMMI

GEQPGDKEDLAGLPFVGPAGRLLDRALEAADIDRDALYVTNAVKHFKFTR

AAGGKRRIHKTPSRTEVVACRPWLIAEMTSVEPDVVVLLGATAAKALLGN

DFRVTQHRGEVLHVDDVPGDPALVATVHPSSLLRGPKEERESAFAGLVDD

LRVAADVRP

UDG (catalytically inactive human UDG, binds to

Uracil in DNA but does not excise)

(SEQ ID NO: 324)

MIGQKTLYSFFSPSPARKRHAPSPEPAVQGTGVAGVPEESGDAAAIPAKK

APAGQEEPGTPPSSPLSAEQLDRIQRNKAAALLRLAARNVPVGFGESWKK

HLSGEFGKPYFIKLMGFVAEERKHYTVYPPPHQVFTWTQMCDIKDVKVVI

LGQEPYHGPNQAHGLCFSVQRPVPPPPSLENIYKELSTDIEDFVHPGHGD

LSGWAKQGVLLLNAVLTVRAHQANSHKERGWEQFTDAVVSWLNQNSNGLV

FLLWGSYAQKKGSAIDRKRHHVLQTAHPSPLSVYRGFFGCRHFSKTNELL

QKSGKKPIDWKEL

In some embodiments, the nucleic acid editing domain is a deaminase domain. In some embodiments, the deaminase is a cytosine deaminase or a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3A deaminase. In some embodiments, the deaminase is an APOBEC3B deaminase. In some embodiments, the deaminase is an APOBEC3C deaminase. In some embodiments, the deaminase is an APOBEC3D deaminase. In some embodiments, the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID). In some embodiments, the demianse is a rat APOBEC1 (SEQ ID NO: 282). In some embodiments, the deminase is a human APOBEC1 (SEQ ID No: 284). In some embodiments, the deaminase is a Petromyzon marinus cytidine deaminase 1 (pmCDA1). In some embodiments, the deminase is a human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a fragment of the human APOBEC3G (SEQ ID NO: 5740). In some embodiments, the deaminase is a human APOBEC3G variant comprising a D316R_D317R mutation (SEQ ID NO: 5739). In some embodiments, the deaminase is a frantment of the human APOBEC3G and comprising mutations corresponding to the D316R_D317R mutations in SEQ ID NO: 275 (SEQ ID NO: 5741).

In some embodiments, the linker comprises a (GGGS)_n(SEQ ID NO: 265), (GGGGS)_n(SEQ ID NO: 5), a (G)_n, an (EAAAK)_n(SEQ ID NO: 6), a (GGS)_n, an SGSETPGTSESATPES (SEQ ID NO: 7), or an (XP)_nmotif, or a combination of any of these, wherein n is independently an integer between 1 and 30.

Suitable UGI protein and nucleotide sequences are provided herein and additional suitable UGI sequences are known to those in the art, and include, for example, those published in Wang et al., Uracil-DNA glycosylase inhibitor gene of bacteriophage PBS2 encodes a binding protein specific for uracil-DNA glycosylase. J. Biol. Chem. 264:1163-1171 (1989); Lundquist et al., Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein. Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase. J. Biol. Chem. 272:21408-21419 (1997); Ravishankar et al., X-ray analysis of a complex of Escherichia coli uracil DNA glycosylase (EcUDG) with a proteinaceous inhibitor. The structure elucidation of a prokaryotic UDG. Nucleic Acids Res. 26:4880-4887 (1998); and Putnam et al., Protein mimicry of DNA from crystal structures of the uracil-DNA glycosylase inhibitor protein and its complex with Escherichia coli uracil-DNA glycosylase. J. Mol. Biol. 287:331-346 (1999), the entire contents of which are incorporated herein by reference. In some embodiments, the optional linker comprises a (GGS)_nmotif, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 19, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, the optional linker comprises a (GGS)n motif, wherein n is 1, 3, or 7. In some embodiments, the optional linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7), which is also referred to as the XTEN linker in the Examples.

In some embodiments, a Cas9 nickase may further facilitate the removal of a base on the non-edited strand in an organism whose genome is edited in vivo. The Cas9 nickase, as described herein, may comprise a D10A mutation in SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260. In some embodiments, the Cas9 nickase of this disclosure may comprise a histidine at mutation 840 of SEQ ID NO: 10, or a corresponding residue in any of SEQ ID NOs: 11-260. Such fusion proteins comprising the Cas9 nickase, can cleave a single strand of the target DNA sequence, e.g., the strand that is not being edited. Without wishing to be bound by any particular theory, this cleavage may inhibit mis-match repair mechanisms that reverse a C to U edit made by the deaminase.

Cas9 Complexes with Guide RNAs

Some aspects of this disclosure provide complexes comprising any of the fusion proteins provided herein, and a guide RNA bound to a Cas9 domain (e.g., a dCas9, a nuclease active Cas9, or a Cas9 nickase) of fusion protein.

In some embodiments, the guide RNA is from 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence. In some embodiments, the guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides long. In some embodiments, the guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a target sequence. In some embodiments, the target sequence is a DNA sequence. In some embodiments, the target sequence is a sequence in the genome of a mammal. In some embodiments, the target sequence is a sequence in the genome of a human. In some embodiments, the 3′ end of the target sequence is immediately adjacent to a canonical PAM sequence (NGG). In some embodiments, the guide RNA is complementary to a sequence associated with a disease or disorder. In some embodiments, the guide RNA is complementary to a sequence associated with a disease or disorder having a mutation in a gene selected from the genes disclosed in any one of Tables 1-3. In some embodiments, the guide RNA comprises a nucleotide sequence of any one of the guide sequences provided in Table 2 or Table 3. Exemplary sequences in the human genome that may be targeted by the complexes of this disclosure are provided herein in Tables 1-3.

Methods of Using Cas9 Fusion Proteins

Some aspects of this disclosure provide methods of using the Cas9 proteins, fusion proteins, or complexes provided herein. For example, some aspects of this disclosure provide methods comprising contacting a DNA molecule (a) with any of the the Cas9 proteins or fusion proteins provided herein, and with at least one guide RNA, wherein the guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence; or (b) with a Cas9 protein, a Cas9 fusion protein, or a Cas9 protein or fusion protein complex with at least one gRNA as provided herein. In some embodiments, the 3′ end of the target sequence is not immediately adjacent to a canonical PAM sequence (NGG). In some embodiments, the 3′ end of the target sequence is immediately adjacent to an AGC, GAG, TTT, GTG, or CAA sequence.

In some embodiments, the target DNA sequence comprises a sequence associated with a disease or disorder. In some embodiments, the target DNA sequence comprises a point mutation associated with a disease or disorder. In some embodiments, the activity of the Cas9 protein, the Cas9 fusion protein, or the complex results in a correction of the point mutation. In some embodiments, the target DNA sequence comprises a T→C point mutation associated with a disease or disorder, and wherein the deamination of the mutant C base results in a sequence that is not associated with a disease or disorder. In some embodiments, the target DNA sequence encodes a protein and wherein the point mutation is in a codon and results in a change in the amino acid encoded by the mutant codon as compared to the wild-type codon. In some embodiments, the deamination of the mutant C results in a change of the amino acid encoded by the mutant codon. In some embodiments, the deamination of the mutant C results in the codon encoding the wild-type amino acid. In some embodiments, the contacting is in vivo in a subject. In some embodiments, the subject has or has been diagnosed with a disease or disorder. In some embodiments, the disease or disorder is cystic fibrosis, phenylketonuria, epidermolytic hyperkeratosis (EHK), Charcot-Marie-Toot disease type 4J, neuroblastoma (NB), von Willebrand disease (vWD), myotonia congenital, hereditary renal amyloidosis, dilated cardiomyopathy (DCM), hereditary lymphedema, familial Alzheimer's disease, HIV, Prion disease, chronic infantile neurologic cutaneous articular syndrome (CINCA), desmin-related myopathy (DRM), a neoplastic disease associated with a mutant PI3KCA protein, a mutant CTNNB1 protein, a mutant HRAS protein, or a mutant p53 protein.

Some embodiments provide methods for using the Cas9 DNA editing fusion proteins provided herein. In some embodiments, the fusion protein is used to introduce a point mutation into a nucleic acid by deaminating a target nucleobase, e.g., a C residue. In some embodiments, the deamination of the target nucleobase results in the correction of a genetic defect, e.g., in the correction of a point mutation that leads to a loss of function in a gene product. In some embodiments, the genetic defect is associated with a disease or disorder, e.g., a lysosomal storage disorder or a metabolic disease, such as, for example, type I diabetes. In some embodiments, the methods provided herein are used to introduce a deactivating point mutation into a gene or allele that encodes a gene product that is associated with a disease or disorder. For example, in some embodiments, methods are provided herein that employ a Cas9 DNA editing fusion protein to introduce a deactivating point mutation into an oncogene (e.g., in the treatment of a proliferative disease). A deactivating mutation may, in some embodiments, generate a premature stop codon in a coding sequence, which results in the expression of a truncated gene product, e.g., a truncated protein lacking the function of the full-length protein.

In some embodiments, the purpose of the methods provide herein is to restore the function of a dysfunctional gene via genome editing. The Cas9 deaminase fusion proteins provided herein can be validated for gene editing-based human therapeutics in vitro, e.g., by correcting a disease-associated mutation in human cell culture. It will be understood by the skilled artisan that the fusion proteins provided herein, e.g., the fusion proteins comprising a Cas9 domain and a nucleic acid deaminase domain can be used to correct any single point T→C or A→G mutation. In the first case, deamination of the mutant C back to U corrects the mutation, and in the latter case, deamination of the C that is base-paired with the mutant G, followed by a round of replication, corrects the mutation.

An exemplary disease-relevant mutation that can be corrected by the provided fusion proteins in vitro or in vivo is the H1047R (A3140G) polymorphism in the PI3KCA protein. The phosphoinositide-3-kinase, catalytic alpha subunit (PI3KCA) protein acts to phosphorylate the 3-OH group of the inositol ring of phosphatidylinositol. The PI3KCA gene has been found to be mutated in many different carcinomas, and thus it is considered to be a potent oncogene.³⁷In fact, the A3140G mutation is present in several NCI-60 cancer cell lines, such as, for example, the HCT116, SKOV3, and T47D cell lines, which are readily available from the American Type Culture Collection (ATCC).³⁸

In some embodiments, a cell carrying a mutation to be corrected, e.g., a cell carrying a point mutation, e.g., an A3140G point mutation in exon 20 of the PI3KCA gene, resulting in a H1047R substitution in the PI3KCA protein, is contacted with an expression construct encoding a Cas9 deaminase fusion protein and an appropriately designed sgRNA targeting the fusion protein to the respective mutation site in the encoding PI3KCA gene. Control experiments can be performed where the sgRNAs are designed to target the fusion enzymes to non-C residues that are within the PI3KCA gene. Genomic DNA of the treated cells can be extracted, and the relevant sequence of the PI3KCA genes PCR amplified and sequenced to assess the activities of the fusion proteins in human cell culture.

It will be understood that the example of correcting point mutations in PI3KCA is provided for illustration purposes and is not meant to limit the instant disclosure. The skilled artisan will understand that the instantly disclosed DNA-editing fusion proteins can be used to correct other point mutations and mutations associated with other cancers and with diseases other than cancer including other proliferative diseases.

The successful correction of point mutations in disease-associated genes and alleles opens up new strategies for gene correction with applications in therapeutics and basic research. Site-specific single-base modification systems like the disclosed fusions of Cas9 and deaminase enzymes or domains also have applications in “reverse” gene therapy, where certain gene functions are purposely suppressed or abolished. In these cases, site-specifically mutating Trp (TGG), Gln (CAA and CAG), or Arg (CGA) residues to premature stop codons (TAA, TAG, TGA) can be used to abolish protein function in vitro, ex vivo, or in vivo.

The instant disclosure provides methods for the treatment of a subject diagnosed with a disease associated with or caused by a point mutation that can be corrected by a Cas9 DNA editing fusion protein provided herein. For example, in some embodiments, a method is provided that comprises administering to a subject having such a disease, e.g., a cancer associated with a PI3KCA point mutation as described above, an effective amount of a Cas9 deaminase fusion protein that corrects the point mutation or introduces a deactivating mutation into the disease-associated gene. In some embodiments, the disease is a proliferative disease. In some embodiments, the disease is a genetic disease. In some embodiments, the disease is a neoplastic disease. In some embodiments, the disease is a metabolic disease. In some embodiments, the disease is a lysosomal storage disease. Other diseases that can be treated by correcting a point mutation or introducing a deactivating mutation into a disease-associated gene will be known to those of skill in the art, and the disclosure is not limited in this respect.

The instant disclosure provides methods for the treatment of additional diseases or disorders, e.g., diseases or disorders that are associated or caused by a point mutation that can be corrected by deaminase-mediated gene editing. Some such diseases are described herein, and additional suitable diseases that can be treated with the strategies and fusion proteins provided herein will be apparent to those of skill in the art based on the instant disclosure. Exemplary suitable diseases and disorders are listed below. It will be understood that the numbering of the specific positions or residues in the respective sequences depends on the particular protein and numbering scheme used. Numbering might be different, e.g., in precursors of a mature protein and the mature protein itself, and differences in sequences from species to species may affect numbering. One of skill in the art will be able to identify the respective residue in any homologous protein and in the respective encoding nucleic acid by methods well known in the art, e.g., by sequence alignment and determination of homologous residues. Exemplary suitable diseases and disorders include, without limitation, cystic fibrosis (see, e.g., Schwank et al., Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell stem cell. 2013; 13: 653-658; and Wu et. al., Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell stem cell. 2013; 13: 659-662, neither of which uses a deaminase fusion protein to correct the genetic defect); phenylketonuria—e.g., phenylalanine to serine mutation at position 835 (mouse) or 240 (human) or a homologous residue in phenylalanine hydroxylase gene (T>C mutation)—see, e.g., McDonald et al., Genomics. 1997; 39:402-405; Bernard-Soulier syndrome (BSS)—e.g., phenylalanine to serine mutation at position 55 or a homologous residue, or cysteine to arginine at residue 24 or a homologous residue in the platelet membrane glycoprotein IX (T>C mutation)—see, e.g., Noris et al., British Journal of Haematology. 1997; 97: 312-320, and Ali et al., Hematol. 2014; 93: 381-384; epidermolytic hyperkeratosis (EHK)—e.g., leucine to proline mutation at position 160 or 161 (if counting the initiator methionine) or a homologous residue in keratin 1 (T>C mutation)—see, e.g., Chipev et al., Cell. 1992; 70: 821-828, see also accession number P04264 in the UNIPROT database at www[dot]uniprot[dot]org; chronic obstructive pulmonary disease (COPD)—e.g., leucine to proline mutation at position 54 or 55 (if counting the initiator methionine) or a homologous residue in the processed form of α₁-antitrypsin or residue 78 in the unprocessed form or a homologous residue (T>C mutation)—see, e.g., Poller et al., Genomics. 1993; 17: 740-743, see also accession number P01011 in the UNIPROT database; Charcot-Marie-Toot disease type 4J—e.g., isoleucine to threonine mutation at position 41 or a homologous residue in FIG4 (T>C mutation)—see, e.g., Lenk et al., PLoS Genetics. 2011; 7: e1002104; neuroblastoma (NB)—e.g., leucine to proline mutation at position 197 or a homologous residue in Caspase-9 (T>C mutation)—see, e.g., Kundu et al., 3 Biotech. 2013, 3:225-234; von Willebrand disease (vWD)—e.g., cysteine to arginine mutation at position 509 or a homologous residue in the processed form of von Willebrand factor, or at position 1272 or a homologous residue in the unprocessed form of von Willebrand factor (T>C mutation)—see, e.g., Lavergne et al., Br. J. Haematol. 1992, see also accession number P04275 in the UNIPROT database; 82: 66-72; myotonia congenital—e.g., cysteine to arginine mutation at position 277 or a homologous residue in the muscle chloride channel gene CLCN1 (T>C mutation)—see, e.g., Weinberger et al., The J. of Physiology. 2012; 590: 3449-3464; hereditary renal amyloidosis—e.g., stop codon to arginine mutation at position 78 or a homologous residue in the processed form of apolipoprotein AII or at position 101 or a homologous residue in the unprocessed form (T>C mutation)—see, e.g., Yazaki et al., Kidney Int. 2003; 64: 11-16; dilated cardiomyopathy (DCM)—e.g., tryptophan to Arginine mutation at position 148 or a homologous residue in the FOXD4 gene (T>C mutation), see, e.g., Minoretti et. al., Int. J. of Mol. Med. 2007; 19: 369-372; hereditary lymphedema—e.g., histidine to arginine mutation at position 1035 or a homologous residue in VEGFR3 tyrosine kinase (A>G mutation), see, e.g., Irrthum et al., Am. J. Hum. Genet. 2000; 67: 295-301; familial Alzheimer's disease—e.g., isoleucine to valine mutation at position 143 or a homologous residue in presenilin1 (A>G mutation), see, e.g., Gallo et. al., J. Alzheimer's disease. 2011; 25: 425-431; Prion disease—e.g., methionine to valine mutation at position 129 or a homologous residue in prion protein (A>G mutation)—see, e.g., Lewis et. al., J. of General Virology. 2006; 87: 2443-2449; chronic infantile neurologic cutaneous articular syndrome (CINCA)—e.g., Tyrosine to Cysteine mutation at position 570 or a homologous residue in cryopyrin (A>G mutation)—see, e.g., Fujisawa et. al. Blood. 2007; 109: 2903-2911; and desmin-related myopathy (DRM)—e.g., arginine to glycine mutation at position 120 or a homologous residue in αβ crystallin (A>G mutation)—see, e.g., Kumar et al., J. Biol. Chem. 1999; 274: 24137-24141. The entire contents of all references and database entries is incorporated herein by reference.

The instant disclosure provides lists of genes comprising pathogenic T>C or A>G mutations. Provided herein, are the names of these genes, their respective SEQ ID NOs, their gene IDs, and sequences flanking the mutation site. (Tables 2 and 3). In some instances, the gRNA sequences that can be used to correct the mutations in these genes are disclosed (Tables 2 and 3).

In some embodiments, a Cas9-deaminase fusion protein recognizes canonical PAMs and therefore can correct the pathogenic T>C or A>G mutations with canonical PAMs, e.g., NGG (listed in Tables 2 and 3, SEQ ID NOs: 2540-2702 and 5084-5260), respectively, in the flanking sequences. For example, the Cas9 proteins that recognize canonical PAMs comprise an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 10, or to a fragment thereof comprising the RuvC and HNH domains of SEQ ID NO: 10.

It will be apparent to those of skill in the art that in order to target a Cas9:nucleic acid editing enzyme/domain fusion protein as disclosed herein to a target site, e.g., a site comprising a point mutation to be edited, it is typically necessary to co-express the Cas9:nucleic acid editing enzyme/domain fusion protein together with a guide RNA, e.g., an sgRNA. As explained in more detail elsewhere herein, a guide RNA typically comprises a tracrRNA framework allowing for Cas9 binding, and a guide sequence, which confers sequence specificity to the Cas9:nucleic acid editing enzyme/domain fusion protein. In some embodiments, the guide RNA comprises a structure 5′-[guide sequence]-guuuuagagcuagaaauagcaaguuaaaauaaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuuuuu-3′ (SEQ ID NO: 601), wherein the guide sequence comprises a sequence that is complementary to the target sequence. The guide sequence is typically 20 nucleotides long. The sequences of suitable guide RNAs for targeting Cas9:nucleic acid editing enzyme/domain fusion proteins to specific genomic target sites will be apparent to those of skill in the art based on the instant disclosure. Such suitable guide RNA sequences typically comprise guide sequences that are complementary to a nucleic sequence within 50 nucleotides upstream or downstream of the target nucleotide to be edited. Some exemplary guide RNA sequences suitable for targeting Cas9:nucleic acid editing enzyme/domain fusion proteins to specific target sequences are provided below.

Base Editor Efficiency

Some aspects of the disclosure are based on the recognition that any of the base editors provided herein are capable of modifying a specific nucleotide base without generating a significant proportion of indels. An “indel”, as used herein, refers to the insertion or deletion of a nucleotide base within a nucleic acid. Such insertions or deletions can lead to frame shift mutations within a coding region of a gene. In some embodiments, it is desirable to generate base editors that efficiently modify (e.g. mutate or deaminate) a specific nucleotide within a nucleic acid, without generating a large number of insertions or deletions (i.e., indels) in the nucleic acid. In certain embodiments, any of the base editors provided herein are capable of generating a greater proportion of intended modifications (e.g., point mutations or deaminations) versus indels. In some embodiments, the base editors provided herein are capable of generating a ratio of intended point mutations to indels that is greater than 1:1. In some embodiments, the base editors provided herein are capable of generating a ratio of intended point mutations to indels that is at least 1.5:1, at least 2:1, at least 2.5:1, at least 3:1, at least 3.5:1, at least 4:1, at least 4.5:1, at least 5:1, at least 5.5:1, at least 6:1, at least 6.5:1, at least 7:1, at least 7.5:1, at least 8:1, at least 10:1, at least 12:1, at least 15:1, at least 20:1, at least 25:1, at least 30:1, at least 40:1, at least 50:1, at least 100:1, at least 200:1, at least 300:1, at least 400:1, at least 500:1, at least 600:1, at least 700:1, at least 800:1, at least 900:1, or at least 1000:1, or more. The number of intended mutations and indels may be determined using any suitable method, for example the methods used in the below Examples.

In some embodiments, the base editors provided herein are capable of limiting formation of indels in a region of a nucleic acid. In some embodiments, the region is at a nucleotide targeted by a base editor or a region within 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides of a nucleotide targeted by a base editor. In some embodiments, any of the base editors provided herein are capable of limiting the formation of indels at a region of a nucleic acid to less than 1%, less than 1.5%, less than 2%, less than 2.5%, less than 3%, less than 3.5%, less than 4%, less than 4.5%, less than 5%, less than 6%, less than 7%, less than 8%, less than 9%, less than 10%, less than 12%, less than 15%, or less than 20%. The number of indels formed at a nucleic acid region may depend on the amount of time a nucleic acid (e.g., a nucleic acid within the genome of a cell) is exposed to a base editor. In some embodiments, an number or proportion of indels is determined after at least 1 hour, at least 2 hours, at least 6 hours, at least 12 hours, at least 24 hours, at least 36 hours, at least 48 hours, at least 3 days, at least 4 days, at least 5 days, at least 7 days, at least 10 days, or at least 14 days of exposing a nucleic acid (e.g., a nucleic acid within the genome of a cell) to a base editor.

Some aspects of the disclosure are based on the recognition that any of the base editors provided herein are capable of efficiently generating an intended mutation, such as a point mutation, in a nucleic acid (e.g. a nucleic acid within a genome of a subject) without generating a significant number of unintended mutations, such as unintended point mutations. In some embodiments, a intended mutation is a mutation that is generated by a specific base editor bound to a gRNA, specifically designed to generate the intended mutation. In some embodiments, the intended mutation is a mutation associated with a disease or disorder. In some embodiments, the intended mutation is a cytosine (C) to thymine (T) point mutation associated with a disease or disorder. In some embodiments, the intended mutation is a guanine (G) to adenine (A) point mutation associated with a disease or disorder. In some embodiments, the intended mutation is a cytosine (C) to thymine (T) point mutation within the coding region of a gene. In some embodiments, the intended mutation is a guanine (G) to adenine (A) point mutation within the coding region of a gene. In some embodiments, the intended mutation is a point mutation that generates a stop codon, for example, a premature stop codon within the coding region of a gene. In some embodiments, the intended mutation is a mutation that eliminates a stop codon. In some embodiments, the intended mutation is a mutation that alters the splicing of a gene. In some embodiments, the intended mutation is a mutation that alters the regulatory sequence of a gene (e.g., a gene promotor or gene repressor). In some embodiments, any of the base editors provided herein are capable of generating a ratio of intended mutations to unintended mutations (e.g., intended point mutations:unintended point mutations) that is greater than 1:1. In some embodiments, any of the base editors provided herein are capable of generating a ratio of intended mutations to unintended mutations (e.g., intended point mutations:unintended point mutations) that is at least 1.5:1, at least 2:1, at least 2.5:1, at least 3:1, at least 3.5:1, at least 4:1, at least 4.5:1, at least 5:1, at least 5.5:1, at least 6:1, at least 6.5:1, at least 7:1, at least 7.5:1, at least 8:1, at least 10:1, at least 12:1, at least 15:1, at least 20:1, at least 25:1, at least 30:1, at least 40:1, at least 50:1, at least 100:1, at least 150:1, at least 200:1, at least 250:1, at least 500:1, or at least 1000:1, or more. It should be appreciated that the characterstics of the base editors described in the “Base Editor Efficiency” section, herein, may be applied to any of the fusion proteins, or methods of using the fusion proteins provided herein.

Methods for Editing Nucleic Acids

Some aspects of the disclosure provide methods for editing a nucleic acid. In some embodiments, the method is a method for editing a nucleobase of a nucleic acid (e.g., a base pair of a double-stranded DNA sequence). In some embodiments, the method comprises the steps of: a) contacting a target region of a nucleic acid (e.g., a double-stranded DNA sequence) with a complex comprising a base editor (e.g., a Cas9 domain fused to a cytidine deaminase domain) and a guide nucleic acid (e.g., gRNA), wherein the target region comprises a targeted nucleobase pair, b) inducing strand separation of said target region, c) converting a first nucleobase of said target nucleobase pair in a single strand of the target region to a second nucleobase, and d) cutting no more than one strand of said target region, where a third nucleobase complementary to the first nucleobase base is replaced by a fourth nucleobase complementary to the second nucleobase; and the method results in less than 20% indel formation in the nucleic acid. It should be appreciated that in some embodiments, step b is omitted. In some embodiments, the first nucleobase is a cytosine. In some embodiments, the second nucleobase is a deaminated cytosine, or a uracil. In some embodiments, the third nucleobase is a guanine. In some embodiments, the fourth nucleobase is an adenine. In some embodiments, the first nucleobase is a cytosine, the second nucleobase is a deaminated cytosine, or a uracil, the third nucleobase is a guanine, and the fourth nucleobase is an adenine. In some embodiments, the method results in less than 19%, 18%, 16%, 14%, 12%, 10%, 8%, 6%, 4%, 2%, 1%, 0.5%, 0.2%, or less than 0.1% indel formation. In some embodiments, the method further comprises replacing the second nucleobase with a fifth nucleobase that is complementary to the fourth nucleobase, thereby generating an intended edited base pair (e.g., C:G→T:A). In some embodiments, the fifth nucleobase is a thymine. In some embodiments, at least 5% of the intended basepaires are edited. In some embodiments, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of the intended basepaires are edited.

In some embodiments, the ratio of intended products to unintended products in the target nucleotide is at least 2:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or 200:1, or more. In some embodiments, the ratio of intended point mutation to indel formation is greater than 1:1, 10:1, 50:1, 100:1, 500:1, or 1000:1, or more. In some embodiments, the cut single strand (nicked strand) is hybridized to the guide nucleic acid. In some embodiments, the cut single strand is opposite to the strand comprising the first nucleobase. In some embodiments, the base editor comprises a Cas9 domain. In some embodiments, the first base is cytosine, and the second base is not a G, C, A, or T. In some embodiments, the second base is uracil. In some embodiments, the first base is cytosine. In some embodiments, the second base is not a G, C, A, or T. In some embodiments, the second base is uracil. In some embodiments, the base editor inhibits base escision repair of the edited strand. In some embodiments, the base editor protects or binds the non-edited strand. In some embodiments, the base editor comprises UGI activity. In some embodiments, the base editor comprises nickase activity. In some embodiments, the intended edited basepair is upstream of a PAM site. In some embodiments, the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides upstream of the PAM site. In some embodiments, the intended edited basepair is downstream of a PAM site. In some embodiments, the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides downstream stream of the PAM site. In some embodiments, the method does not require a canonical (e.g., NGG) PAM site. In some embodiments, the nucleobase editor comprises a linker. In some embodiments, the linker is 1-25 amino acids in length. In some embodiments, the linker is 5-20 amino acids in length. In some embodiments, linker is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length. In some embodiments, the target region comprises a target window, wherein the target window comprises the target nucleobase pair. In some embodiments, the target window comprises 1-10 nucleotides. In some embodiments, the target window is 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, or 1 nucleotides in length. In some embodiments, the target window is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length. In some embodiments, the intended edited base pair is within the target window. In some embodiments, the target window comprises the intended edited base pair. In some embodiments, the method is performed using any of the base editors provided herein. In some embodiments, a target window is a deamination window

In some embodiments, the disclosure provides methods for editing a nucleotide. In some embodiments, the disclosure provides a method for editing a nucleobase pair of a double-stranded DNA sequence. In some embodiments, the method comprises a) contacting a target region of the double-stranded DNA sequence with a complex comprising a base editor and a guide nucleic acid (e.g., gRNA), where the target region comprises a target nucleobase pair, b) inducing strand separation of said target region, c) converting a first nucleobase of said target nucleobase pair in a single strand of the target region to a second nucleobase, d) cutting no more than one strand of said target region, wherein a third nucleobase complementary to the first nucleobase base is replaced by a fourth nucleobase complementary to the second nucleobase, and the second nucleobase is replaced with a fifth nucleobase that is complementary to the fourth nucleobase, thereby generating an intended edited basepair, wherein the efficiency of generating the intended edited basepair is at least 5%. It should be appreciated that in some embodiments, step b is omitted. In some embodiments, at least 5% of the intended basepaires are edited. In some embodiments, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of the intended basepaires are edited. In some embodiments, the method causes less than 19%, 18%, 16%, 14%, 12%, 10%, 8%, 6%, 4%, 2%, 1%, 0.5%, 0.2%, or less than 0.1% indel formation. In some embodiments, the ratio of intended product to unintended products at the target nucleotide is at least 2:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or 200:1, or more. In some embodiments, the ratio of intended point mutation to indel formation is greater than 1:1, 10:1, 50:1, 100:1, 500:1, or 1000:1, or more. In some embodiments, the cut single strand is hybridized to the guide nucleic acid. In some embodiments, the cut single strand is opposite to the strand comprising the first nucleobase. In some embodiments, the first base is cytosine. In some embodiments, the second nucleobase is not G, C, A, or T. In some embodiments, the second base is uracil. In some embodiments, the base editor inhibits base escision repair of the edited strand. In some embodiments, the base editor protects or binds the non-edited strand. In some embodiments, the nucleobase editor comprises UGI activity. In some embodiments, the nucleobase edit comprises nickase activity. In some embodiments, the intended edited basepair is upstream of a PAM site. In some embodiments, the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides upstream of the PAM site. In some embodiments, the intended edited basepair is downstream of a PAM site. In some embodiments, the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides downstream stream of the PAM site. In some embodiments, the method does not require a canonical (e.g., NGG) PAM site. In some embodiments, the nucleobase editor comprises a linker. In some embodiments, the linker is 1-25 amino acids in length. In some embodiments, the linker is 5-20 amino acids in length. In some embodiments, the linker is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length. In some embodiments, the target region comprises a target window, wherein the target window comprises the target nucleobase pair. In some embodiments, the target window comprises 1-10 nucleotides. In some embodiments, the target window is 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, or 1 nucleotides in length. In some embodiments, the target window is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length. In some embodiments, the intended edited base pair occurs within the target window. In some embodiments, the target window comprises the intended edited base pair. In some embodiments, the nucleobase editor is any one of the base editors provided herein.

Kits, Vectors, Cells

Some aspects of this disclosure provide cells comprising a Cas9 protein, a fusion protein, a nucleic acid molecule encoding the fusion protein, a complex comprise the Cas9 protein and the gRNA, and/or a vector as provided herein.

EXAMPLES
Example 1: Cas9 Deaminase Fusion Proteins

A number of Cas9:Deaminase fusion proteins were generated and deaminase activity of the generated fusions was characterized. The following deaminases were tested:

Human AID (hAID):

(SEQ ID NO: 607)

MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGYLR

NKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRG

NPYLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNT

FVENHERTFKAWEGLHENSVRLSRQLRRILLPLYEVDDLRDAFRTLGLLD

Human AID-DC (hAID-DC, truncated version of hAID

with 7-fold increased activity):

(SEQ ID NO: 608)

MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGYLR

NKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRG

NPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNT

FVENHERTFKAWEGLHENSVRLSRQLRRILL

Rat APOBEC1 (rAPOBEC1):

(SEQ ID NO: 284)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI

WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI

TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG

YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ

PQLTFFTIALQSCHYQRLPPHILWATGLK

Human APOBEC1 (hAPOBEC1)

(SEQ ID NO: 5724)

MTSEKGPSTGDPTLRRRIEPWEFDVFYDPRELRKEACLLYEIKWGMSRKI

WRSSGKNTTNHVEVNFIKKFTSERDFHPSMSCSITWFLSWSPCWECSQAI

REFLSRHPGVTLVIYVARLFWHMDQQNRQGLRDLVNSGVTIQIMRASEYY

HCWRNFVNYPPGDEAHWPQYPPLWMMLYALELHCIILSLPPCLKISRRWQ

NHLTFFRLHLQNCHYQTIPPHILLATGLIHPSVAWR

Petromyzon marinus (Lamprey) CDA1 (pmCDA1):

(SEQ ID NO: 609)

MTDAEYVRIHEKLDIYTFKKQFFNNKKSVSHRCYVLFELKRRGERRACFW

GYAVNKPQSGTERGIHAEIFSIRKVEEYLRDNPGQFTINWYSSWSPCADC

AEKILEWYNQELRGNGHTLKIWACKLYYEKNARNQIGLWNLRDNGVGLNV

MVSEHYQCCRKIFIQSSHNQLNENRWLEKTLKRAEKRRSELSIMIQVKIL

HTTKSPAV

Human APOBEC3G (hAPOBEC3G):

(SEQ ID NO: 610)

MELKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKCTRDMATFLA

EDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQH

CWSKFVYSQRELFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTFNFNNE

PWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAE

LCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCI

FTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQ

PWDGLDEHSQDLSGRLRAILQNQEN

Deaminase Activity on ssDNA. A USER (Uracil-Specific Excision Reagent) Enzyme-based assay for deamination was employed to test the activity of various deaminases on single-stranded DNA (ssDNA) substrates. USER Enzyme was obtained from New England Biolabs. An ssDNA substrate was provided with a target cytosine residue at different positions. Deamination of the ssDNA cytosine target residue results in conversion of the target cytosine to a uracil. The USER Enzyme excises the uracil base and cleaves the ssDNA backbone at that position, cutting the ssDNA substrate into two shorter fragments of DNA. In some assays, the ssDNA substrate is labeled on one end with a dye, e.g., with a 5′ Cy3 label (the * in the scheme below). Upon deamination, excision, and cleavage of the strand, the substrate can be subjected to electrophoresis, and the substrate and any fragment released from it can be visualized by detecting the label. Where Cy5 is images, only the fragment with the label will be visible via imaging.

In one USER Enzyme assay, ssDNA substrates were used that matched the target sequences of the various deaminases tested. Expression cassettes encoding the deaminases tested were inserted into a CMV backbone plasmid that has been used previously in the lab (Addgene plasmid 52970). The deaminase proteins were expressed using a TNT Quick Coupled Transcription/Translation System (Promega) according to the manufacturers recommendations. After 90 min of incubation, 5 mL of lysate was incubated with 5′ Cy3-labeled ssDNA substrate and 1 unit of USER Enzyme (NEB) for 3 hours. The DNA was resolved on a 10% TBE PAGE gel and the DNA was imaged using Cy-dye imaging. A schematic representation of the USER Enzyme assay is shown in FIG. 41.

FIG. 1 shows the deaminase activity of the tested deaminases on ssDNA substrates, such as Doench 1, Doench 2, G7′ and VEGF Target 2. The rAPOBEC1 enzyme exhibited a substantial amount of deamination on the single-stranded DNA substrate with a canonical NGG PAM, but not with a negative control non-canonical NNN PAM. Cas9 fusion proteins with APOBEC family deaminases were generated. The following fusion architectures were constructed and tested on ssDNA:

rAPOBEC1-GGS-dCas9 primary sequence

(SEQ ID NO: 611)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNT

NKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIAR

LYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLW

embedded image

rAPOBEC1-(GGS)₃-dCas9 primary sequence

(SEQ ID NO: 612)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNT

NKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIAR

LYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLW

embedded image

(SEQ ID NO: 613)

embedded image

VDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNTNKHVEVNFI

EKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYHHADPR

NRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLEL

YCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK

embedded image

(SEQ ID NO: 614)

embedded image

ETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNTNKH

VEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYH

HADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRL

YVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK

embedded image

(SEQ ID NO: 615)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNT

NKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIAR

LYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLW

embedded image

FIG. 2 shows that the N-terminal deaminase fusions showed significant activity on the single stranded DNA substrates. For this reason, only the N-terminal architecture was chosen for further experiments.

FIG. 3 illustrates double stranded DNA substrate binding by deaminase-dCas9:sgRNA complexes. A number of double stranded deaminase substrate sequences were generated. The sequences are provided below. The structures according to FIG. 3 are identified in these sequences (36 bp: underlined, sgRNA target sequence: bold; PAM: boxed; 21 bp: italicized). All substrates were labeled with a 5′-Cy3 label:

(SEQ ID NO:616)

2:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGTCCCGCGGATTT

embedded image

(SEQ ID NO:617)

3:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCTTCCGCGGATT

embedded image

(SEQ ID NO:618)

4:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCTTCCGCGGAT

embedded image

(SEQ ID NO:619)

5:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCATTCCGCGGA

embedded image

(SEQ ID NO:620)

6:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCTATTCCGCGG

embedded image

(SEQ ID NO:621)

7:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCTTATTCCGCG

embedded image

(SEQ ID NO:622)

8:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCATTATTCCGC

embedded image

(SEQ ID NO:623)

9:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCTATTATTCCG

embedded image

(SEQ ID NO:624)

10:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCATTATATTCC

embedded image

(SEQ ID NO:625)

11:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCTATTATATTC

embedded image

(SEQ ID NO:626)

12:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCTTATTATATT

embedded image

(SEQ ID NO:627)

13:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCATTATTATAT

embedded image

(SEQ ID NO:628)

14:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCTATTATTATA

embedded image

(SEQ ID NO:629)

15:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCATTATTATTA

embedded image

(SEQ ID NO:630)

18:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCCATTATTATTA

embedded image

“-”:

(SEQ ID NO:631)

GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGTA
ATATTAATTTAT

embedded image

(SEQ ID NO:632)

8U:GTAGGTAGTTAGGATGAATGGAAGGTTGGTGTAGATTATTATCUG

embedded image

*In all substrates except for “8U”, the top strand in FIG. 3 is the complement of the sequence specified here. In the case of “8U”, there is a “G” opposite the U.

FIG. 4 shows the results of a double stranded DNA Deamination Assay. The fusions were expressed and purified with an N-terminal His6 tag via both Ni-NTA and sepharose chromatography. In order to assess deamination on dsDNA substrates, the various dsDNA substrates shown on the previous slide were incubated at a 1:8 dsDNA:fusion protein ratio and incubated at 37° C. for 2 hours. Once the dCas9 portion of the fusion binds to the DNA it blocks access of the USER enzyme to the DNA. Therefore, the fusion proteins were denatured following the incubation and the dsDNA was purified on a spin column, followed by incubation for 45 min with the USER Enzyme and resolution of the resulting DNA substrate and substrate fragments on a 10% TBE-urea gel.

FIG. 5 demonstrates that Cas9 fusions can target positions 3-11 of double-stranded DNA target sequences (numbered according to the schematic in FIG. 3). Upper Gel: 1 μM rAPOBEC1-GGS-dCas9, 125 nM dsDNA, 1 eq sgRNA. Mid Gel: 1 μM rAPOBEC1-(GGS)₃-dCas9, 125 nM dsDNA, 1 eq sgRNA. Lower Gel: 1.85 μM rAPOBEC1-XTEN-dCas9, 125 nM dsDNA, 1 eq sgRNA. Based on the data from these gels, positions 3-11 (according to the numbering in FIG. 3) are sufficiently exposed to the activity of the deaminase to be targeted by the fusion proteins tested. Access of the deaminase to other positions is most likely blocked by the dCas9 protein.

The data further indicates that a linker of only 3 amino acids (GGS) is not optimal for allowing the deaminase to access the single stranded portion of the DNA. The 9 amino acid linker [(GGS)₃] (SEQ ID NO: 596) and the more structured 16 amino acid linker (XTEN) allow for more efficient deamination.

FIG. 6 demonstrates that the correct guide RNA, e.g., the correct sgRNA, is required for deaminase activity. The gel shows that fusing the deaminase to dCas9, the deaminase enzyme becomes sequence specific (e.g., using the fusion with an eGFP sgRNA results in no deamination), and also confers the capacity to the deaminase to deaminate dsDNA. The native substrate of the deaminase enzyme is ssDNA, and no deamination occurred when no sgRNA was added. This is consistent with reported knowledge that APOBEC deaminase by itself does not deaminate dsDNA. The data indicates that Cas9 opens the double-stranded DNA helix within a short window, exposing single-stranded DNA that is then accessible to the APOBEC deaminase for cytidine deamination. The sgRNA sequences used are provided below. sequences (36 bp: underlined, sgRNA target sequence: bold; PAM: boxed; 21 bp: italicized)

DNA sequence 8:

(SEQ ID NO: 633)

5’-Cy3-

GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC
ATTATTCCGCGGATTT

embedded image

(SEQ ID NO: 634)

Correct sgRNA sequence (partial 3' sequence):

5’-AUUAUUCCGCGGAUUUAUUUGUUUUAGAGCUAG...-3’

(SEQ ID NO: 635)

eGFP sgRNA sequence (partial 3’-sequence):

5’-CGUAGGCCAGGGUGGUCACGGUUUUAGAGCUAG...-3’

Example 2: Deamination of DNA Target Sequence

Exemplary deamination targets. The dCas9:deaminase fusion proteins described herein can be delivered to a cell in vitro or ex vivo or to a subject in vivo and can be used to effect C to T or G to A transitions when the target nucleotide is in positions 3-11 with respect to a PAM. Exemplary deamination targets include, without limitation, the following: CCR5 truncations: any of the codons encoding Q93, Q102, Q186, R225, W86, or Q261 of CCR5 can be deaminated to generate a STOP codon, which results in a nonfunctional truncation of CCR5 with applications in HIV treatment. APOE4 mutations: mutant codons encoding C11R and C57R mutant APOE4 proteins can be deaminated to revert to the wild-type amino acid with applications in Alzheimer's treatment. eGFP truncations: any of the codons encoding Q158, Q184, Q185 can be deaminated to generate a STOP codon, or the codon encoding M1 can be deaminated to encode I, all of which result in loss of eGFP fluorescence, with applications in reporter systems. eGFP restoration: a mutant codon encoding T65A or Y66C mutant GFP, which does not exhibit substantial fluorescence, can be deaminated to restore the wild-type amino acid and confer fluorescence. PIK3CA mutation: a mutant codon encoding K111E mutant PIK3CA can be deaminated to restore the wild-type amino acid residue with applications in cancer. CTNNB1 mutation: a mutant codon encoding T41A mutant CTNNB1 can be deaminated to restore the wild-type amino acid residue with applications in cancer. HRAS mutation: a mutant codon encoding Q61R mutant HRAS can be deaminated to restore the wild-type amino acid residue with applications in cancer. P53 mutations: any of the mutant codons encoding Y163C, Y236C, or N239D mutant p53 can be deaminated to encode the wild type amino acid sequence with applications in cancer.

The feasibility of deaminating these target sequences in double-stranded DNA is demonstrated in FIGS. 7 and 8. FIG. 7 illustrates the mechanism of target DNA binding of in vivo target sequences by deaminase-dCas9:sgRNA complexes.

FIG. 8 shows successful deamination of exemplary disease-associated target sequences. Upper Gel: CCR5 Q93: coding strand target in pos. 10 (potential off-targets at positions 2, 5, 6, 8, 9); CCR5 Q102: coding strand target in pos. 9 (potential off-targets at positions 1, 12, 14); CCR5 Q186: coding strand target in pos. 9 (potential off-targets at positions 1, 5, 15); CCR5 R225: coding strand target in pos. 6 (no potential off-targets); eGFP Q158: coding strand target in pos. 5 (potential off-targets at positions 1, 13, 16); eGFP Q184/185: coding strand target in pos. 4 and 7 (potential off-targets at positions 3, 12, 14, 15, 16, 17, 18); eGFP M1: template strand target in pos. 12 (potential off-targets at positions 2, 3, 7, 9, 11) (targets positions 7 and 9 to small degree); eGFP T65A: template strand target in pos. 7 (potential off-targets at positions 1, 8, 17); PIK3CA K111E: template strand target in pos. 2 (potential off-targets at positions 5, 8, 10, 16, 17); PIK3CA K111E: template strand target in pos. 13 (potential off-targets at positions 11, 16, 19) X. Lower Gel: CCR5 W86: template strand target in pos. 2 and 3 (potential off-targets at positions 1, 13) X; APOE4 C11R: coding strand target in pos. 11 (potential off-targets at positions 7, 13, 16, 17); APOE4 C57R: coding strand target in pos. 5) (potential off-targets at positions 7, 8, 12); eGFP Y66C: template strand target in pos. 11 (potential off-targets at positions 1, 4, 6, 8, 9, 16); eGFP Y66C: template strand target in pos. 3 (potential off-targets at positions 1, 8, 17); CCR5 Q261: coding strand target in pos. 10 (potential off-targets at positions 3, 5, 6, 9, 18); CTNNB1 T41A: template strand target in pos. 7 (potential off-targets at positions 1, 13, 15, 16) X; HRAS Q61R: template strand target in pos. 6 (potential off-targets at positions 1, 2, 4, 5, 9, 10, 13); p53 Y163C: template strand target in pos. 6 (potential off-targets at positions 2, 13, 14); p53 Y236C: template strand target in pos. 8 (potential off-targets at positions 2, 4); p53 N239D: template strand target in pos. 4 (potential off-targets at positions 6, 8). Exemplary DNA sequences of disease targets are provided below (PAMs (5′-NGG-3′) and target positions are boxed):

(SEQ ID NO: 636)

CCR5 Q93: 5'-Cy3-

GTAGGTAGTTAGGATGAATGGAAGGTTGGTAACTAT
GCTGCCGCC

embedded image

(SEQ ID NO: 637)

CCR5 Q102: 5'-Cy3-

GTAGGTAGTTAGGATGAATGGAAGGTTGGTAAAATA
CAATGTGT

embedded image

(SEQ ID NO: 638)

CCR5 Q186: 5'-Cy3-

GTAGGTAGTTAGGATGAATGGAAGGTTGGTATTTTC
CATACAGT

embedded image

(SEQ ID NO: 639)

CCR5 R225: 5'-Cy3-

embedded image

(SEQ ID NO: 640)

CCR5 W86: 5'-Cy3-

embedded image

(SEQ ID NO: 641)

CCR5 Q261: 5'-Cy3-

GTAGGTAGTTAGGATGAATGGAAGGTTGGTATCCTG
AACACCTT

embedded image

(SEQ ID NO: 642)

APOE4 C11R: 5'-Cy3-

GTAGGTAGTTAGGATGAATGGAAGGTTGGTAGACAT
GGAGGAC

embedded image

(SEQ ID NO: 643)

APOE4 C57R: 5'-Cy3-

embedded image

(SEQ ID NO: 644)

eGFP Q158: 5'-Cy3-

embedded image

(SEQ ID NO: 645)

eGFP Q184/185: 5'-Cy3-

embedded image

(SEQ ID NO: 646)

eGFP M1: 5'-Cy3-

GTAGGTAGTTAGGATGAATGGAAGGTTGGTACCTCG
CCCTTGCTCA

embedded image

(SEQ ID NO: 647)

eGFP T65A: 5'-Cy3-

embedded image

(SEQ ID NO: 648)

eGFP Y66C: 5'-Cy3-

GTAGGTAGTTAGGATGAATGGAAGGTTGGTAAAGCA
CTGCACTC

embedded image

(SEQ ID NO: 649)

eGFP Y66C: 5'-Cy3-

embedded image

(SEQ ID NO: 650)

PIK3CA K111E: 5'-Cy3-

embedded image

(SEQ ID NO: 651)

PIK3CA K111E: 5'-Cy3-

GTAGGTAGTTAGGATGAATGGAAGGTTGGTATTCTC
GATTG

embedded image

(SEQ ID NO: 652)

CTNNB1 T41A: 5'-Cy3-

GTAGGTAGTTAGGATGAATGGAAGGTTGGTAAGGAG
CTGTGG

embedded image

(SEQ ID NO: 653)

HRAS Q61R: 5'-Cy3-

embedded image

(SEQ ID NO: 654)

p53 Y163C: 5'-Cy3-

embedded image

(SEQ ID NO: 655)

p53 Y236C: 5'-Cy3-

embedded image

(SEQ ID NO: 656)

p53 N239D: 5'-Cy3-

embedded image

Example 3: Uracil Glycosylase Inhibitor Fusion Improves Deamination Efficiency

Direct programmable nucleobase editing efficiencies in mammalian cells by dCas9:deaminase fusion proteins can be improved significantly by fusing a uracil glycosylase inhibitor (UGI) to the dCas9:deaminase fusion protein.

FIG. 9 shows in vitro C→T editing efficiencies in human HEK293 cells using rAPOBEC1-XTEN-dCas9:

(SEQ ID NO: 657)

embedded image

Protospacer sequences were as follows:

(SEQ ID NO: 293)

embedded image

(SEQ ID NO: 294)

embedded image

(SEQ ID NO: 295)

embedded image

(SEQ ID NO: 296)

embedded image

(SEQ ID NO: 297)

embedded image

(SEQ ID NO: 298)

embedded image

*PAMs are boxed, C residues within target window (positions 3-11) are numbered and bolded.

FIG. 10 demonstrates that C→T editing efficiencies on the same protospacer sequences in HEK293T cells are greatly enhanced when a UGI domain is fused to the rAPOBEC1:dCas9 fusion protein.

(SEQ ID NO: 658)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNT

NKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIAR

LYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWV

RLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK
SGSETP

embedded image

IIEKETGKOLVICIESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAP

EYKPWALVICIDSNGENKIKML
SGGSPKKKRKV

The percentages in FIGS. 9 and 10 are shown from sequencing both strands of the target sequence. Because only one of the strands is a substrate for deamination, the maximum possible deamination value in this assay is 50%. Accordingly, the deamination efficiency is double the percentages shown in the tables. E.g., a value of 50% relates to deamination of 100% of double-stranded target sequences.

When a uracil glycosylase inhibitor (UGI) was fused to the dCas9:deaminase fusion protein (e.g., rAPOBEC1-XTEN-dCas9-[UGI]-NLS), a significant increase in editing efficiency in cells was observed. This result indicates that in mammalian cells, the DNA repair machinery that cuts out the uracil base in a U:G base pair is a rate-limiting process in DNA editing. Tethering UGI to the dVas9:deaminase fusion proteins greatly increases editing yields.

Without UGI, typical editing efficiencies in human cells were in the ˜2-14% yield range (FIG. 9 and FIG. 10, “XTEN” entries). With UGI (FIG. 10, “UGI” entries) the editing was observed in the ˜6-40% range. Using a UGI fusion is thus more efficient than the current alternative method of correcting point mutations via HDR, which also creates an excess of indels in addition to correcting the point mutation. No indels resulting from treatment with the cas9:deaminase:UGI fusions were observed.

Example 4: Direct, Programmable Conversion of a Target Nucleotide in Genomic DNA without Double-Stranded DNA Cleavage

Current genome-editing technologies introduce double-stranded DNA breaks at a target locus of interest as the first step to gene correction.^39,40Although most genetic diseases arise from mutation of a single nucleobase to a different nucleobase, current approaches to revert such changes are very inefficient and typically induce an abundance of random insertions and deletions (indels) at the target locus as a consequence of the cellular response to double-stranded DNA breaks.^39,40Reported herein is the development of nucleobase editing, a new strategy for genome editing that enables the direct conversion of one target nucleobase into another in a programmable manner, without requiring double-stranded DNA backbone cleavage. Fusions of CRISPR/Cas9 were engineered and the cytidine deaminase enzyme APOBEC1 that retain the ability to be programmed with a guide RNA, do not induce double-stranded DNA breaks, and mediate the direct conversion of cytidine to uracil, thereby effecting a C→T (or G→A) substitution following DNA replication, DNA repair, or transcription if the template strand is targeted. The resulting “nucleobase editors” convert cytidines within a window of approximately five nucleotides, and can efficiently correct a variety of point mutations relevant to human disease in vitro. In four transformed human and murine cell lines, second- and third-generation nucleobase editors that fuse uracil glycosylase inhibitor (UGI), and that use a Cas9 nickase targeting the non-edited strand, respectively, can overcome the cellular DNA repair response to nucleobase editing, resulting in permanent correction of up to 37% or (˜15-75%) of total cellular DNA in human cells with minimal (typically ≤1%) indel formation. In contrast, canonical Cas9-mediated HDR on the same targets yielded an average of 0.7% correction with 4% indel formation. Nucleobase editors were used to revert two oncogenic p53 mutations into wild-type alleles in human breast cancer and lymphoma cells, and to convert an Alzheimer's Disease associated Arg codon in ApoE4 into a non-disease-associated Cys codon in mouse astrocytes. Base editing expands the scope and efficiency of genome editing of point mutations.

The clustered regularly interspaced short palindromic repeat (CRISPR) system is a prokaryotic adaptive immune system that has been adapted to mediate genome engineering in a variety of organisms and cell lines.⁴¹CRISPR/Cas9 protein-RNA complexes localize to a target DNA sequence through base pairing with a guide RNA, and natively create a DNA double-stranded break (DSB) at the locus specified by the guide RNA. In response to DSBs, endogenous DNA repair processes mostly result in random insertions or deletions (indels) at the site of DNA cleavage through non-homologous end joining (NHEJ). In the presence of a homologous DNA template, the DNA surrounding the cleavage site can be replaced through homology-directed repair (HDR). When simple disruption of a disease-associated gene is sufficient (for example, to treat some gain-of-function diseases), targeted DNA cleavage followed by indel formation can be effective. For most known genetic diseases, however, correction of a point mutation in the target locus, rather than stochastic disruption of the gene, is needed to address or study the underlying cause of the disease.⁶⁸

Motivated by this need, researchers have invested intense effort to increase the efficiency of HDR and suppress NHEJ. For example, a small-molecule inhibitor of ligase IV, an essential enzyme in the NHEJ pathway, has been shown to increase HDR efficiency.^42,43However, this strategy is challenging in post-mitotic cells, which typically down-regulate HDR, and its therapeutic relevance is limited by the potential risks of inhibiting ligase IV in non-target cells. Enhanced HDR efficiency can also be achieved by the timed delivery of Cas9-guide RNA complexes into chemically synchronized cells, as HDR efficiency is highly cell-cycle dependent.⁴⁴Such an approach, however, is limited to research applications in cell culture since synchronizing cells is highly disruptive. Despite these developments, current strategies to replace point mutations using HDR in most contexts are very inefficient (typically ˜0.1 to 5%),^{42,43,45,46,75}especially in unmodified, non-dividing cells. In addition, HDR competes with NHEJ during the resolution of double-stranded breaks, and indels are generally more abundant outcomes than gene replacement. These observations highlight the need to develop alternative approaches to install specific modifications in genomic DNA that do not rely on creating double-stranded DNA breaks. A small-molecule inhibitor of ligase IV, an essential enzyme in the NHEJ pathway, has been shown to increase HDR efficiency.^42,43However, this strategy is challenging in post-mitotic cells, which typically down-regulate HDR, and its therapeutic relevance is limited by the potential risks of inhibiting ligase IV in non-target cells. Enhanced HDR efficiency can also be achieved by the timed delivery of Cas9-guide RNA complexes into chemically synchronized cells, as HDR efficiency is highly cell-cycle dependent.⁴⁴Such an approach, however, is limited to research applications in cell culture since synchronizing cells is highly disruptive. In some cases, it is possible to design HDR templates such that the product of successful HDR contains mutations in the PAM sequence and therefore is no longer a substrate for subsequent Cas9 modification, increasing the overall yield of HDR products,⁷⁵although such an approach imposes constraints on the product sequences. Recently, this strategy has been coupled to the use of ssDNA donors that are complementary to the non-target strand and high-efficiency ribonucleoprotein (RNP) delivery to substantially increase the efficiency of HDR, but even in these cases the ratio of HDR to NHEJ outcomes is relatively low (<2).⁸³

It was envisioned that direct catalysis of the conversion of one nucleobase to another at a programmable target locus without requiring DNA backbone cleavage could increase the efficiency of gene correction relative to HDR without introducing undesired random indels at the locus of interest. Catalytically dead Cas9 (dCas9), which contains Asp10Ala and His840Ala mutations that inactivate its nuclease activity, retains its ability to bind DNA in a guide RNA-programmed manner but does not cleave the DNA backbone.^16,47In principle, conjugation of dCas9 with an enzymatic or chemical catalyst that mediates the direct conversion of one nucleobase to another could enable RNA-programmed nucleobase editing. The deamination of cytosine (C) is catalyzed by cytidine deaminases²⁹and results in uracil (U), which has the base pairing properties of thymine (T). dCas9 was fused to cytidine deaminase enzymes in order to test their ability to convert C to U at a guide RNA-specified DNA locus. Most known cytidine deaminases operate on RNA, and the few examples that are known to accept DNA require single-stranded DNA.⁴⁸Recent studies on the dCas9-target DNA complex reveal that at least nine nucleotides of the displaced DNA strand are unpaired upon formation of the Cas9:guide RNA:DNA “R-loop” complex.¹²Indeed, in the structure of the Cas9 R-loop complex the first 11 nucleotides of the protospacer on the displaced DNA strand are disordered, suggesting that their movement is not highly restricted.⁷⁶It has also been speculated that Cas9 nickase-induced mutations at cytosines in the non-template strand might arise from their accessibility by cellular cytidine deaminase enzymes.⁷⁷Recent studies on the dCas9-target DNA complex have revealed that at least 26 bases on the non-template strand are unpaired when Cas9 binds to its target DNA sequence.⁴⁹It was reasoned that a subset of this stretch of single-stranded DNA in the R-loop might serve as a substrate for a dCas9-tethered cytidine deaminase to effect direct, programmable conversion of C to U in DNA (FIG. 11A).

Four different cytidine deaminase enzymes (hAID, hAPOBEC3G, rAPOBEC1, and pmCDA1) were expressed in a mammalian cell lysate-derived in vitro transcription-translation system and evaluated for ssDNA deamination. Of the four enzymes, rAPOBEC1 showed the highest deaminase activity under the tested conditions and was chosen for dCas9 fusion experiments (FIG. 36A). Although appending rAPOBEC1 to the C-terminus of dCas9 abolishes deaminase activity, fusion to the N-terminus of dCas9 preserves deaminase activity on ssDNA at a level comparable to that of the unfused enzyme. Four rAPOBEC1-dCas9 fusions were expressed and purified with linkers of different length and composition (FIG. 36B), and evaluated each fusion for single guide RNA (sgRNA)-programmed dsDNA deamination in vitro (FIGS. 11A to 11C and FIGS. 15A to 15D).

Efficient, sequence-specific, sgRNA-dependent C to U conversion was observed in vitro (FIGS. 11A to 11C). Conversion efficiency was greatest using rAPOBEC1-dCas9 linkers over nine amino acids in length. The number of positions susceptible to deamination (the deamination “activity window”) increases with linker length was extended from three to 21 amino acids (FIGS. 36C to 36F15A to 15D). The 16-residue XTEN linker⁵⁰was found to offer a promising balance between these two characteristics, with an efficient deamination window of approximately five nucleotides, from positions 4 to 8 within the protospacer, counting the end distal to the protospacer-adjacent motif (PAM) as position 1. The rAPOBEC1-XTEN-dCas9 protein served as the first-generation nucleobase editor (NBE1).

Elected were seven mutations relevant to human disease that in theory could be corrected by C to T nucleobase editing, synthesized double-stranded DNA 80-mers of the corresponding sequences, and assessed the ability of NBE1 to correct these mutations in vitro (FIGS. 16A to 16B). NBE1 yielded products consistent with efficient editing of the target C, or of at least one C within the activity window when multiple Cs were present, in six of these seven targets in vitro, with an average apparent editing efficiency of 44% (FIGS. 16A to 16B). In the three cases in which multiple Cs were present within the deamination window, evidence of deamination of some or all of these cytosines was observed. In only one of the seven cases tested were substantial yields of edited product observed (FIGS. 16A to 16B). Although the preferred sequence context for APOBEC1 substrates is reported to be CC or TC,⁵¹it was anticipated that the increased effective molarity of the deaminase and its single-stranded DNA substrate mediated by dCas9 binding to the target locus may relax this restriction. To illuminate the sequence context generality of NBE1, its ability to edit a 60-mer double-stranded DNA oligonucleotide containing a single fixed C at position 7 within the protospacer was assayed, as well as all 36 singly mutated variants in which protospacer bases 1-6 and 8-13 were individually varied to each of the other three bases. Each of these 37 sequences were treated with 1.9 μM NBE1, 1.9 μM of the corresponding sgRNA, and 125 nM DNA for 2 h, similar to standard conditions for in vitro Cas9 assays⁵². High-throughput DNA sequencing (HTS) revealed 50 to 80% C to U conversion of targeted strands (25 to 40% of total sequence reads arising from both DNA strands, one of which is not a substrate for NBE1) (FIG. 12A). The nucleotides surrounding the target C had little effect on editing efficiency was independent of sequence context unless the base immediately 5′ of the target C is a G, in which case editing efficiency was substantially lower (FIGS. 12A to 12B). NBE1 activity in vitro was assessed on all four NC motifs at positions 1 through 8 within the protospacer (FIGS. 12A to 12B). In general NBE1 activity on substrates was observed to follow the order TC≥CC≥AC>GC, with maximum editing efficiency achieved when the target C is at or near position 7. In addition, it was observed that the nucleobase editor is highly processive, and will efficiently convert most of all Cs to Us on the same DNA strand within the 5-base activity window (FIG. 17).

While BE1 efficiently processes substrates in a test tube, in cells a tree of possible DNA repair outcomes determines the fate of the initial U:G product of base editing (FIG. 29A). To test the effectiveness of nucleobase editing in human cells, NBE1 codon usage was optimized for mammalian expression, appended a C-terminal nuclear localization sequence (NLS),⁵³and assayed its ability to convert C to T in human cells on 14Cs in six well-studied target sites throughout the human genome (FIG. 37A).⁵⁴The editable Cs were confirmed within each protospacer in vitro by incubating NBE1 with synthetic 80-mers that correspond to the six different genomic sites, followed by HTS (FIGS. 13A to 13C, FIG. 29B and FIG. 25). Next, HEK293T cells were transfected with plasmids encoding NBE1 and one of the six target sgRNAs, allowed three days for nucleobase editing to occur, extracted genomic DNA from the cells, and analyzed the loci by HTS. Although C to T editing in cells at the target locus was observed for all six cases, the efficiency of nucleobase editing was 1.1% to 6.3% or 0.8%-7.7% of total DNA sequences (corresponding to 2.2% to 12.6% of targeted strands), a 6.3-fold to 37-fold or 5-fold to 36-fold decrease in efficiency compared to that of in vitro nucleobase editing (FIGS. 13A to 13C, FIG. 29B and FIG. 25). It was observed that some base editing outside of the typical window of positions 4 to 8 when the substrate C is preceded by a T, which we attribute to the unusually high activity of APOBEC1 for TC substrates.⁴⁸

It was asked whether the cellular DNA repair response to the presence of U:G heteroduplex DNA was responsible for the large decrease in nucleobase editing efficiency in cells (FIG. 29A). Uracil DNA glycosylase (UDG) catalyzes removal of U from DNA in cells and initiates base excision repair (BER), with reversion of the U:G pair to a C:G pair as the most common outcome (FIG. 29A).⁵⁵Uracil DNA glycosylase inhibitor (UGI), an 83-residue protein from B. subtilis bacteriophage PBS1, potently blocks human UDG activity (IC₅₀=12 μM).⁵⁶UGI was fused to the C-terminus of NBE1 to create the second-generation nucleobase editor NBE2 and repeated editing assays on all six genomic loci. Editing efficiencies in human cells were on average 3-fold higher with NBE2 than with NBE1, resulting in gene conversion efficiencies of up to 22.8% of total DNA sequenced (up to 45.6% of targeted strands) (FIGS. 13A to 13C and FIG. 29B). To test base editing in human cells, BE1 codon usage was optimized for mammalian expression and appended a C-terminal nuclear localization sequence (NLS).⁵³

Similar editing efficiencies were observed when a separate plasmid overexpressing UGI was co-transfected with NBE1 (FIGS. 18A to 18H). However, while the direct fusion of UGI to NBE1 resulted in no significant increase in C to T mutations at monitored non-targeted genomic locations, overexpression of unfused UGI detectably increased the frequency of C to T mutations elsewhere in the genome (FIGS. 18A to 18H). The generality of NBE2-mediated nucleobase editing was confirmed by assessing editing efficiencies on the same six genomic targets in U2OS cells, and observed similar results with those in HEK293T cells (FIG. 19). Importantly, NBE2 typically did not result in any detectable indels (FIG. 13C and FIG. 29C), consistent with the known mechanistic dependence of NHEJ on double-stranded DNA breaks.^57,78Together, these results indicate that conjugating UGI to NBE1 can greatly increase the efficiency of nucleobase editing in human cells.

The permanence of nucleobase editing in human cells was confirmed by monitoring editing efficiencies over multiple cell divisions in HEK293T cells at two of the tested genomic loci. Genomic DNA was harvested at two time points: three days after transfection with plasmids expressing NBE2 and appropriate sgRNAs, and after passaging the cells and growing them for four additional days (approximately five subsequent cell divisions). No significant change in editing efficiency was observed between the non-passaged cells (editing observed in 4.6% to 6.6% of targeted strands for three different target Cs) and passaged cells (editing observed in 4.6% to 6.4% of targeted strands for the same three target Cs), confirming that the nucleobase edits became permanent following cell division (FIG. 20). Indels will on rare occasion arise from the processing of U:G lesions by cellular repair processes, which involve single-strand break intermediates that are known to lead to indels.⁸⁴Given that several hundred endogenous U:G lesions are generated every day per human cell from spontaneous cytidine deaminase,⁸⁵it was anticipate that the total indel frequency from U:G lesion repair is unlikely to increase from BE1 or BE2 activity at a single target locus.

To further increase the efficiency of nucleobase editing in cells, it was anticipated that nicking the non-edited strand may result in a smaller fraction of edited Us being removed by the cell, since eukaryotic mismatch repair machinery uses strand discontinuity to direct DNA repair to any broken strand of a mismatched duplex (FIG. 29A).^58,79,80The catalytic His residue was restored at position 840 in the Cas9 HNH domain,^47,59resulting in the third-generation nucleobase editor NBE3 that nicks the non-edited strand containing a G opposite the targeted C, but does not cleave the target strand containing the C. Because NBE3 still contains the Asp10Ala mutation in Cas9, it does not induce double-stranded DNA cleavage. This strategy of nicking the non-edited strand augmented nucleobase editing efficiency in human cells by an additional 1.4- to 4.8-fold relative to NBE2, resulting in up to 36.3% of total DNA sequences containing the targeted C to T conversion on the same six human genomic targets in HEK293T cells (FIGS. 13A to 13C and FIG. 29B). Importantly, only a small frequency of indels, averaging 0.8% (ranging from 0.2% to 1.6% for the six different loci), was observed from NBE3 treatment (FIG. 13C, FIG. 29C, and FIG. 34). In contrast, when cells were treated with wild-type Cas9, sgRNA, and a single-stranded DNA donor template to mediate HDR at three of these loci C to T conversion efficiencies averaging only 0.7% were observed, with much higher relative indel formation averaging 3.9% (FIGS. 13A to 13C and FIG. 29C). The ratio of allele conversion to NHEJ outcomes averaged >1,000 for BE2, 23 for BE3, and 0.17 for wild-type Cas9 (FIG. 3c). We confirmed the permanence of base editing in human cells by monitoring editing efficiencies over multiple cell divisions in HEK293T cells at the HEK293 site 3 and 4 genomic loci (FIG. 38). These results collectively establish that nucleobase editing can effect much more efficient targeted single-base editing in human cells than Cas9-mediated HDR, and with much less (NBE3) or no (NBE2) indel formation.

Next, the off-target activity of NBE1, NBE2, and NBE3 in human cells was evaluated. The off-target activities of Cas9, dCas9, and Cas9 nickase have been extensively studied (FIGS. 23 to 24 and 31 to 33).^54,60-62Because the sequence preference of rAPOBEC1 has been shown to be independent of DNA bases more than one base from the target C,⁶³consistent with the sequence context independence observed in FIGS. 12A to 12B, it was assumed that potential off-target activity of nucleobase editors arises from off-target Cas9 binding. Since only a fraction of Cas9 off-target sites will have a C within the active window for nucleobase editing, off-target nucleobase editing sites should be a subset of the off-target sites of canonical Cas9 variants. For each of the six sites studied, the top ten known Cas9 off-target loci in human cells that were previously determined using the GUIDE-seq method were sequenced (FIGS. 23 to 27 and 31 to 33).^54,61Detectable off-target nucleobase editing at only a subset (16/34, 47% for NBE1 and NBE2, and 17/34, 50% for NBE3) of known dCas9 off-target loci was observed. In all cases, the off-target base-editing substrates contained a C within the five-base target window. In general, off-target C to T conversion paralleled off-target Cas9 nuclease-mediated genome modification frequencies (FIGS. 23 to 27). Also monitored were C to T conversions at 2,500 distinct cytosines surrounding the six on-target and 34 off-target loci tested, representing a total of 14,700,000 sequence reads derived from approximately 1.8×10⁶cells, and observed no detectable increase in C to T conversions at any of these other sites upon NBE1, NBE2, or NBE3 treatment compared to that of untreated cells (FIG. 28). Taken together, these findings suggest that off-target substrates of nucleobase editors include a subset of Cas9 off-target substrates, and that nucleobase editors in human cells do not induce untargeted C to T conversion throughout the genome at levels that can be detected by the methods used here. No substantial change was observed in editing efficiency between non-passaged HEK293T cells (editing observed in 1.8% to 2.6% of sequenced strands for the three target Cs with BE2, and 6.2% to 14.3% with BE3) and cells that had undergone approximately five cell divisions after base editing (editing observed in 1.9% to 2.3% of sequenced strands for the same target Cs with BE2, and 6.4% to 14.5% with BE3), confirming that base edits in these cells are durable (Extended Data FIG. 6).

Finally, the potential of nucleobase editing to correct three disease-relevant mutations in mammalian cells was tested. The apolipoprotein E gene variant APOE4 encodes two Arg residues at amino acid positions 112 and 158, and is the largest and most common genetic risk factor for late-onset Alzheimer's disease.⁶⁴ApoE variants with Cys residues in positions 112 or 158, including APOE2 (Cys112/Cys158), APOE3 (Cys112/Arg158), and APOE3′ (Arg112/Cys158) have been shown⁶⁵or are presumed⁸¹to confer substantially lower Alzheimer's disease risk than APOE4. Encouraged by the ability of NBE1 to convert APOE4 to APOE3′ in vitro (FIGS. 16A to 16B), this conversion was attempted in immortalized mouse astrocytes in which the endogenous murine APOE gene has been replaced by human APOE4 (Taconic). DNA encoding NBE3 and an appropriate sgRNA was delivered into these astrocytes by nucleofection (nucleofection efficiency of 25%), extracted genomic DNA from all treated cells two days later, and measured editing efficiency by HTS. Conversion of Arg158 to Cys158 was observed in 58-75% of total DNA sequencing reads (44% of nucleofected astrocytes) (FIGS. 14A to 14C and FIG. 30A). Also observed was 36-50% editing of total DNA at the third position of codon 158 and 38-55% editing of total DNA at the first position of Leu159, as expected since all three of these Cs are within the active nucleobase editing window. However, neither of the other two C→T conversions results in a change in the amino acid sequence of the ApoE3′ protein since both TGC and TGT encode Cys, and both CTG and TTG encode Leu. From >1,500,000 sequencing reads derived from 1×10⁶cells evidence of 1.7% indels at the targeted locus following NBE3 treatment was observed (FIG. 35). In contrast, identical treatment of astrocytes with wt Cas9 and donor ssDNA resulted in 0.1-0.3% APOE4 correction and 26-40% indels at the targeted locus, efficiencies consistent with previous reports of single-base correction using Cas9 and HDR^45,75(FIG. 30A and FIG. 40A). Astrocytes treated identically but with an sgRNA targeting the VEGFA locus displayed no evidence of APOE4 base editing (FIG. 34 and FIG. 40A). These results demonstrate how nucleobase editors can effect precise, single-amino acid changes in the coding sequence of a protein as the major product of editing, even when their processivity results in more than one nucleotide change in genomic DNA. The off-target activities of Cas9, dCas9, and Cas9 nickase have been extensively studied.^54,60-62In general, off-target C to T conversions by BE1, BE2, and BE3 paralleled off-target Cas9 nuclease-mediated genome modification frequencies.

The dominant-negative p53 mutations Tyr163Cys and Asn239Asp are strongly associated with several types of cancer.^66-67Both of these mutations can be corrected by a C to T conversion on the template strand (FIGS. 16A to 16B). A human breast cancer cell line homozygous for the p53 Tyr163Cys mutation (HCC1954 cells) was nucleofected with DNA encoding NBE3 and an sgRNA programmed to correct Tyr163Cys. Because the nucleofection efficiency of HCC1954 cells was <10%, a plasmid expressing IRFP was co-nucleofected into these cells to enable isolation of nucleofected cells by fluorescence-activated cell sorting two days after treatment. HTS of genomic DNA revealed correction of the Tyr163Cys mutation in 7.6% of nucleofected HCC1954 cells (FIG. 30B and FIG. 40A to 40B). Also nucleofected was a human lymphoma cell line that is heterozygous for p53 Asn239Asp (ST486 cells) with DNA encoding NBE2 and an sgRNA programmed to correct Asn239Asp with 92% nucleofection efficiency). Correction of the Asn239Asp mutation was observed in 11% of treated ST486 cells (12% of nucleofected ST486 cells). Consistent with the findings in HEK cells, no indels were observed from the treatment of ST486 cells with NBE2, and 0.6% indel formation from the treatment of HCC1954 cells with NBE3. No other DNA changes within at least 50 base pairs of both sides of the protospacer were detected at frequencies above that of untreated controls out of >2,000,000 sequencing reads derived from 2×10⁵cells (FIGS. 14A to 14C, FIG. 30B and Table 1). These results collectively represent the conversion of three disease-associated alleles in genomic DNA into their wild-type forms with an efficiency and lack of other genome modification events that is, to our knowledge, not currently achievable using other methods.

To illuminate the potential relevance of nucleobase editors to address human genetic diseases, the NCBI ClinVar database⁶⁸was searched for known genetic diseases that could in principle be corrected by this approach. ClinVar was filtered by first examining only single nucleotide polymorphisms (SNPs), then removing any nonpathogenic variants. Out of the 24,670 pathogenic SNPs, 3,956 are caused by either a T to C, or an A to G, substitution. This list was further filtered to only include variants with a nearby NGG PAM that would position the SNP within the deamination activity window, resulting in 1,089 clinically relevant pathogenic gene variants that could in principle be corrected by the nucleobase editors described here (FIG. 21 and Table 1). To illuminate the potential relevance of base editors to address human genetic diseases, the NCBI ClinVar database⁶⁸was searched for known genetic diseases that could in principle be corrected by this approach. ClinVar was filtered by first examining only single nucleotide polymorphisms (SNPs), then removing any non-pathogenic variants. Out of the 24,670 pathogenic SNPs, 3,956 are caused by either a T to C, or an A to G, substitution. This list was further filtered to only include variants with a nearby NGG PAM that would position the SNP within the deamination activity window, resulting in 911 clinically relevant pathogenic gene variants that could in principle be corrected by the base editors described here. Of these, 284 contain only one C within the base editing activity window. A detailed list of these pathogenic mutations can be found in Table 1.

TABLE 1

List of 911 base-editable gene variants associated with human disease

with an NGG PAM (SEQ ID NOs: 747 to 1868 appear from top to bottom below,

respectively). The ″Y″ in the protospacer and PAM sequences indicates the base

to be edited, e.g., C. (SEQ ID NOs: 747 to 1868 appear from top to bottom below,

respectively)

Protospacer

dbSNP #
Genotype
and PAM seouence(s)
Associated uenetic disease

755445790
NM_000391.3(TPP1):c.887-
TTTYTTTTTTTTTTTTTTTGAGG
Ceroid lipofuscinosis, neuronal, 2

10A > G

113994167
NM_000018.3(ACADVL):c.848T > C
TTTGYGGTGGAGAGGGGCTTCGG,
Very long chain acyl-CoA

(p.Val283Ala)
TTGYGGTGGAGAGGGGCTTCGGG
dehydrogenase

deficiency

119470018
NM_024996.5(GFM1):c.521A > G
TTGYTAATAAAAGTTAGAAACGG
Combined oxidative phosphorylation

(p.Asn174Ser)

deficiency 1

115650537
NM_000426.3(LAMA2):c.8282T > C
TTGAYAGGGAGCAAGCAGTTCGG,
Merosin deficient congenital

(p.Ile2761Thr)
TGAYAGGGAGCAAGCAGTTCGGG
muscular

dystrophy

587777752
NM_014946.3(SPAST):c.1688-
TTCYGTAAAACATAAAAGTCAGG
Spastic paraplegia 4, autosomal dominant

794726821
NM_001165963.1(SCN1A):c.4055T > C
TTCYGGTTTGTCTTATATTCTGG
Severe myoclonic epilepsy in infancy

(p.Leu1352Pro)

397514745
NM_001130089.1(KARS):c.517T > C
CTTCYATGATCTTCGAGGAGAGG,
Deafness, autosomal recessive 89

(p.Tyr173His)
TTCYATGATCTTCGAGGAGAGG

G

376960358
NM_001202.3(BMP4):c.362A > G
TTCGTGGYGGAAGCTCCTCACGG
Microphthalmia syndromic 6

(p.His121Arg)

606231280
NM_001287223.1(SCN11A):c.1142T > C
CTTCAYTGTGGTCATTTTCCTGG,
Episodic pain syndrome, familial, 3

(pIle381Thr)
TTCAYTGTGGTCATTTTCCTGG

G

387906735
m.608A > G
TTCAGYGTATTGCTTTGAGGAGG

199474663
m.3260A > G
TTAAGTTYTATGCGATTACCGGG
Cardiomyopathy with or without

skeletal myopathy

104894962
NM_003413.3(ZIC3):c.1213A > G
TGTGTTYGCGCAGGGAGCTCGGG,
Heterotaxy, visceral, X-linked

(p.Lys405Glu)
ATGTGTTYGCGCAGGGAGCTCG

G

796053181
NM_021007.2(SCN2A):c.1271T > C
TGTGGYGGCCATGGCCTATGAGG
not provided

(p.Val424Ala)

267606788
NM_000129.3(F13A1):c.728T > C
TGTGAYGGACAGAGCACAAATGG
Factor xiii a subunit, deficiency of

(p.Met243Thr)

397514503
NM_003863.3(DPM2):c.68A > G
TGTAGYAGGTGAAGATGATCAGG
Congenital disorder of glycosylation type

(p.Tyr23Cys)

1u

104893973
NM_000416.2(IFNGR1):c.260T > C
TGTAATAYTTCTGATCATGTTGG
Disseminated atypical mycobacterial

(p.Ile87Thr)

infection, Mycobacterium tuberculosis,

susceptibility to

121908466
NM_005682.6(SDGRG1):c.263A > G
TGGYAGAGGCCCCTGGGGTCAGG
Polymicrogyria, bilateral frontoparietal

(p.Tyr88Cys)

147952488
NM_002437.4(MPV17):c.186 + 2T >
TGGYAAGTTCTCCCCTCAACAGG
Navajo neurohepatopathy

C

21909537
NM_001145.4(ANG):c.121A > G
TGGTTYGGCATCATAGTGCTGGG,
Amyotrophic lateral sclerosis type 9

(p.Lys41Glu)
GTGGTTYGGCATCATAGTGCTG

G

121918489
NM_000141.4(FGFR2):c.1018T > C
TGGGGAAYATACGTGCTTGGCGG,
Crouzon syndrome

(p.Tyr340His)
GGGGAAYATACGTGCTTGGCGGG

121434463
m.12320A > G
GAGTYGCACCAAAATTTTTGGGG,
Mitochondrial myopathy

GGAGTYGCACCAAAATTTTTGGG,

TGGAGTYGCACCAAAATTTTTG

G

121908046
NM_000403.3(GALE):c.101A > G
TGGAAGYTATCGATGACCACAGG
UDPglucose-4-epimerase deficiency

(p.Asn34Ser)

431905512
NM_003764.3(STX11):c.173T > C
TGCYGGTGGCCGACGTGAAGCGG
Hemophagocytic lymphohistiocytosis,

(p.Leu58Pro)

familial, 4

121917905
NM_000124.3(ERCC6):c.2960T > C
TGCYAAAAGACCCAAAACAAAGG
Cerebro-oculo-facio-skeletal syndrome

(p.Leu987Pro)

121918500
NM_000141.4(FGFR2):c.874A > G
TGCTYGATCCACTGGATGTGGGG,
Crouzon syndrome

(p.Lys292Glu)
GTGCTYGATCCACTGGATGTGGG,

CGTGCTYGATCCACTGGATGTG

G

60431989
NM_000053.3(ATP7B):c.3443T > C
TGCTGAYTGGAAACCGTGAGTGG
Wilson disease

(p.Ile1148Thr)

78950939
NM_000250.1(MPO):c.518A > G
GTGCGGYATTTGTCCTGCTCCGG,
Myeloperoxidase deficiency

(p.Tyr173Cys)
TGCGGYATTTGTCCTGCTCCGG

G

115677373
NM_201631.3(TGM5):c.763T > C
TGCGGAGYGGACGGGCAGCGTGG
Peeling skin syndrome, acral type

(p.Trp255Arg)

5030804
NM_000551.3(VHL):c.233A > G
GCGAYTGCAGAAGATGACCTGGG,
Von Hippel-Lindau syndrome

(p.Asn78Ser)
TGCGAYTGCAGAAGATGACCTG

G

397508328
NM_000492.3(CHR):c.1A > G
GCAYGGTCTCTCGGGCGCTGGGG,
Cystic fibrosis

(p.Met1Val)
TGCAYGGTCTCTCGGGCGCTGGG,

CTGCAYGGTCTCTCGGGCGCTGG

137853299
NM_000362.4(TIMP3):c.572A > G
TGCAGYAGCCGCCCTTCTGCCGG
Sorsby fundus dystrophy

(p.Tyr191Cys)

121908549
NM_000334.4(SCN4A):c.3478A > G
TGAYGGAGGGGATGGCGCCTAGG

(p.Ile1160Val)

121909337
NM_001451.2(FOXF1):c.1138T > C
TGATGYGAGGCTGCCGCCGCAGG
Alveolar capillary dysplasia with

(p.Ter380Arg)

misalignment of

pulmonary veins

281875320
NM_005359.5(SMAD4):c.1500A > G
TGAGYATGCATAAGCGACGAAGG
Myhre syndrome

(p.Ile500Met)

730880132
NM_170707.3(LMNA):c.710T > C
TGAGTYTGAGAGCCGGCTGGCGG
Primary dilated cardiomyopathy

(p.Phe237Ser)

81875322
NM_005359.5(SMAD4):c.1498A > G
TGAGTAYGCATAAGCGACGAAGG

(p.Ile500Val)

Myhre syndrome

72556283
NM_000531.5(OTC):c.527A > G
TGAGGYAATCAGCCAGGATCTGG
not provided

(p.Tyr176Cys)

74315311
NM_020435.3(WC2):c.857T > C
TGAGAYGGCCCACCTGGGCTTGG,
Leukodystrophy, hypomyel nating, 2

(p.Met286Thr)
GAGAYGGCCCACCTGGGCTTGGG

121912495
NM_170707.3(LMNA):c.1139T > C
TCTYGGAGGGCGAGGAGGAGAGG
Congenital muscular dystrophy, LMNA-related

(p.Leu380Ser)

128620184
NM_000061.2(BTK):c.1288A > G
TCTYGATGGCCACGTCGTACTGG
X-linked agammaglobulinemia

(p.Lys430Glu)

118192252
NM_004519.3(KCNQ3):c.1403A > G
TCTTTAYTGTTTAAGCCAACAGG
Benign familial neonatal seizures 2, not

(p.Asn468Ser)

specified

121909142
NM_001300.5(KLF6):c.190T > C
TCTGYGGACCAAAATCATTCTGG

(p.Trp64Arg)

104895503
NM_001127255.1(NLRP7):c.2738A > G
TCTGGYTGATACTCAAGTCCAGG
Hydatidiform mole

(p.Asn913Ser)

587783035
NM_000038.5(APC):c.1744-
TCCYAGTAAGAAACAGAATATGG
Familial adenomatous polyposis 1

2A > G

72556289
NM_000531.5(OTC):c.541-
TCCYAAAAGGCACGGGATGAAGG
not provided

2A > G

28937313
NM_005502.3(ABCA1):c.2804A > G
TCCAYTGTGGCCCAGGAAGGAGG,
Tangier disease

(p.Asn935Ser)
CGCTCCAYTGTGGCCCAGGAAGG

143246552
NM_001003811.1(TEX11):c.511A > G
TCCAYGGTCAAGTCAGCCTCAGG,
Spermatogenic failure, X-linked, 2

(p.Met171Val)
CCAYGGTCAAGTCAGCCTCAGGG

587776451
NM_002049.3(GATA1):c.2T > C
CTCCAYGGAGTTCCCTGGCCTGG,
GATA-1-related thrombocytopenia

(p.Met1Thr)
TCCAYGGAGTTCCCTGGCCTGGG,
with dyserythropoiesis

CCAYGGAGTTCCCTGGCCTGGGG

121908403
NM_021102.3(SPINT2):c.488A > G
TCCAYAGATGAAGTTATTGCAGG
Diarrhea 3, secretory sodium, congenital,

(p.Tyr163Cys)

syndromic

281874738
NM_000495.4(COL4A5):c.438 + 2T >
CTCCAGYAAGTTATAAAATTTGG,
Alport syndrome, X-linked recessive

C
TCCAGYAAGTTATAAAATTTGG

G

730880279
NM_030653.3(DDX11):c.2271 + 2T >
TCCAGGYGCGGGCGTCATGCTGG,
Warsaw breakage syndrome

C
CCAGGYGCGGGCGTCATGCTGGG

28940272
NM_017890.4(VPS13B):c.8978A > G
TCAYTGATAAGCAGGGCCCAGGG,
Cohen syndrome, not specified

(p.Asn2993Ser)
TTCAYTGATAAGCAGGGCCCAGG

137852375
NM_000132.3(F8):c.5372T > C
TCAYGGTGAGTTAAGGACAGTGG
Hereditary factor VIII deficiency disease

(p.Met1791Thr)

11567847
NM_021961.5(TEAD1):c.1261T > C
TCATATTYACAGGCTTGTAAAGG

(p.Tyr?His)

786203989
NM_016069.9(PAM16):c.226A > G
CATAGTYCTGCAGAGGAGAGGGG,
Chondrodysplasia, megarbane-dagher-melki

(p.Asn76Asp)
TCATAGTYCTGCAGAGGAGAGGG
type

587776437
NC_012920.1:m.9478T > C
TCAGAAGYTTTTTTCTTCGCAGG
Leigh disease

121912474
NM_000424.3(KRT5):c.20T > C
TCAAGTGYGTCCTTCCGGAGCGG,
Epidermolysis bullosa simplex, Koebner type

(p.Val7Ala)
CAAGTGYGTCCTTCCGGAGCGGG,

AAGTGYGTCCTTCCGGAGCGGGG,

AGTGYGTCCTTCCGGAGCGGGGG

104886461
NM_020533.2(MCOLN1):c.406-
TACYGTGGGCAGAGAAGGGGAGG,
Ganglioside sialidase deficiency

2A > G
AGGTACYGTGGGCAGAGAAGGGG,

CAGGTACYGTGGGCAGAGAAGGG

104894275
NM_000317.2(PTS):c.155A > G
TAAYTGTGCCCATGGCCATTTGG
6-pyruvoyl-tetrahydroptermsynthase

(p.Asn52Ser)

deficiency

587777562
NM_015599.2(PGM3):c.737A > G
TAAATGAYTGAGTTTGCCCTTGG
Immunodeficiency 23

(p.Asn246Ser)

121964906
NM_000027.3(AGA):c.916T > C
GTTATAYGTGCCAATGTGACTGG
Aspartylglycosaminuria

(p.Cys306Arg)

28941769
NM_000356.3(TC0F1):c.149A > G
GTGTGTAYAGATGTCCAGAAGGG
Treacher collins syndrome 1

(p.Tyr50Cys)

121434464
m.12297T > C
GTCYTAGGCCCCAAAAATTTTGG
Cardiomyopathy, mitochondrial

121908407
NM_054027.4(ANKH):c.143T > C
GTCGAGAYGCTGGCCAGCTACGG,
Chondrocalcinosis 2

(p.Met48Thr)
TCGAGAYGCTGGCCAGCTACGGG

59151893
NM_000422.2(KRT17):c.275A > G
GTCAYTGAGGTTCTGCATGGTGG,
Pachyonychia congenita type 2

(p.Asn92Ser)
GCGGTCAYTGAGGTTCTGCATGG

121909499
NM_002427.3(MMP13):c.272T > C
GTCAYGAAAAAGCCAAGATGCGG,

(p.Met91Thr)
TCAYGAAAAAGCCAAGATGCGG

G

61748478
NM_000552.3(VWF):c.2384A > G
GTCAYAGTTCTGGCACGTTTTGG
von Willebrand disease type 2N

(p.Tyr795Cys)

387906889
NM_006796.2(AFG3L2):c.1847A > G
GTAYAGAGGTATTGTTCTTTTGG
Spastic ataxia 5, autosomal recessive

(p.Tyr616Cys)

118203907
NM_000130.4(F5):c.5189A > G
GTAGYAGGCCCAAGCCCGACAGG
Factor V deficiency

(p.Tyr1730Cys)

118203945
NM_013319.2(UBIAD1):c.305A > G
GTAAGTGYTGACCAAATTACCGG
Schnyder crystalline conical dystrophy

(p.Asn102Ser)

267607080
NM_005633.3(SOS1):c.1294T > C
GGTYGGGAGGGAAAAGACATTGG
Noonan syndrome 4, Rasopathy

(p.Trp432Arg)

137852953
NM_012464.4(TLL1):c.1885A > G
GGTTAYGGTGCCGTTAAGTTTGG
Atrial septal defect 6

(p.Ile629Val)

118203949
NM_013319.2(UBISD1):c.692A > G
GGTGTTGYTGGAATGGAGAATGG
Schnyder crystalline conical dystrophy

(p.Asn232Ser)

137852952
NM_012464.4(TLL1):c.713T > C
GGGATTGYTGTTCATGAATTGGG
Atrial septal defect 6

(p.Val238Ala)

41460449
m.3394T > C
GGCYATATACAACTACGCAAAGG
Leber optic atrophy

80357281
NM_007294.3(BRCA1):c.5291T > C
GGGCYAGAAATCTGTTGCTATGG,
Familial cancer of breast, Breast-ovarian

(p.Leu1764Pro)
GGCYAGAAATCTGTTGCTATGGG
cancer, familial 1

5030764
NM_000174.4(GP9):c.182A > G
GGCTGYTGTTGGCCAGCAGAAGG
Bernard-Soulier syndrome type C

(p.Asn61Ser)

72556282
NM_000531.5(OTC):c.526T > C
GGCTGATYACCTCACGCTCCAGG,
not provided

(p.Tyr176His)
GATYACCTCACGCTCCAGGTTGG

121913594
NM_000530.6(MPZ):c.242A > G
GGCATAGYGGAAGATCTATGAGG
Charcot-Marie-Tooth disease type 1B

(p.His81Arg)

587777736
NM_017617.3(NOTCH1):c.1285T > C
GGCAAGYGCATCAACACGCTGGG,
Adams-Oliver syndrome 1, Adams-

(p.Cys429Arg)
GGGCAAGYGCATCAACACGCTGG
Oliver syndrome 5

63750912
NM_016835.4(MAPT):c.1839T > C
GGATAAYATCAAACACGTCCCGG,
Frontotemporal dementia

(p.Asn613=)
GATAAYATCAAACACGTCCCGG

G

121918075
NM_000371.3(TTR):c.401A > G
GGAGYAGGGGCTCAGCAGGGCGG,
Amyloidogenic transthyretin amyloidosis

(p.Tyr134Cys)
ATAGGAGYAGGGGCTCAGCAGGG

730882063
NM_004523.3(KIF11):c.2547 + 2T >
GGAGGYAATAACTTTGTAAGTGG
Microcephaly with or without

C

chorioretinopathy, lymphedema, or

mental retardation

397516156
NM_000257.3(MYH7):c.2546T > C
GGAGAYGGCCTCCATGAAGGAGG
Primary familial hypertrophic

(p.Met849Thr)

cardiomyopathy,

118204430
NM_000035.3(ALDOB):c.442T > C
GGAAGYGGCGTGCTGTGCTGAGG
Hereditary fructosuria

(p.Trp148Arg)

200198778
NM_013382.5(POMT2):c1997A > G
GGAAGYAGTGGTGGAAGTAGAGG
Congenital muscular dystrophy, Congenital

(p.Tyr666Cys)

muscular dystrophy-dystroglycanopathy with

brain and eye anomalies, type A2, Muscular

dystrophy, Congenital muscular dystrophy-

dystroglycanopathy with mental retardation,

type B2

754896795
NM_004006.2(DMD):c.6982A > T
GCTTTTYTTCAAGCTGCCCAAGG
Duchenne muscular dystrophy, Becker

(p.Lys2328Ter)

muscular dystrophy, Dilated cardiomyopathy

3B

148924904
NM_000546.5(TP53):c.488A > G
GCTTGYAGATGGCCATGGCGCGG
Hereditary cancer-predisposing syndrome

(p.Tyr163Cys)

786204770
NM_016035.4(COQ4):c.155T > C
GCTGTYGGCCGCCGGCTCCGCGG
COENZYME Q10 DEFICIENCY, PRIMARY, 7

(p.Leu52Ser)

121909520
NM_001100.3(ACTA1):c.350A > G
CGGYTGGCCTTGGGATTGAGGGG,
Nemaline myopathy 3

(p.Asn117Ser)
GCGGYTGGCCTTGGGATTGAGGG,

CGCGGYTGGCCTTGGGATTGAGG

587776879
NM_004656.3(BAP1):c.438-
GCCYGGGGAAAAACAGAGTCAGG
Tumor predisposition syndrome

2A > G

727504434
NM_000501.3(ELN):c.890-
GCCYGAAAACACAGCCACAGAGG
Supravalvar aortic stenosis

2A > G

119455953
NM_000391.3(TPP1):c.1093T > C
GCCGGGYGTTGGTCTGTCTCTGG
Ceroid lipofuscinosis, neuronal, 2

(p.Cys365Arg)

121964983
NM_000481.3(AMT):c.125A > G
GCCAGGYGGAAGTCATAGAGCGG
Non-ketotic hyperglycinemia

(p.His42Arg)

121908300
NM_001005741.2(GBA):c.751T > C
GCCAGAYACTTTGTGAAGTAAGG,
Gaucher disease, type 1

(p.Tyr251His)
CCAGAYACTTTGTGAAGTAAGG

786205083
NM_003494.3(DYSF):c.3443-
GCCAGAGYGAGTGGCTGGAGTGG
Limb-girdle muscular dystrophy, type 2B

33A > G

121908133
NM_175073.2(APTX):c.602A > G
GCCAAYGGTAACGGGCCTTTGGG,
Adult onset ataxia with oculomotor apraxia

(p.His201Arg)
AGCCAAYGGTAACGGGCCTTTGG

587777195
NM_005017.3(PCYT1A):c.571T > C
GCATGYTTGCTCCAACACAGAGG
Spondylometaphyseal dysplasia with cone-rod

(p.Phe191Leu)

dystrophy

431905520
NM_014714.3(IFT140):c.4078T > C
CAAGCAGYGTGAGCTGCTCCTGG,
Renal dysplasia, retinal pigmentary dystrophy,

(p.Cys1360Arg)
GCAGYGTGAGCTGCTCCTGGAGG
cerebellar ataxia and skeletal dysplasia

121912889
NM_001844.4(COL2A1):c.4172A > G
GCAGTGGYAGGTGATGTTCTGGG
Spondyloperipheral dysplasia, Platyspondylic

(p.Tyr1391Cys)

lethal skeletal dysplasia Torrance type

137854492
NM_001363.4(DKC1):c.I069A > G
GCAGGYAGAGATGACCGCTGTGG
Dyskeratosis congenita X-linked

(p.Thr357Ala)

121434362
NM_152783.4(D2HGDH):c.1315A > G
GCAGGTYACCATCTCCTGGAGGG,
D-2-hydroxyglutaric aciduria 1

(p.Asn439Asp)
TGCAGGTYACCATCTCCTGGAGG

80338732
NM_002764.3(PRPS1):c.344T > C
GCAAATAYGCTATCTGTAGCAGG
Charcot-Marie-Tooth disease, X-

(p.Met115Thr)

linked recessive, type 5

387906675
NM_000313.3(PROS1):c.701A > G
GATTAYATCTGTAGCCTTCGGGG,
Thrombophilia due to protein S deficiency,

(p.Tyr234Cys)
AGATTAYATCTGTAGCCTTCGGG,
autosomal recessive

GAGATTAYATCTGTAGCCTTCGG

28935478
NM_000061.2(BTK):c.1082A > G
GATGGYAGTTAATGAGCTCAGGG,

(p.Tyr361Cys)
TGATGGYAGTTAATGAGCTCAGG

201777056
NM_005050.3(ABCD4):c.956A > G
GATGAGGYAGATGCACACAAAGG
METHYLMALONIC ACIDURIA

(p.Tyr319Cys)

AND HOMOCYSTINURIA, cblJ

121918528
NM_000098.2(CPT2):c.359A > G
GATAGGYACATATCAAACCAGGG,
Carnitine palmitoyltransferase II

(p.Tyr120Cys)
AGATAGGYACATATCAAACCAG
deficiency, infantile

G

267607014
NM_002942.4(ROB02):c.2834T > C
GAGAYTGGAAATTTTGGCCGTGG
Vesicoureteral reflux 2

(p.Ile945Thr)

281865192
NM_025114.3(CEP290):c.2991 + 1655
GATAYTCACAATTACAACTGGGG,
Leber congenital amaurosis 10

A > G
AGATAYTCACAATTACAACTGGG,

GAGATAYTCACAATTACAACTG

386833492
NM_000112.3(5LC26A2):c.-
GAGAGGYGAGAAGAGGGAAGCGG
Diastrophic dysplasia

26 + 2T > C

587779773
NM_001101.3(ACTB):c.356T > C
GAGAAGAYGACCCAGGTGAGTGG
Baraitser-Winter syndrome 1

(p.Met119Thr)

121913512
NM_000222.2(KIT):c.1924A > G
GACTTYGAGTTCAGACATGAGGG,

(p.Lys642Glu)
GGACTTYGAGTTCAGACATGAGG

28939072
NM_006329.3(FBLN5):c.506T > C
GACAYTGATGAATGTCGCTATGG
Age-related macular degeneration 3

(p.Ile169Thr)

104894248
NM_000525.3(KCNJ11):c.776A > G
GACAYGGTAGATGATCAGCGGGG,
Islet cell hyperplasia

(p.His259Arg)
TGACAYGGTAGATGATCAGCGGG,

ATGACAYGGTAGATGATCAGCGG

387907132
NM_016464.4(TMEM138):c.287A > G
GACAYGAAGGGAGATGCTGAGGG,
Joubert syndrome 16

(p.His96Arg)
AGACAYGAAGGGAGATGCTGAGG

121918170
NM_000275.2(OCA2):c.1465A > G
GACATYTGGAGGGTCCCCGATGG
Tyrosinase-positive oculocutaneous albinism

(p.Asn489Asp)

122467173
NM_014009.3(FOXP3):c.970T > C
GACAGAGYTCCTCCACAACATGG
Insulin-dependent diabetes mellitus secretory

(p.Phe324Leu)

diarrhea syndrome

137852268
NM_000133.3(F9):c.1328T > C
GAAYATATACCAAGGTATCCCGG
Hereditary factor IX deficiency disease

(p.Ile443Thr)

149054177
NM_001999.3(FBN2):c.3740T > C
GAATGTAYGATAATGAACGGAGG
not specified, Macular degeneration, early-

(p.Met1247Thr)

onset

137854488
NM_212482.1(FN1):c.2918A > G
GAAGTAAYAGGTGACCCCAGGGG
Glomerulopathy with fibronectin deposits 2

(p.Tyr973Cys)

786204027
NM_005957.4(MTHFR):c.1530 + 2T >
GAAGGYGTGGTAGGGAGGCACGG,
Homocysteinemia due to MTHFR deficiency

C
AAGGYGTGGTAGGGAGGCACGGG,

AGGYGTGGTAGGGAGGCACGGGG

104894223
NM_012193.3(FZD4):c.766A > G
GAAATAYGATGGGGCGCTCAGGG,
Retinopathy of prematurity

(p.Ile256Val)
AGAAATAYGATGGGGCGCTCAGG

137854474
NM_000138.4(FBN1):c.3793T > C
CTTGYGTTATGATGGATTCATGG
Madan syndrome

(p.Cys1265Arg)

587784418
NM_006306.3(SMC1A):c.3254A > G
CTTAYAGATCTCATCAATGTTGG
Congenital muscular hypertrophy-cerebral

(p.Tyr1085Cys)

syndrome

81002805
NM_000059.3(BRCA2):c.316 + 2T >
CTTAGGYAAGTAATGCAATATGG
Familial cancer of breast, Breast-ovarian

C

cancer, familial 2, Hereditary cancer-

predisposing syndrome

121909653
NM_182925.4(FLT4):c.3104A > G
CTGYGGATGCACTGGGGTGCGGG,

(p.His1035Arg)
TCTGYGGATGCACTGGGGTGCGG

786205107
NM_031226.2(CYP19A1):c.743 + 2T >
CTGTGYAAGTAATACAACTTTGG
Aromatase deficiency

C

587777037
NM_001283009.1(RTEL1):c.3730T > C
CTGTGTGYGCCAGGGCTGTGGGG
Dyskeratosis congenita, autosomal recessive, 5

(p.Cys1244Arg)

794728380
NM_000238.3(KCNH2):c.1945 + 6T >
CTGTGAGYGTGCCCAGGGGCGGG,
Cardiac arrhythmia

C
TGAGYGTGCCCAGGGGCGGGCGG

267607987
NM_000251.2(MSH2):c.2005 + 2T >
CTGGYAAAAAACCTGGTTTTTGG,
Hereditary Nonpolyposis Colorectal Neoplasms

C
TGGYAAAAAACCTGGTTTTTGG

C

397509397
NM_006876.2(B4GAT1):c.1168A > G
TGATYTTCAGCCTCCTTTTGGGG,
Congenital muscular dystrophy-

(p.Asn390Asp)
CTGATYTTCAGCCTCCTTTTGGG,
dystroglycanopathy with brain and eye

GCTGATYTTCAGCCTCCTTTTGG
anomalies, type A13

121918381
NM_000040.1(APOC3):c.280A > G
CTGAAGYTGGTCTGACCTCAGGG,

(p.Thr94Ala)
GCTGAAGYTGGTCTGACCTCAGG

104894919
NM_001015877.1(PHF6):c.769A > G
CTCYTGATGTTGTTGTGAGCTGG
Borjeson-Forssman-Lehmann syndrome

(p.Arg257Gly)

267606869
NM_005144.4(HR):c.-218A > G
CTCYAGGGCCGCAGGTTGGAGGG,
Marie Unna hereditary hypotrichosis 1

GCTCYAGGGCCGCAGGTTGGAGG,

GGCGCTCYAGGGCCGCAGGTTGG

139732572
NM_000146.3(FTL):c.1A > G
CTCAYGGTTGGTTGGCAAGAAGG
L-ferritin deficiency

(p.Met1Val)

397515418
NM_018486.2(HDAC8):c.1001A > G
CTCAYGATCTGGGATCTCAGAGG
Cornelia de Lange syndrome 5

(p.His334Arg)

372395294
NM_198056.2(SCN5A):c.1247A > G
CTCAYAGGCCATTGCGACCACGG
not provided

(p.Tyr416Cys)

104895304
NM_000431.3(MVK):c.803T > C
CTCAAYAGATGCCATCTCCCTGG
Hyperimmunoglobulin D with periodic

(p.Ile268Thr)

fever, Mevalonic aciduria

587777188
NM_001165899.1(PDE4D):c.1850T > C
CTATAYTGTTCATCCCCTCTGGG,
Acrodysostosis 2, with or without hormone

(p.Ile617Thr)
ACTATAYTGTTCATCCCCTCTGG
resistance

398123026
NM_003867.3(FGF17):c.560A > G
CGTGGYTGGGGAAGGGCAGCTGG
Hypogonadotropic hypogonadism 20 with or

(p.Asn187Ser)

without anosmia

121964924
NM_001385.2(DPYS):c.1078T > C
CGTAATAYGGGAAAAAGGCGTGG,
Dihydropyrimidinase deficiency

(p.Trp360Arg)
AATAYGGGAAAAAGGCGTGGTGG,

ATAYGGGAAAAAGGCGTGGTGGG

587777301
NM_199189.2(MATR3):c.1864A > G
CGGYTGAACTCTCAGTCTTCTGG
Myopathy, distal, 2

(p.Thr622Ala)

200238879
NM_000527.4(LDLR):c.694 + 2T > C
ACTGCGGYATGGGCGGGGCCAGG,
Familial hypercholesterolem a

CTGCGGYATGGGCGGGGCCAGGG,

CGGYATGGGCGGGGCCAGGGTGG

142951029
NM_145046.4(CALR3):c.245A > G
CGGTYTGAAGCGTGCAGAGATGG
Arrhythmogenic right ventricular

(p.Lys82Arg)

cardiomyopathy, Familial

hypertrophic cardiomyopathy 19,

Hypertrophic cardiomyopathy

786200953
NM_006785.3(MALT1):c.1019-2A > G
CGCYTTGAAAAAAAAAGAAAGGG,
Combined immunodeficiency

TCGCYTTGAAAAAAAAAGAAAG

120074192
NM_000218.2(KCNQ1):c.418A > G
CGCYGAAGATGAGGCAGACCAGG
Atrial fibrillation, familial, 3,

(p.Ser140Gly)

Atrial fibrillation

267606887
NM_005957.4(MTHFR):c.971A > G
CGCGGYTGAGGGTGTAGAAGTGG
Homocystinuria due to MTHFR deficiency

(p.Asn324Ser)

118192117
NM_000540.2(RYR1):c.1205T > C
CGCAYGATCCACAGCACCAATGG
Congenital myopathy with fiber

(p.Met402Thr)

type disproportion, Central core

disease

199473625
NM_198056.2(SCN5A):c.4978A > G
CGAYGTTGAAGAGGGCAGGCAGG,

(p.Ile1660Val)
AGCCCGAYGTTGAAGAGGGCAGG
Brugada syndrome

794726865
NM_000921.4(PDE3A):c.1333A > G
CGAGGYGGTGGTGGTCCAAGTGG
Brachydactyly with hypertension

(p.Thr445Ala)

606231254
NM_005740.2(DNAL4):c.153 + 2T > C
CGAGGYATTGCCAGCAGTGCAGG
Mirror movements 3

786204826
NM_004771.3(MMP20):c.611A > G
CGAAAYGTGTATCTCCTCCCAGG
Amelogenesis imperfecta, hypomaturation type,

(p.His204Arg)

IIA2

796053139
NM_021007.2(SCN2A):c.4308 + 2T >
CGAAATGYAAGTCTAGTTAGAGG,
not provided

C
GAAATGYAAGTCTAGTTAGAGG

137854494
NM_005502.3(ABCA1):c.4429T > C
CCTGTGYGTCCCCCAGGGGCAGG,
Tangier disease

(p.Cys1477Arg)
CTGTGYGTCCCCCAGGGGCAGGG,

TGTGYGTCCCCCAGGGGCAGGGG,

GTGYGTCCCCCAGGGGCAGGGGG

786205144
NM_001103.3(ACTN2):c.683T > C
CCTAAAAYGTTGGATGCTGAAGG
Dilated cardiomyopathy IAA

(p.Met228Thr)

199919568
NM_007254.3(PNKP):c.1029 + 2T > C
CCGGYGAGGCCCTGGGGCGGGGG,
not provided

TCCGGYGAGGCCCTGGGGCGGGG,

ATCCGGYGAGGCCCTGGGGCGGG,

GATCCGGYGAGGCCCTGGGGCGG

28939079
NM_018965.3(TREM2):c.401A > G
TGAYCCAGGGGGTCTATGGGAGG,
Polycystic lipomembranous osteodysplasia with

(p.Asp134Gly)
CGGTGAYCCAGGGGGTCTATGGG,
sclerosing leukoencephalopathy

CCGGTGAYCCAGGGGGTCTATGG

193302855
NM_032520.4(GNPTG):c.610-2A > G
CCCYGAAGGTGGAGGATGCAGGG,
Mucolipidosis III Gamma

GCCCYGAAGGTGGAGGATGCAGG

111033708
NM_000155.3(GALT):c.499T > C
CCCTYGGGTGCAGGTTTGTGAGG
Deficiency of UDPglucose-hexose-1-phosphate

(p.Trp167Arg)

uridylyltransferase

28933378
NM_000174.4(GP9):c.70T > C
CCCAYGTACCTGCCGCGCCCTGG
Bernard Soulier syndrome, Bernard-Soulier

(p.Cys24Arg)

syndrome type C

364897
NM_000157.3(GBA):c.680A > G
CCAYTGGTCTTGAGCCAAGTGGG,
Gaucher disease, Subacute neuronopathic

(p.Asn227Ser)
TCCAYTGGTCTTGAGCCAAGTGG
Gaucher disease, Gaucher disease, type 1

796052551
NM_000833.4(GR1N2A):c.2449A > G
CCAYGTTGTCAATGTCCAGCTGG
not provided

(p.Met817Val)

63751006
NM_002087.3(GRN):c.2T > C
CCAYGTGGACCCTGGTGAGCTGG
Frontotemporal dementia, ubiquitin-positive

(p.Met1Thr)

786203997
NM_001031.4(RPS28):c.1A > G
TGTCCAYGATGGCGGCGCGGCGG,
Diamond-Blackfan anemia with microtia and

(p.Met1Val)
CCAYGATGGCGGCGCGGCGGCGG
cleft palate

121908595
NM_002755.3(MAP2K1):c.389A > G
CCAYAGAAGCCCACGATGTACGG
Cardiofaciocutaneous syndrome 3, Rasopathy

(p.Tyr130Cys)

398122910
NM_000431.3(MVK):c.1039 + 2T > C
CCAGGYATCCCGGGGGTAGGTGG,
Porokeratosis, disseminated superficial actinic

CAGGYATCCCGGGGGTAGGTGGG
1

119474039
NM_020365.4(EIF2B3):c.1037T > C
CCAGAYTGTCAGCAAACACCTGG
Leukoencephalopathy with vanishing white

(p.Ile346Thr)

matter

587777866
NM_000076.2(CDKN1C):c.*5 + 2T > C
CCAAGYGAGTACAGCGCACCTGG,
Beckwith-Wiedemann syndrome

CAAGYGAGTACAGCGCACCTGGG,

AAGYGAGTACAGCGCACCTGGGG

121918530
NM_005587.2(MEF2A):c.788A > G
AGAYTACCACCACCTGGTGGAGG,

(p.Asn263Ser)
CCAAGAYTACCACCACCTGGTGG

483352818
NM_000211.4(ITGB2):c1877 + 2T > C
CATGYGAGTGCAGGCGGAGCAGG
Leukocyte adhesion deficiency type 1

460184
NM_000186.3(CFH):c.3590T > C
CAGYTGAATTTGTGTGTAAACGG
Atypical hemolytic-urem c syndrome 1

(p.Val1197Ala)

121908423
NM_004795.3(KL):c.578A > G
CAGYGGTACAGGGTGACCACGGG,

(p.His193Arg)
CCAGYGGTACAGGGTGACCACGG

281860300
NM_005247.2(FGF3):c.146A > G
CAGYAGAGCTTGCGGCGCCGGGG,
Deafness with labyrinthine aplasia microtia and

(p.Tyr49Cys)
GCAGYAGAGCTTGCGGCGCCGGG,
microdontia (LAMM)

CGCAGYAGAGCTTGCGGCGCCGG

28935488
NM_000169.2(GLA):c.806T > C
CAGTTAGYGATTGGCAACTTTGG
Fabry disease

(p.Val269Ala)

587776514
NM_173560.3(RFX6):c.380 + 2T >
CAGTGGYGAGACTCGCCCGCAGG,
Mitchell-Riley syndrome

C
AGTGGYGAGACTCGCCCGCAGGG

104894117
NM_178138.4(LHX3):c.332A > G
CAGGTGGYACACGAAGTCCTGGG
Pituitary hormone deficiency, combined 3

(p.Tyr111Cys)

34878913
NM_000184.2(HBG2):c.125T > C
CAGAGGTYCTTTGACAGCTTTGG
Cyanosis, transient neonatal

(p.Phe42Ser)

120074124
NM_000543.4(SMPD1):c.911T > C
AGCACYTGTGAGGAAGTTCCTGG,
Sphingomyelin/cholesterol lipidosis, Niemann-

(p.Leu304Pro)
GCACYTGTGAGGAAGTTCCTGGG,
Pick disease, type A, Niemann-Pick disease,

CACYTGTGAGGAAGTTCCTGGGG
type B

281860272
NM_005211.3(CSF1R):c.2320-
CACYGAGGGAAAGCACTGCAGGG,
Hereditary diffuse leukoencephalopathy with

2A > G
GCACYGAGGGAAAGCACTGCAGG
spheroids

128624216
NM_000033.3(ABCD1):c.443A > G
CACTGYTGACGAAGGTAGCAGGG,
Adrenoleukodystrophy

(p.Asn148Ser)
GCACTGYTGACGAAGGTAGCAGG

398124257
NM_012463.3(ATP6V0A2):c.825 + 2T >
CACTGYGAGTAAGCTGGAAGTGG
Cutis laxa with osteodystrophy

C

267606679
NM_004183.3(BEST1):c.704T > C
CACTGGYGTATACACAGGTGAGG
Vitreoretinochoroidopathy dominant

(p.Val235Ala)

397514518
NM_000344.3(SMNI):c.388T > C
CACTGGAYATGGAAATAGAGAGG
Kugelberg-Welander disease

(p.Tyr130His)

143946794
NM_001946.3(DUSP6):c.566A > G
CACTAYTGGGGTCTCGGTCAAGG
Hypogonadotropic hypogonadism 19 with or

(p.Asn189Ser)

without anosmia

397516076
NM_000256.3(MYBPC3):c.821 + 2T > C
GCACGYGAGTGGCCATCCTCAGG,
Familial hypertrophic cardiomyopathy 4, not

CACGYGAGTGGCCATCCTCAGGG
specified

149977726
NM_001257988.1(TYMP):c.665A > G
CACGAGTYTCTTACTGAGAATGG,

(p.Lys222Arg)
GAGTYTCTTACTGAGAATGGAGG

121917770
NM_003361.3(UMOD):c.383A > G
CACAYTGACACATGTGGCCAGGG,
Familial juvenile gout

(p.Asn128Ser)
CCACAYTGACACATGTGGCCAGG

121909008
NM_000492.3(CFTR):c.2738A > G
CACATAAYACGAACTGGTGCTGG
Cystic fibrosis

(p.Tyr913Cys)

137852819
NM_003688.3(CASK):c.2740T > C
CACAGYGGGTCCCTGTCTCCTGG,
FG syndrome 4

(p.Trp914Arg)
ACAGYGGGTCCCTGTCTCCTGGG

74315320
NM_024009.2(GM3):c.421A > G
CAAYGATGAGCTTGAAGATGAGG
Deafness, autosomal recessive

(p.Ile141Val)

80356747
NM_001701.3(BAAT):c.967A > G
CAAYGAAGAGGAATTGCCCCTGG
Atypical hemolytic-uremic syndrome 1

(p.Ile323Val)

180177324
NM_012203.1(GRHPR):c.94A > G
CAAGTYGTTAGCTGCCAACAAGG
Primary hyperoxaluria, type II

(p.Asn312Asp)

281860274
NM_005211.3(CSFIR):c.2381T > C
CAAGAYTGGGGACTTCGGGCTGG
Hereditary diffuse leukoencephalopathy with

(p.Ile794Thr)

spheroids

398122908
NM_005334.2(HCFC1):c.-
CAAGAYGGCGGCTCCCAGGGAGG
Mental retardation 3, X-linked

970T > C

548076633
NM_002693.2(POLG):c.3470A > G
CAAGAGGYTGGTGATCTGCAAGG
not provided

(p.Asn1157Ser)

120074146
NM_000019.3(ACAT1):c.935T > C
CAAGAAYAGTAGGTAAGGCCAGG
Deficiency of acetyl-CoA acetyltransferase

(p.Ile312Thr)

397514489
NM_005340.6(HINT1):c.250T > C
CAAGAAAYGTGCTGCTGATCTGG,
Gamstorp-Wohlfart syndrome

(p.Cys84Arg)
AAGAAAYGTGCTGCTGATCTGGG

587783539
NM_178151.2(DCX):c.2T > C
CAAAATAYGGAACTTGATTTTGG
Heterotopia

(p.Met1Thr)

104894765
NM_005448.2(BMP15):c.704A > G
ATTGAAAYAGAGTAACAAGAAGG
Ovarian dysgenesis 2

(p.Tyr235Cys)

137852429
NM_000132.3(F8):c.1892A > G
ATGYTGGAGGCTTGGAACTCTGG
Hereditary factor VIII deficiency disease

(p.Asn63ISer)

72558441
NM_000531.5(0TC):c.779T > C
ATGTATYAATTACAGACACTTGG
not provided

(p.Leu260Ser)

398123765
NM_003494.3(DYSF):c.1284 + 2T >
ATGGYAAGGAGCAAGGGAGCAGG
Limb-girdle muscular dystrophy, type 2B

C

387906924
NM_020191.2(MRPS22):c.644T > C
ATCYTAGGGTAAGGTGACTTAGG
Combined oxidative phosphorylation deficiency

(p.Leu215Pro)

5

397518039
NM_206933.2(USH2A):c.8559-
ATCYAAAGCAAAAGACAAGCAGG
Retinitis pigmentosa, Usher syndrome, type 2A

2A > G

5742905
NM_000071.2(CBS):c.833T > C
ATCAYTGGGGTGGATCCCGAAGG,
Homocystinuria due to CBS

(p.Ile278Thr)
TCAYTGGGGTGGATCCCGAAGGG
deficiency, Homocystinuria,

vridnxine-resnnnsiv

397507473
NM_004333.4(BRAF):c.1403T > C
ATCATYTGGAACAGTCTACAAGG,
Cardiofaciocutaneous syndrome, Rasopathy

(p.Phe468Ser)
TCATYTGGAACAGTCTACAAGG

786204056
NM_000264.3(PTCH1):c.3168 + 2T >
ATCATTGYGAGTGTATTATAAGG,
Gorlin syndrome

C
TCATTGYGAGTGTATTATAAGGG,

CATTGYGAGTGTATTATAAGGG

72558484
NM_000531.5(0TC):c.1005 + 2T >
ATCATGGYAAGCAAGAAACAAGG
not provided

C

199473074
NM_000335.4(SCN5A):c.688A > G
ATAYAGTTTTCAGGGCCCGGAGG,
Brugada syndrome

(p.Ile230Val)
CTGATAYAGTTTTCAGGGCCCGG

111033273
NM_206933.2(USH2A):c.1606T > C
ATATAGAYGCCTCTGCTCCCAGG
Usher syndrome, type 2A

(p.Cys536Arg)

72556290
NM000531.5(OTC):c.542A > G
ATAGTGTYCCTAAAAGGCACGGG
not provided

(p.Glu181Gly)

121918711
NM_004612.3(TGFBR1):c.1199A > G
ATAGATGYCAGCACGTTTGAAGG
Loeys-Dietz syndrome 1

(p.Asp400Gly)

104886288
NM_000495.4(COL4A5):c.4699T > C
AGTAYGTGAAGCTCCAGCTGTGG
Alport syndrome, X-linked recessive

(p.Cys1567Arg)

144637717
NM_016725.2(FOLR1):c.493 + 2T >
CTTCAGGYGAGGGCTGGGGTGGG,
not provided

C
AGGYGAGGGCTGGGGTGGGCAGG

72558492
NM_000531.5(0TC):c.1034A > G
AGGTGAGYAATCTGTCAGCAGGG
not provided

(p.Tyr345Cys)

62638745
NM_000121.3(EPOR):c.1460A > G
AGGGYTGGAGTAGGGGCCATCGG
Acute myeloid leukemia, M6 type,

(p.Asn487Ser)

Familial erythrocytosis, 1

387907021
NM_031427.3(DNAL1):c.449A > G
AGGGAYTGCCTACAAACACCAGG
Kartagener syndrome, Ciliary dyskinesia,

(p.Asn150Ser)

primary, 16

397514488
NM_001161581.1(POC1A):c.398T > C
AGCYGTGGGACAAGAGCAGCCGG
Short stature, onychodysplasia, facial

(p.Leu133Pro)

dysmorphism, and hypotrichosis

154774633
NM_017882.2(CLN6):c.200T > C
AGCYGGTATTCCCTCTCGAGTGG
Adult neuronal ceroid lipofuscinosis

(p.Leu67Pro)

111033700
NM_000155.3(GALT):c.482T > C
AGCYGGGTGCCCAGTACCCTTGG
Deficiency of UDPglucose-hexose-1-phosphate

(p.Leu161Pro)

uridylyltransferase

128621198
NM_000061.2(BTK):c.1223T > C
GAGCYGGGGACTGGACAATTTGG,
X-linked agammaglobulinemia

(p.Leu408Pro)
AGCYGGGGACTGGACAATTTGGG

137852611
NM_000211.4(ITGB2):c.446T > C
AGCYAGGTGGCGACCTGCTCCGG
Leukocyte adhesion deficiency

(p.Leu149Pro)

121908838
NM_003722.4(TP63):c.697A > G
AGCTTYTTTGTAGACAGGCATGG
Split-hand/foot malformation 4

(p.Lys233Glu)

397515869
NM_000169.2(GLA):c.1153A > G
AGCTGTGYGATGAAGCAGGCAGG
not specified

(p.Thr385Ala)

118204064
NM_000237.2(LPL):c.548A > G
GCTGGAYCGAGGCCTTAAAAGGG,
Hyperlipoproteinemia, type I

(p.Asp183Gly)
AGCTGGAYCGAGGCCTTAAAAGG

128620186
NM_000061.2(BTK):c.2T > C
AGCTAYGGCCGCAGTGATTCTGG
X-linked agammaglobulinemia

(p.Met1Thr)

786204132
NM_014946.3(SPAST):c.1165A > G
ATTGYCTTCCCATTCCCAGGTGG,
Spastic paraplegia 4, autosomal dominant

(p.Thr389Ala)
AGCATTGYCTTCCCATTCCCAGG

199473661
NM_000218.2(KCNQ1):c.550T > C
CAGCAAGBACGTGGGCCTCTGGG,
Congenital long QT syndrome, Cardiac

(p.Tyr184His)
AGCAAGBACGTGGGCCTCTGGGG,
arrhythmia

GCAAGBACGTGGGCCTCTGGGGG

387907129
NM_024599.5(RHBDF2):c.557T > C
AGAYTGTGGATCCGCTGGCCCGG
Howel-Evans syndrome

(p.Ile186Thr)

387906702
NM_006306.3(SMC1A):c.2351T > C
AGAYTGGTGTGCGCAACATCCGG
Congenital muscular hypertrophy-cerebral

(p.Ile784Thr)

syndrome

193929348
NM_000525.3(KCNJ11):c.544A > G
AGAYGAGGGTCTCAGCCCTGCGG
Permanent neonatal diabetes mellitus

(p.Ile182Val)

121908934
NM_004086.2(COCH):c.1535T > C
AGATAYGGCTTCTAAACCGAAGG
Deafness, autosomal dominant 9

(p.Met512Thr)

397514377
NM_000060.3(BTD):c.641A > G
AGAGGYTGTGTTTACGGTAGCGG
Biotinidase deficiency

(p.Asn214Ser)

72552295
NM_000531.5(0TC):c.2T > C
AGAAGAYGCTGTTTAATCTGAGG
not provided

(p.Met1Thr)

201893545
NM_016247.3(IMPG2):c.370T > C
ACTYTTTGGGATCGACTTCCTGG
Macular dystrophy, vitelliform, 5

(p.Phe124Leu)

121434469
m.4290T > C
ACTYTGATAGAGTAAATAATAGG

121918733
NM_006920.4(SCN1A):c.269T > C
ACTTYTATAGTATTGAATAAAGG,
Severe myoclonic epilepsy in infancy

(p.Phe90Ser)
CTTYTATAGTATTGAATAAAGG

G

121434471
m.4291T > C
ACTTYGATAGAGTAAATAATAGG
Hypertension, hypercholesterolemia, and

hypomagnesemia, mitochondrial

606231289
NM_001302946.1(TRNT1):c.497T > C
ACTTYATTTGACTACTTTAATGG
Sideroblastic anemia with B-cell

(p.Leu166Ser)

immunodeficiency, periodic fevers,

and developmental delay

63750067
NM_000517.4(HBA2):c*92A >
CTTYATTCAAAGACCAGGAAGGG,
Hemoglobin H disease, nondeletional

G
ACTTYATTCAAAGACCAGGAAG

G

121918734
NM_006920.4(SCN1A):c.272T > C
ACTTTTAYAGTATTGAATAAAGG,
Severe myoclonic epilepsy in infancy

(p.Ile91Thr)
CTTTTAYAGTATTGAATAAAGG

C

137854557
NM_000267.3(NF1):c.1466A > G
ACTTAYAGCTTCTTGTCTCCAGG
Neurofibromatosis, type 1

(p.Tyr489Cys)

397514626
NM_018344.5(SLC29A3):c.607T > C
ACTGATAYCAGGTGAGAGCCAGG,
Histiocytoss-lymphadenopathy plus syndrome

(p.Ser203Pro)
CTGATAYCAGGTGAGAGCCAGGG

118204440
NM_000512.4(GALNS):c.1460A > G
ACGYTGAGCTGGGGCTGCGCGGG,
Mucopolysaccharidosis, MPS-IV-A

(p.Asn487Ser)
CACGYTGAGCTGGGGCTGCGCGG

587776843
NG_012088.1:g.2209A > G
ACCYTATGATCCGCCCGCCTTGG

137853033
NM_001080463.1(DYNC2H1):c.4610A > G
ACCYGTGAAGGGAACAGAGATGG
Short-rib thoracic dysplasia 3 with or

(p.Gln1537Arg)

without polydactyly

28933698
NM_000435.2(NOTCH3):c.1363T > C
TTCACCYGTATCTGTATGGCAGG,
Cerebral autosomal dominant arteriopathy with

(p.Cys455Arg)
ACCYGTATCTGTATGGCAGGTGG
subcortical infarcts and leukoencephalopathy

587776766
NM_000463.2(UGT1A1):c.1085-
ACCYGAGATGCAAAATAGGGAGG,
Crigler Najjar syndrome, type 1

2A > G
GTGACCYGAGATGCAAAATAGGG,

GGTGACCYGAGATGCAAAATAGG

587781628
NM_001128425.1(MUTYH):c.1187-
ACCYGAGAGGGAGGGCAGCCAGG
Hereditary cancer-predisposing syndrome,

2A > G

Carcinoma of colon

61755817
NM_000322.4(PRPH2):c.736T > C
ACCTGYGGGTGCGTGGCTGCAGG,
Retinitis pigmentosa

(p.Trp246Arg)
CCTGYGGGTGCGTGGCTGCAGGG

121909184
NM_001089.2(ABCA3):c.1702A > G
ACCGTYGTGGCCCAGCAGGACGG
Surfactant metabolism dysfunction, pulmonary,

(p.Asn568Asp)

3

121434466
m.4269A > G
ACAYATTTCTTAGGTTTGAGGGG,

GACAYATTTCTTAGGTTTGAGGG,

AGACAYATTTCTTAGGTTTGAGG

794726768
NM_001165963.1(SCN1A):c.1048A > G
ACAYATATCCCTCTGGACATTGG
Severe myoclonic epilepsy in infancy

(p.Met350Val)

28934876
NM_001382.3(DPAGT1):c.509A > G
ACAYAGTACAGGATTCCTGCGGG,
Congenital disorder of glycosylation type 1J

(p.Tyr170Cys)
GACAYAGTACAGGATTCCTGCGG

104894749
NM_000054.4(AVPR2):c.614A > G
ACAYAGGTGCGACGGCCCCAGGG,
Nephrogenic diabetes insipidus, Nephrogenic

(p.Tyr205Cys)
GACAYAGGTGCGACGGCCCCAGG
diabetes insipidus, X-linked

128621205
NM_000061.2(BTK):c.1741T > C
ACATTYGGGCTTTTGGTAAGTGG
X-linked agammaglobulinemia

(p.Trp581Arg)

28940892
NM_000529.2(MC2R):c.761A > G
ACATGYAGCAGGCGCAGTAGGGG,
ACTH resistance

(p.Tyr254Cys)
GACATGYAGCAGGCGCAGTAGGG,

AGACATGYAGCAGGCGCAGTAGG

794726844
NM_001165963.1(SCN1A):c.1046A > G
ACATAYATCCCTCTGGACATTGG
Severe myoclonic epilepsy in infancy

(p.Tyr349Cys)

587783083
NM_003159.2(CDKL5):c.449A > G
ACAGTYTTAGGACATCATTGTGG
not provided

(p.Lys150Arg)

397514651
NM_000108.4(DLD):c.140T > C
ACAGTTAYAGGTTCTGGTCCTGG,
Maple syrup urine disease, type 3

(p.Ile47Thr)
GTTAYAGGTTCTGGTCCTGGAGG

794727060
NM_001848.2(COL6A1):c.957 + 2T >
ACAAGGYGAGCGTGGGCTGCTGG,
Ullrich congenital muscular dystrophy, Bethlem

C
CAAGGYGAGCGTGGGCTGCTGGG
myopathy

72554346
NM_000531.5(OTC):c.284T > C
ACAAGATYGTCTACAGAAACAGG
not provided

(p.Leu95Ser)

483353031
NM_002136.2(HNRPA1):c.841T > C
AATYTTGGAGGCAGAAGCTCTGG
Chronic progressive multiple sclerosis

(p.Phe281Leu)

104894271
NM_000315.2(PTH):c.52T > C
AATTYGTTTTCTTACAAAATCGG
Hypoparathyroidism familial isolated

(p.Cys18Arg)

267608260
NM_015599.2(PGM3):c.248T > C
AATGTYGGCACCATCCTGGGAGG
Immunodeficiency 23

(p.Leu83Ser)

267606900
NM_018109.3(MTPAP):c.1432A > G
AATGGATYCTGAATGTACAGAGG
Ataxia, spastic, 4, autosomal recessive

(p.Asn478Asp)

796053169
NM_021007.2(SCN2A):c.387-
AATAAAGYAGAATATCGTCAAGG
not provided

2A > G

104894937
NM_000116.4(TAZ):c.352T > C
AAGYGTGTGCCTGTGTGCCGAGG
3-Methylglutaconic aciduria type 2

(p.Cys118Arg)

104893911
NM_001018077.1(NR3C1):c.1712T > C
AAGYGATTGCAGCAGTGAAATGG
Pseudohermaphroditism, female, with

(p.Val571Ala)

hypokalemia, due to glucocorticoid resistance

397514472
NM_004813.2(PEX16):c.992A > G
AAGYAGATTTTCTGCCAGGTGGG,
Peroxisome biogenesis disorder 8B

(p.Tyr331Cys)
GAAGYAGATTTTCTGCCAGGTGG,

GTAGAAGYAGATTTTCTGCCAGG

121918407
NM_001083112.2(GPD2):c.1904T > C
AAGTYTGATGCAGACCAGAAAGG
Diabetes mellitus type 2

(p.Phe635Ser)

63751110
NM_000251.2(MSH2):c.595T > C
AAGGAAYGTGTTTTACCCGGAGG
Hereditary Nonpolyposis Colorectal Neoplasms

(p.Cys199Arg)

119450945
NM_000026.2(ADSL):c.674T > C
AAGAYGGTGACAGAAAAGGCAGG
Adenylosuccinate lyase deficiency

(p.Met225Thr)

113993988
NM_002863.4(PYGL):c.2461T > C
AAGAAYATGCCCAAAACATCTGG
Glycogen storage disease, type VI

(p.Tyr821His)

119485091
NM_022041.3(GAN):c.1268T > C
AAGAAAAYCTACGCCATGGGTGG,
Giant axonal neuropathy

(p.Ile423Thr)
AAAAYCTACGCCATGGGTGGAGG

137852419
NM_000132.3(F8):c.1660A > G
AACYAGAGTAATAGCGGGTCAGG
Hereditary factor VIII deficiency disease

(p.Ser554Gly)

121964967
NM_000071.2(CBS):c.1150A > G
AACTYGGTCCTGCGGGATGGGGG,
Homocystinuria, pyridoxine-responsive

(p.Lys384Glu)
GAACTYGGTCCTGCGGGATGGGG,

GGAACTYGGTCCTGCGGGATGGG,

AGGAACTYGGTCCTGCGGGATGG

137852376
NM_000132.3(F8):c.1754T > C
AACAGAYAATGTCAGACAAGAGG
Hereditary factor VIII deficiency disease

(p.Ile585Thr)

121917930
NM_006920.4(SCN1A):c.3577T > C
AACAAYGGTGGAACCTGAGAAGG
Generalized epilepsy with febrile seizures

(p.Trp1193Arg)

plus, type 1, Generalized epilepsy with

febrile seizures plus, type 2

28939717
NM_003907.2(EIF2B5):c.271A > G
AAATGYTTCCTGTACACCTGTGG
Leukoencephalopathy with vanishing white

(p.Thr91Ala)

matter

80357276
NM_007294.3(BRCA1):c.122A > G
AAATATGYGGTCACACTTTGTGG
Familial cancer of breast, Breast-ovarian

(p.His4lArg)

cancer, familial 1

397515897
NM_000256.3(MYBPC3):c.1351 + 2T >
AAAGGYGGGCCTGGGACCTGAGG
Familial hypertrophic cardiomyopathy

C

4, Cardiomyopathy

397514491
NM_005340.6(HINTI):c.152A > G
AAAAYGTGTTGGTGCTTGAGGGG,
Gamstorp-Wohlfart syndrome

(p.His51Arg)
GAAAAYGTGTTGGTGCTTGAGGG,

AGAAAAYGTGTTGGTGCTTGAGG

387907164
NM_020894.2(UVSSA):c.94T > C
AAAATTYGCAAGTATGTCTTAGG,
UV-sensitive syndrome 3

(p.Cys32Arg)
AAATTYGCAAGTATGTCTTAGG

G

118161496
NM_025152.2(NUBPL):c.815-
TGGTTCYAATGGATGTCTGCTGG,
Mitochondrial complex I deficiency

27T > C
GGTTCYAATGGATGTCTGCTGGG

764313717
NM_005609.2(PYGM):c.425_528del
TGGCTGYCAGGGACCCAGCAAGG,

CTGYCAGGGACCCAGCAAGGAGG

28934568
NM_003242.5(TGFBR2):c.923T > C
AGTTCCYGACGGCTGAGGAGCGG
Loeys-D etz syndrome 2

(p.Leu308Pro)

121913461
NM_007313.2(ABL1):c.814T > C
CCAGYACGGGGAGGTGTACGAGG,

(p.Tyr272His)
CAGYACGGGGAGGTGTACGAGGG

377750405
NM_173551.4(ANKS6):c.1322A > G
AGGGCYGTCGGACCTTCGAGTGG,
Nephronophthisis 16

(p.Gln441Arg)
GGGCYGTCGGACCTTCGAGTGGG,

GGCYGTCGGACCTTCGAGTGGGG

57639980
NM_001927.3(DES):c.1034T > C
ATTCCCYGATGAGGCAGATGCGG,
Myofibrillar myopathy 1

(p.Leu345Pro)
TTCCCYGATGAGGCAGATGCGGG

147391618
NM_020320.3(RARS2):c.35A > G
ATACCYGGCAAGCAATAGCGCGG
Pontocerebellar hypoplasia type 6

(p.Gln12Arg)

182650126
NM_002977.3(SNC9A):c.2215A > G
GTAAYTGCAAGATCTACAAAAGG
Small fiber neuropathy

(p.Ile739Val)

80358278
NM_004700.3(KCNQ4):c.842T > C
ACATYGACAACCATCGGCTATGG
DFNA 2 Nonsyndromic Hearing Loss

(p.Leu281Ser)

786204012
NM_005957.4(MTHFR):c.388T > C
GACCYGCTGCCGTCAGCGCCTGG
Homocysteinemia due to MTHFR deficiency

(p.Cys130Arg)

786204037
NM_005957.4(MTHFR):c.1883T > C
TCCCACYGGACAACTGCCTCTGG
Homocysteinemia due to MTHFR deficiency

(p.Leu628Pro)

202147607
NM_000140.3(FECH):c.1137 + 3A >
GTAGAYACCTTAGAGAACAATGG
Erythropoietic protoporphyria

G

122456136
NM_005183.3(CACNA1F):c.2267T > C
TGCCAYTGCTGTGGACAACCTGG

(p.Ile756Thr)

786204851
NM_007374.2(SIX6):c.110T > C
GTCGCYGCCCGTGGCCCCTGCGG
Cataract, microphthalmia and nystagmus

(p.Leu37Pro)

794728167
NM_000138.4(FBN1):c.1468 + 2T >
ATTGGYACGTGATCCATCCTAGG
Thoracic aortic aneurysms and aortic

C

dissections

121964909
NM_000027.3(AGA):c.214T > C
GACGGCYCTGTAGGCTTTGGAGG
Aspartylglycosaminuria

(p.Ser72Pro)

121964978
NM_000170.2(GLDC):c.2T > C
CGGCCAYGCAGTCCTGTGCCAGG,
Non-ketotic hyperglycinemia

(p.Met1Thr)
GGCCAYGCAGTCCTGTGCCAGGG

121965008
NM_000398.6(CYB5R3):c.446T > C
CTGCYGGTCTACCAGGGCAAAGG
METHEMOGLOBINEMIA, TYPE I

(p.Leu149Pro)

121965064
NM_000128.3(F11):c.901T > C
TGATYTCTTGGGAGAAGAACTGG
Hereditary factor XI deficiency disease

(p.Phe301Leu)

45517398
NM_000548.3(TSC2):c.5150T > C
GCCCYGCACGCAAATGTGAGTGG,
Tuberous sclerosis syndrome

(p.Leu1717Pro)
CCCYGCACGCAAATGTGAGTGGG

786205857
NM_015662.2(IFT172):c.770T > C
TTGTGCYAGGAAGTTATGACAGG
RETINITIS PIGMENTOSA 71

(p.Leu257Pro)

786205904
NM_001135669.1(XPR1):c.653T > C
GCGTTYACGTGTCCCCCCTTTGG,
BASAL GANGLIA

(p.Leu218Ser)
CGTTYACGTGTCCCCCCTTTGGG
CALCIFICATION,

104893704
NM_000388.3(CASR):c.2641T > C
ACGCTYTCAAGGTGGCTGCCCGG,
Hypercalciuric hypercalcemia

(p.Phe881Leu)
CGCTYTCAAGGTGGCTGCCCGGG

104893747
NM_I98159.2(MITF):c.1195T > C
ACTTYCCCTTATTCCATCCACGG,
Waardenburg syndrome type 2A

(p.Ser399Pro)
CTTYCCCTTATTCCATCCACGGG

104893770
NM_000539.3(RHO):c.133T > C
CATGYTTCTGCTGATCGTGCTGG,
Retinitis pigmentosa 4

(p.Phe45Leu)
ATGYTTCTGCTGATCGTGCTGGG

28937596
NM_003907.2(EIF2B5):c.1882T > C
AGGCCYGGAGCCCTGTTTTTAGG
Leukoencephalopathy with vanishing white

(p.Trp628Arg)

matter

104893876
NM_001151.3(SLC25A4):c.293T > C
GCAGCYCTTCTTAGGGGGTGTGG
Autosomal dominant progressive external

(p.Leu98Pro)

ophthalmoplegia with mitochondrial

DNA deletions 2

104893883
NM_006005.3(WFS1):c.2486T > C
ACCATCCYGGAGGGCCGCCTGGG
WFS1-Related Disorders

(p.Leu829Pro)

104893962
NM_000165.4(GJA1):c.52T > C
CTACYCAACTGCTGGAGGGAAGG
Oculodentodigital dysplasia

(p.Serl8Pro)

104893978
NM_000434.3(NEU1):c.718T > C
GCCTCCYGGCGCTACGGAAGTGG,
Sialidosis, type II

(p.Trp240Arg)
CCTCCYGGCGCTACGGAAGTGGG,

CTCCYGGCGCTACGGAAGTGGGG

104894092
NM_002546.3(TNERSF11B):c.349T > C
TAGAGYTCTGCTTGAAACATAGG
Hyperphosphatasemia with bone disease

(p.Phe117Leu)

104894135
NM_000102.3(CYP17A1):c.316T > C
CATCGCGYCCAACAACCGTAAGG,
Complete combined 17-alpha-

(p.Ser106Pro)
ATCGCGYCCAACAACCGTAAGGG
hydroxylase/17,20-lyase

104894151
NM_000102.3(CYP17A1):c.1358T > C
AGCTCTYCCTCATCATGGCCTGG
Combined partial 17-alpha-hydroxylase/17,20-

(p.Phe453Ser)

lyase deficiency

36015961
NM_000518.4(HBB):c.344T > C
TGTGTGCYGGCCCATCACTTTGG
Beta thalassemia intermedia

(p.Leu115Pro)

104894472
NM_152443.2(RDH12):c.523T > C
TCCYCGGTGGCTCACCACATTGG
Leber congenital amaurosis 13

(p.Ser175Pro)

104894587
NM_004870.3(MPDU1):c.356T > C
TTCCYGGTCATGCACTACAGAGG
Congenital disorder of glycosylation type 1F

(p.Leu119Pro)

104894588
NM_004870.3(MPDUI):c.2T > C
AATAYGGCGGCCGAGGCGGACGG
Congenital disorder of glycosylation type 1F

(p.Met1Thr)

104894626
NM_000304.3(PMP22):c.82T > C
TAGCAAYGGATCGTGGGCAATGG
Charcot-Marie-Tooth disease, type LE

(p.Trp28Arg)

104894631
NM_018129.3(PNP0):c.784T > C
ACCTYAACTCTGGGACCTGCTGG
″Pyridoxal 5-phosphate-dependent epilepsy″

(p.Ter262Gln)

104894703
NM_032551.4(KISS1R):c.305T > C
GCCCTGCYGTACCCGCTGCCCGG,

(p.Leu102Pro)
TGCYGTACCCGCTGCCCGGCTGG

104894826
NM_000166.5(GJB1):c.407T > C
ATGYCATCAGCGTGGTGTTCCGG
Dejerine-Sottas disease, X-linked hereditary

(p.Val136Ala)

motor and sensory neuropathy

104894859
NM_001122606.1(LAMP2):c.961T > C
CAGCTACYGGGATGCCCCCCTGG,
Danon disease

(p.Trp321Arg)
AGCTACYGGGATGCCCCCCTGGG

104894931
NM_006517.4(SLC16A2):c.1313T > C
TGAGCYGGTGGGCCCAATGCAGG
Allan-Herndon-Dudley syndrome

(p.Leu438Pro)

104894935
NM_000330.3(RS1):c.38T > C
TTACTTCYCTTTGGCTATGAAGG
Juvenile retinoschisis

(p.Leul3Pro)

104895217
NM_001065.3(TNFRSF1A):c.175T > C
TGCYGTACCAAGTGCCACAAAGG
TNF receptor-associated periodic fever

(p.Cys59Arg)

syndrome (TRAPS)

143889283
NM_003793.3(CTSF):c.692A > G
CTCCAYACTGAGCTGTGCCACGG
Ceroid lipofuscinosis, neuronal, 13

(p.Tyr231Cys)

122459147
NM_001159702.2(FHL1):c.310T > C
GGGGYGCTTCAAGGCCATTGTGG
Myopathy, reducing body, X-linked,

(p.Cys104Arg)

childhood-onset

74552543
NM_020184.3(CNNM4):c.971T > C
AAGCTCCYGGACTTTTTTCTGGG
Cone-rod dystrophy amelogenesis imperfecta

(p.Leu324Pro)

199476117
m.10158T > C
AAAYCCACCCCTTACGAGTGCGG
Leigh disease, Leigh syndrome due to

mitochondrial complex I deficiency,

Mitochondrial complex I deficiency

794727808
NM_020451.2(SEPN1):c.872 + 2T >
TTCCGGYGAGTGGGCCACACTGG
Congenital myopathy with fiber type

C

disproportion, Eichsfeld type

congenital muscular dystrophy

140547520
NM_005022.3(PFN1):c.350A > G
CACCTYCTTTGCCCATCAGCAGG
Amyotrophic lateral sclerosis 18

(p.Glu117Gly)

397514359
NM_000060.3(BTD):c.445T > C
TCACCGCYTCAATGACACAGAGG
Biotinidase deficiency

(p.Phe149Leu)

207460001
m.15197T > C
CTAYCCGCCATCCCATACATTGG
Exercise intolerance

397514406
NM_000060.3(BTD):c.1214T > C
TTCACCCYGGTCCCTGTCTGGGG
Biotinidase deficiency

(p.Leu405Pro)

397514516
NM_006177.3(NRL):c.287T > C
GAGGCCAYGGAGCTGCTGCAGGG
Retinitis pigmentosa 27

(p.Met96Thr)

72554312
NM_000531.5(OTC):c.134T > C
CTCACTCYAAAAAACTTTACCGG
Ornithine carbamoyltransferase deficiency

(p.Leu45Pro)

397514569
NM_178012.4(TUBB2B):c.350T > C
GGTCCYGGATGTGGTGAGGAAGG
Polymicrogyria, asymmetric

(p.Leu117Pro)

397514571
NM_000431.3(MVK):c.122T > C
CGGCYTCAACCCCACAGCAATGG,
Porokeratosis, disseminated superficial actinic

(p.Leu41Pro)
GGCYTCAACCCCACAGCAATGGG
1

794728390
NM_000238.3(KCNH2):c.2396T > C
GCCATCCYGGGTATGGGGTGGGG,
Cardiac arrhythmia

(p.Leu799Pro)
CCATCCYGGGTATGGGGTGGGGG,

CATCCYGGGTATGGGGTGGGGGG

397514713
NM_001199107.1(TBC1D24)c.686T > C
GGTCTYTGACGTCTTCCTGGTGG
Early infantile epileptic encephalopathy 16

(p.Phe229Ser)

397514719
NM_080605.3(B3GALT6):c.193A > G
CGCYGGCCACCAGCACTGCCAGG
Spondyloepimetaphyseal dysplasia with joint

(p.Ser65Gly)

laxity

730880608
NM_000256.3(MYBPC3):c.3796T > C
GAGYGCCGCCTGGAGGTGCGAGG
Cardiomyopathy

(p.Cys1266Arg)

397515329
NM_001382.3(DPAGT1):c.503T > C
AATCCYGTACTATGTCTACATGG,
Congenital disorder of glycosylation type 1J

(p.Leu168Pro)
ATCCYGTACTATGTCTACATGGG,

TCCYGTACTATGTCTACATGGGG

397515465
NM_018127.6(ELAC2):c.460T > C
ATAYTTTCTGGTCCATTGAAAGG
Combined oxidative phosphorylation deficiency

(p.Phe154Leu)

17

397515557
NM_005211.3(CSF1R):c.2483T > C
CATCTYTGACTGTGTCTACACGG
Hereditary diffuse leukoencephalopathy with

(p.Phe828Ser)

spheroids

397515599
NM_194248.2(OTOF):c.3413T > C
AGGTGCYGTTCTGGGGCCTACGG,
Deafness, autosomal recessive 9

(p.Leu1138Pro)
GGTGCYGTTCTGGGGCCTACGGG

397515766
NM_000138.4(FBN1):c.2341T > C
GGACAAYGTAGAAATACTCCTGG
Marfan syndrome

(p.Cys781Arg)

565779970
NM_001429.3(EP300):c.3573T > A
CTTAYTACAGTTACCAGAACAGG
Rubinstein-Taybi syndrome 2

(p.Tyr1191Ter)

786200938
NM_080605.3(B3GALT6):c.1A > G
AGCTTCAYGGCGCCCGCGCCGGG,
Spondyloepimetaphyseal dysplasia with joint

(p.MetlVal)
TCAYGGCGCCCGCGCCGGGCCGG
laxity

28942087
NM_000229.1(LCAT):c.698T > C
ATCTCTCYTGGGGCTCCCTGGGG,
Norum disease

(p.Leu233Pro)
TCTCYTGGGGCTCCCTGGGGTGG

128621203
NM_000061.2(BTK):c.1625T > C
TCGGCCYGTCCAGGTGAGTGTGG
X-linked agammaglobulinemia with

(p.Leu542Pro)

growth hormone deficiency

397515412
NM_006383.3(CIB2):c.368T > C
CTTCAYCTGCAAGGAGGACCTGG
Deafness, autosomal recessive 48

(p.Ile123Thr)

193929364
NM_000352.4(ABCC8):c.404T > C
AAGCYGCTAATTGGTAGGTGAGG
Permanent neonatal diabetes mellitus

(p.Leu135Pro)

730880872
NM_000257.3(MYH7):c.1400T > C
TCGAGAYCTTCGATGTGAGTTGG,
Cardiomyopathy

CGAGAYCTTCGATGTGAGTTGGG

80356474
NM_002977.3(SCN9A):c.2543T > C
AAGATCAYTGGTAACTCAGTAGG,
Primary erythromelalgia

(p.Ile848Thr)
AGATCAYTGGTAACTCAGTAGGG,

GATCAYTGGTAACTCAGTAGGGG

80356489
NM_001164277.1(SLC37A4):c.352T > C
GGGCYGGCCCCCATGTGGGAAGG
Glucose-6-phosphate transport defect

(p.Trp118Arg)

80356536
NM_152296.4(ATP1A3):c.2338T > C
GCCCYTCCTGCTGTTCATCATGG
Dystonia 12

(p.Phe780Leu)

80356596
NM_194248.2(OTOF):c.3032T > C
GATGCYGGTGTTCGACAACCTGG
Deafness, autosomal recessive 9, Auditory

(p.Leu1011Pro)

neuropathy, autosomal recessive, 1

80356689
NM_000083.2(CLCN1):c.857T > C
AGGAGYGCTATTTAGCATCGAGG
Myotonia congenita

(p.Val286Ala)

118203884
m.4409T > C
AGGYCAGCTAAATAAGCTATCGG
Mitochondrial myopathy

587777625
NM_173596.2(SLC39A5):c.911T > C
AGAACAYGCTGGGGCTTTTGCGG
Myopia 24, autosomal dominant

(p.Met304Thr)

587783087
NM_003159.2(CDKL5):c.602T > C
ATTCYTGGGGAGCTTAGCGATGG
not provided

(p.Leu201Pro)

118203951
NM_013319.2(UBIAD1):c.511T > C
TCTGGCYCCTTTCTCTACACAGG,
Schnyder crystalline conical dystrophy

(p.Ser171Pro)
GGCYCCTTTCTCTACACAGGAGG

118204017
NM_000018.3(ACADVL):c.1372T > C
TCGCATCYTCCGGATCTTTGAGG,
Very long chain acyl-CoA dehydrogenase

(p.Phe458Leu)
CGCATCYTCCGGATCTTTGAGGG,
deficiency

GCATCYTCCGGATCTTTGAGGGG

397518466
NM_000833.4(GRIN2A):c.2T > C
CTAYGGGCAGAGTGGGCTATTGG
Focal epilepsy with speech disorder with or

(p.Met1Thr)

without mental retardation

118204069
NM_000237.2(LPL):c.337T > C
GGACYGGCTGTCACGGGCTCAGG
Hyperlipoproteinemia, type I

(p.Trp113Arg)

118204080
NM_000237.2(LPL):c.755T > C
GTGAYTGCAGAGAGAGGACTTGG
Hyperlipoprote nemia, type I

(p.Ile252Thr)

118204111
NM_000190.3(HMBS):c.739T > C
GCTTCGCYGCATCGCTGAAAGGG
Acute intermittent porphyria

(p.Cys247Arg)

80357438
NM_007294.3(BRCA1):c.65T > C
AAATCTYAGAGTGTCCCATCTGG
Familial cancer of breast, Breast-ovarian

(p.Leu22Ser)

cancer, familial 1, Hereditary cancer-

predisposing syndrome

139877390
NM_001040431.2(COA3):c.215A > G
CCAYCTGGGGAGGTAGGTTCAGG

(p.Tyr72Cys)

793888527
NM_005859.4(PURA):c.563T > C
GACCAYTGCGCTGCCCGCGCAGG,
not provided, Mental retardation, autosomal

(p.Ile188Thr)
ACCAYTGCGCTGCCCGCGCAGGG,
dominant 31

CCAYTGCGCTGCCCGCGCAGGGG

561425038
NM_002878.3(RAD51D):c.1A > G
CGCCCAYGTTCCCCGCAGGCCGG
Hereditary cancer-predisposing syndrome

(p.Met1Val)

121907934
NM_024105.3(ALG12):c.473T > C
TCCYGCTGGCCCTCGCGGCCTGG
Congenital disorder of glycosylation type 1G

(p.Leu158Pro)

80358207
NM_153212.2(GM4):c.409T > C
CCTCATCYTCAAGGCCGCCGTGG
Erythrokeratodermia variabilis

(p.Phe137Leu)

80358228
NM_002353.2(TACSTD2):c.557T > C
TCGGCYGCACCCCAAGTTCGTGG
Lattice conical dystrophy Type III

(p.Leu186Pro)

121908076
NM_138691.2(TMC1):c.1543T > C
AGGACCTYGCTGGGAAACAATGG,
Deafness, autosomal recessive 7

(p.Cys515Arg)
ACCTYGCTGGGAAACAATGGTGG,

CCTYGCTGGGAAACAATGGTGGG

121908089
NM_017838.3(NHP2):c.415T > C
GGAGGCTYACGATGAGTGCCTGG,
Dyskeratosis congenita autosomal recessive 1,

(p.Tyr139His)
GGCTYACGATGAGTGCCTGGAGG
Dyskeratosis congenita, autosomal recessive 2

121908154
NM_001243133.1(NLRP3):c.926T > C
GGTGCCTYTGACGAGCACATAGG
Familial cold urticaria, Chronic infantile

(p.Phe309Ser)

neurological, cutaneous and articular syndrome

121908158
NM_001033855.2(DCLRE1C):c.2T > C
GGCGCTAYGAGTTCTTTCGAGGG,
Histiocytic medullary reticulosis

(p.Met1Thr)
GCGCTAYGAGTTCTTTCGAGGGG

CCCCCAYGACGTGCTGGCTGCGG,

796052870
NM_018129.3(PNP0):c.2T > C
CCCCAYGACGTGCTGGCTGCGGG,
not provided

(p.Met1Thr)
CCCAYGACGTGCTGGCTGCGGGG

121908318
NM_020427.2(SLURP1):c.43T > C
GCAGCCYGGAGCATGGGCTGTGG
Acroerythrokeratoderma

(p.Trp15Arg)

121908352
NM_022124.5(CDH23):c.5663T > C
CTCACCTYCAACATCACTGCGGG
Deafness, autosomal recessive 12

(p.Phe1888Ser)

121908520
NM_000030.2(AGXT):c.613T > C
CCTGTACYCGGGCTCCCAGAAGG
Primary hyperoxaluria, type I

(p.Ser205Pro)

121908618
NM_004273.4(CHST3):c.920T > C
CGTGCYGGCCTCGCGCATGGTGG
Spondyloepiphyseal dysplasia with congenital

(p.Leu307Pro)

joint dislocations

11694
NM_006432.3(NPC2):c.199T > C
TATTCAGYCTAAAAGCAGCAAGG
Niemann-Pick disease type C2

(D.Ser67Pro)

121908739
NM_000022.2(ADA):c.320T > C
CCTGCYGGCCAACTCCAAAGTGG
Severe combined immunodeficiency due to

(p.Leu107Pro)

ADA deficiency

80359022
NM_000059.3(BRCA2):c.7958T > C
TGCYTCTTCAACTAAAATACAGG
Familial cancer of breast, Breast-ovarian

(p.Leu2653Pro)

cancer, familial 2

121908902
NM_003880.3(WISP3):c.232T > C
AAAATCYGTGCCAAGCAACCAGG,
Progressive pseudorheumatoid dysplasia

(p.Cys78Arg)
AAATCYGTGCCAAGCAACCAGGG,

AATCYGTGCCAAGCAACCAGGGG

121908947
NM_006892.3(DNMT3B):c.808T > C
CAAGTTCYCCGAGGTGAGTCCGG,
Centromeric instability of chromosomes 1,9 and

(p.Ser270Pro)
AAGTTCYCCGAGGTGAGTCCGGG,
16 and immunodeficiency

121909028
NM_000492.3(CFTR):c.3857T > C
AGTTCYCCGAGGTGAGTCCGGGG
Cystic fibrosis

(p.Phe1286Ser)
AGCCTYTGGAGTGATACCACAGG

121909135
NM_000085.4(CLCNKB):c.1294T > C
CTTTGTCYATGGTGAGTCTGGGG
Bartter syndrome type 3

(p.Tyr432His)

121909143
NM_001300.5(KLF6):c.506T > C
GGAGCYGCCCTCGCCAGGGAAGG

(p.Leu169Pro)

121909182
NM_001089.2(ABCA3):c.302T > C
GCACYTGTGATCAACATGCGAGG
Surfactant metabolism dysfunction, pulmonary,

(p.Leu101Pro)

3

121909200
NM_000503.5(EYA1):c.1459T > C
CACTCYCGCTCATTCACTCCCGG
Melnick-Fraser syndrome

(p.Ser487Pro)

121909247
NM_004970.2(IGFALS):c.1618T > C
GGACYGTGGCTGCCCTCTCAAGG
Acid-labile subunit deficiency

(p.Cys540Arg)

121909253
NM_005570.3(LMAN1):c.2T > C
AGAYGGCGGGATCCAGGCAAAGG
Combined deficiency of factor V and factor

(p.Met1Thr)

VIII, 1

121909385
NM_000339.2(SLC12A3):c.1868T > C
CAACCYGGCCCTCAGCTACTCGG
Familialhypokalemia-hypomagnesemia

(p.Leu623Pro)

121909497
NM_002427.3(MMP13):c.224T > C
TTCTYCGGCTTAGAGGTGACTGG
Spondyloepimetaphyseal dysplasia, Missouri

(p.Phe75Ser)

type

121909508
NM_000751.2(CHRND):c.188T > C
AACCYCATCTCCCTGGTGAGAGG
MYASTHENIC SYNDROME,

(p.Leu63Pro)

CONGENITAL, 3B, FAST-

CHANNEL

121909519
NM_001100.3(ACTA1):c.287T > C
CGAGCYTCGCGTGGCTCCCGAGG
Nemaline myopathy 3

(p.Leu96Pro)

121909572
NM_000488.3(SERPINC1):c.667T > C
TGGGTGYCCAATAAGACCGAAGG
Antithrombin III deficiency

(p.Ser223Pro)

121909677
NM_000821.6(GGCX):c.896T > C
TATGTYCTCCTACGTCATGCTGG
Pseudoxanthoma elasticum-like disorder with

(p.Phe299Ser)

multiple coagulation factor deficiency

121909727
NM_001018077.1(NR3C1):c.2209T > C
CTATTGCYTCCAAACATTTTTGG
Glucocorticoid resistance, generalized

(p.Phe737Leu)

139573311
NM_000492.3(CFTR):c.1400T > C
TTCACYTCTAATGGTGATTATGG,
Cystic fibrosis

(p.Leu467Pro)
TCACYTCTAATGGTGATTATGGG

121912441
NM_000454.4(SOD1):c.341T > C
CATCAYTGGCCGCACACTGGTGG
Amyotrophic lateral sclerosis type 1

(p.Ile114Thr)

121912446
NM_000454.4(SOD1):c.434T > C
CGTTYGGCTTGTGGTGTAATTGG,
Amyotrophic lateral sclerosis type 1

(p.Leu145Ser)
GTTYGGCTTGTGGTGTAATTGGG

121912463
NM_000213.3(ITGB4):c.1684T > C
GGCCAGYGTGTGTGTGAGCCTGG
Epidermolysis bullosa with pyloric atresia

(p.Cys562Arg)

121912492
NM_002292.3(LAMB2):c.961T > C
CCTCAACYGCGAGCAGTGTCAGG
Nephrotic syndrome, type 5, with or

(p.Cys321Arg)

without ocular abnormalities

397516659
NM_001399.4(EDA):c.2T > C
GGCCAYGGGCTACCCGGAGGTGG
Hypohidrotic X-linked ectodermal dysplasia

(p.Met1Thr)

111033589
NM_021044.2(DHH):c.485T > C
GTTGCYGGCGCGCCTCGCAGTGG
46,XY gonadal dysgenesis, complete, dhh-

(p.Leu162Pro)

related

111033622
NM_000206.2(IL2RG):c.343T > C
TGGCYGTCAGTTGCAAAAAAAGG
X-linked severe combined immunodeficiency

(p.Cys115Arg)

121912613
NM_001041.3(SI):c.1859T > C
ATGCYGGAGTTCAGTTTGTTTGG
Sucrase-isomaltase deficiency

(p.Leu620Pro)

121912619
NM_016180.4(SLC45A2):c.1082T > C
GAGTTTCYCATCTACGAAAGAGG
Oculocutaneous albinism type 4

(p.Leu361Pro)

61750581
NM_000552.3(VWF):c.4837T > C
CTGCCYCTGATGAGATCAAGAGG
von Willebrand disease, type 2a

(p.Ser1613Pro)

121912653
NM_000546.5(TP53):c.755T > C
CATCCYCACCATCATCACACTGG
Li-Fraumeni syndrome 1

(p.Leu252Pro)

111033683
NM_000155.3(GALT):c.386T > C
AGGTCAYGTGCTTCCACCCCTGG
Deficiency of UDPglucose-hexose-1-phosphate

(p.Met129Thr)

uridylyltransferase

111033752
NM_000155.3(GALT):c.677T > C
CAGGAGCYACTCAGGAAGGTGGG
Deficiency of UDPglucose-hexose-1-phosphate

(p.Leu226Pro)

uridylyltransferase

121912729
NM_000039.1(APOA1):c.593T > C
GCGCTYGGCCGCGCGCCTTGAGG
Familial visceral amyloidosis, Ostertag type

(p.Leu198Ser)

769452
NM_000041.3(APOE):c.137T > C
AACYGGCACTGGGTCGCTTTTGG

(p.Leu46Pro)

121912762
NM_016124.4(RHD):c.329T > C
ACACYGTTCAGGTATTGGGATGG

(p.Leu110Pro)

111033824
NM_000155.3(GALT):c.1138T > C
CGCCYGACCACGCCGACCACAGG,
Defic ency of UDPglucose-hexose-1-phosphate

(p.Ter380Arg)
GCCYGACCACGCCGACCACAGGG
uridylyltransferase

111033832
NM_000155.3(GALT):c.980T > C
TCCYGCGCTCTGCCACTGTCCGG
Deficiency of UDPglucose-hexose-1-phosphate

(p.Leu327Pro)

uridylyltransferase

730881974
NM_000455.4(STK11):c.545T > C
GGGAACCYGCTGCTCACCACCGG,
Hereditary cancer-predisposing syndrome

(p.Leu182Pro)
AACCYGCTGCTCACCACCGGTGG

1064644
NM_000157.3(GBA):c.703T > C
GGGYCACTCAAGGGACAGCCCGG
Gaucher disease

(p.Ser235Pro)

796052090
NM_138413.3(HOGA1):c.533T > C
GGACCYGCCTGTGGATGCAGTGG
Primary hyperoxaluria, type III

(p.Leu178Pro)

121913141
NM_000208.2(INSR):c.779T > C
CTACCYGGACGGCAGGTGTGTGG
Leprechaunism syndrome

(p.Leu260Pro)

121913272
NM_006218.2(PIK3CA):c.1258T > C
GGAACACYGTCCATTGGCATGGG,
Congenital lipomatous overgrowth, vascular

(p.Cys420Arg)
GAACACYGTCCATTGGCATGGGG
malformations, and epidermal nevi, Neoplasm

of ovary, PIK3CA Related Overgrowth

Spectrum

61751310
NM_000552.3(VWF):c.8317T > C
GCTCCYGCTGCTCTCCGACACGG
von Willebrand disease, type 2a

(p.Cys2773Arg)

312262799
NM_024408.3(NOTCH2):c.1438T > C
TTCACAYGTCTGTGCATGCCAGG
Alagille syndrome 2

(p.Cys480Arg)

121913570
NM_000426.3(LAMA2):c.7691T > C
ATCATTCYTTTGGGAAGTGGAGG,
Merosin deficient congenital

(p.Leu2564Pro)
TCATTCYTTTGGGAAGTGGAGGG
muscular dystrophy

121913640
NM_000257.3(MYH7):c.1046T > C
AACTCCAYGTATAAGCTGACAGG
Familial hypertrophic cardiomyopathy

(p.Met349Thr)

1, Cardiomyopathy

121913642
NM_000257.3(MYH7):c.1594T > C
CATCATGYCCATCCTGGAAGAGG
Dilated cardiomyopathy 1S

(p.Ser532Pro)

119463996
NM_001079802.1(FKTN):c.527T > C
GTAGTCTYTCATGAGAGGAGTGG
Limb-girdle muscular

(p.Phe176Ser)

dystrophy-

587776456
NM_002049.3(GATA1):c.1240T > C
GCTCAYGAGGGCACAGAGCATGG
GATA-1-related thrombocytopenia

(p.Ter414Arg)

with dyserythropoiesis

63750654
NM_000184.2(HBG2):c.-228T > C
ATGCAAAYATCTGTCTGAAACGG
Fetal hemoglobin quantitative trait locus 1

587776519
NM_001999.3(FBN2):c.3725-
AGCAYTGCAACCACATTGTCAGG
Congenital contractural arachnodactyly

15A > G

78365220
NM_000402.4(G6PD):c.473T > C
TGCCCYCCACCTGGGGTCACAGG
Anemia, nonspherocytic hemolytic, due to

(p.Leu158Pro)

G6PD deficiency

63750741
NM_000179.2(MSH6):c.1346T > C
CTGGGGCYGGTATTCATGAAAGG
Hereditary Nonpolyposis Colorectal Neoplasms

(p.Leu449Pro)

587776914
NM_017565.3(FAM20A):c.590-
GTAATCYGCAAAGGAGGAGAAGG,
Enamel-renal syndrome

2A > G
TAATCYGCAAAGGAGGAGAAGG

5030809
NM_000551.3(VHL):c.292T > C
CCCYACCCAACGCTGCCGCCTGG
Von Hippel-Lindau syndrome,

(p.Tyr98His)

Hereditary cancer-predisposing

syndrome

199476132
m.5728T > C
CAATCYACTTCTCCCGCCGCCGG,
Cytochrome-c oxidase deficiency, Mitochondrial

AATCYACTTCTCCCGCCGCCGGG
complex I deficiency

62637012
NM_014336.4(AIPLI):c.715T > C
CTGCCAGYGCCTGCTGAAGAAGG,
Leber congenital amaurosis 4

(p.Cys239Arg)
CCAGYGCCTGCTGAAGAAGGAGG

199476199
NM_207352.3(CYP4V2):c.1021T > C
AAACTGGYCCTTATACCTGTTGG,
Bietti crystalline corneoretinal dystrophy

(p.Ser341Pro)
AACTGGYCCTTATACCTGTTGGG

587777183
NM_006702.4(PNPLA6):c.3053T > C
CCTYTAACCGCAGCATCCATCGG
Boucher Neuhauser syndrome

(p.Phe1018Ser)

199476389
NM_000487.5(ARSA):c.899T > C
GGTCTCTYGCGGTGTGGAAAGGG
Metachromatic leukodystrophy

(p.Leu300Ser)

199476398
NM_016599.4(MYOZ2):c.142T > C
TTAYCCCATCTCAGTAACCGTGG
Familial hypertrophic cardiomyopathy 16

(p.Ser48Pro)

119456967
NM_001037633.1(SIL1):c1370T > C
TTGCYGAAGGAGCTGAGATGAGG
Marinesco-Sj\xc3\xb6grensyndrome

(p.Leu457Pro)

730882253
NM_006888.4(CALM1):c.268T > C
GGCAYTCCGAGTCTTTGACAAGG
Long QT syndrome 14

(p.Phe90Leu)

587777283
NM_012338.3(TSPAN12):c.413A > G
TAATCCAYAATTTGTCATCCTGG
Exudative vitreoretinopathy 5

(p.Tyr138Cys)

587777306
NM_015884.3(MBTPS2):c.1391T > C
GCTYTGCTTTGGATGGACAATGG
Palmoplantar keratoderma, mutilating, with

(p.Phe464Ser)

periorificial keratotic plaques, X-linked

56378716
NM_000250.1(MPO):c.752T > C
TCACTCAYGTTCATGCAATGGGG
Myeloperoxidase deficiency

(p.Met251Thr)

587777390
NM_005026.3(PIK3CD):c.1246T > C
GCAGGACYGCCCCATTGCCTGGG
Activated PI3K-delta syndrome

(p.Cys416Arg)

587777480
NM_003108.3(SOX11):c.I78T > C
TATGGYCCAAGATCGAACGCAGG
Mental retardation, autosomal dominant 27

(p.Ser60Pro)

587777663
NM_001288767.1(ARMC5):c.1379T > C
GCCCGACYGCGGGATGCTGGTGG
Acth-independent macronodular adrenal

(p.Leu460Pro)

hyperplasia 2

61753033
NM_000350.2(ABCA4):c.5819T > C
AAGGCYACATGAACTAACCAAGG
Stargardt disease, Stargardt disease 1, Cone-

(p.Leu1940Pro)

rod dystrophy 3

200488568
NM_002972.3(SBF1):c.4768A > G
CAGGCGYCCTCTTGCTCAGCCGG
Charcot-Marie-Tooth disease, type 4B3

(p.Thr1590Ala)

132630274
NM_000377.2(WAS):c.809T > C
CGGAGTCYGTTCTCCAGGGCAGG
Severe congenital neutropenia X-linked

(p.Leu270Pro)

132630308
NM_001399.4(EDA):c.181T > C
CTGCYACCTAGAGTTGCGCTCGG
Hypohidrotic X-linked ectodermal dysplasia

(p.Tyr61His)

60934003
NM_170707.3(LMNA):c.1589T > C
ACGGCTCYCATCAACTCCACTGG,
Benign scapuloperoneal muscular dystrophy

(p.Leu530Pro)
CGGCTCYCATCAACTCCACTGGG,
with cardiomyopathy

GGCTCYCATCAACTCCACTGGGG

180177160
NM_000030.2(AGXT):c.1076T > C
GGTGCYGCGGATCGGCCTGCTGG,
Primary hyperoxaluria, type I

(p.Leu359Pro)
GTGCYGCGGATCGGCCTGCTGGG

180177222
NM_000030.2(AGXT):c.449T > C
GTGCYGCTGTTCTTAACCCACGG,
Primary hyperoxalu a, type I

(p.Leu150Pro)
TGCYGCTGTTCTTAACCCACGGG

180177254
NM_000030.2(AGXT):c.661T > C
GCTCATCYCCTTCAGTGACAAGG
Primary hyperoxaluria, type I

(p.Ser221Pro)

180177264
NM_000030.2(AGXT):c.757T > C
GGGGCYGTGACGACCAGCCCAGG
Primary hyperoxaluria, type I

(p.Cys253Arg)

180177293
NM_000030.2(AGXT):c.893T > C
GTATCYGCATGGGCGCCTGCAGG
Primary hyperoxaluria, type I

(p.Leu298Pro)

376785840
NM_001282227.1(CECR1):c.1232A > G
GAAATCAYAGGACAAGCCTTTGG
Polyarteritis nodosa

(p.Tyr411Cys)

587779393
NM_000257.3(MYH7):c.4937T > C
GAGCCYCCAGAGCTTGTTGAAGG
Myopathy, distal, 1

(p.Leu1646Pro)

587779410
NM_012434.4(SLC17A5):c.500T > C
ATTGTACYCAGAGCACTAGAAGG
Sialic acid storage disease, severe infantile

(p.Leu167Pro)

type

587779513
NM_000090.3(COL3A1):c.2337 + 2T > C
AGGYAACCCTTAATACTACCTGG
Ehlers-Danlos syndrome, type 4

(p.Gly762_Lys779del)

777539013
NM_020376.3(PNPLA2):c.757 + 2T >
GAACGGYGCGCGGACCCGGGCGG,
Neutral lipid storage disease with myopathy

C
AACGGYGCGCGGACCCGGGCGGG

34557412
NM_012452.2(TNERSF13B):c.310T > C
ACTTCYGTGAGAACAAGCTCAGG
Immunoglobulin A deficiency 2,

(p.Cys104Arg)

Common variable

796052970
NM_001165963.1(SCN1A):c.1094T > C
CAAGCTYTGATACCTTCAGTTGG,
not provided

(p.Phe365Ser)
AAGCTYTGATACCTTCAGTTGGG

724159989
NC_012920.1:m.7505T > C
CCTCCAYGACTTTTTCAAAAAGG
Deafness, nonsyndromic sensorineural,

mitochondrial

796053222
NM_014191.3(SCN8A):c.4889T > C
CGTCYGATCAAAGGCGCCAAAGG,
not provided

(p.Leu1630Pro)
GTCYGATCAAAGGCGCCAAAGGG

118192127
NM_000540.2(RYR1):c.10817T > C
TACTACCYGGACCAGGTGGGTGG,

(p.Leu3606Pro)
ACTACCYGGACCAGGTGGGTGGG,
Central core disease

CTACCYGGACCAGGTGGGTGGGG

118192170
NM_000540.2(RYR1):c.14693T > C
AGGCAYTGGGGACGAGATCGAGG
Malignant hyperthermia susceptibility type 1,

(p.Ile4898Thr)

Central core disease

121917703
NM_005247.2(FGF3):c.466T > C
GTACGTGYCTGTGAACGGCAAGG,
Deafness with labyrinthine aplasia microtia

(p.Ser156Pro)
TACGTGYCTGTGAACGGCAAGGG
and microdontia (LAMM)

690016549
NM_005211.3(CSF1R):c.2450T > C
CCGCCYGCCTGTGAAGTGGATGG
Hereditary diffuse leukoencephalopathy with

(p.Leu817Pro)

spheroids

690016552
NM_005211.3(CSF1R):c.2566T > C
GAATCCCYACCCTGGCATCCTGG
Hereditary diffuse leukoencephalopathy with

(p.Tyr856His)

spheroids

121917738
NM_001098668.2(SFTPA2):c.593T > C
GGAGACTYCCGCTACTCAGATGG,
Idiopathic fibrosing alveolitis, chronic form

(p.Phe198Ser)
GAGACTYCCGCTACTCAGATGGG

690016559
NM_005211.3(CSF1R):c.1957T > C
AGCCYGTACCCATGGAGGTAAGG,
Hereditary diffuse leukoencephalopathy with

(p.Cys653Arg)
GCCYGTACCCATGGAGGTAAGGG
spheroids

690016560
NM_005211.3(CSFIR):c.2717T > C
GCAGAYCTGCTCCTTCCTTCAGG
Hereditary diffuse leukoencephalopathy with

(p.Ile906Thr)

spheroids

121917769
NM_003361.3(UMOD):c.376T > C
GGCCACAYGTGTCAATGTGGTGG,
Familial juvenile gout

(p.Cys126Arg)
GCCACAYGTGTCAATGTGGTGGG

121917773
NM_003361.3(UMOD):c.943T > C
ATGGCACYGCCAGTGCAAACAGG
Glomerulocystic kidney disease

(p.Cys315Arg)

with hyperuricemia and

isosthenuria

121917818
NM_007255.2(B4GALT7):c.617T > C
TGCYCTCCAAGCAGCACTACCGG
Ehlers-Danlos syndrome progeroid type

(p.Leu206Pro)

121917824
NM_021615.4(CHST6):c.827T > C
GGACCYGGCGCGGGAGCCGCTGG
Macular conical dystrophy Type I

(p.Leu276Pro)

121917848
NM_000452.2(SLC10A2):c.728T > C
TTTCYTCTGGCTAGAATTGCTGG
Bile acid malabsorption, primary

(p.Leu243Pro)

121918006
NM_000478.4(ALPL):c.1306T > C
TGGACYATGGTGAGACCTCCAGG
Infantile hypophosphatasia

(p.Tyr436His)

121918010
NM_000478.4(ALPL):c.979T > C
CAAAGGCYTCTTCTTGCTGGTGG,
Infantile hypophosphatasia

(p.Phe327Leu)
GGCYTCTTCTTGCTGGTGGAAGG

121918088
NM_000371.3(TTR):c.400T > C
CCCCYACTCCTATTCCACCACGG

(p.Tyr134His)

121918110
NM_001042465.1(PSAP):c.1055T > C
GAAGCYGCCGAAGTCCCTGTCGG
Gaucher disease, atypical, due to saposin C

(p.Leu352Pro)

deficiency

121918137
NM_00370.4(RNASET2):c.550T > C
CCAGYGCCTTCCACCAAGCCAGG
Leukoencephalopathy, cystic,

(p.Cys184Arg)

without megalencephaly

121918191
NM_001127628.1(FBP1):c.581T > C
GGAGTYCATTTTGGTGGACAAGG
Fructose-biphosphatase deficiency

(p.Phe194Ser)

121918306
NM_006946.2(SPTBN2):c.758T > C
ACCAAGCYGCTGGATCCCGAAGG,
Spinocerebellar ataxia 5

(p.Leu253Pro)
AAGCYGCTGGATCCCGAAGGTGG,

AGCYGCTGGATCCCGAAGGTGGG

121918505
NM_000141.4(FGFR2):c.799T > C
AATGCCYCCACAGTGGTCGGAGG
Pfeiffer syndrome, Neoplasm of stomach

(p.Ser267Pro)

121918643
NM_003126.2(SPTA1):c.620T > C
GTGGAGCYGGTAGCTAAAGAAGG,
Hered tary pyropoikilocytoss, Elliptocytosis 2

(p.Leu207Pro)
TGGAGCYGGTAGCTAAAGAAGGG

121918646
NM_001024858.2(SPTB):c.604T > C
CTCCAGCYGGAAGGATGGCTTGG
Spherocytosis type 2

(p.Trp202Arg)

121918648
NM_001024858.2(SPTB):c.6055T > C
ATGCCYCTGTGGCTGAGGCGTGG

(p.Ser2019Pro)

727504166
NM_000543.4(SMPD1):c.4755T > C
TGAGGCCYGTGGCCTGCTCCTGG,
Niemann-Pick disease, type A, Niemann-Pick

(p.Cys159Arg)
GAGGCCYGTGGCCTGCTCCTGGG
disease, type B

193922915
NM_000434.3(NEU1):c.1088T > C
CAGCYATGGCCAGGCCCCAGTGG
Sialidosis, type II

(p.Leu363Pro)

727504419
NM_000501.3(ELN):c.889 + 2T >
CAGGYAACATCTGTCCCAGCAGG,
Supravalvar aortic stenosis

C
AGGYAACATCTGTCCCAGCAGGG

376395543
NM_000256.3(MYBPC3):c.26-
GAGACYGAAGGGCCAGGTGGAGG
Primary familial hypertrophic

2A > G

cardiomyopathy, Familial hypertrophic

cardiomyopathy 4, Cardiomyopathy

1169305
NM_000545.6(HNF1A):c.1720G > A
GATGCYGGCAGGGTCCTGGCTGG,
Maturity-onset diabetes of the young, type 3

(p.Gly574Ser)
ATGCYGGCAGGGTCCTGGCTGGG,

TGCYGGCAGGGTCCTGGCTGGGG

730880130
NM_000527.4(LDLR):c.1468T > C
CTACYGGACCGACTCTGTCCTGG,
Familial hypercholesterolemia

(p.Trp490Arg)
TACYGGACCGACTCTGTCCTGGG

281860286
NM_018713.2(SLC30A10):c.500T > C
GGCGCTTYCGGGGGGCCTCAGGG
Hypermanganesemia with dystonia,

(p.Phe167Ser)

polycythemia and cirrhosis

730880306
NM_145693.2(LPIN1):c.1441 + 2T >
AAGGYACCGCGGGCCTCGCGCGG,
Myoglobinuria, acute recurrent, autosomal

C
AGGYACCGCGGGCCTCGCGCGGG
recessive

74315452
NM_000454.4(SOD1):c.338T > C
TTGCAYCATTGGCCGCACACTGG
Amyotrophic lateral sclerosis type 1

(p.Ile113Thr)

730880455
NM_000169.2(GLA):c.41T > C
CGCGCYTGCGCTTCGCTTCCTGG
not provided

(p.Leul4Pro)

267606656
NM_054027.4(ANKH):c.1015T > C
AGCTCYGTTTCGTGATGTTTTGG
Craniometaphyseal dysplasia, autosomal

(p.Cys339Arg)

dominant

267606687
NM_033409.3(SLC52A3):c.1238T > C
AGTTACGYCAAGGTGATGCTGGG
Brown-Vialetto-Van laere syndrome

(p.Val413Ala)

267606721
NM_001928.2(CFD):c.640T > C
GGTGYGCGGGGGCGTGCTCGAGG,
Complement factor d deficiency

(p.Cys214Arg)
GTGYGCGGGGGCGTGCTCGAGGG

267606747
NM_001849.3(COL6A2):c.2329T > C
CGCCYGCGACAAGCCACAGCAGG
Ullrich congenital muscular dystrophy

(p.Cys777Arg)

431905515
NM_001044.4(SLC6A3):c.671T > C
CTGCACCYCCACCAGAGCCATGG
Infantile Parkinsonism-dystonia

(p.Leu224Pro)

267606857
NM_000180.3(GUCY2D):c.2846T > C
AGAGAYCGCCAACATGTCACTGG
Cone-rod dystrophy 6

(p.Ile949Thr)

267606880
NM_022489.3(INF2):c.125T > C
GCTGCYCCAGATGCCCTCTGTGG
Focal segmental glomerulosclerosis 5

(p.Leu42Pro)

515726191
NM_015713.4(RRM2B):c.581A > G
AACTCCTYCTACAGCAGCAAAGG
RRM2B-related mitochondrial disease

(p.Glu194Gly)

267606917
NM_004646.3(NPHS1):c.793T > C
GCTGCCGYGCGTGGCCCGAGGGG,
Finnish congenital nephrotic syndrome

(p.Cys265Arg)
CTGCCGYGCGTGGCCCGAGGGGG

267607104
NM_001199107.1(TBC1D24):c.751T > C
CAAGTTCYTCCACAAGGTGAGGG,
Myoclonic epilepsy, familial infantile

(p.Phe251Leu)
TTCYTCCACAAGGTGAGGGCCGG

267607182
NM_144631.5(ZNF513):c.1015T > C
TGGGCGCYGCATGCGAGGAGAGG,
Retinitis pigmentosa 58

(p.Cys339Arg)
CGCYGCATGCGAGGAGAGGCTGG

267607211
NM_000229.1(LCAT):c.508T > C
TATGACYGGCGGCTGGAGCCCGG
Norum disease

(p.Trp170Arg)

267607215
NM_016269.4(LEF1):c.181T > C
GAACGAGYCTGAAATCATCCCGG
Sebaceous tumors, somatic

(p.Ser61Pro)

587783580
NM_178151.2(DCX):c.683T > C
AAAAAACYCTACACTCTGGATGG
Heterotopia

(p.Leu228Pro)

587783644
NM_004004.5(GM2):c.107T > C
GATCCYCGTTGTGGCTGCAAAGG
Hearing impairment

(p.Leu36Pro)

587783653
NM_005682.6(ADGRG1):c.1460T > C
CCCTGCYCACCTGCCTTTCCTGG
Polymicrogyria, bilateral frontoparietal

(p.Leu487Pro)

587783863
NM_000252.2(MTM1):c.958T > C
GGAAYCTTTAAAAAAAGTGAAGG
Severe X-linked myotubular myopathy

(p.Ser320Pro)

267607751
NM_000249.3(MLH1):c.453 + 2T >
ATCACGGYAAGAATGGTACATGG,
Hereditary Nonpolyposis Colorectal Neoplasms

C
TCACGGYAAGAATGGTACATGGG

119103227
NM_000411.6(HLCS):c.710T > C
CTATCYTTCTCAGGGAGGGAAGG
Holocarboxylase synthetase deficiency

(p.Leu237Pro)

119103237
NM_005787.5(ALG3):c.21IT > C
GATTGACYGGAAGGCCTACATGG
Congenital disorder of glycosylation type 1D

(n.Trp71Arg)

398122806
NM_003172.3(SURF1):c.679T > C
CCACYGGCATTATCGAGACCTGG
Congenital myasthenic syndrome,

(p.Trp227Arg)

acetazolamide-responsive

80338747
NM_004525.2(LRP2):c.7564T > C
GTACCTGYACTGGGCTGACTGGG
Donnai Barrow syndrome

(p.Tyr2522His)

398122838
NM_001271723.1(FBX038):c.616T > C
TTCCTYGTATCCCAATGCTAAGG
Distal hereditary motor neuronopathy 2D

(p.Cys206Arg)

398122989
NM_014495.3(ANGPTL3):c.883T > C
ACAAAACYTCAATGAAACGTGGG
Hypobetalipoproteinemia, familial, 2

(p.Phe295Leu)

80338945
NM_004004.5(GM2):c.269T > C
GCTCCYAGTGGCCATGCACGTGG
Deafness, autosomal recessive 1A, Hearing

(p.Leu90Pro)

impairment

80338956
NM_000334.4(SCN4A):c.2078T > C
AAGATCAYTGGCAATTCAGTGGG,
Hyperkalemic Periodic Paralysis Type 1,

(p.Ile693Thr)
AGATCAYTGGCAATTCAGTGGGG,
Paramyotonia congenita of von Eulenburg

GATCAYTGGCAATTCAGTGGGGG

267608131
NM_000179.2(MSH6):c.4001 + 2T >
CGGYAACTAACTAACTATAATGG
Hereditary Nonpolyposis Colorectal Neoplasms

C

587784573
NM_004963.3(GUCY2C):c.2782T > C
TCCCYGTGCTGCTGGAGTTGTGG,
Meconium ileus

(p.Cys928Arg)
CCCYGTGCTGCTGGAGTTGTGGG

267608511
NM_003159.2(CDKL5):c.659T > C
CCAACYTTTTACTATTCAGAAGG
Early infantile epileptic encephalopathy 2

(p.Leu220Pro)

373842615
NM_000118.3(ENG):c.1273-
CCGCCYGCGGGGATAAAGCCAGG,
Haemorrhagic telangiectasia 1

2A > G
CGCCYGCGGGGATAAAGCCAGGG

185492581
NM_000335.4(SCN5A):c.376A > G
GAATCTYCACAGCCGCTCTCCGG
Brugada syndrome

(p.Lys126Glu)

200533370
NM_133499.2(SYN1):c.1699A > G
GATGYCTGACGGGTAGCCTGTGG,
Epilepsy, X-linked, with variable learning

(p.Thr567Ala)
ATGYCTGACGGGTAGCCTGTGGG
disabilities and behavior disorders, not specified

118203981
NM_148960.2(CLDN19):c.269T > C
GCTCCYGGGCTTCGTGGCCATGG
Hypomagnesemia 5, renal, with ocular

(p.Leu90Pro)

involvement

137853892
NM_001235.3(SERPINH1):c.233T > C
GTCGCYAGGGCTCGTGTCGCTGG,
Osteogenesis imperfecta type 10

(p.Leu78Pro)
TCGCYAGGGCTCGTGTCGCTGGG

118204024
NM_000263.3(NAGLU):c.142T > C
GGCCGACYTCTCCGTGTCGGTGG
Mucopolysaccharidosis,MPS-III-B

690016563
NM_005211.3(CSF1R):c.1745T > C
CAACCYGCAGTTTGGTGAGATGG
Hereditary diffuse leukoencephalopathy with

(p.Leu582Pro)

spheroids

58380626
NM_000526.4(KRT14):c.1243T > C
CGCCACCYACCGCCGCCTGCTGG,
Epidermolysis bullosa herpetiformis,

(p.Tyr415His)
CACCYACCGCCGCCTGCTGGAGG,
Dowling-Meara

ACCYACCGCCGCCTGCTGGAGGG

113994151
NM_207346.2(TSEN54):c.277T > C
TTGAAGYCTCCCGCGGTGAGCGG,
Pontocerebellar hypoplasia type 4

(p.Ser93Pro)
AAGYCTCCCGCGGTGAGCGGCGG

113994206
NM_004937.2(CTNS):c.473T > C
TGGTCYGAGCTTCGACTTCGTGG
Cystinosis

(p.Leu158Pro)

62516109
NM_000277.1(PAH):c.638T > C
CCACTTCYTGAAAAGTACTGTGG
Phenylketonuria

(p.Leu213Pro)

370011798
NM_001302946.1(TRNT1):c.668T > C
GCAAYTGCAGAAAATGCAAAAGG
Sideroblastic anemia with B-cell

(p.Ile223Thr)

immunodeficiency, periodic fevers,

and developmental delay

62517167
NM_000277.1(PAH):c.293T > C
AAGATCTYGAGGCATGACATTGG
Mild non-PKU hyperphenylalanemia

(p.Leu98Ser)

12021720
NM_001918.3(DBT):c.1150G > A
GACYCACAGAGCCCAATTTCTGG
Intermediate maple syrup urine disease type 2

(p.Gly384Ser)

104886289
NM_000495.4(COL4A5):c.4756T > C
TCCCCATYGTCCTCAGGGATGGG
Alport syndrome, X-linked recessive

(p.Cys1586Arg)

370471013
NC_012920.1:m.5559A > G
CAACYTACTGAGGGCTTTGAAGG
Leigh disease

121434215
NM_000487.5(ARSA):c.410T > C
GCCTTCCYGCCCCCCCATCAGGG
Metachromatic leukodystrophy, adult type

(p.Leu137Pro)

386134128
NM_000096.3(CP):c.1123T > C
ACACTACYACATTGCCGCTGAGG
Deficiency of ferroxidase

(p.Tyr375His)

121434275
NM_001127328.2(ACADM):c.1136T > C
GTGCAGAYACTTGGAGGCAATGG
Medium-chain acyl-coenzyme

(p.Ile379Thr)

A dehydrogenase deficiency

121434276
NM_001127328.2(ACADM):c.742T >C
CAGCGAYGTTCAGATACTAGAGG
Medium-chain acyl-coenzyme

(p.Cys248Arg)

A dehydrogenase deficiency

121434284
NM_002225.3(IVD):c.134T > C
ATGGGCYAAGCGAGGAGCAGAGG
ISOVALERIC ACIDEMIA, TYPE I

(p.Leu45Pro)

121434334
NM_005908.3(MANBA):c.1513T > C
ATTACGYCCAGTCCTACAAATGG,
Beta-D-mannosidosis

(p.Ser505Pro)
TTACGYCCAGTCCTACAAATGGG,

TACGYCCAGTCCTACAAATGGGG

121434366
NM_000159.3(GCDH):c.883T > C
CGCCCGGYACGGCATCGCGTGGG,
Glutaric aciduria, type 1

(p.Tyr295His)
GCCCGGYACGGCATCGCGTGGGG

60715293
NM_000424.3(KRT5):c.541T > C
GTTTGCCYCCTTCATCGACAAGG
Epidermolysis bullosa herpetiformis,

(p.Ser181Pro)

Dowling-Meara

121434409
NM_001003722.1(GLE1):c.2051T > C
AAGGACAYTCCTGTCCCCAAGGG
Lethal arthrogryposis with anterior horn cell

(p.Ile684Thr)

disease

121434434
NM_001287.5(CLCN7):c.2297T > C
GGGCCYGCGGCACCTGGTGGTGG
Osteopetrosis autosomal recessive 4

(p.Leu766Pro)

121434455
NM_000466.2(PEX1):c.1991T > C
GATGACCYTGACCTCATTGCTGG
Zellweger syndrome

(p.Leu664Pro)

199422317
NM_001099274.1(T1NF2):c.862T > C
CTGYTTCCCTTTAGGAATCTCGG
Aplastic anemia

(p.Phe288Leu)

104895221
NM_001065.3(TNFRSF1A):c.349T > C
CTCTTCTYGCACAGTGGACCGGG
TNF receptor-associated periodic fever

(p.Cys117Arg)

syndrome (TRAPS)

137854459
NM_000138.4(FBN1):c.4987T > C
GGGACAYGTTACAACACCGTTGG
Marfan syndrome

(p.Cys1663Arg)

387907075
NM_024027.4(COLEC11):c.505T > C
CAGCTGYCCTGCCAGGGCCGCGG,
Carnevale syndrome

(p.Ser169Pro)
AGCTGYCCTGCCAGGGCCGCGGG,

GCTGYCCTGCCAGGGCCGCGGGG,

CTGYCCTGCCAGGGCCGCGGGGG

1048095
NM_000352.4(ABCC8):c.674T > C
TGCYGTCCAAAGGCACCTACTGG
Permanent neonatal diabetes mellitus

(p.Leu225Pro)

796065347
NM_019074.3(DLL4):c.1168T > C
GAAYGTCCCCCCAACTTCACCGG
Adams-Oliver syndrome, ADAMS-

(p.Cys390Arg)

OLIVER SYNDROME 6

137852347
NM_000402.4(G6PD):c.1054T > C
AGGGYACCTGGACGACCCCACGG
Anemia, nonspherocytic hemolytic, due to

(p.Tyr352His)

G6PD deficiency

74315327
NM_213653.3(HFE2):c.302T > C
GGACCYCGCCTTCCATTCGGCGG
Hemochromatosis type 2A

(p.Leu101Pro)

137852579
NM_000044.3(AR):c.2033T > C
GTCCYGGAAGCCATTGAGCCAGG

(p.Leu678Pro)

137852636
NM_001166107.1(HMGCS2):c.520T > C
CCCTCYTCAATGCTGCCAACTGG
mitochondrial 3-hydroxy-3-methylglutaryl-

(p.Phe174Leu)

CoA synthase deficiency

137852661
NM_033163.3(FGF8):c.118T > C
TTCCCTGYTCCGGGCTGGCCGGG
Kallmann syndrome 6

(p.Phe40Leu)

121912967
NM_005215.3(DCC):c.503T > C
AGCCCAYGCCAACAATCCACTGG

(p.Met168Thr)

137852806
NM_001039523.2(CHRNA1):c.901T > C
TGTGYTCCTTCTGGTCATCGTGG
Myasthenic syndrome, congenital, fast-channel

(p.Phe301Leu)

137852850
NM_182760.3(SUMF1):c.463T > C
GGCGACYCCTTTGTCTTTGAAGG
Multiple sulfatase deficiency

(p.Ser155Pro)

137852886
NM_000158.3(GBE1):c.671T > C
AATGTACYACCAAGAATCAAAGG
Glycogen storage disease, type IV,

(p.Leu224Pro)

GLYCOGEN STORAGE DISEASE

IV, NONPROGRESSIVE HEPATIC

137852911
NM_000419.3(ITGA2B):c.641T > C
CTGGTGCYTGGGGCTCCTGGCGG
Glanzmann thrombasthenia

(p.Leu214Pro)

137852948
NM_138694.3(PKHD1):c.10658T > C
GAGCCCAYTGAAATACGCTCAGG
Polycystic kidney disease, infantile type

(p.Ile3553Thr)

137852964
NM_024960.4(PANK2):c.178T > C
ATTGACYCAGTCGGATTCAATGG

(p.Ser60Pro)

137853020
NM_006899.3(IDH3B):c.395T > C
TGCGGCYGAGGTAGGTGGTCTGG,
Retinitis pigmentosa 46

(p.Leu132Pro)
GCGGCYGAGGTAGGTGGTCTGGG

137853249
NM_033500.2(HK1):c.1550T > C
GACTTCTYGGCCCTGGATCTTGG,
Hemolytic anemia due to hexokinase deficiency

(p.Leu517Ser)
TTCTYGGCCCTGGATCTTGGAGG

137853270
NM_000444.5(PHEX):c.1664T > C
AGCYCCAGAAGCCTTTCTTTTGG
Familial X-linked hypophosphatemic vitamin

(p.Leu555Pro)

D refractory rickets

137853325
NM_003639.4(IKBKG):c.1249T > C
TGGAGYGCATTGAGTAGGGCCGG
Hypohidrotic ectodermal dysplasia with immune

(p.Cys417Arg)

deficiency, Hyper-IgM immunodeficiency, X-

linked, with hypohidrotic ectodermal dysplasia

28932769
NM_002055.4(GFAP):c.1055T > C
GGACCYGCTCAATGTCAAGCTGG
Alexander disease

(p.Leu352Pro)

397507439
NM_002769.4(PRSS1):c.116T > C
TACCAGGYGTCCCTGAATTCTGG
Hereditary pancreatitis

(p.Val39Ala)

387906446
NM_000132.3(F8):c.1729T > C
AAAGAAYCTGTAGATCAAAGAGG
Hereditary factor VIII deficiency disease

(p.Ser577Pro)

387906482
NM_000133.3(F9):c.1031T > C
ACGAACAYCTTCCTCAAATTTGG
Hereditary factor IX deficiency disease

(p.Ile344Thr)

387906508
NM_000131.4(F7):c.983T > C
GACGTYCTCTGAGAGGACGCTGG
Factor VII deficiency

(p.Phe328Ser)

387906532
NM_001040113.1(MYH11):c.3791T > C
GAAGCYGGAGGCGCAGGTGCAGG
Aortic aneurysm, familial thoracic 4

(p.Leu1264Pro)

387906658
NM_002465.3(MYBPC1):c.2566T > C
CAAACCYATATCCGCAGAGTTGG
Distal arthrogryposis type 1B

(p.Tyr856His)

387906701
NM_003491.3(NAA10):c.109T > C
TGGCCTTYCCTGGCCCCAGGTGG,
N-terinal acetyltransferase deficiency

(p.Ser37Pro)
GGCCTTYCCTGGCCCCAGGTGGG

387906717
NM_000377.2(WAS):c.881T > C
GACTTCAYTGAGGACCAGGGTGG,
Severe congenital neutropenia X-linked

(p.Ile294Thr)
ACTTCAYTGAGGACCAGGGTGGG

387906809
NM_000287.3(PEX6):c.1601T > C
CTTCYGGGCCGGGACCGTGATGG,
Peroxisome biogenesis disorder 4B

(p.Leu534Pro)
TTCYGGGCCGGGACCGTGATGGG

387906965
NM_024513.3(FYCO1):c.4127T > C
CAGCCYGATCCCCATCACTGTGG
Cataract, autosomal recessive congenital 2

(p.Leu1376Pro)

387906967
NM_006147.3(IRF6):c.65T > C
GCCYCTACCCTGGGCTCATCTGG
Van der Woude syndrome, Popliteal pterygium

(p.Leu22Pro)

syndrome

387906982
NM_025132.3(WDR19):c.20T > C
TCTCACYGCTAGAAAAGACTTGG
Asphyxiating thoracic dystrophy 5

(p.Leu7Pro)

387907072
NM_032446.2(MEGF10):c.2320T > C
GGGCAGYGTACTTGCCGCACTGG
Myopathy, areflexia, respiratory distress, and

(p.Cys774Arg)

dysphagia, early-onset, Myopathy, areflexia,

respiratory distress, and dysphagia, early-

onset, mild variant

137854499
NM_005502.3(ABCA1):c.6026T > C
GAGTYCTTTGCCCTTTTGAGAGG
Familial hypoalphalipoproteinemia

(p.Phe2009Ser)

387907117
NM_000196.3(HSD11B2):c.1012T > C
CCGCCGCYATTACCCCGGCCAGG,
Apparent mineralocorticoid excess

(p.Tyr338His)
CGCCGCYATTACCCCGGCCAGGG

387907170
NM_004453.3(ETFDH):c.1130T > C
CCAAAACYCACCTTTCCTGGTGG

(p.Leu377Pro)

387907205
NM_033360.3(KRAS):c.211T > C
GGACCAGYACATGAGGACTGGGG,
Cardiofaciocutaneous syndrome 2

(p.Tyr71His)
CCAGYACATGAGGACTGGGGAGG,

CAGYACATGAGGACTGGGGAGGG

387907240
NM_024110.4(CARD14):c.467T > C
CAGCAGCYGCAGGAGCACCTGGG
Pityriasis rubra pilaris

(p.Leu156Pro)

387907282
NM_152296.4(ATP1A3):c.2431T > C
TGCCATCYCACTGGCGTACGAGG
Alternating hemiplegia of childhood 2

(p.Ser811Pro)

387907361
NM_005120.2(MED12):c.3493T > C
AGGACYCTGAGCCAGGGGCCCGG
Ohdo syndrome, X-linked

(p.Ser1165Pro)

28933970
NM_006194.3(PAX9):c.62T > C
GGCCGCYGCCCAACGCCATCCGG
Tooth agenesis, selective, 3

(p.Leu21Pro)

137854472
NM_000138.4(FBN1):c.3128A > G
TGCACYTGCCGTGGGTGCAGAGG

(p.Lys1043Arg)

727504261
NM_000257.3(MYH7):c.2708A > G
AGCGCYCCTCAGCATCTGCCAGG
Cardiomyopathy, not specified

(p.Glu903Gly)

81002853
NM_000059.3(BRCA2):c.476-
ACCACYGGGGGTAAAAAAAGGGG,
Familial cancer of breast, Breast-ovarian

2A > G
TACCACYGGGGGTAAAAAAAGGG
cancer, familial 2, Hereditary cancer-

predisposing syndrome

119473032
NM_021020.3(LZTS1):c.355A > G
CCCTYCTCGGAGCCCTGTAGAGG

(p.Lys119Glu)

193922801
NM_000540.2(RYR1):c.7043A > G
TTCYCCTCCACGCTCTCGCCTGG
not provided

(p.Glu2348Gly)

36210419
NM_000218.2(KCNQ1):c.652A > G
GCCCCTYGGAGCCCACGCAGAGG
Torsades de pointes, Cardiac arrhythmia

(p.Lys218Glu)

121964989
NM_000108.4(DLD):c.1483A > G
TTCTCYAAAAGCTTCTGATAAGG
Maple syrup urine disease, type 3

(p.Arg495Gly)

28936669
NM_000095.2(COMP):c.1418A > G
ATTGYCGTCGTCGTCGTCGCAGG

(p.Asp473Gly)

28936696
NM_018488.2(TBX4):c.1592A > G
GTACYGTAAGGAAGATTCTCGGG,
Isch opatellar dysplas a

(p.Gln531Arg)
GGTACYGTAAGGAAGATTCTCGG

121965077
NM_000137.2(FAH):c.1141A > G
TCCYGGTCTGACCATTCCCCAGG
Tyros nemia type I

(p.Arg381Gly)

794728203
NM_000138.4(FBN1):c.3344A > G
ACTCAYCAATATCTGCAAAATGG
Thoracic aortic aneurysms and aortic

(p.Asp1115Gly)

dissections

786205436
NM_003002.3(SDHD):c.275A > G
GAATAGYCCATCGCAGAGCAAGG
Fatal infantile mitochondrial cardiomyopathy

(p.Asp92Gly)

72551317
NM_000784.3(CYP27A1):c.776A > G
AGTCCACYTGGGGAGGAAGGTGG
Cholestanol storage disease

(p.Lys259Arg)

786205687
NM_016218.2(POLK):c.1385A > G
ATTCACAYTCTTCAACTTAATGG
Malignant tumor of prostate

(p.Asn462Ser)

794728280
NM_000138.4(FBN1):c.7916A > G
TGTTCAYACTGGAAGCCGGCGGG,
Thoracic aortic aneurysms and aortic

(p.Tyr2639Cys)
CTGTTCAYACTGGAAGCCGGCGG
dissections

28937317
NM_000335.4(SCN5A):c.3971A > G
GCAYTGACCACCACCTCAAGTGG
Long QT syndrome 3, Congenital long QT

(p.Asn1324Ser)

syndrome

786205854
NM_144499.2(GNAT1):c.386A > G
CGGAGYCCTTCCACAGCCGCTGG
NIGHT BLINDNESS,

(p.Asp129Gly)

CONGENITAL

104893776
NM_000539.3(RHO):c.533A > G
GGATGYACCTGAGGACAGGCAGG
Retinitis pigmentosa 4

(p.Tyr178Cys)

28937590
NM_001257342.1(BCS1L):c.232A > G
GACACYGAGGTGCTGAGTACGGG,
GRACILE syndrome

(p.Ser78Gly)
CGACACYGAGGTGCTGAGTACGG

104893866
NM_000320.2(QDPR):c.449A > G
TGCCGYACCCGATCATACCTGGG,
Dihydropteridine reductase deficiency

(p.Tyr150Cys)
ATGCCGYACCCGATCATACCTGG

587776590
NM_015629.3(PRPF31):c.527 + 3A >
GACAYACCCCTGGGTGGTGGAGG,
Retinitis pigmentosa 11

G
GCGGACAYACCCCTGGGTGGTGG

104894015
NM_000162.3(GCK):c.641A > G
GTAGYAGCAGGAGATCATCGTGG
Hyperinsulinem c hypoglycemia familial 3

(p.Tyr214Cys)

202247823
NM_000532.4(PCCB):c.1606A > G
ATATYTGCATGTTTTCTCCAAGG
Propionic acidemia

(p.Asn536Asp)

104894199
NM_000073.2(CD3G):c.1A > G
CCAYGTCAGTCTCTGTCCTCCGG
Immunodeficiency 17

(p.Met1Val)

104894208
NM_001814.4(CTSC):c.857A > G
CTCCYGAGGGCTTAGGATTGGGG,
Papillon-Lenf\xc3\xa8vre syndrome, Haim-

(p.Gln286Arg)
CCTCCYGAGGGCTTAGGATTGGG,
Munk syndrome

ACCTCCYGAGGGCTTAGGATTGG

104894211
NM_001814.4(CTSC):c.1040A > G
TCCTACAYAGTGGTACTCAGAGG
Papillon-Lenxc3\xa8vre

(p.Tyr347Cys)

syndrome, Periodontitis,

104894290
NM_000448.2(RAG1):c.2735A > G
CTGYACTGGCAGAGGGATTCTGG
Histiocytic medullary reticulosis

(p.Tyr912Cys)

104894354
NM_000217.2(KCNA1):c.676A > G
GCGYTTCCACGATGAAGAAGGGG,
Episodic ataxia type 1

(p.Thr226Ala)
AGCGYTTCCACGATGAAGAAGGG,

CAGCGYTTCCACGATGAAGAAGG

104894425
NM_014239.3(EIF2B2):c.638A > G
AGTTGTCYCAATACCTGCTTTGG
Leukoencephalopathy with vanishing white

(p.Glu213Gly)

matter, Ovarioleukodystrophy

104894450
NM_000270.3(PNP):c.383A > G
ATAYCTCCAACCTCAAACTTGGG,
Purine-nucleoside phosphorylase deficiency

(p.Asp128Gly)
GATAYCTCCAACCTCAAACTTGG

147394623
NM_024887.3(DHDDS):c.124A > G
GGCACTYCTTGGCATAGCGACGG
Retinitis pigmentosa 59

(p.Lys42Glu)

60723330
NM_005557.3(KRT16):c.374A > G
GCGGTCAYTGAGGTTCTGCATGG
Pachyonychia congenita, type 1, Palmoplantar

(p.Asn125Ser)

keratoderma, nonepidermolytic, focal

104894634
NM_030665.3(RAI1):c.4685A > G
CTGCTGCYGTCGTCGTCGCTTGG
Smith-Magenis syndrome

(p.Gln1562Arg)

104894730
NM_000363.4(TNNI3):c.532A > G
CCTYCTTCACCTGCTTGAGGTGG,
Familial restrictive cardiomyopathy 1

(p.Lys178Glu)
CCTCCTYCTTCACCTGCTTGAGG

104894816
NM_002049.3(GATA1):c.653A > G
GTCCTGYCCCTCCGCCACAGTGG
GATA-1-related thrombocytopenia

(p.Asp218Gly)

with dyserythropoiesis

794726773
NM_001165963.1(SCN1A):c.1662+303
GTGCCAYACCTGGTGTGGGGAGG
Severe myoclonic epilepsy in infancy

A > G

104894861
NM_000202.6(IDS):c.404A > G
AAAGACTYTTCCCACCGACATGG
Mucopolysaccharidosis, MPS-II

(p.Lys135Arg)

104894874
NM_000266.3(NDP):c.125A > G
TGGYGCCTCATGCAGCGTCGAGG

(p.His42Arg)

191205969
NM_002420.5(TRPM1):c.296T > C
AAGCYCTTAATATCTGTGCATGG
Congenital stationary night blindness, type 1C

(p.Leu99Pro)

794727073
NM_019109.4(ALG1):c.1188-
TAAACYGCAGAGAGAACCAAGGG,
Congenital disorder of glycosylation type 1K

2A > G
GTAAACYGCAGAGAGAACCAAG

G

281875236
NM_001004334.3(GPR179):c.659A > G
CCCACAYATCCATCTGCCTGCGG
Congenital stationary night blindness, type 1E

(p.Tyr220Cys)

28939094
NM_015915.4(ATL1):c.1222A > G
CACCCAYCTTCTTCACCCCTCGG
Spastic paraplegia 3

(p.Met408Val)

281875324
NM_005359.5(SMAD4):c.989A > G
ATCCATTYCAAAGTAAGCAATGG
Juvenile polyposis syndrome, Hereditary

(p.Glu330Gly)

cancer-predisposing syndrome

77173848
NM_000037.3(ANK1):c.-108T > C
GGGCCYGGCCCGCACGTCACAGG
Spherocytosis, type 1, autosomal recessive

150181226
NM_001159772.1(CANT1):c.671T > C
CGTCYGTACGTGGGCGGCCTGGG,
Desbuquois syndrome

(p.Leu224Pro)
GCGTCYGTACGTGGGCGGCCTGG

397514253
NM_000041.3(APOE):c.237-
CGCCCYGCGGCCGAGAGGGCGGG,
Familial type 3 hyperlipoproteinemia

2A > G
GCGCCCYGCGGCCGAGAGGGCGG

397514348
NM_000060.3(BTD):c.278A > G
GTTCAYAGATGTCAAGGTTCTGG
Biotinidase deficiency

(p.Tyr93Cys)

397514415
NM_000060.3(BTD):c.1313A > G
GGCAYACAGCTCTTTGGATAAGG
Biotinidase deficiency

(p.Tyr438Cys)

397514501
NM_007171.3(POMT1):c.430A > G
GAGCATYCTCTGTTTCAAAGAGG
Limb-girdle muscular

(p.Asn144Asp)

dystrophy-

370382601
NM_174917.4(ACSF3):c.IA > G
GGCAGCAYTGCACTGACAGGCGG
not provided

(D.Met1Val)

72554332
NM_000531.5(0TC):c.238A > G
AAGGACTYCCCTTGCAATAAAGG
Ornithine carbamoyltransferase deficiency

(p.Lys80Glu)

397514599
NM_033109.4(PNPT1):c.1424A >
GACTYCAGATGTAACTCTTATGG
Deafness, autosomal recessive 70

G

(p.Glu475Gly)

397514650
NM_000108.4(DLD):c.1444A > G
GACTCYAGCTATATCTTCACAGG
Maple syrup urine disease, type 3

(p.Arg482Gly)

397514675
NM_003156.3(STIMI):c.251A > G
TTCCACAYCCACATCACCATTGG
Myopathy with tubular aggregates

(p.Asp84Gly)

794728378
NM_000238.3(KCNH2):c.1913A > G
ATCYTCTCTGAGTTGGTGTTGGG,
Cardiac arrhythmia

(p.Lys638Arg)
GATCYTCTCTGAGTTGGTGTTGG

397514711
NM_002163.2(IRF8):c.238A > G
AACCTCGYCTTCCAAGTGGCTGG
Autosomal dominant CD11C+/CD1C+ dendritic

(p.Thr80Ala)

cell deficiency

397514729
NM_000388.3(CASR):c.85A > G
CCCCCTYCTTTTGGGCTCGCTGG
Hypocalcemia, autosomal dominant 1, with

(p.Lys29Glu)

bartter syndrome

397514743
NM_022114.3(PRDM16):c.2447A > G
GCCGCCGYTTTGGCTGGCACGGG
Left ventricular noncompaction 8

(p.Asn816Ser)

397514757
NM_005689.2(ABCB6):c.508A > G
TGGGCYGTTCCAAGACACCAGGG,
Dyschromatosis universalis hereditaria 3

(p.Ser170Gly)
GTGGGCYGTTCCAAGACACCAGG

28940313
NM_152443.29RDH12):c.677A > G
CACTGCGYAGGTGGTGACCCCGG
Leber congenital amaurosis 13

(p.Tyr226Cys)

794728538
NM_000218.2(KCNQ1):c.1787A > G
GTCTYCTACTCGGTTCAGGCGGG,
Cardiac arrhythmia

(p.Glu596Gly)
TGTCTYCTACTCGGTTCAGGCGG

794728569
NM_000218.2(KCNQ1):c.605A > G
AGGYCTGTGGAGTGCAGGAGAGG
Cardiac arrhythmia

(p.Asp202Gly)

794728573
NM_000218.2(KCNQ1):c.1515-
GCCYGCAGTGGAGAGAGGAGAGG
Cardiac arrhythmia

2A > G

370874727
NM_003494.3(DYSF):c.3349-
CCGCCCYGGAGACACGAAGCTGG
Limb-girdle muscular dystrophy, type 2B

2A > G

794728859
NM_198056.2(SCN5A):c.2788-
ACCYGTCGAGATAATGGGTCAGG
not provided

2A > G

794728887
NM_198056.2(SCN5A):c.4462A > G
CCTCTGYCATGAAGATGTCCTGG
not provided

(p.Thr1488Ala)

28940878
NM_000372.4(TYR):c.125A > G
CTCCTGYCCCCGCTCCACGGTGG
Tyrosinase-negative oculocutaneous albinism

(p.Asp42Gly)

397515420
NM_172107.2(KCNQ2):c.1636A > G
GCAYGACACTGCAGGGGGGTGGG,
Early infantile epileptic encephalopathy 7

(p.Met546Val)
CGCAYGACACTGCAGGGGGGTGG,

AACCGCAYGACACTGCAGGGGGG

397515428
NM_001410.2(MEGF8):c.7099A > G
GACYCCCGTGAAATGATTCCCGG
Carpenter syndrome 2

(p.Ser2367Gly)

143601447
NM_201631.3(TGM5):c.122T > C
TCAACCYCACCCTGTACTTCAGG
Peeling skin syndrome, acral type

(p.Leu41Pro)

397515519
NM_000207.2(INS):c..59A > G
GGGCYTTATTCCATCTCTCTCGG
Permanent neonatal diabetes mellitus

397515523
NM_000370.3(TTPA):c.191A > G
CAGGYCCAGATCGAAATCCCGGG,
Ataxia with vitamin E deficiency

(p.Asp64Gly)
CCAGGYCCAGATCGAAATCCCGG

397515891
NM_000256.3(MYBPC3):c.1224-
TACTTGCYGTAGAACAGAAGGGG
Familial hypertrophic cardiomyopathy

2A > G

4, Cardiomyopathy

397516082
NM_000256.3(MYBPC3):c.927-
GTCCCYGTGTCCCGCAGTCTAGG
Familial hypertrophic cardiomyopathy

2A > G

4, Cardiomyopathy

397516138
NM_000257.3(MYH7):c.2206A > G
TATCAAYGAACTGTCCCTCAGGG,
Familial hypertrophic cardiomyopathy

(p.Ile736Val)
CTATCAAYGAACTGTCCCTCAGG
1, Cardiomyopathy, not specified

1154510
NM_002150.2(HPD):c.97G > A
ATGACGYGGCCTGAATCACAGGG,
4-Alpha-hydroxyphenylpyruvate hydroxylase

(p.Ala33Thr)
AATGACGYGGCCTGAATCACAGG
deficiency

397516330
NM_000260.3(MYO7A):c.6439-
ATATCCYGGGGGAGCAGAAAGGG,
Usher syndrome, type 1

2A > G
GATATCCYGGGGGAGCAGAAAGG

72556271
NM_000531.5(OTC):c.482A > G
CAGCCCAYTGATAATTGGGATGG
not provided

(p.Asn161Ser)

606231260
NM_023073.3(C5orf42):c.3290-
ATCYATCAAATACAAAAATTTGG
Orofac odigital syndrome 6

2A > G

587777521
NM_004817.3(TJP2):c.1992-
CAGCTCYGAGAAGAAACCACGGG,
Progressive familial intrahepatic cholestasis

2A > G
TCAGCTCYGAGAAGAAACCACGG
4

730880846
NM_000257.3(MYH7):c.617A > G
CTTCYTGCTGCGGTCCCCAATGG
Cardiomyopathy

(p.Lys206Arg)

397517978
NM_206933.2(USH2A):c.12067-
TTCCCYGTAAGAAAATTAACAGG
Usher syndrome, type 2A, Retinitis pigmentosa

2A > G

39

606231409
NM_000216.2(ANOS1):c.1A > G
GCACCAYGGCTGCGGGTCGAGGG,
Kallmann syndrome 1

(p.MetlVal)
GGCACCAYGGCTGCGGGTCGAGG

80356546
NM_003334.3(UBA1):c.1639A > G
TGGCYTGTCACCCGGATATGTGG
Arthrogryposis multiplex congenita, distal,

(p.Ser547Gly)

X-linked

80356584
NM_194248.2(OTOF):c.766-
GACCYGCAGGCAGGAGAAGGGGG,
Deafness, autosomal recessive 9

2A > G
TGACCYGCAGGCAGGAGAAGGGG,

CTGACCYGCAGGCAGGAGAAGGG,

GCTGACCYGCAGGCAGGAGAAGG

730880930
NM_000257.3(MYH7):c.1615A > G
GGAACAYGCACTCCTCTTCCAGG
Cardiomyopathy

(p.Met539Val)

118203947
NM_013319.2(UBIAD1):c.355A > G
TCCYGTCATCACTCTTTTTGTGG
Schnyder crystalline conical dystrophy

(p.Arg119Gly)

60171927
NM_000526.4(KRT14):c.368A > G
GCGGTCAYTGAGGTTCTGCATGG
Epidermolysis bullosa herpetiformis,

(p.Asn123Ser)
Dowling-Meara

199422248
NM_001363.4(DKC1):c.941A > G
AATCYTGGCCCCATAGCAGATGG
Dyskeratosis congenita X-linked

(p.Lys314Arg)

72558467
NM_000531.5(OTC):c.929A > G
TCCACTYCTTCTGGCTTTCTGGG,
not provided

(p.Glu310Gly)
ATCCACTYCTTCTGGCTTTCTGG

72558478
NM_000531.5(OTC):c.988A > G
ACTTTCYGTTTTCTGCCTCTGGG,
not provided

(p.Arg330G1y)
CACTTTCYGTTTTCTGCCTCTGG

118204455
NM_000505.3(F12):c.158A > G
GGTGGYACTGGAAGGGGAAGTGG

(p.Tyr53Cys)

80357477
NM_007294.3(BRCA1):c.5453A > G
TTGYCCTCTGTCCAGGCATCTGG
Familial cancer of breast, Breast-ovarian

(p.Asp1818Gly)

cancer, familial 1

121907908
NM_024426.4(WT1):c.1021A > G
CGCYCTCGTACCCTGTGCTGTGG
Mesothelioma

(p.Ser341Gly)

121907926
NM_000280.4(PAX6):c.1171A > G
GTGGYGCCCGAGGTGCCCATTGG
Optic nerve aplasia, bilateral

(p.Thr391Ala)

121908023
NM_024740.2(ALG9):c.860A > G
TTAYACAAAACAATGTTGAGTGG
Congenital disorder of glycosylation type 1L

(p.Tyr287Cys)

121908148
NM_001243133.1(NLRP3):c.1180A > G
ACAATYCCAGCTGGCTGGGCTGG
Familial cold urticaria

(p.Glu627Gly)

121908166
NM_006492.2(ALX3):c.608A > G
CGGYTCTGGAACCAGACCTGGGG,
Frontonasal dysplasia

(p.Asn203Ser)
GCGGYTCTGGAACCAGACCTGGG,

TGCGGYTCTGGAACCAGACCTGG

121908184
NM_020451.2(SEPN1):c. 1 A > G
CCCAYGGCTGCGGCTGGCGGCGG,
Eichsfeld type congenital muscular dystrophy

(p.MetlVal)
CGGCCCAYGGCTGCGGCTGGCGG

121908258
NM_130468.3(CHST14):c.878A > G
AAGTCAYAGTGCACGGCACAAGG
Ehlers-Danlos syndrome, musculocontractural

(p.Tyr293Cys)

type

121908383
NM_001128425.1(MUTYH):c.1241A > G
AAGCYGCTCTGAGGGCTCCCAGG
Neoplasm of stomach

(p.Gln414Arg)

121908580
NM_004328.4(BCSIL):c.148A > G
GTGYGATCATGTAATGGCGCCGG
Mitochondrial complex III deficiency

(p.Thr50Ala)

121908584
NM_016417.2(GLRX5):c.294A > G
CCTGACCYTGTCGGAGCTCCGGG
Anemia, sideroblastic, pyridoxine-refractory,

(p.Gln98=)

autosomal recessive

121908635
NM_022817.2(PER2):c.1984A > G
GCCACACYCTCTGCCTTGCCCGG
Advanced sleep phase syndrome, familial

(p.Ser662Gly)

121908655
NM_003839.3(TNFRSF11A):c.508A > G
GGGTCYGCATTTGTCCGTGGAGG
Osteopetrosis autosomal recessive 7

(p.Arg170Gly)

29001653
NM_000539.3(RHO):c.886A > G
CGCTCTYGGCAAAGAACGCTGGG,
Retinitis pigmentosa 4

(p.Lys296Glu)
GCGCTCTYGGCAAAGAACGCTGG

56307355
NM_006502.2(POLH):c.1603A > G
AGACTTTYCTGCTTAAAGAAGGG
Xeroderma pigmentosum, variant type

(p.Lys535Glu)

121908919
NM_002977.3(SCN9A):c.1964A > G
CCTTTTCYTGTGTATTTGATTGG
Generalized epilepsy with febrile seizures

(p.Lys655Arg)

plus, type 7, not specified

121908939
NM_006892.3(DNMT3B):c.2450A > G
GACACGYCTGTGTAGTGCACAGG
Centromeric instability of chromosomes 1,9 and

(p.Asp817Gly)

16 and immunodeficiency

121909088
NM_001005360.2(DNM2):c.1684A > G
ACTYCTTCTCTTTCTCCTGAGGG,
Charcot-Marie-Tooth disease, dominant

(p.Lys562Glu)
TACTYCTTCTCTTTCTCCTGAGG
intermediate b, with neutropenia

120074112
NM_000483.4(APOC2):c.1A > G
GCCCAYAGTGTCCAGAGACCTGG
Apolipoprotein C2 deficiency

(p.MetlVal)

121909239
NM_000314.6(PTEN):c.755A > G
ATAYCACCACACACAGGTAACGG
Macrocephaly/autism syndrome

(p.Asp252Gly)

121909251
NM_198217.2(ING1):c.515A > G
TGGYTGCACAGACAGTACGTGGG,
Squamous cell carcinoma of the head and neck

(p.Asn172Ser)
CTGGYTGCACAGACAGTACGTGG

121909396
NM_001174089.1(SLC4A11):c.2518A > G
GATCAYCTTCATGTAGGGCAGGG,
Conical dystrophy and perceptive deafness

(p.Met840Val)
AGATCAYCTTCATGTAGGGCAGG

121909533
NM_000034.3(ALDOA):c.386A > G
CCAYCCAACCCTAAGAGAAGAGG
HNSHA due to aldolase A deficiency

(p.Asp129Gly)

128627255
NM_004006.2(DMD):c.835A > G
TGACCGYGATCTGCAGAGAAGGG,
Dilated cardiomyopathy 3B

(p.Thr279Ala)
CTGACCGYGATCTGCAGAGAAGG

116929575
NM_001085.4(SERPINA3):c.1240A > G
GCTCAYGAAGAAGATGTTCTGGG,

(p.Met414Val)
TGCTCAYGAAGAAGATGTTCTGG

61748392
NM_004992.3(MECP2):c.410A > G
CAACYCCACTTTAGAGCGAAAGG
Mental retardation, X-linked, syndromic 13

(p.Glu137Gly)

61748906
NM_001005741.2(GBA):c.667T > C
CCCACTYGGCTCAAGACCAATGG
Gaucher disease, type 1

(p.Trp223Arg)

199473024
NM_000238.3(KCNH2):c.3118A > G
CTGCYCTCCACGTCGCCCCGGGG,
Sudden infant death syndrome

(p.Ser1040Gly)
CCTGCYCTCCACGTCGCCCCGGG,

GCCTGCYCTCCACGTCGCCCCGG

794728365
NM_000238.3(KCNH2):c.1129-2A > G
GGACCYGCACCCGGGGAAGGCGG
Cardiac arrhythmia

72556293
NM_000531.5(OTC):c.548A > G
AGAGCTAYAGTGTTCCTAAAAGG
not provided

(p.Tyr183Cys)

111033244
NM_000441.1(SLC26A4):c.1151A > G
TGAATYCCTAAGGAAGAGACTGG
Pendred syndrome, Enlarged vestibular

(p.Glu384Gly)

aqueduct syndrome

111033415
NM_000260.3(MY07A):c.1344-
AGCYGCAGGGGCACAGGGATGGG,
Usher syndrome, type 1

2A > G
AAGCYGCAGGGGCACAGGGATGG

121912439
NM_000454.4(SOD1):c.302A > G
AGAATCTYCAATAGACACATCGG
Amyotrophic lateral sclerosis type 1

(p.Glu101Gly)

111033567
NM_002769.4(PRSSI):c.68A > G
ATCYTGTCATCATCATCAAAGGG,
Hereditary pancreatitis

(p.Lys23Arg)
GATCYTGTCATCATCATCAAAG

G

121912565
NM_000901.4(NR3C2):c.2327A > G
TCATCYGTTTGCCTGCTAAGCGG
Pseudohypoaldosteronism type 1 autosomal

(p.Gln776Arg)

dominant

121912574
NM_000901.4(NR3C2):c.2915A > G
CCGACYCCACCTTGGGCAGCTGG
Pseudohypoaldosteronism type 1 autosomal

(p.Glu972Gly)

dominant

121912589
NM_001173464.1(KIF21A):c.2839A > G
ATTCAYATCTGCCTCCATGTTGG
Fibrosis of extraocular muscles, congenital,

(p.Met947Val)

1

111033661
NM_000155.3(GALT):c.253-
ATTCACCYACCGACAAGGATAGG
Deficiency of UDPglucose-hexose-1-phosphate

2A > G

uridylyltransferase

111033669
NM_000155.3(GALT):c.290A > G
GAAGTCGYTGTCAAACAGGAAGG
Deficiency of UDPglucose-hexose-1-phosphate

(p.Asn97Ser)

uridylyltransferase

111033682
NM_000155.3(GALT):c.379A > G
TGACCTYACTGGGTGGTGACGGG,
Deficiency of UDPglucose-hexose-1-phosphate

(p.Lys127Glu)
ATGACCTYACTGGGTGGTGACGG
uridylyltransferase

111033786
NM_000155.3(GALT):c.950A > G
CAGCYGCCAATGGTTCCAGTTGG
Deficiency of UDPglucose-hexose-1-phosphate

(p.Gln317Arg)

uridylyltransferase

121912765
NM_001202.3(BMP4):c.278A > G
CCTCCYCCCCAGACTGAAGCCGG
Microphthalmia syndromic 6

(p.Glu93Gly)

121912856
NM_000094.3(COL7A1):c.425A > G
CACCYTGGGGACACCAGGTCGGG,
Epidermolysis bullosa dystrophica inversa,

(p.Lys142Arg)
TCACCYTGGGGACACCAGGTCGG
autosomal recessive

199474715
NM_152263.3(TPM3):c.505A > G
CCAACTYACGAGCCACCTACAGG
Congenital myopathy with fiber

(p.Lys169Glu)

type disproportion

199474718
NM_152263.3(TPM3):c.733A > G
ATCYCTCAGCAAACTCAGCACGG
Congenital myopathy with fiber

(p.Arg245Gly)

type disproportion

121912895
NM_001844.4(COL2A1):c.2974A > G
CCTCYCTCACCACGTTGCCCAGG
Spondyloepimetaphyseal dysplasia Strudwick

(p.Arg992Gly)

type

121913074
NM_000129.3(F13A1):c.851A > G
ATAGGCAYAGATATTGTCCCAGG
Factor xiii, a subunit, deficiency of

(p.Tyr284Cys)

121913145
NM_000208.2(INSR):c.707A > G
GCTGYGGCAACAGAGGCCTTCGG
Leprechaunism syndrome

(p.His236Arg)

312262745
NM_025137.3(SPG11):c.2608A > G
ACTTAYCCTGGGGAGAAGGATGG
Spastic paraplegia 11, autosomal recessive

(p.Ile870Val)

121913682
NM_000222.2(KIT):c.2459A > G
AGAAYCATTCTTGATGTCTCTGG
Mast cell disease, systemic

(p.Asp820Gly)

587776757
NM_000151.3(G6PC):c.230 + 4A >
GTTCYTACCACTTAAAGACGAGG
Glycogen storage disease type 1A

G

61752063
NM_000330.3(RS1):c.286T > C
TTCTTCGYGGACTGCAAACAAGG
Juvenile retinoschisis

(p.Trp96Arg)

367543065
NM_024549.5(TCTN1):c.221-
AGCAACYGCAGAAAAAAGAGGGG,
Joubert syndrome 13

2A > G
CAGCAACYGCAGAAAAAAGAGG

G

5030773
NM_000894.2(LHB):c.221A > G
CCACCYGAGGCAGGGGCGGCAGG
Isolated lutropin deficiency

(p.Gln74Arg)

199476092
NM_000264.3(PTCH1):c.2479A > G
CGTTACYGAAACTCCTGTGTAGG
Gorlin syndrome, Holoprosencephaly 7, not

(p.Ser827Gly)

specified

398123158
NM_000117.2(EMD):c.450-
CGTTCCCYGAGGCAAAAGAGGGG
not provided

2A > G

199476103
RMRP:n.71A > G
ACTTYCCCCTAGGCGGAAAGGGG,
Metaphyseal chondrodysplasia, McKusick type,

GACTTYCCCCTAGGCGGAAAGGG,
Metaphyseal dysplasia without hypotrichosis

GGACTTYCCCCTAGGCGGAAAGG

5030856
NM_000277.1(PAH):c.1169A > G
CTCYCTGCCACGTAATACAGGGG,
Phenylketonuria, Hyperphenylalaninemia, non-

(p.Glu390Gly)
ACTCYCTGCCACGTAATACAGGG,
pku

AACTCYCTGCCACGTAATACAGG

5030860
NM_000277.1(PAH):c.1241A > G
GGGTCGYAGCGAACTGAGAAGGG,
Phenylketonuria, Hyperphenylalan nem a, non-

(p.Tyr414Cys)
TGGGTCGYAGCGAACTGAGAAGG
pku

87777055
NM_020988.2(GNAO1):c.521A > G
GGATGYCCTGCTCGGTGGGCTGG
Early infantile epileptic encephalopathy 17

(p.Asp174Gly)

587777223
NM_024301.4(FKRP):c.1A > G
CCGCAYGGGGCCGAAGTCTGGGG,
Congenital muscular dystrophy-

(p.Met1Val)
GCCGCAYGGGGCCGAAGTCTGGG,
dystroglycanopathy with brain and eye

AGCCGCAYGGGGCCGAAGTCTGG
anomalies type AS

587777479
NM_003108.3(SOX11):c.347A > G
GTACTTGYAGTCGGGGTAGTCGG
Mental retardation, autosomal dominant 27

(p.Tyr116Cys)

587777496
NM_020435.3(GJC2):c.-170A > G
TTGYTCCCCCCTCGGCCTCAGGG,
Leukodystrophy, hypomyelinating, 2

ATTGYTCCCCCCTCGGCCTCAGG

587777507
NM_022552.4(DNMT3A):c.1943T > C
CTCCYGGTGCTGAAGGACTTGGG,
Tatton-Brown-rahman syndrome

(p.Leu648Pro)
GCTCCYGGTGCTGAAGGACTTGG

587777557
NM_018400.3(SCN3B):c.482T > C
AATCAYGATGTACATCCTTCTGG
Atrial fibrillation, familial, 16

(p.Met161Thr)

587777569
NM_001030001.2(RPS29):c.149T > C
GATAYCGGTTTCATTAAGGTAGG
Diamond-Blackfan anemia 13

(p.Ile50Thr)

587777657
NM_153334.6(SCARF2):c.190T > C
CCACGYGCTGCGCTGGCTGGAGG
Marden Walker like syndrome

(p.Cys64Arg)

587777689
NM_005726.5(TSFM):c.57 + 4A >
ACTTCYCACCGGGTAGCTCCCGG
Combined oxidative phosphorylation deficiency

G

3

796052005
NM_000255.3(MUT):c.329A > G
GCAYACTGGCGGATGGTCCAGGG,
not provided

(p.Tyr110Cys)
AGCAYACTGGCGGATGGTCCAGG

587777809
NM_144596.3(TTC8):c.115-
GTTCCYGGAAAGCATTAAGAAGG
Retinitis pigmentosa 51

2A > G

587777878
NM_000166.5(GJB1):c.580A > G
TAGCAYGAAGACGGTGAAGACGG
X-linked hereditary motor and sensory

(p.Met194Val)

neuropathy

74315420
NM_001029871.3(RSPO4):c.194A > G
CGTACYGGCGGATGCCTTCCCGG
Anonychia

(p.Gln65Arg)

180177219
NM_000030.2(AGCT):c.424-2A > G
AGGCCCYGAGGAAGCAGGGACGG
Primary hyperoxaluria, type I

(p.Gly_142Gln145del)

367610201
NM_002693.2(POLG):c.1808T > C
CTCAYGGCACTTACCTGGGATGG
not provided

(p.Met603Thr)

180177319
NM_012203.1(GRHPR):c.84-
TCACAGCYGCGGGGAAAGGGAGG
Primary hyperoxaluria, type II

2A > G

796052068
NM_000030.2(AGXT):c.777-
GGTACCYGGAAGACACGAGGGGG,
Primary hyperoxaluria, type I

2A > G
TGGTACCYGGAAGACACGAGGGG

61754010
NM_000552.3(VWF):c.1583A > G
TGCCAYTGTAATTCCCACACAGG
von Willebrand disease, type 2a

(p.Asn528Ser)

587778866
NM_000321.2(RB1):c.1927A > G
ATTYCAATGGCTTCTGGGTCTGG
Retinoblastoma

(p.Lys643Glu)

74435397
NM_006331.7(EMG1):c.257A > G
ATAYCTGGCCGCGCTTCCCCAGG
Bowen-Conradi syndrome

(p.Asp86G1y)

796052527
NM_000156.5(GAMT):c.1A > G
CGCTCAYGCTGCAGGCTGGACGG
not provided

(p.MetlVal)

796052637
NM_172107.2(KCNQ2):c.848A > G
GTACYTGTCCCCGTAGCCAATGG
not provided

(p.Lys283Arg)

724159963
NM_032228.5(FAR1):c.1094A > G
GATAYCATACAGGAATGCTGGGG,
Peroxisomal fatty acyl-coa reductase 1 disorder

(p.Asp365Gly)
AGATAYCATACAGGAATGCTGGG,

TAGATAYCATACAGGAATGCTGG

587779722
NM_000090.3(COL3A1):c.1762-2A > G
CACCCYAAAGAAGAAGTGGTCGG
Ehlers-Danlos syndrome, type 4

(p.Gly588_Gln605del)

118192102
m.8296A > G
TTTACAGYGGGCTCTAGAGGGGG
Diabetes-deafness syndrome maternally

transmitted

727502787
NM_001077494.3(NFKB2):c.2594A > G
CTGYCTTCCTTCACCTCTGCTGG
Common variable immunodeficiency 10

(p.Asp865G1y)

727503036
NM_000117.2(EMD):c.266-
AGCCYTGGGAAGGGGGGCAGCGG
Emery-Dreifuss muscular dystrophy 1, X-linked

2A > G

690016544
NM_005861.3(STUB1):c.194A > G
GGCCCGGYTGGTGTAATACACGG
Spinocerebellar ataxia, autosomal recessive 16

(p.Asn65Ser)

690016554
NM_005211.3(CSF1R):c.2655-
GTATCYGGGAGATAGGACAGAGG
Hereditary diffuse leukoencephalopathy with

2A > G

spheroids

118192185
NM_172107.2(KCNQ2):c.1A > G
GCACCAYGGTGCCTGGCGGGAGG
Benign familial neonatal seizures 1

(p.MetlVal)

121917869
NM_012064.3(MIP):c.401A > G
AGATCYCCACTGTGGTTGCCTGG
Cataract 15, multiple types

(p.Glu134Gly)

121918014
NM_000478.4(ALPL):c.1250A > G
AGGCCCAYTGCCATACAGGATGG
Infantile hypophosphatasia

(p.Asn417Ser)

121918036
NM_000174.4(GP9):c.110A > G
GCAGYCCACCCACAGCCCCATGG
Bernard-Soulier syndrome type C

(p.Asp37G1y)

121918089
NM_000371.3(TTR):c.379A > G
CGGCAAYGGTGTAGCGGCGGGGG,
Amylo dogen c transthyretin amyloidosis

(p.Ile127Val)
GCGGCAAYGGTGTAGCGGCGGGG

121918121
NM_000823.3(GHRHR):c.985A > G
CGACTYGGAGAGACGCCTGCAGG
Isolated growth hormone deficiency type 1B

(p.Lys329Glu)

121918333
NM_015335.4(MED13L):c.6068A > G
ATATCAYCTAGAGGGAAGGGGGG,
Transposition of great arteries

(p.Asp2023Gly)
CATATCAYCTAGAGGGAAGGGGG

121918605
NM_001035.2(RYR2):c.12602A > G
CGCCAGCYGCATTTCAAAGATGG
Catecholaminergic polymorphic

(p.Gln4201Arg)

ventricular tachycardia

587781262
NM_002764.3(PRPS1):c.343A > G
TAGCAYATTTGCAACAAGCTTGG
Charcot-Marie-Tooth disease, X-linked

(p.Met115Val)

recessive, type 5, Deafness, high-frequency

sensorineural, X-linked

121918608
NM_001161766.1(AHCY):c.344A > G
GCGGGYACTTGGTGTGGATGAGG
Hypermethioninemia with s-adenosylhomocysteine

(p.Tyr115Cys)

hydrolase deficiency

121918613
NM_000702.3(ATP1A2):c.1033A > G
CTGYCAGGGTCAGGCACACCTGG
Familial hemiplegic migraine type 2

(p.Thr345Ala)

587781339
NM_000535.5(PMS2):c.904-
GCAGACCYGCACAAAATACAAGG
Hereditary cancer-predisposing syndrome

2A > G

121918691
NM_001128177.1(THRB):c.1324A > G
CTTCAYGTGCAGGAAGCGGCTGG
Thyroid hormone resistance, generalized,

(p.Met442Val)

autosomal dominant

121918692
NM_001128177.1(THRB):c.1327A > G
CCACCTYCATGTGCAGGAAGCGG
Thyroid hormone resistance, generalized,

(p.Lys443Glu)

autosomal dominant

727504333
NM_000256.3(MYBPC3):c.2906-
CCGTTCYGTGGGTATAGAGTGGG,
Familial hypertrophic cardiomyopathy 4

2A > G
GCCGTTCYGTGGGTATAGAGTGG

730880805
NM_006204.3(PDE6C):c.1483-
CTTTCYGTTGAAATAAGGATGGG,
Achromatopsia 5

2A > G
TCTTTCYGTTGAAATAAGGATGG

281860296
NM_000551.3(VHL):c.586A > T
GGTCTTYCTGCACATTTGGGTGG
Von Hippel-Lindau syndrome

(p.Lys196Ter)

730880444
NM_000169.2(GLA):c.370-
GTGAACCYGAAATGAGAGGGAGG
not provided

2A > G

756328339
NM_000256.3(MYBPC3):c.1227-
GTACCYGGGTGGGGGCCGCAGGG,
Familial hypertrophic cardiomyopathy

2A > G
TGTACCYGGGTGGGGGCCGCAGG
4, Cardiomyopathy

267606643
NM_013411.4(AK2):c.494A > G
TCAYCTTTCATGGGCTCTTTTGG
Reticular dysgenesis

(p.Asp165Gly)

267606705
NM_005188.3(CBL):c.1144A > G
TATTTYACATAGTTGGAATGTGG
Noonan syndrome-like disorder with or without

(p.Lys382Glu)

juvenile myelomonocytic leukemia

62642934
NM_000277.1(PAH):c.916A > G
GGCCAAYTTCCTGTAATTGGGGG,
Phenylketonuria, Hyperphenylalan nem a non-

(p.Ile306Val)
AGGCCAAYTTCCTGTAATTGGGG
pku

267606782
NM_000117.2(EMD):c.1A > G
TCCAYGGCGGGTGCGGGCTCAGG
Emery-Dreifuss muscular dystrophy, X-linked

(p.MetlVal)

267606820
NM_014053.3(FLVCR1):c.361A > G
AGGCGTYGACCAGCGAGTACAGG
Posterior column ataxia with

(p.Asn121Asp)

retinitis pigmentosa

In some embodiments, any of the base editors provided herein may be used to treat a disease or disorder. For example, any base editors provided herein may be used to correct one or more mutations associated with any of the diseases or disorders provided herein. Exemplary diseases or disorders that may be treated include, without limitation, 3-Methylglutaconic aciduria type 2, 46,XY gonadal dysgenesis, 4-Alpha-hydroxyphenylpyruvate hydroxylase deficiency, 6-pyruvoyl-tetrahydropterin synthase deficiency, achromatopsia, Acid-labile subunit deficiency, Acrodysostosis, acroerythrokeratoderma, ACTH resistance, ACTH-independent macronodular adrenal hyperplasia, Activated PI3K-delta syndrome, Acute intermittent porphyria, Acute myeloid leukemia, Adams-Oliver syndrome 1/5/6, Adenylosuccinate lyase deficiency, Adrenoleukodystrophy, Adult neuronal ceroid lipofuscinosis, Adult onset ataxia with oculomotor apraxia, Advanced sleep phase syndrome, Age-related macular degeneration, Alagille syndrome, Alexander disease, Allan-Herndon-Dudley syndrome, Alport syndrome, X-linked recessive, Alternating hemiplegia of childhood, Alveolar capillary dysplasia with misalignment of pulmonary veins, Amelogenesis imperfecta, Amyloidogenic transthyretin amyloidosis, Amyotrophic lateral sclerosis, Anemia (nonspherocytic hemolytic, due to G6PD deficiency), Anemia (sideroblastic, pyridoxine-refractory, autosomal recessive), Anonychia, Antithrombin III deficiency, Aortic aneurysm, Aplastic anemia, Apolipoprotein C2 deficiency, Apparent mineralocorticoid excess, Aromatase deficiency, Arrhythmogenic right ventricular cardiomyopathy, Familial hypertrophic cardiomyopathy, Hypertrophic cardiomyopathy, Arthrogryposis multiplex congenital, Aspartylglycosaminuria, Asphyxiating thoracic dystrophy, Ataxia with vitamin E deficiency, Ataxia (spastic), Atrial fibrillation, Atrial septal defect, atypical hemolytic-uremic syndrome, autosomal dominant CD11C+/CD1C+ dendritic cell deficiency, Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions, Baraitser-Winter syndrome, Bartter syndrome, Basa ganglia calcification, Beckwith-Wiedemann syndrome, Benign familial neonatal seizures, Benign scapuloperoneal muscular dystrophy, Bernard Soulier syndrome, Beta thalassemia intermedia, Beta-D-mannosidosis, Bietti crystalline corneoretinal dystrophy, Bile acid malabsorption, Biotinidase deficiency, Borjeson-Forssman-Lehmann syndrome, Boucher Neuhauser syndrome, Bowen-Conradi syndrome, Brachydactyly, Brown-Vialetto-Van laere syndrome, Brugada syndrome, Cardiac arrhythmia, Cardiofaciocutaneous syndrome, Cardiomyopathy, Carnevale syndrome, Carnitine palmitoyltransferase II deficiency, Carpenter syndrome, Cataract, Catecholaminergic polymorphic ventricular tachycardia, Central core disease, Centromeric instability of chromosomes 1,9 and 16 and immunodeficiency, Cerebral autosomal dominant arteriopathy, Cerebro-oculo-facio-skeletal syndrome, Ceroid lipofuscinosis, Charcot-Marie-Tooth disease, Cholestanol storage disease, Chondrocalcinosis, Chondrodysplasia, Chronic progressive multiple sclerosis, Coenzyme Q10 deficiency, Cohen syndrome, Combined deficiency of factor V and factor VIII, Combined immunodeficiency, Combined oxidative phosphorylation deficiency, Combined partial 17-alpha-hydroxylase/17,20-lyase deficiency, Complement factor d deficiency, Complete combined 17-alpha-hydroxylase/17,20-lyase deficiency, Cone-rod dystrophy, Congenital contractural arachnodactyly, Congenital disorder of glycosylation, Congenital lipomatous overgrowth, Neoplasm of ovary, PIK3CA Related Overgrowth Spectrum, Congenital long QT syndrome, Congenital muscular dystrophy, Congenital muscular hypertrophy-cerebral syndrome, Congenital myasthenic syndrome, Congenital myopathy with fiber type disproportion, Eichsfeld type congenital muscular dystrophy, Congenital stationary night blindness, Corneal dystrophy, Cornelia de Lange syndrome, Craniometaphyseal dysplasia, Crigler Najjar syndrome, Crouzon syndrome, Cutis laxa with osteodystrophy, Cyanosis, Cystic fibrosis, Cystinosis, Cytochrome-c oxidase deficiency, Mitochondrial complex I deficiency, D-2-hydroxyglutaric aciduria, Danon disease, Deafness with labyrinthine aplasia microtia and microdontia (LAMM), Deafness, Deficiency of acetyl-CoA acetyltransferase, Deficiency of ferroxidase, Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase, Dejerine-Sottas disease, Desbuquois syndrome, DFNA, Diabetes mellitus type 2, Diabetes-deafness syndrome, Diamond-Blackfan anemia, Diastrophic dysplasia, Dihydropteridine reductase deficiency, Dihydropyrimidinase deficiency, Dilated cardiomyopathy, Disseminated atypical mycobacterial infection, Distal arthrogryposis, Distal hereditary motor neuronopathy, Donnai Barrow syndrome, Duchenne muscular dystrophy, Becker muscular dystrophy, Dyschromatosis universalis hereditaria, Dyskeratosis congenital, Dystonia, Early infantile epileptic encephalopathy, Ehlers-Danlos syndrome, Eichsfeld type congenital muscular dystrophy, Emery-Dreifuss muscular dystrophy, Enamel-renal syndrome, Epidermolysis bullosa dystrophica inversa, Epidermolysis bullosa herpetiformis, Epilepsy, Episodic ataxia, Erythrokeratodermia variabilis, Erythropoietic protoporphyria, Exercise intolerance, Exudative vitreoretinopathy, Fabry disease, Factor V deficiency, Factor VII deficiency, Factor xiii deficiency, Familial adenomatous polyposis, breast cancer, ovarian cancer, cold urticarial, chronic infantile neurological, cutaneous and articular syndrome, hemiplegic migraine, hypercholesterolemia, hypertrophic cardiomyopathy, hypoalphalipoproteinemia, hypokalemia-hypomagnesemia, juvenile gout, hyperlipoproteinemia, visceral amyloidosis, hypophosphatemic vitamin D refractory rickets, FG syndrome, Fibrosis of extraocular muscles, Finnish congenital nephrotic syndrome, focal epilepsy, Focal segmental glomerulosclerosis, Frontonasal dysplasia, Frontotemporal dementia, Fructose-biphosphatase deficiency, Gamstorp-Wohlfart syndrome, Ganglioside sialidase deficiency, GATA-1-related thrombocytopenia, Gaucher disease, Giant axonal neuropathy, Glanzmann thrombasthenia, Glomerulocystic kidney disease, Glomerulopathy, Glucocorticoid resistance, Glucose-6-phosphate transport defect, Glutaric aciduria, Glycogen storage disease, Gorlin syndrome, Holoprosencephaly, GRACILE syndrome, Haemorrhagic telangiectasia, Hemochromatosis, Hemoglobin H disease, Hemolytic anemia, Hemophagocytic lymphohistiocytosis, Carcinoma of colon, Myhre syndrome, leukoencephalopathy, Hereditary factor IX deficiency disease, Hereditary factor VIII deficiency disease, Hereditary factor XI deficiency disease, Hereditary fructosuria, Hereditary Nonpolyposis Colorectal Neoplasm, Hereditary pancreatitis, Hereditary pyropoikilocytosis, Elliptocytosis, Heterotaxy, Heterotopia, Histiocytic medullary reticulosis, Histiocytosis-lymphadenopathy plus syndrome, HNSHA due to aldolase A deficiency, Holocarboxylase synthetase deficiency, Homocysteinemia, Howel-Evans syndrome, Hydatidiform mole, Hypercalciuric hypercalcemia, Hyperimmunoglobulin D, Mevalonic aciduria, Hyperinsulinemic hypoglycemia, Hyperkalemic Periodic Paralysis, Paramyotonia congenita of von Eulenburg, Hyperlipoproteinemia, Hypermanganesemia, Hypermethioninemia, Hyperphosphatasemia, Hypertension, hypomagnesemia, Hypobetalipoproteinemia, Hypocalcemia, Hypogonadotropic hypogonadism, Hypogonadotropic hypogonadism, Hypohidrotic ectodermal dysplasia, Hyper-IgM immunodeficiency, Hypohidrotic X-linked ectodermal dysplasia, Hypomagnesemia, Hypoparathyroidism, Idiopathic fibrosing alveolitis, Immunodeficiency, Immunoglobulin A deficiency, Infantile hypophosphatasia, Infantile Parkinsonism-dystonia, Insulin-dependent diabetes mellitus, Intermediate maple syrup urine disease, Ischiopatellar dysplasia, Islet cell hyperplasia, Isolated growth hormone deficiency, Isolated lutropin deficiency, Isovaleric acidemia, Joubert syndrome, Juvenile polyposis syndrome, Juvenile retinoschisis, Kallmann syndrome, Kartagener syndrome, Kugelberg-Welander disease, Lattice corneal dystrophy, Leber congenital amaurosis, Leber optic atrophy, Left ventricular noncompaction, Leigh disease, Mitochondrial complex I deficiency, Leprechaunism syndrome, Arthrogryposis, Anterior horn cell disease, Leukocyte adhesion deficiency, Leukodystrophy, Leukoencephalopathy, Ovarioleukodystrophy, L-ferritin deficiency, Li-Fraumeni syndrome, Limb-girdle muscular dystrophy-dystroglycanopathy, Loeys-Dietz syndrome, Long QT syndrome, Macrocephaly/autism syndrome, Macular corneal dystrophy, Macular dystrophy, Malignant hyperthermia susceptibility, Malignant tumor of prostate, Maple syrup urine disease, Marden Walker like syndrome, Marfan syndrome, Marie Unna hereditary hypotrichosis, Mast cell disease, Meconium ileus, Medium-chain acyl-coenzyme A dehydrogenase deficiency, Melnick-Fraser syndrome, Mental retardation, Merosin deficient congenital muscular dystrophy, Mesothelioma, Metachromatic leukodystrophy, Metaphyseal chondrodysplasia, Methemoglobinemia, methylmalonic aciduria, homocystinuria, Microcephaly, chorioretinopathy, lymphedema, Microphthalmia, Mild non-PKU hyperphenylalanemia, Mitchell-Riley syndrome, mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency, Mitochondrial complex I deficiency, Mitochondrial complex III deficiency, Mitochondrial myopathy, Mucolipidosis III, Mucopolysaccharidosis, Multiple sulfatase deficiency, Myasthenic syndrome, Mycobacterium tuberculosis, Myeloperoxidase deficiency, Myhre syndrome, Myoclonic epilepsy, Myofibrillar myopathy, Myoglobinuria, Myopathy, Myopia, Myotonia congenital, Navajo neurohepatopathy, Nemaline myopathy, Neoplasm of stomach, Nephrogenic diabetes insipidus, Nephronophthisis, Nephrotic syndrome, Neurofibromatosis, Neutral lipid storage disease, Niemann-Pick disease, Non-ketotic hyperglycinemia, Noonan syndrome, Noonan syndrome-like disorder, Norum disease, Macular degeneration, N-terminal acetyltransferase deficiency, Oculocutaneous albinism, Oculodentodigital dysplasia, Ohdo syndrome, Optic nerve aplasia, Ornithine carbamoyltransferase deficiency, Orofaciodigital syndrome, Osteogenesis imperfecta, Osteopetrosis, Ovarian dysgenesis, Pachyonychia, Palmoplantar keratoderma, nonepidermolytic, Papillon-Lef\xc3\xa8vre syndrome, Haim-Munk syndrome, Periodontitis, Peeling skin syndrome, Pendred syndrome, Peroxisomal fatty acyl-coa reductase 1 disorder, Peroxisome biogenesis disorder, Pfeiffer syndrome, Phenylketonuria, Phenylketonuria, Hyperphenylalaninemia, non-PKU, Pituitary hormone deficiency, Pityriasis rubra pilaris, Polyarteritis nodosa, Polycystic kidney disease, Polycystic lipomembranous osteodysplasia, Polymicrogyria, Pontocerebellar hypoplasia, Porokeratosis, Posterior column ataxia, Primary erythromelalgia, hyperoxaluria, Progressive familial intrahepatic cholestasis, Progressive pseudorheumatoid dysplasia, Propionic acidemia, Pseudohermaphroditism, Pseudohypoaldosteronism, Pseudoxanthoma elasticum-like disorder, Purine-nucleoside phosphorylase deficiency, Pyridoxal 5-phosphate-dependent epilepsy, Renal dysplasia, retinal pigmentary dystrophy, cerebellar ataxia, skeletal dysplasia, Reticular dysgenesis, Retinitis pigmentosa, Usher syndrome, Retinoblastoma, Retinopathy, RRM2B-related mitochondrial disease, Rubinstein-Taybi syndrome, Schnyder crystalline corneal dystrophy, Sebaceous tumor, Severe congenital neutropenia, Severe myoclonic epilepsy in infancy, Severe X-linked myotubular myopathy, onychodysplasia, facial dysmorphism, hypotrichosis, Short-rib thoracic dysplasia, Sialic acid storage disease, Sialidosis, Sideroblastic anemia, Small fiber neuropathy, Smith-Magenis syndrome, Sorsby fundus dystrophy, Spastic ataxia, Spastic paraplegia, Spermatogenic failure, Spherocytosis, Sphingomyelin/cholesterol lipidosis, Spinocerebellar ataxia, Split-hand/foot malformation, Spondyloepimetaphyseal dysplasia, Platyspondylic lethal skeletal dysplasia, Squamous cell carcinoma of the head and neck, Stargardt disease, Sucrase-isomaltase deficiency, Sudden infant death syndrome, Supravalvar aortic stenosis, Surfactant metabolism dysfunction, Tangier disease, Tatton-Brown-rahman syndrome, Thoracic aortic aneurysms and aortic dissections, Thrombophilia, Thyroid hormone resistance, TNF receptor-associated periodic fever syndrome (TRAPS), Tooth agenesis, Torsades de pointes, Transposition of great arteries, Treacher Collins syndrome, Tuberous sclerosis syndrome, Tyrosinase-negative oculocutaneous albinism, Tyrosinase-positive oculocutaneous albinism, Tyrosinemia, UDPglucose-4-epimerase deficiency, Ullrich congenital muscular dystrophy, Bethlem myopathy Usher syndrome, UV-sensitive syndrome, Van der Woude syndrome, popliteal pterygium syndrome, Very long chain acyl-CoA dehydrogenase deficiency, Vesicoureteral reflux, Vitreoretinochoroidopathy, Von Hippel-Lindau syndrome, von Willebrand disease, Waardenburg syndrome, Warsaw breakage syndrome, WFS1-Related Disorders, Wilson disease, Xeroderma pigmentosum, X-linked agammaglobulinemia, X-linked hereditary motor and sensory neuropathy, X-linked severe combined immunodeficiency, and Zellweger syndrome.

The development of nucleobase editing advances both the scope and effectiveness of genome editing. The nucleobase editors described here offer researchers a choice of editing with virtually no indel formation (NBE2), or more efficient editing with a low frequency (here, typically ≤1%) of indel formation (NBE3). That the product of base editing is, by definition, no longer a substrate likely contributes to editing efficiency by preventing subsequent product transformation, which can hamper traditional Cas9 applications. By removing the reliance on double-stranded DNA cleavage and stochastic DNA repair processes that vary greatly by cell state and cell type, nucleobase editing has the potential to expand the type of genome modifications that can be cleanly installed, the efficiency of these modifications, and the type of cells that are amenable to editing. It is likely that recent engineered Cas9 variants^69,70,82or delivery methods⁷¹with improved DNA specificity, as well as Cas9 variants with altered PAM specificities,⁷²can be integrated into this strategy to provide additional nucleobase editors with improved DNA specificity or that can target an even wider range of disease-associated mutations. These findings also suggest that engineering additional fusions of dCas9 with enzymes that catalyze additional nucleobase transformations will increase the fraction of the possible DNA base changes that can be made through nucleobase editing. These results also suggest architectures for the fusion of other DNA-modifying enzymes, including methylases and demathylases, that mau enable additional types of programmable genome and epigenome base editing.

Materials and Methods

Cloning. DNA sequences of all constructs and primers used in this paper are listed in the Supplementary Sequences. Plasmids containing genes encoding NBE1, NBE2, and NBE3 will be available from Addgene. PCR was performed using VeraSeq ULtra DNA polymerase (Enzymatics), or Q5 Hot Start High-Fidelity DNA Polymerase (New England Biolabs). NBE plasmids were constructed using USER cloning (New England Biolabs). Deaminase genes were synthesized as gBlocks Gene Fragments (Integrated DNA Technologies), and Cas9 genes were obtained from previously reported plasmids.¹⁸Deaminase and fusion genes were cloned into pCMV (mammalian codon-optimized) or pET28b (E. coli codon-optimized) backbones. sgRNA expression plasmids were constructed using site-directed mutagenesis. Briefly, the primers listed in the Supplementary Sequences were 5′ phosphorylated using T4 Polynucleotide Kinase (New England Biolabs) according to the manufacturer's instructions. Next, PCR was performed using Q5 Hot Start High-Fidelity Polymerase (New England Biolabs) with the phosphorylated primers and the plasmid pFYF1320 (EGFP sgRNA expression plasmid) as a template according to the manufacturer's instructions. PCR products were incubated with DpnI (20 U, New England Biolabs) at 37° C. for 1 h, purified on a QIAprep spin column (Qiagen), and ligated using QuickLigase (New England Biolabs) according to the manufacturer's instructions. DNA vector amplification was carried out using Mach1 competent cells (ThermoFisher Scientific).

In vitro deaminase assay on ssDNA. Sequences of all ssDNA substrates are listed in the Supplementary Sequences. All Cy3-labelled substrates were obtained from Integrated DNA Technologies (IDT). Deaminases were expressed in vitro using the TNT T7 Quick Coupled Transcription/Translation Kit (Promega) according to the manufacturer's instructions using 1 μg of plasmid. Following protein expression, 5 μL of lysate was combined with 35 μL of ssDNA (1.8 μM) and USER enzyme (1 unit) in CutSmart buffer (New England Biolabs) (50 mM potassium acetate, 29 mM Trisacetate, 10 mM magnesium acetate, 100 ug/mL BSA, pH 7.9) and incubated at 37° C. for 2 h. Cleaved U-containing substrates were resolved from full-length unmodified substrates on a 10% TBE-urea gel (Bio-Rad).

Expression and purification of His₆-rAPOBEC1-linker-dCas9 fusions. E. Coli BL21 STAR (DE3)-competent cells (ThermoFisher Scientific) were transformed with plasmids encoding pET28b-His₆-rAPOBEC-linker-dCas9 with GGS, (GGS)₃, (SEQ ID NO: 596) XTEN, or (GGS)₇(SEQ ID NO: 597) linkers. The resulting expression strains were grown overnight in Luria-Bertani (LB) broth containing 100 μg/mL of kanamycin at 37° C. The cells were diluted 1:100 into the same growth medium and grown at 37° C. to OD₆₀₀=˜0.6. The culture was cooled to 4° C. over a period of 2 h, and isopropyl-β-D-1-thiogalactopyranoside (IPTG) was added at 0.5 mM to induce protein expression. After ˜16 h, the cells were collected by centrifugation at 4,000 g and resuspended in lysis buffer (50 mM tris(hydroxymethyl)-aminomethane (Tris)-HCl, pH 7.0, 1 M NaCl, 20% glycerol, 10 mM tris(2-carboxyethyl)phosphine (TCEP, Soltec Ventures)). The cells were lysed by sonication (20 s pulse-on, 20 s pulse-off for 8 min total at 6 W output) and the lysate supernatant was isolated following centrifugation at 25,000 g for 15 min. The lysate was incubated with His-Pur nickel-nitriloacetic acid (nickel-NTA) resin (ThermoFisher Scientific) at 4° C. for 1 h to capture the His-tagged fusion protein. The resin was transferred to a column and washed with 40 mL of lysis buffer. The His-tagged fusion protein was eluted in lysis buffer supplemented with 285 mM imidazole, and concentrated by ultrafiltration (Amicon-Millipore, 100-kDa molecular weight cut-off) to 1 mL total volume. The protein was diluted to 20 mL in low-salt purification buffer containing 50 mM tris(hydroxymethyl)-aminomethane (Tris)-HCl, pH 7.0, 0.1 M NaCl, 20% glycerol, 10 mM TCEP and loaded onto SP Sepharose Fast Flow resin (GE Life Sciences). The resin was washed with 40 mL of this low-salt buffer, and the protein eluted with 5 mL of activity buffer containing 50 mM tris(hydroxymethyl)-aminomethane (Tris)-HCl, pH 7.0, 0.5 M NaCl, 20% glycerol, 10 mM TCEP. The eluted proteins were quantified on a SDSPAGE gel.

In vitro transcription of sgRNAs. Linear DNA fragments containing the T7 promoter followed by the 20-bp sgRNA target sequence were transcribed in vitro using the primers listed in the Supplementary Sequences with the TranscriptAid T7 High Yield Transcription Kit (ThermoFisher Scientific) according to the manufacturer's instructions. sgRNA products were purified using the MEGAclear Kit (ThermoFisher Scientific) according to the manufacturer's instructions and quantified by UV absorbance.

Preparation of Cy3-conjugated dsDNA substrates. Sequences of 80-nucleotide unlabeled strands are listed in the Supplementary Sequences and were ordered as PAGE-purified oligonucleotides from IDT. The 25-nt Cy3-labeled primer listed in the Supplementary Sequences is complementary to the 3′ end of each 80-nt substrate. This primer was ordered as an HPLC-purified oligonucleotide from IDT. To generate the Cy3-labeled dsDNA substrates, the 80-nt strands (5 μL of a 100 μM solution) were combined with the Cy3-labeled primer (5 μL of a 100 μM solution) in NEBuffer 2 (38.25 μL of a 50 mM NaCl, 10 mMTris-HCl, 10 mM MgCl₂, 1 mM DTT, pH 7.9 solution, New England Biolabs) with dNTPs (0.75 μL of a 100 mM solution) and heated to 95° C. for 5 min, followed by a gradual cooling to 45° C. at a rate of 0.1° C./s. After this annealing period, Klenow exo⁻ (5 U, New England Biolabs) was added and the reaction was incubated at 37° C. for 1 h. The solution was diluted with Buffer PB (250 Qiagen) and isopropanol (50 μL) and purified on a QIAprep spin column (Qiagen), eluting with 50 μL of Tris buffer.

Deaminase assay on dsDNA. The purified fusion protein (20 μL of 1.9 μM in activity buffer) was combined with 1 equivalent of appropriate sgRNA and incubated at ambient temperature for 5 min. The Cy3-labeled dsDNA substrate was added to final concentration of 125 nM and the resulting solution was incubated at 37° C. for 2 h. The dsDNA was separated from the fusion by the addition of Buffer PB (100 μL, Qiagen) and isopropanol (25 μL) and purified on a EconoSpin micro spin column (Epoch Life Science), eluting with 20 μL of CutSmart buffer (New England Biolabs). USER enzyme (1 U, New England Biolabs) was added to the purified, edited dsDNA and incubated at 37° C. for 1 h. The Cy3-labeled strand was fully denatured from its complement by combining 5 μL of the reaction solution with 15 μL of a DMSO-based loading buffer (5 mM Tris, 0.5 mM EDTA, 12.5% glycerol, 0.02% bromophenol blue, 0.02% xylene cyan, 80% DMSO). The full-length C-containing substrate was separated from any cleaved, U-containing edited substrates on a 10% TBE-urea gel (Bio-Rad) and imaged on a GE Amersham Typhoon imager.

Preparation of in vitro-edited dsDNA for high-throughput sequencing (HTS). The oligonucleotides listed in the Supplementary Sequences were obtained from IDT. Complementary sequences were combined (5 μL of a 100 μM solution) in Tris buffer and annealed by heating to 95° C. for 5 min, followed by a gradual cooling to 45° C. at a rate of 0.1° C./s to generate 60-bp dsDNA substrates. Purified fusion protein (20 μL of 1.9 μM in activity buffer) was combined with 1 equivalent of appropriate sgRNA and incubated at ambient temperature for 5 min. The 60-mer dsDNA substrate was added to final concentration of 125 nM and the resulting solution was incubated at 37° C. for 2 h. The dsDNA was separated from the fusion by the addition of Buffer PB (100 μL, Qiagen) and isopropanol (25 μL) and purified on a EconoSpin micro spin column (Epoch Life Science), eluting with 20 μL of Tris buffer. The resulting edited DNA (1 μL was used as a template) was amplified by PCR using the HTS primer pairs specified in the Supplementary Sequences and VeraSeq Ultra (Enzymatics) according to the manufacturer's instructions with 13 cycles of amplification. PCR reaction products were purified using RapidTips (Diffinity Genomics), and the purified DNA was amplified by PCR with primers containing sequencing adapters, purified, and sequenced on a MiSeq high-throughput DNA sequencer (IIlumina) as previously described.⁷³

Cell culture. HEK293T (ATCC CRL-3216), U2OS (ATCC-HTB-96) and ST486 cells (ATCC) were maintained in Dulbecco's Modified Eagle's Medium plus GlutaMax (ThermoFisher) supplemented with 10% (v/v) fetal bovine serum (FBS) and penicillin/streptomycin (1×, Amresco), at 37° C. with 5% CO₂. HCC1954 cells (ATCC CRL-2338) were maintained in RPMI-1640 medium (ThermoFisher Scientific) supplemented as described above. Immortalized rat astrocytes containing the ApoE4 isoform of the APOE gene (Taconic Biosciences) were cultured in Dulbecco's Modified Eagle's Medium plus GlutaMax (ThermoFisher Scientific) supplemented with 10% (v/v) fetal bovine serum (FBS) and 200 m/mL Geneticin (ThermoFisher Scientific).

Transfections. HEK293T cells were seeded on 48-well collagen-coated BioCoat plates (Corning) and transfected at approximately 85% confluency. Briefly, 750 ng of NBE and 250 ng of sgRNA expression plasmids were transfected using 1.5 μl of Lipofectamine 2000 (ThermoFisher Scientific) per well according to the manufacturer's protocol. Astrocytes, U2OS, HCC1954, HEK293T and ST486 cells were transfected using appropriate AMAXA NUCLEOFECTOR™ II programs according to manufacturer's instructions. 40 ng of infrared RFP (Addgene plasmid 45457)⁷⁴was added to the nucleofection solution to assess nucleofection efficiencies in these cell lines. For astrocytes, U2OS, and ST486 cells, nucleofection efficiencies were 25%, 74%, and 92%, respectively. For HCC1954 cells, nucleofection efficiency was <10%. Therefore, following trypsinization, the HCC1954 cells were filtered through a 40 micron strainer (Fisher Scientific), and the nucleofected HCC1954 cells were collected on a Beckman Coulter MoFlo XDP Cell Sorter using the iRFP signal (abs 643 nm, em 670 nm). The other cells were used without enrichment of nucleofected cells.

High-throughput DNA sequencing of genomic DNA samples. Transfected cells were harvested after 3 d and the genomic DNA was isolated using the Agencourt DNAdvance Genomic DNA Isolation Kit (Beckman Coulter) according to the manufacturer's instructions. On-target and off-target genomic regions of interest were amplified by PCR with flanking HTS primer pairs listed in the Supplementary Sequences. PCR amplification was carried out with Phusion high-fidelity DNA polymerase (ThermoFisher) according to the manufacturer's instructions using 5 ng of genomic DNA as a template. Cycle numbers were determined separately for each primer pair as to ensure the reaction was stopped in the linear range of amplification (30, 28, 28, 28, 32, and 32 cycles for EMX1, FANCF, HEK293 site 2, HEK293 site 3, HEK293 site 4, and RNF2 primers, respectively). PCR products were purified using RapidTips (Diffinity Genomics). Purified DNA was amplified by PCR with primers containing sequencing adaptors. The products were gel-purified and quantified using the QUANT-IT™ PicoGreen dsDNA Assay Kit (ThermoFisher) and KAPA Library Quantification Kit-Illumina (KAPA Biosystems). Samples were sequenced on an Illumina MiSeq as previously described.⁷³

Data analysis. Sequencing reads were automatically demultiplexed using MiSeq Reporter (Illumina), and individual FASTQ files were analyzed with a custom Matlab script provided in the Supplementary Notes. Each read was pairwise aligned to the appropriate reference sequence using the Smith-Waterman algorithm. Base calls with a Q-score below 31 were replaced with N's and were thus excluded in calculating nucleotide frequencies. This treatment yields an expected MiSeq base-calling error rate of approximately 1 in 1,000. Aligned sequences in which the read and reference sequence contained no gaps were stored in an alignment table from which base frequencies could be tabulated for each locus.

Indel frequencies were quantified with a custom Matlab script shown in the Supplementary Notes using previously described criteria⁷¹. Sequencing reads were scanned for exact matches to two 10-bp sequences that flank both sides of a window in which indels might occur. If no exact matches were located, the read was excluded from analysis. If the length of this indel window exactly matched the reference sequence the read was classified as not containing an indel. If the indel window was two or more bases longer or shorter than the reference sequence, then the sequencing read was classified as an insertion or deletion, respectively.

All publications, patents, patent applications, publication, and database entries (e.g., sequence database entries) mentioned herein, e.g., in the Background, Summary, Detailed Description, Examples, and/or References sections, are hereby incorporated by reference in their entirety as if each individual publication, patent, patent application, publication, and database entry was specifically and individually incorporated herein by reference. In case of conflict, the present application, including any definitions herein, will control.

Supplementary Sequences

Primers used for generating sgRNA transfection plasmids. rev_sgRNA_plasmid was used in all cases. The pFYF1320 plasmid was used as template as noted in Materials and Methods section. SEQ ID NOs: 329-338 appear from top to bottom below, respectively.

rev_sgRNA_plasmid

GGTGTTTCGTCCTTTCCACAAG

fwd_p53_Y163C

GCTTGCAGATGGCCATGGCGGTTTTAGAGCTAGAAATAGCAAGTTAAAAT

AAGGC

fwd_p53_N239D

TGTCACACATGTAGTTGTAGGTTTTAGAGCTAGAAATAGCAAGTTAAAAT

AAGGC

fwd_APOE4_C158R

GAAGCGCCTGGCAGTGTACCGTTTTAGAGCTAGAAATAGCAAGTTAAAAT

AAGGC

fwd_EMX1

GAGTCCGAGCAGAAGAAGAAGTTTTAGAGCTAGAAATAGCAAGTTAAAAT

AAGGC

fwd_FANCF

GGAATCCCTTCTGCAGCACCGTTTTAGAGCTAGAAATAGCAAGTTAAAAT

AAGGC

fwd_HEK293_2

GAACACAAAGCATAGACTGCGTTTTAGAGCTAGAAATAGCAAGTTAAAAT

AAGGC

fwd_HEK293_3

GGCCCAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAAAT

AAGGC

fwd_HEK293_4

GGCACTGCGGCTGGAGGTGGGTTTTAGAGCTAGAAATAGCAAGTTAAAAT

AAGGC

fwd_RNF2

GTCATCTTAGTCATTACCTGGTTTAGAGCTAGAAATAGCAAGTTAAAATA

AGGC

Sequences of all ssDNA substrates used in in vitro deaminase assays. SEQ ID NOs: 339-341 appear from top to bottom below, respectively.

rAPOBEC1 substrate

Cy3-ATTATTATTATTCCGCGGATTTATTTATTTATTTATTTATTT

hAID/pmCDA1 substrate

Cy3-ATTATTATTATTAGCTATTTATTTATTTATTTATTTATTT

hAPOBEC3G substrate

Cy3-ATTATTATTATTCCCGGATTTATTTATTATTTATTTATTT

Primers used for generating PCR products to serve as substrates for T7 transcription of sgRNAs for gel-based deaminase assay. rev_gRNA_T7 was used in all cases. The pFYF1320 plasmid was used as template as noted in Materials and Methods section. SEQ ID NOs: 342-365 appear from top to bottom below, respectively.

rev_sgRNA_T7
AAAAAAAGCACCGACTCGGTG

fwd_sgRNA_T7_dsDNA_2
TAATACGACTCACTATAGGCCGCGGATTTATTTATTTAAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_3
TAATACGACTCACTATAGGTCCGCGGATTTATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_4
TAATACGACTCACTATAGGTTCCGCGGATTTATTTATTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_5
TAATACGACTCACTATAGGATTCCGCGGATTTATTTATTGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_6
TAATACGACTCACTATAGGTATTCCGCGGATTTATTTATGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_7
TAATACGACTCACTATAGGTTATTCCGCGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_8
TAATACGACTCACTATAGGATTATTCCGCGGATTTATTTGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_9
TAATACGACTCACTATAGGTATTATTCCGCGGATTTATTGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_10
TAATACGACTCACTATAGGATTATTATCCGCGGATTTATGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_11
TAATACGACTCACTATAGGTATTATATTCCGCGGATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_12
TAATACGACTCACTATAGGTTATTATATTCCGCGGATTTGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_13
TAATACGACTCACTATAGGATTATTATATTCCGCGGATTGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_14
TAATACGACTCACTATAGGTATTATTATATTCCGCGGATGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_15
TAATACGACTCACTATAGGATTATTATTATTACCGCGGAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_18
TAATACGACTCACTATAGGATTATTATTATTATTACCGCGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_noC
TAATACGACTCACTATAGGATATTAATTTATTTATTTAAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_dsDNA_
TAATACGACTCACTATAGGGGAGGACGTGCGCGGCCGCCGTTTTAGAGCTAGAAATAGCA

APOE4_C112R

fwd_sgRNA_T7_dsDNA_
TAATACGACTCACTATAGGGAAGCGCCTGGCAGTGTACCGTTTTAGAGCTAGAAATAGCA

APOE4_C156R

fwd_sgRNA_T7_dsDNA_
TAATACGACTCACTATAGGCTGTGGCAGTGGCACCAGAAGTTTTAGAGCTAGAAATAGCA

CTNNB1_T41A

fwd_sgRNA_T7_dsDNA_
TAATACGACTCACTATAGGCCTCCCGGCCGGCGOTATCCGTTTTAGAGCTAGAAATAGCA

HRAS_Q61R

fwd_sgRNA_T7_dsDNA_
TAATACGACTCACTATAGGGCTTGCAGATGGCCATGGCGGTTTTAGAGCTAGAAATAGCA

53_Y163C

fwd_sgRNA_T7_dsDNA_
TAATACGACTCACTATAGGACACATGCAGTTGTAGTGGAGTTTTAGAGCTAGAAATAGCA

53_Y236C

fwd_sgRNA_T7_dsDNA_
TAATACGACTCACTATAGGTGTCACACATGTAGTTGTAGGTTTTAGAGCTAGAAATAGCA

53_N239D

Sequences of 80-nucleotide unlabeled strands and Cy3-labeled universal primer used in gel-based dsDNA deaminase assays. SEQ ID NOs: 366-390 appear from top to bottom below, respectively.

Cy3-primer
Cy8-GTAGGTAGTTAGGATGAATGGAAGGTTGGTA

dsDNA_2
GTCCATGGATCCAGAGGTCATCCATTAAATAAATAAATCCGCGGGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_3
GTCCATGGATCCAGAGGTCATCCATAAATAAATAAATCCGCGGAAGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_4
GTCCATGGATCCAGAGGTCATCCATAATAAATAAATCCGCGGAAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_5
GTCCATGGATCCAGAGGTCATCCAAATAAATAAATCCGCGGAATGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_6
GTCCATGGATCCAGAGGTCATCCAATAAATAAATCCGCGGAATAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_7
GTCCATGGATCCAGAGGTCATCCATAAATAAATCCGCGGAATAAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_8
GTCCATGGATCCAGAGGTCATCCAAAATAAATCCGCGGAATAATGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_9
GTCCATGGATCCAGAGGTCATCCAAATAAATCCGCGGAATAATAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_10
GTCCATGGATCCAGAGGTCATCCAATAAATCCGCGGATAATAATGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_11
GTCCATGGATCCAGAGGTCATCCATAAATCCGCGGAATATAATAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_12
GTCCATGGATCCAGAGGTCATCCAAAATCCGCGGAATATAATAAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_13
GTCCATGGATCCAGAGGTCATCCAAATCCGCGGAATATAATAATGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_14
GTCCATGGATCCAGAGGTCATCCAATCCGCGGAATATAATAATAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_15
GTCCATGGATCCAGAGGTCATCCATCCGCGGTAATAATAATAATGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_16
GTCCATGGATCCAGAGGTCATCCAGCGGTAATAATAATAATAATGGCTATACCAACCTTCCATTCATCCTAACTACCTAC

dsDNA_noC
GTCCATGGATCCAGAGGTCATCATCCATTAAATAAATAAATTAATATTACTATACCAACCTTCCATTCCTAACTACCTAC

DsDNA_8U
5Cy3-GTAGGTAGTTAGGATGAATGGAAGGTTGGTGTAGATTATTATCUGCGGATTTATTGGATGACCTCTGGATCCATGGACAT

dsDNA_APCE_
GCACCTCGCCGCGGTACTGCACCAGGCGGCCGCGCACGTCCTCCATGTCTACCAACCTTCCATTCATCCTAACTACCTAC

C112R

dsDNA_APOE_
CGGCGCCCTCGCGGGCCCCGGCCTGGTACACTGCCAGGCGCTTCTGCAGTACCAACCTTCCATTCATCCTAACTACCTAC

C158R

dsDNA_CTNNB1_
GTCTTACCTGGACTCTGGAATCCATTCTGGTGCCACTGCCACAGCTCCTTACCAACCTTCCATTCATCCTAACTACCTAC

T41A

dsDNA_HRAS_
GGAGACGTGCCTGTTGGACATCCTGGATACCGCCGGCCGGGAGGAGTACTACCAACCTTCCATTCATCCTAACTACCTAC

Q61R

dsDNA_p53_
ACCCCCGCCCGGCACCCGCGTCCGCGCCATGGCCATCTGCAAGCAGTCATACCAACCTTCCATTCATCCTAACTACCTAC

Y163C

dsDNA_P53_
AGGTTGGCTCTGACTGTACCACCATCCACTACAACTGCATGTGTAACAGTACCACCTTCCATTCATCCTAACTACCTAC

Y236C

dsDNA_p53_
TGGCTCTGACTGTACCACCATCCACTACAACTACATGTGTGACAGTTCCTACCAACCTTCCATTCATCCTAACTACCTAC

N239D

Primers used for generating PCR products to serve as substrates for T7 transcription of sgRNAs for high-throughput sequencing. rev_gRNA_T7 (above) was used in all cases. The pFYF1320 plasmid was used as template as noted in Materials and Methods section. SEQ ID NOs: 391-442 appear from top to bottom below, respectively.

fwd_sgRNA_T7_HTS_base
TAATACGACTCACTATAGGTTATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_1A
TAATACGACTCACTATAGGATATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_1C
TAATACGACTCACTATAGGCTATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_1G
TAATACGACTCACTATAGGGTATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_2A
TAATACGACTCACTATAGGTAATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_2C
TAATACGACTCACTATAGGTCATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_2G
TAATACGACTCACTATAGGTGATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_3T
TAATACGACTCACTATAGGTTTTTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_3C
TAATACGACTCACTATAGGTTTTTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_3G
TAATACGACTCACTATAGGTTCTTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_4A
TAATACGACTCACTATAGGTTGTTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_4C
TAATACGACTCACTATAGGTTAATTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_4G
TAATACGACTCACTATAGGTTACTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_5A
TAATACGACTCACTATAGGTTAGTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_5C
TAATACGACTCACTATAGGTTATATCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_5G
TAATACGACTCACTATAGGTTATCTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_6A
TAATACGACTCACTATAGGTTATGTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_6C
TAATACGACTCACTATAGGTTATTACGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_6G
TAATACGACTCACTATAGGTTATTCCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_8A
TAATACGACTCACTATAGGTTATTGCSTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_8T
TAATACGACTCACTATAGGTTATTTCATGGATTTATTTAGITTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_8C
TAATACGACTCACTATAGGTTATTTCTTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_9A
TAATACGACTCACTATAGGTTATTTCCTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_9C
TAATACGACTCACTATAGGTTATTTCGAGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_9G
TAATACGACTCACTATAGGTTATTTCGCGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_10A
TAATACGACTCACTATAGGTTATTTCGGGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_10T
TAATACGACTCACTATAGGTTATTTCGTAGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_10C
TAATACGACTCACTATAGGTTATTTCGTTGATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_11A
TAATACGACTCACTATAGGTTATTTCGTGAATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_11T
TAATACGACTCACTATAGGTTATTTCGTGTATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_11C
TAATACGACTCACTATAGGTTATTTCGTGCATTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_12T
TAATACGACTCACTATAGGTTATTTCGTGGTTTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_12C
TAATACGACTCACTATAGGTTATTTCGTGGCTTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_12G
TAATACGACTCACTATAGGTTATTTCGTGGCTTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_13A
TAATACGACTCACTATAGGTTATTTCGTGGGTTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_13C
TAATACGACTCACTATAGGTTATTTCGTGGAATTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_13G
TAATACGACTCACTATAGGTTATTTCGTGGACTTATTTAGTTTTAGAGCTAGAAATAGCA

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGTTCCCCCCCCGATTTATTTAGTTTTAGAGCTAGAAATAGCA

multiC

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGCGCACCCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

TCGCACCC_odd

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGCTCGCACGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

CCTCGCAC_odd

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGCCCTCGCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

ACCCTCGC_odd

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGCACCCTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA

GCACCCTC_odd

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGTCGCACCCGTGGATTTATTAGTTTTAGAGCTAGAAATAGCA

TCGCACCC_even

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGCCTCGCACGTGGATTTATTAGTTTTAGAGCTAGAAATAGCA

CCTCGCAC_even

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGACCCTCGCGTGGATTTATTAGTTTTAGAGCTAGAAATAGCA

ACCCTCGC_even

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGGCACCCTCGTGGATTTATTAGTTTTAGAGCTAGAAATAGCA

GCACCCTC_even

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGGAGTCCGAGCAGAAGAAGAAGTTTTAGAGCTAGAAATAGCA

EMX1

fwd_sgRNA_T7_HTS_
TATACGACTCACTATAGGGGAATCCCTTCTGCAGCACCGTTTTAGAGCTAGAAATAGCA

FANCF

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGGAACACAAAGCATAGACTGCGTTTTAGAGCTAGAAATAGCA

HEK293_site2

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGGGCCCAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCA

HEK293_site3

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGGGCACTGCGGCTGGAGGTGGGTTTTAGAGCTAGAAATAGCA

HEK293_site4

fwd_sgRNA_T7_HTS_
TAATACGACTCACTATAGGGTCATCTTAGTCATTACCTGGTTTTAGAGCTAGAAATAGCA

RNF2

Sequences of in vitro-edited dsDNA for high-throughput sequencing (HTS). Shown are the sequences of edited strands. Reverse complements of all sequences shown were also obtained. dsDNA substrates were obtained by annealing complementary strands as described in Materials and Methods. Oligonucleotides representing the EMX1, FANCF, HEK293 site 2, HEK293 site 3, HEK293 site 4, and RNF2 loci were originally designed for use in the gel-based deaminase assay and therefore have the same 25-nt sequence on their 5′-ends (matching that of the Cy3-primer). SEQ ID NOs: 443-494 appear from top to bottom below, respectively.

Base sequence
ACGTAAACGGCCACAAGTTCTTATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

1A
ACGTAAACGGCCACAAGTTCATATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

1C
ACGTAAACGGCCACAAGTTCCTATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

1G
ACGTAAACGGCCACAAGTTCGTATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

2A
ACGTAAACGGCCACAAGTTCTAATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

2C
ACGTAAACGGCCACAAGTTCTCATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

2G
ACGTAAACGGCCACAAGTTCTGATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

3T
ACGTAAACGGCCACAAGTTCTTTTTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

3C
ACGTAAACGGCCACAAGTTCTTCTTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

3G
ACGTAAACGGCCACAAGTTCTTGTTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

4A
ACGTAAACGGCCACAAGTTCTTAATTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

4C
ACGTAAACGGCCACAAGTTCTTACTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

4G
ACGTAAACGGCCACAAGTTCTTAGTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

5A
ACGTAAACGGCCACAAGTTCTTATATCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

5C
ACGTAAACGGCCACAAGTTCTTATCTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

5G
ACGTAAACGGCCACAAGTTCTTATGTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

6A
ACGTAAACGGCCACAAGTTCTTATTACGTGGATTTATTTATGGCATCTTCTTCAAGGACG

6C
ACGTAAACGGCCACAAGTTCTTATTCCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

6G
ACGTAAACGGCCACAAGTTCTTATTGCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

8A
ACGTAAACGGCCACAAGTTCTTATTTCATGGATTTATTTATGGCATCTTCTTCAAGGACG

8T
ACGTAAACGGCCACAAGTTCTTATTTCTTGGATTTATTTATGGCATCTTCTTCAAGGACG

8C
ACGTAAACGGCCACAAGTTCTTATTTCCTGGATTTATTTATGGCATCTTCTTCAAGGACG

9A
ACGTAAACGGCCACAAGTTCTTATTTCGAGGATTTATTTATGGCATCTTCTTCAAGGACG

9C
ACGTAAACGGCCACAAGTTCTTATTTCGCGGATTTATTTATGGCATCTTCTTCAAGGACG

9G
ACGTAAACGGCCACAAGTTCTTATTTCGGGGATTTATTTATGGCATCTTCTTCAAGGACG

10A
ACGTAAACGGCCACAAGTTCTTATTTCGTAGATTTATTTATGGCATCTTCTTCAAGGACG

10T
ACGTAAACGGCCACAAGTTCTTATTTCGTTGATTTATTTATGGCATCTTCTTCAAGGACG

10C
ACGTAAACGGCCACAAGTTCTTATTTCGTCGATTTATTTATGGCATCTTCTTCAAGGACG

11A
ACGTAAACGGCCACAAGTTCTTATTTCGTGAATTTATTTATGGCATCTTCTTCAAGGACG

11T
ACGTAAACGGCCACAAGTTCTTATTTCGTGTATTTATTTATGGCATCTTCTTCAAGGACG

11C
ACGTAAACGGCCACAAGTTCTTATTTCGTGCATTTATTTATGGCATCTTCTTCAAGGACG

12T
ACGTAAACGGCCACAAGTTCTTATTTCGTGGTTTTATTTATGGCATCTTCTTCAAGGACG

12C
ACGTAAACGGCCACAAGTTCTTATTTCGTGGCTTTATTTATGGCATCTTCTTCAAGGACG

12G
ACGTAAACGGCCACAAGTTCTTATTTCGTGGGTTTATTTATGGCATCTTCTTCAAGGACG

13A
ACGTAAACGGCCACAAGTTCTTATTTCGTGGAATTATTTATGGCATCTTCTTCAAGGACG

13C
ACGTAAACGGCCACAAGTTCTTATTTCGTGGACTTATTTATGGCATCTTCTTCAAGGACG

13G
ACGTAAACGGCCACAAGTTCTTATTTCGTGGAGTTATTTATGGCATCTTCTTCAAGGACG

multiC
ACGTAAACGGCCACAAGTTCTTCCCCCCCCGATTTATTTATGGCATCTTCTTCAAGGACG

TCGCACCC_odd
ACGTAAACGGCCACAAGTTTCGCACCCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

CCTCGCAC_odd
ACGTAAACGGCCACAAGTTCCTCGCACGTGGATTTATTTATGGCATCTTCTTCAAGGACG

ACCCTCGC_odd
ACGTAAACGGCCACAAGTTACCCTCGCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

GCACCCTC_odd
ACGTAAACGGCCACAAGTTGCACCCTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG

TCGCACCC_even
ACGTAAACGGCCACAAGTATTCGCACCCGTGGATTTATTATGGCATCTTCTTCAAGGACG

CCTCGCAC_even
ACGTAAACGGCCACAAGTATCCTCGCACGTGGATTTATTATGGCATCTTCTTCAAGGACG

ACCCTCGC_even
ACGTAAACGGCCACAAGTATACCCTCGCGTGGATTTATTATGGCATCTTCTTCAAGGACG

GCACCCTC_even
ACGTAAACGGCCACAAGTATGCACCCTCGTGGATTTATTATGGCATCTTCTTCAAGGACG

EMX1_invitro
GTAGGTAGTTAGGATGAATGGAAGGTTGGTAGGCCTGAGTCCGAGCAGAAGAAGAAGGGCTCCCATCACATCAACCGGTG

FANCF_invitro
GTAGGTAGTTAGGATGAATGGAAGGTTGGTACTCATGGAATCCCTTCTGCAGCACCTGGATCGCTTTTCCGAGCTTCTGG

HEK293_site2_
GTAGGTAGTTAGGATGAATGGAAGGTTGGTAAACTGGAACACAAAGCATAGACTGCGGGGCGGGCCAGCCTGAATAGCTG

invitro

HEK293_site3_
GTAGGTAGTTAGGATGAATGGAAGGTTGGTACTTGGGGCCCAGACTGAGCACGTGATGGCAGAGGAAAGGAAGCCCTGCT

invitro

HEK293_site4_
GTAGGTAGTTAGGATGAATGGAAGGTTGGTACCGGTGGCACTGCGGCTGGAGGTGGGGGTTAAAGCGGAGACTCTGGTGC

invitro

RNF2_invitro
GTAGGTAGTTAGGATGAATGGAAGGTTGGTATGGCAGTCATCTTAGTCATTACCTGAGGTGTTCGTTGTAACTCATATAA

Primers for HTS of in vitro edited dsDNA. SEQ ID NOs: 495-503 appear from top to bottom below, respectively.

fwd_invitro_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNACGTAAACGGCCACAA

rev_invitro_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCGTCCTTGAAGAAGATGC

fwd_invitro_HEK_targets
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTAGGTAGTTAGGATGAATGGAA

rev_EMX1_invitro
TGGAGTTCAGACGTGTGCTCTTCCGATCTCACCGGTTGATGTGATGG

rev_FANCF_invitro
TGGAGTTCAGACGTGTGCTCTTCCGATCTCCAGAAGCTCGGAAAAGC

rev_HEK293_site2_invitro
TGGAGTTCAGACGTGTGCTCTTCCGATCTCAGCTATTCAGGCTGGC

rev_HEK293_site3_invitro
TGGAGTTCAGACGTGTGCTCTTCCGATCTAGCAGGGCTTCCTTTC

rev_HEK293_site4_invitro
TGGAGTTCAGACGTGTGCTCTTCCGATCTGCACCAGAGTCTCCG

rev_RNF2_invitro
TGGAGTTCAGACGTGTGCTCTTCCGATCTTTATATGAGTTACAACGAACACC

Primers for HTS of on-target and off-target sites from all mammalian cell culture experiments. SEQ ID NOs: 504-579 and 1869-1900 appear from top to bottom below, respectively.

fwd_EMX1_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCAGCTCAGCCTGAGTGTTGA

rev_EMX1_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCTCGTGGGTTTGTGGTTGC

fwd_FANCF_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCATTGCAGAGAGGCGTATCA

rev_FANCF_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGGGGTCCCAGGTGCTGAC

fwd_HEK293_site2_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCAGCCCCATCTGTCAAACT

rev_HEK293_site2_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTTGAATGGATTCCTTGGAAACAATGA

fwd_HEK293_site3_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNATGTGGGCTGCCTAGAAAGG

rev_HEK293_site3_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCCCAGCCAAACTTGTCAACC

fwd_HEK293_site4_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGAACCCAGGTAGCCAGAGAC

rev_HEK293_site4_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTTCCTTTCAACCCGAACGGAG

fwd_RNF2_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCTCTTCTTTATTTCCAGCAATGT

rev_RNF2_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGTTTTCATGTTCTAAAAATGTATCCCA

fwd_p53_Y163C_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTACAGTACTCCCCTGCCCTC

rev_p53_Y163C_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGCTGCTCACCATCGCTATCT

fwd_p53_N239D_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCTCATCTTGGGCCTGTGTT

rev_p53_N239D_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTAAATCGGTAAGAGGTGGGCC

fwd_APOE4_C158R_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGCGGACATGGAGGACGTG

rev_APOE4_C158R_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCTGTTCCACCAGGGGCCC

fwd_EMX1_off1_HIS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTGCCCAATCATTGATGCTTTT

rev_EMX1_off1_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTAGAAACATTTACCATAGACTATCACCT

fwd_EMX1_off2_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAGTAGCCTCTTTCTCAATGTGC

rev_EMX1_off2_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGCTTTCACAAGGATGCAGTCT

fwd_EMX1_off3_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTNNNNGAGCTAGACTCCGAGGGGA

rev_EMX1_off3_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTTCCTCGTCCTGCTCTCACTT

fwd_EMX1_off4_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAGAGGCTGAAGAGGAAGACCA

rev_EMX1_off4_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGGCCCAGCTGTGCATTCTAT

fwd_EMX1_off5_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCAAGAGGGCCAAGTCCTG

rev_EMX1_off5_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCAGCGAGGAGTGACAGCC

fwd_EMX1_off7_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCACTCCACCTGATCTCGGGG

rev_EMX1_off7_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCGAGGAGGGAGGGAGCAG

fwd_EMX1_off8_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNACCACAAATGCCCAAGAGAC

rev_EMX1_off8_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGACACAGTCAAGGGCCGG

fwd_EMX1_off9_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCCACCTTTGAGGAGGCAAA

rev_EMXl_off9_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTTTCCATCTGAGAAGAGAGTGGT

fwd_EMX1_off10_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTCATACCTTGGCCCTTCCT

rev_EMX1_off10_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTTCCCTAGGCCCACACCAG

fwd_FANCF_off1_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAACCCACTGAAGAAGCAGGG

rev_FANCF_off1_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGGTGCTTAATCCGGCTCCAT

fwd_FANCF_off2_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTCCAGTGTTTCCATCCCGAA

rev_FANCF_off2_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCCTCTGACCTCCACAACTCT

fwd_FANCF_off3_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCTGGGTACAGTTCTGCGTGT

rev_FANCF_off3_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTTCACTCTGAGCATCGCCAAG

fwd_FANCF_off4_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTTTAGAGCCAGTGAACTAGAG

rev_FANCF_off4_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGCAAGACAAAATCCTCTTTATACTTTG

fwd_FANCF_off5_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGGGAGGGGACGGCCTTAC

rev_FANCF_off5_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGCCTCTGGCGAACATGGC

fwd_FANCF_off6_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTCCTGGTTAAGAGCATGGGC

rev_FANCF_off6_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGATTGAGTCCCCACAGCACA

fwd_FANCF_off7_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCAGTGTTTCCCATCCCCAA

rev_FANCF_off7_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTTGACCTCCACAACTGGAAAAT

fwd_FANCF_off8_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGCTTCCAGACCCACCTGAAG

rev_FANCF_off9_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTACCGAGGAAAATTGCTTGTCG

fwd_HEK293_site2_off1_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTGTGGAGAGTGAGTAAGCCA

rev_HEK293_site2_off1_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTACGGTAGGATGATTTCAGGCA

fwd_HEK293_site2_off2_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCACAAAGCAGTGTAGCTCAGG

rev_HEK293_site2_off2_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTTTTTTGGTACTCGAGTGTTATTCAG

fwd_HEK293_site3_off1_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTCCCCTGTTGACCTGGAGAA

rev_HEK293_site3_off1_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCACTGTACTTGCCCTGACCA

fwd_HEK293_site3_off2_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTTGGTGTTGACAGGGAGCAA

rev_HEK293_site3_off2_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCTGAGATGTGGGCAGAAGGG

fwd_HEK293_site3_off3_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTGAGAGGGAACAGAAGGGCT

rev_HEK293_site3_off3_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGTCCAAAGGCCCAAGAACCT

fwd_HEK293_site3_off4_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTCCTAGCACTTTGGAAGGTCG

rev_HEK293_site3_off4_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGCTCATCTTAATCTGCTCAGCC

fwd_HEK293_site3_off5_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAAAGGAGCAGCTCTTCCTGG

rev_HEK293_site3_off5_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGTCTGCACCATCTCCCACAA

fwd_HEK293_site4_off1_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGGCATGGCTTCTGAGACTA

rev_HEK293_site4_off1_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGTCTCCCTTGCACTCCCTGTCTTT

fwd_HEK293_site4_off2_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTTTGGCAATGGAGGCATTGG

rev_HEK293_site4_off2_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGAAGAGGCTGCCCATGAGAG

fwd_HEK293_site4_off3_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTCTGAGGCTCGAATCCTG

rev_HEK293_site4_off3_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCTGTGGCCTCCATATCCCTG

fwd_HEK293_site4_off4_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTTTCCACCAGAACTCAGCCC

rev_HEK293_site4_off4_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCCTCGGTTCCTCCACAACAC

fwd_HEK293_site4_off5_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCACGGGAAGGACAGGAGAAG

rev_HEK293_site4_off5_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGCAGGGGAGGGATAAAGCAG

fwd_HEK293_site4_off6_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCACGGGAGATGGCTTATGT

rev_HEK293_site4_off6_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCACATCCTCACTGTGCCACT

fwd_HEK293_site4_off7_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTCAGTCTCGGCCCCTCA

rev_HEK293_site4_off7_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGCCACTGTAAAGCTCTTGGG

fwd_HEK293_site4_off8_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAGGGTAGAGGGACAGAGCTG

rev_HEK293_site4_off8_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGGACCCCACATAGTCAGTGC

fwd_HEK293_site4_off9_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGCTGTCAGCCCTATCTCCATC

rev_HEK293_site4_off9_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTTGGGCAATTAGGACAGGGAC

fwd_HEK293_site4_off10_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGCAGCGGAGGAGGTAGATTG

rev_HEK293_site4_off10_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCTCAGTACCTGGAGTCCCGA

fwd_HEK2_ChIP_off1_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGACAGGCTCAGGAAAGCTGT

rev_HEK2_ChIP_off1_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTACACAAGCCTTTCTCCAGGG

fwd_HEK2_ChIP_off2_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAATAGGGGGTGAGACTGGGG

rev_HEK2_ChIP_off2_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTGCCTCAGACGAGACTTGAGG

fwd_HEK2_ChIP_off3_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGGCCAGCAGGAAAGGAATCT

rev_HEK2_ChIP_off3_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTTGACTGCACCTGTAGCCATG

fwd_HEK2_ChIP_off4_HTS
ACACTCTTTCCGTACACGACGCTCTTCCGATCTNNNNTCAAGGAAATCACCCTGCCC

rev_HEK2_ChIP_off4_HTS
TGGAGTTCAGACGTGTGGTCTTCCGATCTAACTTCCTTGGTGTGCAGCT

fwd_HEK2_ChIP_off5_HTS
ACACTCTTTCCGTACACGACGCTCTTCCGATCTNNNNATGGGCTCAGCTACGTCATG

rev HEK2 ChIP off5 HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTAATAGCAGTGTGGTGGGCAA

fwd_HEK3_ChIP_off1_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCGCACATCCCTTGTCTCTCT

rev_HEK3_ChIP_off1_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCTACTGGAGCACACCCCAAG

fwd_HEK3_ChIP_off2_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTGGGTCACGTAGCTTTGGTC

rev_HEK3_ChIP_off2_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTTGGTGGCCATGTGCAACTAA

fwd_HEK3_ChIp_off3_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCTACTACGTGCCAGCTCAGG

rev_HEK3_ChIP_off3_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTACCTCCCCTCCTCACTAACC

fwd_HEK3_ChIP_off4_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGCCTCAGCTCCATTTCCTGT

rev_HEK3_ChIP_off4_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTAACCTTTATGGCACCAGGGG

fwd_HEK3_ChIP_off5_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGAGCTCAGCATTAGCAGGCT

rev_HEK3_ChIP_off5_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTTTCCTGGCTTTCCGATTCCC

fwd_HEK4_ChIP_off1_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTGCAATTGGAGGAGGAGCT

rev_HEK4_ChIP_off1_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCACCAGCTACAGGCAGAACA

fwd_HEK4_ChIP_off3_HTS
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCTACCCCCAACAGAGATGG

rev_HEK4_ChIP_off3_HTS
TGGAGTTCAGACGTGTGCTCTTCCGATCTCCACACAACTCAGGTCCTCC

Sequences of Single-Stranded Oligonucleotide Donor Templates (ssODNs) Used in HDR Studies.

EMX1 sense

(SEQ ID NO: 580)

TCATCTGTGCCCCTCCCTCCCTGGCCCAGGTGAAGGTGTGGTTCCAGAAC

CGGAGGACAAAGTACAAACGGCAGAAGCTGGAGGAGGAAGGGCCTGAGTT

TGAGCAGAAGAAGAAGGGCTCCCATCACATCAACCGGTGGCGCATTGCCA

CGAAGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAGGGT

EMX1 antisense

(SEQ ID NO: 581)

ACCCTAGTCATTGGAGGTGACATCGATGTCCTCCCCATTGGCCTGCTTCG

TGGCAATGCGCCAGCGGTTGATGTGATGGGAGCCCTTCTTCTTCTGCTCA

AACTGAGGCCGTTCCTCCTCCAGCTTCTGCCGTTTGTACTTTGTCCTCCG

GTTCTGGAACCACACCTTCACCTGGGCCAGGGAGGGAGGGGCACAGATGA

HEK293 site 3 sense

(SEQ ID NO: 582)

CATGCAATTAGTCTATTTCTGCTGCAAGTAAGCATGCATTTGTAGGCTTG

ATGCTTTTTTTCTGCTTCTCCAGCCCTGGCCTGGGTCAATCCTTGGGGCT

TAGACTGAGGACGTGATGGCAGAGGAAAGGAAGCCCTGCTTCCTCCAGAG

GGCGTCGCAGGACAGCTTTTCCTAGACAGGGGCTAGTATGTGCAGCTCCT

HEK293 site 3 antisense

(SEQ ID NO: 583)

AGGAGCTGCACATACTAGCCCCTGTCTAGGAAAAGCTGTCCTGGGACGCC

CTCTGGAGGAAGCAGGGCTTCCTTTCCTCTGCCATCACGTGCTCAGTCTA

AGCCCCAAGGATTGACCCAGGCCAGGGCTGGAGAAGCAGAAAAAAAGCAT

GAAGCCTACAAATGCATGCTTAGTTGCAGCAGAAATAGACTAATTGCATG

HEK site 4 sense

(SEQ ID NO: 584)

GGCTGACAAAGGCCGGGCTGGGTGGAAGGAAGGGAGGAAGGGCGAGGCAG

AGGGTCCAAAGCAGGATGACAGGCAGGGGCACCGCGGCGCCCCGGTGGCA

TTGCGGCTGGAGGTGGGGGTTAAAGCGGAGACTCTGGTGCTGTGTGACTA

CAGTGGGGGCCCTGCCCTCTCTGAGCCCCCGCCTCCAGGCCTGTGTGTGT

HEK site 4 antisense

(SEQ ID NO: 585)

ACACACACAGGCCTGGAGGCGGGGGCTCAGAGAGGGCAGGGCCCCCACTG

TAGTCACACAGCACCAGAGTCTCCGCTTTAACCCCCACCTCCAGCCGCAA

TGCCACCGGGGCGCCGCGGTGCCCCTGCCTGTCATCCTGCTTTGGACCCT

CTGCCTCGCCCTTCCTCCCTTCCTTCCACCCAGCCCGGCCTTTGTCAGCC

APOE4 sense

(SEQ ID NO: 743)

AGCACCGAGGAGCTGCGGGTGCGCCTCGCCTCCCACCTGCGCAAGCTGCG

TAAGCGGCTCCTCCGCGATGCCGATGACCTGCAGAAGTGCCTGGCAGTGT

ACCAGGCCGGGGCCCGCGAGGGCGCCGAGCGCGGCCTCAGCGCCATCCGC

GAGCGCCTGGGGCCCCTGGTGGAACAGGGCCGCGTGCGGGCCGCCACTGT

APOE4 antisense

(SEQ ID NO: 744)

ACAGTGGCGGCCCGCACGCGGCCCTGTTCCACCAGGGGCCCCAGGCGCTC

GCGGATGGCGCTGAGGCCGCGCTCGGCGCCCTCGCGGGCCCCGGCCTGGT

ACACTGCCAGGCACTTCTGCAGGTCATCGGCATCGCGGAGGAGCCGCTTA

CGCAGCTTGCGCAGGTGGGAGGCGAGGCGCACCCGCAGCTCCTCGGTGCT

p53 Y163C sense

(SEQ ID NO: 745)

ACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAGACCTGCCCT

GTGCAGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGC

CATGGCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCT

GCCCCCACCATGAGCGCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTG

p53 Y163C antisense

(SEQ ID NO: 746)

CAGCCCCAGCTGCTCACCATCGCTATCTGAGCAGCGCTCATGGTGGGGGC

AGCGCCTCACAACCTCCGTCATGTGCTGTGACTGCTTGTAGATGGCCATG

GCGCGGACGCGGGTGCCGGGCGGGGGTGTGGAATCAACCCACAGCTGCAC

AGGGCAGGTCTTGGCCAGTTGGCAAAACATCTTGTTGAGGGCAGGGGAGT

Deaminase Gene gBlocks Gene Fragments

hAID

(SEQ ID NO: 586)

CATCCTTGGTACCGAGCTCGGATCCAGCCACCATGGATAGCCTCTTGATG

AATAGACGCAAGTTCCTGTATCAGTTTAAAAACGTGAGATGGGCAAAAGG

CCGACGAGAGACATATCTGTGCTATGTCGTTAAGCGCAGAGATTCAGCCA

CCAGTTTCTCTCTCGACTTCGGCTACCTGCGGAACAAGAATGGTTGCCAT

GTTGAGCTCCTGTTCCTGAGGTATATCAGCGACTGGGATTTGGACCCAGG

GCGGTGCTATAGGGTGACATGGTTTACCTCCTGGTCACCTTGTTATGACT

GCGCGCGGCATGTTGCCGATTTTCTGAGAGGGAACCCTAACCTGTCTCTG

AGGATCTTCACCGCGCGACTGTACTTCTGTGAGGACCGGAAAGCCGAACC

CGAGGGACTGAGACGCCTCCACAGAGCGGGTGTGCAGATTGCCATAATGA

CCTTTAAGGACTACTTCTACTGCTGGAACACCTTCGTCGAAAATCACGAG

CGGACTTTCATGGCTTGGGAAGGATTGCATGAAAACAGCGTCAGGCTCCA

GGCAGCTTCGCCGCATTCTTCTCCCGTTGTACGAGGTTGATGACCTCAGA

GATGCCTTTAGAACACTGGGACTGTAGGCGGCCGCTCGATTGGTTTGGTG

TGGCTCTAA

rAPOBEC1 (mammalian)

(SEQ ID NO: 587)

CATCCTTGGTACCGAGCTCGGATCCAGCCACCATGAGCTCAGAGACTGGC

CCAGTGGCTGTGGACCCCACATTGAGACGGCGGATCGAGCCCCATGAGTT

TGAGGTATTCTTCGATCCGAGAGAGCTCCGCAAGGAGACCTGCCTGCTTT

ACGAAATTAATTGGGGGGGCCGGCACTCCATTTGGCGACATACATCACAG

AACACTAACAAGCACGTCGAAGTCAACTTCATCGAGAAGTTCACGACAGA

AAGATATTTCTGTCCGAACACAAGGTGCAGCATTACCTGGTTTCTCAGCT

GGAGCCCATGCGGCGAATGTAGTAGGGCCATCACTGAATTCCTGTCAAGG

TATCCCCACGTCACTCTGTTTATTTACATCGCAAGGCTGTACCACCACGC

TGACCCCCGCAATCGACAAGGCCTGCGGGATTTGATCTCTTCAGGTGTGA

CTATCCAAATTATGACTGAGCAGGAGTCAGGATACTGCTGGAGAAACTTT

GTGAATTATAGCCCGAGTAATGAAGCCCACTGGCCTAGGTATCCCCATCT

GTGGGTACGACTGTACGTTCTTGAACTGTACTGCATCATACTGGGCCTGC

CTCCTTGTCTCAACATTCTGAGAAGGAAGCAGCCACAGCTGACATTCTTT

ACCATCGCTCTTCAGTCTTGTCATTACCAGCGACTGCCCCCACACATTCT

CTGGGCCACCGGGTTGAAATGAGCGGCCGCTCGATTGGTTTGGTGTGGCT

CTAA

pmCDA1

(SEQ ID NO: 588)

CATCCTTGGTACCGAGCTCGGATCCAGCCACCATGACAGACGCTGAATAT

GTTAGGATCCATGAAAAACTGGATATCTATACATTTAAGAAGCAGTTCTT

CAATAACAAAAAGTCAGTATCTCACAGATGCTATGTCCTGTTCGAACTCA

AGAGAAGAGGAGAAAGGCGGGCCTGTTTCTGGGGGTACGCGGTTAATAAA

CCCCAGTCOGGGACCGAGAGGGGGATTCACGCCGAGATCTTTTCAATTAG

GAAGGTTGAAGAGTATCTTCGCGACAATCCCGGTCAGTTCACAATTAACT

GGTACAGCTCCTGGAGCCCTTGCGCTGATTGCGCCGAGAAAATACTCGAA

TGGTACAACCAGGAGTTGAGAGGCAATGGCCACACTCTCAAGATTTGGGC

TTGCAAGCTTTACTACGAGAAGAACGCGAGAAATCAGATTGGCTTGTGGA

ACCTCAGGGACAACGGGGTCGGGTTGAATGTTATGGTGTCCGAACATTAC

CAGTGCTGTAGAAAGATCTTCATTCAGTCCAGTCACAATCAGCTGAACGA

GAACAGATGGCTGGAGAAAACACTGAAACGGGCAGAGAAAAGGCGCTCAG

AGCTGAGTATCATGATCCAGGTCAAAATCCTGCATACAACCAAAAGCCCG

GCTGTATAAGCGGCCGCTCGATTGGTTTGGTGTGGCTCTAA

haPOBEC3G

(SEQ ID NO: 589)

CATCCTTGGTACCGAGCTCGGATCCAGCCACCATGGAGCTGAAGTATCAC

CCTGAGATGCGGTTTTTCCACTGGTTTAGTAAGTGGCGCAAACTTCATCG

GGATCAGGAGTATGAAGTGACCTGGTATATCTCTTGGTCTCCCTGCACAA

AATGTACACGCGACATGGCCACATTTCTGGCCGAGGATCCAAAGGTGACG

CTCACAATCTTTGTGGCCCGCCTGTATTATTTCTGGGACCCGGATTATCA

GGAGGCACTTAGGTCATTGTGCCAAAAGCGCGACGGACCACGGGCGACTA

TGAAAATCATGAATTATGACGAATTCCAGCATTGCTGGAGTAAGTTTGTG

TACAGCCAGCGGGAGCTGTTCGAGCCCTGGAACAATCTTCCCAAGTACTA

CATACTGCTTCACATTATGTTGGGGGAGATCCTTCGGCACTCTATGGATC

CTCCTACCTTTACGTTTAACTTTAATAATGAGCCTTGGGTTCGCGGGCGC

CATGAAACCTATTTGTGCTACGAGGTCGAGCGGATGCATAATGATACGTG

GGTCCTGCTGAATCAGAGGAGGGGGTTTCTGTGTAACCAGGCTCCACATA

AACATGGATTTCTCGAGGGGCGGCACGCCGAACTGTGTTTCCTTGATGTG

ATACCTTTCTGGAAGCTCGACCTTGATCAAGATTACAGGGTGACGTGTTT

CACCTCCTGGTCACCCTGCTTCAGTTGCGCCCAAGAGATGGCTAAATTTA

TCAGTAAGAACAAGCATGTGTCCCTCTGTATTTTTACAGCCAGAATTTAT

GATGACCAGGGCCGGTGCCAGGAGGGGCTGCGGACACTCGCTGAGGCGGG

CGCGAAGATCAGCATAATGACATACTCCGAATTCAAACACTGTTGGGACA

CTTTTGTGGACCACCAGGGCTGCCCATTTCAGCCGTGGGATGGGCTCGAC

GAACATAGTCAGGATCTCTCAGGCCGGCTGCGAGCCATATTGCAGAACCA

GGAGAATTAGGCGGCCGCTCGATTGGTTTGGTGTGGCTCTAA

rAPOBEC1(E. Coli)

(SEQ ID NO: 590)

GGCCGGGGATTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATAC

CATGGATGTCTTCTGAAACCGGTCCGGTTGCGGTTGACCCGACCCTGCGT

CGTCGTATCGAACCGCACGAATTCGAAGTTTTCTTCGACCCGCGTGAAC|

GCGTAAAGAAACCTGCCTGCTGTACGAAATCAACTGGGGTGGTCGTCACT

CTATCTGGCGTCACACCTCTCAGAACACCAACAAACACGTTGAAGTTAAC

TTCATCGAAAAATTCACCACCGAACGTTACTTCTGCCCGAACACCCGTTG

CTCTATCACCTGGTTCCTGTCTTGGTCTCCGTGCGGTGAATGCTCTCGTG

CGATCACCGAATTCCTGTCTCGTTACCCGCACGTTACCCTGTTCATCTAC

ATCGCGCGTCTGTACCACCACGCGGACCCGCGTAACCGTCAGGGTCTGCG

TGACCTGATCTCTTCTGGTGTTACCATCCAGATCATGACCGAACAGGAAT

CTGGTTACTGCTGGCGTAACTTCGTTAACTACTCTCCGTCTAACGAAGCG

CACTGGCCGCGTTACCCGCACCTGTGGGTTCGTCTGTACGTTCTGGAACT

GTACTGCATCATCCTGGGTCTGCCGCCGTGCCTGAACATCCTGCGTCGTA

AACAGCCGCAGCTGACCTTCTTCACCATCGCGCTGCAGTCTTGCCACTAC

CAGCGTCTGCCGCCGCACATCCTGTGGGCGACCGGTCTGAAAGGTGGTAG

TGGAGGGAGCGGCGGTTCAATGGATAAGAAATAC

Amino Acid Sequences of NBE1, NBE2, and NBE3.

NBE1 for E. Coli expression (His6-rAPOBEC1-XTEN-dCas9)

(SEQ ID NO: 591)

MGSSHHHHHHMSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSRNRHTSQNTN

KHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYHHADPRNRQGL

RDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQPQ

LTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSK

KFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL

EESFLVEEDK|KHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDL

NPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSL

GLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSA

SMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL

VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRF

AWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTE

GMRKPAFLSGEQKKAIVDLLFKTNRKVTVQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDK

DFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQS

GKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDEL

VKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQ

NGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQL

LNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLK

SKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIG

KATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQT

GGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSS

FEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKL

KGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNL

GAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSPKKKRKV

NBE1 for Mammalian expression (rAPOBEC1-XTEN-dCas9-NLS)

(SEQ ID NO: 592)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNTNKHVEVNFIEKF

TTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQ

IMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSC

HYQRLPPHILWATGLKSGSETPGTSESATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDR

HSIKKNLIGALLFDSGETAEAT|RLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKK

HERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLF

IQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDL

AEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQ

DLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQ

RTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITP

WNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQ

KKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILE

DIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFA

NRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVI

EMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDI

NRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNL

TKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQF

YKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIM

NFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRN

SDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKG

YKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSFEDNEQKQL

FVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSPKKKRKV

Alternative NBE1 for Mammalian expression with human APOBEC1 (hAPOBEC1-XTEN-

dCas9-NLS)

(SEQ ID NO: 5737)

MTSEKGPSTGDPTLRRRIEPWEFDVFYDPRELRKEACLLYEIKWGMSRKIWRSSGKNTTN

HVEVNFIKKFTSERDFHPSMSCSITWFLSWSPCWECSQAIREFLSRHPGVTLVIYVARLFW

HMDQQNRQGLRDLVNSGVTIQIMRASEYYHCWRNFVNYPPGDEAHWPQYPPLWMMLY

ALELHCIILSLPPCLKISRRWQNHLTFFRLHLQNCHYQTIPPHILLATGLIHPSVAWRGSETP

GTSESATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALL

FDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKK

HERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGD

LNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKK

NGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAA

KNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQ

SKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIH

LGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPW

NFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMR

KPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYH

DLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRY

TGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQ

GDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQK

NSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSD

YDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQ

RKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVK

VITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDY

KVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVW

DKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGG

FDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKD

LIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNE

QKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTL

TNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSPKKK

RKV

NBE2 (rAPOBEC1-XTEN-dCas9-UGI-NLS)

(SEQ ID NO: 593)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNTNKHVEVNFIEKF

TTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQ

IMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSC

HYQRLPPHILWATGLKSGSETPGTSESATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDR

HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKK

HERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLF

IQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDL

AEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQ

DLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQ

RTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITP

WNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQ

KKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILE

DIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFA

NRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVI

EMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDI

NRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNL

TKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQF

YKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIM

NFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRN

SDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKG

YKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQL

FVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIG

NKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGGSPKKKRKV

NBE3 (rAPOBEC1-XTEN-Cas9n-UGI-NLS)

(SEQ ID NO: 594)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNTNKHVEVNFIEKF

TTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTTQ

IMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSC

HYQRLPPHILWATGLKSGSETPGTSESATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDR

HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKK

HERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLF

IQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDL

AEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQ

DLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQ

RTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETFP

WNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQ

KKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILE

DIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFA

NRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTNKVVDELVKVMGRHKPENIVI

EMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDI

NRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNL

TKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQF

YKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIM

NFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRN

SDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKG

YKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQL

FVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESIMLPEEVEEVIG

NKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGGSPKKKRKV

pmCDA1-XTEN-dCas9-UGI (bacteria)

(SEQ ID NO: 5742)

MTDAEYVRIHEKLDIYTFKKQFFNNKKSVSHRCYVLFELKRRGERRACFWGYAVNKPQS

GTERGIHAEIFSIRKVEEYLRDNPGQFTINWYSSWSPCADCAEKILEWYNQELRGNGHTL

KIWACKLYYEKNARNQIGLWNLRDNGVGLNVMVSEHYQCCRKIFIQSSHNQLNENRWL

EKTLKRAEKRRSELSIMIQVKILHTTKSPAVSGSETPGTSESATPESDKKYSIGLAIGTNSV

GWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRK

NRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYH

LRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFE

ENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLA

EDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS

MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILE

KMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEK

ILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLP

NEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVK

QLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLT

LFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLK

SDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVV

DELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENT

QLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKN

RGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL

VETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNY

HHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS

NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ

TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSV

KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQ

KGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVIL

ADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEV

LDATLIHQSITGLYETRIDLSQLGGDSGGSMTNLSDIIEKETGKQLVIQESILMLPEEVEEVI

GNKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKML

pmCDA1-XTEN-nCas9-UGI-NLS (mammalian construct)

(SEQ ID NO: 5743)

MTDAEYVRIHEKLDIYTFKKQFFNNKKSVSHRCYVLFELKRRGERRACFWGYAVNKPQS

GTERGIHAEIFSIRKVEEYLRDNPGQFTINWYSSWSPCADCAEKILEWYNQELRGNGHTL

KIWACKLYYEKNARNQIGLWNLRDNGVGLNVMVSEHYQCCRKIFIQSSHNQLNENRWL

EKTLKRAEKRRSELSIMIQVKILHTTKSPAVSGSETPGTSESATPESDKKYSIGLAIGTNSV

GWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRK

NRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYH

LRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFE

ENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLA

EDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS

MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILE

KMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEK

ILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLP

NEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVK

QLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLT

LFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLK

SDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVV

DELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENT

QLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKN

RGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL

VETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNY

HHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS

NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ

TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSV

KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQ

KGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVIL

ADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEV

LDATLIHQSITGLYETRIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIG

NKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGGSPKKKR

KV

huAPOBEC3G-XTEN-dCas9-UGI (bacteria)

(SEQ ID NO: 5744)

MDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHGFLE

GRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCIFTARIY

DDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGR

LRAILQSGSETPGTSESATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDR

HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL

EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMI

KFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLE

NLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIG

DQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL

PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRT

FDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMT

RKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTK

VKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDR

FNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKV

MKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKED

IQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMAREN

QTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQ

ELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ

LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDE

NDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLE

SEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETN

GETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKD

WDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAK

GYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKL

KGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA

ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD

SGGSMTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLL

TSDAPEYKPWALVIQDSNGENKIKML

huAPOBEC3G-XTEN-nCas9-UGI-NLS (mammalian construct)

(SEQ ID NO: 5745)

MDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHGFLE

GRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCIFTARIY

DDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGR

LRAILQSGSETPGTSESATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDR

HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL

EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMI

KFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLE

NLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIG

DQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL

PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRT

FDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMT

RKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTK

VKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDR

FNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKV

MKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKED

IQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMAREN

QTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQ

ELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ

LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDE

NDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLE

SEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETN

GETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKD

WDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAK

GYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKL

KGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA

ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD

SGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLT

SDAPEYKPWALVIQDSNGENKIKMLSGGSPKKKRKV

huAPOBEC3G(D316R_D317R)-XTEN-nCas9-UGI-NLS (mammalian construct)

(SEQ ID NO: 5746)

MDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHGFLE

GRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCIFTARIY

RRQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGR

LRAILQSGSETPGTSESATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDR

HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL

EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMI

KFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLE

NLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIG

DQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL

PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRT

FDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMT

RKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTK

VKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDR

FNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKV

MKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKED

IQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMAREN

QTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQ

ELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ

LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDE

NDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLE

SEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETN

GETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKD

WDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAK

GYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKL

KGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA

ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD

SGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLT

SDAPEYKPWALVIQDSNGENKIKMLSGGSPKKKRKV

Base Calling Matlab Script

(SEQ ID NO: 595)

WTnuc = ′GCGGACATGGAGGACGTGCGCGGCCGCCTGGTGCAGTACCG

CGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGCTGCGGGTGC

GCCTCGCCTCCCACCTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGATGCC

GATGACCTGCAGAAGCGCCTGGCAGTGTACCAGGCCGGGGCCCGCGAGGG

CGCCGAGCGCGGCCTCAGCGCCATCCGCGAGCGCCTGGGGCCCCTGGTGG

AACAG′;

%cycle through fastq files for different samples files=dir(‘*.fastq’);

for d=1:20

filename=files(d).name;

%read fastq file

[header,seqs,qscore]=fastqread(filename);

seqsLength=length(seqs); % number of sequences seqsFile=

strrep(filename,‘.fastq’,”); % trims off .fastq

%create a directory with the same name as fastq file ifexist(seqsFile,‘dir’);

error(‘Directory already exists. Please rename or move it before moving on.’);

end

mkdir(seqsFile); % make directory

wtLength=length(WTnuc); % length of wildtype sequence

%% aligning back to the wildtype nucleotide sequence

%

% A1N is a matrix of the nucleotide alignment window=1:wtLength;

sBLength=length(seqs); % number of sequences

% counts number of skips nSkips = 0;

ALN=repmat(“,[sBLengthwtLength]);

% iterate through each sequencing read for i = 1:sBLength

%If you only have forward read fastq files leave as is

%If you have R1 foward and R2 is reverse fastq files uncomment the

%next four lines of code and the subsequent end statement

% ifmod(d,2)==0;

% reverse=seqrcomplement(seqs{i});

% [score,alignment,start]=

swalign(reverse,WTnuc,‘Alphabet’,‘NT’);

% else

[score,alignment,start]=swalign(seqs{i},WTnuc,‘Alphabet’,‘NT’);

% end

% length of the sequencing read len=

length(alignment(3,:));

% if there is a gap in the alignment, skip = 1 and we will

% throw away the entire read skip = 0;

for j = 1:len

if (alignment(3,j)==‘−‘∥alignment(1,j)==’−’) skip = 1;

break;

end

%in addition if the qscore for any given base in the read is

%below 31 the nucleotide is turned into an N (fastq qscores that are not letters)

ifisletter(qscore{i}(start(1)+j−1)) else

alignment(1,j)=‘N’;

end

end

if skip == 0 && len>10

ALN(i, start(2):(start(2)+length(alignment)−1))=alignment(1,:);

end

end

% with the alignment matrices we can simply tally up the occurrences of

% each nucleotide at each column in the alignment these

% tallies ignore bases annotated as N

% due to low qscores

TallyNTD=zeros(5,wtLength); fori=1:wtLength

TallyNTD(:,i)=[sum(ALN(:,i)=‘A’),sum(ALN(:,i)==‘C’),sum(ALN(:,i)==‘G’),sum(A

LN(:,i)==‘T’),sum(ALN(:,i)==‘N’)];

end

% we then save these tally matrices in the respective folder for

% further processing

save(strcat(seqsFile,‘/TallyNTD’),‘TallyNTD’); dlmwrite(strcat(seqsFile,‘/TallyNTD.txt’),TallyNTD,‘precision’,

‘%.3f’,‘newline’,‘pc’); end

INDEL Detection Matlab Script

%cycle through fastq files for different samples files=dir(‘*.fastq’);

%specify start and width of indel window as well as length of each flank indelstart=154;

width=30; flank=10;

for d=1:3

filename=files(d).name;

%read fastq file

[header,seqs,qscore]=fastqread(filename);

seqsLength=length(seqs); % number of sequences seqsFile

=strcat(strrep(filename,‘.fastq’,”),‘_INDELS’);

%create a directory with the same name as fastq file+_INDELS ifexist(seqsFile,‘dir’);

error(‘Directory already exists. Please rename or move it before moving on.’);

end

mkdir(seqsFile); % make directory

wtLength = length(WTnuc); % length of wildtype sequence sBLength =

length(seqs); % number of sequences

% initialize counters and cell arrays

nSkips = 0; notINDEL=0;

ins={ };

dels={ }; NumIns=0;

NumDels=0;

% iterate through each sequencing read for i = 1:sBLength

%search for 10BP sequences that should flank both sides of the “INDEL WINDOW”

windowstart=strfind(seqs{i},WTnuc(indelstart−flank:indelstart));

windowend=strfind(seqs {i},WTnuc(indelstart+width:indelstart+width+flank

));

%if the flanks are found proceed

iflength(windowstart)==1 && length(windowend)==1

%if the sequence length matches the INDEL window length save as

%not INDEL

if windowend−windowstart==width+flank notINDEL=notINDEL+1;

%if the sequence is two or more bases longer than the INDEL

%window length save as an Insertion

elseif windowend−windowstart>=width+flank+2 NumIns=NumIns+1;

ins {NumIns}=seqs{i};

%if the sequence is two or more bases shorter than the INDEL

%window length save as a Deletion

elseif windowend−windowstart<=width+flank−2 NumDels=NumDels+1;

dels {NumDels}=seqs {i};

%keep track of skipped sequences that are either one base

%shorter or longer than the INDEL window width else

nSkips=nSkips+1;

end

%keep track of skipped sequences that do not possess matching flank

%sequences else

nSkips=nSkips+1;

end

end

fid=fopen(strcat(seqsFile,‘/summary.txt’),‘wt’);

fprintf(fid, ‘Skipped reads %i\n not INDEL %i\n Insertions %i\n Deletions

%i\n’, [nSkips, notINDEL, NumIns, NumDels]); fclose(fid);

save(strcat(seqsFile,‘/nSkips’),‘nSkips’); save(strcat(seqsFile,‘/notINDEL’),‘notINDEL’);

save(strcat(seqsFile,‘/NumIns’),‘NumIns’); save(strcat(seqsFile,‘/NumDels’),‘NumDels’);

save(strcat(seqsFile,‘/dels’),‘dels’);

C = dels;

fid = fopen(strcat(seqsFile,‘/dels.txt’),‘wt’); fprintf(fid,‘“%s”\n’,C{:});

fclose(fid);

save(strcat(seqsFile,‘/ins’),‘ins’); C = ins;

fid = fopen(strcat(seqsFile, ‘/ins.txt’),‘wt’); fprintf(fid,‘“%s”\n’,C{:});

fclose(fid);

end

Example 5: Cas9 Variant Sequences

The disclosure provides Cas9 variants, for example Cas9 proteins from one or more organisms, which may comprise one or more mutations (e.g., to generate dCas9 or Cas9 nickase). In some embodiments, one or more of the amino acid residues, identified below by an asterek, of a Cas9 protein may be mutated. In some embodiments, the D10 and/or H840 residues of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, are mutated. In some embodiments, the D10 residue of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, is mutated to any amino acid residue, except for D. In some embodiments, the D10 residue of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, is mutated to an A. In some embodiments, the H840 residue of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 11-260, is an H. In some embodiments, the H840 residue of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, is mutated to any amino acid residue, except for H. In some embodiments, the H840 residue of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, is mutated to an A. In some embodiments, the D10 residue of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 11-260, is a D.

A number of Cas9 sequences from various species were aligned to determine whether corresponding homologous amino acid residues of D10 and H840 of SEQ ID NO: 10 or SEQ ID NO: 11 can be identified in other Cas9 proteins, allowing the generation of Cas9 variants with corresponding mutations of the homologous amino acid residues. The alignment was carried out using the NCBI Constraint-based Multiple Alignment Tool (COBALT (accessible at st-va.ncbi.nlm.nih.gov/tools/cobalt), with the following parameters. Alignment parameters: Gap penalties −11,−1; End-Gap penalties −5,−1. CDD Parameters: Use RPS BLAST on; Blast E-value 0.003; Find Conserved columns and Recompute on. Query Clustering Parameters: Use query clusters on; Word Size 4; Max cluster distance 0.8; Alphabet Regular.

An exemplary alignment of four Cas9 sequences is provided below. The Cas9 sequences in the alignment are: Sequence 1 (S1): SEQ ID NO: 11|WP_010922251|gi 499224711|type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]; Sequence 2 (S2): SEQ ID NO: 12|WP_039695303|gi 746743737|type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus gallolyticus]; Sequence 3 (S3): SEQ ID NO: 13|WP_045635197|gi 782887988|type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mitis]; Sequence 4 (S4): SEQ ID NO: 14|5AXW_A|gi 924443546|Staphylococcus aureus Cas9. The HNH domain (bold and underlined) and the RuvC domain (boxed) are identified for each of the four sequences. Amino acid residues 10 and 840 in S1 and the homologous amino acids in the aligned sequences are identified with an asterisk following the respective amino acid residue.

S1
1
--MDKK-YSIGLD*IGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLI--GALLFDSG--ETAEATRLKRTARRRYT
73

S2
1
--MTKKNYSIGLD*IGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLL--GALLFDSG--ETAEATRLKRTARRRYT
74

S3
1
--M-KKGYSIGLD*IGTNSVGFAVITDDYKVPSKKMKVLGNTDKRFIKKNLI--GALLFDEG--TTAEARRLKRTARRRYT
73

S4
1
GSHMKRNYILGLD*IGITSVGYGII--DYET-----------------RDVIDAGVRLFKEANVENNEGRRSKRGARRLKR
61

S1
74
RRKNRICYLQEIFSNEMAKVDDSFEHRLEESELVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRL
153

S2
75
RRKNRLRYLQEIFANETAKVDESFFQRLDESFLTDDDKTEDSHPIFGNKAEEDAYHQKFPTIYHLRKHLADSSEKADLRL
154

S3
74
RRKNRLRYLQEIFSEEMSKVDSSFEHRLDDSFLIPEDKRESKYPIFATLTEEKEYHKQFPTIYHLRKQLADSKEKTDLRL
153

S4
62
RRRHRIQRVKKLL--------------FDYNLLTD--------------------HSELSGINPYEARVKGLSQKLSEEE
107

S1
154
IYLALAHNIKERGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEK
233

S2
155
VYLALAHMIKERGHFLIEGELNAENTDVQKIFADFVGVYNRTFDDSHLSEITVDVASILTEKISKSRRLENLIKYYPTEK
234

S3
154
TYLALAHMIKYRGHFLYEEAFDIKNNDIQKIFNEFISIYDNTFEGSSLSGQNAQVEAIFTDKISKSAKRERVLKLEPDEK
233

S4
108
FSAALLHLAKRRG------------------------VHNVNEVEEDT--------------------------------
131

S1
234
KNGLFGNLIALSLGLTPNEKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEIT
313

S2
235
KNTLFGNLIALALGLQPNEKTNFKLSEDAKLQFSKDTYEEDLEELLGKIGDDYADLFTSAKNLYDAILLSGILTVDDNST
314

S3
234
STGLFSEFLKLIVGNQADFKKHFDLEDKAPLQFSKDTYDEDLENLLGQIGDDFTDLFVSAKKLYDAILLSGILTVTDPST
313

S4
132
-----GNELS------------------TKEQISRN--------------------------------------------
144

S1
314
KAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKM--DGTEELLV
391

S2
315
KAPLSASMIKRYVEHHEDLEKLKEFIKANKSELYHDIFKDKNKNGYAGYIENGVKQDEFYKYLKNILSKIKIDGSDYFLD
394

S3
314
KAPLSASMIERYENHQNDLAALKQFIKNNLPEKYDEVFSDQSKDGYAGYIDGKTTQETFYKYIKNLLSKF--EGTDYFLD
391

S4
145
----SKALEEKYVAELQ-------------------------------------------------LERLKKDG------
165

S1
392
KLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEE
471

S2
395
KIEREDFLRKQRTFDNGSIPHQIHLQEMHAILRRQGDYYPFLKEKQDRIEKILTFRIPYYVGPLVRKDSRFAWAEYRSDE
474

S3
392
KIEREDFLRKQRTFDNGSIPHQIHLQEMNAILRRQGEYYPFLKDNKEKIEKILTFRIPYYVGPLARGNRDFAWLTRNSDE
471

S4
166
--EVRGSINRFKTSD--------YVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGP--GEGSPFGW------K
227

S1
472
TITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL
551

S2
475
KITPWNFDKVIDKEKSAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVNEQGKE-SFFDSNMKQEIFDH
553

S3
472
AIRPWNFEEIVDKASSAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIAEGLRDYQFLDSGQKKQIVNQ
551

S4
228
DIKEW---------------YEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEK---LEYYEKFQIIEN
289

S1
552
LEKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDR---FNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFED
628

S2
554
VFKENRKVTKEKLLNYLNKEFPEYRIKDLIGLDKENKSFNASLGTYHDLKKIL-DKAFLDDKVNEEVIEDIIKTLTLFED
632

S3
552
LEKENRKVTEKDIIHYLHN-VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDKEEMDDAKNEAILENIVHTLTIFED
627

S4
290
VFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEF---TNLKVYHDIKDITARKEII---ENAELLDQIAKILTIYQS
363

S1
629
REMIEERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKED
707

S2
633
KDMIHERLQKYSDIFTANQLKKLER-RHYTGWGRLSYKLINGIRNKENNKTILDYLIDDGSANRNFMQLINDDTLPFKQI
711

S3
628
REMIKQRLAQYDSLFDEKVIKALTR-RHYTGWGKLSAKLINGICDKQTGNTILDYLIDDGKINRNFMQLINDDGLSFKEI
706

S4
364
SEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDE------LWHTNDNQIAIFNRLKLVP---------
428

S1
708

embedded image

781

S2
712

embedded image

784

S3
707

embedded image

779

S4
429

embedded image

505

S1
782

KRIEEGIKELGSQIL-------KEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSD----YDVDH*IVPQSFLKDD

850

S2
785

KKLQNSLKELGSNILNEEKPSYIEDKVENSHLQNDQLFLYYIQNGKDMYTGDELDIDHLSD----YDIDH*IIPQAFIKDD

860

S3
780

KRIEDSLKILASGL---DSNILKENPTDNNQLQNDRLFLYYLQNGKDMYTGEALDINQLSS----YDIDH*IIPQAFIKDD

852

S4
506

ERIEEIIRTTGK---------------ENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDH*IIPRSVSFDN

570

S1
851

embedded image

922

S2
861

embedded image

932

S3
853

embedded image

924

S4
571

embedded image

650

S1
923

embedded image

1002

S2
933

embedded image

1012

S3
925

embedded image

1004

S4
651

embedded image

712

S1
1003

embedded image

1077

S2
1013

embedded image

1083

S3
1005

embedded image

1081

S4
713

embedded image

764

S1
1078

embedded image

1149

S2
1084

embedded image

1158

S3
1082

embedded image

1156

S4
765

embedded image

835

S1
1150
EKGKSKKLKSVKELLGITIMERSSFEKNPI-DFLEAKG-----YKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKG
1223

S2
1159
EKGKAKKLKTVKELVGISIMERSFFEENPV-EFLENKG-----YHNIREDKLIKLPKYSLFEFEGGRRRLLASASELQKG
1232

S3
1157
EKGKAKKLKTVKTLVGITIMEKAAFEENPI-TFLENKG-----YHNVRKENILCLPKYSLFELENGRRRLLASAKELQKG
1230

S4
836
DPQTYQKLK--------LIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKV
907

S1
1224
NELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEITEQISEFSKRVILADANLDKVLSAYNKH------
1297

S2
1233
NEMVLPGYLVELLYHAHRADNF-----NSTEYLNYVSEHKKEFEKVLSCVEDFANLYVDVEKNLSKIRAVADSM------
1301

S3
1231
NEIVLPVYLTTLLYHSKNVHKL-----DEPGHLEYIQKHRNEFKDLLNLVSEFSQKYVLADANLEKIKSLYADN------
1299

S4
908
VKLSLKPYRFD-VYLDNGVYKFV-----TVKNLDVIK--KENYYEVNSKAYEEAKKLKKISNQAEFIASFYNNDLIKING
979

S1
1298
RDKPIREQAENITHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSIT--------GLYETRI----DLSQL
1365

S2
1302
DNFSIEEISNSFINLLTLTALGAPADFNFLGEKIPRKRYTSTKECLNATLIHQSIT--------GLYETRI----DLSKL
1369

S3
1300
EQADIEILANSFINLLTFTALGAPAAFKFFGKDIDRKRYTTVSEILNATLIHQSIT--------GLYETWI----DLSKL
1367

S4
980
ELYRVIGVNNDLLNRIEVNMIDITYR-EYLENMNDKRPPRIIKTIASKT---QSIKKYSTDILGNLYEVKSKKHPQIIKK
1055

S1
1366
GGD 1368

S2
1370
GEE 1372

S3
1368
GED 1370

S4
1056
G-- 1056

The alignment demonstrates that amino acid sequences and amino acid residues that are homologous to a reference Cas9 amino acid sequence or amino acid residue can be identified across Cas9 sequence variants, including, but not limited to Cas9 sequences from different species, by identifying the amino acid sequence or residue that aligns with the reference sequence or the reference residue using alignment programs and algorithms known in the art. This disclosure provides Cas9 variants in which one or more of the amino acid residues identified by an asterisk in SEQ ID NOs: 11-14 (e.g., S1, S2, S3, and S4, respectively) are mutated as described herein. The residues D10 and H840 in Cas9 of SEQ ID NO: 10 that correspond to the residues identified in SEQ ID NOs: 11-14 by an asterisk are referred to herein as “homologous” or “corresponding” residues. Such homologous residues can be identified by sequence alignment, e.g., as described above, and by identifying the sequence or residue that aligns with the reference sequence or residue. Similarly, mutations in Cas9 sequences that correspond to mutations identified in SEQ ID NO: 10 herein, e.g., mutations of residues 10, and 840 in SEQ ID NO: 10, are referred to herein as “homologous” or “corresponding” mutations. For example, the mutations corresponding to the D10A mutation in SEQ ID NO: 10 or 51 (SEQ ID NO: 11) for the four aligned sequences above are D11A for S2, D10A for S3, and D13A for S4; the corresponding mutations for H840A in SEQ ID NO: 10 or S1 (SEQ ID NO: 11) are H850A for S2, H842A for S3, and H560A for S4.

A total of 250 Cas9 sequences (SEQ ID NOs: 11-260) from different species were aligned using the same algorithm and alignment parameters outlined above. Amino acid residues homologous to residues 10, and 840 of SEQ ID NO: 10 were identified in the same manner as outlined above. The alignments are provided below. The HNH domain (bold and underlined) and the RuvC domain (boxed) are identified for each of the four sequences. Single residues corresponding to amino acid residues 10, and 840 in SEQ ID NO: 10 are boxed in SEQ ID NO: 11 in the alignments, allowing for the identification of the corresponding amino acid residues in the aligned sequences.

WP_010922251.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 11

WP_039695303.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus gallolyticus]
SEQ ID NO: 12

WP_045635197.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mitis]
SEQ ID NO: 13

5AXW_A
Cas9, Chain A, Crystal Structure [Staphylococcus Aureus]
SEQ ID NO: 14

WP_009880683.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 15

WP_010922251.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 16

WP_011054416.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 17

WP_011284745.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 18

WP_011285506.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 19

WP_011527619.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 20

WP_012560673.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 21

WP_014407541.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 22

WP_020905136.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 23

WP_023080005.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 24

WP_023610282.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 25

WP_030125963.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 26

WP_030126706.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 27

WP_031488318.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 28

WP_032460140.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 29

WP_032461047.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 30

WP_032462016.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 31

WP_032462936.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 32

WP_032464890.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 33

WP_033888930.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 34

WP_038431314.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 35

WP_038432938.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 36

WP_038434062.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]
SEQ ID NO: 37

BAQ51233.1
CRISPR-associated protein, Csn1 family [Streptococcus pyogenes]
SEQ ID NO: 38

KGE60162.1
hypothetical protein MGAS2111_0903 [Streptococcus pyogenes MGAS2111]
SEQ ID NO: 39

KGE60856.1
CRISPR-associated endonuclease protein [Streptococcus pyogenes SS1447]
SEQ ID NO: 40

WP_002989955.1
MULTISPECIES: type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus]
SEQ ID NO: 41

WP_003030002.1
MULTISPECIES: type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus]
SEQ ID NO: 42

WP_003065552.1
MULTISPECIES: type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus]
SEQ ID NO: 43

WP_001040076.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 44

WP_001040078.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 45

WP_001040080.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 46

WP_001040081.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 47

WP_001040083.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 48

WP_001040085.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 49

WP_001040087.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 50

WP_001040088.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 51

WP_001040089.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 52

WP_001040090.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 53

WP_001040091.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 54

WP_001040092.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 55

WP_001040094.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 56

WP_001040095.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 57

WP_001040096.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 58

WP_001040097.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 59

WP_001040098.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 60

WP_001040099.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 61

WP_001040100.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 62

WP_001040104.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 63

WP_001040105.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 64

WP_001040106.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 65

WP_001040107.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 66

WP_001040108.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 67

WP_001040109.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 68

WP_001040110.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 69

WP_015058523.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 70

WP_017643650.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 71

WP_017647151.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 72

WP_017648376.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 73

WP_017649527.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 74

WP_017771611.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 75

WP_017771984.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 76

CFQ25032.1
CRISPR-associated protein [Streptococcus agalactiae]
SEQ ID NO: 77

CFV16040.1
CRISPR-associated protein [Streptococcus agalactiae]
SEQ ID NO: 78

KLJ37842.1
CRISPR-associated protein Csn1 [Streptococcus agalactiae]
SEQ ID NO: 79

KLJ72361.1
CRISPR-associated protein Csn1 [Streptococcus agalactiae]
SEQ ID NO: 80

KLL20707.1
CRISPR-associated protein Csn1 [Streptococcus agalactiae]
SEQ ID NO: 81

KLL42645.1
CRISPR-associated protein Csn1 [Streptococcus agalactiae]
SEQ ID NO: 82

WP_047207273.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 83

WP_047209694.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 84

WP_050198062.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 85

WP_050201642.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 86

WP_050204027.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 87

WP_050881965.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 88

WP_050886065.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae]
SEQ ID NO: 89

AHN30376.1
CRISPR-associated protein Csn1 [Streptococcus agalactiae 138P]
SEQ ID NO: 90

EAO78426.1
reticulocyte binding protein [Streptococcus agalactiae H36B]
SEQ ID NO: 91

CCW42055.1
CRISPR-associated protein, SAG0894 family [Streptococcus agalactiae ILRI112]
SEQ ID NO: 92

WP_003041502.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus anginosus]
SEQ ID NO: 93

WP_037593752.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus anginosus]
SEQ ID NO: 94

WP_049516684.1
CRISPR-associated protein Csn1 [Streptococcus anginosus]
SEQ ID NO: 95

GAD46167.1
hypothetical protein ANG6_0662 [Streptococcus anginosus T5]
SEQ ID NO: 96

WP_018363470.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus caballi]
SEQ ID NO: 97

WP_003043819.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus canis]
SEQ ID NO: 98

WP_006269658.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus constellatus]
SEQ ID NO: 99

WP_048800889.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus constellatus]
SEQ ID NO: 100

WP_012767106.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus dysgalactiae]
SEQ ID NO: 101

WP_014612333.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus dysgalactiae]
SEQ ID NO: 102

WP_015017095.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus dysgalactiae]
SEQ ID NO: 103

WP_015057649.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus dysgalactiae]
SEQ ID NO: 104

WP_048327215.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus dysgalactiae]
SEQ ID NO: 105

WP_049519324.1
CRISPR-associated protein Csn1 [Streptococcus dysgalactiae]
SEQ ID NO: 106

WP_012515931.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus equi]
SEQ ID NO: 107

WP_021320964.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus equi]
SEQ ID NO: 108

WP_037581760.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus equi]
SEQ ID NO: 109

WP_004232481.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus equinus]
SEQ ID NO: 110

WP_009854540.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus gallolyticus]
SEQ ID NO: 111

WP_012962174.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus gallolyticus]
SEQ ID NO: 112

WP_039695303.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus gallolyticus]
SEQ ID NO: 113

WP_014334983.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus infantarius]
SEQ ID NO: 114

WP_003099269.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus iniae]
SEQ ID NO: 115

AHY15608.1
CRISPR-associated protein Csn1 [Streptococcus iniae]
SEQ ID NO: 116

AHY17476.1
CRISPR-associated protein Csn1 [Streptococcus iniae]
SEQ ID NO: 117

ESR09100.1
hypothetical protein IUSA1_08595 [Streptococcus iniae IUSA1]
SEQ ID NO: 118

AGM98575.1
CRISPR-associated protein Cas9/Csn1, subtype II/NMEMI [Streptococcus iniae SF1]
SEQ ID NO: 119

ALF27331.1
CRISPR-associated protein Csn1 [Streptococcus intermedius]
SEQ ID NO: 120

WP_018372492.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus massiliensis]
SEQ ID NO: 121

WP_045618028.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mitis]
SEQ ID NO: 122

WP_045635197.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mitis]
SEQ ID NO: 123

WP_002263549.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 124

WP_002263887.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 125

WP_002264920.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 126

WP_002269043.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 127

WP_002269448.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 128

WP_002271977.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 129

WP_002272766.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 130

WP_002273241.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 131

WP_002275430.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 132

WP_002276448.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 133

WP_002277050.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 134

WP_002277364.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 135

WP_002279025.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 136

WP_002279859.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 137

WP_002280230.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 138

WP_002281696.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 139

WP_002282247.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 140

WP_002282906.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 141

WP_002283846.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 142

WP_002287255.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 143

WP_002288990.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 144

WP_002289641.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 145

WP_002290427.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 146

WP_002295753.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 147

WP_002296423.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 148

WP_002304487.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 149

WP_002305844.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 150

WP_002307203.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 151

WP_002310390.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 152

WP_002352408.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 153

WP_012997688.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 154

WP_014677909.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 155

WP_019312892.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 156

WP_019313659.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 157

WP_019314093.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 158

WP_019315370.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 159

WP_019803776.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 160

WP_019805234.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 161

WP_024783594.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 162

WP_024784288.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 163

WP_024784666.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 164

WP_024784894.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 165

WP_024786433.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans]
SEQ ID NO: 166

WP_049473442.1
CRISPR-associated protein Csn1 [Streptococcus mutans]
SEQ ID NO: 167

WP_049474547.1
CRISPR-associated protein Csn1 [Streptococcus mutans]
SEQ ID NO: 168

EMC03581.1
hypothetical protein SMU69_09359 [Streptococcus mutans NLML4]
SEQ ID NO: 169

WP_000428612.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus oralis]
SEQ ID NO: 170

WP_000428613.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus oralis]
SEQ ID NO: 171

WP_049523028.1
CRISPR-associated protein Csn1 [Streptococcus parasanguinis]
SEQ ID NO: 172

WP_003107102.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus parauberis]
SEQ ID NO: 173

WP_054279288.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus phocae]
SEQ ID NO: 174

WP_049531101.1
CRISPR-associated protein Csn1 [Streptococcus pseudopneumoniae]
SEQ ID NO: 175

WP_049538452.1
CRISPR-associated protein Csn1 [Streptococcus pseudopneumoniae]
SEQ ID NO: 176

WP_049549711.1
CRISPR-associated protein Csn1 [Streptococcus pseudopneumoniae]
SEQ ID NO: 177

WP_007896501.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pseudoporcinus]
SEQ ID NO: 178

EFR44625.1
CRISPR-associated protein, Csn1 family [Streptococcus pseudoporcinus SPIN 20026]
SEQ ID NO: 179

WP_002897477.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sanguinis]
SEQ ID NO: 180

WP_002906454.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sanguinis]
SEQ ID NO: 181

WP_009729476.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sp. F0441]
SEQ ID NO: 182

CQR24647.1
CRISPR-associated protein [Streptococcus sp. FF10]
SEQ ID NO: 183

WP_000066813.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sp. M334]
SEQ ID NO: 184

WP_009754323.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sp. taxon 056]
SEQ ID NO: 185

WP_044674937.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus suis]
SEQ ID NO: 186

WP_044676715.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus suis]
SEQ ID NO: 187

WP_044680361.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus suis]
SEQ ID NO: 188

WP_044681799.1
type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus suis]
SEQ ID NO: 189

WP_049533112.1
CRISPR-associated protein Csn1 [Streptococcus suis]
SEQ ID NO: 190

WP_029090905.1
type II CRISPR RNA-guided endonuclease Cas9 [Brochothrix thermosphacta]
SEQ ID NO: 191

WP_006506696.1
type II CRISPR RNA-guided endonuclease Cas9 [Catenibacterium mitsuokai]
SEQ ID NO: 192

AIT42264.1
Cas9hc:NLS:HA [Cloning vector pYB196]
SEQ ID NO: 193

WP_034440723.1
type II CRISPR endonuclease Cas9 [Clostridiales bacterium S5-A11]
SEQ ID NO: 194

AKQ21048.1
Cas9 [CRISPR-mediated gene targeting vector p(bh5p68-Cas9)]
SEQ ID NO: 195

WP_004636532.1
type II CRISPR RNA-guided endonuclease Cas9 [Dolosigranulum pigrum]
SEQ ID NO: 196

WP_002364836.1
MULTISPECIES: type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus]
SEQ ID NO: 197

WP_016631044.1
MULTISPECIES: type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus]
SEQ ID NO: 198

EMS75795.1
hypothetical protein H318_06676 [Enterococcus durans IPLA 655]
SEQ ID NO: 199

WP_002373311.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis]
SEQ ID NO: 200

WP_002378009.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis]
SEQ ID NO: 201

WP_002407324.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis]
SEQ ID NO: 202

WP_002413717.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis]
SEQ ID NO: 203

WP_010775580.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis]
SEQ ID NO: 204

WP_010818269.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis]
SEQ ID NO: 205

WP_010824395.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis]
SEQ ID NO: 206

WP_016622645.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis]
SEQ ID NO: 207

WP_033624816.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis]
SEQ ID NO: 208

WP_033625576.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis]
SEQ ID NO: 209

WP_033789179.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis]
SEQ ID NO: 210

WP_002310644.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium]
SEQ ID NO: 211

WP_002312694.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium]
SEQ ID NO: 212

WP_002314015.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium]
SEQ ID NO: 213

WP_002320716.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium]
SEQ ID NO: 214

WP_002330729.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium]
SEQ ID NO: 215

WP_002335161.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium]
SEQ ID NO: 216

WP_002345439.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium]
SEQ ID NO: 217

WP_034867970.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium]
SEQ ID NO: 218

WP_047937432.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium]
SEQ ID NO: 219

WP_010720994.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus hirae]
SEQ ID NO: 220

WP_010737004.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus hirae]
SEQ ID NO: 221

WP_034700478.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus hirae]
SEQ ID NO: 222

WP_007209003.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus italicus]
SEQ ID NO: 223

WP_023519017.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus mundtii]
SEQ ID NO: 224

WP_010770040.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus phoeniculicola]
SEQ ID NO: 225

WP_048604708.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus sp. AM1]
SEQ ID NO: 226

WP_010750235.1
type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus villorum]
SEQ ID NO: 227

AII16583.1
Cas9 endonuclease [Expression vector pCas9]
SEQ ID NO: 228

WP_029073316.1
type II CRISPR RNA-guided endonuclease Cas9 [Kandleria vitulina]
SEQ ID NO: 229

WP_031589969.1
type II CRISPR RNA-guided endonuclease Cas9 [Kandleria vitulina]
SEQ ID NO: 230

KDA45870.1
CRISPR-associated protein Cas9/Csn1, subtype II/NMEMI [Lactobacillus animalis]
SEQ ID NO: 231

WP_039099354.1
type II CRISPR RNA-guided endonuclease Cas9 [Lactobacillus curvatus]
SEQ ID NO: 232

AKP02966.1
hypothetical protein ABB45_04605 [Lactobacillus farciminis]
SEQ ID NO: 233

WP_010991369.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria innocua]
SEQ ID NO: 234

WP_033838504.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria innocua]
SEQ ID NO: 235

EHN60060.1
CRISPR-associated protein, Csn1 family [Listeria innocua ATCC 33091]
SEQ ID NO: 236

EFR89594.1
crispr-associated protein, Csn1 family [Listeria innocua FSL S4-378]
SEQ ID NO: 237

WP_038409211.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria ivanovii]
SEQ ID NO: 238

EFR95520.1
crispr-associated protein Csn1 [Listeria ivanovii FSL F6-596]
SEQ ID NO: 239

WP_003723650.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes]
SEQ ID NO: 240

WP_003727705.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes]
SEQ ID NO: 241

WP_003730785.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes]
SEQ ID NO: 242

WP_003733029.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes]
SEQ ID NO: 243

WP_003739838.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes]
SEQ ID NO: 244

WP_014601172.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes]
SEQ ID NO: 245

WP_023548323.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes]
SEQ ID NO: 246

WP_031665337.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes]
SEQ ID NO: 247

WP_031669209.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes]
SEQ ID NO: 248

WP_033920898.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes]
SEQ ID NO: 249

AKI42028.1
CRISPR-associated protein [Listeria monocytogenes]
SEQ ID NO: 250

AKI50529.1
CRISPR-associated protein [Listeria monocytogenes]
SEQ ID NO: 251

EFR83390.1
crispr-associated protein Csn1 [Listeria monocytogenes FSL F2-208]
SEQ ID NO: 252

WP_046323366.1
type II CRISPR RNA-guided endonuclease Cas9 [Listeria seeligeri]
SEQ ID NO: 253

AKE81011.1
Cas9 [Plant multiplex genome editing vector pYLCRISPR/Cas9Pubi-H]
SEQ ID NO: 254

CUO82355.1
Uncharacterized protein conserved in bacteria [Roseburia hominis]
SEQ ID NO: 255

WP_033162887.1
type II CRISPR RNA-guided endonuclease Cas9 [Sharpea azabuensis]
SEQ ID NO: 256

AGZ01981.1
Cas9 endonuclease [synthetic construct]
SEQ ID NO: 257

AKA60242.1
nuclease deficient Cas9 [synthetic construct]
SEQ ID NO: 258

AK540380.1
Cas9 [Synthetic plasmid pFC330]
SEQ ID NO: 259

4UN5_B
Cas9, Chain B, Crystal Structure
SEQ ID NO: 260

WP_010922251
1
MDKK- custom character

--EATRLKRTARRRYT
73

WP_039695303
1
MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EATRLKRTARRRYT
74

WP_045635197
1
K-KG-YSIGLDIGTNSVGFAVITDDYKVPSKKMKVLGNTDKRFIKKNLIGALLFDEGTTA--EARRLKRTARRRYT
73

5AXW_A
1
MKRN-YILGLDIGITSVGYGII--DYET------------RDVIDA---GVRLFKEANVEnnEGRRSKRGARRLKR
61

WP_009880683

----------------------------------------------------------------------------

WP_010922251
1
MDKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_011054416
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKLKGLGNTDRHGIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_011284745
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_011285506
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_011527619
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGEIA--EATRLKRTARRRYT
73

WP_012560673
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_014407541
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFGSGETA--EATRLKRTARRRYT
73

WP_020905136
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_023080005
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKLKVLGNTDRHGIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_023610282
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKLKVLGNTDRHGIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_030125963
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_030126706
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHGIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_031488318
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_032460140
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_032461047
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTERHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_032462016
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTERHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_032462936
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTERHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_032464890
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTERHSIKKNLIGALLFDSGEIA--EATRLKRTARRRYT
73

WP_033888930

----------------------------------------------------------------------------

WP_038431314
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_038432938
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_038434062
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

BAQ51233

----------------------------------------------------------------------------

KGE60162

----------------------------------------------------------------------------

KGE60856

----------------------------------------------------------------------------

WP_002989955
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGEIA--EATRLKRTARRRYT
73

WP_003030002
1
MDQK-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT
73

WP_003065552
1
MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EATRLKRTARRRYT
74

WP_001040076
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKIRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040078
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040080
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040081
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040083
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040085
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040087
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040088
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040089
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040090
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040091
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040092
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040094
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040095
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040096
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040097
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040098
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040099
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040100
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040104
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_001040105
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTSRRRYT
73

WP_001040106
1
MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT
73

WP_001040107
1
MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT
73

WP_001040108
1
MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT
73

WP_001040109
1
MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT
73

WP_001040110
1
MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT
73

WP_015058523
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_017643650
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_017647151
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT
73

WP_017648376
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT
73

WP_017649527
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_017771611
1
MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT
73

WP_017771984
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

CFQ25032
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

CFV16040
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

KLJ37842
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

KLJ72361
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

KLL20707
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

KLL42645
1
MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT
73

WP_047207273
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGRNTA--ADRRLKRTARRRYT
73

WP_047209694
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_050198062
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_050201642
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_050204027
1
MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT
73

WP_050881965
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

WP_050886065
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

AHN30376
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

EAO78426
1
MNKP-YSIGXDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT
73

CCW42055
1
MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRIARRRYT
73

WP_003041502
1
MNQK-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT
73

WP_037593752
1
MKKE-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT
74

WP_049516684
1
MKKE-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT
74

GAD46167
1
MKKE-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT
73

WP_018363470
1
MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EATRLKRTARRRYT
74

WP_003043819
1
MEKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTNRKSIKKNLMGALLFDSGETA--EATRLKRTARRRYT
73

WP_006269658
1
MGKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT
73

WP_048800889
1
MTQK-YSIGLDIGTNSVGWAIVTDDYKVPAKKMKILGNTNKQYIKKNLLGALLFDSGETA--KATRLKRTARRRYT
73

WP_012767106
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_014612333
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_015017095
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_015057649
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_048327215
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_049519324
1
MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_012515931
1
MKKP-YTIALDIGTNSVGWVVVTDDYRVPTKKMKVLGNTERKTIKKNLIGALLFDSGETA--EGTRLKRTARRRYT
73

WP_021320964
1
MKKP-YTIALDIGTNSVGWVVVTDDYRVPTKKMKVLGNTERKTIKKNLIGALLFDSGETA--EGTRLKRTARRRYT
73

WP_037581760
1
MKKP-YTIALDIGTNSVGWVVVTDDYRVPTKKMKVLGNTERKTIKKNLIGALLFDSGETA--EGTRLKRTARPRYT
73

WP_004232481
1
M-EKtYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EATRLKRAARRRYT
73

WP_009854540
1
MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EATRLKRTARRRYT
74

WP_012962174
1
MTEKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDNGETA--EATRLKRTARRRYT
74

WP_039695303
1
MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EATRLKRTARRRYT
74

WP_014334983
1
M-EKsYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EVTRLKRTARRRYT
73

WP_003099269
1
MRKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMRIQGTTDRTSIKKNLIGALLFDNGETA--EATRLKRTTRRRYT
73

AHY15608
1
MRKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMRIQGTTDRTSIKKNLIGALLFDNGETA--EATRLKRTTRRRYT
73

AHY17476
1
MRKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMRIQGTTDRTSIKKNLIGALLFDNGETA--EATRLKRTTRRRYT
73

ESR09100

----------------------------------------------------------------------------

AGM98575
1
MRKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMRIQGTTDRTSIKKNLIGALLFDNGETA--EATRLKRTTRRRYT
73

ALF27331
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_018372492
1
MKKP-YSIGLDIGTNSVGWAVVMEDYKVPSKKMKVLGNTDKQSIKKNLIGALLFDSGETAv--ERRLNRTTSRRYD
73

WP_045618028
1
NNKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKHFIKKNLLGALLFDEGTTA--EDRRLKRTARRRYT
74

WP_045635197
1
K-KG-YSIGLDIGTNSVGFAVITDDYKVPSKKMKVLGNTDKRFIKKNLIGALLFDEGTTA--EARRLKRTARRRYT
73

WP_002263549
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002263887
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002264920
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002269043
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002269448
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002271977
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002272766
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002273241
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002275430
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT
73

WP_002276448
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002277050
1
MKKS-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002277364
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT
73

WP_002279025
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002279859
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002280230
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT
73

WP_002281696
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT
73

WP_002282247
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002282906
1
MKKP-YSIGLDIGTNSVGWSVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002283846
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002287255
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVSAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002288990
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002289641
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTTRRRYT
73

WP_002290427
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002295753
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002296423
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002304487
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002305844
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002307203
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002310390
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_002352408
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_012997688
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT
73

WP_014677909
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPDKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_019312892
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT
73

WP_019313659
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_019314093
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_019315370
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_019803776
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_019805234
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_024783594
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_024784288
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT
73

WP_024784666
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT
73

WP_024784894
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTTRRRYT
73

WP_024786433
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT
73

WP_049473442
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT
73

WP_049474547
1
MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTTRRRYT
73

EMC03581
1
MDL--------IGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT
66

WP_000428612
1
ENKN-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKRFIKKNLIGALLFDEGTTA--EARRLKRTARRRYT
74

WP_000428613
1
ENKN-YSIGLDIGTNSVGWSVITDDYKVPSKKMKVLGNTDKRFIKKNLIGALLFDEGTTA--EARRLKRTARRRYT
74

WP_049523028
1
K-KP-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTNKESIKKNLIGALLFDAGNTA--ADRRLKRTARRRYT
73

WP_003107102
1
--------------------------------MKVLGNTDRQTVKKNMIGTLLFDSGETA--EARRLKRTARRRYT
42

WP_054279288
1
-KKS-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTSRQSIKKNMIGALLFDEGGPA--ASTRVKRTTRRRYT
75

WP_049531101
1
SNKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA--EDRRLKRTARRRYT
74

WP_049538452
1
SNKP-YSIGLDIGTNSVGWVIITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA--EDRRLKRTARRRYT
74

WP_049549711
1
SNKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMTVLGNTDKHFIKKNLIGALLFDEGTTA--EDRRLKRTARRRYT
74

WP_007896501
1
--YS-YSIGLDIGTNSVGWAVINEDYKVPAKKMTVFGNTDRKTIKKNLLGTVLFDSGETA--QARRLKRTNRRRYT
75

EFR44625
1
-----------------------------------------------MLGTVLFDSGETA--QARRLKRTNRRRYT
27

WP_002897477
1
K-KP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMRVFGDTDRSHIKKNLLGTLLFDDGNTA--ESRRLKRTARRRYT
73

WP_002906454
1
K-KP-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA--EDRRLKRTSRRRYT
73

WP_009729476
1
ENKN-YSIGLDIGTNSVGWSVITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA--EARRLKRTARRRYT
74

CQR24647
1
MKKP-YSIGLDIGTNSVGWSVVTDDYKVPAKKMKVLGNTDKEYIKKNLIGALLFDSGETA--EATRMKRTARRRYT
73

WP_000066813
1
SNKS-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA--EDRRLKRTARRRYT
74

WP_009754323
1
NNNN-YSIGLDIGTNSVGWAVITDDYKVPSKKMRVLGNTDKRFIKKNLIGALLFDEGTTA--EDRRLKRTARRRYT
74

WP_044674937
1
MKKK-YAIGIDIGTNSVGWSVVTDDYKVPSKKMKVFGNTEKRYIKKNLLGTLLFDEGNTA--ENRRLKRTARRRYT
73

WP_044676715
1
MKKK-YAIGIDIGTNSVGWSVVTDDYKVPSKKMKVFGNTEKRYIKKNLLGTLLFDEGNTA--ENRRLKRTARRRYT
73

WP_044680361
1
MKKK-YAIGIDIGTNSVGWSVVTDDYKVPSKKMKVFGNTEKRYIKKNLLGTLLFDEGNTA--ENRRLKRTARRRYT
73

WP_044681799
1
MKKK-YAIGIDIGTNSVGWSVVTDDYKVPSKKMKVFGNTEKRYIKKNLLGTLLFDEGNTA--ENRRLKRTARRRYT
73

WP_049533112
1
MDQK-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT
73

WP_029090905
1
-----------------------------------------------MWGVSLFEAGKTA--AERRGYRSTRRRLN
27

WP_006506696
1
I-VD-YCIGLDLGTGSVGWAVVDMNHRLMKRN------------GKHLWGSRLFSNAETA--ANRRASRSIRRRYN
60

AIT42264
1
MDKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_034440723
1
-MKN-YTIGLDIGTNSVGWAVIKDDLTLVRKKIKISGNTDKKEVKKNLWGSFLFEQGDTA--QDTRVKRIARRRYE
72

AKQ21048
1
MDKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

WP_004636532
1
MQKN-YTIGLDIGTNSVGWAVMKDDYTLIRKRMKVLGNTDIKKIKKNFWGVRLFDEGETA--KETRLKRGTRRRYQ
73

WP_002364836
1
MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS
73

WP_016631044
1
--------------------------------------------------MRLFEEGHTA--EDRRLKRTARRRIS
24

EMS75795

----------------------------------------------------------------------------

WP_002373311
1
MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS
73

WP_002378009
1
MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS
73

WP_002407324
1
MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS
73

WP_002413717
1
MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS
73

WP_010775580
1
MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS
73

WP_010818269
1
MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS
73

WP_010824395
1
MKKD-YVIGLDIGSNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS
73

WP_016622645
1
MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS
73

WP_033624816
1
MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS
73

WP_033625576
1
MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS
73

WP_033789179
1
MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS
73

WP_002310644
1
MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA
73

WP_002312694
1
MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA
73

WP_002314015
1
MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA
73

WP_002320716
1
MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA
73

WP_002330729
1
MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA
73

WP_002335161
1
MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA
73

WP_002345439
1
MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA
73

WP_034867970
1
MTKD-YTIGLDIGTNSVGWAVLTDDYQLMKRKMSVHGNTEKKKIKKNFWGARLFDEGQTA--EFRRTKRTNRRRLA
73

WP_047937432
1
MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA
73

WP_010720994
1
MTKD-YTIGLDIGTNSVGWAVLTDDYQLMKRKMSVHGNTEKKKIKKNFWGARLFDEGQTA--EFRRTKRTNRRRLA
73

WP_010737004
1
MTKD-YTIGLDIGTNSVGWAVLTDDYQLMKRKMSVHGNTEKKKIKKNFWGARLFDEGQTA--EFRRTKRTNRRRLA
73

WP_034700478
1
MTKD-YTIGLDIGTNSVGWAVLTDDYQLMKRKMSVHGNTEKKKIKKNFWGARLFDEGQTA--EFRRTKRTNRRRLA
73

WP_007209003
1
MKND-YTIGLDIGTNSVGYSVVTDDYKVISKKMNVFGNTEKKSIKKNFWGVRLFESGQTA--QEARMKRTSRRRIA
73

WP_023519017
1
MEKE-YTIGLDIGTNSVGWAVLTDDYRLVARKMSIQGDSNRKKIKKNFWGARLFEEGKTA--QFRRIKRTNRRRIA
73

WP_010770040
1
MKKE-YTIGLDIGTNSVGWAVLTENYDLVKKKMKVYGNTETKYLKKNLWGVRLFDEGETA--ADRRLKRTTRRRYS
73

WP_048604708
1
MGKE-YTIGLDIGTNSVGWAVLQEDLDLVRRKMKVYGNTEKNYLKKNFWGVDLFDEGMTA--KDTRLKRTTRRRYF
73

WP_010750235
1
MNKA-YTLGLDIGTNSVGWAVVTDDYRLMAKKMPVHSKMEKKKIKKNFWGARLFDEGQTA--EERRNKRATRRRLR
73

AII16583
1
ADKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
112

WP_029073316
1
NNKI-YNIGLDIGDASVGWAVVDEHYNLLKRH------------GKHMWGSRLFTQANTA--VERRSSRSTRRRYN
65

WP_031589969
1
NNKI-YNIGLDIGDASVGWAVVDEHYNLLKRH------------GKHMWGSRLFTQANTA--VERRSSRSTRRRYN
65

KDA45870
1
LKKD-YSIGLDIGTNSVGHAVVTDDYKVPTKKMKVFGDTSKKTIKKNMLGVLLFNEGQTA--ADTRLKRGARRRYT
74

WP_039099354
1
MSRP-YNIGLDIGTSSIGWSVVDDQSKLVSVR------------GKYGYGVRLYDEGQTA--AERRSFRTTRRRLK
61

AKP02966
1
KEQP-YNIGLDIGTGSVGWAVTNDNYDLLNIK------------KKNLWGVRLFEGAQTA--KETRLNRSTRRRYR
64

WP_010991369
1
MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKIAGDSEKKQIKKNFWGVRLFDEGQTA--ADRRMARTARRRIE
73

WP_033838504
1
MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKIAGDSEKKQIKKNFWGVRLFDEGQTA--ADRRMARTARRRIE
73

EHN60060
1
MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKIAGDSEKKQIKKNFWGVRLFDEGQTA--ADRRMARTARRRIE
76

EFR89594

----------------------------------------------------------------------------

WP_038409211
1
MRKP-YTIGLDIGTNSVGWAVLTDQYNLVKRKMKVAGSAEKKQIKKNFWGVRLFDEGEVA--AGRRMNRTTRRRIE
73

EFR95520

----------------------------------------------------------------------------

WP_003723650
1
MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE
73

WP_003727705
1
MKNP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE
73

WP_003730785
1
MKNP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE
73

WP_003733029
1
MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKISGDSEKKQIKKNFWGVRLFEKGETA--AKRRMSRTARRRIE
73

WP_003739838
1
MKNP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDEGETA--ADRRMNRTARRRIE
73

WP_014601172
1
MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE
73

WP_023548323
1
MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE
73

WP_031665337
1
MKNP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE
73

WP_031669209
1
MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKISGDSEKKQIKKNFWGVRLFEKGETA--AKRRMSRTARRRIE
73

WP_033920898
1
MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE
73

AKI42028
1
MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE
76

AKI50529
1
MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE
76

EFR83390

----------------------------------------------------------------------------

WP_046323366
1
MKKP-YTIGLDIGTNSVGWAALTDQYDLVKRKMKVAGNSEKKQIKKNLWGVRLVDEGKTA--AHRRVNRTTRRRIE
73

AKE81011
1
ADKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
89

CUO82355
1
I-VD-YCIGLDLGTGSVGWAVVDMNHRLMKRN------------GKHLWGSRLFSNAETA--ATRRSSRSIRRRYN
64

WP_033162887
1
KDIR-YSIGLDIGTNSVGWAVMDEHYELLKKG------------NHHMWGSRLFDAAEPA--ATRRASRSIRRRYN
65

AGZ01981
1
ADKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
106

AKA60242
1
MDKK-YSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

AKS40380
1
MDKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
73

4UN5_B
1
MDKK-YSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT
77

WP_010922251
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGN custom character

V-DEVAYHEKYPTIY custom character

LRKKLV
143

WP_039695303
75
RRKNRLRYLQEIFANEIAKVDESFFQRLDE-SFLT--DDDKT---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA
144

WP_045635197
74
RRKNRLRYLQEIFSEEMSKVDSSFFHRLDD-SFLI--PEDKR---E SKYPIFATLT-EEKEYHKQFPTIYHLRKQLA
143

5AXW_A
62
RRRHRIQRVKKLLFD---------YNLLTDhSELS----------G --NPYEARVK--------------GLSQKLS
104

WP_009880683

---------------------------------------------- -------------------------------

WP_010922251
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

WP_011054416
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_011284745
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

WP_011285506
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

WP_011527619
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

WP_012560673
74
RRKNRICYLQEIFSNEIAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_014407541
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_020905136
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

WP_023080005
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_023610282
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_030125963
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

WP_030126706
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_031488318
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_032460140
74
RRKNRICYLQEIFSNEIAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_032461047
74
RRKNRICYLQEIFSNEIAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_032462016
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

WP_032462936
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_032464890
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

WP_033888930

---------------------------------------------- -------------------------------

WP_038431314
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_038432938
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_038434062
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

BAQ51233
1
----------------MAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
54

KGE60162

---------------------------------------------- -------------------------------

KGE60856

---------------------------------------------- -------------------------------

WP_002989955
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

WP_003030002
74
RRRNRLRYLQEIFAEEMNKVDENFFQRLDD-SFLV--DEDKR---G ERHPIFGNIA-AEVKYHDDFPTIYHLRKHLA
143

WP_003065552
75
RRKNRLRYLQEIFAEEMTKVDESFFQRLDE-SFLRwdDDNKK---L GRYPIFGNKA-DVVKYHQEFPTIYHLRKHLA
146

WP_001040076
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKYYHEKFPTIYHLRKELA
143

WP_001040078
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFPTIYHLRKELA
143

WP_001040080
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_001040081
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_001040083
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_001040085
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_001040087
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_001040088
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_001040089
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_001040090
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_001040091
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_001040092
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

WP_001040094
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA
143

WP_001040095
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA
143

WP_001040096
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA
143

WP_001040097
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA
143

WP_001040098
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA
143

WP_001040099
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA
143

WP_001040100
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA
143

WP_001040104
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYXIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_001040105
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_001040106
74
CRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

WP_001040107
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

WP_001040108
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

WP_001040109
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

WP_001040110
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

WP_015058523
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

WP_017643650
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA
143

WP_017647151
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

WP_017648376
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

WP_017649527
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFPTIYHLRKELA
143

WP_017771611
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

WP_017771984
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

CFQ25032
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

CFV16040
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

KLJ37842
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

KLJ72361
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

KLL20707
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

KLL42645
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

WP_047207273
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_047209694
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA
143

WP_050198062
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_050201642
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_050204027
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

WP_050881965
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

WP_050886065
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

AHN30376
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA
143

EAO78426
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA
143

CCW42055
74
RRRNRILYLQEIFAEKMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFPTIYHLRKELA
143

WP_003041502
74
RRRNRLRYLQEIFAEEMMQVDESFFQRLDD-SFLV--DEDKR---G ERHPIFGNIA-AEVKYHDEFPTIYHLRKHLA
143

WP_037593752
75
RRKNRLRYLQEIFTEEMNKVDENFFQRLDD-SFLV--EEDKQ---G SKYPIFGTLK-EEKEYHKKFKTIYHLREELA
144

WP_049516684
75
RRRNRLRYLQEIFAEEMMQVDESFFQRLDD-SFLV--EEDKR---G SRYPIFGNIA-AEVKYHDDFPTIYHLRKHLV
144

GAD46167
74
RRKNRLRYLQEIFTEEMNKVDENFFQRLDD-SFLV--EEDKQ---G SKYPIFGTLK-EEKEYHKKFKTIYHLREELA
143

WP_018363470
75
RRKNRLRYLQDIFTEEMAKVDDSFFQRLDE-SFLT--DNDKN---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA
144

WP_003043819
74
RRKNRIRYLQEIFANEMAKLDDSFFQRLEE-SFLV--EEDKK---N ERHPIFGNLA-DEVAYHRNYPTIYHLRKKLA
143

WP_006269658
74
RRKNRLRYLQEIFTGEMNKVDENFFQRLDD-SFLV--DEDKR---G EHHPIFGNIA-AEVKYHDDFPTIYHLRRHLA
143

WP_048800889
74
RRKNRLRYLQEIFIEEMNKVDENFFQRLDD-SFLV--TEDKR---G SKYPIFGTLK-EEKEYYKEFETIYHLRKRLA
143

WP_012767106
74
RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_014612333
74
RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_015017095
74
RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_015057649
74
RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_048327215
74
RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_049519324
74
RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA
143

WP_012515931
74
RRKNRLRYLKEIFTEEMAKVDDGFFQRLED-SFYV--LEDKE---G NKHPIFANLA-DEVAYHKKYPTIYHLRKELV
143

WP_021320964
74
RRKNRLRYLKEIFTEEMAKVDDGFFQRLED-SFYV--LEDKE---G NKHPIFANLA-DEVAYHKKYPTIYHLRKELV
143

WP_037581760
74
RRKNRLRFLKEIFTEEMAKVDDGFFQRLED-SFYV--LEDKE---G NKHPIFANLA-DEVAYHKKYPTIYHLRKELV
143

WP_004232481
74
RRKNRLRYLQEIFAKEMAKVDESFFQRLEE-SFLT--DDDKT---F DSHPIFGNKA-EEDTYHQEFPTIYHLRKHLA
143

WP_009854540
75
RRKNRLRYLQEIFAEEMTKVDESFFYRLDE-SFLT--TDEKD---F ERHPIFGNKA-EEDAYHQKFPTIYHLRNYLA
144

WP_012962174
75
RRKNRLRYLQEIFAEEMAKVDESFFYRLDE-SFLT--TDDKD---F ERHPIFGNKA-DEIKYHQEFPTIYHLRKHLA
144

WP_039695303
75
RRKNRLRYLQEIFANEIAKVDESFFQRLDE-SFLT--DDDKT---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA
144

WP_014334983
74
RRKNRLRYLQEIFAKEMTKVDESFFQRLEE-SFLT--DDDKT---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKYLA
143

WP_003099269
74
RRKYRIKELQKIFSSEMNELDIAFFPRLSE-SFLV--SDDKE---F ENHPIFGNLK-DEITYHNDYPTIYHLRQTLA
143

AHY15608
74
RRKYRIKELQKIFSSEMNELDIAFFPRLSE-SFLV--SDDKE---F ENHPIFGNLK-DEITYHNDYPTIYHLRQTLA
143

AHY17476
74
RRKYRIKELQKIFSSEMNELDIAFFPRLSE-SFLV--SDDKE---F ENHPIFGNLK-DEITYHNDYPTIYHLRQTLA
143

ESR09100

---------------------------------------------- -------------------------------

AGM98575
74
RRKYRIKELQKIFSSEMNELDIAFFPRLSE-SFLV--SDDKE---F ENHPIFGNLK-DEITYHNDYPTIYHLRQTLA
143

ALF27331
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_018372492
74
RRRNRIRYLQHIFAEEMNRADENFFHRLKE-SFFV--EEDKT---Y SKYPIFGTLE-EEKNYHKNYPTIYHLRKTLA
143

WP_045618028
75
RRKNRLRYLQEIFTEEMSKVDISFFHRLDD-SFLV--PEDKR---G SKYPIFATLE-EEKEYHKNFPTIYHLRKHLA
144

WP_045635197
74
RRKNRLRYLQEIFSEEMSKVDSSFFHRLDD-SFLI--PEDKR---E SKYPIFATLT-EEKEYHKQFPTIYHLRKQLA
143

WP_002263549
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002263887
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002264920
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLDE-SFLT--DDDKN---F DSYPIFGNKA-EEDAYHQKFPTIYHLRKHLA
143

WP_002269043
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002269448
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002271977
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002272766
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002273241
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002275430
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002276448
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002277050
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLDE-SFLT--DDDKN---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA
143

WP_002277364
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002279025
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-FFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002279859
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLDE-SFLT--DDDKN---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA
143

WP_002280230
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002281696
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002282247
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLDE-SFLT--DDDKN---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA
143

WP_002282906
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002283846
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002287255
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002288990
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002289641
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002290427
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002295753
74
RRRNRILYLQEIFSEEMGKVNDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002296423
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002304487
74
RRRNRILYLQEIFAEEMMQVDESFFQRLDD-SFLV--EEDKR---G SRYPIFGTLK-EEKKYHKEFKTIYHLREKLA
143

WP_002305844
74
RRRNRILYLQEIFSEEMDKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002307203
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002310390
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_002352408
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_012997688
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_014677909
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_019312892
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_019313659
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_019314093
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_019315370
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ECHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_019803776
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_019805234
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_024783594
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_024784288
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLDE-SFLT--DDDKN---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA
143

WP_024784666
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_024784894
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

WP_024786433
74
RRRNRILYLQEIFAEEMNKVDDSFFHRLDE-SFLT--DDDKN---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA
143

WP_049473442
74
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYYENFPTIYHLRQYLA
143

WP_049474547
74
RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
143

EMC03581
67
RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA
136

WP_000428612
75
RRKNRLRYLQEIFAEEMSKVDSSFFHRLDD-SFLI--PEDKK---G SKYPIFATLI-EEKEYHKQFPTIYHLRKQLA
144

WP_000428613
75
RRKNRLRYLQEIFAEEMSKVDSSFFHRLDD-SFLI--PEDKR---G SKYPIFATLA-EEKEYHKQFPTIYHLRKQLA
144

WP_049523028
74
RRRNRILYLQEIFAAEMNKVDESFFHRLDD-SFLV--PEDKR---G SKYPIFGTLE-EEKEYHKQFPTIYYLRKILA
143

WP_003107102
43
RRINRIKYLQSIFDDEMSKIDSAFFQRIKD-SFLV--PDDKN---D DRHPIFGNIK-DEVDYHKNYPTIYHLRKKLA
112

WP_054279288
76
RRKNRLCYLRDIFESEMHTIDKHFFLRLED-SFLH--KSDKR---Y EAHPIFGTLQ-EEKAYHDNYPTIYHLRKALA
145

WP_049531101
75
RRKNRLRYLQEIFSEEISKVDNSFFHRLDD-SFLV--PEDKR---G SKYPIFATLT-EEKEYYKQFPTIYHLRKQLA
144

WP_049538452
75
RRKNRLRYLQEIFAEEMNKVDSSFFHRLDD-SFLV--PEDKR---G SKYPIFATLA-EEKEYHKNFPTIYHLRKQLA
144

WP_049549711
75
RRKNRLRYLQEIFSGEMSKVDSSFFHRLDD-SFLV--PEDKR---G SKYPIFATLV-EEKEYHKQFPTIYHLRKQLA
144

WP_007896501
76
RRRYRLCQLQNIFATEMVKVDDTFFQRLSE-SFFY--YQDKA---F DKHPIFGNSK-EERAYHKTYPTIYHLRKDLA
145

EFR44625
28
RRRYRLCQLQNIFATEMVKVDDTFFQRLSE-SFFY--YQDKA---F DKHPIFGNSK-EERAYHKTYPTIYHLRKDLA
97

WP_002897477
74
RRRNRILYLQEIFTESMNEIDESFFHRLDD-SFLV--PEDKR---G SKYPIFATLQ-EEKEYHKQFPTIYHLRKQLA
143

WP_002906454
74
RRKNRLRYLQEIFSEEISKLDSSFFHRLDD-SFLV--PEDKR---G SKYPIFATLE-EEKEYHKKFPTIYHLRKHLA
143

WP_009729476
75
RRKNRLRYLQEIFSEEIGKVDSSFFHRLDD-SFLI--PEDKR---G SKYPIFATLA-EEKKYHKQFPTIYHLRKQLA
144

CQR24647
74
RRRNRILYLQDIFSPELNQVDESFLHRLDD-SFLVa--EDKR---G ERHVIFGNIA-DEVKYHKEFPTIYHLRKHLA
143

WP_000066813
75
RRKNRLRYLQEIFSQEISKVDSSFFHRLDD-FFLV--PEDKR---G SKYPIFATLV-EEKEYHKKFPTIYHLRKHLA
144

WP_009754323
75
RRKNRLRYLQEIFAEEMSKVDSSFFHRLDD-SFLV--PEDKS---G SKYPIFATLA-EEKEYHKKFPTIYHLRKHLA
144

WP_044674937
74
RRRNRILYLQEIFAEEINKIDDSFFQRLDD-SFLIv--EDKQ---G SKHPIFGTLQ-EEKKYHKQFPTIYHLRKQLA
143

WP_044676715
74
RRRNRILYLQEIFAEEINKIDDSFFQRLDD-SFLIv--EDKQ---G SKHPIFGTLQ-EEKEYHKQFPTIYHLRKQLA
143

WP_044680361
74
RRRNRILYLQEIFAEEINKIDDSFFQRLDD-SFLIv--EDKQ---G SKHPIFGTLQ-EEKEYHKQFPTIYHLRKQLA
143

WP_044681799
74
RRRNRILYLQEIFAEEINKIDDSFFQRLDD-SFLIv--EDKQ---G SKHPIFGTLQ-EEKKYHKQFPTIYHLRKQLA
143

WP_049533112
74
RRRNRLRYLQEIFAEEMNKVDENFFQRLDD-SFLV--DEDKR---G ERHPIFGNIA-AEVKYHDDFPTIYHLRKHLA
143

WP_029090905
28
HRKFRLRLLEDMFEKEILSKDPSFFIRLKE-AFLSpkDEQKQ---F ----LFNDKDyTDADYYEQYKTIYHLRYDLI
100

WP_006506696
61
KRRERIRLLRAILQDMVLEKDPTFFIRLEHtSFLD--EEDKAkylG DNYNLFIDEDfNDYTYYHKYPTIYHLRKALC
139

AIT42264
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

WP_034440723
73
RRRFRIRELQKIFDKSMGEVDSNFFHRLDE-SFLV--EEDKE---Y SKYPIFSNEK-EDKNYYDKYPTIYHLRKDLA
142

AKQ21048
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

WP_004636532
74
RRRNRLIYLQDIFQQPMLAIDENFFHRLDD-SFFV--PDDKS---Y DRHPIFGSLE-EEVAYHNTYPTIYHLRKHLA
143

WP_002364836
74
RRRNRLRYLQAFFEEAMTDLDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
143

WP_016631044
25
RRRNRLRYLQAFFEEAMTDLDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
94

EMS75795

---------------------------------------------- -------------------------------

WP_002373311
74
RRRNRLRYLQAFFEEAMTDLDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
143

WP_002378009
74
RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
143

WP_002407324
74
RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
143

WP_002413717
74
RRRNRLRYLQAFFEEAMTDLDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
143

WP_010775580
74
RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
143

WP_010818269
74
RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
143

WP_010824395
74
RRRNRLRYLQAFFEEAMTDLDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
143

WP_016622645
74
RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
143

WP_033624816
74
RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
143

WP_033625576
74
RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
143

WP_033789179
74
RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA
143

WP_002310644
74
RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA
143

WP_002312694
74
RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--PDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA
143

WP_002314015
74
RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA
143

WP_002320716
74
RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA
143

WP_002330729
74
RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA
143

WP_002335161
74
RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA
143

WP_002345439
74
RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA
143

WP_034867970
74
RRKYRLSKLQDLFAEELCKQDDCFFVRLEE-SFLV--PEEKQ---Y KPASIFPTLE-EEKEYYQKYPTIYHLRQKLV
143

WP_047937432
74
RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA
143

WP_010720994
74
RRKYRLSKLQDLFAEELCKQDDCFFVRLEE-SFLV--PEEKQ---Y KPASIFPTLE-EEKEYYQKYPTIYHLRQKLV
143

WP_010737004
74
RRKYRLSKLQDLFAEELCKQDDCFFVRLEE-SFLV--PEEKQ---Y KPASIFPTLE-EEKEYYQKYPTIYHLRQKLV
143

WP_034700478
74
RRKYRLSKLQDLFAEELCKQDDCFFVRLEE-SFLV--PEEKQ---Y KPASIFPTLE-EEKEYYQKYPTIYHLRQKLV
143

WP_007209003
74
RRKNRICYLQEIFQPEMNHLDNNFFYRLNE-SFLVa--DDAK---Y DKHPIFGTLD-EEIHFHEQFPTIYHLRKYLA
143

WP_023519017
74
RRRQRVLALQDIFAEEIHKKDPNFFARLEE-GDRV--EADKR---F AKFPVFATLS-EEKNYHRQYPTIYHLRHDLA
143

WP_010770040
74
RRRNRICRLQDLFTEEMNQVDANFFHRLQE-SFLV--PDEKE---F ERHAIFGKME-EEVSYYREFPTIYHLRKHLA
143

WP_048604708
74
RRRQRISYLQTFFQEEMNRIDPNFFNRLDE-SFLI--EEDKL---S ERHPIFGTIE-EEVAYHKNYATIYHLRKELA
143

WP_010750235
74
RRKYRILELQKIFSEEILKKDSHFFARLDE-SFLI--PEDKQ---Y ARFPIFPTLL-EEKAYYQNYPTIYHLRQKLA
143

AII16583
113
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
182

WP_029073316
66
KRRERIRLLRGIMEDMVLDVDPTFFIRLANvSFLD--QEDKKdylK SNYNLFIDKDfNDKTYYDKYPTIYHLRKHLC
144

WP_031589969
66
KRRERIRLLREIMEDMVLDVDPTFFIRLANvSFLD--QEDKKdylK SNYNLFIDKDfNDKTYYDKYPTIYHLRKHLC
144

KDA45870
75
RRKNRLRYLQEIFAPALAKVDPNFFYRLEE-SSLVa--EDKK---Y DVYPIFGKRE-EELLYHDTHKTIYHLRSELA
144

WP_039099354
62
RRKWRLGLLREIFEPYITPVDDTFFLRKKQ-SNLS--PKDQR---K -QTSLFNDRT--DRAFYDDYPTIYHLRYKLM
132

AKP02966
65
RRKNRINWLNEIFSEELANTDPSFLIRLQN-SWVSkkDPDRK---R DKYNLFIDNPyTDKEYYREFPTIFHLRKELI
137

WP_010991369
74
RRRNRISYLQGIFAEEMSKTDANFFCRLSD-SFYV--DNEKR---N SRHPFFATIE-EEVEYHKNYPTIYHLREELV
143

WP_033838504
74
RRRNRISYLQGIFAEEMSKTDANFFCRLSD-SFYV--DNEKR---N SRHPFFATIE-EEVEYHKNYPTIYHLREELV
143

EHN60060
77
RRRNRISYLQGIFAEEMSKTDANFFCRLSD-SFYV--DNEKR---N SRHPFFATIE-EEVEYHKNYPTIYHLREELV
146

EFR89594

---------------------------------------------- -------------------------------

WP_038409211
74
RRRNRIAYLQEIFAAEMAEVDANFFYRLED-SFYI--ESEKR---H SRHPFFATIE-EEVAYHEEYKTIYHLREKLV
143

EFR95520

---------------------------------------------- -------------------------------

WP_003723650
74
RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHDNYRTIYHLREKLV
143

WP_003727705
74
RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV
143

WP_003730785
74
RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV
143

WP_003733029
74
RRRNRISYLQEIFAIQMNEVDDNFFNRLKE-SFYA--ESDKK---Y NRHPFFGTVE-EEVAYYKDFPTIYHLRKELI
143

WP_003739838
74
RRRNRISYLQEIFALEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV
143

WP_014601172
74
RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV
143

WP_023548323
74
RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV
143

WP_031665337
74
RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV
143

WP_031669209
74
RRRNRISYLQEIFAIQMNEVDDNFFNRLKE-SFYA--ESDKK---Y NRHPFFGTVE-EEVAYYKDFPTIYHLRKELI
143

WP_033920898
74
RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV
143

AKI42028
77
RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV
146

AKI50529
77
RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV
146

EFR83390

---------------------------------------------- -------------------------------

WP_046323366
74
RRRNRISYLQEIFTAEMFEVDANFFYRLED-SFYI--ESEKR---Q SRHPFFATIE-EEVAYHENYRTIYHLREKLV
143

AKE81011
90
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
159

CUO82355
65
KRRERIRLLRAILQDMVLEKDPTFFIRLEHtSFLD--EEDKAkylG DNYNLFIDEDfNDYTYYHKYPTIYHLRKALC
143

WP_033162887
66
KRRERIRLLRDLLGDMVMEVDPTFFIRLLNvSFLD--EEDKQkn1G DNYNLFIEKDfNDKTYYDKYPTIYHLRKELC
144

AGZ01981
107
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
176

AKA60242
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

AKS40380
74
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
143

4UN5_B
78
RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV
147

WP_010922251
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDV custom character

KL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

WP_039695303
145
DSSEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKI--FADFVGVYNRT--FDDS-H LSEITVDVA---SI
212

WP_045635197
144
DSKEKTDLRLIYLALAHMIKYRGHFLYEEA-FDIKNNDIQKI--FNEFISIYDNT--FEGS-S LSGQNAQVE---AI
211

5AXW_A
105
EEEFSA-------ALLHLAKRRG---VHNV------NEVE------------EDT----GN-- -------E------
134

WP_009880683

--------------------------------------------------------------- --------------

WP_010922251
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

WP_011054416
144
DSTDKVDLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_011284745
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

WP_011285506
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

WP_011527619
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

WP_012560673
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_014407541
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQIYNQL--FEEN-- INASRVDAK---AI
211

WP_020905136
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

WP_023080005
144
DSTDKVDLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_023610282
144
DSTDKVDLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_030125963
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

WP_030126706
144
DSTDKVDLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_031488318
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_032460140
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_032461047
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGG-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_032462016
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INANGVDAK---AI
211

WP_032462936
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_032464890
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

WP_033888930
1
---------------------------------PDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
36

WP_038431314
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_038432938
144
DSTDKVDLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_038434062
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

BAQ51233
55
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
122

KGE60162

--------------------------------------------------------------- --------------

KGE60856

--------------------------------------------------------------- --------------

WP_002989955
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

WP_003030002
144
DISQKADLRLVYLALAHMIKFRGHFLIEGQ-LKAENTNVQAL--FKDFVEVYDKT--VEES-H LSEMTVDAL---SI
211

WP_003065552
147
DSSEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKI--FADFVGVYDRT--FDDS-H LSEITVDAA---SI
214

WP_001040076
144
DKKEKADLRLVYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQDVDVE---AI
212

WP_001040078
144
DKQEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-H LLSQNVDVE---AI
212

WP_001040080
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNIT--FENN-D LLSQNVDVE---AI
212

WP_001040081
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTI--FENN-D LLSQNVDVE---AI
212

WP_001040083
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

WP_001040085
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

WP_001040087
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

WP_001040088
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

WP_001040089
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

WP_001040090
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

WP_001040091
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

WP_001040092
144
DKKEKADLRLVYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTS--FENN-H LLSQNVDVE---AI
212

WP_001040094
144
DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI
212

WP_001040095
144
DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI
212

WP_001040096
144
DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI
212

WP_001040097
144
DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI
212

WP_001040098
144
DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI
212

WP_001040099
144
DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI
212

WP_001040100
144
DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI
212

WP_001040104
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

WP_001040105
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

WP_001040106
144
DKKEKANLRLVYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI
212

WP_001040107
144
DKKEKADLRLVYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI
212

WP_001040108
144
DKKEKADLRLVYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI
212

WP_001040109
144
DKKEKANLRLVYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI
212

WP_001040110
144
DKKEKANLRLVYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI
212

WP_015058523
144
DKKEKADLRLVYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTS--FENN-H LLSQNVDVE---AI
212

WP_017643650
144
DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI
212

WP_017647151
144
DKKEKADLRLFYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDIE---GI
212

WP_017648376
144
DKKEKADLRLFYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI
212

WP_017649527
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

WP_017771611
144
DKKEKADLRLVYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI
212

WP_017771984
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

CFQ25032
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

CFV16040
144
DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI
212

KLJ37842
144
DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI
212

KLJ72361
144
DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI
212

KLL20707
144
DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI
212

KLL42645
144
DKKEKANLRLVYLALAHIIKERGHFLIEDDsEDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI
212

WP_047207273
144
DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI
212

WP_047209694
144
DKKEKADLRLIYLALAHIIKERGHFLIEDDsEDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI
212

WP_050198062
144
DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI
212

WP_050201642
144
DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI
212

WP_050204027
144
DKKEKANLRLVYLALAHIIKERGHFLIEDDsEDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI
212

WP_050881965
144
DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI
212

WP_050886065
144
DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI
212

AHN30376
144
DKKEKADLRLVYLALAHIIKERGHFLIEDDrEDVRNTDIQKQ--YQAFLEIFDTS--FENN-H LLSQNVDVE---AI
212

EA078426
144
DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI
212

CCW42055
144
DKKEKADLRLVYLALAHIIKERGHFLIEDDrEDVRNTDIQKQ--YQAFLEIFDTT--FENN-H LLSQNVDVE---AI
212

WP_003041502
144
DISQKADLRLVYLALAHMIKERGHFLIEGQ-LKAENTNVQAL--FKDEVEVYDKT--VEES-H LSEITVDAL---SI
211

WP_037593752
145
NSKEKADLRLVYLALAHMIKERGHFLYEGD-LKAENTDVQAL--FKDEVEEYDKT--IEES-H LSEITVDAL---SI
212

WP_049516684
145
DISQKADLRLVYLALAHMIKERGHFLIEGQ-LKAENTNVQAL--FKDEVEVYDKT--VEES-H LSEMTVDAL---SI
212

GAD46167
144
NSKEKADLRLVYLALAHMIKERGHFLYEGD-LKAENTDVQAL--FKDEVEEYDKT--IEES-H LSEITVDAL---SI
211

WP_018363470
145
DSTEKADLRLVYLALAHMIKERGHFLIEGE-LNAENTDVQKL--FTDEVGVYDRT--FDDS-H LSEITVDAA---SI
212

WP_003043819
144
DSPEKADLRLIYLALAHIIKERGHFLIEGK-LNAENSDVAKL--FYQLIQTYNQL--FEES-- LDEIEVDAK---GI
211

WP_006269658
144
DTSKKADLRLVYLALAHMIKERGHFLYEGD-LKAENTDVQAL--FKDEVEEYDKT--IEES-H LSEITVDAL---SI
211

WP_048800889
144
DSTGKVDLRLVYLALAHMIKERGHFLIEGQ-LKAENTDVQTL--ENDEVEVYDKT--IEES-H LAEITVDAL---SI
211

WP_012767106
144
DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDMDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_014612333
144
DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEK-- INASGVDAK---AI
211

WP_015017095
144
DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDMDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_015057649
144
DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDMDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_048327215
144
DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDMDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_049519324
144
DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI
211

WP_012515931
144
DNPQKADLRLIYLAVAHIIKERGHFLIEGT-LSSKNNNLQKS--FDHLVDTYNLL--FEEQ-- LLTEGINAK---EL
211

WP_021320964
144
DNPQKADLRLIYLAVAHIIKERGHFLIEGT-LSSKNNNLQKS--FDHLVDTYNLL--FEEQ-- LLTEGINAK---EL
211

WP_037581760
144
DNPQKADLRLIYLAVAHIIKERGHFLIEGT-LSSKNNNLQKS--FDHLVDTYNLL--FEEQ-- LLTEGINAK---EL
211

WP_004232481
144
DSPEKVDLRLVYLALAHMIKERGHFLIEGQ-LNAENTDVQKI--FADEVGVYDRT--FDDS-H LSEITVDAA---SI
211

WP_009854540
145
DSSEKADLRLVYLALAHMIKYRGHFLIEGK-LNAENTDVQKL--FTDEVGVYDRT--FDDS-H LSEITVDVA---ST
212

WP_012962174
145
DSHEKADLRLIYLALAHMIKERGHFLIEGE-LNAENTDVQKL--FEAFVEVYDRT--FDDS-N LSEITVDAS---SI
212

WP_039695303
145
DSSEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKI--FADFVGVYNRT--FDDS-H LSEITVDVA---SI
212

WP_014334983
144
DSQEKADLRLVYLALAHMIKYRGHFLIEGE-LNAENTDVQKL--FNVFVETYDKI--VDES-H LSEIEVDAS---SI
211

WP_003099269
144
DSDQKADLRLIYLALAHIIKFRGHFLIEGN-LDSENTDVHVL--FLNLVNIYNNL--FEED-- VETASIDAE---KI
211

AHY15608
144
DSDQKADLRLIYLALAHIIKFRGHFLIEGN-LDSENTDVHVL--FLNLVNIYNNL--FEED-- VETASIDAE---KI
211

AHY17476
144
DSDQKADLRLIYLALAHIIKFRGHFLIEGN-LDSENTDVHVL--FLNLVNIYNNL--FEED-- VETASIDAE---KI
211

ESR09100

--------------------------------------------------------------- --------------

AGM98575
144
DSDQKADLRLIYLALAHIIKFRGHFLIEGN-LDSENTDVHVL--FLNLVNIYNNL--FEED-- VETASIDAE---KI
211

ALF27331
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---El
211

WP_018372492
144
DTPDKMDIRLIYLALAHIIKYRGHFLIEGD-LDIENIGIQDS--FKSFIEEYNTQ--FGTK-- -LDSTTKVE---Al
209

WP_045618028
145
DSKEKADFRLIYLALAHIIKYRGHFLYEES-FDIKNNDIQKI--FNEFISIYDNT--FEGS-S LNGQNAQVE---AI
212

WP_045635197
144
DSKEKTDLRLIYLALAHMIKYRGHFLYEEA-FDIKNNDIQKI--FNEFISIYDNT--FEGS-S LSGQNAQVE---AI
211

WP_002263549
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002263887
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002264920
144
DSTEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKL--FADFVGVYDRT--FDDS-H LSEITVDAS---SI
211

WP_002269043
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002269448
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002271977
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002272766
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002273241
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002275430
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002276448
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002277050
144
DSTEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKL--FADFVGVYDRT--FDDS-H LSEITVDAS---SI
211

WP_002277364
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002279025
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002279859
144
DSTEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKL--FADFVGVYDRT--FDDS-H LSEITVDAS---SI
211

WP_002280230
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002281696
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002282247
144
DSTEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKL--FADFVGVYDRT--FDDS-H LSEITVDAS---SI
211

WP_002282906
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002283846
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002287255
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002288990
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002289641
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002290427
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002295753
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002296423
144
DNPEKTDLRLVYLALAHIIKFGGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002304487
144
NSTEKADLRLVYLSLAHMIKFRGHFLIEGQ-LKAENTNVQAL--FKDFVEVYDKT--VEES-H LSEMTVDAL---SI
211

WP_002305844
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002307203
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQKL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002310390
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_002352408
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_012997688
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_014677909
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_019312892
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_019313659
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_019314093
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQKL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_019315370
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_019803776
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_019805234
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_024783594
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_024784288
144
DSTEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKL--FADFVGVYDRT--FDDS-H LSEITVDAS---SI
211

WP_024784666
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_024784894
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_024786433
144
DSTEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKL--FADFVGVYDRT--FDDS-H LSEITVDAS---SI
211

WP_049473442
144
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

WP_049474547
144
DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
211

EMC03581
137
DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI
204

WP_000428612
145
DSKEKTDLRLIYLALAHMIKYRGHFLYEDT-FDIKNNDIQKI--FNEFISIYNNT--FEGN-S LSGQNVQVE---AI
212

WP_000428613
145
DSKEKTDLRLIYLALAHMIKYRGHFLYEDT-FDIKNNDIQKI--FSEFISIYDNT--FEGS-S LSGQNAQVE---AI
212

WP_049523028
144
DSKEKVDLRLIYLALAHIIKYRGHFLYEDS-FDIKNNDIQKI--FNEFTILYDNT--FEES-S LSKGNAQVE---EI
211

WP_003107102
113
DSDEKADLRLIYLALAHIIKFRGHFLIEGD-LDSQNTDVNAL--FLKLVDTYNLM--FEDD-- IDTQTIDAT---VI
180

WP_054279288
146
DNTEKADLRLIYLALAHIIKFRGHFLIEGA-LSANNTDVQQL--VHALVDAYNIM--FEED-- LDIEAIDVK---AI
213

WP_049531101
145
DSKEKADLRLIYLTLAHMIKYRGHFLYEES-FDIKNNDIQKI--FNEFISIYDNT--FEGS-S LSGQNAQVE---AI
212

WP_049538452
145
DSKEKADLRLIYLALAHMIKYRGHFLYEEA-FDIKNNDIQKI--FNEFINIYDNT--FEGS-S LSGQNEQVE---AI
212

WP_049549711
145
DSKEKADLRLIYLVLAHMIKYRGHFLYEEA-FDIKNNDIQKI--FNEFISIYDNT--FEGS-S LSGQNAQVE---TI
212

WP_007896501
146
DRDQKADLRLIYLALSHIIKFRGHFLIEGK-LNSENTDVQKL--FIALVTVYNLL--FEEE-- IAGETCDAK---AL
213

EFR44625
98
DRDQKADLRLIYLALSHIIKFRGHFLIEGK-LNSENTDVQKL--FIALVTVYNLL--FEEE-- IAGETCDAK---AL
165

WP_002897477
144
DSKEKSDVRLIYLALAHMIKYRGHFLYEET-FDIKNNDIQKI--FNEFINIYDNT--FEGS-S LSGQNAQVE---AI
211

WP_002906454
144
DSKEKTDLRLIYLALAHMIKYRGHFLYEES-FDIKNNDIQKI--FNEFISIYDNT--FEGS-S LSGQNAQVE---AI
211

WP_009729476
145
DSKEKTDLRLIYLALAHMIKYRGHFLYEEA-FDIKNNDIQKI--FNEFISIYNNT--FEGN-S LSGQNVQVE---AI
212

CQR24647
144
DSSEKADLRLVYLALAHIIKYRGHFLIDEP-IDIRNMNSQNL--FKEFLLAFDGI--QVDC-Y LASKHTDIS---GI
211

WP_000066813
145
DSKEKTDLRLIYLALAHMIKYRGHFLYEES-FDIKNNDIQKI--FSEFISIYDNT--FEGK-S LSGQNAQVE---AI
212

WP_009754323
145
DSKEKADLRLIYLALAHITKYRGHFLYEEA-FDIKNNDIQKI--FNEFINIYDNT--FEGS-S LSGQNAQVE---AI
212

WP_044674937
144
DSSQKADIRLIYLALAHIIKYRGHELFEGD-LKSENKDVQHL--FNDEVEMFDKT--VEGS-Y LSENLPNVA---DV
211

WP_044676715
144
DSSQKADIRLIYLALAHIIKYRGHELFEGD-LKSENKDVQHL--FNDEVEMFDKT--VEGS-Y LSENLPNVA---DV
211

WP_044680361
144
DSSQKADIRLIYLALAHIIKYRGHELFEGD-LKSENKDVQHL--FNDEVEMFDKT--VEGS-Y LSENLPNVA---DV
211

WP_044681799
144
DSSQKADIRLIYLALAHIIKYRGHELFEGD-LKSENKDVQHL--FNDEVEMFDKT--VEGS-Y LSENLPNVA---DV
211

WP_049533112
144
DISQKADLRLVYLALAHMIKERGHFLIEGQ-LKAENTNVQAL--FKDEVEVYDKT--VEES-H LSEMTVDAL---SI
211

WP_029090905
101
SQHRQFDIREVYLAIHHLIKYRGHFIYEDQtFTTDGNQLQHH--IKAIITMINST1---NR-- IIPETIDINvfeKI
171

WP_006506696
140
ESTEKADPRLIYLALHHIVKYRGNFLYEGQkFNMDASNIEDK--LSDIFTQFTSFnnIPYEdD --KKNLEIL---EI
210

AIT42264
144
DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

WP_034440723
143
DSNQKADLRLIYLALAHMIKYRGHFLIEGD-LKMDGISISES--FQEFIDSYNEVcaLEDE-N NDELLTQIE---NI
217

AKQ21048
144
DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

WP_004636532
144
DNPEKADLRLVYTALAHIVKYRGHFLIEGE-LNTENTSISET--FEQFLDTYSDI--FKEQ-- LVGDISKVE---EI
210

WP_002364836
144
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE
217

WP_016631044
95
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENTSVKDQ--FQQFMVIYNQT--FVNGeS PLPESVLIE---EE
168

EMS75795

--------------------------------------------------------------- --------------

WP_002373311
144
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENTSVKEQ--FQQFMVIYNQT--FVNGeS PLPESVLIE---EE
217

WP_002378009
144
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE
217

WP_002407324
144
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE
217

WP_002413717
144
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE
217

WP_010775580
144
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE
217

WP_010818269
144
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE
217

WP_010824395
144
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENTSVKDQ--FQQFMVIYNQT--FVNGeS PLPESVLIE---EE
217

WP_016622645
144
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEK--FQQFMIIYNQT--FVNGeG PLPESVLIE---EE
217

WP_033624816
144
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKDQ--FQQFMVIYNQT--FVNGeS PLPESVLIE---EE
217

WP_033625576
144
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE
217

WP_033789179
144
DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE
217

WP_002310644
144
DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV
216

WP_002312694
144
DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-G KLDEAVDCS---FV
216

WP_002314015
144
DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV
216

WP_002320716
144
DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV
216

WP_002330729
144
DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV
216

WP_002335161
144
DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV
216

WP_002345439
144
DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV
216

WP_034867970
144
DSTEKEDLRLVYLALAHLLKYRGHFLFEGD-LDTENTSIEES--FRVFLEQYSKQ--SDQP-- -LIVHQPVL---TI
209

WP_047937432
144
DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV
216

WP_010720994
144
DSTEKGDLRLVYLALAHLLKYRGHFLFEGD-LDTENTSIEES--FRVFLEQYGKQ--SDQP-- -LIVHQPVL---TI
209

WP_010737004
144
DSTEKEDLRLVYLALAHLLKYRGHFLFEGD-LDTENTSIEES--FRVFLEQYSKQ--SDQP-- -LIVHQPVL---TI
209

WP_034700478
144
DSTEKEDLRLVYLALAHLLKYRGHFLFEGD-LDTENTSIEES--FRVFLEQYGKQ--SDQP-- -LIVHQPVL---TI
209

WP_007209003
144
DGDEKADLRLVYLAIAHIIKFRGNFLIEGE-LNTENNSVIELs--KVFVQLYNQT1-SELE-- FIDESIDFS---EV
214

WP_023519017
144
NSKEQADIRLVYLAIAHCLKYRGHFLFEGE-LDTENTSVTEN--YQQFLQAYQQF--FPEP-- -IGDLDDAV---PI
209

WP_010770040
144
DTSEQADLRLVYLALAHIVKYRGHFLIEGE-LNTENSSVSET--FRTFIQVYNQI--FRENe- PLAVPDNIE---EL
212

WP_048604708
144
DAEEKADLRLVYLALAHIIKYRGHFLIEGR-LSTENTSTEET--FKTFLQKYNQT--FN---- PVDETISIG---SI
208

WP_010750235
144
DSTEKADIRLVYLALAHMIKYRGHFLFEGE-LDTENTSVEET--FKEFIDIYNEQ--FEEG-- -IIFYKDIP---LI
209

AII16583
183
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
250

WP_029073316
145
ESKEKEDPRLIYLALHHIVKYRGNFLYEGQkFSMDVSNIEDK--MIDVLRQFNEIn1FEYVeD --KKIDEVL---NV
215

WP_031589969
145
ESKEKEDPRLIYLALHHIVKYRGNFLYEGQkFSMDVSNIEDK--MIDVLRQFNEIn1FEYVeD --KKIDEVL---NV
215

KDA45870
145
NNDRPADLRLVYLALAHIIKYRGNELLEGE-IDLRTTDINKV--FAEFSETLNEN--SDEN1G ----KLDVA---DI
209

WP_039099354
133
TEKRQFDIREIYLAMHHIVKYRGHFLNEAPvSSEKSSEINLVahFDRLNTIFADL--FSESgF -TDKLAEVK---AL
206

AKP02966
138
INKNKADIRLVYLALHNILKYRGNFTYEHQkFNISTLNSNLS---KELIELNQQLikYDIS-- -FPDNCDWNhisDI
208

WP_010991369
144
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTQNTSVDGI--YKQFIQTYNQV--FASGiE KLEDNKDVA---KI
217

WP_033838504
144
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTQNTSVDGI--YKQFIQTYNQV--FASGiE KLEDNKDVA---KI
217

EHN60060
147
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTQNTSVDGI--YKQFIQTYNQV--FASGiE KLEDNKDVA---KI
220

EFR89594

--------------------------------------------------------------- --------------

WP_038409211
144
NSSDKADLRLVYLALAHIIKYRGNFLIEGM-LDTKNTSVDEV--FKQFIQTYNQI--FASDiE RLEENKEVA---EI
217

EFR95520

--------------------------------------------------------------- --------------

WP_003723650
144
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDEV--YKQFIETYNQV--FMSNiE KVEENIEVA---NI
217

WP_003727705
144
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDEV--YKQFIQTYNQV--FMSNiE KVEENTEVA---SI
217

WP_003730785
144
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDEV--YKQFIQTYNQV--FMSNiE KVEENTEVA---SI
217

WP_003733029
144
DSQKKADLRLVYLALAHIIKYRGHFLIEGA-LDTKNTSIDEM--FKQFLQIYNQV--FANDiE KTEKNQEVA---QI
217

WP_003739838
144
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YKQFIQTYNQV--FISNiE KMEENTTVA---DI
217

WP_014601172
144
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YEQFIQTYNQV--FMSNiE KVEENIEVA---NI
217

WP_023548323
144
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YEQFILTYNQV--FMSNiE KVEENIEVA---NI
217

WP_031665337
144
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YEQFIQTYNQV--FMSNiE KVEENIEVA---NI
217

WP_031669209
144
DSQKKADLRLVYLALAHIIKYRGHFLIEGA-LDTKNTSIDEM--FKQFLQIYNQV--FANDiE KTEKNQEVA---QI
217

WP_033920898
144
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YEQFIQTYNQV--FMSNiE KVEENIEVA---NI
217

AKI42028
147
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YEQFIQTYNQV--FMSNiE KVEENIEVA---NI
220

AKI50529
147
NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YEQFIQTYNQV--FMSNiE KVEENIEVA---NI
220

EFR83390

--------------------------------------------------------------- --------------

WP_046323366
144
NSSDKADLRLVYLALAHIIKYRGNFLIEGK-LDTKNTSVDEV--FKQFIKTYNQV--FASDiE RIEENNEVA---KI
217

AKE81011
160
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
227

CUO82355
144
ESTEKADPRLIYLALHHIVKYRGNFLYEGQkFNMDASNIEDK--LSDVFTQFADFnnIPYEdD --KKNLEIL---EI
214

WP_033162887
145
ENKEKADPRLIYLALHHIVKYRGNFLYEGQsFTMDNSDIEER--LNSAIEKFMSIneFDNRiV --SDINSMI---AV
215

AGZ01981
177
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
244

AKA60242
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

AKS40380
144
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
211

4UN5_B
148
DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI
215

WP_010922251
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED- custom character

---KLQ--LSKDTYDDDLDN
277

WP_039695303
213
LTEK-ISKSRRLENLIKY-Y-PT EKKNTLFGNLIALALGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE
278

WP_045635197
212
FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEDK-A---PLQ--FSKDTYDEDLEN
277

5AXW_A
135
LSTK--------EQISRN-S--K ------------------LEEKyVa--ELQ------------------------
157

WP_009880683

------- ----------------------

WP_010922251
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_011054416
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_011284745
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_011285506
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_011527619
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_012560673
212
LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_014407541
212
LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_020905136
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_023080005
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_023610282
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_030125963
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_030126706
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_031488318
212
LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_032460140
212
LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_032461047
212
LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_032462016
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_032462936
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALLLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_032464890
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_033888930
37
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
102

WP_038431314
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_038432938
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-T---KLQ--LSKDTYDDDLDN
277

WP_038434062
212
LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

BAQ51233
123
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
188

KGE60162

----------------------- ------------------------------------------------------

KGE60856

----------------------- ------------------------------------------------------

WP_002989955
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_003030002
212
LTEK-VSKSRRLENLIAH-Y-PA EKKNTLFGNLIALSLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEG
277

WP_003065552
215
LTEK-ISKSRRLENLIKY-Y-PT EKKNTLFGNLIALALGLQPNFKMNF--KLSED-A---KLQ--FSKDSYEEDLGE
280

WP_001040076
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040078
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040080
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040081
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040083
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040085
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040087
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040088
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040089
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040090
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040091
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040092
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040094
213
LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040095
213
LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040096
213
LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040097
213
LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040098
213
LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040099
213
LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040100
213
LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040104
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040105
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040106
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040107
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040108
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040109
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_001040110
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_015058523
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_017643650
213
LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_017647151
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_017648376
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_017649527
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_017771611
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_017771984
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

CFQ25032
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

CFV16040
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

KLJ37842
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

KLJ72361
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

KLL20707
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

KLL42645
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_047207273
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_047209694
213
LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_050198062
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_050201642
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_050204027
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_050881965
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_050886065
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

AHN30376
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

EA078426
213
LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

CCW42055
213
LTDK-ISKSAKKDRILAQ-Y-PD QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN
278

WP_003041502
212
LTEK-VSKSRRLENLIAH-Y-PA EKKNTLFGNLIALFLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEG
277

WP_037593752
213
LTEK-VSKSSRLENLIAH-Y-PT EKKNTLFGNLIALSLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEE
278

WP_049516684
213
LTEK-VSKSRRLENLVEC-Y-PT EKKNTLFGNLIALSLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEG
278

GAD46167
212
LTEK-VSKSSRLENLIAH-Y-PT EKKNTLFGNLIALSLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEE
277

WP_018363470
213
LTEK-ISKSRRLENLINN-Y-PK EKKNTLFGNLIALALGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE
278

WP_003043819
212
LSAR-LSKSKRLEKLIAV-F-PN EKKNGLFGNIIALALGLTPNFKSNF--DLTED-A---KLQ--LSKDTYDDDLDE
277

WP_006269658
212
LTEK-VSKSSRLENLIAH-Y-PT EKKNTLFGNLIALSLDLHPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEG
277

WP_048800889
212
LTEK-VSKSRRLENLVKC-Y-PT EKKNTLFGNLIALSLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEE
277

WP_012767106
212
LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_014612333
212
LSAR-LSKSKRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_015017095
212
LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_015057649
212
LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_048327215
212
LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_049519324
212
LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_012515931
212
LSAA-LSKSKRLENLISL-I-PG QKKTGIFGNIIALSLGLTPNFKANF--GLSKD-V---KLQ--LAKDTYADDLDS
277

WP_021320964
212
LSAA-LSKSKRLENLISL-I-PG QKKTGIFGNIIALSLGLTPNFKANF--GLSKD-V---KLQ--LAKDTYADDLDS
277

WP_037581760
212
LSAA-LSKSKRLENLISL-I-PG QKKTGIFGNIIALSLGLTPNFKANF--GLSKD-V---KLQ--LAKDTYADDLDS
277

WP_004232481
212
LTEK-ISKSRRLENLIKQ-Y-PT EKKNTLFGNLVALALGLQPNFKTNF--KLSED-A---KLQ--FSKDTYDEDLEE
277

WP_009854540
213
LTEK-ISKSRRLENLIKY-Y-PT EKKNTLFGNLIALALGLQPNFKMNF--KLSED-A---KLQ--FSKDTYEEDLEE
278

WP_012962174
213
LTEK-FSKSRRLENLIKH-Y-PT EKKNTLFGNLVALALGLQPNFKTSF--KLSED-A---KLQ--FSKDTYEEDLEE
278

WP_039695303
213
LTEK-ISKSRRLENLIKY-Y-PT EKKNTLFGNLIALALGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE
278

WP_014334983
212
LTEK-VSKSRRLENLIKQ-Y-PT EKKNTLFGNLIALALGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE
277

WP_003099269
212
LTSK-TSKSRRLENLIAE-I-PN QKRNMLFGNLVSLALGLTPNFKTNF--ELLED-A---KLQ--ISKDSYEEDLDN
277

AHY15608
212
LTSK-TSKSRRLENLIAE-I-PN QKRNMLFGNLVSLALGLTPNFKTNF--ELLED-A---KLQ--ISKDSYEEDLDN
277

AHY17476
212
LTSK-TSKSRRLENLIAE-I-PN QKRNMLFGNLVSLALGLTPNFKTNF--ELLED-A---KLQ--ISKDSYEEDLDN
277

ESR09100

----------------------- ------------------------------------------------------

AGM98575
212
LTSK-TSKSRRLENLIAE-I-PN QKRNMLFGNLVSLALGLTPNFKTNF--ELLED-A---KLQ--ISKDSYEEDLDN
277

ALF27331
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_018372492
210
FTEN-SSKAKRVETILGL-F-PD ETAAGNLDKFLKLMLGNQADFKKVF--DLEEK----iTLQ--FSKDSYEEDLEL
275

WP_045618028
213
FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYDEDLEN
278

WP_045635197
212
FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEDK-A---PLQ--FSKDTYDEDLEN
277

WP_002263549
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002263887
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002264920
212
LTEK-ISKSRRLEKLINN-Y-PK EKKNTLFRNLVALSLGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE
277

WP_002269043
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV
277

WP_002269448
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002271977
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEDLEE
277

WP_002272766
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEDLEE
277

WP_002273241
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002275430
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002276448
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002277050
212
LTEK-ISKSRRLEKLINN-Y-PK EKKNTLFGNLIALSLGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE
277

WP_002277364
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002279025
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002279859
212
LTEK-ISKSRRLEKLINN-Y-PK EKKNTLFGNLIALSLGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEELEV
277

WP_002280230
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002281696
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002282247
212
LTEK-ISKSRRLEKLINN-Y-PK EKKNTLFGNLIALSLGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE
277

WP_002282906
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002283846
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV
277

WP_002287255
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002288990
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV
277

WP_002289641
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGCFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002290427
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV
277

WP_002295753
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002296423
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV
277

WP_002304487
212
LTEK-VSKSRRLENLVEC-Y-PT EKKNTLFGNLIALSLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEG
277

WP_002305844
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_002307203
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--LSKDTYEEELEV
277

WP_002310390
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV
277

WP_002352408
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV
277

WP_012997688
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_014677909
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV
277

WP_019312892
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_019313659
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIIGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_019314093
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--LSKDTYEEELEV
277

WP_019315370
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_019803776
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-V---PLQ--FSKDTYEEELEV
277

WP_019805234
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV
277

WP_024783594
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_024784288
212
LTEK-ISKSRRLEKLINN-Y-PK EKKNTLFGNLIALSLGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE
277

WP_024784666
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_024784894
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

WP_024786433
212
LTEK-ISKSRRLEKLINN-Y-PK EKKNTLFGNLIALSLGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE
277

WP_049473442
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEDLEE
277

WP_049474547
212
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
277

EMC03581
205
LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV
270

WP_000428612
213
FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSRDTYDEDLEN
278

WP_000428613
213
FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLGEK-A---PLQ--FSKDTYDEDLEN
278

WP_049523028
212
FTDK-ISKSAKRDRVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYEEDLES
277

WP_003107102
181
LTEK-MSKSRRLENLIAK-I-PN QKKNTLFGNLISLSLGLTPNFKANF--ELSED-A---KLQ--ISKESFEEDLDN
246

WP_054279288
214
LTEK-ISKTRRLENLISN-I-PG QKKNGLFGNLIALSLGLTPNFKSHF--NLPED-A---KLQ--LAKDTYDEELNN
279

WP_049531101
213
FTDK-ISKSTKRERVLKL-F-PD QKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYDEDLEN
278

WP_049538452
213
FSDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYDEDLEN
278

WP_049549711
213
FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLGEK-A---PLQ--FSKDTYDEDLEN
278

WP_007896501
214
LTAK-TSKSKRLESLISE-F-PG QKKNGLFGNLLALALGLRPNFKSNF--GLSED-A---KLQ--ITKDTYEEELDN
279

EFR44625
166
LTAK-TSKSKRLESLISE-F-PG QKKNGLFGNLLALALGLRPNFKSNF--GLSED-A---KLQ--ITKDTYEEELDN
231

WP_002897477
212
FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYDEELEN
277

WP_002906454
212
FTDK-ISKSTKRERVLKL-F-SD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYDEDLEN
277

WP_009729476
213
FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSRDTYDEDLEN
278

CQR24647
212
ITAK-ISKSRKVEAVLEQ-F-PD QKKNSFFGNMVSLVFGLMPNEKSNF--ELDED-A---KLQ--FSRDSYDEDLEN
277

WP_000066813
213
FTDK-ISKSTKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYDEDLEN
278

WP_009754323
213
FTGK-ISKSVKREHVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---SLQ--FSKDTYDEDLEN
278

WP_044674937
212
LVEK-VSKSRRLENILHY-F-PN EKKNGLFGNFLALALGLQPNEKTNF--ELAED-A---KIQ--FSKETYEEDLEE
277

WP_044676715
212
LVEK-VSKSRRLENILHY-F-PN EKKNGLFGNFLTLALGLQPNEKTNF--ELAED-A---KIQ--FSKETYEEDLEE
277

WP_044680361
212
LVEK-VSKSRRLENILHY-F-PN EKKNGLFGNFLALALGLQPNEKTNF--ELAED-A---KIQ--FSKETYEEDLEE
277

WP_044681799
212
LVEK-VSKSRRLENILHY-F-PN EKKNGLFGNFLALALGLQPNEKTNF--ELAED-A---KIQ--FSKETYEEDLEE
277

WP_049533112
212
LTEK-VSKSRRLENLIAH-Y-PA EKKNTLFGNLIALSLGLQPNEKTNF--QLSED-A---KLQ--FSKDTYEEDLEG
277

WP_029090905
172
LLDRmMNRSSKVKFLIEL---TG KQDKPLLKELFNLIVGLKAKPASIFe---QEN1AtivETM-nMSTEQVQLDLLT
243

WP_006506696
211
LKKP-LSKKAKVDEVMTL-IaPE KDYKSAFKELVTGIAGNKMNVTKMI1cEPIKQ-Gds-EIK1kFSDSNYDDQFSE
283

AIT42264
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_034440723
218
FKQD-ISRSKKLDQAIAL-F-QG -KRQSLFGIFLTLIVGNKANFQKIF--NLEDD----iKLD--LKEEDYDENLEE
283

AKQ21048
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

WP_004636532
211
LSSK-QSRSRKHEQIMAL-F-PN ENKLGNFGRFMMLIVGNTSNFKPVF--DLDDE-Y---KLK--LSDETYEEDLDT
276

WP_002364836
218
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG
283

WP_016631044
169
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG
234

EM575795
1
----------------------- ----------------------------MDEE-A---KIQ--LSKESYEEELES
20

WP_002373311
218
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG
283

WP_002378009
218
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG
283

WP_002407324
218
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG
283

WP_002413717
218
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG
283

WP_010775580
218
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KIKitYASESYEEDLEG
285

WP_010818269
218
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG
283

WP_010824395
218
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG
283

WP_016622645
218
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG
283

WP_033624816
218
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG
283

WP_033625576
218
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG
283

WP_033789179
218
LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG
283

WP_002310644
217
FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EE-A---KLQ--FSKETYEEDLEE
281

WP_002312694
217
FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EEeA---KLQ--FSKETYEEDLEE
282

WP_002314015
217
FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EEeA---KLQ--FSKETYEEDLEE
282

WP_002320716
217
FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EEeA---KLQ--FSKETYEEDLEE
282

WP_002330729
217
FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EE-A---KLQ--FSKETYEEDLEE
281

WP_002335161
217
FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EEeA---KLQ--FSKETYEEDLEE
282

WP_002345439
217
FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EEeA---KLQ--FSKETYEEDLEE
282

WP_034867970
210
LTDK-LSKTKKVEEILKY-Y-PT EKINSFFAQCLKLIVGNQANFKRIF--DLEAE-V---KLQ--FSKETYEEDLES
275

WP_047937432
217
FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EEeA---KLQ--FSKETYEEDLEE
282

WP_010720994
210
LTDK-LSKTKKVEEILKY-Y-PT EKINSFFAQCLKLIVGNQANFKRIF--DLEAE-V---KLQ--FSKETYEEDLES
275

WP_010737004
210
LTDK-LSKTKKVEEILKY-Y-PT EKINSFFAQCLKLIVGNQANFKRIF--DLEAE-V---KLQ--FSKETYEEDLES
275

WP_034700478
210
LTDK-LSKTKKVEEILKY-Y-PT EKINSFFAQCLKLIVGNQANFKRIF--DLEAE-V---KLQ--FSKETYEEDLES
275

WP_007209003
215
LTQQ-LSKSERADNVLKL-F-PD EKGTGIFAQFIKLIVGNQGNFKKVF--QLEED----qKLQ--LSTDDYEENIEN
280

WP_023519017
210
LTER-LSKAKRVEKVLAY-Y-PS EKSTGNFAQFLKLMVGNQANFKKTF--DLEEE-M---KLN--FTRDCYEEDLNE
275

WP_010770040
213
FSEK-VSRARKVEAILSV-Y-SE EKSTGTLAQFLKLMVGNQGRFKKTF--DLEED-G---IIQ--IPKEEYEEELET
278

WP_048604708
209
FADK-VSRAKKAEGVLAL-F-PD EKRNGTFDQFLKMIVGNQGNFKKTF--ELEED-A---KLQ--FSKEEYDESLEA
274

WP_010750235
210
LTDK-LSKSKKVEKILQY-Y-PK EKTTGCLAQFLKLIVGNQGNFKQAF--HLDEE-V---KIQ--ISKETYEEDLEK
275

AII16583
251
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
316

WP_029073316
216
LKEP-LSKKHKADKAFAL-FdTT KDNKAAYKELCAALAGNKFNVTKMLkeAELHD-EdekDISfkFSDATFDDAFVE
289

WP_031589969
216
LKEP-LSKKHKAEKAFAL-FdTT KDNKAAYKELCAALAGNKFNVTKMLkeAELHD-EdekDISfkFSDATFDDAFVE
289

KDA45870
210
FKDNtFSKTKKSEELLKL---SG -KKNQLAHQLFKMMVGNMGSFKKVL--GTDEE----hKLS--FGKDTYEDDLND
275

WP_039099354
207
LLDNhQSASNRQRQALLLiYtPS KQNKAIATELLKAILGLKAKFNVLT--GIEAEdVktwTLT--FNAENFDEEMVK
285

AKP02966
209
LIGR-GNATQKSSNILNN-F--T KETKKLLKEVINLILGNVAHLNTIFktSLTKDeE---KLS--FSGKDIESKLDD
278

WP_010991369
218
LVEK-VTRKEKLERILKL-Y-PG EKSAGMFAQFISLIVGSKGNFQKPF--DLIEK-S---DIE--CAKDSYEEDLES
283

WP_033838504
218
LVEK-VTRKEKLERILKL-Y-PG EKSAGMFAQFISLIVGSKGNFQKPF--DLIEK-S---DIE--CAKDSYEEDLES
283

EHN60060
221
LVEK-VTRKEKLERILKL-Y-PG EKSAGMFAQFISLIVGSKGNFQKPF--DLIEK-S---DIE--CAKDSYEEDLES
286

EFR89594
1
---------------LKL-Y-PG EKSTGMFAQFISLIVGSKGNFQKPF--DLIEK-S---DIE--CAKDSYEEDLES
52

WP_038409211
218
LSEK-LTRREKLDKILKL-Y-TG EKSTGMFARFINLIIGSKGDFKKVF--DLDEK-A---EIE--CAKDTYEEDLEA
283

EFR95520

----------------------- ------------------------------------------------------

WP_003723650
218
LAGK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLET
283

WP_003727705
218
LAGK-FTRREKFERILRL-Y-PG EKSTGMFAQFISLIVGNKGNFQKVF--NLVEK-T---DIE--CAKDSYEEDLEA
283

WP_003730785
218
LAGK-FTRREKFERILRL-Y-PG EKSTGMFAQFISLIVGNKGNFQKVF--NLVEK-T---DIE--CAKDSYEEDLEA
283

WP_003733029
218
LAEK-FTRKDKLDKILSL-Y-PG EKTTGVFAQFVNIIVGSTGKEKKHF--NLHEK-K---DIN--CAEDTYDTDLES
283

WP_003739838
218
LAGK-FTRKEKLERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLVEK-T---DIE--CAKDSYEEDLEA
283

WP_014601172
218
LAGK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLEA
283

WP_023548323
218
LAGK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLET
283

WP_031665337
218
LAGK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLET
283

WP_031669209
218
LAEK-FTRKDKLDKILSL-Y-PG EKTTGVFAQFVNIIVGSTGKEKKHF--NLHEK-K---DIN--CAEDTYDTDLES
283

WP_033920898
218
LARK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLET
283

AKI42028
221
LAGK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLEA
286

AKI50529
221
LARK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLET
286

EFR83390

----------------------- ------------------------------------------------------

WP_046323366
218
FSEK-LTKREKLDKILNL-Y-PN EKSTDLFAQFISLIIGSKGNEKKFF--NLTEK-T---DIE--CAKDSYEEDLEV
283

AKE81011
228
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLEGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
293

CUO82355
215
LKKP-LSKKAKVDEVMAL-IsPE KEFKSAYKELVTGIAGNKMNVTKMIlcESIKQ-Gds-EIK1kFSDSNYDDQFSE
287

WP_033162887
216
LSKI-YQRSKKADDLLKI-MnPT KEEKAAYKEFTKALVGLKFNISKMIlaQEVKK-Gdt-DIV1eFSNANYDSTIDE
288

AGZ01981
245
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLEGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
310

AKA60242
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLEGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

AKS40380
212
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLEGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
277

4UN5_B
216
LSAR-LSKSRRLENLIAQ-L-PG EKKNGLEGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN
281

WP_010922251
278
LLAQIGDQYADLFLAA custom character

NLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_039695303
279
LLGKIGDDYADLFTSAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKAN-KSELYHDIFKDKNK
357

WP_045635197
278
LLGQIGDDFTDLFVSAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQNDLAALKQFIKNN-LPEKYDEVFSDQSK
356

5AXW_A
158
---------------------------------------------------------LERLKKDG-------EVR-----
168

WP_009880683
1
---------------------------------------LSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
40

WP_010922251
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_011054416
278
LLAQIGDQYADLFLAAKNLSDATLLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_011284745
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_011285506
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_011527619
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_012560673
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_014407541
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_020905136
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_023080005
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_023610282
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_030125963
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKASLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_030126706
278
LLAQIGDQYADLFLAAKNLSDATLLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_031488318
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_032460140
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_032461047
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_032462016
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_032462936
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_032464890
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_033888930
103
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
181

WP_038431314
278
LLAQIGDQYADLFLAAKNLSDATLLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_038432938
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_038434062
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

BAQ51233
189
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
267

KGE60162

--------------------------------------------------------------------------------

KGE60856

--------------------------------------------------------------------------------

WP_002989955
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_003030002
278
LLGEIGDEYADLFASAKNLYDAILLSGILTVDDNSTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK
356

WP_003065552
281
LLGKIGDDYADLFTSAKNLYDAILLSGILIVDDNSTKAPLSASMIKRYVEHQEDLEKLKEFIKAN-KSELYHDIFKDKNK
359

WP_001040076
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIVADSSK
357

WP_001040078
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040080
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040081
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040083
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040085
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040087
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040088
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040089
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040090
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040091
279
LLRQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040092
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSAYMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040094
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQHYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040095
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040096
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040097
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040098
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040099
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040100
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040104
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040105
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_001040106
279
LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK
357

WP_001040107
279
LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK
357

WP_001040108
279
LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK
357

WP_001040109
279
LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK
357

WP_001040110
279
LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK
357

WP_015058523
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_017643650
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_017647151
279
LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK
357

WP_017648376
279
LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK
357

WP_017649527
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_017771611
279
LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTALSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK
357

WP_017771984
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

CFQ25032
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKASLSDSMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

CFV16040
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

KLJ37842
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

KLJ72361
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

KLL20707
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

KLL42645
279
LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK
357

WP_047207273
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_47209694
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_050198062
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_050201642
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_050204027
279
LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK
357

WP_050881965
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_050886065
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

AHN30376
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

EA078426
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

CCW42055
279
LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK
357

WP_003041502
278
LLGEVGDEYADLFASAKNLYDAILLSGILTVDDNSTKAPLSASMVKRYEEHQKDLKKFEDFIKVN-ALDQYNAIFKDKNK
356

WP_037593752
279
LLGEIGDEYADLFASAKNLYDAILLSGILAVDDNTTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK
357

WP_049516684
279
LLGEIGDEYADLFASAKNLYDAILLSGILAVDDNTTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APAQYDDIFKDETK
357

GAD46167
278
LLGEIGDEYADLFASAKNLYDAILLSGILAVDDNTTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK
356

WP_018363470
279
LLGKIGDDYADLFTSSKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKAN-KSELYHDIFKDKTQ
357

WP_003043819
278
LLGQIGDQYADLFSAAKNLSDAILLSDILRSNSEVTKAPLSASMVKRYDEHHQDLALLKTLVRQQ-FPEKYAEIFKDDTK
356

WP_006269658
278
FLGEVGDEYADLFASAKNLYDAILLSGILTVDDNSTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK
356

WP_048800889
278
LLGKIGDDYADLFTSAKNLYDTILLSGILAVDDNSTKALLSASMIKRYEEHQKDLKKLKDFIKVN-APAQYDDIFKDETK
356

WP_012767106
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_014612333
278
LLAQIGNQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_015017095
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_015057649
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_048327215
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_049519324
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_012515931
278
LLAQIGDQYADLFLAAKNLSDAILLSDILTESDEITRAPLSASMVKRYREHHKDLVTLKTLIKDQ-LPEKYQEIFLDKTK
356

WP_021320964
278
LLAQIGDQYADLFLAAKNLSDAILLSDILTESDEITRAPLSASMVKRYREHHKDLVTLKTLIKDQ-LPEKYQEIFLDKTK
356

WP_037581760
278
LLAQIGDQYADLFLAAKNLSDAILLSDILTESDEITRAPLSASMVKRYREHHKDLVTLKTLIKDQ-LPEKYQEIFLDKTK
356

WP_004232481
278
LLGKIGDDYADLFTAAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYEEHHEDLEKLKTFIKVN-NFDKYHEIFKDKSK
356

WP_009854540
279
LLGKIGDDYADLFTSAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKAN-KSELYHDIFKDKNK
357

WP_012962174
279
LIGKIGDEYADLFTSAKNLYDAILLSGILTVADNTTKAPLSASMIKRYNEHQVDLKKLKEFIKNN-ASDKYDEIFNDKDK
357

WP_039695303
279
LLGKIGDDYADLFTSAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKAN-KSELYHDIFKDKNK
357

WP_014334983
278
LLGKVGDDYADLFISAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKIN-KLKLYHDIFKDKTK
356

WP_003099269
278
LLAQIGDQYADLFIAAKKLSDAILLSDIITVKGASTKAPLSASMVQRYEEHQQDLALLKNLVKKQ-IPEKYKEIFDNKEK
356

AHY15608
278
LLAQIGDQYADLFIAAKKLSDAILLSDIITVKGASTKAPLSASMVQRYEEHQQDLALLKNLVKKQ-IPEKYKEIFDNKEK
356

AHY17476
278
LLAQIGDQYADLFIAAKKLSDAILLSDIITVKGASTKAPLSASMVQRYEEHQQDLALLKNLVKKQ-IPEKYKEIFDNKEK
356

ESR09100

--------------------------------------------------------------------------------

AGM98575
278
LLAQIGDQYADLFIAAKKLSDAILLSDIITVKGASTKAPLSASMVQRYEEHQQDLALLKNLVKKQ-IPEKYKEIFDNKEK
356

ALF27331
278
LLAQIEDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_018372492
276
LLSKIDEEYAALFDLAKKVYDAVLLSNILTVKEKNTKAPLSASMIKRYEEHKDDLKAFKRFFRER-LPEKYETMFKDLTK
354

WP_045618028
279
LLVQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIDRYENHQKDLAALKQFIKTN-LPEKYDEVFSDQSK
357

WP_045635197
278
LLGQIGDDFTDLFVSAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQNDLAALKQFIKNN-LPEKYDEVFSDQSK
356

WP_002263549
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002263887
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002264920
278
LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN-KPELYHDIFKDETK
356

WP_002269043
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002269448
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002271977
278
LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002272766
278
LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002273241
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002275430
278
LLTQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002276448
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002277050
278
LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN-KPELYHDIFKDETK
356

WP_002277364
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002279025
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTADDSSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002279859
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002280230
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002281696
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002282247
278
LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN-KPELYHDIFKDETK
356

WP_002282906
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002283846
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002287255
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002288990
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002289641
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLTQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002290427
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002295753
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002296423
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002304487
278
LLGEIGDEYADLFASAKNLYDAILLSGILAVDDNTTKAPLSASMVKRYKEHKEELAAFKRFIKEK-LPKKYEEIFKDDTK
356

WP_002305844
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002307203
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002310390
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_002352408
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_012997688
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_014677909
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_019312892
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_019313659
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTQAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_019314093
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_019315370
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLTQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_019803776
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_019805234
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_024783594
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_024784288
278
LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN-KPELYHDIFKDETK
356

WP_024784666
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLVQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_024784894
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLTQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_024786433
278
LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN-KPELYHDIFKDETK
356

WP_049473442
278
LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
356

WP_049474547
278
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLTQLKQFIRQK-LSDKYNEVFSDVSK
356

EMC03581
271
LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK
349

WP_000428612
279
LLGQIGDDFADLFVAAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLATLKQFIKTN-LPEKYDEVFSDQSK
357

WP_000428613
279
LLGQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLAVLKQFIKNN-LPEKYDEVFSDQSK
357

WP_049523028
278
LLGQIGDVYADLFVVAKKLYDAILLAGILSVKDPGTKAPLSASMIERYDNHQNDLSALKQFVRRN-LPEKYAEVFSDDSK
356

WP_003107102
247
LLAQIGDQYADLFIAAKNLSDAILLSDILTVKGVNTKAPLSASMVQRFNEHQDDLKLLKKLVKVQ-LPEKYKEIFDIKDK
325

WP_054279288
280
LLTQIGDEYADLFLSAKNLSDAILLSDILTVNGDGTQAPLSASLIKRYEEHRQDLALLKQMFKEQ-LPDLYRDVFTDENK
358

WP_049531101
279
LLGQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLAALKQFIKNN-LPEKYDEVFSDQSK
357

WP_049538452
279
LLGQIGDGFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYQNHQNDLASLKQFIKNN-LPEKYDEVFSDQSK
357

WP_049549711
279
LLGQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLTTLKQFIKNN-LPEKYDEVFSDQSK
357

WP_007896501
280
LLAEIGDHYADLFLAAKNLSDAILLSDILTLSDENTRAPLSASMIKRYEEHQEDLALLKKLVKEQ-MPEKYWEIFSNAKK
358

EFR44625
232
LLAEIGDHYADLFLAAKNLSDAILLSDILTLSDENTRAPLSASMIKRYEEHQEDLALLKKLVKEQ-MPEKYWEIFSNAKK
310

WP_002897477
278
LLGQIGDDFADLFLIAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLAALKQFIKNN-LPEKYVEVFSDQSK
356

WP_002906454
278
LLGQIGDGFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQEDLAALKQFIKNN-LSEKYAEVFSDQSK
356

WP_009729476
279
LLGQIGDDFADLFLVAKKLYDAILLSGILTVTNPSTKAPLSASMIERYENHQKDLASLKQFIKNN-LPEKYDEVFSDQSE
357

CQR24647
278
LLGIIGDEYADVFVAAKKVYDSILLSGILTTNNHSTKAPLSASMIDRYDEHNSDKKLLRDFIRTNiGKEVFKEVFYDTSK
357

WP_000066813
279
LLGQIGDDFADLFLVAKKLYDAILLSGILTVKDLSTKAPLSASMIERYENHQKDLAALKQFIQNN-LQEKYDEVFSDQSK
357

WP_009754323
279
LLGQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQEDLAALKQFIKNN-LPEKYAEVFSDQSK
357

WP_044674937
278
LLGKIGDDYADLFIATKSLYDGILLAGILSTTDSTTKAPLSSSMVNRYEEHKKDLALLKNFIHQN-LSDSYKEVENDKLK
356

WP_044676715
278
LLGKIGDDYADLFIATKSLYDGILLAGILSTTDSTTKAPLSSSMVNRYEEHQKDLALLKNFIHQN-LSDSYKEVENDKLK
356

WP_044680361
278
LLGKIGDDYADLFIATKSLYDGILLAGILSTTDSTTKAPLSSSMVNRYEEHQKDLALLKNFIHQN-LSDSYKEVENDKLK
356

WP_044681799
278
LLGKIGDDYADLFIATKSLYDGILLAGILSTTDSTTKAPLSSSMVNRYEEHKKDLALLKNFIHQN-LSDSYKEVENDKLK
356

WP_049533112
278
LLGEIGDEYADLFASAKNLYDAILLSGILTVDDNSTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK
356

WP_029090905
244
LADVLADEEYDLLLTAQKIYSAIILDESMDGYEYFA-----EAKKESYRKHQEELVLVKKMLKSNaITNDERAKF---EY
315

WP_006506696
284
VEKDLGE-YVEFVDALHNVYSWVELQTIMGATHTD-NASISEAMVSRYNKHHDDLKLLKDCIKNN-VPNKYFDMFRNDSE
360

AIT42264
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_034440723
284
LLSNIDEGYRDVFLQAKNVYNAIELSKILKTDGKETKAPLSAQMVELYNQHREDLKKYKDYIKAY-LPEKYGETFKDATK
362

AKQ21048
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

WP_004636532
277
LLGMTDDVFLDVFMAAKNVYDAVEMSAIISTDTGNSKAVLSNQMINFYDEHKVDLAQLKQFFKTH-LPDKYYECFSDPSK
355

WP_002364836
284
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK
362

WP_016631044
235
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK
313

EMS75795
21
LLEKSGEEFRDVFLQAKKVYDAILLSDILSTKKQNSKAKLSLGMIERYDSHKKDLEELKQFVKAN-LPEKTAIFFKDSSK
99

WP_002373311
284
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK
362

WP_002378009
284
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK
362

WP_002407324
284
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK
362

WP_002413717
284
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK
362

WP_010775580
286
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK
364

WP_010818269
284
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK
362

WP_010824395
284
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK
362

WP_016622645
284
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSYAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK
362

WP_033624816
284
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK
362

WP_033625576
284
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK
362

WP_033789179
284
ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK
362

WP_002310644
282
LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV
360

WP_002312694
283
LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV
361

WP_002314015
283
LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV
361

WP_002320716
283
LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV
361

WP_002330729
282
LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV
360

WP_002335161
283
LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV
361

WP_002345439
283
LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV
361

WP_034867970
276
LLEKIGDEYLDIFLQAKKVHDAILLSEIISSTVKHTKAKLSSGMVERYERHKADLAKFKQFVKEN-VPQKATVFFKDTTK
354

WP_047937432
283
LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV
361

WP_010720994
276
LLEKIGDEYLDIFLQAKKVHDAILLSEIISSTVKHTQAKLSSGMVERYERHKADLAKFKQFVKEN-VPQKATVFFKDTTK
354

WP_010737004
276
LLEKIGDEYLDIFLQAKKVHDAILLSEIISSTVKHTKAKLSSGMVERYERHKADLAKFKQFVKEN-VPQKATVFFKDTTK
354

WP_034700478
276
LLEKIGDEYLDIFLQAKKVHDAILLSEIISSTVKHTQAKLSSGMVERYERHKADLAKFKQFVKEN-VPQKATVFFKDTTK
354

WP_007209003
281
LLAIIGDEYGDIFVAAQNLYQAILLAGILTSTEK-TRAKLSASMIQRYEEHAKDLKLLKRFVKEH-IPDKYAEIFNDATK
358

WP_023519017
276
LLEKTSDDYAELFLKAKGVYDAILLSQILSKSDDETKAKLSANMKLRFEEHQRDLKQLKELVRRD-LPKKYDDFFKNRSK
354

WP_010770040
279
LLAIIGDEYAEIFSATKSVYDAVALSGILSVTDGDTKAKLSASMVERYEAHQKDLVQFKQFIRKE-LPEMYAPIFRDNSV
357

WP_048604708
275
LLGEIGDEYADVFEAAKNVYNAVELSGILTVTDNSTKAKLSASMIKRYEDHKTDLKLFKEFIRKN-LPEKYHEIFNDKNT
353

WP_010750235
276
LLRKSNEEMIDVFLQVKKVYDAILLSDILSTKMKDTKAKLSAGMIERYQNHKKDLEELKQFVRAH-LHEKVTVFFKDSSK
354

AII16583
317
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
395

WP_029073316
290
KQPLLGD-CVEFIDLLHDIYSWVELQNILGSAHTS-EPSISAAMIQRYEDHKNDLKLLKDVIRKY-LPKKYFEVFRDEKS
366

WP_031589969
290
KQPLLGD-CVEFIDLLHDIYSWVELQNILGSAHTS-EPSISAAMIQRYEDHKNDLKLLKDVIRKY-LPKKYFEVFRDEKS
366

KDA45870
276
LLAEAGDQYLDIFVAAKKVYDAAILASILDVKDTQTKTVFSQAMIERYEEHQKDLIELKRVFKKY-LPEKCHDFFSE-PK
353

WP_039099354
286
LESSLDDNAHQIIESLQELYSGVLLAGIVPENQSLS-----QAMITKYDDHQKHLKMLKAVREAL-APEDRQRLKQAYDQ
359

AKP02966
279
LDSILDDDQFTVLDTANRIYSTITLNEIL-----NGESYFSMAKVNQYENHAIDLCKLRDMWHTT----KNEKAV-GLSR
348

WP_010991369
284
LLALIGDEYAELFVAAKNAYSAVVLSSIITVAETETNAKLSASMIERFDTHEEDLGELKAFIKLH-LPKHYEEIFSNTEK
362

WP_033838504
284
LLALIGDEYAELFVAAKNAYSAVVLSSIITVAETETNAKLSASMIERFDTHEEDLGELKAFIKLH-LPKHYEEIFSNTEK
362

EHN60060
287
LLALIGDEYAELFVAAKNAYSAVVLSSIITVAETETNAKLSASMIERFDTHEEDLGELKAFIKLH-LPKHYEEIFSNTEK
365

EFR89594
53
LLALIGDEYAELFVAAKNAYSAVVLSSIITVAETETNAKLSASMIERFDTHEEDLGELKAFIKLH-LPKHYEEIFSNTEK
131

WP_038409211
284
LLAKIGDEYAEIFVAAKSTYNAVVLSNIITVTDTETKAKLSASMIERFDKHAKDLKRLKAFFKMQ-LPEKFNEVFNDIEK
362

EFR95520

--------------------------------------------------------------------------------

WP_003723650
284
LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTDTETNAKLSASMIERFDAHEKDLVELKAFIKLN-LPKQYEEIFSNAAI
362

WP_003727705
284
LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTATETNAKLSASMIERFDAHEKELGELKAFIKLH-LPKQYQEIFNNAEI
362

WP_003730785
284
LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTATETNAKLSASMIERFDAHEKELGELKAFIKLH-LPKQYQEIFNNAEI
362

WP_003733029
284
LLAIIGDEFAEVFVAAKNAYNAVVLSNIITVTDSTTRAKLSASLIERFENHKEDLKKMKRFVRTY-LPEKYDEIFDDTEK
362

WP_003739838
284
LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTDTETNAKLSASMIERFDAHEKDLSELKAFIKLH-LPKQYEEIFSNVAI
362

WP_014601172
284
LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTATETNAKLSASMIERFDAHEKDLGELKAFIKLH-LPKQYQEIFNNAAI
362

WP_023548323
284
LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTDTETNAKLSASMIERFDAHEKDLVELKAFIKLN-LPKQYEEIFSNAAI
362

WP_031665337
284
LLAIIGDEYAELFVAAKNTYNAVVLSSIITVNDTETNAKLSASMIERFDAHEKDLVELKAFIKLN-LPKQYEEIFSNAAI
362

WP_031669209
284
LLAIIGDEFAEVFVAAKNAYNAVVLSNIITVTDSTTRAKLSASLIERFENHKEDLKKMKRFVRTY-LPEKYDEIFDDTEK
362

WP_033920898
284
LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTDTETNAKLSASMIERFDAHEKDLVELKAFIKLN-LPKQYEEIFSNAAI
362

AKI42028
287
LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTATETNAKLSASMIERFDAHEKDLGELKAFIKLH-LPKQYQEIFNNAAI
365

AKI50529
287
LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTDTETNAKLSASMIERFDAHEKDLVELKAFIKLN-LPKQYEEIFSNAAI
365

EFR83390

--------------------------------------------------------------------------------

WP_046323366
284
LLARVGDEYAEIFVAAKNAYNAVVLSSIITVSNTETKAKLSASMIERFDKHDKDLKRMKAFFKVR-LPENFNEVFNDVEK
362

AKE81011
294
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
372

CUO82355
288
VENDLGE-YVEFIDSLHNIYSWVELQTIMGATHTD-NASISEAMVSRYNKHHEDLQLLKKCIKDN-VPKKYFDMFRNDSE
364

WP_033162887
289
LQSELGE-YIEFIEMLHNIYSWVELQAILGATHTD-NPSISAAMVERYEEHKKDLRVLKKVIREE-LPDKYNEVFRKDNR
365

AGZ01981
311
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
389

AKA60242
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

AKS40380
278
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
356

4UN5_B
282
LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK
360

WP_010922251
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNG custom character

IPHQIHLGEL
419

WP_039695303
358
--NGYAG YIEN G VKQDEFYKYLKNILSK-IkiDGSDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
422

WP_045635197
357
--DGYAG YIDG K TTQETFYKYIKNLLSK-F--EGTDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

5AXW_A
169
------G SINR - ---------------K------TSDYVk----------------------------EA
183

WP_009880683
41
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL
103

WP_010922251
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_011054416
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPYQIHLGEL
419

WP_011284745
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_011285506
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_011527619
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_012560673
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_014407541
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_020905136
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_023080005
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPYQIHLGEL
419

WP_023610282
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPYQIHLGEL
419

WP_030125963
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_030126706
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPYQIHLGEL
419

WP_031488318
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_032460140
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_032461047
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_032462016
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_032462936
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_032464890
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNRKDLLRKQRTFDNGSIPHQIHLGEL
419

WP_033888930
182
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
244

WP_038431314
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_038432938
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPYQIHLGEL
419

WP_038434062
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

BAQ51233
268
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
330

KGE60162

------- ---- - ----------------------------------------------------------

KGE60856

------- ---- - ----------------------------------------------------------

WP_002989955
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_003030002
357
--KGYAG YIEN G VKQDEFYKYLKGILLQ-I--NGSGDFL--DKIDREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_003065552
360
--NGYAG YIEN G VKQDEFYKYLKNTLSK-Ia--GSDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
422

WP_001040076
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040078
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040080
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040081
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040083
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040085
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040087
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040088
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040089
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040090
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040091
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040092
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040094
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040095
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040096
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040097
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040098
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040099
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040100
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040104
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040105
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040106
358
--DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040107
358
--DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040108
358
--DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040109
358
--DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_001040110
358
--DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_015058523
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_017643650
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_017647151
358
--DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_017648376
358
--DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_017649527
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_017771611
358
--DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

WP_017771984
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

CFQ25032
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

CFV16040
358
--DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL
420

KLJ37842
358
--DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

KLJ72361
358
--DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

ELL20707
358
--DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

KLL42645
358
--DGYAG YIEG K TNQGAFYKYLSELLTK-Q--EGSEYFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

WP_047207273
358
--DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

WP_047209694
358
--DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EGSEYLL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

WP_050198062
358
--DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

WP_050201642
358
--DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

WP_050204027
358
--DGYAG YIES K TNQGAFYKYLSELLTK-Q--EGSEYFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

WP_050881965
358
--DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

WP_050886065
358
--DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

AHN30376
358
--DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSEYFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

EA078426
358
--DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

CCW42055
358
--DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EGSEYLL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL
420

WP_003041502
357
--KGYAG YIES G VKQDEFYKYLEGILLQ-I--NGSGDFL--DKIDREDFLREQRTEDNGSIPHQIHLQEM
419

WP_037593752
358
--KGYAG YIES G VEQDEFYKYLEGILLK-I--NGSGDFL--DKIDCEDFLREQRTEDNGSIPHQIHLQEM
420

WP_049516684
358
--NGYAG YIEN G VKQDEFYKYLENTLSK-I--DGSDYFL--DKIDREDFLREQRTEDNGSIPHQIHLQEM
420

GAD46167
357
--KGYAG YIES G VEQDEFYKYLEGILLK-I--NGSGDFL--DKIDCEDFLREQRTEDNGSIPHQIHLQEM
419

WP_018363470
358
--NGYAG YIEN G VKQDEFYKYLEGILTK-I--NGSDYFL--DKIEREDFLREQRTEDNGSIPHQIHLQEM
420

WP_003043819
357
--NGYAG YVGI G ATQEEFYKFIKPILEK-M--DGAEELLa--KLNRDDLLREQRTEDNGSIPHQIHLKEL
429

WP_006269658
357
--KGYAS YIES G VKQDEFYKYLEGILLK-I--NGSGDFL--DKIDREDFLREQRTEDNGSIPHQIHLQEM
419

WP_048800889
357
--NGYAG YIEN G VKQDEFYKYLENTLSK-I--DGSGYFL--DKIEREDFLREQRTEDNGSIPHQIHLQEM
419

WP_012767106
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLREQRTEDNGSIPHQIHLGEL
419

WP_014612333
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLREQRTEDNGSIPHQIHLGEL
419

WP_015017095
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLREQRTEDNGSIPHQIHLGEL
419

WP_015057649
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLREQRTEDNGSIPHQIHLGEL
419

WP_048327215
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLREQRTEDNGSIPHQIHLGEL
419

WP_049519324
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLREQRTEDNGSIPHQIHLGEL
419

WP_012515931
357
--NGYAG YIEG Q VSQEEFYKYLKPILAR-L--DGSEPLL1--KIDREDFLREQRTEDNGSIPHQIHLEEL
419

WP_021320964
357
--NGYAG YIEG Q VSQEEFYKYLKPILAR-L--DGSEPLL1--KIDREDFLREQRTEDNGSIPHQIHLEEL
419

WP_037581760
357
--NGYAG YIEG Q VSQEEFYKYLKPILAR-L--DGSEPLL1--KIDREDFLREQRTEDNGSIPHQIHLEEL
419

WP_004232481
357
--NGYAG YIEN G VKQDIFYKHLKSIISE-K--NGGQYFL--DKIEREDFLREQRTEDNGSIPYQIHLQEM
419

WP_009854540
358
--NGYAG YIEN G VKQDEFYKYLENTLSK-I--DGSDYFL--DKIEREDFLREQRTEDNGSIPHQIHLQEM
420

WP_012962174
358
--NGYAG YIEN G VKQDEFYKYLETTLSK-I--DGSDYFL--DKIEREDFLREQRTEDNGSIPHQIHLQEM
420

WP_039695303
358
--NGYAG YIEN G VKQDEFYKYLKNILSK-IkiDGSDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
422

WP_014334983
357
--NGYAG YIDN G VKQDEFYKYLKTILTK-I--DDSDYFL--DKIERDDFLRKQRTFDNGSIPHQIHLQEM
419

WP_003099269
357
--NGYAG YIDG K TSQEEFYKYIKPILLK-L--DGTEKLIs--KLEREDFLRKQRTFDNGSIPHQIHLNEL
419

AHY15608
357
--NGYAG YIDG K TSQEEFYKYIKPILLK-L--DGTEKLIs--KLEREDFLRKQRTFDNGSIPHQIHLNEL
419

AHY17476
357
--NGYAG YIDG K TSQEEFYKYIKPILLK-L--DGTEKLIs--KLEREDFLRKQRTFDNGSIPHQIHLNEL
419

ESR09100

------- ---- - ----------------------------------------------------------

AGM98575
357
--NGYAG YIDG K TSQEEFYKYIKPILLK-L--DGTEKLIs--KLEREDFLRKQRTFDNGSIPHQIHLNEL
419

ALF27331
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_018372492
355
--PSYAA YVSG A VTEDDFYKFSKGLLID-V--EGAEYFL--EKIEREDFLRKQRTFDNGAIPNQVHVKEL
432

WP_045618028
358
--DGYAG YIDG K TTQEAFYKYIKNLLSK-L--EGADYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
420

WP_045635197
357
--DGYAG YIDG K TTQETFYKYIKNLLSK-F--EGTDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002263549
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002263887
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002264920
357
--NGYAG YIEN G VKQDEFYKYLKNTLSK-I--AGSDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002269043
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002269448
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002271977
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002272766
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002273241
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002275430
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002276448
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002277050
357
--NGYAG YIEN G VKQDEFYKYLKNTLSK-I--AGSDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002277364
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002279025
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002279859
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002280230
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002281696
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002282247
357
--NGYAG YIEN G VKQDEFYKYLKNTLSK-I--TGSDYFL--DQIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002282906
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002283846
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002287255
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002288990
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002289641
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002290427
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002295753
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002296423
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002304487
357
--NGYAG YVGA D ATEEEFYKYVKGILNK-V--EGADVWL--DKIDREDFLRKQRTFDNGSIPHQIHLQEM
429

WP_002305844
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002307203
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002310390
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002352408
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_012997688
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_014677909
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_019312892
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_019313659
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_019314093
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_019315370
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGNGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_019803776
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_019805234
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_024783594
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_024784288
357
--NGYAG YIEN G VKQDEFYKYLKNTLSK-I--TGSDYFL--DQIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_024784666
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_024784894
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_024786433
357
--NGYAG YIEN G VKQDEFYKYLKNTLSK-I--AGSDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_049473442
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_049474547
357
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

EMC03581
350
--DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
412

WP_000428612
358
--DGYAG YIDG K TTQESFYKYIKNLLSK-F--EGADYFL--EKIEREDFLRKQRTFDNGSIPHQIHLQEM
420

WP_000428613
358
--DGYAG YIDG K TTQEAFYKYIKNLLSK-F--EGTDYFL--EKIEREDFLRKQRTFDNGSIPHQIHLQEM
420

WP_049523028
357
--DGYAG YIDG K TTQEGFYKYIKNLISK-I--EGAEYFL--EKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_003107102
326
--NGYAG YING K TSQEDFYKYIKPILSK-L--KGAESLIs--KLEREDFLRKQRTFDNGSIPHQIHLNEL
388

WP_054279288
359
--DGYAG YISG K TSQEAFYKYIKPILET-L--DGAEDFLt--KINREDFLRKQRTFDNGSIPHQIHLGEL
421

WP_049531101
358
--EGYAG YIDS K TTQEAFYKYIKNLLSK-I--DGADYLL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
420

WP_049538452
358
--DGYAG YVDG K TTQEAFYKYIKNLLSK-F--EGADYFL--EKIEREDFLRKQRTFDNGSIPHQIHLQEM
420

WP_049549711
358
--DGYAG YIDG K TTQEAFYKYIKNLLSK-F--EGTDYFL--EKIEREDFLRKQRTFDNGSIPHQIHLQEM
420

WP_007896501
359
--NGYAG YIEG K VSQEDFYRYIKPILSR-L--KGGDEFLa--KIDRDDFLRKQRTFDNGSIPHQIHLKEL
421

EFR44625
311
--NGYAG YIEG K VSQEDFYRYIKPILSR-L--KGGDEFLa--KIDRDDFLRKQRTFDNGSIPHQIHLKEL
373

WP_002897477
357
--DGYAG YIDG K TTQEAFYKYIKNLLSK-F--EGADYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_002906454
357
--DGYAG FIDG K TTQEAFYKYIKNLLSK-L--EGADYFL--NKIEREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_009729476
358
--DGYAG YIDG K TTQETFYKYIKNLLSK-F--EGADYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
420

CQR24647
358
--NGYAG YIDG K TNQEDFYKYLKNLLQK-V--DGGDYFI--EKIEREDFLRKQRTFDNGSIPHQVHLDEM
420

WP_000066813
358
--DGYAG YIDG K TTQEAFYKYIKNLLSK-F--EGADYFL--DKIEREDFLKKQRTFDNGSIPHQIHLQEM
420

WP_009754323
358
--DGYAG YIDG K TTQEAFYKYIKNLLSK-F--EGADYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM
420

WP_044674937
357
--DGYAG YIEG K TTQENFYRFIKKAIEK-I--EGSDYFI--DKIDREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_044676715
357
--DGYAG YIEG K TTQENFYRFIKKAIEK-I--EGSNYFI--DKIDREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_044680361
357
--DGYAG YIEG K TTQENFYRFIKKAIEK-I--EGSNYFI--DKIDREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_044681799
357
--DGYAG YIEG K TTQENFYRFIKKAIEK-I--EGSDYFI--DKIDREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_049533112
357
--KGYAG YIEN G VKQDEFYKYLKGILLQ-I--NGSGDFL--DKIDREDFLRKQRTFDNGSIPHQIHLQEM
419

WP_029090905
316
fyTDYIG YEES K SKEERLFKHIELLLAKeNv1TTVEHAL1eKNITFASLLPLQRSSRNAVIPYQVHEKEL
403

WP_006506696
361
ksKGYYN YINR K APVDEFYKYVKKCIEK-VdtPEAKQILn--DIELENFLLKQNSRTNGSVPYQMQLDEM
429

AIT42264
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_034440723
363
--NGYAG YIDG K TSQEDFYKFVKAQLKG---eENGEYFL--EAIENENFLRKQRSFYNGVIPYQIHLQEL
425

AKQ21048
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

WP_004636532
356
--NGYAG YIDG K TNQEDFYKYIEKVMKT-IksDKKDYFL--DKIDREVFLRKQRSFYNSVIPHQIHLQEM
420

WP_002364836
363
--DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
427

WP_016631044
314
--DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
378

EMS75795
100
--NGYAG YIDG K TTQEDFYKFLKKELNG-I--AGSERFM--EKVDQENFLLKQRTTANGVIPHQVHLTEL
162

WP_002373311
363
--DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
427

WP_002378009
363
--DGYAG YITH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
427

WP_002407324
363
--DGYAG YITH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
427

WP_002413717
363
--DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
427

WP_010775580
365
--DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
429

WP_010818269
363
--DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
427

WP_010824395
363
--DGYAG YITH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
427

WP_016622645
363
--DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
427

WP_033624816
363
--DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
427

WP_033625576
363
--DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
427

WP_033789179
363
--DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL
427

WP_002310644
361
--NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL
423

WP_002312694
362
--NGYAG YIEG H ATQEAFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLSEL
424

WP_002314015
362
--NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL
424

WP_002320716
362
--NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL
424

WP_002330729
361
--NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL
423

WP_002335161
362
--NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL
424

WP_002345439
362
--NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL
424

WP_034867970
355
--NGYAG YIKG K TTQEEFYKFVKKELSG-V--VGSEPFL--EKIDQETFLLKQRTYTNGVIPHQVHLIEL
417

WP_047937432
362
--NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL
424

WP_010720994
355
--NGYAG YIKG K TTQEEFYKFVKKELSG-V--VGSEPFL--EKIDQETFLLKQRTYTNGVIPHQVHLIEL
417

WP_010737004
355
--NGYAG YIKG K TTQEEFYKFVKKELSG-V--VGSEPFL--EKIDQETFLLKQRTYTNGVIPHQVHLIEL
417

WP_034700478
355
--NGYAG YIKG K TTQEEFYKFVKKELSG-V--VGSEPFL--EKIDQETFLLKQRTYTNGVIPHQVHLIEL
417

WP_007209003
359
--NGYAG YIDG K TKEEEFYKYLKTTLVQ---kSGYQYFI--EKIEQENFLRKQRIYDNGVIPHQVHAEEL
421

WP_023519017
355
--NGYAG YVKG K ATQEDFYKFLRTELAG-L--EESQSIM--EKIDLEIYLLKQRTFANGVIPHQIHLVEM
417

WP_010770040
358
--SGYAG YVEN S VTQAEFYKYIKKAIEK-V--PGAEYFL--EKIEQETFLDKQRTFNNGVIPHQIHLEEL
422

WP_048604708
354
--DGYAG YIDN S TSQEKFYKYITNLIEK-I--DGAEYFL--KKIENEDFLRKQRTFDNGIIPHQIHLEEL
418

WP_010750235
355
--DGYAG YIDG K TTQADFYKFLKKELTG-V--PGSEPML--AKIDQENFLLKQRTPTNGVIPHQVHLTEF
417

AII16583
396
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTEDNGSIPHQIHLGEL
458

WP_029073316
367
kkNNYCN YINH K TPVDEFYKYIKKLIEK-IddPDVKTILn--KIELESFMLKQNSRTNGAVPYQMQLDEL
435

WP_031589969
367
kkNNYCN YINH K TPVDEFYKYIKKLIEK-IddPDVKTILn--KIELESFMLKQNSRTNGAVPYQMQLDEL
435

KDA45870
354
-iSGYAG YIDG K VSEEDFYKYTKKTLKG-I--PETEEILq--KIDANNYLRKQRTFDNGAIPHQVHLKEL
417

WP_039099354
360
------- YVDG K -SKEDFYGDITKALKNnPdhPIVSEIKk--LIELDQFMPKQRTKDNGAIPHQLHQQEL
425

AKP02966
349
--QAYDD YINK K ---KELYTSLKKFLKVaLp-TNLAKEAe-EKISKGTYLVKPRNSENGVVPYQLNKIEM
415

WP_010991369
363
--HGYAG YIDG - TKQADFYKYMKMTLEN-I--EGADYFI--AKIEKENFLRKQRTFDNGAIPHQLHLEEL
425

WP_033838504
363
--HGYAG YIDG - TKQADFYKYMKMTLEN-I--EGADYFI--AKIEKENFLRKQRTFDNGAIPHQLHLEEL
425

EHN60060
366
--HGYAG YIDG - TKQADFYKYMKMTLEN-I--EGADYFI--AKIEKENFLRKQRTFDNGAIPHQLHLEEL
428

EFR89594
132
--HGYAG YIDG - TKQADFYKYMKTTLEN-I--EGADYFI--AKIEKENFLRKQRTFDNGAIPHQLHLEEL
194

WP_038409211
363
--DGYAG YIDG - TTQEKFYKYMKKMLAN-I--DGADYFI--DQIEEENFLRKQRTFDNGTIPHQLHLEEL
425

EFR95520
1
------- ---- - ---------MKKMLAN-I--DGADYFI--DQIEEENFLRKQRTFDNGTIPHQLHLEEL
44

WP_003723650
363
--DGYAG YIDG - TKQVDFYKYLKTILEN-I--EGSDYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL
425

WP_003727705
363
--DGYAG YIDG - TKQVDFYKYLKTTLEN-V--EGADYFI--TKIEEENFLRKQRTFDNGVIPHQLHLEEL
425

WP_003730785
363
--DGYAG YIDG - TKQVDFYKYLKTTLEN-V--EGADYFI--TKIEEENFLRKQRTFDNGVIPHQLHLEEL
425

WP_003733029
363
--HGYAG YISG - TKQADFYKYMKATLEK-I--EGADYFI--AKIEEENFLRKQRTFDNGVIPHQLHLEEL
425

WP_003739838
363
--DGYAG YIDG - TKQVDFYKYLKTLLEN-I--EGADYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL
425

WP_014601172
363
--DGYAG YIDG - TKQVDFYKYLKTILEN-I--EGADYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL
425

WP_023548323
363
--DGYAG YIDG - TKQVDFYKYLKTTLEN-V--EGADYFI--TKIEEENFLRKQRTFDNGVIPHQLHLEEL
425

WP_031665337
363
--DGYAG YIDG - TKQVDFYKYLKTILEN-I--EGSDYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL
425

WP_031669209
363
--HGYAG YISG - TKQADFYKYMKATLEK-I--EGADYFI--AKIEEENFLRKQRTFDNGVIPHQLHLEEL
425

WP_033920898
363
--DGYAG YIDG - TKQVDFYKYLKTILEN-I--EGADYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL
425

AKI42028
366
--DGYAG YIDG - TKQVDFYKYLKTILEN-I--EGADYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL
428

AKI50529
366
--DGYAG YIDG - TKQVDFYKYLKTILEN-I--EGADYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL
428

EFR83390

------- ---- - ----------------------------------------------------------

WP_046323366
363
--DGYAG YIEG - TKQEAFYKYMKKMLEH-V--EGADYFI--NQIEEENFLRKQRTFDNGAIPHQLHLEEL
425

AKE81011
373
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
435

CUO82355
365
kvKGYYN YINR K APVDEFYKFVKKCIEK-VdtPEAKQILh--DIELENFLLKQNSRTNGSVPYQMQLDEM
433

WP_033162887
366
klHNYLG YIKY D TPVEEFYKYIKGLLAK-VdtDEAREILe--RIDLEKFMLKQNSRTNGSIPYQMQKDEM
434

AGZ01981
390
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
452

AKA60242
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

AKS40380
357
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
419

4UN5_B
361
--NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL
423

WP_010922251
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFE custom character

VVDKGA
486

WP_039695303
423
HAILRRQGDYYPFLKE--KQD RIEKILTFRIPYYVGPL VRKD--SRFAWAEY---RSDEKITPWNFDKVIDKEK
489

WP_045635197
420
NAILRRQGEYYPFLKD--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDEAIRPWNFEEIVDKAS
486

5AXW_A
184
KQLLKVQKAYHQLDQSfi--D TYIDLLETRRTYYEGPG ---Eg-SPFGWKDI----------------------
229

WP_009880683
104
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
170

WP_010922251
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_011054416
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_011284745
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_011285506
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_011527619
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_012560673
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_014407541
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_020905136
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_023080005
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_023610282
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_030125963
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_030126706
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_031488318
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_032460140
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_032461047
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_032462016
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_032462936
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_032464890
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_033888930
245
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
311

WP_038431314
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_038432938
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_038434062
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

BAQ51233
331
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
397

KGE60162

--------------------- ----------------- ------------------------------------

KGE60856

--------------------- ----------------- ------------------------------------

WP_002989955
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_003030002
420
HAILRRQEEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK
486

WP_003065552
423
HAILRRQGDYYPFLKE--NQD RIEKILTFRIPYYVGPL ARKD--SRFSWAEY---HSDEKITPWNFDKVIDKEK
489

WP_001040076
421
RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040078
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040080
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040081
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040083
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040085
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040087
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040088
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040089
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040090
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040091
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040092
421
KAIIRRQSEYYPFLKE--NQD KIEKILTFRIPYYVGPL ARGN--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040094
421
RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040095
421
RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040096
421
RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040097
421
RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040098
421
RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040099
421
RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040100
421
RAIIRRQSEYYPLLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040104
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040105
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_001040106
421
KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA
487

WP_001040107
421
KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA
487

WP_001040108
421
KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA
487

WP_001040109
421
KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA
487

WP_001040110
421
KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA
487

WP_015058523
421
KAIIRRQSEYYPFLKE--NQD KIEKILTFRIPYYVGPL ARGN--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_017643650
421
RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_017647151
421
KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA
487

WP_017648376
421
KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA
487

WP_017649527
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_017771611
421
KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA
487

WP_017771984
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

CFQ25032
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

CFV16040
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

KLJ37842
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

KLJ72361
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

KLL20707
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

KLL42645
421
KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA
487

WP_047207273
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_047209694
421
RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_050198062
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_050201642
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_050204027
421
KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA
487

WP_050881965
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

WP_050886065
421
KDIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

AHN30376
421
KAIIRRQSEYYPFLKE--NQD KIEKILTFRIPYYVGPL ARGN--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

EA078426
421
KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK
487

CCW42055
421
RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA
487

WP_003041502
420
HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK
486

WP_037593752
421
HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK
487

WP_049516684
421
HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK
487

GAD46167
420
HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK
486

WP_018363470
421
HAILRRQGDYYPFLKE--NQE EIEKILTFRIPYYVGPL ARKD--SRFAWAEY---RSDEKITPWNFDKVIDKEK
487

WP_003043819
430
HAILRRQEEFYPFLKE--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWLTR---KSEEAITPWNFEEVVDKGA
496

WP_006269658
420
HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK
486

WP_048800889
420
HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL VRKG--SRFAWAEY---KADEKITPWNFDDILDKEK
486

WP_012767106
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_014612333
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_015017095
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_015057649
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_048327215
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_049519324
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_012515931
420
HAILRRQEVEYPFLKD--NRK KIESLLTFRIPYYVGPL ARG-h-SRFAWVKR---KFDGAIRPWNFEEIVDEEA
486

WP_021320964
420
HAILRRQEVEYPFLKD--NRK KIESLLTFRIPYYVGPL ARG-h-SRFAWVKR---KFDGAIRPWNFEEIVDEEA
486

WP_037581760
420
HAILRRQEVEYPFLKD--NRK KIESLLTFRIPYYVGPL ARG-h-SRFAWVKR---KFDGAIRPWNFEEIVDEEA
486

WP_004232481
420
RTILRRQGEYYPFLKE--NQA KIEKILTFRIPYYVGPL ARKN--SRFAWAKY---HSDEPITPWNFDEVVDKEK
486

WP_009854540
421
HAILRRQGDYYPFLKE--KQD RIEKILTFRIPYYVGPL VRKD--SRFAWAEY---RSDEKITPWNFDKVIDKEK
487

WP_012962174
421
HAILRRQGEHYAFLKE--NQA KIEKILTFRIPYYVGPL ARKN--SRFAWAEY---HSDEKITPWNFDEIIDKEK
487

WP_039695303
423
HAILRRQGDYYPFLKE--KQD RIEKILTFRIPYYVGPL VRKD--SRFAWAEY---RSDEKITPWNFDKVIDKEK
489

WP_014334983
420
HSILRRQGDYYPFLKE--NQA KIEKILTFRIPYYVGPL ARKD--SRFAWANY---HSDEPITPWNFDEVVDKEK
486

WP_003099269
420
KAIIRRQEKFYPFLKE--NQK KIEKLFTFKIPYYVGPL ANG-q-SSFAWLKR---QSNESITPWNFEEVVDQEA
486

AHY15608
420
KAIIRRQEKFYPFLKE--NQK KIEKLFTFKIPYYVGPL ANG-q-SSFAWLKR---QSNESITPWNFEEVVDQEA
486

AHY17476
420
KAIIRRQEKFYPFLKE--NQK KIEKLFTFKIPYYVGPL ANG-q-SSFAWLKR---QSNESITPWNFEEVVDQEA
486

ESR09100

--------------------- ----------------- ------------------------------------

AGM98575
420
KAIIRRQEKFYPFLKE--NQK KIEKLFTFKIPYYVGPL ANG-q-SSFAWLKR---QSNESITPWNFEEVVDQEA
486

ALF27331
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYIGPL ARGK--SDFSWLSR---KSADKITPWNFDEIVDKES
486

WP_018372492
433
QAIILNQSKYYPFLAE--NKE KIEKILTFRIPYYVGPL ARGN--SSFAWLQR---KSDEAIRPWNFEQVVDMET
499

WP_045618028
421
NAIIRRQGEHYPFLQE--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAR
487

WP_045635197
420
NAILRRQGEYYPFLKD--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDEAIRPWNFEEIVDKAS
486

WP_002263549
420
RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002263887
420
RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002264920
420
HAILRRQGDYYPFLKE--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002269043
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002269448
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002271977
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002272766
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002273241
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002275430
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002276448
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002277050
420
HAILRRQGDYYPFLKE--NQD RIEKILTFRIPYYVGPL ARKN--SRFAWAEY---HSDEAVMPWNFDQVIDKES
486

WP_002277364
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002279025
420
RAIIRRQSEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002279859
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002280230
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002281696
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002282247
420
HAILRRQGDYYPFLKE--NQD RIEKILTFRIPYYVGPL ARKN--SRFAWAEY---HSDEAVTPWNFDQVIDKES
486

WP_002282906
420
RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002283846
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002287255
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002288990
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002289641
420
RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ASGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002290427
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002295753
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002296423
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002304487
430
HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL VRKG--SRFAWAEY---KADEKITPWNFDDILDKEK
496

WP_002305844
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002307203
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002310390
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_002352408
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_012997688
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_014677909
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_019312892
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_019313659
420
RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_019314093
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_019315370
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_019803776
420
RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_019805234
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_024783594
420
RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_024784288
420
HAILRRQGDYYPFLKE--NQD RIEKILTFRIPYYVGPL ARKN--SRFAWAEY---HSDEAVTPWNFDQVIDKES
486

WP_024784666
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_024784894
420
RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ASGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_024786433
420
HAILRRQGDYYPFLKE--NQD RIEKILTFRIPYYVGPL ARKN--SRFAWAEY---HSDEAVTPWNFDQVIDKES
486

WP_049473442
420
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

WP_049474547
420
RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ASGK--SDFAWLSR---KSADKITPWNFDEIVDKES
486

EMC03581
413
RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES
479

WP_000428612
421
NAILRRQGEHYPFLKE--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAS
487

WP_000428613
421
NAILRRQGEHYPFLKD--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDEAIRPWNFEEIVDKAS
487

WP_049523028
420
NAILRHQGEYYPFLKE--NKD KIEQILTFRIPYYVGPL ARGN--SDFAWLSR---NSDEAIRPWNFEEMVDKSS
486

WP_003107102
389
KSIIRRQEKYYPFLKD--KQV RIEKIFTFRIPYFVGPL ANG-n-SSFAWVKR---RSNESITPWNFEEVVEQEA
455

WP_054279288
422
QAILERQQAYYPFLKD--NQE KIEKILTFRIPYYIGPL ARG-n-SRFAWLTR---TSDQKITPWNFDEMVDQEA
488

WP_049531101
421
NAILRRQGEHYPFLKE--NRE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAS
487

WP_049538452
421
NAILRRQGEHYPFLKE--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAS
487

WP_049549711
421
NAILRRQGEHYPFLKE--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAS
487

WP_007896501
422
HAILRRQEKYYPFLAE--QKE KIEQLLCFRIPYYVGPL AKGGn-SSFAWLKR---RSDEPITPWNFKDVVDEEA
489

EFR44625
374
HAILRRQEKYYPFLAE--QKE KIEQLLCFRIPYYVGPL AKGGn-SSFAWLKR---RSDEPITPWNFKDVVDEEA
441

WP_002897477
420
NAILRRQGEHYPFLKE--NRE KIEKILTFRIPYYVGPL ARDN--RDFSWLTR---NSDEPIRPWNFEEVVDKAR
486

WP_002906454
420
NAILRRQGEHYLFLKE--NRE KIEKILAFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEVVDKAS
486

WP_009729476
421
NAILRRQGEHYPFLKE--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAS
487

CQR24647
421
KAILRRQGEFYPFLKE--NAE KIQQILTFKIPYYVGPL ARGN--SRFAWASY---NSNEKMTPWNFDNVIDKTS
487

WP_000066813
421
NAIIRRQGEHYPFLQE--NKE KIEKILTFRIPYYVGPL ARGN--GDFAWLTR---NSDQAIRPWNFEEIVDQAS
487

WP_009754323
421
NAILRRQGEHYPLLKE--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAS
487

WP_044674937
420
HAIIRRQAEFYPFLVE--NQD KIEKILTFRIPYYVGPL ARGK--SEFAWLNR---KSDEKIRPWNFDEMVDKET
486

WP_044676715
420
HAIIRRQAEFYPFLVE--NQD KIEKILTFRIPYYVGPL ARGK--SEFAWLNR---KSDEKIRPWNFDEMVDKET
486

WP_044680361
420
HAIIRRQAEFYPFLVE--NQD KIEKILTFRIPYYVGPL ARGK--SEFAWLNR---KSDEKIRPWNFDEMVDKET
486

WP_044681799
420
HAIIRRQAEFYPFLVE--NQD KIEKILTFRIPYYVGPL ARGK--SEFAWLNR---KSDEKIRPWNFDEMVDKET
486

WP_049533112
420
HAILRRQEEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK
486

WP_029090905
404
VAILENQATYYPELLE--QKD NIHKLLTFRIPYYVGPL ADQKd-SEFAWMVR---KQAGKITPFNFEEMVDIDA
471

WP_006506696
430
IKIIDNQAEYYPILKE--KRE QLLSILTFRIPYYFGPL ETSEh----AWIKRlegKENQRILPWNYQDIVDVDA
498

AIT42264
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_034440723
426
TAVLDQQEKHYSFLKE--NRD KIISLLTFRIPYYVGPL AKGE--SRFAWLER--sNSEEKIKPWNEDKIVDIDK
493

AKQ21048
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

WP_004636532
421
QAILDRQSQYYPFLAE--NRD KIESLVTFRIPYYVGPL TVSDq-SEFAWMER---QSDEPIRPWNFDEIVNKER
488

WP_002364836
428
QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ
495

WP_016631044
379
QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ
446

EMS75795
163
KAIIERQKPYYPSLEE--ARD KMIRLLTFRIPYYVGPL AQGEetSSFAWLER---KTPEKVTPWNATEVIDYSA
231

WP_002373311
428
QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ
495

WP_002378009
428
QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-NTFAWLKR---QSEEPIRPWNLQETVDLDQ
495

WP_002407324
428
QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ
495

WP_002413717
428
QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ
495

WP_010775580
430
QAIIHRQAAYYPFLKE--NQK KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ
497

WP_010818269
428
QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ
495

WP_010824395
428
QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ
495

WP_016622645
428
QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ
495

WP_033624816
428
QAIIHRQAAYYPFLKE--NQK KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ
495

WP_033625576
428
QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QNEKPIRPWNLQETVDLDQ
495

WP_033789179
428
QAIIHRQAAYYPFLKE--NQK KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ
495

WP_002310644
424
RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG
492

WP_002312694
425
RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG
493

WP_002314015
425
RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG
493

WP_002320716
425
RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG
493

WP_002330729
424
RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG
492

WP_002335161
425
RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG
493

WP_002345439
425
RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG
493

WP_034867970
418
KAIIDQQKQHYPFLEE--AGP KIIALFKFRIPYYVGPL AKEQeaSSFAWIER---KTAEKINPWNFSEVVDIEK
486

WP_047937432
425
RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG
493

WP_010720994
418
KAIIDQQKQHYPFLEE--AGP KIIALFKFRIPYYVGPL AKEQeaSSFAWIER---KTAEKINPWNFSEVVDIEK
486

WP_010737004
418
KAIIDQQKQHYPFLEE--AGP KIIALFKFRIPYYVGPL AKEQeaSSFAWIER---KTAEKINPWNFSEVVDIEK
486

WP_034700478
418
KAIIDQQKQHYPFLEE--AGP KIIALFKFRIPYYVGPL AKEQeaSSFAWIER---KTAEKINPWNFSEVVDIEK
486

WP_007209003
422
RAILRKQEKYYSFLKE--NHE KIEQIFKVRIPYYVGPL AKHNeqSRFAWNIR---KSDEPIRPWNMNDVVDENA
490

WP_023519017
418
REIMDRQKRFYPFLKG--AQG KIEKLLTFRIPYYVGPL AQEGq-SPFAWIKR---KSPSQITPWNFAEVVDKEN
485

WP_010770040
423
EAIIQKQATYYPFLAD--NKE EMKQLVTFRIPYYVGPL ADGN--SPFAWLER---ISSEPIRPGNLAEVVDIKK
489

WP_048604708
419
KAILHHQAMYYPFLQE--KFS NFVDLLTFRIPYYVGPL ANGN--SRFSWLSR---KSDEPIRPWNLAEVVDLSK
485

WP_010750235
418
KAIIDQQKQYYPFLEK--SKE KMIQLLTFRIPYYVGPL AQDKetSSFAWLER---KTTEKIKPWNAKDVIDYGA
486

AII16583
459
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
525

WP_029073316
436
NKILENQSVYYSDLKD--NED KIRSILTFRIPYYFGPL ITKDr--QFDWIIKkegKENERILPWNANEIVDVDK
506

WP_031589969
436
NKILENQSVYYSDLKD--NED KIRSILTFRIPYYFGPL ITKDr--QFDWIIKkegKENERILPWNANEIVDVDK
506

KDA45870
418
VAIVENQGKYYPFLRE--NKD KFEKILNFRIPYYVGPL ARGN--SKFAWLTR--a-GEGKITPYNFDEMIDKET
484

WP_039099354
426
DRIIENQQQYYPWLAE-1NPN KLDELVAFRVPYYVGPL QQQSsdAKFAWMIR---KAEGQITPWNFDDKVDRQA
509

AKP02966
416
EKIIDNQSQYYPFLKE--NKE KLLSILSFRIPYYVGPL -QSSekNPFAWMER---KSNGHARPWNFDEIVDREK
483

WP_010991369
426
EAILHQQAKYYPFLKE--NYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
492

WP_033838504
426
EAILHQQAKYYPFLKE--NYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
492

EHN60060
429
EAILHQQAKYYPFLKE--NYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
495

EFR89594
195
EAILHQQAKYYPFLKE--NYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
261

WP_038409211
426
EAILHQQAKYYPFLRK--DYE KIRSLVTFRIPYFIGPL ANGQ--SDFAWLTR---KADGEIRPWNIEEKVDFGK
492

EFR95520
45
EAILHQQAKYYPFLRK--DYE KIRSLVTFRIPYFIGPL ANGQ--SDFAWLTR---KADGEIRPWNIEEKVDFGK
111

WP_003723650
426
EAIIHQQAKYYPFLKE--DYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
492

WP_003727705
426
EAILHQQAKYYPFLRE--GYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KDDGEIRPWNIEEKVDFGK
492

WP_003730785
426
EAILHQQAKYYPFLRE--GYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KDDGEIRPWNIEEKVDFGK
492

WP_003733029
426
EAILHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
492

WP_003739838
426
EAILHQQAKYYPFLKE--AYD KIKSLVTFRIPYFVGPL ANGQ--SDFAWLTR---KADGEIRPWNIEEKVDFGK
492

WP_014601172
426
EAIIHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
492

WP_023548323
426
EAILHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
492

WP_031665337
426
EAIIHQQAKYYTFLKE--DYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
492

WP_031669209
426
EAILHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
492

WP_033920898
426
EAIIHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
492

AKI42028
429
EAIIHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
495

AKI50529
429
EAIIHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK
495

EFR83390

--------------------- ----------------- ------------------------------------

WP_046323366
426
EAILHQQAKYYPFLKV--DYE KIKSLVTFRIPYFVGPL ANGQ--SEFSWLTR---KADGEIRPWNIEEKVDFGK
492

AKE81011
436
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
502

CUO82355
434
IKIIDNQAKYYPVLKE--KRE QLLSILTFRIPYYFGPL ETSEh----AWIKRlegKENQRILPWNYQDTVDVDA
502

WP_033162887
435
IQIIDNQSVYYPQLKE--NRD KLISILEFRIPYYFGPL AHSE----FAWIKKfedKQKERILPWNYDQIVDIDA
503

AGZ01981
453
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
519

AKA60242
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

AKS40380
420
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
486

4UN5_B
424
HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA
490

WP_010922251
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSG custom character

QKKAIVDLLFK--TNR-KVTV
561

WP_039695303
490
SAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVN--EQGKES-FFDSNMKQEIFDHVFK--ENR-KVTK
563

WP_045635197
487
SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVNQLFK--ENR-KVTE
561

5AXW_A
230
--KEWYEMLMGHCTYFFEELRSVKYAYNADLYNALNDLNNLVITR--DENEKLeYYE---KFQIIENVFK--QKK-KPTL
299

WP_009880683
171
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
245

WP_010922251
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_011054416
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_011284745
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_011285506
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_011527619
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_012560673
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_014407541
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_020905136
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_023080005
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_023610282
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_030125963
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_030126706
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_031488318
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPeFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_032460140
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_032461047
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_032462016
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_032462936
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_032464890
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_033888930
312
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
386

WP_038431314
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_038432938
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_038434062
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

BAQ51233
398
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
472

KGE60162

--------------------------------------------------------------------------------

KGE60856

--------------------------------------------------------------------------------

WP_002989955
487
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
561

WP_003030002
487
SAEKFITRMTLNDLYLPEEKVLPKHSLLYETFTVYNELTKVKYVN--EQGEAK-FFDANMKQEIFDHVFK--ENR-KVTK
560

WP_003065552
490
SAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVN--EQGKDS-FFDSNMKQEIFDHVFK--ENR-KVTK
563

WP_001040076
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIFNSLFK--EKR-KVTE
562

WP_001040078
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040080
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040081
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040083
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040085
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040087
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040088
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040089
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040090
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040091
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040092
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNVKQEIFDGVFK--EHR-KVSK
561

WP_001040094
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE
562

WP_001040095
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE
562

WP_001040096
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE
562

WP_001040097
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE
562

WP_001040098
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE
562

WP_001040099
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE
562

WP_001040100
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE
562

WP_001040104
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040105
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040106
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040107
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040108
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040109
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_001040110
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_015058523
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNVKQEIFDGVFK--EHR-KVSK
561

WP_017643650
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE
562

WP_017647151
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_017648376
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_017649527
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_017771611
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

WP_017771984
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

CFQ25032
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

CFV16040
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK
561

KLJ37842
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK
561

KLJ72361
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK
561

KLL20707
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK
561

KLL42645
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK
561

WP_047207273
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK
561

WP_047209694
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIFNELFK--EKR-KVTE
562

WP_050198062
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK
561

WP_050201642
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK
561

WP_050204027
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK
561

WP_050881965
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK
561

WP_050886065
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK
561

AHN30376
488
SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDENVKQEIEDGVEK--EHR-KVSK
561

EA078426
488
SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK
561

CCW42055
488
SAEAFIHCMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EYR-KVSK
561

WP_003041502
487
SAEKFITRMTLNDLYLPEEKVLPKHELLYETFTVYNELTKVKYVN--EQGEAK-FFDANMKQEIFDHVFK--ENR-KVTK
560

WP_037593752
488
SAEKFITRMTLNDLYLPEEKVLPKHSPLYETFTVYNELTKVKYVN--EQGEAK-FFDTNMKQEIFDHVFK--ENR-KVTK
561

WP_049516684
488
SAEKFITRMTLNDLYLPEEKVLPKHSPLYETFTVYNELTKVKYVN--EQGEAK-FFDTNMKQEIFDHVFK--ENR-KVTK
561

GAD46167
487
SAEKFITRMTLNDLYLPEEKVLPKHSPLYETFTVYNELTKVKYVN--EQGEAK-FFDTNMKQEIFDHVFK--ENR-KVTK
560

WP_018363470
488
SAEKFITRMTLNDLYLPEEKVLPKHSHVYETFAVYNELTKVKYVN--EQGKDS-FFDSNMKQEIFDHVFK--ENR-KVTK
561

WP_003043819
497
SAQSFIERMTNEDEQLPNKKVLPKHELLYEYFTVYNELTKVKYVT--ERMRKPeFLSGEQKKAIVDLLFK--TNR-KVTV
571

WP_006269658
487
SAEKFITRMTLNDLYLPEEKVLPKHSPLYEAFTVYNELTKVKYVN--EQGEAK-FFDTNMKQEIFDHVFK--ENR-KVTK
560

WP_048800889
487
SAEKFITRMTLNDLYLPEEKVLPKHSLLYEIFTVYNELTKVKYVN--EQGEAK-FFDANMKQEIFDHVEK--ENP-KVTK
560

WP_012767106
487
SAQSFIERMTNEDKNLPNEKVLPKHELLYEYFTVYNELTKVKYVT--EGMRKPeFLEGKQKEAIVDLLFK--TNR-KVTV
561

WP_014612333
487
SAQSFIERMTNEDKNLPNEKVLPKHELLYEYFTVYNELTKVKYVT--EGMRKPeFLEGKQKEAIVDLLFK--TNR-KVTV
561

WP_015017095
487
SAQSFIERMTNEDKNLPNEKVLPKHELLYEYFTVYNELTKVKYVT--EGMRKPeFLEGKQKEAIVDLLFK--TNR-KVTV
561

WP_015057649
487
SAQSFIERMTNEDKNLPNEKVLPKHELLYEYFTVYNELTKVKYVT--EGMRKPeFLEGKQKEAIVDLLFK--TNR-KVTV
561

WP_048327215
487
SAQSFIERMTNEDKNLPNEKVLPKHELLYEYFTVYNELTKVKYVT--EGMRKPeFLEGKQKEAIVDLLFK--TNR-KVTV
561

WP_049519324
487
SAQSFIERMTNEDKNLPNEKVLPKHELLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV
561

WP_012515931
487
SAQIFIEKMTKNDLYLPNEKVLPKHELLYETFTVYNELTKVKYAT--EGMTRPqFLEADQKQAIVDLLFK--TNR-KVTV
561

WP_021320964
487
SAQIFIEKMTKNDLYLPNEKVLPKHELLYETFTVYNELTKVKYAT--EGMTRPqFLEADQKQAIVDLLFK--TNR-KVTV
561

WP_037581760
487
SAQIFIEKMTKNDLYLPNEKVLPKHELLYETFTVYNELTKVKYAT--EGMTRPqFLEADQKQAIVDLLFK--TNR-KVTV
561

WP_004232481
487
SAEKFITRMTLNDLYLPEEKVLPKHEYVYETFAVYNELTKIKYVN--EQGKSF-FFDANMKQEIFDHVFK--ENR-KVTK
560

WP_009854540
488
SAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVN--EQGKES-FFDSNMKQEIFDHVFK--ENR-KVTK
561

WP_012962174
488
SAEKFITRMTLNDLYLPEEKVLPKHELVYETYTVYNELTKVKYVN--EQGKEN-FFDANMKQEIFEHVFK--ENR-KVTK
561

WP_039695303
490
SAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVN--EQGKES-FFDSNMKQEIFDHVFK--ENR-KVTK
563

WP_014334983
487
SAEKFITRMTLNDLYLPEEKVLPKHSHVYETFTVYNELTKIKYVN--EQGESF-FFDANMKQEIFDHVFK--ENR-KVTK
560

WP_003099269
487
SARAFIERMTNFDTYLPEEKVLPKHSPLYEMFMVYNELTKVKYQT--EGMKRPvFLSSEDKEEIVNLLFK--KER-KVTV
561

AHY15608
487
SARAFIERMTNFDTYLPEEKVLPKHSPLYEMFMVYNELTKVKYQT--EGMKRPvFLSSEDKEEIVNLLFK--KER-KVTV
561

AHY17476
487
SARAFIERMTNFDTYLPEEKVLPKHSPLYEMFMVYNELTKVKYQT--EGMKRPvFLSSEDKEEIVNLLFK--KER-KVTV
561

ESR09100

--------------------------------------------------------------------------------

AGM98575
487
SARAFIERMTNFDTYLPEEKVLPKHSPLYEMFMVYNELTKVKYQT--EGMKRPvFLSSEDKEEIVNLLFK--KER-KVTV
561

ALF27331
487
SAEAFINRMTNYDLYLPNQKVLPRHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_018372492
500
SASRFIERMTLHDLYLPDEKVLPRHSLIYEKYTVFNELTKVRFTP--EGGKEV-YFSKTDKENIFDSLFK--RYR-KVTK
573

WP_045618028
488
SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKQQIVTQLFK--EKR-KVTE
562

WP_045635197
487
SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVNQLFK--ENR-KVTE
561

WP_002263549
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002263887
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELIKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002264920
487
SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002269043
487
SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002269448
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002271977
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002272766
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002273241
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002275430
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002276448
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002277050
487
SAQAFIEHMTNNDLYLPNEKVLPKHSPLYEKYTVYNELTKIKYVT--EIGEAK-FFDANLKQEIFDGLFK--HER-KVTK
560

WP_002277364
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002279025
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGETA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002279859
487
SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002280230
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002281696
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002282247
487
SAQAFIEHMTNNDLYLPNEKVLPKHSPLYEKYTVYNELTKIKYVT--EIGEAK-FFDANLKQEIFDGLFK--HER-KVTK
560

WP_002282906
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002283846
487
SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002287255
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002288990
487
SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002289641
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002290427
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002295753
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002296423
487
SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002304487
497
SAEKFITRMTLNDLYLPEEKVLPKHSLLYETFTVYNELTKVKYVN--EQGEAK-FFDANMKQEIFDHVFK--ENR-KVTK
570

WP_002305844
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002307203
487
SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002310390
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_002352408
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_012997688
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_014677909
487
SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_019312892
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_019313659
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_019314093
487
SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_019315370
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_019803776
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_019805234
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_024783594
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_024784288
487
SAQAFIEHMTNNDLYLPNEKVLPKHSPLYEKYTVYNELTKIKYVT--EIGEAK-FFDANLKQEIFDGLFK--HER-KVTK
560

WP_024784666
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_024784894
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_024786433
487
SAQAFIEHMTNNDLYLPNEKVLPKHSPLYEKYTVYNELTKIKYVT--EIGEAK-FFDANLKQEIFDGLFK--HER-KVTK
560

WP_049473442
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

WP_049474547
487
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
560

EMC03581
480
SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK
553

WP_000428612
488
SAESFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSRQKKDIFYTLFKaeDKR-KVTE
564

WP_000428613
488
SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVTQLFK--EKR-KVTE
562

WP_049523028
487
SAEDFIHRMTNYDLYLPEEKVLPKHSLLYETFTVYNELTKVKYIA--EGMKDYqFLDSGQKKQIVNQLFK--EKR-KVTE
561

WP_003107102
456
SAKVFIERMTNFDTYLPEEKVLPKHSLLYEMFTVYNELTKVKYQA--EGMRKPeFLSSEEKIEIVSNLFK--TER-KVTV
530

WP_054279288
489
SAQAFIERMTNFDEYLPQEKVLPKHSLTYEYFTVYNELTKVKYVT--EGMTKPeFLSAGQKEQIVELLFK--KYR-KVTV
563

WP_049531101
488
SAEAFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKKIINQLFK--EKR-KVTE
562

WP_049538452
488
SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVNQLFK--EKR-KVTE
562

WP_049549711
488
SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVNQLFK--EKR-KVTE
562

WP_007896501
490
SAQAFIEGMTNYDTYLPEEKVLPKHSPLYEMFTVYNELTKVKYIA--ENMTKPlYLSAEQKEATIDHLFK--QTR-KVTV
564

EFR44625
442
SAQAFIEGMTNYDTYLPEEKVLPKHSPLYEMFTVYNELTKVKYIA--ENMTKPlYLSAEQKEATIDHLFK--QTR-KVTV
516

WP_002897477
487
SAEDFIHRMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVNQLFK--EKR-KVTE
561

WP_002906454
487
SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVNQLFK--DKR-KVTE
561

WP_009729476
488
SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVTQLFK--EKR-KVTE
562

CQR24647
488
SAQAFIERMTNNDLYLPDQKVLPKHSLLYQKFAVYNELTKIKYVT--ETGEAR-LEDVFLKKEIFDGLEK--KER-KVTK
561

WP_000066813
488
SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLTRYqFLDKKQKKDIFDTFFKaeNKR-KVTE
564

WP_009754323
488
SAESFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFFDSGQKKQIVNQLFK--EKR-KVTE
562

WP_044674937
487
SAENFITRMTNYDQYLPDQKVLPKHSLLYEKFAVYNELTKVKFIA--EGMRDYqFLDSGQKKDIVKTLFK--TKR-KVTA
561

WP_044676715
487
SAENFITRMTNYDQYLPDQKVLPKHSLLYEKFAVYNELTKVRYVT--EQGKSF-FFDANMKQEIFDGVEK--VYR-KVTK
560

WP_044680361
487
SAENFITRMTNYDQYLPDQKVLPKHSLLYEKFAVYNELTKVRYVT--EQGKSF-FFDANMKQEIFDGVEK--VYR-KVTK
560

WP_044681799
487
SAENFITRMTNYDQYLPDQKVLPKHSLLYEKFAVYNELTKVKFIA--EGMRDYqFLDSGQKKDIVKTLFK--TKR-KVTA
561

WP_049533112
487
SAEKFITRMTLNDLYLPEEKVLPKHSLLYETFTVYNELTKVKYVN--EQGEAK-FFDANMKQEIFDHVEK--ENR-KVTK
560

WP_029090905
472
SSEAFIKRMTNKCTYLIHEDVIPKHSFSYAKFEVLNELNKIRLDG------KP--IDIPLKKRIFEGLFL---EKtKVTQ
540

WP_006506696
499
TAEGFIKRMRSYCTYFPDEEVLPKNSLIVSKYEVYNELNKIRVDD--------kLLEVDVKNDIYNELFM--KNK-TVTE
567

AIT42264
487
SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV
561

WP_034440723
494
SAELFIENLTSRDTYLPDEPVLPKRSLIYQKFTIFNELTKISYID--ERGILQ-NFSSREKIAIENDLFK---NKsKVTK
567

AKQ21048
487
SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV
561

WP_004636532
489
SAEKFIERMTNMDTYLLEEKVLPKRSLLYQTFEVYNELTKVRYTN--EQGKTE-KLNRQQKAEIIETLFK-qKNR--VRE
562

WP_002364836
496
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
569

WP_016631044
447
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
520

EMS75795
232
SAMKFIQRMINYDTYLPTEKVLPKHSILYQKYTIFNELTKVAYKD--ERGIKH-QESSKEKREIFKELFQ--KQR-KVTV
305

WP_002373311
496
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
569

WP_002378009
496
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
569

WP_002407324
496
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
569

WP_002413717
496
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
569

WP_010775580
498
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
571

WP_010818269
496
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
569

WP_010824395
496
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
569

WP_016622645
496
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
569

WP_033624816
496
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
569

WP_033625576
496
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
569

WP_033789179
496
SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK
569

WP_002310644
493
SAVRFIERMINTDMYMPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YFSSIEKKEIFHELFE--KNR-KVTK
566

WP_002312694
494
SAVRFIERMINTDMYMPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YFSSIEKKEIFHELFE--KNR-KVTK
567

WP_002314015
494
SAVRFIERMNNTDMYIPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YFSSIEKKEIFHELFE--KNR-KVTK
567

WP_002320716
494
SAVRFIERMINTDMYIPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YFSSIEKKEIFHELFE--KNR-KVTK
567

WP_002330729
493
SAVRFIERMINTDMYIPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YESSIEKKEIFHELFE--KNR-KVTK
566

WP_002335161
494
SAVRFIERMINTDMYMPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YESSIEKKEIFHELFE--KNR-KVTK
567

WP_002345439
494
SAVRFIERMINTDMYIPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YESSIEKKEIFHELFE--KNR-KVTK
567

WP_034867970
487
SAMRFIQRMTKQDTYLPTEKVLPKNSLLYQKYMIFNELTKVSYKD--ERGVKQ-YFSGDEKQQIFKQLFQ--KERgKITV
561

WP_047937432
494
SAVRFIERMINTDMYMPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YESSIEKKEIFHELFE--KNR-KVTK
567

WP_010720994
487
SAMRFIQRMTKQDTYLPTEKVLPKNSLFYQKYMIFNELTKVSYKD--ERGVKQ-YFSGDEKQQIFKQLFQ--KERgKITV
561

WP_010737004
487
SAMRFIQRMTKQDTYLPTEKVLPKNSLLYQKYMIFNELTKVSYKD--ERGVKQ-YFSGDEKQQIFKQLFQ--KERgKITV
561

WP_034700478
487
SAMRFIQRMTKQDTYLPTEKVLPKNSLLYQKYMIFNELTKVSYKD--ERGVKQ-YFSGDEKQQIFKQLFQ--KERgKITV
561

WP_007209003
491
SAVAFIERMTIKDIYL-NENVLPRHSLIYEKFTVFNELTKVLYAD--DRGVFQ-RFSAEEKEDIFEKLFK--SER-KVTK
563

WP_023519017
486
SAIEFIERMTNQDTYLPKEKVLPKQSLIYQRFMIFNELTKVSYTD--ERGKSH-YFSSEQKRKIFNELFK--QHP-RVTE
559

WP_010770040
490
SATKFIERMTNEDTYLPTEKVLPKHSMIYEKYMVYNELTKVSYVD--ERGMNQ-RFSGEEKKQIVEELFK--QSR-KVTK
563

WP_048604708
486
SAELFIERMTNFDLYLPSEKVLPKHSMLYEKYTVYNELTKVTYKD--EQGKVQ-NFSSEEKERIFIDLFK--QHR-KVTK
559

WP_010750235
487
SATKFIQRMINYDTYLPTEKVLPKYSMLYQKYTIFNELTKVAYKD--DRGIKH-QFSSEEKLRIFQELFK--KQR-RVTK
560

AII16583
526
SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV
600

WP_029073316
507
TADEFIKRMRNFCTYFPDEPVLAKNSLTVSKYEVLNEINKLRIND--------hLIKRDIKDKMLHTLFM--DHK-SISA
575

WP_031589969
507
TADEFIKRMRNFCTYFPDEPVMAKNSLTVSKYEVLNEINKLRIND--------hLIKRDMKDKMLHTLFM--DHK-SISA
575

KDA45870
485
SAEDFIKRMTINDLYLPTEPVLPKHSLLYERYTIFNELAGVRYVT--ENGEAK-YEDAQTKRSIFE-LFK1--DR-KVSE
557

WP_039099354
510
SANEFIKRMTTTDTYLLAEDVLPKQSLIYQRFEVLNELNGLKIDD--QPITTE------LKQAIFTDLFM---QKtSVTV
578

AKP02966
484
SSNKFIRRMTVTDSYLVGEPVLPKNSLIYQRYEVLNELNNIRITEn1KTNPTGsRLTVETKQHIYNELFK--NYK-KITV
560

WP_010991369
493
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYLVYNELTKVRYIN--DQGKTS-YFSGQEKEQIENDLFK--QKR-KVKK
566

WP_033838504
493
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYLVYNELTKVRYIN--DQGKTS-YFSGQEKEQIENDLFK--QKR-KVKK
566

EHN60060
496
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYLVYNELTKVRYIN--DQGKTS-YFSGQEKEQIENDLFK--QKR-KVKK
569

EFR89594
262
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYLVYNELTKVRYIN--DQGKTS-YFSGQEKEQIENDLFK--QKR-KVKK
335

WP_038409211
493
SAIDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTH-HFSGQEKQQIFNGLFK--QQR-KVKK
566

EFR95520
112
SAIDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTH-HFSGQEKQQIFNGLFK--QQR-KVKK
185

WP_003723650
493
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTN-YFSGREKQQVFNDLFK--QKR-KVKK
566

WP_003727705
493
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTN-YFSGREKQQIENDLFK--QKR-KVKK
566

WP_003730785
493
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTN-YFSGREKQQIENDLFK--QKR-KVKK
566

WP_003733029
493
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID--DQGKTN-YFSGQEKQQIENDLFK--QKR-KVKK
566

WP_003739838
493
SAVDFIEKMTNKDTYLPKENVLPKHSLYYQKYMVYNELTKVRYID--DQGKTN-YFSGQEKQQIENDYFK--QKR-KVSK
566

WP_014601172
493
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID--DQGKTN-YFSGQEKQQIENDLFK--QKR-KVKK
566

WP_023548323
493
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTN-YFSGQEKQQIENDLFK--QKR-KVKK
566

WP_031665337
493
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID--DQGKTN-YFSGQEKQQIENDLFK--QKR-KVKK
566

WP_031669209
493
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID--DQGKTN-YFSGQEKQQIENDLFK--QKR-KVKK
566

WP_033920898
493
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTN-YESGQEKQQIENDLEK--QKR-KVKK
566

AKI42028
496
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID--DQGKTN-YESGQEKQQIENDLEK--QKR-KVKK
569

AKI50529
496
SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTN-YESGQEKQQIENDLEK--QKR-KVKK
569

EFR83390
1
---------------------------------------------------------------IFNDLEK--QKR-KVKK
14

WP_046323366
493
SAIDFIEKMTNKDTYLPKENVLPKHSMCYQKYMVYNELTKIRYTD--DQGKTH-YESGQEKQQIENDLEK--QKR-KVKK
566

AKE81011
503
SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV
577

CUO82355
503
TAEGFIKRMRSYCTYFPDEEVLPKNSLIVSKYEVYNELNKIRVDD--------kLLEVDVKNDIYNELFM--KNK-TVTE
571

WP_033162887
504
TAEGFIERMKNTGTYFPDEPVMAKNSLTVSKFEVLNELNKIRING--------kLIAVETKKELLSDLFM--KNK-TITD
572

AGZ01981
520
SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV
594

AKA60242
487
SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV
561

AKS40380
487
SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV
561

4UN5_B
491
SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV
565

WP_010922251
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_039695303
564
EKLLNYLNKE--FPEYRIKDLIGLDKEnkSFNASLGTYHDLKKIL-DK AFLDDKVNEEVIEDIIKTLTLFEDKDMIH
637

WP_045635197
562
KDIIHYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDAKNEAILENIVHTLTIFEDREMIK
632

5AXW_A
300
KQIAKEILVNe--EDIKGYRVTSTGKPe---FTNLKVYHDIKDITARK ------ENAELLDQIAKILTIYQSSEDIQ
368

WP_009880683
246
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
317

WP_010922251
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_011054416
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_011284745
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_011285506
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_011527619
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_012560673
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_014407541
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGAYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDRGMIE
633

WP_020905136
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_023080005
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNTSLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE
633

WP_023610282
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNTSLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE
633

WP_030125963
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_030126706
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_031488318
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_032460140
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_032461047
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_032462016
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_032462936
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE
633

WP_032464890
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_033888930
387
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
458

WP_038431314
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_038432938
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNTSLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE
633

WP_038434062
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

BAQ51233
473
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
544

KGE60162

------------------------------------------------ -----------------------------

KGE60856

------------------------------------------------ -----------------------------

WP_002989955
562
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_003030002
561
DKLLNYLNKE--FEEFRIVNLTGLDKEnkAFNSSLGTYHDLRKIL-DK SFLDDKANEKTIEDIIQTLTLFEDREMIR
634

WP_003065552
564
EKLLNYLNKE--FPEYRIKDLIGLDKEnkSFNASLGTYHDLKKIL-DK AFLDDKVNEEVIEDIIKTLTLFEDKDMIH
637

WP_001040076
563
KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIK
632

WP_001040078
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040080
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040081
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040083
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIIQTLTLFEDREMIK
635

WP_001040085
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040087
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040088
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040089
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040090
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040091
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040092
562
KQLLDFLAKE--FEEFRIVDVTGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTITLFEDREMIK
635

WP_001040094
563
KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR
632

WP_001040095
563
KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR
632

WP_001040096
563
KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR
632

WP_001040097
563
KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR
632

WP_001040098
563
KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR
632

WP_001040099
563
KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR
632

WP_001040100
563
KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR
632

WP_001040104
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040105
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040106
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040107
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040108
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040109
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_001040110
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_015058523
562
KQLLDFLAKE--FEEFRIVDVTGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTITLFEDREMIK
635

WP_017643650
563
KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR
632

WP_017647151
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_017648376
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_017649527
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_017771611
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_017771984
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

CFQ25032
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

CFV16040
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

KLJ37842
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

KLJ72361
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

KLL20707
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

KLL42645
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_047207273
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_047209694
563
KDIISELNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR
632

WP_050198062
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_050201642
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_050204027
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_050881965
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_050886065
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

AHN30376
562
KQLLDFLAKE--FEEFRIVDVTGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTITLFEDREMIK
635

EA078426
562
KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

CCW42055
562
KQLLDFLAKE--FEEFRIVDVTGLDKEnkAFNASLGTYHDLEKIL-GK DFLDNPDNESILEDIVQTLTLFEDREMIK
635

WP_003041502
561
DKLLNYLNKE--FEEFRIVNLTGLDKEnkVENSSLGTYHDLRKIL-NK SFLDNKENAQIIEDIIQTLTLFEDREMIR
634

WP_037593752
562
DKLLNYLNKE--FEEFRIVNLTGLDKEnkAENSSLGTYHDLRKIL-DK SFLDDKANEKTIEDIIQTLTLFEDREMIR
635

WP_049516684
562
DKLLNYLNKE--FEEFRIVNLTGLDKEnkAFNASLGTYHDLRKIL-DK SFLDDKVNEKIIEDIIQTLTLFEDREMIR
635

GAD46167
561
DKLLNYLNKE--FEEFRIVNLTGLDKEnkAENSSLGTYHDLRKIL-DK SFLDDKANEKTIEDIIQTLTLFEDREMIR
634

WP_018363470
562
EKLLNYLDKE--FPEYRIQDLVGLDKEnkSFNASLGTYHDLKKIL-DK SFLDDKVNEEVIEDIIKTLTLFEDREMIQ
635

WP_003043819
572
KQLKEDYFKK--IECEDSVEIIGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
643

WP_006269658
561
DKLLNYLNKE--FEEFRIVNLTGLDKEnkAENSSLGTYHDLRKIL-DK SFLDDKANEKTIEDIIQTLTLFEDREMIR
634

WP_048800889
561
DKLLNYLDKE--FDEFRIVDLTGLDKEnkAFNASLGTYHDLRKIL-DK SFLDDKANEKTIEDIIQTLTLFEDREMIR
634

WP_012767106
562
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE
633

WP_014612333
562
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE
633

WP_015017095
562
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE
633

WP_015057649
562
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE
633

WP_048327215
562
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE
633

WP_049519324
562
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE
633

WP_012515931
562
KQLKENYFKK--IECWDSVEITGVEDS---FNASLGTYHDLLKIIQDK DFLDNPDNQKIIEDIILTLTLFEDKKMIS
633

WP_021320964
562
KQLKENYFKK--IECWDSVEITGVEDS---FNASLGTYHDLLKIIQDK DFLDNPDNQKIIEDIILTLTLFEDKKMIS
633

WP_037581760
562
KQLKENYFKK--IECWDSVEITGVEDS---FNASLGTYHDLLKIIQDK DFLDNPDNQKIIEDIILTLTLFEDKKMIS
633

WP_004232481
561
AKLLSYLNNE--FEEFRINDLIGLDKDskSFNASLGTYHDLKKIL-DK SFLDDKTNEQIIEDIVLTLTLFEDRDMIH
634

WP_009854540
562
EKLLNYLNKE--FPEYRIKDLIGLDKEnkSFNASLGTYHDLKKIL-DK AFLDDKVNEEVIEDIIKTLTLFEDKDMIH
635

WP_012962174
562
DKFLNYLNKE--FPEYRIQDLIGLDKEnkSFNASLGTYHDLKKIL-DK SFLDDKTNETIIEDIIQTLTLFEDRDMIR
635

WP_039695303
564
EKLLNYLNKE--FPEYRIKDLIGLDKEnkSFNASLGTYHDLKKIL-DK AFLDDKVNEEVIEDIIKTLTLFEDKDMIH
637

WP_014334983
561
AKLLSYLNNE--FEEFRINDLIGLDKDskSFNASLGTYHDLKKIL-DK SFLDDKTNGQIIEDIVLTLTLFEDRDMIH
634

WP_003099269
562
KQLKEEYESK--MKCFHTVTILGVEDR---FNASLGTYHDLLKIFKDK AFLDDEANQDILEEIVWTLTLFEDQAMIE
633

AHY15608
562
KQLKEEYESK--MKCFHTVTILGVEDR---FNASLGTYHDLLKIFKDK AFLDDEANQDILEEIVWTLTLFEDQAMIE
633

AHY17476
562
KQLKEEYESK--MKCFHTVTILGVEDR---FNASLGTYHDLLKIFKDK AFLDDEANQDILEEIVWTLTLFEDQAMIE
633

ESR09100

------------------------------------------------ -----------------------------

AGM98575
562
KQLKEEYESK--MKCFHTVTILGVEDR---FNASLGTYHDLLKIFKDK AFLDDEANQDILEEIVWTLTLFEDQAMIE
633

ALF27331
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_018372492
574
RKLKDFIEKElgYGYIDIDNIKGVEEQ---FNASYTTYQDLLKIIGDK EFLDNEENKDLLEEIIYILTVFEDRKMIE
647

WP_045618028
563
KDIIQYLHN---VDSYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDSKNEAILENIVHTLTIFEDREMIK
633

WP_045635197
562
KDIIHYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDAKNEAILENIVHTLTIFEDREMIK
632

WP_002263549
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002263887
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002264920
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002269043
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002269448
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002271977
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002272766
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002273241
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002275430
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002276448
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002277050
561
KKLRTFLDKN--FDEFRIVDIQGLDKEteTENASYATYQDLLKVIKDK VFMDNPENAEILENIVLTLTLFEDREMIK
635

WP_002277364
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002279025
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002279859
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002280230
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002281696
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002282247
561
KKLRTFLDKN--FDEFRIVDIQGLDKEteTENASYATYQDLLKVIKDK VFMDNPENAEILENIVLTLTLFEDREMIK
635

WP_002282906
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002283846
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002287255
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002288990
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002289641
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002290427
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002295753
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002296423
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002304487
571
DKLLNYLNKE--FEEFRIVNLTGLDKEnkVENSSLGTYHDLRKIL-NK SFLDNKENEQIIEDIIQTLTLFEDREMIR
644

WP_002305844
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002307203
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002310390
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_002352408
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_012997688
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_014677909
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_019312892
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_019313659
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_019314093
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_019315370
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_019803776
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_019805234
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_024783594
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_024784288
561
KKLRTFLDKN--FDEFRIVDIQGLDKEteTFNASYATYQDLLKVIKDK VFMDNPENAEILENIVLTLTLFEDREMIK
635

WP_024784666
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_024784894
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_024786433
561
KKLRTFLDKN--FDEFRIVDIQGLDKEteTFNASYATYQDLLKVIKDK VFMDNPENAEILENIVLTLTLFEDREMIK
635

WP_049473442
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

WP_049474547
561
DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
634

EMC03581
554
DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR
627

WP_000428612
565
KDIIQYLHT---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDPNNEEILENIVHTLTIFEDREMIK
635

WP_000428613
563
KDIIQFLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDSKNEEILENIVHTLTIFEDREMIK
633

WP_049523028
562
KDIIHYLHN---VDGYDGIELKGIEKH---FNSSLSTYHDLLKIIKDK EFMDDPKNEEIFENIVHTLTIFEDRVMIK
632

WP_003107102
531
KQLKENYFNK--IRCLDSITISGVEDK---FNASLGTYHDLLNIIKNQ KILDDEQNQDSLEDIVLTLTLFEDEKMIA
602

WP_054279288
564
KQLKEDFFSK--IECFDTVDISGVEDK---FNASLGTYHDLLKIIKDK AFLDNSENENIIEDIILTLTLFEDKEMIA
635

WP_049531101
563
KDLIHYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK RFMDEPKNQEILENIVHTLTIFEDREMIK
633

WP_049538452
563
KDIIQYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDSKNEEILENIVHTLTIFEDREMIK
633

WP_049549711
563
KDIIHYLHT---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDSKNEAILENIVHTLTIFEDREMIK
633

WP_007896501
565
KDLKEKYFSQ--IEGLENVDVTGVEGA---FNASLGTYNDLLKIIKDK AFLDDEANAEILEEIVLILTLFQDEKLIE
636

EFR44625
517
KDLKEKYFSQ--IEGLENVDVTGVEGA---FNASLGTYNDLLKIIKDK AFLDDEANAEILEEIVLILTLFQDEKLIE
588

WP_002897477
562
KDIIHYLHN---VDGYDGIELKGIEKQ---FNANLSTYHDLLKITKDK EFMDDPKNEEILENIVHTLTIFEDREMIK
632

WP_002906454
562
KDIIHYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDNPKNGEILENIIHTLTIFEDREMIK
632

WP_009729476
563
KDIIQFLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK AFMDDAKNEAILENIVHTLTIFEDREMIK
633

CQR24647
562
KKILNFLDKN--FDEFRITDIQGLDNEtgNENASYGTYHDLLKIIGDK EFMDSSDNVDVLEDIVLSLTLFEDREMIK
636

WP_000066813
565
KDIIHYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK AFMDDSKNEEILENIIHTLTIFEDREMIK
635

WP_009754323
563
KDIIHYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDNHKNQEILENIVHTLTIFEDREMIK
633

WP_044674937
562
KDIKAYL-EN--SNGYAGVELKGLEEQ---FNASLPTYHDLLKILRDK AFIDAEENQEILEDIVLTLTLFEDREMIR
632

WP_044676715
561
EKLMDFLGKE--FDEFRIVDLLGLDKDnkSFNASLGTYHDLKKIV-SK DLLDNPENEDILENVVLTLTLFEDREMIR
634

WP_044680361
561
EKLMDFLGKE--FDEFRIVDLLGLDKDnkSFNASLGTYHDLKKIV-SK DLLDNPENEDILENVVLTLTLFEDREMIR
634

WP_044681799
562
KDIKAYL-EN--SNGYAGVELKGLEEQ---FNASLPTYHDLLKILRDK AFIDAEENQEILEDIVLTLTLFEDREMIR
632

WP_049533112
561
DKLLNYLGKE--FDEFRIVDLTGLDKEnkVENSSLGTYHDLRKIL-DK SFLDNKENEQIIEDIIQTLTLFEDREMIR
634

WP_029090905
541
TSLKKWLAEH---EHMTVSVVQGTQKEt-EFATSLQAEHREVKIF-DR ETVSNPANEEMFEKIIYWSTVFEDKKIMR
612

WP_006506696
568
KKLKNWLVNNqcCS--KDAEIKGFQKEn-QESTSLTPWIDETNIFGKI ----DQSNFDLIENIIYDLTVFEDKKIMK
637

AIT42264
562
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_034440723
568
NQLVKYIENK---EQIIAPEIKGIEDS---FNSNYSTYIDLSKIPDMK --LLEKDEDEILEEIIKILTIFEDRKMRK
637

AKQ21048
562
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

WP_004636532
563
KDIANYLEQ---YGYVDGTDIKGVEDK---FNASLSTYNDLAKIDGAK AYLDDPEYADVWEDIIKILTIFEDKAMRK
633

WP_002364836
570
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
641

WP_016631044
521
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
592

EMS75795
306
KKLQQFLSAN--YN-IEDAEILGVDKA---FNSSYATYHDFLDLAKPN ELLEQPEMNAMFEDIVKILTIFEDREMIR
381

WP_002373311
570
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
641

WP_002378009
570
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
641

WP_002407324
570
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
641

WP_002413717
570
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
641

WP_010775580
572
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
643

WP_010818269
570
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
641

WP_010824395
570
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
641

WP_016622645
570
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
641

WP_033624816
570
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
641

WP_033625576
570
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
641

WP_033789179
570
KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR
641

WP_002310644
567
KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK
641

WP_002312694
568
KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK
642

WP_002314015
568
KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK
642

WP_002320716
568
KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK
642

WP_002330729
567
KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK
641

WP_002335161
568
KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK
642

WP_002345439
568
KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK
642

WP_034867970
562
KKLQNFLYTH--YH-IENAQIFGIEKA---FNASYSTYHDFMKLAKTN EWLEQPEMEPIFEDIVKILTIFEDRQMIK
637

WP_047937432
568
KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK
642

WP_010720994
562
KKLQNFLYTH--YH-IENAQIFGIEKA---FNASYSTYHDFMKLAKTN EWLEQPEMEPIFEDIVKILTIFEDRQMIK
637

WP_010737004
562
KKLQNFLYTH--YH-IENAQIFGIEKA---FNASYSTYHDFMKLAKTN EWLEQPEMEPIFEDIVKILTIFEDRQMIK
637

WP_034700478
562
KKLQNFLYTH--YH-IENAQIFGIEKA---FNASYSTYHDFMKLAKTN EWLEQPEMEPIFEDIVKILTIFEDRQMIK
637

WP_007209003
564
KKLENYLRIE1---SISSPSVKGIEEQ---FNANFGTYLDLKKFDELH PYLDDEKYQDTLEEVIKVLTVFEDRSMIQ
634

WP_023519017
560
KQLRKFLELN--EQ-IDSTEIKGIETS---FNASYSTYHDLLKLS--- TLLDDPDMTTMFEEIIKILTIFEDREMIR
631

WP_010770040
564
KLLEKFLSNE--FG-LVDVAIKGIE-T--SFNAGYGTYHDFLKIGITR EQLDKEENSETLEEIVKILTVFEDRKMIR
634

WP_048604708
560
KDLSNFLRNE--YN-LDDVIIDGIE-N--KFNASFNTYHDFLKLKIDP KVLDDPANEPMFEEIVKILTIFEDRKMLR
630

WP_010750235
561
KKLQHFLSAN--YN-IEDAEILGVDKV---FNSSYATYHDFLELAKPY ELLEQPEMEEMFEDIVKIITIFEDREMVR
636

AII16583
601
KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
672

WP_029073316
576
NAMKKWLVKNqyFSNTDDIKIEGFQKEn-ACSTSLTPWIDFTKIFGEI ----NNSNYELIEKIIYDVTVFEDKKILR
647

WP_031589969
576
NAMKKWLVKNqyFSNTDDIKIEGFQKEn-ACSTSLTPWIDFTKIFGKI ----NESNYDFIEKIIYDVTVFEDKKILR
647

KDA45870
558
KMVIKHLKVV--MPAIRIQALKGLDNGk--FNASYGTYKDLVDMGVAP ELLNDEVNSEKWEDIIKTLTIFEGRKLIK
630

WP_039099354
579
KNIQDYLVSEk--RYASRPAITGLSDEnk-FNSRLSTYHDLKTIVGDA --VDDVDKQADLEKCIEWSTIFEDGKIYS
650

AKP02966
561
KKLTKWLIAQg---YYKNPILIGLSQKd-EFNSTLTTYLDMKKIFGSS -FMENNKNYNQIEELIEWLTIFEDKQILN
632

WP_010991369
567
KDLELFLRNM--SH-VESPTIEGLE-D--SFNSSYSTYHDLLKVGIKQ EILDNPVNTEMLENIVKILTVFEDKRMIK
637

WP_033838504
567
KDLELFLRNM--SH-VESPTIEGLE-D--SFNSSYSTYHDLLKVGIKQ EILDNPVNTEMLENIVKILTVFEDKRMIK
637

EHN60060
570
KDLELFLRNM--SH-VESPTIEGLE-D--SFNSSYSTYHDLLKVGIKQ EILDNPVNTEMLENIVKILTVFEDKRMIK
640

EFR89594
336
KDLELFLRNM--SH-VESPTIEGLE-D--SFNSSYSTYHDLLKVGIKQ EILDNPVNTEMLENIVKILTVFEDKRMIK
406

WP_038409211
567
KDLERFLYTI--NH-IESPTIEGVE-D--AFNSSFATYHDLQKGGVTQ EILDNPLNADMLEEIVKILTVFEDKRMIK
637

EFR95520
186
KDLERFLYTI--NH-IESPTIEGVE-D--AFNSSFATYHDLQKGGVTQ EILDNPLNADMLEEIVKILTVFEDKRMIK
256

WP_003723650
567
KDLELFLRNI--NH-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKPMIK
637

WP_003727705
567
KDLELFLRNI--NH-IESPTIEGLE-D--SFNASYATYHDLLKVGLKQ EILDNPLNTEILEDIVKILTVFEDKRMIK
637

WP_003730785
567
KDLELFLRNI--NH-IESPTIEGLE-D--SFNASYATYHDLLKVGLKQ EILDNPLNTEILEDIVKILTVFEDKRMIK
637

WP_003733029
567
KDLELFLRNI--NQ-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK
637

WP_003739838
567
KDLEQFLRNM--SH-IESPTIEGLE-D--SFNSSYATYHDLLKVGIKQ EVLENPLNTEMLEDIVKILTVFEDKRMIK
637

WP_014601172
567
KDLELFLRNI--NH-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKPMIK
637

WP_023548323
567
KDLELFLRNI--NH-VESPTIEGLE-D--SFNASYATYHDLMKVGIKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK
637

WP_031665337
567
KDLELFLRNI--NQ-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK
637

WP_031669209
567
KDLELFLRNI--NQ-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK
637

WP_033920898
567
KDLELFLRNI--NH-VESPTIEGLE-D--SFNASYATYHDLMKVGIKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK
637

AKI42028
570
KDLELFLRNI--NH-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKPMIK
640

AKI50529
570
KDLELFLRNI--NH-VESPTIEGLE-D--SFNASYATYHDLMKVGIKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK
640

EFR83390
15
KDLELFLRNI--NQ-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK
85

WP_046323366
567
KDLELFLYNM--NH-VESPTVEGVE-D--AFNSSETTYHDLQKVGVPQ EILDDPLNTEMLEEIIKILTVFEDKRMIN
637

AKE81011
578
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
649

CUO82355
572
KKLKNWLVNNqcCR--KDAEIKGFQKEn-QESTSLTPWIDETNIFGKI ----DQSNFDLIEKIIYDLTVFEDKKIMK
641

WP_033162887
573
KKLKDWLVTHqyYDINEELKIEGYQKD1-QESTSLAPWIDETKIFGEI ----NASNYQLIEKIIYDISIFEDKKILK
644

AGZ01981
595
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
666

AKA60242
562
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

AKS40380
562
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
633

4UN5_B
566
KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE
637

WP_010922251
634
ERLKTYAHLFDDKVMKQLKR-RRYTGW custom character

RLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNF custom character

QLIHDDSL
702

WP_039695303
638
ERLQKYSDIFTANQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG---SANRNFMQLINDDTL
706

WP_045635197
633
QRLAQYDSLFDEKVIKALTR-RHYTGWGKLSAKLINGICDK QTGNTILDYLI DDG---KINRNFMQLINDDGL
701

5AXW_A
369
EELTNLNSELTQEEIEQISN1KGYTGTHNLSLKAINLILDE ---------LW -------TNDNQIAIFNRLKL
426

WP_009880683
318
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
386

WP_010922251
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_011054416
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_011284745
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_011285506
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_011527619
634
ERLKTYAHLFDDKVMKQLKR-RRYTVWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_012560673
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_014407541
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_020905136
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_023080005
634
ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLINDDSL
702

WP_023610282
634
ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLINDDSL
702

WP_030125963
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_030126706
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_031488318
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_032460140
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_032461047
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_032462016
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_032462936
634
ERLKKYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_032464890
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_033888930
459
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
527

WP_038431314
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_038432938
634
ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLINDDSL
702

WP_038434062
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

BAQ51233
545
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
613

KGE60162

----------------------------------------- ----------- ---------------------

KGE60856

----------------------------------------- ----------- ---------------------

WP_002989955
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_003030002
635
QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL
703

WP_003065552
638
ERLQKYSDIFTADQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG---SANRNFMQLINDDTL
706

WP_001040076
633
KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL
701

WP_001040078
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_001040080
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_001040081
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_001040083
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_001040085
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_001040087
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_001040088
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_001040089
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_001040090
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_001040091
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_001040092
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDR ESQKTILDYLI SDG---RANRNFMQLINDDGL
704

WP_001040094
633
KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL
701

WP_001040095
633
KRLDIYKDFFTESQLKKLYR-RHYTGWERLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL
701

WP_001040096
633
KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL
701

WP_001040097
633
KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL
701

WP_001040098
633
KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL
701

WP_001040099
633
KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL
701

WP_001040100
633
KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL
701

WP_001040104
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_001040105
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_001040106
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL
704

WP_001040107
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL
704

WP_001040108
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL
704

WP_001040109
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL
704

WP_001040110
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL
704

WP_015058523
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDR ESQKTILDYLI SDG---RANRNFMQLINDDGL
704

WP_017643650
633
KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL
701

WP_017647151
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---KSNRNFMQLIHDDGL
704

WP_017648376
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---KSNRNFMQLIHDDGL
704

WP_017649527
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_017771611
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL
704

WP_017771984
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

CFQ25032
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

CFV16040
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

KLJ37842
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

KLJ72361
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

KLL20707
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
718

KLL42645
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL
704

WP_047207273
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_047209694
633
KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL
701

WP_050198062
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_050201642
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_050204027
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL
704

WP_050881965
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

WP_050886065
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

AHN30376
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDR ESQKIILDYLI SDG---RANRNFMQLINDDGL
704

EA078426
636
KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL
704

CCW42055
636
KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL
704

WP_003041502
635
QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL
703

WP_037593752
636
QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL
704

WP_049516684
636
QRLQKYSDIFTTQQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL
704

GAD46167
635
QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL
703

WP_018363470
636
QRLQKYSDIFTKQQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG---SANRNFMQLINDDAL
704

WP_003043819
644
ERLKTYAHLFDDKVMKQLKR-RHYTGWGRLSRKMINGIRDK QSGKTILDFLK -DGf---SNRNFMQLIHDDSL
712

WP_006269658
635
QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL
703

WP_048800889
635
QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILEYLV DDG---YANRNFMQLINDDTL
703

WP_012767106
634
ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLINDDSL
702

WP_014612333
634
ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLINDDSL
702

WP_015017095
634
ERLKTYAHLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFIQLIHDDSL
702

WP_015057649
634
ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLINDDSL
702

WP_048327215
634
ERLKTYAHLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFIQLIHDDSL
702

WP_049519324
634
ERLKTYAHLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFIQLIHDDSL
702

WP_012515931
634
KRLDQYAHLFDKVVLNKLER-HHYTGWGRLSGKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDSEL
702

WP_021320964
634
KRLDQYAHLFDKVVLNKLER-HHYTGWGRLSGKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDSEL
702

WP_037581760
634
KRLDQYAHLFDKVVLNKLER-HHYTGWGRLSGKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDSEL
702

WP_004232481
635
ERLQKYSDIFTSQQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDFLI DDG---DANRNFMQLINDDSL
703

WP_009854540
636
ERLQKYSDIFTANQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG---SANRNFMQLINDDTL
704

WP_012962174
636
QRLQKYSDIFTPQQLKKLER-RHYTGWGRLSYKLINGIRNK ENGKSILDYLI DDG---YANRNFMQLISDDTL
704

WP_039695303
638
ERLQKYSDIFTANQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG---SANRNFMQLINDDTL
706

WP_014334983
635
ERLQKYSDFFTSQQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDFLI DDG---HANRNFMQLINDESL
703

WP_003099269
634
RRLVKYADVFEKSVLKKLKK-RHYTGWGRLSQKLINGIKDK QTGKTILGFLK -DGv---ANRNFMQLINDSSL
702

AHY15608
634
RRLVKYADVFEKSVLKKLKK-RHYTGWGRLSQKLINGIKDK QTGKTILGFLK -DGv---ANRNFMQLINDSSL
702

AHY17476
634
RRLVKYADVFEKSVLKKLKK-RHYTGWGRLSQKLINGIKDK QTGKTILGFLK -DGv---ANRNFMQLINDSSL
702

ESR09100

----------------------------------------- ----------- ---------------------

AGM98575
634
RRLVKYADVFEKSVLKKLKK-RHYTGWGRLSQKLINGIKDK QTGKTILGFLK -DGv---ANRNFMQLINDSSL
702

ALF27331
635
KRLENYSDLLTKEQVKNLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_018372492
648
KRLSELNIPFENKIIKKLAR-KKYTGWGNLSRKLIDGIRNR ETNRTILGHLI DDGf---SNRNLMQLINDDGL
716

WP_045618028
634
QRLAHYASIFDEKVIKALTR-RHYTGWGKLSAKLINGIYDK QSKKTILDYLI DDG---EINRNFMQLINDDGL
702

WP_045635197
633
QRLAQYDSLFDEKVIKALTR-RHYTGWGKLSAKLINGICDK QTGNTILDYLI DDG---KINRNFMQLINDDGL
701

WP_002263549
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002263887
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002264920
635
KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002269043
635
KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002269448
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002271977
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002272766
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002273241
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002275430
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG---NSNRNFMQLINDDAL
703

WP_002276448
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002277050
636
QRLAKYADVFDKKVIDQLAR-RHYTGWGRLSAKLLNGIRDK QSCKTIMDYLI DDA---QSNRNLMQLITDDNL
704

WP_002277364
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002279025
635
KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002279859
635
KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002280230
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002281696
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002282247
636
QRLAKYADVFDKKVIDQLAR-RHYTGWGRLSAKLLNGIRDK QSCKTIMDYLI DDA---QSNRNLMQLITDDNL
704

WP_002282906
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002283846
635
KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002287255
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002288990
635
KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002289641
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002290427
635
KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002295753
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002296423
635
KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002304487
645
QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRDK QSNKTILGYLI DDG---YSNRNFMQLINDDAL
713

WP_002305844
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002307203
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG---NSNRNFMQLINDDAL
703

WP_002310390
635
KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_002352408
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG---NSNRNFMQLINDDAL
703

WP_012997688
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_014677909
635
KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_019312892
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_019313659
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_019314093
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG---NSNRNFMQLINDDAL
703

WP_019315370
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG---NSNRNFMQLINDDAL
703

WP_019803776
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_019805234
635
KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_024783594
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_024784288
636
QRLAKYADVFDKKVIDQLAR-RHYTGWGRLSAKLLNGIRDK QSCKTIMDYLI DDA---QSNRNLMQLITDDNL
704

WP_024784666
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_024784894
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_024786433
636
QRLAKYADVFDKKVIDQLAR-RHYTGWGRLSAKLLNGIRDK QSCKTIMDYLI DDA---QSNRNLMQLITDDNL
704

WP_049473442
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

WP_049474547
635
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
703

EMC03581
628
KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL
696

WP_000428612
636
QRLAQYDSLFDEKVIKALTR-RHYTGWGKLSSKLINGIRDK QTGKTILDYLM DDG---YNNRNFMQLINDDEL
704

WP_000428613
634
QRLAQYDSLFDEKVIKALIR-RHYTGWGKLSAKLIDGICDK QTGNTILDYLI DDG---KNNRNFMQLINDDGL
702

WP_049523028
633
QRLNQYDSIFDEKVIKALTR-RHYTGWGKLSAKLINGIRDK KTSKTILDYLI DDG---YSNRNFMQLINDDGL
701

WP_003107102
603
KRLSKYESIFDPSILKKLKK-RHYTGWGRLSQKLINGIRDK QTGKTILDFLI -DGq---ANRNFMQLINDPSL
671

WP_054279288
636
NRLAVYEDLFDQNVLKQLKR-RHYTGWGRLSKQLINGMRDK HTGKTILDFLK -DGf---INRNFMQLINDDNL
704

WP_049531101
634
QRLAQYASIFDEKVIKTLTR-RHYTGWGKLSAKLINCIRDR KTGKTILDYLI DDG---YNNRNFMQLINDDGL
702

WP_049538452
634
QRLAQYDSIFDEKVIKALTR-RHYTGWGKLSAKLINGIRDK QTGKTILDYLI DDG---YSNRNFMQLINDDGL
702

WP_049549711
634
QRLAQYDSLFDKKVIKALTR-RHYTGWGKLSAKLINGICDK QTGNTILDYLI DDG---EINRNFMQLINDDGL
702

WP_007896501
637
KRLAKYANLFEKSVLKKLRK-RHYRGWGRLSRQLIDGMKDK ASGKTILDFLK -DDf---ANRNFIQLINDSSL
705

EFR44625
589
KRLAKYANLFEKSVLKKLRK-RHYRGWGRLSRQLIDGMKDK ASGKTILDFLK -DDf---ANRNFIQLINDSSL
657

WP_002897477
633
QRLAQYDTLFDEKVIKALTR-RHYTGWGKLSAKLINGIRDK QSGKTILDYLI DDD---KINRNFMQLINDDGL
701

WP_002906454
633
QRLAQYDTLFDEKVIKALTR-RHYTGWGKLSAKLINGIRDK QTGKTILEYLI DDG---DCNRNFMQLINDDGL
701

WP_009729476
634
QRLAQYDSLFDEKVIKALTR-RHYTGWGKLSAKLINGISDK QTGNTILDYLI DDG---EINRNFMQLINDDGL
702

CQR24647
637
QRLLKYEDIFSKKVIANLTR-RHYTGWGRLSAKLINGIKDK HSRKTILDYLI DDG---HSNRNFMQLINDDNL
705

WP_000066813
636
QRLAQYDSLFDEKVIKALTR-RHYTGWGKLSAKLINGIRDK KSGKTILDYLI DDG---EINRNFMQLIHDDGL
704

WP_009754323
634
QRLAQYDSIFDEKVIKALTR-RHYTGWGKLSAKLINGICDK KTGKTILDYLI DDG---YNNRNFMQLINDDGL
702

WP_044674937
633
KRLEKYKDILTEEQRKKLER-RHYTGWGRLSAKLINGILDK VTRKTILGYLI DDG---TSNRNFMQLINDDTL
701

WP_044676715
635
KRLEKYKDVLTEEQRKKLER-RHYTGWGRLSAKLINGIRDK VTRKTILDYLI DDG---TSNRNFMQLINDDTL
703

WP_044680361
635
KRLEKYKDVLTEEQRKKLER-RHYTGWGRLSAKLINGIRDK VTRKTILDYLI DDG---TSNRNFMQLINDDTL
703

WP_044681799
633
KRLEKYKDILTEEQRKKLER-RHYTGWGRLSAKLINGILDK VTRKTILGYLI DDG---TSNRNFMQLINDDTL
701

WP_049533112
635
QRLQKYSDIFTKAQLKKLER-CHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL
703

WP_029090905
613
RKLSEYPQLTEQQQVQLAQV--RFRGWGRLSQRLINRIKTP EDHKLSINEIL ------QTNENFMQIIRNKDY
682

WP_006506696
638
RRLKKKYALPDDKVKQILKL--KYKDWSRLSKKLLDGIVAD SV--TVLDVLE -------SRLNLMEIINDKDL
705

AIT42264
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_034440723
638
RQLMKFKDKLSEKAINQLSK-KHYTGWGQLSEKLINGIRDE QSNKTILDYLI DNGcpkNMNRNFMQLINDDTL
710

AKQ21048
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

WP_004636532
634
KQLQTYSDTLSPEILKKLER-KHYTGWGRFSKKLINGLRDE GSNKTILDYLK DEGssgPTNRNFMQLIRDNTL
706

WP_002364836
642
TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILGYLI DDGvskHYNRNFMQLINDSQL
714

WP_016631044
593
TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvskHYNRNFMQLINDSQL
665

EMS75795
382
TQLKKYQSVLGDGFEKKLVK-KHYTGWGRLSERLINGIRDK KTNKTILDYLI DDDfpyNRNRNFMQLINDDSL
454

WP_002373311
642
TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvskHYNRNFMQLINDSQL
714

WP_002378009
642
TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvskHYNRNFMQLINDSQL
714

WP_002407324
642
TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvskHYNRNFMQLINDSQL
714

WP_002413717
642
TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvskHYNRNFMQLINDSQL
714

WP_010775580
644
TQLSTFKGQFSEEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvskHYNRNFMQLINDSQL
716

WP_010818269
642
TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILGYLI DDGvskHYNRNFMQLINDSQL
714

WP_010824395
642
TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvskHYNRNFMQLINDSQL
714

WP_016622645
642
TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvskHYNRNFMQLINDSQL
714

WP_033624816
642
TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvskHYNRNFMQLINDSQL
714

WP_033625576
642
TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvskHYNRNFMQLINDSQL
714

WP_033789179
642
TQLSTFKGQFSEEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvskHYNRNFMQLINDSQL
714

WP_002310644
642
TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL
714

WP_002312694
643
TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL
715

WP_002314015
643
TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL
715

WP_002320716
643
TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL
715

WP_002330729
642
TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL
714

WP_002335161
643
TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL
715

WP_002345439
643
TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNCMQLINDDSL
715

WP_034867970
638
HQLSKYQEVFGEKLLKEFAR-KHYTGWGRFSAKLIHGIRDR KTNKTILDYLI DDDvpaNRNRNLMQLINDEHL
710

WP_047937432
643
TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL
715

WP_010720994
638
HQLSKYQEVFGEKLLKEFAR-KHYTGWGRFSAKLIHGIRDR KTNKTILDYLI DDDvpaNRNRNLMQLINDEHL
710

WP_010737004
638
HQLSKYQEVFGEKLLKEFAR-KHYTGWGRFSAKLIHGIRDR KTNKTILDYLI DDDvpaNRNRNLMQLINDEHL
710

WP_034700478
638
HQLSKYQEVFGEKLLKEFAR-KHYTGWGRFSAKLIHGIRDR KTNKTILDYLI DDDvpaNRNRNLMQLINDEHL
710

WP_007209003
635
NQLEQLPLNLSTKTIKALSR-RKYTGWGRLSARLIDGIHDK NSGKTILDYLI DESdsyIVNRNFMQLINDDHL
707

WP_023519017
632
EQLKPYETVLGLPAIKKLAK-KHYTGWGRLSEKMIQGMREK QSRKTILDYLI DDDfpcNRNRNFMQLINDDHL
704

WP_010770040
635
EQLKKYTYLFDEEVLKKLER-RHYTGWGRLSAKLLIGIKEK RTHKTILDYLI DDGgkqPINRNLMQLINDSDL
707

WP_048604708
631
EQLSKFSDRLSEKTIKDLER-RHYTGWGRLSAKLINGIHDK QSNKTILDYLI DDApkkNINRNFMQLINDNRL
703

WP_010750235
637
TQLKKYQRILGEEIFKKLVK-KKYTGWGRLSKRLINGIRDQ KTNKTILDYLI DDDfpyNRNRNFMQLINDDHL
709

AII16583
673
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
741

WP_029073316
648
RRLKKEYDLDEEKIKKILKL--KYSGWSRLSKKLLSGIKTK RTPETVLEVME -------TNMNLMQVINDEKL
717

WP_031589969
648
RRLKKEYDLDEEKIKKILKL--KYSGWSRLSKKLLSGIKTK RTPETVLEVME -------TNMNLMQVINDEKL
717

KDA45870
631
RRLENYRDFLGEDILRKLSR-KKYTGWGRLSAKLLDGIYDK KTHKTILDCLM EDYs-----QNFMQLINDDTY
698

WP_039099354
651
AKLNEIDWLTDQQRVQLAAK--RYRGWGRLSAKLLTQIVN- ANGQRIMDLLW -------TTDNFMRIVHSE--
712

AKP02966
633
EKLHSSNYSYTSDQIKKISN-MRYKGWGRLSKKILTCITTE TNTPKSLQLSN -DLm-wTTNNNFISIISNDKY
706

WP_010991369
638
EQLQQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLMGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL
706

WP_033838504
638
EQLQQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLMGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL
706

EHN60060
641
EQLQQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLMGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL
709

EFR89594
407
EQLQQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLMGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL
475

WP_038409211
638
EQLQSFSDVLDGTILKKLER-RHYTGWGRLSAKLLTGIRDK HSHLTILDYLM DDG----LNRNLMQLINDSNL
706

EFR95520
257
EQLQSFSDVLDGTILKKLER-RHYTGWGRLSAKLLTGIRDK HSHLTILDYLM DDG----LNRNLMQLINDSNL
325

WP_003723650
638
EQLQQFSDVLDGGVLKKLER-RHYTGWGRLSAKLLVGIREK QSHLTILDYLM DDG----LNRNLMQLINDSNL
706

WP_003727705
638
EQLEQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL
706

WP_003730785
638
EQLEQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL
706

WP_003733029
638
EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL
706

WP_003739838
638
EQLQQFSDVLDGAVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL
706

WP_014601172
638
EQLQQFSDVLDGGVLKKLER-RHYTGWGRLSAKLLVGIREK QSHLTILDYLM DDG----LNRNLMQLINDSNL
706

WP_023548323
638
EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL
706

WP_031665337
638
EQLQQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILEYLM DDG----LNRNLMQLINDSNL
706

WP_031669209
638
EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL
706

WP_033920898
638
EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL
706

AKI42028
641
EQLQQFSDVLDGGVLKKLER-RHYTGWGRLSAKLLVGIREK QSHLTILDYLM DDG----LNRNLMQLINDSNL
709

AKI50529
641
EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL
709

EFR83390
86
EQLQQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILEYLM DDG----LNRNLMQLINDSNL
154

WP_046323366
638
ERLQEFSNVLDEAVLKKLER-RHYTGWGRLSAKLLIGIRDK ESHLTILDYLM DDK----HNRNLMQLINDSNL
706

AKE81011
650
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
718

CUO82355
642
RRLKKKYALPDDKIKQILKL--KYKDWSRLSKKLLDGIVAD SV--TVLDVLE -------SRLNLMEIINDKEL
709

WP_033162887
645
RRLKKVYQLDDLLVDKILKL--NYTGWSRLSEKLLTGMTAD KA--TVLFVLE -------SNKNLMEIINDEKL
712

AGZ01981
667
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
735

AKA60242
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

AKS40380
634
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
702

4UN5_B
638
ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL
706

WP_010922251
703
TFKEDIQKAQVSG-QG custom character

RENQ TTQKGQKNS
777

WP_039695303
707
PFKQIIQKSQVVG-DVDD-IEAVVHDLPGSPAIKKGILQSVKIVDELVKVMG-GNPDNIVIEMARENQ TTNRGRSQS
780

WP_045635197
702
SFKEIIQKAQVIG-KTDD-VKQVVQELSGSPAIKKGILQSIKIVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS
775

5AXW_A
427
VPKKVDLSQQKEI---PT---TLVDDFILSPVVKRSFIQSIKVINAIIKKYG--LPNDIIIELAREKN --------S
487

WP_009880683
387
TFKEDLQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
461

WP_010922251
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_011054416
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_011284745
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_011285506
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_011527619
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_012560673
703
TFKEDLQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_014407541
703
TFKEDIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS
776

WP_020905136
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_023080005
703
TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS
776

WP_023610282
703
TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS
776

WP_030125963
703
TFKEDLQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_030126706
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_031488318
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_032460140
703
TFKEDLQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_032461047
703
TFKEDLQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_032462016
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_032462936
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_032464890
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_033888930
528
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
602

WP_038431314
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_038432938
703
TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS
776

WP_038434062
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKIVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

BAQ51233
614
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
688

KGE60162

-------------------------------------------------------------------- ---------

KGE60856

-------------------------------------------------------------------- ---------

WP_002989955
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_003030002
704
SFKEEIARAQIIG-DVDD-IANVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANIIIEMARENQ MTDKGRRNS
777

WP_003065552
707
PFKQIIQKSQVVG-DVDD-IEAVVHDLPGSPAIKKGILQSVKIVDELVKVMG-DNPDNIVIEMARENQ TTNRGRSQS
780

WP_001040076
702
SFKPIIDKARTGS-HSDN-LKEVIGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS
775

WP_001040078
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040080
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040081
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040083
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040085
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040087
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040088
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040089
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040090
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVVG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040091
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040092
705
SFKSIISKAQSGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040094
702
SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS
775

WP_001040095
702
SFKPIIDKARTGS-HLDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS
775

WP_001040096
702
SFKPIIDKARTGS-HLDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS
775

WP_001040097
702
SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRL
775

WP_001040098
702
SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS
775

WP_001040099
702
SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS
775

WP_001040100
702
SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS
775

WP_001040104
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040105
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_001040106
705
SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT
778

WP_001040107
705
SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT
778

WP_001040108
705
SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT
778

WP_001040109
705
SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT
778

WP_001040110
705
SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT
778

WP_015058523
705
SFKSIISKAQSGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_017643650
702
SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRL
775

WP_017647151
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_017648376
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_017649527
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_017771611
705
SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT
778

WP_017771984
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

CFQ25032
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

CFV16040
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

KLJ37842
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

KLJ72361
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

KLL20707
719
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
792

KLL42645
705
SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNKGRRNT
778

WP_047207273
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_047209694
702
SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS
775

WP_050198062
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_050201642
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_050204027
705
SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT
778

WP_050881965
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

WP_050886065
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

AHN30376
705
SFKSIISKAQSGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

EA078426
705
SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS
778

CCW42055
705
SFKSIISKAQSGS-HSDN-LKEVVSELAGSPAIKKGILQSLKIVDELVKVMG-YKPEQIVVEMARENQ TTNQGRRNS
778

WP_003041502
704
SFKEEIAKAQIIG-DVDD-IANVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANIIIEMARENQ TTDRGRRNS
777

WP_037593752
705
SFKEEIARAQIIG-DVDD-IANVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANIIIEMARENQ TTDKGRRNS
778

WP_049516684
705
SFKEEIARAQIIG-DVDD-IANVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANIIIEMARENQ TTDKGRRNS
778

GAD46167
704
SFKEEIARAQIIG-DVDD-IANVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANIIIEMARENQ TTDKGRRNS
777

WP_018363470
705
SFKQIIQEAQVVG-DVDD-IETVVHDLPGSPAIKKGILQSVKIVDELIKVMG-DNPDNIVIEMARENQ TTNRGRSQS
778

WP_003043819
713
TFKEEIEKAQVSG-QGDS-LHEQIADLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTTKGLQQS
786

WP_006269658
704
SFKEEIARAQIID-DVDD-IANVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANIIIEMARENQ TTDKGRRNS
777

WP_048800889
704
PFKQIIKDAQAID-DVDD-IELIVHDLPGSPAIKKGILQSIKIVDELVKVMG-YNPDNIVIEMARENQ TTTKGRRNS
777

WP_012767106
703
TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQSVKVVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS
776

WP_014612333
703
TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQSVKVVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS
776

WP_015017095
703
TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQSVKVVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS
776

WP_015057649
703
TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQSVKVVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS
776

WP_048327215
703
TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQSVKVVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS
776

WP_049519324
703
TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQSVKVVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS
776

WP_012515931
703
SFIDEIAKAQVIG-KTEY-SKDLVGNLAGSPAIKKGISQTIKIVDELVKIMG-YLPQQIVIEMARENQ TTAQGIKNA
776

WP_021320964
703
SFIDEIAKAQVIG-KTEY-SKDLVGNLASSPAIKKGISQTIKIVDELVKIMG-YLPQQIVIEMARENQ TTAQGIKNA
776

WP_037581760
703
SFIDEIAKAQVIG-KTEY-SKDLVGNLAGSPAIKKGISQTIKIVDELVKIMG-YLPQQIVIEMARENQ TTAQGIKNA
776

WP_004232481
704
SFKTTIQEAQVVG-DVDD-IEAVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPQNIVIEMARENQ ITGYGRNRS
777

WP_009854540
705
PFKQIIQKSQVVG-DVDD-IEAVVHDLPGSPAIKKGILQSVKIVDELVKVMG-DNPDNIVIEMARENQ TTNRGRSQS
778

WP_012962174
705
PFKQIIKDAQIIG-DIDD-VTSVVRELPGSPAIKKGILQSVKIVDELVKVMG-HNPDNIVIEMARENQ TTNRGRNQS
778

WP_039695303
707
PFKQIIQKSQVVG-DVDD-IEAVVHDLPGSPAIKKGILQSVKIVDELVKVMG-GNPDNIVIEMARENQ TTNRGRSQS
780

WP_014334983
704
SFKTIIQEAQVVG-DVDD-IEAVVHDLPGSPAIKKGILQSVKIVDELVKVMG-DNPDNIVIEMARENQ TTGYGRNKS
777

WP_003099269
703
DFAKIIKNEQEKTiKNES-LEETIANLAGSPAIKKGILQSIKIVDEIVKIMG-QNPDNIVIEMARENQ STMQGIKNS
777

AHY15608
703
DFAKIIKNEQEKTiKNES-LEETIANLAGSPAIKKGILQSIKIVDEIVKIMG-QNPDNIVIEMARENQ STMQGIKNS
777

AHY17476
703
DFAKIIKNEQEKTiKNES-LEETIANLAGSPAIKKGILQSIKIVDEIVKIMG-QNPDNIVIEMARENQ STMQGIKNS
777

ESR09100

-------------------------------------------------------------------- ---------

AGM98575
703
DFAKIIKNEQEKTiKNES-LEETIANLAGSPAIKKGILQSIKIVDEIVKIMG-QNPDNIVIEMARENQ STMQGIKNS
777

ALF27331
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_018372492
717
DFKEIIRKAQTIE-NIDT-NQALVSSLPGSPAIKKGILQSLNIVDEIIAIMG-YAPTNIVIEMARENQ TTQKGRDNS
790

WP_045618028
703
SFKEIIQKAQVVG-KTND-VKQVVQELPGSPAIKKGILQSIKLVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS
776

WP_045635197
702
SFKEIIQKAQVIG-KTDD-VKQVVQELSGSPAIKKGILQSIKIVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS
775

WP_002263549
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002263887
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002264920
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002269043
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002269448
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRQNS
777

WP_002271977
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002272766
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002273241
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTKQGRRNS
777

WP_002275430
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002276448
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTKQGRRNS
777

WP_002277050
705
TFKDDIVKAQYVD-NSDD-LHQVVQSLAGSPAIKKGILQSLKIVDELVKVMG-KEPEQIVVEMARENQ TTAKGRRNS
778

WP_002277364
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002279025
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002279859
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002280230
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTKQGRRNS
777

WP_002281696
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002282247
705
TFKDDIVKAQYVD-NSDD-LHQVVQSLAGSPAIKKGILQSLKIVDELVKVMG-KEPEQIVVEMARENQ TTAKGRRNS
778

WP_002282906
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002283846
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002287255
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002288990
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002289641
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002290427
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSLAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002295753
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTKQGRRNS
777

WP_002296423
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002304487
714
SFKEEIAKAQVIG-EMDG-LNQVVSDIAGSPAIKKGILQSLKIVDELVKVMG-HNPANIVIEMARENQ TTAKGRRSS
787

WP_002305844
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTKQGRRNS
777

WP_002307203
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002310390
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSLAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_002352408
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGQRNS
777

WP_012997688
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_014677909
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_019312892
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_019313659
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_019314093
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_019315370
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_019803776
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_019805234
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSLAIKKGILQNLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_024783594
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_024784288
705
TFKDDIVKAQYVD-NSDD-LHQVVQSLAGSPAIKKGILQSLKIVDELVKVMG-KEPEQIVVEMARENQ TTAKGRRNS
778

WP_024784666
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_024784894
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_024786433
705
TFKDDIVKAQYVD-NSDD-LHQVVQSLAGSPAIKKGILQSLKIVDELVKVMG-KEPEQIVVEMARENQ TTAKGRRNS
778

WP_049473442
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

WP_049474547
704
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
777

EMC03581
697
SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS
770

WP_000428612
705
SFKEIIKKAQVVG-KTDD-VKQVVQELPGSPAIKKGILQSIKLVDELVKVMG-HEPESIVIEMARENQ TTARGKKNS
778

WP_000428613
703
SFKEITQKAQVVG-KTDD-VKQVVQELPGSPAIKKGILQSIKIVDELVKVMG-HTPESIVIEMARENQ TTARGKKNS
776

WP_049523028
702
SFKETIQKAQVVG-ETND-VKQVVQELPGSPAIKKGILQSIKIVDELVKVMG-HAPESVVIEMARENQ TTNKGKSKS
775

WP_003107102
672
DFASIIKEAQEKTiKSEK-LEETIANLAGSPAIKKGILQSVKIVDEVVKVMG-YEPSNIVIEMARENQ STQRGINNS
746

WP_054279288
705
SFKEEIKKAQEGG-LKDS-INDQIRDLAGSPAIKKGILQTINIVDEIVKIMG-KAPQHIVVEMARDVQ KTDIGVKQS
778

WP_049531101
703
SFKEIIQESQVVG-KPDD-VKQIVQELPGSSAIKKGILQSIKLVDELVKVMG-HDPESIVIEMARENQ TTARGKKNS
776

WP_049538452
703
SFKEIIQKAQVFG-KTND-VKQVVQELPGSPAIKKGILQSIKIVEELVKVMG-HEPESIVIEMARENQ TTTRGKKNS
776

WP_049549711
703
SFKKIIQKSQVVG-ETDD-VKQVVRELPGSPAIKKGILQSIKIVDELVKVMD-HAPESIVIEMARENQ TTARGKKNS
776

WP_007896501
706
DFEKLIDDAQKKAiKRES-LTEAVANLAGSPAIKKGILQSLKVVDEIVKVMG-HNPDNIVIEMSRENQ TTAQGLKNA
780

EFR44625
658
DFEKLIDDAQKKAiKRES-LTEAVANLAGSPAIKKGILQSLKVVDEIVKVMG-HNPDNIVIEMSRENQ TTAQGLKNA
732

WP_002897477
702
SFKEIIQKAQVVG-KTDD-VKQVVQELPGSPAIKKGILQSIKIVDELVKVMG-YALESIVIEMARENQ TTARGKKNS
775

WP_002906454
702
SFKEIIQKAQVVG-KTDD-VKQVVQEIPGSPAIKKGILQSIKIVDELVKVMG-HNPESIVIEMARENQ TTAKGKKNS
775

WP_009729476
703
SFKEIIQKAQVVG-KTND-VKQVVQELPGSPAIKKGILQSIKIVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS
776

CQR24647
706
SFKDEIANSQVIG-DGDD-LHQVVQELAGSPAIKKGILQSLKIVDELVKVMG-YNPEQIVVEMARENQ TTARGRNNS
779

WP_000066813
705
SFKEIIQKAQVFG-KTND-VKQVVQELPGSPAIKKGILQSIKIVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS
778

WP_009754323
703
SFKEIIQKAQVVG-KTDD-LTQVVRELSGSPAIKKGILQSIKIVDELVKIMG-YAPESIVIEMARENQ TTAKGKKNS
776

WP_044674937
702
SFVDEIRLAQGSG-EAED-YRAEVQNLAGSPAIKKGILQSLKIVDELIEVMG-YDPEHIVVEMARENQ FTNQGRRNS
775

WP_044676715
704
SFVDEIRLAQGSG-EAED-YRAEVQNLAGSPAIKKGILQSLKIVDELIEVMG-YDPEHIVVEMARENQ FTNQGRRNS
777

WP_044680361
704
SFVDEIRLAQGSG-EAED-YRAEVQNLAGSPAIKKGILQSLKIVDELIEVMG-YDPEHIVVEMARENQ FTNQGRRNS
777

WP_044681799
702
SFVDEIRLAQGSG-EAED-YRAEVQNLAGSPAIKKGILQSLKIVDELIEVMG-YDPEHIVVEMARENQ FTNQGRRNS
775

WP_049533112
704
SEKEETAKAQVIG-ETDD-LNQVVSDIAGSPAIKKGILQSLKIVDELVKVMG-YNPANIVIEMARENQ TTDKGRRNS
777

WP_029090905
683
LFKKIIEEQFENEtALLN--KQRIDELAASPANKKGIWQATKIVKELEKVLQ-QPAENIFIEFARSDE ES----KRS
752

WP_006506696
706
GYAQMIEEATSCPeDGKE-TYEEVERLAGSPALKRGIWQSLQIVEEITKVMK-CRPKYIYIEFERSEE -----KERT
776

AIT42264
703
TEKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_034440723
711
SFKEKIRKAQDIN-QVND-IKEIVKDLPGSPAIKKGIYQSIRIVDEIIRKMK-DRPKNIVIEMARENQ TTQEGKNKS
784

AKQ21048
703
TEKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

WP_004636532
707
SFKKKIEDAQTIE-DTTH-IYDTVAELPGSPAIKKGIRQALKIVEEIIDIIG-YEPENIVVEMARESQ TTKKGKDLS
780

WP_002364836
715
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
788

WP_016631044
666
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
739

EMS75795
455
SFKEELANELALA-GNQS-LLEVVEALLGSPAIKKGIWQTLKIVEELIEIIG-YNPKNIVVEMARENQ RT----NRS
524

WP_002373311
715
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
788

WP_002378009
715
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
788

WP_002407324
715
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
788

WP_002413717
715
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
788

WP_010775580
717
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
790

WP_010818269
715
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
788

WP_010824395
715
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
788

WP_016622645
715
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
788

WP_033624816
715
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
788

WP_033625576
715
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
788

WP_033789179
715
SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS
788

WP_002310644
715
SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS
788

WP_002312694
716
SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS
789

WP_002314015
716
SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS
789

WP_002320716
716
SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS
789

WP_002330729
715
SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS
788

WP_002335161
716
SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS
789

WP_002345439
716
SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS
789

WP_034867970
711
SFKEEIAKATVFS-KHKS-LVDVIQDLPGSPAIKKGIWQSLKIVEELIAIIG-YKPKNIVIEMARENQ KT----HRT
780

WP_047937432
716
SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS
789

WP_010720994
711
SFKEEIAKATVFS-KHKS-LVDVIQDLPGSPAIKKGIWQSLKIVEELIAIIG-YKPKNIVIEMARENQ KT----HRT
780

WP_010737004
711
SFKEEIAKATVFS-KHKS-LVDVIQDLPGSPAIKKGIWQSLKIVEELIAIIG-YKPKNIVIEMARENQ KT----HRT
780

WP_034700478
711
SFKEEIAKATVFS-KHKS-LVDVIQDLPGSPAIKKGIWQSLKIVEELIAIIG-YKPKNIVIEMARENQ KT----HRT
780

WP_007209003
708
SFKKIIEDSQPYK-EQQS-AEEIVSELSGSPAIKKGILQSLKIVDELVAIMG-YKPKNIVVEMARENQ TTGRGKQNS
781

WP_023519017
705
SFKETIANELIMS-DSNV-LLDQVKAIPGSPAVKKGIWQSIKIVEEIIGIIG-KAPKNIVIEMARENQ RTSR----S
774

WP_010770040
708
SFKSEIAEAQSDM-NTED-LHEVVQNLAGSPAIKKGILQSLKIVDELVDIMG-SLPKNIVVEMARENQ TTSRGRTNS
781

WP_048604708
704
TFKEEIEKEQLKA-NSEEsLIEIVQNLAGSPAIKKGIFQSLKIVDELVEIMG-YAPTNIVVEMARENQ TTANGRRNS
778

WP_010750235
710
SFKEEIAKELTLS-DKQS-LLEVVEAIPGSPAIKKGIWQTLKIVEELIAIIG-YKPKNIVIEMARENQ TTTGGKNRS
783

AII16583
742
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
816

WP_029073316
718
GFKKTIDDANSTSvSGKF-SYAEVQELAGSPAIKRGIWQALLIVDEIKKIMK-HEPAHVYIEFARNED -----KERK
788

WP_031589969
718
GFKKTIDDANSTSvSGKF-SYAEVQELAGSPAIKRGIWQALLIVDEIKKIMK-HEPAHVYIEFARNED -----KERK
788

KDA45870
699
SFKETIKNAQVIE-KEET-LAKTVQELPGSPAIKKGILQSLEIVDEIIKVMG-YKPKSIVVEMARETQ --THGTRKR
771

WP_039099354
713
DFDKLITEANQMM-LAENdVQDVINDLYTSPQNKKALRQILLVVNDIQKAMKgQAPERILIEFAREDE VNPRLSVQR
788

AKP02966
707
DFKNYIENHNLNKnEDQN-ISNLVNDIHVSPALKRGITQSIKIVQEIVKFMG-HAPKYIFIEVTRETK TTSRGKRIQ
785

WP_010991369
707
SFKSIIEKEQVTT-ADKD-IQSIVADLAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIVVEMARENQ TTGKGKNNS
780

WP_033838504
707
SFKSIIEKEQVTT-ADKD-IQSIVADLAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIVVEMARENQ TTGKGKNNS
780

EHN60060
710
SFKSIIEKEQVTT-ADKD-IQSIVADLAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIVVEMARENQ TTGKGKNNS
783

EFR89594
476
SFKSIIEKEQVTT-ADKD-IQSIVADLAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIVVEMARENQ TTGKGKNNS
549

WP_038409211
707
SFKSIIEKEQVST-ADKG-IQSIVAELAGSPAIKKGILQSLKIVDELVGIMG-YPPQTIVVEMARENQ TTGKGKNNS
780

EFR95520
326
SFKSIIEKEQVST-ADKG-IQSIVAELAGSPAIKKGILQSLKIVDELVGIMG-YPPQTIVVEMARENQ TTGKGKNNS
399

WP_003723650
707
SFKSIIEKEQVST-TDKD-LQSIVAELAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTGKGKNNS
780

WP_003727705
707
SFKSIIEKEQVST-TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTGKGKNNS
780

WP_003730785
707
SFKSIIEKEQVST-TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTGKGKNNS
780

WP_003733029
707
SFKSIIEKEQVST-TDKD-LQSIVAELAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIVVEMARENQ TTNKGKNNS
780

WP_003739838
707
SFKSIIEKEQVST-TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTVKGKNNS
780

WP_014601172
707
SFKSIIEKEQVST-TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTGKGKNNS
780

WP_023548323
707
SFKSIIEKEQVST-ADKD-LQSIVADLAGSPAIKKGILQSLKVVEELVSVMG-YPPQTIVVEMARENQ TTNKGKNNS
780

WP_031665337
707
SFKSIIEKEQVST-TDKD-LQSIVAELAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTGKGKNNS
780

WP_031669209
707
SFKSIIEKEQVST-ADKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIVVEMARENQ TTNKGKNNS
780

WP_033920898
707
SFKSIIEKEQVST-ADKD-LQSIVADLAGSPAIKKGILQSLKVVEELVSVMG-YPPQTIVVEMARENQ TTNKGKNNS
780

AKI42028
710
SFKSIIEKEQVST-TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTGKGKNNS
783

AKI50529
710
SFKSIIEKEQVST-ADKD-LQSIVADLAGSPAIKKGILQSLKVVEELVSVMG-YPPQTIVVEMARENQ TTNKGKNNS
783

EFR83390
155
SFKSIIEKEQVST-TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTVKGKNNS
228

WP_046323366
707
SFKSIIEKEQVST-ADKD-IQSIVADLAGSPAIKKGILQSLKIVDELVGIMG-YPPQTIVVEMARENQ TTGKGKNNS
780

AKE81011
719
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
793

CUO82355
710
GYAQMIEEASSCPkDGKF-TYEEVAKLAGSPALKRGIWQSLQIVEEITKVMK-CRPKYIYIEFERSEE -----KERT
780

WP_033162887
713
GYKQIIEESNMQDiEGPF-KYDEVKKLAGSPAIKRGIWQALLVVREITKFMK-HEPSHIYIEFAREEQ -----KVRK
783

AGZ01981
736
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
810

AKA60242
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

AKS40380
703
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
777

4UN5_B
707
TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS
781

WP_010922251
778

custom character

841

WP_039695303
781
QQRLKKLQNSLK PSYI E----DK--VE---NSHLQNDQLFLYYIQNGKDMYTGDEL--D--IDHLSDYDIDHI
851

WP_045635197
776
QQRYKRIEDSLK ILAS NILKENP--TD---NNQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSSYDIDHI
843

5AXW_A
488
KDAQKMINEMQK QTNE EIIRTTGk--E---NAKYLIEKIKLHDMQEGKCLYSLEAIplEd1LNNPFNYEVDHI
561

WP_009880683
462
RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
525

WP_010922251
778
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_011054416
778
RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_011284745
778
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_011285506
778
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_011527619
778
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_012560673
778
RERMKRIEEGIK ELGS DILKEYP--VE---TTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_014407541
777
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
840

WP_020905136
778
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_023080005
777
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
840

WP_023610282
777
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
840

WP_030125963
778
RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_030126706
778
RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_031488318
778
RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_032460140
778
RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_032461047
778
RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_032462016
778
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_032462936
778
RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_032464890
778
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_033888930
603
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
666

WP_038431314
778
RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_038432938
777
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
840

WP_038434062
778
RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

BAQ51233
689
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
752

KGE60162
1
------------ ---- -------------------------------------QEL--D--INRLSGYDVDHI
16

KGE60856

------------ ---- ---------------------------------------------------------

WP_002989955
778
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_003030002
778
QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI
840

WP_003065552
781
QQRLKKLQNSLK PSYI E----DK--VE---NSHLQNDQLFLYYIQNGKDMYTGDEL--D--IDHLSDYDIDHI
851

WP_001040076
776
RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI
846

WP_001040078
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040080
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040081
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040083
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040085
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDDLSQYDIDHI
846

WP_001040087
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040088
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040089
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040090
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040091
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040092
779
RQRYKLLEDGVK NLAS DILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040094
776
RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI
846

WP_001040095
776
RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI
846

WP_001040096
776
RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI
846

WP_001040097
776
RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI
846

WP_001040098
776
RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI
846

WP_001040099
776
RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI
846

WP_001040100
776
RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI
846

WP_001040104
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040105
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040106
779
RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040107
779
RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040108
779
RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGETL--D--IDNLSQYDIDHI
846

WP_001040109
779
RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_001040110
779
RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_015058523
779
RQRYKLLEDGVK NLAS DILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_017643650
776
RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDLI
846

WP_017647151
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGKAL--D--IDNLSQYDIDHI
846

WP_017648376
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGKAL--D--IDNLSQYDIDHI
846

WP_017649527
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_017771611
779
RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_017771984
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

CFQ25032
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

CFV16040
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

KLJ37842
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

KLJ72361
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

KLL20707
793
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
860

KLL42645
779
RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_047207273
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_047209694
776
RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI
846

WP_050198062
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_050201642
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_050204027
779
RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_050881965
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

WP_050886065
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

AHN30376
779
RQRYKLLEDGVK NLAS DILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDSLSQYDIDHI
846

EA078426
779
RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI
846

CCW42055
779
RQRYKLLDDGVR NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTEKAL--D--IDNLSQYDIDHI
846

WP_003041502
778
QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI
840

WP_037593752
779
QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI
841

WP_049516684
779
QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI
841

GAD46167
778
QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI
840

WP_018363470
779
QQRLKKLQNSLK PSYI E----DK--VE---NSHLQNDQLFLYYIQNGKDMYTGDEL--D--IDHLSDYDIDHI
849

WP_003043819
787
RERKKRIEEGIK ELES QILKENP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
850

WP_006269658
778
QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI
840

WP_048800889
778
QQRLKLLQDSLT PVSI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGEEL--D--IHHLSDYDIDHI
840

WP_012767106
777
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
840

WP_014612333
777
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
840

WP_015017095
777
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
840

WP_015057649
777
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
840

WP_048327215
777
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
840

WP_049519324
777
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
840

WP_012515931
777
RQRMRKLEETAK KLGS NILKEHP--VD---NSQLQNDKRYLYYLQNGKDMYTGDDL--D--IDYLSSYDIDHI
840

WP_021320964
777
RQRMRKLEETAK KLGS NILKEHP--VD---NSQLQNDKRYLYYLQNGKDMYTGDDL--D--IDYLSSYDIDHI
840

WP_037581760
777
RQRMRKLEETAK KLGS NILKEHP--VD---NSQLQNDKRYLYYLQNGKDMYTGDDL--D--IDYLSSYDIDHI
840

WP_004232481
778
NQRLKRLQDSLK PSYV D----SK--VE---NSHLQNDRLFLYYIQNGKDMYTGEEL--D--IDHLSDYDIDHI
848

WP_009854540
779
QQRLKKLQSSLK PSYI E----DK--VE---NSHLQNDQLFLYYIQNGKDMYTGDEL--D--IDHLSDYDIDHI
849

WP_012962174
779
QQRLKKLQDSLK PSYI E----GK--VE---NNHLQDDRLFLYYIQNGKDMYTGDEL--D--IDHLSDYDIDHI
849

WP_039695303
781
QQRLKKLQNSLK PSYI E----DK--VE---NSHLQNDQLFLYYIQNGKDMYTGDEL--D--IDHLSDYDIDHI
851

WP_014334983
778
NQRLKRLQDSLK PSYV D----SK--VE---NSHLQNDRLFLYYIQNGKDMYTGEEL--D--IDRLSDYDIDHI
848

WP_003099269
778
RQRLRKLEEVHK NTGS KILKEYN--VS---NTQLQSDRLYLYLLQDGKDMYTGKEL--D--YDNLSQYDIDHI
841

AHY15608
778
RQRLRKLEEVHK NTGS KILKEYN--VS---NTQLQSDRLYLYLLQDGKDMYTGKEL--D--YDNLSQYDIDHI
841

AHY17476
778
RQRLRKLEEVHK NTGS KILKEYN--VS---NTQLQSDRLYLYLLQDGKDMYTGKEL--D--YDNLSQYDIDHI
841

ESR09100

------------ ---- ---------------------------------------------------------

AGM98575
778
RQRLRKLEEVHK NTGS KILKEYN--VS---NTQLQSDRLYLYLLQDGKDMYTGKEL--D--YDNLSQYDIDHI
841

ALF27331
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_018372492
791
AQRLKKIEDGIK -LGS DLLKQNP--IQd--NKDLQKEKLFLYYMQNGIDLYTGQPLncD--PDSLAFYDVDHI
857

WP_045618028
777
QQRYKRIEDALK NLAH NILKEHP--TD---NIQLQNDRLFLYYLQNGKDMYTGKSL--D--INQLSSCDIDHI
844

WP_045635197
776
QQRYKRIEDSLK ILAS NILKENP--TD---NNQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSSYDIDHI
843

WP_002263549
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002263887
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002264920
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002269043
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002269448
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002271977
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002272766
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002273241
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002275430
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002276448
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002277050
779
QQRYKRLKEAIK DLNH KILKEHP--TD---NQALQNNRLFLYYLQNGRDMYTGESL--D--INRLSDYDIDHV
846

WP_002277364
778
QQRLKGLTDSIK EFGS QILKEHP--VE---HSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002279025
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002279859
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002280230
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002281696
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002282247
779
QQRYKRLKEAIK DLNH KILKEHP--TD---NQALQNNRLFLYYLQNGRDMYTGESL--D--INRLSDYDIDHV
846

WP_002282906
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002283846
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002287255
778
QQRLKGLTDSIK EFGS QILKEHP--VE---HSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002288990
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002289641
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002290427
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002295753
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002296423
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002304487
788
QKRYKRLEEAIK DLNH KILKEHP--TD---NQALQNDRLFLYYLQNGRDMYTEDPL--D--INRLSDYDIDHI
855

WP_002305844
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002307203
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002310390
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_002352408
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_012997688
778
QQRLKGLTDSIK EFGS QILKEHP--VK---HSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_014677909
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_019312892
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_019313659
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_019314093
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_019315370
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_019803776
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_019805234
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_024783594
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_024784288
779
QQRYKRLKEAIK DLNH KILKEHP--TD---NQALQNNRLFLYYLQNGRDMYTGESL--D--INRLSDYDIDHV
846

WP_024784666
778
QQRLKGLTDSIK EFGS QILKEHP--VE---HSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_024784894
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_024786433
779
QQRYKRLKEAIK DLNH KILKEHP--TD---NQALQNNRLFLYYLQNGRDMYTGESL--D--INRLSDYDIDHV
846

WP_049473442
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

WP_049474547
778
QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
841

EMC03581
771
QQRLKGLTDSIK EFGS QILKEHP--VE---HSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI
834

WP_000428612
779
QQRYKRIEDSLK ILAS KILKEHP--TD---NIQLQNDRLFLYYLQNGRDMYTGKPL--D--INQLSSYDIDHI
846

WP_000428613
777
QQRYKRIEDALK NLAS NILKEHP--TN---NIQLQNDRLFLYYLQNGRDMYTGKPL--D--INQLSSYDIDHI
844

WP_049523028
776
QQRLKTLSDAIS ELG- NILKEHP--TD---NIQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSNYDIDHI
839

WP_003107102
747
RERLRKLEEVHK NIGS KILKEHE--IS---NAQLQSDRVYLYLLQDGKDMYTGKDL--D--FDRLSQYDIDHI
810

WP_054279288
779
RERMKRVQEVLK KLGS QLLKEHP--VE---NFQLQNERLYLYYLQNGKDMYTGEEL--S--ISNLSHYDIDHI
842

WP_049531101
777
QQRYKRIEDSLK ILAS NILKEHP--TD---NIQLQNDRLFLYYLQNGKDMYTGNPL--D--INHLSSYDIDHI
844

WP_049538452
777
QQRYKRIENSLK ILAS KILKEHP--TD---NNQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSSCDIDHI
844

WP_049549711
777
QQRYKRIEDSLK ILAS NILKENP--TD---NNQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSSYDIDHI
844

WP_007896501
781
RQRLKKIKEVHK KTGS RILEDNSerIT---NLTLQDNRLYLYLLQDGKDMYTGQDL--D--INNLSQYDIDHI
846

EFR44625
733
RQRLKKIKEVHK KTGS RILEDNSerIT---NLTLQDNRLYLYLLQDGKDMYTGQDL--D--INNLSQYDIDHI
798

WP_002897477
776
QQRYKRIEDALK NLAP NILKENP--TD---NIQLKNDRLFLYYLQNGKDMYTGKPL--D--INQLSSYDIDHI
843

WP_002906454
776
QQRYKRIEDALK NLAP NILKENP--TD---NIQLQNDRLFLYYLQNGKDMYTGKAI--D--INQLSNYDIDHI
843

WP_009729476
777
QQRYKRIEDSLK ILAS KILKEHP--TD---NIQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSSCDIDHI
844

CQR24647
780
QQRLGSLTKAIQ DFGS DILKRYP--VE---NNQLQNDQLYLYYLQNGKDMYTGDTL--D--IHNLSQYDIDHI
843

WP_000066813
779
QQRYKRIEDSLK NLAS NILKENP--TD---NIQLQNDRLFLYYLQNGRDMYTGKPL--E--INQLSNYDIDHI
846

WP_009754323
777
QQRYKRIEDALK NLAP TISKENP--TD---NIQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSSYDIDHI
844

WP_044674937
776
QQRYKKIENAIK NLNS KILKEYP--TN---NQALQNDRLFLYYLQNGKDMYTDEEL--D--IDQLSQYDIDHI
843

WP_044676715
778
QQRYKKIENAIK NLNS KILKEYP--TN---NQALQNDRLFLYYLQNGKDMYTDEEL--D--IDQLSQYDIDHI
845

WP_044680361
778
QQRYKKIENAIK NLNS KILKEYP--TN---NQALQNDRLFLYYLQNGKDMYTDEEL--D--IDQLSQYDIDHI
845

WP_044681799
776
QQRYKKIENAIK NLNS KILKEYP--TN---NQALQNDRLFLYYLQNGKDMYTDEEL--D--IDQLSQYDIDHI
843

WP_049533112
778
QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI
840

WP_029090905
753
TPRDKFIEKAYA ETDT EHLKELK---Qr--SKQLSSQRLFLYFIQNGKCMYSGEHL--D--IERLDSYEVDHI
823

WP_006506696
777
ESKIKKLENVYK DEQT SVLEELKg-FDn--TKKISSDSLFLYFTQLGKCMYSGKKL--D--IDSLDKYQIDHI
849

AIT42264
778
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_034440723
785
KARLKKIQEGLE NLDS HVEKQAL---D---EEMLKSPKYYLYCLQNGKDIYTGKDL--D--IGQLQTYDIDHI
848

AKQ21048
778
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

WP_004636532
781
KERLEKLTEAIK EFDG --VKVKD--LK---NENLRNDRLYLYYLQNGRDMYTNEPL--D--INNLSKYDIDHI
845

WP_002364836
789
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
852

WP_016631044
740
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
803

EMS75795
525
KPRLKALEEALK SFDS PLLKEQP--VD---NQALQKDRLYLYYLQNGKDMYTGEAL--D--IDRLSEYDIDHI
588

WP_002373311
789
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
852

WP_002378009
789
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
852

WP_002407324
789
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
852

WP_002413717
789
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
852

WP_010775580
791
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
854

WP_010818269
789
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
852

WP_010824395
789
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
852

WP_016622645
789
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
852

WP_033624816
789
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
852

WP_033625576
789
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
852

WP_033789179
789
IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI
852

WP_002310644
789
RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI
852

WP_002312694
790
RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI
853

WP_002314015
790
RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI
853

WP_002320716
790
RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI
853

WP_002330729
789
RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI
852

WP_002335161
790
RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI
853

WP_002345439
790
RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI
853

WP_034867970
781
SPRLKALENGLK QIGS TLLKEQP--TD---NKALQKERLYLYYLQNGRDMYTGEPL--E--IENLHQYEVDHI
844

WP_047937432
790
RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI
853

WP_010720994
781
KPRLKALENGLK QIGS TLLKEQP--TD---NKALQKERLYLYYLQNGRDMYTGEPL--E--IENLHQYEVDHI
844

WP_010737004
781
SPRLKALENGLK QIGS TLLKEQP--TD---NKALQKERLYLYYLQNGRDMYTGEPL--E--IENLHQYEVDHI
844

WP_034700478
781
KPRLKALENGLK QIGS TLLKEQP--TD---NKALQKERLYLYYLQNGRDMYTGEPL--E--IENLHQYEVDHI
844

WP_007209003
782
KPRLKGIENGLK EFSD SVLKGSS--ID---NKQLQNDRLYLYYLQNGKDMYTGHEL--D--IDHLSTYDIDHI
845

WP_023519017
775
RPRLKALEEALK NIDS PLLKDYP--TD---NQALQKDRLYLYYLQNGKDMYTGEPL--E--IHRLSEYDIDHI
838

WP_010770040
782
NPRMKALEEAMR NLRS NLLKEYP--TD---NQALQNDRLYLYYLQNGKDMYTGLDL--S--LHNLSSYDIDHI
845

WP_048604708
779
RPRLKNLEKAID DLDS EILKKHP--VD---NKALQKDRLYLYYLQNGKDMYTNEEL--D--IHKLSTYDIDHI
842

WP_010750235
784
KPRLKSLEEALK NFDS QLLKERP--VD---NQSLQKDRLYLYYLQNGKDMYTGESL--D--IDRLSEYDIDHI
847

AII16583
817
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
880

WP_029073316
789
DSFVNQMLKLYK DFED EANKHLKg-EDa--KSKIRSERLKLYYTQMGKCMYTGKSL--D--IDRLDTYQVDHI
860

WP_031589969
789
DSFVNQMLKLYK DFED EANKHLKg-EDa--KSKIRSERLKLYYTQMGKCMYTGKSL--D--IDRLDTYQVDHI
860

KDA45870
772
EDRVQQIVKNLK ELPK ------P---S---NAELSDERKYLYCLQNGRDMYTGAPL--D--YDHLQFYDVDHI
833

WP_039099354
789
KRQVEQVYQNIS EL-- EIRNELK---D1-sNSALSNTRLFLYFMQGGRDMYTGDSL--N--IDRLSTYDIDHI
856

AKP02966
786
RLQSKLLNKANG -LVP EELKKHKn--D------LSSERIMLYFLQNGKSLYSEESL--N--INKLSDYQVDHI
858

WP_010991369
781
RPRYKSLEKAIK EFGS QILKEHP--TD---NQELRNNRLYLYYLQNGKDMYTGQDL--D--IHNLSNYDIDHI
844

WP_033838504
781
RPRYKSLEKAIK EFGS QILKEHP--TD---NQELRNNRLYLYYLQNGKDMYTGQDL--D--IHNLSNYDIDHI
844

EHN60060
784
RPRYKSLEKAIK EFGS QILKEHP--TD---NQELRNNRLYLYYLQNGKDMYTGQDL--D--IHNLSNYDIDHI
847

EFR89594
550
RPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQDL--D--IHNLSNYDIDHI
613

WP_038409211
781
KPRFISLEKAIK EFGS QILKEHP--TD---NQCLKNDRLYLYYLQNGKDMYTGKEL--D--IHNLSNYDIDHI
844

EFR95520
400
KPRFISLEKAIK EFGS QILKEHP--TD---NQCLKNDRLYLYYLQNGKDMYTGKEL--D--IHNLSNYDIDHI
463

WP_003723650
781
KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI
844

WP_003727705
781
KPRYKSLEKAIK DFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDIYTGQEL--D--IHNLSNYDIDHI
844

WP_003730785
781
KPRYKSLEKAIK DFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDIYTGQEL--D--IHNLSNYDIDHI
844

WP_003733029
781
KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI
844

WP_003739838
781
RPRYKSLEKAIK EFGS QILKEHP--TD---NQELRNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI
844

WP_014601172
781
KPRYKSLEKAIK EFGS KILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI
844

WP_023548323
781
KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI
844

WP_031665337
781
KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI
844

WP_031669209
781
KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI
844

WP_033920898
781
KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI
844

AKI42028
784
KPRYKSLEKAIK EFGS KILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI
847

AKI50529
784
KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI
847

EFR83390
229
RPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDIYTGQEL--D--IHNLSNYDIDHI
292

WP_046323366
781
KPRFTSLEKAIK ELGS QILKEHP--TD---NQGLKNDRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHV
844

AKE81011
794
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
857

CUO82355
781
ESKIKKLENVYK DEQT SVLEELKg-FDn--TKKISSDSLFLYFTQLGKCMYSGKKL--D--IDSLDKYQIDHI
853

WP_033162887
784
ESKIAKLQKIYE NLQT QVYESLKk-EDa--KKRMETDALYLYYLQMGKSMYSGKPL--D--IDKLSTYQIDHI
855

AGZ01981
811
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
874

AKA60242
778
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDAI
841

AKS40380
778
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI
841

4UN5_B
782
RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDAI
845

WP_010922251
842

VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKEDNLTK
A--ERG custom character

910

WP_039695303
852
IPQAFIKDDSIDNRVLTSSAKNRG-KSDD--VP S--LDIVRARKA-EWVRLYKSGLISKRKFDNLTKA--ERGGLTE
920

WP_045635197
844
IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--IEVVQKRKA-FWQQLLDSKLISERKFNNLTKA--ERGGLDE
912

5AXW_A
562
IPRSVSFDNSFNNKVLVKQEEASK-KGNR--TP Fqy-LSSSDSKI-SYETFKKHILNLAKGKGRISKTk-KEYLLEE
632

WP_009880683
526
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE
594

WP_010922251
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_011054416
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_011284745
842
VPQSFIKDDSIDNKVLTRSDKNRG-KSNN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_011285506
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_011527619
842
VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_012560673
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_014407541
841
VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
909

WP_020905136
842
VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_023080005
841
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
909

WP_023610282
841
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
909

WP_030125963
842
VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_030126706
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_031488318
842
VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_032460140
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_032461047
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_032462016
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_032462936
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_032464890
842
VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_033888930
667
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
735

WP_038431314
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_038432938
841
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
909

WP_038434062
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE
910

BAQ51233
753
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
821

KGE60162
17
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
85

KGE60856

--------------------------------- --------------------------------------------

WP_002989955
842
VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_003030002
841
IPQAFIKDNSLDNRVLTRSDKNRG-KSDD--VP S--IEVVHEMKS-FWSKLLSVKLITQRKFDNLTKA--ERGGLTE
909

WP_003065552
852
IPQAFIKDDSIDNRVLTSSAKNRG-KSDD--VP S--LDIVRARKA-EWVRLYKSGLISKRKFDNLTKA--ERGGLTE
920

WP_001040076
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040078
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040080
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040081
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040083
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040085
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040087
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040088
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040089
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040090
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040091
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040092
847
VPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--IDIVKARKA-FWKKLLDAKLISQRKYDNLTKA--ERGGLTP
915

WP_001040094
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040095
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040096
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040097
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040098
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040099
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040100
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040104
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040105
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040106
847
VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040107
847
VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040108
847
VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040109
847
VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_001040110
847
VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_015058523
847
VPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--IDIVKARKA-FWKKLLDAKLISQRKYDNLTKA--ERGGLTP
915

WP_017643650
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_017647151
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_017648376
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_017649527
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_017771611
847
VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_017771984
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

CFQ25032
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

CFV16040
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

KLJ37842
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

KLJ72361
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

KLL20707
861
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
929

KLL42645
847
VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_047207273
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_047209694
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_050198062
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_050201642
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_050204027
847
VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_050881965
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_050886065
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

AHN30376
847
VPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--IDIVKARKA-FWKKLLDAKLISQRKYDNLTKA--ERGGLTP
915

EA078426
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

CCW42055
847
IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS
915

WP_003041502
841
IPQAYIKDDSFDNRVLTSSSENRG-KSDN--VP S--IEVVCARKA-DWMRLRKAGLISQRKFDNLTKA--ERGGLTE
909

WP_037593752
842
IPQAFIKDNSLDNRVLTRSDKNRG-KSDD--VP S--IEVVHEMKS-FWSKLLSVKLITQRKFDNLTKA--ERGGLTE
910

WP_049516684
842
IPQAFIKDNSLDNRVLTRSDKNRG-KSDD--VP S--IEVVHEMKS-FWSKLLSVKLITQRKFDNLTKA--ERGGLTE
910

GAD46167
841
IPQAFIKDNSLDNRVLTRSDKNRG-KSDD--VP S--IEVVHEMKS-FWSKLLSVKLITQRKFDNLTKA--ERGGLTE
909

WP_018363470
850
IPQAFIKDDSIDNRVLTSSAKNRG-KSDD--VP S--LGIVRARKA-EWVRLYKSGLISKRKFDNLTKA--ERGGLTE
918

WP_003043819
851
VPQSFIKDDSIDNKVLTRSVENRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
919

WP_006269658
841
IPQAFIKDNSLDNRVLTRSDKNRG-KSDD--VP S--IEVVHEMKS-FWSKLLSVKLITQRKFDNLTKA--ERGGLTE
909

WP_048800889
841
IPQAFIKDDSIDNRVLTSSAKNRG-KSDN--VP N--LEVVCDRKA-DWIRLREAGLISQRKFDNLTKA--ERGGLTE
909

WP_012767106
841
VPQSFIKDDSIDNKILTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
909

WP_014612333
841
VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
909

WP_015017095
841
VPQSFIKDDSIDNKVLTRSDKNRG-KSDD--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
909

WP_015057649
841
VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
909

WP_048327215
841
VPQSFIKDDSIDNKVLTRSDKNRG-KSDD--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
909

WP_049519324
841
VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
909

WP_012515931
841
IPQSFIKNNSIDNKVLTSQGANRG-KLDN--VP S--EAIVRKMKG-YWQSLLRAGAISKQKFDNLTKA--ERGGLTQ
909

WP_021320964
841
IPQSFIKNNSIDNKVLTSQGANRG-KLDN--VP S--EAIVRKMKG-YWQSLLRAGAISKQKFDNLTKA--ERGGLTQ
909

WP_037581760
841
IPQSFIKNNSIDNKVLTSQGANRG-KLDN--VP S--EAIVRKMKG-YWQSLLRAGAISKQKFDNLTKA--ERGGLTQ
909

WP_004232481
849
IPQAFIKDNSIDNRVLTSSAKNRG-KSDD--VP S--IEIVRNRKS-YWYKLYKSGLISKRKFDNLTKA--ERGGLTE
917

WP_009854540
850
IPQAFIKDDSIDNRVLTSSAKNRG-KSDD--VP S--LDIVRARKA-EWVRLYKSGLISKRKFDNLTKA--ERGGLTE
918

WP_012962174
850
IPQAFIKDDSIDNRVLTSSAKNRG-KSDD--VP S--LDIVHDRKA-DWIRLYKSGLISKRKFDNLTKA--ERGGLTE
918

WP_039695303
852
IPQAFIKDDSIDNRVLTSSAKNRG-KSDD--VP S--LDIVRARKA-EWVRLYKSGLISKRKFDNLTKA--ERGGLTE
920

WP_014334983
849
IPQAFIKDNSIDNKVLTSSAKNRG-KSDD--VP S--IEIVRNRRS-YWYKLYKSGLISKRKFDNLTKA--ERGGLTE
917

WP_003099269
842
IPQSFIKDNSIDNTVLTTQASNRG-KSDN--VP N--IETVNKMKS-FWYKQLKSGAISQRKFDHLTKA--ERGALSD
910

AHY15608
842
IPQSFIKDNSIDNTVLTTQASNRG-KSDN--VP N--IETVNKMKS-FWYKQLKSGAISQRKFDHLTKA--ERGALSD
910

AHY17476
842
IPQSFIKDNSIDNTVLTTQASNRG-KSDN--VP N--IETVNKMKS-FWYKQLKSGAISQRKFDHLTKA--ERGALSD
910

ESR09100

--------------------------------- --------------------------------------------

AGM98575
842
IPQSFIKDNSIDNTVLTTQASNRG-KSDN--VP N--IETVNKMKS-FWYKQLKSGAISQRKFDHLTKA--ERGALSD
910

ALF27331
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_018372492
858
VPRSYIKNDSFDNKVLTTSKGNRK-KLDD--VP A--KEVVEKMEN-TWRRLHAAGLISDIKLSYLMKGe-----LTE
923

WP_045618028
845
IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEIVQKRKA-FWQQLLDSKLISERKFNNLTKA--ERGGLDE
913

WP_045635197
844
IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--IEVVQKRKA-FWQQLLDSKLISERKFNNLTKA--ERGGLDE
912

WP_002263549
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002263887
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002264920
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKG--ERGGLTD
910

WP_002269043
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002269448
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--EDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002271977
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002272766
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKP-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002273241
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002275430
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKP-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002276448
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002277050
847
IPQAFIKDNSIDNRVLTSSKANRG-KSDD--VP S--EDVVNRMRP-FWNKLLSSGLISQRKYNNLTKK--E---LTP
912

WP_002277364
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002279025
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKP-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002279859
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKG--ERGGLTD
910

WP_002280230
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002281696
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002282247
847
IPQAFIKDNSIDNRVLTSSKANRG-KSDD--VP S--EDVVNRMRP-FWNKLLSSGLISQRKYNNLTKK--E---LTL
912

WP_002282906
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002283846
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002287255
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002288990
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002289641
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002290427
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKG--ERGGLTD
910

WP_002295753
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002296423
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002304487
856
IPQAFIKDNSIDNRVLTRSDKNRG-KSDD--VP S--EEVVHKMKP-FWSKLLSAKLITQRKFDNLTKA--ERGGLTD
924

WP_002305844
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002307203
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_002310390
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKG--ERGGLTD
910

WP_002352408
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_012997688
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_014677909
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_019312892
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_019313659
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_019314093
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_019315370
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKP-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_019803776
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_019805234
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKG--ERGGLTD
910

WP_024783594
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_024784288
847
IPQAFIKDNSIDNRVLTSSKANRG-KSDD--VP S--EDVVNRMRP-FWNKLLSSGLISQRKYNNLTKK--E---LTL
912

WP_024784666
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_024784894
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_024786433
847
IPQAFIKDNSIDNRVLTSSKANRG-KSDD--VP S--EDVVNRMRP-FWNKLLSSGLISQRKYNNLTKK--E---LTL
912

WP_049473442
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKP-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

WP_049474547
842
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
910

EMC03581
835
IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD
903

WP_000428612
847
VPQAFIKDDSLDNRVLTSLKDNRG-KSDN--VP S--LEVVEKMKT-FWQQLLDSKLISYRKFNNLTKA--ERGGLDE
915

WP_000428613
845
VPQAFIKDDSLDNRVLTSLKDNRG-KSDN--VP S--IEVVQKRKA-FWQQLLDSKLISERKFNNLTKA--ERGGLDE
913

WP_049523028
840
IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEIVEKMKG-FWQQLLDSKLISERKFNNLTKA--ERGGLDE
908

WP_003107102
811
IPQSFIKDNSIDNIVLTSQESNRG-KSDN--VP Y--IAIVNKMKS-YWQHQLKSGAISQRKEDNLTKA--ERGGLSE
879

WP_054279288
843
IPRSFIKDDSIDNKVLTRSEHNRG-KTDN--VP S--IEVVKRMKP-YWQKLLDTKVISQRKFDNLTKA--ERGGLQE
911

WP_049531101
845
IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEVVQKRKA-FWQQLLESKLISERKFNNLTKA--ERGGLNE
913

WP_049538452
845
IPQAFIKDDSLDNRVLTSSKENRG-KSDN--VP C--LEVVDKMKV-FWQQLLDFKLISYRKFNNLTKA--ERGGLDE
913

WP_049549711
845
IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEVVQKRKA-FWQQLLDSKLISERKFNNLTKAerERDGLNE
915

WP_007896501
847
IPQSFIKDNSIDNLVLTTQKANRG-KSDN--VP S--IEVVRDMKDrVWRRQLANGAISRQKFDHLTKA--ERGGLAD
916

EFR44625
799
IPQSFIKDNSIDNLVLTTQKANRG-KSDN--VP S--IEVVRDMKDrVWRRQLANGAISRQKFDHLTKA--ERGGLAD
868

WP_002897477
844
IPQAFIKDDSIDNRVLTSSKDNRG-KSDN--VP S--LEVVQKRKA-FWQQLLDSKLISERKFNNLTKA--ERGGLDE
912

WP_002906454
844
IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--IEVVQKRKA-FWQQLLDSKLISERKFNNLTKA--KRGGLDE
912

WP_009729476
845
IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEVVDKMKV-FWQQLLDSKLISYRKFNNLTKA--ERGGLNE
913

CQR24647
844
IPQSFIKDNSLDNRVLTNSKSNRG-KSDN--VP S--NEVVKRMKG-FWLKQLDAKLISQRKFDNLTKA--ERGGLSA
912

WP_000066813
847
IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEVVEKMKA-FWQQLLDSKLISERKFNNLTKAerERGGLNE
917

WP_009754323
845
IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEVVKKRKA-FWQQLLDSKLISERKFNNLTKA--ERGGLDE
913

WP_044674937
844
IPQAFIKDDSLDNKVLTKSAKNRG-KSDD--VP S--LEIVHKKKN-FWKQLLDSQLISQRKFDNLTKA--ERGGLTN
912

WP_044676715
846
IPQAFIKDDSLDNKVLTKSAKNRG-KSDD--VP S--LEIVHKKKN-FWKQLLDSQLISQRKFDNLTKA--ERGGLTN
914

WP_044680361
846
IPQAFIKDDSLDNKVLTKSAKNRG-KSDD--VP S--LEIVHKKKN-FWKQLLDSQLISQRKFDNLTKA--ERGGLTN
914

WP_044681799
844
IPQAFIKDDSLDNKVLTKSAKNRG-KSDD--VP S--LEIVHKKKN-FWKQLLDSQLISQRKFDNLTKA--ERGGLTN
912

WP_049533112
841
IPQAFIKDDSFDNRVLTSSSENRG-KSDN--VP S--IEVVRARKA-DWMRLRKAGLISQRKFDNLTKA--ERGGLTE
909

WP_029090905
824
LPQSYIKDNSIENLALVKKVENQR-KKDS11LN S---SIINQNYS-RWEQLKNAGLIGEKKFRNLTRTk-----ITD
890

WP_006506696
850
VPQSLVKDDSEDNRVLVVPSENQR-KLDD1vVP ---FDIRDKMYR-FWKLLFDHELISPKKFYSLIKTe-----YTE
916

AIT42264
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_034440723
849
IPRSFITDNSEDNLVLTSSTVNRG-KLDN--VP Sp--DIVRQQKG-FWKQLLRAGLMSQRKFNNLTKGk-----LTD
914

AKQ21048
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

WP_004636532
846
IPQSFTTDNSIDNKVLVSRTKNQGnKSDD--VP S--INIVHKMKP-FWRQLHKAGLISDRKFKNLTKA--EHGGLTE
915

WP_002364836
853
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
921

WP_016631044
804
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
872

EMS75795
589
IPRSFIVDNSIDNKVLVSSKENRL-KMDD--VP D--QKVVIRMRR-YWEKLLRANLISERKFAYLTKLe-----LTP
654

WP_002373311
853
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KKVVKKMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
921

WP_002378009
853
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
921

WP_002407324
853
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
921

WP_002413717
853
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
921

WP_010775580
855
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKKMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
923

WP_010818269
853
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
921

WP_010824395
853
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
921

WP_016622645
853
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
921

WP_033624816
853
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKKMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
921

WP_033625576
853
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKKMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
921

WP_033789179
853
IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKKMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL
921

WP_002310644
853
IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE
918

WP_002312694
854
IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE
919

WP_002314015
854
IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE
919

WP_002320716
854
IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE
919

WP_002330729
853
IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE
918

WP_002335161
854
IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE
919

WP_002345439
854
IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE
919

WP_034867970
845
IPRSFIVDNSIDDKVLVASKQNQK-KRDD--VP K--KQIVNEQRI-FWNQLKEAKLISTKKYAYLTKIe-----LTP
910

WP_047937432
854
IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE
919

WP_010720994
845
IPRSFIVDNSIDNKVLVASKQNQK-KRDD--VP K--KQIVNEQRI-FWNQLKEAKLISPKKYAYLTKIe-----LTP
910

WP_010737004
845
IPRSFIVDNSIDNKVLVASKQNQK-KRDD--VP K--KQIVNEQRI-FWNQLKEAKLISPKKYAYLTKIe-----LTP
910

WP_034700478
845
IPRSFIVDNSIDNKVLVASKQNQK-KRDD--VP N--KQIVNEQRI-FWNQLKEAKLISPKKYAYLTKIe-----LTP
910

WP_007209003
846
IPQSFLTDNSIDNRVLTTSKSNRG-KSDN--VP S--EEVVRKMDR-FWRKLLNAKLISERKYTNLTKKe-----LTE
911

WP_023519017
839
IPRSFIVDNSLDNKVLVSSKVNRG-KLDN--AP D--PLVVKRMRS-HWEKLHQAKLISDKKLANLTKQn-----LTE
904

WP_010770040
846
VPQSFTTDNSLDNRVLVSSKENRG-KKDD--VP S--KEVVQKNIT-LWETLKNSNLISQKKYDNLTKG--LRGGLTE
914

WP_048604708
843
IPQSFIVDNSLDNRVLVSSSKNRG-KLDD--VP S--KEVVKKMRA-FWESLYRSGLISKKKFDNLVKA--ESGGLSE
911

WP_010750235
848
IPRSFIVDHSLDNKVLVSSKENRL-KKDD--VP D--SKVVKRMKA-YWEKLLRANLISERKFSYLTKLe-----LTD
913

AII16583
881
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
949

WP_029073316
861
VPQSLLKDDSIDNKVLVLSSENQR-KLDDlvIP ---EMIRNKMFG-FWNKLYENKIISPKKFYSLIKSe-----YSD
927

WP_031589969
861
VPQSLLKDDSIDNKVLVLSSENQR-KLDDlvIP ---SSIRNKMYG-FWEKLFNNKIISPKKFYSLIKTe-----FNE
927

KDA45870
834
IPQSFLKDDSIENKVLTIKKENVR-KTNG--LP S--EAVIQKMGS-FWKKLLDAGAMTNKKYDNLRRN1--HGGLNE
902

WP_039099354
857
LPQSFIKDNSLDNRVLVSQRMNRS-KADQ--VP S--VELGQKMQI-QWEQMLRAGLITKKKYDNLTLNp--------
923

AKP02966
859
LPRTYIPDDSLENKALVLAKENQR-KADD11LN S---NVIDKNLE-RWTYMLNNNMMGLKKFKNLTRRv-----ITD
925

WP_010991369
845
VPQSFITDNSIDNLVLTSSAGNRE-KGDD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
913

WP_033838504
845
VPQSFITDNSIDNLVLTSSAGNRE-KGDD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
913

EHN60060
848
VPQSFITDNSIDNLVLTSSAGNRE-KGDD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
916

EFR89594
614
VPQSFITDNSIDNLVLTSSAGNRE-KGND--VP P--LEIVQKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
682

WP_038409211
845
IPQSFITDNSIDNRVLVSSTANRE-KGDN--VP L--LEVVRKRKA-FWEKLYQAKLMSKRKFDYLTKA--ERGGLTE
913

EFR95520
464
IPQSFITDNSIDNRVLVSSTANRE-KGDN--VP L--LEVVRKRKA-FWEKLYQAKLMSKRKFDYLTKA--ERGGLTE
532

WP_003723650
845
VPQSFITDNSIDNLVLTSSAGNRE-KGGD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
913

WP_003727705
845
VPQSFITDNSIDNLVLTSSAGNRE-KGGD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
913

WP_003730785
845
VPQSFITDNSIDNLVLTSSAGNRE-KGGD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
913

WP_003733029
845
VPQSFITDNSVDNLVLTSSAGNRE-KGDN--VP P--LEIVQKRKI-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
913

WP_003739838
845
VPQSFITDNSIDNLVLTSSAGNRE-KGDD--VP P--LEIVRKRKV-FWEKLFQGNLMSKRKFDYLTKA--ERGGLTE
913

WP_014601172
845
VPQSFITDNSIDNLVLTSSAGNRE-KGGD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTD
913

WP_023548323
845
VPQSFITDNSIDNLVLTSSAGNRE-KGDN--VP P--LEIVQKRKI-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
913

WP_031665337
845
VPQSFITDNSIDNLVLTSSAGNRE-KGGD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
913

WP_031669209
845
VPQSFITDNSVDNLVLTSSAGNRE-KGDN--VP P--LEIVQKRKI-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
913

WP_033920898
845
VPQSFITDNSIDNLVLTSSAGNRE-KGDN--VP P--LEIVQKRKI-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
913

AKI42028
848
VPQSFITDNSIDNLVLTSSAGNRE-KGGD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTD
916

AKI50529
848
VPQSFITDNSIDNLVLTSSAGNRE-KGDN--VP P--LEIVQKRKI-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
916

EFR83390
293
VPQSFITDNSIDNLVLTSSAGNRE-KGDD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE
361

WP_046323366
845
VPQSFITDNSIDNRVLASSAANRE-KGDN--VP S--LEVVRKRKV-YWEKLYQAKLMSKRKFDYLTKA--ERGGLTE
913

AKE81011
858
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
926

CUO82355
854
VPQSLVKDDSFDNRVLVLPSENQR-KLDD1vVP ---FDIRDKMYR-FWKLLFDHELISPKKFYSLIKTe-----YTE
920

WP_033162887
856
LPQSLIKDDSFDNRVLVLPEENQW-KLDSetVP ---FEIRNKMIG-FWQMLHENGLMSNKKFFSLIRTd-----FSD
922

AGZ01981
875
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
943

AKA60242
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

AKS40380
842
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
910

4UN5_B
846
VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE
914

WP_010922251
911

custom character

981

WP_039695303
921
AD KAGFIKRQLVETRQITKHVAQILDARFNTEHDENDKVIR--DVKVITLKSNLVSQFRKDF EFYKVREINDY
991

WP_045635197
913
RD KVGFIKRQLVETRQITKHVAQILDARYNTEVNEKDKKNR--TVKIITLKSNLVSNERKEF RLYKVREINDY
983

5AXW_A
633
RD QKDFINRNLVDTRYATRGLMNLLRSYFR---------VNn1DVKVKSINGGFTSFLRRKW KFKKERNKGYK
702

WP_009880683
595
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY
665

WP_010922251
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_011054416
911
LD KVGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY
981

WP_011284745
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_011285506
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_011527619
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_012560673
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY
981

WP_014407541
910
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
980

WP_020905136
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_023080005
910
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
980

WP_023610282
910
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
980

WP_030125963
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_030126706
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_031488318
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_032460140
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY
981

WP_032461047
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY
981

WP_032462016
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_032462936
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY
981

WP_032464890
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_033888930
736
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
806

WP_038431314
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_038432938
910
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
980

WP_038434062
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

BAQ51233
822
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
892

KGE60162
86
LD KVGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY
156

KGE60856

-- ------------------------------------------------------------ -----------

WP_002989955
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_003030002
910
ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGNKRRIR--NVKIITLKSNLVSNFRKEF ELYKVREINDY
980

WP_003065552
921
AD KAGFIKRQLVETRQITKHVAQILDARFNTESDENDKVIR--DVKVITLKSNLVSQFRKDF EFYKVREINDY
991

WP_001040076
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF VFYKIREVNNY
986

WP_001040078
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY
986

WP_001040080
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040081
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040083
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040085
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040087
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040088
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040089
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040090
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040091
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040092
916
DD KAGFIQRQLVETRQITKHVARILDERFNNKVDDNNKPIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040094
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040095
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040096
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040097
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040098
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040099
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040100
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040104
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040105
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_001040106
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY
986

WP_001040107
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY
986

WP_001040108
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY
986

WP_001040109
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY
986

WP_001040110
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY
986

WP_015058523
916
DD KAGFIQRQLVETRQITKHVARILDERFNNKVDDNNKPIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_017643650
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_017647151
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_017648376
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_017649527
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_017771611
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY
986

WP_017771984
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

CFQ25032
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

CFV16040
916
DD KARFIQRQLVEIRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

KLJ37842
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTVKSNLVSNFRKEF GFYKIREVNNY
986

KLJ72361
916
DD KARFIQRQLVETRQITKHVARILDELFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

KLL20707
930
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
1000

KLL42645
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY
986

WP_047207273
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_047209694
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_050198062
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_050201642
916
DD KARFIQRQLVETRQITKHVASILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_050204027
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY
986

WP_050881965
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

WP_050886065
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

AHN30376
916
DD KAGFIQRQLVETRQITKHVARILDERFNNKVDDNNKPIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

EA078426
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY
986

CCW42055
916
DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY
986

WP_003041502
910
ND KAGFIKRQLVETRQITKHVAQVLDARFNAKHDENKKVIR--DVKIITLKSNLVSQFRKDF KFYKVREINDY
980

WP_037593752
911
ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGAQRRIR--NVKIITLKSNLVSNFRKEF ELYKVREINDY
981

WP_049516684
911
ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGAQRRIR--NVKIITLKSNLVSNFRKEF ELYKVREINDY
981

GAD46167
910
ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGAQRRIR--NVKIITLKSNLVSNFRKEF ELYKVREINDY
980

WP_018363470
919
AD KAGFIKRQLVETRQITKHVAQILDARFNTERDENDKVIR--DVKVITLKSNLVSQFRKEF KFYKVREINDY
989

WP_003043819
920
AD KAGFIKRQLVETRQITKHVARILDSRMNTKRDKNDKPIR--EVKVITLKSKLVSDFRKDF QLYKVRDINNY
990

WP_006269658
910
ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGNKRRIR--NVKIITLKSNLVSNFRKEF ELYKVREINDY
980

WP_048800889
910
ND KAGFIHRQLVETRQITKHVAQILDARFNPKRDDNKKVIR--DVKIITLKSNLVSQFRRDF KLYKVREINDY
980

WP_012767106
910
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY
980

WP_014612333
910
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY
980

WP_015017095
910
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY
980

WP_015057649
910
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY
980

WP_048327215
910
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY
980

WP_049519324
910
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY
980

WP_012515931
910
VD KAGFIQRQLVETRQITKHVAQILDSRFNTEFDDHNKRIR--KVHIITLKSKLVSDFRKEF GLYKIRDINHY
980

WP_021320964
910
VD KAGFIQRQLVETRQITKHVAQILDSRFNTEFDDHNKRIR--KVHIITLKSKLVSDFRKEF GLYKIRDINHY
980

WP_037581760
910
VD KAGFIQLQLVETRQITKHVAQILDSRFNTEFDDHNKRIR--KVHIITLKSKLVSDFRKEF GLYKIRDINHY
980

WP_004232481
918
TD KAGFIKRQLVETRQITKHVAQILDARFNTKCDENDKVIR--DVKVITLKSSLVSQFRKEF KFYKVREINDY
988

WP_009854540
919
AD KAGFIKRQLVETRQITKHVAQILDARFNTEHDENDKVIR--DVKVITLKSNLVSQFRKDF EFYKVREINDY
989

WP_012962174
919
ND KAGFIKRQLVETRQITKHVAQILDSRFNTERDENDKVIR--NVKVITLKSNLVSQFRKDF KFYKVREINDY
989

WP_039695303
921
AD KAGFIKRQLVETRQITKHVAQILDARFNTEHDENDKVIR--DVKVITLKSNLVSQFRKDF EFYKVREINDY
991

WP_014334983
918
AD KAGFIKRQLVETRQITKHVAQILDARFNTKRDENDKVIR--DVKVITLKSNLVSQFRKEF KFYKVREINDY
988

WP_003099269
911
FD KAGFIKRQLVETRQITKHVAQILDSRFNSNLTEDSKSNR--NVKIITLKSKMVSDFRKDF GFYKLREVNDY
981

AHY15608
911
FD KAGFIKRQLVETRQITKHVAQILDSRFNSNLTEDSKSNR--NVKIITLKSKMVSDFRKDF GFYKLREVNDY
981

AHY17476
911
FD KAGFIKRQLVETRQITKHVAQILDSRFNSNLTEDSKSNR--NVKIITLKSKMVSDFRKDF GFYKLREVNDY
981

ESR09100

-- ------------------------------------------------------------ -----------

AGM98575
911
FD KAGFIKRQLVETRQITKHVAQILDSRFNSNLTEDSKSNR--NVKIITLKSKMVSDFRKDF GFYKLREVNDY
981

ALF27331
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_018372492
924
ED KAGFIRRQLVETRQITKHVARLLDEKLNRKKNENGEKLR--TTKIITLKSVFASRFRANF DLYKLRELNHY
994

WP_045618028
914
RD KVGFIKRQLVETRQITKHVAQILDARFNTEVTEKDKKDR--SVKIITLKSNLVSNFRKEF RLYKVREINDY
984

WP_045635197
913
RD KVGFIKRQLVETRQITKHVAQILDARYNTEVNEKDKKNR--TVKIITLKSNLVSNFRKEF RLYKVREINDY
983

WP_002263549
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002263887
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002264920
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002269043
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002269448
911
DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002271977
911
DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002272766
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002273241
911
DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002275430
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002276448
911
DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002277050
913
DD KAGFIKRQLVETRQITKHVARMLDERFNKEFDDNNKRIR--RVKIVTLKSNLVSSFRKEF ELYKVREINDY
983

WP_002277364
911
DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002279025
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002279859
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002280230
911
DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002281696
911
DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002282247
913
DD KAGFIKRQLVETRQITKHVARMLDERFNKEFDDNNKRIR--RVKIVTLKSNLVSSFRKEF ELYKVREINDY
983

WP_002282906
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002283846
911
DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002287255
911
DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002288990
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002289641
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002290427
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002295753
911
DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002296423
911
DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002304487
925
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
995

WP_002305844
911
DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002307203
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002310390
911
DD KAGFIKHQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_002352408
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_012997688
911
DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_014677909
911
DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_019312892
911
DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_019313659
911
DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_019314093
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_019315370
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_019803776
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_019805234
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_024783594
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_024784288
913
DD KAGFIKRQLVETRQITKHVARMLDERFNKEFDDNNKRIR--RVKIVTLKSNLVSSFRKEF ELYKVREINDY
983

WP_024784666
911
DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_024784894
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_024786433
913
DD KAGFIKRQLVETRQITKHVARMLDERFNKEFDDNNKRIR--RVKIVTLKSNLVSSFRKEF ELYKVREINDY
983

WP_049473442
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

WP_049474547
911
DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
981

EMC03581
904
DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY
974

WP_000428612
916
RD KVGFIKRQLVETRQITKHVAQILDARYNTEVNEKDKKNR--TVKIITLKSNLVSNFRKEF RLYKIREINDY
986

WP_000428613
914
RD KVGFIKRQLVETRQITKHVAQILDARFNKEVNEKDKKNR--TVKIITLKSNLVSNFRKEF RLYKVREINDY
984

WP_049523028
909
RD KVGFIKRQLVETRQITKHVAQILDDRFNAEVNEKNQKLR--SVKIITLKSNLVSNFRKEF GLYKVREINDY
979

WP_003107102
880
YD KAGFIKRQLVETRQITKHVAQILNNRFNNNVDDSSKNKR--PVKIITLKSKMVSDFRKEF GFYKIREVNDY
950

WP_054279288
912
SD KANFIQRQLVETRQITKHVAQILDSRFNTERDEKDRPIR--RVKVITLKSKFVSDFRQDF GFYKLREINDY
982

WP_049531101
914
RD KVGFIKRQLVETRQITKHVAQILDSRFNTKVNEKNQKIR--TVKIITLKSNLVSNFRKEF RLYKVREINDY
984

WP_049538452
914
RD KVGFIRRQLVETRQITKHVAQILDSRFNTEVTEKDKKNR--NVKIITLKSNLVSNFRKEF GLYKVREINDY
984

WP_049549711
916
LD KVGFIKRQLVETRQITKHVAQILDARFNKEVTEKDKKNR--NVKIITLKSNLVSNFRKEF RLYKVREINDY
986

WP_007896501
917
SD KARFLRRQLVETRQITKHVAQLLDSRFNSKSNQNKKLAR--NVKIITLKSKIVSDFRKDF GLYKLREVNNY
987

EFR44625
869
SD KARFLRRQLVETRQITKHVAQLLDSRFNSKSNQNKKLAR--NVKIITLKSKIVSDFRKDF GLYKLREVNNY
939

WP_002897477
913
RD KVGFIRRQLVETQQITKNVAQILDARFNTEVKEKNQKIR--TVKIITLKSNLVSNFRKEF GLYKVREINNY
983

WP_002906454
913
RD KVGFIKRQLVETRQITKHVAQLLDTRENTEVNEENQKIR--TVKIITLKSNLVSNFRKEF GLYKVREINDY
983

WP_009729476
914
LD KVGFIKRQLVETRQITKHVAQILDARFNKEVTEKDKKNR--TVKIITLKSNLVSNFRKEF ELYKVREINDY
984

CQR24647
913
ED KAGFIKRQLVETRQITKHVARILDERFNRDFDKNDKRIR--NVKIVTLKSNLVSNFRKEF GFYKVREINNF
983

WP_000066813
918
LD KVGFIKRQLVETRQITKHVAQFLDARFNKEVTEKDKKNR--NVKIITLKSNLVSNFRKEF GLYKVREINDY
988

WP_009754323
914
RD KVGFIKRQLVETRQITKHVARILDARENTEVSEKNQKIR--SVKIITLKSNLVSNFRKEF KLYKVREINDY
984

WP_044674937
913
ED KARFIQRQLVETRQITKHVARILDTRENTKLDEAGNRIRdpKVNIITLKSNLVSQFRKDY QLYKVREINNY
985

WP_044676715
915
ED KARFIQRQLVETRQITKHVARILDTRENTKLDEAGNRIRdpKVNIITLKSNLVSQFRKDY QLYKVREINNY
987

WP_044680361
915
ED KARFIQRQLVETRQITKHVARILDTRENTKLDEAGNRIRdpKVNIITLKSNLVSQFRKDY QLYKVREINNY
987

WP_044681799
913
ED KARFIQRQLVETRQITKHVARILDTRENTKLDEAGNRIRdpKVNIITLKSNLVSQFRKDY QLYKVREINNY
985

WP_049533112
910
ND KAGFIKRQLVETRQITKHVAQVLDARFNAKHDENKKVIR--DVKIITLKSNLVSQFRKDF KFYKVREINDY
980

WP_029090905
891
RD KEGFIARQLVETRQITKHVTQLLQQEY-----------K-dTTKVFAIKATLVSGLRRKF EFIKNRNVNDY
951

WP_006506696
917
RD EERFINRQLVETRQITKNVTQIIEDHYST-------------TKVAAIRANLSHEFRVKN HIYKNRDINDY
976

AIT42264
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_034440723
915
RD RQQFINRQLVETRQITKHVANLLSHHLNEK-----KEVG--EINIVLLKSALTSQFRKKE DFYKVREVNDY
980

AKQ21048
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
981

WP_004636532
916
AD RAHFLNRQLVETRQITKHVANLLDSQYNTAEEQ-----R---INIVLLKSSMTSRFRKEF KLYKVREINDY
980

WP_002364836
922
ED KAHFIQRQLVETRQITKNVAGILDQRYNANSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
987

WP_016631044
873
ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
938

EMS75795
655
ED KARFIQRQLVETRQITKHVAAILDQYFN-QPEE-SK-NK--GIRIITLKSSLVSQFRKTF GINKVREINNH
722

WP_002373311
922
ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
987

WP_002378009
922
ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
987

WP_002407324
922
ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
987

WP_002413717
922
ED KAHFIQRQLVETRQITKNVAGILNQRYNANSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
987

WP_010775580
924
ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
989

WP_010818269
922
ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
987

WP_010824395
922
ED KAHFIQRQLVETRQITKNVAGILDQLYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
987

WP_016622645
922
ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
987

WP_033624816
922
ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
987

WP_033625576
922
ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
987

WP_033789179
922
ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY
987

WP_002310644
919
ED KAGFIKRQLVETRQITKHVAGILHHREN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY
988

WP_002312694
920
ED KAGFIKRQLVETRQITKHVAGILHHREN-KAEDTNDPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY
989

WP_002314015
920
ED KAGFIKRQLVETRQITKHVAGILHHREN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY
989

WP_002320716
920
ED KAGFIKRQLVETRQITKHVAGILHHREN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY
989

WP_002330729
919
ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY
988

WP_002335161
920
ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY
989

WP_002345439
920
ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY
989

WP_034867970
911
ED KARFIQRQLVETRQITKHVANILHQSFN-QEEEGTD-CD--GVQIITLKATLTSQFRQTF GLYKVREINPH
979

WP_047937432
920
ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY
989

WP_010720994
911
ED KARFIQRQLVETRQITKHVANILHQSFN-QEEEGTD-CD--GVQIITLKATLTSQFRQTF GLYKVREINPH
979

WP_010737004
911
ED KARFIQRQLVETRQITKHVANILHQSFN-QEEEGTD-CD--GVQIITLKATLTSQFRQTF GLYKVREINPH
979

WP_034700478
911
ED KARFIQRQLVETRQITKHVANILHQSFN-QEEEGTD-CD--GVQIITLKATLTSQFRQTF GLYKVREINPH
979

WP_007209003
912
SD KAGFLKRQLVETRQITKHVATILDSKFNE--DSNNRDVQ-----IITLKSALVSEFRKTF NLYKVREINDL
977

WP_023519017
905
AD KARFIQRQLVETRQITKHVANLLHQHFN-LPEEVSA-TE--KTSIITLKSTLTSQFRQMF DIYKVREINHH
973

WP_010770040
915
DD RAHFIKRQLVETRQITKHVARILDQRFNSQKDEEGKTIR--AVRVVTLKSSLTSQFRKQF AIHKVREINDY
985

WP_048604708
912
DD KAGFIHRQLVETRQITKNVARILHQRFNSEKDEEGNLIR--KVRIITLKSALTSQFRKNY GIYKIREINDY
982

WP_010750235
914
DD KARFIQRQLVETRQITKHVAAILHQYFN-QTQELEK-EK--DIRIITLKSSLVSQFRQVF GIHKVREINHH
982

AII16583
950
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY
1020

WP_029073316
928
KD KERFINRQIVETRQITKHVAQIISNHYET-------------TKVVTVRADLSHAFRERY HIYKNRDINDF
987

WP_031589969
928
KD QERFINRQIVETRQITKHVAQIIDNHYEN-------------TKVVTVRADLSHQFRERY HIYKNRDINDF
987

KDA45870
903
KL KERFIERQLVETRQITKYVAQLLDQRLN--YDGNGVELD-eKIAIVTLKAQLASQFRSEF KLRKVRALNNL
972

WP_039099354
924
-D MKGFINRQLVETRQVIKLATNLLMEQYGED-----------NIELITVKSGLTHQMRTEF DFPKNRNLNNH
990

AKP02966
926
KD KLGFIHRQLVQTSQMVKGVANILNSMYK---NQGTTCIQ--------ARANLSTAFRKAL ELVKNRNINDF
999

WP_010991369
914
AD KARFIHRQLVETRQITKNVANILHQRFNYEKDDHGNTMK--QVRIVTLKSALVSQFRKQF QLYKVRDVNDY
984

WP_033838504
914
AD KARFIHRQLVETRQITKNVANILHQRFNYEKDDHGNTMK--QVRIVTLKSALVSQFRKQF QLYKVRDVNDY
984

EHN60060
917
AD KARFIHRQLVETRQITKNVANILHQRFNYEKDDHGNTMK--QVRIVTLKSALVSQFRKQF QLYKVRDVNDY
987

EFR89594
683
AD KARFIHRQLVETRQITKNVANILHQRFNYGKDDHGNTMK--QVRIVTLKSALVSQFRKQF QLYKVRGVNDY
753

WP_038409211
914
AD KANFIQRQLVETRQITKNVANILYQRFNCKQDENGNEVE--QVRIVTLKSTLVSQFRKQF QLYKVREVNDY
984

EFR95520
533
AD KANFIQRQLVETRQITKNVANILYQRFNCKQDENGNEVE--QVRIVTLKSTLVSQFRKQF QLYKVREVNDY
603

WP_003723650
914
AD KARFIHRQLVETRQITKNVANILYQRFNKETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNGY
984

WP_003727705
914
AD KARFIHRQLVETRQITKNVANILHQRFNKETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNDY
984

WP_003730785
914
AD KARFIHRQLVETRQITKNVANILHQRFNKETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNDY
984

WP_003733029
914
AD KARFIHRQLVETRQITKNVANILHQRFNYKTDGNKDTME--TVRIVTLKSALVSQFRKQF QFYKVREVNDY
984

WP_003739838
914
AD KATFIHRQLVETRQITKNVANILHQRFNNETDNHGNNME--QVRIVMLKSALVSQFRKQF QLYKVREVNDY
984

WP_014601172
914
AD KARFIHRQLVETRQITKNVANILHQRFNNETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNDY
984

WP_023548323
914
AD KARFIHRQLVETRQITKNVANILHQRFNYKTDDNEDTME--PVRIVTLKSALVSQFRKQF QLYKVREVNDY
984

WP_031665337
914
AD KARFIHRQLVETRQITKNVANILHQRFNKETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNDY
984

WP_031669209
914
AD KARFIHRQLVETRQITKNVANILHQRFNYKTDGNKDTME--TVRIVTLKSALVSQFRKQF QFYKVREVNDY
984

WP_033920898
914
AD KARFIHRQLVETRQITKNVANILHQRFNYKTDDNEDTME--PVRIVTLKSALVSQFRKQF QLYKVREVNDY
984

AKI42028
917
AD KARFIHRQLVETRQITKNVANILHQRFNNETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNDY
987

AKI50529
917
AD KARFIHRQLVETRQITKNVANILHQRFNYKTDDNEDTME--PVRIVTLKSALVSQFRKQF QLYKVREVNDY
987

EFR83390
362
AD KARFIHRQLVETRQITKNVANILHQRFNNETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNDY
432

WP_046323366
914
AD KARFIHRQLVETRQITKNVANILHQRFNCKKDESGNVIE--QVRIVTLKAALVSQFRKQF QLYKVREVNDY
984

AKE81011
927
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY
997

CUO82355
921
RD EERFINRQLVETRQITKNVTQIIEDHYST-------------TKVAAIRANLSHEFRVKN HIYKNRDINDY
980

WP_033162887
923
KD KERFINRQLVETRQIIKNVAVIINDHYTN-------------TNIVTVRAELSHQFRERY KIYKNRDINDF
982

AGZ01981
944
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY
1014

AKA60242
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY
981

AKS40380
911
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY
981

4UN5_B
915
LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY
985

WP_010922251
982

custom character

1051

WP_039695303
992
HHAHDAYLNAVVGTALLKKYPKL-ASEFVYGEYKKYDI S---SD------ KATAK--YfFYSNLM-NFFKTKVK
1058

WP_045635197
984
HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGEYQKYDL SkdpKEV---EK ATEKY--F-FYSNLL-NFFKEEVH
1055

5AXW_A
703
HHAEDALI--------------IaNADFIFKEWKKLDK Nq-mFE----EK ETEQEykEiFITPHQiKHIKDFKD
771

WP_009880683
666
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDI S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
735

WP_010922251
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_011054416
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_011284745
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_011285506
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_011527619
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_012560673
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDI S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_014407541
981
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1050

WP_020905136
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_023080005
981
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1050

WP_023610282
981
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1050

WP_030125963
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_030126706
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_031488318
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_032460140
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDI S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_032461047
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDI S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_032462016
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_032462936
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_032464890
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_033888930
807
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
876

WP_038431314
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_038432938
981
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1050

WP_038434062
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

BAQ51233
893
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
962

KGE60162
157
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
226

KGE60856

-------------------------------------- ------------ ------------------------

WP_002989955
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_003030002
981
HHAHDAYLNAVVGNALLLKYPQL-EPEFVYGEYPKYN- S---YR---sRK SATEK--F1FYSNIL-RFFKKE--
1041

WP_003065552
992
HHAHDAYLNAVVGTALLKKYPKL-ASEFVYGEYKKYDI S---SD------ KATAK--YfFYSNLM-NFFKRVIR
1058

WP_001040076
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040078
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGLYRRKK- L---SKI---VR ATRKM--F-FYSNLM-NMFKRVVR
1057

WP_001040080
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040081
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040083
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040085
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040087
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040088
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040089
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040090
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040091
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040092
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040094
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040095
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040096
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040097
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040098
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040099
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040100
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040104
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040105
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040106
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040107
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040108
987
HHAHDAYLNAVVAKAILTKYPQL-EREFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040109
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_001040110
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_015058523
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_017643650
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_017647151
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_017648376
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_017649527
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_017771611
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_017771984
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

CFQ25032
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

CFV16040
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

KLJ37842
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

KLJ72361
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

KLL20707
1001
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1063

KLL42645
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_047207273
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_047209694
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_050198062
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_050201642
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_050204027
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_050881965
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_050886065
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

AHN30376
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

EA078426
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

CCW42055
987
HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT
1049

WP_003041502
981
HHAHDAYLNAVIGTALLKKYPKL-ASEFVYGEFKKYDV S---DK---eIG KATAK--YfFYSNLM-NFFKKEVK
1050

WP_037593752
982
HHAHDAYLNAVVGNALLLKYPQL-EPEFVYGEYPKYN- S---YR---sRK SATEK--F1FYSNIL-RFFKKE--
1042

WP_049516684
982
HHAHDAYLNAVVGNALLLKYPQL-EPEFVYGEYPKYN- S---YR---sRK SATEK--F1FYSNIL-RFFKKE--
1042

GAD46167
981
HHAHDAYLNAVVGNALLLKYPQL-EPEFVYGEYPKYN- S---YR---sRK SATEK--F1FYSNIL-RFFKKE--
1041

WP_018363470
990
HHAHDAYLNAVVGTALLKKYPKL-APEFVYGEYKKYDV S---SDDhseMG KATAK--YfFYSNLM-NFFKRVIR
1062

WP_003043819
991
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEVK
1060

WP_006269658
981
HHAHDAYLNAVVGNALLLKYPQL-EPEFVYGEYPKYN- S---YR---sRK SATEK--F1FYSNIL-RFFKKE--
1041

WP_048800889
981
HHAHDAYLNAVVGTALLKKYPKL-TSEFVYGEYKKYDV S---DND--eIG KATAK--YfFYSNLM-NFFKTEVK
1051

WP_012767106
981
HHAHDAYLNAVVGTALIKKYTKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEIT
1050

WP_014612333
981
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEIT
1050

WP_015017095
981
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEIT
1050

WP_015057649
981
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEIT
1050

WP_048327215
981
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEIT
1050

WP_049519324
981
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEIT
1050

WP_012515931
981
HHAHDAYLNAVVAKAILGKYPQL-APEFVYGDYPKYN- S---FKEr--QK ATQKM--L-FYSNIL-KFFKDQES
1043

WP_021320964
981
HHAHDAYLNAVVAKAILGKYPQL-APEFVYGDYPKYN- S---FKEr--QK ATQKT--L-FYSNIL-KFFKDQES
1043

WP_037581760
981
HHAHDAYLNAVVAKAILGKYPQL-APEFVYGDYPKYN- S---FKEr--QK ATQKT--L-FYSNIL-KFFKDQES
1043

WP_004232481
989
HHAHDAYLNAVVGTALLKKYPKL-APEFVYGEYKKYDV S---SDNhseLG KATAK--YfFYSNLM-NFFKTEVK
1061

WP_009854540
990
HHAHDAYLNAVVGTALLKKYPKL-ASEFVYGEYKKYDI S---SD------ KATAK--YfFYSNLM-NFFKTKVK
1056

WP_012962174
990
HHAHDAYLNAVVGTALLKKYPKL-APEFVYGEYKKYDI S---GD------ KATAK--YfFYSNLM-NFFKRVIR
1056

WP_039695303
992
HHAHDAYLNAVVGTALLKKYPKL-ASEFVYGEYKKYDI S---SD------ KATAK--YfFYSNLM-NFFKTKVK
1058

WP_014334983
989
HHAHDAYLNAVVGTALLKKYPKL-TPEFVYGEYKKYDV S---SDDyseMG KATAK--YfFYSNLM-NFFKTEVK
1061

WP_003099269
982
HHAQDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHYDL P---DSS1--GK ATTRM--F-FYSNLM-NFFKKEIK
1051

AHY15608
982
HHAQDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHYDL P---DSS1--GK ATTRM--F-FYSNLM-NFFKKEIK
1051

AHY17476
982
HHAQDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHYDL P---DSS1--GK ATTRM--F-FYSNLM-NFFKKEIK
1051

ESR09100

-------------------------------------- ------------ ------------------------

AGM98575
982
HHAQDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHYDL P---DSS1--GK ATTRM--F-FYSNLM-NFFKKEIK
1051

ALF27331
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_018372492
995
HHAHDAYLNAVVAQALLKVYPKF-ERELVYGSYVKESI ----FS----RK ATERM---rMYNNIL-KFISKD--
1055

WP_045618028
985
HHAHDPYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL TkdpKEV---EK ATEKY--F-FYSNLL-NFFKEEVH
1056

WP_045635197
984
HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGEYQKYDL SkdpKEV---EK ATEKY--F-FYSNLL-NFFKEEVH
1055

WP_002263549
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002263887
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002264920
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002269043
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002269448
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002271977
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002272766
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HE---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002273241
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002275430
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HE---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002276448
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002277050
984
HHAHDAYLNAVVVKALLVKYPKL-EPEFVYGEYPKYN- S---YR---eRK ATQKM--F-FYSNIM-NMFKSKVK
1046

WP_002277364
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002279025
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HE---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002279859
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002280230
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002281696
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002282247
984
HHAHDAYLNAVVVKALLVKYPKL-EPEFVYGEYPKYN- S---YR---eRK ATQKM--F-FYSNIM-NMFKSKVK
1046

WP_002282906
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002283846
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002287255
982
HHTHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002288990
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002289641
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002290427
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002295753
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002296423
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002304487
996
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKG--
1055

WP_002305844
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002307203
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002310390
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_002352408
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_012997688
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_014677909
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_019312892
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_019313659
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_019314093
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_019315370
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HE---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_019803776
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_019805234
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_024783594
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_024784288
984
HHAHDAYLNAVVVKALLVKYPKL-EPEFVYGEYLKYN- S---YR---eRK ATQKM--F-FYSNIM-NMFKSKVK
1046

WP_024784666
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_024784894
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_024786433
984
HHAHDAYLNAVVVKALLVKYPKL-EPEFVYGEYPKYN- S---YR---eRK ATQKM--F-FYSNIM-NMFKSKVK
1046

WP_049473442
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HE---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

WP_049474547
982
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1041

EMC03581
975
HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD--
1034

WP_000428612
987
HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SkdpKEI---EK ATEKY--F-FYSNLL-NFFKEEVH
1058

WP_000428613
985
HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SrnpKEV---EK ATEKY--F-FYSNLL-NFFKEEVH
1056

WP_049523028
980
HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL TkdpKEI---EK ATEKY--F-FYSNLL-NFFKDKVY
1051

WP_003107102
951
HHAHDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHYDL S---DTS1--GK ATAKM--F-FYSNIM-NFFKKEVR
1020

WP_054279288
983
HHAHDAYLNAVVGTALLKMYPKL-ASEFVYGDYQKYDL S---GKAs--GH ATAKY--F-FYSNLM-NFFKSEVK
1052

WP_049531101
985
HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SrdpKEI---EK ATEKY--F-FYSNLL-NFFKEEVH
1056

WP_049538452
985
HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SkdpKDI---EK ATEKY--F-FYSNLL-NFFKEEVH
1056

WP_049549711
987
HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKNDL SkdpKDI---EK ATEKY--F-FYSNLL-NFFKEEVH
1058

WP_007896501
988
HHAHDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHFDL S---DPS1--GK ATAKV--F-FYSNIM-NFFKEELS
1057

EFR44625
940
HHAHDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHFDL S---DPS1--GK ATAKV--F-FYSNIM-NFFKEELS
1009

WP_002897477
984
HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL FkpsKEI---EK ATEKY--F-FYSNLL-NFFKEEVL
1055

WP_002906454
984
HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SkasNTI---DK ATEKY--F-FYSNLL-NFFKEKVR
1055

WP_009729476
985
HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SkdpKEI---EK ATEKY--F-FYSNLL-NFFKEEVH
1056

CQR24647
984
HHAHDAYLNAVVAKALLIRYPKL-EPEFVYGEYPKYN- S---YRE---RK ATEKM--F-FYSNIM-NMFKTTIK
1046

WP_000066813
989
HHAHDAYLNAVLAKAILKKYPKL-EPEFVYGDYQKYDL SrepKEV---EK ATQKY--F-FYSNLL-NFFKEEVH
1060

WP_009754323
985
HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SkdpKEV---EK ATEKY--F-FYSNLL-NFFKEEVH
1056

WP_044674937
986
HHAHDAYLNAVVATALLKKYPQL-APEFVYGDYPKYN- S---YKS---RK ATEKV--L-FYSNIM-NFFRRVLV
1048

WP_044676715
988
HHAHDAYLNAVVATALLKKYPQL-APEFVYGDYPKYN- S---YKS---RK ATEKV--L-FYSNIM-NFFRRVLV
1050

WP_044680361
988
HHAHDAYLNAVVATALLKKYPQL-APEFVYGDYPKYN- S---YKS---RK ATEKV--L-FYSNIM-NFFRRVLV
1050

WP_044681799
986
HHAHDAYLNAVVATALLKKYPQL-APEFVYGDYPKYN- S---YKS---RK ATEKV--L-FYSNIM-NFFRRVLV
1048

WP_049533112
981
HHAHDAYLNAVIGTALLKKYPKL-ASEFVYGEFKKYDV S---DK---eIG KATAK--YfFYSNLM-NFFKKEVK
1050

WP_029090905
952
HHAQDAFLVAFLGTNITSNYPKI-EMEYLFKGYQHYLN ------Ev--GK AAKPKftF-IVENLS---------
1007

WP_006506696
977
HHAHDAYIVALIGGFMRDRYPNMhDSKAVYSEYMKMFR ----NKNd--QK -----g---FVINSM-NYPY-EV-
1038

AIT42264
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_034440723
981
HHAHDAYLNGVIALKLLELYPYM-AKDLIYGKYSYHRK G---------DK ATQAK--Y-KMSNII-ERFSQDL-
1041

AKQ21048
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

WP_004636532
981
HHGHDAYLNAVVATTIMKVYPNL-KPQFVYGQYKKTSM ----FKE---EK ATARK--H-FYSNIT-KFFKKEKV
1042

WP_002364836
988
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED--
1047

WP_016631044
939
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED--
998

EMS75795
723
HHAHDAYLNGVVAIALLKKYPKL-EPEFVYGNYTKFNL ----AT---eNK ATAKK--E-FYSNIL-RFFEKE--
782

WP_002373311
988
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQA ----FKE---NK ATAKT--I-IYTNLM-RFFTED--
1047

WP_002378009
988
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED--
1047

WP_002407324
988
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED--
1047

WP_002413717
988
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED--
1047

WP_010775580
990
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQA ----FKE---NK ATAKA--I-IYTNLL-RFFTED--
1049

WP_010818269
988
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED--
1047

WP_010824395
988
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKT--I-IYTNLM-RFFTED--
1047

WP_016622645
988
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED--
1047

WP_033624816
988
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQA ----FKE---NK AMAKA--I-IYTNLL-RFFTED--
1047

WP_033625576
988
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQA ----FKE---NK ATAKA--I-IYTNLM-RFFTEV--
1047

WP_033789179
988
HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQA ----FKE---NK ATAKA--I-IYTNLL-RFFTED--
1047

WP_002310644
989
HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD--
1048

WP_002312694
990
HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD--
1049

WP_002314015
990
HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD--
1049

WP_002320716
990
HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD--
1049

WP_002330729
989
HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD--
1048

WP_002335161
990
HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD--
1049

WP_002345439
990
HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD--
1049

WP_034867970
980
HHAHDAYLNGFIANVLLKRYPKL-APEFVYGKYVKYSL ----AR---eNK ATAKK--E-FYSNIL-KFLESD--
1039

WP_047937432
990
HHAHDAYLNGVIALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD--
1049

WP_010720994
980
HHAHDAYLNGFIANVLLKRYPKL-APEFVYGKYVKYSL ----AR---eNK ATAKK--E-FYSNIL-KFLESD--
1039

WP_010737004
980
HHAHDAYLNGFIANVLLKRYPKL-APEFVYGKYVKYSL ----AR---eNK ATAKK--E-FYSNIL-KFLESD--
1039

WP_034700478
980
HHAHDAYLNGFIANVLLKRYPKL-APEFVYGKYVKYSL ----AR---eNK ATAKK--E-FYSNIL-KFLESD--
1039

WP_007209003
978
HHAHDAYLNAVVALSLLRVYPQL-KPEFVYGEYGKNS- ----IHDq--NK ATIKK---qFYSNIT-RYFASK--
1037

WP_023519017
974
HHAHDAYLNGVVAMTLLKKYPKL-APEFVYGSYIKGDI ----NQ---iNK ATAKK--E-FYSNIM-KFFESE--
1033

WP_010770040
986
HHGHDAYLNGVVANSLLRVYPQL-QPEFVYGDYPKFNA ----YKA---NK ATAKK--Q-LYTNIM-KFFAED--
1045

WP_048604708
983
HHAHDAYLNGVVATALLKIYPQL-EPEFVYGEFHRFNA ----FKE---NK ATAKK--Q-FYSNLM-EFSKSD--
1042

WP_010750235
983
HHAHDAYLNAVVALALLKKYPRL-APEFVYGSFAKFHL ----VK---eNK ATAKK--E-FYSNIL-KFFEKE--
1042

AII16583
1021
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1090

WP_029073316
988
HHAHDAYIATILGTYIGHRFESL-DAKYIYGEYQKIFR ----NKNk--DK ---KDg---FILNSM-RNLYADK-
1052

WP_031589969
988
HHAHDAYIATILGTYIGHRFESL-DAKYIYGEYKRIFR ----QKNk--GK ---NDg---FILNSM-RNIYADK-
1052

KDA45870
973
HHAHDAYLNAVVANLIMAKYPEL-EPEFVYGKYRKTK- ----FKG1--GK ATAKN---tLYANVL-YFLKENEV
1034

WP_039099354
991
HHAFDAYLTAFVGLYLLKRYPKL-KPYFVYGEYQKAS- ----QQ----DK ---RN--F----NFL-NGLKKD--
1043

AKP02966
1000
HHAQDAYLASFLGTYRLRRFPTD-EMLLMNGEYNKFYG -----KElysKK -SRKN-gF-IISPLV---------
1062

WP_010991369
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1044

WP_033838504
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1044

EHN60060
988
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1047

EFR89594
754
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
813

WP_038409211
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-RFFAKE--
1044

EFR95520
604
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-RFFAKE--
663

WP_003723650
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1044

WP_003727705
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1044

WP_003730785
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1044

WP_003733029
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFGW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1044

WP_003739838
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1044

WP_014601172
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFGQK--
1044

WP_023548323
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1044

WP_031665337
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1044

WP_031669209
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1044

WP_033920898
985
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1044

AKI42028
988
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFGQK--
1047

AKI50529
988
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
1047

EFR83390
433
HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK--
492

WP_046323366
985
HHAHDAYLNCVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAKK--
1044

AKE81011
998
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1067

CUO82355
981
HHAHDAYIVALIGGFMRDRYPNMhDSKAVYSEYMKMFR ----NKNd--QK -----g---FVINSM-NYPY-EV-
1042

WP_033162887
983
HHAHDAYIACIVGQFMHQNFEHL-DAKIIYGQYK---- -----KNy--KK ---NYg---FILNSM-NHLQSDI-
1042

AGZ01981
1015
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1084

AKA60242
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

AK540380
982
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1051

4UN5_B
986
HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT
1055

WP_010922251
1052

custom character

GGFSK ESIL-PKR-
1114

WP_039695303
1059
YAD-GTVFERPIIE T-NAD-GE-IAWNKQIDFEKVRKVLS-YPQVNIVKKVETQT GGFSK ESIL-PKG-
1120

WP_045635197
1056
YAD-GTIVKRENIE Y-SKDLGE-IAWNKEKDFAIIKKVLS-LPQVNIVKKREVQT GGFSK ESIL-PKG-
1118

5AXW_A
772
YKYsHRVDKKPNRE VNNLN-GL---YDKDND--KLKKLINkSPEKLLMYHHDPQT --YQK KLIMeQYGd
852

WP_009880683
736
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
798

WP_010922251
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_011054416
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_011284745
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_011285506
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_011527619
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_012560673
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_014407541
1051
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1113

WP_020905136
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_023080005
1051
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1113

WP_023610282
1051
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1113

WP_030125963
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_030126706
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_031488318
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_032460140
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_032461047
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_032462016
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_032462936
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_032464890
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_033888930
877
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
939

WP_038431314
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_038432938
1051
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1113

WP_038434062
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

BAQ51233
963
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1025

KGE60162
227
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
289

KGE60856
1
------------IE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
52

WP_002989955
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_003030002
1042
-----------DIQ T-NED-GE-IAWNKEKHIKILRKVLS-YPQVNIVKKTEEQT GGFSK ESIL-PKG-
1093

WP_003065552
1059
YSN-GKVIVRPVVE Y-SKD-TEdIAWDKKSNERTICKVLS-YPQVNIVKKVETQT GGFSK ESIL-PKG-
1121

WP_001040076
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040078
1058
LAD-GSIVVRPVIE TGRYM-GK-TAWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1120

WP_001040080
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040081
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040083
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040085
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040087
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040088
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040089
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040090
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040091
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040092
1050
LAD-ETVVVKDDIE VNNET-GE-IAWDKKKHFATVRKVLS-YPQVNIVKKTEVQT GGFSK ESIL-AHS-
1112

WP_001040094
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040095
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEVQT GGFSK ESIL-AHG-
1112

WP_001040096
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEVQT GGFSK ESIL-AHG-
1112

WP_001040097
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040098
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040099
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040100
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040104
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040105
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040106
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040107
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040108
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040109
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_001040110
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_015058523
1050
LAD-ETVVVKDDIE VNNET-GE-IAWDKKKHFATVRKVLS-YPQVNIVKKTEVQT GGFSK ESIL-AHS-
1112

WP_017643650
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_017647151
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_017648376
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_017649527
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_017771611
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_017771984
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

CFQ25032
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

CFV16040
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

KLJ37842
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

KLJ72361
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

KLL20707
1064
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1126

KLL42645
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_047207273
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_047209694
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_050198062
1050
LAD-GTVVIKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_050201642
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_050204027
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_050881965
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_050886065
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

AHN30376
1050
LAD-ETVVVKDDIE VNNET-GE-IAWDKKKHFATVRKVLS-YPQVNIVKKTEVQT GGFSK ESIL-AHS-
1112

EA078426
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

CCW42055
1050
LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-
1112

WP_003041502
1051
FAD-GTVVERPDIE T-SED-GE-IAWNKQTDFKIVRKVLS-YPQVNIVKKTEVQT HGLDR PSPK-PKP-
1122

WP_037593752
1043
-----------DIQ T-NED-GE-IAWNKEKHIKILRKVLS-YPQVNIVKKTEEQT GGFSK ESIL-PKG-
1094

WP_049516684
1043
-----------DIQ T-NED-GE-IAWNKEKHIKILRKVLS-YPQVNIVKKTEEQT GGFSK ESIL-PKG-
1094

GAD46167
1042
-----------DIQ T-NED-GE-IAWNKEKHIKILRKVLS-YPQVNIVKKTEEQT GGFSK ESIL-PKG-
1093

WP_018363470
1063
YSN-GKVIVRPVVE Y-SKDtGE-IAWNKRTDFEKVRKVLS-YPQVNIVKKVETQT GGFSK ESIL-PKG-
1125

WP_003043819
1061
LAN-GEIRKRPLIE TNGET-GE-VVWNKEKDFATVRKVLA-MPQVNIVKKTEVQT GGFSK ESIL-SKR-
1123

WP_006269658
1042
-----------DIQ T-NED-GE-IAWNKEKHIKILRKVLS-YPQVNIVKKTEEQT GGFSK ESIL-PKG-
1093

WP_048800889
1052
FAD-GTVVERPDIE T-SED-GE-IAWNKQTDFKIVRKVLS-YPQVNIVKKVEKQT GRFSK ESIL-PKG-
1113

WP_012767106
1051
LAN-GEIRKRPLIE TNEET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GALTN ESIY-ARG-
1113

WP_014612333
1051
LAN-GEIRKRPLIE TNEET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GALTN ESIY-ARG-
1113

WP_015017095
1051
LAN-GEIRKRPLIE TNEET-GE-IVWNKGRDFATVRKVLS-MPQVNIVKKTEVQT GALTN ESIY-ARG-
1113

WP_015057649
1051
LAN-GEIRKRPLIE TNEET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GALTN ESIY-ARG-
1113

WP_048327215
1051
LAN-GEIRKRPLIE TNEET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GALTN ESIY-ARG-
1113

WP_049519324
1051
LAN-GEIRKRPLIE TNEET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GALTN ESIY-ARG-
1113

WP_012515931
1044
L------------H VNSD--GE-EIWNANKHLPIIKNVLS-IPQVNIVKKTEVQT GGFYK ESIL-SKG-
1094

WP_021320964
1044
L------------H VNSD--GE-EIWNANKHLPIIKNVLS-IPQVNIVKKTEVQT GGFYK ESIL-SKG-
1094

WP_037581760
1044
L------------H VNSD--GE-EIWNANKHLPIIKNVLS-IPQVNIVKKTEVQT GGFYK ESIL-SKG-
1094

WP_004232481
1062
YAD-GRVFERPDIE T-NAD-GE-VVWNKQRDFNIVRKVLS-YPQVNIVKKVEVQT GGFSK ESIL-PKG-
1123

WP_009854540
1057
YAD-GTVFERPIIE T-NAD-GE-IAWNKQIDFEKVRKVLS-YPQVNIVKKVETQT GGFSK ESIL-PKG-
1118

WP_012962174
1057
YSN-GKVVVRPVIE C-SKDtGE-IAWNKQTDFEKVRRVLS-YPQVNIVKKVETQT GGFSK ESIL-PKG-
1119

WP_039695303
1059
YAD-GTVFERPIIE T-NAD-GE-IAWNKQIDFEKVRKVLS-YPQVNIVKKVETQT GGFSK ESIL-PKG-
1120

WP_014334983
1062
YAD-GRVFERPDIE T-NAD-GE-VVWNKQKDFDIVRKVLS-YPQVNIVKKVEAQT GGFSK ESIL-SKG-
1123

WP_003099269
1052
LAD-DTIFTRPQIE VNTET-GE-IVWDKVKDMQTIRKVMS-YPQVNIVMKTEVQT GGFSK ESIW-PKG-
1114

AHY15608
1052
LAD-DTIFTRPQIE VNTET-GE-IVWDKVKDMQTIRKVMS-YPQVNIVMKTEVQT GGFSK ESIW-PKG-
1114

AHY17476
1052
LAD-DTIFTRPQIE VNTET-GE-IVWDKVKDMQTIRKVMS-YPQVNIVMKTEVQT GGFSK ESIW-PKG-
1114

ESR09100

-------------- ----------------------------------------- ----- ---------

AGM98575
1052
LAD-DTIFTRPQIE VNTET-GE-IVWDKVKDMQTIRKVMS-YPQVNIVMKTEVQT GGFSK ESIW-PKG-
1114

ALF27331
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_018372492
1056
--K----------K --DQEtGE-IVWDKKEIENIVKKVIY-SSPVNIVKKREEQS GALFK QSNM-AVGy
1108

WP_045618028
1057
YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATIKKVLS-LPQVNIVKKTEEQT GGLFD NNIV-SKKk
1124

WP_045635197
1056
YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFAIIKKVLS-LPQVNIVKKREVQT GGFSK ESIL-PKG-
1118

WP_002263549
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002263887
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002264920
1042
-----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002269043
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002269448
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002271977
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002272766
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002273241
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002275430
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002276448
1042
-----------DVR T-DRN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002277050
1047
LAD-DQIVERPMIE VNDET-GE-IAWDKTKHITTVKKVLS-YPQVNIVKKVEEQT GGLFD -----PKS-
1111

WP_002277364
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002279025
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002279859
1042
-----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002280230
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002281696
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002282247
1047
LAD-DQIVERPMIE VNDET-GE-IAWDKTKHITTVKKVLS-YPQVNIVKKVEEQT GGLFD -----PKS-
1111

WP_002282906
1042
-----------DVR I-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002283846
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002287255
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002288990
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002289641
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002290427
1042
-----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFFK ESIL-PKG-
1093

WP_002295753
1042
-----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002296423
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002304487
1056
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1107

WP_002305844
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002307203
1042
-----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_002310390
1042
-----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFFK ESIL-PKG-
1093

WP_002352408
1042
-----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_012997688
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_014677909
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_019312892
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_019313659
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_019314093
1042
-----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_019315370
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_019803776
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_019805234
1042
-----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFFK ESIL-PKG-
1093

WP_024783594
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_024784288
1047
LAD-DQIVERPMIE VNDET-GE-IAWDKTKHITTVKKVLS-YPQVNIVKKVEEQT GGLFD -----PKS-
1111

WP_024784666
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_024784894
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_024786433
1047
LAD-DQIVERPMIE VNDET-GE-IAWDKTKHITTVKKVLS-YPQVNIVKKVEEQT GGLFD -----PKS-
1111

WP_049473442
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

WP_049474547
1042
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1093

EMC03581
1035
-----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-
1086

WP_000428612
1059
YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATIKKVLS-LPQVNIVKKREVQT GGFSK ESIL-PKG-
1121

WP_000428613
1057
YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATIKKVLS-YPQVNIVKKREVQT GGFSK ESIL-PKG-
1119

WP_049523028
1052
YAD-GTIIQRGNVE Y-SKDtGE-IAWNKKRDFAIVRKVLS-YPQVNIVKKTEEQT GGFSK ESIL-PKG-
1114

WP_003107102
1021
LAD-GTVITRPQIE TNTET-GE-IVWDKVKDIKTIRKVLS-IPQINVVKKTEVQT GGFSK ESIL-SKR-
1083

WP_054279288
1053
LAN-GNIIKRSPIE VNEET-GE-IVWDKTKDFGTVRKVLS-APQVNIVKKTEIQT GGFSN ETIL-SKG-
1115

WP_049531101
1057
YAD-GTIVKRENIE Y-SKDtGE-IAWNKEIDFATIRKILS-LSQVNIVKKTEEQT GGLFD NNIV-SKKk
1124

WP_049538452
1057
YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATIKKILS-LPQVNIVKKTEEQT GGLFD NNIV-SKKk
1124

WP_049549711
1059
YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATIKKVLS-YPQVNIVKKTEEQT GGLFD NNIV-SKEk
1126

WP_007896501
1058
LAD-GTLMKRPVIE TNTET-GE-VVWDKVKDFKTIRKVLS-YPQVNIVKKTEIQS GAFSK ESVL-SKG-
1120

EFR44625
1010
LAD-GTLMKRPVIE TNTET-GE-VVWDKVKDFKTIRKVLS-YPQVNIVKKTEIQS GAFSK ESVL-SKG-
1072

WP_002897477
1056
YAD-GTIRKRENIE Y-SKDtGE-IAWDKEKDFATIKKVLS-YPQVNIVKKREVQT GGFSK ESIL-PKG-
1118

WP_002906454
1056
YAD-GTIKKRENIE Y-SNDtGE-IAWNKEKDFATIKKVLS-LPQVNIVKKTEEQT GGLFD NNIV-SKKk
1123

WP_009729476
1057
YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATIKKVLS-LPQVNIVKKREVQT GGFSK ESIL-PKG-
1119

CQR24647
1047
LAD-GRVVEKPVIE ANEET-GE-IAWDKTKHFANVKKVLS-YPQVSIVKKVEEQT GGFSK ESIL-PKG-
1109

WP_000066813
1061
YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATVKKVLS-LPQVNIVKKTEVQT GGFSK ESIL-PKG-
1123

WP_009754323
1057
YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFVTIKKVLS-YPQVNIVKKREVQT GGFSK ESIL-PKG-
1119

WP_044674937
1049
YSKtGEVRIRPVIE VNKET-GE-IVWDKKSDFRTVRKVLS-YPQVNVVKKVEMQT GGFSK ESIL-QHG-
1112

WP_044676715
1051
YSKtGEVRIRPVIE VNKET-GE-IVWDKKSDFRTVRKVLS-YPQVNVVKKVEMQT GGFSK ESIL-QHG-
1114

WP_044680361
1051
YSKtGEVRIRPVIE VNKET-GE-IVWDKKSDFRTVRKVLS-YPQVNVVKKVEMQT GGFSK ESIL-QHG-
1114

WP_044681799
1049
YSKtGEVRIRPVIE VNKET-GE-IVWDKKSDFKTVRKVLS-YPQVNVVKKVEMQT GGFSK ESIL-QHG-
1112

WP_049533112
1051
FAD-GTVVERPDIE T-SED-GE-IAWNKQTDFKIVRKVLS-YPQVNIVKKTEVQT HGLDR PSPK-PKP-
1122

WP_029090905
1008
-KQ----------Q --NSTtGE-VKWNPEVDIAKLKRILN-FKQCNIVRKVEEQS GALFK ETIY-PVEe
1061

WP_006506696
1039
--D----------- ------GK-LIWNP-DLINEIKKCFY-YKDCYCTTKLDQKS GQLFN -TVL-SNDa
1084

AIT42264
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_034440723
1042
------------LA --NPD-GE-IAWEKDKDLNTIRKVLS-SKQINIIKKAEEGK GRLFK ETIN-SRPs
1092

AKQ21048
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

WP_004636532
1043
-------------- VNEET-GE-ILWDTERHLSTIKRVLS-WKQMNIVKKVEKQK GQLWK ETIY-PKG-
1092

WP_002364836
1048
--E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1098

WP_016631044
999
--E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1049

EMS75795
783
--E----------Y SYDEN-GE-IFWDKARHIPQIKKVIS-SHQVNIVKKVEVQT GGFYK ETVN-PKG-
834

WP_002373311
1048
--E----------P RFTKD-SE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1098

WP_002378009
1048
--E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1098

WP_002407324
1048
--E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1098

WP_002413717
1048
--E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1098

WP_010775580
1050
--E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1100

WP_010818269
1048
--E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1098

WP_010824395
1048
--E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1098

WP_016622645
1048
--E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1098

WP_033624816
1048
--E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1098

WP_033625576
1048
--E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1098

WP_033789179
1048
--E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG-
1098

WP_002310644
1049
--T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK-
1100

WP_002312694
1050
--T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK-
1101

WP_002314015
1050
--T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK-
1101

WP_002320716
1050
--T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK-
1101

WP_002330729
1049
--T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSE ETVE-PKK-
1100

WP_002335161
1050
--T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK-
1101

WP_002345439
1050
--T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK-
1101

WP_034867970
1040
--E----------P FCDEN-GE-IYWEKSHHLPRIKKVLS-SHQVNVVKKVEQQK GGFYK ETVN-SKE-
1091

WP_047937432
1050
--T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK-
1101

WP_010720994
1040
--E----------P FCDEN-GE-IYWEKSHHLPRIKKVLS-SHQVNVVKKVEQQK GGFYK ETVN-SKE-
1091

WP_010737004
1040
--E----------P FCDEN-GE-IYWEKSHHLPRIKKVLS-SHQVNVVKKVEQQK GGFYK ETVN-SKE-
1091

WP_034700478
1040
--E----------P FCDEN-GE-IYWEKSHHLPRIKKVLS-SHQVNVVKKVEQQK GGFYK ETVN-SKE-
1091

WP_007209003
1038
--D----------- IINDD-GE-ILWNKQETIAQVIKTLG-MHQVNVVKKVEIQK GGFSK ESIQ-PKG-
1089

WP_023519017
1034
--E----------I ICDEQ-GE-VIWNKKRDLSTIKKTIG-AHQVNIVKKVEKQK GGFYK ETIN-SKA-
1085

WP_010770040
1046
--A----------V IIDEN-GE-ILWDK-KNIATVKKVMS-YPQMNIVKKPEIQT GSFSK ETIK-PKG-
1096

WP_048604708
1043
--K----------V IIDEN-GE-ILWNQ-KKIVTVKKVMN-YRQMNIVKKVEIQK GGFSK ESIL-PKG-
1093

WP_010750235
1043
--E----------Q FCDEN-GE-IFWDKRKHIQQIKKVIS-SHQVNIVKKVEVQT GSFYK ETVN-TKE-
1094

AIII6583
1091
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1153

WP_029073316
1053
--D----------- ----T-GE-VVWDP-EWISRIKKCFY-YKDCFVTKKLEENN GSFFN -TVR-PNDe
1099

WP_031589969
1053
--D----------- ----T-GE-IVWDP-NYIDRIKKCFY-YKDCFVTKKLEENN GTFFN -TVL-PNDt
1099

KDA45870
1035
YPF----------- -----------WDKARDLPTIKRYLY-RAQVNKVRKAERQT GGFSD EMLV-PKS-
1078

WP_039099354
1044
-------------E LVDEN-TEaVIWNKESGLAYLNKIYQ-FKKILVTREVHENS GALFN QTLYaAKDd
1097

AKP02966
1063
--N-------GTTQ --DRNtGE-IIWNVG-FRDKILKIFN-YHQCNVTRKTEIKT GQFYD QTIYsPKNp
1118

WP_010991369
1045
--D----------R IIDEN-GE-ILWDK-KYLDTVKKVMS-YRQMNIVKKTEIQK GEFSK ATIK-PKG-
1095

WP_033838504
1045
--D----------R IIDEN-GE-ILWDK-KYLDTVKKVMS-YRQMNIVKKTEIQK GEFSK ATIK-PKG-
1095

EHN60060
1048
--D----------R IIDEN-GE-ILWDK-KYLDTVKKVMS-YRQMNIVKKTEIQK GEFSK ATIK-PKG-
1098

EFR89594
814
--D----------R IIDEN-GE-ILWDK-KYLDTVKKVMS-YRQMNIVKKTEIQK GEFSK ATIK-PKG-
864

WP_038409211
1045
--N----------Q IIDKN-GE-ILWDN-RYLDTIKKVLS-YRQMNIVKKTEIQK GEFSN ATVN-PKG-
1095

EFR95520
664
--N----------Q IIDKN-GE-ILWDN-RYLDTIKKVLS-YRQMNIVKKTEIQK GEFSN ATVN-PKG-
714

WP_003723650
1045
--E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQMNIVKKTEIQK GEFSK ATIK-PKG-
1095

WP_003727705
1045
--E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQINIVKKTEIQK GEFSK ATIK-PKG-
1095

WP_003730785
1045
--E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQINIVKKTEIQK GEFSK ATIK-PKG-
1095

WP_003733029
1045
--D----------R IIDEN-GE-ILWDK-RYLETVKKVLG-YRQMNIVKKTEIQK GEFSN VTPN-PKG-
1095

WP_003739838
1045
--E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQMNIVKKTEIQK GEFSK ATIK-PKG-
1095

WP_014601172
1045
--E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQMNIVKKTEIQK GEFSK ATIK-PKG-
1095

WP_023548323
1045
--E----------R IIDEN-GE-ILWDK-KYLETIKKVLN-YRQMNIVKKTEIQK GEFSN QNPK-PRG-
1095

WP_031665337
1045
--E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQMNIVKKTEIQK GEFSK ATIK-PKG-
1095

WP_031669209
1045
--D----------R IIDEN-GE-ILWDK-RYLETVKKVLG-YRQMNIVKKTEIQK GEFSN VTPN-PKG-
1095

WP_033920898
1045
--E----------R IIDEN-GE-ILWDK-KYLETIKKVLN-YRQMNIVKKTEIQK GEFSN QNPK-PRG-
1095

AKI42028
1048
--E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQMNIVKKTEIQK GEFSK ATIK-PKG-
1098

AKI50529
1048
--E----------R IIDEN-GE-ILWDK-KYLETIKKVLN-YRQMNIVKKTEIQK GEFSN QNPK-PRG-
1098

EFR83390
493
--E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQMNIVKKTEIQK GEFSK ATIK-PKG-
543

WP_046323366
1045
--D----------R IIDEN-GE-ILWDK-KYLDTIKKVLN-YRQMNIVKKTEIQK GEFSN ATAN-PKG-
1095

AKE81011
1068
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
130

CUO82355
1043
--D----------- ------GK-LIWNP-DLINEIKKCFY-YKDCYCTTKLDQKS GQMFN -TVL-PNDa
1088

WP_033162887
1043
--D----------- ----T-GE-VMWDP-AKIGKIKSCFY-YKDVYVTKKLEQNS GTLFN -TVL-PNDa
1089

AGZ01981
1085
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1147

AKA60242
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

AKS40380
1052
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1114

4UN5_B
1056
LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR-
1118

WP_010922251
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_039695303
1121
--DSD KLIPRKTkKV-YW-DTKKYGGFDSPTVAYSV-FVVAD--VE--KGKAKKLKTVKELVGISIME RSFFEE
1185

WP_045635197
1119
--NSD KLIPRKT-KDILL-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KAAFEE
1183

5AXW_A
853
--EKN -LYKYYEeTGNYL---TKYSKKDNGPVIKKI------------KYYGNKLNAHLDITDDYPNS -VKLSL
912

WP_009880683
799
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELVGITIME RSSFEK
860

WP_010922251
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_011054416
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_011284745
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_011285506
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_011527619
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_012560673
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELVGITIME RSSFEK
1176

WP_014407541
1114
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1175

WP_020905136
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGLTIME RSSFEK
1176

WP_023080005
1114
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1175

WP_023610282
1114
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1175

WP_030125963
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_030126706
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_031488318
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_032460140
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELVGITIME RSSFEK
1176

WP_032461047
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELVGITIME RSSFEK
1176

WP_032462016
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_032462936
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_032464890
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_033888930
940
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1001

WP_038431314
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_038432938
1114
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1175

WP_038434062
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

BAQ51233
1026
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1087

KGE60162
290
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
351

KGE60856
53
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
114

WP_002989955
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_003030002
1094
--ESD KLIPRKT-KNSYW-NPKKYGGFDSPVVAYSI-LVFAD--VE--KGKSKKLRKVQDMVGITIME KKRFEK
1158

WP_003065552
1122
--DSD KLIPRKTkKA-YW-DTKKYGGFDSPTVAYSV-FVVAD--VE--KGKAKKLKTVKELVGISIME RSFFEE
1186

WP_001040076
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040078
1121
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSKFEK
1185

WP_001040080
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040081
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040083
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040085
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040087
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040088
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040089
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040090
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040091
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040092
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVLAD--IK--KGKAQKLKTVKELIGITIME RERFEK
1177

WP_001040094
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040095
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040096
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040097
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040098
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040099
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPKVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040100
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040104
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040105
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_001040106
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK
1177

WP_001040107
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK
1177

WP_001040108
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK
1177

WP_001040109
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK
1177

WP_001040110
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK
1177

WP_015058523
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVLAD--IK--KGKAQKLKTVKELIGITIME RERFEK
1177

WP_017643650
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_017647151
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_017648376
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_017649527
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_017771611
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK
1177

WP_017771984
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVAAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

CFQ25032
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

CFV16040
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

KLJ37842
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

KLJ72361
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

KLL20707
1127
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1191

KLL42645
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK
1177

WP_047207273
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_047209694
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_050198062
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_050201642
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_050204027
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK
1177

WP_050881965
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_050886065
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

AHN30376
1113
--NSD KLIPRKT-KDIYL-DPKKYGGEDSPIVAYSV-LVLAD--IK--KGKAQKLKTVKELIGITIME RERFEK
1177

EA078426
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

CCW42055
1113
--NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK
1177

WP_003041502
1123
--DSS ENLVGVK-RNL---DPKKYGGYAGISNSYAV-LVKAI--IE--KGVKKKETMVLEFQGISILD RITFEK
1185

WP_037593752
1095
--ESD KLIPRKT-KNSYW-NPKKYGGFDSPVVAYSI-LVFAD--VE--KGKSKKLRKVQDMVGITIME KKRFEK
1159

WP_049516684
1095
--ESD KLIPRKT-KNSYW-NPKKYGGFDSPVVAYSI-LVFAD--VE--KGKSKKLRKVQDMVGITIME KKRFEK
1159

GAD46167
1094
--ESD KLIPRKT-KNSYW-NPKKYGGFDSPVVAYSI-LVFAD--VE--KGKSKKLRKVQDMVGITIME KKRFEK
1158

WP_018363470
1126
--DSD KLIPRKTkKV-LW-EPKKYGGEDSPTVAYSV-LVVAD--VE--KGKTKKLKTVKELVGISIME RSFFEK
1190

WP_003043819
1124
--ESA KLIP----RKKGW-DTRKYGGFGSPTVAYSI-LVVAK--VE--KGKAKKLKSVKVLVGITIME KGSYEK
1185

WP_006269658
1094
--ESD KLIPRKT-KNSYW-DPKKYGGFDSPVVAYSI-LVFAD--VE--KGKSKKLRKVQDMVGITIME KKRFEK
1158

WP_048800889
1114
--DSD KLIARKTkEN-YW-DTKKYGGEDSPTVAYSV-LVVAD--IK--KGKAKKLKTVKELVGISIME RPFFEK
1178

WP_012767106
1114
--SFD KLIS----RKHRF-ESSKYGGEGSPTVTYSV-LVVAKskVQ--DGKVKKIKTGKELIGMTLLD KLVFEK
1177

WP_014612333
1114
--SFD KLIS----RKHRF-ESSKYGGEGSPTVTYSV-LVVAKskVQ--DGKVKKIKTGKELIGITLLD KLVFEK
1177

WP_015017095
1114
--SFD KLIS----RKHRF-ESSKYGGEGSPTVTYSV-LVVAKskVQ--DGKVKKIKTGKELIGITLLD KLVFEK
1177

WP_015057649
1114
--SFD KLIS----RKHRF-ESSKYGGEGSPTVTYSV-LVVAKskVQ--DGKVKKIKTGKELIGITLLD KLVFEK
1177

WP_048327215
1114
--SFD KLIS----RKHRF-ESSKYGGEGSPTVTYSV-LVVAKckVQ--DGKVKKIKTGKELIGITLLD KLVFEK
1177

WP_049519324
1114
--SFD KLIS----RKHRF-ESSKYGGEGSPTVTYSV-LVVAKskVQ--DGKVKKIKTGKELIGITLLD KLVFEK
1177

WP_012515931
1095
--NSD KLIP----RKNNW-DTRKYGGFDSPTVAYSV-LVIAK--ME--KGKAKVLKPVKEMVGITIME RTAFEE
1156

WP_021320964
1095
--NSD KLIP----RKNNW-DTRKYGGFDSPTVAYSV-LVIAK--ME--KGKAKVLKPVKEMVGITIME RIAFEE
1156

WP_037581760
1095
--NSD KLIP----RKNNW-DTRKYGGFDSPTVAYSV-LVIAK--ME--KGKAKVLKPVKEMVGITIME RIAFEE
1156

WP_004232481
1124
--DSD KLIPRKTkKL-QW-ETQKYGGEDSPTVAYSV-LVVAD--VE--KGKTRKLKTVKELVGISIME RSSFEE
1188

WP_009854540
1119
--DSD KLIPRKTkKV-YW-DTKKYGGEDSPTVAYSV-FVVAD--VE--KGKAKKLKTVKELVGISIME RSFFEE
1183

WP_012962174
1120
--NSD KLIPRKTkKF-RW-DTPKYGGEDSPNIAYSV-FVIAD--VE--KGKAKKLKTVKELVGISIME RSSFEE
1184

WP_039695303
1121
--DSD KLIPRKTkKV-YW-DTKKYGGFDSPTVAYSV-FVVAD--VE--KGKAKKLKTVKELVGISIME RSFFEE
1185

WP_014334983
1124
--DSD KLIPRKTkKV-YW-NTKKYGGFDSPTVAYSV-LVVAD--IE--KGKAKKLKTVKELVGISIME RSFFEE
1188

WP_003099269
1115
--DSD KLIA----RKKSW-DPKKYGGFDSPIIAYSV-LVVAK--IA--KGKTQKLKTIKELVGIKIME QDEFEK
1176

AHY15608
1115
--DSD KLIA----RKKSW-DPKKYGGFDSPIIAYSV-LVVAK--IA--KGKTQKLKTIKELVGIKIME QDEFEK
1176

AHY17476
1115
--DSD KLIA----RKKSW-DPKKYGGFDSPIIAYSV-LVVAK--IA--KGKTQKLKTIKELVGIKIME QDEFEK
1176

ESR09100
1
----- -------------------------------------------------------------ME QDEFEK
8

AGM98575
1115
--DSD KLIA----RKKSW-DPKKYGGFDSPIIAYSV-LVVAK--IA--KGKTQKLKTIKELVGIKIME QDEFEK
1176

ALF27331
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAN--IE--KGKSKKLKLVKDLVGITIME RTIFEK
1158

WP_018372492
1109
---NN KLIP----RKKDW-SVDKYGGFIEPAESYSLaIFYTD--IN-----GKKPKKKSTIIAISRME KKDYEK
1167

WP_045618028
1125
vvDAS KLTPIKS-G---L-SPEKYGGYARPTIAYSV-LVIAD--IE--KGKAKKLKRIKEMVGITVQD KKKFEA
1188

WP_045635197
1119
--NSD KLIPRKT-KDILL-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KAAFEE
1183

WP_002263549
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002263887
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002264920
1094
--DSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002269043
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002269448
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002271977
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002272766
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002273241
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002275430
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002276448
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002277050
1112
--PLE KLVPLKK----AL-NPEKYGGYQKPTTAYPI-LLIVD---------------TKQLIPISVMD KKRFEQ
1166

WP_002277364
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002279025
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002279859
1094
--DSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002280230
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002281696
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002282247
1112
--PLE KLVPLKK----AL-NPEKYGGYQKPTTAYPI-LLIVD---------------TKQLIPISVMD KKRFEQ
1166

WP_002282906
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002283846
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002287255
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002288990
1094
--NSY KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002289641
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002290427
1094
--DSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002295753
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002296423
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002304487
1108
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1172

WP_002305844
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002307203
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002310390
1094
--DSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_002352408
1094
--DSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_012997688
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_014677909
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_019312892
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_019313659
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_019314093
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_019315370
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_019803776
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_019805234
1094
--DSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_024783594
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KSKSKKLKTVKALVGVTIME KMTFER
1158

WP_024784288
1112
--PLE KLVPLKK----AL-NPEKYGGYQKPTTAYPI-LLIVD---------------TKQLIPISVMD KKRFEQ
1166

WP_024784666
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_024784894
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_024786433
1112
--PLE KLVPLKK----AL-NPEKYGGYQKPTTAYPI-LLIVD---------------TKQLIPISVMD KKRFEQ
1166

WP_049473442
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

WP_049474547
1094
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1158

EMC03581
1087
--NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER
1151

WP_000428612
1122
--NSD KLIPRKT-KDILW-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKRLKTVKTLVGITIME KATFEK
1186

WP_000428613
1120
--NSD KLIPRKT-KDILW-ETTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KAAFEE
1184

WP_049523028
1115
--NSD KLIPRKT-KNVQL-DTTKYGGFDSPVIAYSI-LLVAD--VE--KGKSKKLKTVKSLIGITIME KVKFEA
1179

WP_003107102
1084
--DSD KLIP----RKNNW-DPKKYGGFGSPIIAYSV-LVVAK--VT--KGKSQKTKSVKELVGITIME QNEFEK
1145

WP_054279288
1116
--KSS KLIP----RKNKWrDTTKYGGFNTPTVAYSV-LVVAK--VE--KGKAKKLKPVKELVGITIME RTKFEA
1178

WP_049531101
1125
vvDAS KLIPIKS-G---L-SPEKYGGYARPTIAYSV-LVIAD--IE--KGKAKKLKRIKEMVGITIQD KKKFEA
1188

WP_049538452
1125
vvDAS KLIPIKS-G---L-SPEKYGGYARPTIAYSV-LVIAD--IE--KGKTKKLKRIKEMIGITVQD KKIFES
1188

WP_049549711
1127
vvDAS KLIPIKS-G---L-SPEKYGGYARPTIAYSV-LVIAD--IE--KGKTKKLKRIKEMVGITIQD KKKFEA
1190

WP_007896501
1121
--NSD KLIE----RKKGW-DPKKYGGFDSPNTAYSI-FVVAK--VA--KRKAQKLKTVKEIVGITIME QAEYEK
1182

EFR44625
1073
--NSD KLIE----RKKGW-DPKKYGGFDSPNTAYSI-FVVAK--VA--KRKAQKLKTVKEIVGITIME QAEYEK
1134

WP_002897477
1119
--NSD KLIPRKT-KDILW-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KAAFEE
1183

WP_002906454
1124
vvDAS KLIPIKS-S---L-SPEKYGGYARPTIAYSV-LVIAD--IEkgKGKAKKLKRIKEIVGITIQD KKKFES
1189

WP_009729476
1120
--NSD KLIPRKT-KDILW-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KDAFEK
1184

CQR24647
1110
--GSD KLIARKT-KNNYL-STQKYGGFDSPTVAYSI-MFVAD--IE--KGKSKRLKTVKEMIGITIME RSRFES
1174

WP_000066813
1124
--NSD KLIPRKT-KEILW-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KATFEK
1188

WP_009754323
1120
--NSD KLIPRKT-KDILW-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KAAFEK
1184

WP_044674937
1113
--DSD KLIPRKT-EKFYL-DTKKYGGFDSPTIAYSV-LLIAD--IE--KGKAKKLKRVKELIGITIME RMAFEK
1177

WP_044676715
1115
--DSD KLIPRKT-EKFYL-DTKKYGGFDSPTIAYSV-LLIAD--IE--KGKAKKLKRVKELIGITIME RMAFEK
1179

WP_044680361
1115
--DSD KLIPRKT-EKFYL-DTKKYGGFDSPTIAYSV-LLIAD--IE--KGKAKKLKRVKELIGITIME RMAFEK
1179

WP_044681799
1113
--DSD KLIPRKT-EKFYL-DTKKYGGFDSPTIAYSV-LLIAD--IE--KGKAKKLKRVKELIGITIME RMAFEK
1177

WP_049533112
1123
--DSS ENLVGVK-RNL---DPKKYGGYAGISNSYAV-LVKAI--IE--KGVKKKETMVLEFQGISILD RITFEK
1185

WP_029090905
1062
--SSS KTIP----LKKHL-DTAIYGGYTAVNYASYA---LIQ--FK----KGRKLK--REIIGIPLAV QTRIDN
1117

WP_006506696
1085
haDKG AVVP---vNKNRS-DVHKYGGFSG--LQYTI----VA--IEggKKKGKKTELVKKISGVPLHL KAASIN
1149

AIT42264
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_034440723
1093
k-KTE KRIP----IKNNL-DPNIYGGYIEEKMAYYI----AInyLE--NGKTKK-----AIVGISIKD KKDFEG
1149

AKQ21048
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

WP_004636532
1093
--DSS KLIP----VKEGM-DPQKYGGLSQVSEAFAV-VIT----HE--KGKKKQLK--SDLISIPIVD QKAYEQ
1150

WP_002364836
1099
--PSN KLIP----VKNGL-DPQKYGGFDSPIVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ
1156

WP_016631044
1050
--PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ
1107

EMS75795
835
--KPD KLIQ----RKAGW-DVSKYGGFGSPVVAYAV-AFI----YE--KGKAR--KKAKAIEGITIMK QSLFEQ
892

WP_002373311
1099
--PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ
1156

WP_002378009
1099
--PSN KLIP----VKNGL-DPQKYGGFDSPIVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ
1156

WP_002407324
1099
--PSN KLIP----VKNGL-DPQKYGGFDSPIVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ
1156

WP_002413717
1099
--PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ
1156

WP_010775580
1101
--PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ
1158

WP_010818269
1099
--PSN KLIP----VKNGL-DPQKYGGFDSPIVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ
1156

WP_010824395
1099
--PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ
1156

WP_016622645
1099
--PSN KLIP----VKNGL-DPQKYGGFDSPIVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ
1156

WP_033624816
1099
--PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ
1156

WP_033625576
1099
--PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTKFEQ
1156

WP_033789179
1099
--PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ
1156

WP_002310644
1101
--DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ
1158

WP_002312694
1102
--DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ
1159

WP_002314015
1102
--DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ
1159

WP_002320716
1102
--DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ
1159

WP_002330729
1101
--DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ
1158

WP_002335161
1102
--DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ
1159

WP_002345439
1102
--DSS KLLP----RKNNW-DPTKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ
1159

WP_034867970
1092
--KPD KLIE----RKNNW-DVTKYGGFGSPVIAYAI-AFV----YA--KGKTQ--KKTRAIEGITIME QAAFEK
1149

WP_047937432
1102
--DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ
1159

WP_010720994
1092
--KPD KLIE----RKNNW-DVTKYGGFGSPVIAYAI-AFV----YA--KGKTQ--KKTKAIEGITIME QAAFEK
1149

WP_010737004
1092
--KPD KLIE----RKNNW-DVTKYGGFGSPVIAYAI-AFV----YA--KGKTQ--KKTRAIEGITIME QAAFEK
1149

WP_034700478
1092
--KPD KLIE----RKNNW-DVTKYGGFGSPVIAYAI-AFV----YA--KGKTQ--KKTRAIEGITIME QAAFEK
1149

WP_007209003
1090
--ESQ KLIR----RKQQW-NTKKYGGFDSPVVAYAI---LLS--FD--KGK-RKARSFK-IVGITIQD RESFEG
1147

WP_023519017
1086
--NPE KLIP----RKASL-DPLKYGGYGSPLVAYTV-IFI----FE--KGKQK--KVTKGIEGITVME QLRFEQ
1143

WP_010770040
1097
--DSD KLIS----RKTNW-SPKLYGGFDSPQVAYSV-II--T--YE--KGK-KKVRA-KAIVGITIME QSLFKK
1154

WP_048604708
1094
--DSD KLIS----RKKEW-DTTKYGGFDSPNVAYSV-VI--R--YE--KGK-TRKLV-KTIVGITIME RAAFEK
1151

WP_010750235
1095
--KPD KLIK----RKNNW-DVTKYGGFGSPVVAYAV-VFT----YE--KGKNH--KKAKAIEGITIME QALFEK
1152

AII16583
1154
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1215

WP_029073316
1100
hsEKG AKVP---vNKLRS-NVHKYGGFEG--LKYSI----VA--IKgkKKKGKKIIDVNKLVGIPLMY KNVDDE
1164

WP_031589969
1100
nsDKD ATVP---vNKYRS-NVNKYGGFSG--VNSFI----VA--IKgkKKKGKKVIEVNKLTGIPLMY KNADEE
1164

KDA45870
1079
--DSG KLLP----RKEGL-DPVKYGGYAKAVESYAV-LITAD-eVK--KGKTKKVKT---LVNIPIID SKKYEA
1138

WP_039099354
1098
k-ASG QLIPAKQdRPTAL-----YGGYSGKTVAYMC---IVR--IKnkKGDLYKVCGVETSWLAQLKQ KKAFLK
1170

AKP02966
1119
k---- KLIA----QKKDM-DPNIYGGFSGDNKSSIT---IVK--ID-----NNKIKPVA--IPIRLIN ----DK
1172

WP_010991369
1096
--NSS KLIP----RKTNW-DPMKYGGLDSPNMAYAV-VI--E--YA--KGK-NKLVFEKKIIRVTIME RKAFEK
1154

WP_033838504
1096
--NSS KLIS----RKTNW-DPMKYGGLDSPNMAYAV-VI--E--YA--KGK-NKLVFEKKIIRVTIME RKAFEK
1154

EHN60060
1099
--NSS KLIS----RKTNW-DPMKYGGLDSPNMAYAV-VI--E--YA--KGK-NKLVFEKKIIRVTIME RKAFEK
1157

EFR89594
865
--NSS KLIP----RKTNW-DPMKYGGLDSPNMAYAV-VI--E--YA--KGK-NKLVFEKKIIRVTIME RKAFEK
923

WP_038409211
1096
--NSS KLIS----RKADW-NPIKYGGFDGSNMAYSI-VI--E--YE--KRK-KKTVIKKELIQINIME RVAFEK
1154

EFR95520
715
--NSS KLIS----RKADW-NPIKYGGFDGSNMAYSI-VI--E--YE--KRK-KKTVIKKELIQINIME RVAFEK
773

WP_003723650
1096
--NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KKIVIEKKLIQINIME RKMFEK
1154

WP_003727705
1096
--NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KKIVIEKKLIQINIME RKMFEK
1154

WP_003730785
1096
--NSS KLIP----RKENW-DPVKYGGLDSPNMAYAV-II--E--HA--KGK-KKIVIEKKLIQINIME RKMFEK
1154

WP_003733029
1096
--KSN KLIP----RKKDW-DPIKYGGFDGSKMAYAI-II--E--YE--KQK-RKVRIEKKLIQINIME REAFEK
1154

WP_003739838
1096
--NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KKVVFEKKIIRITIME RKAFEK
1154

WP_014601172
1096
--NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KKLIFEKKIIRITIME RKMFEK
1154

WP_023548323
1096
--DSS KLIP----KKTNL-NPIKYGGFEGSNMAYAI-II--E--HE--KRK-KKVTIEKKLIQINIME RKAFEK
1154

WP_031665337
1096
--NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KRIVIEKKLIQINIME RKMFEK
1154

WP_031669209
1096
--KSN KLIP----RKKDW-DPIKYGGFDGSKMAYAI-II--E--YE--KQK-RKVRIEKKLIQINIME REAFEK
1154

WP_033920898
1096
--DSS KLIP----KKTNL-NPIKYGGFEGSNMAYAI-II--E--HE--KRK-KKVTIEKKLIQINIME RKAFEK
1154

AKI42028
1099
--NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KKLIFEKKIIRITIME RKMFEK
1157

AKI50529
1099
--DSS KLIP----KKTNL-NPIKYGGFEGSNMAYAI-II--E--HE--KRK-KKVTIEKKLIQINIME RKAFEK
1157

EFR83390
544
--NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KKIVIEKKLIQINIME RKMFEK
602

WP_046323366
1096
--NSS KLIP----RKADW-DPIKYGGFDGSNMAYAI-VI--E--HE--KRK-KKTVIKKELIQINIME RTAFEK
1154

AKE81011
1131
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1192

CUO82355
1089
hsAKG AVIP---vNKNRK-DVNKYGGFSG--LQYVI----AA--IEgtKKKGKKLVKVRKLSGIPLYL KQADIK
1153

WP_033162887
1090
hsEKG ATVP---1NKYRA-DVHKYGGFGN--VQSII----VA--IEgkKKKGKKLIDVRKLTSIPLHL KNAPVE
1154

AGZ01981
1148
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1209

AKA60242
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

AKS40380
1115
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1176

4UN5_B
1119
--NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK
1180

WP_010922251
1177
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -G custom character

LQKGNELALPSKYVNFLYLA
1239

WP_039695303
1186
NPV---EFLE---NKGYHN--I-REDKLIK--LPKYSLFE---FEGGRRRLLAS ASELQKGNEMVLPGYLVELLYHA
1248

WP_045635197
1184
NPI---TFLE---NKGYHN--V-RKENILC--LPKYSLFE---LENGRRRLLAS AKELQKGNEIVLPVYLTTLLYHS
1246

5AXW_A
913
KPYrfdVYLD---NGVYKFvtV-KNLDVIK----KENYYE---VNSKAYEEAKK -KKISNQAEFIASFYNNDLIKIN
978

WP_009880683
861
DPV---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
923

WP_010922251
1177
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_011054416
1177
DPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_011284745
1177
NPI---DFLE---AKGYKE--V-RKDLIVK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_011285506
1177
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_011527619
1177
NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_012560673
1177
DPV---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_014407541
1176
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1238

WP_020905136
1177
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_023080005
1176
NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1238

WP_023610282
1176
NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1238

WP_030125963
1177
NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_030126706
1177
NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_031488318
1177
NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_032460140
1177
DPV---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_032461047
1177
DPV---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_032462016
1177
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_032462936
1177
NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_032464890
1177
NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_033888930
1002
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1064

WP_038431314
1177
NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_038432938
1176
NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1238

WP_038434062
1177
NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

BAQ51233
1088
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1150

KGE60162
352
DPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
414

KGE60856
115
DPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
177

WP_002989955
1177
NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_003030002
1159
HPV---DFLE---QRGYRN--V-RLEKIIK--LPKYSLFE---LENKRRRLLAS ARELQKGNELVIPQRFTTLLYHS
1221

WP_003065552
1187
NPV---EFLE---NKGYHN--I-REDKLIK--LPKYSLFE---FEGGKRRLLAS ASELQKGNEMVIPGHLVKLLYHA
1249

WP_001040076
1178
NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040078
1186
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1248

WP_001040080
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040081
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGETIDRLQKGNELALPTQFMKFLYLA
1240

WP_001040083
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040085
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040087
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040088
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040089
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040090
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040091
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040092
1178
NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

WP_001040094
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040095
1178
NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

WP_001040096
1178
NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

WP_001040097
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS ADELQKGNELALPTQFMKFLYLA
1240

WP_001040098
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040099
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040100
1178
NPS---AFLE---SKGYLD--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040104
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040105
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_001040106
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

WP_001040107
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

WP_001040108
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

WP_001040109
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

WP_001040110
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

WP_015058523
1178
NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

WP_017643650
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS ADELQKGNELALPTQFMKFLYLA
1240

WP_017647151
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_017648376
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_017649527
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_017771611
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

WP_017771984
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

CFQ25032
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

CFV16040
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

KLJ37842
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

KLJ72361
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

KLL20707
1192
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1254

KLL42645
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

WP_047207273
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_047209694
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_050198062
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_050201642
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_050204027
1178
NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

WP_050881965
1178
NLS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_050886065
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

AHN30376
1178
NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA
1240

EA078426
1178
NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

CCW42055
1178
NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA
1240

WP_003041502
1186
DKR---AFLL---GKGYKD--I-K--KIIE--LPKYSLFE---LKDGSRRMLAS RGEIHKGNELFVPQKFTTLLYHA
1253

WP_037593752
1160
NPV---DFLE---QRGYRN--V-RLEKIIK--LPKYSLFE---LENKRRRLLAS ARELQKGNELVIPQRFTTLLYHS
1222

WP_049516684
1160
HPV---DFLE---QRGYRN--V-RLEKIIK--LPKYSLFE---LENKRRRLLAS ARELQKGNELVIPQRFTTLLYHS
1222

GAD46167
1159
NPV---DFLE---QRGYRN--V-RLEKIIK--LPKYSLFE---LENKRRRLLAS ARELQKGNELVIPQRFTTLLYHS
1221

WP_018363470
1191
NPV---EFLK---NKGYQN--V-QEDKLMK--LPKYSLFE---FEGGRRRLLAS ATELQKGNEIMLSAHLVALLYHA
1253

WP_003043819
1186
DPI---GFLE---AKGYKD--I-KKELIFK--LPKYSLFE---LENGRRRMLAS --ELQKANELVLPQHLVRLLYYT
1248

WP_006269658
1159
NPV---DFLE---QRGYRN--V-RLEKIIK--LPKYSLFE---LENKRRRLLAS AKELQKGNELVIPQRFTTLLYHS
1221

WP_048800889
1179
NPI---MFLE---SKGYRN--I-QKDKLIK--LPKYSLFE---FEGGRRRLLAS AVELQKGNEMVLPQYLNNLLYHA
1241

WP_012767106
1178
NPL---KFIE---DKGYGN--V-QIDKCIK--LPKYSLFE---FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY--
1245

WP_014612333
1178
NPL---KFIE---DKGYGN--V-QIDKCIK--LPKYSLFE---FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY--
1245

WP_015017095
1178
NPL---KFIE---DKGYGN--V-QIDKCIK--LPKYSLFE---FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY--
1245

WP_015057649
1178
NPL---KFIE---DKGYGN--V-QIDKCIK--LPKYSLFE---FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY--
1245

WP_048327215
1178
NPL---KFIE---DKGYGN--V-QIDKCIK--LPKYSLFE---FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY--
1245

WP_049519324
1178
NPL---KFIE---DKGYGN--V-QIDKCIK--LPKYSLFE---FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY--
1245

WP_012515931
1157
NPV---VFLE---ARGYRE--I-QEHLIIK--LPKYSLFE---LENGRRRLLAS -SELQKGNELFLPVDYMTFLYLA
1219

WP_021320964
1157
NPV---VFLE---AKGYRE--I-QEHLIIK--LPKYSLFE---LENGRRRLLAS -SELQKGNELFLPVDYMTFLYLA
1219

WP_037581760
1157
NPV---VFLE---AKGYRE--I-QEHLIIK--LPKYSLFE---LENGRRRLLAS -SELQKGNELFLPVDYMTFLYLA
1219

WP_004232481
1189
NPV---SFLE---KKGYHN--V-QEDKLIK--LPKYSLFE---FEGGRRRLLAS ATELQKGNEVVLPQYMVNLLYHS
1251

WP_009854540
1184
NPV---EFLE---NKGYHN--I-REDKLIK--LPKYSLFE---FEGGRRRLLAS ASELQKGNEMVLPGYLVELLYHA
1246

WP_012962174
1185
NPV---VFLE---KKGYQN--V-QEDNLIK--LPKYSLFE---FEGGRRRLLAS ASELQKGNEVVLSRHLVELLYHA
1247

WP_039695303
1186
NPV---EFLE---NKGYHN--I-REDKLIK--LPKYSLFE---FEGGRRRLLAS ASELQKGNEMVLPGYLVELLYHA
1248

WP_014334983
1189
NPV---SFLE---KKGYHN--V-QEDKLIK--LPKYSLFE---FEGGRRRLLAS ATELQKGNEVMLPAHLVELLYHA
1251

WP_003099269
1177
DPI---AFLE---KKGYQD--I-QTSSIIK--LPKYSLFE---LENGRKRLLAS --ELQKGNELALPNKYVKFLYLA
1239

AHY15608
1177
DPI---AFLE---KKGYQD--I-QTSSIIK--LPKYSLFE---LENGRKRLLAS --ELQKGNELALPNKYVKFLYLA
1239

AHY17476
1177
DPI---AFLE---KKGYQD--I-QTSSIIK--LPKYSLFE---LENGRKRLLAS --ELQKGNELALPNKYVKFLYLA
1239

ESR09100
9
DPI---AFLE---KKGYQD--I-QTSSIIK--LPKYSLFE---LENGRKRLLAS -KELQKGNELALPNKYVKFLYLA
71

AGM98575
1177
DPI---AFLE---KKGYQD--I-QTSSIIK--LPKYSLFE---LENGRKRLLAS --ELQKGNELALPNKYVKFLYLA
1239

ALF27331
1159
NPV---AFLE---RKGYRN--V-QEENIVK--LPKYSLFE---LENGRRRLLAS ARELQKGNEIVLPNHLGTMLYHA
1221

WP_018372492
1168
EPEr---FLA---QKGFER--V-EKT--IK--LPKYSLFE---MEKGRRRLLAS SGELQKGNQVLLPEHLIRLLSYA
1228

WP_045618028
1189
NPI---AYLE---ECGYKN--I-NPNLIIK--LPKYSLFE---FNNGQRRLLAS SIELQKGNELIVPYHFTALLYHA
1251

WP_045635197
1184
NPI---TFLE---NKGYHN--V-RKENILC--LPKYSLFE---LENGRRRLLAS AKELQKGNEIVLPVYLTTLLYHS
1246

WP_002263549
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002263887
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002264920
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002269043
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002269448
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002271977
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002272766
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002273241
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002275430
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002276448
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002277050
1167
NPV---KFLK---DKGYQQ--I-EKNNFVK--LPKYTLVD---IGNGIKRLWAS SKEVHKGNQLVVSKKSQDLLYHA
1229

WP_002277364
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002279025
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002279859
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002280230
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002281696
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002282247
1167
NPV---KFLK---DKGYQQ--I-EKNNFVK--LPKYTLVD---IGNGIKRLWAS SKEVHKGNQLVVSKKSQDLLYHA
1229

WP_002282906
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002283846
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002287255
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002288990
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002289641
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002290427
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002295753
1159
DPI---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002296423
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002304487
1173
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLETLLYHA
1235

WP_002305844
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002307203
1159
DPI---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002310390
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_002352408
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPDHLGTLLYHA
1221

WP_012997688
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_014677909
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_019312892
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_019313659
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_019314093
1159
DPI---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_019315370
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_019803776
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_019805234
1159
DPI---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_024783594
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_024784288
1167
NPV---KFLK---DKGYQQ--I-EKNNFVK--LPKYTLVD---IGNGIKRLWAS SKEVHKGNQLVVSKKSQDLLYHA
1229

WP_024784666
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_024784894
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_024786433
1167
NPV---KFLK---DKGYQQ--I-EKNNFVK--LPKYTLVD---IGNGIKRLWAS SKEVHKGNQLVVSKKSQDLLYHA
1229

WP_049473442
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

WP_049474547
1159
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1221

EMC03581
1152
DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA
1214

WP_000428612
1187
SPI---AFLE---NKGYHN--V-RKENILC--LPKYSLFE---LKNGRRRMLAS AKELQKGNEIVLPVHLTTLLYHA
1249

WP_000428613
1185
NPI---TFLE---NKGYHN--V-RKENILC--LPKYSLFE---LENGRRRLLAS AKELQKGNEIVLPVYLTTLLYHS
1247

WP_049523028
1180
NPV---AFLE---GKGYQN--V-VEENIIR--LPKYSLFE---LENGRRRMLAS AKELQKGNEMVLPSYLIALLYHA
1242

WP_003107102
1146
DRI---TFLE---KKGYQD--I-QESLIIK--LPKFSLFE---LENGRKRLLAS --ELQKGNELSLPNKYIQFLYLA
1208

WP_054279288
1179
NPI---AFLE---SKGYHD--I-QEHLMIT--LPKYSLFE---LENGRRRLLAS --ELQKGNEMVLPQHLVTFLYRV
1241

WP_049531101
1189
NPT---AYLE---EYGYKN--I-NPNLIIK--LPKYSLFK---FNDGQRRLLAS SIELQKGNELILPYHFTTLLYHA
1251

WP_049538452
1189
NPI---AYLE---ECGYKN--I-NPNLIIK--LPKYSLFE---FNGGQRRLLAS SIELQKGNELILPYHFTALLYHT
1251

WP_049549711
1191
NPI---AYLE---ECGYKN--I-NPNLIIK--LPKYSLFE---FNGGQRRLLAS SIELQKGNELILPYHFTALLYHA
1253

WP_007896501
1183
DNI---AFLE---KKGYQD--I-QEKLLIK--LPKYSLFE---LENGRRRLLAS --EFQKGNELALSGKYMKFLYLA
1245

EFR44625
1135
DNI---AFLE---KKGYQD--I-QEKLLIK--LPKYSLFE---LENGRRRLLAS --EFQKGNELALSGKYMKFLYLA
1197

WP_002897477
1184
NPI---TFLE---NKGYHN--V-RKENILC--LPKYSLFE---LENGRRRLLAS AKELQKGNEIVLPVCLTTLLYHS
1246

WP_002906454
1190
NPV---TYLE---ECGYKN--I-NSNLIIK--LPKYSLFE---FNDGQRRLLAS SIELQKGNELILPYHLTALLYHA
1252

WP_009729476
1185
NPI---AFLE---NKGYHN--V-CKENILC--LPKYSLFE---LENGRRRLLAS AKELQKCNEIVLPVYLTTLLYHS
1247

CQR24647
1175
NSV---TFLE---EKGYRN--I-RENTIIK--FPKYSLFE---LENGRRRLLAS AIELQKGNEMFLPQQFVNLLYHA
1237

WP_000066813
1189
NPI---TFLE---NKGYHN--V-RKENILC--LPKYSLFE---LESGRRRMLAS AKELQKGNEIVLPVYLTTLLYHS
1251

WP_009754323
1185
NPI---TFLE---NKGYHN--V-RKENILC--LPKYSLFE---LENGRRRLLAS AKELQKGNEIVLPVYLTTLLYHS
1247

WP_044674937
1178
NPI---EFLE---HKGYKN--I-LEKNIIK--LPKYSLFE---LENGRRRLLAS AKELQKGNEMILPPHLVTLLYHS
1240

WP_044676715
1180
NPI---EFLE---HKGYKN--I-LEKNIIK--LPKYSLFE---LENGRRRLLAS AKELQKGNEMILPPHLVTLLYHS
1242

WP_044680361
1180
NPI---EFLE---HKGYKN--I-LEKNIIK--LPKYSLFE---LENGRRRLLAS AKELQKGNEMILPPHLVTLLYHS
1242

WP_044681799
1178
NPI---EFLE---HKGYKN--I-LEKNIIK--LPKYSLFE---LENGRRRLLAS AKELQKGNEMILPPHLVTLLYHS
1240

WP_049533112
1186
DKR---AFLL---GKGYKD--I-K--KIIE--LPKYSLFE---LKDGSRRMLAS RGEIHKGNELFVPQKFTTLLYHA
1253

WP_029090905
1118
SETslqAYIA---EQIKSE--VeILN----grILKYQLIS----NNGNRLYIAG -SERHNARQLIVSDEAAKVIWLI
1181

WP_006506696
1150
EKI---NYIE--eKEGLSD--VrIIK---Dn-IPVNQMIEm----DGGEYLLTS --EYVNARQLVLNEKQCALIADI
1211

AIT42264
1177
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_034440723
1150
QTT---EYLG---KIGFNK--AsIIN---S--FKNYTLFE---LENGSRRMIVG KGELQKGNQMYLPQNLLEFVYHL
1217

AKQ21048
1177
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

WP_004636532
1151
HPT---AYLE---EAGYNN--P-TV--LHE--LFKYQLFE---LEDGSRRMIAS AKEFQKGNQMVLPLELVELLYHA
1211

WP_002364836
1157
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA
1217

WP_016631044
1108
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA
1168

EM575795
893
DPI---GFLS---NKGYSN--V-TKF--IK--LSKYTLYE---LENGRRRMVAS -KEAQKANSFILPEKLVTLLYHA
953

WP_002373311
1157
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA
1217

WP_002378009
1157
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYQ---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA
1217

WP_002407324
1157
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA
1217

WP_002413717
1157
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA
1217

WP_010775580
1159
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA
1219

WP_010818269
1157
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA
1217

WP_010824395
1157
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA
1217

WP_016622645
1157
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA
1217

WP_033624816
1157
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPERLLTLLYHA
1217

WP_033625576
1157
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA
1217

WP_033789179
1157
NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA
1217

WP_002310644
1159
SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA
1219

WP_002312694
1160
SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA
1220

WP_002314015
1160
SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA
1220

WP_002320716
1160
SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA
1220

WP_002330729
1159
SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA
1219

WP_002335161
1160
SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA
1220

WP_002345439
1160
SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA
1220

WP_034867970
1150
DPT---TFLK---EKGFPQ--V-TEF--IK--LPKYTLFE---FDNGRRRFLAS -KESQKGNPFILSDQLVTLLYHA
1210

WP_047937432
1160
SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA
1220

WP_010720994
1150
DPT---TFLK---DKGFPQ--V-TEF--IK--LPKYTLFE---FDNGRRRFLAS -KESQKGNPFILSDQLVTLLYHA
1210

WP_010737004
1150
DPT---TFLK---EKGFPQ--V-TEF--IK--LPKYTLFE---FDNGRRRFLAS -KESQKGNPFILSDQLVTLLYHA
1210

WP_034700478
1150
DPT---TFLK---DKGFPH--V-TEF--IK--LPKYTLFE---FDNGRRRFLAS -KESQKGNPFILSDQLVTLLYHA
1210

WP_007209003
1148
NPI1---YLS---KKDYHN---pKVEAI----LPKYSLFE---FENGRRRMVAS -SETQKGNQLIIPGHLMELLYHS
1208

WP_023519017
1144
DPR---EFLK---TKGYEG--V-KQW--LI--LPKYILFE---AQGGYRRMIAS -QETQKANSLILPENLVTLLYHA
1204

WP_010770040
1155
DPV---SLLE---EKGYAN--P-EV--LIH--LPKYTLYE---LENGRRRLLAS ANEAQKGNQLVLPASLVTLLYHA
1215

WP_048604708
1152
NER---EFLK---NKGYQN--P-QI--CMK--LPKYSLYE---FDDGRRRLLAS AKEAQKGNQMVLPAHLVTFLYHA
1212

WP_010750235
1153
DPI---SFLI---EKGYSN--V-NQF--IK--LPKYTLFE---LANGQRRMLAS -QELQKANSFILPEKLVTLLYHA
1213

AII16583
1216
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1278

WP_029073316
1165
TKI---NYIK--eSEGLEE--VkIIK---E--ILKNQLIET----NGGLFYVTS --EIVNARQLILDFNCTRIIDGI
1225

WP_031589969
1165
IKI---NYLK--qAEDLEE--VqIGK---E--ILKNQLIEk----DGGLYYIVA --EIINAKQLILNESQTKLVCEI
1225

KDA45870
1139
DPT---AYLA---SRGYTNvtNsFIL-------PKYSLLEd---PEGRRRYLAS -KEFQKANELILPQHLVELLYWV
1199

WP_039099354
1171
QKI-spQFTKv---KKQKGtiV-KVVEDFEv-IAPHILINqrfFDNGQELTLGS ----HNEQELILDKTAVKLLNGA
1241

AKP02966
1173
KTL--qNWLE---ENVKHKksIqIIK---Nn-VPIGQIIY------SKKVGLLS -REIANRQQLILPPEHSALLRIL
1237

WP_010991369
1155
DEK---AFLE---EQGYRQ--P-KV--LAK--LPKYTLYE---CEEGRRRMLAS ANEAQKGNQQVLPNHLVTLLHHA
1215

WP_033838504
1155
DEK---AFLE---EQGYRQ--P-KV--LAK--LPKYTLYE---CEEGRRRMLAS ANEAQKGNQQVLPNHLVTLLHHV
1215

EHN60060
1158
DEK---AFLE---EQGYRQ--P-KV--LAK--LPKYTLYE---CEEGRRRMLAS ANEAQKGNQQVLPNHLVTLLHHV
1218

EFR89594
924
DEK---AFLE---EQGYRQ--P-KV--LAK--LPKYTLYE---CEEGRRRMLAS ANEAQKGNQQVLPNHLVTLLHHA
984

WP_038409211
1155
DQK---AFLE---EKGYYS--P-KV--LTK--IPKYTLYE---CENGRRRMLGS ANEAQKGNQMVLPNHLMTLLYHA
1215

EFR95520
774
DQK---AFLE---EKGYYS--P-KV--LTK--IPKYTLYE---CENGRRRMLGS ANEAQKGNQMVLPNHLMTLLYHA
834

WP_003723650
1155
DEE---AFLE---EKGYRH--P-KV--LTK--LPKYTLYE---CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA
1215

WP_003727705
1155
DEE---AFLE---EKGYHQ--P-KV--LTK--LPKYTLYE---CEKGRRRMLSS ANEAQKGNQLVLSNHLVSLLYHA
1215

WP_003730785
1155
DEE---AFLE---EKGYHQ--P-KV--LTK--LPKYTLYE---CEKGRRRMLSS ANEAQKGNQLVLSNHLVSLLYHA
1215

WP_003733029
1155
DEK---TFLE---EKGYHQ--P-KV--LIK--VPKYTLYE---CKNGRRRMLGS ANEAHKGNQMLLPNHLMALLYHA
1215

WP_003739838
1155
DEK---SFLE---KQGYRQ--P-KV--LTK--LPKYTLYE---CENGRRRMLAS ANEAQKGNQQVLKGQLITLLHHA
1215

WP_014601172
1155
DEE---AFLE---EKGYRH--P-KV--LTK--LPKYTLYE---CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA
1215

WP_023548323
1155
DEK---VFLE---GKGYHQ--P-KV--LTK--LPKYALYE---CENGRRRMLGS ANEVHKGNQMLLPNHLMTLLYHA
1215

WP_031665337
1155
DEE---AFLE---EKGYRH--P-KV--LTK--LPKYTLYE---CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA
1215

WP_031669209
1155
DEK---TFLE---EKGYHQ--P-KV--LIK--VPKYTLYE---CENGRRRMLGS ANEAHKGNQMLLPNHLMALLYHA
1215

WP_033920898
1155
DEK---VFLE---GKGYHQ--P-KV--LTK--LPKYALYE---CENGRRRMLGS ANEVHKGNQMLLPNHLMTLLYHA
1215

AKI42028
1158
DEE---AFLE---EKGYRH--P-KV--LTK--LPKYTLYE---CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA
1218

AKI50529
1158
DEK---VFLE---GKGYHQ--P-KV--LTK--LPKYALYE---CENGRRRMLGS ANEVHKGNQMLLPNHLMTLLYHA
1218

EFR83390
603
DEE---AFLE---EKGYRH--P-KV--LTK--LPKYTLYE---CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA
663

WP_046323366
1155
DQK---EFLE---GKGYRN--P-KV--ITK--IPKYTLYE---CENGRRRMLGS ANEAQKGNQMVLPNHLMTLLYHA
1215

AKE81011
1193
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1255

CUO82355
1154
EQI---EYVE--kEEKLSD--VkIIK---Nn-IPLNQLIEi----DGRQYLLTS --ECVNAMQLVLNEEQCKLIADI
1215

WP_033162887
1155
EQL---SYIAspeHEDLID--VrIVK---E--ILKNQLIEi----DGGLYYVTS --EYVTARQLSLNEQSCKLISEI
1217

AGZ01981
1210
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1272

AKA60242
1177
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

AK540380
1177
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1239

4UN5_B
1181
NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA
1243

WP_010922251
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_039695303
1249
HRAD----NFNS-TEYLN--YVSEHKKEFEKVLSCVEDFANLYVDVE--KNLSKIR-A VAD-SM---DNFSIEE--
1308

WP_045635197
1247
KNVH----KLDE-PGHLE--YIQKHRNEFKDLLNLVSEFSQKYVLAD--ANLEKIK-S LYA-DN---EQADIEI--
1306

5AXW_A
979
GELYRVIgVNND1LNRIE---VNMIDITYREYLENMNDKRPPRIIKTiaSKTQSIK-K LYEvKSk--KHPQIIKkg
1056

WP_009880683
924
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
989

WP_010922251
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_011054416
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_011284745
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_011285506
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_011527619
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_012560673
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_014407541
1239
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1304

WP_020905136
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_023080005
1239
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1304

WP_023610282
1239
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1304

WP_030125963
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_030126706
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_031488318
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_032460140
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_032461047
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_032462016
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_032462936
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_032464890
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_033888930
1065
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1130

WP_038431314
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_038432938
1239
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1304

WP_038434062
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

BAQ51233
1151
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1216

KGE60162
415
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
480

KGE60856
178
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
243

WP_002989955
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_003030002
1222
YQIE----KNYE-PEHRE--YVEKHKDEFKELLEYISVFSRKYVLAD--NNLTKIE-M LFS-KN---KDAEVSS--
1281

WP_003065552
1250
QRIN----SENS-TKYLD--YVSAHKKEFEKVLSCVEDFANLYVDVE--KNLSKIR-A VAD-SM---DNFSIEE--
1309

WP_001040076
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDIFQIINDFSKRVILAD--ANLEKIN-R LYQ-DNk--ENIPVDE--
1306

WP_001040078
1249
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1314

WP_001040080
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040081
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040083
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040085
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040087
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040088
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040089
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040090
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040091
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040092
1241
SRYNESKgKPEEiEKKQE--FVNQHISYFDDILQLINDFSKRVILAD--ANLEKIN-K LYS-DNk--DNTPVDE--
1306

WP_001040094
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE--
1306

WP_001040095
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE--
1306

WP_001040096
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE--
1306

WP_001040097
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE--
1306

WP_001040098
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE--
1306

WP_001040099
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE--
1306

WP_001040100
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE--
1306

WP_001040104
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040105
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040106
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040107
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040108
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040109
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_001040110
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_015058523
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYS-DNk--DNTPVDE--
1306

WP_017643650
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE--
1306

WP_017647151
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_017648376
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_017649527
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_017771611
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_017771984
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

CFQ25032
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

CFV16040
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

KLJ37842
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

KLJ72361
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

KLL20707
1255
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1320

KLL42645
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_047207273
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_047209694
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE--
1306

WP_050198062
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_050201642
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_050204027
1241
SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_050881965
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_050886065
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

AHN30376
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYS-DNk--DNTPVDE--
1306

EA078426
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

CCW42055
1241
SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE--
1306

WP_003041502
1254
KRIN----NPIN-KDHIE--YVKKHRDDFKELLNYVLEFNEKYVGAT--KNGERLK-E AVA-DF---DSKSNEE--
1313

WP_037593752
1223
YQIE----KNYE-PEHRE--YVEKHKDEFKELLEYISVFSRKYVLAD--NNLTKIE-M LFS-KN---KDAEVSS--
1282

WP_049516684
1223
YRIE----KDYE-PEHRE--YVEKHKDEFKELLEYISVFSRKYVLAD--NNLTKIE-M LFS-KN---KDAEVSS--
1282

GAD46167
1222
YQIE----KNYE-PEHRE--YVEKHKDEFKELLEYISVFSRKYVLAD--NNLTKIE-M LFS-KN---KDAEVSS--
1281

WP_018363470
1254
HRIG----NFNS-AEHLK--YVSEHKKEFEEVLSCVENFANVYVDVE--KNLSKIR-A AAD-SM---DNFSIEE--
1313

WP_003043819
1249
QNISATTgSNNLg-------YIEQHREEFKEIFEKIIDFSEKYILKN--KVNSNLK-S SFD-EQfavSDSIL--1-
1310

WP_006269658
1222
YRIE----KDYE-PEHRE--YVEKHKDEFKELLEYISVFSRKYVLAD--NNLTKIE-M LFS-KN---KDAEVSS--
1281

WP_048800889
1242
HRID----NSDN-SEHLK--YITEHKEEFGKLLSYIENFAKSYVDVD--KNLEKIQ-L AVE-KI---DSFSVKE--
1301

WP_012767106
1246
-HAHKIEsSKE--LEHEA--YILDHYNDLYQLLSYIERFASLYVDVE--KNISKVK-E LFS-NI---ESYSISEi-
1308

WP_014612333
1246
-HAHKIEsSKE--LEHEA--YILDHYNDLYQLLSYIERFASLYVDVE--KNISKVK-E LFS-NI---ESYSISEi-
1308

WP_015017095
1246
-HAHKIEsSKE--LEHEA--YILDHYNDLYQLLSYIERFASLYVDVE--KNISKVK-E LFS-NI---ESYSISEi-
1308

WP_015057649
1246
-HAHKIEsSKE--LEHEA--YILDHYNDLYQLLSYIERFASLYVDVE--KNISKVK-E LFS-NI---ESYSISEi-
1308

WP_048327215
1246
-HAHKIEsSKE--LEHEA--YILDHYNDLYQLLSYIERFASLYVDVE--KNISKVK-E LFS-NI---ESYSISEi-
1308

WP_049519324
1246
-HAHKIEsSKE--LEHEA--YILDHYNDLYQLLSYIERFASLYVDVE--KNISKVK-E LFS-NI---ESYSISEi-
1308

WP_012515931
1220
AHYHELTgSSEDvLRKKY--FVDRHLHYFDDIIQMINDFAERHILAS--SNLEKIN-H TYH-NN---SDLPVNEr-
1285

WP_021320964
1220
AHYHELTgSSEDvLRKKY--FVERHLHYFDDIIQMINDFAERHILAS--SNLEKIN-H TYH-NN---SDLPINEr-
1285

WP_037581760
1220
AHYHELTgSSEDvLRKKY--FVERHLHYFDDIIQMINDFAERHILAS--SNLEKIN-H TYH-NN---SDLPVNEr-
1285

WP_004232481
1252
QHVN----NSHK-PEHLN--YVKQHKDEFKDIFNLIISIARINILKP--KVVDNL--- -IN-EF---TEYGQED--
1308

WP_009854540
1247
HRAD----NFNS-TEYLN--YVSEHKKEFEKVLSCVEDFANLYVDVE--KNLSKIR-A VAD-SM---DNFSIEE--
1306

WP_012962174
1248
HRVN----SFNN-SEHLK--YVSEHKKEFGEVLSCVENFAKSYVDVE--KNLGKIR-A VAD-KI---DTFSIED--
1307

WP_039695303
1249
HRAD----NENS-TEYLN--YVSEHKKEFEKVLSCVEDFANLYVDVE--KNLSKIR-A VAD-SM---DNFSIEE--
1308

WP_014334983
1252
HRID----SFNS-TEHLK--YVSEHKKEFEKVLSCVENFSNLYVDVE--KNLSKVR-A AAE-SM---TNFSLEE--
1311

WP_003099269
1240
SHYTKFTgKEEDrEKKRS--YVESHLYYFDEIMQIIVEYSNRYILAD--SNLIKIQ-N LYK-EKd---NFSIEEq-
1305

AHY15608
1240
SHYTKFTgKEEDrEKKRS--YVESHLYYFXEVKSSF---------------------- ------------------
1273

AHY17476
1240
SHYTKFTgKEEDrEKKRS--YVESHLYXFX---------------------------- ------------------
1267

ESR09100
72
SHYTKFTgKEEDrEKKRS--YVESHLYYFDEIMQIIVEYSNRYILAD--SNLIKIQ-N LYK--Ek--DNFSIEEq-
137

AGM98575
1240
SHYTKFTgKEEDrEKKRS--YVESHLYYFDVRLSQVFRVTNVEF-------------- ------- ----------
1281

ALF27331
1222
KNIH----KVDE-PKHLD--YVKKHKDEFKELLDVVSNFSKKNILAE--SNLEKIE-E LYA-QN---NNKDITE--
1281

WP_018372492
1229
KKVDVLVkSKDD---DYD---LEEHRAEFAELLDCIKKFNDMYILAS--SNMSKIE-E IYQ-KNi---DAPIEE--
1289

WP_045618028
1252
QRIN----KISE-PIHKQ--YVETHQSEFKELLTAIISLSKKYI-QK--PNVESL--- LQQ-AF---DQSDKDIyq
1310

WP_045635197
1247
KNVH----KLDE-PGHLE--YIQKHRNEFKDLLNLVSEFSQKYVLAD--ANLEKIK-S LYA-DN---EQADIEI--
1306

WP_002263549
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002263887
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002264920
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002269043
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002269448
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002271977
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002272766
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002273241
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002275430
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002276448
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002277050
1230
HHL-------DN-DYSNE--YVKNHYQQFDILFNEITSFSKKCKLGK--EHIQKIE-E AYSkER---DSASIEE--
1287

WP_002277364
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002279025
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002279859
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002280230
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002281696
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002282247
1230
HHL-------DN-DYSNE--YVKNHYQQFDILFNEITSFSKKCKLGK--EHIQKIE-E AYSkER---DFASIEE--
1287

WP_002282906
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002283846
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002287255
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002288990
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002289641
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002290427
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002295753
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002296423
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002304487
1236
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1295

WP_002305844
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002307203
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002310390
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_002352408
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_012997688
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_014677909
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_019312892
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_019313659
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_019314093
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_019315370
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_019803776
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_019805234
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_024783594
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_024784288
1230
HHL-------DN-DYSNE--YVKNHYQQFDILFNEITSFSKKCKLGK--EHIQKIE-E AYSkER---DFASIEE--
1287

WP_024784666
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_024784894
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_024786433
1230
HHL-------DN-DYSNE--YVKNHYQQFDILFNEITSFSKKCKLGK--EHIQKIE-E AYSkER---DSASIEE--
1287

WP_049473442
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

WP_049474547
1222
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1281

EMC03581
1215
KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE--
1274

WP_000428612
1250
KNIH----RLDE-PEHLE--YIQKHRNEFKGLLNLVSEFSQKYVLAD--ANLEKIK-N LYA-DN---EQADIEI--
1309

WP_000428613
1248
KNVH----KLDE-PEHLE--YIQKHRNEFKDLLNLVSEFSQKYVLAD--ANLEKIQ-N LYA-DN---EQADIEI--
1307

WP_049523028
1243
KRIQ----KKDE-PEHLE--YIKQHHSEFNDLLNFVSEFSQKYVLAE--SNLEKIK-N LYI-DN---EQTNMEE--
1302

WP_003107102
1209
SRYTSFSgKEEDrEKHRH--FVESHLHYFDEIKDIIADFSRRYILAD--ANLEKIL-T LYN-EKn---QFSIEEq-
1274

WP_054279288
1242
SKRDK--gTQSEnME-----YISNHKEKFIEIFHYIIRYAEKNVIKP--KVIERLN-D TENqKF---NDSDLTE1-
1303

WP_049531101
1252
QRIN----KISE-PIHKQ--YVETHQSEFEELLTTIISLSKKYI-QK--PIVESL--- LQQ-AF---EQADKDIyq
1310

WP_049538452
1252
QRIN----KISE-PIHKQ--YVEAHQNEFKELLTTIISLSKKYI-QK--PNVESL--- LQQ-AF---EQADKDIyq
1310

WP_049549711
1254
QRIN----KFSE-PIHKQ--YVEAHQNEFKELLTIIISLSKKYI-QK--PNVESL--- LHQ-AF---EQADNDIyq
1312

WP_007896501
1246
SRYDKLSsKIESeQQKKL--FVEQHLHYFDEILDIVVKHATCYIKAE--NNLKKII-S LYK-KK---EAYSINEq-
1311

EFR44625
1198
SRYDKLSsKIESeQQKKL--FVEQHLHYFDEILDIVVKHATCYIKAE--NNLKKII-S LYK-KK---EAYSINEq-
1263

WP_002897477
1247
KNLH----KLDE-PEHLE--YIQKHRNEFKDLLNLVSEFSQKYILAE--ANLEKIK-D LYA-DN---EQADIEI--
1306

WP_002906454
1253
QRIN----KISE-PIHKQ--YVEAHQNEFKELLTTIISLSKKYI-QK--PNVELL--- LQQ-AF---DQADKDIyq
1311

WP_009729476
1248
KNVH----KLDE-PGHLE--YIQKHRNEFKDLLNLVSEFSQKYVLAD--ANLEKIK-N LYA-DN---EQADIEI--
1307

CQR24647
1238
QHAN----KEDS----VI--YLEKHRHELSELFHHIIGVSEKTILKP--KVEMTLN-E AFE-KHf--EFDEVSE--
1295

WP_000066813
1252
KNVH----KLDE-PEHLE--YIQKHRYEFKDLLNLVSEFSQKYVLAD--ANLEKIK-N LYA-DN---EQADIEI--
1311

WP_009754323
1248
KNVH----KLDE-PEHLE--YIQKHRYEFKDLLNLVSEFSQKYVLAE--ANLEKIK-S LYV-DN---EQADIEI--
1307

WP_044674937
1241
SNIH----KITE-PIHLN--YVNKNKHEFKELLRHISDFSTRYILAQ--DRLSKIE-E LYD-KN---DGDDISD--
1300

WP_044676715
1243
SNIH----KITE-PIHLN--YVNKNKHEFKELLRHISDFSTRYILAQ--DRLSKIE-E LYD-KN---DGDDISD--
1302

WP_044680361
1243
SNIH----KITE-PIHLN--YVNKNKHEFKELLRHISDFSTRYILAQ--DRLSKIE-E LYD-KN---DGDDISD--
1302

WP_044681799
1241
SNIH----KITE-PIHLN--YVNKNKHEFKELLRHISDFSTRYILAQ--DRLSKIE-E LYD-KN---DGDDISD--
1300

WP_049533112
1254
KRIN----NPIN-KDHIE--YVKKHRDDFKELLNYVLEFNEKYVGAT--KNGERLK-E AVA-DF---DSKSNEE--
1313

WP_029090905
1182
STKQA-----DE-AMFLKyyRLEHLEAVFEEL---IRKQAADYQIFE--KLIKKIEvN FYS----c----TYNEk-
1240

WP_006506696
1212
YNAIYKQ-DYDN1DDILMi-----------QLYIELTNKMKVLYPAY-rGIAEKFE-S YVV----i----SKEEk-
1268

AIT42264
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_034440723
1218
KHYNE-----DE--TSHK--FIVEHKAYFDELLNYIVEFANKYLELE--NSIEKIK-D LYH-----gKGPDVEEke
1276

AKQ21048
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

WP_004636532
1212
NRYDKVK-----fPDSIE--YVHDNLAKFDDLLEYVIDFSNKYINAD--KNVQKIQ-K IYK-EH---GTEDVEL--
1271

WP_002364836
1218
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE--
1277

WP_016631044
1169
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE--
1228

EM575795
954
QHYDEIAhKESF-----D--YVNDHLSEFREILDQVIDFSNRYTIAA--KNTEKIA-E LFE-QN---QESTVQS--
1013

WP_002373311
1218
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE--
1277

WP_002378009
1218
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE--
1277

WP_002407324
1218
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE--
1277

WP_002413717
1218
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE--
1277

WP_010775580
1220
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE--
1279

WP_010818269
1218
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE--
1277

WP_010824395
1218
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE--
1277

WP_016622645
1218
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE--
1277

WP_033624816
1218
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE--
1277

WP_033625576
1218
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-TN---QTADVKE--
1277

WP_033789179
1218
KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE--
1277

WP_002310644
1220
KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK--
1279

WP_002312694
1221
KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK--
1280

WP_002314015
1221
KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK--
1280

WP_002320716
1221
KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK--
1280

WP_002330729
1220
KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK--
1279

WP_002335161
1221
KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK--
1280

WP_002345439
1221
KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK--
1280

WP_034867970
1211
QHYDKITyQESF-----D--YVNTHLSDFSAILTEVLAFAEKYTLAD--KNIERIQ-E LYE-EN---KYGETSM--
1270

WP_047937432
1221
KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK--
1280

WP_010720994
1211
QHYDKITyQESF-----D--YVNTHLSDFSAILTEVLAFAEKYTLAD--KNIERIQ-E LYE-EN---KYGEISM--
1270

WP_010737004
1211
QHYDKITyQESF-----D--YVNTHLSDFSAILTEVLAFAEKYTLAD--KNIERIQ-E LYE-EN---KYGETSM--
1270

WP_034700478
1211
QHYDKITyQESF-----D--YVNTHLSDFSAILTEVLAFAEKYTLAD--KNIERIQ-E LYE-EN---KYGEISM--
1270

WP_007209003
1209
KKIIN--gKNSD---SVS--YIQNNKEKFREIFEYIVDFSSKYISAD--ANLNKIE-K IFE-NNfh----KASEqe
1269

WP_023519017
1205
RHYDEINhKVSF-----D--YVNAHKEGENDIFDFISDEGVRYILAP--QHLEKIK-V AYE-KN---KEVDLKE--
1264

WP_010770040
1216
KQVDE-----DS-GKSEE--YVREHRAEFAEILNYVQAFSETKILAN--KNLQTIL-K LYE-EN---KEADIKE--
1274

WP_048604708
1213
KHCNE-----KP-D-SLK--YVTEHQSGFSEIMAHVKDFAEKYTLVD--KNLEKIL-S LYA-KN---MDSEVKE--
1270

WP_010750235
1214
NHYDEIAyKDSY-----D--YVNEHFSNFQDILDKVIIFAEKYTSAP--QKLNQII-A TYE-KN---QEADRKI--
1273

AII16583
1279
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1344

WP_029073316
1226
YKAMKYK-NYSE1SQEEIm-----------NVYDIFVEKLKLYYPTY-kNIATNFE-N FEN----i----SDEEk-
1282

WP_031589969
1226
YKAMKYK-NYDN1DSEKIi-----------DLYRLLINKMELYYPEYrkQLVKKFE-D LKV----i----SIEEk-
1283

KDA45870
1200
NAKDG--------EQKLE-----DHKAEFKELFDKIMEFADKYVVAP--KNSEKIR-R LYE-ENq-----DATPme
1253

WP_039099354
1242
LPLTQ-----SEeLAEQV----------YDEILDQVMHYFPLYDTNQfrAKLSAGKaA DGN-KMv-----QVGQqv
1306

AKP02966
1238
QIPDE------DpDQILAf----YDKNILVEILQELITKMKKFYPFY--KNEQEFLaS FNQ--------ATTSEk-
1296

WP_010991369
1216
ANCEV-----SD-GKSLD--YIESNREMFAELLAHVSEFAKRYTLAE--ANLNKIN-Q LFE-QN---KEGDIKA--
1274

WP_033838504
1216
ANCEV-----SD-GKSLD--YIESNREMFAELLAHVSEFAKRYTLAE--ANLNKIN-Q LFE-QN---KEGDIKA--
1274

EHN60060
1219
ANCEV-----SD-GKSLD--YIESNREMFAELLAHVSEFAKRYTLAE--ANLNKIN-Q LFE-QN---KEGDIKA--
1277

EFR89594
985
ANCEV-----SD-GKSLD--YIESNREMFAELLAHVSEFAKRYTLAE--ANLNKIN-Q LFE-QN---KEGDIKA--
1043

WP_038409211
1216
KNCEA-----ND-GESLA--YIEMHREMFAELLAYISEFAKRYTLAN--DRLEKIN-M FFE-QN---KKGDIKV--
1274

EFR95520
835
KNCEA-----ND-GESLA--YIEMHREMFAELLAYISEFAKRYTLAN--DRLEKIN-M FFE-QN---KKGDIKV--
893

WP_003723650
1216
KNCEA-----SD-GKSLK--YIEAHRETFSELLAQVSEFATRYTLAD--ANLSKIN-N LFE-QN---KEGDIKA--
1274

WP_003727705
1216
KNCEA-----SD-GKSLK--YIEAHRETFSELLAQVSEFATKYTLAD--ANLSKIN-N LFE-QN---KEGDIKA--
1274

WP_003730785
1216
KNCEA-----SD-GKSLK--YIEAHRETFSELLAQVSEFATKYTLAD--ANLSKIN-N LFE-QN---KEGDIKA--
1274

WP_003733029
1216
EKYEA-----ID-GESLA--YIEVHRALFDELLAYISEFARKYTLSN--DRLDEIN-M LYE-RN---KDGDVKS--
1274

WP_003739838
1216
KNCEA-----SD-GKSLD--YIESNREMFGELLAHVSEFAKRYTLAD--ANLSKIN-Q LFE-QN---KDNDIKV--
1274

WP_014601172
1216
KNCEA-----SD-GKSLK--YIEAHRETFSELLAQVSEFATRYTLAD--ANLSKIN-N LFE-QN---KEGDIQA--
1274

WP_023548323
1216
EKREA-----ID-GESLA--YIEAHKAVFGELLAHISEFARKYTLAN--DKLDEIN-M LYE-RN---KDGDVKS--
1274

WP_031665337
1216
KNCEA-----SD-GKSLK--YIEAHRETFSELLAQVSEFATRYTLAD--ANLSKIN-N LFE-QN---KEGDIKA--
1274

WP_031669209
1216
EKYEA-----ID-GESLA--YIEVHRALFDELLAYISEFARKYTLSN--DRLDEIN-M LYE-RN---KDGDVKS--
1274

WP_033920898
1216
EKREA-----ID-GESLA--YIEAHKAVFGELLAHISEFARKYTLAN--DKLDEIN-M LYE-RN---KDGDVKS--
1274

AKI42028
1219
KNCEA-----SD-GKSLK--YIEAHRETFSELLAQVSEFATRYTLAD--ANLSKIN-N LFE-QN---KEGDIQA--
1277

AKI50529
1219
EKREA-----ID-GESLA--YIEAHKAVFGELLAHISEFARKYTLAN--DKLDEIN-M LYE-RN---KDGDVKS--
1277

EFR83390
664
KNCEA-----SD-GKSLK--YTEAHRETFSELLAQVSEFATRYTLAD--ANLSKIN-N LFE-QN---KEGDIKX--
722

WP_046323366
1216
KNCEA-----SD-GKSLA--YIESHREMFAELLDSISEFASRYTLAD--ANLEKIN-T IFE-QN---KSGDVKV--
1274

AKE81011
1256
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1321

CUO82355
1216
YNAIYKQ-DFDG1DNMLMi-----------QLYLQLIDKLKTLYPIY-mGIVEKFE-K FVS----i----SKEEk-
1272

WP_033162887
1218
YAAMLKK-RYEY1DEEEIf-----------DLYLQLLQKMDTLYPAY-kGIAKRFF-D FKN----i----DVVEk-
1274

AGZ01981
1273
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1338

AKA60242
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

AK540380
1240
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1305

4UN5_B
1244
SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq-
1309

WP_010922251
1306
-AE---NII HLFTLTNLGAP-AAFKYFD-- custom character

TI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_039695303
1309
ISN---SFI NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL NATLIHQSITGLYETRIDLSKL--
1369

WP_045635197
1307
LAN---SFI NLLTFTALGAP-AAFKFFG--KDI--DRK--R-YTTVSEIL NATLIHQSITGLYETWIDLSKL--
1367

5AXW_A

--------- ----------------------------------------- ------------------------

WP_009880683
990
-AE---NII HLFTLTNLGAP-AAFKCFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL--
1049

WP_010922251
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_011054416
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_011284745
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATFIHQSITGLYETRIDLSQL--
1365

WP_011285506
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_011527619
1306
-AE---NII HLFTLTNLGAP-TAFKYFD--TTI--DRK--R-YTSTKEVL DATFIHQSITGLYETRIDLSQL--
1365

WP_012560673
1306
-AE---NII HLFTLTNLGAP-AAFKCFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_014407541
1305
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1364

WP_020905136
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_023080005
1305
-AK---NII HLFTLTNLGAP-AAFKYFD--TTI--ERN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL--
1364

WP_023610282
1305
-AK---NII HLFTLTNLGAP-AAFKYFD--TTI--ERN--R-YKSIKEVL DATLIHQSITGLYEIRIDLSQL--
1364

WP_030125963
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_030126706
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_031488318
1306
-AE---NII HLFTLTNFGAP-AAFIYFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_032460140
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_032461047
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_032462016
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_032462936
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_032464890
1306
-AE---NII HLFTLTNLGAP-TAFKYFD--TTI--DRK--R-YTSTKEVL DATFIHQSITGLYETRIDLSQL--
1365

WP_033888930
1131
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1190

WP_038431314
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_038432938
1305
-AK---NII HLFTLTNLGAP-AAFKYFD--TTI--ERN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL--
1364

WP_038434062
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL--
1365

BAQ51233
1217
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1276

KGE60162
481
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
540

KGE60856
244
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
303

WP_002989955
1306
-AE---NII HLFTLTNLGAP-TAFKYFD--TTI--DRK--R-YTSTKEVL DATFIHQSITGLYETRIDLSQL--
1365

WP_003030002
1282
LAK---SFI SLLTFTAFGAP-AAFNFFG--ENI--DRK--R-YTSVTECL NATLIHQSITGLYETRIDLSKL--
1342

WP_003065552
1310
ISN---SFI NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL NATLIHQSITGLYETRIDLSKI--
1370

WP_001040076
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040078
1315
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLSKL--
1375

WP_001040080
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040081
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040083
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040085
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040087
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040088
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040089
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040090
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040091
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040092
1307
LAK---NII NLFTFTSLGAP-AAFKFFD--KSV--DRK--R-YTSTKEVL DSTLIHQSITGLYETRIDLGKL--
1367

WP_001040094
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040095
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040096
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040097
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040098
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040099
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHKSITGLYETRIDLGKL--
1367

WP_001040100
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040104
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040105
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040106
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040107
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040108
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_001040109
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQFITGLYETRIDLGKL--
1367

WP_001040110
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_015058523
1307
LAK---NII NLFTFTSLGAP-AAFKFFD--KSV--DRK--R-YTSTKEVL DSTLIHQSITGLYETRIDLGKL--
1367

WP_017643650
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_017647151
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_017648376
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_017649527
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_017771611
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_017771984
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

CFQ25032
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

CFV16040
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

KLJ37842
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

KLJ72361
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

KLL20707
1321
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1381

KLL42645
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_047207273
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_047209694
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHKSITGLYETRIDLGKL--
1367

WP_050198062
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_050201642
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_050204027
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_050881965
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KII--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_050886065
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

AHN30376
1307
LAK---NII NLFTFTSLGAP-AAFKFFD--KSV--DRK--R-YTSTKEVL DSTLIHQSITGLYETRIDLGKL--
1367

EA078426
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

CCW42055
1307
LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL--
1367

WP_003041502
1314
ICT---SFL GLFELTSLGSA-SDFEFLG--VKI--PRY--RdYTPSSLLK DSTLIHQSITGLYETRIDLSKL--
1383

WP_037593752
1283
LAK---SFI SLLTFTAFGAP-AAFNFFG--ENI--DRK--R-YTSVTECL NATLIHQSITGLYETRIDLSKL--
1343

WP_049516684
1283
LAK---SFI SLLTFTAFGAP-AAFNFFG--ENI--DRK--R-YTSVTECL NATLIHQSITGLYETRIDLSKL--
1343

GAD46167
1282
LAK---SFI SLLTFTAFGAP-AAFNFFG--ENI--DRK--R-YTSVTECL NATLIHQSITGLYETRIDLSKL--
1342

WP_018363470
1314
ISD---SFI NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YNSTKECL NATLIHQSITGLYETRIDLSKL--
1374

WP_003043819
1311
-SN---SFV SLLKYTSFGAS-GGFTFLD--LDVkqGRL--R-YQTVTEVL DATLIYQSITGLYETRTDLSQL--
1372

WP_006269658
1282
LAK---SFI SLLTFTAFGAP-AAFNFFG--ENI--DRK--R-YTSVTECL NATLIHQSITGLYETRIDLSKL--
1342

WP_048800889
1302
ISN---SFI HLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL NATLIHQSITGLYETQTDLSKL--
1362

WP_012767106
1309
-CS---SVI NLLTLTASGAP-ADFKFLG--TTI--PRK--R-YGSPQSIL SSTLIHQSITGLYETRIDLSQL--
1368

WP_014612333
1309
-CS---SVI NLLTLTASGAP-ADFKFLG--TTI--PRK--R-YGSPQSIL SSTLIHQSITGLYETRIDLSQL--
1368

WP_015017095
1309
-CS---SVI NLLTLTASGAP-ADFKFLG--TTI--PRK--R-YGSPQSIL SSTLIHQSITGLYETRIDLSQL--
1368

WP_015057649
1309
-CS---SVI NLLTLTASGAP-ADFKFLG--TTI--PRK--R-YGSPQSIL SSTLIHQSITGLYETRIDLSQL--
1368

WP_048327215
1309
-CS---SVI NLLTLTASGAP-ADFKFLG--TTI--PRK--R-YGSPQSIL SSTLIHQSITGLYETRIDLSQL--
1368

WP_049519324
1309
-CS---SVI NLLTLTASGAP-ADFKFLG--TTI--PRK--R-YGSPQSIL SSTLIHQSITGLYETRIDLSQL--
1368

WP_012515931
1286
-AE---NII NVFTFVALGAP-AAFKFFD--ATI--DRK--R-YTSTKEVL NATLIHQSVTGLYETRIDLSQL--
1345

WP_021320964
1286
-AE---NII NVFTFVALGAP-AAFKFFD--ATI--DRK--R-YTSTKEVL NATLIHQSVTGLYETRIDLSQL--
1345

WP_037581760
1286
-AE---NII NVFTFVALGAP-AAFKFFD--ATI--DRK--R-YTSTKEVL NATLIHQSVTGLYETRIDLSQL--
1345

WP_004232481
1309
ISS1seSFI NLLKFISFGAP-GAFKFLK--LDV--KQSn1R-YKSTTEAL SATLIHQSVTGLYETRIDLSKL--
1374

WP_009854540
1307
ISN---SFI NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL TATLIHQSITGLYETRIDLSKL--
1367

WP_012962174
1308
ISI---SFV NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL NATLIHQSITGLYETRIDLSKL--
1368

WP_039695303
1309
ISN---SFI NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL NATLIHQSITGLYETRIDLSKL--
1369

WP_014334983
1312
ISA---SFI NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL SATLIHQSVTGLYETRIDLSKL--
1372

WP_003099269
1306
-AI---NML NLFTFTDLGAP-SAFKFFN--GDI--DRK--R-YSSTNEII NSTLIYQSPTGLYETRIDLSKL--
1365

AHY15608

--------- ----------------------------------------- ------------------------

AHY17476

--------- ----------------------------------------- ------------------------

ESR09100
138
-AI---NML NLFTFTDLGAP-SAFKFFNg--DI--DRK--R-YSSTNEII NSTLIYQSPTGLYETRIDLSKL--
197

AGM98575

--------- ----------------------------------------- ------------------------

ALF27331
1282
LAS---SFI NLLTFTAIGAP-AAFKFFD--NNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSRL--
1342

WP_018372492
1290
VAR---SFV -LLNFTMMGAA-TDFKFFG--QII--PRK--R-YPSTTECL KSTLIHQSVTGLYETRIDLSKL--
1350

WP_045618028
1311
LSE---SFI SLLKLISFGAP-GTFKFLG--VEI--SQSnvR-YQSVSSCF NATLIHQSITGLYETRIDLSKL--
1373

WP_045635197
1307
LAN---SFI NLLTFTALGAP-AAFKFFG--KDI--DRK--R-YTTVSEIL NATLIHQSITGLYETWIDLSKL--
1367

WP_002263549
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL--
1342

WP_002263887
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL--
1342

WP_002264920
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002269043
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL--
1342

WP_002269448
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002271977
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002272766
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002273241
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002275430
1282
LSS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002276448
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002277050
1288
LAD---GFI KLLGFTQLGAT-SPFSFLG--IKL--NQK--Q-YTGKKDYL EATLIHQSITGLYETRIDLNKL--
1352

WP_002277364
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002279025
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002279859
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002280230
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002281696
1282
LSS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002282247
1288
LAD---GFI KLLGFTQLGAT-SPFSFLG--IKL--NQK--Q-YTGKKDYL EATLIHQSITGLYETRIDLSKL--
1352

WP_002282906
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002283846
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002287255
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002288990
1282
LAS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002289641
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002290427
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002295753
1282
LAS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002296423
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002304487
1296
LAS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL--
1356

WP_002305844
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002307203
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002310390
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_002352408
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_012997688
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_014677909
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_019312892
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_019313659
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL--
1342

WP_019314093
1282
LAS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_019315370
1282
LSS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_019803776
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL--
1342

WP_019805234
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_024783594
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL--
1342

WP_024784288
1288
LAD---GFI KLLGFTQLGAT-SPFSFLG--IKL--NQK--Q-YTGKKDYL EATLIHQSITGLYETRIDLSKL--
1352

WP_024784666
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_024784894
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_024786433
1288
LAD---GFI KLLGFTQLGAT-SPFSFLG--IKL--NQK--Q-YTGKKDYL EATLIHQSITGLYETRIDLSKL--
1352

WP_049473442
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1342

WP_049474547
1282
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL KATLIHQSITGLYETRIDLSKL--
1342

EMC03581
1275
LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL--
1335

WP_000428612
1310
LAN---SFI NLLTFTALGAP-AAFKFFG--KDV--DRK--R-YTTVSEIL NATLIHQSITGLYETRIDLSKL--
1370

WP_000428613
1308
LAN---SFI NLLTFTALGAP-AAFKFFG--KDI--DRK--R-YTTVSEIL NATLIHQSITGLYETRIDLSKL--
1368

WP_049523028
1303
IAN---SFI NLLTFTAFGAP-AVFKFFG--KDI--ERK--R-YSTVTEIL KATLIHQSLTGLYETRIDLSKL--
1363

WP_003107102
1275
-AT---NML NLFTFTGLGAP-ATLKFFN--VDI--DRK--R-YTSSTEIL NSTLIRQSITGLYETRIDLSKI--
1334

WP_054279288
1304
-SI---SFL NLFKFTSFGAP-EKFTFLN--SEIkqDDV--R-YRSTKECL NSTLIHQSVTGLYETRIDLSQF--
1365

WP_049531101
1311
LSE---SFI SLLKLTSFGAP-GAFRFLG--VEI--SQSnvR-YQSVSSCF NATLIHQSITGLYETRIDLSKL--
1373

WP_049538452
1311
LSE---SFI SLLKLTSFGAP-GAFKFLG--VEI--SQSsvR-YKPNSQFL DATLIHQSITGLYETRIDLSKL--
1373

WP_049549711
1313
LSE---SFI SLLKLTSFGAP-GAFKFLG--AEI--SQSsvR-YKPNSQFL DTTLIHQSITGLYETRIDLSKL--
1375

WP_007896501
1312
-AL---NML NLFIFTSLGAP-STFVFFD--ETI--DRK--R-YTTSSDVL NGILIQQSITGLYETRIDLSRF--
1371

EFR44625
1264
-AL---NML NLFIFTSLGAP-STFVFFD--ETI--DRK--R-YTTSSDVL NGILIQQSITGLYETRIDLSRF--
1323

WP_002897477
1307
LAN---SFI NLLTFTALGAP-AAFKFFG--KDV--DRK--R-YTTVSEIL NATLIHQSITGLYETRIDLSKL--
1367

WP_002906454
1312
LSE---SFI SLLKLTSFGAP-GAFKFLG--VEI--SQSsvR-YKPNSQFL DTTLIHQSITGLYETRIDLSKL--
1374

WP_009729476
1308
LAN---SFI NLLTFTALGAP-AAFKFFG--KDV--DRK--R-YTTVSEIL NATLIHQSITGLYETRIDLSKL--
1368

CQR24647
1296
LAQ---SFI SLLKFTAFGAP-GGFKFLD--ADI--KQSn1R-YQTVTEVL SSTLIHQSVTGLYETRIDLSKL--
1358

WP_000066813
1312
LAN---SFI NLLTFTALGAP-AAFKFLG--KDV--DRK--R-YTTVSEIL NATLIHQSITGLYETRIDLSKL--
1372

WP_009754323
1308
LAN---SFI NLLTFTALGAP-AAFKFFG--KDV--DRK--R-YTTVSEIL NATLIHQSITGLYETRIDLSKL--
1368

WP_044674937
1301
LTS---SFV NLLTFTAIGAP-AAFKFLG--SVI--DRK--R-YTSIAEIL EATLIHQSVTGLYETRIDLSKL--
1361

WP_044676715
1303
LTS---SFV NLLTFTAIGAP-AAFKFLG--SVI--DRK--R-YTSIAEIL EATLIHQSVTGLYETRIDLSKL--
1363

WP_044680361
1303
LTS---SFV NLLTFTAIGAP-AAFKFLG--SVI--DRK--R-YTSIAEIL EATLIHQSVTGLYETRIDLSKL--
1363

WP_044681799
1301
LTS---SFV NLLTFTAIGAP-AAFKFLG--SVI--DRK--R-YTSIAEIL EATLIHQSVTGLYETRIDLSKL--
1361

WP_049533112
1314
ICT---SFL GLFELTSLGSA-SDFEFLG--VKI--PRY--RdYTPSSLLK DSTLIHQSITGLYETRIDLSKL--
1383

WP_029090905
1241
-VK----VI ELLKITQANATnGDLKLLK----M-sNREg-R-LGSVSVAL DFKIINQSVTGLYQSIEDYNN---
1300

WP_006506696
1269
-AN----II QMLIVMHRGPQnGNIVYDDf--KI-sDRIg-R-LKTKNHNL NIVFISQSPTGIYTKKYKL-----
1329

AIT42264
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_034440723
1277
LVE---SFI NLLAITKCGPA-ADITFLG--EKI--SRK--R-YRSTNCLW GSEVIFQSPTGLYETRLRLE----
1335

AKQ21048
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

WP_004636532
1272
TVE---SFV NLMTFTAMGAP-ATFKFYG--ESI--TRS--R-YTSITEFR GSTLIFQSITGLYETRYKL-----
1329

WP_002364836
1278
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV-----
1335

WP_016631044
1229
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSPTGLYETRRKV-----
1286

EM575795
1014
LSQ---SFI NLMQLNAMGAP-ADFKFFD--VII--PRK--R-YPSLTEIW ESTITYQSITGLRETRTRMATLwd
1076

WP_002373311
1278
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV-----
1335

WP_002378009
1278
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV-----
1335

WP_002407324
1278
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV-----
1335

WP_002413717
1278
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV-----
1335

WP_010775580
1280
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV-----
1337

WP_010818269
1278
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV-----
1335

WP_010824395
1278
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV-----
1335

WP_016622645
1278
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV-----
1335

WP_033624816
1278
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV-----
1335

WP_033625576
1278
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV-----
1335

WP_033789179
1278
IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV-----
1335

WP_002310644
1280
LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK---
1339

WP_002312694
1281
LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK---
1340

WP_002314015
1281
LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK---
1340

WP_002320716
1281
LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK---
1340

WP_002330729
1280
LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK---
1339

WP_002335161
1281
LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK---
1340

WP_002345439
1281
LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK---
1340

WP_034867970
1271
IAQ---SFL QLLQFNAIGAP-ADFKFFG--VTI--PRK--R-YTSLTEIW DATIIYQSVTGLYETRIRMGDLwa
1333

WP_047937432
1281
LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK---
1340

WP_010720994
1271
IAQ---SFL QLLQFNAIGAP-ADFKFFG--VTI--PRK--R-YTSLTEIW DATIIYQSVTGLYETRIRMGDLwa
1333

WP_010737004
1271
IAQ---SFL QLLQFNAIGAP-ADFKFFG--VTI--PRK--R-YTSLTEIW DATIIYQSVTGLYETRIRMGDLwa
1333

WP_034700478
1271
IAQ---SFL QLLQFNAIGAP-ADFKFFG--VTI--PRK--R-YTSLTEIW DATIIYQSVTGLYETRIRMGDLwa
1333

WP_007209003
1270
IAK---SFI NLLTFTAMGAP-ADFEFFG--EKI--PRK--R-YVSISEII DAVFIHQSITGLYETRVRLTEV--
1330

WP_023519017
1265
MID---AIL SLLKFTLFGAS-VEFKFFD--IKI---LK--R-YKSLTDIW EATIIYQSVTGLYERRVEVRKLwd
1326

WP_010770040
1275
IAE---SFV NLMKFSAYGAP-MDFKFFG--KTI--PRS--R-YTSVGELL SATIINQSITGLYETRRKL-----
1332

WP_048604708
1271
IAQ---SFV DLMQLNAFGAP-ADFKFFG--ETI--PRK--R-YTSVNELL EATIINQSITGLYETRRRL-----
1328

WP_010750235
1274
MAH---SFV NLMQFNALGAP-ADFKFFD--TTI--TRK--R-YTSLTEIW QSTIIYQSVTGLYETRRRMADLwd
1336

AII16583
1345
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1404

WP_029073316
1283
-CE----VI QMLVVMHAGPQnGNITFDDf--KL-sNRLg-R-LNCKTISL TTVFIADSPTGMYSKKYKL-----
1343

WP_031589969
1284
-CN----II QILATLHCNSSiGKIMYSDf--KI-sTTIg-R-LNGRTISL DISFIAESPTGMYSKKYKL-----
1344

KDA45870
1254
LGK---NFV ELLRYTADGAA-SDFKFFG--ENI--PRK--R-YNSAGSLL NGTLIYQSKTGLYETRIDLGKL--
1314

WP_039099354
1307
ILDr----V -LIGLHANAAV-SDLGVLKisTPL--GKM--Q---QPSGIS DTQIIYQSPTGLFERRVALRDL--
1368

AKP02966
1297
INS1-eELI TLLHANSTSAH-LIFNNIE-kKAF--GRK-------THGLT DTDFIYQSVTGLYETRIHIE----
1356

WP_010991369
1275
IAQ---SFV DLMAFNAMGAP-ASFKFFE--TTI--ERK--R-YNNLKELL NSTIIYQSITGLYESRKRL-----
1332

WP_033838504
1275
IAQ---SFV DLMAFNAMGAP-ASFKFFE--TTI--ERK--R-YNNLKELL NSTIIYQSITGLYESRKRL-----
1332

EHN60060
1278
IAQ---SFV DLMAFNAMGAP-ASFKFFE--TTI--ERK--R-YNNLKELL NSTIIYQSITGLYESRKRL-----
1335

EFR89594
1044
IAQ---SFV DLMAFNAMGAP-ASFKFFE--TTI--ERK--R-YNNLKELL NSTIIYQSITGLYESRKRL-----
1101

WP_038409211
1275
IAK---SFD KLKVFNAFGAP-RDFEFFE--TTI--KRK--R-YYNIKELL NATIIYQSITGLYEARKRL-----
1332

EFR95520
894
IAK---SFD KLKVFNAFGAP-RDFEFFE--TTI--KRK--R-YYNIKELL NATIIYQSITGLYEARKRL-----
951

WP_003723650
1275
IAQ---SFV DLMAFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL-----
1332

WP_003727705
1275
IAQ---SFV DLMAFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL-----
1332

WP_003730785
1275
IAQ---SFV DLMAFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL-----
1332

WP_003733029
1275
IAE---SFV SLKKFNAFGVH-QDFSFFG--TKI--ERK--R-DRKLNELL NSTIIYQSITGLYESRKRL-----
1332

WP_003739838
1275
IAQ---SFV NLMAFNAMGAP-ASFKFFE--ATI--ERK--R-YTNLKELL SATIIYQSITGLYEARKRL-----
1332

WP_014601172
1275
IAQ---SFV DLMAFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL-----
1332

WP_023548323
1275
IAE---SFV SLKKFNAFGVH-KDFNFFG--TTI--KRK--R-DRKLKELL NSTIIYQSITGLYESRKRL-----
1332

WP_031665337
1275
IAQ---SFV DLMAFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL-----
1332

WP_031669209
1275
IAE---SFV SLKKFNAFGVH-QDFSFFG--TKI--ERK--R-DRKLNELL NSTIIYQSITGLYESRKRL-----
1332

WP_033920898
1275
IAE---SFV SLKKFNAFGVH-KDFNFFG--TTI--KRK--R-DRKLKELL NSTIIYQSITGLYESRKRL-----
1332

AKI42028
1278
IAQ---SFV DLMAFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL-----
1335

AKI50529
1278
IAE---SFV SLKKFNAFGVH-KDFNFFG--TTI--KRK--R-DRKLKELL NSTIIYQSITGLYESRKRL-----
1335

EFR83390
723
IAQ---SFV DLMVFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL-----
780

WP_046323366
1275
IAQ---SFV NLLEFNAMGAP-ASFKYFE--TNI--ERK--R-YNNLKELL NATIIYQSITGLYEARKRL-----
1332

AKE81011
1322
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1381

CUO82355
1273
-AN----VI QMLIIMHKGPQnGNIIYDDf--NV-gKRIg-R-LNGRTFYL NIEFISQSPTGIYTKKYKL-----
1333

WP_033162887
1275
-CD----VI QILIIMHAGPMnGNIMYDDf--KF-tNRIg-R-FTHKNIDL KTTFISTSVTGLFSKKYKL-----
1335

AGZ01981
1339
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1398

AKA60242
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

AKS40380
1306
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1365

4UN5_B
1310
-AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL--
1369

WP_010922251
1366
GGD
1368

WP_039695303
1370
GEE
1372

WP_045635197
1368
GED
1370

5AXW_A

---

WP_009880683
1050
GGD
1052

WP_010922251
1366
GGD
1368

WP_011054416
1366
GGD
1368

WP_011284745
1366
GGD
1368

WP_011285506
1366
GGD
1368

WP_011527619
1366
GGD
1368

WP_012560673
1366
GGD
1368

WP_014407541
1365
GGD
1367

WP_020905136
1366
GGD
1368

WP_023080005
1365
GGD
1367

WP_023610282
1365
GGD
1367

WP_030125963
1366
GGD
1368

WP_030126706
1366
GGD
1368

WP_031488318
1366
GGD
1368

WP_032460140
1366
GGD
1368

WP_032461047
1366
GGD
1368

WP_032462016
1366
GGD
1368

WP_032462936
1366
GGD
1368

WP_032464890
1366
GGD
1368

WP_033888930
1191
GGD
1193

WP_038431314
1366
GGD
1368

WP_038432938
1365
GGD
1367

WP_038434062
1366
GGD
1368

BAQ51233
1277
GGD
1279

KGE60162
541
GGD
543

KGE60856
304
GGD
306

WP_002989955
1366
GGD
1368

WP_003030002
1343
GED
1345

WP_003065552
1371
GEE
1373

WP_001040076
1368
GED
1370

WP_001040078
1376
GED
1378

WP_001040080
1368
GED
1370

WP_001040081
1368
GED
1370

WP_001040083
1368
GED
1370

WP_001040085
1368
GED
1370

WP_001040087
1368
GED
1370

WP_001040088
1368
GGD
1370

WP_001040089
1368
GED
1370

WP_001040090
1368
GED
1370

WP_001040091
1368
GED
1370

WP_001040092
1368
GED
1370

WP_001040094
1368
GED
1370

WP_001040095
1368
GEG
1370

WP_001040096
1368
GEG
1370

WP_001040097
1368
GED
1370

WP_001040098
1368
GED
1370

WP_001040099
1368
GED
1370

WP_001040100
1368
GED
1370

WP_001040104
1368
GED
1370

WP_001040105
1368
GED
1370

WP_001040106
1368
GED
1370

WP_001040107
1368
GED
1370

WP_001040108
1368
GED
1370

WP_001040109
1368
GED
1370

WP_001040110
1368
GED
1370

WP_015058523
1368
GED
1370

WP_017643650
1368
GED
1370

WP_017647151
1368
GED
1370

WP_017648376
1368
GED
1370

WP_017649527
1368
GED
1370

WP_017771611
1368
GED
1370

WP_017771984
1368
GED
1370

CFQ25032
1368
GED
1370

CFV16040
1368
GED
1370

KLJ37842
1368
GED
1370

KLJ72361
1368
GGD
1370

KLL20707
1382
GED
1384

KLL42645
1368
GED
1370

WP_047207273
1368
GED
1370

WP_047209694
1368
GED
1370

WP_050198062
1368
GED
1370

WP_050201642
1368
GED
1370

WP_050204027
1368
GED
1370

WP_050881965
1368
GED
1370

WP_050886065
1368
GED
1370

AHN30376
1368
GED
1370

EA078426
1368
GED
1370

CCW42055
1368
GED
1370

WP_003041502
1384
GED
1386

WP_037593752
1344
GED
1346

WP_049516684
1344
GED
1346

GAD46167
1343
GED
1345

WP_018363470
1375
GEE
1377

WP_003043819
1373
GGD
1375

WP_006269658
1343
GED
1345

WP_048800889
1363
GED
1365

WP_012767106
1369
GGD
1371

WP_014612333
1369
GGD
1371

WP_015017095
1369
GGD
1371

WP_015057649
1369
GGD
1371

WP_048327215
1369
GGD
1371

WP_049519324
1369
GGD
1371

WP_012515931
1346
GEN
1348

WP_021320964
1346
GEN
1348

WP_037581760
1346
GEN
1348

WP_004232481
1375
GEE
1377

WP_009854540
1368
GEE
1370

WP_012962174
1369
GEE
1371

WP_039695303
1370
GEE
1372

WP_014334983
1373
GEE
1375

WP_003099269
1366
GGK
1368

AHY15608

---

AHY17476

---

ESR09100
198
GGK
200

AGM98575

---

ALF27331
1343
GGD
1345

WP_018372492
1351
GEN
1353

WP_045618028
1374
GED
1376

WP_045635197
1368
GED
1370

WP_002263549
1343
GGD
1345

WP_002263887
1343
GGD
1345

WP_002264920
1343
GGD
1345

WP_002269043
1343
GGD
1345

WP_002269448
1343
GGD
1345

WP_002271977
1343
GGD
1345

WP_002272766
1343
GGD
1345

WP_002273241
1343
GGD
1345

WP_002275430
1343
GGD
1345

WP_002276448
1343
GGD
1345

WP_002277050
1353
GGD
1355

WP_002277364
1343
GGD
1345

WP_002279025
1343
GGD
1345

WP_002279859
1343
GGD
1345

WP_002280230
1343
GGD
1345

WP_002281696
1343
GGD
1345

WP_002282247
1353
GGD
1355

WP_002282906
1343
GGD
1345

WP_002283846
1343
GGD
1345

WP_002287255
1343
GGD
1345

WP_002288990
1343
GGD
1345

WP_002289641
1343
GGD
1345

WP_002290427
1343
GGD
1345

WP_002295753
1343
GGD
1345

WP_002296423
1343
GGD
1345

WP_002304487
1357
GGD
1359

WP_002305844
1343
GGD
1345

WP_002307203
1343
GGD
1345

WP_002310390
1343
GGD
1345

WP_002352408
1343
GGD
1345

WP_012997688
1343
GGD
1345

WP_014677909
1343
GGD
1345

WP_019312892
1343
GGD
1345

WP_019313659
1343
GGD
1345

WP_019314093
1343
GGD
1345

WP_019315370
1343
GGD
1345

WP_019803776
1343
GGD
1345

WP_019805234
1343
GGD
1345

WP_024783594
1343
GGD
1345

WP_024784288
1353
GGD
1355

WP_024784666
1343
GGD
1345

WP_024784894
1343
GGD
1345

WP_024786433
1353
GGD
1355

WP_049473442
1343
GGD
1345

WP_049474547
1343
GGD
1345

EMC03581
1336
GGD
1338

WP_000428612
1371
GED
1373

WP_000428613
1369
GED
1371

WP_049523028
1364
GEE
1366

WP_003107102
1335
GGD
1337

WP_054279288
1366
GGD
1368

WP_049531101
1374
GED
1376

WP_049538452
1374
GED
1376

WP_049549711
1376
GED
1378

WP_007896501
1372
GGD
1374

EFR44625
1324
GGD
1326

WP_002897477
1368
GEE
1370

WP_002906454
1375
GED
1377

WP_009729476
1369
GED
1371

CQR24647
1359
GGE
1361

WP_000066813
1373
GED
1375

WP_009754323
1369
GED
1371

WP_044674937
1362
GGD
1364

WP_044676715
1364
GGD
1366

WP_044680361
1364
GGD
1366

WP_044681799
1362
GGD
1364

WP_049533112
1384
GED
1386

WP_029090905

---

WP_006506696

---

A1T42264
1366
GGD
1389

WP_034440723

AKQ21048
1366
GGD
1384

WP_004636532
1330
-ED
1332

WP_002364836
1336
-VD
1337

WP_016631044
1287
-VD
1288

EMS75795
1077
GEQ
1079

WP_002373311
1336
-VD
1337

WP_002378009
1336
-VD
1337

WP_002407324
1336
-VD
1337

WP_002413717
1336
-VD
1337

WP_010775580
1338
-VD
1339

WP_010818269
1336
-VD
1337

WP_010824395
1336
-VD
1337

WP_016622645
1336
-VD
1337

WP_033624816
1336
-VD
1337

WP_033625576
1336
-VD
1337

WP_033789179
1336
-VD
1337

WP_002310644

---

WP_002312694

---

WP_002314015

---

WP_002320716

---

WP_002330729

---

WP_002335161

---

WP_002345439

---

WP_034867970
1334
GEQ
1336

WP_047937432

---

WP_010720994
1334
GEQ
1336

WP_010737004
1334
GEQ
1336

WP_034700478
1334
GEQ
1336

WP_007209003

---

WP_023519017
1327
GER
1330

WP_010770040
1333
-VD
1334

WP_048604708
1329
-GD
1330

WP_010750235
1337
GVQ
1339

AII16583
1405
GGD
1424

WP_029073316

---

WP_031589969

---

KDA45870

---

WP_039099354

---

AKP02966

---

WP_010991369
1333
-DD
1334

WP_033838504
1333
-DD
1334

EHN60060
1336
-DD
1337

EFR89594
1102
-DD
1103

WP_038409211
1333
-ED
1334

EFR95520
952
-ED
953

WP_003723650
1333
-DD
1334

WP_003727705
1333
-DD
1334

WP_003730785
1333
-DD
1334

WP_003733029
1333
-DN
1334

WP_003739838
1333
-DG
1334

WP_014601172
1333
-DD
1334

WP_023548323
1333
-DS
1334

WP_031665337
1333
-DD
1334

WP_031669209
1333
-DN
1334

WP_033920898
1333
-DS
1334

AKI42028
1336
-DD
1337

AKI50529
1336
-DS
1337

EFR83390
781
-DD
782

WP_046323366
1333
-DD
1334

AKE81011
1382
GGD
1400

CUO82355

---

WP_033162887

---

AGZ01981
1399
GGD
1417

AKA60242
1366
GGD
1368

AKS40380
1366
GGD
1376

4UN5_B
1370
GGD
1372

TABLE 2

T to C changes with NGG PAM. Table 2 shows a list of T to C mutations that may

be corrected using any of the base editors provided herein. GRNAs and gRNAall indicate the

protospacer and PAM sequence, where the PAM sequence is the last 3 nucleotides of each of

the sequences in GRNAs and gRNAall.

SEQ

SEQ

SEQ

Gene
Gene
ID

ID

ID

Name
ID
Symbol
NO:
Flanks
NO:
GRNAs
NO:
gRNAall

NM_000071.2
875
CBS
2540
[′CTGAAGCCGC
2703-
[′ATCAYTGGGGTG
2907-
[′ATCAYTGGGGTG

(CBS):c.833T>C

GCCCTCTGCAG
2704
GATCCCGAAGG′,
2908
GATCCCGAAGG′,

(p.Ile278Thr)

ATCAYTGGGGT

′TCAYTGGGGTGGA

′TCAYTGGGGTGG

GGATCCCGAA

TCCCGAAGGG′]

ATCCCGAAGGG′]

GGGTCCATC′]

NM_001385.2
1807
DPYS
2541
[′TGTTGAAGAT
2705-
[′CGTAATAYGGGA
2909-
[′CGTAATAYGGGA

(DPYS):c.1078T>C

CGGATGTCCGT
2707
AAAAGGCGTGG′,
2911
AAAAGGCGTGG′,

(p.Trp360Arg)

AATAYGGGAA

′AATAYGGGAAAA

′AATAYGGGAAAA

AAAGGCGTGG

AGGCGTGGTGG′,

AGGCGTGGTGG′,

TGGGTTTCAC′]

′ATAYGGGAAAAA

′ATAYGGGAAAAA

GGCGTGGTGGG′]

GGCGTGGTGGG′]

NM_000027.3
175
AGA
2542
[′TCCAGAATTC
2708
[′GTTATAYGTGCC
2912
[′GTTATAYGTGCC

(AGA):c.916T>C

TTTGGGGCTGT

AATGTGACTGG′]

AATGTGACTGG′]

(p.Cys306Arg)

TATAYGTGCCA

ATGTGACTGGA

AGTTACGG′]

NM_000035.3
229
ALDOB
2543
[′GAAAGATGGT
2709
[′GGAAGYGGCGTG
2913
[′GGAAGYGGCGT

(ALDOB):c.442T>C

GTTGACTTTGG

CTGTGCTGAGG′]

GCTGTGCTGAGG′]

(p.Trp148Arg)

GAAGYGGCGT

GCTGTGCTGAG

GATTGCCGA′]

NM_173560.3
222546
RFX6
2544
[′GCAGACACAG
2710-
[′CAGTGGYGAGAC
2914-
[′CAGTGGYGAGAC

(RFX6):c.380+2T>C

CTCACGCTGCA
2711
TCGCCCGCAGG′,
2915
TCGCCCGCAGG′,

GTGGYGAGAC

′AGTGGYGAGACTC

′AGTGGYGAGACT

TCGCCCGCAGG

GCCCGCAGGG′]

CGCCCGCAGGG′]

GTACACTGA′]

NM_153704.5
91147
TMEM67
2545
[′AGAACGTTTT
2712
[′TGGAHGTGCCTTT
2916
[′TGGAHGTGCCTT

(TMEM67):c.1843T>C

GTCACTTATGT

GCTCTGAAGG′]

TGCTCTGAAGG′]

(p.Cys615Arg)

TGGAHGTGCCT

TTGCTCTGAAG

GTAAGTTT′]

NM_000124.3
2074
ERCC6
2546
[′AAGCAGTTTT
2713
[′TGCYAAAAGACC
2917
[′TGCYAAAAGACC

(ERCC6):c.2960T>C

TGACAAATAG

CAAAACAAAGG′]

CAAAACAAAGG′]

(p.Leu987Pro)

AGTGCYAAAA

GACCCAAAAC

AAAGGCGGTTT′]

NM_020435.3
57165
GJC2
2547
[′TGCCTGCTGC
2714
[′TGAGAYGGCCCA
2918-
[′TGAGAYGGCCCA

(GJC2):c.857T>C

TCAACCTCTGT

CCTGGGCTTGG′]
2919
CCTGGGCTTGG′,

(p.Met286Thr)

GAGAYGGCCC

′GAGAYGGCCCAC

ACCTGGGCTTG

CTGGGCTTGGG′]

GGCAGCGCG′]

NM_000920.3
5091
PC
2548
[′CGGTTTATTG
2715
[′CCAGAAGBGGTC
2920
[′CCAGAAGBGGTC

(PC):c.434T>C

GGCCAAGCCC

CGCAAGATGGG′]

CGCAAGATGGG′]

(p.Val145Ala)

AGAAGBGGTC

CGCAAGATGG

GAGACAAGGTG′]

NM_000026.2
158
ADSL
2549
[′TCCAAGGTAG
2716
[′AAGAYGGTGACA
2921
[′AAGAYGGTGAC

(ADSL):c.674T>C

AGCAGCTTGAC

GAAAAGGCAGG′]

AGAAAAGGCAGG′]

(p.Met225Thr)

AAGAYGGTGA

CAGAAAAGGC

AGGATTTAAG′]

NM_000391.3
1200
TPP1
2550
[′TCTCTCAGGT
2717
[′GCCGGGYGTTGG
2922
[′GCCGGGYGTTGG

(TPP1):c.1093T>C

GACAGTGGGG

TCTGTCTCTGG′]

TCTGTCTCTGG′]

(p.Cys365Arg)

CCGGGYGTTG

GTCTGTCTCTG

GAAGACACCA′]

NM_004183.3
7439
BEST1
2551
[′TACGACTGGA
2718
[′CACTGGYGTATA
2923
[′CACTGGYGTATA

(BEST1):c.704T>C

TTAGTATCCCA

CACAGGTGAGG′]

CACAGGTGAGG′]

(p.Val235Ala)

CTGGYGTATAC

ACAGGTGAGG

ACTAGGCTG′]

NM_000019.3
38
ACAT1
2552
[′CTCAATGTTA
2719
[′CAAGAAYAGTAG
2924
[′CAAGAAYAGTA

(ACAT1):c.935T>C

CACCACTGGCA

GTAAGGCCAGG′]

GGTAAGGCCAGG′]

(p.Ile312Thr)

AGAAYAGTAG

GTAAGGCCAG

GCGAGGTGGC′]

NM_000543.4
6609
SMPD1
2553
[′CGGGCCCTGA
2720
[′CACYTGTGAGGA
2925-
[′AGCACYTGTGAG

(SMPD1):c.911T>C

CCACCGTCACA

AGTTCCTGGGG′]
2927
GAAGTTCCTGG′,

(p.Leu304Pro)

GCACYTGTGA

′GCACYTGTGAGG

GGAAGTTCCTG

AAGTTCCTGGG′,

GGGCCAGTG′]

′CACYTGTGAGGA

AGTTCCTGGGG′]

NM_000527.4
3949
LDLR
2554
[′ACAAATCTGA
2721
[′CGGYATGGGCGG
2928-
[′ACTGCGGYATGG

(LDLR):c.694+2T>C

CGAGGAAAAC

GGCCAGGGTGG′]
2930
GCGGGGCCAGG′,

TGCGGYATGG

′CTGCGGYATGGG

GCGGGGCCAG

CGGGGCCAGGG′,

GGTGGGGGCGG′]

′CGGYATGGGCGG

GGCCAGGGTGG′]

NM_012464.4
7092
TLL1
2555
[′AAGAACTGTG
2722
[′GGGATTGYTGTTC
2931
[′GGGATTGYTGTT

(TLL1):c.713T>C

ATAAATTTGGG

ATGAATTGGG′]

CATGAATTGGG′]

(p.Val238Ala)

ATTGYTGTTCA

TGAATTGGGTC

ATGTGATA′]

NM_000112.3
1836
SLC26A2
2556
[′CCTGCAGCGG
2723
[′GAGAGGYGAGAA
2932
[′GAGAGGYGAGA

(SLC26A2):c.-26+2T>C

CCCGGACCCG

GAGGGAAGCGG′]

AGAGGGAAGCGG′]

AGAGGYGAGA

AGAGGGAAGC

GGACCAGGGA

A′]

NM_001005741.2
2629
GBA
2557
[′CATCTACCAC
2724
[′GCCAGAYACTTT
2933-
[′GCCAGAYACTTT

(GBA):c.751T>C

CAGACCTGGG

GTGAAGTAAGG′]
2934
GTGAAGTAAGG′,

(p.Tyr251His)

CCAGAYACTTT

′CCAGAYACTTTGT

GTGAAGTAAG

GAAGTAAGGG′]

GGATCAGCAA′]

NM_020365.4
8891
EIF2B3
2558
[′CCACCAGTCC
2725
[′CCAGAYTGTCAG
2935
[′CCAGAYTGTCAG

(EIF2B3):c.1037T>C

ATTCGTCAGCC

CAAACACCTGG′]

CAAACACCTGG′]

(p.Ile346Thr)

CAGAYTGTCA

GCAAACACCT

GGTAAGTGCT′]

NM_022041.3
8139
GAN
2559
[′TGCTATGCAG
2726
[′AAGAAAAYCTAC
2936-2937
[′AAGAAAAYCTAC

(GAN):c.1268T>C

CTATGAAAAA

GCCATGGGTGG′]

GCCATGGGTGG′,

(p.Ile423Thr)

GAAAAYCTAC

′AAAAYCTACGCC

GCCATGGGTG

ATGGGTGGAGG′]

GAGGCTCCTAC′]

NM_054027.4
56172
ANKH
2560
[′GCTGTCAAGG
2727-
[′GTCGAGAYGCTG
2938-2939
[′GTCGAGAYGCTG

(ANKH):c.143T>C

AGGATGCAGT
2728
GCCAGCTACGG′,

GCCAGCTACGG′,

(p.Met48Thr)

CGAGAYGCTG

′TCGAGAYGCTGGC

′TCGAGAYGCTGG

GCCAGCTACG

CAGCTACGGG′]

CCAGCTACGGG′]

GGCTGGCGTAC′]

NM_006329.3
10516
FBLN5
2561
[′TTGCTTGCAT
2729
[′GACAYTGATGAA
2940
[′GACAYTGATGAA

(FBLN5):c.506T>C

TTCTGTTTCCA

TGTCGCTATGG′]

TGTCGCTATGG′]

(p.Ile169Thr)

GACAYTGATG

AATGTCGCTAT

GGTTACTGC′]

NM_004086.2
−1
—
2562
[′GCACCTCTGG
2730
[′AGATAYGGCTTC
2941
[′AGATAYGGCTTC

(COCH):c.1535T>C

ATGACCTGAA

TAAACCGAAGG′]

TAAACCGAAGG′]

(p.Met512Thr)

AGATAYGGCTT

CTAAACCGAA

GGAGTCTCAT′]

NM_002942.4
6092
ROBO2
2563
[′AATAGCAACA
2731
[′GAGAYTGGAAAT
2942
[′GAGAYTGGAAAT

(ROBO2):c.2834T>C

GTGGCCCAAAT

TTTGGCCGTGG′]

TTTGGCCGTGG′]

(p.Ile945Thr)

GAGAYTGGAA

ATTTTGGCCGT

GGAGGTAAG′]

NM_001300.5
1316
KLF6
2564
[′CAAATTTGAC
2732
[′TCTGYGGACCAA
2943
[′TCTGYGGACCAA

(KLF6):c.190T>C

AGCCAGGAAG

AATCATTCTGG′]

AATCATTCTGG′]

(p.Trp64Arg)

ATCTGYGGACC

AAAATCATTCT

GGCTCGGGA′]

NM_030653.3
1663
DDX11
2565
[′CTGGCATATT
2733
[′TCCAGGYGCGGG
2944-2945
[′TCCAGGYGCGGG

(DDX11):c.2271+2T>C

CCAGGTGCATC

CGTCATGCTGG′]

CGTCATGCTGG′,

CAGGYGCGGG

′CCAGGYGCGGGC

CGTCATGCTGG

GTCATGCTGGG′]

GCTTGGGTC′]

NM_001451.2
2294
FOXF1
2566
[′CCAAGACATC
2734
[′TGATGYGAGGCT
2946
[′TGATGYGAGGCT

(FOXF1):c.1138T>C

AAGCCTTGCGT

GCCGCCGCAGG′]

GCCGCCGCAGG′]

(p.Ter380Arg)

GATGYGAGGC

TGCCGCCGCAG

GCCCTCCTG′]

NM_000435.2
4854
NOTCH3
2567
[′CCTCGACCGC
2735
[′ACCYGTATCTGTA
294-72948
[′TTCACCYGTATC

(NOTCH3):c.1363T>C

ATAGGCCAGTT

TGGCAGGTGG′]

TGTATGGCAGG′,

(p.Cys455Arg)

CACCYGTATCT

′ACCYGTATCTGTA

GTATGGCAGGT

TGGCAGGTGG′]

GGGTGGTG′]

NM_002427.3
4322
MMP13
2568
[′CTTGACGATA
2736-
[′GTCAYGAAAAAG
2949-2950
[′GTCAYGAAAAA

(MMP13):c.272T>C

ACACCTTAGAT
2737
CCAAGATGCGG′,

GCCAAGATGCGG′,

(p.Met91Thr)

GTCAYGAAAA

′TCAYGAAAAAGCC

′TCAYGAAAAAGC

AGCCAAGATG

AAGATGCGGG′]

CAAGATGCGGG′]

CGGGGTTCCT′]

NM_000211.4
3689
ITGB2
2569
[′GATGACCTCA
2738
[′AGCYAGGTGGCG
2951
[′AGCYAGGTGGCG

(ITGB2):c.446T>C

GGAATGTCAA

ACCTGCTCCGG′]

ACCTGCTCCGG′]

(p.Leu149Pro)

GAAGCYAGGT

GGCGACCTGCT

CCGGGCCCTC′]

NM_005502.3
19
ABCA1
2570
[′CAAAATCAAG
2739-
[′CCTGTGYGTCCCC
2952-2955
[′CCTGTGYGTCCC

(ABCA1):c.4429T>C

AAGATGCTGCC
2740
CAGGGGCAGG′,

CCAGGGGCAGG′,

(p.Cys1477Arg)

TGTGYGTCCCC

′CTGTGYGTCCCCC

′CTGTGYGTCCCCC

CAGGGGCAGG

AGGGGCAGGG′]

AGGGGCAGGG′,

GGGGCTGCC′]

′TGTGYGTCCCCCA

GGGGCAGGGG′,

′GTGYGTCCCCCA

GGGGCAGGGGG′]

m.12297T>C
4568
MT-TL2
2571
[′AAAGGATAAC
2741
[′GTCYTAGGCCCC
2956
[′GTCYTAGGCCCC

AGCTATCCATT

AAAAATTTTGG′]

AAAAATTTTGG′]

GGTCYTAGGCC

CCAAAAATTTT

GGTGCAAC′]

m.4290T>C
4565
MT-TI
2572
[′AAATATGTCT
2742
[′ACTYTGATAGAG
2957
[′ACTYTGATAGAG

GATAAAAGAG

TAAATAATAGG′]

TAAATAATAGG′]

TTACTYTGATA

GAGTAAATAA

TAGGAGCTTA′]

m.4291T>C
4565
MT-TI
2573
[′AATATGTCTG
2743
[′ACTTYGATAGAG
2958
[′ACTTYGATAGAG

ATAAAAGAGT

TAAATAATAGG′]

TAAATAATAGG′]

TACTTYGATAG

AGTAAATAAT

AGGAGCTTAA′]

m.3394T>C
4535
MT-ND1
2574
[′GCTTACCGAA
2744
[′GGCYATATACAA
2959
[′GGCYATATACAA

CGAAAAATTCT

CTACGCAAAGG′]

CTACGCAAAGG′]

AGGCYATATA

CAACTACGCA

AAGGCCCCAA′]

NM_002764.3
5631
PRPS1
2575
[′ATCTCAGCCA
2745
[′GCAAATAYGCTA
2960
[′GCAAATAYGCTA

(PRPS1):c.344T>C

AGCTTGTTGCA

TCTGTAGCAGG′]

TCTGTAGCAGG′]

(p.Met115Thr)

AATAYGCTATC

TGTAGCAGGTG

CAGATCAT′]

NM_000132.3
2157
F8
2576
[′AGAGCAGAA
2746
[′TCAYGGTGAGTT
2961
[′TCAYGGTGAGTT

(F8):c.5372T>C

GTTGAAGATA

AAGGACAGTGG′]

AAGGACAGTGG′]

(p.Met1791Thr)

ATATCAYGGTG

AGTTAAGGAC

AGTGGAATTAC′]

NM_000132.3
2157
F8
2577
[′CCTTTCAATA
2747
[′AACAGAYAATGT
2962
[′AACAGAYAATGT

(F8):c.1754T>C

TATGTAATTAA

CAGACAAGAGG′]

CAGACAAGAGG′]

(p.Ile585Thr)

CAGAYAATGT

CAGACAAGAG

GAATGTCATC′]

NM_000133.3
2158
F9
2578
[′TGTGCAATGA
2748
[′GAAYATATACCA
2963
[′GAAYATATACCA

(F9):c.1328T>C

AAGGCAAATA

AGGTATCCCGG′]

AGGTATCCCGG′]

(p.Ile443Thr)

TGGAAYATAT

ACCAAGGTATC

CCGGTATGTC′]

NM_000169.2
−1
—
2579
[′TTATTTCATTC
2749
[′CAGTTAGYGATT
2964
[′CAGTTAGYGATT

(GLA):c.806T>C

TTTTTCTCAGT

GGCAACTTTGG′]

GGCAACTTTGG′]

(p.Val269Ala)

TAGYGATTGGC

AACTTTGGCCT

CAGCTGG′]

NM_000116.4
6901
TAZ
2580
[′CTCCCACTTC
2750
[′AAGYGTGTGCCT
2965
[′AAGYGTGTGCCT

(TAZ):c.352T>C

TTCAGCTTGGG

GTGTGCCGAGG′]

GTGTGCCGAGG′]

(p.Cys118Arg)

CAAGYGTGTG

CCTGTGTGCCG

AGGTGAGCT′]

NM_000061.2
695
BTK
2581
[′GGTGAACTCC
2751
[′AGCTAYGGCCGC
2966
[′AGCTAYGGCCGC

(BTK):c.2T>C

AGAAAGAAGA

AGTGATTCTGG′]

AGTGATTCTGG′]

(p.Met1Thr)

AGCTAYGGCC

GCAGTGATTCT

GGAGAGCATC′]

NM_000061.2
695
BTK
2582
[′AAGGACCTGA
2752
[′AGCYGGGGACTG
2967-2968
[′GAGCYGGGGACT

(BTK):c.1223T>C

CCTTCTTGAAG

GACAATTTGGG′]

GGACAATTTGG′,

(p.Leu408Pro)

GAGCYGGGGA

′AGCYGGGGACTG

CTGGACAATTT

GACAATTTGGG′]

GGGGTAGTG′]

NM_000061.2
695
BTK
2583
[′CAAGTTCAGC
2753
[′ACATTYGGGCTTT
2969
[′ACATTYGGGCTT

(BTK):c.1741T>C

AGCAAATCTG

TGGTAAGTGG′]

TTGGTAAGTGG′]

(p.Trp581Arg)

ACATTYGGGCT

TTTGGTAAGTG

GATAAGATT′]

NM_014009.3
50943
FOXP3
2584
[′GATTCATCCC
2754
[′GACAGAGYTCCT
2970
[′GACAGAGYTCCT

(FOXP3):c.970T>C

CACCCTCTGAC

CCACAACATGG′]

CCACAACATGG′]

(p.Phe324Leu)

AGAGYTCCTCC

ACAACATGGA

CTACTTCAA′]

NM_003688.3
8573
CASK
2585
[′TGAGCTCGTG
2755-
[′CACAGYGGGTCC
2971-2972
[′CACAGYGGGTCC

(CASK):c.2740T>C

TGCACAGCCCC
2756
CTGTCTCCTGG′,

CTGTCTCCTGG′,

(p.Trp914Arg)

ACAGYGGGTC

′ACAGYGGGTCCCT

′ACAGYGGGTCCC

CCTGTCTCCTG

GTCTCCTGGG′]

TGTCTCCTGGG′]

GGTCTATTA′]

NM_004992.3
4204
MECP2
2586
[′GACACATCCC
2757
[′GATTBTGACTTCA
2973-2974
[′GATTBTGACTTC

(MECP2):c.464T>C

TGGACCCTAAT

CGGTAACTGG′]

ACGGTAACTGG′,

(p.Phe155Ser)

GATTBTGACTT

′ATTBTGACTTCAC

CACGGTAACTG

GGTAACTGGG′]

GGAGAGGG′]

NM_000431.3
4598
MVK
2587
[′ATCGTGGCCC
2758
[′CTCAAYAGATGC
2975
[′CTCAAYAGATGC

(MVK):c.803T>C

CCCTCCTGACC

CATCTCCCTGG′]

CATCTCCCTGG′]

(p.Ile268Thr)

TCAAYAGATG

CCATCTCCCTG

GAGTGTGAG′]

NM_021961.5
7003
TEAD1
2588
[′TGAACACGGA
2759
[′TCATATTYACAG
2976
[′TCATATTYACAG

(TEAD1):c.1261T>C

GCACAACATC

GCTTGTAAAGG′]

GCTTGTAAAGG′]

(p.Tyr?His)

ATATTYACAGG

CTTGTAAAGGA

CTGAACATG′]

NM_005633.3
6654
SOS1
2589
[′CGAGATTCAG
2760
[′GGTYGGGAGGGA
2977
[′GGTYGGGAGGG

(SOS1):c.1294T>C

AAGAATATTG

AAAGACATTGG′]

AAAAGACATTGG′]

(p.Trp432Arg)

ATGGTYGGGA

GGGAAAAGAC

ATTGGACAGTG′]

NM_006920.4
−1
—
2590
[′TGTGGAAGAA
2761
[′AACAAYGGTGGA
2978
[′AACAAYGGTGG

(SCN1A):c.3577T>C

GGCAGAGGAA

ACCTGAGAAGG′]

AACCTGAGAAGG′]

(p.Trp1193Arg)

AACAAYGGTG

GAACCTGAGA

AGGACGTGTTT′]

NM_000141.4
2263
FGFR2
2591
[′TGTAACTTTT
2762-
[′TGGGGAAYATAC
2979-2980
[′TGGGGAAYATAC

(FGFR2):c.1018T>C

GAGGACGCTG
2763
GTGCTTGGCGG′,

GTGCTTGGCGG′,

(p.Tyr340His)

GGGAAYATAC

′GGGGAAYATACGT

′GGGGAAYATACG

GTGCTTGGCGG

GCTTGGCGGG′]

TGCTTGGCGGG′]

GTAATTCTAT′]

NM_000174.4
2815
GP9
2592
[′GGCCACCAAG
2764
[′CCCAYGTACCTG
2981
[′CCCAYGTACCTG

(GP9):c.70T>C

GACTGCCCCAG

CCGCGCCCTGG′]

CCGCGCCCTGG′]

(p.Cys24Arg)

CCCAYGTACCT

GCCGCGCCCTG

GAAACCAT′]

NM_000175.3
2821
GPI
2593
[′CTGGGAAAGC
2765
[′AAAABAGAGCCT
2982
[′AAAABAGAGCCT

(GPI):c.1574T>C

AGCTGGCTAA

GAGCTTGATGG′]

GAGCTTGATGG′]

(p.Ile525Thr)

GAAAABAGAG

CCTGAGCTTGA

TGGCAGTGCT′]

NM_000315.2
5741
PTH
2594
[′AGTTATGATT
2766
[′AATTYGTTTTCTT
2983
[′AATTYGTTTTCTT

(PTH):c.52T>C

GTCATGTTGGC

ACAAAATCGG′]

ACAAAATCGG′]

(p.Cys18Arg)

AATTYGTTTTC

TTACAAAATCG

GATGGGAA′]

NM_000222.2
3815
KIT
2595
[′CCCATGTATG
2767
[′AAGGNTGTTGAG
2984
[′AAGGNTGTTGAG

(KIT):c.1676T>C

AAGTACAGTG

GAGATAAATGG′]

GAGATAAATGG′]

(p.Val559Ala)

GAAGGNTGTT

GAGGAGATAA

ATGGAAACAAT′]

NM_016835.4
4137
MAPT
2596
[′AGTCCAAGTG
2768-
[′GGATAAYATCAA
2985-2986
[′GGATAAYATCAA

(MAPT):c.1839T>C

TGGCTCAAAG
2769
ACACGTCCCGG′,

ACACGTCCCGG′,

(p.Asn613=)

GATAAYATCA

′GATAAYATCAAAC

′GATAAYATCAAA

AACACGTCCCG

ACGTCCCGGG′]

CACGTCCCGGG′]

GGAGGCGGCA′]

NM_170707.3
4000
LMNA
2597
[′GAGATCCACG
2770
[′TCTYGGAGGGCG
2987
[′TCTYGGAGGGCG

(LMNA):c.1139T>C

CCTACCGCAAG

AGGAGGAGAGG′]

AGGAGGAGAGG′]

(p.Leu380Ser)

CTCTYGGAGG

GCGAGGAGGA

GAGGTGGGCT′]

NM_000424.3
3852
KRT5
2598
[′GCCACCATGT
2771-
[′TCAAGTGYGTCCT
2988-2991
[′TCAAGTGYGTCC

(KRT5):c.20T>C

CTCGCCAGTCA
2773
TCCGGAGCGG′,

TTCCGGAGCGG′,

(p.Val7Ala)

AGTGYGTCCTT

′CAAGTGYGTCCTT

′CAAGTGYGTCCTT

CCGGAGCGGG

CCGGAGCGGG′,

CCGGAGCGGG′,

GGCAGTCGT′]

′AAGTGYGTCCTTC

′AAGTGYGTCCTTC

CGGAGCGGGG′]

CGGAGCGGGG′,

′AGTGYGTCCTTCC

GGAGCGGGGG′]

NM_000184.2
3048
HBG2
2599
[′GTTGTCTACC
2774
[′CAGAGGTYCTTT
2992
[′CAGAGGTYCTTT

(HBG2):c.125T>C

CATGGACCCA

GACAGCTTTGG′]

GACAGCTTTGG′]

(p.Phe42Ser)

GAGGTYCTTTG

ACAGCTTTGGC

AACCTGTCC′]

NM_000515.4
2688
GH1
2600
[′AGGAAACAC
2775
[′TGAGYGGATGCC
2993
[′TGAGYGGATGCC

(GH1):c.291+6T>C

AACAGAAATC

TTCTCCCCAGG′]

TTCTCCCCAGG′]

CGTGAGYGGA

TGCCTTCTCCC

CAGGCGGGGAT′]

NM_002087.3
2896
GRN
2601
[′TCCTTGGTAC
2776
[′CCAYGTGGACCC
2994
[′CCAYGTGGACCC

GRN):c.2T>C

TTTGCAGGCAG

TGGTGAGCTGG′]

TGGTGAGCTGG′]

(p.Met1Thr)

ACCAYGTGGA

CCCTGGTGAGC

TGGGTGGCC′]

NM_001083112.2
2820
GPD2
2602
[′AGGTATAAGA
2777
[′AAGTYTGATGCA
2995
[′AAGTYTGATGCA

(GPD2):c.1904T>C

AGAGATTTCAT

GACCAGAAAGG′]

GACCAGAAAGG′]

(p.Phe635Ser)

AAGTYTGATGC

AGACCAGAAA

GGCTTTATT′]

NM_00101807
2908
NR3C1
2603
[′CTCAACATGT
2778
[′AAGYGATTGCAG
2996
[′AAGYGATTGCAG

7.1(NR3C1):c.1712T>C

TAGGAGGGCG

CAGTGAAATGG′]

CAGTGAAATGG′]

(p.Val571Ala)

GCAAGYGATT

GCAGCAGTGA

AATGGGCAAAG′]

NM_006306.3
8243
SMC1A
2621
[′GTGTTTGAAG
2798
[′AGAYTGGTGTGC
3017
[′AGAYTGGTGTGC

(SMC1A):c.2351T>C

AGTTTTGTCGG

GCAACATCCGG′]

GCAACATCCGG′]

(p.11e784Thr)

GAGAYTGGTG

TGCGCAACATC

CGGGAGTTT′]

NM_002242.4
−1
—
2622
[′TGGTGTAATG
2799
[′GTTDGTGGAAAG
3018
[′GTTDGTGGAAAG

(KCN.113):c.722T>C

GAGTGATAGT

ATGAAGAATGG′]

ATGAAGAATGG′]

(p.Leu241Pro)

ACGTTDGTGGA

AAGATGAAGA

ATGGACATTC′]

NM_000199.3
6448
SGSH
2623
[′CCCCAGCGTT
2800
[′TCCGGGGRTGAC
3019
[′TCCGGGGRTGAC

(SGSH):c.892T>C

TTGGGTGCTCC

ACCAGTAAGGG′]

ACCAGTAAGGG′]

(p.Ser298Pro)

GGGGRTGACA

CCAGTAAGGG

TTCAGCAGTG′]

NM_020191.2
56945
MRPS22
2624
[′CCAATAATTT
2801
[′ATCYTAGGGTAA
3020
[′ATCYTAGGGTAA

(MRPS22):c.644T>C

TCAAGGAAGA

GGTGACTTAGG′]

GGTGACTTAGG′]

(p.Leu215Pro)

AAATCYTAGG

GTAAGGTGACT

TAGGTTTTAT′]

NM_017882.2
54982
CLN6
2625
[′CCCATTCTTC
2802
[′AGCYGGTATTCC
3021
[′AGCYGGTATTCC

(CLN6):c.200T>C

CATTTGCTCCG

CTCTCGAGTGG′]

CTCTCGAGTGG′]

(p.Leu67Pro)

CAGCYGGTATT

CCCTCTCGAGT

GGTTTCCA′]

NM_014874.3
9927
MFN2
2626
[′GTAGTCCTCA
2803
[′AATGWGAGTCAT
3022
[′AATGWGAGTCA

(MFN2):c.1392+2T>C

AGGTTTATAAG

GGAGCAACAGG′]

TGGAGCAACAGG′]

AATGWGAGTC

ATGGAGCAAC

AGGTCCTCTT′]

NM_024599.5
79651
RHBDF2
2627
[′GCTTACCGCC
2804
[′AGAYTGTGGATC
3023
[′AGAYTGTGGATC

(RHBDF2):c.557T>C

CCCCTCCCTTC

CGCTGGCCCGG′]

CGCTGGCCCGG′]

(p.11e186Thr)

CAGAYTGTGG

ATCCGCTGGCC

CGGGGCCGG′]

NM_020894.2
57654
UVSSA
2628
[′GAAAATGAA
2805
[′AAAATTYGCAAG
3024-3025
[′AAAATTYGCAAG

(UVSSA):c.94T>C

GGAACTGAAG

TATGTCTTAGG′]

TATGTCTTAGG′,

(p.Cys32Arg)

AAAATTYGCA

′AAATTYGCAAGT

AGTATGTCTTA

ATGTCTTAGGG′]

GGGTTCAGTAA′]

NM_001161581.1
25886
POC1A
2629
[′GCCAGTGATG
2806
[′AGCYGTGGGACA
3026
[′AGCYGTGGGACA

(POC1A):c.398T>C

ACAAGACTGTT

AGAGCAGCCGG′]

AGAGCAGCCGG′]

(p.Leu133Pro)

AAGCYGTGGG

ACAAGAGCAG

CCGGGAATGT′]

NM_005340.6
3094
HINT1
2630
[′ACACTTAATG
2807-
[′CAAGAAAYGTGC
3027-3028
[′CAAGAAAYGTGC

(HINT1):c.250T>C

ATTGTTGGCAA
2808
TGCTGATCTGG′,

TGCTGATCTGG′,

(p.Cys84Arg)

GAAAYGTGCT

′AAGAAAYGTGCTG

′AAGAAAYGTGCT

GCTGATCTGGG

CTGATCTGGG′]

GCTGATCTGGG′]

CCTGAATAA′]

NM_000495
1287
COL4A5
2631
[′TTTCCTGGTTT
2809
[′TCCAGYAAGTTA
3029-3030
[′CTCCAGYAAGTT

(COL4A5):c.438+2T>C

ACAGGGTCCTC

TAAAATTTGGG′]

ATAAAATTTGG′,

CAGYAAGTTAT

′TCCAGYAAGTTA

AAAATTTGGG

TAAAATTTGGG′]

ATTATGAT′]

NM_000344.3
6606
SMN1
2632
[′AACCTGTGTT
2810
[′CACTGGAYATGG
3031
[′CACTGGAYATGG

(SMN1):c.388T>C

GTGGTTTACAC

AAATAGAGAGG′]

AAATAGAGAGG′]

(p.Tyr130His)

TGGAYATGGA

AATAGAGAGG

AGCAAAATCT′]

NM_005334.2
3054
HCFC1
2633
[′TTAGTTGTTA
2811
[′CAAGAYGGCGGC
3032
[′CAAGAYGGCGG

(HCFC1):c.-970T>C

CTTCTTCACAC

TCCCAGGGAGG′]

CTCCCAGGGAGG′]

AAGAYGGCGG

CTCCCAGGGA

GGAGGCATGA′]

NM_000431.3
4598
MVK
2634
[′GTGGCATCAC
2812
[′CCAGGYATCCCG
3033-3034
[′CCAGGYATCCCG

(MVK):c.1039+2T>C

ACTCCTCAAGC

GGGGTAGGTGG′]

GGGGTAGGTGG′,

CAGGYATCCC

′CAGGYATCCCGG

GGGGGTAGGT

GGGTAGGTGGG′]

GGGCCAGGCT′]

NM_018344.5
55315
SLC29A3
2635
[′TATGAGGAAC
2813
[′ACTGATAYCAGG
3035-3036
[′ACTGATAYCAGG

(SLC29A3):c.607T>C

TCCCAGGCACT

TGAGAGCCAGG′]

TGAGAGCCAGG′,

(p.Ser203Pro)

GATAYCAGGT

′CTGATAYCAGGT

GAGAGCCAGG

GAGAGCCAGGG′]

GTCCGGGCAG′]

NM_000108.4
1738
DLD
2636
[′GTAGTTGATG
2815
[′ACAGTTAYAGGT
3037-3038
[′ACAGTTAYAGGT

(DLD):c.140T>C

CTGATGTAACA

TCTGGTCCTGG′,

TCTGGTCCTGG′,

(p.Ile47Thr)

GTTAYAGGTTC

′GTTAYAGGTTCTG

′GTTAYAGGTTCTG

TGGTCCTGGAG

GTCCTGGAGG′]

GTCCTGGAGG′]

GATATGTT′]

NM_004333.4
673
BRAF
2637
[′GGACAAAGA
2816-
[′ATCATYTGGAAC
3039-3040
[′ATCATYTGGAAC

(BRAF):c.1403T>C

ATTGGATCTGG
2817
AGTCTACAAGG′,

AGTCTACAAGG′,

(p.Phe468Ser)

ATCATYTGGAA

′TCATYTGGAACAG

′TCATYTGGAACA

CAGTCTACAAG

TCTACAAGGG′]

GTCTACAAGGG′]

GGAAAGTGG′]

NM_000540.2
6261
RYR1
2638
[′CAGGAGGAGT
2818
[′CGCAYGATCCAC
3041
[′CGCAYGATCCAC

(RYR1):c.1205T>C

CCCAGGCCGCC

AGCACCAATGG′]

AGCACCAATGG′]

(p.Met402Thr)

CGCAYGATCC

ACAGCACCAA

TGGCCTATAC′]

NM_000256.3
4607
MYBPC3
2639
[′GTAGCACGGA
2819
[′AAAGGYGGGCCT
3042
[′AAAGGYGGGCCT

(MYBPC3):c.1351+2T>C

GCTCTTTGTGA

GGGACCTGAGG′]

GGGACCTGAGG′]

AAGGYGGGCC

TGGGACCTGA

GGATGTGGGA′]

NM_000256.3
4607
MYBPC3
2640
[′CCTCCTATCA
2820
[′CACGYGAGTGGC
3043-3044
CCATCCTCAGG′,

GCCTTCCGCCG

CATCCTCAGGG′]

′CACGYGAGTGGC

(MYBPC3):c.821+2T>C

CACGYGAGTG

CATCCTCAGGG′]

GCCATCCTCAG

GGCCTGGGG′]

NM_000257.3
4625
MYH7
2641
[′AAGAGTGCAG
2821
[′GGAGAYGGCCTC
3045
[′GGAGAYGGCCTC

(MYH7):c.2546T>C

AAAGAGAGAA

CATGAAGGAGG′]

CATGAAGGAGG′]

(p.Met849Thr)

GGAGAYGGCC

TCCATGAAGG

AGGAGTTCACA′]

NM_206933.2
7399
USH2A
2642
[′CGACACAACA
2822
[′ATATAGAYGCCT
3046
[′ATATAGAYGCCT

(USH2A):c.1606T>C

AGCCAGCCAT

CTGCTCCCAGG′]

CTGCTCCCAGG′]

(p.Cys536Arg)

ATAGAYGCCTC

TGCTCCCAGGA

GAGCTTCAC′]

NM_000059.3
675
BRCA2
2643
[′TAGATAAATT
2823
[′CTTAGGYAAGTA
3047
[′CTTAGGYAAGTA

(BRCA2):c.316+2T>C

CAAATTAGACT

ATGCAATATGG′]

ATGCAATATGG′]

TAGGYAAGTA

ATGCAATATGG

TAGACTGGG′]

NM_007294.3
672
BRCA1
2644
[′CTCTTCTTCC
2824
[′GGCYAGAAATCT
3048-3049
[′GGGCYAGAAATC

(BRCA1):c.5291T>C

AGATCTTCAGG

GTTGCTATGGG′]

TGTTGCTATGG′,

(p.Leu1764Pro)

GGGCYAGAAA

′GGCYAGAAATCT

TCTGTTGCTAT

GTTGCTATGGG′]

GGGCCCTTC′]

NM_00113008
3735
KARS
2645
[′AGCTTCTGGG
2825
[′TTCYATGATCTTC
3050-3051
[′CTTCYATGATCT

9.1(KARS):c.517T>C

GGAAAGCTCA

GAGGAGAGGG′]

TCGAGGAGAGG′,

(p.Tyr173His)

TCTTCYATGAT

′TTCYATGATCTTC

CTTCGAGGAG

GAGGAGAGGG′]

AGGGGGTGAA′]

NM_00128300
−1
—
2646
[′CGGGCCCCTC
2826
[′CTGTGTGYGCCA
3052
[′CTGTGTGYGCCA

9.1(RTEL1):c.3730T>C

TCAGCAGGCTG

GGGCTGTGGGG′]

GGGCTGTGGGG′]

(p.Cys1244Arg)

TGTGYGCCAG

GGCTGTGGGG

CAGAGGACGT′]

NM_005554.3
3853
KRT6A
2647
[′GAGATCGCCA
2827
[′TGCBGGAGGGTG
3053
[′TGCBGGAGGGTG

(KRT6A):c.1406T>C

CCTACCGCAAG

AGGAGTGCAGG′]

AGGAGTGCAGG′]

(p.Leu469Pro)

CTGCBGGAGG

GTGAGGAGTG

CAGGTGGGTA′]

NM_000218.2
3784
KCNQ1
2648
[′CTGGTCCGCC
2828
[′AGCAAGBACGTG
3054-3056
[′CAGCAAGBACGT

(KCNQ1):c.550T>C

GGCTGCCGCA

GGCCTCTGGGG′]

GGGCCTCTGGG′,

(p.Tyr184His)

GCAAGBACGT

′AGCAAGBACGTG

GGGCCTCTGGG

GGCCTCTGGGG′,

GGCGGCTGCG′]

′GCAAGBACGTGG

NM_198056.2
6331
SCN5A
2649
[′GAGATGGACG
2829
[′CCAGAHGGAGGA
3057
[′CCAGAHGGAGG

(SCN5A):c.5624T>C

CCCTGAAGATC

GAAGTTCATGG′]

AGAAGTTCATGG′]

(p.Met1875Thr)

CAGAHGGAGG

AGAAGTTCATG

GCAGCCAAC′]

NM_006920.4
6323
SCN1A
2650
[′TGTTGTGTTC
2830-
[′ACTTYTATAGTAT
3058-3059
[′ACTTYTATAGTA

(SCN1A):c.269T>C

CTGTCTTACAG
2831
TGAATAAAGG′,

TTGAATAAAGG′,

(p.Phe90Ser)

ACTTYTATAGT

′CTTYTATAGTATT

′CTTYTATAGTATT

ATTGAATAAA

GAATAAAGGG′]

GAATAAAGGG′]

GGGAAGGCC′]

NM_006920.4
6323
SCN1A
2651
[′TGTGTTCCTG
2832-
[′ACTTTTAYAGTAT
3060-3061
[′ACTTTTAYAGTA

(SCN1A):c.272T>C

TCTTACAGACT
2833
TGAATAAAGG′,

TTGAATAAAGG′,

(p.Ile91Thr)

TTTAYAGTATT

′CTTTTAYAGTATT

′CTTTTAYAGTATT

GAATAAAGGG

GAATAAAGGG′]

GAATAAAGGG′]

AAGGCCATC′]

NM_006514.3
6336
SCN10A
2652
[′GGAGTCAGGG
2834-
[′GAGGARGAGGGC
3062-3064
[′GAGGARGAGGG

(SCN10A):c.1661T>C

TTGCTGGGTTG
2836
TTCTAGGGAGG′,

CTTCTAGGGAGG′,

(p.Leu554Pro)

AGGARGAGGG

′AGGARGAGGGCTT

′AGGARGAGGGCT

CTTCTAGGGAG

CTAGGGAGGG′,

TCTAGGGAGGG′,

GGGGCCTTG′]

′GGARGAGGGCTTC

′GGARGAGGGCTT

TAGGGAGGGG′]

CTAGGGAGGGG′]

NM_000251.2
4436
MSH2
2653
[′AACAGATGTT
2837-
[′CTGGYAAAAAAC
3065-3066

(MSH2):c.2005+2T>C

CCACATCATTA
2838
CTGGTTTTTGG′,

[′CTGGYAAAAAAC

CTGGYAAAAA

′TGGYAAAAAACCT

CTGGTTTTTGG′,

ACCTGGTTTTT

GGTTTTTGGG′]

′TGGYAAAAAACC

GGGCTTTGT′]

TGGTTTTTGGG′]

NM_000251.2
4436
MSH2
2654
[′CCTCATCCAG
2839
[′AAGGAAYGTGTT
3067
[′AAGGAAYGTGTT

(MSH2):c.595T>C

ATTGGACCAA

TTACCCGGAGG′]

TTACCCGGAGG′]

(p.Cys199Arg)

AGGAAYGTGT

TTTACCCGGAG

GAGAGACTGC′]

NM_001005741.2
2629
GBA
2655
[′TTCACCGCTC
2840
[′GCCRAGTGGGTG
3068-3070
[′GAGCCRAGTGGG

(GBA):c.667T>C

CATTGGTCTTG

ATGTCCAGGGG′]

TGATGTCCAGG′,

(p.Trp223Arg)

AGCCRAGTGG

′AGCCRAGTGGGT

GTGATGTCCAG

GATGTCCAGGG′,

GGGCTGGCA′]

′GCCRAGTGGGTG

ATGTCCAGGGG′]

NM_003494.3
8291
DYSF
2656
[′GAGGTCAGCT
2841
[′ATGGYAAGGAGC
3071
[′ATGGYAAGGAG

(DYSF):c.1284+2T>C

TTGCGGGGAA

AAGGGAGCAGG′]

CAAGGGAGCAGG′]

AATGGYAAGG

AGCAAGGGAG

CAGGAGGGTTC′]
2842
[′CACTGYGAGTAA
3072
[′CACTGYGAGTAA

NM_012463.3
2354
ATP6V50A2
2657
[′ACCCGCATCC

GCTGGAAGTGG′]

GCTGGAAGTGG′]

(ATP6V0A2):c.825+2T>C

AGGATCTCTAC

ACTGYGAGTA

AGCTGGAAGT

GGATTGCCTC′]

NM_016725.2
2348
FOLR1
2658
[′ACAAGGGCTG
2843
[′AGGYGAGGGCTG
3073-3074
[′CTTCAGGYGAGG

(FOLR1):c.493+2T>C

GAACTGGACTT

GGGTGGGCAGG′]

GCTGGGGTGGG′,

CAGGYGAGGG

′AGGYGAGGGCTG

CTGGGGTGGG

GGGTGGGCAGG′]

CAGGAATGGA′]

NM_003764.3
8676
STX11
2659
[′GACATTCAGG
2844
[′TGCYGGTGGCCG
3075
[′TGCYGGTGGCCG

(STX11):c.173T>C

ATGAAAACCA

ACGTGAAGCGG′]

ACGTGAAGCGG′]

(p.Leu58Pro)

GCTGCYGGTG

GCCGACGTGA

AGCGGCTGGGA′]

NM_014714.3
9742
IFT140
2660
[′GGACCCCAAG
2845
[′GCAGYGTGAGCT
3076-3077
[′CAAGCAGYGTGA

(1FT140):c.4078T>C

GAGTCCATCAA

GCTCCTGGAGG′]

GCTGCTCCTGG′,

(p.Cys1360Arg)

GCAGYGTGAG

′GCAGYGTGAGCT

CTGCTCCTGGA

GCTCCTGGAGG′]

GGAACCAGA′]

NM_000531.5
5009
OTC
2661
[′GAAAACAGA
2846
[′ATCATGGYAAGC
3078
[′ATCATGGYAAGC

(OTC):c.1005+2T>C

AAGTGGACAA

AAGAAACAAGG′]

AAGAAACAAGG′]

TCATGGYAAG

CAAGAAACAA

GGAATGGAGGAT′]

NM_000531.5
5009
OTC
2662
[′CTAAAAAACT
2847
[′AAGAAABTAAAT
3079
[′AAGAAABTAAAT

(OTC):c.158T>C

TTACCGGAGA

ATATGCTATGG′]

ATATGCTATGG′]

(p.Ile53Thr)

AGAAABTAAA

TATATGCTATG

GCTATCAGCA′]

NM_000531.5
5009
OTC
2663
[′GAGAAAAGA
2848
[′ACAAGATYGTCT
3080
[′ACAAGATYGTCT

(OTC):c.284T>C

AGTACTCGAAC

ACAGAAACAGG′]

ACAGAAACAGG′]

(p.Leu95Ser)

AAGATYGTCTA

CAGAAACAGG

TAAGTCCACT′]

NM_000531.5
5009
OTC
2664
[′CGTCCTTTAC
2849
[′AGAAGAYGCTGT
3081
[′AGAAGAYGCTGT

(OTC):c.2T>C

ACAATTAAAA

TTAATCTGAGG′]

TTAATCTGAGG′]

(p.Met1Thr)

GAAGAYGCTG

TTTAATCTGAG

GATCCTGTTA′]

NM_000531.5
5009
OTC
2665
[′CCATCCTATC
2850
[′GGCTGATYACCT
3082-3083
[′GGCTGATYACCT

(OTC):c.526T>C

CAGATCCTGGC

CACGCTCCAGG′]

CACGCTCCAGG′,

(p.Tyr176His)

TGATYACCTCA

′GATYACCTCACG

CGCTCCAGGTT

CTCCAGGTTGG′]

GGTTTATT′]

NM_000531.5
5009
OTC
2666
[′GAAGCAGCGC
2851
[′ATGTATYAATTAC
3084
[′ATGTATYAATTA

(OTC):c.779T>C

ATGGAGGCAA

AGACACTTGG′]

CAGACACTTGG′]

(p.Leu260Ser)

TGTATYAATTA

CAGACACTTGG

ATAAGCATG′]

NM_000322.4
5961
PRPH2
2667
[′CCACCAGACG
2852-
[′ACCTGYGGGTGC
3085-3086
[′ACCTGYGGGTGC

(PRPH2):c.736T>C

GAGGAGCTCA
2853
GTGGCTGCAGG′,

GTGGCTGCAGG′,

(p.Trp246Arg)

ACCTGYGGGT

′CCTGYGGGTGCGT

′CCTGYGGGTGCG

GCGTGGCTGCA

GGCTGCAGGG′]

TGGCTGCAGGG′]

GGGCTGCCCT′]

NM_000211.4
3689
ITGB2
2668
[′CCCCTCACCC
2854
[′CATGYGAGTGCA
3087
[′CATGYGAGTGCA

(ITGB2):c.1877+2T>C

TGTGGCAAGTA

GGCGGAGCAGG′]

GGCGGAGCAGG′]

CATGYGAGTG

CAGGCGGAGC

AGGCAGGGCG′]

NM_015474.3
25939
SAMHD1
2669
[′TTTGTGTTGA
2855
[′GGTGTRAAGAGT
3088
[′GGTGTRAAGAGT

(SAMHD1):c.1106T>C

TAAGCTCTACG

TGCGAGTGTGG′]

TGCGAGTGTGG′]

(p.Leu369Ser)

GTGTRAAGAGT

TGCGAGTGTGG

AACATGTC′]

NM_001101.3
60
ACTB
2670
[′AACCCCAAGG
2856
[′GAGAAGAYGACC
3089
[′GAGAAGAYGAC

(ACTB):c.356T>C

CCAACCGCGA

CAGGTGAGTGG′]

CCAGGTGAGTGG′]

(p.Met119Thr)

GAAGAYGACC

CAGGTGAGTG

GCCCGCTACCT′]

NM_015713.4
50484
RRM2B
2671
[′CTCGATGAGA
2857
[′CCATAGRAACAG
3090
[′CCATAGRAACAG

(RRM2B):c.368T>C

ATTTGAAAGCC

CGAGCCTCTGG′]

CGAGCCTCTGG′]

(p.Phe123Ser)

ATAGRAACAG

CGAGCCTCTGG

AACCTGCAC′]

NM_015599.2
5238
PGM3
2672
[′TTGGTTGATC
2858
[′AATGTYGGCACC
3091
[′AATGTYGGCACC

(PGM3):c.248T>C

CTTTGGGTGAA

ATCCTGGGAGG′]

ATCCTGGGAGG′]

(p.Leu83Ser)

ATGTYGGCACC

ATCCTGGGAG

GAACATGCC′]

NM_002136.2
3178
HNRNPA1
2673
[′GAATTACAAC
2859-
[′TTCAAATBTTGGA
3092-3094
[′TTCAAATBTTGG

(HNRNPA1):c.817T>C

AATCAGTCTTC
2861
CCCATGAAGG′,

ACCCATGAAGG′,

(p.Phe273Leu)

AAATBTTGGAC

′TCAAATBTTGGAC

′TCAAATBTTGGAC

CCATGAAGGG

CCATGAAGGG′,

CCATGAAGGG′,

AGGAAATTT′]

′AATBTTGGACCCA

′AATBTTGGACCC

TGAAGGGAGG′]

ATGAAGGGAGG′]

NM_002136.2
3178
HNRNPA1
2674
[′TTTTGGACCC
2862
[′AATYTTGGAGGC
3095
[′AATYTTGGAGGC

(HNRNPA1):c.841T>C

ATGAAGGGAG

AGAAGCTCTGG′]

AGAAGCTCTGG′]

(p.Phe281Leu)

GAAATYTTGG

AGGCAGAAGC

TCTGGCCCCTA′]

NM_022552.4
1788
DNMT3A
2675
[′CGCAAAATAC
2863
[′GCGRAGAGGTGG

(DNMT3A):c.2705T>C

TCCTTCAGCGG

CGGATGACTGG′]
3096
[′GCGRAGAGGTGG

(p.Phe902Ser)

AGCGRAGAGG

CGGATGACTGG′]

TGGCGGATGA

CTGGCACGCT′]

NM_000076.2
1028
CDKN1C
2676
[′GCGCAAGAG
2864-
[′CCAAGYGAGTAC
3097-3099
[′CCAAGYGAGTAC

(CDKN1C):c.*5+2T>C

GCTGCGGTGA
2866
AGCGCACCTGG′,

AGCGCACCTGG′,

GCCAAGYGAG

′CAAGYGAGTACA

′CAAGYGAGTACA

TACAGCGCACC

GCGCACCTGGG′,

GCGCACCTGGG′,

TGGGGGGGCGC′]

′AAGYGAGTACAG

′AAGYGAGTACAG

CGCACCTGGGG′]

CGCACCTGGGG′]

NC_012920.1:m.9478T>C
4514
MTCO3
2677
[′ATAATCCTAT
2867
[′TCAGAAGYTTTTT
3100
[′TCAGAAGYTTTT

TTATTACCTCA

TCTTCGCAGG′]

TTCTTCGCAGG′]

GAAGYTTTTTT

CTTCGCAGGAT

TTTTCTGA′]

NM_002049.3
2623
GATA1
2678
[′CGCAGGTTAA
2868-
[′TCCAYGGAGTTC
3101-3103
[′CTCCAYGGAGTT

(GATA1):c.2T>C

TCCCCAGAGGC
2869
CCTGGCCTGGG′,

CCCTGGCCTGG′,

(p.Met1Thr)

TCCAYGGAGTT

′CCAYGGAGTTCCC

′TCCAYGGAGTTC

CCCTGGCCTGG

TGGCCTGGGG′]

CCTGGCCTGGG′,

GGTCCCTG′]

′CCAYGGAGTTCC

CTGGCCTGGGG′]

NM_005740.2
10126
DNAL4
2679
[′GAGAAATTCT
2870
[′CGAGGYATTGCC
3104
[′CGAGGYATTGCC

(DNAL4):c.153+2T>C

CCAACAACAA

AGCAGTGCAGG′]

AGCAGTGCAGG′]

CGAGGYATTG

CCAGCAGTGC

AGGCGGCCCCT′]

NM_001287223.1
11280
SCN11A
2680
[′GGGCTCTACT
2871
[′TTCAYTGTGGTCA
3105-3106
[′CTTCAYTGTGGT

(SCN11A):c.1142T>C

CAGTCTTCTTC

TTTTCCTGGG′]

CATTTTCCTGG′,

(p.Ile381Thr)

TTCAYTGTGGT

′TTCAYTGTGGTCA

CATTTTCCTGG

TTTTCCTGGG′]

GCTCCTTC′]

NM_001302946.1
51095
TRNT1
2681
[′TAATGAATAG
2872
[′ACTTYATTTGACT
3107
[′ACTTYATTTGAC

(TRNT1):c.497T>C

GTTTTGATGGC

ACTTTAATGG′]

TACTTTAATGG′]

(p.Leu166Ser)

ACTTYATTTGA

CTACTTTAATG

GTTATGAA′]

NM_178151.2
1641
DCX
2682
[′AGGTCTCTGA
2873
[′CAAAATAYGGAA
3108
[′CAAAATAYGGA

(DCX):c.2T>C

GGTTCCACCAA

CTTGATTTTGG′]

ACTTGATTTTGG′]

(p.Met1Thr)

AATAYGGAAC

TTGATTTTGGA

CACTTTGAC′]

NM_000169.2
−1
—
2683
[′TGGACATCTT
2874
[′GAGAGAAYTGTT
3109
[′GAGAGAAYTGTT

(GLA):c.758T>C

TTAACCAGGA

GATGTTGCTGG′]

GATGTTGCTGG′]

(p.Ile253Thr)

GAGAAYTGTT

GATGTTGCTGG

ACCAGGGGGT′]

NM_170707.3
4000
LMNA
2684
[′ATTGACAATG
2875
[′TGAGTYTGAGAG
3110
[′TGAGTYTGAGAG

(LMNA):c.710T>C

GGAAGCAGCG

CCGGCTGGCGG′]

CCGGCTGGCGG′]

(p.Phe237Ser)

TGAGTYTGAG

AGCCGGCTGG

CGGATGCGCTG′]

NM_000256.3
4607
MYBPC3
2685
[′CAGAAAGCCG
2876-
[′ACCATGGBGAGC
3111-3113
[′ACCATGGBGAGC

(MYBPC3):c.3330+2T>C

ACAAGAAGAC
2878
CCAGGGTCTGG′,

CCAGGGTCTGG′,

CATGGBGAGC

′CCATGGBGAGCCC

′CCATGGBGAGCC

CCAGGGTCTGG

AGGGTCTGGG′,

CAGGGTCTGGG′,

GGTCCCCACG′]

′CATGGBGAGCCCA

′CATGGBGAGCCC

GGGTCTGGGG′]

AGGGTCTGGGG′]

NM_005957.4
4524
MTHFR
2686
[′AGCGGGGGCT
2879-
[′GAAGGYGTGGTA
3114-3116
[′GAAGGYGTGGTA

(MTHFR):c.1530+2T>C

ATGTCTTCCAG
2881
GGGAGGCACGG′,

GGGAGGCACGG′,

AAGGYGTGGT

′AAGGYGTGGTAG

′AAGGYGTGGTAG

AGGGAGGCAC

GGAGGCACGGG′,

GGAGGCACGGG′,

GGGGTGCCCC′]

′AGGYGTGGTAGG

′AGGYGTGGTAGG

GAGGCACGGGG′]

GAGGCACGGGG′]

NM_000264.3
5727
PTCH1
2687
[′AACCCCTGGA
2882-
[′ATCATTGYGAGT
3117-3119
[′ATCATTGYGAGT

(PTCH1):c.3168+2T>C

CGGCCGGGAT
2884
GTATTATAAGG′,

GTATTATAAGG′,

CATTGYGAGTG

′TCATTGYGAGTGT

′TCATTGYGAGTGT

TATTATAAGGG

ATTATAAGGG′,

ATTATAAGGG′,

GCTTTGTGG′]

′CATTGYGAGTGTA

′CATTGYGAGTGT

TTATAAGGGG′]

ATTATAAGGGG′]

NM_000030.2
189
AGXT
2688
[′CTTCCTGGTT
2885
[′CATTYGGGGGCA
3120
[′CATTYGGGGGCA

(AGXT):c.322T>C

GGGGCCAATG

GCGAGCCGTGG′]

GCGAGCCGTGG′]

(p.Trp108Arg)

GCATTYGGGG

GCAGCGAGCC

GTGGACATCGG′]

NM_000023.2
6442
SGCA
2689
[′ACTCGGCAGA
2886
[′CTGGAGAYTGGG
3121
[′CTGGAGAYTGGG

(SGCA):c.371T>C

GGCTGGTGCTG

GACCCAGAAGG′]

GACCCAGAAGG′]

(p.Ile124Thr)

GAGAYTGGGG

ACCCAGAAGG

TACCTCTAGC′]

NM_001103.3
88
ACTN2
2690
[′GAGAAGCACC
2887
[′CCTAAAAYGTTG
3122
[′CCTAAAAYGTTG

(ACTN2):c.683T>C

TGGATATTCCT

GATGCTGAAGG′]

GATGCTGAAGG′]

(p.Met228Thr)

AAAAYGTTGG

ATGCTGAAGGT

GAGATGAAA′]

NM_001165963.1
−1
—
2691
[′ATTCCATCCA
2888
[′TTCYGGTTTGTCT
3123
[′TTCYGGTTTGTC

(SCN1A):c.4055T>C

TCATGAATGTG

TATATTCTGG′]

TTATATTCTGG′]

(p.Leu1352Pro)

CTTCYGGTTTG

TCTTATATTCT

GGCTAATT′]

NM_001165963.1
6323
SCN1A
2692
[′CTAATAAATT
2889
[′TGTGGHGGCCAT
3124
[′TGTGGHGGCCAT

(SCN1A):c.1265T>C

TGATCCTGGCT

GGCCTACGAGG′]

GGCCTACGAGG′]

(p.Val422Ala)

GTGGHGGCCA

TGGCCTACGAG

GAACAGAAT′]

NM_000426.3
3908
LAMA2
2693
[′GCAGAATCAG
2890-
[′TTGAYAGGGAGC
3125-3126
[′TTGAYAGGGAGC

(LAMA2):c.8282T>C

AACCAGCTCTT
2891
AAGCAGTTCGG′,

AAGCAGTTCGG′,

(p.Ile2761Thr)

TTGAYAGGGA

′TGAYAGGGAGCA

′TGAYAGGGAGCA

GCAAGCAGTTC

AGCAGTTCGGG′]

AGCAGTTCGGG′]

GGGCTTTCA′]

NM_000257.3
−1
—
2694
[′TCCCGGAAGC
2892
[′AGCYGATTGAGA
3127
[′AGCYGATTGAGA

(MYH7):c.5117T>C

TGGCGGAGCA

CTAGTGAGCGG′]

CTAGTGAGCGG′]

(p.Leu1706Pro)

GGAGCYGATT

GAGACTAGTG

AGCGGGTGCAG′]

NM_001399.4
1896
EDA
2695
[′TCTGACTCCC
2893-
[′ACCAGGKGAGTC
3128-3130
[′CACCAGGKGAGT

(EDA):c.396+2T>C

AGGACGGGCA
2894
ACCTAGTAGGG′,

CACCTAGTAGG′,

CCAGGKGAGT

′CCAGGKGAGTCAC

′ACCAGGKGAGTC

CACCTAGTAGG

CTAGTAGGGG′]

ACCTAGTAGGG′,

GGCGGCGGCG′]

′CCAGGKGAGTCA

CCTAGTAGGGG′]

NM_001848.2
1291
COL6A1
2696
[′TCCAGGGGAC
2895-
[′ACAAGGYGAGCG
3131-3132
[′ACAAGGYGAGC

(COL6A1):c.957+2T>C

CCAAGGGCTA
2896
TGGGCTGCTGG′,

GTGGGCTGCTGG′,

CAAGGYGAGC

′CAAGGYGAGCGT

′CAAGGYGAGCGT

GTGGGCTGCTG

GGGCTGCTGGG′]

GGGCTGCTGGG′]

GGAGGGGGGA′]

NM_000238.3
3757
KCNH2
2697
[′CTGCGTCATG
2897-
[′CTGTGAGYGTGC
3133-3134
[′CTGTGAGYGTGC

(KCNH2):c.1945+6T>C

CTCATTGGCTG
2898
CCAGGGGCGGG′,

CCAGGGGCGGG′,

TGAGYGTGCCC

′TGAGYGTGCCCAG

′TGAGYGTGCCCA

AGGGGCGGGC

GGGCGGGCGG′]

GGGGCGGGCGG′]

GGCGGGGAG′]

NM_021007.2
6326
SCN2A
2698
[′CTAATAAATT
2899
[′TGTGGYGGCCAT
3135
[′TGTGGYGGCCAT

(SCN2A):c.1271T>C

TGATCTTGGCT

GGCCTATGAGG′]

GGCCTATGAGG′]

(p.Val424Ala)

GTGGYGGCCA

TGGCCTATGAG

GAACAGAAT′]

NM_021007.2
6326
SCN2A
2699
[′TATGCAGCTG
2900-
[′CGAAATGYAAGT
3136-3137
[′CGAAATGYAAGT

(SCN2A):c.4308+2T>C

TTGATTCACGA
2901
CTAGTTAGAGG′,

CTAGTTAGAGG′,

AATGYAAGTCT

′GAAATGYAAGTCT

′GAAATGYAAGTC

AGTTAGAGGG

AGTTAGAGGG′]

TAGTTAGAGGG′]

AAATTGTTT′]

NM_000083.2
1180
CLCN1
2700
[′CCCCGCGAAG
2902-
[′CTTTGTYTGACAA
3138-3139
[′CTTTGTYTGACA

(CLCN1):c.1283T>C

CCATCAGTACT
2903
CAATACATGG′,

ACAATACATGG′,

(p.Phe428Ser)

TTGTYTGACAA

′TTTGTYTGACAAC

′TTTGTYTGACAAC

CAATACATGG

AATACATGGG′]

AATACATGGG′]

GTGAAACAC′]

NM_004550.4
4720
NDUFS2
2701
[′CATTATGCTC
2904
[′GGAGTGAYGCTT
3140
[′GGAGTGAYGCTT

(NDUFS2):c.875T>C

TCCACAGTGGA

CGGGGCTCAGG′]

CGGGGCTCAGG′]

(p.Met292Thr)

GTGAYGCTTCG

GGGCTCAGGC

ATCCAGTGG′]

NM_000546.5
7157
TP53
2702
[′CACACGCAAA
2905-
[′CTCGGRTAAGAT
3141-3143
[′ACTCGGRTAAGA

(TP53):c.584T>C

TTTCCTTCCAC
2906
GCTGAGGAGGG′,

TGCTGAGGAGG′,

(p.Ile195Thr)

TCGGRTAAGAT

′TCGGRTAAGATGC

′CTCGGRTAAGAT

GCTGAGGAGG

TGAGGAGGGG′]

GCTGAGGAGGG′,

GGCCAGACC′]

′TCGGRTAAGATG

CTGAGGAGGGG′]

TABLE 3

A to G with NGG PAM. Table 2 shows a list of A to G mutations that may be

corrected using any of the base editors provided herein. GRNAs and gRNAall indicate the

protospacer and PAM sequence, where the PAM sequence is the last 3 nucleotides of each of

the sequences in GRNAs and gRNAall.

SEQ

SEQ

SEQ

Gene
Gene
ID

ID

ID

Name
ID
Symbol
NO:
Flanks
NO:
GRNAs
NO:
gRNAall

NM_017547.3
55572
FOXRED1
5084
[′GTGGGCCCCCACC
5261
[′CCACCCGCTAGT
5464-
[′CCCACCCGCTAG

(FOXRED1):c.1289A>G

CGCTAGTTGTCAVC

TGTCAVCATGT′]
5466
TTGTCAVCATG′,

(p.Asn430Ser)

ATGTACTTTGCTACT

′CCACCCGCTAGTT

GGCTTCAGT′]

GTCAVCATGT′,

′CCCGCTAGTTGTC

AVCATGTACT′]

NM_000071.2
875
CBS
5085
[′GGTGACTCCCCCAT
5262
[′CCCCATCCCGCA
5467-
[′CCCCCATCCCGC

(CBS):c.1150A>G

CCCGCAGGACCRAG

GGACCRAGTTC′]
5470
AGGACCRAGTT′,

(p.Lys384Glu)

TTCCTGAGCGACAG

′CCCCATCCCGCA

GTGGATGCT′]

GGACCRAGTTC′,

′CCCATCCCGCAG

GACCRAGTTCC′,

′CCATCCCGCAGG

ACCRAGTTCCT′]

NM_000552.3
7450
VWF
5086
[′GAGTGTACCAAAA
5263
[′CCAAAACGTGCC
5471
[′CCAAAACGTGCC

(VWF):c.2384A>G

CGTGCCAGAACTRT

AGAACTRTGAC′]

AGAACTRTGAC′]

(p.Tyr795Cys)

GACCTGGAGTGCAT

GAGCATGGGC′]

NM_000552.3
7450
VWF
5087
[′ACCTGCGGCCTGT
5264
[′CCTGTGTGGGAA
5472
[′CCTGTGTGGGAA

(VWF):c.1583A>G

GTGGGAATTACART

TTACARTGGCA′]

TTACARTGGCA′]

(p.Asn528Ser)

GGCAACCAGGGCGA

CGACTTCCTT′]

NM_000308.2
5476
CTSA
5088
[′CTTTAGAAATACC
5265
[′CCAGATCCTATT
5473
[′CCAGATCCTATT

(CTSA):c.1238A>G

AGATCCTATTATRTA

ATRTAATGGAG′]

ATRTAATGGAG′]

(p.Tyr413Cys)

ATGGAGATGTAGAC

ATGGCCTGC′]

NM_000277.1
5053
PAH
5089
[′TTCTATTTTCCCCC
5266
[′CCCCCAATTACA
5474-
[′CCCCCAATTACA

(PAH):c.916A>G

AATTACAGGAARTT

GGAARTTGGCC′]
5476
GGAARTTGGCC′,

(p.Ile306Val)

GGCCTTGCCTCTCTG

′CCCCAATTACAG

GGTGCACC′]

GAARTTGGCCT′,

′CCCAATTACAGG

AARTTGGCCTT′]

NM_000512.4
2588
GALNS
5090
[′TTGGTCCCCGCGCA
5267
[′CCGCGCAGCCCC
5477
[′CCGCGCAGCCCC

(GALNS):c.1460A>G

GCCCCAGCTCARCG

AGCTCARCGTG′]

AGCTCARCGTG′]

(p.Asn487Ser)

TGTGCAACTGGGCG

GTCATGGTA′]

NM_013319.2
29914
UBIAD1
5091
[′GTGCACGGGGCCG
5268
[′CCGGTAATTTGG
5478
[′CCGGTAATTTGG

(UBIAD1):c.305A>G

GTAATTTGGTCARC

TCARCACTTAC′]

TCARCACTTAC′]

(p.Asn102Ser)

ACTTACTATGACTTT

TCCAAGGGC′]

NM_013319.2
29914
UBIAD1
5092
[′AGCACCGAGGCCA
5269
[′CCATTCTCCATT
5479
[′CCATTCTCCATT

(UBIAD1):c.695A>G

TTCTCCATTCCARCA

CCARCAACACC′]

CCARCAACACC′]

(p.Asn232Ser)

ACACCAGGGACATG

GAGTCCGAC′]

NM_000275.2
4948
OCA2
5093
[′TGCCACTGCCATCG
5270
[′CCATCGGGGACC
5480
[′CCATCGGGGACC

(OCA2):c.1465A>G

GGGACCCTCCARAT

CTCCARATGTC′]

CTCCARATGTC′]

(p.Asn489Asp)

GTCATTATTGTTTCC

AACCAAGA′]

NM_001127255.1
−1
—
5094
[′CTCACAAACCTGG
5271
[′CCTGGACTTGAG
5481
[′CCTGGACTTGAG

(NLRP7):c.2738A>G

ACTTGAGTATCARC

TATCARCCAGA′]

TATCARCCAGA′]

(p.Asn913Ser)

CAGATAGCTCGTGG

ATTGTGGATT′]

NM_152783.4
728294
D2HGDH
5095
[′TGCCCTTGTCCCTC
5272
[′CCTCCAGGAGAT
5482-
[′CCCTCCAGGAGA

(D2HGDH):c.1315A>G

CAGGAGATGGTRAC

GGTRACCTGCA′]
5483
TGGTRACCTGC′,

(p.Asn439Asp)

CTGCACCTCAATGT

′CCTCCAGGAGAT

GACGGCGGA′]

GGTRACCTGCA′]

NM_022132.4
64087
MCCC2
5096
[′TGTGGCCTGTGCCC
5273
[′CCCAAGTGCCTA
5484
[′CCCAAGTGCCTA

(MCCC2):c.1309A>G

AAGTGCCTAAGDTA

AGDTAACCCTC′]

AGDTAACCCTC′]

(p.Ile437Val)

ACCCTCATCATTGG

GGGCTCCTA′]

NM_000022.2
100
ADA
5097
[′TTCCCAACCCCTTT
5274
[′CCCCTTTCTTCCC
5485-
[′CCCCTTTCTTCCC

(ADA):c.219-2A>G

CTTCCCTTCCCRGGG

TTCCCRGGGG′]
5487
TTCCCRGGGG′,

GCTGCCGGGAGGCT

′CCCTTTCTTCCCT

ATCAAAAG′]

TCCCRGGGGC′,

′CCTTTCTTCCCTT

CCCRGGGGCT′]

NM_017780.3
55636
CHD7
5098
[′TTTAGTAATTGCCC
5275
[′CCCCATTGTCCA
5488
[′CCCCATTGTCCA

(CHD7):c.3082A>G

CATTGTCCACARTC

CARTCCCCAAC′]

CARTCCCCAAC′]

(p.Ile1028Val)

CCCAACTGGGAAAG

GGAATTCCG′]

NM_000483.4
−1
—
5099
[′TCAATGTTCCAGGT
5276
[′CCAGGTCTCTGG
5489
[′CCAGGTCTCTGG

(APOC2):c.1A>G

CTCTGGACACTRTG

ACACTRTGGGC′]

ACACTRTGGGC′]

(p.MetlVal)

GGCACACGACTCCT

CCCAGCTCT′]

NM_000391.3
1200
TPP1
5100
[′TGTCCCTCATGCCG
5277
[′CCGGCCTGGATT
5490
[′CCGGCCTGGATT

(TPP1):c.887-10A>G

GCCTGGATTTTYTTT

TTYTTTTTTTT′]

TTYTTTTTTTT′]

TTTTTTTTTTTTGAG

GGATGGG′]

NM_017890.4
157680
VPS13B
5101
[′CTTCTGCCCTGGGC
5278
[′CCTGGGCCCTGC
5491
[′CCTGGGCCCTGC

(VPS13B):c.8978A>G

CCTGCTTATCARTG

TTATCARTGAA′]

TTATCARTGAA′]

(p.Asn2993Ser)

AATCCAAATGGGAC

CTCTGGCTA′]

NM_000226.3
3857
KRT9
5102
[′GAGAAGAGCACCA
5279
[′CCATGCAGGAAC
5492
[′CCATGCAGGAAC

(KRT9):c.482A>G

TGCAGGAACTCADT

TCADTTCTCGG′]

TCADTTCTCGG′]

(p.Asn161Ser)

TCTCGGCTGGCCTCT

TACTTGGAT′]

NM_000529.2
4158
MC2R
5103
[′CCAAGTAACCCCT
5280-
[′CCCTACTGCGCC
5493-
[′CCCCTACTGCGC

(MC2R):c.761A>G

ACTGCGCCTGCTRC
5281
TGCTRCATGTC′,
5495
CTGCTRCATGT′,

(p.Tyr254Cys)

ATGTCTCTCTTCCAG

′CCTACTGCGCCTG

′CCCTACTGCGCCT

GTGAACGGC′]

CTRCATGTCT′]

GCTRCATGTC′,

′CCTACTGCGCCTG

CTRCATGTCT′]

NM_005957.4
4524
MTHFR
5104
[′CCAGGCCTCCACTT
5282
[′CCACTTCTACAC
5496
[′CCACTTCTACAC

(MTHFR):c.971A>G

CTACACCCTCARCC

CCTCARCCGCG′]

CCTCARCCGCG′]

(p.Asn324Ser)

GCGAGATGGCTACC

ACAGAGGTG′]

NM_000403.3
2582
GALE
5105
[′GGCTACTTGCCTGT
5283
[′CCTGTGGTCATC
5497
[′CCTGTGGTCATC

(GALE):c.101A>G

GGTCATCGATARCT

GATARCTTCCA′]

GATARCTTCCA′]

(p.Asn34Ser)

TCCATAATGCCTTCC

GTGGTGAG′]

NM_000356.3
6949
TCOF1
5106
[′CAGCCCGTAACCC
5284-
[′CCCTTCTGGACA
5498-
[′CCCTTCTGGACA

(TCOF1):c.149A>G

TTCTGGACATCTRTA
5285
TCTRTACACAC′,
5499
TCTRTACACAC′,

(p.Tyr50Cys)

CACACTGGCAACAG

′CCTTCTGGACATC

′CCTTCTGGACATC

TAAGTGGTG′]

TRTACACACT′]

TRTACACACT′]

NM_012464.4
7092
TLL1
5107
[′ACTTCTTACCAAAC
5286
[′CCAAACTTAACG
5500
[′CCAAACTTAACG

(TLL1):c.1885A>G

TTAACGGCACCRTA

GCACCRTAACC′]

GCACCRTAACC′]

(p.Ile629Val)

ACCACCCCTGGCTG

GCCCAAGGA′]

NM_000112.3
1836
SLC26A2
5108
[′GGAAATGTATGCC
5287
[′CCATTGGCTTTT
5501
[′CCATTGGCTTTT

(SLC26A2):c.1273A>G

ATTGGCTTTTGTRAT

GTRATATCATC′]

GTRATATCATC′]

(p.Asn425Asp)

ATCATCCCTTCCTTC

TTCCACTG′]

NM_000157.3
2629
GBA
5109
[′ACATCACCCACTTG
5288
[′CCACTTGGCTCA
5502
[′CCACTTGGCTCA

(GBA):c.680A>G

GCTCAAGACCARTG

AGACCARTGGA′]

AGACCARTGGA′]

(p.Asn227Ser)

GAGCGGTGAATGGG

AAGGGGTCA′]

NM_175073.2
54840
APTX
5110
[′GATAAATACCCAA
5289-
[′CCCAAAGGCCCG
5503-
[′CCCAAAGGCCCG

(APTX):c.602A>G

AGGCCCGTTACCRT
5290
TTACCRTTGGC′,
5504
TTACCRTTGGC′,

(p.His201Arg)

TGGCTGGTCTTACC

′CCAAAGGCCCGT

′CCAAAGGCCCGT

GTGGACCTCC′]

TACCRTTGGCT′]

TACCRTTGGCT′]

NM_020638.2
8074
FGF23
5111
[′TGGCGCACCCCAT
5291
[′CCCCATCAGACC
5505-
[′CCCCATCAGACC

(FGF23):c.211A>G

CAGACCATCTACRG

ATCTACRGTGA′]
5507
ATCTACRGTGA′,

(p.Ser71Gly)

TGAGTAGGGCTTCA

′CCCATCAGACCA

GGCTGGGAAG′]

TCTACRGTGAG′,

′CCATCAGACCAT

CTACRGTGAGT′]

NM_021102.3
10653
SPINT2
5112
[′AGGAACTCCTGCA
5292
[′CCTGCAATAACT
5508
[′CCTGCAATAACT

(SPINT2):c.488A>G

ATAACTTCATCTRTG

TCATCTRTGGA′]

TCATCTRTGGA′]

(p.Tyr163Cys)

GAGGCTGCCGGGGC

AATAAGAAC′]

NM_004795.3
9365
KL
5113
[′GTGCAGCCCGTGG
5293
[′CCGTGGTCACCC
5509
[′CCGTGGTCACCC

(KL):c.578A>G

TCACCCTGTACCRCT

TGTACCRCTGG′]

TGTACCRCTGG′]

(p.His193Arg)

GGGACCTGCCCCAG

CGCCTGCAG′]

NM_012193.3
−1
—
5114
[′GTTTTCCTACCCTG
5294-
[′CCCTGAGCGCCC
5510-
[′CCCTGAGCGCCC

(FZD4):c.766A>G

AGCGCCCCATCRTA
5295
CATCRTATTTC′,
5511
CATCRTATTTC′,

(p.Ile256Val)

TTTCTCAGTATGTGC

′CCTGAGCGCCCC

′CCTGAGCGCCCC

TATAATAT′]

ATCRTATTTCT′]

ATCRTATTTCT′]

NM_001099274.1
26277
TINF2
5115
[′ATGGGCCTCCACT
5296
[′CCACTAGGGGAG
5512
[′CCACTAGGGGAG

(TINF2):c.838A>G

AGGGGAGGCCATDA

GCCATDAGGAG′]

GCCATDAGGAG′]

(p.Lys280Glu)

GGAGCGCCCCACAG

TCATGCTGTT′]

NM_005682.6
9289
ADGRG1
5116
[′TCCTTCCCTGACCC
5297
[′CCCCAGGGGCCT
5513
[′CCCCAGGGGCCT

(ADGRG1):c.263A>G

CAGGGGCCTCTRCC

CTRCCACTTCT′]

CTRCCACTTCT′]

(p.Tyr88Cys)

ACTTCTGCCTCTACT

GGAACCGA′]

NM_000369.2
7253
TSHR
5117
[′CCGCAGTACAACC
5298
[′CCCAGGGGACAA
5514
[′CCCAGGGGACAA

(TSHR):c.1856A>G

CAGGGGACAAAGRT

AGRTACCAAAA′]

AGRTACCAAAA′]

(p.Asp619Gly)

ACCAAAATTGCCAA

GAGGATGGCT′]

NM_024009.2
2707
GJB3
5118
[′ATGCCGCGCCTGG
5299
[′CCTGGTGCAGTG
5515
[′CCTGGTGCAGTG

(GJB3):c.497A>G

TGCAGTGTGCCADC

TGCCADCGTGG′]

TGCCADCGTGG′]

(p.Asn166Ser)

GTGGCCCCCTGCCC

CAACATCGTG′]

NM_003722.4
8626
TP63
5119
[′TATCCGCGCCATGC
5300
[′CCATGCCTGTCT
5516
[′CCATGCCTGTCT

(TP63):c.697A>G

CTGTCTACAAARAA

ACAAARAAGCT′]

ACAAARAAGCT′]

(p.Lys233Glu)

GCTGAGCACGTCAC

GGAGGTGGT′]

NM_003494.3
8291
DYSF
5120
[′CAGCTCTTAACCAC
5301
[′CCACTCCAGCCA
5517
[′CCACTCCAGCCA

(DYSF):c.3443-33A>G

TCCAGCCACTCRCT

CTCRCTCTGGC′]

CTCRCTCTGGC′]

CTGGCACCTCTGTTT

TTTCCCTT′]

NM_003494.3
8291
DYSF
5121
[′AACTTGTCCCCTCC
5302
[′CCCCTCCCTGTG
5518-
[′CCCCTCCCTGTG

(DYSF):c.1285-2A>G

CTGTGTCTTCTRGCT

TCTTCTRGCTG′]
5520
TCTTCTRGCTG′,

GTGCAGCAAGATCT

′CCCTCCCTGTGTC

TGGAGAAG′]

TTCTRGCTGT′,

′CCTCCCTGTGTCT

TCTRGCTGTG′]

NM_002408.3
4247
MGAT2
5122
[′CTTATACTTTTCCT
5303
[′CCTAGAAGAGGA
5521
[′CCTAGAAGAGGA

(MGAT2):c.785A>G

AGAAGAGGATCRCT

TCRCTACTTAG′]

TCRCTACTTAG′]

(p.His262Arg)

ACTTAGCCCCAGAC

TTTTACCAT′]

NM_000492.3
1080
CFTR
5123
[′GTGATTATCACCA
5304
[′CCAGCACCAGTT
5522
[′CCAGCACCAGTT

(CFTR):c.2738A>G

GCACCAGTTCGTRT

CGTRTTATGTG′]

CGTRTTATGTG′]

(p.Tyr913Cys)

TATGTGTTTTACATT

TACGTGGGA′]

NM_001814.4
1075
CTSC
5124
[′TCTCAGACCCCAAT
5305
[′CCCCAATCCTAA
5523-
[′CCCCAATCCTAA

(CTSC):c.857A>G

CCTAAGCCCTCRGG

GCCCTCRGGAG′]
5525
GCCCTCRGGAG′,

(p.Gln286Arg)

AGGTTGTGTCTTGTA

′CCCAATCCTAAG

GCCAGTAT′]

CCCTCRGGAGG′,

′CCAATCCTAAGC

CCTCRGGAGGT′]

NM_005144.4
55806
HR
5125
[′TCCGACCCCTCCAA
5306
[′CCTCCAACCTGC
5526-
[′CCTCCAACCTGC

(HR):c.-218A>G

CCTGCGGCCCTRGA

GGCCCTRGAGC′]
5527
GGCCCTRGAGC′,

GCGCCCCCGCCGCC

′CCAACCTGCGGC

CCGGGGGAA′]

CCTRGAGCGCC′]

NM_018488.2
9496
TBX4
5126
[′TCCTTGTCCCGAGA
5307
[′CCCGAGAATCTT
5528-
[′CCCGAGAATCTT

(TBX4):c.1592A>G

ATCTTCCTTACRGTA

CCTTACRGTAC′]
5529
CCTTACRGTAC′,

(p.G1n531Arg)

CCATTCAGGAATGG

′CCGAGAATCTTCC

GGACTGTG′]

TTACRGTACC′]

NM_001089.2
21
ABCA3
5127
[′ACAGATCACCGTC
5308
[′CCGTCCTGCTGG
5530
[′CCGTCCTGCTGG

(ABCA3):c.1702A>G

CTGCTGGGCCACRA

GCCACRACGGT′]

GCCACRACGGT′]

(p.Asn568Asp)

CGGTGCCGGGAAGA

CCACCACCCT′]

NM_000525.3
37671
KCNJ1
5128
[′CTGGTGGCCCCGCT
5309-
[′CCCCGCTGATCA
5531-
[′CCCCGCTGATCA

(KCNDJ11):c.776A>G

GATCATCTACCRTG
5310
TCTACCRTGTC′,
5533
TCTACCRTGTC′,

(p.His259Arg)

TCATTGATGCCAAC

′CCCGCTGATCATC

′CCCGCTGATCATC

AGCCCACTC′]

TACCRTGTCA′]

TACCRTGTCA′,

′CCGCTGATCATCT

ACCRTGTCAT′]

NM_005587.2
4205
MEF2A
5129
[′TCTCCCCCTCCACC
5311
[′CCACCAGGTGGT
5534
[′CCACCAGGTGGT

(MEF2A):c.788A>G

AGGTGGTGGTARTC

GGTARTCTTGG′]

GGTARTCTTGG′]

(p.Asn263Ser)

TTGGAATGAACAGT

AGGAAACCA′]

NM_000098.2
1376
CPT2
5130
[′TTTTTAGGACCCTG
5312
[′CCTGGTTTGATA
5535-
[′CCCTGGTTTGAT

(CPT2):c.359A>G

GTTTGATATGTRCCT

TGTRCCTATCT′]
5536
ATGTRCCTATC′,

(p.Tyr120Cys)

ATCTGCTCGAGACT

′CCTGGTTTGATAT

CCGTTGTT′]

GTRCCTATCT′]

NM_178138.4
8022
LHX3
5131
[′GTGCGCCGCGCCC
5313-
[′CCCAGGACTTCG
5537-
[′CCCAGGACTTCG

(LHX3):c.332A>G

AGGACTTCGTGTRC
5314
TGTRCCACCTG′,
5538
TGTRCCACCTG′,

(p.Tyr111Cys)

CACCTGCACTGCTTT

′CCAGGACTTCGT

′CCAGGACTTCGT

GCCTGCGTC′]

GTRCCACCTGC′]

GTRCCACCTGC′]

NM_005502.3
19
ABCA1
5132
[′CAGATCACCTCCTT
5315
[′CCTCCTTCCTGG
5539-
[′CCTCCTTCCTGG

(ABCA1):c.2804A>G

CCTGGGCCACARTG

GCCACARTGGA′]
5540
GCCACARTGGA′,

(p.Asn935Ser)

GAGCGGGGAAGAC

′CCTTCCTGGGCCA

GACCACCATG′]

CARTGGAGCG′]

m.3260A>G
4567
MT-TL1
5133
[′GATGGCAGAGCCC
5316-
[′CCCGGTAATCGC
5541-
[′CCCGGTAATCGC

GGTAATCGCATARA
5317
ATARAACTTAA′,
5542
ATARAACTTAA′,

ACTTAAAACTTTAC

′CCGGTAATCGCA

′CCGGTAATCGCA

AGTCAGAGGT′]

TARAACTTAAA′]

TARAACTTAAA′]

m.4269A>G
4565
MT-TI
5134
[′GCATTCCCCCTCAA
5318-
[′CCCTCAAACCTA
5543-
[′CCCTCAAACCTA

ACCTAAGAAATRTG
5319
AGAAATRTGTC′,
5544
AGAAATRTGTC′,

TCTGATAAAAGAGT

′CCTCAAACCTAA

′CCTCAAACCTAA

TACTTTGAT′]

GAAATRTGTCT′]

GAAATRTGTCT′]

m.14495A>G
4541
MT-
5135
[′TCCAAAGACAACC
5320
[′CCATCATTCCCC
5545
[′CCATCATTCCCC

ND6

ATCATTCCCCCTRA

CTRAATAAATT′]

CTRAATAAATT′]

ATAAATTAAAAAAA

CTATTAAACC′]

NM_002764.3
5631
PRPS1
5136
[′CCAATCTCAGCCA
5321
[′CCAAGCTTGTTG
5546
[′CCAAGCTTGTTG

(PRPS1):c.341A>G

AGCTTGTTGCAART

CAARTATGCTA′]

CAARTATGCTA′]

(p.Asn114Ser)

ATGCTATCTGTAGC

AGGTGCAGAT′]

NM_000054.4
554
AVPR2
5137
[′GCGGAGCCCTGGG
5322
[′CCTGGGGCCGTC
5547
[′CCTGGGGCCGTC

(AVPR2):c.614A>G

GCCGTCGCACCTRT

GCACCTRTGTC′]

GCACCTRTGTC′]

(p.Tyr205Cys)

GTCACCTGGATTGC

CCTGATGGTG′]

NM_000033.3
215
ABCD1
5138
[′ATCGCCCTCCCTGC
5323-
[′CCCTGCTACCTT
5548-
[′CCCTGCTACCTT

(ABCD1):c.443A>G

TACCTTCGTCARCA
5324
CGTCARCAGTG′,
5549
CGTCARCAGTG′,

(p.Asn148Ser)

GTGCCATCCGTTAC

′CCTGCTACCTTCG

′CCTGCTACCTTCG

CTGGAGGGC′]

TCARCAGTGC′]

TCARCAGTGC′]

NM_000061.2
695
BTK
5139
[′AGCACCATCCCTG
5325-
[′CCCTGAGCTCAT
5550-
[′CCCTGAGCTCAT

(BTK):c.1082A>G

AGCTCATTAACTRC
5326
TAACTRCCATC′,
5551
TAACTRCCATC′,

(p.Tyr361Cys)

CATCAGCACAACTC

′CCTGAGCTCATTA

′CCTGAGCTCATTA

TGCAGGTGAG′]

ACTRCCATCA′]

ACTRCCATCA′]

NM_003413.3
7547
ZIC3
5140
[′CTACACGCACCCG
5327
[′CCGAGCTCCCTG
5552-
[′CCCGAGCTCCCT

(ZIC3):c.1213A>G

AGCTCCCTGCGCRA

CGCRAACACAT′]
5553
GCGCRAACACA′,

(p.Lys405Glu)

ACACATGAAGGTAA

′CCGAGCTCCCTGC

TTACCTCTTT′]

GCRAACACAT′]

NM_005448.2
9210
BMP15
5141
[′TTGGACATTGCCTT
5328
[′CCTTCTTGTTACT
5554
[′CCTTCTTGTTACT

(BMP15):c.704A>G

CTTGTTACTCTRTTT

CTRTTTCAAT′]

CTRTTTCAAT′]

(p.Tyr235Cys)

CAATGATACTCATA

AAAGCATT′]

NM_001363.4
1736
DKC1
5142
[′ATTAATGACCACA
5329
[′CCACAGCGGTCA
5555
[′CCACAGCGGTCA

(DKC1):c.1069A>G

GCGGTCATCTCTRC

TCTCTRCCTGC′]

TCTCTRCCTGC′]

(p.Thr357Ala)

CTGCGACCATGGTA

TAGTAGCCAA′]

NM_000481.3
275
AMT
5143
[′CGCAGGACACCGC
5330
[′CCGCTCTATGAC
5556
[′CCGCTCTATGAC

(AMT):c.125A>G

TCTATGACTTCCRCC

TTCCRCCTGGC′]

TTCCRCCTGGC′]

(p.His42Arg)

TGGCCCACGGCGGG

AAAATGGTG′]

NM_003361.3
7369
UMOD
5144
[′TGCCACGCCCTGG
5331
[′CCTGGCCACATG
5557-
[′CCCTGGCCACAT

(UMOD):c.383A>G

CCACATGTGTCART

TGTCARTGTGG′]
5558
GTGTCARTGTG′,

(p.Asn128Ser)

GTGGTGGGCAGCTA

′CCTGGCCACATGT

CTTGTGCGTA′]

GTCARTGTGG′]

NM_001382.3
1798
DPAGT1
5145
[′TCTCTCCCCGCAGG
5332
[′CCGCAGGAATCC
5559
[′CCGCAGGAATCC

(DPAGT1):c.509A>G

AATCCTGTACTRTGT

TGTACTRTGTC′]

TGTACTRTGTC′]

(p.Tyr170Cys)

CTACATGGGGCTGC

TGGCAGTG′]

NM_001128177.1
7068
THRB
5146
[′CTGCCATGCCAGC
5333
[′CCAGCCGCTTCC
5560
[′CCAGCCGCTTCC

(THRB):c.1324A>G

CGCTTCCTGCACRT

TGCACRTGAAG′]

TGCACRTGAAG′]

(p.Met442Val)

GAAGGTGGAATGCC

CCACAGAACT′]

NM_000141.4
2263
FGFR2
5147
[′TGCCCAGCCCCAC
5334
[′CCCACATCCAGT
5561-
[′CCCCACATCCAG

(FGFR2):c.874A>G

ATCCAGTGGATCRA

GGATCRAGCAC′]
5563
TGGATCRAGCA′,

(p.Lys292Glu)

GCACGTGGAAAAGA

′CCCACATCCAGT

ACGGCAGTAA′]

GGATCRAGCAC′,

′CCACATCCAGTG

GATCRAGCACG′]

NM_000371.3
7276
TTR
5148
[′ACCATTGCCGCCCT
5335-
[′CCGCCCTGCTGA
5564-
[′CCGCCCTGCTGA

(TTR):c.401A>G

GCTGAGCCCCTRCT
5337
GCCCCTRCTCC′,
5566
GCCCCTRCTCC′,

(p.Tyr134Cys)

CCTATTCCACCACG

′CCCTGCTGAGCCC

′CCCTGCTGAGCCC

GCTGTCGTC′]

CTRCTCCTAT′,

CTRCTCCTAT′,

′CCTGCTGAGCCCC

′CCTGCTGAGCCCC

TRCTCCTATT′]

TRCTCCTATT′]

NM_000371.3
7276
TTR
5149
[′CGACTCCGGCCCC
5338
[′CCCCCGCCGCTA
5567-
[′CCCCCGCCGCTA

(TTR):c.379A>G

CGCCGCTACACCRT

CACCRTTGCCG′]
5569
CACCRTTGCCG′,

(p.Ile127Val)

TGCCGCCCTGCTGA

′CCCCGCCGCTAC

GCCCCTACTC′]

ACCRTTGCCGC′,

′CCCGCCGCTACA

CCRTTGCCGCC′]

NM_000174.4
2815
GP9
5150
[′ACCCGCCACCTTCT
5339
[′CCTTCTGCTGGC
5570
[′CCTTCTGCTGGC

(GP9):c.182A>G

GCTGGCCAACARCA

CAACARCAGCC′]

CAACARCAGCC′]

(p.Asn61Ser)

GCCTTCAGTCCGTG

CCCCCGGGA′]

NM_000222.2
3815
KIT
5151
[′ACGGGAAGCCCTC
5340-
[′CCCTCATGTCTG
5571-
[′CCCTCATGTCTG

(KIT):c.1924A>G

ATGTCTGAACTCRA
5341
AACTCRAAGTC′,
5572
AACTCRAAGTC′,

(p.Lys642Glu)

AGTCCTGAGTTACC

′CCTCATGTCTGAA

′CCTCATGTCTGAA

TTGGTAATCA′]

CTCRAAGTCC′]

CTCRAAGTCC′]

NM_000530.6
4359
MPZ
5152
[′TCCCCTCATTCCTC
5342
[′CCTCATAGATCT
5573
[′CCTCATAGATCT

(MPZ):c.242A>G

ATAGATCTTCCRCT

TCCRCTATGCC′]

TCCRCTATGCC′]

(p.His8lArg)

ATGCCAAGGGACAA

CCCTACATT′]

NM_000233.3
−1
—
5153
[′AAAATGGCAATCC
5343
[′CCTCATCTTCAC
5574
[′CCTCATCTTCAC

(LHCGR):c.1733A>G

TCATCTTCACCGRTT

CGRTTTCACCT′]

CGRTTTCACCT′]

(p.Asp578Gly)

TCACCTGCATGGCA

CCTATCTCT′]

NM_000421.3
−1
—
5154
[′CCGCCGCGTCCGC
5344
[′CCGCCGCCTCCG
5575
[′CCGCCGCCTCCG

(KRT10):c.1374-2A>G

CGCCTCCGGAACYA

GAACYAAACGG′]

GAACYAAACGG′]

AACGGGGTGAGGTC

ACATTCGGTT′]

NM_000422.2
3872
KRT17
5155
[′TGAGAAGGCCACC
5345
[′CCACCATGCAGA
5576-
[′CCACCATGCAGA

(KRT17):c.274A>G

ATGCAGAACCTCVA

ACCTCVATGAC′]
5577
ACCTCVATGAC′,

(p.Asn92Asp)

TGACCGCCTGGCCT

′CCATGCAGAACC

CCTACCTGGA′]

TCVATGACCGC′]

NM_000422.2
3872
KRT17
5156
[′GAGAAGGCCACCA
5346
[′CCACCATGCAGA
5578-
[′CCACCATGCAGA

(KRT17):c.275A>G

TGCAGAACCTCART

ACCTCARTGAC′]
5579
ACCTCARTGAC′,

(p.Asn92Ser)

GACCGCCTGGCCTC

′CCATGCAGAACC

CTACCTGGAC′]

TCARTGACCGC′]

NM_000823.3
2692
GHRHR
5157
[′TTGTCTTTCCTGCA
5347
[′CCTGCAGGCGTC
5580
[′CCTGCAGGCGTC

(GHRHR):c.985A>G

GGCGTCTCTCCRAG

TCTCCRAGTCG′]

TCTCCRAGTCG′]

(p.Lys329Glu)

TCGACACTTTTCCTG

ATCCCACT′]

NM_000407.4
−1
—
5158
[′GCCGGCCGCCCCG
5348-
[′CCCCGAGCGTGC
5581-
[′CCCCGAGCGTGC

(GP1BB):c.338A>G

AGCGTGCGCCCTDC
5349
GCCCTDCCGCG′,
5583
GCCCTDCCGCG′,

(p.Tyr113Cys)

CGCGACCTGCGTTG

′CCCGAGCGTGCG

′CCCGAGCGTGCG

CGTGGCGCCC′]

CCCTDCCGCGA′]

CCCTDCCGCGA′,

′CCGAGCGTGCGC

CCTDCCGCGAC′]

NM_001146040.1
2741
GLRA1
5159
[′CCTCCACCCCCACT
5350-
[′CCCCACTCTAGG
5584-
[′CCCCACTCTAGG

(GLRA1):c.920A>G

CTAGGTGTCCTVTGT
5351
TGTCCTVTGTG′,
5586
TGTCCTVTGTG′,

(p.Tyr307Cys)

GAAAGCCATTGACA

′CCCACTCTAGGTG

′CCCACTCTAGGTG

TTTGGATG′]

TCCTVTGTGA′]

TCCTVTGTGA′,

′CCACTCTAGGTGT

CCTVTGTGAA′]

NM_182925.4
2324
FLT4
5160
[′CGCCTCCCCGCACC
5352
[′CCGCACCCCAGT
5587
[′CCGCACCCCAGT

(FLT4):c.3104A>G

CCAGTGCATCCRCA

GCATCCRCAGA′]

GCATCCRCAGA′]

(p.His1035Arg)

GAGACCTGGCTGCT

CGGAACATT′]

NM_212482.1
2335
FN1
5161
[′ACCGGGCTGTCCC
5353-
[′CCCCTGGGGTCA
5588-
[′CCCCTGGGGTCA

(FN1):c.2918A>G

CTGGGGTCACCTRT
5354
CCTRTTACTTC′,
5589
CCTRTTACTTC′,

(p.Tyr973Cys)

TACTTCAAAGTCTTT

′CCCTGGGGTCAC

′CCCTGGGGTCAC

GCAGTGAGC′]

CTRTTACTTCA′]

CTRTTACTTCA′]

NM_000121.3
2057
EPOR
5162
[′GGCTTATCCGATG
5355
[′CCGATGGCCCCT
5590
[′CCGATGGCCCCT

(EPOR):c.1460A>G

GCCCCTACTCCARC

ACTCCARCCCT′]

ACTCCARCCCT′]

(p.Asn487Ser)

CCTTATGAGAACAG

CCTTATCCCA′]

NM_001735.2
727
C5
5163
[′CGTCTACCCCCTCA
5356-
[′CCCCTCACCCAA
5591-
[′CCCCTCACCCAA

(C5):c.1115A>G

CCCAATCTACCYTG
5357
TCTACCYTGAT′,
5593
TCTACCYTGAT′,

(p.Lys372Arg)

ATGGGATATGGAAT

′CCCTCACCCAATC

′CCCTCACCCAATC

CCCAGGCTT′]

TACCYTGATG′]

TACCYTGATG′,

′CCTCACCCAATCT

ACCYTGATGG′]

NM_001844.4
1280
COL2A1
5164
[′ACGGAAGGCTCCC
5358-
[′CCCAGAACATCA
5594-
[′CCCAGAACATCA

(COL2A1):c.4172A>G

AGAACATCACCTRC
5359
CCTRCCACTGC′,
5595
CCTRCCACTGC′,

(p.Tyr1391Cys)

CACTGCAAGAACAG

′CCAGAACATCAC

′CCAGAACATCAC

CATTGCCTAT′]

CTRCCACTGCA′]

CTRCCACTGCA′]

NM_001904.3
1499
CTNNB1
5165
[′CTCTGGAATCCATT
5360
[′CCATTCTGGTGC
5596
[′CCATTCTGGTGC

(CTNNB1):c.121A>G

CTGGTGCCACTNCC

CACTNCCACAG′]

CACTNCCACAG′]

(p.Thr41Ala)

ACAGCTCCTTCTCTG

AGTGGTAA′]

NM_000040.1
345
APOC3
5166
[′GGATTTGGACCCT
5361-
[′CCCTGAGGTCAG
5597-
[′CCCTGAGGTCAG

(APOC3):c.280A>G

GAGGTCAGACCARC
5362

5598
ACCARCTTCAG′,

(p.Thr94Ala)

TTCAGCCGTGGCTG

′CCTGAGGTCAGA

′CCTGAGGTCAGA

CCTGAGACCT′]

CCARCTTCAGC′]

CCARCTTCAGC′]

NM_000488.3
462
SERPINC1
5167
[′TGCAGAGCAATCC
5363
[′CCAGAGCGGCCA
5599
[′CCAGAGCGGCCA

(SERPINC1):c.655A>G

AGAGCGGCCATCRA

TCRACAAATGG′]

TCRACAAATGG′]

CAAATGGGTGTCCA

(p.Asn219Asp)

ATAAGACCGA′]

NM_001085.4
12
SERPINA3
5168
[′TACAGACACCCAG
5364
[′CCCAGAACATCT
5600-
[′CCCAGAACATCT

(SERPINA3):c.1240A>G

AACATCTTCTTCRTG

TCTTCRTGAGC′]
5601
TCTTCRTGAGC′,

(p.Met414Val)

AGCAAAGTCACCAA

′CCAGAACATCTTC

TCCCAAGCA′]

TTCRTGAGCA′]

NM_001145.4
−1
—
5169
[′CTTCCTGACCCAGC
5365
[′CCAGCACTATGA
5602-
[′CCCAGCACTATG

(ANG):c.121A>G

ACTATGATGCCRAA

TGCCRAACCAC′]
5603
ATGCCRAACCA′,

(p.Lys41Glu)

CCACAGGGCCGGGA

′CCAGCACTATGA

TGACAGATA′]

TGCCRAACCAC′]

NM_001100.3
58
ACTA1
5170
[′GAGGCCCCCCTCA
5366
[′CCTCAATCCCAA
5604-
[′CCCTCAATCCCA

(ACTA1):c.350A>G

ATCCCAAGGCCARC

GGCCARCCGCG′]
5605
AGGCCARCCGC′,

(p.Asn117Ser)

CGCGAGAAGATGAC

′CCTCAATCCCAA

CCAGATCATG′]

GGCCARCCGCG′]

NM_014053.3
28982
FLVCR1
5171
[′GATCTTCAGCCTGT
5367
[′CCTGTACTCGCT
5606
[′CCTGTACTCGCT

(FLVCR1):c.361A>G

ACTCGCTGGTCRAC

GGTCRACGCCT′]

GGTCRACGCCT′]

(p.Asn121Asp)

GCCTTTCAGTGGAT

CCAGTACAG′]

NM_000334.4
6329
SCN4A
5172
[′GAAGCAGGCCTTC
5368
[′CCTTCGACATCA
5607
[′CCTTCGACATCA

(SCN4A):c.4078A>G

GACATCACCATCRT

CCATCRTGATC′]

CCATCRTGATC′]

(p.Met1360Val)

GATCCTCATCTGCCT

CAACATGGT′]

NM_004519.3
3786
KCNQ3
5173
[′GAACCAAAGCCTG
5369
[′CCTGTTGGCTTA
5608
[′CCTGTTGGCTTA

(KCNQ3):c.1403A>G

TTGGCTTAAACART

AACARTAAAGA′]

AACARTAAAGA′]

(p.Asn468Ser)

AAAGAGCGTTTCCG

CACGGCCTTC′]

NM_007375.3
23435
TARDBP
5174
[′AATGCCGAACCTA
5370
[′CCTAAGCACAAT
5609
[′CCTAAGCACAAT

(TARDBP):c.800A>G

AGCACAATAGCART

AGCARTAGACA′]

AGCARTAGACA′]

(p.Asn267Ser)

AGACAGTTAGAAAG

AAGTGGAAGA′]

NM_032520.4
84572
GNPTG
5175
[′TGCTGCCCCTGCAT
5371
[′CCTGCATCCTCC
5610
[′CCTGCATCCTCC

(GNPTG):c.6102A>G

CCTCCACCTTCRGG

ACCTTCRGGGC′]

ACCTTCRGGGC′]

GCCATGAGAAGTTG

CTGAGGACA′]

NM_000495.4
1287
COL4A5
5176
[′AGAACTTCCATTG
5372
[′CCATTGATGGCT
5611
[′CCATTGATGGCT

(COL4A5):c.466-2A>G

ATGGCTTCTTTTRGG

TCTTTTRGGGT′]

TCTTTTRGGGT′]

GTGAACCAGGTAGT

ATAATTATG′]

NM_000495.4
12875
COMA
5177
[′TTGCTATCCTTTCT
5373
[′CCTTTCTTTATCT
5612
[′CCTTTCTTTATCT

(COL4A5):c.1340-2A>G

TTATCTTACTCRGGT

TACTCRGGTG′]

TACTCRGGTG′]

GATGAGATATGTGA

ACCAGGCC′]

NM_000060.3
686
BTD
5178
[′CTCATGAACCAGA
5374
[′CCAGAACCTTGA
5613
[′CCAGAACCTTGA

(BTD):c.278A>G

ACCTTGACATCTRT

CATCTRTGAAC′]

CATCTRTGAAC′]

(p.Tyr93Cys)

GAACAGCAAGTGAT

GACTGCAGCC′]

NM_000060.3
686
BTD
5179
[′CTTGTTGACCGCTA
5375
[′CCGCTACCGTAA
5614
[′CCGCTACCGTAA

(BTD):c.641A>G

CCGTAAACACARCC

ACACARCCTCT′]

ACACARCCTCT′]

(p.Asn214Ser)

TCTACTTTGAGGCA

GCATTCGAT′]

NM_000094.3
1294
COL7A1
5180
[′CAGCTGGCCCGAC
5376
[′CCCGACCTGGTG
5615-
[′CCCGACCTGGTG

(COL7A1):c.425A>G

CTGGTGTCCCCARG

TCCCCARGGTG′]
5616
TCCCCARGGTG′,

(p.Lys142Arg)

GTGATCCCTACCCC

′CCGACCTGGTGTC

TACCATGCCT′]

CCCARGGTGA′]

NM_005247.2
2248
FGF3
5181
[′GGGGCGCCCCGGC
5377-
[′CCCGGCGCCGCA
5617-
[′CCCGGCGCCGCA

(FGF3):c.146A>G

GCCGCAAGCTCTRC
5378
AGCTCTRCTGC′,
5618
AGCTCTRCTGC′,

(p.Tyr49Cys)

TGCGCCACGAAGTA

′CCGGCGCCGCAA

′CCGGCGCCGCAA

CCACCTCCAG′]

GCTCTRCTGCG′]

GCTCTRCTGCG′]

NM_000313.3
5627
PROS1
5182
[′TGTGAATGCCCCG
5379-
[′CCCGAAGGCTAC
5619-
[′CCCCGAAGGCTA

(PROS1):c.701A>G

AAGGCTACAGATRT
5380
AGATRTAATCT′,
5621
CAGATRTAATC′,

(p.Tyr234Cys)

AATCTCAAATCAAA

′CCGAAGGCTACA

′CCCGAAGGCTAC

GTCTTGTGAA′]

GATRTAATCTC′]

AGATRTAATCT′,

′CCGAAGGCTACA

GATRTAATCTC′]

NM_004612.3
7046
TGFBR1
5183
[′TTCTGCCACCTCTG
5381
[′CCTCTGTACAAA
5622
[′CCTCTGTACAAA

(TGFBR1):c.134A>G

TACAAAAGACARTT

AGACARTTTTA′]

AGACARTTTTA′]

(p.Asn45Ser)

TTACTTGTGTGACA

GATGGGCTC′]

m.608A>G
4558
MT-TF
5184
[′GTAGCTTACCTCCT
5382
[′CCTCCTCAAAGC
5623-
[′CCTCCTCAAAGC

CAAAGCAATACRCT

AATACRCTGAA′]
5624
AATACRCTGAA′,

GAAAATGTTTAGAC

′CCTCAAAGCAAT

GGGCTCACA′]

ACRCTGAAAAT′]

NM_001376.4
1778
DYNC1H1
5185
[′CTAAGAATAACCA
5383
[′CCAATCAGGTAA
5625
[′CCAATCAGGTAA

(DYNC1H1):c.2909A>G

ATCAGGTAATCTRC

TCTRCTTGAAT′]

TCTRCTTGAAT′]

(p.Tyr970Cys)

TTGAATCCACCAAT

TGAAGAGTGC′]

NM_000459.4
7010
TEK
5186
[′ATGCTCTCTTCCTT
5384
[′CCTTCCCTCCAG
5626
[′CCTTCCCTCCAG

(TEK):c.2690A>G

CCCTCCAGGCTVCT

GCTVCTTGTAC′]

GCTVCTTGTAC′]

(p.Tyr897Cys)

TGTACCTGGCCATT

GAGTACGCG′]

NM_014191.3
6334
SCN8A
5187
[′CATGTACATTGCCA
5385
[′CCATCATCCTGG
5627
[′CCATCATCCTGG

(SCN8A):c.5302A>G

TCATCCTGGAGRAC

AGRACTTCAGT′]

AGRACTTCAGT′]

(p.Asn1768Asp)

TTCAGTGTAGCCAC

AGAGGAAAG′]

NM_002552.4
5000
ORC4
5188
[′CATCATAAAAACC
5386
[′CCAAACACTTCT
5628
[′CCAAACACTTCT

(ORC4):c.521A>G

AAACACTTCTCTRT

CTRTAATCTTT′]

CTRTAATCTTT′]

(p.Tyr174Cys)

AATCTTTTTGACATT

TCTCAGTCT′]

NM_004813.2
9409
PEX16
5189
[′TACTTGCCCACCTG
5387-
[′CCACCTGGCAGA
5629-
[′CCACCTGGCAGA

(PEX16):c.992A>G

GCAGAAAATCTRCT
5388
AAATCTRCTTC′,
5630
AAATCTRCTTC′,

(p.Tyr331Cys)

TCTACAGTTGGGGC

′CCTGGCAGAAAA

′CCTGGCAGAAAA

TGACAGACC′]

TCTRCTTCTAC′]

TCTRCTTCTAC′]

NM_016952.4
50937
CDON
5190
[′GTTTTTGTTTTCCC
5389
[′CCCTCAAAGGTT
5631
[′CCCTCAAAGGTT

(CDON):c.2368A>G

TCAAAGGTTCARCA

CARCATACAAA′]

CARCATACAAA′]

(p.Thr790Ala)

TACAAATTTAGGGT

CATTGCCAT′]

NM_016464.4
51524
TMEM138
5191
[′TACTTTGCCCTCAG
5390-
[′CCCTCAGCATCT
5632-
[′CCCTCAGCATCT

(TMEM138):c.287A>G

CATCTCCCTTCRTGT
5391
CCCTTCRTGTC′,
5633
CCCTTCRTGTC′,

(p.His96Arg)

CTGGGTCATGGTAA

′CCTCAGCATCTCC

′CCTCAGCATCTCC

GAGTGGCA′]

CTTCRTGTCT′]

CTTCRTGTCT′]

NM_005022.3
5216
PFN1
5192
[′GTTGATCAAACCA
5392
[′CCACCGTGGACA
5634
[′CCACCGTGGACA

(PFN1):c.350A>G

CCGTGGACACCTYC

CCTYCTTTGCC′]

CCTYCTTTGCC′]

(p.Glu117Gly)

TTTGCCCATCAGCA

GGACTAGCGC′]

NM_022787.3
64802
NMNAT1
5193
[′GGTCATCCTGGCCC
5393
[′CCCCTTTGCAGA
5635
[′CCCCTTTGCAGA

(NMNAT1):c.817A>G

CTTTGCAGAGARAC

GARACACTGCA′]

GARACACTGCA′]

(p.Asn273Asp)

ACTGCAGAAGCTAA

GACATAGGA′]

NM_005340.6
3094
HINT1
5194
[′GACATTTCCCCTCA
5394-
[′CCCCTCAAGCAC
5636-
[′CCCCTCAAGCAC

(HINT1):c.152A>G

AGCACCAACACRTT
5396
CAACACRTTTT′,
5638
CAACACRTTTT′,

(p.His5lArg)

TTCTGGTGATACCC

′CCCTCAAGCACC

′CCCTCAAGCACC

AAGAAACAT′]

AACACRTTTTC′,

AACACRTTTTC′,

′CCTCAAGCACCA

′CCTCAAGCACCA

ACACRTTTTCT′]

ACACRTTTTCT′]

NM_005211.3
1436
CSF1R
5195
[′GACTAACCCTGCA
5397
[′CCTGCAGTGCTT
5639
[′CCTGCAGTGCTT

(CSF1R):c.2320-2A>G

GTGCTTTCCCTCRGT

TCCCTCRGTGC′]

TCCCTCRGTGC′]

GCATCCACCGGGAC

GTGGCAGCG′]

NM_001039958.1
145873
MESP2
5196
[′GCGGCAGAGCGCC
5398
[′CCAGCGAGCGGG
5640
[′CCAGCGAGCGGG

(MESP2):c.271A>G

AGCGAGCGGGAGRA

AGRAACTGCGC′]

AGRAACTGCGC′]

(p.Lys91Glu)

ACTGCGCATGCGCA

CGCTGGCCCG′]

NM_001099274.1
26277
TINF2
5197
[′TAGGGGAGGCCAT
5399
[′CCATAAGGAGCG
5641
[′CCATAAGGAGCG

(TINF2):c.850A>G

AAGGAGCGCCCCRC

CCCCRCAGTCA′]

CCCCRCAGTCA′]

(p.Thr284Ala)

AGTCATGCTGTTTCC

CTTTAGGAA′]

NM_003863.3
8818
DPM2
5198
[′GCCGTTAGCCTGAT
5400
[′CCTGATCATCTT
5642
[′CCTGATCATCTT

(DPM2):c.68A>G

CATCTTCACCTRCTA

CACCTRCTACA′]

CACCTRCTACA′]

(p.Tyr23Cys)

CACCGCCTGGGTGA

TTCTCTTG′]

NM_000530.6
4359
MPZ
5199
[′AAGGATGGCTCCA
5401
[′CCATTGTCATAC
5643
[′CCATTGTCATAC

(MPZ):c.347A>G

TTGTCATACACARC

ACARCCTAGAC′]

ACARCCTAGAC′]

(p.Asn116Ser)

CTAGACTACAGTGA

CAATGGCACG′]

NM_000138.4
2200
FBN1
5200
[′ACCCGGATTTGCC
5402
[′CCACAAAAGAA
5644
[′CCACAAAAGAA

(FBN1):c.3058A>G

ACAAAAGAAATTRC

ATTRCAAATGGA′]

ATTRCAAATGGA′]

(p.Thr1020Ala)

AAATGGAAAGCCTT

TCTTCAAAGG′]

NM_000169.2
−1
—
5201
[′GGCCTGTAATCCTG
5403
[′CCTGCCTGCTTC
5645
[′CCTGCCTGCTTC

(GLA):c.1153A>G

CCTGCTTCATCRCAC

ATCRCACAGCT′]

ATCRCACAGCT′]

(p.Thr385Ala)

AGCTCCTCCCTGTG

AAAAGGAA′]

NM_000257.3
4625
MYH7
5202
[′AGCGGCCATCCCT
5404
[′CCCTGAGGGACA
5646-
[′CCCTGAGGGACA

(MYH7):c.2206A>G

GAGGGACAGTTCRT

GTTCRTTGATA′]
5647
GTTCRTTGATA′,

(p.Ile736Val)

TGATAGCAGGAAGG

′CCTGAGGGACAG

GGGCAGAGAA′]

TTCRTTGATAG′]

NM_018972.2
54332
GDAP1
5203
[′AGCATGTATTACCC
5405
[′CCCACGGGTACA
5648
[′CCCACGGGTACA

(GDAP1):c.368A>G

ACGGGTACAACRTT

ACRTTACCGAG′]

ACRTTACCGAG′]

(p.His123Arg)

ACCGAGAGCTGCTT

GACTCCTTG′]

NM_001946.3
1848
DUSP6
5204
[′ACTACCATCCGAG
5406
[′CCGAGTCTGTTG
5649
[′CCGAGTCTGTTG

(DUSP6):c.566A>G

TCTGTTGCACTAYTG

CACTAYTGGGG′]

CACTAYTGGGG′]

(p.Asn189Ser)

GGGTCTCGGTCAAG

GTCAGACTC′]

NM_003867.3
8822
FGF17
5205
[′TACCAAGGCCAGC
5407
[′CCAGCTGCCCTT
5650
[′CCAGCTGCCCTT

(FGF17):c.560A>G

TGCCCTTCCCCARCC

CCCCARCCACG′]

CCCCARCCACG′]

(p.Asn187Ser)

ACGCCGAGAAGCAG

AAGCAGTTC′]

NM_015560.2
4976
OPA1
5206
[′TTTTTATTTTTCCT
5408
[′CCTGAGTAGACC
5651
[′CCTGAGTAGACC

(OPA1):c.1146A>G

GAGTAGACCATRTC

ATRTCCTTAAA′]

ATRTCCTTAAA′]

(p.Ile382Met)

CTTAAATGTAAAAG

GCCCTGGAC′]

NM_002972.3
6305
SBF1
5207
[′AAGGCCATGCCCT
5409
[′CCCTCCAGCACC
5652-
[′CCCTCCAGCACC

(SBF1):c.1249A>G

CCAGCACCTTCAYC

TTCAYCAGGAA′]
5653
TTCAYCAGGAA′,

(p.Met417Val)

AGGAAATCGTCCTC

′CCTCCAGCACCTT

TACCAGCCCA′]

CAYCAGGAAA′]

NM_006876.2
11041
B4GAT1
5208
[′GTTCCATCCCCAAA
5410
[′CCAAAAGGAGG
5654-
[′CCCCAAAAGGAG

(B4GAT1):c.1168A>G

AGGAGGCTGAARAT

CTGAARATCAGC′]
5656
GCTGAARATCA′,

(p.Asn390Asp)

CAGCACAATAAGAT

′CCCAAAAGGAGG

CCTATATCG′]

CTGAARATCAG′,

′CCAAAAGGAGGC

TGAARATCAGC′]

NM_000218.2
3784
KCNQ1
5209
[′CGCACCCACGTCC
5411
[′CCAGGGCCGCGT
5657
[′CCAGGGCCGCGT

(KCNQ1):c.332A>G

AGGGCCGCGTCTRC

CTRCAACTTCC′]

CTRCAACTTCC′]

(p.Tyr111Cys)

AACTTCCTCGAGCG

TCCCACCGGC′]

NM_000492.3
1080
CFTR
5210
[′CAGGGACCCCAGC
5412
[′CCAGCGCCCGAG
5658-
[′CCCAGCGCCCGA

(CFTR):c.1A>G

GCCCGAGAGACCRT

AGACCRTGCAG′]
5659
GAGACCRTGCA′,

(p.MetlVal)

GCAGAGGTCGCCTC

′CCAGCGCCCGAG

TGGAAAAGGC′]

AGACCRTGCAG′]

NM_007294.3
672
BRCA1
5211
[′GAACCTGTCTCCAC
5413
[′CCACAAAGTGTG
5660
[′CCACAAAGTGTG

(BRCA1):c.122A>G

AAAGTGTGACCRCA

ACCRCATATTT′]

ACCRCATATTT′]

(p.His41Arg)

TATTTTGCAAGTAA

GTTTGAATG′]

NM_007294.3
672
BRCA1
5212
[′GTTTTCTCCTTCCA
5414
[′CCTTCCATTTATC
5661-
[′CCTTCCATTTATC

(BRCA1):c.44852A>G

TTTATCTTTCTRGGT

TTTCTRGGTC′]
5662
TTTCTRGGTC′,

CATCCCCTTCTAAAT

′CCATTTATCTTTC

GCCCATC′]

TRGGTCATCC′]

NM_014795.3
9839
ZEB2
5213
[′AAACACAAGCACC
5415
[′CCACCTTATCGA
5663
[′CCACCTTATCGA

(ZEB2):c.3134A>G

ACCTTATCGAGCRC

GCRCTCAAGGC′]

GCRCTCAAGGC′]

(p.His1045Arg)

TCAAGGCTTCACTC

GGGCGAGAAG′]

NM_001287.5
1186
CLCN7
5214
[′TGTCCCGGCCTGCA
5416
[′CCTGCAGAGCTT
5664
[′CCTGCAGAGCTT

(CLCN7):c.296A>G

GAGCTTGGACTRTG

GGACTRTGACA′]

GGACTRTGACA′]

(p.Tyr99Cys)

ACAACAGTGAGAAC

CAGCTGTTC′]

NM_080605.3
126792
B3GALT6
5215
[′CGCCACGCCCGCC
5417
[′CCCGCCGCAGCA
5665-
[′CCCGCCGCAGCA

(B3GALT6):c.1A>G

GCAGCAGCTTCAYG

GCTTCAYGGCG′]
5667
GCTTCAYGGCG′,

(p.MetlVal)

GCGCCCGCGCCGGG

′CCGCCGCAGCAG

CCGGCGGCCC′]

CTTCAYGGCGC′,

′CCGCAGCAGCTT

CAYGGCGCCCG′]

NM_000207.2
−1
—
5216
[′TCCTGCACCGAGA
5418
[′CCGAGAGAGATG
5668
[′CCGAGAGAGATG

(1NS):c.*59A>G

GAGATGGAATAARG

GAATAARGCCC′]

GAATAARGCCC′]

CCCTTGAACCAGCC

CTGCTGTGCC′]

NM_000784.3
1593
CYP27A1
5217
[′TGGGCCCTGTACC
5419
[′CCACCTCTCAAA
5669
[′CCACCTCTCAAA

(CYP27A1):c.1061A>G

ACCTCTCAAAGGRC

GGRCCCTGAGA′]

GGRCCCTGAGA′]

(p.Asp354Gly)

CCTGAGATCCAGGA

GGCCTTGCAC′]

NM_000540.2
6261
RYR1
5218
[′CTACCTGTACACCG
5420
[′CCGTGGTGGCCT
5670
[′CCGTGGTGGCCT

(RYRO:c.14572A>G

TGGTGGCCTTCRAC

TCRACTTCTTC′]

TCRACTTCTTC′]

(p.Asn4858Asp)

TTCTTCCGCAAGTTC

TACAACAA′]

NM_000238.3
3757
KCNH2
5219
[′CACCCCGGCCGCA
5421
[′CCGCATCGCCGT
5671
[′CCGCATCGCCGT

(KCNH2):c.1478A>G

TCGCCGTCCACTNC

CCACTNCTTCA′]

CCACTNCTTCA′]

(p.Tyr493Cys)

TTCAAGGGCTGGTT

CCTCATCGAC′]

NM_000335.4
6331
SCN5A
5220
[′CCGAGTCCTCCGG
5422
[′CCGGGCCCTGAA
5672
[′CCGGGCCCTGAA

(SCN5A):c.688A>G

GCCCTGAAAACTRT

AACTRTATCAG′]

AACTRTATCAG′]

(p.Ile230Val)

ATCAGTCATTTCAG

GTGAAAATCA′]

NM_000169.2
−1
—
5221
[′TATTTTACCCATTG
5423
[′CCCATTGTTTTCT
5673-
[′CCCATTGTTTTCT

(GLA):c.548-2A>G

TTTTCTCATACRGGT

CATACRGGTT′]
5674
CATACRGGTT′,

TATAAGCACATGTC

′CCATTGTTTTCTC

CTTGGCCC′]

ATACRGGTTA′]

NM_000146.3
2512
FTL
5222
[′GTTAGCTCCTTCTT
5424
[′CCTTCTTGCCAA
5675
[′CCTTCTTGCCAA

(FTL):c.1A>G

GCCAACCAACCRTG

CCAACCRTGAG′]

CCAACCRTGAG′]

(p.MetlVal)

AGCTCCCAGATTCG

TCAGAATTA′]

NM_000531.5
5009
OTC
5223
[′GTCATGGTGTCCCT
5425-
[′CCCTGCTGACAG
5676-
[′CCCTGCTGACAG

(OTC):c.1034A>G

GCTGACAGATTRCT
5426
ATTRCTCACCT′,
5677
ATTRCTCACCT′,

(p.Tyr345Cys)

CACCTCAGCTCCAG

′CCTGCTGACAGA

′CCTGCTGACAGA

AAGCCTAAA′]

TTRCTCACCTC′]

TTRCTCACCTC′]

NM_000531.5
5009
OTC
5224
[′TGTTTTCTTACCAC
5427
[′CCACACAAGATA
5678
[′CCACACAAGATA

(OTC):c.350A>G

ACAAGATATTCDTT

TTCDTTTGGGT′]

TTCDTTTGGGT′]

(p.His117Arg)

TGGGTGTGAATGAA

AGTCTCACG′]

NM_000531.5
5009
OTC
5225
[′TACCATCCTATCCA
5428
[′CCAGATCCTGGC
5679
[′CCAGATCCTGGC

(OTC):c.524A>G

GATCCTGGCTGDTT

TGDTTACCTCA′]

TGDTTACCTCA′]

(p.Asp175Gly)

ACCTCACGCTCCAG

GTTGGTTTA′]

NM_000531.5
5009
OTC
5226
[′CATCCTATCCAGAT
5429
[′CCAGATCCTGGC
5680
[′CCAGATCCTGGC

(OTC):c.527A>G

CCTGGCTGATTRCCT

TGATTRCCTCA′]

TGATTRCCTCA′]

(p.Tyr176Cys)

CACGCTCCAGGTTG

GTTTATTT′]

NM_000531.5
5009
OTC
5227
[′TCTCCTTCATCCCG
5430
[′CCGTGCCTTTTA
5681-
[′CCCGTGCCTTTT

(OTC):c.542A>G

TGCCTTTTAGGRAC

GGRACACTATA′]
5682
AGGRACACTAT′,

(p.Glu181Gly)

ACTATAGCTCTCTG

′CCGTGCCTTTTAG

AAAGGTCTT′]

GRACACTATA′]

NM_024301.4
79147
FKRP
5228
[′CCAGCTAGCCCCA
5431
[′CCCCAGACTTCG
5683-
[′CCCCAGACTTCG

(FKRP):c.1A>G

GACTTCGGCCCCRT

GCCCCRTGCGG′]
5685
GCCCCRTGCGG′,

(p.MetlVal)

GCGGCTCACCCGCT

′CCCAGACTTCGG

GCCAGGCTGC′]

CCCCRTGCGGC′,

′CCAGACTTCGGC

CCCRTGCGGCT′]

NM_000321.2
5925
RB1
5229
[′AGCCTTCCAGACC
5432
[′CCCAGAAGCCAT
5686
[′CCCAGAAGCCAT

(RBO:c.1927A>G

CAGAAGCCATTGRA

TGRAATCTACC′]

TGRAATCTACC′]

(p.Lys643Glu)

ATCTACCTCTCTTTC

ACTGTTTTA′]

NM_015713.4
50484
RRM2B
5230
[′AAAAGATCCTGAG
5433
[′CCTGAGAAGAAA
5687
[′CCTGAGAAGAAA

(RRM2B):c.581A>

AAGAAAACTCCTYC

ACTCCTYCTAC′]

ACTCCTYCTAC′]

G(p.Glu194Gly)

TACAGCAGCAAAGG

CCACCACTCT′]

NM_000219.5
3753
KCNE1
5231
[′CACTCGAACGACC
5434
[′CCCATTCAACGT
5688
[′CCCATTCAACGT

(KCNE1):c.242A>G

CATTCAACGTCTDC

CTDCATCGAGT′]

CTDCATCGAGT′]

(p.Tyr81Cys)

ATCGAGTCCGATGC

CTGGCAAGAG′]

NM_003108.3
6664
SOX11
5232
[′AAGCACATGGCCG
5435
[′CCGACTACCCCG
5689
[′CCGACTACCCCG

(SOX11):c.347A>G

ACTACCCCGACTRC

ACTRCAAGTAC′]

ACTRCAAGTAC′]

(p.Tyr116Cys)

AAGTACCGGCCCCG

GAAAAAGCCC′]

NM_002764.3
5631
PRPS1
5233
[′AATCTCAGCCAAG
5436
[′CCAAGCTTGTTG
5690
[′CCAAGCTTGTTG

(PRPSO:c.343A>G

CTTGTTGCAAATRTG

CAAATRTGCTA′]

CAAATRTGCTA′]

(p.Met115Val)

CTATCTGTAGCAGG

TGCAGATCA′]

NM_000546.5
7157
TP53
5234
[′TCTCCTCCCTGCTT
5437
[′CCTGCTTCTGTCT
5691
[′CCTGCTTCTGTCT

(TP53):c.1101-2A>G

CTGTCTCCTACRGCC

CCTACRGCCA′]

CCTACRGCCA′]

ACCTGAAGTCCAAA

AAGGGTCA′]

NM_000166.5
2705
GJB1
5235
[′CGAGAAAACCGTC
5438
[′CCGTCTTCACCG
5692
[′CCGTCTTCACCG

(GJB1):c.580A>G

TTCACCGTCTTCRTG

TCTTCRTGCTA′]

TCTTCRTGCTA′]

(p.Met194Val)

CTAGCTGCCTCTGG

CATCTGCAT′]

NM_003159.2
6792
CDKL5
5236
[′TTAATCAGCCACA
5439
[′CCACAATGATGT
5693
[′CCACAATGATGT

(CDKL5):c.449A>G

ATGATGTCCTAARA

CCTAARACTGT′]

CCTAARACTGT′]

(p.Lys150Arg)

CTGTGTGACTTTGGT

AAGTTAAAA′]

NM_000053.3
540
ATP7B
5237
[′ATCCAGACCACCTT
5440
[′CCACCTTCATAG
5694-
[′CCACCTTCATAG

(ATP7B):c.122A>G

CATAGCCAACAYTG

CCAACAYTGTC′]
5695
CCAACAYTGTC′,

(p.Asn41Ser)

TCAAAAGCAAAACT

′CCTTCATAGCCAA

CTTCTTCAT′]

CAYTGTCAAA′]

NM_006306.3
8243
SMC1A
5238
[′GTGGCTACCAACA
5441
[′CCAACATTGATG
5696
[′CCAACATTGATG

(SMC1A):c.3254A>G

TTGATGAGATCTRT

AGATCTRTAAG′]

AGATCTRTAAG′]

(p.Tyr1085Cys)

AAGGCCCTGTCCCG

CAATAGCAGT′]

NM_005154.4
9101
USP8
5239
[′GAACCTTCCAAAC
5442
[′CCAAACTGAAGC
5697
[′CCAAACTGAAGC

(USP8):c.2150A>G

TGAAGCGCTCCTDC

GCTCCTDCTCC′]

GCTCCTDCTCC′]

(p.Tyr717Cys)

TCCTCCCCAGATAT

AACCCAGGCT′]

NM_000117.2
2010
EMD
5240
[′TCTGCTACCGCTGC
5443
[′CCGCTGCCCCCC
5698
[′CCGCTGCCCCCC

(EMD):c.266-2A>G

CCCCCTTCCCARGG

TTCCCARGGCT′]

TTCCCARGGCT′]

CTACAATGACGACT

ACTATGAAG′]

NM_207352.3
285440
CYP4V2
5241
[′CTACGTGCCCTTCT
5444
[′CCCTTCTCTGCT
5699-
[′CCCTTCTCTGCT

(CYP4V2):c.1393A>G

CTGCTGGCCCCRGG

GGCCCCRGGAA′]
5700
GGCCCCRGGAA′,

(p.Arg465Gly)

AACTGTATAGGTTT

′CCTTCTCTGCTGG

GTATCCATC′]

CCCCRGGAAC′]

NM_000546.5
7157
TP53
5242
[′CTGTACCACCATCC
5445
[′CCATCCACTACA
5701
[′CCATCCACTACA

(TP53):c.709A>G

ACTACAACTACRTG

ACTACRTGTGT′]

ACTACRTGTGT′]

(p.Met237Val)

TGTAACAGTTCCTG

CATGGGCGG′]

NM_016069.9
−1
—
5243
[′CTCACCCGTCCCCT
5446
[′CCTCTCCTCTGC
5702-
[′CCCCTCTCCTCT

(PAM16):c.226A>G

CTCCTCTGCAGRAC

AGRACTATGAA′]
5704
GCAGRACTATG′,

(p.Asn76Asp)

TATGAACACTTATTT

′CCCTCTCCTCTGC

AAGGTGAA′]

AGRACTATGA′,

′CCTCTCCTCTGCA

GRACTATGAA′]

NM_006785.3
10892
MALT1
5244
[′AACACCCCCTTTCT
5447
[′CCTTTCTTTTTTT
5705
[′CCTTTCTTTTTTT

(MALT1):c.1019-2A>G

TTTTTTTTCAARGCG

TTCAARGCGA′]

TTCAARGCGA′]

AAGGACAAGGTTGC

CCTTTTGA′]

NM_004771.3
9313
MMP20
5245
[′GGAGAAGGCCTGG
5448
[′CCTGGGAGGAGA
5706
[′CCTGGGAGGAGA

(MMP20):c.611A>G

GAGGAGATACACRT

TACACRTTTCG′]

TACACRTTTCG′]

(p.His204Arg)

TTCGACAATGCTGA

GAAGTGGACT′]

NM_003159.2
6792
CDKL5
5246
[′CACAATGATGTCCT
5449
[′CCTAAAACTGTG
5707
[′CCTAAAACTGTG

(CDKL5):c.458A>G

AAAACTGTGTGRCT

TGRCTTTGGTA′]

TGRCTTTGGTA′]

(p.Asp153Gly)

TTGGTAAGTTAAAA

AGAAATTAA′]

NM_001204830.1
−1
—
5247
[′CCGGACTACTGCCT
5450
[′CCTATCACCATT
5708
[′CCTATCACCATT

(LIPT1):c.535A>G

ATCACCATTGCRCTT

GCRCTTTATTA′]

GCRCTTTATTA′]

(p.Thr179Ala)

TATTATGTAGTACTG

ATGGGAC′]

NM_000921.4
5139
PDE3A
5248
[′AGTTTCTTCCACTT
5451
[′CCACTTGGACCA
5709
[′CCACTTGGACCA

(PDE3A):c.1333A>G

GGACCACCACCRCC

CCACCRCCTCG′]

CCACCRCCTCG′]

(p.Thr445Ala)

TCGGCCACAGGTCT

ACCCACCTT′]

NM_000182.4
3030
HADHA
5249
[′TTGCTCAATTCCAG
5452
[′CCAGTCTTTACC
5710
[′CCAGTCTTTACC

(HADHA):c.9192A>G

TCTTTACCACCYAA

ACCYAAAAAAC′]

ACCYAAAAAAC′]

AAAACATATAAAGC

ACTTGCTCA′]

NM_000169.2
−1
—
5250
[′GTGTACTCCTGTGA
5453
[′CCTGTGAGTGGC
5711
[′CCTGTGAGTGGC

(GLA):c.620A>G

GTGGCCTCTTTRTAT

CTCTTTRTATG′]

CTCTTTRTATG′]

(p.Tyr207Cys)

GTGGCCCTTTCAAA

AGGTGAGA′]

NM_000238.3
3757
KCNH2
5251
[′TGGTCCAGCCTGG
5454
[′CCTGGAGATCAC
5712
[′CCTGGAGATCAC

(KCNH2):c.2582A>G

AGATCACCTTCANC

CTTCANCCTGC′]

CTTCANCCTGC′]

(p.Asn861Ser)

CTGCGAGATGTGAG

TTGGCTGCCC′]

NM_000218.2
3784
KCNQ1
5252
[′GCTCCCCCTCTCCT
5455
[′CCTGCACTCCAC
5713
[′CCTGCACTCCAC

(KCNQ1):c.605A>G

GCACTCCACAGRCC

AGRCCTCATCG′]

AGRCCTCATCG′]

(p.Asp202Gly)

TCATCGTGGTCGTG

GCCTCCATG′]

NM_012203.1
9380
GRHPR
5253
[′CACCATGTCCTTGT
5456
[′CCTTGTTGGCAG
5714
[′CCTTGTTGGCAG

(GRHPR):c.934A>G

TGGCAGCTAACRAC

CTAACRACTTG′]

CTAACRACTTG′]

(p.Asn312Asp)

TTGCTGGCTGGCCT

GAGAGGGGA′]

NM_021007.2
6326
SCN2A
5254
[′ACTTTGTCTTCCTT
5457
[′CCTTGACGATAT
5715
[′CCTTGACGATAT

(SCN2A):c.3872A>G

GACGATATTCTRCTT

TCTRCTTTATT′]

TCTRCTTTATT′]

TATTCAATATGCTCA

TTATGTG′]

NM_002693.2
8542
POLG
5255
[′GTGGGCATCAGCC
5458
[′CCGTGAGCATGC
5716
[′CCGTGAGCATGC

(POLG):c.2840A>G

GTGAGCATGCCARA

CARAATCTTCA′]

CARAATCTTCA′]

(p.Lys947Arg)

ATCTTCAACTACGG

CCGCATCTAT′]

NM_020533.2
57192
MCOLN1
5256
[′TCTGAGTGCCTGTT
5459
[′CCTGTTCTCGCT
5717
[′CCTGTTCTCGCT

(MCOLN1):c.1406A>G

CTCGCTCATCARTG

CATCARTGGGG′]

CATCARTGGGG′]

(p.Asn469Ser)

GGGACGACATGTTT

GTGACGTTC′]

NM_000069.2
779
CACNA1S
5257
[′TCGCTTTCCCATCC
5460
[′CCCATCCTTTTCC
5718-
[′CCCATCCTTTTCC

(CACNA1S):c.3526-2A>G

TTTTCCTTCCCRGGG

TTCCCRGGGC′]
5719
TTCCCRGGGC′,

CTACTTTGGAGACC

′CCATCCTTTTCCT

CCTGGAAT′]

TCCCRGGGCT′]

NM_017662.4
140803
TRPM6
5258
[′CAAGCTGTCTACCT
5461
[′CCTCTTCGTGCA
5720
[′CCTCTTCGTGCA

(TRPM6):c.3173A>G

CTTCGTGCAATRTAT

ATRTATCATCA′]

ATRTATCATCA′]

(p.Tyr1058Cys)

CATCATGGTGAACC

TGTTGATT′]

NM_006642.3
10806
SDCCAG8
5259
[′AATAAACCCTCTG
5462
[′CCTCTGCTTTTGC
5721
[′CCTCTGCTTTTGC

(SDCCAG8):c.2212A>G

CTTTTGCTCTATRGT

TCTATRGTTA′]

TCTATRGTTA′]

TAATCAGCTCAAAG

ATTTGTTGC′]

NM_003560.2
8398
PLA2G6
5260
[′CAGCATGCCCTGCT
5463
[′CCCTGCTCTGTG
5722-
[′CCCTGCTCTGTG

(PLA2G6):c.1349-2A>G

CTGTGCCTCACRGA

CCTCACRGAAC′]
5723
CCTCACRGAAC′,

ACTACAGGATCTCA

′CCTGCTCTGTGCC

TGCACATCT′]

TCACRGAACT′]

Example 6: Next Generation C to T Editors

Other families of cytidine deaminases as alternatives to base etitor 3 (BE3) constructs were examined. The different C to T editors were developed to have a narrow or different editing window, alternate sequence specificity to expand targetable substrates, and to have higher activity.

Using the methods described in Example 4, the pmCDA1 (cytidine deaminase 1 from Petromyzon marinus) activity at the HeK-3 site is evaluated (FIG. 42). The pmCDA1-nCas9-UGI-NLS (nCas9 indicates the Cas9 nickase described herein) construct is active on some sites (e.g., the C bases on the complementary strand at position 9, 5, 4, and 3) that are not accessible with rAPOBEC1 (BE3).

The pmCDA1 activity at the HeK-2 site is given in FIG. 43. The pmCDA1-XTEN-nCas9-UGI-NLS construct is active on sites adjacent to “G,” while rAPOBEC1 analog (BE3 construct) has low activity on “C”s that are adjacent to “G”s, e.g., the C base at position 11 on the complementary strand.

The percent of total sequencing reads with target C converted to T (FIG. 44), C converted to A (FIG. 45), and C converted to G (FIG. 46) are shown for CDA and APOBEC1 (the BE3 construct).

The huAPOBEC3G activity at the HeK-2 site is shown in FIG. 47. Two constructs were used: huAPOBEC3G-XTEN-nCas9-UGI-NLS and huAPOBEC3G*(D316R_D317R)-XTEN-nCas9-UGI-NLS. The huAPOBEC3G-XTEN-nCas9-UGI-NLS construct has different sequence specificity than rAPOBEC1 (BE3), as shown in FIG. 47, the editing window appears narrow, as indicated by APOBEC3G's decreased activity at position 4 compared to APOBEC1. Mutations made in huAPOBEC3G (D316R and D317R) increased ssDNA binding and resulted in an observable effect on expanding the sites which were edited (compare APOBEC3G with APOBEC3G_RR in FIG. 47). Mutations were chosen based on APOBEC3G crystal structure, see: Holden et al., Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implication. Nature. (2008); 121-4, the entire contents of which are incorporated herein by reference.

Example 7: pmCDA1/huAPOBEC3G/rAPOBEC1 Work in E. coli

LacZ selection optimization for the A to I conversion was performed using a bacterial strain with lacZ encoded on the F plasmid. A critical glutamic acid residue was mutated (e.g., GAG to GGG, Glu to Gly mutation) so that G to A by a cytidine deaminase would restore lacZ activity (FIG. 48). Strain CC102 was selected for the selection assay. APOBEC1 and CDA constructs were used in a selection assay to optimize G to A conversion.

To evaluate the effect of copy number of the plasmids encoding the deaminase constructs on lacZ reversion frequency, the CDA and APOBEC1 deaminases were cloned into 4 plasmids with different replication origins (hence different copy numbers), SC101, CloDF3, RSF1030, and PUC (copy number: PUC>RSF1030>CloDF3>SC101) and placed under an inducible promoter. The plasmids were individually transformed into E. coli cells harboring F plasmid containing the mutated LacZ gene. The expression of the deaminases were induced and LacZ activity was detected for each construct (FIG. 49). As shown in FIG. 49, CDA exhibited significantly higher activity than APOBEC1 in all instances, regardless of the plasmid copy number the deaminases were cloned in. Further, In terms of the copy number, the deaminase activity was positively correlated with the copy number of the plasmid they are cloned in, i.e., PUC>CloDF3>SC101.

LacZ reversions were confirmed by sequencing of the genomic DNA at the lacZ locus. To obtain the genomic DNA containing the corrected LacZ gene, cells were grown media containing X-gal, where cells having LacZ activity form blue colonies. Blue colonies were selected and grown in minimal media containing lactose. The cells were spun down, washed, and re-plated on minimal media plates (lactose). The blue colony at the highest dilution was then selected, and its genomic DNA was sequenced at the lacZ locus (FIG. 50).

A chloramphenicol reversion assay was designed to test the activity of different cytidine deaminases (e.g., CDA, and APOBEC1). A plasmid harboring a mutant CAT1 gene which confers chloramphenicol resistance to bacteria is constructed with RSF1030 as the replication origin. The mutant CAT1 gene encodings a CAT1 protein that has a H195R (CAC to CGC) mutation, rendering the protein inactive (FIG. 51). Deamination of the C base-paired to the G base in the CGC codon would convert the codon back to a CAC codon, restoring the activity of the protein. As shown in FIG. 52, CDA outperforms rAPOBEC in E. coli in restoring the activity of the chloramphenicol resistance gene. The minimum inhibitory concentration (MIC) of chlor in S1030 with the selection plasmid (pNMG_ch_5) was approximately 1 μg/mL. Both rAPOBEC-XTEN-dCas9-UGI and CDA-XTEN-dCas9-UGI induced DNA correction on the selection plasmid (FIG. 53).

Next, the huAPOBEC3G-XTEN-dCas9-UGI protein was tested in the same assay. Interestingly, huAPOBEC3G-XTEN-dCas9-UGI exhibited different sequence specificity than the rAPOBEC1-XTEN-dCas9-UGI fusion protein. Only position 8 was edited with APOBEC3G-XTEN-dCas9-UGI fusion, as compared to the rAPOBEC11-XTEN-dCas9-UGIfusion (in which positions 3, 6, and 8 were edited) (FIG. 54).

Example 8: C to T Base Editors with Less Off Target Editing

Current base editing technologies allow for the sequence-specific conversion of a C:G base pair into a T:A base pair in genomic DNA. This is done via the direct catalytic conversion of cytosine to uracil by a cytidine deaminase enzyme and thus, unlike traditional genome editing technologies, does not introduce double-stranded DNA breaks (DSBs) into the DNA as a first step. See, Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., and Liu, D. R. (2016), “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.” Nature 533, 420-424; the entire contents of which are incorporated by reference herein. Instead, catalytically dead SpCas9 (dCas9) or a SpCas9 nickase (dCas9(A840H)) is tethered to a cytidine deaminase enzyme such as rAPOBEC1, pmCDA1, or hAPOBEC3G. The genomic locus of interest is encoded by an sgRNA, and DNA binding and local denaturation is facilitated by the dCas9 portion of the fusion. However, just as wt dCas9 and wt Cas9 exhibit off-target DNA binding and cleavage, current base editors also exhibit C to T editing at Cas9 off-target loci, which limits their therapeutic usefulness.

It has been reported that the introduction of just three to four mutations into SpCas9 that neutralize nonspecific electrostatic interactions between the protein and the sugar-phosphate backbone of its target DNA, increases the DNA binding specificity of SpCas9. See, Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., and Joung, J. K. (2016) “High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.” Nature 529, 490-495; and Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., and Zhang, F. (2015) “Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84-88; the entire contents of each are hereby incorporated by reference herein. Four reported neutralizing mutations were therefore incorporated into the initially reported base editor BE3 (SEQ ID NO: 285), and found that off-target C to T editing of this enzyme is also drastically reduced (FIG. 55), with no decrease in on-target editing (FIG. 56).

As shown in FIG. 55, HEK293T cells were transfected with plasmids expressing BE3 or HF-BE3 and a sgRNA matching the EMX1 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target locus, plus the top ten known Cas9 off-target loci for the EMX1 sgRNA, as previously determined by Joung and coworkers using the GUIDE-seq method. See Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) “GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.” Nat Biotech 33, 187-197; the entire contents of which are incorporated by reference herein. EMX1 off-target 5 locus did not amplify and is not shown. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed (FIG. 55). Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for BE3 and HF-BE3.

In FIG. 56, HEK293T cells were transfected with plasmids expressing BE3 or HF-BE3 and sgRNAs matching the genomic loci indicated using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci. The percentage of total DNA sequencing reads with all four bases at the target Cs within each protospacer are shown for treatment with BE3 or HF-BE3 (FIG. 56). Frequencies of indel formation are shown as well.

Primary Protein Sequence of HF-BE3 (SEQ ID NO: 285):

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI

WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI

TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG

YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ

PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESDKKYS

IGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG

ETALATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL

VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL

ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGV

DAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF

DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL

RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSK

NGYAGYIDGGASQLEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFD

NGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLA

RGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTAFDKNLPNEK

VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN

RKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDF

LDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRY

TGWGALSRKLINGIRDKQSGKTILDFLKSDGFANRNFMALIHDDSLTFKE

DIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKP

ENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL

QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKV

LTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG

GLSELDKAGFIKRQLVETRAITKHVAQILDSRMNTKYDENDKLIREVKVI

TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLES

EFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGE

IRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFS

KESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKK

LKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFEL

ENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ

LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA

ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLY

ETRIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGN

KPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLS

GGSPKKKRKV

Example 9: Development of Base Editors that Use Cas9 Variants and Modulation of the Base Editor Processivity to Increase the Target Range and Precision of the Base Editing Technology

Unlike traditional genome editing platforms, base editing technology allows precise single nucleotide changes in the DNA without inducing double-stranded breaks (DSBs). See, Komor, A. C. et al. Nature 533, 420-424 (2016). The current generation of base editor uses the NGG PAM exclusively. This limits its ability to edit desired bases within the genome, as the base editor needs to be placed at a precise location where the target base is placed within a 4-base region (the ‘deamination window’), approximately 15 bases upstream of the PAM. See, Komor, A. C. et al. Nature 533, 420-424 (2016). Moreover, due to the high processivity of cytidine deaminase, the base editor may convert all cytidines within its deamination window into thymidines, which could induce amino acid changes other than the one desired by the researcher. See, Komor, A. C. et al. Nature 533, 420-424 (2016).

Expanding the Scope of Base Editing Through the Development of Base Editors with Cas9 Variants

Cas9 homologs and other RNA-guided DNA binders that have different PAM specificities were incorporated into the base editor architecture. See, Kleinstiver, B. P. et al. Nature 523, 481-485 (2015); Kleinstiver, B. P. et al. Nature Biotechnology 33, 1293-1298 (2015); and Zetsche, B. et al. Cell 163, 759-771 (2015); the entire contents of each are incorporated by reference herein. Furthermore, innovations that have broadened the PAM specificities of various Cas9 proteins were also incorporated to expand the target reach of the base editor even more. See, Kleinstiver, B. P. et al. Nature 523, 481-485 (2015); and Kleinstiver, B. P. et al. Nature Biotechnology 33, 1293-1298 (2015). The current palette of base editors is summarized in Table 4.

Base Editor
Reference for Cas9

Species
PAM
Name
variant

S. pyogenes

. . . NGG
BE3
Wild-type

. . . NGA
VQR BE3 or
Kleinstiver, B. P. et al.

EQR BE3

. . . NGCG
VRER BE3
Kleinstiver, B. P. et al.

S. aureus

. . . NNGRRT
SaBE3
Wild-type

. . . NNNRRT
SaKKH BE3
Kleinstiver, B. P. et al.

L.

TTTN . . .
dCpfl BE2
Zetsche, B. et al.

bacterium

Modulating Base Editor's Processivity Through Site-Directed Mutagenesis of rAPOBEC1

It was reasoned that the processivity of the base editor could be modulated by making point mutations in the deaminase enzyme. The incorporation of mutations that slightly reduce the catalytic activity of deaminase in which the base editor could still catalyze on average one round of cytidine deamination but was unlikely to access and catalyze another deamination within the relevant timescale were pursued. In effect, the resulting base editor would have a narrower deamination window.

rAPOBEC1 mutations probed in this work are listed in Table 5. Some of the mutations resulted in slight apparent impairment of rAPOBEC1 catalysis, which manifested as preferential editing of one cytidine over another when multiple cytidines are found within the deamination window. Combining some of these mutations had an additive effect, allowing the base editor to discriminate substrate cytidines with higher stringency. Some of the double mutants and the triple mutant allowed selective editing of one cytidine among multiple cytidines that are right next to one another (FIG. 57).

TABLE 5

rAPOBEC1 Point Mutations Investigated

rAPOBEC1 mutation
Corresponding mutation

studied in this work
in APOBEC3G
Reference

H121R/H122R
D315R/D316R
Holden, L. G. et al.

R126A
R320A
Chen, K-M. et al.

R126E
R320E
Chen, K-M. et al.

R118A
R313A
Chen, K-M. et al.

W90A
W285A
Chen, K-M. et al.

W90Y
W285Y

R312E
R326E

Base Editor PAM Expansion and Processivity Modulation

The next generation of base editors were designed to expand editable cytidines in the genome by using other RNA-guided DNA binders (FIG. 58). Using a NGG PAM only allows for a single target within the “window” whereas the use of multiple different PAMs allows for Cas9 to be positioned anywhere to effect selective deamination. A variety of new base editors have been created from Cas9 variants (FIG. 59 and Table 4). Different PAM sites (NGA, FIG. 60; NGCG, FIG. 61; NNGRRT, FIG. 62; and NNHRRT, FIG. 63) were explored. Selective deamination was successfully achieved through kinetic modulation of cytidine deaminase point mutagenesis (FIG. 65 and Table 5).

The effect of various mutations on the deamination window was then investigated in cell culture using spacers with multiple cytidines (FIGS. 66 and 67).

Further, the effect of various mutations on different genomic sites with limited numbers of cytidines was examined (FIGS. 68 to 71). It was found that approximately one cytidine will be edited within the deamination windown in the spacer, while the rest of the cytidines will be left intact. Overall, the preference for editing is as follows: C₆>C₅>>C₇≈C₄.

Base Editing Using Cpf1

Cpf1, a Cas9 homolog, can be obtained as AsCpf1, LbCpf1, or from any other species. Schematics of fusion constructs, including BE2 and BE3 equivalents, are shown in FIG. 73. The BE2 equivalent uses catalytically inactive Cpf2 enzyme (dCpf1) instead of Cas9, while the BE3 equivalent includes the Cpf1 mutant, which nicks the target strand. The bottom schematic depicts different fusion architectures to combine the two innovations illustrated above it (FIG. 73). The base editing results of HEK293T cell TTTN PAM sites using Cpf1 BE2 were examined with different spacers (FIGS. 64A to 64C). In some embodiments, Cpf1 may be used in place of a Cas9 domain in any of the base editors provided herein. In some embodiments, the Cpf1 is a protein that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 99.5% identical to SEQ ID NO 313.

Full Protein Sequence of Cpf1 (SEQ ID NO: 313):

MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEKRAKDYKKA

KQIIDKYHQFFIEEILSSVCISEDLLQNYSDVYFKLKKSDDDNLQKDFKS

AKDTIKKQISEYIKDSEKFKNLFNQNLIDAKKGQESDLILWLKQSKDNGI

ELFKANSDITDIDEALEIIKSFKGWTTYFKGFHENRKNVYSSNDIPTSII

YRIVDDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAELLTFDIDYKT

SEVNQRVFSLDEVFEIANFNNYLNQSGITKFNTIIGGKFVNGENTKRKGI

NEYINLYSQQINDKTLKKYKMSVLFKQILSDTESKSFVIDKLEDDSDVVT

TMQSFYEQIAAFKTVEEKSIKETLSLLFDDLKAQKLDLSKIYFKNDKSLT

DLSQQVFDDYSVIGTAVLEYITQQIAPKNLDNPSKKEQELIAKKTEKAKY

LSLETIKLALEEFNKHRDIDKQCRFEEILANFAAIPMIFDEIAQNKDNLA

QISIKYQNQGKKDLLQASAEDDVKAIKDLLDQTNNLLHKLKIFHISQSED

KANILDKDEHFYLVFEECYFELANIVPLYNKIRNYITQKPYSDEKFKLNF

ENSTLANGWDKNKEPDNTAILFIKDDKYYLGVMNKKNNKIFDDKAIKENK

GEGYKKIVYKLLPGANKMLPKVFFSAKSIKFYNPSEDILRIRNHSTHTKN

GSPQKGYEKFEFNIEDCRKFIDFYKQSISKHPEWKDFGFRFSDTQRYNSI

DEFYREVENQGYKLTFENISESYIDSVVNQGKLYLFQIYNKDFSAYSKGR

PNLHTLYWKALFDERNLQDVVYKLNGEAELFYRKQSIPKKITHPAKEAIA

NKNKDNPKKESVFEYDLIKDKRFTEDKFFFHCPITINFKSSGANKFNDEI

NLLLKEKANDVHILSIDRGERHLAYYTLVDGKGNIIKQDTFNIIGNDRMK

TNYHDKLAAIEKDRDSARKDWKKINNIKEMKEGYLSQVVHEIAKLVIEYN

AIVVFEDLNFGFKRGRFKVEKQVYQKLEKMLIEKLNYLVFKDNEFDKTGG

VLRAYQLTAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYE

SVSKSQEFFSKFDKICYNLDKGYFEFSFDYKNFGDKAAKGKWTIASFGSR

LINFRNSDKNHNWDTREVYPTKELEKLLKDYSIEYGHGECIKAAICGESD

KKFFAKLTSVLNTILQMRNSKTGTELDYLISPVADVNGNFFDSRQAPKNM

PQDADANGAYHIGLKGLMLLGRIKNNQEGKKLNLVIKNEEYFEFVQNRNN

Example 10: Increased Fidelity of Base Editing

Examining the difference between plasmid delivery of BE3 and HF-BE3, it was found that the two edit on-target loci with comparable efficiency (FIGS. 74 and 75). However, HF-BE3 edited off-target loci much less than BE3, meaning that HF-BE3 has a much higher DNA specificity than BE3 (FIG. 76). Deaminase protein lipofection to HEK cells demonstrated that protein delivery of BE3 results in comparable on-target activity, but much better specificity, than plasmid DNA delivery of BE3. Using improved transfection procedures and better plasmids (n=2), the experiment used the following conditions: protein delivery was 125 nM Cas9:sgRNA complex, plasmid delivery was 750 ng BE3/HF-BE3 plasmid+250 ng sgRNA plasmid, and lipofection was with 1.5 μL of Lipofectamine 2000 per well. EMX-1 off target site 2 and FANCF off-target site 1 showed the most off-target editing with BE3, compared to all of the off-targets assayed (FIGS. 77 and 78), while HEK-3 showed no significant editing at off-targets for any of the delivery methods (FIG. 79). HEK-4 shows some C-to-G editing on at the on-target site, while its off-target sites 1, 3, and 4 showed the most off-target editing of all the assayed sites (FIG. 80).

Delivery of BE3 Protein via Micro-Injection to Zebrafish

TYR guide RNAs were tested in an in vitro assay for sgRNA activity (FIGS. 81 and 82). The % HTS reads shows how many C residues were converted to T residues during a 2 h incubation with purified BE3 protein and PCR of the resulting product. Experiments used an 80-mer synthetic DNA substrate with the target deamination site in 60 bp of its genomic context. This is not the same as % edited DNA strands because only one strand was nicked, so the product is not amplified by PCR. The proportion of HTS reads edited is equal to x/(2−x), where x is the actual proportion of THS reads edited. For 60% editing, the actual proportion of bases edited is 75%. “Off target” is represents BE3 incubated with the same DNA substrate, while bound to an off-target sgRNA. It was found sgRNAs sgRH_13, sgHR_17, and possibly sgHR_16 appeared to be promising targets for in vivo injection experiments.

The delivery of BE3 protein in was tested in vivo in zebrafish. Zebrafish embryos (n=16-24) were injected with either scrambled sgRNA, sgHR_13, sgHR_16, or sgHR_17 and purified BE3. Three embryos from each condition were analyzed independently (single embryo) and for each condition, all of the injected embryos were pooled and sequenced as a pool. The results are shown in FIGS. 83 to 85.

Example 11: Uses of Base Editors to Treat Disease

Base editors or complexes provided herein (e.g., BE3) may be used to modify nucleic acids. For example, base editors may be used to change a cytosine to a thymine in a nucleic acid (e.g., DNA). Such changes may be made to, inter alia, alter the amino acid sequence of a protein, to destroy or create a start codon, to create a stop codon, to disrupt splicing donors, to disrupt splicing acceptors or edit regulatory sequences. Examples of possible nucleotide changes are shown in FIG. 86.

Base editors or complexes provided herein (e.g., BE3) may be used to edit an isoform of Apolipoprotein E in a subject. For example, an Apolipoprotein E isoform may be edited to yield an isoform associated with a lower risk of developing Alzheimer's disease. Apolipoprotein E has four isoforms that differ at amino acids 112 and 158. APOE4 is the largest and most common genetic risk factor for late-onset Alzheimer's disease. Arginine residue 158 of APOE4, encoded by the nucleic acid sequence CGC, may be changed to a cysteine by using a base editor (e.g., BE3) to change the CGC nucleic acid sequence to TGC, which encodes cysteine at residue 158. This change yields an APOE3r isoform, which is associated with lower Alzheimer's disease risk. See FIG. 87.

It was tested whether base editor BE3 could be used to edit APOE4 to APOE3r in mouse astrocytes (FIG. 88). APOE 4 mouse astrocytes were nucleofected with Cas9+template or BE3, targeting the nucleic acid encoding Arginine 158 of APOE4. The Cas9+template yielded only 0.3% editing with 26% indels, while BE3 yielded 75% editing with 5% indels. Two additional base-edited cytosines are silent and do not yield changes to the amino acid sequence (FIG. 88).

Base editors or complexes provided herein may be used to treat prion protein diseases such as Creutzfeldt-Jakob disease and fatal familial insomnia, for example, by introducing mutations into a PRNP gene. Reverting PRNP mutations may not yield therapeutic results, and intels in PRNP may be pathogenic. Accordingly, it was tested whether PRNP could be mutated using base editors (e.g., BE3) to introduce a premature stop codon in the PRNP gene. BE3, associated with its guide RNA, was introduced into HEK cells or glioblastoma cells and was capable of editing the PRNP gene to change the encoded arginine at residue 37 to a stop codon. BE3 yielded 41% editing (FIG. 89).

Additional genes that may be edited include the following: APOE editing of Arg 112 and Arg 158 to treat increased Alzheimer's risk; APP editing of Ala 673 to decrease Alzheimer's risk; PRNP editing of Arg 37 to treat fatal familial insomnia and other prion protein diseases; DMD editing of the exons 23 and 51 splice sites to treat Duchenne muscular dystrophy; FTO editing of intron 1 to treat obesity risk; PDS editing of exon 8 to treat Pendred syndrome (genetic deafness); TMC1 editing of exon 8 to treat congenital hearing loss; CYBB editing of various patient-relevant mutations to treat chronic granulomatous disease. Additional diseases that may be treated using the base editors provided herein are shown in Table 6, below.

UGI also plays a key role. Knocking out UDG (which UGI inhibits) was shown to dramatically improve the cleanliness and efficiency of C to T base editing (FIG. 90). Furthermore, base editors with nickase and without UGI were shown to produce a mixture of outcomes, with very high indel rates (FIG. 91).

Example 12: Expanding the Targeting Scope of Base Editing

Base editing is a new approach to genome editing that uses a fusion protein containing a catalytically defective Streptococcus pyogenes Cas9, a cytidine deaminase, and an inhibitor of base excision repair to induce programmable, single-nucleotide C→T (or G→A) changes in DNA without generating double-strand DNA breaks, without requiring a donor DNA template, and without inducing an excess of stochastic insertions and deletions¹. The development of five new C→T (or G→A) base editors that use natural and engineered Cas9 variants with different protospacer-adjacent motif (PAM) specificities to expand the number of sites that can be targeted by base editing by 2.5-fold are described herein. Additionally, new base editors containing mutated cytidine deaminase domains that narrow the width of the apparent editing window from approximately 5 nucleotides to 1 or 2 nucleotides were engineered, enabling the discrimination of neighboring C nucleotides that would previously be edited with comparable efficiency. Together, these developments substantially increase the targeting scope of base editing.

CRISPR-Cas9 nucleases have been widely used to mediate targeted genome editing². In most genome editing applications, Cas9 forms a complex with a single guide RNA (sgRNA) and induces a double-stranded DNA break (DSB) at the target site specified by the sgRNA sequence. Cells primarily respond to this DSB through the non-homologuous end-joining (NHEJ) repair pathway, which results in stochastic insertions or deletions (indels) that can cause frameshift mutations that disrupt the gene. In the presence of a donor DNA template with a high degree of homology to the sequences flanking the DSB, gene correction can be achieved through an alternative pathway known as homology directed repair (HDR).^3,4Unfortunately, under most non-perturbative conditions HDR is inefficient, dependent on cell state and cell type, and dominated by a larger frequency of indels.^3,4As most of the known genetic variations associated with human disease are point mutations, methods that can more efficiently and cleanly make precise point mutations are needed.

Base editing, which enables targeted replacement of a C:G base pair with a T:A base pair in a programmable manner without inducing DSBs¹, has been recently described. Base editing uses a fusion protein between a catalytically inactivated (dCas9) or nickase form of Streptococcus pyogenes Cas9 (SpCas9), a cytidine deaminase such as APOBEC1, and an inhibitor of base excision repair such as uracil glycosylase inhibitor (UGI) to convert cytidines into uridines within a five-nucleotide window specified by the sgRNA.¹The third-generation base editor, BE3, converts C:G base pairs to T:A base pairs, including disease-relevant point mutations, in a variety of cell lines with higher efficiency and lower indel frequency than what can be achieved using other genome editing methods¹. Subsequent studies have validated the deaminase-dCas9 fusion approach in a variety of settings^6,7.

Efficient editing by BE3 requires the presence of an NGG PAM that places the target C within a five-nucleotide window near the PAM-distal end of the protospacer (positions 4-8, counting the PAM as positions 21-23)¹. This PAM requirement substantially limits the number of sites in the human genome that can be efficiently targeted by BE3, as many sites of interest lack an NGG 13- to 17-nucleotides downstream of the target C. Moreover, the high activity and processivity of BE3 results in conversion of all Cs within the editing window to Ts, which can potentially introduce undesired changes to the target locus. Herein, new C:G to T:A base editors that address both of these limitations are described.

It was thought that any Cas9 homolog that binds DNA and forms an “R-loop” complex⁸containing a single-stranded DNA bubble could in principle be converted into a base editor. These new base editors would expand the number of targetable loci by allowing non-NGG PAM sites to be edited. The Cas9 homolog from Staphylococcus aureus (SaCas9) is considerably smaller than SpCas9 (1053 vs. 1368 residues), can mediate efficient genome editing in mammalian cells, and requires an NNGRRT PAM⁹. SpCas9 was replaced with SaCas9 in BE3 to generate SaBE3 and transfected HEK293T cells with plasmids encoding SaBE3 and sgRNAs targeting six human genomic loci (FIGS. 92A and 92B). After 3 d, the genomic loci were subjected to high-throughput DNA sequencing (HTS) to quantify base editing efficiency. SaBE3 enabled C to T base editing of target Cs at a variety of genomic sites in human cells, with very high conversion efficiencies (approximately 50-75% of total DNA sequences converted from C to T, without enrichment for transfected cells) arising from targeting Cs at positions 6-11. The efficiency of SaBE3 on NNGRRT-containing target sites in general exceeded that of BE3 on NGG-containing target sites¹. Perhaps due to its higher average efficiency, SaBE3 can also result in detectable base editing at target Cs at positions outside of the canonical BE3 activity window (FIG. 92C). In comparison, BE3 showed significantly reduced editing under the same conditions (0-11%), in accordance with the known SpCas9 PAM preference (FIG. 106A)¹⁰. These data show that SaBE3 can facilitate very efficient base editing at sites not accessible to BE3.

The targeting range of base editors was further expanded by applying recently engineered Cas9 variants that expand or alter PAM specificities. Joung and coworkers recently reported three SpCas9 mutants that accept NGA (VQR-Cas9), NGAG (EQR-Cas9), or NGCG(VRER-Cas9) PAM sequences¹¹. In addition, Joung and coworkers engineered a SaCas9 variant containing three mutations (SaKKH-Cas9) that relax its PAM requirement to NNNRRT¹². The SpCas9 portion of BE3 was replaced with these four Cas9 variants to produce VQR-BE3, EQR-BE3, VRER-BE3, and SaKKH-BE3, which target NNNRRT,NGA, NGAG, and NGCG PAMs respectively. HEK293T cells were transfected with plasmids encoding these constructs and sgRNAs targeting six genomic loci for each new base editor, and measured C to T base conversions using HTS.

SaKKH-BE3 edited sites with NNNRRT PAMs with efficiencies up to 62% of treated, non-enriched cells (FIG. 92D). As expected, SaBE3 was unable to efficiently edit targets containing PAMs that were NNNHRRT (where H=A, C, or T) (FIG. 92D). VQR-BE3, EQR-BE3, and VRER-BE3 exhibited more modest, but still substantial base editing efficiencies of up to 50% of treated, non-enriched cells at genomic loci with the expected PAM requirements with an editing window similar to that of BE3 (FIGS. 92E and 92F). Base editing efficiencies of VQR-BE3, EQR-BE3, and VRER-BE3 in general closely paralleled the reported PAM requirements of the corresponding Cas9 nucleases; for example, EQR-BE3 was unable to efficiently edit targets containing NGAH PAM sequences (FIG. 92F). In contrast, BE3 was unable to edit sites with NGA or NGCG PAMs efficiently (0-3%), likely due to its PAM restrictions (FIG. 106B).

Collectively, the properties of SaBE3, SaKKH-BE3, VQR-BE3, EQR-BE3, and VRER-BE3 establish that base editors exhibit a modularity that facilitates their ability to exploit Cas9 homologs and engineered variants.

Next, base editors with altered activity window widths were developed. All Cs within the activity window of BE3 can be efficiently converted to Ts¹. The ability to modulate the width of this window would be useful in cases in which it is important to edit only a subset of Cs present in the BE3 activity window.

The length of the linker between APOBEC1 and dCas9 was previously observed to modulate the number of bases that are accessible by APOBEC1 in vitro¹. In HEK293T cells, however, varying the linker length did not significantly modulate the width of the editing window, suggesting that in the complex cellular milieu, the relative orientation and flexibility of dCas9 and the cytidine deaminase are not strongly determined by linker length (FIG. 96). Next, it was thought that truncating the 5′ end of the sgRNA might narrow the base editing window by reducing the length of single-stranded DNA accessible to the deaminase upon formation of the RNA-DNA heteroduplex. HEK293T cells were co-transfected with plasmids encoding BE3 and sgRNAs of different spacer lengths targeting a locus with multiple Cs in the editing window. No consistent changes in the width of base editing when using truncated sgRNAs with 17- to 19-base spacers were observed (FIGS. 95A to 95C). Truncating the sgRNA spacer to fewer than 17 bases resulted in large losses in activity (FIG. 95A).

As an alternative approach, it was thought that mutations to the deaminase domain might narrow the width of the editing window through multiple possible mechanisms. First, some mutations may alter substrate binding, the conformation of bound DNA, or substrate accessibility to the active site in ways that reduce tolerance for non-optimal presentation of a C to the deaminase active site. Second, because the high activity of APOBEC1 likely contributes to the deamination of multiple Cs per DNA binding event,^1,13,14mutations that reduce the catalytic efficiency of the deaminase domain of a base editor might prevent it from catalyzing successive rounds of deamination before dissociating from the DNA. Once any C:G to T:A editing event has taken place, the sgRNA no longer perfectly matches the target DNA sequence and re-binding of the base editor to the target locus should be less favorable. Both strategies were tested in an effort to discover new base editors that distinguish among multiple cytidines within the original editing window.

Given the absence of an available APOBEC1 structure, several mutations previously reported to modulate the catalytic activity of APOBEC3G, a cytidine deaminase from the same family that shares 42% sequence similarity of its active site-containing domain to that of APOBEC1, were identified¹⁵. Corresponding APOBEC1 mutations were incorporated into BE3 and evaluated their effect on base editing efficiency and editing window width in HEK293T cells at two C-rich genomic sites containing Cs at positions 3, 4, 5, 6, 8, 9, 10, 12, 13, and 14 (site A); or containing Cs at positions 5, 6, 7, 8, 9, 10, 11, and 13 (site B).

The APOBEC1 mutations R118A and W90A each led to dramatic loss of base editing efficiency (FIG. 97C). R132E led to a general decrease in editing efficiency but did not change the substantially narrow the shape of the editing window (FIG. 97C). In contrast, several mutations that narrowed the width of the editing window while maintaining substantial editing efficiency were found (FIGS. 93A and 97C). The “editing window width” was defined to represent the artificially calculated window width within which editing efficiency exceeds the half-maximal value for that target. The editing window width of BE3 for the two C-rich genomic sites tested was 5.0 (site A) and 6.1 (site B) nucleotides.

R126 in APOBEC1 is predicted to interact with the phosphate backbone of ssDNA¹³. Previous studies have shown that introducing the corresponding mutation into APOBEC3G decreased catalysis by at least 5-fold¹⁴. Interestingly, when introduced into APOBEC1 in BE3, R126A and R126E increased or maintained activity relative to BE3 at the most strongly edited positions (C5, C6, and C7), while decreasing editing activity at other positions (FIGS. 93A and 97C). Each of these two mutations therefore narrowed the width of the editing window at site A and site B to 4.4 and 3.4 nucleotides (R126A), or to 4.2 and 3.1 nucleotides (R126E), respectively (FIGS. 93A and 97C).

W90 in APOBEC1 (corresponding to W285 in APOBEC3G) is predicted to form a hydrophobic pocket in the APOBEC3G active site and assist in substrate binding¹³. Mutating this residue to Ala abrogated APOBEC3G's catalytic activity¹³. In BE3, W90A almost completely abrogated base editing efficiency (FIG. 97C). In contrast, it was found that W90Y only modestly decreased base editing activity while narrowing the editing window width at site A and site B to 3.8 and 4.9 nucleotides, respectively (FIG. 93A). These results demonstrate that mutations to the cytidine deaminase domain can narrow the activity window width of the corresponding base editors.

W90Y, R126E, and R132E, the three mutations that narrowed the editing window without drastically reducing base editing activity, were combined into doubly and triply mutated base editors. The double mutant W90Y+R126E resulted in a base editor (YE1-BE3) with BE3-like maximal editing efficiencies, but substantially narrowed editing window width (width at site A and site B=2.9 and 3.0 nucleotides, respectively (FIG. 93A). The W90Y+R132E base editor (YE2-BE3) exhibited modestly lower editing efficiencies (averaging 1.4-fold lower maximal editing yields across the five sites tested compared with BE3), and also substantially narrowed editing window width (width at site A and site B=2.7 and 2.8 nucleotides, respectively) (FIG. 97C). The R126E+R132E double mutant (EE-BE3) showed similar maximal editing efficiencies and editing window width as YE2-BE3 (FIG. 97C). The triple mutant W90Y+R126E+R132E (YEE-BE3) exhibited 2.0-fold lower average maximal editing yields but very little editing beyond the C6 position and an editing window width of 2.1 and 1.4 nucleotides for site A and site B, respectively (FIG. 97C). These data taken together indicate that mutations in the cytidine deaminase domain can strongly affect editing window widths, in some cases with minimal or only modest effects on editing efficiency.

The base editing outcomes of BE3, YE1-BE3, YE2-BE3, EE-BE3, and YEE-BE3 were further compared in HEK293T cells targeting four well-studied human genomic sites that contain multiple Cs within the BE3 activity window¹. These target loci contained target Cs at positions 4 and 5 (HEK site 3), positions 4 and 6 (HEK site 2), positions 5 and 6 (EMX1), or positions 6, 7, 8, and 11 (FANCF). BE3 exhibited little (<1.2-fold) preference for editing any Cs within the position 4-8 activity window. In contrast, YE1-BE3, exhibited a 1.3-fold preference for editing C5 over C4 (HEK site 3), 2.6-fold preference for C6 over C4 (HEK site 2), 2.0-fold preference for C5 over C6 (EMX1), and 1.5-fold preference for C6 over C7 (FANCF) (FIG. 93B). YE2-BE3 and EE-BE3 exhibited somewhat greater positional specificity (narrower activity window) than YE1-BE3, averaging 2.4-fold preference for editing C5 over C4 (HEK site 3), 9.5-fold preference for C6 over C4 (HEK site 2), 2.9-fold preference for C5 over C6 (EMX1), and 2.6-fold preference for C7 over C6 (FANCF) (FIG. 93B). YEE-BE3 showed the greatest positional selectivity, with a 2.9-fold preference for editing C5 over C4 (HEK site 3), 29.7-fold preference for C6 over C4 (HEK site 2), 7.9-fold preference for C5 over C6 (EMX1), and 7.9-fold preference for C7 over C6 (FANCF) (FIG. 93B). The findings establish that mutant base editors can discriminate between adjacent C5, even when both nucleotides are within the BE3 editing window.

The product distributions of these four mutants and BE3 were further analyzed by HTS to evaluate their apparent processivity. BE3 generated predominantly T4-T5 (HEK site 3), T4-T6 (HEK site 2), and T5-T6 (EMX1) products in treated HEK293T cells, resulting in, on average, 7.4-fold more products containing two Ts, than products containing a single T. In contrast, YE1-BE3, YE2-BE3, EE-BE3, and YEE-BE3 showed substantially higher preferences for singly edited C4-T5, C4-T6, and T5-C6 products (FIG. 93C). YE1-BE3 yielded products with an average single-T to double-T product ratio of 1.4. YE2-BE3 and EE-BE3 yielded products with an average single-T to double-T product ratio of 4.3 and 5.1, respectively (FIG. 93C). Consistent with the above results, the YEE-BE3 triple mutant favored single-T products by an average of 14.3-fold across the three genomic loci. (FIG. 93C). For the target site in which only one C is within the target window (HEK site 4, at position C5), all four mutants exhibited comparable editing efficiencies as BE3 (FIG. 98). These findings indicate that these BE3 mutants have decreased apparent processivity and can favor the conversion of only a single C at target sites containing multiple Cs within the BE3 editing window. These data also suggest a positional preference of C5>C6>C7≈C4 for these mutant base editors, although this preference could differ depending on the target sequence.

The window-modulating mutations in APOBEC1 were applied to VQR-BE3, allowing selective base editing of substrates at sites targeted by NGA PAM (FIG. 107A). However, when these mutations were applied to SaKKH-BE3, a linear decrease in base editing efficiency was observed without the improvement in substrate selectivity, suggesting a different kinetic equilibrium and substrate accessibility of this base editor than those of BE3 and its variants (FIG. 107B).

The five base editors with altered PAM specificities described in this study together increase the number of disease-associated mutations in the ClinVar database that can in principle be corrected by base editing by 2.5-fold (FIGS. 94A and 94B). Similarly, the development of base editors with narrowed editing windows approximately doubles the fraction of ClinVar entries with a properly positioned NGG PAM that can be corrected by base editing without comparable modification of a non-target C (from 31% for BE3 to 59% for YEE-BE3) (FIGS. 94A and 94B).

In summary, the targeting scope of base editing was substantially expanded by developing base editors that use Cas9 variants with different PAM specificities, and by developing a collection of deaminase mutants with varying editing window widths. In theory, base editing should be possible using other programmable DNA-binding proteins (such as Cpf1¹⁶) that create a bubble of single-stranded DNA that can serve as a substrate for a single-strand-specific nucleotide deaminase enzyme.

Materials and Methods

Cloning. PCR was performed using Q5 Hot Start High-Fidelity DNA Polymerase (New England Biolabs). Plasmids for BE and sgRNA were constructed using USER cloning (New England Biolabs), obtained from previously reported plasmids¹. DNA vector amplification was carried out using NEB 10beta competent cells (New England Biolabs).

Cell culture. HEK293T (ATCC CRL-3216) were cultured in Dulbecco's Modified Eagle's Medium plus GlutaMax (ThermoFisher) supplemented with 10% (v/v) fetal bovine serum (FBS), at 37° C. with 5% CO₂. Immortalized rat astrocytes containing the ApoE4 isoform of the APOE gene (Taconic Biosciences) were maintained in Dulbecco's Modified Eagle's Medium plus GlutaMax (ThermoFisher Scientific) supplemented with 10% (v/v) fetal bovine serum (FBS) and 200 μg/mL Geneticin (ThermoFisher Scientific).

Transfections. HEK293T cells were seeded on 48-well collagen-coated BioCoat plates (Corning) and transfected at approximately 85% confluency. 750 ng of BE and 250 ng of sgRNA expression plasmids were transfected using 1.5 μl of Lipofectamine 2000 (ThermoFisher Scientific) per well according to the manufacturer's protocol.

Data analysis. Nucleotide frequencies were assessed using a previously described MATLAB script ¹. Briefly, the reads were aligned to the reference sequence via the Smith-Waterman algorithm. Base calls with Q-scores below 30 were replaced with a placeholder nucleotide (N). This quality threshold results in nucleotide frequencies with an expected theoretical error rate of 1 in 1000.

Analyses of base editing processivity were performed using a custom python script. This program trims sequencing reads to the 20 nucleotide protospacer sequence as determined by a perfect match for the 7 nucleotide sequences that should flank the target site. These targets were then consolidated and sorted by abundance to assess the frequency of base editing products.

Bioinformatic analysis of the ClinVar database of human disease-associated mutations was performed in a manner similar to that previously described but with small adjustments¹. These adjustments enable the identification of targets with PAMs of customizable length and sequence. In addition, this improved script includes a priority ranking of target C positions (C5>C6>C7>C8≈C4), thus enabling the identification of target sites in which the on-target C is either the only cytosine within the window or is placed at a position with higher predicted editing efficiency than any off-target C within the editing window.

REFERENCES FOR EXAMPLE 12

1 Komor, A. C. et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420-424 (2016).

2 Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nature biotechnology 32, 347-355 (2014).

3 Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).

4 Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protocols 8, 2281-2308 (2013).

5 Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862-D868 (2015).

6 Nishida, K. et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 353, aaf8729-1-8 (2016).

7 Ma, Y. et al. Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells. Nat. Methods doi:10.1038/nmeth.4027 (2016).

8 Jiang, F. et al. Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage. Science 351, 867-71 (2016).

9 Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186-191 (2015).

10 Zhang, Y. et al. Comparison of non-canonical PAMs for CRISPR/Cas9-mediated DNA cleavage in human cells. Sci. Rep. 4, (2014).

11 Kleinstiver, B. P. et. al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523, 481-485 (2015).

12 Kleinstiver, B. P. et. al. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat. Biotechnol. 33, 1293-1298 (2015).

13 Holden, L. G. et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 452, 121-124 (2008).

14 Chen, K.-M. et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452, 116-119 (2008).

15 Harris, R. S., Petersen-Mahrt, S. K. & Neuberger, M. S. RNA Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA Mutators. Molecular Cell 10, 1247-1253 (2002).

16 Zetsche, B. et al. Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. Cell 163, 759-771 (2015).

Example 13

Using improved transfection procedures and better plasmids, biological replicates (n=3) were used to install the four HF mutations into the Cas9 portion of BE3. The mutations do not significantly effect on-targeting editing with plasmid delivery (FIG. 99). At the tested concentration, BE3 protein delivery works; however, the on-target editing is lower than for plasmid delivery (FIG. 100). Protein delivery of BE3 with the HF mutations installed reduces on-targeting editing efficiency but still yields some edited cells (FIG. 101).

Both lipofection and installing HF mutations were shown to decrease off-target deamination events. For the four sites shown in FIG. 102, the off-target sites (OT) with the highest GUIDE-Seq reads and deamination events were assayed (Komor et al., Nature, 2016). The specificity ratio was calculated by dividing the off-target editing by the on-target editing at the closest corresponding C. In cases where off-target editing was not detectable, the ratio was set to 100. Thus, a higher specificity ratio indicates a more specific construct. BE3 plasmid delivery showed much higher off-target/on-target editing than protein delivery of BE3, plasmid delivery of HF-BE3, or protein delivery of HF-BE3 (FIGS. 102 and 105).

Purified proteins HF-BE3 and BE3 were analyzed in vitro for their capabilities to convert C to T residues at different positions in the spacer with the most permissive motif. Both BE3 and HF-BE3 proteins were found to have the same “window” for base editing (FIGS. 103 and 104).

A list of the disease targets is given in Table 9. The base to be edited in Table 9 is indicated in bold and underlined.

TABLE 9

Base Editor Disease Targets

GENE
DISEASE
SPACER
PAM
EDITOR
DEFECT
CELL

RB1
RETINOBLASTOMA
AATCTAGTAAATAAATTGATGT
AAAAGT
SAKKH-BE3
SPLICING
J82

IMPAIRMENT

PTEN
CANCER
GACCAACGGCTAAGTGAAGA
TGA
VQR-BE3
W111R
MC116

PIK3CA
CANCER
TCCTTTCTTCACGGTTGCCT
ACTGGT
SAKKH-BE3
K111R
CRL-5853

PIK3CA
CANCER
CTCCTGCTCAGTGATTTCAG
AGA
VQR-BE3
Q546R
CRL-2505

TP53
CANCER
TGTCACACATGTAGTTGTAG
TGG
YEE-BE3
N239E
SNU475

HRAS
CANCER
CCTCCCGGCCGGCGGTATCC
AGG
YEE-BE3
Q61R
MC/CAR

TABLE 6

Exemplary diseases that may be treated using base editors. The protospacer and

PAM sequences are shown in the sgRNA (PAM) column. The PAM sequence is shown in

parentheses and with the base to be edited indicated by underlining.

gene
Base

Disease target
symbol
changed
sgRNA (PAM)
Base editor

Prion disease
PRNP
R37*
GGCAGCCGATACCCGGGGCA(GGG)
BE3

GGGCAGCCGATACCCGGGGC(AGG)

Pendred syndrome
Slc26a4
c.919-2A >
TTATTGTCCGAAATAAAAGA(AGA)
BE3

ATTGTCCGAAATAAAAGAAG(AGG)
(VQR

TTGTCCGAAATAAAAGAAGA(GGA)
SaCas9)

GTCCGAAATAAAAGAAGAGGAAAA(AAT)

GTCCGAAATAAAAGAAGAGGAAAAA(ATT)

Congenital deafness
Tmc1
c.545A > G
CAGGAAGCACGAGGCCACTG(AGG)
BE3

AACAGGAAGCACGAGGCCAC(TGA)
YE-BE3

AGGAAGCACGAGGCCACTGA(GGA)
YEE-BE3

Acquired deafness
SNHL
S33F
TTGGATTCTGGAATCCATTC(TGG)
BE3

Alzheimer's Disease
APP
A673T
TCTGCATCCATCTTCACTTC(AGA)
BE3 VQR

Niemann-Pick Disease Type C
NPC1
|1061T
CTTACAGCCAGTAATGTCAC(CGA)
BE3 VQR

Additional exemplary genes in the human genome that may be targeted by the base editors or complexes of this disclosure are provided herein in Tables 7 and 8. Table 7 includes gene mutations that may be correcteded by changing a cytosine (C) to a thymine (T), for example, using a BE3 nucleobase editor. Table 8 includes gene mutations that may be corrected by changing a guanine (G) to an adenine (A), for example, using a BE3 nucleobase editor.

TABLE 7

Human gene mutations that may be corrected by changing a cytosine (C) to a thymine (T). The gene name, gene symbol, and dbSNP database reference

number (RS#) are indicated. Also indicated are exemplary protospacers with their PAM sequences (gRNAs

and gRNAall) and the base to be edited, e.g., a C, indicated by a “Y”. The “gRNAs” sequences, from top to bottom,

correspond to SEQ ID NOs: 1914-2091. The “gRNA all” sequences, from top to bottom, correspond to SEQ ID NOs: 2192-2540, 3144-3433.

Name
RS# (dbSNP)
GeneSymbol
gRNAs
gRNAall
Phenotypes

NM_000138.4(FBN1):
137854465
FBN1
[ ]
[ ]
[ ]

c.3220T > C

(p.Cys1074Arg)

NM_001927.3(DES):
57955682
DES
[ ]
[ ]
[‘Myofibrillar

c.1154T > C

myopathy 1’, ‘not

(p.Leu385Pro)

provided’]

NM_025152.2(NUBPL):
118161496
NUBPL
[ ]
[‘TGGTTCYAATGG
[‘Mitochondrial

c.815-27T > C

ATGTCTGCTGG’,
complex I

‘GGTTCYAATGGA
deficiency’, ‘not

TGTCTGCTGGG’]
provided’]

NM_003000.2(SDHB):
786202732
SDHB
[ ]
[ ]
[‘Hereditary cancer-

c.574T > C

predisposing

(p.Cys192Arg)

syndrome’]

NM_004586.2(RPS6KA3):
122454131
RPS6KA3
[ ]
[ ]
[‘Coffin-Lowry

c.803T > C

syndrome’]

(p.Phe268Ser)

NM_005609.2(PYGM):
764313717
PYGM
[ ]
[‘TGGCTGYCAGG
[ ]

c.425_528del

GACCCAGCAAGG’,

‘CTGYCAGGGACC

CAGCAAGGAGG’]

NM_000124.3(ERCC6):
373227647
ERCC6
[ ]
[ ]
[‘Cockayne

c.2830-2A > G

syndrome, type B’]

NM_000059.3(BRCA2):
81002805
BRCA2
[‘CTTAG
[‘CTTAGGYAAGTA
[‘Familial cancer of

c.316 + 2T > C

GYAAG
ATGCAATATGG’]
breast’, ‘Breast-

TAATG

ovarian cancer,

CAATA

familial 2’,

TGG’]

‘Hereditary cancer-

predisposing

syndrome’]

NM_003242.5(TGFBR2):
28934568
TGFBR2
[ ]
[‘AGTTCCYGACGG
[‘Loeys-Dietz

c.923T > C

CTGAGGAGCGG’]
syndrome 2’]

(p.Leu308Pro)

NM_000410.3(HFE):
28934596
HFE
[ ]
[ ]
[‘Hemochromatosis

c.314T > C (p.Ile105Thr)

type 1’]

NM_000308.2(CTSA):
28934603
CTSA
[ ]
[ ]
[‘Combined

c.247T > C

deficiency of

(p.Trp83Arg)

sialidase AND beta

galactosidase’]

NM_033290.3(MID1):
28934611
MID1
[ ]
[ ]
[‘Opitz-Frias

c.1877T > C

syndrome’]

(p.Leu626Pro)

NM_000329.2(RPE65):
62653011
RPE65
[ ]
[ ]
[‘Leber congenital

c.1102T > C

amaurosis 2’,

(p.Tyr368His)

‘Retinitis pigmentosa

20’, ‘not provided’]

NM_007313.2(ABL1):
121913461
ABL1
[ ]
[‘CCAGYACGGGG
[ ]

c.814T > C

AGGTGTACGAGG’,

(p.Tyr272His)

‘CAGYACGGGGAG

GTGTACGAGGG’]

NM_000546.5(TP53):
28934873
TP53
[ ]
[ ]
[‘Li-Fraumeni

c.398T > C

syndrome 1’]

(p.Met133Thr)

NM_000490.4(AVP):
28934878
AVP
[ ]
[ ]
[‘Neurohypophyseal

c.200T > C (p.Val67Ala)

diabetes insipidus’]

NM_021961.5(TEAD1):
11567847
TEAD1
[‘TCATA
[‘TCATATTYACAG
[ ]

c.1261T > C

TTYAC
GCTTGTAAAGG’]

(p.Tyr?His)

AGGCT

TGTAA

AGG’]

NM_002609.3(PDGFRB):
397509381
PDGFRB
[ ]
[ ]
[‘Basal ganglia

c.1973T > C

calcification,

(p.Leu658Pro)

idiopathic, 4’]

NM_005236.2(ERCC4):
397509402
ERCC4
[ ]
[ ]
[‘Fanconi anemia,

c.689T > C

complementation

(p.Leu230Pro)

group Q’]

NM_005236.2(ERCC4):
397509403
ERCC4
[ ]
[ ]
[‘XERODERMA

c.706T > C

PIGMENTOSUM,

(p.Cys236Arg)

TYPE

F/COCKAYNE

SYNDROME’]

NM_173551.4(ANKS6):
377750405
ANKS6
[ ]
[‘AGGGCYGTCGG
[‘Nephronophthisis

c.1322A > G

ACCTTCGAGTGG’,
16’]

(p.Gln441Arg)

‘GGGCYGTCGGAC

CTTCGAGTGGG’,

‘GGCYGTCGGACC

TTCGAGTGGGG1

NM_000142.4(FGFR3):
80053154
FGFR3
[ ]
[ ]
[‘Hypochondroplasia’]

c.1612A > G

(p.Ile538Val)

NM_000441.1(SLC26A4):
80338848
SLC26A4
[ ]
[ ]
[‘Pendred syndrome’,

c.707T > C

‘Enlarged vestibular

(p.Leu236Pro)

aqueduct syndrome’]

NM_000518.4(HBB):
35849199
HBB
[ ]
[ ]
[ ]

c.337T > C

(p.Cys113Arg)

NM_000104.3(CYP1B1):
72549389
CYP1B1
[ ]
[ ]
[‘Irido-corneo-

c.2T > C (p.Met1Thr)

trabecular

dysgenesis’]

NM_000169.2(GLA):
28935196
—
[ ]
[ ]
[‘Fabry disease’]

c.484T > C

(p.Trp162Arg)

NM_001927.3(DES):
57639980
DES
[ ]
[‘ATTCCCYGATGA
[‘Myofibrillar

c.1034T > C

GGCAGATGCGG’,
myopathy 1’, ‘not

(p.Leu345Pro)

‘TTCCCYGATGAG
provided’]

GCAGATGCGGG]

NM_006517.4(SLC16A2):
122455132
SLC16A2
[ ]
[ ]
[‘Allan-Herndon-

c.1190T > C

Dudley syndrome’]

(p.Leu397Pro)

NM_020320.3(RARS2):
147391618
RARS2
[ ]
[‘ATACCYGGCAA
[‘Pontocerebellar

c.35A > G

GCAATAGCGCGG’]
hypoplasia type 6’]

(p.Gln12Arg)

NM_000239.2(LYZ):
121913547
LYZ
[ ]
[ ]
[‘Familial visceral

c.221T > C (p.Ile74Thr)

amyloidosis,

Ostertag type’]

NM_002977.3(SCN9A):
182650126
—
[ ]
[‘GTAAYTGCAAG
[‘Small fiber

c.2215A > G

ATCTACAAAAGG’]
neuropathy’, ‘not

(p.Ile739Val)

provided’]

NM_004700.3(KCNQ4):
80358278
KCNQ4
[ ]
[‘ACATYGACAAC
[‘DFNA 2

c.842T > C

CATCGGCTATGG’]
Nonsyndromic

(p.Leu281Ser)

Hearing Loss’]

NM_000169.2(GLA):c.
28935488
—
[‘CAGTT
[‘CAGTTAGYGATT
[‘Fabry disease’]

806T > C

AGYGA
GGCAACTTTGG’]

(p.Val269Ala)

TTGGC

AACTT

TGG’]

NM_000228.2(LAMB3):
370148688
LAMB3
[ ]
[ ]
[‘Junctional

c.565-2A > G

epidermolysis

bullosa gravis of

Herlitz’]

NM_052867.2(NALCN):
786203987
NALCN
[ ]
[ ]
[‘CONGENITAL

c.1526T > C

CONTRACTURES

(p.Leu509Ser)

OF THE LIMBS

AND FACE,

HYPOTONIA,

AND

DEVELOPMENTAL

DELAY’]

NM_001031.4(RP528):
786203997
RP528
[‘CCAY
[‘TGTCCAYGATGG
[‘Diamond-Blackfan

c.1A > G (p.Met1Val)

GATGG
CGGCGCGGCGG’,
anemia with

CGGCG
‘CCAYGATGGCGG
microtia and cleft

CGGCG
CGCGGCGGCGG’]
palate’]

GCGG’]

NM_005957.4(MTHFR):
786204012
MTHFR
[ ]
[‘GACCYGCTGCCG
[‘Homocysteinemia

c.388T > C

TCAGCGCCTGG’]
due to MTHFR

(p.Cys130Arg)

deficiency’]

NM_005957.4(MTHFR):
786204027
MTHFR
[‘GAAG
[‘GAAGGYGTGGT
[‘Homocysteinemia

c.1530 + 2T > C

GYGTG
AGGGAGGCACGG’,
due to MTHFR

GTAGG
‘AAGGYGTGGTAG
deficiency’]

GAGGC
GGAGGCACGGG’,

ACGG’,
‘AGGYGTGGTAGG

‘AAGGY
GAGGCACGGG’]

GTGGT

AGGGA

GGCAC

GGG’,

‘AGGYG

TGGTA

GGGAG

GCACG

GGG’]

NM_005957.4(MTHFR):
786204034
MTHFR
[ ]
[ ]
[‘Homocysteinemia

c.1793T > C

due to MTHFR

(p.Leu598Pro)

deficiency’]

NM_005957.4(MTHFR):
786204037
MTHFR
[ ]
[‘TCCCACYGGACA
[‘Homocysteinemia

c.1883T > C

ACTGCCTCTGG’]
due to MTHFR

(p.Leu628Pro)

deficiency’]

NM_000264.3(PTCH1):
786204056
PTCH1
[‘ATCAT
[‘ATCATTGYGAGT
[‘Gorlin syndrome’]

c.3168 + 2T > C

TGYGA
GTATTATAAGG’,

GTGTA
‘TCATTGYGAGTG

TTATA
TATTATAAGGG’,

AGG’,
‘CATTGYGAGTGT

‘TCATT
ATTATAAGGGG’]

GYGAG

TGTAT

TATAA

GGG’,

‘CATTG

YGAGT

GTATT

ATAAG

GGG’]

NM_000182.4(HADHA):
200017313
HADHA
[ ]
[ ]
[‘Mitochondrial

c.919-2A > G

trifunctional protein

deficiency’, ‘Long-

chain 3-

hydroxyacyl-CoA

dehydrogenase

deficiency’, ‘not

provided’]

NM_000030.2(AGXT):
180177271
AGXT
[ ]
[ ]
[‘Primary

c.806T > C

hyperoxaluria, type

(p.Leu269Pro)

I’]

NM_006121.3(KRT1):
57837128
KRT1
[ ]
[ ]
[‘Ichthyosis, cyclic,

c.1436T > C

with epidermolytic

(p.Ile479Thr)

hyperkeratosis’, ‘not

provided’]

NM_000521.3(HEXB):
820878
HEXB
[ ]
[ ]
[‘Sandhoff disease,

c.185C > T

infantile type’]

(p.Ser62Leu)

NM_000140.3(FECH):
202147607
FECH
[ ]
[‘GTAGAYACCTTA
[‘Erythropoietic

c.1137 + 3A > G

GAGAACAATGG’]
protoporphyria’]

NM_015046.5(SETX):
29001584
SETX
[ ]
[ ]
[‘Amyotrophic

c.1166T > C

lateral sclerosis type

(p.Leu389Ser)

4’]

NM_020365.4(EIF2B3):
119474039
EIF2B3
[‘CCAG
[‘CCAGAYTGTCAG
[‘Leukoencephalopat

c.1037T > C

AYTGT
CAAACACCTGG’]
hy with vanishing

(p.Ile346Thr)

CAGCA

white matter’]

AACAC

CTGG’]

NM_139058.2(ARX):
28936077
ARX
[ ]
[ ]
[‘Mental retardation,

c.98T > C (p.Leu33Pro)

with or without

seizures, ARX-

related, X-linked’]

NM_005183.3(CACNA1F):
122456136
CACNA1F
[ ]
[‘TGCCAYTGCTGT
[ ]

c.2267T > C

GGACAACCTGG’]

(p.Ile756Thr)

NM_007374.2(SIX6):
786204851
SIX6
[ ]
[GTCGCYGCCCGT
[‘Cataract,

c.110T > C (p.Leu37Pro)

GGCCCCTGCGG’]
microphthalmia and

nystagmus’]

NM_000339.2(SLC12A3):
28936387
SLC12A3
[ ]
[ ]
[‘Familial

c.1261T > C

hypokalemia-

(p.Cys421Arg)

hypomagnesemia’]

NM_003865.2(HESX1):
28936416
HESX1
[ ]
[ ]
[‘Pituitary hormone

c.77T > C (p.Ile26Thr)

deficiency,

combined 5’]

NM_022114.3(PRDM16):
202115331
PRDM16
[ ]
[ ]
[‘Dilated

c.2660T > C

cardiomyopathy

(p.Leu887Pro)

1LL’]

NM_001159287.1(TPI1):
121964847
TPI1
[ ]
[ ]
[‘Triosephosphate

c.832T > C

isomerase

(p.Phe278Leu)

deficiency’]

NM_001692.3(ATP6V1B1):
121964880
ATP6V1B1
[ ]
[ ]
[ ]

c.242T > C

(p.Leu81Pro)

NM_000490.4(AVP):
121964893
AVP
[ ]
[ ]
[‘Neurohypophyseal

c.61T > C (p.Tyr21His)

diabetes insipidus’]

NM_000027.3(AGA):
121964906
AGA
[‘GTTAT
[‘GTTATAYGTGCC
[‘Aspartylglycosaminuria’]

c.916T > C

AYGTG
AATGTGACTGG’]

(p.Cys306Arg)

CCAAT

GTGAC

TGG’]

NM_000138.4(FBN1):
794728167
FBN1
[ ]
[‘ATTGGYACGTGA
[‘Thoracic aortic

c.1468 + 2T > C

TCCATCCTAGG’]
aneurysms and

aortic dissections’]

NM_000027.3(AGA):
121964909
AGA
[ ]
[‘GACGGCYCTGTA
[‘Aspartylglycosaminuria’]

c.214T > C (p.Ser72Pro)

GGCTTTGGAGG’]

NM_004453.3(ETFDH):
377686388
ETFDH
[ ]
[ ]
[‘Glutaric aciduria,

c.1001T > C

type 2’]

(p.Leu334Pro)

NM_001385.2(DPYS):
121964924
DPYS
[‘CGTA
[‘CGTAATAYGGG
[‘Dihydropyrimidinase

c.1078T > C

ATAYG
AAAAAGGCGTGG’,
deficiency’]

(p.Trp360Arg)

GGAAA
‘AATAYGGGAAAA

AAGGC
AGGCGTGGTGG’,

GTGG’,
‘ATAYGGGAAAAA

‘AATAY
GGCGTGGTGGG’]

GGGAA

AAAGG

CGTGG

TGG’,

‘ATAYG

GGAAA

AAGGC

GTGGT

GGG’]

NM_004453.3(ETFDH):
121964953
ETFDH
[ ]
[ ]
[‘Glutaric acidemia

c.2T > C (p.Met1Thr)

IIC’]

NM_000071.2(CBS):
121964968
CBS
[ ]
[ ]
[‘Homocystinuria,

c.1616T > C

pyridoxine-

(p.Leu539Ser)

responsive’]

NM_000170.2(GLDC):
121964978
GLDC
[ ]
[‘CGGCCAYGCAG
[‘Non-ketotic

c.2T > C (p.Met1Thr)

TCCTGTGCCAGG’,
hyperglycinemia’]

‘GGCCAYGCAGTC

CTGTGCCAGGG’]

NM_000108.4(DLD):
121964991
DLD
[ ]
[ ]
[‘Maple syrup urine

c.1178T > C

disease, type 3’]

(p.Ile393Thr)

NM_014425.3(INVS):
121964995
INVS
[ ]
[ ]
[‘Infantile

c.1478T > C

nephronophthisis’]

(p.Leu493Ser)

NM_000398.6(CYB5R3):
121965006
CYB5R3
[ ]
[ ]
[‘Methemoglobinemia

c.382T > C

type 2’]

(p.Ser128Pro)

NM_000398.6(CYB5R3):
121965008
CYB5R3
[ ]
[‘CTGCYGGTCTAC
[‘METHEMOGLOBINEMIA,

c.446T > C

CAGGGCAAAGG’]
TYPE I’]

(p.Leu149Pro)

NM_000398.6(CYB5R3):
121965011
CYB5R3
[ ]
[ ]
[‘Methemoglobinemia

c.610T > C

type 2’]

(p.Cys204Arg)

NM_000398.6(CYB5R3):
121965013
CYB5R3
[ ]
[ ]
[‘METHEMOGLOBINEMIA,

c.218T > C

TYPE I’]

(p.Leu73Pro)

NM_001103.3(ACTN2):
786205144
ACTN2
[‘CCTA
[‘CCTAAAAYGTTG
[‘Dilated

c.683T > C

AAAYG
GATGCTGAAGG’]
cardiomyopathy

(p.Met228Thr)

TTGGA

1AA’]

TGCTG

AAGG’]

NM_000548.3(TSC2):
45517281
TSC2
[ ]
[ ]
[‘Tuberous sclerosis

c.3106T > C

syndrome’,

(p.Ser1036Pro)

‘Tuberous sclerosis

2’]

NM_000203.4(IDUA):
121965027
IDUA
[ ]
[ ]
[‘Mucopolysaccharidosis,

c.1469T > C

MPS-I-H/S’,

(p.Leu490Pro)

‘Hurler syndrome’,

‘not provided’]

NM_001122764.1(PPOX):
28936677
PPOX
[ ]
[ ]
[‘Variegate

c.35T > C

porphyria’]

(p.Ile12Thr)

NM_000525.3(KCNJ11):
28936678
KCNJ11
[ ]
[ ]
[‘Islet cell

c.440T > C

hyperplasia’]

(p.Leu147Pro)

NM_001025107.2(ADAR):
28936680
ADAR
[ ]
[ ]
[‘Symmetrical

c.1883T > C

dyschromatosis of

(p.Leu628Pro)

extremities’]

NM_001025107.2(ADAR):
28936681
ADAR
[ ]
[ ]
[‘Symmetrical

c.2609T > C

dyschromatosis of

(p.Phe870Ser)

extremities’]

NM_000557.4(GDF5):
28936683
—
[ ]
[ ]
[‘Brachydactyly type

c.1322T > C

A2’, ‘Fibular

(p.Leu441Pro)

hypoplasia and

complex

brachydactyly’]

NM_000274.3(OAT):
121965037
OAT
[ ]
[ ]
[Ornithine

c.163T > C (p.Tyr55His)

aminotransferase

deficiency’]

NM_000274.3(OAT):
121965043
OAT
[ ]
[ ]
[Ornithine

c.1205T > C

aminotransferase

(p.Leu402Pro)

deficiency’]

NM_000223.3(KRT12):
28936695
KRT12
[ ]
[ ]
[‘Meesman corneal

c.386T > C

dystrophy’, ‘not

(p.Met129Thr)

provided’]

NM_000128.3(F11):
121965064
F11
[ ]
[‘TGATYTCTTGGG
[‘Hereditary factor

c.901T > C

AGAAGAACTGG’]
XI deficiency

(p.Phe301Leu)

disease’]

NM_000128.3(F11):
121965069
F11
[ ]
[ ]
[‘Hereditary factor

c.166T > C (p.Cys56Arg)

XI deficiency

disease’]

NM_000235.3(LIPA):
121965086
LIPA
[ ]
[ ]
[‘Lysosomal acid

c.599T > C

lipase deficiency’]

(p.Leu200Pro)

NM_001199.3(BMP1):
786205217
BMP1
[ ]
[ ]
[‘Osteogenesis

c.*241T > C

imperfecta type 13’]

NM_004974.3(KCNA2):
786205231
KCNA2
[ ]
[ ]
[‘EPILEPTIC

c.788T > C

ENCEPHALOPATHY,

(p.Ile263Thr)

EARLY

INFANTILE, 32’]

NM_000548.3(TSC2):
45517398
TSC2
[ ]
[‘GCCCYGCACGC
[‘Tuberous sclerosis

c.5150T > C

AAATGTGAGTGG’,
syndrome’, ‘not

(p.Leu1717Pro)

‘CCCYGCACGCAA
provided’]

ATGTGAGTGG’]

NM_000212.2(ITGB3):
5918
ITGB3
[ ]
[ ]
[‘Myocardial

c.176T > C

infarction’,

(p.Leu59Pro)

‘Posttransfusion

purpura’,

‘Thrombocytopenia,

neonatal

alloimmune’,

‘Fracture, hip,

susceptibility to’]

m.9191T > C
386829069
MT-ATP6
[ ]
[ ]
[‘Leigh disease’]

NM_000419.3(ITGA2B):
76811038
ITGA2B
[ ]
[ ]
[‘Glanzmann

c.1787T > C

thrombasthenia’]

(p.Ile596Thr)

NM_002294.2(LAMP2):
730880485
LAMP2
[ ]
[ ]
[‘Cardiomyopathy’,

c.864 + 2T > C

‘Danon disease’]

NM_000138.4(FBN1):
794728264
FBN1
[ ]
[ ]
[‘Thoracic aortic

c.7111T > C

aneurysms and

(p.Trp2371Arg)

aortic dissections’]

NM_000531.5(OTC):
72554315
OTC
[ ]
[ ]
[‘not provided’]

c.143T > C (p.Phe48Ser)

NM_178454.4(DRAM2):
786205662
DRAM2
[ ]
[ ]
[‘Retinal dystrophy’]

c.79T > C

(p.Tyr27His)

NM_000138.4(FBN1):
794728272
FBN1
[ ]
[ ]
[‘Thoracic aortic

c.7531T > C

aneurysms and

(p.Cys2511Arg)

aortic dissections’]

NM_016218.2(POLK):
786205684
POLK
[ ]
[ ]
[‘Malignant tumor of

c.609T > C (p.Asn203=)

prostate’]

NM_016218.2(POLK):
786205688
POLK
[ ]
[ ]
[‘Malignant tumor of

c.*66T > C

prostate’]

NM_000354.5(SERPINA7):
28937312
SERPINA7
[ ]
[ ]
[ ]

c.740T > C

(p.Leu247Pro)

NM_000531.5(OTC):
72554346
OTC
[‘ACAA
[‘ACAAGATYGTCT
[‘not provided’]

c.284T > C (p.Leu95Ser)

GATYG
ACAGAAACAGG’]

TCTAC

AGAAA

CAGG’]

NM_015662.2(IFT172):
786205857
IFT172
[ ]
[‘TTGTGCYAGGAA
[‘RETINITIS

c.770T > C

GTTATGACAGG’]
PIGMENTOSA 71’]

(p.Leu257Pro)

NM_000531.5(OTC):
72554359
OTC
[ ]
[ ]
[‘not provided’]

c.386 + 2T > C

NM_001135669.1(XPR1):
786205901
XPR1
[ ]
[ ]
[‘BASAL

c.434T > C

GANGLIA

(p.Leu145Pro)

CALCIFICATION,

IDIOPATHIC, 6’]

NM_001135669.1(XPR1):
786205903
XPR1
[ ]
[ ]
[‘BASAL

c.419T > C

GANGLIA

(p.Leu140Pro)

CALCIFICATION,

IDIOPATHIC, 6’]

NM_001135669.1(XPR1):
786205904
XPR1
[ ]
[‘GCGTTYACGTGT
[‘BASAL

c.653T > C

CCCCCCTTTGG’,
GANGLIA

(p.Leu218Ser)

‘CGTTYACGTGTC
CALCIFICATION,

CCCCCTTTGGG’]
IDIOPATHIC, 6’]

NM_181457.3(PAX3):
104893654
PAX3
[ ]
[ ]
[‘Klein-Waardenberg

c.268T > C

syndrome’]

(p.Tyr90His)

NM_001987.4(ETV6):
786205155
ETV6
[ ]
[ ]
[‘Thrombocytopenia’,

c.1046T > C

‘LEUKEMIA,

(p.Leu349Pro)

ACUTE

LYMPHOBLASTIC;

ALL’]

NM_000055.2(BCHE):
104893684
BCHE
[ ]
[ ]
[‘Deficiency of

c.1004T > C

butyrylcholine

(p.Leu335Pro)

esterase’]

NM_000388.3(CASR):
104893696
CASR
[ ]
[ ]
[‘Hypocalcemia,

c.382T > C

autosomal dominant

(p.Phe128Leu)

1’]

NM_000388.3(CASR):
104893698
CASR
[ ]
[ ]
[‘Hypocalcemia,

c.1835T > C

autosomal dominant

(p.Phe612Ser)

1’]

NM_000388.3(CASR):
104893704
CASR
[ ]
[‘ACGCTYTCAAGG
[‘Hypercalciuric

c.2641T > C

TGGCTGCCCGG’,
hypercalcemia’]

(p.Phe881Leu)

‘CGCTYTCAAGGT

GGCTGCCCGGG’]

NM_000388.3(CASR):
104893708
CASR
[ ]
[ ]
[‘Hypocalcemia,

c.374T > C

autosomal dominant

(p.Leu125Pro)

1’, ‘Hypocalcemia,

autosomal dominant

1, with bartter

syndrome’]

NM_000388.3(CASR):
104893711
CASR
[ ]
[ ]
[‘Hypocalcemia,

c.2362T > C

autosomal dominant

(p.Phe788Leu)

1’]

NM_000388.3(CASR):
104893717
CASR
[ ]
[ ]
[‘Hypocalciuric

c.38T > C (p.Leu13Pro)

hypercalcemia,

familial, type 1’]

NM_006580.3(CLDN16):
104893725
CLDN16
[ ]
[ ]
[‘Primary

c.500T > C

hypomagnesemia’]

(p.Leu167Pro)

NM_006580.3(CLDN16):
104893731
CLDN16
[ ]
[ ]
[‘Primary

c.434T > C

hypomagnesemia’]

(p.Leu145Pro)

NM_000041.3(APOE):
429358
APOE
[ ]
[ ]
[‘Familial type 3

c.388T > C

hyperlipoproteinemia’]

(p.Cys130Arg)

NM_198159.2(MITF):
104893744
MITF
[ ]
[ ]
[‘Waardenburg

c.1051T > C

syndrome type 2A’]

(p.Ser351Pro)

NM_198159.2(MITF):
104893747
MITF
[ ]
[‘ACTTYCCCTTAT
[‘Waardenburg

c.1195T > C

TCCATCCACGG’,
syndrome type 2A’]

(p.Ser399Pro)

‘CTTYCCCTTATTC

CATCCACGGG’]

NM_001122757.2(POU1F1):
104893758
POU1F1
[ ]
[ ]
[‘Pituitary hormone

c.655T > C

deficiency,

(p.Trp219Arg)

combined 1’]

NM_000539.3(RHO):
104893770
RHO
[ ]
[‘CATGYTTCTGCT
[‘Retinitis

c.133T > C (p.Phe45Leu)

GATCGTGCTGG’,
pigmentosa 4’]

‘ATGYTTCTGCTG

ATCGTGCTGGG’]

NM_003106.3(SOX2):
104893802
—
[ ]
[ ]
[‘Microphthalmia

c.290T > C

syndromic 3’]

(p.Leu97Pro)

NM_024009.2(GJB3):
28937583
GJB3
[ ]
[ ]
[‘Erythrokeratodermia

c.101T > C

variabilis’]

(p.Leu34Pro)

NM_003907.2(EIF2B5):
28937596
EIF2B5
[ ]
[AGGCCYGGAGC
[‘Leukoencephalopathy

c.1882T > C

CCTGTTTTTAGG’]
with vanishing

(p.Trp628Arg)

white matter’]

NM_000551.3(VHL):
104893827
VHL
[ ]
[ ]
[‘Pheochromocytoma’]

c.188T > C (p.Leu63Pro)

NM_000320.2(QDPR):
104893865
QDPR
[ ]
[ ]
[‘Dihydropteridine

c.106T > C

reductase

(p.Trp36Arg)

deficiency’]

NM_001151.3(SLC25A4):
104893876
SLC25A4
[ ]
[‘GCAGCYCTTCTT
[‘Autosomal

c.293T > C

AGGGGGTGTGG’]
dominant

(p.Leu98Pro)

progressive external

ophthalmoplegia

with mitochondrial

DNA deletions 2’]

NM_006005.3(WFS1):
104893883
WFS1
[ ]
[‘ACCATCCYGGA
[‘WFS1-Related

c.2486T > C

GGGCCGCCTGGG’]
Disorders’]

(p.Leu829Pro)

NM_001018077.1(NR3C1):
104893911
NR3C1
[‘AAGY
[‘AAGYGATTGCA
[‘Pseudohermaphroditism,

c.1712T > C

GATTG
GCAGTGAAATGG’]
female, with

(p.Val571Ala)

CAGCA

hypokalemia, due to

GTGAA

glucocorticoid

ATGG’]

resistance’]

NM_001018077.1(NR3C1):
104893912
NR3C1
[ ]
[ ]
[‘Glucocorticoid

c.2318T > C

resistance,

(p.Leu773Pro)

generalized’]

NM_003122.4(SPINK1):
104893938
SPINK1
[ ]
[ ]
[‘Hereditary

c.2T > C (p.Met1Thr)

pancreatitis’]

NM_000165.4(GJA1):
104893962
GJA1
[ ]
[‘CTACYCAACTGC
[‘Oculodentodigital

c.52T > C (p.Ser18Pro)

TGGAGGGAAGG’]
dysplasia’]

NM_000416.2(IFNGR1):
104893973
IFNGR1
[‘TGTA
[‘TGTAATAYTTCT
[‘Disseminated

c.260T > C

ATAYT
GATCATGTTGG’]
atypical

(p.Ile87Thr)

TCTGA

mycobacterial

TCATG

infection’,

TTGG’]

‘Mycobacterium

tuberculosis,

susceptibility to’]

NM_000434.3(NEU1):
104893978
NEU1
[ ]
[‘GCCTCCYGGCGC
[‘Sialidosis, type II’]

c.718T > C

TACGGAAGTGG’,

(p.Trp240Arg)

‘CCTCCYGGCGCT

ACGGAAGTGGG’,

‘CTCCYGGCGCTA

CGGAAGTGGGG’]

NM_153704.5(TMEM67):
202149403
TMEM67
[ ]
[ ]
[‘Joubert syndrome

c.755T > C

6’]

(p.Met252Thr)

NM_000162.3(GCK):
104894010
GCK
[ ]
[ ]
[‘Maturity-onset

c.391T > C

diabetes of the

(p.Ser131Pro)

young, type 2’]

NM_004577.3(PSPH):
104894036
PSPH
[ ]
[ ]
[‘Deficiency of

c.155T > C

phosphoserine

(p.Met52Thr)

phosphatase’]

NM_000193.3(SHH):
104894052
SHH
[ ]
[ ]
[‘Single upper

c.995T > C

central incisor’]

(p.Val332Ala)

NM_000282.3(PCCA):
202247815
PCCA
[ ]
[ ]
[‘Propionic

c.491T > C

acidemia’]

(p.Ile164Thr)

NM_002546.3(TNFRSF11B):
104894092
TNFRSF11B
[ ]
[‘TAGAGYTCTGCT
[‘Hyperphosphatasemia

c.349T > C

TGAAACATAGG’]
with bone

(p.Phe117Leu)

disease’]

NM_000532.4(PCCB):
202247822
PCCB
[ ]
[ ]
[‘Propionic

c.1556T > C

acidemia’]

(p.Leu519Pro)

NM_006412.3(AGPAT2):
104894100
AGPAT2
[ ]
[ ]
[‘Congenital

c.683T > C

generalized

(p.Leu228Pro)

lipodystrophy type

1’]

NM_000238.3(KCNH2):
794728388
KCNH2
[ ]
[ ]
[‘Cardiac

c.2366T > C

arrhythmia’]

(p.Ile789Thr)

NM_001243133.1(NLRP3):
28937896
NLRP3
[ ]
[ ]
[‘Familial cold

c.1058T > C

urticaria’]

(p.Leu353Pro)

NM_021020.3(LZTS1):
28937897
LZTS1
[ ]
[ ]
[ ]

c.85T > C (p.Ser29Pro)

NM_000102.3(CYP17A1):
104894135
CYP17A1
[ ]
[CATCGCGYCCAA
[‘Complete

c.316T > C

CAACCGTAAGG’,
combined 17-alpha-

(p.Ser106Pro)

‘ATCGCGYCCAAC
hydroxylase/17,20-

AACCGTAAGGG’]
lyase deficiency’]

NM_000102.3(CYP17A1):
104894143
CYP17A1
[ ]
[ ]
[‘Complete

c.1216T > C

combined 17-alpha-

(p.Trp406Arg)

hydroxylase/17,20-

lyase deficiency’]

NM_000102.3(CYP17A1):
104894151
CYP17A1
[ ]
[AGCTCTYCCTCA
[‘Combined partial

c.1358T > C

TCATGGCCTGG’]
17-alpha-

(p.Phe453Ser)

hydroxylase/17,20-

lyase deficiency’]

NM_005097.3(LGI1):
104894166
LGI1
[ ]
[ ]
[‘Epilepsy, lateral

c.136T > C (p.Cys46Arg)

temporal lobe,

autosomal

dominant’]

NM_005097.3(LGI1):
104894167
LGI1
[ ]
[ ]
[‘Epilepsy, lateral

c.695T > C

temporal lobe,

(p.Leu232Pro)

autosomal

dominant’]

NM_000281.3(PCBD1):
104894177
PCBD1
[ ]
[ ]
[‘Hyperphenylalaninemia,

c.244T > C

BH4-deficient, D’]

(p.Cys82Arg)

NM_003476.4(CSRP3):
104894205
CSRP3
[ ]
[ ]
[‘Familial

c.131T > C

hypertrophic

(p.Leu44Pro)

cardiomyopathy 12’,

‘not specified’]

NM_000315.2(PTH):c.
104894272
PTH
[ ]
[ ]
[‘Hypoparathyroidism

67T > C (p.Ser23Pro)

familial isolated’]

NM_005055.4(RAPSN):
104894293
RAPSN
[ ]
[ ]
[‘Myasthenic

c.848T > C

syndrome,

(p.Leu283Pro)

congenital,

associated with

acetylcholine

receptor deficiency’,

‘MYASTHENIC

SYNDROME,

CONGENITAL, 11,

ASSOCIATED

WITH

ACETYLCHOLINE

RECEPTOR

DEFICIENCY’]

NM_000518.4(HBB):c.
36015961
HBB
[ ]
[IGTGTGCYGGCC
[‘Beta thalassemia

344T > C

CATCACTTTGG’]
intermedia’]

(p.Leu115Pro)

NM_005055.4(RAPSN):
104894300
RAPSN
[ ]
[ ]
[‘MYASTHENIC

c.41T > C

SYNDROME,

(p.Leu14Pro)

CONGENITAL, 11,

ASSOCIATED

WITH

ACETYLCHOLINE

RECEPTOR

DEFICIENCY’]

NM_000531.5(OTC):c.
72552295
OTC
[‘AGAA
[‘AGAAGAYGCTG
[‘not provided’]

2T > C (p.Met1Thr)

GAYGC
TTTAATCTGAGG’]

TGTTT

AATCT

GAGG’]

NM_020661.2(AICDA):
104894320
AICDA
[ ]
[ ]
[‘Immunodeficiency

c.238T > C

with hyper IgM type

(p.Trp80Arg)

2’]

NM_020661.2(AICDA):
104894321
AICDA
[ ]
[ ]
[‘Immunodeficiency

c.317T > C

with hyper IgM type

(p.Leu106Pro)

2’]

NM_020661.2(AICDA):
104894327
AICDA
[ ]
[ ]
[‘Immunodeficiency

c.452T > C

with hyper IgM type

(p.Phe151Ser)

2’]

NM_000486.5(AQP2):
104894329
—
[ ]
[ ]
[ ]

c.646T > C

(p.Ser216Pro)

NM_020638.2(FGF23):
104894343
FGF23
[ ]
[ ]
[‘Tumoral calcinosis,

c.287T > C

familial,

(p.Met96Thr)

hyperphosphatemic’]

NM_021044.2(DHH):c.
104894346
DHH
[ ]
[ ]
[‘46,XY gonadal

2T > C (p.Met1Thr)

dysgenesis, partial,

with minifascicular

neuropathy’]

NM_000217.2(KCNA1):
104894352
KCNA1
[ ]
[ ]
[‘Episodic ataxia

c.1223T > C

type 1’]

(p.Val408Ala)

NM_000432.3(MYL2):
104894370
MYL2
[ ]
[ ]
[‘Familial

c.52T > C

hypertrophic

(p.Phe18Leu)

cardiomyopathy 10’]

NM_080911.2(UNG):c.
104894380
UNG
[ ]
[ ]
[‘Immunodeficiency

752T > C

with hyper IgM type

(p.Phe251Ser)

5’]

NM_000192.3(TBX5):
104894384
TBX5
[ ]
[ ]
[‘Holt-Oram

c.161T > C (p.Ile54Thr)

syndrome’]

NM_175929.2(FGF14):
104894393
FGF14
[ ]
[ ]
[‘Spinocerebellar

c.449T > C

ataxia 27’]

(p.Phe150Ser)

NM_007262.4(PARK7):
28938172
PARK7
[ ]
[ ]
[‘Parkinson disease

c.497T > C

7’]

(p.Leu166Pro)

NM_004004.5(GJB2):
104894397
GJB2
[ ]
[ ]
[‘Deafness,

c.229T > C

autosomal recessive

(p.Trp77Arg)

1A’, ‘not provided’]

NM_001130089.1(KARS):
397514745
KARS
[‘TTCYA
[‘CTTCYATGATCT
[‘Deafness,

c.517T > C

TGATC
TCGAGGAGAGG’,
autosomal recessive

(p.Tyr173His)

TTCGA
‘TTCYATGATCTTC
89’]

GGAGA
GAGGAGAGGG’]

GGG’]

NM_000161.2(GCH1):
104894434
GCH1
[ ]
[ ]
[‘Dystonia, dopa-

c.662T > C

responsive, with or

(p.Met221Thr)

without

hyperphenylalaninemia,

autosomal

recessive’]

NM_032409.2(PINK1):
28940285
—
[ ]
[ ]
[‘Parkinson disease

c.1040T > C

6, autosomal

(p.Leu347Pro)

recessive early-

onset’]

NM_006177.3(NRL):
104894463
NRL
[ ]
[ ]
[‘Retinal

c.479T > C

degeneration,

(p.Leu160Pro)

autosomal recessive,

clumped pigment

type’]

NM_152443.2(RDH12):
104894472
RDH12
[ ]
[ICCYCGGTGGCT
[‘Leber congenital

c.523T > C

CACCACATTGG’]
amaurosis 13’]

(p.Ser175Pro)

NM_002435.2(MPI):
104894495
MPI
[ ]
[ ]
[‘Congenital disorder

c.413T > C

of glycosylation type

(p.Met138Thr)

1B’]

NM_001159702.2(FHL1):
122458144
FHL1
[ ]
[ ]
[‘Myopathy,

c.457T > C

reducing body, X-

(p.Cys153Arg)

linked, childhood-

onset’]

NM_183235.2(RAB27A):
104894498
RAB27A
[ ]
[ ]
[‘Griscelli syndrome

c.389T > C

type 2’]

(p.Leu130Pro)

NM_001018005.1(TPM1):
104894504
TPM1
[ ]
[ ]
[‘Familial

c.284T > C

hypertrophic

(p.Val95Ala)

cardiomyopathy 3’,

‘Cardiomyopathy’]

NM_000485.2(APRT):
104894508
APRT
[ ]
[ ]
[‘Adenine

c.329T > C

phosphoribosyltransferase

(p.Leu110Pro)

deficiency’]

NM_000303.2(PMM2):
104894534
PMM2
[ ]
[ ]
[‘Carbohydrate-

c.131T > C

deficient

(p.Val44Ala)

glycoprotein

syndrome type I’]

NM_024006.5(VKORC1):
104894540
VKORC1
[ ]
[ ]
[‘Warfarin response’]

c.134T > C

(p.Val45Ala)

NM_001614.3(ACTG1):
104894547
ACTG1
[ ]
[ ]
[‘Deafness,

c.1109T > C

autosomal dominant

(p.Val370Ala)

20’]

NM_001128085.1(ASPA):
104894548
—
[ ]
[ ]
[‘Spongy

c.454T > C

degeneration of

(p.Cys152Arg)

central nervous

system’]

NM_004870.3(MPDU1):
104894587
MPDU1
[ ]
[‘TCCYGGTCATG
[‘Congenital disorder

c.356T > C

CACTACAGAGG’]
of glycosylation type

(p.Leu119Pro)

1F’]

NM_004870.3(MPDU1):
104894588
MPDU1
[ ]
[‘AATAYGGCGGC
[‘Congenital disorder

c.2T > C (p.Met1Thr)

CGAGGCGGACGG’]
of glycosylation type

1F’]

NM_004870.3(MPDU1):
104894589
MPDU1
[ ]
[ ]
[‘Congenital disorder

c.221T > C

of glycosylation type

(p.Leu74Ser)

1F’]

NM_153006.2(NAGS):
104894605
—
[ ]
[ ]
[‘Hyperammonemia,

c.1289T > C

type III’]

(p.Leu430Pro)

NM_000304.3(PMP22):
104894617
PMP22
[ ]
[ ]
[Charcot-Marie-

c.47T > C

Tooth disease, type

(p.Leu16Pro)

IA’]

NM_000304.3(PMP22):
104894626
PMP22
[ ]
[TAGCAAYGGAT
[Charcot-Marie-

c.82T > C

CGTGGGCAATGG’]
Tooth disease, type

(p.Trp28Arg)

IE’]

NM_018129.3(PNPO):
104894631
PNPO
[ ]
[ACCTYAACTCTG
[“Pyridoxal 5’-

c.784T > C

GGACCTGCTGG’]
phosphate-

(p.Ter262Gln)

dependent epilepsy”]

NM_173477.4(USH1G):
104894651
USH1G
[ ]
[ ]
[‘Usher syndrome,

c.143T > C

type 1G’]

(p.Leu48Pro)

NM_000371.3(TTR):c.
104894665
TTR
[ ]
[ ]
[‘Amyloidogenic

191T > C (p.Phe64Ser)

transthyretin

amyloidosis’,

‘AMYLOIDOSIS,

LEPTOMENINGEAL,

TRANSTHYRETIN-

RELATED’]

NM_024301.4(FKRP):
104894691
FKRP
[ ]
[ ]
[‘Limb-girdle

c.899T > C

muscular dystrophy-

(p.Val300Ala)

dystroglycanopathy,

type C5’]

NM_032551.4(KISS1R):
104894703
KISS1R
[ ]
[‘GCCCTGCYGTAC
[ ]

c.305T > C

CCGCTGCCCGG’,

(p.Leu102Pro)

‘TGCYGTACCCGC

TGCCCGGCTGG’]

NM_000660.5(TGFB1):
104894719
TGFB1
[ ]
[ ]
[‘Diaphyseal

c.673T > C

dysplasia’]

(p.Cys225Arg)

NM_000229.1(LCAT):
794726664
LCAT
[ ]
[ ]
[‘Fish-eye disease’]

c.524-22T > C

NM_003332.3(TYROBP):
104894732
TYROBP
[ ]
[ ]
[‘Polycystic

c.2T > C

lipomembranous

(p.Met1Thr)

osteodysplasia with

sclerosing

leukoencephalopathy’]

NM_000074.2(CD40LG):
104894769
CD40LG
[ ]
[ ]
[‘Immunodeficiency

c.464T > C

with hyper IgM type

(p.Leu155Pro)

1’]

NM_000495.4(COL4A5):
281874738
COL4A5
[‘TCCA
[‘CTCCAGYAAGTT
[‘Alport syndrome,

c.438 + 2T > C

GYAAG
ATAAAATTTGG’,
X-linked recessive’]

TTATA
‘TCCAGYAAGTTA

AAATT
TAAAATTTGGG’]

TGGG’]

NM_000495.4(COL4A5):
281874745
COL4A5
[ ]
[ ]
[‘Alport syndrome,

c.4690T > C

X-linked recessive’]

(p.Cys1564Arg)

NM_178152.2(DCX):c.
104894781
DCX
[ ]
[ ]
[‘Lissencephaly, X-

373T > C

linked’, ‘Subcortical

(p.Tyr125His)

laminar heterotopia,

X-linked’]

NM_006579.2(EBP):c.
104894795
EBP
[ ]
[ ]
[‘MEND

53T > C (p.Leu18Pro)

SYNDROME’]

NM_001097642.2(GJB1):
104894813
GJB1
[ ]
[ ]
[‘X-linked hereditary

c.397T > C

motor and sensory

(p.Trp133Arg)

neuropathy’]

NM_001165963.1(SCN1A):
794726761
SCN1A
[ ]
[ ]
[‘Severe myoclonic

c.2690T > C

epilepsy in infancy’]

(p.Leu897Ser)

NM_000166.5(GJB1):
104894826
GJB1
[ ]
[‘ATGYCATCAGCG
[‘Dejerine-Sottas

c.407T > C

TGGTGTTCCGG’]
disease’, ‘X-linked

(p.Val136Ala)

hereditary motor and

sensory neuropathy’]

NM_001165963.1(SCN1A):
794726771
SCN1A
[ ]
[ ]
[‘Severe myoclonic

c.769T > C

epilepsy in infancy’,

(p.Cys257Arg)

‘not provided’]

NM_001165963.1(SCN1A):
794726782
SCN1A
[ ]
[ ]
[‘Severe myoclonic

c.1033T > C

epilepsy in infancy’]

(p.Cys345Arg)

NM_001122606.1(LAMP2):
104894859
LAMP2
[ ]
[CAGCTACYGGG
[‘Danon disease’]

c.961T > C

ATGCCCCCCTGG’,

(p.Trp321Arg)

‘AGCTACYGGGAT

GCCCCCCTGGG’]

m.10237T > C
193302927
MT-ND3
[ ]
[ ]
[‘Leber optic

atrophy’]

NM_033290.3(MID1):
104894866
MID1
[ ]
[ ]
[‘Opitz-Frias

c.884T > C

syndrome’]

(p.Leu295Pro)

m.10663T > C
193302933
MT-ND4L
[ ]
[ ]
[‘Leber optic

atrophy’]

NM_001165963.1(SCN1A):c
794726821
—
[‘TTCYG
[‘TTCYGGTTTGTC
[‘Severe myoclonic

.4055T > C

GTTTG
TTATATTCTGG’]
epilepsy in infancy’]

(p.Leu1352Pro)

TCTTAT

ATTCT

GG’]

NM_000475.4(NR0B1):
104894907
NR0B1
[ ]
[ ]
[‘Congenital adrenal

c.890T > C

hypoplasia, X-

(p.Leu297Pro)

linked’]

NM_022567.2(NYX):
104894911
NYX
[ ]
[ ]
[‘Congenital

c.302T > C (p.Ile101Thr)

stationary night

blindness, type 1A’]

NM_000513.2(OPN1MW):
104894914
OPN1MW
[ ]
[ ]
[‘Colorblindness,

c.607T > C

partial, deutan

(p.Cys203Arg)

series’, ‘Cone

monochromatism’]

NM_006517.4(SLC16A2):
104894931
SLC16A2
[ ]
[‘TGAGCYGGTGG
[‘Allan-Herndon-

c.1313T > C

GCCCAATGCAGG’]
Dudley syndrome’]

(p.Leu438Pro)

NM_000330.3(RS1):c.
104894935
RS1
[ ]
[‘TTACTTCYCTTT
[‘Juvenile

38T > C (p.Leu13Pro)

GGCTATGAAGG’]
retinoschisis’, ‘not

provided’]

NM_000116.4(TAZ):c.
104894937
TAZ
[‘AAGY
[‘AAGYGTGTGCCT
[‘3-Methylglutaconic

352T > C

GTGTG
GTGTGCCGAGG’]
aciduria type 2’]

(p.Cys118Arg)

CCTGT

GTGCC

GAGG’]

NM_006517.4(SLC16A2):
104894938
SLC16A2
[ ]
[ ]
[‘Allan-Herndon-

c.1481T > C

Dudley syndrome’]

(p.Leu494Pro)

NM_001109878.1(TBX22):
104894946
TBX22
[ ]
[ ]
[‘Cleft palate with

c.641T > C

ankyloglossia’]

(p.Leu214Pro)

NM_001011658.3(TRAPPC2):
104894948
—
[ ]
[ ]
[‘Spondyloepiphyseal

c.248T > C

dysplasia tarda’]

(p.Phe83Ser)

NM_003140.2(SRY):c.
104894956
SRY
[ ]
[ ]
[‘46,XY sex reversal,

326T > C

type 1’]

(p.Phe109Ser)

NM_003140.2(SRY):c.
104894968
SRY
[ ]
[ ]
[‘46,XY sex reversal,

203T > C (p.Ile68Thr)

type 1’]

NM_201269.2(ZNF644):
146936371
ZNF644
[ ]
[ ]
[‘Myopia 21,

c.1759A > G

autosomal

(p.Ile587Val)

dominant’]

NM_001004434.2(SLC30A2):
587776926
SLC30A2
[ ]
[ ]
[‘Reduced zinc in

c.161A > G

breast milk’]

(p.His54Arg)

NM_000492.3(CFTR):
373002889
CFTR
[ ]
[ ]
[‘Cystic fibrosis’]

c.3469-20T > C

NM_001848.2(COL6A1):
794727060
COL6A1
[‘ACAA
[‘ACAAGGYGAGC
[‘Ullrich congenital

c.957 + 2T > C

GGYGA
GTGGGCTGCTGG’,
muscular dystrophy’,

GCGTG
‘CAAGGYGAGCGT
‘Bethlem myopathy’]

GGCTG
GGGCTGCTGGG’]

CTGG’,

‘CAAGG

YGAGC

GTGGG

CTGCT

GGG’]

m.4336T > C
41456348
MT-TQ
[ ]
[ ]
[ ]

NM_001065.3(TNFRSF1A):
104895217
TNFRSF1A
[ ]
[‘TGCYGTACCAAG
[‘TNF receptor-

c.175T > C

TGCCACAAAGG’]
associated periodic

(p.Cys59Arg)

fever syndrome

(TRAPS)’]

NM_003072.3(SMARCA4):
281875229
SMARCA4
[ ]
[ ]
[‘Mental retardation,

c.3032T > C

autosomal dominant

(p.Met1011Thr)

16’, ‘not provided’]

NM_019885.3(CYP26B1):
281875232
CYP26B1
[ ]
[ ]
[‘Radiohumeral

c.436T > C

fusions with other

(p.Ser146Pro)

skeletal and

craniofacial

anomalies’, ‘not

provided’]

NM_000182.4(HADHA):
781222705
HADHA
[ ]
[ ]
[‘Mitochondrial

c.180 + 3A > G

trifunctional protein

deficiency’, ‘Long-

chain 3-

hydroxyacyl-CoA

dehydrogenase

deficiency’, ‘not

provided’]

NM_000208.2(INSR):
587776819
INSR
[ ]
[ ]
[‘Pineal hyperplasia

c.1124-2A > G

AND diabetes

mellitus syndrome’]

NM_006329.3(FBLN5):
28939072
FBLN5
[‘GACA
[‘GACAYTGATGA
[‘Age-related

c.506T > C

YTGAT
ATGTCGCTATGG’]
macular

(p.Ile169Thr)

GAATG

degeneration 3’]

TCGCT

ATGG’]

NM_000431.3(MVK):
104895304
MVK
[‘CTCA
[‘CTCAAYAGATGC
[‘Hyperimmunoglobulin

c.803T > C

AYAGA
CATCTCCCTGG’]
D with periodic

(p.Ile268Thr)

TGCCA

fever’, ‘Mevalonic

TCTCC

aciduria’]

CTGG’]

NM_024960.4(PANK2):
28939088
PANK2
[ ]
[ ]
[‘Hypoprebetalipo-

c.437T > C

proteinemia,

(p.Met146Thr)

acanthocytosis,

retinitis pigmentosa,

and pallidal

degeneration’]

NM_005359.5(SMAD4):
281875321
SMAD4
[ ]
[ ]
[‘Myhre syndrome’,

c.1499T > C

‘not provided’]

(p.Ile500Thr)

NM_003793.3(CTSF):
143889283
CTSF
[ ]
[‘CTCCAYACTGAG
[‘Ceroid

c.692A > G

CTGTGCCACGG’]
lipofuscinosis,

(p.Tyr231Cys)

neuronal, 13’]

NM_001159702.2(FHL1):
122459147
FHL1
[ ]
[‘GGGGYGCTTCA
[‘Myopathy,

c.310T > C

AGGCCATTGTGG’]
reducing body, X-

(p.Cys104Arg)

linked, childhood-

onset’]

NM_001159702.2(FHL1):
122459149
FHL1
[ ]
[ ]
[‘Emery-dreifuss

c.625T > C

muscular dystrophy

(p.Cys209Arg)

6’]

NM_006214.3(PHYH):
201578674
PHYH
[ ]
[ ]
[‘Refsum disease,

c.135-2A > G

adult, 1’]

NM_006329.3(FBLN5):
28939370
FBLN5
[ ]
[ ]
[‘Autosomal

c.679T > C

recessive cutis laxa

(p.Ser227Pro)

type IA’]

NM_004329.2(BMPR1A):
199476089
BMPR1A
[ ]
[ ]
[‘Juvenile polyposis

c.1409T > C

syndrome’]

(p.Met470Thr)

NM_005154.4(USP8):
672601307
USP8
[ ]
[ ]
[‘Pituitary dependent

c.2152T > C

hypercortisolism’]

(p.Ser718Pro)

NM_020184.3(CNNM4):
74552543
CNNM4
[ ]
[‘AAGCTCCYGGA
[‘Cone-rod

c.971T > C

CTTTTTTCTGGG’]
dystrophy

(p.Leu324Pro)

amelogenesis

imperfecta’]

NM_000734.3(CD247):
672601318
CD247
[ ]
[ ]
[‘Immunodeficiency

c.2T > C (p.Met1Thr)

due to defect in cd3-

zeta’]

NM_016042.3(EXOSC3):
672601332
EXOSC3
[ ]
[ ]
[‘Pontocerebellar

c.712T > C

hypoplasia, type 1b’]

(p.Trp238Arg)

NC_012920.1:m.1448
199476104
MT-ND6
[ ]
[ ]
[‘Leber optic

4T > C

atrophy’, ‘Leigh

disease’]

m.10158T > C
199476117
MT-ND3
[ ]
[‘AAAYCCACCCCT
[‘Leigh disease’,

TACGAGTGCGG’]
‘Leigh syndrome due

to mitochondrial

complex I

deficiency’,

‘Mitochondrial

complex I

deficiency’]

NM_020451.2(SEPN1):
794727808
SEPN1
[ ]
[‘TCCGGYGAGTG
[‘Congenital

c.872 + 2T > C

GGCCACACTGG’]
myopathy with fiber

type disproportion’,

‘Eichsfeld type

congenital muscular

dystrophy’]

NM_005022.3(PFN1):
140547520
PFN1
[ ]
[‘CACCTYCTTTGC
[‘Amyotrophic

c.350A > G

CCATCAGCAGG’]
lateral sclerosis 18’]

(p.Glu117Gly)

NM_032551.4(KISS1R):
28939719
KISS1R
[ ]
[ ]
[ ]

c.443T > C

(p.Leu148Ser)

NM_000084.4(CLCN5):
273585645
CLCN5
[ ]
[ ]
[‘Dent disease 1’]

c.674T > C

(p.Leu225Pro)

NM_000030.2(AGXT):
536352238
AGXT
[ ]
[ ]
[‘Primary

c.605T > A

hyperoxaluria, type

(p.Ile202Asn)

I’]

NM_000060.3(BTD):
397514333
BTD
[ ]
[ ]
[‘Biotinidase

c.212T > C (p.Leu71Pro)

deficiency’]

NM_000060.3(BTD):
397514347
BTD
[ ]
[ ]
[‘Biotinidase

c.248T > C (p.Leu83Ser)

deficiency’]

NM_000060.3(BTD):
397514359
BTD
[ ]
[‘TCACCGCYTCAA
[‘Biotinidase

c.445T > C

TGACACAGAGG’]
deficiency’]

(p.Phe149Leu)

NM_000060.3(BTD):
397514382
BTD
[ ]
[ ]
[‘Biotinidase

c.743T > C (p.Ile248Thr)

deficiency’]

NM_000060.3(BTD):
397514384
BTD
[ ]
[ ]
[‘Biotinidase

c.764T > C (p.Ile255Thr)

deficiency’]

NM_000060.3(BTD):
397514389
BTD
[ ]
[ ]
[‘Biotinidase

c.833T > C

deficiency’]

(p.Leu278Pro)

NM_000061.2(BTK):
128620186
BTK
[‘AGCT
[‘AGCTAYGGCCG
[‘X-linked

c.2T > C (p.Met1Thr)

AYGGC
CAGTGATTCTGG’]
agammaglobulinemia’]

CGCAG

TGATT

CTGG’]

m.15572T > C
207459996
MT-CYB
[ ]
[ ]
[‘Familial colorectal

cancer’]

NM_000060.3(BTD):
397514399
BTD
[ ]
[ ]
[‘Biotinidase

c.1096T > C

deficiency’]

(p.Ser366Pro)

m.15197T > C
207460001
MT-CYB
[ ]
[‘CTAYCCGCCATC
[‘Exercise

CCATACATTGG’]
intolerance’]

m.14849T > C
207460004
MT-CYB
[ ]
[ ]
[ ]

NM_000060.3(BTD):
397514406
BTD
[ ]
[‘TTCACCCYGGTC
[‘Biotinidase

c.1214T > C

CCTGTCTGGGG’]
deficiency’]

(p.Leu405Pro)

NM_000060.3(BTD):
397514408
BTD
[ ]
[ ]
[‘Biotinidase

c.1252T > C

deficiency’]

(p.Cys418Arg)

NM_000060.3(BTD):
397514412
BTD
[ ]
[ ]
[‘Biotinidase

c.1267T > C

deficiency’]

(p.Cys423Arg)

NM_001128177.1(THRB):
121918703
THRB
[ ]
[ ]
[‘Thyroid hormone

c.1336T > C

resistance,

(p.Cys446Arg)

generalized,

autosomal

dominant’]

NM_000060.3(BTD):
397514422
BTD
[ ]
[ ]
[‘Biotinidase

c.1459T > C

deficiency’]

(p.Trp487Arg)

NM_198056.2(SCN5A):
397514447
SCN5A
[ ]
[ ]
[‘Progressive

c.3963 + 2T > C

familial heart block

type 1A’]

NM_020461.3(TUBGCP6):
368449236
TUBGCP6
[ ]
[ ]
[‘Microcephaly with

c.2546A > G

chorioretinopathy,

(p.Glu849Gly)

autosomal

recessive’]

NM_006225.3 (PLCD1):
397514471
PLCD1
[ ]
[ ]
[‘Leukonychia

c.562T > C

totalis’]

(p.Cys188Arg)

NM_001161581.1(POC1A):
397514488
POC1A
[‘AGCY
[‘AGCYGTGGGAC
[‘Short stature,

c.398T > C

GTGGG
AAGAGCAGCCGG’]
onychodysplasia,

(p.Leu133Pro)

ACAAG

facial dysmorphism,

AGCAG

and hypotrichosis’]

CCGG’]

NM_005340.6(HINT1):
397514489
HINT1
[‘CAAG
[‘CAAGAAAYGTG
[‘Gamstorp-Wohlfart

c.250T > C

AAAYG
CTGCTGATCTGG’,
syndrome’]

(p.Cys84Arg)

TGCTG
‘AAGAAAYGTGCT

CTGAT
GCTGATCTGGG’]

CTGG’,

‘AAGAA

AYGTG

CTGCT

GATCT

GGG’]

NM_000051.3(ATM):
786203606
ATM
[ ]
[ ]
[‘Ataxia-

c.2T > C (p.Met1Thr)

telangiectasia

syndrome’,

‘Hereditary cancer-

predisposing

syndrome’]

NM_004281.3(BAG3):
397514507
BAG3
[ ]
[ ]
[‘Dilated

c.1385T > C

cardiomyopathy

(p.Leu462Pro)

1HH’]

NM_183075.2(CYP2U1):
397514515
CYP2U1
[ ]
[ ]
[‘Spastic paraplegia

c.784T > C

56, autosomal

(p.Cys262Arg)

recessive’]

NM_006177.3(NRL):
397514516
NRL
[ ]
MAGGCCAYGGA
[‘Retinitis

c.287T > C (p.Met96Thr)

GCTGCTGCAGGG’]
pigmentosa 27’]

NM_000344.3(SMN1):
397514518
SMN1
[‘CACT
[‘CACTGGAYATG
[‘Kugelberg-

c.388T > C

GGAYA
GAAATAGAGAGG’]
Welander disease’]

(p.Tyr130His)

TGGAA

ATAGA

GAGG’]

NM_152692.4(C1GALT1C1):
397514537
C1GALT1C1
[ ]
[ ]
[‘Polyagglutinable

c.577T > C

erythrocyte

(p.Ser193Pro)

syndrome’]

NM_024531.4(SLC52A2):
397514538
SLC52A2
[ ]
[ ]
[Brown-Vialetto-

c.368T > C

Van Laere syndrome

(p.Leu123Pro)

2’]

NM_000138.4(FBN1):
794728238
FBN1
[ ]
[ ]
[‘Thoracic aortic

c.5746T > C

aneurysms and

(p.Cys1916Arg)

aortic dissections’]

NM_000138.4(FBN1):
794728246
FBN1
[ ]
[ ]
[‘Thoracic aortic

c.6274T > C

aneurysms and

(p.Trp2092Arg)

aortic dissections’]

NM_017802.3(DNAAF5):
397514561
DNAAF5
[ ]
[ ]
[‘Ciliary dyskinesia,

c.2384T > C

primary, 18’]

(p.Leu795Pro)

NM_206933.2(USH2A):
151148854
USH2A
[ ]
[ ]
[‘Usher syndrome,

c.12295-2A > G

type 2A’]

NM_000531.5 (OTC):
72554312
OTC
[ ]
[‘CTCACTCYAAAA
[‘Ornithine

c.134T > C (p.Leu45Pro)

AACTTTACCGG’]
carbamoyltransferase

deficiency’, ‘not

provided’]

NM_178012.4(TUBB2B):
397514569
TUBB2B
[ ]
[‘GGTCCYGGATGT
[‘Polymicrogyria,

c.350T > C

GGTGAGGAAGG’]
asymmetric’]

(p.Leu117Pro)

NM_000431.3(MVK):
397514570
MVK
[ ]
[ ]
[‘Porokeratosis,

c.764T > C

disseminated

(p.Leu255Pro)

superficial actinic 1’]

NM_000431.3(MVK):
397514571
MVK
[ ]
[‘CGGCYTCAACCC
[‘Porokeratosis,

c.122T > C

CACAGCAATGG’,
disseminated

(p.Leu41Pro)

‘GGCYTCAACCCC
superficial actinic 1’]

ACAGCAATGGG’]

NM_000531.5 (OTC):
72554320
OTC
[ ]
[ ]
[‘not provided’]

c.167T > C (p.Met56Thr)

NM_000531.5 (OTC):
72554324
OTC
[ ]
[ ]
[‘not provided’]

c.188T > C (p.Leu63Pro)

NM_000531.5 (OTC):
72554328
OTC
[ ]
[ ]
[‘not provided’]

c.227T > C (p.Leu76Ser)

NM_004055.4(CAPN5):
397514602
CAPN5
[ ]
[ ]
[‘Vitreoretinopathy,

c.731T > C

neovascular

(p.Leu244Pro)

inflammatory’]

NM_133497.3(KCNV2):
397514604
KCNV2
[ ]
[ ]
[‘Retinal cone

c.491T > C

dystrophy 3B’]

(p.Phe164Ser)

NM_006567.3(FARS2):
397514611
FARS2
[ ]
[ ]
[‘Combined

c.986T > C

oxidative

(p.Ile329Thr)

phosphorylation

deficiency 14’]

NM_018344.5(SLC29A3):
397514626
SLC29A3
[‘ACTG
[‘ACTGATAYCAG
[‘Histiocytosis-

c.607T > C

ATAYC
GTGAGAGCCAGG’,
lymphadenopathy

(p.Ser203Pro)

AGGTG
‘CTGATAYCAGGT
plus syndrome’]

AGAGC
GAGAGCCAGGG’]

CAGG’]

NM_000108.4(DLD):
397514651
DLD
[‘ACAG
[‘ACAGTTAYAGGT
[‘Maple syrup urine

c.140T > C (p.Ile47Thr)

TTAYA
TCTGGTCCTGG’,
disease, type 3’]

GGTTC
‘GTTAYAGGTTCT

TGGTC
GGTCCTGGAGG’]

CTGG’,

‘GTTAY

AGGTT

CTGGT

CCTGG

AGG’]

NM_020632.2(ATP6V0A4):
3807153
ATP6V0A4
[ ]
[ ]
[‘Renal tubular

c.1739T > C

acidosis, distal,

(p.Met580Thr)

autosomal

recessive’]

NM_000238.3(KCNH2):
794728380
KCNH2
[‘CTGTG
[‘CTGTGAGYGTGC
[‘Cardiac

c.1945 + 6T > C

AGYGT
CCAGGGGCGGG’,
arrhythmia’]

GCCCA
‘TGAGYGTGCCCA

GGGGC
GGGGCGGGCGG’]

GGG’,

‘TGAGY

GTGCC

CAGGG

GCGGG

CGG’]

NM_001033053.2(NLRP1):
397514692
NLRP1
[ ]
[ ]
[‘Corneal

c.230T > C

intraepithelial

(p.Met77Thr)

dyskeratosis and

ectodermal

dysplasia’]

NM_000238.3(KCNH2):
794728390
KCNH2
[ ]
[‘GCCATCCYGGGT
[‘Cardiac

c.2396T > C

ATGGGGTGGGG’,
arrhythmia’]

(p.Leu799Pro)

‘CCATCCYGGGTA

TGGGGTGGGGG’,

‘CATCCYGGGTAT

GGGGTGGGGGG’]

NM_014845.5(FIG4):
397514707
FIG4
[ ]
[ ]
[‘Yunis Varon

c.524T > C

syndrome’]

(p.Leu175Pro)

NM_001199107.1(TBC1D24):
397514713
TBC1D24
[ ]
[‘GGTCTYTGACGT
[‘Early infantile

c.686T > C

CTTCCTGGTGG’]
epileptic

(p.Phe229Ser)

encephalopathy 16’]

NM_080605.3(B3GALT6):
397514719
B3GALT6
[ ]
[‘CGCYGGCCACC
[‘Spondyloepimetap

c.193A > G

AGCACTGCCAGG’]
hyseal dysplasia

(p.Ser65Gly)

with joint laxity’]

NM_004183.3(BEST1):
28940274
BEST1
[ ]
[ ]
[‘Vitelliform

c.253T > C

dystrophy’, ‘not

(p.Tyr85His)

provided’]

NM_005689.2(ABCB6):
397514756
ABCB6
[ ]
[ ]
[‘Dyschromatosis

c.1067T > C

universalis

(p.Leu356Pro)

hereditaria 3’]

NM_000551.3(VHL):
28940297
VHL
[ ]
[ ]
[ ]

c.488T > C

(p.Leu163Pro)

NM_000218.2(KCNQ1):
794728522
KCNQ1
[ ]
[ ]
[‘Cardiac

c.1025T > C

arrhythmia’]

(p.Leu342Pro)

NM_000218.2(KCNQ1):
794728528
KCNQ1
[ ]
[ ]
[‘Cardiac

c.1251 + 2T > C

arrhythmia’]

NM_000498.3(CYP11B2):
72554627
—
[ ]
[ ]
[‘Corticosterone

c.1382T > C

methyloxidase type

(p.Leu461Pro)

1 deficiency’]

NM_130799.2(MEN1):
794728649
MEN1
[ ]
[ ]
[‘not provided’]

c.547T > C

(p.Trp183Arg)

NM_213653.3(HFE2):
28940586
HFE2
[ ]
[ ]
[‘Hemochromatosis

c.238T > C

type 2A’]

(p.Cys80Arg)

NM_198056.2(SCN5A):
794728934
SCN5A
[ ]
[ ]
[‘not provided’]

c.4299 + 6T > C

NM_000548.3(TSC2):
397515247
TSC2
[ ]
[ ]
[‘Tuberous sclerosis

c.1946 + 2T > C

syndrome’]

NM_000256.3(MYBPC3):
730880608
MYBPC3
[ ]
MAGYGCCGCCT
[‘Cardiomyopathy’]

c.3796T > C

GGAGGTGCGAGG’]

(p.Cys1266Arg)

NM_016381.5(TREX1):
79993407
TREX1
[ ]
[ ]
[‘Aicardi Goutieres

c.530T > C

syndrome 1’]

(p.Val177Ala)

NM_001382.3(DPAGT1):
397515329
DPAGT1
[ ]
[‘AATCCYGTACTA
[‘Congenital disorder

c.503T > C

TGTCTACATGG’,
of glycosylation type

(p.Leu168Pro)

‘ATCCYGTACTAT
1J’]

GTCTACATGGG’,

‘TCCYGTACTATG

TCTACATGGGG’]

NM_000372.4(TYR):
28940877
TYR
[ ]
[ ]
[‘Tyrosinase-

c.265T > C (p.Cys89Arg)

negative

oculocutaneous

albinism’, ‘not

provided’]

NM_000375.2(UROS):
397515348
UROS
[ ]
[ ]
[‘Congenital

c.-26-177T > C

erythropoietic

porphyria’]

NM_015102.4(NPHP4):
28940891
NPHP4
[ ]
[ ]
[‘Nephronophthisis

c.2972T > C

4’]

(p.Phe991Ser)

NM_020822.2(KCNT1):
397515406
KCNT1
[ ]
[ ]
[‘Epilepsy, nocturnal

c.2386T > C

frontal lobe, 5’]

(p.Tyr796His)

NM_000061.2(BTK):
128621200
BTK
[ ]
[ ]
[‘X-linked

c.1516T > C

agammaglobulinemia’]

(p.Cys506Arg)

NM_006383.3(CIB2):
397515411
CIB2
[ ]
[ ]
[‘Deafness,

c.272T > C (p.Phe91Ser)

autosomal recessive

48’]

NM_000061.2(BTK):
128621205
BTK
[‘ACATT
[‘ACATTYGGGCTT
[‘X-linked

c.1741T > C

YGGGC
TTGGTAAGTGG’]
agammaglobulinemia’]

(p.Trp581Arg)

TTTTG

GTAAG

TGG’]

NM_018127.6(ELAC2):
397515465
ELAC2
[ ]
[‘ATAYTTTCTGGT
[‘Combined

c.460T > C

CCATTGAAAGG’]
oxidative

(p.Phe154Leu)

phosphorylation

deficiency 17’]

NM_199355.2(ADAMTS18):
397515468
ADAMTS18
[ ]
[ ]
[‘Microcornea,

c.605T > C

myopic chorioretinal

(p.Leu202Pro)

atrophy, and

telecanthus’]

NM_023110.2(FGFR1):
397515481
FGFR1
[ ]
[ ]
[‘Hartsfield

c.494T > C

syndrome’]

(p.Leu165Ser)

NM_001059.2(TACR3):
397515483
TACR3
[ ]
[ ]
[‘Hypogonadotropic

c.766T > C

hypogonadism 11

(p.Tyr256His)

with or without

anosmia’]

m.14325T > C
397515505
MT-ND6
[ ]
[ ]
[‘Leber optic

atrophy’]

NM_004333.4(BRAF):
794729219
BRAF
[ ]
[ ]
[‘Cardiofaciocutaneous

c.1783T > C

syndrome’]

(p.Phe595Leu)

NM_000370.3(TTPA):
397515525
TTPA
[ ]
[ ]
[‘Ataxia with

c.548T > C

vitamin E

(p.Leu183Pro)

deficiency’]

NM_000375.2(UROS):
397515527
UROS
[ ]
[ ]
[‘Congenital

c.139T > C

erythropoietic

(p.Ser47Pro)

porphyria’]

NM_001006657.1(WDR35):
397515533
WDR35
[ ]
[ ]
[‘Cranioectodermal

c.1592T > C

dysplasia 2’]

(p.Leu531Pro)

NM_004595.4(SMS):
397515552
SMS
[ ]
[ ]
[‘Snyder Robinson

c.449T > C (p.Ile150Thr)

syndrome’]

NM_005211.3(CSF1R):
397515557
CSF1R
[ ]
[‘CATCTYTGACTG
[‘Hereditary diffuse

c.2483T > C

TGTCTACACGG’]
leukoencephalopathy

(p.Phe828Ser)

with spheroids’]

NM_000026.2(ADSL):
777821034
ADSL
[ ]
[ ]
[‘not provided’]

c.1339T > C

(p.Ser447Pro)

NM_194248.2(OTOF):
397515599
OTOF
[ ]
[‘AGGTGCYGTTCT
[‘Deafness,

c.3413T > C

GGGGCCTACGG’,
autosomal recessive

(p.Leu1138Pro)

‘GGTGCYGTTCTG
9’]

GGGCCTACGGG’]

NM_002608.2(PDGFB):
397515632
PDGFB
[ ]
[ ]
[‘Idiopathic basal

c.356T > C

ganglia calcification

(p.Leu119Pro)

5’]

NM_000404.2(GLB1):
72555390
GLB1
[ ]
[ ]
[‘Gangliosidosis

c.152T > C (p.Ile51Thr)

GM1 type 3’]

NM_000116.4(TAZ):
397515741
TAZ
[ ]
[ ]
[‘3-Methylglutaconic

c.310T > C

aciduria type 2’]

(p.Phe104Leu)

NM_000138.4(FBN1):
397515766
FBN1
[ ]
[‘GGACAAYGTAG
[‘Marfan syndrome’]

c.2341T > C

AAATACTCCTGG’]

(p.Cys781Arg)

NM_000138.4(FBN1):
397515802
FBN1
[ ]
[ ]
[‘Marfan syndrome’]

c.4222T > C

(p.Cys1408Arg)

NM_000112.3(SLC26A2):
386833492
SLC26A2
[‘GAGA
[‘GAGAGGYGAGA
[‘Diastrophic

c.-26 + 2T > C

GGYGA
AGAGGGAAGCGG’]
dysplasia’]

GAAGA

GGGAA

GCGG’]

NM_000256.3(MYBPC3):
397515897
MYBPC3
[‘AAAG
[‘AAAGGYGGGCC
[‘Familial

c.1351 + 2T > C

GYGGG
TGGGACCTGAGG’]
hypertrophic

CCTGG

cardiomyopathy 4’,

GACCT

‘Cardiomyopathy’]

GAGG’]

NM_000045.3(ARG1):
28941474
ARG1
[ ]
[ ]
[‘Arginase

c.32T > C (p.Ile11Thr)

deficiency’]

NM_004820.3(CYP7B1):
587777222
CYP7B1
[ ]
[ ]
[‘Spastic paraplegia’,

c.889A > G

‘Spastic paraplegia

(p.Thr297Ala)

5A]

NM_017909.3(RMND1):
144972972
RMND1
[ ]
[ ]
[‘Combined

c.713A > G

oxidative

(p.Asn238Ser)

phosphorylation

deficiency 11’]

NM_000314.6(PTEN):
794729664
PTEN
[ ]
[ ]
[‘Macrocephaly/autism

c.545T > C

syndrome’]

(p.Leu182Ser)

NM_000256.3(MYBPC3):
397516076
MYBPC3
[‘CACG
[‘GCACGYGAGTG
[‘Familial

c.821 + 2T > C

YGAGT
GCCATCCTCAGG’,
hypertrophic

GGCCA
‘CACGYGAGTGGC
cardiomyopathy 4’,

TCCTC
CATCCTCAGGG’]
‘not specified’]

AGGG’]

NM_000257.3(MYH7):
397516103
MYH7
[ ]
[ ]
[Cardiomyopathy’,

c.1370T > C

‘not specified’]

(p.Ile457Thr)

NM_000257.3(MYH7):
397516130
MYH7
[ ]
[ ]
[‘Familial

c.2093T > C

hypertrophic

(p.Val698Ala)

cardiomyopathy 1’,

‘not specified’]

NM_000257.3(MYH7):
397516156
MYH7
[‘GGAG
[‘GGAGAYGGCCT
[‘Primary familial

c.2546T > C

AYGGC
CCATGAAGGAGG’]
hypertrophic

(p.Met849Thr)

CTCCA

cardiomyopathy’,

TGAAG

‘Cardiomyopathy’]

GAGG’]

NM_000271.4(NPC1):
120074134
NPC1
[ ]
[ ]
[‘Niemann-Pick

c.1133T > C

disease type C1’]

(p.Val378Ala)

NM_000520.4(HEXA):
28941771
HEXA
[ ]
[ ]
[ ]

c.538T > C

(p.Tyr180His)

NM_024426.4(WT1):
28941777
WT1
[ ]
[ ]
[‘Diffuse mesangial

c.1351T > C

sclerosis’]

(p.Phe451Leu)

NM_024426.4(WT1):
28941779
WT1
[ ]
[ ]
[‘Frasier syndrome’]

c.1378T > C

(p.Phe460Leu)

NM_000257.3(MYH7):
397516258
MYH7
[ ]
[ ]
[‘Dilated

c.602T > C

cardiomyopathy 1S’,

(p.Ile201Thr)

‘Cardiomyopathy’]

NM_000257.3(MYH7):
397516269
MYH7
[ ]
[ ]
[‘Primary familial

c.788T > C

hypertrophic

(p.Ile263Thr)

cardiomyopathy’,

‘Familial

hypertrophic

cardiomyopathy 1’,

‘Cardiomyopathy’]

NM_001429.3(EP300):
565779970
EP300
[ ]
[‘CTTAYTACAGTT
[‘Rubinstein-Taybi

c.3573T > A

ACCAGAACAGG’]
syndrome 2’]

(p.Tyr1191Ter)

NM_080605.3(B3GALT6):
786200938
B3GALT6
[ ]
[AGCTTCAYGGCG
[‘Spondyloepimetaphyseal

c.1A > G

CCCGCGCCGGG’,
dysplasia with

(p.Met1Val)

‘TCAYGGCGCCCG
joint laxity’]

CGCCGGGCCGG’]

NM_032551.4(KISS1R):
587777844
KISS1R
[ ]
[ ]
[ ]

c.937T > C

(p.Tyr313His)

NM_000257.3(MYH7):
369437262
MYH7
[ ]
[ ]
[‘Familial

c.5326A > G

hypertrophic

(p.Ser1776Gly)

cardiomyopathy 1’,

‘Cardiomyopathy’,

‘not specified’]

NM_000441.1(SLC26A4):
397516420
SLC26A4
[ ]
[ ]
[‘Pendred syndrome’,

c.164 + 2T > C

‘Enlarged vestibular

aqueduct syndrome’]

NM_000441.1(SLC26A4):
397516432
SLC26A4
[ ]
[ ]
[‘Pendred syndrome’,

c.765 + 2T > C

‘Enlarged vestibular

aqueduct syndrome’]

NM_000551.3(VHL):
397516445
VHL
[ ]
[ ]
[‘Von Hippel-Lindau

c.497T > C

syndrome’,

(p.Val166Ala)

‘Hereditary cancer-

predisposing

syndrome’]

NM_000256.3(MYBPC3):
730880624
MYBPC3
[ ]
[ ]
[‘Cardiomyopathy’]

c.709T > C

(p.Tyr237His)

NM_000531.5(OTC):
72556252
OTC
[ ]
[ ]
[‘not provided’]

c.392T > C

(p.Leu131Ser)

NM_000531.5(OTC):
72556253
OTC
[ ]
[ ]
[‘not provided’]

c.394T > C

(p.Ser132Pro)

NM_000531.5(OTC):
72556259
OTC
[ ]
[ ]
[‘not provided’]

c.416T > C

(p.Leu139Ser)

NM_000531.5(OTC):
72556269
OTC
[ ]
[ ]
[‘not provided’]

c.476T > C (p.Ile159Thr)

NM_000531.5(OTC):
72556273
OTC
[ ]
[ ]
[‘not provided’]

c.490T > C

(p.Ser164Pro)

NM_000531.5(OTC):
72556282
OTC
[‘GGCT
[‘GGCTGATYACCT
[‘not provided’]

c.526T > C

GATYA
CACGCTCCAGG’,

(p.Tyr176His)

CCTCA
‘GATYACCTCACG

CGCTC
CTCCAGGTTGG’]

CAGG’]

NM_000531.5(OTC):
72556286
OTC
[ ]
[ ]
[‘not provided’]

c.536T > C

(p.Leu179Pro)

NM_000229.1(LCAT):
28942087
LCAT
[ ]
[‘ATCTCTCYTGGG
[‘Norum disease’]

c.698T > C

GCTCCCTGGGG’,

(p.Leu233Pro)

‘TCTCYTGGGGCT

CCCTGGGGTGG’]

NM_174936.3(PCSK9):
28942112
PCSK9
[ ]
[ ]
[‘Hypercholesterolemia,

c.646T > C

autosomal

(p.Phe216Leu)

dominant, 3’]

NM_004572.3(PKP2):
794729098
PKP2
[ ]
[ ]
[‘not provided’]

c.2386T > C

(p.Cys796Arg)

NM_000061.2(BTK):
128621198
BTK
[‘AGCY
[‘GAGCYGGGGAC
[‘X-linked

c.1223T > C

GGGGA
TGGACAATTTGG’,
agammaglobulinemia’]

(p.Leu408Pro)

CTGGA
‘AGCYGGGGACTG

CAATT
GACAATTTGGG’]

TGGG’]

NM_000061.2(BTK):
128621203
BTK
[ ]
[ICGGCCYGTCCA
[‘X-linked

c.1625T > C

GGTGAGTGTGG’]
agammaglobulinemia

(p.Leu542Pro)

with growth

hormone

deficiency’]

NM_006383.3(CIB2):
397515412
CIB2
[ ]
[‘CTTCAYCTGCAA
[‘Deafness,

c.368T > C (p.Ile123Thr)

GGAGGACCTGG’]
autosomal recessive

48’]

NM_001943.3(DSG2):
397516709
DSG2
[ ]
[ ]
[‘Arrhythmogenic

c.523 + 2T > C

right ventricular

cardiomyopathy,

type 10’,

‘Cardiomyopathy’]

NM_032575.2(GLIS2):
587777353
GLIS2
[ ]
[ ]
[‘Nephronophthisis

c.523T > C

7’]

(p.Cys175Arg)

NM_000492.3(CFTR):
139304906
CFTR
[ ]
[ ]
[‘Cystic fibrosis’]

c.3230T > C

(p.Leu1077Pro)

NM_000492.3(CFTR):
139468767
CFTR
[ ]
[ ]
[‘Cystic fibrosis’, ‘not

c.1853T > C

provided’]

(p.Ile618Thr)

NM_002755.3(MAP2K1):
397516793
MAP2K1
[ ]
[ ]
[‘Cardiofaciocutaneous

c.388T > C

syndrome 3’]

(p.Tyr130His)

NM_000525.3(KCNJ11):
193929352
KCNJ11
[ ]
[ ]
[‘Permanent neonatal

c.755T > C

diabetes mellitus’]

(p.Val252Ala)

NM_000352.4(ABCC8):
193929364
ABCC8
[ ]
[‘AAGCYGCTAATT
[‘Permanent neonatal

c.404T > C

GGTAGGTGAGG’]
diabetes mellitus’]

(p.Leu135Pro)

NM_000071.2(CBS):
5742905
CBS
[‘ATCA
[‘ATCAYTGGGGTG
[‘Homocystinuria

c.833T > C (p.Ile278Thr)

YTGGG
GATCCCGAAGG’,
due to CBS

GTGGA
‘TCAYTGGGGTGG
deficiency’,

TCCCG
ATCCCGAAGGG’]
‘Homocystinuria,

AAGG’,

pyridoxine-

‘TCAYT

responsive’, ‘not

GGGGT

provided’]

GGATC

CCGAA

GGG’]

NM_001038.5(SCNN1A):
5742912
SCNN1A
[ ]
[ ]
[‘Bronchiectasis with

c.1477T > C

or without elevated

(p.Trp493Arg)

sweat chloride 2’,

‘not specified’]

NM_000030.2(AGXT):
138584408
AGXT
[ ]
[ ]
[‘Primary

c.2T > C (p.Met1Thr)

hyperoxaluria, type

I’]

NM_005633.3(SOS1):
397517153
SOS1
[ ]
[ ]
[‘Noonan syndrome

c.1649T > C

4’, ‘Rasopathy’]

(p.Leu550Pro)

NM_014714.3(IFT140):
431905520
IFT140
[‘GCAG
[CAAGCAGYGTG
[‘Renal dysplasia,

c.4078T > C

YGTGA
AGCTGCTCCTGG’,
retinal pigmentary

(p.Cys1360Arg)

GCTGC
‘GCAGYGTGAGCT
dystrophy, cerebellar

TCCTG
GCTCCTGGAGG’]
ataxia and skeletal

GAGG’]

dysplasia’]

NM_022168.3(IFIH1):
587777447
IFIH1
[ ]
[ ]
[‘Aicardi-goutieres

c.1009A > G

syndrome 7’]

(p.Arg337Gly)

NG_012123.1:g.2493
1024611
CCL2
[ ]
[ ]
[‘Coronary artery

A > G

disease, modifier of’,

‘Coronary artery

disease,

development of, in

hiv’,

‘Mycobacterium

tuberculosis,

susceptibility to’]

m.3394T > C
41460449
MT-ND1
[‘GGCY
[‘GGCYATATACA
[‘Leber optic

ATATA
ACTACGCAAAGG’]
atrophy’]

CAACT

ACGCA

AAGG’]

NM_001127328.2(ACADM):
77931234
ACADM
[ ]
[ ]
[‘Medium-chain

c.997A > G

acyl-coenzyme A

(p.Lys333Glu)

dehydrogenase

deficiency’, ‘not

provided’]

NM_005859.4(PURA):
587782995
PURA
[ ]
[ ]
[‘Neonatal

c.299T > C

hypotonia’,

(p.Leu100Pro)

‘Intellectual

disability’, ‘Seizures’,

‘Delayed speech and

language

development’,

‘Global

developmental

delay’, ‘Mental

retardation,

autosomal dominant

31’]

NM_000368.4(T5C1):
118203396
TSC1
[ ]
[ ]
[‘Tuberous sclerosis

c.539T > C

syndrome’,

(p.Leu180Pro)

‘Tuberous sclerosis

1’]

NM_000256.3(MYBPC3):
730880695
MYBPC3
[ ]
[ ]
[‘Cardiomyopathy’]

c.1696T > C

(p.Cys566Arg)

m.7275T > C
267606884
MT-CO1
[ ]
[ ]
[‘Familial colorectal

cancer’]

NM_000257.3(MYH7):
730880872
MYH7
[ ]
[‘TCGAGAYCTTCG
[‘Cardiomyopathy’]

c.1400T > C

ATGTGAGTTGG’,

(p.Ile467Thr)

‘CGAGAYCTTCGA

TGTGAGTTGGG’]

NM_002977.3(SCN9A):
80356469
SCN9A
[ ]
[ ]
[‘Primary

c.647T > C

erythromelalgia’]

(p.Phe216Ser)

NM_002977.3(SCN9A):
80356474
—
[ ]
[‘AAGATCAYTGGT
[‘Primary

c.2543T > C

AACTCAGTAGG’,
erythromelalgia’]

(p.Ile848Thr)

‘AGATCAYTGGTA

ACTCAGTAGGG’,

‘GATCAYTGGTAA

CTCAGTAGGGG’]

NM_001164277.1(SLC37A4):
80356489
SLC37A4
[ ]
[‘GGGCYGGCCCC
[‘Glucose-6-

c.352T > C

CATGTGGGAAGG’]
phosphate transport

(p.Trp118Arg)

defect’, ‘not

provided’]

NM_001457.3(FLNB):
80356501
FLNB
[ ]
[ ]
[ ]

c.4804T > C

(p.Ser1602Pro)

NM_152296.4(ATP1A3):
80356536
ATP1A3
[ ]
[‘GCCCYTCCTGCT
[‘Dystonia 12’]

c.2338T > C

GTTCATCATGG’]

(p.Phe780Leu)

NM_206933.2(USH2A):
397518022
—
[ ]
[ ]
[‘Usher syndrome,

c.5857 + 2T > C

type 2A’]

NM_194248.2(OTOF):
80356586
OTOF
[ ]
[ ]
[‘Deafness,

c.1544T > C

autosomal recessive

(p.Ile515Thr)

9’, ‘Auditory

neuropathy,

autosomal recessive,

1’]

NM_000335.4(SCN5A):
45589741
SCN5A
[ ]
[ ]
[‘Acquired long QT

c.3745T > C

syndrome’]

(p.Phe1249Leu)

NM_194248.2(OTOF):
80356596
OTOF
[ ]
[GATGCYGGTGTT
[‘Deafness,

c.3032T > C

CGACAACCTGG’]
autosomal recessive

(p.Leu1011Pro)

9’, ‘Auditory

neuropathy,

autosomal recessive,

1’]

NM_000525.3(KCNJ11):
80356610
KCNJ11
[ ]
[ ]
[‘Permanent neonatal

c.124T > C

diabetes mellitus’,

(p.Cys42Arg)

‘Transient neonatal

diabetes mellitus 3’,

‘MATURITY-

ONSET DIABETES

OF THE YOUNG,

TYPE 13’]

NM_000257.3(MYH7):
730880900
MYH7
[ ]
[ ]
[‘Cardiomyopathy’]

c.2723T > C

(p.Leu908Pro)

NM_152296.4(ATP1A3):
606231433
ATP1A3
[ ]
[ ]
[‘Alternating

c.1112T > C

hemiplegia of

(p.Leu371Pro)

childhood 2’]

NM_000083.2(CLCN1):
80356689
CLCN1
[ ]
[AGGAGYGCTATT
[‘Myotonia

c.857T > C

TAGCATCGAGG’]
congenita’]

(p.Val286Ala)

NM_000083.2(CLCN1):
80356701
CLCN1
[ ]
[ ]
[‘Myotonia

c.920T > C

congenita’]

(p.Phe307Ser)

NM_007375.3(TARDBP):
80356744
TARDBP
[ ]
[ ]
[‘Amyotrophic

c.*83T > C

lateral sclerosis type

10’]

NM_152296.4(ATP1A3):
606231449
ATP1A3
[ ]
[ ]
[‘Dystonia 12’]

c.1250T > C

(p.Leu417Pro)

NM_001876.3(CPT1A):
80356793
CPT1A
[ ]
[ ]
[Carnitine

c.1451T > C

palmitoyltransferase

(p.Leu484Pro)

I deficiency’]

NM_000088.3(COL1A1):
72656353
COL1A1
[ ]
[ ]
[‘Osteogenesis

c.4391T > C

imperfecta type III’]

(p.Leu1464Pro)

NM_000089.3(COL1A2):
72656357
COL1A2
[ ]
[ ]
[‘Ehlers-Danlos

c.279 + 2T > C

syndrome, type 7B’]

NM_015046.5(SETX):
116205032
SETX
[ ]
[ ]
[‘Spinocerebellar

c.1807A > G

ataxia autosomal

(p.Asn603Asp)

recessive 1’]

m.4409T > C
118203884
MT-TM
[ ]
[‘AGGYCAGCTAA
[‘Mitochondrial

ATAAGCTATCGG’]
myopathy’]

m.5874T > C
118203891
MT-TY
[ ]
[ ]
[ ]

NM_000130.4(F5):
118203911
F5
[ ]
[ ]
[‘Thrombophilia due

c.1160T > C (p.Ile387Thr)

to activated protein

C resistance’]

NM_173596.2(SLC39A5):
587777625
SLC39A5
[ ]
[‘AGAACAYGCTG
[‘Myopia 24,

c.911T > C

GGGCTTTTGCGG’]
autosomal

(p.Met304Thr)

dominant’]

NM_024120.4(NDUFAF5):
118203929
NDUFAF5
[ ]
[ ]
[‘Mitochondrial

c.686T > C

complex I

(p.Leu229Pro)

deficiency’]

NM_003159.2(CDKL5):
587783087
CDKL5
[ ]
[‘ATTCYTGGGGAG
[‘not provided’]

c.602T > C

CTTAGCGATGG’]

(p.Leu201Pro)

NM_000046.3(ARSB):
118203939
ARSB
[ ]
[ ]
[‘MUCOPOLYSAC

c.349T > C

CHARIDOSIS,

(p.Cys117Arg)

TYPE VI,

SEVERE’]

NM_000046.3(ARSB):
118203940
ARSB
[ ]
[ ]
[‘MUCOPOLYSAC

c.707T > C

CHARIDOSIS,

(p.Leu236Pro)

TYPE VI, MILD’]

NM_013319.2(UBIAD1):
118203951
UBIAD1
[ ]
[‘TCTGGCYCCTTT
[‘Schnyder

c.511T > C

CTCTACACAGG’,
crystalline corneal

(p.5er171Pro)

‘GGCYCCTTTCTCT
dystrophy’]

ACACAGGAGG’]

NM_138387.3(G6PC3):
118203969
G6PC3
[ ]
[ ]
[‘Severe congenital

c.554T > C

neutropenia 4,

(p.Leu185Pro)

autosomal

recessive’]

NM_006364.2(5EC23A):
118204000
SEC23A
[ ]
[ ]
[‘Craniolenticulosutural

c.1144T > C

dysplasia’]

(p.Phe382Leu)

NM_000429.2(MAT1A):
118204004
MAT1A
[ ]
[ ]
[‘Methionine

c.914T > C

adenosyltransferase

(p.Leu305Pro)

deficiency,

autosomal

recessive’]

NM_000018.3(ACADVL):
118204017
ACADVL
[ ]
[‘TCGCATCYTCCG
[‘Very long chain

c.1372T > C

GATCTTTGAGG’,
acyl-CoA

(p.Phe458Leu)

‘CGCATCYTCCGG
dehydrogenase

ATCTTTGAGGG’,
deficiency’]

‘GCATCYTCCGGA

TCTTTGAGGGG’]

NM_000833.4(GRIN2A):
397518466
GRIN2A
[ ]
[‘CTAYGGGCAGA
[‘Focal epilepsy with

c.2T > C

GTGGGCTATTGG’]
speech disorder with

(p.Met1Thr)

or without mental

retardation’]

NM_015702.2(MMADHC):
118204044
MMADHC
[ ]
[ ]
[‘Homocystinuria,

c.776T > C

cblD type, variant 1’]

(p.Leu259Pro)

NM_018077.2(RBM28):
118204055
RBM28
[ ]
[ ]
[‘Alopecia,

c.1052T > C

neurologic defects,

(p.Leu351Pro)

and endocrinopathy

syndrome’]

NM_000237.2(LPL):
118204061
LPL
[ ]
[ ]
[‘Hyperlipoproteinemia,

c.662T > C (p.Ile221Thr)

type I’]

NM_000237.2(LPL):
118204069
LPL
[ ]
[‘GGACYGGCTGTC
[‘Hyperlipoproteinemia,

c.337T > C

ACGGGCTCAGG’]
type I’]

(p.Trp113Arg)

NM_000237.2(LPL):
118204080
LPL
[ ]
[‘GTGAYTGCAGA
[‘Hyperlipoproteinemia,

c.755T > C (p.Ile252Thr)

GAGAGGACTTGG’]
type I’]

NM_000155.3(GALT):
111033726
GALT
[ ]
[ ]
[‘Deficiency of

c.580T > C

UDPglucose-

(p.Phe194Leu)

hexose-1-phosphate

uridylyltransferase’]

NM_000190.3(HMBS):
118204111
HMBS
[ ]
[‘GCTTCGCYGCAT
[‘Acute intermittent

c.739T > C

CGCTGAAAGGG’]
porphyria’]

(p.Cys247Arg)

NM_000190.3(HMBS):
118204119
HMBS
[ ]
[ ]
[‘Acute intermittent

c.242T > C

porphyria’]

(p.Leu81Pro)

NM_001363.4(DKC1):
199422253
DKC1
[ ]
[ ]
[‘Dyskeratosis

c.1193T > C

congenita X-linked’]

(p.Leu398Pro)

NM_004278.3(PIGL):
145303331
PIGL
[ ]
[ ]
[‘Zunich

c.500T > C

neuroectodermal

(p.Leu167Pro)

syndrome’]

NM_000531.5(OTC):
72558407
OTC
[ ]
[ ]
[‘not provided’]

c.602T > C

(p.Leu201Pro)

NM_000531.5(OTC):
72558441
OTC
[‘ATGT
[‘ATGTATYAATTA
[‘not provided’]

c.779T > C

ATYAA
CAGACACTTGG’]

(p.Leu260Ser)

TTACA

GACAC

TTGG’]

NM_000531.5(OTC):
72558449
OTC
[ ]
[ ]
[‘not provided’]

c.803T > C

(p.Met268Thr)

NM_000256.3(MYBPC3):
372371774
MYBPC3
[ ]
[ ]
[‘Primary dilated

c.1814A > G

cardiomyopathy’,

(p.Asp605Gly)

‘Cardiomyopathy’,

‘not specified’]

NM_000531.5(OTC):
72558471
OTC
[ ]
[ ]
[‘not provided’]

c.947T > C

(p.Phe316Ser)

NM_000531.5(OTC):
72558484
OTC
[‘ATCAT
[‘ATCATGGYAAG
[‘not provided’]

c.1005 + 2T > C

GGYAA
CAAGAAACAAGG’]

GCAAG

AAACA

AGG’]

NM_000531.5(OTC):
72558489
OTC
[ ]
[ ]
[‘not provided’]

c.1018T > C

(p.Ser340Pro)

NM_000531.5(OTC):
72558490
OTC
[ ]
[ ]
[‘not provided’]

c.1022T > C

(p.Leu341Pro)

NM_007294.3(BRCA1):
80357281
BRCA1
[‘GGCY
[‘GGGCYAGAAAT
[‘Familial cancer of

c.5291T > C

AGAAA
CTGTTGCTATGG’,
breast’, ‘Breast-

(p.Leu1764Pro)

TCTGTT
‘GGCYAGAAATCT
ovarian cancer,

GCTAT
GTTGCTATGGG’]
familial 1’]

GGG’]

NM_000035.3(ALDOB):
118204430
ALDOB
[‘GGAA
[‘GGAAGYGGCGT
[‘Hereditary

c.442T > C

GYGGC
GCTGTGCTGAGG’]
fructosuria’]

(p.Trp148Arg)

GTGCT

GTGCT

GAGG’]

NM_000512.4(GALNS):
118204436
GALNS
[ ]
[ ]
[‘Mucopolysaccharidosis,

c.413T > C

MPS-IV-A’]

(p.Val138Ala)

NM_024782.2(NHEJ1):
118204452
NHEJ1
[ ]
[ ]
[‘Severe combined

c.367T > C

immunodeficiency

(p.Cys123Arg)

with microcephaly,

growth retardation,

and sensitivity to

ionizing radiation’]

NM_007294.3(BRCA1):
80357438
BRCA1
[ ]
[‘AAATCTYAGAGT
[‘Familial cancer of

c.65T > C

GTCCCATCTGG’]
breast’, ‘Breast-

(p.Leu22Ser)

ovarian cancer,

familial 1’,

‘Hereditary cancer-

predisposing

syndrome’]

m.12297T > C
121434464
MT-TL2
[‘GTCYT
[‘GTCYTAGGCCCC
[‘Cardiomyopathy,

AGGCC
AAAAATTTTGG’]
mitochondrial’]

CCAAA

AATTT

TGG’]

NM_001040431.2(COA3):
139877390
COA3
[ ]
[‘CCAYCTGGGGA
[ ]

c.215A > G

GGTAGGTTCAGG’]

(p.Tyr72Cys)

m.10010T > C
121434476
MT-TG
[ ]
[ ]
[‘Exercise

intolerance’]

NM_000860.5(HPGD):
121434481
HPGD
[ ]
[ ]
[‘Digital clubbing,

c.577T > C

isolated congenital’]

(p.Ser193Pro)

NM_024915.3(GRHL2):
587777737
GRHL2
[ ]
[ ]
[‘Ectodermal

c.1192T > C

dysplasia/short

(p.Tyr398His)

stature syndrome’]

NM_032374.4(APOPT1):
587777786
APOPT1
[ ]
[ ]
[‘Cytochrome-c

c.353T > C

oxidase deficiency’]

(p.Phe1185er)

NM_001605.2(AARS):
143370729
AARS
[ ]
[ ]
[‘EPILEPTIC

c.2251A > G

ENCEPHALOPATHY,

(p.Arg751Gly)

EARLY

INFANTILE, 29’]

NM_000257.3(MYH7):
730880744
MYH7
[ ]
[ ]
[‘Cardiomyopathy’]

c.2479T > C

(p.Trp827Arg)

NM_017415.2(KLHL3):
199469630
KLHL3

[‘Pseudohypoaldosteronism,

c.1160T > C

type 2’]

(p.Leu387Pro)

NM_017415.2(KLHL3):
199469642
KLHL3

[‘Pseudohypoaldosteronism,

c.1280T > C

type 2’]

(p.Met427Thr)

NM_005859.4(PURA):
793888527
PURA
[ ]
[‘GACCAYTGCGCT
[‘not provided’,

c.563T > C

GCCCGCGCAGG’,
‘Mental retardation,

(p.Ile188Thr)

‘ACCAYTGCGCTG
autosomal dominant

CCCGCGCAGGG’,
31’]

‘CCAYTGCGCTGC

CCGCGCAGGGG’]

NM_007294.3(BRCA1):
80358026
BRCA1
[ ]
[ ]
[‘Familial cancer of

c.212 + 2T > C

breast’, ‘Breast-

ovarian cancer,

familial 1’]

NM_002878.3(RAD51D):
561425038
—
[ ]
[‘CGCCCAYGTTCC
[‘Hereditary cancer-

c.1A > G

CCGCAGGCCGG’]
predisposing

(p.Met1Val)

syndrome’]

NM_018960.4(GNMT):
121907888
GNMT
[ ]
[ ]
[‘Glycine N-

c.149T > C

methyltransferase

(p.Leu50Pro)

deficiency’]

NM_007294.3(BRCA1):
80358089
BRCA1
[ ]
[ ]
[‘Breast-ovarian

c.5074 + 2T > C

cancer, familial 1’]

NC_012920.1:m.1198
200911567
MT-ND4
[ ]
[ ]
[‘Leigh disease’]

4T > C

NM_000280.4(PAX6):
121907925
PAX6
[ ]
[ ]
[‘Congenital ocular

c.773T > C

coloboma’,

(p.Phe258Ser)

‘Coloboma of optic

disc’]

NM_020117.9(LARS):
201861847
LARS
[ ]
[ ]
[‘Infantile liver

c.1118A > G

failure syndrome 1’]

(p.Tyr373Cys)

NM_024105.3(ALG12):
121907934
ALG12
[ ]
[‘TCCYGCTGGCCC
[‘Congenital disorder

c.473T > C

TCGCGGCCTGG’]
of glycosylation type

(p.Leu158Pro)

1G’]

NM_000152.3(GAA):
121907936
GAA
[ ]
[ ]
[‘Glycogen storage

c.953T > C

disease type II,

(p.Met318Thr)

infantile’]

NM_000520.4(HEXA):
121907968
HEXA
[ ]
[ ]
[‘Tay-Sachs disease’]

c.1453T > C

(p.Trp485Arg)

NM_000520.4(HEXA):
121907974
HEXA
[ ]
[ ]
[‘Tay-Sachs disease’]

c.632T > C

(p.Phe211Ser)

NM_000053.3(ATP7B):
121908000
ATP7B
[ ]
[ ]
[‘Wilson disease’]

c.2123T > C

(p.Leu708Pro)

NM_000375.2(UROS):
121908012
UROS
[ ]
[ ]
[‘Congenital

c.217T > C

erythropoietic

(p.Cys73Arg)

porphyria’]

NM_153212.2(GJB4):
80358207
GJB4
[ ]
[‘CCTCATCYTCAA
[‘Erythrokeratodermia

c.409T > C

GGCCGCCGTGG’]
variabilis’]

(p.Phe137Leu)

NM_000403.3(GALE):
121908045
GALE
[ ]
[ ]
[‘UDPglucose-4-

c.548T > C

epimerase

(p.Leu183Pro)

deficiency’]

NM_002353.2(TACSTD2):
80358228
TACSTD2
[ ]
[ICGGCYGCACCC
[‘Lattice corneal

c.557T > C

CAAGTTCGTGG’]
dystrophy Type III’]

(p.Leu186Pro)

NM_001563.3(IMPG1):
713993047
IMPG1
[ ]
[ ]
[‘Macular dystrophy,

c.461T > C

vitelliform, 4’]

(p.Leu154Pro)

NM_138691.2(TMC1):
121908076
TMC1
[ ]
[‘AGGACCTYGCTG
[‘Deafness,

c.1543T > C

GGAAACAATGG’,
autosomal recessive

(p.Cys515Arg)

‘ACCTYGCTGGGA
7’]

AACAATGGTGG’,

‘CCTYGCTGGGAA

ACAATGGTGGG’]

NM_000271.4(NPC1):
80358259
NPC1
[ ]
[ ]
[‘Niemann-Pick

c.3182T > C

disease type C1’]

(p.Ile1061Thr)

NM_006432.3(NPC2):
80358264
NPC2
[ ]
[ ]
[‘Niemann-Pick

c.295T > C

disease type C2’]

(p.Cys99Arg)

NM_017838.3(NHP2):
121908089
NHP2
[ ]
[‘GGAGGCTYACG
[‘Dyskeratosis

c.415T > C

ATGAGTGCCTGG’,
congenita autosomal

(p.Tyr139His)

‘GGCTYACGATGA
recessive 1’,

GTGCCTGGAGG’]
‘Dyskeratosis

congenita,

autosomal recessive

2’]

NM_005857.4(ZMPSTE24):
121908093
ZMPSTE24
[ ]
[ ]
[‘Mandibuloacral

c.1018T > C

dysplasia with type

(p.Trp340Arg)

B lipodystrophy’,

‘not provided’]

NM_001195794.1(CLRN1):
121908142
CLRN1
[ ]
[ ]
[‘Usher syndrome,

c.488T > C

type 3’]

(p.Leu163Pro)

NM_057176.2(BSND):
121908144
BSND
[ ]
[ ]
[‘Sensorineural

c.35T > C (p.Ile12Thr)

deafness with mild

renal dysfunction’]

NM_001243133.1(NLRP3):
121908152
NLRP3
[ ]
[ ]
[‘Familial cold

c.1718T > C

urticaria’, ‘Chronic

(p.Phe573Ser)

infantile

neurological,

cutaneous and

articular syndrome’]

NM_001243133.1(NLRP3):
121908154
NLRP3
[ ]
[‘GGTGCCTYTGAC
[‘Familial cold

c.926T > C

GAGCACATAGG’]
urticaria’, ‘Chronic

(p.Phe309Ser)

infantile

neurological,

cutaneous and

articular syndrome’]

NM_153741.1(DPM3):
121908155
DPM3
[ ]
[ ]
[‘Congenital disorder

c.254T > C

of glycosylation type

(p.Leu85Ser)

1O’]

NM_001033855.2(DCLRE1C):
121908158
DCLRE1C
[ ]
[‘GGCGCTAYGAG
[‘Histiocytic

c.2T > C

TTCTTTCGAGGG’,
medullary

(p.Met1Thr)

‘GCGCTAYGAGTT
reticulosis’]

CTTTCGAGGGG’]

NM_017696.2(MCM9):
587777871
MCM9
[ ]
[ ]
[‘Premature ovarian

c.1732 + 2T > C

failure 1’, ‘Ovarian

dysgenesis 4’]

NM_031433.3(MFRP):
121908190
—
[ ]
[ ]
[‘Nanophthalmos 2’]

c.545T > C

(p.Ile182Thr)

NM_001127221.1(CACNA1A):
121908213
CACNA1A
[ ]
[ ]
[‘Familial

c.2141T > C

hemiplegic migraine

(p.Val714Ala)

type 1’]

NM_001127221.1(CACNA1A):
121908233
CACNA1A
[ ]
[ ]
[‘Episodic ataxia

c.4469T > C

type 2’]

(p.Phe1490Ser)

NM_133459.3(CCBE1):
121908254
CCBE1
[ ]
[ ]
[‘Hennekam

c.520T > C

lymphangiectasia-

(p.Cys174Arg)

lymphedema

syndrome’]

NM_018129.3(PNPO):
796052870
PNPO
[ ]
[‘CCCCCAYGACGT
[‘not provided’]

c.2T > C (p.Met1Thr)

GCTGGCTGCGG’,

‘CCCCAYGACGTG

CTGGCTGCGGG’,

‘CCCAYGACGTGC

TGGCTGCGGGG’]

NM_014845.5(FIG4):
121908287
FIG4
[ ]
[ ]
[‘Charcot-Marie-

c.122T > C (p.Ile41Thr)

Tooth disease, type

4J’, ‘not provided’]

NM_001005741.2(GBA):
121908300
GBA
[‘GCCA
[‘GCCAGAYACTTT
[‘Gaucher disease,

c.751T > C

GAYAC
GTGAAGTAAGG’,
type 1’]

(p.Tyr251His)

TTTGT
‘CCAGAYACTTTG

GAAGT
TGAAGTAAGGG’]

AAGG’]

NM_020427.2(SLURP1):
121908318
SLURP1
[ ]
[‘GCAGCCYGGAG
[Acroerythro-

c.43T > C

CATGGGCTGTGG’]
keratoderma’]

(p.Trp15Arg)

NM_020427.2(SLURP1):
121908319
SLURP1
[ ]
[ ]
[‘Acroerythro-

c.229T > C

keratoderma’]

(p.Cys77Arg)

NM_000787.3(DBH):
74853476
DBH
[ ]
[ ]
[‘Dopamine beta

c.339 + 2T > C

hydroxylase

deficiency’]

NM_017882.2(CLN6):
154774633
CLN6
[‘AGCY
[‘AGCYGGTATTCC
[‘Adult neuronal

c.200T > C

GGTAT
CTCTCGAGTGG’]
ceroid

(p.Leu67Pro)

TCCCT

lipofuscinosis’, ‘not

CTCGA

provided’]

GTGG’]

NM_022124.5(CDH23):
121908352
CDH23
[ ]
[‘CTCACCTYCAAC
[‘Deafness,

c.5663T > C

ATCACTGCGGG’]
autosomal recessive

(p.Phe1888Ser)

12’]

NM_054027.4(ANKH):
121908407
ANKH
[‘GTCG
[‘GTCGAGAYGCT
[‘Chondrocalcinosis

c.143T > C

AGAYG
GGCCAGCTACGG’,
2’]

(p.Met48Thr)

CTGGC
‘TCGAGAYGCTGG

CAGCT
CCAGCTACGGG’]

ACGG’,

‘TCGAG

AYGCT

GGCCA

GCTAC

GGG’]

NM_004924.4(ACTN4):
121908417
ACTN4
[ ]
[ ]
[‘Focal segmental

c.784T > C

glomerulosclerosis

(p.Ser262Pro)

1’]

NM_014384.2(ACAD8):
121908418
ACAD8
[ ]
[ ]
[‘Deficiency of

c.455T > C

isobutyryl-CoA

(p.Met152Thr)

dehydrogenase’]

NM_153717.2(EVC):
121908426
EVC
[ ]
[ ]
[‘Chondroectodermal

c.919T > C

dysplasia’, ‘Curry-

(p.Ser307Pro)

Hall syndrome’]

NM_001040108.1(MLH3):
121908439
MLH3
[ ]
[ ]
[‘Hereditary

c.3826T > C

nonpolyposis

(p.Trp1276Arg)

colorectal cancer

type 7’]

NM_013339.3(ALG6):
121908444
ALG6
[ ]
[ ]
[‘Congenital disorder

c.1432T > C

of glycosylation type

(p.Ser478Pro)

1C’]

NM_003835.3(RGS9):
121908449
RGS9
[ ]
[ ]
[‘Prolonged

c.895T > C

electroretinal

(p.Trp299Arg)

response

suppression’]

NM_022336.3(EDAR):
121908451
EDAR
[ ]
[ ]
[‘Autosomal

c.259T > C

recessive

(p.Cys87Arg)

hypohidrotic

ectodermal dysplasia

syndrome’]

NM_014270.4(SLC7A9):
121908485
SLC7A9
[ ]
[ ]
[‘Cystinuria’]

c.131T > C

(p.Ile44Thr)

NM_000030.2(AGXT):
121908520
AGXT
[ ]
[CCTGTACYCGGG
[‘Primary

c.613T > C

CTCCCAGAAGG’]
hyperoxaluria, type

(p.Ser205Pro)

I’]

NM_000030.2(AGXT):
121908525
AGXT
[ ]
[ ]
[‘Primary

c.731T > C

hyperoxaluria, type

(p.Ile244Thr)

I’]

NM_000026.2(ADSL):
119450940
ADSL
[ ]
[ ]
[‘Adenylosuccinate

c.1312T > C

lyase deficiency’]

(p.Ser438Pro)

NM_000026.2(ADSL):
119450945
ADSL
[‘AAGA
[‘AAGAYGGTGAC
[‘Adenylosuccinate

c.674T > C

YGGTG
AGAAAAGGCAGG’]
lyase deficiency’]

(p.Met225Thr)

ACAGA

AAAGG

CAGG’]

NM_014985.3(CEP152):
200879436
CEP152
[ ]
[ ]
[‘Seckel syndrome

c.2000A > G

5’, ‘not specified’]

(p.Lys667Arg)

NM_002755.3(MAP2K1):
121908594
MAP2K1
[ ]
[ ]
[‘Cardiofaciocutaneous

c.158T > C

syndrome 3’,

(p.Phe53Ser)

‘Rasopathy’]

NM_004820.3(CYP7B1):
121908612
CYP7B1
[ ]
[ ]
[‘Spastic paraplegia

c.647T > C

5A’]

(p.Phe216Ser)

NM_004273.4(CHST3):
121908616
CHST3
[ ]
[ ]
[‘Spondyloepiphyseal

c.776T > C

dysplasia with

(p.Leu259Pro)

congenital joint

dislocations’]

NM_004273.4(CHST3):
121908618
CHST3
[ ]
[‘CGTGCYGGCCTC
[‘Spondyloepiphyseal

c.920T > C

GCGCATGGTGG’]
dysplasia with

(p.Leu307Pro)

congenital joint

dislocations’]

NM_004273.4(CHST3):
121908620
CHST3
[ ]
[ ]
[‘Spondyloepiphyseal

c.857T > C

dysplasia with

(p.Leu286Pro)

congenital joint

dislocations’]

NM_000050.4(ASS1):
121908646
ASS1
[ ]
[ ]
[ ]

c.535T > C

(p.Trp179Arg)

NM_030761.4(WNT4):
121908653
WNT4
[ ]
[ ]
[‘Mullerian aplasia

c.35T > C (p.Leu12Pro)

and

hyperandrogenism’]

NM_006432.3(NPC2):
11694
NPC2
[ ]
[‘TATTCAGYCTAA
[‘Niemann-Pick

c.199T > C (p.Ser67Pro)

AAGCAGCAAGG’]
disease type C2’]

NM_003839.3(TNFRSF11A):
121908656
TNFRSF11A
[ ]
[ ]
[‘Osteopetrosis

c.523T > C

autosomal recessive

(p.Cys175Arg)

7’]

NM_000022.2(ADA):
121908739
ADA
[ ]
[‘CCTGCYGGCCAA
[‘Severe combined

c.320T > C

CTCCAAAGTGG’]
immunodeficiency

(p.Leu107Pro)

due to ADA

deficiency’]

NM_000140.3(FECH):
2272783
FECH
[ ]
[ ]
[‘Erythropoietic

c.315-48T > C

protoporphyria’]

NM_000059.3(BRCA2):
80358979
BRCA2
[ ]
[ ]
[‘Familial cancer of

c.7529T > C

breast’, ‘Breast-

(p .Leu2510Pro)

ovarian cancer,

familial 2’, ‘Fanconi

anemia,

complementation

group D1’]

NM_003722.4(TP63):
121908837
TP63
[ ]
[ ]
[‘Ectrodactyly,

c.1033T > C

ectodermal

(p.Cys345Arg)

dysplasia, and cleft

lip/palate syndrome

3’]

NM_003722.4(TP63):
121908845
TP63
[ ]
[ ]
[‘Hay-Wells

c.1646T > C

syndrome of

(p.Ile549Thr)

ectodermal

dysplasia’, ‘Rapp-

Hodgkin ectodermal

dysplasia syndrome’]

NM_000059.3(BRCA2):
80359022
BRCA2
[ ]
[‘TGCYTCTTCAAC
[‘Familial cancer of

c.7958T > C

TAAAATACAGG’]
breast’, ‘Breast-

(p.Leu2653Pro)

ovarian cancer,

familial 2’]

NM_000369.2(TSHR):
121908861
TSHR
[ ]
[ ]
[‘Hyperthyroidism,

c.1891T > C

nonautoimmune’,

(p.Phe631Leu)

‘Thyroid adenoma,

hyperfunctioning’]

NM_000369.2(TSHR):
121908864
TSHR
[ ]
[ ]
[‘Hyperthyroidism,

c.1358T > C

nonautoimmune’]

(p.Met453Thr)

NM_000369.2(TSHR):
121908874
TSHR
[ ]
[ ]
[‘Hyperthyroidism,

c.1526T > C

nonautoimmune’]

(p.Val509Ala)

NM_000369.2(TSHR):
121908884
TSHR
[ ]
[ ]
[‘Hypothyroidism,

c.1798T > C

congenital,

(p.Cys600Arg)

nongoitrous, 1’]

NM_000369.2(TSHR):
121908885
TSHR
[ ]
[ ]
[‘Hypothyroidism,

c.1400T > C

congenital,

(p.Leu467Pro)

nongoitrous, 1’]

NM_001457.3(FLNB):
121908896
FLNB
[ ]
[ ]
[‘Boomerang

c.703T > C

dysplasia’]

(p.Ser235Pro)

NM_003880.3(WISP3):
121908902
WISP3
[ ]
[‘AAAATCYGTGCC
[‘Progressive

c.232T > C

AAGCAACCAGG’,
pseudorheumatoid

(p.Cys78Arg)

‘AAATCYGTGCCA
dysplasia’]

AGCAACCAGGG’,

‘AATCYGTGCCAA

GCAACCAGGGG’]

NM_003880.3(WISP3):
121908903
WISP3
[ ]
[ ]
[‘Progressive

c.1000T > C

pseudorheumatoid

(p.Ser334Pro)

dysplasia’]

NM_002977.3(SCN9A):
121908914
—
[ ]
[ ]
[‘Paroxysmal

c.4382T > C

extreme pain

(p.Ile1461Thr)

disorder’]

NM_004086.2(COCH):
121908929
—
[ ]
[ ]
[‘Deafness,

c.349T > C

autosomal dominant

(p.Trp117Arg)

9’]

NM_004086.2(COCH):
121908934
—
[‘AGAT
[‘AGATAYGGCTTC
[‘Deafness,

c.1535T > C

AYGGC
TAAACCGAAGG’]
autosomal dominant

(p.Met512Thr)

TTCTA

9’]

AACCG

AAGG’]

NM_006892.3(DNMT3B):
121908947
DNMT3B
[ ]
[‘CAAGTTCYCCGA
[‘Centromeric

c.808T > C

GGTGAGTCCGG’,
instability of

(p.Ser270Pro)

‘AAGTTCYCCGAG
chromosomes 1,9

GTGAGTCCGGG’,
and 16 and

‘AGTTCYCCGAGG
immunodeficiency’]

TGAGTCCGGGG’]

NM_000226.3(KRT9):
61157095
KRT9
[ ]
[ ]
[‘Epidermolytic

c.503T > C

palmoplantar

(p.Leu168Ser)

keratoderma’, ‘not

provided’]

NM_000051.3(ATM):
730881326
—
[ ]
[ ]
[‘Hereditary cancer-

c.8584 + 2T > C

predisposing

syndrome’]

NM_000492.3(CFTR):
121909028
CFTR
[ ]
[‘AGCCTYTGGAGT
[‘Cystic fibrosis’]

c.3857T > C

GATACCACAGG’]

(p.Phe1286Ser)

NM_000492.3(CFTR):
121909041
CFTR
[ ]
[ ]
[‘Cystic fibrosis’]

c.3763T > C

(p.Ser1255Pro)

NM_001040667.2(HSF4):
121909048
HSF4
[ ]
[ ]
[‘Cataract, zonular’]

c.341T > C

(p.Leu114Pro)

NM_005025.4(SERPINI1):
121909051
SERPINI1
[ ]
[ ]
[‘Familial

c.145T > C

encephalopathy with

(p.Ser49Pro)

neuroserpin

inclusion bodies’]

NM_002700.2(POU4F3):
121909057
POU4F3
[ ]
[ ]
[‘Deafness,

c.668T > C

autosomal dominant

(p.Leu223Pro)

15’]

NM_003322.4(TULP1):
121909074
TULP1
[ ]
[ ]
[‘Retinitis

c.1471T > C

pigmentosa 14’]

(p.Phe491Leu)

NM_003322.4(TULP1):
121909076
TULP1
[ ]
[ ]
[‘Retinitis

c.1145T > C

pigmentosa’,

(p.Phe382Ser)

‘Retinitis pigmentosa

14’]

NM_003000.2(SDHB):
33927012
SDHB
[ ]
[ ]
[‘Pheochromocytom

c.487T > C

a’, ‘Hereditary

(p.Ser163Pro)

Paraganglioma-

Pheochromocytoma

Syndromes’,

‘Hereditary cancer-

predisposing

syndrome’, ‘Cowden

syndrome 2’, ‘not

specified’, ‘not

provided’]

NM_005603.4(ATP8B1):
121909099
ATP8B1
[ ]
[ ]
[‘Progressive

c.863T > C

intrahepatic

(p.Leu288Ser)

cholestasis’]

NM_005603.4(ATP8B1):
121909100
ATP8B1
[ ]
[ ]
[‘Progressive

c.1982T > C

intrahepatic

(p.Ile661Thr)

cholestasis’, ‘Benign

recurrent

intrahepatic

cholestasis 1’]

NM_000483.4(APOC2):
120074115
—
[ ]
[ ]
[‘Apolipoprotein C2

c.142T > C

deficiency’]

(p.Trp48Arg)

NM_000543.4(SMPD1):
120074124
SMPD1
[‘CACY
[AGCACYTGTGA
[‘Sphingomyelin/cho

c.911T > C

TGTGA
GGAAGTTCCTGG’,
lesterol lipidosis’,

(p.Leu304Pro)

GGAAG
‘GCACYTGTGAGG
‘Niemann-Pick

TTCCT
AAGTTCCTGGG’,
disease, type A’,

GGGG1
‘CACYTGTGAGGA
‘Niemann-Pick

AGTTCCTGGGG’]
disease, type B’, ‘not

provided’]

NM_000085.4(CLCNKB):
121909135
CLCNKB
[ ]
[‘CTTTGTCYATGG
[‘Bartter syndrome

c.1294T > C

TGAGTCTGGGG’]
type 3’]

(p.Tyr432His)

NM_001300.5(KLF6):
121909139
KLF6
[ ]
[ ]
[ ]

c.346T > C

(p.Ser116Pro)

m.12338T > C
201863060
MT-NDS
[ ]
[ ]
[‘Leber optic

atrophy’]

NM_001300.5(KLF6):
121909142
KLF6
[‘TCTGY
[‘TCTGYGGACCAA
[ ]

c.190T > C

GGACC
AATCATTCTGG’]

(p.Trp64Arg)

AAAAT

CATTC

TGG’]

NM_001300.5(KLF6):
121909143
KLF6
[ ]
[‘GGAGCYGCCCTC
[ ]

c.506T > C

GCCAGGGAAGG’]

(p.Leu169Pro)

NM_000271.4(NPC1):
120074136
NPC1
[ ]
[ ]
[‘Niemann-Pick

c.337T > C

disease type Cl’]

(p.Cys113Arg)

NM_000019.3(ACAT1):
120074146
ACAT1
[‘CAAG
[‘CAAGAAYAGTA
[‘Deficiency of

c.935T > C

AAYAG
GGTAAGGCCAGG’]
acetyl-CoA

(p.Ile312Thr)

TAGGT

acetyltransferase’]

AAGGC

CAGG’]

NM_017890.4(VPS13B):
120074155
VPS13B
[ ]
[ ]
[‘Cohen syndrome’]

c.8459T > C

(p.Ile2820Thr)

NM_017653.3(DYM):
120074165
DYM
[ ]
[ ]
[‘Smith McCort

c.1624T > C

dysplasia’]

(p.Cys542Arg)

NM_001089.2(ABCA3):
121909182
ABCA3
[ ]
[‘GCACYTGTGATC
[‘Surfactant

c.302T > C

AACATGCGAGG’]
metabolism

(p.Leu101Pro)

dysfunction,

pulmonary, 3’]

NM_001089.2(ABCA3):
121909183
ABCA3
[ ]
[ ]
[‘Surfactant

c.4658T > C

metabolism

(p.Leu1553Pro)

dysfunction,

pulmonary, 3’]

NM_001089.2(ABCA3):
121909185
ABCA3
[ ]
[ ]
[‘Surfactant

c.977T > C

metabolism

(p.Leu326Pro)

dysfunction,

pulmonary, 3’]

NM_000474.3(TWIST1):
121909189
TWIST1
[ ]
[ ]
[‘Saethre-Chotzen

c.392T > C

syndrome’]

(p.Leu131Pro)

NM_000503.5(EYA1):
121909200
EYA1
[ ]
[‘CACTCYCGCTCA
[‘Melnick-Fraser

c.1459T > C

TTCACTCCCGG’]
syndrome’]

(p.Ser487Pro)

NM_000358.2(TGFBI):
121909214
TGFBI
[ ]
[ ]
[‘Lattice corneal

c.1619T > C

dystrophy type 3A’]

(p.Phe540Ser)

NM_000426.3(LAMA2):
115650537
LAMA2
[‘TTGA
[‘TTGAYAGGGAG
[‘Merosin deficient

c.8282T > C

YAGGG
CAAGCAGTTCGG’,
congenital muscular

(p.Ile2761Thr)

AGCAA
‘TGAYAGGGAGCA
dystrophy’]

GCAGT
AGCAGTTCGGG’]

TCGG’,

‘TGAYA

GGGAG

CAAGC

AGTTC

GGG’]

NM_000314.6(PTEN):
121909226
PTEN
[ ]
[ ]
[‘Cowden syndrome

c.209T > C

1’, ‘Hereditary

(p.Leu70Pro)

cancer-predisposing

syndrome’]

NM_000314.6(PTEN):
121909230
PTEN
[ ]
[ ]
[‘Lhermitte-Duclos

c.335T > C

disease’]

(p.Leull2Pro)

NM_000314.6(PTEN):
121909240
PTEN
[ ]
[ ]
[‘Macrocephaly/autis

c.722T > C

m syndrome’]

(p.Phe241Ser)

NM_004970.2(IGFALS):
121909247
IGFALS
[ ]
[‘GGACYGTGGCT
[‘Acid-labile subunit

c.1618T > C

GCCCTCTCAAGG’]
deficiency’]

(p.Cys540Arg)

NM_005570.3(LMAN1):
121909253
LMAN1
[ ]
[AGAYGGCGGGA
[‘Combined

c.2T > C (p.Met1Thr)

TCCAGGCAAAGG’]
deficiency of factor

V and factor VIII,

1’]

NM_005055.4(RAPSN):
121909256
RAPSN
[ ]
[ ]
[‘Pena-Shokeir

c.416T > C

syndrome type I’]

(p.Phe139Ser)

NM_000391.3(TPP1):
755445790
TPP1
[‘TTTYT
[‘TTTYTTTTTTTTT
[‘Ceroid

c.887-10A > G

TTTTTT
TTTTTTGAGG’]
lipofuscinosis,

TTTTTT

neuronal, 2’, ‘not

TTGAG

provided’]

G’]

NM_006302.2(MOGS):
121909292
MOGS
[ ]
[ ]
[‘Congenital disorder

c.1954T > C

of glycosylation type

(p.Phe652Leu)

2B’]

NM_005379.3(MYO1A):
121909306
MYO1A
[ ]
[ ]
[‘Deafness,

c.2728T > C

autosomal dominant

(p.Ser910Pro)

48’]

NM_178151.2(DCX):
587783521
DCX
[ ]
[ ]
[‘Heterotopia’]

c.128T > C (p.Leu43Ser)

NM_001127221.1(CACNA1A):
121909326
CACNA1A
[ ]
[ ]
[‘Spinocerebellar

c.5126T > C

ataxia 6’, ‘Familial

(p.Ile1709Thr)

hemiplegic migraine

type 1’, ‘Episodic

ataxia type 2’]

NM_001451.2(FOXF1):
121909337
FOXF1
[‘TGAT
[‘TGATGYGAGGCT
[‘Alveolar capillary

c.1138T > C

GYGAG
GCCGCCGCAGG’]
dysplasia with

(p.Ter380Arg)

GCTGC

misalignment of

CGCCG

pulmonary veins’]

CAGG’]

NM_000163.4(GHR):
121909357
GHR
[ ]
[ ]
[‘Laron-type isolated

c.341T > C

somatotropin

(p.Phel 14Ser)

defect’]

NM_000163.4(GHR):
121909367
GHR
[ ]
[ ]
[‘Laron-type isolated

c.512T > C (p.Ile171Thr)

somatotropin

defect’]

NM_000339.2(SLC12A3):
121909385
SLC12A3
[ ]
[CAACCYGGCCCT
[‘Familial

c.1868T > C

CAGCTACTCGG’]
hypokalemia-

(p.Leu623Pro)

hypomagnesemia’]

NM_001174089.1(SLC4A11):
121909394
SLC4A11
[ ]
[ ]
[‘Corneal dystrophy

c.2480T > C

and perceptive

(p.Leu827Pro)

deafness’]

NM_001174089.1(SLC4A11):
121909395
SLC4A11
[ ]
[ ]
[‘Corneal dystrophy

c.589T > C

and perceptive

(p.Ser197Pro)

deafness’]

NM_000519.3(HBD):
34975911
HBD
[ ]
[ ]
[‘delta Thalassemia’]

c.-127T > C

NM_002427.3(MMP13):
121909497
MMP13
[ ]
[‘TTCTYCGGCTTA
[‘Spondyloepimetap

c.224T > C

GAGGTGACTGG’]
hyseal dysplasia,

(p.Phe75Ser)

Missouri type’]

NM_002427.3(MMP13):
121909498
MMP13
[ ]
[ ]
[ ]

c.221T > C

(p.Phe74Ser)

NM_002427.3(MMP13):
121909499
MMP13
[‘GTCA
[‘GTCAYGAAAAA
[ ]

c.272T > C

YGAAA
GCCAAGATGCGG’,

(p.Met91Thr)

AAGCC
‘TCAYGAAAAAGC

AAGAT
CAAGATGCGGGG]

GCGG’,

‘TCAYG

AAAAA

GCCAA

GATGC

GGG’]

NM_000751.2(CHRND):
121909506
CHRND
[ ]
[ ]
[‘Lethal multiple

c.283T > C

pterygium

(p.Phe95Leu)

syndrome’]

NM_000751.2(CHRND):
121909508
CHRND
[ ]
[‘AACCYCATCTCC
[‘MYASTHENIC

c.188T > C

CTGGTGAGAGG’]
SYNDROME,

(p.Leu63Pro)

CONGENITAL, 3B,

FAST-CHANNEL’]

NM_001100.3(ACTA1):
121909519
ACTA1
[ ]
[‘CGAGCYTCGCGT
[‘Nemaline

c.287T > C

GGCTCCCGAGG’]
myopathy 3’]

(p.Leu96Pro)

NM_001100.3(ACTA1):
121909530
ACTA1
[ ]
[ ]
[‘Congenital

c.668T > C

myopathy with fiber

(p.Leu223Pro)

type disproportion’]

NM_000488.3(SERPINC1):
121909565
SERPINC1
[ ]
[ ]
[‘Antithrombin III

c.1141T > C

deficiency’]

(p.Ser381Pro)

NM_000488.3(SERPINC1):
121909569
SERPINC1
[ ]
[ ]
[‘Antithrombin III

c.442T > C

deficiency’]

(p.Ser148Pro)

NM_000488.3(SERPINC1):
121909572
SERPINC1
[ ]
[‘TGGGTGYCCAAT
[‘Antithrombin III

c.667T > C

AAGACCGAAGG’]
deficiency’]

(p.Ser223Pro)

NM_000488.3(SERPINC1):
121909573
SERPINC1
[ ]
[ ]
[‘Antithrombin III

c.379T > C

deficiency’]

(p.Cys127Arg)

NM_023110.2(FGFR1):
121909633
FGFR1
[ ]
[ ]
[‘Interfrontal

c.899T > C

craniofaciosynostosi

(p.Ile300Thr)

s’]

NM_023110.2(FGFR1):
121909634
FGFR1
[ ]
[ ]
[‘Osteoglophonic

c.1141T > C

dysplasia’]

(p.Cys381Arg)

NM_182925.4(FLT4):
121909651
FLT4
[ ]
[ ]
[‘Hereditary

c.3131T > C

lymphedema type I’]

(p.Leu1044Pro)

NM_182925.4(FLT4):
121909655
FLT4
[ ]
[ ]
[‘Hereditary

c.3257T > C

lymphedema type I’]

(p.Ile1086Thr)

NM_000145.3(FSHR):
121909659
FSHR
[ ]
[ ]
[‘Ovarian dysgenesis

c.479T > C

l’]

(p.Ile160Thr)

NM_000145.3(FSHR):
121909664
FSHR
[ ]
[ ]
[‘Ovarian

c.1634T > C

hyperstimulation

(p.Ile545Thr)

syndrome’]

NM_000821.6(GGCX):
121909677
GGCX
[ ]
[‘TATGTYCTCCTA
[‘Pseudoxanthoma

c.896T > C

CGTCATGCTGG’]
elasticum-like

(p.Phe299Ser)

disorder with

multiple coagulation

factor deficiency’]

NM_001018077.1(NR3C1):
121909727
NR3C1
[ ]
[‘CTATTGCYTCCA
[‘Glucocorticoid

c.2209T > C

AACATTTTTGG’]
resistance,

(p.Phe737Leu)

generalized’]

NM_005271.3(GLUD1):
121909732
GLUD1
[ ]
[ ]
[‘Hyperinsulinism-

c.1501T > C

hyperammonemia

(p.Ser501Pro)

syndrome’]

NM_004614.4(TK2):
142291440
TK2
[ ]
[ ]
[‘Mitochondrial

c.278A > G (p.Asn93Ser)

DNA depletion

syndrome 2’]

NM_032977.3(CASP10):
121909776
CASP10
[ ]
[ ]
[‘Neoplasm of

c.440T > C

stomach’]

(p.Met147Thr)

NM_000250.1(MPO):
78950939
MPO
[‘TGCG
[‘GTGCGGYATTTG
[‘Myeloperoxidase

c.518A > G

GYATT
TCCTGCTCCGG’,
deficiency’]

(p.Tyr173Cys)

TGTCC
‘TGCGGYATTTGT

TGCTC
CCTGCTCCGGG’]

CGGG’]

NM_001139.2(ALOX12B):
199766569
ALOX12B
[ ]
[ ]
[‘Autosomal

c.1562A > G

recessive congenital

(p.Tyr521Cys)

ichthyosis 2’]

NM_022041.3(GAN):
119485091
GAN
[‘AAGA
[‘AAGAAAAYCTA
[‘Giant axonal

c.1268T > C

AAAYC
CGCCATGGGTGG’,
neuropathy’]

(p.Ile423Thr)

TACGC
‘AAAAYCTACGCC

CATGG
ATGGGTGGAGG’]

GTGG’]

NM_014009.3(FOXP3):
122467173
FOXP3
[‘GACA
[‘GACAGAGYTCCT
[‘Insulin-dependent

c.970T > C

GAGYT
CCACAACATGG’]
diabetes mellitus

(p.Phe324Leu)

CCTCC

secretory diarrhea

ACAAC

syndrome’]

ATGG’]

NM_014009.3(FOXP3):
122467175
FOXP3
[ ]
[ ]
[‘Insulin-dependent

c.1099T > C

diabetes mellitus

(p.Phe367Leu)

secretory diarrhea

syndrome’]

NM_004239.3(TRIP11):
139539448
TRIP11
[ ]
[ ]
[‘Achondrogenesis,

c.2102A > G

type IA’]

(p.Asn701Ser)

NM_001104.3(ACTN3):
1815739
ACTN3
[ ]
[ ]
[‘Sprinting

c.1729C > T

performance’, ‘Actn3

(p.Arg577Ter)

deficiency’]

NM_002693.2(POLG):
368587966
POLG
[ ]
[ ]
[‘not provided’]

c.2636A > G

(p.Gln879Arg)

NM_000552.3(VWF):
61748497
VWF
[ ]
[ ]
[‘von Willebrand

c.3178T > C

disease type 2N’,

(p.Cys1060Arg)

‘not provided’]

NM_000552.3(VWF):
61748511
VWF
[ ]
[ ]
[‘von Willebrand

c.3445T > C

disease type 1’, ‘not

(p.Cys1149Arg)

provided’]

NM_000184.2(HBG2):
34878913
HBG2
[‘CAGA
[‘CAGAGGTYCTTT
[‘Cyanosis, transient

c.125T > C

GGTYC
GACAGCTTTGG’]
neonatal’]

(p.Phe42Ser)

TTTGA

CAGCT

TTGG’]

NM_000371.3(TTR):
138065384
TTR
[ ]
[ ]
[‘Cardiomyopathy’,

c.190T > C (p.Phe64Leu)

‘not specified’]

NM_000402.4(G6PD):
76723693
G6PD
[ ]
[ ]
[‘Glucose 6

c.1058T > C

phosphate

(p.Leu353Pro)

dehydrogenase

deficiency’, ‘Anemia,

nonspherocytic

hemolytic, due to

G6PD deficiency’,

‘not provided’]

NM_177405.2(CECR1):
775440641
CECR1
[ ]
[ ]
[‘Idiopathic livedo

c.355A > G

reticularis with

(p.Thr119Ala)

systemic

involvement’]

NM_000218.2(KCNQ1):
199472685
KCNQ1

[‘Congenital long

c.401T > C

QT syndrome’,

(p.Leu134Pro)

‘Cardiac arrhythmia’]

NM_000218.2(KCNQ1):
199472705
KCNQ1

[‘Atrial fibrillation,

c.625T > C

familial, 3’, ‘Atrial

(p.Ser209Pro)

fibrillation’]

NM_000218.2(KCNQ1):
199472716
KCNQ1

[‘Congenital long

c.752T > C

QT syndrome’,

(p.Leu251Pro)

‘Cardiac arrhythmia’,

‘Long QT syndrome,

LQT1 subtype’]

NM_000218.2(KCNQ1):
199472729
KCNQ1

[‘Congenital long

c.824T > C

QT syndrome’,

(p.Phe275Ser)

‘Long QT syndrome,

LQT1 subtype’]

NM_000218.2(KCNQ1):
199472731
KCNQ1

[‘Congenital long

c.832T > C

QT syndrome’]

(p.Tyr278His)

NM_000218.2(KCNQ1):
199472733
KCNQ1

[‘Congenital long

c.845T > C

QT syndrome’]

(p.Leu282Pro)

NM_000257.3(MYH7):
730880849
MYH7
[ ]
[ ]
[‘Cardiomyopathy’]

c.730T > C

(p.Phe244Leu)

NM_000218.2(KCNQ1):
199472740
KCNQ1

[‘Congenital long

c.908T > C

QT syndrome’]

(p.Leu303Pro)

NM_000218.2(KCNQ1):
199472741
KCNQ1

[‘Congenital long

c.913T > C

QT syndrome’,

(p.Trp305Arg)

‘Long QT syndrome,

LQT1 subtype’]

NM_000218.2(KCNQ1):
199472764
KCNQ1

[‘Congenital long

c.1045T > C

QT syndrome’,

(p.Ser349Pro)

‘Long QT syndrome,

LQT1 subtype’]

NM_000218.2(KCNQ1):
199472766
KCNQ1

[‘Congenital long

c.1117T > C

QT syndrome’]

(p.Ser373Pro)

NM_000218.2(KCNQ1):
199472772
KCNQ1

[‘Congenital long

c.1165T > C

QT syndrome’]

(p.Ser389Pro)

NM_000218.2(KCNQ1):
199472774
KCNQ1

[‘Congenital long

c.1174T > C

QT syndrome’]

(p.Trp392Arg)

NM_000218.2(KCNQ1):
199472786
KCNQ1

[‘Congenital long

c.1541T > C

QT syndrome’,

(p.Ile514Thr)

‘Long QT syndrome,

LQT1 subtype’]

NM_000218.2(KCNQ1):
199472803
KCNQ1

[‘Congenital long

c.1696T > C

QT syndrome’]

(p.Ser566Pro)

NM_000218.2(KCNQ1):
199472818
—

[‘Congenital long

c.1805T > C

QT syndrome’]

(p.Leu602Pro)

NM_000218.2(KCNQ1):
199472823
KCNQ1

[‘Congenital long

c.608T > C

QT syndrome’,

(p.Leu203Pro)

‘Cardiac arrhythmia’]

NM_000238.3(KCNH2):
199472826
KCNH2

[‘Congenital long

c.65T > C

QT syndrome’]

(p.Phe22Ser)

NM_000238.3(KCNH2):
199472831
KCNH2

[‘Congenital long

c.86T > C

QT syndrome’]

(p.Phe29Ser)

NM_000238.3(KCNH2):
199472832
KCNH2

[‘Congenital long

c.89T > C

QT syndrome’]

(p.Ile30Thr)

NM_000238.3(KCNH2):
199472843
KCNH2

[‘Congenital long

c.160T > C

QT syndrome’]

(p.Tyr54His)

NM_001165963.1(SCN1A):
796052961
SCN1A
[ ]
[ ]
[‘not provided’]

c.662T > C

(p.Leu221Pro)

NM_000238.3(KCNH2):
199472853
KCNH2

[‘Congenital long

c.287T > C

QT syndrome’]

(p.Ile96Thr)

NM_000238.3(KCNH2):
199472859
KCNH2

[‘Congenital long

c.322T > C

QT syndrome’]

(p.Cys108Arg)

NM_000238.3(KCNH2):
199472881
KCNH2

[‘Congenital long

c.872T > C

QT syndrome’]

(p.Met291Thr)

NM_000238.3(KCNH2):
199472893
KCNH2

[‘Congenital long

c.1238T > C

QT syndrome’]

(p.Leu413Pro)

NM_000238.3(KCNH2):
199472898
KCNH2

[‘Congenital long

c.1279T > C

QT syndrome’]

(p.Tyr427His)

NM_000238.3(KCNH2):
199472904
KCNH2

[‘Congenital long

c.1387T > C

QT syndrome’]

(p.Phe463Leu)

NM_000238.3(KCNH2):
199472918
KCNH2
[ ]
[ ]
[‘Congenital long

c.1655T > C

QT syndrome’,

(p.Leu552Ser)

‘Cardiac arrhythmia’]

NM_000061.2(BTK):
128622212
BTK
[ ]
[ ]
[‘X-linked

c.1955T > C

agammaglobulinemi

(p.Leu652Pro)

a’]

NM_000238.3(KCNH2):
199472924
KCNH2

[‘Congenital long

c.1691T > C

QT syndrome’]

(p.Leu564Pro)

NM_000238.3(KCNH2):
199472927
KCNH2

[‘Congenital long

c.1702T > C

QT syndrome’]

(p.Trp568Arg)

NM_000138.4(FBN1):
794728333
FBN1
[ ]
[ ]
[‘Thoracic aortic

c.5726T > C

aneurysms and

(p.Ile1909Thr)

aortic dissections’]

NM_015884.3(MBTPS2):
122468179
MBTPS2
[ ]
[ ]
[‘IFAP syndrome

c.1424T > C

with or without

(p.Phe475Ser)

BRESHECK

syndrome’]

NM_000238.3(KCNH2):
199472980
KCNH2

[‘Congenital long

c.1985T > C

QT syndrome’]

(p.Ile662Thr)

NM_000238.3(KCNH2):
199472981
KCNH2

[‘Congenital long

c.2033T > C

QT syndrome’]

(p.Leu678Pro)

NM_000238.3(KCNH2):
199472983
KCNH2

[‘Congenital long

c.2078T > C

QT syndrome’,

(p.Leu693Pro)

‘Cardiac arrhythmia’]

NM_000238.3(KCNH2):
199472994
KCNH2

[‘Congenital long

c.2309T > C

QT syndrome’]

(p.Val770Ala)

NM_000238.3(KCNH2):
199473026
KCNH2

[‘Congenital long

c.3146T > C

QT syndrome’]

(p.Leu1049Pro)

NM_000335.4(SCN5A):
199473052
SCN5A

[‘Brugada

c.278T > C

syndrome’]

(p.Phe93Ser)

NM_000335.4(SCN5A):
199473066
SCN5A

[‘Brugada

c.544T > C

syndrome’]

(p.Cys182Arg)

NM_000335.4(SCN5A):
199473073
SCN5A

[‘Cardiac conduction

c.689T > C

defect, nonspecific’]

(p.Ile230Thr)

NM_000335.4(SCN5A):
199473103
SCN5A

[‘Brugada

c.1187T > C

syndrome’]

(p.Val396Ala)

NM_000335.4(SCN5A):
199473105
SCN5A

[‘Congenital long

c.1190T > C

QT syndrome’]

(p.Ile397Thr)

NM_000335.4(SCN5A):
199473141
SCN5A

[‘Congenital long

c.2018T > C

QT syndrome’]

(p.Leu673Pro)

NM_000335.4(SCN5A):
199473164
SCN5A

[‘Brugada

c.2516T > C

syndrome’]

(p.Leu839Pro)

NM_000335.4(SCN5A):
199473178
SCN5A

[‘Brugada

c.2783T > C

syndrome’]

(p.Leu928Pro)

NM_000335.4(SCN5A):
199473179
SCN5A

[‘Brugada

c.2804T > C

syndrome’]

(p.Leu935Pro)

NM_198056.2(SCN5A):
199473183
SCN5A
[ ]
[ ]
[‘Congenital long

c.3010T > C

QT syndrome’, ‘not

(p.Cys1004Arg)

specified’, ‘not

provided’]

NM_000335.4(SCN5A):
199473205
SCN5A
[ ]
[ ]
[‘Brugada

c.3679T > C

syndrome’]

(p.Tyr1227His)

NM_000335.4(SCN5A):
199473210
SCN5A

[‘Brugada

c.3713T > C

syndrome’]

(p.Leu1238Pro)

NM_000492.3(CFTR):
139573311
CFTR
[ ]
[‘TTCACYTCTAAT
[‘Cystic fibrosis’]

c.1400T > C

GGTGATTATGG’,

(p.Leu467Pro)

‘TCACYTCTAATG

GTGATTATGGG’]

NM_000335.4(SCN5A):
199473219
SCN5A

[‘Brugada

c.3929T > C

syndrome’]

(p.Leu1310Pro)

NM_000335.4(SCN5A):
199473228
SCN5A

[‘Brugada

c.4027T > C

syndrome’]

(p.Phe1343Leu)

NM_000335.4(SCN5A):
199473229
SCN5A

[‘Brugada

c.4028T > C

syndrome’]

(p.Phe1343Ser)

NM_000335.4(SCN5A):
199473231
SCN5A

[‘Brugada

c.4034T > C

syndrome’]

(p.Leu1345Pro)

NM_000335.4(SCN5A):
199473251
SCN5A

[‘Brugada

c.4340T > C

syndrome’]

(p.Ile1447Thr)

NM_198056.2(SCN5A):
199473263
SCN5A

[‘Congenital long

c.4493T > C

QT syndrome’, ‘not

(p.Met1498Thr)

provided’]

NM_000335.4(SCN5A):
199473275
SCN5A

[‘Brugada

c.4742T > C

syndrome’]

(p.Leu1581Pro)

NM_000335.4(SCN5A):
199473277
SCN5A

[‘Congenital long

c.4778T > C

QT syndrome’]

(p.Phe1593Ser)

NM_000335.4(SCN5A):
199473302
SCN5A

[‘Brugada

c.5179T > C

syndrome’]

(p.Cys1727Arg)

NM_000219.5(KCNE1):
199473355
KCNE1

[‘Congenital long

c.158T > C

QT syndrome’]

(p.Phe53Ser)

NM_000219.5(KCNE1):
199473361
KCNE1

[‘Congenital long

c.259T > C

QT syndrome’]

(p.Trp87Arg)

NM_000891.2(KCNJ2):
199473374
KCNJ2

[‘Ventricular

c.301T > C

tachycardia’]

(p.Cys101Arg)

NM_000218.2(KCNQ1):
199473399
KCNQ1
[ ]
[ ]
[‘Congenital long

c.560T > C

QT syndrome’,

(p.Leu187Pro)

‘Cardiac arrhythmia’,

‘Long QT syndrome,

LQT1 subtype’]

NM_000218.2(KCNQ1):
199473401
KCNQ1

[‘Congenital long

c.572T > C

QT syndrome’,

(p.Leu191Pro)

‘Long QT syndrome,

LQT1 subtype’]

NM_000218.2(KCNQ1):
199473402
KCNQ1

[‘Congenital long

c.1052T > C

QT syndrome’,

(p.Phe351Ser)

‘Long QT syndrome,

LQT1 subtype’]

NM_000218.2(KCNQ1):
199473403
KCNQ1

[‘Congenital long

c.1058T > C

QT syndrome’,

(p.Leu353Pro)

‘Cardiac arrhythmia’,

‘Long QT syndrome,

LQT1 subtype’]

NM_000238.3(KCNH2):
199473417
KCNH2

[‘Congenital long

c.202T > C

QT syndrome’,

(p.Phe68Leu)

‘Cardiac arrhythmia’]

NM_000218.2(KCNQ1):
199473448
KCNQ1

[‘Congenital long

c.341T > C

QT syndrome’,

(p.Leull4Pro)

‘Long QT syndrome,

LQT1

subtype’]

NM_000218.2(KCNQ1):
199473458
KCNQ1

[‘Congenital long

c.716T > C

QT syndrome’,

(p.Leu239Pro)

‘Long QT syndrome,

LQT1

subtype’]

NM_000218.2(KCNQ1):
199473459
KCNQ1

[‘Congenital long

c.742T > C

QT syndrome’,

(p.Trp248Arg)

‘Cardiac arrhythmia’]

NM_000218.2(KCNQ1):
199473460
KCNQ1

[‘Long QT

c.797T > C

syndrome’,

(p.Leu266Pro)

‘Congenital long QT

syndrome’, ‘Cardiac

arrhythmia’]

NM_000218.2(KCNQ1):
199473461
KCNQ1

[‘Congenital long

c.829T > C

QT syndrome’]

(p.Ser277Pro)

NM_000218.2(KCNQ1):
199473466
KCNQ1

[‘Congenital long

c.910T > C

QT syndrome’,

(p.Trp304Arg)

‘Long QT syndrome,

LQT1 subtype’]

NM_000218.2(KCNQ1):
199473478
KCNQ1

[‘Congenital long

c.1550T > C

QT syndrome’]

(p.Ile517Thr)

NM_000218.2(KCNQ1):
199473481
KCNQ1

[‘Congenital long

c.1661T > C

QT syndrome’,

(p.Val554Ala)

‘Long QT syndrome,

LQT1 subtype’]

NM_000218.2(KCNQ1):
199473485
KCNQ1

[‘Congenital long

c.2T > C (p.Met1Thr)

QT syndrome’,

‘KCNQ1-related

Jervell and Lange-

Nielsen syndrome’]

NM_000238.3(KCNH2):
199473495
KCNH2

[‘Congenital long

c.260T > C

QT syndrome’]

(p.Leu87Pro)

NM_000238.3(KCNH2):
199473519
KCNH2

[‘Congenital long

c.1700T > C

QT syndrome’]

(p.Ile567Thr)

NM_000238.3(KCNH2):
199473520
KCNH2

[‘Congenital long

c.1705T > C

QT syndrome’]

(p.Tyr569His)

NM_000238.3(KCNH2):
199473523
KCNH2

[‘Congenital long

c.1816T > C

QT syndrome’]

(p.Ser606Pro)

NM_000238.3(KCNH2):
199473526
KCNH2

[‘Congenital long

c.1889T > C

QT syndrome’]

(p.Val630Ala)

NM_000238.3(KCNH2):
199473530
KCNH2

[‘Congenital long

c.1945T > C

QT syndrome’]

(p.Ser649Pro)

NM_000238.3(KCNH2):
199473537
KCNH2

[‘Congenital long

c.2452T > C

QT syndrome’]

(p.Ser818Pro)

NM_000238.3(KCNH2):
199473539
KCNH2

[‘Congenital long

c.2573T > C

QT syndrome’]

(p.Ile858Thr)

NM_000335.4(SCN5A):
199473557
SCN5A

[‘Brugada

c.407T > C

syndrome’]

(p.Leu136Pro)

NM_020166.4(MCCC1):
119103215
MCCC1
[ ]
[ ]
[‘3 Methylcrotonyl-

c.1310T > C

CoA carboxylase 1

(p.Leu437Pro)

deficiency’]

NM_198056.2(SCN5A):
199473564
SCN5A

[‘Brugada

c.944T > C

syndrome’, ‘not

(p.Leu315Pro)

provided’]

NM_002972.3(SBF1):
587776986
SBF1
[ ]
[ ]
[‘Charcot-Marie-

c.1249A > G

Tooth disease, type

(p.Met417Val)

4B3’]

NM_000335.4(SCN5A):
199473586
SCN5A

[‘Brugada

c.2551T > C

syndrome’]

(p.Phe851Leu)

NM_000335.4(SCN5A):
199473588
SCN5A

[‘Brugada

c.2743T > C

syndrome’]

(p.Cys915Arg)

NM_000335.4(SCN5A):
199473607
SCN5A

[‘Brugada

c.4046T > C

syndrome’]

(p.Ile1349Thr)

NM_000335.4(SCN5A):
199473615
SCN5A

[‘Sudden infant

c.4453T > C

death syndrome’]

(p.Phe1485Leu)

NM_000335.4(SCN5A):
199473627
SCN5A

[‘Sudden infant

c.5111T > C

death syndrome’]

(p.Phe1704Ser)

NM_000891.2(KCNJ2):
199473656
KCNJ2

[‘Congenital long

c.650T > C

QT syndrome’]

(p.Leu217Pro)

NM_000218.2(KCNQ1):
199473661
KCNQ1
[‘AGCA
[‘CAGCAAGBACG
[‘Congenital long

c.550T > C

AGBAC
TGGGCCTCTGGG’,
QT syndrome’,

(p.Tyr184His)

GTGGG
‘AGCAAGBACGTG
‘Cardiac arrhythmia’]

CCTCT
GGCCTCTGGGG’,

GGGG’]
‘GCAAGBACGTGG

GCCTCTGGGGG’]

NM_000238.3(KCNH2):
199473665
KCNH2

[‘Congenital long

c.206T > C

QT syndrome’]

(p.Leu69Pro)

NM_001130823.1(DNMT1):
199473692
DNMT1

[‘Hereditary sensory

c.1531T > C

neuropathy type IE’]

(p.Tyr511His)

NM_031226.2(CYP19Al):
786205107
—
[‘CTGTG
[‘CTGTGYAAGTAA
[‘Aromatase

c.743 + 2T > C

YAAGT
TACAACTTTGG’]
deficiency’]

AATAC

AACTT

TGG’]

NM_016373.3(WW0X):
119487098
WWOX
[ ]
[ ]
[ ]

c.872T > C

(p.Leu291Pro)

NM_001287223.1(SCN11A):
606231280
SCN11A
[‘TTCAY
[‘CTTCAYTGTGGT
[‘Episodic pain

c.1142T > C

TGTGG
CATTTTCCTGG’,
syndrome, familial,

(p.Ile381Thr)

TCATTT
‘TTCAYTGTGGTC
3’]

TCCTG
ATTTTCCTGGG’]

GG’]

NM_003640.3(IKBKAP):
111033171
IKBKAP
[ ]
[ ]
[‘Familial

c.2204 + 6T > C

dysautonomia’, ‘not

provided’]

NM_000238.3(KCNH2):
794728368
KCNH2
[ ]
[ ]
[‘Cardiac

c.1282T > C

arrhythmia’]

(p.Ser428Pro)

NM_000441.1(SLC26A4):
111033254
SLC26A4
[ ]
[ ]
[‘Pendred syndrome’,

c.1588T > C

‘Enlarged vestibular

(p.Tyr530His)

aqueduct syndrome’]

NM_206933.2(USH2A):
111033264
USH2A
[ ]
[ ]
[‘Usher syndrome,

c.10561T > C

type 2A’]

(p.Trp3521Arg)

NM_206933.2(USH2A):
111033273
USH2A
[‘ATAT
[‘ATATAGAYGCCT
[‘Usher syndrome,

c.1606T > C

AGAYG
CTGCTCCCAGG’]
type 2A’]

(p.Cys536Arg)

CCTCT

GCTCC

CAGG’]

NM_001363.4(DKC1):
121912300
DKC1
[ ]
[ ]
[‘Dyskeratosis

c.1049T > C

congenita X-linked’]

(p.Met350Thr)

NM_000274.3(OAT):
121965054
OAT
[ ]
[ ]
[Ornithine

c.1180T > C

aminotransferase

(p.Cys394Arg)

deficiency’]

NM_001302946.1(TRNT1):
606231289
TRNT1
[‘ACTTY
[‘ACTTYATTTGAC
[‘Sideroblastic

c.497T > C

ATTTG
TACTTTAATGG’]
anemia with B-cell

(p.Leu166Ser)

ACTAC

immunodeficiency,

TTTAA

periodic fevers, and

TGG’]

developmental

delay’]

NM_000454.4(SOD1):
121912441
SOD1
[ ]
[‘CATCAYTGGCCG
[‘Amyotrophic

c.341T > C

CACACTGGTGG’]
lateral sclerosis type

(p.Ile114Thr)

l’]

NM_000454.4(SOD1):
121912446
SOD1
[ ]
[‘CGTTYGGCTTGT
[‘Amyotrophic

c.434T > C

GGTGTAATTGG’,
lateral sclerosis type

(p.Leu145Ser)

‘GTTYGGCTTGTG
l’]

GTGTAATTGGG’]

NM_000454.4(SOD1):
121912449
SOD1
[ ]
[ ]
[‘Amyotrophic

c.455T > C

lateral sclerosis type

(p.Ile152Thr)

l’]

NM_000213.3(ITGB4):
121912461
ITGB4
[ ]
[ ]
[‘Epidermolysis

c.467T > C

bullosa with pyloric

(p.Leu156Pro)

atresia’]

NM_000213.3(ITGB4):
121912463
ITGB4
[ ]
[‘GGCCAGYGTGT
[‘Epidermolysis

c.1684T > C

GTGTGAGCCTGG’]
bullosa with pyloric

(p.Cys562Arg)

atresia’]

NM_000213.3(ITGB4):
121912465
ITGB4
[ ]
[ ]
[‘Epidermolysis

c.112T > C

bullosa with pyloric

(p.Cys38Arg)

atresia’]

NM_002198.2(IRF1):
121912470
IRF1
[ ]
[ ]
[‘Non-small cell lung

c.31T > C (p.TrpllArg)

cancer’]

NM_000424.3(KRT5):
121912474
KRT5
[‘TCAA
[‘TCAAGTGYGTCC
[‘Epidermolysis

c.20T > C (p.Val7Ala)

GTGYG
TTCCGGAGCGG’,
bullosa simplex,

TCCTTC
‘CAAGTGYGTCCT
Koebner type’]

CGGAG
TCCGGAGCGGG’,

CGG’,
‘AAGTGYGTCCTT

‘CAAGT
CCGGAGCGGGG’,

GYGTC
‘AGTGYGTCCTTC

CTTCC
CGGAGCGGGGG’]

GGAGC

GGG’,

‘AAGTG

YGTCC

TTCCG

GAGCG

GGG’]

NM_002292.3(LAMB2):
121912492
LAMB2
[ ]
[CCTCAACYGCGA
[‘Nephrotic

c.961T > C

GCAGTGTCAGG’]
syndrome, type 5,

(p.Cys321Arg)

with or without

ocular

abnormalities’]

NM_170707.3(LMNA):
121912495
LMNA
[‘TCTYG
[‘TCTYGGAGGGC
[‘Congenital

c.1139T > C

GAGGG
GAGGAGGAGAGG’]
muscular dystrophy,

(p.Leu380Ser)

CGAGG

LMNA-related’, ‘not

AGGAG

provided’]

AGG’]

NM_001399.4(EDA):
397516659
EDA
[ ]
[‘GGCCAYGGGCT
[‘Hypohidrotic X-

c.2T > C (p.Met1Thr)

ACCCGGAGGTGG’]
linked ectodermal

dysplasia’]

NM_000493.3(C0L10Al):
111033549
—
[ ]
[ ]
[‘Metaphyseal

c.1951T > C

chondrodysplasia,

(p.Trp651Arg)

Schmid type’]

NM_000233.3(LHCGR):
121912526
—
[ ]
[ ]
[‘Gonadotropin-

c.1193T > C

independent familial

(p.Met398Thr)

sexual precocity’]

NM_000233.3(LHCGR):
121912527
—
[ ]
[ ]
[‘Leydig cell

c.391T > C

hypoplasia, partial’]

(p.Cys131Arg)

NM_000493.3(COL10Al):
111033555
—
[ ]
[ ]
[‘Metaphyseal

c.1798T > C

chondrodysplasia,

(p.Ser600Pro)

Schmid type’]

NM_000233.3(LHCGR):
121912533
—
[ ]
[ ]
[‘Gonadotropin-

c.1103T > C

independent familial

(p.Leu368Pro)

sexual precocity’]

NM_000233.3(LHCGR):
121912537
—
[ ]
[ ]
[‘Leydig cell

c.1627T > C

agenesis’]

(p.Cys543Arg)

NM_000233.3(LHCGR):
121912538
—
[ ]
[ ]
[‘Leydig cell

c.1505T > C

agenesis’]

(p.Leu502Pro)

NM_000901.4(NR3C2):
121912563
NR3C2
[ ]
[ ]
[‘Pseudohypoaldoste

c.2771T > C

ronism type 1

(p.Leu924Pro)

autosomal

dominant’]

NM_021044.2(DHH):
111033589
DHH
[ ]
[‘GTTGCYGGCGCG
[‘46,XY gonadal

c.485T > C

CCTCGCAGTGG’]
dysgenesis,

(p.Leu162Pro)

complete, dhh-

related’]

NM_000901.4(NR3C2):
121912567
NR3C2
[ ]
[ ]
[‘Pseudohypoaldoste

c.2936T > C

ronism type 1

(p.Leu979Pro)

autosomal

dominant’]

NM_000517.4(HBA2):
111033603
HBA2
[ ]
[ ]
[‘alpha Thalassemia’]

c.2T > C (p.Met1Thr)

NM_000762.5(CYP2A6):
111033610
—
[ ]
[ ]
[‘Tegafur response’]

c.670T > C

(p.Ser224Pro)

NM_000660.5(TGFB1):
111033611
TGFB1
[ ]
[ ]
[‘Diaphyseal

c.241T > C

dysplasia’]

(p.Tyr81His)

NM_001173464.1(KIF21A):
121912588
KIF21A
[ ]
[ ]
[‘Fibrosis of

c.1067T > C

extraocular muscles,

(p.Met356Thr)

congenital, 1’]

NM_000206.2(IL2RG):
111033622
IL2RG
[ ]
[‘TGGCYGTCAGTT
[‘X-linked severe

c.343T > C

GCAAAAAAAGG’]
combined

(p.Cys115Arg)

immunodeficiency’]

NM_001041.3(SI):
121912613
SI
[ ]
[‘ATGCYGGAGTTC
[‘Sucrase-isomaltase

c.1859T > C (p.Leu620Pro)

AGTTTGTTTGG’]
deficiency’]

NM_016180.4(SLC45A2):
121912619
SLC45A2
[ ]
[‘GAGTTTCYCATC
[‘Oculocutaneous

c.1082T > C

TACGAAAGAGG’]
albinism type 4’, ‘not

(p.Leu361Pro)

provided’]

NM_000552.3(VWF):
61750581
VWF
[ ]
[‘CTGCCYCTGATG
[‘von Willebrand

c.4837T > C

AGATCAAGAGG’]
disease, type 2a’, ‘not

(p.Ser1613Pro)

provided’]

NM_000552.3(VWF):
61750584
VWF
[ ]
[ ]
[‘von Willebrand

c.4883T > C

disease, type 2a’, ‘not

(p.Ile1628Thr)

provided’]

NM_000180.3(GUCY2D):
61749755
GUCY2D
[ ]
[ ]
[‘Leber congenital

c.1694T > C

amaurosis 1’, ‘not

(p.Phe565Ser)

provided’]

NM_003235.4(TG):
121912647
TG
[ ]
[ ]
[‘Iodotyrosyl

c.3733T > C

coupling defect’]

(p.Cys1245Arg)

NM_000546.5(TP53):
121912653
TP53
[ ]
[‘CATCCYCACCAT
[‘Li-Fraumeni

c.755T > C

CATCACACTGG’]
syndrome 1’]

(p.Leu252Pro)

NM_000155.3(GALT):
111033679
GALT
[ ]
[ ]
[‘Deficiency of

c.350T > C

UDPglucose-

(p.Phel 17Ser)

hexose- 1-phosphate

uridylyltransferase’]

NM_000155.3(GALT):
111033680
GALT
[ ]
[ ]
[‘Deficiency of

c.374T > C

UDPglucose-

(p.Val125Ala)

hexose- 1-phosphate

uridylyltransferase’]

NM_000155.3(GALT):
111033683
GALT
[ ]
[‘AGGTCAYGTGCT
[‘Deficiency of

c.386T > C

TCCACCCCTGG’]
UDPglucose-

(p.Met129Thr)

hexose- 1-phosphate

uridylyltransferase’]

NM_000546.5(TP53):
121912662
TP53
[ ]
[ ]
[‘Li-Fraumeni

c.1031T > C

syndrome 1’]

(p.Leu344Pro)

NM_000155.3(GALT):
111033687
GALT
[ ]
[ ]
[‘Deficiency of

c.416T > C

UDPglucose-

(p.Leu139Pro)

hexose- 1-phosphate

uridylyltransferase’]

NM_000155.3(GALT):
111033701
GALT
[ ]
[ ]
[‘Deficiency of

c.452T > C

UDPglucose-

(p.Val151Ala)

hexose- 1-phosphate

uridylyltransferase’]

NM_000155.3(GALT):
111033708
GALT
[‘CCCTY
[‘CCCTYGGGTGCA
[‘Deficiency of

c.499T > C

GGGTG
GGTTTGTGAGG’]
UDPglucose-

(p.Trp167Arg)

CAGGT

hexose-1-phosphate

TTGTG

uridylyltransferase’]

AGG’]

NM_000155.3(GALT):
111033710
GALT
[ ]
[ ]
[‘Deficiency of

c.507 + 2T > C

UDPglucose-

hexose- 1-phosphate

uridylyltransferase’]

NM_000155.3(GALT):
111033715
GALT
[ ]
[ ]
[‘Deficiency of

c.512T > C

UDPglucose-

(p.Phe171Ser)

hexose-1-phosphate

uridylyltransferase’]

NM_000341.3(SLC3A1):
121912693
—
[ ]
[ ]
[‘Cystinuria’]

c.2033T > C

(p.Leu678Pro)

NM_000540.2(RYR1):
147012990
RYR1
[ ]
[ ]
[‘Minicore myopathy

c.9242T > C

with external

(p.Met3081Thr)

ophthalmoplegia’]

NM_000155.3(GALT):
111033728
GALT
[ ]
[ ]
[‘Deficiency of

c.584T > C

UDPglucose-

(p.Leu195Pro)

hexose- 1-phosphate

uridylyltransferase’]

NM_000155.3(GALT):
111033741
GALT
[ ]
[ ]
[‘Deficiency of

c.650T > C

UDPglucose-

(p.Leu217Pro)

hexose- 1-phosphate

uridylyltransferase’]

NM_000155.3(GALT):
111033748
GALT
[ ]
[ ]
[‘Deficiency of

c.687 + 2T > C

UDPglucose-

hexose- 1-phosphate

uridylyltransferase’]

NM_000039.1(APOA1):
121912726
—
[ ]
[ ]
[‘Familial visceral

c.220T > C

amyloidosis,

(p.Trp74Arg)

Ostertag type’]

NM_000155.3(GALT):
111033752
GALT
[ ]
[‘CAGGAGCYACT
[‘Deficiency of

c.677T > C

CAGGAAGGTGGG’]
UDPglucose-

(p.Leu226Pro)

hexose-1-phosphate

uridylyltransferase’]

NM_000039.1(APOA1):
121912729
APOA1
[ ]
[‘GCGCTYGGCCGC
[‘Familial visceral

c.593T > C

GCGCCTTGAGG’]
amyloidosis,

(p.Leu198Ser)

Ostertag type’]

NM_000155.3(GALT):
111033757
GALT
[ ]
[ ]
[‘Deficiency of

c.745T > C

UDPglucose-

(p.Trp249Arg)

hexose-1-phosphate

uridylyltransferase’]

NM_001681.3(ATP2A2):
121912734
ATP2A2
[ ]
[ ]
[‘Keratosis

c.1678T > C

follicularis’]

(p.Cys560Arg)

NM_000041.3(APOE):
769452
APOE
[ ]
[‘AACYGGCACTG
[ ]

c.137T > C

GGTCGCTTTTGG’]

(p.Leu46Pro)

NM_000342.3(SLC4A1):
121912753
SLC4A1
[ ]
[ ]
[‘Renal tubular

c.2317T > C

acidosis, distal, with

(p.Ser773Pro)

normal red cell

morphology’]

NM_003002.3(SDHD):
80338846
SDHD
[ ]
[ ]
[‘Hereditary

c.284T > C

Paraganglioma-

(p.Leu95Pro)

Pheochromocytoma

Syndromes’]

NM_016124.4(RHD):
121912762
RHD
[ ]
[‘ACACYGTTCAGG
[ ]

c.329T > C

TATTGGGATGG’]

(p.Leu110Pro)

NM_003002.3(SDHD):
80338847
SDHD
[ ]
[ ]
[‘Hereditary

c.416T > C

Paraganglioma-

(p.Leu139Pro)

Pheochromocytoma

Syndromes’,

‘Paragangliomas 1’]

NM_001822.5(CHN1):
121912794
CHN1
[ ]
[ ]
[‘Duane syndrome

c.427T > C

type 2’]

(p.Tyr143His)

NM_000155.3(GALT):
111033824
GALT
[ ]
[CGCCYGACCAC
[‘Deficiency of

c.1138T > C

GCCGACCACAGG’,
UDPglucose-

(p.Ter380Arg)

‘GCCYGACCACGC
hexose-1-phosphate

CGACCACAGGG’]
uridylyltransferase’]

m.3271T > C
199474658
MT-TL1
[ ]
[ ]
[‘Juvenile myopathy,

encephalopathy,

lactic acidosis AND

stroke’]

NM_000155.3(GALT):
111033832
GALT
[ ]
[‘TCCYGCGCTCTG
[‘Deficiency of

c.980T > C

CCACTGTCCGG’]
UDPglucose-

(p.Leu327Pro)

hexose-1-phosphate

uridylyltransferase’]

m.3290T > C
199474665
MT-TL1
[ ]
[ ]
[‘Sudden infant

death syndrome’]

NM_020549.4(CHAT):
121912820
CHAT
[ ]
[ ]
[‘Familial infantile

c.629T > C

myasthenia’]

(p.Leu210Pro)

NM_020549.4(CHAT):
121912823
CHAT
[ ]
[ ]
[‘Familial infantile

c.1007T > C

myasthenia’]

(p.Ile336Thr)

NM_000155.3(GALT):
111033849
GALT
[ ]
[ ]
[‘Deficiency of

c.328 + 2T > C

UDPglucose-

hexose-1 -phosphate

uridylyltransferase’]

NM_000267.3(NF1):
199474737
NF1
[ ]
[ ]
[‘Neurofibromatosis,

c.1595T > C

type 1’, ‘not

(p.Leu532Pro)

provided’]

NM_000455.4(STK11):
730881974
STK11
[ ]
[‘GGGAACCYGCT
[‘Hereditary cancer-

c.545T > C

GCTCACCACCGG’,
predisposing

(p.Leu182Pro)

‘AACCYGCTGCTC
syndrome’]

ACCACCGGTGG’]

NM_001042492.2(NF1):
199474762
NF1
[ ]
[ ]
[‘Hereditary cancer-

c.2288T > C

predisposing

(p.Leu763Pro)

syndrome’, ‘not

provided’]

NM_001042492.2(NF1):
199474792
NF1
[ ]
[ ]
[‘Neurofibromatosis,

c.5858T > C

type 1’, ‘not

(p.Leu1953Pro)

provided’]

m.7512T > C
199474817
MT-TS1
[ ]
[ ]
[‘MERRF/MELAS

overlap syndrome’]

m.7510T > C
199474820
MT-TS1
[ ]
[ ]
[‘Deafness,

nonsyndromic

sensorineural,

mitochondrial’]

m.7511T > C
199474821
MT-TS1
[ ]
[ ]
[‘Deafness,

nonsyndromic

sensorineural,

mitochondrial’]

m.2991T > C
199474823
MT-RNR2
[ ]
[ ]
[‘Chloramphenicol

resistance’]

NM_201253.2(CRB1):
62635656
CRB1
[ ]
[ ]
[‘Retinitis

c.3122T > C

pigmentosa 12’, ‘not

(p.Met1041Thr)

provided’]

m.7587T > C
199474825
MT-OO2
[ ]
[ ]
[‘Cytochrome-c

oxidase deficiency’]

NM_000400.3(ERCC2):
121913025
ERCC2
[ ]
[ ]
[‘Xeroderma

c.1454T > C

pigmentosum, group

(p.Leu485Pro)

D’]

NM_000157.3(GBA):
1064644
GBA
[ ]
[‘GGGYCACTCAA
[‘Gaucher disease’]

c.703T > C

GGGACAGCCCGG’]

(p.Ser235Pro)

NM_001113755.2(TYMP):
121913042
TYMP
[ ]
[ ]
[ ]

c.854T > C

(p.Leu285Pro)

NM_000122.1(ERCC3):
121913045
ERCC3
[ ]
[ ]
[‘Xeroderma

c.296T > C

pigmentosum,

(p.Phe99Ser)

complementation

group b’]

NM_000186.3(CFH):
121913052
CFH
[ ]
[ ]
[‘Factor H

c.1606T > C

deficiency’]

(p.Cys536Arg)

NM_138413.3(HOGA1):
796052090
HOGA1
[ ]
[‘GGACCYGCCTGT
[‘Primary

c.533T > C

GGATGCAGTGG’]
hyperoxaluria, type

(p.Leu178Pro)

III’]

NM_004370.5(COL12A1):
796052093
COL12A1
[ ]
[ ]
[‘BETHLEM

c.7001T > C

MYOPATHY 2’]

(p.Ile2334Thr)

NM_000043.4(FAS):
121913084
FAS
[ ]
[ ]
[ ]

c.532T > C

(p.Cys178Arg)

NM_000208.2(INSR):
121913141
INSR
[ ]
[CTACCYGGACG
[‘Leprechaunism

c.779T > C

GCAGGTGTGTGG’]
syndrome’]

(p.Leu260Pro)

NM_000208.2(INSR):
121913152
INSR
[ ]
[ ]
[‘Leprechaunism

c.164T > C

syndrome’]

(p.Val55Ala)

NM_000026.2(ADSL):
374259530
ADSL
[ ]
[ ]
[‘Adenylosuccinate

c.340T > C

lyase deficiency’,

(p.Tyr114His)

‘not provided’]

NM_153490.2(KRT13):
60440396
KRT13
[ ]
[ ]
[‘White sponge

c.356T > C

nevus 2’, ‘not

(p.Leull9Pro)

provided’]

NM_022455.4(NSD1):
587784162
NSD1
[ ]
[ ]
[‘Sotos syndrome 1’]

c.5885T > C

(p.Ile1962Thr)

NM_006218.2(PIK3CA):
121913272
PIK3CA
[ ]
[‘GGAACACYGTC
[‘Congenital

c.1258T > C

CATTGGCATGGG’,
lipomatous

(p.Cys420Arg)

‘GAACACYGTCCA
overgrowth, vascular

TTGGCATGGGG’]
malformations, and

epidermal nevi’,

‘Neoplasm of ovary’,

‘PIK3CA Related

Overgrowth

Spectrum’]

NM_000552.3(VWF):
61751310
VWF
[ ]
[‘GCTCCYGCTGCT
[‘von Willebrand

c.8317T > C

CTCCGACACGG’]
disease, type 2a’, ‘not

(p.Cys2773Arg)

provided’]

NM_000335.4(SCN5A):
45563942
SCN5A
[ ]
[ ]
[‘Primary dilated

c.5504T > C

cardiomyopathy’,

(p.Ile1835Thr)

‘Dilated

cardiomyopathy 1E’,

‘not provided’]

NM_183415.2(UBE3B):
398123020
UBE3B
[ ]
[ ]
[‘Kaufman

c.1741 + 2T > C

oculocerebrofacial

syndrome’]

NM_000021.3(PSEN1):
63750218
PSEN1
[ ]
[ ]
[‘Alzheimer disease,

c.1175T > C

type 3’, ‘not

(p.Leu392Pro)

provided’]

NM_000350.2(ABCA4):
61751392
ABCA4
[ ]
[ ]
[‘Stargardt disease

c.1622T > C

1’, ‘Cone-rod

(p.Leu541Pro)

dystrophy 3’, ‘not

provided’]

NM_007313.2(ABL1):
121913457
ABL1
[ ]
[ ]
[ ]

c.1109T > C

(p.Met370Thr)

NM_024408.3(NOTCH2):
312262793
NOTCH2
[ ]
[ ]
[‘Alagille syndrome

c.1117T > C

2’]

(p.Cys373Arg)

NM_024408.3(NOTCH2):
312262799
NOTCH2
[ ]
[‘TTCACAYGTCTG
[‘Alagille syndrome

c.1438T > C

TGCATGCCAGG’]
2’]

(p.Cys480Arg)

NM_003611.2(0FD1):
312262809
OFD1
[ ]
[ ]
[‘Oral-facial-digital

c.111 + 2T > C

syndrome’, ‘not

provided’]

NM_003611.2(0FD1):
312262819
OFD1
[ ]
[ ]
[‘Oral-facial-digital

c.274T > C (p.Ser92Pro)

syndrome’]

NM_020631.4(PLEKHG5):
63750315
PLEKHG5
[ ]
[ ]
[‘Distal spinal

c.1940T > C

muscular atrophy,

(p.Phe647Ser)

autosomal recessive

4’]

NM_001288953.1(TTC7A):
149602485
TTC7A
[ ]
[ ]
[‘Multiple

c.1912T > C

gastrointestinal

(p.Ser638Pro)

atresias’]

NM_000391.3(TPP1):
119455953
TPP1
[‘GCCG
[‘GCCGGGYGTTG
[‘Ceroid

c.1093T > C

GGYGT
GTCTGTCTCTGG’]
lipofuscinosis,

(p.Cys365Arg)

TGGTC

neuronal, 2’, ‘not

TGTCT

provided’]

CTGG’]

NM_000426.3(LAMA2):
121913570
LAMA2
[ ]
[‘ATCATTCYTTTG
[‘Merosin deficient

c.7691T > C

GGAAGTGGAGG’,
congenital muscular

(p.Leu2564Pro)

‘TCATTCYTTTGGG
dystrophy’]

AAGTGGAGGG’]

NM_000426.3(LAMA2):
121913573
LAMA2
[ ]
[ ]
[‘Congenital

c.2584T > C

muscular dystrophy

(p.Cys862Arg)

due to partial

LAMA2 deficiency’]

NM_000530.6(MPZ):
121913587
MPZ
[ ]
[ ]
[‘Charcot-Marie-

c.404T > C (p.Ile135Thr)

Tooth disease type

1B’]

NM_201253.2(CRB1):
62636291
CRB1
[ ]
[ ]
[‘Retinitis

c.3541T > C

pigmentosa 12’, ‘not

(p.Cys1181Arg)

provided’]

NM_000257.3(MYH7):
121913640
MYH7
[ ]
[‘AACTCCAYGTAT
[‘Familial

c.1046T > C

AAGCTGACAGG’]
hypertrophic

(p.Met349Thr)

cardiomyopathy 1’,

‘Cardiomyopathy’]

NM_000257.3(MYH7):
121913642
MYH7
[ ]
[‘CATCATGYCCAT
[‘Dilated

c.1594T > C

CCTGGAAGAGG’]
cardiomyopathy 1S’]

(p.Ser532Pro)

NM_000257.3(MYH7):
121913654
MYH7
[ ]
[ ]
[‘Familial

c.5378T > C

hypertrophic

(p.Leu1793Pro)

cardiomyopathy 1’,

‘Myosin storage

myopathy’, ‘Left

ventricular

noncompaction 5’,

‘Cardiomyopathy’]

NM_001127500.1(MET):
121913668
MET
[ ]
[ ]
[‘Renal cell

c.3446T > C

carcinoma,

(p.Met1149Thr)

papillary, 1’]

NM_002443.3(MSMB):
10993994
MSMB
[ ]
[ ]
[‘Prostate cancer,

c.-89T=

hereditary, 13’]

NM_001079802.1(FKTN):
119463996
FKTN
[ ]
[‘GTAGTCTYTCAT
[‘Limb-girdle

c.527T > C

GAGAGGAGTGG’]
muscular dystrophy-

(p.Phe176Ser)

dystroglycanopathy,

type C4’]

NM_000169.2(GLA):
140329381
—
[ ]
[ ]
[‘Fabry disease’]

c.865A > T (p.Ile289Phe)

NM_000420.2(KEL):
8176038
KEL
[ ]
[ ]
[ ]

c.1790T > C

(p.Leu597Pro)

NM_003999.2(OSMR):
63750567
OSMR
[ ]
[ ]
[‘Primary localized

c.2072T > C

cutaneous

(p.Ile691Thr)

amyloidosis 1’]

NC_012920.1:m.9478
587776437
MT-003
[‘TCAG
[‘TCAGAAGYTTTT
[‘Leigh disease’]

T > C

AAGYT
TTCTTCGCAGG’]

TTTTTC

TTCGC

AGG’]

NM_002775.4(HTRA1):
587776447
HTRA1
[ ]
[ ]
[‘Cerebral autosomal

c.1091T > C

recessive

(p.Leu364Pro)

arteriopathy with

subcortical infarcts

and

leukoencephalopath

3’]

NM_002049.3(GATA1):
587776451
GATA1
[‘TCCA
[‘CTCCAYGGAGTT
[‘GATA-1-related

c.2T > C (p.Met1Thr)

YGGAG
CCCTGGCCTGG’,
thrombocytopenia

TTCCCT
‘TCCAYGGAGTTC
with

GGCCT
CCTGGCCTGGG’,
dyserythropoiesis’]

GGG’,
‘CCAYGGAGTTCC

‘CCAYG
CTGGCCTGGGG’]

GAGTT

CCCTG

GCCTG

GGG’]

NM_000021.3(PSEN1):
63750599
PSEN1
[ ]
[ ]
[‘Alzheimer disease,

c.254T > C

familial, 3, with

(p.Leu85Pro)

spastic paraparesis

and apraxia’, ‘not

provided’]

NM_002049.3(GATA1):
587776456
GATA1
[ ]
[‘GCTCAYGAGGG
[‘GATA-1-related

c.1240T > C

CACAGAGCATGG’]
thrombocytopenia

(p.Ter414Arg)

with

dyserythropoiesis’]

NM_006158.4(NEFL):
62636505
NEFL
[ ]
[ ]
[‘Charcot-Marie-

c.281T > C

Tooth disease type

(p.Leu94Pro)

2E’, ‘not provided’]

NM_000184.2(HBG2):
63750654
HBG2
[ ]
[‘ATGCAAAYATCT
[‘Fetal hemoglobin

c.-228T > C

GTCTGAAACGG’]
quantitative trait

locus 1’]

NM_000353.2(TAT):
587776512
TAT
[ ]
[ ]
[‘Tyrosinemia type

c.236-5A > G

2’]

NM_173560.3(RFX6):
587776514
RFX6
[‘CAGT
[‘CAGTGGYGAGA
[‘Mitchell-Riley

c.380 + 2T > C

GGYGA
CTCGCCCGCAGG’,
syndrome’]

GACTC
‘AGTGGYGAGACT

GCCCG
CGCCCGCAGGG’]

CAGG’,

‘AGTGG

YGAGA

CTCGC

CCGCA

GGG’]

NM_001999.3(FBN2):
587776519
FBN2
[ ]
[‘AGCAYTGCAAC
[‘Congenital

c.3725-15A > G

CACATTGTCAGG’]
contractural

arachnodactyly’]

NM_000404.2(GLB1):
587776526
GLB1
[ ]
[ ]
[‘GM1-

c.1480-2A > G

GANGLIOSIDOSIS,

TYPE I, WITH

CARDIAC

INVOLVEMENT’]

NM_000402.4(G6PD):
78365220
G6PD
[ ]
[‘TGCCCYCCACCT
[‘Anemia,

c.473T > C

GGGGTCACAGG’]
nonspherocytic

(p.Leu158Pro)

hemolytic, due to

G6PD deficiency’,

‘not provided’]

NM_000179.2(MSH6):
63750741
MSH6
[ ]
[‘CTGGGGCYGGT
[‘Hereditary

c.1346T > C

ATTCATGAAAGG’]
Nonpolyposis

(p.Leu449Pro)

Colorectal

Neoplasms’]

NM_145046.4(CALR3):
142951029
CALR3
[‘CGGT
[‘CGGTYTGAAGC
[‘Arrhythmogenic

c.245A > G

YTGAA
GTGCAGAGATGG’]
right ventricular

(p.Lys82Arg)

GCGTG

cardiomyopathy’,

CAGAG

‘Familial

ATGG’]

hypertrophic

cardiomyopathy 19’,

‘Hypertrophic

cardiomyopathy’]

NM_000260.3(MY07A):
368657015
MY07A
[ ]
[ ]
[‘Usher syndrome,

c.5573T > C

type 1’]

(p.Leu1858Pro)

NM_024753.4(TTC21B):
766132877
TTC21B
[ ]
[ ]
[‘Nephronophthisis

c.2758-2A > G

12’]

NM_001195129.1(PRSS56):
730882161
PRSS56
[ ]
[ ]
[‘Microphthalmia,

c.1183T > C

isolated 6’]

(p.Cys395Arg)

NM_001184.3(ATR):
587776690
ATR
[ ]
[ ]
[‘Seckel syndrome

c.2022A > G

1’]

(p.Gly674=)

NM_000354.5(SERPINA7):
587776720
SERPINA7
[ ]
[ ]
[ ]

c.623-2A > G

NM_000133.3(F9):c.2
587776735
F9
[ ]
[ ]
[‘Hereditary factor

77 + 2T > C

IX deficiency

disease’]

NM_004006.2(DMD):
587776747
DMD
[ ]
[ ]
[‘Becker muscular

c.9225-285A > G

dystrophy’]

NM_016835.4(MAPT):
63750912
MAPT
[‘GGAT
[‘GGATAAYATCA
[‘Frontotemporal

c.1839T > C

AAYAT
AACACGTCCCGG’,
dementia’, ‘not

(p.Asn613=)

CAAAC
‘GATAAYATCAAA
provided’]

ACGTC
CACGTCCCGGG’]

CCGG’,

‘GATAA

YATCA

AACAC

GTCCC

GGG’]

NM_000321.2(RB1):
587776780
RB1
[ ]
[ ]
[‘Retinoblastoma’]

c.1960 + 2T > C

NM_006517.4(SLC16A2):
367543059
SLC16A2
[ ]
[ ]
[‘Allan-Herndon-

c.1253T > C

Dudley syndrome’]

(p.Leu418Pro)

NM_000421.3(KRT10):
587776815
—
[ ]
[ ]
[‘Erythroderma,

c.1374-2A > G

ichthyosiform,

congenital reticular’]

NM_000251.2(MSH2):
63750961
MSH2
[ ]
[ ]
[‘Hereditary

c.2089T > C

Nonpolyposis

(p.Cys697Arg)

Colorectal

Neoplasms’]

NM_002618.3(PEX13):
61752115
PEX13
[ ]
[ ]
[‘Peroxisome

c.977T > C

biogenesis disorder

(p.Ile326Thr)

11B’]

NM_001079867.1(PEX2):
61752128
PEX2
[ ]
[ ]
[‘Peroxisome

c.739T > C

biogenesis disorder

(p.Cys247Arg)

5A’]

NM_017929.5(PEX26):
61752132
PEX26
[ ]
[ ]
[‘Peroxisome

c.134T > C

biogenesis disorder

(p.Leu45Pro)

7B’]

NG_012088.1:g.2209
587776843
IL10
[‘ACCY
[‘ACCYTATGATCC
[ ]

A > G

TATGA
GCCCGCCTTGG’]

TCCGC

CCGCC

TTGG’]

NM_001735.2(C5):
587776846
C5
[ ]
[ ]
[‘Leiner disease’]

c.1115A > G

(p.Lys372Arg)

NM_002087.3(GRN):
63751006
GRN
[‘CCAY
[‘CCAYGTGGACCC
[‘Frontotemporal

c.2T > C (p.Met1Thr)

GTGGA
TGGTGAGCTGG’]
dementia, ubiquitin-

CCCTG

positive’, ‘not

GTGAG

provided’]

CTGG’]

NM_004656.3(BAP1):
587776878
BAP1
[ ]
[ ]
[‘Tumor

c.2057-2A > G

predisposition

syndrome’]

NM_004656.3(BAP1):
587776879
BAP1
[‘GCCY
[‘GCCYGGGGAAA
[‘Tumor

c.438-2A > G

GGGGA
AACAGAGTCAGG’]
predisposition

AAAAC

syndrome’]

AGAGT

CAGG’]

NM_004329.2(BMPR1A):
199476087
BMPR1A
[ ]
[ ]
[‘Juvenile polyposis

c.370T > C

syndrome’,

(p.Cys124Arg)

‘Hereditary cancer-

predisposing

syndrome’]

NM_000510.2(FSHB):
5030777
FSHB
[ ]
[ ]
[‘Follicle-stimulating

c.298T > C

hormone deficiency,

(p.Cys100Arg)

isolated’]

NM_001009944.2(PKD1):
199476100
PKD1
[ ]
[ ]
[‘Polycystic kidney

c.2534T > C

disease, adult type’]

(p.Leu845Ser)

NM_004963.3(GUCY2C):
587776905
GUCY2C
[ ]
[ ]
[‘Meconium ileus’]

c.1160A > G

(p.Asp387Gly)

m.14487T > C
199476109
MT-ND6
[ ]
[ ]
[‘Leigh disease’,

‘Leigh syndrome due

to mitochondrial

complex I

deficiency’]

NM_017565.3(FAM20A):
587776912
—
[ ]
[ ]
[‘Enamel-renal

c.813-2A > G

syndrome’]

NM_017565.3(FAM20A):
587776914
FAM20A
[ ]
[‘GTAATCYGCAA
[‘Enamel-renal

c.590-2A > G

AGGAGGAGAAGG’,
syndrome’]

‘TAATCYGCAAAG

GAGGAGAAGGG’]

NM_014165.3(NDUFAF4):
63751061
NDUFAF4
[ ]
[ ]
[‘Mitochondrial

c.194T > C

complex I

(p.Leu65Pro)

deficiency’]

m.4160T > C
199476119
MT-ND1
[ ]
[ ]
[‘Leber optic

atrophy’]

NM_000551.3(VHL):
5030809
VHL
[ ]
[‘CCCYACCCAACG
[‘Von Hippel-Lindau

c.292T > C (p.Tyr98His)

CTGCCGCCTGG’]
syndrome’,

‘Hereditary cancer-

predisposing

syndrome’]

m.3949T > C
199476124
MT-ND1
[ ]
[ ]
[‘Juvenile myopathy,

encephalopathy,

lactic acidosis AND

stroke’]

m.6742T > C
199476126
MT-CO1
[ ]
[ ]
[ ]

m.6721T > C
199476127
MT-CO1
[ ]
[ ]
[ ]

m.5692T > C
199476131
MT-TN
[ ]
[ ]
[ ]

m.5728T > C
199476132
MT-TN
[ ]
[‘CAATCYACTTCT
[‘Cytochrome-c

CCCGCCGCCGG’,
oxidase deficiency’,

‘AATCYACTTCTC
‘Mitochondrial

CCGCCGCCGGG’]
complex ]

deficiency’]

m.9101T > C
199476134
MT-ATP6
[ ]
[ ]
[‘Leber optic

atrophy’]

m.8851T > C
199476136
MT-ATP6
[ ]
[ ]
[‘Leigh disease’,

‘Striatonigral

degeneration,

infantile,

mitochondrial’]

m.9185T > C
199476138
MT-ATP6
[ ]
[ ]
[‘Leigh disease’]

NM_000277.1(PAH):
5030841
PAH
[ ]
[ ]
[‘Phenylketonuria’,

c.143T > C (p.Leu48Ser)

‘not provided’]

NM_000277.1(PAH):
5030845
PAH
[ ]
[ ]
[‘Phenylketonuria’,

c.691T > C

‘not provided’]

(p.Ser231Pro)

NM_000251.2(MSH2):
63751110
MSH2
[‘AAGG
[‘AAGGAAYGTGT
[‘Hereditary

c.595T > C

AAYGT
TTTACCCGGAGG’]
Nonpolyposis

(p.Cys199Arg)

GTTTT

Colorectal

ACCCG

Neoplasms’]

GAGG’]

NM_000039.1(AP0A1):
28931575
—
[ ]
[ ]
[ ]

c.341T > C

(p.Leull4Pro)

NM_001288953.1(TTC7A):
587776972
TTC7A
[ ]
[ ]
[‘Multiple

c.2366T > C

gastrointestinal

(p.Leu789Pro)

atresias’]

NM_014336.4(AIPL1):
62637012
AIPL1
[ ]
[CTGCCAGYGCCT
[‘Leber congenital

c.715T > C

GCTGAAGAAGG’,
amaurosis 4’, ‘not

(p.Cys239Arg)

‘CCAGYGCCTGCT
provided’]

GAAGAAGGAGG’]

NM_000155.3(GALT):
367543254
GALT
[ ]
[ ]
[‘Deficiency of

c.336T > C (p.Ser112=)

UDPglucose-

hexose-1-phosphate

uridylyltransferase’]

NM_207352.3(CYP4V2):
199476191
CYP4V2
[ ]
[ ]
[‘Bietti crystalline

c.655T > C

corneoretinal

(p.Tyr219His)

dystrophy’]

NM_207352.3(CYP4V2):
199476199
CYP4V2
[ ]
[AAACTGGYCCTT
[‘Bietti crystalline

c.1021T > C

ATACCTGTTGG’,
corneoretinal

(p.Ser341Pro)

‘AACTGGYCCTTA
dystrophy’]

TACCTGTTGGG’]

NM_001142519.1(FAM111A):
587777012
FAM111A
[ ]
[ ]
[‘Kenny-Caffey

c.1531T > C

syndrome type 2’]

(p.Tyr511His)

NM_000435.2(NOTCH3):
367543285
NOTCH3
[ ]
[ ]
[‘Infantile

c.4556T > C

myofibromatosis 1’,

(p.Leu1519Pro)

‘Infantile

myofibromatosis 2’]

NM_000021.3(PSEN1):
63751163
PSEN1
[ ]
[ ]
[‘Alzheimer disease,

c.749T > C

type 3’, ‘not

(p.Leu250Ser)

provided’]

NM_001283009.1(RTEL1):
587777037
—
[‘CTGTG
[‘CTGTGTGYGCCA
[‘Dyskeratosis

c.3730T > C

TGYGC
GGGCTGTGGGG’]
congenita,

(p.Cys1244Arg)

CAGGG

autosomal recessive,

CTGTG

5’]

GGG’]

NM_001135021.1(ELMOD3):
587777040
ELMOD3
[ ]
[ ]
[‘Deafness,

c.794T > C

autosomal recessive

(p.Leu265Ser)

88’]

NM_001001557.2(GDF6):
63751220
GDF6
[ ]
[ ]
[‘Klippel-Feil

c.866T > C

syndrome 1,

(p.Leu289Pro)

autosomal

dominant’]

NM_014754.2(PTDSS1):
587777090
PTDSS1
[ ]
[ ]
[Lenz-Majewski

c.794T > C

hyperostosis

(p.Leu265Pro)

syndrome’]

NM_052844.3(WDR34):
587777098
WDR34
[ ]
[ ]
[‘Short-rib thoracic

c.1307A > G

dysplasia 11 with or

(p.Lys436Arg)

without

polydactyly’]

NM_001290048.1(ATL3):
587777108
ATL3
[ ]
[ ]
[‘Hereditary sensory

c.521A > G

neuropathy type IF’]

(p.Tyr174Cys)

NM_001018005.1(TPM1):
199476312
TPM1
[ ]
[ ]
[‘Primary familial

c.515T > C

hypertrophic

(p.Ile172Thr)

cardiomyopathy’,

‘Cardiomyopathy’,

‘not provided’]

NM_018849.2(ABCB4):
58238559
ABCB4
[ ]
[ ]
[‘Cholecystitis’]

c.523A > G

(p.Thr175Ala)

NM_001018005.1(TPM1):
199476321
TPM1
[ ]
[ ]
[‘Cardiomyopathy’,

c.842T > C

‘not specified’, ‘not

(p.Met281Thr)

provided’]

NM_005763.3(AASS):
587777122
AASS
[ ]
[ ]
[‘Hyperlysinemia’]

c.874A > G

(p.Ile292Val)

NM_194442.2(LBR):
587777171
LBR
[ ]
[ ]
[‘Greenberg

c.1639A > G

dysplasia’]

(p.Asn547Asp)

NM_006702.4(PNPLA6):
587777183
PNPLA6
[ ]
[‘CCTYTAACCGCA
[‘Boucher Neuhauser

c.3053T > C

GCATCCATCGG’]
syndrome’]

(p.Phe1018Ser)

NM_000487.5(ARSA)
199476389
ARSA
[ ]
[‘GGTCTCTYGCGG
[‘Metachromatic

:c.899T > C

TGTGGAAAGGG’]
leukodystrophy’, ‘not

(p.Leu300Ser)

provided’]

NM_016599.4(MYOZ2):
199476398
MYOZ2
[ ]
[‘TTAYCCCATCTC
[‘Familial

c.142T > C

AGTAACCGTGG’]
hypertrophic

(p.Ser48Pro)

cardiomyopathy 16’,

‘not provided’]

NM_014740.3(EIF4A3):
587777204
EIF4A3
[ ]
[ ]
[‘Richieri Costa

c.809A > G

Pereira syndrome’]

(p.Asp270G1y)

NM_001040436.2(YARS2):
587777215
YARS2
[ ]
[ ]
[‘Myopathy, lactic

c.1303A > G

acidosis, and

(p.Ser435Gly)

sideroblastic anemia

2’]

NM_001278503.1(STT3A):
587777216
STT3A
[ ]
[ ]
[‘Congenital disorder

c.1877T > C

of glycosylation type

(p.Val626Ala)

1w’]

NM_001037633.1(SIL1):
119456967
SIL1
[ ]
[‘TTGCYGAAGGA
[Marinesco-

c.1370T > C

GCTGAGATGAGG’]
Sj\xc3\xb6gren

(p.Leu457Pro)

syndrome’]

NM_006888.4(CALM1):
730882253
CALM1
[ ]
[‘GGCAYTCCGAGT
[‘Long QT syndrome

c.268T > C

CTTTGACAAGG’]
14’]

(p.Phe90Leu)

NM_001003811.1(TEX11):
143246552
TEX11
[‘TCCA
[‘TCCAYGGTCAAG
[‘Spermatogenic

c.511A > G

YGGTC
TCAGCCTCAGG’,
failure, X-linked, 2’]

(p.Met171Val)

AAGTC
‘CCAYGGTCAAGT

AGCCT
CAGCCTCAGGG’]

CAGG’]

NM_033419.4(PGAP3):
587777252
PGAP3
[ ]
[ ]
[‘Hyperphosphatasia

c.914A > G

with mental

(p.Asp305Gly)

retardation

syndrome 4’]

NM_000021.3(PSEN1):
63751399
PSEN1
[ ]
[ ]
[‘Alzheimer disease,

c.338T > C

type 3’,

(p.Leull3Pro)

‘Frontotemporal

dementia’, ‘not

provided’]

NM_000097.5(CPOX):
587777271
CPOX
[ ]
[ ]
[‘Harderoporphyria’]

c.980A > G

(p.His327Arg)

NM_005654.5(NR2F1):
587777276
NR2F1
[ ]
[ ]
[‘Bosch-boonstra-

c.755T > C

schaaf optic atrophy

(p.Leu252Pro)

syndrome’]

NM_012338.3(TSPAN12):
587777283
TSPAN12
[ ]
[‘TAATCCAYAATT
[‘Exudative

c.413A > G

TGTCATCCTGG’]
vitreoretinopathy 5’]

(p.Tyr138Cys)

NM_003181.3(T):
587777303
T
[ ]
[ ]
[‘Sacral agenesis

c.512A > G (p.His171Arg)

with vertebral

anomalies’]

NM_015884.3(MBTPS2):
587777306
MBTPS2
[ ]
[‘GCTYTGCTTTGG
[‘Palmoplantar

c.1391T > C

ATGGACAATGG’]
keratoderma,

(p.Phe464Ser)

mutilating, with

periorificial

keratotic plaques, X-

linked’]

NM_020435.3(GJC2):
74315311
GJC2
[‘TGAG
[‘TGAGAYGGCCC
[‘Leukodystrophy,

c.857T > C

AYGGC
ACCTGGGCTTGG’,
hypomyelinating, 2’]

(p.Met286Thr)

CCACC
‘GAGAYGGCCCAC

TGGGC
CTGGGCTTGGG’]

TTGG’]

NM_005356.4(LCK):
587777335
LCK
[ ]
[ ]
[‘Immunodeficiency

c.1022T > C

22’]

(p.Leu341Pro)

NM_005861.3(STUB1):
587777345
—
[ ]
[ ]
[‘Spinocerebellar

c.719T > C

ataxia, autosomal

(p.Met240Thr)

recessive 16’]

NM_000250.1(MPO):
56378716
MPO
[ ]
[‘TCACTCAYGTTC
[‘Myeloperoxidase

c.752T > C

ATGCAATGGGG’]
deficiency’]

(p.Met251Thr)

NM_017890.4(VPS13B):
587777382
VPS13B
[ ]
[ ]
[‘Cohen syndrome’]

c.11119 + 2T > C

NM_005026.3(PIK3CD):
587777390
PIK3CD
[ ]
[‘GCAGGACYGCC
[‘Activated PI3K-

c.1246T > C

CCATTGCCTGGG’]
delta syndrome’]

(p.Cys416Arg)

NM_002633.2(PGM1):
587777401
PGM1
[ ]
[ ]
[‘Congenital disorder

c.1547T > C

of glycosylation type

(p.Leu516Pro)

it’]

NM_000261.1(MYOC):
74315328
MYOC
[ ]
[ ]
[‘Primary open angle

c.1309T > C

glaucoma juvenile

(p.Tyr437His)

onset 1’]

NM_001159287.1(TPI1):
587777440
TPI1
[ ]
[ ]
[‘Triosephosphate

c.833T > C

isomerase

(p.Phe278Ser)

deficiency’]

NM_000414.3(HSD17B4):
587777443
HSD17B4
[ ]
[ ]
[‘Gonadal

c.1547T > C

dysgenesis with

(p.Ile516Thr)

auditory

dysfunction,

autosomal recessive

inheritance’]

NM_005359.5(SMAD4):
377767339
SMAD4
[ ]
[ ]
[‘Juvenile polyposis

c.970T > C

syndrome’]

(p.Cys324Arg)

NM_000211.4(ITGB2):
483352818
ITGB2
[‘CATG
[‘CATGYGAGTGC
[‘Leukocyte

c.1877 + 2T > C

YGAGT
AGGCGGAGCAGG’]
adhesion deficiency

GCAGG

type 1’]

CGGAG

CAGG’]

NM_005359.5(SMAD4):
377767348
SMAD4
[ ]
[ ]
[‘Juvenile polyposis

c.1087T > C

syndrome’]

(p.Cys363Arg)

NM_001128159.2(VPS53):
587777465
VPS53
[ ]
[ ]
[‘Pontocerebellar

c.2084A > G

hypoplasia, type 2e’]

(p.Gln695Arg)

NM_000249.3(MLH1):
63751616
MLH1
[ ]
[ ]
[‘Hereditary

c.1745T > C

Nonpolyposis

(p.Leu582Pro)

Colorectal

Neoplasms’]

NM_003108.3(SOX11):
587777480
SOX11
[ ]
[‘TATGGYCCAAG
[‘Mental retardation,

c.178T > C

ATCGAACGCAGG’]
autosomal dominant

(p.Ser60Pro)

27’]

NM_020630.4(RET):
377767404
RET
[ ]
[ ]
[ ]

c.1888T > C

(p.Cys630Arg)

NM_017565.3(FAM20A):
587777530
—
[ ]
[ ]
[‘Enamel-renal

c.720-2A > G

syndrome’]

NM_015599.2(PGM3):
587777562
PGM3
[‘TAAA
[‘TAAATGAYTGA
[‘Immunodeficiency

c.737A > G

TGAYT
GTTTGCCCTTGG’]
23’]

(p.Asn246Ser)

GAGTT

TGCCC

TTGG’]

NM_015599.2(PGM3):
587777565
PGM3
[ ]
[ ]
[‘Immunodeficiency

c.1352A > G

23’]

(p.Gln451Arg)

NM_000206.2(IL2RG):
137852511
IL2RG
[ ]
[ ]
[‘X-linked severe

c.452T > C

combined

(p.Leu151Pro)

immunodeficiency’]

NM_198282.3(TMEM173):
587777609
TMEM173
[ ]
[ ]
[‘Sting-associated

c.461A > G

vasculopathy,

(p.Asn154Ser)

infantile-onset’]

NM_000329.2(RPE65):
61752909
RPE65
[ ]
[ ]
[‘Retinitis

c.1022T > C

pigmentosa 20’, ‘not

(p.Leu341Ser)

provided’]

NM_001127899.3(CLCN5):
151340623
CLCN5
[ ]
[ ]
[‘Dent disease 1’]

c.1768T > C

(p.Ser590Pro)

NM_005027.3(PIK3R2):
587777624
PIK3R2
[ ]
[ ]
[‘Megalencephaly

c.1202T > C

polymicrogyria-

(p.Leu401Pro)

polydactyly

hydrocephalus

syndrome’]

NM_007315.3(STAT1):
587777629
STAT1
[ ]
[ ]
[‘Immunodeficiency

c.854A > G

31C’]

(p.Gln285Arg)

NM_139276.2(STAT3):
587777648
STAT3
[ ]
[ ]
[‘Autoimmune

c.1175A > G

disease,

(p.Lys392Arg)

multisystem,

infantile-onset’]

NM_001037811.2(HSD17B10):
587777651
HSD17B10
[ ]
[ ]
[2-methy1-3-

c.257A > G

hydroxybutyric

(p.Asp86Gly)

aciduria’]

NM_001288767.1(ARMC5):
587777661
ARMC5
[ ]
[ ]
[‘Acth-independent

c.1928T > C

macronodular

(p.Leu643Pro)

adrenal hyperplasia

2’]

NM_001288767.1(ARMC5):
587777663
ARMC5
[ ]
[‘GCCCGACYGCG
[‘Acth-independent

c.1379T > C

GGATGCTGGTGG’]
macronodular

(p.Leu460Pro)

adrenal hyperplasia

2’]

NM_007315.3(STAT1):
587777704
STAT1
[ ]
[ ]
[‘Immunodeficiency

c.2018A > G

31a’]

(p.Lys673Arg)

NM_007315.3(STAT1):
587777705
STAT1
[ ]
[ ]
[‘Immunodeficiency

c.1909A > G

31a’]

(p.Lys637Glu)

NM_014845.5(FIG4):
587777713
FIG4
[ ]
[ ]
[‘Charcot-Marie-

c.50T > C (p.Leu17Pro)

Tooth disease, type

4J’]

4J’]

NM_000350.2(ABCA4):
61753033
ABCA4
[ ]
[‘AAGGCYACATG
[‘Stargardt disease’,

c.5819T > C

AACTAACCAAGG’]
‘Stargardt disease 1’,

(p.Leu1940Pro)

‘Cone-rod dystrophy

3’, ‘not provided’]

NM_002972.3(SBF1):
200488568
SBF1
[ ]
[CAGGCGYCCTCT
[Charcot-Marie-

c.4768A > G

TGCTCAGCCGG’]
Tooth disease, type

(p.Thr1590Ala)

4B3’]

NM_000377.2(WAS):
132630272
WAS
[ ]
[ ]
[ ]

c.244T > C (p.Ser82Pro)

NM_000377.2(WAS):
132630274
WAS
[ ]
[‘CGGAGTCYGTTC
[‘Severe congenital

c.809T > C

TCCAGGGCAGG’]
neutropenia X-

(p.Leu270Pro)

linked’]

NM_001128834.2(PLP1):
132630279
PLP1
[ ]
[ ]
[‘Pelizaeus-

c.487T > C

Merzbacher disease’,

(p.Trp163Arg)

‘not provided’]

NM_001128834.2(PLP1):
132630283
PLP1
[ ]
[ ]
[‘Pelizaeus-

c.671T > C

Merzbacher disease’]

(p.Leu224Pro)

NM_001128834.2(PLP1):
132630288
PLP1
[ ]
[ ]
[‘Spastic paraplegia

c.560T > C

2’]

(p.Ile187Thr)

NM_001128834.2(PLP1):
132630291
PLP1
[ ]
[ ]
[‘Spastic paraplegia

c.710T > C

2’]

(p.Phe237Ser)

NM_001015877.1(PHF6):
132630300
PHF6
[ ]
[ ]
[‘Borjeson-

c.2T > C

Forssman-Lehmann

(p.Met1Thr)

syndrome’]

NM_001399.4(EDA):
132630308
EDA
[ ]
[‘CTGCYACCTAGA
[‘Hypohidrotic X-

c.181T > C (p.Tyr61His)

GTTGCGCTCGG’]
linked ectodermal

dysplasia’]

NM_001205019.1(GK):
132630330
GK
[ ]
[ ]
[‘Deficiency of

c.1525T > C

glycerol kinase’]

(p.Trp509Arg)

NM_000076.2(CDKN1C):
587777866
CDKN1C
[‘CCAA
[‘CCAAGYGAGTA
[‘Beckwith-

c.*5 + 2T > C

GYGAG
CAGCGCACCTGG’,
Wiedemann

TACAG
‘CAAGYGAGTACA
syndrome’]

CGCAC
GCGCACCTGGG’,

CTGG’,
‘AAGYGAGTACAG

‘CAAGY
CGCACCTGGGG’]

GAGTA

CAGCG

CACCT

GGG’,

‘AAGYG

AGTAC

AGCGC

ACCTG

GGG’]

NM_000271.4(NPC1):
483352888
NPC1
[ ]
[ ]
[‘Niemann-Pick

c.2054T > C

disease type C1’]

(p.Ile685Thr)

NM_170707.3(LMNA):
60934003
LMNA
[ ]
[ACGGCTCYCATC
[‘Benign

c.1589T > C

AACTCCACTGG’,
scapuloperoneal

(p.Leu530Pro)

‘CGGCTCYCATCA
muscular dystrophy

ACTCCACTGGG’,
with

‘GGCTCYCATCAA
cardiomyopathy’,

CTCCACTGGGG’]
‘not provided’]

NM_001165963.1(SCN1A):
372098964
—
[ ]
[ ]
[‘Severe myoclonic

c.5536A > T

epilepsy in infancy’]

(p.Lys1846Ter)

NM_130838.1(UBE3A):
587784526
UBE3A
[ ]
[ ]
[‘Angelman

c.2485T > C

syndrome’]

(p.Tyr829His)

NM_014588.5(VSX1):
74315436
VSX1
[ ]
[ ]
[‘Keratoconus 1’]

c.50T > C (p.Leu17Pro)

NM_000404.2(GLB1):
398123354
GLB1
[ ]
[ ]
[‘Mucopolysaccharid

c.457 + 2T > C

osis, MPS-IV-B’,

‘Infantile GM1

gangliosidosis’,

‘Juvenile GM > l<

gangliosidosis’,

‘Gangliosidosis

GM1 type 3’, ‘not

provided’]

NM_003159.2(CDKL5):
267608430
CDKL5
[ ]
[ ]
[‘Atypical Rett

c.145 + 2T > C

syndrome’, ‘not

provided’]

NM_002764.3(PRPS1):
180177153
PRPS1
[ ]
[ ]
[‘Deafness, high-

c.869T > C

frequency

(p.Ile290Thr)

sensorineural, X-

linked’]

NM_000030.2(AGXT):
180177160
AGXT
[ ]
[‘GGTGCYGCGGA
[‘Primary

c.1076T > C

TCGGCCTGCTGG’,
hyperoxaluria, type

(p.Leu359Pro)

‘GTGCYGCGGATC
I’]

GGCCTGCTGGG’]

NM_000030.2(AGXT):
180177165
AGXT
[ ]
[ ]
[‘Primary

c.1151T > C

hyperoxaluria, type

(p.Leu384Pro)

I’]

NM_000030.2(AGXT):
180177222
AGXT
[ ]
[GTGCYGCTGTTC
[‘Primary

c.449T > C

TTAACCCACGG’,
hyperoxaluria, type

(p.Leu150Pro)

‘TGCYGCTGTTCTT
I’]

AACCCACGGG’]

NM_000268.3(NF2):
74315492
NF2
[ ]
[ ]
[‘Neurofibromatosis,

c.1079T > C

type 2’]

(p.Leu360Pro)

NM_000030.2(AGXT):
180177254
AGXT
[ ]
[‘GCTCATCYCCTT
[‘Primary

c.661T > C

CAGTGACAAGG’]
hyperoxaluria, type

(p.Ser221Pro)

I’]

NM_000030.2(AGXT):
180177264
AGXT
[ ]
[‘GGGGCYGTGAC
[‘Primary

c.757T > C

GACCAGCCCAGG’]
hyperoxaluria, type

(p.Cys253Arg)

I’]

NM_000030.2(AGXT):
180177268
AGXT
[ ]
[ ]
[‘Primary

c.77T > C (p.Leu26Pro)

hyperoxaluria, type

I’]

NM_000030.2(AGXT):
180177287
AGXT
[ ]
[ ]
[‘Primary

c.851T > C

hyperoxaluria, type

(p.Leu284Pro)

I’]

NM_000030.2(AGXT):
180177293
AGXT
[ ]
[GTATCYGCATGG
[‘Primary

c.893T > C

GCGCCTGCAGG’]
hyperoxaluria, type

(p.Leu298Pro)

I’]

NM_012203.1(GRHPR):
180177305
GRHPR
[ ]
[ ]
[‘Primary

c.203T > C

hyperoxaluria, type

(p.Leu68Pro)

II’]

NM_000017.3(ACADS):
796051904
ACADS
[ ]
[ ]
[‘not provided’]

c.1057T > C

(p.Ser353Pro)

NM_000406.2(GNRHR):
606231406
GNRHR
[ ]
[ ]
[‘Hypogonadotropic

c.392T > C

hypogonadism’]

(p.Met131Thr)

NM_000255.3(MUT):
796052007
MUT
[ ]
[ ]
[‘not provided’]

c.842T > C

(p.Leu281Ser)

NM_000030.2(AGXT):
796052063
AGXT
[ ]
[ ]
[‘Primary

c.947T > C

hyperoxaluria, type

(p.Leu316Pro)

I’]

NM_138413.3(HOGA1):
796052087
HOGA1
[ ]
[ ]
[‘Primary

c.875T > C

hyperoxaluria, type

(p.Met292Thr)

III’]

NM_013382.5(POMT2):
200198778
POMT2
[‘GGAA
[‘GGAAGYAGTGG
[‘Congenital

c.1997A > G

GYAGT
TGGAAGTAGAGG’]
muscular dystrophy’,

(p.Tyr666Cys)

GGTGG

‘Congenital

AAGTA

muscular dystrophy-

GAGG’]

dystroglycanopathy

with brain and eye

anomalies, type A2’,

‘Muscular

dystrophy’,

‘Congenital

muscular dystrophy-

dystroglycanopathy

with mental

retardation, type B2’,

‘not provided’]

NM_015909.3(NBAS):
796052121
NBAS
[ ]
[ ]
[‘Infantile liver

c.3164T > C

failure syndrome 2’]

(p.Leu1055Pro)

NM_000263.3(NAGLU):
796052122
NAGLU
[ ]
[ ]
[‘Charcot-Marie-

c.1208T > C

Tooth disease,

(p.Ile403Thr)

axonal type 2V’]

NM_203290.2(POLR1C):
796052125
POLR1C
[ ]
[ ]
[‘LEUKODYSTROPHY,

c.436T > C

HYPOMYELINATING,

(p.Cys146Arg)

11’]

NM_018359.3(UFSP2):
796052130
—
[ ]
[ ]
[‘Hip dysplasia,

c.868T > C

beukes type’]

(p.Tyr290His)

NM_000053.3(ATP7B):
201738967
ATP7B
[ ]
[ ]
[‘Wilson disease’]

c.122A > G

(p.Asn41Ser)

NM_001356.4(DDX3X):
796052224
DDX3X
[ ]
[ ]
[‘not provided’]

c.704T > C

(p.Leu235Pro)

NM_001356.4(DDX3X):
796052226
DDX3X
[ ]
[ ]
[‘not provided’]

c.1541T > C

(p.Ile514Thr)

NM_001356.4(DDX3X):
796052232
DDX3X
[ ]
[ ]
[‘not provided’]

c.1175T > C

(p.Leu392Pro)

NM_000321.2(RB1):
587778839
RB1
[ ]
[ ]
[‘Retinoblastoma’]

c.2663 + 2T > C

NM_000321.2(RB1):
587778848
RB1
[ ]
[ ]
[‘Retinoblastoma’]

c.1472T > C

(p.Leu491Pro)

NM_006894.5(FMO3):
28363581
FMO3
[ ]
[ ]
[‘Trimethylaminuria’

c.1079T > C

]

(p.Leu360Pro)

NM_172107.2(KCNQ2):
796052620
KCNQ2
[ ]
[ ]
[‘not provided’]

c.583T > C

(p.Ser195Pro)

NM_001282227.1(CECR1):
376785840
CECR1
[ ]
[‘GAAATCAYAGG
[‘Polyarteritis

c.1232A > G

ACAAGCCTTTGG’]
nodosa’]

(p.Tyr411Cys)

NM_170707.3(LMNA):
61295588
LMNA
[ ]
[ ]
[‘Dilated

c.644T > C

cardiomyopathy 1A’,

(p.Leu215Pro)

‘not provided’]

NM_005249.4(FOXG1):
796052482
FOXG1
[ ]
[ ]
[‘not provided’]

c.673T > C

(p.Trp225Arg)

NM_000806.5(GABRA1):
796052491
GABRA1
[ ]
[ ]
[‘not provided’]

c.788T > C

(p.Met263Thr)

NM_000251.2(MSH2):
587779084
MSH2
[ ]
[ ]
[‘Hereditary

c.1319T > C

Nonpolyposis

(p.Leu440Pro)

Colorectal

Neoplasms’]

NM_003401.3(XRCC4):
587779351
XRCC4
[ ]
[ ]
[‘Ateleiotic

c.127T > C

dwarfism’]

(p.Trp43Arg)

NM_198056.2(SCN5A):
372395294
SCN5A
[‘CTCA
[‘CTCAYAGGCCAT
[‘not provided’]

c.1247A > G

YAGGC
TGCGACCACGG’]

(p.Tyr416Cys)

CATTG

CGACC

ACGG’]

NM_000257.3(MYH7):
587779392
—
[ ]
[ ]
[‘Myopathy, distal,

c.4835T > C

l’]

(p.Leu1612Pro)

NM_000257.3(MYH7):
587779393
—
[ ]
[‘GAGCCYCCAGA
[‘Myopathy, distal,

c.4937T > C

GCTTGTTGAAGG’]
l’]

(p.Leu1646Pro)

NM_000404.2(GLB1):
587779404
GLB1
[ ]
[ ]
[‘Infantile GM1

c.922T > C

gangliosidosis’]

(p.Phe308Leu)

NM_012434.4(SLC17A5):
587779410
SLC17A5
[ ]
[‘ATTGTACYCAGA
[‘Sialic acid storage

c.500T > C

GCACTAGAAGG’]
disease, severe

(p.Leu167Pro)

infantile type’]

NM_000257.3(MYH7):
587779414
—
[ ]
[ ]
[‘Myopathy, distal,

c.4442T > C

l’]

(p.Leu1481Pro)

NM_000090.3(COL3A1):
587779429
COL3A1
[ ]
[ ]
[‘Ehlers-Danlos

c.2022 + 2T > C

syndrome, type 4’]

(p.Gly660_Lys674del)

NM_004453.3(ETFDH):
765742496
ETFDH
[ ]
[ ]
[‘not provided’]

c.1852T > C

(p.Ter618Gln)

NM_000090.3(COL3A1):
587779513
COL3A1
[ ]
[‘AGGYAACCCTTA
[‘Ehlers-Danlos

c.2337 + 2T > C

ATACTACCTGG’]
syndrome, type 4’]

(p.Gly762_Lys779del)

NM_000310.3(PPT1):
796052927
PPT1
[ ]
[ ]
[‘not provided’]

c.2T > C (p.Met1Thr)

NM_020376.3(PNPLA2):
777539013
PNPLA2
[ ]
[‘GAACGGYGCGC
[‘Neutral lipid

c.757 + 2T > C

GGACCCGGGCGG’,
storage disease with

‘AACGGYGCGCGG
myopathy’]

ACCCGGGCGGG’]

NM_000090.3(COL3A1):
587779532
COL3A1
[ ]
[ ]
[‘Ehlers-Danlos

c.3039 + 6T > C

syndrome, type 4’]

(p.Asp1013_Gly1014i

nsVSSSFYSTSQ)

NM_012452.2(TNFRSF13B):
34557412
TNFRSF13B
[ ]
[‘ACTTCYGTGAGA
[‘Immunoglobulin A

c.310T > C

ACAAGCTCAGG’]
deficiency 2’,

(p.Cys104Arg)

‘Common variable

immunodeficiency

2’]

NM_000570.4(FCGR3B):
147574249
FCGR3B
[ ]
[ ]
[ ]

c.244A=

(p.Asn82=)

NM_001165963.1(SCN1A):
796052970
SCN1A
[ ]
[‘CAAGCTYTGATA
[‘not provided’]

c.1094T > C

CCTTCAGTTGG’,

(p.Phe365Ser)

‘AAGCTYTGATAC

CTTCAGTTGGG’]

NC_012920.1:m.7505
724159989
MT-TS1
[ ]
[‘CCTCCAYGACTT
[‘Deafness,

T > C

TTTCAAAAAGG’]
nonsyndromic

sensorineural,

mitochondrial’]

NM_000663.4(ABAT):
724159991
ABAT
[ ]
[ ]
[‘Gamma-

c.1433T > C

aminobutyric acid

(p.Leu478Pro)

transaminase

deficiency’]

NM_153818.1(PEX10):
724160000
PEX10
[ ]
[ ]
[‘Peroxisome

c.890T > C

biogenesis disorder

(p.Leu297Pro)

6B’]

NM_153818.1(PEX10):
724160002
PEX10
[ ]
[ ]
[‘Peroxisome

c.2T > C (p.Met1Thr)

biogenesis disorder

6B’]

NM_000090.3(COL3A1):
587779618
COL3A1
[ ]
[ ]
[‘Ehlers-Danlos

c.4399T > C

syndrome, type 4’]

(p.Ter1467Gln)

NM_002485.4(NBN):
61754966
NBN
[ ]
[ ]
[‘Microcephaly,

c.511A > G (p.Ile171Val)

normal intelligence

and

immunodeficiency’,

‘Aplastic anemia’,

‘Hereditary cancer-

predisposing

syndrome’,

‘Leukemia, acute

lymphoblastic,

susceptibility to’,

‘not specified’, ‘not

provided’]

NM_000090.3(COL3A1):
587779684
COL3A1
[ ]
[ ]
[‘Ehlers-Danlos

c.2553 + 2T > C

syndrome, type 4’]

(p.Gly816_Ala851del)

NM_021007.2(SCN2A):
796053139
SCN2A
[‘CGAA
[‘CGAAATGYAAG
[‘not provided’]

c.4308 + 2T > C

ATGYA
TCTAGTTAGAGG’,

AGTCT
‘GAAATGYAAGTC

AGTTA
TAGTTAGAGGG’]

GAGG’,

‘GAAAT

GYAAG

TCTAG

TTAGA

GGG’]

NM_021007.2(SCN2A):
796053152
SCN2A
[ ]
[ ]
[‘not provided’]

c.4718T > C

(p.Leu1573Pro)

NM_001101.3(ACTB):
587779773
ACTB
[‘GAGA
[‘GAGAAGAYGAC
[‘Baraitser-Winter

c.356T > C

AGAYG
CCAGGTGAGTGG’
syndrome 1’]

(p.Met119Thr)

ACCCA
]

GGTGA

GTGG’]

NM_021007.2(SCN2A):
796053191
SCN2A
[ ]
[ ]
[‘not provided’]

c.2306T > C

(p.Ile769Thr)

NM_014191.3(SCN8A):
796053222
SCN8A
[ ]
[‘CGTCYGATCAAA
[‘not provided’]

c.4889T > C

GGCGCCAAAGG’,

(p.Leu1630Pro)

‘GTCYGATCAAAG

GCGCCAAAGGG’]

NM_012415.3(RAD54B):
114216685
RAD54B
[ ]
[ ]
[‘Malignant

c.1778A > G

lymphoma, non-

(p.Asn593Ser)

Hodgkin’]

NM_007215.3(POLG2):
201936720
POLG2
[ ]
[ ]
[‘Autosomal

c.1105A > G

dominant

(p.Arg369Gly)

progressive external

ophthalmoplegia

with mitochondrial

DNA deletions 4’,

‘not specified’]

NM_004006.2(DMD):
754896795
DMD
[‘GCTTT
[‘GCTTTTYTTCAA
[‘Duchenne

c.6982A > T

TYTTC
GCTGCCCAAGG’]
muscular dystrophy’,

(p.Lys2328Ter)

AAGCT

‘Becker muscular

GCCCA

dystrophy’, ‘Dilated

AGG’]

cardiomyopathy 3B’]

NM_001061.4(TBXAS1):
140005285
TBXAS1
[ ]
[ ]
[‘not provided’]

c.248T > C

(p.Leu83Pro)

NM_000540.2(RYR1):
118192127
RYR1
[ ]
[‘TACTACCYGGAC
[‘Central core

c.10817T > C

CAGGTGGGTGG’,
disease’, ‘not

(p.Leu3606Pro)

‘ACTACCYGGACC
provided’]

AGGTGGGTGGG’,

‘CTACCYGGACCA

GGTGGGTGGGG’]

NM_000138.4(FBN1):
727503054
FBN1
[ ]
[ ]
[‘Thoracic aortic

c.7754T > C

aneurysms and

(p.Ile2585Thr)

aortic dissections’,

‘Marfan syndrome’]

NM_001128227.2(GNE):
28937594
GNE
[ ]
[ ]
[‘Inclusion body

c.2228T > C

myopathy 2’,

(p.Met743Thr)

‘Nonaka myopathy’]

NM_000540.2(RYR1):
118192170
RYR1
[ ]
[AGGCAYTGGGG
[‘Malignant

c.14693T > C

ACGAGATCGAGG’]
hyperthermia

(p.Ile4898Thr)

susceptibility type

1’, ‘Central core

disease’, ‘not

provided’]

NM_005247.2(FGF3):
121917703
FGF3
[ ]
[‘GTACGTGYCTGT
[‘Deafness with

c.466T > C

GAACGGCAAGG’,
labyrinthine aplasia

(p.Ser156Pro)

‘TACGTGYCTGTG
microtia and

AACGGCAAGGG’]
microdontia

(LAMM)’]

NM_005247.2(FGF3):
121917706
FGF3
[ ]
[ ]
[‘Deafness with

c.17T > C (p.Leu6Pro)

labyrinthine aplasia

microtia and

microdontia

(LAMM)’]

NM_005211.3(CSF1R):
690016549
CSF1R
[ ]
[‘CCGCCYGCCTGT
[‘Hereditary diffuse

c.2450T > C

GAAGTGGATGG’]
leukoencephalopathy

(p.Leu817Pro)

with spheroids’]

NM_005211.3(CSF1R):
690016550
CSF1R
[ ]
[ ]
[‘Hereditary diffuse

c.2480T > C

leukoencephalopathy

(p.Ile827Thr)

with spheroids’]

NM_005211.3(CSF1R):
690016552
CSF1R
[ ]
[‘GAATCCCYACCC
[‘Hereditary diffuse

c.2566T > C

TGGCATCCTGG’]
leukoencephalopathy

(p.Tyr856His)

with spheroids’]

NM_001098668.2(SFTPA2):
121917738
SFTPA2
[ ]
[‘GGAGACTYCCG
[‘Idiopathic fibrosing

c.593T > C

CTACTCAGATGG’,
alveolitis, chronic

(p.Phe198Ser)

‘GAGACTYCCGCT
form’]

ACTCAGATGGM

NM_005211.3(CSF1R):
690016559
CSF1R
[ ]
[‘AGCCYGTACCCA
[‘Hereditary diffuse

c.1957T > C

TGGAGGTAAGG’,
leukoencephalopathy

(p.Cys653Arg)

‘GCCYGTACCCAT
with spheroids’]

GGAGGTAAGGG’]

NM_005211.3(CSF1R):
690016560
CSF1R
[ ]
[‘GCAGAYCTGCTC
[‘Hereditary diffuse

c.2717T > C

CTTCCTTCAGG’]
leukoencephalopath

(p.Ile906Thr)

y with spheroids’]

NM_000540.2(RYR1):
118192179
RYR1
[ ]
[ ]
[‘Central core

c.14378T > C

disease’, ‘not

(p.Leu4793Pro)

provided’]

NM_199292.2(TH):
121917763
TH
[ ]
[ ]
[‘Segawa syndrome,

c.707T > C (p.Leu236Pro)

autosomal

recessive’]

NM_000256.3(MYBPC3):
727503176
MYBPC3
[ ]
[ ]
[‘Familial

c.2994 + 2T > C

hypertrophic

cardiomyopathy 4’]

NM_003361.3(UMOD):
121917769
UMOD
[ ]
[‘GGCCACAYGTGT
[‘Familial juvenile

c.376T > C

CAATGTGGTGG’,
gout’]

(p.Cys126Arg)

‘GCCACAYGTGTC

AATGTGGTGGG’]

NM_003361.3(UMOD):
121917773
UMOD
[ ]
[‘ATGGCACYGCC
[‘Glomerulocystic

c.943T > C

AGTGCAAACAGG’
kidney disease with

(p.Cys315Arg)

]
hyperuricemia and

isosthenuria’]

NM_024649.4(BBS1):
121917778
—
[ ]
[ ]
[‘Bardet-Biedl

c.1553T > C

syndrome 1’]

(p.Leu518Pro)

NM_172107.2(KCNQ2):
118192186
KCNQ2
[ ]
[ ]
[‘Benign familial

c.2T > C (p.Met1Thr)

neonatal seizures 1’]

NM_014324.5(AMACR):
121917814
—
[ ]
[ ]
[‘Alpha-methylacyl-

c.154T > C

CoA racemase

(p.Ser52Pro)

deficiency’, ‘Bile

acid synthesis

defect, congenital,

4’]

NM_014324.5(AMACR):
121917816
—
[ ]
[ ]
[‘Bile acid synthesis

c.320T > C

defect, congenital,

(p.Leu107Pro)

4’]

NM_007255.2(B4GALT7):
121917818
B4GALT7
[ ]
[‘TGCYCTCCAAGC
[‘Ehlers-Danlos

c.617T > C

AGCACTACCGG’]
syndrome progeroid

(p.Leu206Pro)

type’]

NM_021615.4(CHST6):
121917824
CHST6
[ ]
[‘GGACCYGGCGC
[‘Macular corneal

c.827T > C

GGGAGCCGCTGG’]
dystrophy Type I’]

(p.Leu276Pro)

NM_006261.4(PROP1):
121917841
PROP1
[ ]
[ ]
[‘Pituitary hormone

c.263T > C

deficiency,

(p.Phe88Ser)

combined 2’]

NM_000452.2(SLC10A2):
121917848
SLC10A2
[ ]
[‘TTTCYTCTGGCT
[‘Bile acid

c.728T > C

AGAATTGCTGG’]
malabsorption,

(p.Leu243Pro)

primary’]

NM_000322.4(PRPH2):
61755802
PRPH2
[ ]
[ ]
[‘Patterned

c.637T > C

dystrophy of retinal

(p.Cys213Arg)

pigment epithelium’,

‘not provided’, ‘Leber

congenital

amaurosis 18’]

NM_000517.4(HBA2):
41341344
HBA2
[ ]
[ ]
[‘Hemoglobin H

c.89T > C (p.Leu30Pro)

disease,

nondeletional’]

NM_002181.3(IHH):
121917857
IHH
[ ]
[ ]
[‘Acrocapitofemoral

c.569T > C (p.Val190Ala)

dysplasia’]

NM_000322.4(PRPH2):
61755817
PRPH2
[‘ACCT
[‘ACCTGYGGGTGC
[‘Retinitis

c.736T > C

GYGGG
GTGGCTGCAGG’,
pigmentosa’, ‘not

(p.Trp246Arg)

TGCGT
‘CCTGYGGGTGCG
provided’]

GGCTG
TGGCTGCAGGG’]

CAGG’,

‘CCTGY

GGGTG

CGTGG

CTGCA

GGG’]

NM_005413.3(SIX3):
121917880
SIX3
[ ]
[ ]
[‘Holoprosencephaly

c.749T > C

2’]

(p.Val250Ala)

NM_000124.3(ERCC6):
121917905
ERCC6
[‘TGCY
[‘TGCYAAAAGAC
[Cerebro-oculo-

c.2960T > C

AAAAG
CCAAAACAAAGG’
facio-skeletal

(p.Leu987Pro)

ACCCA
]
syndrome’]

AAACA

AAGG’]

NM_006920.4(SCN1A):
121917919
—
[ ]
[ ]
[‘Severe myoclonic

c.4729T > C

epilepsy in infancy’,

(p.Cys1577Arg)

‘not provided’]

NM_006920.4(SCN1A):
121917926
—
[ ]
[ ]
[‘Severe myoclonic

c.5113T > C

epilepsy in infancy’,

(p.Cys1705Arg)

‘not provided’]

NM_006920.4(SCN1A):
121917930
—
[‘AACA
[‘AACAAYGGTGG
[‘Generalized

c.3577T > C

AYGGT
AACCTGAGAAGG’]
epilepsy with febrile

(p.Trp1193Arg)

GGAAC

seizures plus, type

CTGAG

1’, ‘Generalized

AAGG’]

epilepsy with febrile

seizures plus, type

2’]

NM_006920.4(SCN1A):
121917938
SCN1A
[ ]
[ ]
[‘Severe myoclonic

c.838T > C

epilepsy in infancy’]

(p.Trp280Arg)

NM_000478.4(ALPL):
121918006
ALPL
[ ]
[IGGACYATGGTG
[‘Infantile

c.1306T > C

AGACCTCCAGG’]
hypophosphatasia’]

(p.Tyr436His)

NM_000478.4(ALPL):
121918010
ALPL
[ ]
[CAAAGGCYTCTT
[‘Infantile

c.979T > C

CTTGCTGGTGG’,
hypophosphatasia’]

(p.Phe327Leu)

‘GGCYTCTTCTTGC

TGGTGGAAGG’]

NM_000301.3(PLG):
121918029
PLG
[ ]
[ ]
[‘Dysplasminogenem

c.1771T > C

ia’]

(p.5er591Pro)

NM_000174.4(GP9):
121918038
GP9
[ ]
[ ]
[‘Bernard-Soulier

c.20T > C (p.Leu7Pro)

syndrome type C’]

NM_000371.3(TTR):
121918079
TTR
[ ]
[ ]
[‘Amyloidogenic

c.224T > C (p.Leu75Pro)

transthyretin

amyloidosis’]

NM_000371.3(TTR):
121918083
TTR
[ ]
[ ]
[‘Amyloidogenic

c.88T > C (p.Cys30Arg)

transthyretin

amyloidosis’,

‘Cardiomyopathy’]

NM_000371.3(TTR):
121918084
TTR
[ ]
[ ]
[‘Amyloidogenic

c.272T > C (p.Val91Ala)

transthyretin

amyloidosis’]

NM_000371.3(TTR):
121918088
TTR
[ ]
[‘TCCCYACTCCTA
[ ]

c.400T > C (p.Tyr134His)

TTCCACCACGG’]

NM_012275.2(IL36R
148755083
IL36RN
[ ]
[ ]
[‘Pustular psoriasis,

N):c.115 + 6T > C

generalized’]

NM_000371.3(TTR):
121918094
TTR
[ ]
[ ]
[‘Amyloidogenic

c.95T > C (p.Leu32Pro)

transthyretin

amyloidosis’]

NM_000371.3(TTR):
121918100
TTR
[ ]
[ ]
[‘AMYLOIDOSIS,

c.265T > C (p.Tyr89His)

LEPTOMENINGEA

L,

TRANSTHYRETIN

-RELATED’]

NM_001042465.1(PSAP):
121918110
PSAP
[ ]
[‘GAAGCYGCCGA
[‘Gaucher disease,

c.1055T > C

AGTCCCTGTCGG’]
atypical, due to

(p.Leu352Pro)

saposin C

deficiency’]

NM_013251.3(TAC3):
121918123
TAC3
[ ]
[ ]
[‘not provided’]

c.269T > C

(p.Met90Thr)

NM_199069.1(NDUFAF3):
121918136
NDUFAF3
[ ]
[ ]
[‘Mitochondrial

c.2T > C

complex I

(p.Met1Thr)

deficiency’]

NM_003730.4(RNASET2):
121918137
RNASET2
[ ]
[CCAGYGCCTTCC
[‘Leukoencephalopat

c.550T > C

ACCAAGCCAGG’]
hy, cystic, without

(p.Cys184Arg)

megalencephaly’]

NM_203395.2(IYD):
121918139
IYD
[ ]
[ ]
[‘Iodotyrosine

c.347T > C (p.Ile116Thr)

deiodination defect’]

NM_001127628.1(FBP1):
121918191
FBP1
[ ]
[‘GGAGTYCATTTT
[‘Fructose-

c.581T > C

GGTGGACAAGG’]
biphosphatase

(p.Phe194Ser)

deficiency’]

NM_015506.2(MMACHC):
121918240
MMACHC
[ ]
[ ]
[‘Methylmalonic

c.347T > C

acidemia with

(p.Leull6Pro)

homocystinuria’]

NM_000255.3(MUT):
121918249
MUT
[ ]
[ ]
[‘METHYLMALON

c.313T > C

IC ACIDURIA,

(p.Trp105Arg)

mut(0) TYPE’]

NM_022370.3(ROBO3):
121918275
ROB03
[ ]
[ ]
[‘Gaze palsy,

c.14T > C

familial horizontal,

(p.Leu5Pro)

with progressive

scoliosis’]

NM_018400.3(SCN3B):
121918282
SCN3B
[ ]
[ ]
[‘Brugada

c.29T > C

syndrome’, ‘Brugada

(p.Leul0Pro)

syndrome 7’,

‘Cardiac arrhythmia’,

‘Atrial fibrillation,

familial, 16’]

NM_004183.3(BEST1):
121918288
BEST1
[ ]
[ ]
[‘Bestrophinopathy,

c.122T > C

autosomal recessive’,

(p.Leu41Pro)

‘not provided’]

NM_020166.4(MCCC1):
772395858
MCCC1
[ ]
[ ]
[‘3 Methylcrotonyl-

c.640-2A > G

CoA carboxylase 1

deficiency’]

NM_004817.3(TJP2):
121918299
TJP2
[ ]
[ ]
[‘Hypercholanemia,

c.143T > C (p.Val48Ala)

familial’]

NM_006946.2(SPTBN2):
121918306
SPTBN2
[ ]
[‘ACCAAGCYGCT
[‘Spinocerebellar

c.758T > C

GGATCCCGAAGG’,
ataxia 5’]

(p.Leu253Pro)

‘AAGCYGCTGGAT

CCCGAAGGTGG’,

‘AGCYGCTGGATC

CCGAAGGTGGG’]

NM_000214.2(JAG1):
121918352
JAG1
[ ]
[ ]
[‘Alagille syndrome

c.110T > C

l’]

(p.Leu37Ser)

NM_007194.3(CHEK2):
17879961
CHEK2
[ ]
[ ]
[‘Familial cancer of

c.470T > C

breast’, ‘Hereditary

(p.Ile157Thr)

cancer-predisposing

syndrome’, ‘Li-

Fraumeni syndrome

2’, ‘not specified’]

NM_015384.4(NIPBL):
727503772
NIPBL
[ ]
[ ]
[‘Cornelia de Lange

c.7637T > C

syndrome 1’]

(p.Leu2546Pro)

NM_001083112.2(GPD2):
121918407
GPD2
[‘AAGT
[‘AAGTYTGATGCA
[‘Diabetes mellitus

c.1904T > C

YTGAT
GACCAGAAAGG’]
type 2’]

(p.Phe635Ser)

GCAGA

CCAGA

AAGG’]

NM_021957.3(GYS2):
121918424
GYS2
[ ]
[ ]
[‘Hypoglycemia with

c.1447T > C

deficiency of

(p.Ser483Pro)

glycogen synthetase

in the liver’]

NM_018849.2(ABCB4):
121918443
ABCB4
[ ]
[ ]
[‘Progressive

c.1207T > C

familial intrahepatic

(p.Tyr403His)

cholestasis 3’]

NM_000212.2(ITGB3):
121918447
—
[ ]
[ ]
[‘Glanzmann

c.2332T > C

thrombasthenia’]

(p.Ser778Pro)

NM_000506.3(F2):
121918481
F2
[ ]
[ ]
[‘Hereditary factor II

c.1139T > C

deficiency disease’]

(p.Met380Thr)

NM_000141.4(FGFR2):
121918489
FGFR2
[‘TGGG
[‘TGGGGAAYATA
[‘Crouzon

c.1018T > C

GAAYA
CGTGCTTGGCGG’,
syndrome’]

(p.Tyr340His)

TACGT
‘GGGGAAYATACG

GCTTG
TGCTTGGCGGG’]

GCGG’,

‘GGGGA

AYATA

CGTGC

TTGGC

GGG’]

NM_000141.4(FGFR2):
121918505
FGFR2
[ ]
[‘AATGCCYCCACA
[‘Pfeiffer syndrome’,

c.799T > C

GTGGTCGGAGG’]
‘Neoplasm of

(p.Ser267Pro)

stomach’]

NM_002739.3(PRKCG):
121918512
PRKCG
[ ]
[ ]
[‘Spinocerebellar

c.355T > C

ataxia 14’]

(p.Ser119Pro)

NM_002739.3(PRKCG):
121918516
PRKCG
[ ]
[ ]
[‘Spinocerebellar

c.1927T > C

ataxia 14’]

(p.Phe643Leu)

NM_015107.2(PHF8):
121918524
PHF8
[ ]
[ ]
[Siderius X-linked

c.836T > C

mental retardation

(p.Phe279Ser)

syndrome’]

NM_000311.3(PRNP):
74315405
PRNP
[ ]
[ ]
[‘Gerstmann-

c.593T > C

Straussler-Scheinker

(p.Phe198Ser)

syndrome’, ‘Genetic

prion diseases’]

NM_015665.5(AAAS):
121918550
AAAS
[ ]
[ ]
[Glucocorticoid

c.787T > C

deficiency with

(p.Ser263Pro)

achalasia’]

NM_003018.3(SFTPC):
121918560
SFTPC
[ ]
[ ]
[‘Surfactant

c.581T > C

metabolism

(p.Leu194Pro)

dysfunction,

pulmonary, 2’]

NM_000322.4(PRPH2):
121918563
PRPH2
[ ]
[ ]
[‘Patterned

c.554T > C

dystrophy of retinal

(p.Leu185Pro)

pigment epithelium’,

‘Retinitis pigmentosa

7, digenic’, ‘not

provided’, ‘Leber

congenital

amaurosis 181

NM_000322.4(PRPH2):
121918565
PRPH2
[ ]
[ ]
[‘Macular dystrophy,

c.2T > C (p.Met1Thr)

vitelliform, adult-

onset’, ‘not

provided’]

NM_001035.2(RYR2):
121918602
RYR2
[ ]
[ ]
[‘Arrhythmogenic

c.1298T > C

right ventricular

(p.Leu433Pro)

cardiomyopathy,

type 2’,

‘Catecholaminergic

polymorphic

ventricular

tachycardia’, ‘Long

QT syndrome’]

NM_001199138.1(NLRC4):
587781260
NLRC4
[ ]
[ ]
[‘Syndrome of

c.1022T > C

entercolitis and

(p.Val341Ala)

autoinflmmation

caused by mutation

of NLRC4

(SCAN4)’,

‘Autoinflammation

with infantile

enterocolitis’]

NM_000702.3(ATP1A2):
121918617
ATP1A2
[ ]
[ ]
[‘Familial

c.857T > C

hemiplegic migraine

(p.Ile286Thr)

type 2’]

NM_006920.4(SCN1A):
121918627
—
[ ]
[ ]
[‘Generalized

c.4250T > C

epilepsy with febrile

(p.Val1417Ala)

seizures plus, type

1’, ‘Generalized

epilepsy with febrile

seizures plus, type

2’]

NM_006920.4(SCN1A):
121918631
SCN1A
[ ]
[ ]
[‘Generalized

c.434T > C

epilepsy with febrile

(p.Met145Thr)

seizures plus, type

2’]

NM_006920.4(SCN1A):
121918632
—
[ ]
[ ]
[‘Familial

c.4462T > C

hemiplegic migraine

(p.Phe1488Leu)

type 3’]

NM_003126.2(SPTA1):
121918636
SPTA1
[ ]
[ ]
[‘Elliptocytosis 2’]

c.781T > C

(p.Ser261Pro)

NM_003126.2(SPTA1):
121918643
SPTA1
[ ]
[‘GTGGAGCYGGT
[‘Hereditary

c.620T > C

AGCTAAAGAAGG’,
pyropoikilocytosis’,

(p.Leu207Pro)

‘TGGAGCYGGTAG
‘Elliptocytosis 2’]

CTAAAGAAGGG’]

NM_001024858.2(SPTB):
121918646
SPTB
[ ]
[CTCCAGCYGGA
[‘Spherocytosis type

c.604T > C

AGGATGGCTTGG’]
2’]

(p.Trp202Arg)

NM_001024858.2(SPTB):
121918648
SPTB
[ ]
[‘ATGCCYCTGTGG
[ ]

c.6055T > C

CTGAGGCGTGG’]

(p.Ser2019Pro)

NM_001128177.1(THRB):
121918699
THRB
[ ]
[ ]
[ ]

c.929T > C

(p.Met310Thr)

NM_001128177.1(THRB):
121918704
THRB
[ ]
[ ]
[‘Thyroid hormone

c.1373T > C

resistance,

(p.Val458Ala)

generalized,

autosomal

recessive’]

NM_000421.3(KRT10):
60118264
—
[ ]
[ ]
[‘Bullous

c.482T > C

ichthyosiform

(p.Leu161Ser)

erythroderma’, ‘not

provided’]

NM_006920.4(SCN1A):
121918733
SCN1A
[‘ACTTY
[‘ACTTYTATAGTA
[‘Severe myoclonic

c.269T > C

TATAG
TTGAATAAAGG’,
epilepsy in infancy’]

(p.Phe90Ser)

TATTG
‘CTTYTATAGTATT

AATAA
GAATAAAGGG’]

AGG’,

‘CTTYT

ATAGT

ATTGA

ATAAA

GGG’]

NM_006920.4(SCN1A):
121918734
SCN1A
[‘ACTTT
[‘ACTTTTAYAGTA
[‘Severe myoclonic

c.272T > C

TAYAG
TTGAATAAAGG’,
epilepsy in infancy’]

(p.Ile91Thr)

TATTG
‘CTTTTAYAGTATT

AATAA
GAATAAAGGAG’]

AGG’,

‘CTTTT

AYAGT

ATTGA

ATAAA

GGG’]

NM_006920.4(SCN1A):
121918740
—
[ ]
[ ]
[‘Severe myoclonic

c.3827T > C

epilepsy in infancy’]

(p.Leu1276Pro)

NM_000543.4(SMPD1):
727504166
SMPD1
[ ]
[IGAGGCCYGTG
[‘Niemann-Pick

c.475T > C

GCCTGCTCCTGG’,
disease, type A’,

(p.Cys159Arg)

‘GAGGCCYGTGGC
‘Niemann-Pick

CTGCTCCTGGG’]
disease, type B’]

NM_006920.4(SCN1A):
121918773
SCN1A
[ ]
[ ]
[‘Severe myoclonic

c.568T > C

epilepsy in infancy’]

(p.Trp190Arg)

NM_006920.4(SCN1A):
121918783
—
[ ]
[ ]
[‘Severe myoclonic

c.5522T > C

epilepsy in infancy’,

(p.Met1841Thr)

‘Generalized

epilepsy with febrile

seizures plus, type

1’]

NM_002538.3(0CLN):
267606926
OCLN
[ ]
[ ]
[‘Band-like

c.656T > C

calcification with

(p.Phe219Ser)

simplified gyration

and polymicrogyria’]

NM_000434.3(NEU1):
193922915
NEU1
[ ]
[CAGCYATGGCC
[Sialidosis, type II’]

c.1088T > C

AGGCCCCAGTGG’]

(p.Leu363Pro)

NM_198578.3(LRRK2):
35870237
LRRK2
[ ]
[ ]
[‘Parkinson disease

c.6059T > C

8, autosomal

(p.Ile2020Thr)

dominant’]

NM_000501.3(ELN):
727504419
ELN
[ ]
[‘CAGGYAACATCT
[Supravalvar aortic

c.889 + 2T > C

GTCCCAGCAGG’,
stenosis’]

‘AGGYAACATCTG

TCCCAGCAGGG’]

NM_001085.4(SERPINA3):
1800463
SERPINA3
[ ]
[ ]
[ ]

c.233T > C

(p.Leu78Pro)

NM_000238.3(KCNH2):
199473425
KCNH2

[‘Congenital long

c.1736T > C

QT syndrome’]

(p.Met579Thr)

NM_001211.5(BUB1B):
28989185
—
[ ]
[ ]
[‘Mosaic variegated

c.3035T > C

aneuploidy

(p.Leu1012Pro)

syndrome’,

‘Premature

chromatid separation

trait’]

NM_000256.3(MYBPC3):
376395543
MYBPC3
[ ]
[‘GAGACYGAAGG
[‘Primary familial

c.26-2A > G

GCCAGGTGGAGG’]
hypertrophic

cardiomyopathy’,

‘Familial

hypertrophic

cardiomyopathy 4’,

‘Cardiomyopathy’]

NM_000051.3(ATM):
587781927
ATM
[ ]
[ ]
[‘Ataxia-

c.4776 + 2T > C

telangiectasia

syndrome’,

‘Hereditary cancer-

predisposing

syndrome’]

NM_006412.3(AGPAT2):
116807569
AGPAT2
[ ]
[ ]
[‘Congenital

c.589-2A > G

generalized

lipodystrophy type

1’]

NM_000545.6(HNF1A):
1169305
HNFlA
[ ]
[GATGCYGGCAG
[‘Maturity-onset

c.1720G > A

GGTCCTGGCTGG’,
diabetes of the

(p.Gly574Ser)

‘ATGCYGGCAGGG
young, type 3’]

TCCTGGCTGGG’,

‘TGCYGGCAGGGT

CCTGGCTGGGG’]

NM_024514.4(CYP2R1):
61495246
CYP2R1
[ ]
[ ]
[‘Vitamin d

c.296T > C

hydroxylation-

(p.Leu99Pro)

deficient rickets,

type 1b’]

NM_012213.2(MLYCD):
28937908
MLYCD
[ ]
[ ]
[‘Deficiency of

c.119T > C

malonyl-CoA

(p.Met40Thr)

decarboxylase’]

NM_001101.3(ACTB):
587779771
ACTB
[ ]
[ ]
[‘Baraitser-Winter

c.224T > C

syndrome 1’]

(p.Ile75Thr)

NM_021007.2(SCN2A):
796053181
SCN2A
[‘TGTG
[‘TGTGGYGGCCAT
[‘not provided’]

c.1271T > C

GYGGC
GGCCTATGAGG’]

(p.Val424Ala)

CATGG

CCTAT

GAGGl

NM_002880.3(RAF1):
727505017
RAF1
[ ]
[ ]
[‘Rasopathy’, ‘not

c.769T > C

specified’]

(p.Ser257Pro)

NM_000527.4(LDLR):
730880130
LDLR
[ ]
[CTACYGGACCG
[‘Familial

c.1468T > C

ACTCTGTCCTGG’,
hypercholesterolemial

(p.Trp490Arg)

‘TACYGGACCGAC

TCTGTCCTGGG]

NM_170707.3(LMNA):
730880132
LMNA
[‘TGAG
[‘TGAGTYTGAGA
[‘Primary dilated

c.710T > C

TYTGA
GCCGGCTGGCGG’]
cardiomyopathy’]

(p.Phe237Ser)

GAGCC

GGCTG

GCGG’]

NM_000080.3(CHRNE):
193919341
—
[ ]
[ ]
[‘MYASTHENIC

c.223T > C

SYNDROME,

(p.Trp75Arg)

CONGENITAL, 4B,

FAST-CHANNEL’]

NM_005211.3(CSF1R):
281860270
CSF1R
[ ]
[ ]
[‘Hereditary diffuse

c.2297T > C

leukoencephalopath

(p.Met766Thr)

y with spheroids’]

NM_005211.3(CSF1R):
281860274
CSF1R
[‘CAAG
[‘CAAGAYTGGGG
[‘Hereditary diffuse

c.2381T > C

AYTGG
ACTTCGGGCTGG’]
leukoencephalopathy

(p.Ile794Thr)

GGACT

with spheroids’]

TCGGG

CTGG’]

NM_005211.3(CSF1R):
281860277
CSF1R
[ ]
[ ]
[‘Hereditary diffuse

c.2546T > C

leukoencephalopath

(p.Phe849Ser)

y with spheroids’]

NM_005211.3(CSF1R):
281860279
CSF1R
[ ]
[ ]
[‘Hereditary diffuse

c.2624T > C

leukoencephalopath

(p.Met875Thr)

y with spheroids’]

NM_018713.2(SLC30A10):
281860284
SLC30A10
[ ]
[ ]
[‘Hypermanganesem

c.266T > C

ia with dystonia,

(p.Leu89Pro)

polycythemia and

cirrhosis’]

NM_018713.2(SLC30A10):
281860286
SLC30A10
[ ]
[‘GGCGCTTYCGGG
[‘Hypermanganesem

c.500T > C

GGGCCTCAGGG’]
ia with dystonia,

(p.Phe167Ser)

polycythemia and

cirrhosis’]

NM_018713.2(SLC30A10):
281860291
SLC30A10
[ ]
[ ]
[‘Hypermanganesem

c.1046T > C

ia with dystonia,

(p.Leu349Pro)

polycythemia and

cirrhosis’]

NM_016218.2(POLK):
772307321
POLK
[ ]
[ ]
[‘Malignant tumor of

c.2287T > A

prostate’]

(p.Tyr763Asn)

NM_000570.4(FCGR3B):
448740
FCGR3B
[ ]
[ ]
[ ]

c.194A > G

(p.Asn65Ser)

NM_030653.3(DDX11):
730880279
DDX11
[‘TCCA
[‘TCCAGGYGCGG
[‘Warsaw breakage

c.2271 + 2T > C

GGYGC
GCGTCATGCTGG’,
syndrome’]

GGGCG
‘CCAGGYGCGGGC

TCATG
GTCATGCTGGG’]

CTGG’]

NM_145693.2(LPIN1):
730880306
LPIN1
[ ]
[AAGGYACCGCG
[‘Myoglobinuria,

c.1441 + 2T > C

GGCCTCGCGCGG’,
acute recurrent,

‘AGGYACCGCGGG
autosomal

CCTCGCGCGGG’]
recessive’]

NM_002546.3(TNFRSH1B):
200071478
TNFRSF11B
[ ]
[ ]
[‘Hyperphosphatase

c.226A > C

mia with bone

(p.Thr76Pro)

disease’]

NM_000166.5(GJB1):
116840817
GJB1
[ ]
[ ]
[‘X-linked hereditary

c.145T > C (p.Ser49Pro)

motor and sensory

neuropathy’]

NM_005159.4(ACTC1):
730880398
—
[ ]
[ ]
[‘Cardiomyopathy’]

c.755T > C

(p.Ile252Thr)

NM_020166.4(MCCC1):
147741073
MCCC1
[ ]
[ ]
[‘3 Methylcrotonyl-

c.205A > T

CoA carboxylase 1

(p.Lys69Ter)

deficiency’]

NM_000454.4(SOD1):
74315452
SOD1
[ ]
[‘TTGCAYCATTGG
[‘Amyotrophic

c.338T > C

CCGCACACTGG’]
lateral sclerosis type

(p.Ile113Thr)

1’]

NM_000169.2(GLA):
730880455
—
[ ]
[‘CGCGCYTGCGCT
[‘not provided’]

c.41T > C (p.Leu14Pro)

TCGCTTCCTGG’]

NM_152743.3(BRAT1):
727505363
BRAT1
[ ]
[ ]
[‘Rigidity and

c.176T > C

multifocal seizure

(p.Leu59Pro)

syndrome, lethal

neonatal’]

NM_005633.3(SOS1):
727505381
SOS1
[ ]
[ ]
[‘Noonan syndrome’,

c.2104T > C

‘Rasopathy’]

(p.Tyr702His)

m.1095T > C
267606618
MT-RNR1
[ ]
[ ]
[‘Aminoglycoside-

induced deafness’,

‘Auditory

neuropathy’,

‘Deafness,

nonsyndromic

sensorineural,

mitochondrial’, ‘not

specified’]

m.1291T > C
267606620
MT-RNR1
[ ]
[ ]
[‘Deafness,

nonsyndromic

sensorineural,

mitochondrial’]

NM_020247.4(ADCK3):
606231138
ADCK3
[ ]
[ ]
[‘Coenzyme Q10

c.1398 + 2T > C

deficiency, primary,

4’]

NM_000256.3(MYBPC3):
730880616
MYBPC3
[ ]
[ ]
[‘Cardiomyopathy’]

c.467T > C

(p.Leu156Pro)

NM_022458.3(LMBR1):
606231149
LMBR1
[ ]
[ ]
[‘Triphalangeal

c.423 + 4842T > C

thumb’, ‘Preaxial

polydactyly 2’]

NM_022458.3(LMBR1):
606231152
LMBR1
[ ]
[ ]
[‘Triphalangeal

c.423 + 4808T > C

thumb’, ‘Preaxial

polydactyly 2’]

NM_021102.3(SPINT2):
606231155
SPINT2
[ ]
[ ]
[‘Diarrhea 3,

c.337 + 2T > C

secretory sodium,

congenital,

syndromic’]

NM_001004127.2(ALG11):
267606652
ALG11
[ ]
[ ]
[‘Congenital disorder

c.257T > C

of glycosylation type

(p.Leu86Ser)

1P’]

NM_054027.4(ANKH):
267606656
ANKH
[ ]
[‘AGCTCYGTTTCG
[‘Craniometaphyseal

c.1015T > C

TGATGTTTTGG’]
dysplasia, autosomal

(p.Cys339Arg)

dominant’]

NM_054027.4(ANKH):
267606658
—
[ ]
[ ]
[‘Craniometaphyseal

c.1172T > C

dysplasia, autosomal

(p.Leu391Pro)

dominant’]

NM_175073.2(APTX):
267606665
APTX
[ ]
[ ]
[‘Adult onset ataxia

c.668T > C

with oculomotor

(p.Leu223Pro)

apraxia’]

NM_004183.3(BEST1):
267606679
BEST1
[‘CACT
[‘CACTGGYGTATA
[‘Vitreoretinochoroid

c.704T > C

GGYGT
CACAGGTGAGG’]
opathy dominant’]

(p.Val235Ala)

ATACA

CAGGT

GAGG’]

NM_004183.3(BEST1):
267606680
BEST1
[ ]
[ ]
[‘Retinitis

c.614T > C

pigmentosa 50’]

(p.Ile205Thr)

NM_033409.3(SLC52A3):
267606685
SLC52A3
[ ]
[ ]
[Brown-Vialetto-

c.670T > C

Van laere

(p.Phe224Leu)

syndrome’]

NM_033409.3(SLC52A3):
267606687
SLC52A3
[ ]
[‘AGTTACGYCAA
[Brown-Vialetto-

c.1238T > C

GGTGATGCTGGG’]
Van laere

(p.Val413Ala)

syndrome’]

NM_004056.4(CA8):
267606695
CA8
[ ]
[ ]
[‘Cerebellar ataxia,

c.298T > C (p.Ser100Pro)

mental retardation,

and dysequilibrium

syndrome 3’]

NM_000256.3(MYBPC3):
730880702
MYBPC3
[ ]
[ ]
[‘Cardiomyopathy’]

c.3713T > C

(p.Leu1238Pro)

NM_001928.2(CFD):
267606721
CFD
[ ]
[‘GGTGYGCGGGG
[‘Complement factor

c.640T > C

GCGTGCTCGAGG’,
d deficiency’]

(p.Cys214Arg)

‘GTGYGCGGGGGC

GTGCTCGAGGM

NM_005740.2(DNAL4):
606231254
DNAL4
[‘CGAG
[‘CGAGGYATTGCC
[‘Mirror movements

c.153 + 2T > C

GYATT
AGCAGTGCAGG’]
3’]

GCCAG

CAGTG

CAGG’]

NM_020975.4(RET):
74799832
RET
[ ]
[ ]
[‘Multiple endocrine

c.2753T > C

neoplasia, type 2a’,

(p.Met918Thr)

‘Multiple endocrine

neoplasia, type 2b’,

‘Multiple endocrine

neoplasia, type 2’,

‘Pheochromocytoma’,

‘not provided’]

NM_001849.3(COL6A2):
267606747
COL6A2
[ ]
[‘CGCCYGCGACA
[‘Ullrich congenital

c.2329T > C

AGCCACAGCAGG’]
muscular dystrophy’]

(p.Cys777Arg)

NM_001006657.1(WDR35):
431905505
WDR35
[ ]
[ ]
[‘Short rib

c.781T > C

polydactyly

(p.Trp261Arg)

syndrome 5’]

NM_003764.3(STX11):
431905512
STX11
[‘TGCY
[‘TGCYGGTGGCCG
[‘Hemophagocytic

c.173T > C

GGTGG
ACGTGAAGCGG’]
lymphohistiocytosis,

(p.Leu58Pro)

CCGAC

familial, 4’]

GTGAA

GCGG’]

NM_001044.4(SLC6A3):
431905515
SLC6A3
[ ]
[‘CTGCACCYCCAC
[‘Infantile

c.671T > C

CAGAGCCATGG’]
Parkinsonism-

(p.Leu224Pro)

dystonia’]

NM_000277.1(PAH):
62642930
PAH
[ ]
[ ]
[‘Phenylketonuria’,

c.764T > C

‘not provided’]

(p.Leu255Ser)

NM_000277.1(PAH):
62642936
PAH
[ ]
[ ]
[‘Phenylketonuria’,

c.932T > C

‘not provided’]

(p.Leu311Pro)

NM_000118.3(ENG):
267606783
ENG
[ ]
[ ]
[‘Osler hemorrhagic

c.2T > C (p.Met1Thr)

telangiectasia

syndrome’]

NM_000129.3(F13A1):
267606788
F13A1
[‘TGTG
[‘TGTGAYGGACA
[‘Factor xiii, a

c.728T > C

AYGGA
GAGCACAAATGG’]
subunit, deficiency

(p.Met243Thr)

CAGAG

of’]

CACAA

ATGG’]

NM_000257.3(MYH7):
606231328
MYH7
[ ]
[ ]
[‘Familial

c.1952A > G

cardiomyopathy’]

(p.His651Arg)

NM_014053.3(FLVCR1):
267606821
FLVCR1
[ ]
[ ]
[‘Posterior column

c.574T > C

ataxia with retinitis

(p.Cys192Arg)

pigmentosa’]

NM_005249.4(FOXG1):
267606828
FOXG1
[ ]
[ ]
[‘Rett syndrome,

c.643T > C

congenital variant’]

(p.Phe215Leu)

NM_015474.3(SAMHD1):
515726140
SAMHD1
[ ]
[ ]
[‘Aicardi Goutieres

c.1153A > G

syndrome 5’]

(p.Met385Val)

NM_015474.3(SAMHD1):
515726141
SAMHD1
[ ]
[ ]
[‘Aicardi Goutieres

c.1411-2A > G

syndrome 5’]

NM_000180.3(GUCY2D):
267606857
GUCY2D
[ ]
[‘AGAGAYCGCCA
[‘Cone-rod

c.2846T > C

ACATGTCACTGG’]
dystrophy 6’]

(p.Ile949Thr)

NM_022489.3(INF2):
267606877
INF2
[ ]
[ ]
[‘Focal segmental

c.556T > C

glomerulosclerosis

(p.Ser186Pro)

5’]

NM_000257.3(MYH7):
730880863
MYH7
[ ]
[ ]
[‘Cardiomyopathy’]

c.1048T > C

(p.Tyr350His)

NM_022489.3(INF2):
267606880
INF2
[ ]
[‘GCTGCYCCAGAT
[‘Focal segmental

c.125T > C (p.Leu42Pro)

GCCCTCTGTGG’]
glomerulosclerosis

5’]

m.4681T > C
267606889
MT-ND2
[ ]
[ ]
[‘Leigh disease’,

‘Leigh syndrome due

to mitochondrial

complex I

deficiency’]

m.10191T > C
267606890
MT-ND3
[ ]
[ ]
[‘Leigh disease’,

‘Mitochondrial

complex I

deficiency’]

m.10563T > C
267606892
MT-ND4L
[ ]
[ ]
[‘Familial colorectal

cancer’]

m.12706T > C
267606893
MT-NDS
[ ]
[ ]
[‘Leigh disease’,

‘Leigh syndrome due

to mitochondrial

complex I

deficiency’]

NM_015713.4(RRM2B):
515726190
RRM2B
[ ]
[ ]
[‘RRM2B-related

c.556A > G

mitochondrial

(p.Arg186G1y)

disease’]

NM_015713.4(RRM2B):
515726191
RRM2B
[ ]
[‘AACTCCTYCTAC
[‘RRM2B-related

c.581A > G

AGCAGCAAAGG’]
mitochondrial

(p.Glu194G1y)

disease’]

NM_000315.2(PTH):
104894271
PTH
[‘AATT
[‘AATTYGTTTTCT
[‘Hypoparathyroidism

c.52T > C (p.Cys18Arg)

YGTTT
TACAAAATCGG’]
familial isolated’]

TCTTA

CAAAA

TCGG’]

NM_001136271.2(NKX2-6):
267606914
NKX2-6
[ ]
[ ]
[‘Persistent truncus

c.451T > C

arteriosus’]

(p.Phe151Leu)

NM_004646.3(NPHS1):
267606917
NPHS1
[ ]
[‘GCTGCCGYGCGT
[‘Finnish congenital

c.793T > C

GGCCCGAGGGG’,
nephrotic

(p.Cys265Arg)

‘CTGCCGYGCGTG
syndrome’]

GCCCGAGGGGG’]

NM_000406.2(GNRHR):
515726219
GNRHR
[ ]
[ ]
[‘Hypogonadotropic

c.94A > G

hypogonadism’]

(p.Thr32Ala)

NM_152296.4(ATP1A3):
606231436
ATP1A3
[ ]
[ ]
[‘Alternating

c.2270T > C

hemiplegia of

(p.Leu757Pro)

childhood 2’]

NM_000513.2(OPN1MW):
267606927
OPN1MW
[ ]
[ ]
[‘Cone dystrophy 5,

c.529T > C

X-linked’]

(p.Trp177Arg)

NM_152296.4(ATP1A3):
606231448
ATP1A3
[ ]
[ ]
[‘Dystonia 12’]

c.1144T > C

(p.Trp382Arg)

NM_024411.4(PDYN):
267606940
PDYN
[ ]
[ ]
[‘Spinocerebellar

c.632T > C

ataxia 23’]

(p.Leu211Ser)

NM_000444.5(PHEX):
267606945
PHEX
[ ]
[ ]
[‘Familial X-linked

c.755T > C

hypophosphatemic

(p.Phe252Ser)

vitamin D refractory

rickets’]

NM_001543.4(NDST1):
606231458
NDST1
[ ]
[ ]
[‘Mental retardation,

c.1918T > C

autosomal recessive

(p.Phe640Leu)

46’]

NM_013382.5(POMT2):
267606964
POMT2
[ ]
[ ]
[‘Congenital

c.2242T > C

muscular dystrophy-

(p.Trp748Arg)

dystroglycanopathy

with mental

retardation, type

B2’]

NM_006121.3(KRT1):
57695159
KRT1
[ ]
[ ]
[‘Bullous

c.482T > C

ichthyosiform

(p.Leu161Pro)

erythroderma’, ‘not

provided’]

NM_016203.3(PRKAG2):
267606976
PRKAG2
[ ]
[ ]
[‘Familial

c.1459T > C

hypertrophic

(p.Tyr487His)

cardiomyopathy 6’,

‘not provided’]

NM_016203.3(PRKAG2):
267606979
PRKAG2
[ ]
[ ]
[‘Familial

c.1642T > C

hypertrophic

(p.Ser548Pro)

cardiomyopathy 6’,

‘not provided’]

NM_198965.1(PTHLH):
267606985
PTHLH
[ ]
[ ]
[‘Brachydactyly type

c.179T > C

E2’]

(p.Leu60Pro)

NM_198965.1(PTHLH):
267606986
PTHLH
[ ]
[ ]
[‘Brachydactyly type

c.131T > C

E2’]

(p.Leu44Pro)

NM_004990.3(MARS):
140467171
MARS
[ ]
[ ]
[‘Interstitial lung and

c.1108T > C

liver disease’]

(p.Phe370Leu)

NM_173560.3(RFX6):
267607012
RFX6
[ ]
[ ]
[‘Mitchell-Riley

c.649T > C

syndrome’]

(p.Ser217Pro)

NM_002942.4(ROBO2):
267607014
ROB02
[‘GAGA
[‘GAGAYTGGAAA
[‘Vesicoureteral

c.2834T > C

YTGGA
TTTTGGCCGTGG’]
reflux 2’]

(p.Ile945Thr)

AATTT

TGGCC

GTGG’]

NM_178857.5(RP1L1):
267607018
RP1L1
[ ]
[ ]
[‘Occult macular

c.2878T > C

dystrophy’]

(p.Trp960Arg)

NM_002880.3(RAF1):
730881003
RAF1
[ ]
[ ]
[‘Rasopathy’]

c.1423T > C

(p.Phe475Leu)

NM_015272.3(RPGRIP1L):
267607020
RPGRIP1L
[ ]
[ ]
[‘Joubert syndrome

c.1975T > C

7’, ‘COACH

(p.Ser659Pro)

syndrome’]

NM_015559.2(SETBP1):
267607038
SETBP1
[ ]
[ ]
[‘Schinzel-Giedion

c.2612T > C

syndrome’]

(p.Ile871Thr)

NM_000433.3(NCF2):
137878529
NCF2
[ ]
[ ]
[‘Chronic

c.481A > G

granulomatous

(p.Lys161Glu)

disease, autosomal

recessive

cytochrome b-

positive, type 2’]

NM_001041.3(SI):
267607049
SI
[ ]
[ ]
[‘Sucrase-isomaltase

c.1022T > C (p.Leu341Pro)

deficiency’]

NM_005633.3(SOS 1):
267607080
SOS 1
[‘GGTY
[‘GGTYGGGAGGG
[‘Noonan syndrome

c.1294T > C

GGGAG
AAAAGACATTGG’]
4’, ‘Rasopathy’]

(p.Trp432Arg)

GGAAA

AGACA

TTGG’]

NM_018136.4(ASPM):
587783225
ASPM
[ ]
[ ]
[‘Primary autosomal

c.2419 + 2T > C

recessive

microcephaly 5’]

NM_001199107.1(TBC1D24):
267607104
TBC1D24
[ ]
[‘CAAGTTCYTCCA
[‘Myoclonic

c.751T > C

CAAGGTGAGGG’,
epilepsy, familial

(p.Phe251Leu)

‘TTCYTCCACAAG
infantile’]

GTGAGGGCCGG’]

NM_153704.5(TMEM67):
267607115
TMEM67
[ ]
[ ]
[‘Joubert syndrome

c.1769T > C

6’, ‘COACH

(p.Phe590Ser)

syndrome’]

NM_153704.5(TMEM67):
267607119
TMEM67
[ ]
[ ]
[‘Joubert syndrome

c.2498T > C

6’, ‘COACH

(p.Ile833Thr)

syndrome’]

NM_133378.4(TTN):
267607156
—
[ ]
[ ]
[‘Distal myopathy

c.100163T > C

Markesbery-Griggs

(p.Leu33388Pro)

type’]

m.12811T > C
199974018
MT-ND5
[ ]
[ ]
[‘Leber optic

atrophy’]

NM_144631.5(ZNF513):
267607182
ZNF513
[ ]
[‘TGGGCGCYGCAT
[‘Retinitis

c.1015T > C

GCGAGGAGAGG’,
pigmentosa 58’]

(p.Cys339Arg)

‘CGCYGCATGCGA

GGAGAGGCTGG’]

NM_004737.4(LARGE):
267607209
LARGE
[ ]
[ ]
[‘Congenital

c.1483T > C

muscular dystrophy-

(p.Trp495Arg)

dystroglycanopathy

with brain and eye

anomalies, type A6’]

NM_000229.1(LCAT):
267607211
LCAT
[ ]
[‘TATGACYGGCG
[‘Norum disease’]

c.508T > C

GCTGGAGCCCGG’]

(p.Trp170Arg)

NM_016269.4(LEF1):
267607215
—
[ ]
[‘GAACGAGYCTG
[‘Sebaceous tumors,

c.181T > C (p.Ser61Pro)

AAATCATCCCGG’]
somatic’]

NM_139248.2(LIPH):
267607219
LIPH
[ ]
[ ]
[‘Woolly hair,

c.322T > C

autosomal recessive

(p.Trp108Arg)

2, with or without

hypotrichosis’]

NM_004268.4(MED17):
267607232
MED17
[ ]
[ ]
[‘Microcephaly,

c.1112T > C

postnatal

(p.Leu371Pro)

progressive, with

seizures and brain

atrophy’]

NM_000530.6(MPZ):
267607241
MPZ
[ ]
[ ]
[ ]

c.341T > C (p.Ile114Thr)

NM_000489.4(ATRX):
122445094
ATRX
[ ]
[ ]
[‘ATR-X syndrome’]

:c.4840T > C

(p.Cys1614Arg)

NM_000489.4(ATRX):
122445097
ATRX
[ ]
[ ]
[‘ATR-X syndrome’]

c.6250T > C

(p.Tyr2084His)

NM_000489.4(ATRX):
122445109
ATRX
[ ]
[ ]
[ ]

c.1226T > C

(p.Leu409Ser)

NM_000489.4(ATRX):
122445110
ATRX
[ ]
[ ]
[‘Multiple congenital

c.6149T > C

anomalies’]

(p.Ile2050Thr)

NM_178151.2(DCX):
587783536
DCX
[ ]
[ ]
[‘Heterotopia’]

c.272T > C (p.Leu91Pro)

NM_178151.2(DCX):
587783539
DCX
[‘CAAA
[‘CAAAATAYGGA
[‘Heterotopia’]

c.2T > C (p.Met1Thr)

ATAYG
ACTTGATTTTGG’]

GAACT

TGATT

TTGG’]

NM_178151.2(DCX):
587783551
DCX
[ ]
[ ]
[‘Heterotopia’]

c.412T > C

(p.Tyr138His)

NM_000212.2(ITGB3):
398122374
—
[ ]
[ ]
[‘Platelet-type

c.2231T > C

bleeding disorder

(p.Leu744Pro)

16’]

NM_178151.2(DCX):
587783574
DCX
[ ]
[ ]
[‘Heterotopia’]

c.641T > C (p.Ile214Thr)

NM_178151.2(DCX):
587783580
DCX
[ ]
[‘AAAAAACYCTA
[‘Heterotopia’]

c.683T > C

CACTCTGGATGG’]

(p.Leu228Pro)

NM_001005360.2(DNM2):
587783597
DNM2
[ ]
[ ]
[‘Myopathy,

c.1862T > C

centronuclear’]

(p.Leu621Pro)

NM_006579.2(EBP):
587783609
EBP
[ ]
[ ]
[‘Chondrodysplasia

c.310T > C (p.Tyr104His)

punctata 2 X-linked

dominant’]

NM_004004.5(GJB2):
587783644
GJB2
[ ]
[‘GATCCYCGTTGT
[‘Hearing

c.107T > C

GGCTGCAAAGG’]
impairment’]

(p.Leu36Pro)

NM_005682.6(ADGRG1):
587783653
ADGRG1
[ ]
[VCCTGCYCACCT
[‘Polymicrogyria,

c.1460T > C

GCCTTTCCTGG’]
bilateral

(p.Leu487Pro)

frontoparietal’]

NM_000525.3(KCNJ11):
587783675
KCNJ11
[ ]
[ ]
[‘Diabetes mellitus’]

c.988T > C

(p.Tyr330His)

NM_170707.3(LMNA):
267607593
LMNA
[ ]
[ ]
[‘Dilated

c.799T > C

cardiomyopathy 1A’,

(p.Tyr267His)

‘not provided’]

NM_000252.2(MTM1):
587783780
MTM1
[ ]
[ ]
[‘Severe X-linked

c.1353 + 2T > C

myotubular

myopathy’]

NM_000252.2(MTM1):
587783783
MTM1
[ ]
[ ]
[‘Severe X-linked

c.1367T > C

myotubular

(p.Phe456Ser)

myopathy’]

NM_000252.2(MTM1):
587783794
MTM1
[ ]
[ ]
[‘Severe X-linked

c.1433T > C

myotubular

(p.Phe478Ser)

myopathy’]

NM_000252.2(MTM1):
587783801
MTM1
[ ]
[ ]
[‘Severe X-linked

c.1495T > C

myotubular

(p.Trp499Arg)

myopathy’]

NM_000252.2(MTM1):
587783816
MTM1
[ ]
[ ]
[‘Severe X-linked

c.260T > C

myotubular

(p.Leu87Pro)

myopathy’]

NM_000252.2(MTM1):
587783851
MTM1
[ ]
[ ]
[‘Severe X-linked

c.683T > C

myotubular

(p.Leu228Pro)

myopathy’]

NM_000252.2(MTM1):
587783863
MTM1
[ ]
[‘GGAAYCTTTAAA
[‘Severe X-linked

c.958T > C

AAAAGTGAAGG’]
myotubular

(p.Ser320Pro)

myopathy’]

NM_000526.4(KRT14):
59629244
KRT14
[ ]
[ ]
[‘Epidermolysis

c.1151T > C

bullosa simplex,

(p.Leu384Pro)

Koebner type’, ‘not

provided’]

NM_000249.3(MLH1):
267607751
MLH1
[ ]
[ATCACGGYAAG
[‘Hereditary

c.453 + 2T > C

AATGGTACATGG’,
Nonpolyposis

‘TCACGGYAAGAA
Colorectal

TGGTACATGGG’]
Neoplasms’]

NM_002764.3(PRPS1):
80338676
PRPS1
[ ]
[ ]
[‘Arts syndrome’,

c.455T > C

‘not provided’]

(p.Leu152Pro)

NM_022132.4(MCCC2):
119103222
MCCC2
[ ]
[ ]
[‘3-methylcrotonyl

c.499T > C

CoA carboxylase 2

(p.Cys167Arg)

deficiency’]

NM_000411.6(HLCS):
119103227
HLCS
[ ]
[‘CTATCYTTCTCA
[‘Holocarboxylase

c.710T > C

GGGAGGGAAGG’]
synthetase

(p.Leu237Pro)

deficiency’]

NM_005787.5(ALG3):
119103237
ALG3
[ ]
MATTGACYGGA
[‘Congenital disorder

c.211T > C

AGGCCTACATGG’]
of glycosylation type

(p.Trp71Arg)

1D’]

NM_005609.2(PYGM):
119103254
PYGM
[ ]
[ ]
[‘Glycogen storage

c.1187T > C

disease, type V’]

(p.Leu396Pro)

m.3250T > C
199474664
MT-TL1
[ ]
[ ]
[ ]

NM_002764.3(PRPS1):
80338732
PRPS1
[‘GCAA
[‘GCAAATAYGCT
[Charcot-Marie-

:c.344T > C

ATAYG
ATCTGTAGCAGG’]
Tooth disease, X-

(p.Met115Thr)

CTATC

linked recessive,

TGTAG

type 5’]

CAGG’]

NM_003172.3(SURF1):
398122806
SURF1
[ ]
[‘CCACYGGCATTA
[‘Congenital

c.679T > C

TCGAGACCTGG’]
myasthenic

(p.Trp227Arg)

syndrome,

acetazolamide-responsive’]

NM_004525.2(LRP2):
80338747
LRP2
[ ]
[‘GTACCTGYACTG
[‘Donnai Barrow

c.7564T > C

GGCTGACTGGG’]
syndrome’]

(p.Tyr2522His)

NM_006329.3(FBLN5):
80338766
FBLN5
[ ]
[ ]
[‘Autosomal

c.649T > C

recessive cutis laxa

(p.Cys217Arg)

type IA’]

NM_001271723.1(FBXO38):
398122838
FBXO38
[ ]
[‘TTCCTYGTATCC
[‘Distal hereditary

c.616T > C

CAATGCTAAGG’]
motor neuronopathy

(p.Cys206Arg)

2D’]

NM_133433.3(NIPBL):
587784032
NIPBL
[ ]
[ ]
[‘Cornelia de Lange

c.7062 + 2T > C

syndrome 1’]

NM_000334.4(SCN4A):
80338790
SCN4A
[ ]
[ ]
[‘Hyperkalemic

c.4468T > C

Periodic Paralysis

(p.Phe1490Leu)

Type 1’]

NM_058216.2(RAD51C):
730881931
RAD51C
[ ]
[ ]
[‘Hereditary cancer-

c.404 + 2T > C

predisposing

syndrome’]

NM_001111.4(ADAR):
398122897
ADAR
[ ]
[ ]
[‘Aicardi-goutieres

c.2615T > C

syndrome 6’]

(p.Ile872Thr)

NM_005334.2(HCFC1):
398122908
HCFC1
[‘CAAG
[‘CAAGAYGGCGG
[‘Mental retardation

c.-970T > C

AYGGC
CTCCCAGGGAGG’
3, X-linked’]

GGCTC
]

CCAGG

GAGG’]

NM_000431.3(MVK):
398122910
MVK
[‘CCAG
[‘CCAGGYATCCCG
[‘Porokeratosis,

c.1039 + 2T > C

GYATC
GGGGTAGGTGG’,
disseminated

CCGGG
‘CAGGYATCCCGG
superficial actinic 1’]

GGTAG
GGGTAGGTGGG’]

GTGG’]

NM_000431.3(MVK):
398122911
MVK
[ ]
[ ]
[‘Porokeratosis,

c.1094T > C

disseminated

(p.Phe365Ser)

superficial actinic 1’]

NM_005050.3(ABCD4):
201777056
ABCD4
[‘GATG
[‘GATGAGGYAGA
[‘METHYLMALONIC

c.956A > G

AGGYA
TGCACACAAAGG’]
ACIDURIA

(p.Tyr319Cys)

GATGC

AND

ACACA

HOMOCYSTINURI

AAGG’]

A, cb1J TYPE’, ‘not

provided’]

NM_000251.2(MSH2):
267607987
MSH2
[‘CTGG
[‘CTGGYAAAAAA
[‘Hereditary

c.2005 + 2T > C

YAAAA
CCTGGTTTTTGG’,
Nonpolyposis

AACCT
‘TGGYAAAAAACC
Colorectal

GGTTT
TGGTTTTTGGG’]
Neoplasms’]

TTGG’,

‘TGGYA

AAAAA

CCTGG

TTTTTG

GG’]

NM_000518.4(HBB):
35693898
HBB
[ ]
[ ]
[‘Hemoglobinopathy’]

c.257T > C (p.Phe86Ser)

NM_001194998.1(CEP152):
398122977
CEP152
[ ]
[ ]
[‘Primary autosomal

c.3149T > C

recessive

(p.Leu1050Pro)

microcephaly 9’]

NM_022455.4(NSD1):
587784171
NSD1
[ ]
[ ]
[‘Sotos syndrome 1’]

c.5989T > C

(p.Tyr1997His)

NM_014495.3(ANGPTL3):
398122989
—
[ ]
[‘ACAAAACYTCA
[‘Hypobetalipoprotei

c.883T > C

ATGAAACGTGGG’]
nemia, familial, 2’]

(p.Phe295Leu)

NM_024577.3(SH3TC2):
80338927
SH3TC2
[ ]
[ ]
[‘Charcot-Marie-

c.1982T > C

Tooth disease, type

(p.Leu661Pro)

4C’]

NM_000551.3(VHL):
730882033
VHL
[ ]
[ ]
[‘Hereditary cancer-

c.227T > C (p.Phe76Ser)

predisposing

syndrome’]

NM_004004.5(GJB2):
80338945
GJB2
[ ]
[‘GCTCCYAGTGGC
[‘Deafness,

c.269T > C

CATGCACGTGG’]
autosomal recessive

(p.Leu90Pro)

1A’, ‘Hearing

impairment’, ‘not

provided’]

NM_000334.4(SCN4A):
80338956
SCN4A
[ ]
[‘AAGATCAYTGG
[‘Hyperkalemic

c.2078T > C

CAATTCAGTGGG’,
Periodic Paralysis

(p.Ile693Thr)

‘AGATCAYTGGCA
Type 1’,

ATTCAGTGGGG’,
‘Paramyotonia

‘GATCAYTGGCAA
congenita of von

TTCAGTGGGGG’]
Eulenburg’]

NM_004523.3(KIF11):
730882063
KIF11
[‘GGAG
[‘GGAGGYAATAA
[‘Microcephaly with

c.2547 + 2T > C

GYAAT
CTTTGTAAGTGG’]
or without

AACTT

chorioretinopathy,

TGTAA

lymphedema, or

GTGG’]

mental retardation’]

NM_003060.3(SLC22A5):
68018207
SLC22A5
[ ]
[ ]
[‘Renal carnitine

c.1051T > C

transport defect’]

(p.Trp351Arg)

NM_001070.4(TUBG1):
398123045
TUBG1
[ ]
[ ]
[‘Cortical dysplasia,

c.1160T > C

complex, with other

(p.Leu387Pro)

brain malformations

4’]

NM_000441.1(SLC26A4):
60284988
—
[ ]
[ ]
[‘Pendred syndrome’,

c.-103T > C

‘Enlarged vestibular

aqueduct syndrome’]

NM_000016.5(ACADM):
398123074
ACADM
[ ]
[ ]
[‘Medium-chain

c.233T > C

acyl-coenzyme A

(p.Ile78Thr)

dehydrogenase

deficiency’, ‘not

provided’]

NM_000179.2(MSH6):
267608131
MSH6
[ ]
[VGGYAACTAACT
[‘Hereditary

c.4001 + 2T > C

AACTATAATGG’]
Nonpolyposis

Colorectal

Neoplasms’]

NM_000019.3(ACAT1):
398123096
ACAT1
[ ]
[ ]
[‘Deficiency of

c.730 + 2T > C

acetyl-CoA

acetyltransferase’,

‘not provided’]

NM_000430.3(PAFAH1B1):
587784288
PAFAH1B1
[ ]
[ ]
[‘Lissencephaly 1’]

c.841T > C

(p.Cys281Arg)

NM_000899.4(KITLG):
730882156
KITLG
[ ]
[ ]
[‘Familial

c.98T > C

progressive

(p.Val33Ala)

hyperpigmentation

with or without

hypopigmentation’]

NM_015599.2(PGM3):
267608260
PGM3
[‘AATG
[‘AATGTYGGCACC
[‘Immunodeficiency

c.248T > C

TYGGC
ATCCTGGGAGG’]
23’]

(p.Leu83Ser)

ACCAT

CCTGG

GAGG’]

NM_000169.2(GLA):
398123223
—
[ ]
[ ]
[‘Fabry disease’]

c.899T > C

(p.Leu300Pro)

NM_001256047.1(C19orf12):
146170087
Cl9orf12
[ ]
[ ]
[‘Neurodegeneration

c.391A > G

with brain iron

(p.Lys131Glu)

accumulation 4’]

NM_172337.2(0TX2):
370761964
OTX2
[ ]
[ ]
[‘Pituitary hormone

c.674A > G

deficiency,

(p.Asn225Ser)

combined 6’]

NM_000202.6(IDS):
398123250
IDS
[ ]
[ ]
[‘Mucopolysaccharid

c.587T > C (p.Leu196Ser)

osis, MPS-II’, ‘not

provided’]

NM_000252.2(MTM1):
398123274
MTM1
[ ]
[ ]
[‘Severe X-linked

c.688T > C

myotubular

(p.Trp230Arg)

myopathy’, ‘not

provided’]

NM_022445.3(TPK1):
371271054
TPK1
[ ]
[ ]
[‘THIAMINE

c.656A > G

METABOLISM

(p.Asn219Ser)

DYSFUNCTION

SYNDROME 5

(EPISODIC

ENCEPHALOPATHY

TYPE)’]

NM_014139.2(SCN11A):
483352920
SCN11A
[ ]
[ ]
[‘NEUROPATHY,

c.2432T > C

HEREDITARY

(p.Leu811Pro)

SENSORY AND

AUTONOMIC,

TYPE VII’]

NM_000733.3(CD3E):
483352928
CD3E
[ ]
[ ]
[‘Immunodeficiency

c.520 + 2T > C

18’]

NM_017653.3(DYM):
775414124
DYM
[ ]
[ ]
[‘Dyggve-Melchior-

c.621-2A > G

Clausen syndrome’]

NM_001253816.1(SL052A2):
148234606
5LC52A2
[ ]
[ ]
[Brown-Vialetto-

c.1016T > C

Van Laere syndrome

(p.Leu339Pro)

2’]

NM_004963.3(GUCY2C):
587784573
—
[ ]
[‘TCCCYGTGCTGC
[‘Meconium ileus’]

c.2782T > C

TGGAGTTGTGG’,

(p.Cys928Arg)

‘CCCYGTGCTGCT

GGAGTTGTGGG’]

NM_003159.2(CDKL5):
267608511
CDKL5
[ ]
[‘CCAACYTTTTAC
[‘Early infantile

c.659T > C

TATTCAGAAGG’]
epileptic

(p.Leu220Pro)

encephalopathy 2’]

NM_000528.3(MAN2B1):
398123457
MAN2B1
[ ]
[ ]
[‘not provided’]

c.2436 + 2T > C

NM_002136.2(HNRNPA1):
483353031
HNRNPA1
[‘AATY
[‘AATYTTGGAGGC
[‘Chronic

c.841T > C

TTGGA
AGAAGCTCTGG’]
progressive multiple

(p.Phe281Leu)

GGCAG

sclerosis’]

AAGCT

CTGG’]

NM_006920.4(SCN1A):
398123595
—
[ ]
[ ]
[‘Severe myoclonic

c.4251 + 2T > C

epilepsy in infancy’,

‘Generalized

epilepsy with febrile

seizures plus, type

2’]

NM_002225.3(IVD):
398123683
IVD
[ ]
[ ]
[‘Isovaleryl-CoA

c.465 + 2T > C

dehydrogenase

deficiency’, ‘not

provided’]

NM_000118.3(ENG):
373842615
ENG
[ ]
[‘CCGCCYGCGGG
[‘Haemorrhagic

c.1273-2A > G

GATAAAGCCAGG’,
telangiectasia 1’]

‘CGCCYGCGGGGA

TAAAGCCAGGG’]

NM_005859.4(PURA):
793888535
PURA
[ ]
[ ]
[‘not provided’]

c.218T > C

(p.Phe73Ser)

NM_003494.3(DYSF):
398123765
DYSF
[‘ATGG
[‘ATGGYAAGGAG
[‘Limb-girdle

c.1284 + 2T > C

YAAGG
CAAGGGAGCAGG’]
muscular dystrophy,

AGCAA
]
type 2B’, ‘not

GGGAG

provided’]

CAGG’]

NM_004006.2(DMD):
398123885
DMD
[ ]
[ ]
[‘Dilated

c.2380 + 2T > C

cardiomyopathy 3B’]

NM 006364.2(SEC23A):
138568622
SEC23A
[ ]
[ ]
[‘Craniolenticulosutu

c.2104A > G

ral dysplasia’]

(p.Met702Val)

NM_000335.4(SCN5A):
185492581
SCN5A
[ ]
[‘GAATCTYCACAG
[‘Brugada

c.376A > G

CCGCTCTCCGG’]
syndrome’]

(p.Lys126Glu)

NM_015865.6(SLC14Al):
78242949
SLC14A1
[ ]
[ ]
[ ]

c.871T > C

(p.Ser291Pro)

NM_003995.3(NPR2):
796065355
NPR2
[ ]
[ ]
[‘SHORT

c.226T > C (p.Ser76Pro)

STATURE WITH

NONSPECIFIC

SKELETAL

ABNORMALITIES’]

NM_012463.3(ATP6V0A2):
398124257
ATP6V0A2
[‘CACT
[‘CACTGYGAGTA
[‘Cutis laxa with

c.825 + 2T > C

GYGAG
AGCTGGAAGTGG’]
osteodystrophy’, ‘not

TAAGC

provided’]

TGGAA

GTGG’]

NM_014795.3(ZEB2):
398124282
ZEB2
[ ]
[ ]
[‘Mowat-Wilson

c.73 + 2T > C

syndrome’]

NM_000424.3(KRT5):
57599352
KRT5
[ ]
[ ]
[‘Epidermolysis

c.1388T > C

bullosa simplex,

(p.Leu463Pro)

Koebner type’, ‘not

provided’]

NM_133499.2(SYN1):
200533370
SYN1
[ ]
[‘GATGYCTGACG
[‘Epilepsy, X-linked,

c.1699A > G

GGTAGCCTGTGG’,
with variable

(p.Thr567Ala)

‘ATGYCTGACGGG
learning disabilities

TAGCCTGTGGG’]
and behavior

disorders’, ‘not

specified’]

NM_148960.2(CLDN19):
118203981
CLDN19
[ ]
[‘GCTCCYGGGCTT
[‘Hypomagnesemia

c.269T > C

CGTGGCCATGG’]
5, renal, with ocular

(p.Leu90Pro)

involvement’]

NM_018006.4(TRMU):
118203990
TRMU
[ ]
[ ]
[‘Liver failure acute

c.229T > C

infantile’]

(p.Tyr77His)

NM_000056.3(BCKDHB):
398124593
BCKDHB
[ ]
[ ]
[‘Maple syrup urine

c.752T > C

disease’, ‘not

(p.Val251Ala)

provided’]

NM_182680.1(AMELX):
104894737
—
[ ]
[ ]
[‘Amelogenesis

c.2T > C

imperfecta, type 1E’]

(p.Met1Thr)

NM_018105.2(THAP1):
118204013
THAP1
[ ]
[ ]
[‘Dystonia 6,

c.241T > C

torsion’]

(p.Phe81Leu)

NM_001235.3(SERPINH1):
137853892
SERPINH1
[ ]
[GTCGCYAGGGCT
[‘Osteogenesis

c.233T > C

CGTGTCGCTGG’,
imperfecta type 10’]

(p.Leu78Pro)

‘TCGCYAGGGCTC

GTGTCGCTGGG’]

NM_004482.3(GALNT3):
761396172
GALNT3
[ ]
[ ]
[‘Tumoral calcinosis,

c.516_688del

familial,

hyperphosphatemic’]

NM_000263.3(NAGLU):
118204024
NAGLU
[ ]
[‘GGCCGACYTCTC
[‘Mucopolysaccharid

c.142T > C

CGTGTCGGTGG’]
osis, MPS-III-B’]

(p.Phe48Leu)

NM_000559.2(HBG1):
35710727
HBG1
[ ]
[ ]
[‘Fetal hemoglobin

c.-251T > C

quantitative trait

locus 1’]

NM_000527.4(LDLR):
200238879
LDLR
[‘CGGY
[‘ACTGCGGYATG
[‘Familial

c.694 + 2T > C

ATGGG
GGCGGGGCCAGG’,
hypercholesterolemia’]

CGGGG
‘CTGCGGYATGGG

CCAGG
CGGGGCCAGGG’,

GTGG’]
‘CGGYATGGGCGG

GGCCAGGGTGG’]

NM_001012515.2(FECH):
118204039
FECH
[ ]
[ ]
[‘Erythropoietic

c.1268T > C

protoporphyria’]

(p.Phe423Ser)

NM_005211.3(CSF1R):
690016563
CSF1R
[ ]
[‘CAACCYGCAGTT
[‘Hereditary diffuse

c.1745T > C

TGGTGAGATGG’]
leukoencephalopathy

(p.Leu582Pro)

with spheroids’]

NM_000526.4(KRT14):
58380626
KRT14
[ ]
[‘CGCCACCYACCG
[‘Epidermolysis

c.1243T > C

CCGCCTGCTGG’,
bullosa

(p.Tyr415His)

‘CACCYACCGCCG
herpetiformis,

CCTGCTGGAGG’,
Dowling-Meara’,

‘ACCYACCGCCGC
‘not provided’]

CTGCTGGAGGG’]

NM_006493.2(CLN5):
201615354
CLN5
[ ]
[ ]
[‘not provided’]

c.2T > C (p.Met1Thr)

NM_002863.4(PYGL):
113993988
PYGL
[‘AAGA
[‘AAGAAYATGCC
[‘Glycogen storage

c.2461T > C

AYATG
CAAAACATCTGG’]
disease, type VI’]

(p.Tyr821His)

CCCAA

AACAT

CTGG’]

NM_016038.2(SBDS):
113993993
SBDS
[ ]
[ ]
[‘Shwachman

c.258 + 2T > C

syndrome’, ‘Aplastic

anemia,

susceptibility to’]

NM_000110.3(DPYD):
1801265
DPYD
[ ]
[ ]
[‘Dihydropyrimidine

c.85T > C

dehydrogenase

(p.Cys29Arg)

deficiency’]

NM_001034116.1(EIF2B4):
113994038
EIF2B4
[ ]
[ ]
[‘Ovarioleukodystrophy’]

c.1393T > C

(p.Cys465Arg)

NM_001165963.1(SCN1A):
794726793
SCN1A
[ ]
[ ]
[‘Severe myoclonic

c.323T > C

epilepsy in infancy’]

(p.Leu108Pro)

NM_001034116.1(EIF2B4):
113994040
EIF2B4
[ ]
[ ]
[‘Ovarioleukodystrophy’]

c.1465T > C

(p.Tyr489His)

NM_004304.4(ALK):
113994092
ALK
[ ]
[ ]
[‘Neuroblastoma 3’]

c.3749T > C

(p.Ile1250Thr)

NM_207346.2(TSEN54):
113994151
TSEN54
[ ]
[‘TTGAAGYCTCCC
[‘Pontocerebellar

c.277T > C

GCGGTGAGCGG’,
hypoplasia type 4’]

(p.Ser93Pro)

‘AAGYCTCCCGCG

GTGAGCGGCGG’]

NM_000018.3(ACADVL):
113994167
ACADVL
[‘TTTGY
[‘TTTGYGGTGGAG
[‘Very long chain

c.848T > C

GGTGG
AGGGGCTTCGG’,
acyl-CoA

(p.Val283Ala)

AGAGG
‘TTGYGGTGGAGA
dehydrogenase

GGCTT
GGGGCTTCGGG’]
deficiency’, ‘not

CGG’,

provided’]

‘TTGYG

GTGGA

GAGGG

GCTTC

GGG’]

NM_000430.3(PAFAH1B1):
113994202
PAFAH1B1
[ ]
[ ]
[‘Lissencephaly 1’]

c.569-10T > C

NM_004937.2(CTNS):
113994206
CTNS
[ ]
[‘TGGTCYGAGCTT
[‘Cystinosis’]

c.473T > C

CGACTTCGTGG’]

(p.Leu158Pro)

NM_000546.5(TP53):
148924904
TP53
[‘GCTTG
[‘GCTTGYAGATGG
[‘Hereditary cancer-

c.488A > G

YAGAT
CCATGGCGCGG’]
predisposing

(p.Tyr163Cys)

GGCCA

syndrome’]

TGGCG

CGG’]

NM_004211.3(SLC6A5):
281864925
SLC6A5
[ ]
[ ]
[‘Hyperekplexia 3’]

c.1444T > C

(p.Trp482Arg)

NM_024312.4(GNPTAB):
281864973
GNPTAB
[ ]
[ ]
[‘Pseudo-Hurler

c.1208T > C

polydystrophy’]

(p.Ile403Thr)

NM_024312.4(GNPTAB):
281865006
GNPTAB
[ ]
[ ]
[‘I cell disease’]

c.3002T > C

(p.Leu1001Pro)

NM_000540.2(RYR1):
118192123
RYR1
[ ]
[ ]
[‘Central core

c.7358T > C

disease’, ‘not

(p.Ile2453Thr)

provided’]

NM_000748.2(CHRNB2):
281865070
CHRNB2
[ ]
[ ]
[‘Epilepsy, nocturnal

c.923T > C

frontal lobe, type 3’]

(p.Val308Ala)

NM_000526.4(KRT14):
28928893
KRT14
[ ]
[ ]
[‘Epidermolysis

c.356T > C

bullosa

(p.Met119Thr)

herpetiformis,

Dowling-Meara’,

‘not provided’]

NM_000093.4(COL5A1):
183495554
—
[ ]
[ ]
[‘Ehlers-Danlos

c.5137-11T > A

syndrome, classic

type’]

NM_000277.1(PAH):
62516109
PAH
[ ]
[CCACTTCYTGAA
[‘Phenylketonuria’,

c.638T > C

AAGTACTGTGG’]
‘not provided’]

(p.Leu213Pro)

NM_000531.5 (OTC):
72558427
OTC
[ ]
[ ]
[‘not provided’]

c.663 + 2T > C

NM_000531.5 (OTC):
72558431
OTC
[ ]
[ ]
[Ornithine

c.717 + 2T > C

carbamoyltransferas

e deficiency’, ‘not

provided’]

NM_000531.5 (OTC):
72558445
OTC
[ ]
[ ]
[‘not provided’]

c.793T > C

(p.Trp265Arg)

NM_000493.3(COL10Al):
111033545
—
[ ]
[ ]
[‘Metaphyseal

c.1841T > C

chondrodysplasia,

(p.Leu614Pro)

Schmid type’]

NM_000493.3(COL10Al):
111033546
—
[ ]
[ ]
[‘Metaphyseal

c.1771T > C

chondrodysplasia,

(p.Cys591Arg)

Schmid type’]

NM_000493.3(COL10Al):
111033552
—
[ ]
[ ]
[‘Metaphyseal

c.2011T > C

chondrodysplasia,

(p.Ser671Pro)

Schmid type’]

NM_004614.4(TK2):
138439950
TK2
[ ]
[ ]
[‘Mitochondrial

c.173A > G (p.Asn58Ser)

DNA depletion

syndrome 2’]

NM_004614.4(TK2):
281865497
TK2
[ ]
[ ]
[‘Mitochondrial

c.644T > C

DNA depletion

(p.Leu215Pro)

syndrome 2’]

NM_004614.4(TK2):
281865499
TK2
[ ]
[ ]
[‘Mitochondrial

c.156 + 2T > C

DNA depletion

syndrome 2’]

NM_153026.2(PRICKLE1):
281865564
PRICKLE1
[ ]
[ ]
[‘Progressive

c.1414T > C

myoclonus epilepsy

(p.Tyr472His)

with ataxia’]

NM_017882.2(CLN6):
143781303
CLN6
[ ]
[ ]
[‘not provided’]

c.767A > G

(p.Asp256Gly)

NM_130838.1(UBE3A):
111033597
UBE3A
[ ]
[ ]
[‘Angelman

c.389T > C

syndrome’]

(p.Ile130Thr)

NM_001198799.2(ASCC1):
146370051
ASCC1
[ ]
[ ]
[ ]

c.953A > G

(p.Asn318Ser)

NM_000174.4(GP9):
28933378
GP9
[‘CCCA
[VCCAYGTACCTG
[‘Bernard Soulier

c.70T > C (p.Cys24Arg)

YGTAC
CCGCGCCCTGG’]
syndrome’, ‘Bernard-

CTGCC

Soulier syndrome

GCGCC

type C’]

CTGG’]

NM_001173464.1(KIF21A):
121912587
KIF21A
[ ]
[ ]
[‘Fibrosis of

c.3029T > C

extraocular muscles,

(p.Ile1010Thr)

congenital, 1’]

NM_001302946.1(TRNT1):
370011798
TRNT1
[ ]
[‘GCAAYTGCAGA
[‘Sideroblastic

c.668T > C

AAATGCAAAAGG’]
anemia with B-cell

(p.Ile223Thr)

immunodeficiency,

periodic fevers, and

developmental

delay’]

NM_000371.3(TTR):
121918091
TTR
[ ]
[ ]
[‘Amyloidogenic

c.250T > C (p.Phe84Leu)

transthyretin

amyloidosis’]

m.5814T > C
200077222
MT-TC
[ ]
[ ]
[‘Juvenile myopathy,

encephalopathy,

lactic acidosis AND

stroke’]

NM_000277.1(PAH):
62517167
PAH
[ ]
[‘AAGATCTYGAG
[‘Mild non-PKU

c.293T > C (p.Leu98Ser)

GCATGACATTGG’]
hyperphenylalanemia’,

‘not provided’]

NM_017882.2(CLN6):
796052355
CLN6
[ ]
[ ]
[‘not provided’]

c.486 + 2T > C

NM_001813.2(CENPE):
141488085
CENPE
[ ]
[ ]
[‘Primary autosomal

c.4063A > G

recessive

(p.Lys1355Glu)

microcephaly 13’]

NM_001918.3(DBT):
12021720
DBT
[ ]
[‘GACYCACAGAG
[‘Intermediate maple

c.1150G > A

CCCAATTTCTGG’]
syrup urine disease

(p.Gly384Ser)

type 2’]

NM_000495.4(COL4A5):
104886288
COL4A5
[‘AGTA
[‘AGTAYGTGAAG
[‘Alport syndrome,

c.4699T > C

YGTGA
CTCCAGCTGTGG’]
X-linked recessive’]

(p.Cys1567Arg)

AGCTC

CAGCT

GTGG’]

NM_000495.4(COL4A5):
104886289
COL4A5
[ ]
[‘TCCCCATYGTCC
[‘Alport syndrome,

c.4756T > C

TCAGGGATGGG’]
X-linked recessive’]

(p.Cys1586Arg)

NM_000495.4(COL4A5):
104886310
COL4A5
[ ]
[ ]
[‘Alport syndrome,

c.5032T > C

X-linked recessive’]

(p.Cys1678Arg)

NM_000155.3(GALT):
111033700
GALT
[‘AGCY
[‘AGCYGGGTGCC
[‘Deficiency of

c.482T > C

GGGTG
CAGTACCCTTGG’]
UDPglucose-

(p.Leu161Pro)

CCCAG

hexose- 1-phosphate

TACCC

uridylyltransferase’]

TTGG’]

NM_001199252.2(SGOL1):
199815268
—
[ ]
[ ]
[‘Chronic atrial and

c.67A > G

intestinal

(p.Lys23Glu)

dysrhythmia’]

NC_012920.1:m.5559
370471013
MT-TW
[ ]
[‘CAACYTACTGAG
[‘Leigh disease’]

A > G

GGCTTTGAAGG’]

NM_000487.5(ARSA):
121434215
ARSA
[ ]
[‘GCCTTCCYGCCC
[‘Metachromatic

c.410T > C

CCCCATCAGGG’]
leukodystrophy,

(p.Leu137Pro)

adult type’]

NM_000051.3(ATM):
121434218
—
[ ]
[ ]
[ ]

c.7967T > C

(p.Leu2656Pro)

NM_000096.3(CP):
386134125
CP
[ ]
[ ]
[‘Deficiency of

c.650T > C (p.Phe217Ser)

ferroxidasel

NM_000096.3(CP):
386134128
CP
[ ]
[‘ACACTACYACAT
[‘Deficiency of

c.1123T > C (p.Tyr375His)

TGCCGCTGAGG’]
ferroxidasel

NM_000268.3(NF2):
121434261
NF2
[ ]
[ ]
[‘Neurofibromatosis,

c.185T > C (p.Phe62Ser)

type 2’]

NM_000495.4(COL4A5):
104886423
COL4A5
[ ]
[ ]
[‘Alport syndrome,

c.4803 + 121T > C

X-linked recessive’]

NM_024529.4(CDC73):
121434264
CDC73
[ ]
[ ]
[‘Hyperparathyroidism

c.191T > C

1’]

(p.Leu64Pro)

NM_001061.4(TBXAS1):
199422114
TBXAS1
[ ]
[ ]
[ ]

c.1463T > C

(p.Leu488Pro)

NM_001127328.2(ACADM):
121434275
ACADM
[ ]
[‘GTGCAGAYACTT
[‘Medium-chain

c.1136T > C

GGAGGCAATGG’]
acyl-coenzyme A

(p.Ile379Thr)

dehydrogenase

deficiency’]

NM_001127328.2(ACADM):
121434276
ACADM
[ ]
[CAGCGAYGTTCA
[‘Medium-chain

c.742T > C

GATACTAGAGG’]
acyl-coenzyme A

(p.Cys248Arg)

dehydrogenase

deficiency’]

NM_000016.5(ACADM):
121434280
ACADM
[ ]
[ ]
[‘Medium-chain

c.199T > C

acyl-coenzyme A

(p.Tyr67His)

dehydrogenase

deficiency’, ‘not

provided’]

NM_002225.3(IVD):
121434284
IVD
[ ]
[ATGGGCYAAGC
[‘ISOVALERIC

c.134T > C (p.Leu45Pro)

GAGGAGCAGAGG’]
ACIDEMIA, TYPE

I’]

NM_005957.4(MTHFR):
121434297
MTHFR
[ ]
[ ]
[‘Homocystinuria

c.968T > C

due to MTHFR

(p.Leu323Pro)

deficiency’]

NM_000136.2(FANCC):
104886458
—
[ ]
[ ]
[‘Fanconi anemia,

c.1661T > C

complementation

(p.Leu554Pro)

group C’, ‘not

provided’]

NM_005908.3(MANBA):
121434334
MANBA
[ ]
[‘ATTACGYCCAGT
[Beta-D-

c.1513T > C

CCTACAAATGG’,
mannosidosis’]

(p.Ser505Pro)

‘TTACGYCCAGTC

CTACAAATGGG’,

‘TACGYCCAGTCC

TACAAATGGGG’]

NM_000244.3(MEN1):
386134256
MEN1
[ ]
[ ]
[‘Multiple endocrine

c.518T > C

neoplasia, type 1’]

(p.Leu173Pro)

NM_199242.2(UNC13D):
121434353
UNC13D
[ ]
[ ]
[‘Hemophagocytic

c.1208T > C

lymphohistiocytosis,

(p.Leu403Pro)

familial, 3’]

NM_152783.4(D2HGDH):
121434360
D2HGDH
[ ]
[ ]
[‘D-2-

c.1331T > C

hydroxyglutaric

(p.Val444Ala)

aciduria 1’]

NM_207118.2(GTF2H5):
121434365
GTF2H5
[ ]
[ ]
[‘Photosensitive

c.62T > C

trichothiodystrophy’]

(p.Leu21Pro)

NM_000159.3(GCDH):
121434366
GCDH
[ ]
[‘CGCCCGGYACG
[‘Glutaric aciduria,

c.883T > C

GCATCGCGTGGG’,
type 1’]

(p.Tyr295His)

‘GCCCGGYACGGC

ATCGCGTGGGG’]

NM_018668.4(VPS33B):
121434385
VPS33B
[ ]
[ ]
[‘Arthrogryposis

c.89T > C

renal dysfunction

(p.Leu30Pro)

cholestasis

syndrome’]

NM_000424.3(KRT5):
60715293
KRT5
[ ]
[GTTTGCCYCCTT
[‘Epidermolysis

c.541T > C

CATCGACAAGG’]
bullosa

(p.Ser181Pro)

herpetiformis,

Dowling-Meara’,

‘not provided’]

NM_001003722.1(GLE1):
121434409
GLE1
[ ]
[‘AAGGACAYTCCT
[‘Lethal

c.2051T > C

GTCCCCAAGGG’]
arthrogryposis with

(p.Ile684Thr)

anterior horn cell

disease’]

NM_003659.3(AGPS):
121434413
AGPS
[ ]
[ ]
[‘Rhizomelic

c.1406T > C

chondrodysplasia

(p.Leu469Pro)

punctata type 3’]

NM_004550.4(NDUFS2):
121434429
NDUFS2
[ ]
[ ]
[‘Mitochondrial

c.1237T > C

complex I

(p.Ser413Pro)

deficiency’, ‘not

provided’]

NM_001287.5(CLCN7):
121434434
CLCN7
[ ]
[‘GGGCCYGCGGC
[‘Osteopetrosis

c.2297T > C

ACCTGGTGGTGG’]
autosomal recessive

(p.Leu766Pro)

4’]

m.14709T > C
121434453
MT-TE
[ ]
[ ]
[‘Diabetes-deafness

syndrome

maternally

transmitted’]

NM_000466.2(PEX1):
121434455
PEX1
[ ]
[‘GATGACCYTGAC
[‘Zellweger

c.1991T > C

CTCATTGCTGG’]
syndrome’]

(p.Leu664Pro)

NM_198253.2(TERT):
199422307
TERT
[ ]
[ ]
[‘Aplastic anemia’]

c.3043T > C

(p.Cys1015Arg)

m.4290T > C
121434469
MT-TI
[‘ACTYT
[‘ACTYTGATAGAG
[ ]

GATAG
TAAATAATAGG’]

AGTAA

ATAAT

AGG’]

m.4291T > C
121434471
MT-TI
[‘ACTTY
[‘ACTTYGATAGAG
[‘Hypertension,

GATAG
TAAATAATAGG’]
hypercholesterolemia,

AGTAA

and

ATAAT

hypomagnesemia,

AGG’]

mitochondrial’]

m.9997T > C
121434475
MT-TG
[ ]
[ ]
[‘Primary familial

hypertrophic

cardiomyopathy’]

NM_001099274.1(TINF2):
199422316
TINF2
[ ]
[ ]
[‘Dyskeratosis

c.860T > C

congenita autosomal

(p.Leu287Pro)

dominant’]

NM_001099274.1(TINF2):
199422317
TINF2
[ ]
[‘CTGYTTCCCTTT
[‘Aplastic anemia’]

c.862T > C

AGGAATCTCGM

(p.Phe288Leu)

NM_000430.3(PAFAH1B1):
121434484
PAFAH1B1
[ ]
[ ]
[‘Subcortical band

c.505T > C

heterotopia’]

(p.Ser169Pro)

NM_000430.3(PAFAH1B1):
121434486
PAFAH1B1
[ ]
[ ]
[‘Lissencephaly 1’]

c.92T > C

(p.Phe31Ser)

NM_005535.2(IL12RB1):
121434495
IL12RB1
[ ]
[ ]
[‘Immunodeficiency

c.592T > C

301

(p.Cys198Arg)

NM_030662.3(MAP2K2):
121434499
MAP2K2
[ ]
[ ]
[‘Cardiofaciocutaneo

c.400T > C

us syndrome 4’,

(p.Tyr134His)

‘Rasopathy’, ‘Noonan

syndrome and

Noonan-related

syndrome’]

NM_001065.3(TNFRSFl A):
104895221
TNFRSF1A
[ ]
[‘CTCTTCTYGCAC
[‘TNF receptor-

c.349T > C

AGTGGACCGGG’]
associated periodic

(p.Cys117Arg)

fever syndrome

(TRAPS)’]

NM_000123.3(ERCC5):
121434575
—
[ ]
[ ]
[‘Xeroderma

c.2573T > C

pigmentosum, group

(p.Leu858Pro)

G’]

NM_001493.2(GDI1):
121434607
GDI1
[ ]
[ ]
[‘X-Linked Mental

c.275T > C

Retardation 41’]

(p.Leu92Pro)

NM_020061.5(0PN1LW):
121434621
OPN1LW
[ ]
[ ]
[‘Cone

c.607T > C

monochromatism’]

(p.Cys203Arg)

NM_024420.2(PLA2G4A):
121434634
PLA2G4A
[ ]
[ ]
[ ]

c.331T > C

(p.Ser111Pro)

NM_005557.3(KRT16):
60944949
KRT16
[ ]
[ ]
[‘Pachyonychia

c.395T > C

congenita, type 1’,

(p.Leu132Pro)

‘not provided’]

NM_000485.2(APRT):
28999113
APRT
[ ]
[ ]
[‘Adenine

c.407T > C

phosphoribosyltransf

(p.Met136Thr)

erase deficiency’,

‘APRT deficiency,

Japanese type’]

NM_005270.4(GLI2):
144372453
GLI2
[ ]
[ ]
[‘Holoprosencephaly

c.4663T > C

9’, ‘not specified’]

(p.Ser1555Pro)

NM_024753.4(TTC21B):
387907060
TTC21B
[ ]
[ ]
[‘Asphyxiating

c.2384T > C

thoracic dystrophy

(p.Leu795Pro)

4’]

NM_000155.3(GALT):
111033846
GALT
[ ]
[ ]
[‘Deficiency of

c.680T > C

UDPglucose-

(p.Leu227Pro)

hexose-1-phosphate

uridylyltransferase’]

NM_000138.4(FBN1):
137854459
FBN1
[ ]
[‘GGGACAYGTTA
[‘Marfan syndrome’]

c.4987T > C

CAACACCGTTGG’]

(p.Cys1663Arg)10):

NM_032446.2(MEGF
387907073
MEGF10
[ ]
[ ]
[‘Myopathy,

c.976T > C

areflexia, respiratory

(p.Cys326Arg)

distress, and

dysphagia, early-

onset, mild variant’]

NM_024027.4(COLEC11):
387907075
COLEC11
[ ]
[CAGCTGYCCTGC
[‘Carnevale

c.505T > C

CAGGGCCGCGG’,
syndrome’]

(p.Ser169Pro)

‘AGCTGYCCTGCC

AGGGCCGCGGG’,

‘GCTGYCCTGCCA

GGGCCGCGGGG’,

‘CTGYCCTGCCAG

GGCCGCGGGGG’]

NM_001946.3(DUSP6):
143946794
DUSP6
[‘CACT
[‘CACTAYTGGGGT
[‘Hypogonadotropic

c.566A > G

AYTGG
CTCGGTCAAGG’]
hypogonadism 19

(p.Asn189Ser)

GGTCT

with or without

CGGTC

anosmia’]

AAGG’]

NM_000138.4(FBN1):
137854474
FBN1
[‘CTTGY
[‘CTTGYGTTATGA
[‘Marfan syndrome’]

c.3793T > C

GTTAT
TGGATTCATGG’]

(p.Cys1265Arg)

GATGG

ATTCA

TGG’]

NM_022068.3(PIEZO2):
587777453
PIEZ02
[ ]
[ ]
[‘Oculomelic

c.2134A > G

amyoplasia’]

(p.Met712Val)

NM_000570.4(FCGR3B):
2290834
FCGR3B
[ ]
[ ]
[ ]

c.316A=

(p.Ile106=)

NM_000352.4(ABCC8):
1048095
ABCC8
[ ]
[‘TGCYGTCCAAAG
[‘Permanent neonatal

c.674T > C

GCACCTACTGG’]
diabetes mellitus’]

(p.Leu225Pro)

NM_153490.2(KRT13):
59897026
KRT13
[ ]
[ ]
[‘White sponge

c.332T > C

nevus 2’, ‘not

(p.Leull1Pro)

provided’]

NM_000132.3(F8):
28933669
F8
[ ]
[ ]
[‘Hereditary factor

c.1174T > C (p.Ser392Pro)

VIII deficiency

disease’]

NM_000492.3(CFTR):
397508144
CFTR
[ ]
[ ]
[‘Cystic fibrosis’]

c.1021T > C

(p.Ser341Pro)

NM_000133.3(F9):
137852255
F9
[ ]
[ ]
[‘Hereditary factor

c.1058T > C (p.Val353Ala)

IX deficiency

disease’]

NM_001202.3(BMP4):
376960358
BMP4
[‘TTCGT
[‘TTCGTGGYGGAA
[‘Microphthalmia

c.362A > G

GGYGG
GCTCCTCACGG’]
syndromic 6’]

(p.His121Arg)

AAGCT

CCTCA

CGG’]

NM_000133.3(F9):
137852268
F9
[‘GAAY
[‘GAAYATATACC
[‘Hereditary factor

c.1328T > C (p.Ile443Thr)

ATATA
AAGGTATCCCGG’]
IX deficiency

CCAAG

disease’]

GTATC

CCGG’]

NM_000133.3(F9):
137852269
F9
[ ]
[ ]
[‘Hereditary factor

c.1357T > C

IX deficiency

(p.Trp453Arg)

disease’]

NM_000435.2(NOTCH3):
28933698
NOTCH3
[‘ACCY
[‘TTCACCYGTATC
[‘Cerebral autosomal

c.1363T > C

GTATC
TGTATGGCAGG’,
dominant

(p.Cys455Arg)

TGTAT
‘ACCYGTATCTGT
arteriopathy with

GGCAG
ATGGCAGGTGG’]
subcortical infarcts

GTGG’]

and

leukoencephalopath

3’]

NM_019074.3(DLL4):
796065347
DLL4
[ ]
[‘GAAYGTCCCCCC
[‘Adams-Oliver

c.1168T > C

AACTTCACCGG’]
syndrome’,

(p.Cys390Arg)

‘ADAMS-OLIVER

SYNDROME 6’]

NM_000032.4(ALAS2):
137852310
ALAS2
[ ]
[ ]
[‘Hereditary

c.595T > C

sideroblastic

(p.Tyr199His)

anemia’]

NM_019074.3(DLL4):
796065351
DLL4
[ ]
[ ]
[‘Adams-Oliver

c.583T > C

syndrome’]

(p.Phe195Leu)

NM_000402.4(G6PD):
137852347
G6PD
[ ]
[‘AGGGYACCTGG
[‘Anemia,

c.1054T > C

ACGACCCCACGG’]
nonspherocytic

(p.Tyr352His)

hemolytic, due to

G6PD deficiency’]

NM_007325.4(GRIA3):
137852352
GRIA3
[ ]
[ ]
[‘Mental retardation,

c.2117T > C

X-linked,

(p.Met706Thr)

syndromic, wu type’]

NM_000132.3(F8):
137852365
F8
[ ]
[ ]
[‘Hereditary factor

c.6554T > C

VIII deficiency

(p.Leu2185Ser)

disease’]

NM_000132.3(F8):
137852375
F8
[‘TCAY
[‘TCAYGGTGAGTT
[‘Hereditary factor

c.5372T > C

GGTGA
AAGGACAGTGG’]
VIII deficiency

(p.Met1791Thr)

GTTAA

disease’]

GGACA

GTGG’]

NM_000132.3(F8):
137852376
F8
[‘AACA
[‘AACAGAYAATG
[‘Hereditary factor

c.1754T > C (p.Ile585Thr)

GAYAA
TCAGACAAGAGG’]
VIII deficiency

TGTCA

disease’]

GACAA

GAGG’]

NM_001127695.1(CTSA):
137854546
CTSA
[ ]
[ ]
[‘Galactosialidosis,

c.707T > C

early infantile’]

(p.Leu236Pro)

NM_000132.3(F8):
137852405
F8
[ ]
[ ]
[‘Hereditary factor

c.935T > C (p.Phe312Ser)

VIII deficiency

disease’]

NM_000132.3(F8):
137852407
F8
[ ]
[ ]
[‘Hereditary factor

c.980T > C (p.Leu327Pro)

VIII deficiency

disease’]

NM_000308.2(CTSA):
137854548
CTSA
[ ]
[ ]
[‘Galactosialidosis,

c.1271T > C

late infantile’]

(p.Met424Thr)

NM_000132.3(F8):
137852413
F8
[ ]
[ ]
[‘Hereditary factor

c.1481T > C (p.Ile494Thr)

VIII deficiency

disease’]

NM_001250.5(CD40):
28931586
CD40
[ ]
[ ]
[‘Immunodeficiency

c.247T > C

with hyper IgM type

(p.Cys83Arg)

3’]

NM_000165.4(GJA1):
121912969
GJA1
[ ]
[ ]
[‘Oculodentodigital

c.32T > C (p.Leu11Pro)

dysplasia’]

NM_000132.3(F8):
137852430
F8
[ ]
[ ]
[‘Hereditary factor

c.1958T > C (p.Val653Ala)

VIII deficiency

disease’]

NM_001972.2(ELANE):
28931611
ELANE
[ ]
[ ]
[‘Severe congenital

c.211T > C

neutropenia

(p.Cys7lArg)

autosomal

dominant’]

NM_000098.2(CPT2):
74315297
CPT2
[ ]
[ ]
[‘CARNITINE

c.1342T > C

PALMITOYLTRA

(p.Phe448Leu)

NSFERASE II

DEFICIENCY,

LATE-ONSET’, ‘not

provided’]

NM_213653.3(HFE2):
74315326
HFE2
[ ]
[ ]
[‘Hemochromatosis

c.842T > C

type 2A’]

(p.Ile281Thr)

NM_213653.3(HFE2):
74315327
HFE2
[ ]
[‘GGACCYCGCCTT
[‘Hemochromatosis

c.302T > C

CCATTCGGCGG’]
type 2A’]

(p.Leu101Pro)

NM_000194.2(HPRT1):
137852480
HPRT1
[ ]
[ ]
[‘Lesch-Nyhan

c.122T > C

syndrome’]

(p.Leu41Pro)

NM_000261.1(MY0C):
74315338
MYOC
[ ]
[ ]
[‘Primary open angle

c.1297T > C

glaucoma juvenile

(p.Cys433Arg)

onset 1’]

NM_000194.2(HPRT1):
137852495
HPRT1
[ ]
[ ]
[‘Lesch-nyhan

c.170T > C

syndrome,

(p.Met57Thr)

neurologic variant’]

NM_000267.3(NF1):
137854564
NF1
[ ]
[ ]
[‘Neurofibromatosis,

c.3728T > C

type 1’]

(p.Leu1243Pro)

NM_000291.3(PGK1):
137852531
PGK1
[ ]
[ ]
[‘Phosphoglycerate

c.263T > C

kinase 1 deficiency’]

(p.Leu88Pro)

NM_000291.3(PGK1):
137852533
PGK1
[ ]
[ ]
[‘Phosphoglycerate

c.946T > C

kinase 1 deficiency’]

(p.Cys316Arg)

NM_000291.3(PGK1):
137852534
PGK1
[ ]
[ ]
[‘Phosphoglycerate

c.758T > C

kinase 1 deficiency’]

(p.Ile253Thr)

NM_170784.2(MKKS):
74315398
MKKS
[ ]
[ ]
[‘Bardet-Biedl

c.830T > C

syndrome 6’, ‘not

(p.Leu277Pro)

provided’]

NM_000451.3(SHOX):
137852559
SHOX
[ ]
[ ]
[Leri Weill

c.877T > C

dyschondrosteosis’]

(p.Ter293Arg)

NM_001029871.3(RSPO4):
74315421
RSPO4
[ ]
[ ]
[‘Anonychia’]

c.319T > C

(p.Cys107Arg)

NM_000044.3(AR):
137852579
AR
[ ]
[‘GTCCYGGAAGC
[ ]

c.2033T > C

CATTGAGCCAGG’]

(p.Leu678Pro)

NM_000044.3(AR):
137852592
AR
[ ]
[ ]
[‘Reifenstein

c.2423T > C

syndrome’]

(p.Met808Thr)

NM_000044.3(AR):
137852597
AR
[ ]
[ ]
[‘Androgen

c.2596T > C (p.Ser866Pro)

resistance

syndrome’]

NM_172201.1(KCNE2):
74315447
KCNE2
[ ]
[ ]
[‘Long QT syndrome

c.161T > C

6’, ‘Congenital long

(p.Met54Thr)

QT syndrome’,

‘Cardiac arrhythmia’]

NM_172201.1(KCNE2):
74315448
KCNE2
[ ]
[ ]
[‘Long QT syndrome

c.170T > C

6’, ‘Cardiac

(p.Ile57Thr)

arrhythmia’, ‘not

provided’]

NM_000211.4(ITGB2):
137852611
ITGB2
[‘AGCY
[‘AGCYAGGTGGC
[‘Leukocyte

c.446T > C

AGGTG
GACCTGCTCCGG’]
adhesion

(p.Leu149Pro)

GCGAC

deficiency’]

CTGCT

CCGG’]

NM_000211.4(ITGB2):
137852617
ITGB2
[ ]
[ ]
[‘Leukocyte

c.412T > C

adhesion

(p.Ser138Pro)

deficiency’]

NM_000023.2(SGCA):
137852622
SGCA
[ ]
[ ]
[‘Limb-girdle

c.524T > C

muscular dystrophy,

(p.Val175Ala)

type 2D’]

NM_001166107.1(HMGCS2):
137852636
HMGCS2
[ ]
[‘CCCTCYTCAATG
[‘mitochondrial 3-

c.520T > C

CTGCCAACTGG’]
hydroxy-3-

(p.Phe174Leu)

methylglutaryl-CoA

synthase deficiency’]

NM_001886.2(CRYBA4):
74315486
CRYBA4
[ ]
[ ]
[‘Cataract 23’]

c.281T > C

(p.Phe94Ser)

NM_001886.2(CRYBA4):
74315487
CRYBA4
[ ]
[ ]
[‘Cataract 23’]

c.206T > C

(p.Leu69Pro)

NM_002047.2(GARS):
137852644
GARS
[ ]
[ ]
[‘Distal hereditary

c.548T > C

motor neuronopathy

(p.Leu183Pro)

type 5’]

NM_000268.3(NF2):
74315493
NF2
[ ]
[ ]
[‘Neurofibromatosis,

c.1604T > C

type 2’]

(p.Leu535Pro)

NM_000095.2(COMP):
137852653
COMP
[ ]
[ ]
[‘Pseudo-

c.982T > C

achondroplastic

(p.Cys328Arg)

spondyloepiphyseal

dysplasia syndrome’]

NM_000095.2(COMP):
137852656
COMP
[ ]
[ ]
[‘Pseudo-

c.1042T > C

achondroplastic

(p.Cys348Arg)

spondyloepiphyseal

dysplasia syndrome’]

NM_017929.5(PEX26):
74315506
PEX26
[ ]
[ ]
[‘Peroxisome

c.2T > C (p.Met1Thr)

biogenesis disorder

7B’]

NM_033163.3(FGF8):
137852661
FGF8
[ ]
[‘TTCCCTGYTCCG
[‘Kallmann

c.118T > C

GGCTGGCCGGG’]
syndrome 6’]

(p.Phe40Leu)

NM_007315.3(STAT1):
137852677
STAT1
[ ]
[ ]
[‘Immunodeficiency

c.2117T > C

31a’]

(p.Leu706Ser)

NM_007315.3(STAT1):
137852678
STAT1
[ ]
[ ]
[‘Mycobacterial and

c.1799T > C

viral infections,

(p.Leu600Pro)

susceptibility to,

autosomal

recessive’]

NM_000336.2(SCNN1B):
137852707
SCNN1B
[ ]
[ ]
[‘Pseudoprimary

c.1858T > C

hyperaldosteronism’]

(p.Tyr620His)

NM_005215.3(DCC):
121912967
DCC
[ ]
[‘AGCCCAYGCCA
[ ]

c.503T > C

ACAATCCACTGG’]

(p.Met168Thr)

NM_001034850.2(FAM134B):
137852738
FAM134B
[ ]
[ ]
[‘Hereditary sensory

c.873 + 2T > C

and autonomic

neuropathy type

IIA’]

NM_000182.4(HADHA):
137852772
HADHA
[ ]
[ ]
[‘Mitochondrial

c.1025T > C

trifunctional protein

(p.Leu342Pro)

deficiency’]

NM_001165974.1(UR0C1):
137852796
UROC1
[ ]
[ ]
[‘Urocanate

c.209T > C

hydratase

(p.Leu70Pro)

deficiency’]

NM_000405.4(GM2A):
137852797
GM2A
[ ]
[ ]
[‘Tay-Sachs disease,

c.412T > C

variant AB’]

(p.Cys138Arg)

NM_001039523.2(CHRNA1):
137852806
CHRNA1
[ ]
[‘TGTGYTCCTTCT
[‘Myasthenic

c.901T > C

GGTCATCGTGG’]
syndrome,

(p.Phe301Leu)

congenital,

fast-channel’]

NM_003688.3(CASK):
137852817
CASK
[ ]
[ ]
[‘FG syndrome 4’]

c.802T > C

(p.Tyr268His)

NM_003688.3(CASK):
137852819
CASK
[‘CACA
[‘CACAGYGGGTC
[‘FG syndrome 4’]

c.2740T > C

GYGGG
CCTGTCTCCTGG’,

(p.Trp914Arg)

TCCCT
‘ACAGYGGGTCCC

GTCTC
TGTCTCCTGGG’]

CTGG’,

‘ACAGY

GGGTC

CCTGT

CTCCT

GGG’]

NM_182760.3(SUMF1):
137852848
SUMF1
[ ]
[ ]
[‘Multiple sulfatase

c.1006T > C

deficiency’]

(p.Cys336Arg)

NM_182760.3(SUMF1):
137852850
SUMF1
[ ]
[‘GGCGACYCCTTT
[‘Multiple sulfatase

c.463T > C

GTCTTTGAAGG’]
deficiency’, ‘not

(p.Ser155Pro)

provided’]

NM_000158.3(GBE1):
137852886
GBE1
[ ]
[‘AATGTACYACCA
[‘Glycogen storage

c.671T > C

AGAATCAAAGG’]
disease, type IV’,

(p.Leu224Pro)

‘GLYCOGEN

STORAGE

DISEASE IV,

NONPROGRESSIVE

HEPATIC’]

m.8356T > C
118192099
MT-TK
[ ]
[ ]
[‘Myoclonus with

epilepsy with ragged

red fibers’,

‘MERRF/MELAS

overlap syndrome’]

NM_024312.4(GNPTAB):
137852900
GNPTAB
[ ]
[ ]
[‘Pseudo-Hurler

c.1120T > C

polydystrophy’, ‘I

(p.Phe374Leu)

cell disease’]

NM_031924.4(RSPH3):
142800871
RSPH3
[ ]
[ ]
[‘Kartagener

c.631-2A > G

syndrome’]

NM_058172.5(ANTXR2):
137852905
ANTXR2
[ ]
[ ]
[‘Hyaline

c.566T > C

fibromatosis

(p.Ile189Thr)

syndrome’]

NM_000419.3(ITGA2B):
137852911
ITGA2B
[ ]
[CTGGTGCYTGGG
[‘Glanzmann

c.641T > C

GCTCCTGGCGG’]
thrombasthenia’]

(p.Leu214Pro)

NM_001171507.2(MCFD2):
137852914
MCFD2
[ ]
[ ]
[‘Factor v and factor

c.407T > C

viii, combined

(p.Ile136Thr)

deficiency of, 2’]

NM_000540.2(RYR1):
118192117
RYR1
[‘CGCA
[‘CGCAYGATCCAC
[‘Congenital

c.1205T > C

YGATC
AGCACCAATGG’]
myopathy with fiber

(p.Met402Thr)

CACAG

type disproportion’,

CACCA

‘Central core

ATGG’]

disease’, ‘not

provided’]

NM_000540.2(RYR1):
118192131
RYR1
[ ]
[ ]
[‘Central core

c.13703T > C

disease’, ‘not

(p.Leu4568Pro)

provided’]

NM_000540.2(RYR1):
118192138
RYR1
[ ]
[ ]
[‘Central core

c.13949T > C

disease’, ‘not

(p.Leu4650Pro)

provided’]

NM_138694.3(PKHD1):
137852948
PKHD1
[ ]
[‘GAGCCCAYTGA
[‘Polycystic kidney

c.10658T > C

AATACGCTCAGG’]
disease, infantile

(p.Ile3553Thr)

type’]

NM_012464.4(TLL1):
137852952
TLL1
[‘GGGA
[‘GGGATTGYTGTT
[‘Atrial septal defect

c.713T > C

TTGYT
CATGAATTGGG’]
6’]

(p.Val238Ala)

GTTCA

TGAAT

TGGG’]

NM_000540.2(RYR1):
118192156
RYR1
[ ]
[ ]
[‘Central core

c.14762T > C

disease’, ‘not

(p.Phe4921Ser)

provided’]

NM_024960.4(PANK2):
137852964
PANK2
[ ]
[‘ATTGACYCAGTC
[ ]

c.178T > C

GGATTCAATGG’]

(p.Ser60Pro)

NM_001001486.1(ATP2C1):
137853015
ATP2C1
[ ]
[ ]
[‘Familial benign

c.1751T > C

pemphigus’]

(p.Leu584Pro)

NM_014363.5(SACS):
137853017
SACS
[ ]
[ ]
[‘Spastic ataxia

c.5836T > C

Charlevoix-

(p.Trp1946Arg)

Saguenay type’]

NM_014363.5(SACS):
137853018
SACS
[ ]
[ ]
[‘Spastic ataxia

c.9742T > C

Charlevoix-

(p.Trp3248Arg)

Saguenay type’]

NM_014363.5(SACS):
137853019
SACS
[ ]
[ ]
[‘Spastic ataxia

c.3161T > C

Charlevoix-

(p.Phe1054Ser)

Saguenay type’]

NM_006899.3(IDH3B):
137853020
IDH3B
[ ]
[‘TGCGGCYGAGG
[‘Retinitis

c.395T > C

TAGGTGGTCTGG’,
pigmentosa 46’]

(p.Leu132Pro)

‘GCGGCYGAGGTA

GGTGGTCTGGG’]

NM_001139.2(ALOX12B):
137853023
ALOX12B
[ ]
[ ]
[‘Autosomal

c.1277T > C

recessive congenital

(p.Leu426Pro)

ichthyosis 2’]

NM_001080463.1(DYNC2H1):
137853028
DYNC2H1
[ ]
[ ]
[‘Short-rib thoracic

c.3719T > C

dysplasia 3 with or

(p.Ile1240Thr)

without

polydactyly’]

NM_006009.3(TUBA1A):
137853048
TUBA1A
[ ]
[ ]
[‘Lissencephaly 3’]

c.1190T > C

(p.Leu397Pro)

NM_004519.3(KCNQ3):
118192249
KCNQ3
[ ]
[ ]
[‘Benign familial

c.925T > C

neonatal seizures 2’]

(p.Trp309Arg)

NM_000531.5 (OTC):
1800324
OTC
[ ]
[ ]
[Ornithine

c.332T > C

carbamoyltransferas

(p.Leull1Pro)

e deficiency’]

NM_001172567.1(MYD88):
137853065
MYD88
[ ]
[ ]
[‘Myd88 deficiency’]

c.317T > C

(p.Leu106Pro)

NM_002241.4(KCNJ10):
137853068
KCNJ10
[ ]
[ ]
[SeSAME

c.418T > C

syndrome’]

(p.Cys140Arg)

NM_000455.4(STK11):
137853077
STK11
[ ]
[ ]
[‘Peutz-Jeghers

c.200T > C

syndrome’]

(p.Leu67Pro)

NM_000518.4(HBB):
35256489
HBB
[ ]
[ ]
[‘Beta thalassemia

c.332T > C

major’]

(p.Leull1Pro)

NM_005094.3(5LC27A4):
137853133
5LC27A4
[ ]
[ ]
[‘Ichthyosis

c.739T > C

prematurity

(p.Ser247Pro)

syndrome’]

NM_001145308.4(LRTOMT):
137853186
LRTOMT
[ ]
[ ]
[‘Deafness,

c.313T > C

autosomal recessive

(p.Trp105Arg)

631

NM_178012.4(TUBB2B):
137853194
TUBB2B
[ ]
[ ]
[‘Polymicrogyria,

c.514T > C

asymmetric’]

(p.Ser172Pro)

NM_178012.4(TUBB2B):
137853195
TUBB2B
[ ]
[ ]
[‘Polymicrogyria,

c.683T > C

asymmetric’]

(p.Leu228Pro)

NM_178012.4(TUBB2B):
137853196
TUBB2B
[ ]
[ ]
[‘Polymicrogyria,

c.793T > C

asymmetric’]

(p.Phe265Leu)

NM_001082971.1(DDC):
137853209
DDC
[ ]
[ ]
[‘Deficiency of

c.925T > C

aromatic-L-amino-

(p.Phe309Leu)

acid decarboxylase’]

NM_006121.3(KRT1):
137853225
KRT1
[ ]
[ ]
[‘Bullous

c.1424T > C

ichthyosiform

(p.Leu475Pro)

erythroderma’]

NM_033500.2(HK1):
137853249
HK1
[ ]
[‘GACTTCTYGGCC
[‘Hemolytic anemia

c.1550T > C

CTGGATCTTGG’,
due to hexokinase

(p.Leu517Ser)

‘TTCTYGGCCCTG
deficiency’]

GATCTTGGAGG’]

NM_000249.3(MLH1):
63749859
MLH1
[ ]
[ ]
[‘Hereditary

c.229T > C

Nonpolyposis

(p.Cys77Arg)

Colorectal

Neoplasms’]

NM_000444.5(PHEX):
137853270
PHEX
[ ]
[‘AGCYCCAGAAG
[‘Familial X-linked

c.1664T > C

CCTTTCTTTTGG’]
hypophosphatemic

(p.Leu555Pro)

vitamin D refractory

rickets’]

NM_000321.2(RB1):
137853296
RB1
[ ]
[ ]
[‘Retinoblastoma’]

c.2134T > C

(p.Cys712Arg)

NM_007313.2(ABL1):
137853304
ABL1
[ ]
[ ]
[ ]

c.988T > C

(p.Phe330Leu)

NM_003639.4(IKBKG):
137853325
IKBKG
[ ]
[‘TGGAGYGCATTG
[‘Hypohidrotic

c.1249T > C

AGTAGGGCCGG’]
ectodermal dysplasia

(p.Cys417Arg)

with immune

deficiency’, ‘Hyper-

IgM

immunodeficiency,

X-linked, with

hypohidrotic

ectodermal

dysplasia’]

NM_017534.5(MYH2):
786201023
—
[ ]
[ ]
[‘Inclusion body

c.5609T > C

myopathy 3’]

(p.Leu1870Pro)

NM_000314.6(PTEN):
786201044
PTEN
[ ]
[ ]
[‘Hereditary cancer-

c.406T > C

predisposing

(p.Cys136Arg)

syndrome’]

NM_001257988.1(TYMP):
149977726
TYMP
[‘CACG
[‘CACGAGTYTCTT
[ ]

c.665A > G

AGTYT
ACTGAGAATGG’,

(p.Lys222Arg)

CTTAC
‘GAGTYTCTTACT

TGAGA
GAGAATGGAGG’]

ATGG’]

NM_016725.2(FOLR1):
144637717
FOLR1
[‘AGGY
[‘CTTCAGGYGAG
[‘not provided’]

c.493 + 2T > C

GAGGG
GGCTGGGGTGGG’,

CTGGG
‘AGGYGAGGGCTG

GTGGG
GGGTGGGCAGG’]

CAGG’]

NM_002225.3(IVD):
748026507
IVD
[ ]
[ ]
[‘not provided’]

c.295 + 2T > C

NM_000175.3(GPI):
137853587
GPI
[ ]
[ ]
[ ]

c.1016T > C

(p.Leu339Pro)

NM_002055.4(GFAP):
28932769
GFAP
[ ]
[‘GGACCYGCTCA
[‘Alexander disease’,

c.1055T > C

ATGTCAAGCTGG’]
‘not provided’]

(p.Leu352Pro)

NM_020921.3(NIN):
187464517
NIN
[ ]
[ ]
[‘Seckel syndrome

c.3665A > G

7’]

(p.Gln1222Arg)

NM_005603.4(ATP8B1)
387906381
ATP8B1
[ ]
[ ]
[‘Progressive

:c.2097 + 2T > C

intrahepatic cholestasis’]

NM_005144.4(HR):
387906382
HR
[ ]
[ ]
[‘Marie Unna

c.-320T > C

hereditary

hypotrichosis 1’]

NM_001303.3(COX10):
387906383
COX10
[ ]
[ ]
[‘Congenital

c.2T > C (p.Met1Thr)

myasthenic

syndrome,

acetazolamide-responsive’]

NM_004415.2(DSP):
749730642
DSP
[ ]
[ ]
[‘not provided’]

c.4961T > C

(p.Leu1654Pro)

NM_000392.4(ABCC2):
387906396
ABCC2
[ ]
[ ]
[‘Dubin-Johnson

c.1967 + 2T > C

syndrome’]

NM_002769.4(PRSS1):
397507439
—
[ ]
[TACCAGGYGTCC
[‘Hereditary

c.116T > C

CTGAATTCTGG’]
pancreatitis’]

(p.Val39Ala)

NM_130439.3(MXI1):
387906417
MXI1
[ ]
[ ]
[‘Malignant tumor of

c.552 + 2T > C

prostate’]

m.8528T > C
387906422
—
[ ]
[ ]
[‘Cardiomyopathy,

infantile

hypertrophic’]

NM_000132.3(F8):
387906430
F8
[ ]
[ ]
[‘Hereditary factor

c.985T > C (p.Cys329Arg)

VIII deficiency

disease’]

NM_000132.3(F8):
387906443
F8
[ ]
[ ]
[‘Hereditary factor

c.1417T > C (p.Tyr473His)

VIII deficiency

disease’]

NM_000132.3(F8):
387906446
F8
[ ]
[‘AAAGAAYCTGT
[‘Hereditary factor

c.1729T > C (p.Ser577Pro)

AGATCAAAGAGG’]
VIII deficiency

disease’]

NM_004333.4(BRAF):
397507473
BRAF
[‘ATCAT
[‘ATCATYTGGAAC
[‘Cardiofaciocutaneo

c.1403T > C

YTGGA
AGTCTACAAGG’,
us syndrome’,

(p.Phe468Ser)

ACAGT
‘TCATYTGGAACA
‘Rasopathy’]

CTACA
GTCTACAAGGG’]

AGG’,

‘TCATY

TGGAA

CAGTC

TACAA

GGG’]

NM_004333.4(BRAF):
397507475
BRAF
[ ]
[ ]
[‘Cardiofaciocutaneo

c.1454T > C

us syndrome’,

(p.Leu485Ser)

‘Rasopathy’]

NM_005188.3(CBL):
397507492
CBL
[ ]
[ ]
[‘Rasopathy’]

c.1201T > C

(p.Cys401Arg)

NM_000133.3(F9):
387906474
F9
[ ]
[ ]
[‘Hereditary factor

c.52T > C (p.Cys18Arg)

IX deficiency

disease’]

NM_005249.4(FOXG1):
786205008
FOXG1
[ ]
[ ]
[‘Rett syndrome,

c.700T > C

congenital variant’,

(p.Ser234Pro)

‘not provided’]

NM_000133.3(F9):
387906481
F9
[ ]
[ ]
[‘Hereditary factor

c.82T > C (p.Cys28Arg)

IX deficiency

disease’]

NM_000133.3(F9):
387906482
F9
[ ]
[‘ACGAACAYCTTC
[‘Hereditary factor

c.1031T > C (p.Ile344Thr)

CTCAAATTTGG’]
IX deficiency

disease’]

m.11253T > C
200145866
MT-ND4
[ ]
[ ]
[‘Leber optic

atrophy’]

NM_000131.4(F7):
387906507
F7
[ ]
[ ]
[‘Factor VII

c.38T > C (p.Leu13Pro)

deficiency’]

NM_000131.4(F7):
387906508
F7
[ ]
[‘GACGTYCTCTGA
[‘Factor VII

c.983T > C (p.Phe328Ser)

GAGGACGCTGG’]
deficiency’]

NM_000422.2(KRT17):
28933089
KRT17
[ ]
[ ]
[‘Pachyonychia

c.296T > C

congenita type 2’,

(p.Leu99Pro)

‘not provided’]

NM_001040113.1(MYH11):
387906532
MYH11
[ ]
[‘GAAGCYGGAGG
[‘Aortic aneurysm,

c.3791T > C

CGCAGGTGCAGG’]
familial thoracic 4’]

(p.Leu1264Pro)

NM_013246.2(CLCF1):
137853934
—
[ ]
[ ]
[‘Cold-induced

c.46T > C

sweating syndrome

(p.Cys16Arg)

2’]

NM_013246.2(CLCF1):
137853935
—
[ ]
[ ]
[‘Cold-induced

c.676T > C

sweating syndrome

(p.Ter226Arg)

2’]

NM_001077620.2(PRCD):
527236092
—
[ ]
[ ]
[‘Retinitis

c.2T > C

pigmentosa’]

(p.Met1Thr)

NM_000488.3(SERPINC1):
387906575
SERPINC1
[ ]
[ ]
[‘Antithrombin III

c.68T > C

deficiency’]

(p.Leu23Pro)

NM_206933.2(USH2A):
527236118
USH2A
[ ]
[ ]
[‘Retinitis

c.9751T > C

pigmentosa’]

(p.Cys3251Arg)

NM_001458.4(FLNC):
387906586
FLNC
[ ]
[ ]
[‘Myopathy, distal,

c.752T > C

4’]

(p.Met251Thr)

NM_000781.2(CYP11A1):
387906601
CYP11A1
[ ]
[ ]
[‘Adrenal

c.665T > C

insufficiency,

(p.Leu222Pro)

congenital, with

46,XY sex reversal,

partial or complete’]

NM_000548.3(TSC2):
137853995
TSC2
[ ]
[ ]
[‘Tuberous sclerosis

c.2410T > C

syndrome’,

(p.Cys804Arg)

‘Tuberous sclerosis

2’, ‘not provided’]

NM_001145661.1(GATA2):
387906633
GATA2
[ ]
[ ]
[‘Lymphedema,

c.1117T > C

primary, with

(p.Cys373Arg)

myelodysplasia’]

NM_002693.2(POLG):
548076633
POLG
[‘CAAG
[‘CAAGAGGYTGG
[‘not provided’]

c.3470A > G

AGGYT
TGATCTGCAAGG’]

(p.Asn1157Ser)

GGTGA

TCTGC

AAGG’]

NM_002465.3(MYBPC1):
387906657
MYBPC1
[ ]
[ ]
[‘Distal

c.706T > C

arthrogryposis type

(p.Trp236Arg)

1B’]

NM_002465.3(MYBPC1):
387906658
MYBPC1
[ ]
[‘CAAACCYATATC
[‘Distal

c.2566T > C

CGCAGAGTTGG’]
arthrogryposis type

(p.Tyr856His)

1B’]

NM_003392.4(WNT5A):
387906663
WNT5A
[ ]
[ ]
[‘Robinow

c.544T > C

syndrome’]

(p.Cys182Arg)

NM_005188.3(CBL):
387906665
CBL
[ ]
[ ]
[‘Rasopathy’]

c.1186T > C

(p.Cys396Arg)

NM_006902.4(PRRX1):
387906667
PRRX1
[ ]
[ ]
[‘Dysgnathia

c.338T > C

complex’]

(p.Phel 13Ser)

NM_001111035.1(ACP5):
387906672
—
[ ]
[ ]
[‘Spondyloenchondr

c.602T > C

odysplasia with

(p.Leu201Pro)

immune

dysregulation’]

NM_002734.4(PRKAR1A):
387906693
PRKAR1A
[ ]
[ ]
[‘Acrodysostosis 1

c.1117T > C

with or without

(p.Tyr373His)

hormone resistance’]

NM_002734.4(PRKAR1A):
387906695
PRKAR1A
[ ]
[ ]
[‘Acrodysostosis 1

c.980T > C

with or without

(p.Ile327Thr)

hormone resistance’]

NM_003491.3(NAA10):
387906701
NAA10
[ ]
[‘TGGCCTTYCCTG
[‘N-terminal

c.109T > C

GCCCCAGGTGG’,
acetyltransferase

(p.Ser37Pro)

‘GGCCTTYCCTGG
deficiency’]

CCCCAGGTGGG’]

NM_006306.3(SMC1A):
387906702
SMC1A
[‘AGAY
[‘AGAYTGGTGTGC
[‘Congenital

c.2351T > C

TGGTG
GCAACATCCGG’]
muscular

(p.Ile784Thr)

TGCGC

hypertrophy-cerebral

AACAT

syndrome’]

CCGG’]

NM_000377.2(WAS):
387906716
WAS
[ ]
[ ]
[‘Severe congenital

c.814T > C

neutropenia X-

(p.Ser272Pro)

linked’]

NM_000377.2(WAS):
387906717
WAS
[ ]
[‘GACTTCAYTGAG
[‘Severe congenital

c.881T > C

GACCAGGGTGG’,
neutropenia X-

(p.Ile294Thr)

‘ACTTCAYTGAGG
linked’]

ACCAGGGTGGG’]

m.12201T > C
387906733
MT-TH
[ ]
[ ]
[‘Deafness,

nonsyndromic

sensorineural,

mitochondrial’]

NM_139125.3(MASP1):
387906753
MASP1
[ ]
[ ]
[‘Michels syndrome’]

c.1888T > C

(p.Cys630Arg)

NM_007315.3(STAT1):
387906763
STAT1
[ ]
[ ]
[‘Immunodeficiency

c.520T > C

31C’]

(p.Cys174Arg)

NM_053025.3(MYLK):
387906781
—
[ ]
[ ]
[‘Aortic aneurysm,

c.5275T > C

familial thoracic 7’]

(p.Ser1759Pro)

NM_000287.3(PEX6):
387906809
PEX6
[ ]
[‘CTTCYGGGCCGG
[‘Peroxisome

c.1601T > C

GACCGTGATGG’,
biogenesis disorder

(p.Leu534Pro)

‘TTCYGGGCCGGG
4B’]

ACCGTGATGGG’]

NM_000174.4(GP9):
28933377
GP9
[ ]
[ ]
[‘Bernard-Soulier

c.167T > C (p.Leu56Pro)

syndrome type C’]

NM_004153.3(ORC1):
387906827
ORC1
[ ]
[ ]
[‘Meier-Gorlin

c.266T > C

syndrome 1’]

(p.Phe89Ser)

NM_021252.4(RAB18):
387906833
RAB18
[ ]
[ ]
[‘Warburg micro

c.619T > C

syndrome 3’]

(p.Ter207Gln)

NM_000702.3(ATP1A2):
28933398
ATP1A2
[ ]
[ ]
[‘Familial

c.2291T > C

hemiplegic migraine

(p.Leu764Pro)

type 2’]

NM_000702.3(ATP1A2):
28933399
ATP1A2
[ ]
[ ]
[‘Familial

c.2659T > C

hemiplegic migraine

(p.Trp887Arg)

type 2’]

NM_000702.3(ATP1A2):
28933400
ATP1A2
[ ]
[ ]
[‘Familial

c.2192T > C

hemiplegic migraine

(p.Met731Thr)

type 2’]

NM_020433.4(JPH2):
387906897
JPH2
[ ]
[ ]
[‘Familial

c.421T > C

hypertrophic

(p.Tyr141His)

cardiomyopathy 17’]

NM_173170.1(IL36RN):
387906914
IL36RN
[ ]
[ ]
[‘Pustular psoriasis,

c.80T > C

generalized’]

(p.Leu27Pro)

NM_004990.3(MARS):
201555303
MARS
[ ]
[ ]
[‘Interstitial lung and

c.1568T > C

liver disease’]

(p.Ile523Thr)

NM_020191.2(MRPS22):
387906924
MRPS22
[‘ATCYT
[‘ATCYTAGGGTAA
[‘Combined

c.644T > C

AGGGT
GGTGACTTAGG’]
oxidative

(p.Leu215Pro)

AAGGT

phosphorylation

GACTT

deficiency 5’]

AGG’]

NM_022445.3(TPK1):
387906936
TPK1
[ ]
[ ]
[‘THIAMINE

c.119T > C

METABOLISM

(p.Leu40Pro)

DYSFUNCTION

SYNDROME 5

(EPISODIC

ENCEPHALOPATHY

TYPE)’]

NM_020634.1(GDF3):
387906945
GDF3
[ ]
[ ]
[‘Congenital ocular

c.914T > C

coloboma’,

(p.Leu305Pro)

‘Microphthalmia,

isolated 7’]

NM_024513.3(FYCO1):
387906965
FYCO1
[ ]
[CAGCCYGATCCC
[‘Cataract, autosomal

c.4127T > C

CATCACTGTGG’]
recessive congenital

(p.Leu1376Pro)

2’]

NM_006147.3(IRF6):
387906967
IRF6
[ ]
[‘GCCYCTACCCTG
[‘Van der Woude

c.65T > C (p.Leu22Pro)

GGCTCATCTGG’]
syndrome’, ‘Popliteal

pterygium

syndrome’]

NM_025132.3(WDR19):
387906980
WDR19
[ ]
[ ]
[‘Cranioectodermal

c.2129T > C

dysplasia 4’,

(p.Leu710Ser)

‘SENIOR-LOKEN

SYNDROME 8’]

NM_025132.3(WDR19):
387906982
WDR19
[ ]
[‘TCTCACYGCTAG
[‘Asphyxiating

c.20T > C

AAAAGACTTGG’]
thoracic dystrophy

(p.Leu7Pro)

5’]

NM_014874.3(MFN2):
387906990
MFN2
[ ]
[ ]
[ ]

c.647T > C

(p.Phe216Ser)

NM_016097.4(IER3IP1):
387907012
IER3IP1
[ ]
[ ]
[‘Microcephaly,

c.233T > C

epilepsy, and

(p.Leu78Pro)

diabetes syndrome’]

NM_022489.3(INF2):
387907034
INF2
[ ]
[ ]
[‘Charcot-Marie-

c.310T > C

Tooth disease,

(p.Cys104Arg)

dominant

intermediate E’]

NM_022489.3(INF2):
387907037
INF2
[ ]
[ ]
[‘Charcot-Marie-

c.383T > C

Tooth disease,

(p.Leu128Pro)

dominant

intermediate E’]

NM_003235.4(TG):
137854433
TG
[ ]
[ ]
[‘Iodotyrosyl

c.3229T > C

coupling defect’]

(p.Cys1077Arg)

NM_058246.3(DNAJB6):
387907046
DNAJB6
[ ]
[ ]
[‘Limb-girdle

c.277T > C

muscular dystrophy,

(p.Phe93Leu)

type 1E’]

NM_032446.2(MEGF10):
387907072
MEGF10
[ ]
[‘GGGCAGYGTAC
[‘Myopathy,

c.2320T > C

TTGCCGCACTGG’]
areflexia, respiratory

(p.Cys774Arg)

distress, and

dysphagia, early-

onset’, ‘Myopathy,

areflexia, respiratory

distress, and

dysphagia, early-

onset, mild variant’]

NM_005502.3(ABCA1):
137854494
ABCA1
[‘CCTGT
[‘CCTGTGYGTCCC
[‘Tangier disease’]

c.4429T > C

GYGTC
CCAGGGGCAGG’,

(p.Cys1477Arg)

CCCCA
‘CTGTGYGTCCCC

GGGGC
CAGGGGCAGGG’,

AGG’,
‘TGTGYGTCCCCC

‘CTGTG
AGGGGCAGGGG’,

YGTCC
‘GTGYGTCCCCCA

CCCAG
GGGGCAGGGGG’]

GGGCA

GGG’]

NM_005502.3(ABCA1):
137854499
ABCA1
[ ]
[‘GAGTYCTTTGCC
[‘Familial

c.6026T > C

CTTTTGAGAGG’]
hypoalphalipoprotei

(p.Phe2009Ser)

nemia’]

NM_015175.2(NBEAL2):
387907113
NBEAL2
[ ]
[ ]
[‘Gray platelet

c.1163T > C

syndrome’]

(p.Leu388Pro)

NM_000196.3(HSD11B2):
387907117
HSD11B2
[ ]
[‘CCGCCGCYATTA
[‘Apparent

c.1012T > C

CCCCGGCCAGG’,
mineralocorticoid

(p.Tyr338His)

‘CGCCGCYATTAC
excess’]

CCCGGCCAGGG’]

NM_024599.5(RHBDF2):
387907129
RHBDF2
[‘AGAY
[‘AGAYTGTGGATC
[‘Howel-Evans

c.557T > C

TGTGG
CGCTGGCCCGG’]
syndrome’]

(p.Ile186Thr)

ATCCG

CTGGC

CCGG’]

NM_001077488.3(GNAS):
137854531
GNAS
[ ]
[ ]
[‘Pseudohypoparathy

c.299T > C

roidism type 1A’]

(p.LeulOOPro)

NM_001256714.1(DNAAF3):
387907151
DNAAF3
[ ]
[ ]
[‘Kartagener

c.386T > C

syndrome’, ‘Ciliary

(p.Leu129Pro)

dyskinesia, primary,

2’]

NM_020894.2(UVSSA):
387907164
UVSSA
[‘AAAA
[‘AAAATTYGCAA
[‘UV-sensitive

c.94T > C

TTYGC
GTATGTCTTAGG’,
syndrome 3’]

(p.Cys32Arg)

AAGTA
‘AAATTYGCAAGT

TGTCTT
ATGTCTTAGGG’]

AGG’]

NM_000267.3(NF1):
137854558
NF1
[ ]
[ ]
[‘Neurofibromatosis,

c.1523T > C

type 1’]

(p.Leu508Pro)

NM_000267.3(NF1):
137854561
NF1
[ ]
[ ]
[‘Neurofibromatosis,

c.6200T > C

familial spinal’]

(p.Leu2067Pro)

NM_004453.3(ETFDH):
387907170
ETFDH
[ ]
[‘CCAAAACYCAC
[ ]

c.1130T > C

CTTTCCTGGTGG’]

(p.Leu377Pro)

NM_000267.3(NF1):
137854563
NF1
[ ]
[ ]
[‘Neurofibromatosis,

c.1070T > C

type 1’,

(p.Leu357Pro)

‘Neurofibromatosis,

familial spinal’]

NM_024306.4(FA2H):
387907172
FA2H
[ ]
[ ]
[‘Spastic paraplegia

c.707T > C

35’]

(p.Phe236Ser)

NM_001004127.2(ALG11):
387907182
—
[ ]
[ ]
[‘Congenital disorder

c.1142T > C

of glycosylation type

(p.Leu381Ser)

1P’]

NM_021167.4(GATAD1):
387907188
GATAD1
[ ]
[ ]
[‘Cardiomyopathy,

c.304T > C

dilated, 2b’]

(p.Ser102Pro)

NM_033360.3(KRAS):
387907205
KRAS
[ ]
[‘GGACCAGYACA
[‘Cardiofaciocutaneous

c.211T > C

TGAGGACTGGGG’,
syndrome 2’]

(p.Tyr71His)

‘CCAGYACATGAG

GACTGGGGAGG’,

‘CAGYACATGAGG

ACTGGGGAGGG’]

NM_006265.2(RAD21):
387907213
—
[ ]
[ ]
[‘Cornelia de Lange

c.1753T > C

syndrome 4’]

(p.Cys585Arg)

NM_000222.2(KIT):
387907217
KIT
[ ]
[ ]
[ ]

c.1859T > C

(p.Val620Ala)

NM_000335.4(SCN5A):
137854615
SCN5A
[ ]
[ ]
[‘Brugada

c.5380T > C

syndrome’, ‘Brugada

(p.Tyr1794His)

syndrome 1’]

NM_000076.2(CDKN1C):
387907224
CDKN1C
[ ]
[ ]
[‘Intrauterine growth

c.827T > C

retardation,

(p.Phe276Ser)

metaphyseal

dysplasia, adrenal

hypoplasia

congenita, and

genital anomalies’]

NM_005691.3(ABCC9):
387907229
ABCC9
[ ]
[ ]
[‘Hypertrichotic

c.3058T > C

osteochondrodysplas

(p.Ser1020Pro)

ia’]

NM_012343.3(NNT):
387907233
NNT
[ ]
[ ]
[‘Glucocorticoid

c.2930T > C

deficiency 4’]

(p.Leu977Pro)

NM_024110.4(CARD14):
387907240
CARD14
[ ]
[‘CAGCAGCYGCA
[‘Pityriasis rubra

c.467T > C

GGAGCACCTGGG’]
pilaris’]

(p.Leu156Pro)

NM_002501.3(NFIX):
387907254
NFIX
[ ]
[ ]
[‘Sotos syndrome 2’]

c.179T > C

(p.Leu60Pro)

NM_001165963.1(SCN1A):
764444350
SCN1A
[ ]
[ ]
[‘Severe myoclonic

c.121A > T

epilepsy in infancy’]

(p.Lys41Ter)

NM_005022.3(PFN1):
387907265
PFN1
[ ]
[ ]
[‘Amyotrophic

c.341T > C

lateral sclerosis 18’]

(p.Met114Thr)

NM_001172567.1(MYD88):
387907272
MYD88
[ ]
[ ]
[‘Macroglobulinemia,

c.818T > C

waldenstrom,

(p.Leu273Pro)

somatic’]

NM_152296.4(ATP1A3):
387907282
ATP1A3
[ ]
[‘TGCCATCYCACT
[‘Alternating

c.2431T > C

GGCGTACGAGG’]
hemiplegia of

(p.Ser811Pro)

childhood 2’]

NM_022787.3(NMNAT1):
387907290
NMNAT1
[ ]
[ ]
[‘Leber congenital

c.838T > C

amaurosis 9’]

(p.Ter280Gln)

NM_005120.2(MED12):
387907361
MED12
[ ]
[‘AGGACYCTGAG
[‘Ohdo syndrome,

c.3493T > C

CCAGGGGCCCGG’]
X-linked’]

(p.Ser1165Pro)

NM_006194.3(PAX9):
28933970
PAX9
[ ]
[‘GGCCGCYGCCC
[‘Tooth agenesis,

c.62T > C (p.Leu21Pro)

AACGCCATCCGG’]
selective, 3’]

NM_000492.3(CFTR):
397508435
CFTR
[ ]
[ ]
[‘Cystic fibrosis’]

c.2780T > C

(p.Leu927Pro)

NM_177976.2(ARL6):
137854907
ARL6
[ ]
[ ]
[‘Bardet-Biedl

c.272T > C (p.Ile91Thr)

syndrome’]

TABLE 8

Human gene mutations that may be corrected by changing a guanine (G) to an

adenine (A). The gene name, gene symbol, and dbSNP database reference number (RS#) are

indicated. Also indicated are exemplary protospacers with their PAM sequences (gRNAs and

gRNAall) and the base to be edited e.g., a C, indicated by a “Y”. The “gRNAs” sequences,

from top to bottom, correspond to SEQ ID NOs: 3434-3601. The “gRNA all” sequences,

from top to bottom, correspond to SEQ ID NOs: 3602-4266.

RS#

Name
(dbSNP)
GeneSymbol
gRNAs
gRNAall
Phenotypes

NM_000138.4
137854472
FBN1
[ ]
[′TGCACYTGCCGT
[ ]

(FBN1):c.3128A>G

GGGTGCAGAGG′]

(p.Lys1043Arg)

NM_000237.2
268
LPL
[ ]
[ ]
[′Hyperlipidemia,

(LPL):c.953A>G

familial combined′]

(p.Asn318Ser)

NM_000257.3
727504261
MYH7
[ ]
[′AGCGCYCCTCAG
[′Cardiomyopathy′,

(MYH7):c.2708A>G

CATCTGCCAGG′]
′not specified′]

(p.Glu903Gly)

NM_000059.3
81002853
BRCA2
[ ]
[′ACCACYGGGGG
[′Familial cancer of

(BRCA2):c.476-2A>G

TAAAAAAAGGGG′,
breast′, ′Breast-

′TACCACYGGGGG
ovarian cancer,

TAAAAAAAGGG′,
familial 2′,

′ATACCACYGGGG
′Hereditary cancer-

GTAAAAAAAGG′]
predisposing

syndrome′]

NM_000059.3
81002862
BRCA2
[ ]
[ ]
[′Familial cancer of

(BRCA2):c.9118-2A>G

breast′, ′Breast-

ovarian cancer,

familial 2′]

NM_000059.3
81002895
BRCA2
[ ]
[ ]
[′Familial cancer of

(BRCA2):c.9649-2A>G

breast′, ′Breast-

ovarian cancer,

familial 2′]

NM_000387.5
28934589
SLC25A20
[ ]
[ ]
[′Carnitine

(SLC25A20):c.713A>G

acylcarnitine

(p.Gln238Arg)

translocase

deficiency′, ′not

provided′]

NM_000060.3
28934601
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.755A>G

deficiency′]

(p.Asp252Gly)

NM_172107.2
28939683
KCNQ2
[ ]
[ ]
[′Benign familial

(KCNQ2):c.851A>G

neonatal seizures 1′]

(p.Tyr284Cys)

NM_006158.4
58982919
NEFL
[ ]
[ ]
[′Charcot-Marie-

(NEFL):c.293A>G

Tooth disease, type

(p.Asn98Ser)

IF′, ′not provided′]

NM_000019.3
199524907
ACAT1
[ ]
[ ]
[′Deficiency of

(ACAT1):c.473A>G

acetyl-CoA

(p.Asn158Ser)

acetyltransferase′]

NM_007294.3
397509212
BRCA1
[ ]
[ ]
[′Familial cancer of

(BRCA1):c.4987-2A>G

breast′]

NM_007294.3
80358163
BRCA1
[ ]
[ ]
[′Familial cancer of

(BRCA1):c.213-12A>G

breast′, ′Hereditary

breast and ovarian

cancer syndrome′,

′Breast-ovarian

cancer, familial 1′,

′Hereditary cancer-

predisposing

syndrome′]

NM_001382.3
28934876
DPAGT1
[′ACAYAGT
[′ACAYAGTACAG
[′Congenital disorder

(DPAGT1):c.509A>G

ACAGGATT
GATTCCTGCGGG′,
of glycosylation type

(p.Tyr170Cys)

CCTGCGGG′,
′GACAYAGTACAG
1J′]

′GACAYAG
GATTCCTGCGG′]

TACAGGAT

TCCTGCGG′]

NM_032237.4
397509386
POMK
[ ]
[ ]
[′Congenital

(POMK):c.773A>G

muscular dystrophy-

(p.Gln258Arg)

dystroglycanopathy

with brain and eye

anomalies, type

A12′]

NM_201647.2
397509387
STAMBP
[ ]
[ ]
[′Microcephaly-

(STAMBP):c.125A>G

capillary

(p.Glu42Gly)

malformation

syndrome′]

NM_006876.2
397509397
B4GAT1
[′CTGATYT
[′TGATYTTCAGCC
[′Congenital

(B4GAT1):c.1168A>G

TCAGCCTC
TCCTTTTGGGG′,
muscular dystrophy-

(p.Asn390Asp)

CTTTTGGG′,
′CTGATYTTCAGC
dystroglycanopathy

′GCTGATYT
CTCCTTTTGGG′,
with brain and eye

TCAGCCTC
′GCTGATYTTCAG
anomalies, type

CTTTTGG′]
CCTCCTTTTGG′]
A13′]

NM_004315.4
397509415
ASAH1
[ ]
[ ]
[′Farber

(ASAH1):c.965+4A>G

lipogranulomatosis′]

NM_000257.3
730880875
MYH7
[ ]
[ ]
[′Cardiomyopathy′]

(MYH7):c.1477A>G

(p.Met493Val)

NM_021020.3
119473032
LZTS1
[ ]
[′CCCTYCTCGGAG
[ ]

(LZTS1):c.355A>G

CCCTGTAGAGG′]

(p.Lys119Glu)

NM_022455.4
587784163
NSD1
[ ]
[ ]
[′Sotos syndrome 1′]

(NSD1):c.5893-2A>G

NM_006894.5
72549322
FMO3
[ ]
[ ]
[′Trimethylaminuria′]

(FMO3):c.182A>G

(p.Asn61Ser)

NM_000403.3
121908046
GALE
[′TGGAAGY
[′TGGAAGYTATCG
[′UDPglucose-4-

(GALE):c.101A>G

TATCGATG
ATGACCACAGG′]
epimerase

(p.Asn34Ser)

ACCACAGG′]

deficiency′]

NM_000314.6
757498880
PTEN
[ ]
[ ]
[′Hereditary cancer-

(PTEN):c.527A>G

predisposing

(p.Tyr176Cys)

syndrome′]

NM_000053.3
193922103
ATP7B
[ ]
[ ]
[′Wilson disease′,

(ATP7B):c.2305A>G

′not specified′, ′not

(p.Met769Val)

provided′]

NM_000173.6
121908064
GP1BA
[ ]
[ ]
[′Pseudo von

(GP1BA):c.763A>G

Willebrand disease′]

(p.Met255Val)

NM_000422.2
59151893
KRT17
[′GTCAYTG
[′GTCAYTGAGGTT
[′Pachyonychia

(KRT17):c.275A>G

AGGTTCTG
CTGCATGGTGG′,
congenita type 2′,

(p.Asn92Ser)

CATGGTGG′]
′GCGGTCAYTGAG
′not provided′]

GTTCTGCATGG′]

NM_000288.3
62653611
PEX7
[ ]
[ ]
[′Rhizomelic

(PEX7):c.854A>G

chondrodysplasia

(p.His285Arg)

punctata type 1′]

NM_003742.2
11568372
ABCB11
[ ]
[ ]
[′Progressive

(ABCB11):c.890A>G

familial intrahepatic

(p.Glu297Gly)

cholestasis 2′,

′Benign recurrent

intrahepatic

cholestasis 2′]

NM_012243.2
141952252
SLC35A3
[ ]
[ ]
[′Arthrogryposis,

(SLC35A3):c.886A>G

mental retardation,

(p.Ser296Gly)

and seizures′]

NM_000061.2
28935478
BTK
[′GATGGYA
[′GATGGYAGTTA
[ ]

(BTK):c.1082A>G

GTTAATGA
ATGAGCTCAGGG′,

(p.Tyr361Cys)

GCTCAGGG′,
′TGATGGYAGTTA

′TGATGGY
ATGAGCTCAGG′]

AGTTAATG

AGCTCAGG′]

NM_000169.2
28935495
—
[ ]
[ ]
[′Fabry disease′]

(GLA):c.815A>G

(p.Asn272Ser)

NM_016069.9
786203989
—
[′TCATAGT
[′CATAGTYCTGCA
[′Chondrodysplasia,

(PAM16):c.226A>G

YCTGCAGA
GAGGAGAGGGG′,
megarbane-dagher-

(p.Asn76Asp)

GGAGAGG
′TCATAGTYCTGC
melki type′]

G′]
AGAGGAGAGGG′]

NM_058163.1
786203996
TSR2
[ ]
[ ]
[′Diamond-Blackfan

(TSR2):c.191A>G

anemia with

(p.Glu64Gly)

microtia and cleft

palate′, ′DIAMOND-

BLACKFAN

ANEMIA 14 WITH

MANDIBULOFACIAL

DYSOSTOSIS′]

NM_001098398.1
794727994
—
[ ]
[ ]
[ ]

(COPA):c.728A>G

(p.Asp243Gly)

NM_005957.4
786204024
MTHFR
[ ]
[ ]
[′Homocysteinemia

(MTHFR):c.1114A>G

due to MTHFR

(p.Lys372Glu)

deficiency′]

NM_012193.3
80358293
—
[ ]
[ ]
[′Exudative

(FZD4):c.1024A>G

vitreoretinopathy 1′]

(p.Met342Val)

NM_000186.3
460184
CFH
[′CAGYTGA
[′CAGYTGAATTTG
[′Atypical

(CFH):c.3590T>C

ATTTGTGT
TGTGTAAACGG′]
hemolytic-uremic

(p.Val1197Ala)

GTAAACGG′]

syndrome 1′]

NM_014846.3
80338865
KIAA0196
[ ]
[ ]
[′Spastic paraplegia

(KIAA0196):c.1411A>G

8′]

(p.Asn471Asp)

NM_014946.3
786204132
SPAST
[′AGCATTG
[′ATTGYCTTCCCA
[′Spastic paraplegia

(SPAST):c.1165A>G

YCTTCCCA
TTCCCAGGTGG′,
4, autosomal

(p.Thr389Ala)

TTCCCAGG′]
AGCATTGYCTTC
dominant′]

CCATTCCCAGG′]

NM_000925.3
28935769
PDHB
[ ]
[ ]
[′Pyruvate

(PDHB):c.395A>G

dehydrogenase E1-

(p.Tyr132Cys)

beta deficiency′]

NM_000090.3
794728050
COL3A1
[ ]
[ ]
[′Thoracic aortic

(COL3A1):c.2338-2A>G

aneurysms and

aortic dissections′]

NM_000540.2
193922746
RYR1
[ ]
[ ]
[′King Denborough

(RYR1):c.97A>G

syndrome′, ′not

(p.Lys33Glu)

provided′]

NM_000540.2
193922801
RYR1
[ ]
[′TTCYCCTCCACG
[′not provided′]

(RYR1):c.7043A>G

CTCTCGCCTGG′]

(p.Glu2348Gly)

NM_000218.2
36210419
KCNQ1
[ ]
[′GCCCCTYGGAGC
[′Torsades de

(KCNQ1):c.652A>G

CCACGCAGAGG′]
pointes′, ′Cardiac

(p.Lys218Glu)

arrhythmia′]

NM_000540.2
193922886
RYR1
[ ]
[ ]
[′Minicore myopathy

(RYR1):c.14647-1449A>G

with external

ophthalmoplegia′,

′not provided′]

NM_004429.4
28936071
EFNB1
[ ]
[ ]
[′Craniofrontonasal

(EFNB1):c.472A>G

dysplasia′]

(p.Met158Val)

NM_007254.3
199919568
PNKP
[′CCGGYGA
[′CCGGYGAGGCC
[′not provided′]

(PNKP):c.1029+2T>C

GGCCCTGG
CTGGGGCGGGGG′,

GGCGGGGG′,
′TCCGGYGAGGCC

′TCCGGYG
CTGGGGCGGGG′,

AGGCCCTG
′ATCCGGYGAGGC

GGGCGGG
CCTGGGGCGGG′,

G′]
′GATCCGGYGAGG

CCCTGGGGCGG′]

NM_005448.2
104894765
BMP15
[′ATTGAAA
[′ATTGAAAYAGA
[′Ovarian dysgenesis

(BMP15):c.704A>G

YAGAGTAA
GTAACAAGAAGG′]
2′]

(p.Tyr235Cys)

CAAGAAGG′]

NM_004415.2
794728111
DSP
[ ]
[ ]
[′not provided′]

(DSP):c.1141-2A>G

NM_016035.4
786204770
COQ4
[′GCTGTYG
[′GCTGTYGGCCGC
[′COENZYME Q10

(COQ4):c.155T>C

GCCGCCGG
CGGCTCCGCGG′]
DEFICIENCY,

(p.Leu52Ser)

CTCCGCGG′]

PRIMARY, 7′]

NM_015717.4
200837270
CD207
[ ]
[ ]
[′Birbeck granule

(CD207):c.790T>C

deficiency′]

(p.Trp264Arg)

NM_004771.3
786204826
MMP20
[′CGAAAYG
[′CGAAAYGTGTAT
[′Amelogenesis

(MMP20):c.611A>G

TGTATCTC
CTCCTCCCAGG′]
imperfecta,

(p.His204Arg)

CTCCCAGG′]

hypomaturation

type, IIA2′]

NM_003392.4
786204836
WNT5A
[ ]
[ ]
[′Robinow

(WNT5A):c.257A>G

syndrome′]

(p.Tyr86Cys)

NM_000918.3
786204843
P4HB
[ ]
[ ]
[′Cole Carpenter

(P4HB):c.1178A>G

syndrome′]

(p.Tyr393Cys)

NM_000314.6
786204855
PTEN
[ ]
[ ]
[′Hereditary cancer-

(PTEN):c.139A>G

predisposing

(p.Arg47Gly)

syndrome′]

NM_000314.6
786204858
PTEN
[ ]
[ ]
[′Hereditary cancer-

(PTEN):c.320A>G

predisposing

(p.Asp107Gly)

syndrome′]

NM_000447.2
28936379
PSEN2
[ ]
[ ]
[′Alzheimer disease,

(PSEN2):c.715A>G

type 4′, ′not

(p.Met239Val)

provided′]

NM_005263.3
28936381
GFIl
[ ]
[ ]
[′Severe congenital

(GFI1):c.1145A>G

neutropenia 2,

(p.Asn382Ser)

autosomal

dominant′]

NM_005263.3
28936382
GFIl
[ ]
[ ]
[′Neutropenia,

(GFI1):c.1208A>G

nonimmune chronic

(p.Lys403Arg)

idiopathic, of

adults′]

NM_000314.6
786204865
PTEN
[ ]
[ ]
[′Hereditary cancer-

(PTEN):c.512A>G

predisposing

(p.Gln171Arg)

syndrome′]

NM_000314.6
786204926
PTEN
[ ]
[ ]
[′Hereditary cancer-

(PTEN):c.254-2A>G

predisposing

syndrome′]

NM_001103.3
786204951
ACTN2
[ ]
[ ]
[′Familial

(ACTN2):c.1883A>G

hypertrophic

(p.Glu628Gly)

cardiomyopathy 23′]

NM_003159.2
786204973
CDKL5
[ ]
[ ]
[′Early infantile

(CDKL5):c.-162-2A>G

epileptic

encephalopathy 2′]

NM_001159287.1
121964849
TPI1
[ ]
[ ]
[′Triosephosphate

(TPI1):c.622A>G

isomerase

(p.Ile208Val)

deficiency′]

NM_003159.2
786204979
CDKL5
[ ]
[ ]
[′Early infantile

(CDKL5):c.2277-2A>G

epileptic

encephalopathy 2′]

NM_003159.2
786204985
CDKL5
[ ]
[ ]
[′Early infantile

(CDKL5):c.458A>G

epileptic

(p.Asp153Gly)

encephalopathy 2′]

NM_003159.2
786204991
CDKL5
[ ]
[ ]
[′Early infantile

(CDKL5):c.91A>G

epileptic

(p.Arg31Gly)

encephalopathy 2′]

NM_001007792.1
121964869
NTRK1
[ ]
[ ]
[′Hereditary

(NTRK1):c.986A>G

insensitivity to pain

(p.Tyr329Cys)

with anhidrosis′]

NM_001007792.1
121964870
NTRK1
[ ]
[ ]
[′Hereditary

(NTRK1):c.1651A>G

insensitivity to pain

(p.Met551Val)

with anhidrosis′]

NM_004360.3
121964872
CDH1
[ ]
[ ]
[′Hereditary diffuse

(CDH1):c.2512A>G

gastric cancer′,

(p.Ser838Gly)

′Hereditary cancer-

predisposing

syndrome′,

′Neoplasm of ovary′]

NM_003122.4
17107315
SPINK1
[ ]
[ ]
[′Hereditary

(SPINK1):c.101A>G

pancreatitis′,

(p.Asn34Ser)

′Tropical calcific

pancreatitis′,

′Pancreatitis,

chronic,

susceptibility to′]

NM_021098.2
786205050
CACNA1H
[ ]
[ ]
[′Primary

(CACNA1H):c.4645A>G

hyperaldosteronism′]

(p.Met1549Val)

NM_001385.2
121964923
DPYS
[ ]
[ ]
[′Dihydropyrimidinase

(DPYS):c.1001A>G

deficiency′]

(p.Gln334Arg)

NM_003494.3
786205083
DYSF
[′GCCAGAG
[′GCCAGAGYGAG
[′Limb-girdle

(DYSF):c.3443-33A>G

YGAGTGGC
TGGCTGGAGTGG′]
muscular dystrophy,

TGGAGTGG′]

type 2B′]

NM_003816.2
786205086
ADAM9
[ ]
[ ]
[ ]

(ADAM9):c.411-8A>G

NM_000532.4
121964961
PCCB
[ ]
[ ]
[′Propionic

(PCCB):c.1304A>G

acidemia′]

(p.Tyr435Cys)

NM_000071.2
121964967
CBS
[′AACTYGG
[′AACTYGGTCCTG
[′Homocystinuria,

(CBS):c.1150A>G

TCCTGCGG
CGGGATGGGGG′,
pyridoxine-

(p.Lys384Glu)

GATGGGGG′]
′GAACTYGGTCCT
responsive′]

GCGGGATGGGG′,

′GGAACTYGGTCC

TGCGGGATGGG′,

′AGGAACTYGGTC

CTGCGGGATGG′]

NM_000093.4
786205101
COL5A1
[ ]
[ ]
[′Ehlers-Danlos

(COL5A1):c.655-2A>G

syndrome, classic

type′]

NM_000481.3
121964983
AMT
[′GCCAGGY
[′GCCAGGYGGAA
[′Non-ketotic

(AMT):c.125A>G

GGAAGTCA
GTCATAGAGCGG′]
hyperglycinemia′]

(p.His42Arg)

TAGAGCGG′]

NM_000108.4
121964987
DLD
[ ]
[ ]
[′Maple syrup urine

(DLD):c.214A>G

disease, type 3′]

(p.Lys72Glu)

NM_000108.4
121964989
DLD
[ ]
[′TTCTCYAAAAGC
[′Maple syrup urine

(DLD):c.1483A>G

TTCTGATAAGG′]
disease, type 3′]

(p.Arg495Gly)

NM_000108.4
121964993
DLD
[ ]
[ ]
[′Maple syrup urine

(DLD):c.1081A>G

disease, type 3′]

(p.Met361Val)

NM_001918.3
121965002
DBT
[ ]
[ ]
[ ]

(DBT):c.1355A>G

(p.His452Arg)

NM_030813.5
786205138
CLPB
[ ]
[ ]
[3-

(CLPB):c.1850A>G

METHYLGLUTACONIC

(p.Tyr617Cys)

ACIDURIA

WITH

CATARACTS,

NEUROLOGIC

INVOLVEMENT,

AND

NEUTROPENIA′]

NM_006610.3
72550870
MASP2
[ ]
[ ]
[′MASP2

(MASP2):c.359A>G

deficiency′]

(p.Asp120Gly)

NM_000398.6
121965018
CYB5R3
[ ]
[ ]
[′METHEMO-

(CYB5R3):c.719A>G

GLOBINEMIA,

(p.Asp240Gly)

TYPE I′]

NM_000095.2
28936668
COMP
[ ]
[ ]
[ ]

(COMP):c.1358A>G

(p.Asn453Ser)

NM_000095.2
28936669
COMP
[ ]
[′ATTGYCGTCGTC
[ ]

(COMP):c.1418A>G

GTCGTCGCAGG′]

(p.Asp473Gly)

NM_003816.2
786205151
ADAM9
[ ]
[ ]
[ ]

(ADAM9):c.1396-2A>G

NM_001204830.1
786205156
—
[ ]
[ ]
[′LIPOYL-

(LIPT1):c.535A>G

TRANSFERASE 1

(p.Thr179Ala)

DEFICIENCY′]

NM_000274.3
121965046
OAT
[ ]
[ ]
[′Ornithine

(OAT):c.734A>G

aminotransferase

(p.Tyr245Cys)

deficiency′]

NM_018488.2
28936696
TBX4
[ ]
[′GTACYGTAAGG
[′Ischiopatellar

(TBX4):c.1592A>G

AAGATTCTCGGG′,
dysplasia′]

(p.Gln531Arg)

′GGTACYGTAAGG

AAGATTCTCGG′]

NM_001110556.1
786205183
FLNA
[ ]
[ ]
[′X-linked

(FLNA):c.1829-2A>G

periventricular

heterotopia′]

NM_003865.2
28936704
HESX1
[ ]
[ ]
[′Growth hormone

(HESX1):c.541A>G

deficiency with

(p.Thr181Ala)

pituitary anomalies′]

NM_000137.2
121965077
FAH
[ ]
[′TCCYGGTCTGAC
[′Tyrosinemia type

(FAH):c.1141A>G

CATTCCCCAGG′]
I′]

(p.Arg381Gly)

NM_000137.2
121965078
FAH
[ ]
[ ]
[′Tyrosinemia type

(FAH):c.836A>G

I′]

(p.Gln279Arg)

NM_006129.4
786205219
BMP1
[ ]
[ ]
[′Osteogenesis

(BMP1):c.808A>G

imperfecta type 13′]

(p.Met270Val)

NM_001987.4
786205226
ETV6
[ ]
[ ]
[′Thrombocytopenia

(ETV6):c.1252A>G

5′]

(p.Arg418Gly)

NM_014423.3
786205233
AFF4
[ ]
[ ]
[′CHOPS

(AFF4):c.760A>G

SYNDROME′]

(p.Thr254Ala)

NM_000140.3
786205247
FECH
[ ]
[ ]
[′Erythropoietic

(FECH):c.68_194del

protoporphyria′]

NM_000138.4
794728203
FBN1
[ ]
[′ACTCAYCAATAT
[′Thoracic aortic

(FBN1):c.3344A>G

CTGCAAAATGG′]
aneurysms and

(p.Asp1115Gly)

aortic dissections′]

NM_198270.3
786205257
NHS
[ ]
[ ]
[′Nance-Horan

(NHS):c.853-2A>G

syndrome′]

NM_005502.3
2853578
ABCA1
[ ]
[ ]
[′Tangier disease′]

(ABCA1):c.1790A>G

(p.Gln597Arg)

NM_003002.3
786205436
SDHD
[ ]
[′GAATAGYCCATC
[′Fatal infantile

(SDHD):c.275A>G

GCAGAGCAAGG′]
mitochondrial

(p.Asp92Gly)

cardiomyopathy′]

NM_005259.2
1805086
—
[ ]
[ ]
[ ]

(MSTN):c.458A>G

(p.Lys153Arg)

NM_198056.2
1805124
SCN5A
[ ]
[ ]
[′Progressive

(SCN5A):c.1673A>G

familial heart block

(p.His558Arg)

type 1A′, ′not

specified′, ′not

provided′]

NM_000784.3
72551317
CYP27A1
[ ]
[′AGTCCACYTGGG
[′Cholestanol storage

(CYP27Al):c.776A>G

GAGGAAGGTGG′]
disease′]

(p.Lys259Arg)

NM_000784.3
72551320
CYP27A1
[ ]
[ ]
[′Cholestanol storage

(CYP27Al):c.1061A>G

disease′]

(p.Asp354Gly)

NM_000463.2
72551348
—
[ ]
[ ]
[′Crigler-Najjar

(UGT1A1):c.992A>G

syndrome, type II′]

(p.Gln331Arg)

NM_000463.2
72551351
—
[ ]
[ ]
[′Crigler Najjar

(UGT1A1):c.1070A>G

syndrome, type 1′]

(p.Gln357Arg)

NM_016218.2
786205687
POLK
[ ]
[′ATTCACAYTCTT
[′Malignant tumor of

(POLK):c.1385A>G

CAACTTAATGG′]
prostate′]

(p.Asn462Ser)

NM_016218.2
786205689
POLK
[ ]
[ ]
[′Malignant tumor of

(POLK):c.181A>G

prostate′]

(p.Asn61Asp)

NM_016218.2
786205692
POLK
[ ]
[ ]
[′Malignant tumor of

(POLK):c.1477A>G

prostate′]

(p.Lys493Glu)

NM_000138.4
794728280
FBN1
[ ]
[′TGTTCAYACTGG
[′Thoracic aortic

(FBN1):c.7916A>G

AAGCCGGCGGG′,
aneurysms and

(p.Tyr2639Cys)

′CTGTTCAYACTG
aortic dissections′]

GAAGCCGGCGG′]

NM_000132.3
28937272
F8
[ ]
[ ]
[′Hereditary factor

(F8):c.1331A>G

VIII deficiency

(p.Lys444Arg)

disease′]

NM_000531.5
72554340
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.268A>G

(p.Ser90Gly)

NM_005502.3
28937313
ABCA1
[′TCCAYTG
[′TCCAYTGTGGCC
[′Tangier disease′]

(ABCA1):c.2804A>G

TGGCCCAG
CAGGAAGGAGG′,

(p.Asn935Ser)

GAAGGAG
′CGCTCCAYTGTG

G′]
GCCCAGGAAGG′]

NM_004380.2
28937315
CREBBP
[ ]
[ ]
[′Rubinstein-Taybi

(CREBBP):c.3524A>G

syndrome′]

(p.Tyr1175Cys)

NM_000335.4
28937317
SCN5A
[ ]
[′GCAYTGACCACC
[′Long QT syndrome

(SCN5A):c.3971A>G

ACCTCAAGTGG′]
3′, ′Congenital long

(p.Asn1324Ser)

QT syndrome′]

NM_000891.2
786205818
KCNJ2
[ ]
[ ]
[′Cardiac

(KCNJ2):c.901A>G

arrhythmia′]

(p.Met301Val)

NM_144499.2
786205854
GNAT1
[ ]
[′CGGAGYCCTTCC
[′NIGHT

(GNAT1):c.386A>G

ACAGCCGCTGG′]
BLINDNESS,

(p.Asp129Gly)

CONGENITAL

STATIONARY,

TYPE 1G′]

NM_000523.3
104893635
HOXD13
[ ]
[ ]
[′Syndactyly type 5′]

(HOXD13):c.974A>G

(p.Gln325Arg)

NM_013953.3
104893660
—
[ ]
[ ]
[′Thyroid agenesis′]

(PAX8):c.160A>G

(p.Ser54Gly)

NM_014585.5
104893663
SLC40A1
[ ]
[ ]
[′Hemochromatosis

(SLC40A1):c.470A>G

type 4′]

(p.Asp157Gly)

NM_003124.4
104893665
SPR
[ ]
[ ]
[′Sepiapterin

(SPR):c.448A>G

reductase

(p.Arg150Gly)

deficiency′]

NM_000258.2
104893748
MYL3
[ ]
[ ]
[′Familial

(MYL3):c.445A>G

hypertrophic

(p.Met149Val)

cardiomyopathy 8′,

′Cardiomyopathy′,

′Hypertrophic

cardiomyopathy′]

NM_000539.3
104893776
RHO
[ ]
[′GGATGYACCTG
[′Retinitis

(RHO):c.533A>G

AGGACAGGCAGG′]
pigmentosa 4′]

(p.Tyr178Cys)

NM_000539.3
104893777
RHO
[ ]
[ ]
[′Retinitis

(RHO):c.569A>G

pigmentosa 4′]

(p.Asp190Gly)

NM_000539.3
104893786
RHO
[ ]
[ ]
[′Retinitis

(RHO):c.44A>G

pigmentosa′,

(p.Asn15Ser)

′Retinitis pigmentosa

4′]

NM_001814.4
28937571
CTSC
[ ]
[ ]
[′Periodontitis,

(CTSC):c.1235A>G

aggressive, 1′]

(p.Tyr412Cys)

NM_001701.3
28937579
BAAT
[ ]
[ ]
[′Hypercholanemia,

(BAAT):c.226A>G

familial′]

(p.Met76Val)

NM_001257342.1
28937590
BCS1L
[ ]
[′GACACYGAGGT
[′GRACILE

(BCS1L):c.232A>G

GCTGAGTACGGG′,
syndrome′]

(p.Ser78Gly)

′CGACACYGAGGT

GCTGAGTACGG′]

NM_004407.3
104893834
DMP1
[ ]
[ ]
[′Autosomal

(DMP1):c.1A>G

recessive

(p.Met1Val)

hypophosphatemic

vitamin D refractory

rickets′]

NM_000406.2
104893836
GNRHR
[ ]
[ ]
[′Hypogonadotropic

(GNRHR):c.317A>G

hypogonadism′]

(p.Gln106Arg)

NM_172250.2
104893849
MMAA
[ ]
[ ]
[′Methylmalonic

(MMAA):c.620A>G

aciduria cblA type′]

(p.Tyr207Cys)

NM_000320.2
104893866
QDPR
[ ]
[′TGCCGYACCCGA
[′Dihydropteridine

(QDPR):c.449A>G

TCATACCTGGG′,
reductase

(p.Tyr150Cys)

′ATGCCGYACCCG
deficiency′]

ATCATACCTGG′]

NM_015629.3
587776590
PRPF31
[ ]
[′GACAYACCCCTG
[′Retinitis

(PRPF31):c.527+3A>G

GGTGGTGGAGG′,
pigmentosa 11′]

′GCGGACAYACCC

CTGGGTGGTGG′]

NM_000112.3
104893920
SLC26A2
[ ]
[ ]
[′Diastrophic

(SLC26A2):c.1273A>G

dysplasia′,

(p.Asn425Asp)

′Achondrogenesis,

type IB′]

NM_000344.3
104893922
SMN1
[ ]
[ ]
[′Werdnig-Hoffmann

(SMN1):c.815A>G

disease′]

(p.Tyr272Cys)

NM_000344.3
104893932
SMN1
[ ]
[ ]
[′Kugelberg-

(SMN1):c.784A>G

Welander disease′]

(p.Ser262Gly)

NM_000409.3
104893967
GUCA1A
[ ]
[ ]
[′Cone dystrophy 3′]

(GUCA1A):c.296A>G

(p.Tyr99Cys)

NM_182548.3
104893975
LHFPL5
[ ]
[ ]
[′Deafness,

(LHFPL5):c.380A>G

autosomal recessive

(p.Tyr127Cys)

67′]

NM_001024630.3
104893993
RUNX2
[ ]
[ ]
[′Cleidocranial

(RUNX2):c.598A>G

dysostosis′,

(p.Thr200Ala)

′Cleidocranial

dysplasia, forme

fruste, dental

anomalies only′]

NM_000162.3
104894015
GCK
[ ]
[′GTAGYAGCAGG
[′Hyperinsulinemic

(GCK):c.641A>G

AGATCATCGTGG′]
hypoglycemia

(p.Tyr214Cys)

familial 3′]

NM_001002010.2
104894028
NT5C3A
[ ]
[ ]
[′Uridine 5-prime

(NT5C3A):c.686A>G

monophosphate

(p.Asn229Ser)

hydrolase

deficiency,

hemolytic anemia

due to′]

NM_203288.1
104894039
RP9
[ ]
[ ]
[′Retinitis

(RP9):c.509A>G

pigmentosa 9′]

(p.Asp170Gly)

NM_000474.3
104894059
TWIST1
[ ]
[ ]
[′Saethre-Chotzen

(TWIST1):c.466A>G

syndrome′]

(p.Ile156Val)

NM_000532.4
202247823
PCCB
[ ]
[′ATATYTGCATGT
[′Propionic

(PCCB):c.1606A>G

TTTCTCCAAGG′]
acidemia′, ′not

(p.Asn536Asp)

provided′]

NM_021615.4
28937877
CHST6
[ ]
[ ]
[′Macular corneal

(CHST6):c.521A>G

dystrophy Type I′]

(p.Lys174Arg)

NM_178138.4
104894117
LHX3
[′CAGGTGG
[′CAGGTGGYACA
[′Pituitary hormone

(LHX3):c.332A>G

YACACGAA
CGAAGTCCTGGG′]
deficiency,

(p.Tyr111Cys)

GTCCTGGG′]

combined 3′]

NM_004897.4
104894171
MINPP1
[ ]
[ ]
[′Thyroid cancer,

(MINPP1):c.809A>G

follicular′]

(p.Gln270Arg)

NM_000073.2
104894199
CD3G
[ ]
[′CCAYGTCAGTCT
[′Immunodeficiency

(CD3G):c.1A>G

CTGTCCTCCGG′]
17′]

(p.Met1Val)

NM_001885.2
104894201
CRYAB
[ ]
[ ]
[′Alpha-B

(CRYAB):c.358A>G

crystallinopathy′]

(p.Arg120Gly)

NM_001814.4
104894208
CTSC
[ ]
[′CTCCYGAGGGCT
[′Papillon-

(CTSC):c.857A>G

TAGGATTGGGG′,
Lef\xc3\xa8vre

(p.Gln286Arg)

′CCTCCYGAGGGC
syndrome′, ′Haim-

TTAGGATTGGG′,
Munk syndrome′]

′ACCTCCYGAGGG

CTTAGGATTGG′]

NM_001814.4
104894211
CTSC
[ ]
[′TCCTACAYAGTG
[′Papillon-

(CTSC):c.1040A>G

GTACTCAGAGG′]
Lef\xc3\xa8vre

(p.Tyr347Cys)

syndrome′,

′Periodontitis,

aggressive, 1′]

NM_012193.3
104894223
—
[′GAAATAY
[′GAAATAYGATG
[′Retinopathy of

(FZD4):c.766A>G

GATGGGGC
GGGCGCTCAGGG′,
prematurity′]

(p.Ile256Val)

GCTCAGGG′,
′AGAAATAYGATG

′AGAAATA
GGGCGCTCAGG′]

YGATGGGG

CGCTCAGG′]

NM_005343.2
104894227
—
[ ]
[ ]
[′Costello

(HRAS):c.350A>G

syndrome′]

(p.Lys117Arg)

NM_145014.2
104894232
—
[ ]
[ ]
[′Hydrolethalus

(HYLS1):c.632A>G

syndrome′]

(p.Asp211Gly)

NM_000525.3
104894248
KCNJ11
[′GACAYGG
[′GACAYGGTAGA
[′Islet cell

(KCNJ11):c.776A>G

TAGATGAT
TGATCAGCGGGG′,
hyperplasia′]

(p.His259Arg)

CAGCGGGG′]
′TGACAYGGTAGA

TGATCAGCGGG′,

′ATGACAYGGTAG

ATGATCAGCGG′]

NM_000317.2
104894275
PTS
[′TAAYTGT
[′TAAYTGTGCCCA
[′6-pyruvoyl-

(PTS):c.155A>G

GCCCATGG
TGGCCATTTGG′]
tetrahydropterin

(p.Asn52Ser)

CCATTTGG′]

synthase deficiency′]

NM_000317.2
104894278
PTS
[ ]
[ ]
[′Hyperphenyl-

(PTS):c.139A>G

alaninemia, bh4-deficient,

(p.Asn47Asp)

a, due to partial pts

deficiency′]

NM_000317.2
104894279
PTS
[ ]
[ ]
[′Hyperphenyl-

(PTS):c.347A>G

alaninemia, bh4-deficient,

(p.Asp116Gly)

a, due to partial pts

deficiency′]

NM_022051.2
119476045
EGLN1
[ ]
[ ]
[′Erythrocytosis,

(EGLN1):c.1121A>G

familial, 3′]

(p.His374Arg)

NM_015915.4
119476048
ATL1
[ ]
[ ]
[′Spastic paraplegia

(ATL1):c.773A>G

3′]

(p.His258Arg)

NM_000448.2
104894290
RAG1
[ ]
[′CTGYACTGGCAG
[′Histiocytic

(RAG1):c.2735A>G

AGGGATTCTGG′]
medullary

(p.Tyr912Cys)

reticulosis′]

NM_000448.2
104894292
RAG1
[ ]
[ ]
[′Histiocytic

(RAG1):c.1286A>G

medullary

(p.Asp429Gly)

reticulosis′]

NM_003002.3
104894304
SDHD
[ ]
[ ]
[′Hereditary

(SDHD):c.341A>G

Paraganglioma-

(p.Tyr114Cys)

Pheochromocytoma

Syndromes′,

′Paragangliomas 1′]

NM_015141.3
72552293
GPD1L
[ ]
[ ]
[′Brugada syndrome

(GPD1L):c.370A>G

2′, ′Primary familial

(p.Ile124Val)

hypertrophic

cardiomyopathy′,

′Long QT

syndrome′, ′Sudden

infant death

syndrome′,

′Cardiomyopathy′]

NM_020661.2A
104894322
AICDA
[ ]
[ ]
[′Immunodeficiency

(AICDA):c.415A>G

with hyper IgM type

(p.Met139Val)

2′]

NM_014365.2
104894351
HSPB8
[ ]
[ ]
[′Charcot-Marie-

(HSPB8):c.421A>G

Tooth disease′,

(p.Lys141Glu)

′Distal hereditary

motor neuronopathy

type 2A′]

NM_000217.2
104894354
KCNA1
[ ]
[′GCGYTTCCACGA
[′Episodic ataxia

(KCNA1):c.676A>G

TGAAGAAGGGG′,
type 1′]

(p.Thr226Ala)

′AGCGYTTCCACG

ATGAAGAAGGG′,

′CAGCGYTTCCAC

GATGAAGAAGG′]

NM_014239.3
104894425
EIF2B2
[ ]
[′AGTTGTCYCAAT
[′Leukoencephalopathy

(EIF2B2):c.638A>G

ACCTGCTTTGG′]
with vanishing

(p.Glu213Gly)

white matter′,

′Ovarioleuko-

dystrophy′]

NM_002408.3
104894447
MGAT2
[ ]
[ ]
[′Carbohydrate-

(MGAT2):c.785A>G

deficient

(p.His262Arg)

glycoprotein

syndrome type II′]

NM_002408.3
104894448
MGAT2
[ ]
[ ]
[′Carbohydrate-

(MGAT2):c.952A>G

deficient

(p.Asn318Asp)

glycoprotein

syndrome type II′]

NM_000270.3
104894450
PNP
[ ]
[′ATAYCTCCAACC
[′Purine-nucleoside

(PNP):c.383A>G

TCAAACTTGGG′,
phosphorylase

(p.Asp128Gly)

′GATAYCTCCAAC
deficiency′]

CTCAAACTTGG′]

NM_000270.3
104894452
PNP
[ ]
[ ]
[′Purine-nucleoside

(PNP):c.575A>G

phosphorylase

(p.Tyr192Cys)

deficiency′]

NM_005982.3
104894478
SIX1
[ ]
[ ]
[′Melnick-Fraser

(SIX1):c.386A>G

syndrome′,

(p.Tyr129Cys)

′Branchiootic

syndrome 3′]

NM_000101.3
104894510
CYBA
[ ]
[ ]
[′Granulomatous

(CYBA):c.281A>G

disease, chronic,

(p.His94Arg)

autosomal recessive,

cytochrome b-

negative′]

NM_024887.3
147394623
DHDDS
[ ]
[′GGCACTYCTTGG
[′Retinitis

(DHDDS):c.124A>G

CATAGCGACGG′]
pigmentosa 59′]

(p.Lys42Glu)

NM_024006.5
104894541
VKORC1
[ ]
[ ]
[′Warfarin response′]

(VKORC1):c.172A>G

(p.Arg58Gly)

NM_001128085.1
104894550
—
[ ]
[ ]
[′Spongy

(ASPA):c.692A>G

degeneration of

(p.Tyr231Cys)

central nervous

system′]

NM_001128085.1
104894551
—
[ ]
[ ]
[′Spongy

(ASPA):c.71A>G

degeneration of

(p.Glu24Gly)

central nervous

system′]

NM_000019.3
148639841
ACAT1
[ ]
[ ]
[′Deficiency of

(ACAT1):c.472A>G

acetyl-CoA

(p.Asn158Asp)

acetyltransferase′,

′not provided′]

NM_014254.2
150736997
TMEM5
[ ]
[ ]
[′Congenital

(TMEM5):c.1016A>G

muscular dystrophy-

(p.Tyr339Cys)

dystroglycanopathy

with brain and eye

anomalies, type

A10′]

NM_005557.3
60723330
KRT16
[ ]
[′GCGGTCAYTGA
[′Pachyonychia

(KRT16):c.374A>G

GGTTCTGCATGG′]
congenita, type 1′,

(p.Asn125Ser)

′Palmoplantar

keratoderma,

nonepidermolytic,

focal′, ′not provided′]

NM_005450.4
104894602
NOG
[ ]
[ ]
[′Tarsal carpal

(NOG):c.665A>G

coalition syndrome′,

(p.Tyr222Cys)

′Cushing

symphalangism′]

NM_030665.3
104894634
RAI1
[ ]
[′CTGCTGCYGTCG
[′Smith-Magenis

(RAI1):c.4685A>G

TCGTCGCTTGG′]
syndrome′]

(p.Gln1562Arg)

NM_000346.3
104894647
SOX9
[ ]
[ ]
[′Acampomelic

(SOX9):c.517A>G

campomelic

(p.Lys173Glu)

dysplasia′]

NM_024301.4
104894679
FKRP
[ ]
[ ]
[′Congenital

(FKRP):c.926A>G

muscular dystrophy-

(p.Tyr309Cys)

dystroglycanopathy

without mental

retardation, type

B5′]

NM_000495.4
281874691
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.2394A>G

X-linked recessive′]

(p.Lys798=)

NM_001604.5
794726661
PAX6
[ ]
[ ]
[′Congenital

(PAX6):c.1075-2A>G

aniridia′]

NM_000363.4
104894728
TNNI3
[ ]
[ ]
[′Familial restrictive

(TNNI3):c.569A>G

cardiomyopathy 1′,

(p.Asp190Gly)

′Familial

hypertrophic

cardiomyopathy 7′]

NM_000363.4
104894730
TNNI3
[ ]
[′CCTYCTTCACCT
[′Familial restrictive

(TNNI3):c.532A>G

GCTTGAGGTGG′,
cardiomyopathy 1′]

(p.Lys178Glu)

′CCTCCTYCTTCAC

CTGCTTGAGG′]

NM_000054.4
104894752
AVPR2
[ ]
[ ]
[′Nephrogenic

(AVPR2):c.839A>G

diabetes insipidus,

(p.Tyr280Cys)

X-linked′]

NM_000074.2
104894772
CD40LG
[ ]
[ ]
[′Immunodeficiency

(CD40LG):c.386A>G

with hyper IgM type

(p.Glu129Gly)

1′]

NM_000495.4
281874752
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.4977-2A>G

X-linked recessive′]

NM_001165963.1
794726722
—
[ ]
[ ]
[′Severe myoclonic

(SCN1A):c.5264A>G

epilepsy in infancy′]

(p.Asp1755Gly)

NM_000495.4
281874756
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.547-2A>G

X-linked recessive′]

NM_000495.4
281874758
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.610-2A>G

X-linked recessive′]

NM_032520.4
193302855
GNPTG
[′CCCYGAA
[′CCCYGAAGGTG
[′Mucolipidosis III

(GNPTG):c.610-2A>G

GGTGGAGG
GAGGATGCAGGG′,
Gamma′]

ATGCAGGG′]
′GCCCYGAAGGTG

GAGGATGCAGG′]

NM_002049.3
104894816
GATA1
[ ]
[′GTCCTGYCCCTC
[′GATA-1-related

(GATA1):c.653A>G

CGCCACAGTGG′]
thrombocytopenia

(p.Asp218Gly)

with

dyserythropoiesis′]

NM_000157.3
364897
GBA
[′CCAYTGG
[′CCAYTGGTCTTG
[′Gaucher disease′,

(GBA):c.680A>G

TCTTGAGC
AGCCAAGTGGG′,
′Subacute

(p.Asn227Ser)

CAAGTGGG′,
′TCCAYTGGTCTT
neuronopathic

′TCCAYTGG
GAGCCAAGTGG′]
Gaucher disease′,

TCTTGAGC

′Gaucher disease,

CAAGTGG′]

type 1′]

NM_001097642.2
104894819
GJB1
[ ]
[ ]
[′X-linked hereditary

(GJB1):c.194A>G

motor and sensory

(p.Tyr65Cys)

neuropathy′]

NM_000166.5
104894822
GJB1
[ ]
[ ]
[′X-linked hereditary

(GJB1):c.614A>G

motor and sensory

(p.Asn205Ser)

neuropathy′]

NM_001165963.1
773407463
SCN1A
[ ]
[ ]
[′Severe myoclonic

(SCN1A):c.747T>G

epilepsy in infancy′]

(p.Asp249Glu)

NM_000169.2
104894830
—
[ ]
[ ]
[′Fabry disease′,

(GLA):c.886A>G

′Fabry disease,

(p.Met296Val)

cardiac variant′]

NM_000169.2
104894835
—
[ ]
[ ]
[′Fabry disease′]

(GLA):c.101A>G

(p.Asn34Ser)

NM_001165963.1
794726773
SCN1A
[ ]
[′GTGCCAYACCTG
[′Severe myoclonic

(SCN1A):c.1662+3A>G

GTGTGGGGAGG′]
epilepsy in infancy′]

NM_000169.2
104894852
—
[ ]
[ ]
[′Fabry disease′]

(GLA):c.1228A>G

(p.Thr410Ala)

NM_000202.6
104894861
IDS
[ ]
[′AAAGACTYTTCC
[′Mucopolysaccharidosis,

(IDS):c.404A>G

CACCGACATGG′]
MPS-II′]

(p.Lys135Arg)

NM_001165963.1
794726803
SCN1A
[ ]
[ ]
[′Severe myoclonic

(SCN1A):c.383+1A>G

epilepsy in infancy′]

NM_000266.3
104894870
NDP
[ ]
[ ]
[′Atrophia bulborum

(NDP):c.131A>G

hereditaria′]

(p.Tyr44Cys)

NM_000266.3
104894874
NDP
[ ]
[′TGGYGCCTCATG
[ ]

(NDP):c.125A>G

CAGCGTCGAGG′]

(p.His42Arg)

NM_001128227.2
121908634
GNE
[ ]
[ ]
[′Inclusion body

(GNE):c.604A>G

myopathy 2′]

(p.Met202Val)

NM_001165963.1
794726816
—
[ ]
[ ]
[′Severe myoclonic

(SCN1A):c.3880-2A>G

epilepsy in infancy′]

NM_001165963.1
794726844
SCN1A
[′ACATAYA
[′ACATAYATCCCT
[′Severe myoclonic

(SCN1A):c.1046A>G

TCCCTCTG
CTGGACATTGG′]
epilepsy in infancy′]

(p.Tyr349Cys)

GACATTGG′]

NM_001015877.1
104894917
PHF6
[ ]
[ ]
[′Borjeson-

(PHF6):c.700A>G

Forssman-Lehmann

(p.Lys234Glu)

syndrome′]

NM_001015877.1
104894918
PHF6
[ ]
[ ]
[′Borjeson—

(PHF6):c.686A>G

Forssman-Lehmann

(p.His229Arg

syndrome′]

NM_001015877.1
104894919
PHF6
[′CTCYTGA
[′CTCYTGATGTTG
[Borjeson-

(PHF6):c.769A>G

TGTTGTTG
TTGTGAGCTGG′]
Forssman-Lehmann

(p.Arg257Gly)

TGAGCTGG′]

syndrome′]

NM_000307.4
104894922
POU3F4
[ ]
[ ]
[′Deafness, X-linked

(POU3F4):c.1000A>G

2′]

(p.Lys334Glu)

NM_000330.3
104894929
—
[ ]
[ ]
[′Juvenile

(RS1):c.667T>C

retinoschisis′]

(p.Cys223Arg)

NM_003413.3
104894962
ZIC3
[′TGTGTTY
[′TGTGTTYGCGCA
[′Heterotaxy,

(ZIC3):c.1213A>G

GCGCAGGG
GGGAGCTCGGG′,
visceral, X-linked′]

(p.Lys405Glu)

AGCTCGGG′,
′ATGTGTTYGCGC

′ATGTGTTY
AGGGAGCTCGG′]

GCGCAGGG

AGCTCGG′]

NM_002420.5
191205969
TRPM1
[ ]
[′AAGCYCTTAATA
[′Congenital

(TRPM1):c.296T>C

TCTGTGCATGG′]
stationary night

(p.Leu99Pro)

blindness, type 1C′]

NM_004006.2
794727030
DMD
[ ]
[ ]
[′Duchenne

(DMD):c.1150-2A>G

muscular dystrophy′,

′Becker muscular

dystrophy′]

NM_203290.2
371802902
POLR1C
[ ]
[ ]
[′LEUKODYSTROPHY,

(POLR1C):c.221A>G

HYPOMYELINATING,

(p.Asn74Ser)

11′]

NM_019109.4
794727073
ALG1
[ ]
[′TAAACYGCAGA
[′Congenital disorder

(ALG1):c.1188-2A>G

GAGAACCAAGGG′,
of glycosylation type

′GTAAACYGCAGA
1K′]

GAGAACCAAGG′]

NM_004463.2
794727099
FGD1
[ ]
[ ]
[′Aarskog

(FGD1):c.2016-2A>G

syndrome′]

NM_024110.4
281875213
CARD14
[ ]
[ ]
[′Psoriasis

(CARD14):c.425A>G

susceptibility 2′, ′not

(p.Glu142Gly)

provided′]

NM_001004334.3
281875236
GPR179
[ ]
[′CCCACAYATCCA
[′Congenital

(GPR179):c.659A>G

TCTGCCTGCGG′]
stationary night

(p.Tyr220Cys)

blindness, type 1E′,

′not provided′]

NM_018965.3
28939079
TREM2
[′CCGGTGA
[′TGAYCCAGGGG
[′Polycystic

(TREM2):c.401A>G

YCCAGGGG
GTCTATGGGAGG′,
lipomembranous

(p.Asp134Gly)

GTCTATGG′]
′CGGTGAYCCAGG
osteodysplasia with

GGGTCTATGGG′,
sclerosing

′CCGGTGAYCCAG
leukoencephalopathy′]

GGGGTCTATGG′]

NM_015915.4
28939094
ATL1
[ ]
[′CACCCAYCTTCT
[′Spastic paraplegia

(ATL1):c.1222A>G

TCACCCCTCGG′]
3′]

(p.Met408Val)

NM_002437.4
147952488
MPV17
[′TGGYAAG
[′TGGYAAGTTCTC
[′Navajo

(MPV17):c.186+2T>C

TTCTCCCC
CCCTCAACAGG′]
neurohepatopathy′,

TCAACAGG′]

′not provided′]

NM_005359.5
281875320
SMAD4
[′TGAGYAT
[′TGAGYATGCATA
[′Myhre syndrome′,

(SMAD4):c.1500A>G

GCATAAGC
AGCGACGAAGG′]
′not provided′]

(p.Ile500Met)

GACGAAG

G′]

NM_005359.5
281875322
SMAD4
[′TGAGTAY
[′TGAGTAYGCATA
[′Hereditary cancer-

(SMAD4):c.1498A>G

GCATAAGC
AGCGACGAAGG′]
predisposing

(p.Ile500Val)

GACGAAG

syndrome′, ′Myhre

G′]

syndrome′, ′not

provided′]

NM_005359.5
281875324
SMAD4
[ ]
[′ATCCATTYCAAA
[′Juvenile polyposis

(SMAD4):c.989A>G

GTAAGCAATGG′]
syndrome′,

(p.Glu330Gly)

′Hereditary cancer-

predisposing

syndrome′, ′not

provided′]

NM_000342.3
5036
SLC4A1
[ ]
[ ]
[ ]

(SLC4A1):c.166A>G

(p.Lys56Glu)

NM_000518.4
33985472
HBB
[ ]
[ ]
[ ]

(HBB):c.*113A>G

NM_001127255.1
104895503
—
[′TCTGGYT
[′TCTGGYTGATAC
[′Hydatidiform

(NLRP7):c.2738A>G

GATACTCA
TCAAGTCCAGG′]
mole′]

(p.Asn913Ser)

AGTCCAGG′]

NM_000037.3
77173848
ANK1
[ ]
[′GGGCCYGGCCC
[′Spherocytosis, type

(ANK1):c.-108T>C

GCACGTCACAGG′]
1, autosomal

recessive′]

NM_201631.3
115677373
TGM5
[′TGCGGAG
[′TGCGGAGYGGA
[′Peeling skin

(TGM5):c.763T>C

YGGACGG
CGGGCAGCGTGG′
syndrome, acral

(p.Trp255Arg)

GCAGCGTG
]
type′]

G′]

NM_020435.3
587776888
GJC2
[ ]
[ ]
[′Leukodystrophy,

(GJC2):c.-167A>G

hypomyelinating, 2′]

NM_130466.3
672601304
UBE3B
[ ]
[ ]
[′Kaufman

(UBE3B):c.1A>G

oculocerebrofacial

(p.Met1Val)

syndrome′]

NM_022124.5
794727649
—
[ ]
[ ]
[′Usher syndrome,

(CDH23):c.146-2A>G

type 1D′]

NM_014191.3
672601319
SCN8A
[ ]
[ ]
[′Early infantile

(SCN8A):c.667A>G

epileptic

(p.Arg223Gly)

encephalopathy 13′]

NM_001164405.1
672601337
BHLHA9
[ ]
[ ]
[′Syndactyly type 9′]

(BHLHA9):c.211A>G

(p.Asn71Asp)

NM_021830.4
672601360
C10orf2
[ ]
[ ]
[′Perrault syndrome 5′]

(C10orf2):c.1754A>G

(p.Asn585Ser)

NM_002887.3
672601372
RARS
[ ]
[ ]
[′Leukodystrophy,

(RARS):c.5A>G

hypomyelinating, 9′]

(p.Asp2Gly)

NM_002887.3
672601375
RARS
[ ]
[ ]
[′Leukodystrophy,

(RARS):c.1A>G

hypomyelinating, 9′]

(p.Met1Val)

NM_001943.3
397514038
DSG2
[ ]
[ ]
[′Arrhythmogenic

(DSG2):c.1880-2A>G

right ventricular

cardiomyopathy,

type 10′,

′Cardiomyopathy′]

NM_024422.4
397514042
DSC2
[ ]
[ ]
[′Arrhythmogenic

(DSC2):c.631-2A>G

right ventricular

cardiomyopathy,

type 11′,

′Cardiomyopathy′]

NM_001159772.1
150181226
CANT1
[ ]
[′CGTCYGTACGTG
[′Desbuquois

(CANT1):c.671T>C

GGCGGCCTGGG′,
syndrome′]

(p.Leu224Pro)

′GCGTCYGTACGT

GGGCGGCCTGG′]

NM_031418.2
587776923
ANO3
[ ]
[ ]
[′Dystonia 24′]

(ANO3):c.2053A>G

(p.Ser685Gly)

NM_014191.3
202151337
SCN8A
[ ]
[ ]
[′Early infantile

(SCN8A):c.5302A>G

epileptic

(p.Asn1768Asp)

encephalopathy 13′]

NM_000367.3
1142345
TPMT
[ ]
[ ]
[′Thiopurine

(TPMT):c.719A>G

methyltransferase

(p.Tyr240Cys)

deficiency′]

NM_003907.2
28939717
EIF2B5
[′AAATGYT
[′AAATGYTTCCTG
[′Leukoencephalopathy

(EIF2B5):c.271A>G

TCCTGTAC
TACACCTGTGG′]
with vanishing

(p.Thr91Ala)

ACCTGTGG′]

white matter′]

NM_004006.2
794727890
DMD
[ ]
[ ]
[′Duchenne

(DMD):c.10554-2A>G

muscular dystrophy′,

′Becker muscular

dystrophy′, ′Dilated

cardiomyopathy 3B′]

NM_000084.4
273585644
CLCN5
[ ]
[ ]
[′Dent disease 1′]

(CLCN5):c.815A>G

(p.Tyr272Cys)

NM_000084.4
273585649
CLCN5
[ ]
[ ]
[′Dent disease 1′]

(CLCN5):c.1637A>G

(p.Lys546Arg)

NM_000041.3
397514253
APOE
[ ]
[′CGCCCYGCGGCC
[′Familial type 3

(APOE):c.237-2A>G

GAGAGGGCGGG′,
hyperlipoproteinemia′]

′GCGCCCYGCGGC

CGAGAGGGCGG′]

NM_000155.3
2070074
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.940A>G

UDPglucose-

(p.Asn314Asp)

hexose-1-phosphate

uridylyltransferase′,

′not provided′]

NM_005045.3
794727998
RELN
[ ]
[ ]
[′EPILEPSY,

(RELN):c.2288A>G

FAMILIAL

(p.Asp763Gly)

TEMPORAL

LOBE, 7′]

NM_001914.3
794728010
CYB5A
[ ]
[ ]
[′Methemoglobinemia

(CYB5A):c.130-2A>G

type 4′]

NM_001613.2
794728019
ACTA2
[ ]
[ ]
[′Thoracic aortic

(ACTA2):c.1A>G

aneurysms and

(p.Met1Val)

aortic dissections′]

NM_000109.3
370644567
DMD
[ ]
[ ]
[′Becker muscular

(DMD):c.1700T>C

dystrophy′,

(p.Leu567Pro)

′Exertional myalgia,

muscle stiffness and

myoglobinuria′, ′not

provided′]

NM_000060.3
397514341
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.194A>G

deficiency′]

(p.His65Arg)

NM_000060.3
397514348
BTD
[ ]
[′GTTCAYAGATGT
[′Biotinidase

(BTD):c.278A>G

CAAGGTTCTGG′]
deficiency′]

(p.Tyr93Cys)

NM_000060.3
397514353
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.356A>G

deficiency′]

(p.Asn119Ser)

NM_000060.3
397514354
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.364A>G

deficiency′]

(p.Arg122Gly)

NM_000060.3
397514366
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.515A>G

deficiency′]

(p.Asn172Ser)

NM_000060.3
397514370
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.583A>G

deficiency′]

(p.Asn195Asp)

NM_000060.3
397514371
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.584A>G

deficiency′, ′not

(p.Asn195Ser)

provided′]

NM_000060.3
397514377
BTD
[′AGAGGYT
[′AGAGGYTGTGTT
[′Biotinidase

(BTD):c.641A>G

GTGTTTAC
TACGGTAGCGG′]
deficiency′]

(p.Asn214Ser)

GGTAGCGG′]

NM_000061.2
128620184
BTK
[′TCTYGAT
[′TCTYGATGGCCA
[′X-linked

(BTK):c.1288A>G

GGCCACGT
CGTCGTACTGG′]
agammaglobulinemia′]

(p.Lys430Glu)

CGTACTGG′]

NM_001002294.2
2266780
FMO3
[ ]
[ ]
[′Trimethylaminuria′]

(FMO3):c.923A>G

(p.Glu308Gly)

m.15579A>G
207460002
MT-CYB
[ ]
[ ]
[′Multisystem

disorder′]

NM_000060.3
397514415
BTD
[ ]
[′GGCAYACAGCT
[′Biotinidase

(BTD):c.1313A>G

CTTTGGATAAGG′]
deficiency′]

(p.Tyr438Cys)

NM_000060.3
397514431
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.1619A>G

deficiency′]

(p.Tyr540Cys)

NM_000023.2
397514451
SGCA
[ ]
[ ]
[′Limb-girdle

(SGCA):c.410A>G

muscular dystrophy,

(p.Glu137Gly)

type 2D′]

NM_004813.2
397514472
PEX16
[′AAGYAGA
[′AAGYAGATTTTC
[′Peroxisome

(PEX16):c.992A>G

TTTTCTGC
TGCCAGGTGGG′,
biogenesis disorder

(p.Tyr331Cys)

CAGGTGGG′,
′GAAGYAGATTTT
8B′]

′GAAGYAG
CTGCCAGGTGG′,

ATTTTCTG
′GTAGAAGYAGAT

CCAGGTGG′,
TTTCTGCCAGG′]

′GTAGAAG

YAGATTTT

CTGCCAGG′]

NM_000933.3
397514480
PLCB4
[ ]
[ ]
[′Auriculocondylar

(PLCB4):c.1868A>G

syndrome 1′,

(p.Tyr623Cys)

′Auriculocondylar

syndrome 2′]

NM_005340.6
397514491
HINT1
[′AAAAYGT
[′AAAAYGTGTTG
[′Gamstorp-Wohlfart

(HINT1):c.152A>G

GTTGGTGC
GTGCTTGAGGGG′,
syndrome′]

(p.His5lArg)

TTGAGGGG′,
′GAAAAYGTGTTG

′GAAAAYG
GTGCTTGAGGG′,

TGTTGGTG
′AGAAAAYGTGTT

CTTGAGGG′,
GGTGCTTGAGG′]

′AGAAAAY

GTGTTGGT

GCTTGAGG′]

NM_007171.3
397514501
POMT1
[ ]
[′GAGCATYCTCTG
[′Limb-girdle

(POMT1):c.430A>G

TTTCAAAGAGG′]
muscular dystrophy-

(p.Asn144Asp)

dystroglycanopathy,

type C1′]

NM_003863.3
397514503
DPM2
[′TGTAGYA
[′TGTAGYAGGTG
[′Congenital disorder

(DPM2):c.68A>G

GGTGAAGA
AAGATGATCAGG′]
of glycosylation type

(p.Tyr23Cys)

TGATCAGG′]

1u′]

NM_174917.4
370382601
ACSF3
[ ]
[′GGCAGCAYTGC
[′not provided′]

(ACSF3):c.1A>G

ACTGACAGGCGG′]

(p.Met1Val)

NM_183075.2
397514514
CYP2U1
[ ]
[ ]
[′Spastic paraplegia

(CYP2U1):c.1139A>G

56, autosomal

(p.Glu380Gly)

recessive′]

NM_000344.3
397514517
SMN1
[ ]
[ ]
[′Kugelberg-

(SMN1):c.389A>G

Welander disease′]

(p.Tyr130Cys)

NM_000138.4
794728216
FBN1
[ ]
[ ]
[′Thoracic aortic

(FBN1):c.4337-2A>G

aneurysms and

aortic dissections′]

NM_012082.3
397514521
—
[ ]
[ ]
[′Double outlet right

(ZFPM2):c.2209A>G

ventricle′]

(p.Lys737Glu)

NM_001168272.1
397514536
ITPR1
[ ]
[ ]
[′Spinocerebellar

(ITPR1):c.1759A>G

ataxia 29′]

(p.Asn587Asp)

NM_178012.4
397514568
TUBB2B
[ ]
[ ]
[′Polymicrogyria,

(TUBB2B):c.767A>G

asymmetric′]

(p.Asn256Ser)

NM_000531.5
72554317
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.155A>G

(p.Glu52Gly)

NM_001866.2
397514584
COX7B
[ ]
[ ]
[′Aplasia cutis

(COX7B):c.41-2A>G

congenita,

reticulolinear, with

microcephaly, facial

dysmorphism, and

other congenital

anomalies′]

NM_001099922.2
397514587
ALG13
[ ]
[ ]
[′Congenital disorder

(ALG13):c.339A>G

of glycosylation type

(p.Ala113=)

1s′]

NM_000531.5
72554332
OTC
[ ]
[′AAGGACTYCCCT
[′Ornithine

(OTC):c.238A>G

TGCAATAAAGG′]
carbamoyltransferase

(p.Lys80Glu)

deficiency′, ′not

provided′]

NM_001083614.1
397514591
EARS2
[ ]
[ ]
[′Combined

(EAR52):c.502A>G

oxidative

(p.Arg168Gly)

phosphorylation

deficiency 12′]

NM_001083614.1
397514595
EARS2
[ ]
[ ]
[′Combined

(EARS2):c.193A>G

oxidative

(p.Lys65Glu)

phosphorylation

deficiency 12′]

NM_198578.3
34805604
LRRK2
[ ]
[ ]
[′Parkinson disease

(LRRK2):c.3364A>G

8, autosomal

(p.Ile1122Val)

dominant′]

NM_033109.4
397514598
PNPT1
[ ]
[ ]
[′Combined

(PNPT1):c.1160A>G

oxidative

(p.Gln387Arg)

phosphorylation

deficiency 13′]

NM_033109.4
397514599
PNPT1
[ ]
[′GACTYCAGATGT
[′Deafness,

(PNPT1):c.1424A>G

AACTCTTATGG′]
autosomal recessive

(p.Glu475Gly)

70′]

NM_000531.5
72554344
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.277A>G

(p.Thr93Ala)

NM_000390.2
397514603
CHM
[ ]
[ ]
[′Choroideremia′]

(CHM):c.1520A>G

(p.His507Arg)

NM_181690.2
397514605
AKT3
[ ]
[ ]
[′Megalencephaly-

(AKT3):c.686A>G

polymicrogyria-

(p.Asn229Ser)

polydactyly-

hydrocephalus

syndrome 2′]

NM_006567.3
397514610
FARS2
[ ]
[ ]
[′Mitochondrial

(FARS2):c.431A>G

encephalomyopathy′,

(p.Tyr144Cys)

′Combined

oxidative

phosphorylation

deficiency 14′,

′Global

developmental

delay′]

NM_000531.5
72554358
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.377A>G

(p.Asp126Gly)

NM_005609.2
397514631
PYGM
[ ]
[ ]
[′Glycogen storage

(PYGM):c.152A>G

disease, type V′]

(p.Asp51Gly)

NM_000130.4
6025
F5
[ ]
[ ]
[′Recurrent

(F5):c.1601G>A

abortion′,

(p.Arg534Gln)

′Thrombophilia due

to factor V Leiden′]

NM_000108.4
397514650
DLD
[ ]
[′GACTCYAGCTAT
[′Maple syrup urine

(DLD):c.1444A>G

ATCTTCACAGG′]
disease, type 3′]

(p.Arg482Gly)

NM_138554.4
4986790
TLR4
[ ]
[ ]
[′Endotoxin

(TLR4):c.896A>G

hyporesponsiveness′]

(p.Asp299Gly)

NM_003156.3
397514675
STIM1
[ ]
[′TTCCACAYCCAC
[′Myopathy with

(STIM1):c.251A>G

ATCACCATTGG′]
tubular aggregates′]

(p.Asp84Gly)

NM_003156.3
397514677
STIM1
[ ]
[ ]
[′Myopathy with

(STIM1):c.326A>G

tubular aggregates′]

(p.His109Arg)

NM_000238.3
794728377
KCNH2
[ ]
[ ]
[′Cardiac

(KCNH2):c.1900A>G

arrhythmia′]

(p.Thr634Ala)

NM_000238.3
794728378
KCNH2
[ ]
[′ATCYTCTCTGAG
[′Cardiac

(KCNH2):c.1913A>G

TTGGTGTTGGG′,
arrhythmia′]

(p.Lys638Arg)

′GATCYTCTCTGA

GTTGGTGTTGG′]

NM_001457.3
121908895
FLNB
[ ]
[ ]
[′Atelosteogenesis

(FLNB):c.604A>G

type 1′]

(p.Met202Val)

NM_001893.4
397514693
CSNK1D
[ ]
[ ]
[′Advanced sleep

(CSNK1D):c.137A>G

phase syndrome,

(p.His46Arg)

familial, 2′]

NM_002163.2
397514710
IRF8
[ ]
[ ]
[′Monocyte and

(IRF8):c.322A>G

dendritic cell

(p.Lys108Glu)

deficiency,

autosomal

recessive′]

NM_002163.2
397514711
IRF8
[ ]
[′AACCTCGYCTTC
[′Autosomal

(IRF8):c.238A>G

CAAGTGGCTGG′]
dominant

(p.Thr80Ala)

CD11C+/CD1C+

dendritic cell

deficiency′]

NM_001127217.2
397514715
SMAD9
[ ]
[ ]
[′Primary pulmonary

(SMAD9):c.127A>G

hypertension 2′]

(p.Lys43Glu)

NM_001035.2
794728784
RYR2
[ ]
[ ]
[′not provided′]

(RYR2):c.12290A>G

(p.Asn4097Ser)

NM_000388.3
397514729
CASR
[ ]
[′CCCCCTYCTTTT
[′Hypocalcemia,

(CASR):c.85A>G

GGGCTCGCTGG′]
autosomal dominant

(p.Lys29Glu)

1, with bartter

syndrome′]

NM_003793.3
397514731
CTSF
[ ]
[ ]
[′Ceroid

(CTSF):c.962A>G

lipofuscinosis,

(p.Gln321Arg)

neuronal, 13′]

NM_173076.2
28940269
ABCA12
[ ]
[ ]
[′Autosomal

(ABCA12):c.4139A>G

recessive congenital

(p.Asn1380Ser)

ichthyosis 4A′]

NM_017890.4
28940272
VPS13B
[′TCAYTGA
[′TCAYTGATAAGC
[′Cohen syndrome′,

(VPS13B):c.8978A>G

TAAGCAGG
AGGGCCCAGGG′,
′not specified′]

(p.Asn2993Ser)

GCCCAGGG′,
′TTCAYTGATAAG

′TTCAYTGA
CAGGGCCCAGG′]

TAAGCAGG

GCCCAGG′]

NM_022114.3
397514743
PRDM16
[ ]
[′GCCGCCGYTTTG
[′Left ventricular

(PRDM16):c.2447A>G

GCTGGCACGGG′]
noncompaction 8′]

(p.Asn816Ser)

NM_005689.2
397514757
ABCB6
[ ]
[′TGGGCYGTTCCA
[′Dyschromatosis

(ABCB6):c.508A>G

AGACACCAGGG′,
universalis

(p.Ser170Gly)

′GTGGGCYGTTCC
hereditaria 3′]

AAGACACCAGG′]

NM_015335.4
28940309
MED13L
[ ]
[ ]
[′Transposition of

(MED13L):c.752A>G

great arteries′]

(p.Glu251Gly)

NM_152443.2
28940313
RDH12
[ ]
[′CACTGCGYAGGT
[′Leber congenital

(RDH12):c.677A>G

GGTGACCCCGG′]
amaurosis 13′]

(p.Tyr226Cys)

NM_000517.4
41457746
HBA2
[ ]
[ ]
[ ]

(HBA2):c.96-2A>G

NM_000218.2
794728538
KCNQ1
[ ]
[′GTCTYCTACTCG
[′Cardiac

(KCNQ1):c.1787A>G

GTTCAGGCGGG′,
arrhythmia′]

(p.Glu596Gly)

′TGTCTYCTACTCG

GTTCAGGCGG′]

NM_000218.2
794728569
KCNQ1
[ ]
[′AGGYCTGTGGA
[′Cardiac

(KCNQ1):c.605A>G

GTGCAGGAGAGG′]
arrhythmia′]

(p.Asp202Gly)

NM_000218.2
794728573
KCNQ1
[ ]
[′GCCYGCAGTGG
[′Cardiac

(KCNQ1):c.1515-2A>G

AGAGAGGAGAGG′]
arrhythmia′]

NM_000498.3
72554626
—
[ ]
[ ]
[′Corticosterone

(CYP11B2):c.1492A>G

methyloxidase type

(p.Thr498Ala)

2 deficiency′]

NM_000169.2
28935197
—
[ ]
[ ]
[′Fabry disease′, ′not

(GLA):c.644A>G

provided′]

(p.Asn215Ser)

NM_000218.2
12720458
KCNQ1
[ ]
[ ]
[′Congenital long

(KCNQ1):c.1085A>G

QT syndrome′,

(p.Lys362Arg)

′Cardiac arrhythmia′,

′Long QT syndrome,

LQT1 subtype′]

NM_001035.2
794728787
RYR2
[ ]
[ ]
[′not provided′]

(RYR2):c.12533A>G

(p.Asn4178Ser)

NM_003494.3
370874727
DYSF
[ ]
[′CCGCCCYGGAG
[′Limb-girdle

(DYSF):c.3349-2A>G

ACACGAAGCTGG′]
muscular dystrophy,

type 2B′]

NM_001035.2
794728814
RYR2
[ ]
[ ]
[′not provided′]

(RYR2):c.568A>G

(p.Arg190Gly)

NM_198056.2
794728859
SCN5A
[ ]
[′ACCYGTCGAGAT
[′not provided′]

(SCN5A):c.2788-2A>G

AATGGGTCAGG′]

NM_198056.2
794728886
SCN5A
[ ]
[ ]
[′not provided′]

(SCN5A):c.4453A>G

(p.Ile1485Val)

NM_198056.2
794728887
SCN5A
[ ]
[′CCTCTGYCATGA
[′not provided′]

(SCN5A):c.4462A>G

AGATGTCCTGG′]

(p.Thr1488Ala)

NM_001927.3
794728995
DES
[ ]
[ ]
[′not provided′]

(DES):c.1324A>G

(p.Thr442Ala)

NM_001613.2
397515325
ACTA2
[ ]
[ ]
[′Aortic aneurysm,

(ACTA2):c.145A>G

familial thoracic 6′]

(p.Met49Val)

NM_000782.4
6068812
CYP24A1
[ ]
[ ]
[′Idiopathic

(CYP24A1):c.1226T>C

hypercalcemia of

(p.Leu409Ser)

infancy′]

NM_000372.4
28940878
TYR
[ ]
[′CTCCTGYCCCCG
[′Tyrosinase-

(TYR):c.125A>G

CTCCACGGTGG′]
negative

(p.Asp42Gly)

oculocutaneous

albinism′, ′not

provided′]

NM_000372.4
28940881
TYR
[ ]
[ ]
[′Tyrosinase-

(TYR):c.1A>G

negative

(p.Met1Val)

oculocutaneous

albinism′,

′Oculocutaneous

albinism type 1B′,

′not provided′]

NM_000403.3
28940884
GALE
[ ]
[ ]
[′UDPglucose-4-

(GALE):c.770A>G

epimerase

(p.Lys257Arg)

deficiency′]

NM_000529.2
28940892
MC2R
[′ACATGYA
[′ACATGYAGCAG
[′ACTH resistance′]

(MC2R):c.761A>G

GCAGGCGC
GCGCAGTAGGGG′

(p.Tyr254Cys)

AGTAGGGG′,
′GACATGYAGCAG

′GACATGY
GCGCAGTAGGG′,

AGCAGGCG
′AGACATGYAGCA

CAGTAGGG′]
GGCGCAGTAGG′]

NM_000061.2
128621195
BTK
[ ]
[ ]
[′X-linked

(BTK):c.919A>G

agammaglobulinemia′]

(p.Arg307Gly)

NM_000061.2
128621206
BTK
[ ]
[ ]
[′X-linked

(BTK):c.1766A>G

agammaglobulinemia′]

(p.Glu589Gly)

NM_018486.2
397515416
HDAC8
[ ]
[ ]
[′Cornelia de Lange

(HDAC8):c.539A>G

syndrome 5′]

(p.His180Arg)

NM_018486.2
397515418
HDAC8
[′CTCAYGA
[′CTCAYGATCTGG
[′Cornelia de Lange

(HDAC8):c.1001A>G

TCTGGGAT
GATCTCAGAGG′]
syndrome 5′]

(p.His334Arg)

CTCAGAGG′]

NM_172107.2
397515420
KCNQ2
[ ]
[′GCAYGACACTG
[′Early infantile

(KCNQ2):c.1636A>G

CAGGGGGGTGGG′,
epileptic

(p.Met546Val)

′CGCAYGACACTG
encephalopathy 7′]

CAGGGGGGTGG′,

′AACCGCAYGACA

CTGCAGGGGGG′]

NM_001410.2
397515428
MEGF8
[ ]
[′GACYCCCGTGA
[′Carpenter

(MEGF8):c.7099A>G

AATGATTCCCGG′]
syndrome 2′]

(p.Ser2367Gly)

NM_004247.3
397515431
EFTUD2
[ ]
[ ]
[′Growth and mental

(EFTUD2):c.623A>G

retardation,

(p.His208Arg)

mandibulofacial

dysostosis,

microcephaly, and

cleft palate′]

NM_004572.3
794729133
PKP2
[ ]
[ ]
[′not provided′]

(PKP2):c.1171-2A>G

NM_018972.2
397515442
GDAP1
[ ]
[ ]
[′Charcot-Marie-

(GDAP1):c.368A>G

Tooth disease type

(p.His123Arg

2K′]

NM_014795.3
397515449
ZEB2
[ ]
[ ]
[′Mowat-Wilson

(ZEB2):c.3134A>G

syndrome′]

(p.His1045Arg)

NM_002336.2
397515473
LRP6
[ ]
[ ]
[′Coronary artery

(LRP6):c.1298A>G

disease, autosomal

(p.Asn433Ser)

dominant 2′]

NM_001015879.1
397515484
AURKC
[ ]
[ ]
[′Infertility

(AURKC):c.379-2A>G

associated with

multi-tailed

spermatozoa and

excessive DNA′]

NM_000495.4
397515497
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.3107-4A>G

X-linked recessive′]

NM_201631.3
143601447
TGM5
[ ]
[′TCAACCYCACCC
[′Peeling skin

(TGM5):c.122T>C

TGTACTTCAGG′]
syndrome, acral

(p.Leu41Pro)

type′]

NM_013254.3
756751089
TBK1
[ ]
[ ]
[′FRONTOTEMPORAL

(TBK1):c.1201A>G

DEMENTIA

(p.Lys401Glu)

AND/OR

AMYOTROPHIC

LATERAL

SCLEROSIS 4′]

NM_000207.2
397515519
—
[ ]
[′GGGCYTTATTCC
[′Permanent neonatal

(INS):c.*59A>G

ATCTCTCTCGG′]
diabetes mellitus′]

NM_000370.3
397515523
TTPA
[ ]
[′CAGGYCCAGAT
[′Ataxia with

(TTPA):c.191A>G

CGAAATCCCGGG′,
vitamin E

(p.Asp64Gly)

′CCAGGYCCAGAT
deficiency′]

CGAAATCCCGG′]

NM_001006657.1
397515535
WDR35
[ ]
[ ]
[′Cranioectodermal

(WDR35):c.2912A>G

dysplasia 2′]

(p.Tyr971Cys)

NM_000424.3
61348633
KRT5
[ ]
[ ]
[′Epidermolysis

(KRT5):c.1424A>G

bullosa

(p.Glu475Gly)

herpetiformis,

Dowling-Meara′,

′not provided′]

NM_004595.4
397515551
SMS
[ ]
[ ]
[′Snyder Robinson

(SMS):c.443A>G

syndrome′]

(p.Gln148Arg)

NM_001256850.1
794729266
—
[ ]
[ ]
[′not provided′]

(TTN):c.45629-2A>G

NM_000404.2
72555361
GLB1
[ ]
[ ]
[′Infantile GM1

(GLB1):c.947A>G

gangliosidosis′]

(p.Tyr316Cys)

NM_000404.2
72555368
GLB1
[ ]
[ ]
[′Mucopolysaccharidosis,

(GLB1):c.1498A>G

MPS-IV-B′]

(p.Thr500Ala)

NM_000404.2
72555371
GLB1
[ ]
[ ]
[′GM1-

(GLB1):c.1772A>G

GANGLIOSIDOSIS,

(p.Tyr591Cys)

TYPE I, WITH

CARDIAC

INVOLVEMENT′]

NM_000487.5
2071421
ARSA
[ ]
[ ]
[′Metachromatic

(ARSA):c.1055A>G

leukodystrophy′, ′not

(p.Asn352Ser)

provided′]

NM_001037811.2
122461163
HSD17B10
[ ]
[ ]
[2-methy1-3-

(HSD17B10):c.713A>G

hydroxybutyric

(p.Asn238Ser)

aciduria′]

NM_000138.4
397515756
FBN1
[ ]
[ ]
[′Marfan syndrome′]

(FBN1):c.1148-2A>G

NM_001875.4
28940283
CPS1
[ ]
[ ]
[′Congenital

(CPS1):c.1010A>G

hyperammonemia,

(p.His337Arg)

type I′]

NM_000169.2
397515869
—
[′AGCTGTG
[′AGCTGTGYGATG
[′not specified′, ′not

(GLA):c.1153A>G

YGATGAAG
AAGCAGGCAGG′]
provided′]

(p.Thr385Ala)

CAGGCAGG′]

NM_000256.3
397515891
MYBPC3
[ ]
[′TACTTGCYGTAG
[′Familial

(MYBPC3):c.1224-2A>G

AACAGAAGGGG′]
hypertrophic

cardiomyopathy 4′,

′Cardiomyopathy′]

NM_000048.3
28941472
ASL
[ ]
[ ]
[′Argininosuccinate

(ASL):c.857A>G

lyase deficiency′,

(p.Gln286Arg)

′not provided′]

NM_000256.3
397515937
MYBPC3
[ ]
[ ]
[′Primary familial

(MYBPC3):c.1928-2A>G

hypertrophic

cardiomyopathy′,

′Familial

hypertrophic

cardiomyopathy 4′,

′Cardiomyopathy′]

NM_002693.2
774610098
POLG
[ ]
[ ]
[′not provided′]

(POLG):c.1283T>C

(p.Leu428Pro)

NM_004628.4
794729657
XPC
[ ]
[ ]
[′Xeroderma

(XPC):c.413-24A>G

pigmentosum, group C′]

NM_030973.3
794729668
MED25
[ ]
[ ]
[′BASEL-

(MED25):c.116A>G

VANAGAITE-

(p.Tyr39Cys)

SMIRIN-YOSEF

SYNDROME′]

NM_001955.4
587777231
EDN1
[ ]
[ ]
[′Auriculocondylar

(EDN1):c.271A>G

syndrome 3′]

(p.Lys91Glu)

NM_003002.3
11214077
SDHD
[ ]
[ ]
[′Pheochromocytoma′,

(SDHD):c.149A>G

′Merkel cell

(p.His50Arg)

carcinoma′,

′Hereditary cancer-

predisposing

syndrome′,

′Carcinoid tumor of

intestine′, ′Cowden

syndrome 3′, ′not

specified′, ′not

provided′]

NM_001003722.1
386833693
GLE1
[ ]
[ ]
[′Lethal

(GLE1):c.433-10A>G

arthrogryposis with

anterior horn cell

disease′]

NM_000371.3
11541796
TTR
[ ]
[ ]
[′Amyloidogenic

(TTR):c.185A>G

transthyretin

(p.Glu62Gly)

amyloidosis′]

NM_000256.3
397516082
MYBPC3
[ ]
[′GTCCCYGTGTCC
[′Familial

(MYBPC3):c.927-2A>G

CGCAGTCTAGG′]
hypertrophic

cardiomyopathy 4′,

′Cardiomyopathy′]

NM_001148.4
72544141
ANK2
[ ]
[ ]
[′Long QT

(ANK2):c.4373A>G

syndrome′,

(p.Glu1458Gly)

′Congenital long QT

syndrome′, ′Long

QT syndrome 4′,

′Cardiac arrhythmia,

ankyrin B-related′,

′Cardiac arrhythmia′]

NM_000257.3
397516138
MYH7
[ ]
[′TATCAAYGAACT
[′Familial

(MYH7):c.2206A>G

GTCCCTCAGGG′,
hypertrophic

(p.Ile736Val)

′CTATCAAYGAAC
cardiomyopathy 1′,

TGTCCCTCAGG′]
′Cardiomyopathy′,

′not specified′]

NM_000356.3
28941769
TCOF1
[′GTGTGTA
[′GTGTGTAYAGAT
[′Treacher collins

(TCOF1):c.149A>G

YAGATGTC
GTCCAGAAGGG′]
syndrome 1′]

(p.Tyr50Cys)

CAGAAGGG′]

NM_002150.2
1154510
HPD
[ ]
[′ATGACGYGGCCT
[4-Alpha—

(HPD):c.97G>A

GAATCACAGGG′,
hydroxyphenylpyruvate

(p.Ala33Thr)

′AATGACGYGGCC
hydroxylase

TGAATCACAGG′]
deficiency′]

NM_000375.2
28941775
UROS
[ ]
[ ]
[′Congenital

(UROS):c.184A>G

erythropoietic

(p.Thr62Ala)

porphyria′]

NM_001008216.1
28940883
GALE
[ ]
[ ]
[′UDPglucose-4-

(GALE):c.308A>G

epimerase

(p.Asp103Gly)

deficiency′]

NM_000260.3
397516330
MYO7A
[ ]
[′ATATCCYGGGG
[′Usher syndrome,

(MYO7A):c.6439-2A>G

GAGCAGAAAGGG′,
type 1′]

′GATATCCYGGGG

GAGCAGAAAGG′]

NM_033071.3
606231134
SYNE1
[ ]
[ ]
[′Spinocerebellar

(SYNE1):c.15705-12A>G

ataxia, autosomal

recessive 8′]

NM_000187.3
120074172
HGD
[ ]
[ ]
[′Alkaptonuria′]

(HGD):c.1112A>G

(p.His371Arg)

NM_000053.3
60431989
ATP7B
[′TGCTGAY
[′TGCTGAYTGGAA
[′Wilson disease′]

(ATP7B1:c.3443T>C

TGGAAACC
ACCGTGAGTGG′]

(p.Ile1148Thr)

GTGAGTGG′]

NM_000441.1
397516411
—
[ ]
[ ]
[′Pendred syndrome′,

(SLC26A4):c.-3-2A>G

′Enlarged vestibular

aqueduct syndrome′]

NM_003041.3
61742739
—
[ ]
[ ]
[′Familial renal

(SLC5A2):c.1961A>G

glucosuria′]

(p.Asn654Ser)

NM_000551.3
397516441
VHL
[ ]
[ ]
[′Von Hippel-Lindau

(VHL):c.467A>G

syndrome′]

(p.Tyr156Cys)

NM_000531.5
72556270
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.481A>G

(p.Asn161Asp)

NM_000531.5
72556271
OTC
[ ]
[′CAGCCCAYTGAT
[′not provided′]

(OTC):c.482A>G

AATTGGGATGG′]

(p.Asn161Ser)

NM_000531.5
72556289
OTC
[′TCCYAAA
[′TCCYAAAAGGC
[′not provided′]

(OTC):c.541-2A>G

AGGCACGG
ACGGGATGAAGG′]

GATGAAGG′]

NM_000531.5
72556290
OTC
[′ATAGTGT
[′ATAGTGTYCCTA
[′not provided′]

(OTC):c.542A>G

YCCTAAAA
AAAGGCACGGG′]

(p.Glu181Gly)

GGCACGGG′]

NM_000527.4
28942085
LDLR
[ ]
[ ]
[′Familial

(LDLR):c.2483A>G

hypercholesterolemia′,

(p.Tyr828Cys)

′not provided′]

NM_000271.4
28942105
NPC1
[ ]
[ ]
[′Niemann-Pick

(NPC1):c.3467A>G

disease type C1′]

(p.Asn1156Ser)

NM_000271.4
28942106
NPC1
[ ]
[ ]
[′NIEMANN-PICK

(NPC1):c.3263A>G

DISEASE, TYPE

(p.Tyr1088Cys)

C1, JUVENILE

FORM′]

NM_020247.4
119468008
ADCK3
[ ]
[ ]
[′Coenzyme Q10

(ADCK3):c.1541A>G

deficiency, primary,

(p.Tyr514Cys)

4′]

NM_001063.3
41295774
TF
[ ]
[ ]
[ ]

(TF):c.956A>G

(p.His319Arg)

NM_172201.1
74424227
KCNE2
[ ]
[ ]
[′Congenital long

(KCNE2):c.281A>G

QT syndrome′]

(p.Glu94Gly)

NM_002294.2
397516743
LAMP2
[ ]
[ ]
[′Danon disease′]

(LAMP2):c.65-2A>G

NM_002880.3
397516822
RAF1
[ ]
[ ]
[′Noonan syndrome

(RAF1):c.524A>G

5′]

(p.His175Arg)

NM_033360.3
193929331
KRAS
[ ]
[ ]
[′Noonan syndrome

(KRAS):c.13A>G

3′, ′Rasopathy′]

(p.Lys5Glu)

NM_000525.3
193929337
KCNJ11
[ ]
[ ]
[′Permanent neonatal

(KCNJ11):c.155A>G

diabetes mellitus′]

(p.Gln52Arg)

NM_000525.3
193929348
KCNJ11
[′AGAYGAG
[′AGAYGAGGGTC
[′Permanent neonatal

(KCNJ11):c.544A>G

GGTCTCAG
TCAGCCCTGCGG′]
diabetes mellitus′]

(p.Ile182Val)

CCCTGCGG′]

NM_000525.3
193929356
KCNJ11
[ ]
[ ]
[′Permanent neonatal

(KCNJ11):c.989A>G

diabetes mellitus′,

(p.Tyr330Cys)

′Neonatal insulin-

dependent diabetes

mellitus′]

NM_001288953.1
139010200
TTC7A
[ ]
[ ]
[′Multiple

(TTC7A):c.1715A>G

gastrointestinal

(p.Lys572Arg)

atresias′]

NM_024809.4
374349989
TCTN2
[ ]
[ ]
[′Meckel syndrome

(TCTN2):c.1506-2A>G

type 8′]

NM_012275.2
187015338
IL36RN
[ ]
[ ]
[′Pustular psoriasis,

(IL36RN):c.104A>G

generalized′]

(p.Lys35Arg)

NM_178517.3
200024253
PIGW
[ ]
[ ]
[′Hyperphosphatasia

(PIGW):c.499A>G

with mental

(p.Met167Val)

retardation

syndrome 5′]

NM_015662.2
149614625
—
[ ]
[ ]
[′Short-rib thoracic

(IFT172):c.5179T>C

dysplasia 10 with or

(p.Cys1727Arg)

without

polydactyly′]

NM_000226.3
58597584
KRT9
[ ]
[ ]
[′Epidermolytic

(KRT9):c.469A>G

palmoplantar

(p.Met157Val)

keratoderma′, ′not

provided′]

NM_023073.3
606231260
C5orf42
[ ]
[′ATCYATCAAATA
[′Orofaciodigital

(C5orf42):c.3290-2A>G

CAAAAATTTGG′]
syndrome 6′]

NM_005633.3
397517172
SOS1
[ ]
[ ]
[′Noonan syndrome

(SOS1):c.508A>G

4′, ′Rasopathy′, ′not

(p.Lys170Glu)

provided′]

NM_006306.3
587784418
SMC1A
[′CTTAYAG
[′CTTAYAGATCTC
[′Congenital

(SMC1A):c.3254A>G

ATCTCATC
ATCAATGTTGG′]
muscular

(p.Tyr1085Cys)

AATGTTGG′]

hypertrophy-cerebral

syndrome′]

NM_006218.2
397517201
PIK3CA
[ ]
[ ]
[′Neoplasm of

(PIK3CA):c.1637A>G

ovary′]

(p.Gln546Arg)

NM_006218.2
397517202
PIK3CA
[ ]
[ ]
[′Non-small cell lung

(PIK3CA):c.3073A>G

cancer′]

(p.Thr1025Ala)

NM_002354.2
606231281
EPCAM
[ ]
[ ]
[′Diarrhea 5, with

(EPCAM):c.492-2A>G

tufting enteropathy,

congenital′]

NM_033056.3
397517452
PCDH15
[ ]
[ ]
[′Usher syndrome,

(PCDH15):c.1998-2A>G

type 1F′]

NM_000301.3
73015965
PLG
[ ]
[ ]
[′Plasminogen

(PLG):c.112A>G

deficiency, type I′]

(p.Lys38Glu)

NM_000155.3
111033692
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.424A>G

UDPglucose-

(p.Met142Val)

hexose-1-phosphate

uridylyltransferase′]

NM_000096.3
386134132
CP
[ ]
[ ]
[′Deficiency of

(CP):c.2953A>G

ferroxidase′]

(p.Met985Val)

NM_000197.1
119481074
HSD17B3
[ ]
[ ]
[′Testosterone 17-

(HSD17B3):c.703A>G

beta-dehydrogenase

(p.Met235Val)

deficiency′]

NM_000197.1
119481079
HSD17B3
[ ]
[ ]
[′Testosterone 17-

(HSD17B3):c.389A>G

beta-dehydrogenase

(p.Asn130Ser)

deficiency′]

NM_015474.3
515726139
SAMHD1
[ ]
[ ]
[′Aicardi Goutieres

(SAMHD1):c.1106T>C

syndrome 5′]

(p.Leu369Ser)

NM_004817.3
587777521
TJP2
[ ]
[′CAGCTCYGAGA
[′Progressive

(TJP2):c.1992-2A>G

AGAAACCACGGG′,
familial intrahepatic

′TCAGCTCYGAGA
cholestasis 4′]

AGAAACCACGG′]

NM_000257.3
730880846
MYH7
[ ]
[′CTTCYTGCTGCG
[′Cardiomyopathy′]

(MYH7):c.617A>G

GTCCCCAATGG′]

(p.Lys206Arg)

NM_020919.3
386134184
ALS2
[ ]
[ ]
[′Juvenile primary

(ALS2):c.2980-2A>G

lateral sclerosis′]

m.10044A>G
41362547
MT-TG
[ ]
[ ]
[′Sudden death′]

NM_002977.3
80356468
SCN9A
[ ]
[ ]
[′Primary

(SCN9A):c.406A>G

erythromelalgia′]

(p.Ile136Val)

NM_001128425.1
34612342
MUTYH
[ ]
[ ]
[′MYH-associated

(MUTYH):c.536A>G

polyposis′,

(p.Tyr179Cys)

′Hereditary cancer-

predisposing

syndrome′,

′Endometrial

carcinoma′,

′Carcinoma of

colon′, ′not

specified′, ′not

provided′]

NM_206933.2
397517978
USH2A
[ ]
[′TTCCCYGTAAGA
[′Usher syndrome,

(USH2A):c.12067-2A>G

AAATTAACAGG′]
type 2A′, ′Retinitis

pigmentosa 39′]

NM_000216.2
606231409
ANOS1
[ ]
[′GCACCAYGGCT
[′Kallmann

(ANOS1):c.1A>G

GCGGGTCGAGGG′,
syndrome 1′]

(p.Met1Val)

′GGCACCAYGGCT

GCGGGTCGAGG′]

NM_206933.2
397518003
USH2A
[ ]
[ ]
[′Usher syndrome,

(USH2A):c.1841-2A>G

type 2A′]

NM_000368.4
118203576
TSC1
[ ]
[ ]
[′Tuberous sclerosis

(TSC1):c.1760A>G

syndrome′,

(p.Lys587Arg)

′Tuberous sclerosis

1′, ′Hereditary

cancer-predisposing

syndrome′, ′not

specified′]

NM_021830.4
80356540
C10orf2
[ ]
[ ]
[′Mitochondrial

(C10orf2):c.1523A>G

DNA depletion

(p.Tyr508Cys)

syndrome 7

(hepatocerebral

type)′, ′not

provided′]

NM_003334.3
80356546
UBA1
[ ]
[′TGGCYTGTCACC
[′Arthrogryposis

(UBA1):c.1639A>G

CGGATATGTGG′]
multiplex congenita,

(p.Ser547Gly)

distal, X-linked′]

NM_206933.2
397518039
USH2A
[′ATCYAAA
[′ATCYAAAGCAA
[′Retinitis

(USH2A):c.8559-2A>G

GCAAAAG
AAGACAAGCAGG′]
pigmentosa′, ′Usher

ACAAGCAGG′]

syndrome, type 2A′]

NM_000038.5
587783035
APC
[′TCCYAGT
[′TCCYAGTAAGA
[′Familial

(APC):c.1744-2A>G

AAGAAAC
AACAGAATATGG′]
adenomatous

AGAATATGG′]

polyposis 1′]

NM_194248.2
80356584
OTOF
[ ]
[′GACCYGCAGGC
[′Deafness,

(OTOF):c.766-2A>G

AGGAGAAGGGGG′,
autosomal recessive

′TGACCYGCAGGC
9′]

AGGAGAAGGGG′,

′CTGACCYGCAGG

CAGGAGAAGGG′,

′GCTGACCYGCAG

GCAGGAGAAGG′]

NM_000525.3
80356621
KCNJ11
[ ]
[ ]
[′Permanent neonatal

(KCNJ11):c.509A>G

diabetes mellitus′]

(p.Lys170Arg)

NM_000352.4
80356634
ABCC8
[ ]
[ ]
[′Permanent neonatal

(ABCC8):c.215A>G

diabetes mellitus′]

(p.Asn72Ser)

NM_000352.4
80356653
ABCC8
[ ]
[ ]
[′Permanent neonatal

(ABCC8):c.4270A>G

diabetes mellitus′]

(p.Ile1424Val)

NM_000207.2
80356672
—
[ ]
[ ]
[′Permanent neonatal

(INS):c.323A>G

diabetes mellitus′]

(p.Tyr108Cys)

NM_000083.2
80356699
CLCN1
[ ]
[ ]
[′Myotonia

(CLCN1):c.382A>G

congenita′,

(p.Met128Val)

′Congenital

myotonia, autosomal

dominant form′]

NM_001008211.1
267606929
OPTN
[ ]
[ ]
[′Amyotrophic

(OPTN):c.1433A>G

lateral sclerosis type

(p.Glu478Gly)

12′]

NM_007375.3
80356717
TARDBP
[ ]
[ ]
[′Amyotrophic

(TARDBP):c.506A>G

lateral sclerosis type

(p.Asp169Gly)

10′]

NM_007375.3
80356730
TARDBP
[ ]
[ ]
[′Amyotrophic

(TARDBP):c.1009A>G

lateral sclerosis type

(p.Met337Val)

10′]

NM_007375.3
80356731
TARDBP
[ ]
[ ]
[′Amyotrophic

(TARDBP):c.1028A>G

lateral sclerosis type

(p.Gln343Arg)

10′]

NM_001701.3
80356747
BAAT
[′CAAYGAA
[′CAAYGAAGAGG
[′Atypical

(BAAT):c.967A>G

GAGGAATT
AATTGCCCCTGG′]
hemolytic-uremic

(p.Ile323Val)

GCCCCTGG′]

syndrome 1′]

NM_012463.3
80356753
ATP6V0A2
[ ]
[ ]
[′Cutis laxa with

(ATP6V0A2):c.732-2A>G

osteodystrophy′]

NM_001876.3
80356778
CPT1A
[ ]
[ ]
[′Carnitine

(CPT1A):c.1361A>G

palmitoyltransferase

(p.Asp454Gly)

I deficiency′]

NM_001876.3
80356787
CPT1A
[ ]
[ ]
[′Carnitine

(CPT1A):c.1079A>G

palmitoyltransferase

(p.Glu360Gly)

I deficiency′]

NM_001876.3
80356791
CPT1A
[ ]
[ ]
[′Carnitine

(CPT1A):c.1493A>G

palmitoyltransferase

(p.Tyr498Cys)

I deficiency′]

NM_003159.2
587783072
CDKL5
[ ]
[ ]
[′Atypical Rett

(CDKL5):c.211A>G

syndrome′, ′not

(p.Asn71Asp)

provided′]

NM_000257.3
730880930
MYH7
[ ]
[′GGAACAYGCAC
[′Cardiomyopathy′]

(MYH7):c.1615A>G

TCCTCTTCCAGG′]

(p.Met539Val)

m.5843A>G
118203894
MT-TY
[ ]
[ ]
[ ]

NM_000130.4
118203905
F5
[ ]
[ ]
[ ]

(F5):c.1000A>G

(p.Arg334Gly)

NM_000130.4
118203907
F5
[′GTAGYAG
[′GTAGYAGGCCC
[′Factor V

(F5):c.5189A>G

GCCCAAGC
AAGCCCGACAGG′]
deficiency′]

(p.Tyr1730Cys)

CCGACAGG′]

NM_000052.6
151340632
ATP7A
[ ]
[ ]
[′Menkes kinky-hair

(ATP7A):c.3911A>G

syndrome′, ′Cutis

(p.Asn1304Ser)

laxa, X-linked′]

NM_007294.3
80356890
BRCA1
[ ]
[ ]
[′Familial cancer of

(BRCA1):c.5053A>G

breast′, ′Breast-

(p.Thr1685Ala)

ovarian cancer,

familial 1′,

′Hereditary cancer-

predisposing

syndrome′]

NM_000046.3
118203943
ARSB
[ ]
[ ]
[′Mucopolysaccharidosis

(ARSB):c.629A>G

type VI′, ′not

(p.Tyr210Cys)

provided′]

NM_013319.2
118203945
UBIAD1
[′GTAAGTG
[′GTAAGTGYTGAC
[′Schnyder

(UBIAD1):c.305A>G

YTGACCAA
CAAATTACCGG′]
crystalline corneal

(p.Asn102Ser)

ATTACCGG′]

dystrophy′]

NM_013319.2
118203947
UBIAD1
[ ]
[′TCCYGTCATCAC
[′Schnyder

(UBIAD1):c.355A>G

TCTTTTTGTGG′]
crystalline corneal

(p.Arg119Gly)

dystrophy′]

NM_013319.2
118203949
UBIAD1
[′GGTGTTG
[′GGTGTTGYTGGA
[′Schnyder

(UBIAD1):c.695A>G

YTGGAATG
ATGGAGAATGG′]
crystalline corneal

(p.Asn232Ser)

GAGAATGG′]

dystrophy′]

NM_013319.2
118203950
UBIAD1
[ ]
[ ]
[′Schnyder

(UBIAD1):c.335A>G

crystalline corneal

(p.Asp112Gly)

dystrophy′]

NM_024334.2
144811578
TMEM43
[ ]
[ ]
[′Emery-Dreifuss

(TMEM43):c.271A>G

muscular dystrophy

(p.Ile91Val)

7, autosomal

dominant′, ′not

provided′]

NM_012073.4
118203986
CCT5
[ ]
[ ]
[′Neuropathy,

(CCT5):c.440A>G

hereditary sensory,

(p.His147Arg)

with spastic

paraplegia,

autosomal

recessive′]

NM_000033.3
128624216
ABCD1
[′CACTGYT
[′CACTGYTGACGA
[′Adrenoleukodystrophy′]

(ABCD1):c.443A>G

GACGAAG
AGGTAGCAGGG′,

(p.Asn148Ser)

GTAGCAGG
′GCACTGYTGACG

G′]
AAGGTAGCAGG′]

NM_000146.3
139732572
FTL
[′CTCAYGG
[′CTCAYGGTTGGT
[′L-ferritin

(FTL):c.1A>G

TTGGTTGG
TGGCAAGAAGG′]
deficiency′]

(p.Met1Val)

CAAGAAGG′]

NM_000785.3
118204012
CYP27B1
[ ]
[ ]
[′Vitamin D-

(CYP27B1):c.566A>G

dependent rickets,

(p.Glu189Gly)

type 1′]

NM_000252.2
397518445
MTM1
[ ]
[ ]
[′Severe X-linked

(MTM1):c.1261-10A>G

myotubular

myopathy′]

NM_139281.2
118204022
WDR36
[ ]
[ ]
[′Glaucoma 1, open

(WDR36):c.1064A>G

angle, G′]

(p.Asn355Ser)

NM_000392.4
72558202
ABCC2
[ ]
[ ]
[′Dubin-Johnson

(ABCC2):c.4145A>G

syndrome′]

(p.Gln1382Arg)

NM_000165.4
397518464
GJA1
[ ]
[ ]
[′Oculodentodigital

(GJA1):c.617A>G

dysplasia′]

(p.Lys206Arg)

NM_000833.4
397518469
GRIN2A
[ ]
[ ]
[′Focal epilepsy with

(GRIN2A):c.1123-2A>G

speech disorder with

or without mental

retardation′]

NM_015702.2
118204046
MMADHC
[ ]
[ ]
[′Homocystinuria,

(MMADHC):c.746A>G

cblD type, variant 1′]

(p.Tyr249Cys)

NM_000526.4
60171927
KRT14
[ ]
[′GCGGTCAYTGA
[′Epidermolysis

(KRT14):c.368A>G

GGTTCTGCATGG′]
bullosa

(p.Asn123Ser)

herpetiformis,

Dowling-Meara′,

′not provided′]

NM_000237.2
118204064
LPL
[′AGCTGGA
[′GCTGGAYCGAG
[′Hyperlipoproteinemia,

(LPL):c.548A>G

YCGAGGCC
GCCTTAAAAGGG′,
type I′]

(p.Asp183Gly)

TTAAAAGG′]
′AGCTGGAYCGAG

GCCTTAAAAGG′]

NM_016247.3
201893545
IMPG2
[′ACTYTTT
[′ACTYTTTGGGAT
[′Macular dystrophy,

(IMPG2):c.370T>C

GGGATCGA
CGACTTCCTGG′]
vitelliform, 5′]

(p.Phe124Leu)

CTTCCTGG′]

NM_004035.6
118204090
ACOX1
[ ]
[ ]
[′Pseudoneonatal

(ACOX1):c.832A>G

adrenoleukodystrophy′]

(p.Met278Val)

NM_004035.6
118204092
ACOX1
[ ]
[ ]
[′Pseudoneonatal

(ACOX1):c.926A>G

adrenoleukodystrophy′]

(p.Gln309Arg)

NM_000190.3
118204118
HMBS
[ ]
[ ]
[′Porphyria, acute

(HMBS):c.1A>G

intermittent,

(p.Met1Val)

nonerythroid

variant′]

NM_001363.4
199422248
DKC1
[ ]
[′AATCYTGGCCCC
[′Dyskeratosis

(DKC1):c.941A>G

ATAGCAGATGG′]
congenita X-linked′]

(p.Lys314Arg)

NM_000078.2
2303790
CETP
[ ]
[ ]
[′Hyperalphalipo-

(CETP):c.1376A>G

proteinemia′]

(p.Asp459Gly)

NM_000531.5
72558405
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.595A>G

(p.Asn199Asp)

NM_000531.5
72558406
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.596A>G

(p.Asn199Ser)

NM_000531.5
72558411
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.613A>G

(p.Met205Val)

NM_000531.5
72558432
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.717+3A>G

NM_000531.5
72558433
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.718-2A>G

NM_000531.5
72558443
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.788A>G

(p.Asp263Gly)

NM_000531.5
72558444
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.790A>G

(p.Thr264Ala)

NM_000531.5
72558467
OTC
[ ]
[′TCCACTYCTTCT
[′not provided′]

(OTC):c.929A>G

GGCTTTCTGGG′,

(p.Glu310Gly)

′ATCCACTYCTTCT

GGCTTTCTGG′]

NM_000531.5
72558478
OTC
[ ]
[′ACTTTCYGTTTT
[′not provided′]

(OTC):c.988A>G

CTGCCTCTGGG′,

(p.Arg330Gly)

′CACTTTCYGTTTT

CTGCCTCTGG′]

NM_000488.3
121909571
SERPINC1
[ ]
[ ]
[′Antithrombin III

(SERPINC1):c.655A>G

deficiency′]

(p.Asn219Asp)

NM_007294.3
80357276
BRCA1
[′AAATATG
[′AAATATGYGGTC
[′Familial cancer of

(BRCA1):c.122A>G

YGGTCACA
ACACTTTGTGG′]
breast′, ′Breast-

(p.His41Arg)

CTTTGTGG′]

ovarian cancer,

familial 1′]

NM_007294.3
80357287
BRCA1
[ ]
[ ]
[′Familial cancer of

(BRCA1):c.1A>G

breast′, ′Breast-

(p.Met1Val)

ovarian cancer,

familial 1′,

′Hereditary cancer-

predisposing

syndrome′]

NM_198056.2
373172185
SCN5A
[ ]
[ ]
[′not provided′]

(SCN5A):c.1134T>A

(p.Tyr378Ter)

m.7526A>G
121434454
MT-TD
[ ]
[ ]
[ ]

NM_007294.3
80357382
BRCA1
[ ]
[ ]
[′Familial cancer of

(BRCA1):c.211A>G

breast′, ′Hereditary

(p.Arg71Gly)

breast and ovarian

cancer syndrome′,

′Breast-ovarian

cancer, familial 1′,

′Hereditary cancer-

predisposing

syndrome′]

NM_000512.4
118204440
GALNS
[′ACGYTGA
[′ACGYTGAGCTG
[′Mucopolysaccharidosis,

(GALNS):c.1460A>G

GCTGGGGC
GGGCTGCGCGGG′,
MPS-IV-A′]

(p.Asn487Ser)

TGCGCGGG′,
′CACGYTGAGCTG

′CACGYTG
GGGCTGCGCGG′]

AGCTGGGG

CTGCGCGG′]

NM_000505.3
118204455
F12
[ ]
[′GGTGGYACTGG
[ ]

(F12):c.158A>G

AAGGGGAAGTGG′]

(p.Tyr53Cys)

NM_007294.3
80357477
BRCA1
[ ]
[′TTGYCCTCTGTC
[′Familial cancer of

(BRCA1):c.5453A>G

CAGGCATCTGG′]
breast′, ′Breast-

(p.Asp1818Gly)

ovarian cancer,

familial 1′]

NM_032492.3
587777730
JAGN1
[ ]
[ ]
[′Severe congenital

(JAGN1):c.485A>G

neutropenia′, ′Severe

(p.Gln162Arg)

congenital

neutropenia 6,

autosomal

recessive′]

NM_000257.3
730880732
MYH7
[ ]
[ ]
[′Cardiomyopathy′]

(MYH7):c.2087A>G

(p.Asn696Ser)

NM_000430.3
121434482
PAFAH1B1
[ ]
[ ]
[′Lissencephaly 1′]

(PAFAH1B1):c.446A>G

(p.His149Arg)

NM_000363.4
730881077
TNNI3
[ ]
[ ]
[′Cardiomyopathy′]

(TNNI3):c.547A>G

(p.Lys183Glu)

NM_018105.2
267607111
THAP1
[ ]
[ ]
[′Dystonia 6,

(THAP1):c.266A>G

torsion′]

(p.Lys89Arg)

NM_016599.4
140126678
MYOZ2
[ ]
[ ]
[′Familial

(MYOZ2):c.738A>G

hypertrophic

(p.Ile246Met)

cardiomyopathy 16′,

′not specified′, ′not

provided′]

NM_000161.2
41298442
GCH1
[ ]
[ ]
[′Dystonia 5, Dopa-

(GCH1):c.671A>G

responsive type′,

(p.Lys224Arg)

′Dystonia, dopa-

responsive, with or

without

hyperphenylalaninemia,

autosomal

recessive′]

NM_017415.2
199469627
KLHL3

[′Pseudohypo-

(KLHL3):c.926A>G

aldosteronism, type 2′]

(p.Gln309Arg)

NM_017415.2
199469645
KLHL3

[′Pseudohypo-

(KLHL3):c.1670A>G

aldosteronism, type 2′,

(p.Tyr557Cys)

′Pseudohypo

aldosteronism type 2D′]

NM_003590.4
199469650
CUL3

[′Pseudohypo-

(CUL3):c.1207-26A>G

aldosteronism, type 2′]

NM_003590.4
199469656
CUL3

[′Pseudohypo-

(CUL3):c.1238A>G

aldosteronism, type 2′,

(p.Asp413Gly)

′Pseudohypo-

aldosteronism type 2E′]

NM_003590.4
199469658
CUL3

[′Pseudohypo-

(CUL3):c.1376A>G

aldosteronism, type 2′]

(p.Lys459Arg)

NM_003590.4
199469661
CUL3

[′Pseudohypo-

(CUL3):c.1377+3A>G

aldosteronism, type 2′]

NM_007294.3
80358015
BRCA1
[ ]
[ ]
[′Hereditary breast

(BRCA1):c.4096+3A>G

and ovarian cancer

syndrome′, ′Breast-

ovarian cancer,

familial 1′,

′Hereditary cancer-

predisposing

syndrome′]

NM_007294.3
80358065
BRCA1
[ ]
[ ]
[′Breast-ovarian

(BRCA1):c.135-2A>G

cancer, familial 1′]

NM_024426.4
121907902
WT1
[ ]
[ ]
[′Drash syndrome′]

(WT1):c.1391A>G

(p.Asp464Gly)

NM_007294.3
80358083
BRCA1
[ ]
[ ]
[′Familial cancer of

(BRCA1):c.212+3A>G

breast′, ′Breast-

ovarian cancer,

familial 1′]

NM_024426.4
121907908
WT1
[ ]
[′CGCYCTCGTACC
[′Mesothelioma′]

(WT1):c.1021A>G

CTGTGCTGTGG′]

(p.Ser341Gly)

NM_007294.3
80358096
BRCA1
[ ]
[ ]
[′Breast-ovarian

(BRCA1):c.4676-2A>G

cancer, familial 1′,

′Hereditary cancer-

predisposing

syndrome′]

NM_000280.4
121907926
PAX6
[ ]
[′GTGGYGCCCGA
[′Optic nerve

(PAX6):c.1171A>G

GGTGCCCATTGG′]
aplasia, bilateral′]

(p.Thr391Ala)

NM_000520.4
121907976
HEXA
[ ]
[ ]
[′Tay-Sachs disease′]

(HEXA):c.611A>G

(p.His204Arg)

NM_000159.3
141437721
GCDH
[ ]
[ ]
[′Glutaric aciduria,

(GCDH):c.1213A>G

type 1′]

(p.Met405Val)

NM_024740.2
121908023
ALG9
[ ]
[′TTAYACAAAAC
[′Congenital disorder

(ALG9):c.860A>G

AATGTTGAGTGG′]
of glycosylation type

(p.Tyr287Cys)

1L′]

NM_003051.3
80358222
SLC16A1
[ ]
[ ]
[′Erythrocyte lactate

(SLC16A1):c.610A>G

transporter defect′]

(p.Lys204Glu)

NM_000229.1
121908057
LCAT
[ ]
[ ]
[′Fish-eye disease′]

(LCAT):c.463A>G

(p.Asn155Asp)

NM_000639.2
80358238
FASLG
[ ]
[ ]
[′Autoimmune

(FASLG):c.466A>G

lymphoproliferative

(p.Arg156Gly)

syndrome′]

NM_001369.2
147499872
DNAH5
[ ]
[ ]
[′Ciliary dyskinesia,

(DNAH5):c.1121T>C

primary, 3′]

(p.Ile374Thr)

NM_138691.2
121908074
TMC1
[ ]
[ ]
[′Deafness,

(TMC1):c.1960A>G

autosomal recessive

(p.Met654Val)

7′]

NM_024301.4
121908110
FKRP
[ ]
[ ]
[′Congenital

(FKRP):c.1387A>G

muscular dystrophy-

(p.Asn463Asp)

dystroglycanopathy

(with or without

mental retardation)

type B5′, ′Limb-

girdle muscular

dystrophy-

dystroglycanopathy,

type C5′, ′Muscular

dystrophy′,

′Congenital

muscular dystrophy-

dystroglycanopathy

with brain and eye

anomalies type A5′,

′Congenital

muscular dystrophy-

dystroglycanopathy

without mental

retardation, type B5′,

′not provided′]

NM_175073.2
121908133
APTX
[′GCCAAYG
[′GCCAAYGGTAA
[′Adult onset ataxia

(APTX):c.602A>G

GTAACGGG
CGGGCCTTTGGG′,
with oculomotor

(p.His201Arg)

CCTTTGGG′]
′AGCCAAYGGTAA
apraxia′]

CGGGCCTTTGG′]

NM_001243133.1
121908148
NLRP3
[ ]
[′ACAATYCCAGCT
[′Familial cold

(NLRP3):c.1880A>G

GGCTGGGCTGG′]
urticaria′]

(p.Glu627Gly)

NM_006492.2
121908166
ALX3
[ ]
[′CGGYTCTGGAAC
[′Frontonasal

(ALX3):c.608A>G

CAGACCTGGGG′,
dysplasia 1′]

(p.Asn203Ser)

′GCGGYTCTGGAA

CCAGACCTGGG′,

′TGCGGYTCTGGA

ACCAGACCTGG′]

NM_020451.2
121908184
SEPN1
[ ]
[′CCCAYGGCTGCG
[′Eichsfeld type

(SEPN1):c.1A>G

GCTGGCGGCGG′,
congenital muscular

(p.Met1Val)

′CGGCCCAYGGCT
dystrophy′]

GCGGCTGGCGG′]

NM_001127221.1
121908219
CACNA1A
[ ]
[ ]
[′Familial

(CACNA1A):c.4151A>G

hemiplegic migraine

(p.Tyr1384Cys)

type 1′]

NM_005249.4
199502880
FOXG1
[ ]
[ ]
[′not provided′]

(FOXG1):c.686T>A

(p.Ile229Asn)

NM_130468.3
121908258
CHST14
[ ]
[′AAGTCAYAGTG
[′Ehlers-Danlos

(CHST14):c.878A>G

CACGGCACAAGG′]
syndrome,

(p.Tyr293Cys)

musculocontractural

type′]

NM_013391.3
121908331
DMGDH
[ ]
[ ]
[′Dimethylglycine

(DMGDH):c.326A>G

dehydrogenase

(p.His109Arg)

deficiency′]

NM_015166.3
121908344
MLC1
[ ]
[ ]
[′Megalencephalic

(MLC1):c.422A>G

leukoencephalopathy

(p.Asn141Ser)

with subcortical

cysts 1′]

NM_000441.1
121908361
SLC26A4
[ ]
[ ]
[′Enlarged vestibular

(SLC26A4):c.1105A>G

aqueduct syndrome′]

(p.Lys369Glu)

NM_000441.1
121908362
SLC26A4
[ ]
[ ]
[′Pendred syndrome′,

(SLC26A4):c.2168A>G

′Enlarged vestibular

(p.His723Arg)

aqueduct syndrome′]

NM_015560.2
121908376
OPA1
[ ]
[ ]
[′Optic Atrophy

(OPA1):c.1745A>G

Type 1′]

(p.Tyr582Cys)

NM_001128425.1
121908383
MUTYH
[ ]
[′AAGCYGCTCTGA
[′Neoplasm of

(MUTYH):c.1241A>G

GGGCTCCCAGG′]
stomach′]

(p.Gln414Arg)

NM_015247.2
121908389
CYLD
[ ]
[ ]
[′Familial multiple

(CYLD):c.2240A>G

trichoepitheliomata′,

(p.Glu747Gly)

′Spiegler-Brooke

syndrome′]

NM_021102.3
121908403
SPINT2
[′TCCAYAG
[′TCCAYAGATGA
[′Diarrhea 3,

(SPINT2):c.488A>G

ATGAAGTT
AGTTATTGCAGG′]
secretory sodium,

(p.Tyr163Cys)

ATTGCAGG′]

congenital,

syndromic′]

NM_004924.4
121908415
ACTN4
[ ]
[ ]
[′Focal segmental

(ACTN4):c.763A>G

glomerulosclerosis

(p.Lys255Glu)

1′]

NM_004795.3
121908423
KL
[′CAGYGGT
[′CAGYGGTACAG
[ ]

(KL):c.578A>G

ACAGGGTG
GGTGACCACGGG′,

(p.His193Arg)

ACCACGGG′,
′CCAGYGGTACAG

′CCAGYGG
GGTGACCACGG′]

TACAGGGT

GACCACGG′]

NM_005682.6
121908466
ADGRG1
[′TGGYAGA
[′TGGYAGAGGCC
[′Polymicrogyria,

(ADGRG1):c.263A>G

GGCCCCTG
CCTGGGGTCAGG′]
bilateral

(p.Tyr88Cys)

GGGTCAGG′]

frontoparietal′]

NM_139025.4
121908473
ADAMTS13
[ ]
[ ]
[′Upshaw-Schulman

(ADAMTS13):c.1582A>G

syndrome′]

(p.Arg528Gly)

NM_014270.4
121908487
SLC7A9
[ ]
[ ]
[′Cystinuria′]

(SLC7A9):c.695A>G

(p.Tyr232Cys)

NM_004211.3
121908494
SLC6A5
[ ]
[ ]
[′Hyperekplexia 3′]

(SLC6A5):c.1472A>G

(p.Tyr491Cys)

NM_004211.3
121908497
SLC6A5
[ ]
[ ]
[′Hyperekplexia 3′]

(SLC6A5):c.1526A>G

(p.Asn509Ser)

NM_182643.2
121908500
DLC1
[ ]
[ ]
[′Carcinoma of

(DLC1):c.2875A>G

colon′]

(p.Thr959Ala)

NM_014946.3
121908512
SPAST
[ ]
[ ]
[′Spastic paraplegia

(SPAST):c.1322A>G

4, autosomal

(p.Asp441Gly)

dominant′]

NM_014946.3
121908514
SPAST
[ ]
[ ]
[′Spastic paraplegia

(SPAST):c.1157A>G

4, autosomal

(p.Asn386Ser)

dominant′]

NM_000026.2
119450944
ADSL
[ ]
[ ]
[′Adenylosuccinate

(ADSL):c.736A>G

lyase deficiency′]

(p.Lys246Glu)

NM_000334.4
121908549
SCN4A
[′TGAYGGA
[′TGAYGGAGGGG
[ ]

(SCN4A):c.3478A>G

GGGGATGG
ATGGCGCCTAGG′]

(p.Ile1160Val)

CGCCTAGG′]

NM_000334.4
121908561
SCN4A
[ ]
[ ]
[′Paramyotonia

(SCN4A):c.421A>G

congenita of von

(p.Ile141Val)

Eulenburg′]

NM_004328.4
121908580
BCS1L
[ ]
[′GTGYGATCATGT
[′Mitochondrial

(BCS1L):c.148A>G

AATGGCGCCGG′]
complex III

(p.Thr50Ala)

deficiency′]

NM_152384.2
121908582
BBS5
[ ]
[ ]
[′Bardet-Biedl

(BBS5):c.547A>G

syndrome 5′]

(p.Thr183Ala)

NM_016417.2
121908584
GLRX5
[ ]
[′CCTGACCYTGTC
[′Anemia,

(GLRX5):c.294A>G

GGAGCTCCGGG′]
sideroblastic,

(p.Gln98=)

pyridoxine-refractory,

autosomal

recessive′]

NM_006206.4
121908589
PDGFRA
[ ]
[ ]
[ ]

(PDGFRA):c.1664A>G

(p.Tyr555Cys)

NM_002755.3
121908595
MAP2K1
[′CCAYAGA
[′CCAYAGAAGCC
[′Cardiofaciocutaneous

(MAP2K1):c.389A>G

AGCCCACG
CACGATGTACGG′]
syndrome 3′,

(p.Tyr130Cys)

ATGTACGG′]

′Rasopathy′]

NM_012082.3
121908601
ZFPM2
[ ]
[ ]
[′Double outlet right

(ZFPM2):c.89A>G

ventricle′, ′Tetralogy

(p.Glu30Gly)

of Fallot′,

′Diaphragmatic

hernia 3′]

NM_012082.3
121908604
—
[ ]
[ ]
[′Diaphragmatic

(ZFPM2):c.2527A>G

hernia 3′]

(p.Thr843Ala)

NM_022817.2
121908635
PER2
[ ]
[′GCCACACYCTCT
[′Advanced sleep

(PER2):c.1984A>G

GCCTTGCCCGG′]
phase syndrome,

(p.Ser662Gly)

familial′]

NM_030761.4
121908650
WNT4
[ ]
[ ]
[′Mullerian aplasia

(WNT4):c.647A>G

and

(p.Glu216Gly)

hyperandrogenism′]

NM_003839.3
121908655
TNFRSF11A
[ ]
[′GGGTCYGCATTT
[′Osteopetrosis

(TNFRSF11A):c.508A>G

GTCCGTGGAGG′]
autosomal recessive

(p.Arg170Gly)

7′]

NM_000539.3
29001653
RHO
[ ]
[′CGCTCTYGGCAA
[′Retinitis

(RHO):c.886A>G

AGAACGCTGGG′,
pigmentosa 4′]

(p.Lys296Glu)

′GCGCTCTYGGCA

AAGAACGCTGG′]

NM_004006.2
128626244
DMD
[ ]
[ ]
[′Duchenne

(DMD):c.2317A>G

muscular dystrophy′]

(p.Lys773Glu)

NM_003722.4
121908838
TP63
[′AGCTTYT
[′AGCTTYTTTGTA
[′Split-hand/foot

(TP63):c.697A>G

TTGTAGAC
GACAGGCATGG′]
malformation 4′]

(p.Lys233Glu)

AGGCATGG′]

NM_003722.4
121908844
TP63
[ ]
[ ]
[′Ectrodactyly,

(TP63):c.1052A>G

ectodermal

(p.Asp351Gly)

dysplasia, and cleft

lip/palate syndrome

3′]

NM_003722.4
121908847
TP63
[ ]
[ ]
[′ADULT

(TP63):c.1054A>G

syndrome′,

(p.Arg352Gly)

′Orofacial cleft 8′]

NM_000369.2
121908859
TSHR
[ ]
[ ]
[′Thyroid adenoma,

(TSHR):c.1856A>G

hyperfunctioning′]

(p.Asp619Gly)

NM_000369.2(TSHR):
121908879
TSHR
[ ]
[ ]
[′Hyperthyroidism,

c.548A>G

familial gestational′]

(p.Lys183Arg)

NM_003060.3
121908888
SLC22A5
[ ]
[ ]
[′Renal carnitine

(SLC22A5):c.632A>G

transport defect′, ′not

(p.Tyr211Cys)

provided′]

NM_006502.2
56307355
POLH
[ ]
[′AGACTTTYCTGC
[′Xeroderma

(POLH):c.1603A>G

TTAAAGAAGGG′]
pigmentosum,

(p.Lys535Glu)

variant type′]

NM_002977.3
121908919
—
[ ]
[′CCTTTTCYTGTG
[′Generalized

(SCN9A):c.1964A>G

TATTTGATTGG′]
epilepsy with febrile

(p.Lys655Arg)

seizures plus, type

7′, ′not specified′]

NM_002977.3
121908920
SCN9A
[ ]
[ ]
[′Febrile seizures,

(SCN9A):c.184A>G

familial, 3b′]

(p.Ile62Val)

NM_006892.3
121908939
DNMT3B
[ ]
[′GACACGYCTGTG
[′Centromeric

(DNMT3B):c.2450A>G

TAGTGCACAGG′]
instability of

(p.Asp817Gly)

chromosomes 1,9

and 16 and

immunodeficiency′]

NM_001130978.1
121908954
DYSF
[ ]
[ ]
[′Miyoshi muscular

(DYSF):c.3892A>G

dystrophy 1′, ′Limb-

(p.Ile1298Val)

girdle muscular

dystrophy, type 2B′,

′not specified′]

NM_001130978.1
121908961
DYSF
[ ]
[ ]
[′Limb-girdle

(DYSF):c.5264A>G

muscular dystrophy,

(p.Glu1755Gly)

type 2B′]

NM_016203.3
121908988
PRKAG2
[ ]
[ ]
[′Familial

(PRKAG2):c.1148A>G

hypertrophic

(p.His383Arg)

cardiomyopathy 6′]

NM_000492.3
121909008
CFTR
[′CACATAA
[′CACATAAYACG
[′Cystic fibrosis′]

(CFTR):c.2738A>G

YACGAACT
AACTGGTGCTGG′]

(p.Tyr913Cys)

GGTGCTGG′]

NM_000492.3
121909031
CFTR
[ ]
[ ]
[′Cystic fibrosis′]

(CFTR):c.326A>G

(p.Tyr109Cys)

NM_000492.3
121909046
CFTR
[ ]
[ ]
[′Cystic fibrosis′]

(CFTR):c.650A>G

(p.Glu217Gly)

NM_001040667.2
121909050
HSF4
[ ]
[ ]
[′Cataract, zonular′]

(HSF4):c.256A>G

(p.Ile86Val)

NM_005025.4
121909052
SERPINI1
[ ]
[ ]
[′Familial

(SERPINI1):c.1013A>G

encephalopathy with

(p.His338Arg)

neuroserpin

inclusion bodies′]

NM_005422.2
121909058
TECTA
[ ]
[ ]
[′Deafness,

(TECTA):c.5609A>G

autosomal dominant

(p.Tyr1870Cys)

12′]

NM_170695.3
121909068
TGIF1
[ ]
[ ]
[′Holoprosencephaly

(TGIF1):c.838A>G

4′]

(p.Thr280Ala)

NM_001005360.2
121909088
DNM2
[ ]
[′ACTYCTTCTCTT
[′Charcot-Marie-

(DNM2):c.1684A>G

TCTCCTGAGGG′,
Tooth disease,

(p.Lys562Glu)

′TACTYCTTCTCTT
dominant

TCTCCTGAGG′]
intermediate b, with

neutropenia′]

NM_000483.4
120074112
—
[ ]
[′GCCCAYAGTGTC
[′Apolipoprotein C2

(APOC2):c.1A>G

CAGAGACCTGG′]
deficiency′]

(p.Met1Val)

NM_000543.4
120074123
SMPD1
[ ]
[ ]
[′Niemann-Pick

(SMPD1):c.1154A>G

disease, type B′]

(p.Asn385Ser)

NM_000019.3
120074145
ACAT1
[ ]
[ ]
[′Deficiency of

(ACAT1):c.278A>G

acetyl-CoA

(p.Asn93Ser)

acetyltransferase′]

NM_138477.2
120074166
CDAN1
[ ]
[ ]
[′Congenital

(CDAN1):c.1796A>G

dyserythropoietic

(p.Asn599Ser)

anemia, type I′]

NM_000187.3
120074173
HGD
[ ]
[ ]
[′Alkaptonuria′]

(HGD):c.1102A>G

(p.Met368Val)

NM_001089.2
121909184
ABCA3
[′ACCGTYG
[′ACCGTYGTGGCC
[′Surfactant

(ABCA3):c.1702A>G

TGGCCCAG
CAGCAGGACGG′]
metabolism

(p.Asn568Asp)

CAGGACGG′]

dysfunction,

pulmonary, 3′]

NM_000503.5
121909197
EYA1
[ ]
[ ]
[ ]

(EYA1):c.1639A>G

(p.Arg547Gly)

NM_000218.2
120074192
KCNQ1
[′CGCYGAA
[′CGCYGAAGATG
[′Atrial fibrillation,

(KCNQ1):c.418A>G

GATGAGGC
AGGCAGACCAGG′]
familial, 3′, ′Atrial

(p.Ser140Gly)

AGACCAGG′]

fibrillation′]

NM_000314.6
121909222
PTEN
[ ]
[ ]
[′Cowden syndrome

(PTEN):c.368A>G

1′]

(p.His123Arg)

NM_000314.6
121909238
PTEN
[ ]
[ ]
[′Hereditary cancer-

(PTEN):c.278A>G

predisposing

(p.His93Arg)

syndrome′,

′Macrocephaly/autism

syndrome′]

NM_000314.6
121909239
PTEN
[ ]
[′ATAYCACCACAC
[′Macrocephaly/autism

(PTEN):c.755A>G

ACAGGTAACGG′]
syndrome′]

(p.Asp252Gly)

NM_198217.2
121909251
ING1
[ ]
[′TGGYTGCACAG
[′Squamous cell

(ING1):c.515A>G

ACAGTACGTGGG′,
carcinoma of the

(p.Asn172Ser)

′CTGGYTGCACAG
head and neck′]

ACAGTACGTGG′]

NM_012338.3
200519776
TSPAN12
[ ]
[ ]
[′Exudative

(TSPAN12):c.734T>C

vitreoretinopathy 5′]

(p.Leu245Pro)

NM_001001557.2
121909353
GDF6
[ ]
[ ]
[′Klippel-Feil

(GDF6):c.1271A>G

syndrome 1,

(p.Lys424Arg)

autosomal

dominant′]

NM_000163.4
121909360
GHR
[ ]
[ ]
[′Laron-type isolated

(GHR):c.594A>G

somatotropin

(p.Glu198=)

defect′]

NM_000256.3
121909375
MYBPC3
[ ]
[ ]
[′Familial

(MYBPC3):c.175A>G

hypertrophic

(p.Thr59Ala)

cardiomyopathy 4′]

NM_001174089.1
121909396
SLC4A11
[ ]
[′GATCAYCTTCAT
[′Corneal dystrophy

(SLC4A11):c.2518A>G

GTAGGGCAGGG′,
and perceptive

(p.Met840Val)

′AGATCAYCTTCA
deafness′]

TGTAGGGCAGG′]

NM_001100.3
121909520
ACTA1
[′GCGGYTG
[′CGGYTGGCCTTG
[′Nemaline

(ACTA1):c.350A>G

GCCTTGGG
GGATTGAGGGG′,
myopathy 3′]

(p.Asn117Ser)

ATTGAGGG′,
′GCGGYTGGCCTT

′CGCGGYT
GGGATTGAGGG′,

GGCCTTGG
′CGCGGYTGGCCT

GATTGAGG′]
TGGGATTGAGG′]

NM_000034.3
121909533
ALDOA
[ ]
[′CCAYCCAACCCT
[′HNSHA due to

(ALDOA):c.386A>G

AAGAGAAGAGG′]
aldolase A

(p.Asp129Gly)

deficiency′]

NM_000495.4
104886388
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.3455-9A>G

X-linked recessive′]

NM_001145.4
121909541
—
[ ]
[ ]
[′Amyotrophic

(ANG):c.208A>G

lateral sclerosis type

(p.Ile70Val)

9′]

NM_000051.3
3092857
ATM
[ ]
[ ]
[′Hereditary cancer-

(ATM):c.3118A>G

predisposing

(p.Met1040Val)

syndrome′, ′not

specified′]

NM_023110.2
121909631
FGFR1
[ ]
[ ]
[′Osteoglophonic

(FGFR1):c.1121A>G

dysplasia′]

(p.Tyr374Cys)

NM_182925.4
121909653
FLT4
[′CTGYGGA
[′CTGYGGATGCAC
[ ]

(FLT4):c.3104A>G

TGCACTGG
TGGGGTGCGGG′,

(p.His1035Arg)

GGTGCGGG′,
′TCTGYGGATGCA

′TCTGYGG
CTGGGGTGCGG′]

ATGCACTG

GGGTGCGG′]

NM_000145.3
121909663
FSHR
[ ]
[ ]
[′Ovarian

(FSHR):c.1345A>G

hyperstimulation

(p.Thr449Ala)

syndrome′]

NM_001017420.2
80359862
ESCO2
[ ]
[ ]
[′Roberts-SC

(ESCO2):c.1132-7A>G

phocomelia

syndrome′]

NM_001017420.2
80359869
ESCO2
[ ]
[ ]
[′Roberts-SC

(ESCO2):c.1674-2A>G

phocomelia

syndrome′]

NM_024577.3
80359890
SH3TC2
[ ]
[ ]
[′Charcot-Marie-

(SH3TC2):c.505T>C

Tooth disease, type

(p.Tyr169His)

4C′, ′Charcot-Marie-

Tooth disease, type

IV′,

′Mononeuropathy of

the median nerve,

mild′]

NM_032119.3
121909763
ADGRV1
[ ]
[ ]
[′Usher syndrome,

(ADGRV1):c.18131A>G

type 2C′]

(p.Tyr6044Cys)

NM_001360.2
121909766
DHCR7
[ ]
[ ]
[′Smith-Lemli-Opitz

(DHCR7):c.839A>G

syndrome′]

(p.Tyr280Cys)

NM_000517.4
121909803
HBA2
[ ]
[ ]
[′Hemoglobin H

(HBA2):c.1A>G

disease,

(p.Met1Val)

nondeletional′]

NM_004006.2
128627255
DMD
[ ]
[′TGACCGYGATCT
[′Dilated

(DMD):c.835A>G

GCAGAGAAGGG′,
cardiomyopathy 3B′]

(p.Thr279Ala)

′CTGACCGYGATC

TGCAGAGAAGG′]

NM_015896.3
200913791
ZMYND10
[ ]
[ ]
[′Kartagener

(ZMYND10):c.797T>C

syndrome′, ′Ciliary

(p.Leu266Pro)

dyskinesia, primary,

22′]

NM_001085.4
116929575
SERPINA3
[ ]
[′GCTCAYGAAGA
[ ]

(SERPINA3):c.1240A>G

AGATGTTCTGGG′,

(p.Met414Val)

′TGCTCAYGAAGA

AGATGTTCTGG′]

NM_058216.2
587780835
RAD51C
[ ]
[ ]
[′Fanconi anemia,

(RAD51C):c.1027-2A>G

complementation

group O′]

NM_006231.3
398122515
POLE
[ ]
[ ]
[′Facial

(POLE):c.4444+3A>G

dysmorphism,

immunodeficiency,

livedo, and short

stature′]

NM_002769.4
144422014
—
[ ]
[ ]
[′Hereditary

(PRSS1):c.161A>G

pancreatitis′]

(p.Asn54Ser)

NM_001204316.1
398122522
PRLR
[ ]
[ ]
[′Hyperprolactinemia′]

(PRLR):c.635A>G

(p.His212Arg)

NM_004992.3
61748392
MECP2
[ ]
[′CAACYCCACTTT
[′Mental retardation,

(MECP2):c.410A>G

AGAGCGAAAGG′]
X-linked, syndromic

(p.Glu137Gly)

13′]

NM_020366.3
376517859
RPGRIP1
[ ]
[ ]
[′Cone-rod

(RPGRIP1):c.3749-2A>G

dystrophy 13′]

NM_000552.3
61748478
VWF
[′GTCAYAG
[′GTCAYAGTTCTG
[′von Willebrand

(VWF):c.2384A>G

TTCTGGCA
GCACGTTTTGG′]
disease type 2N′,

(p.Tyr795Cys)

CGTTTTGG′]

′not provided′]

NM_001040613.2
183973249
TMEM70
[ ]
[ ]
[′Nuclearly-encoded

(TMEM70):c.*7-2A>G

mitochondrial

complex V (ATP

synthase) deficiency

2′]

NM_001005741.2
78198234
GBA
[ ]
[ ]
[′Gaucher disease,

(GBA):c.1049A>G

perinatal lethal′]

(p.His350Arg)

NM_000218.2
199472678
KCNQ1
[ ]
[ ]
[′Congenital long

(KCNQ1):c.332A>G

QT syndrome′,

(p.Tyr111Cys)

′Cardiac arrhythmia′,

′Long QT syndrome,

LQT1 subtype′]

NM_000218.2
199472679
KCNQ1

[′Congenital long

(KCNQ1):c.344A>G

QT syndrome′,

(p.Glu115Gly)

′Long QT syndrome,

LQT1 subtype′]

NM_000218.2
199472689
KCNQ1

[′Atrial fibrillation′]

(KCNQ1):c.440A>G

(p.Gln147Arg)

NM_000218.2
199472700
KCNQ1
[ ]
[ ]
[′Congenital long

(KCNQ1):c.592A>G

QT syndrome′]

(p.Ile198Val)

NM_001943.3
752432726
DSG2
[ ]
[ ]
[′Cardiomyopathy′]

(DSG2):c.880A>G

(p.Lys294Glu)

NM_000218.2
199472728
KCNQ1
[ ]
[ ]
[′Sudden infant

(KCNQ1):c.820A>G

death syndrome′,

(p.Ile274Val)

′Congenital long QT

syndrome′, ′Cardiac

arrhythmia′]

NM_000218.2
199472732
KCNQ1

[′Congenital long

(KCNQ1):c.842A>G

QT syndrome′]

(p.Tyr281Cys)

NM_000218.2
199472750
KCNQ1

[′Congenital long

(KCNQ1):c.950A>G

QT syndrome′]

(p.Asp317Gly)

NM_000218.2
199472754
KCNQ1

[′Congenital long

(KCNQ1):c.964A>G

QT syndrome′,

(p.Thr322Ala)

′Cardiac arrhythmia′,

′Long QT syndrome,

LQT1 subtype′]

NM_000218.2
199472770
KCNQ1

[′Congenital long

(KCNQ1):c.1138A>G

QT syndrome′]

(p.Arg380Gly)

NM_000218.2
199472777
KCNQ1

[′Congenital long

(KCNQ1):c.1193A>G

QT syndrome′,

(p.Lys398Arg)

′Cardiac arrhythmia′]

NM_000218.2
199472798
KCNQ1

[′Congenital long

(KCNQ1):c.1640A>G

QT syndrome′]

(p.Gln547Arg)

NM_000218.2
199472801
KCNQ1

[′Congenital long

(KCNQ1):c.1669A>G

QT syndrome′]

(p.Lys557Glu)

NM_000218.2
199472808
KCNQ1

[′Congenital long

(KCNQ1):c.1705A>G

QT syndrome′]

(p.Lys569Glu)

NM_001005741.2
61748906
GBA
[ ]
[′CCACTYGGCTC
[′Gaucher disease,

(GBA):c.667T>C

AAGACCAATGG′]
type 1′, ′not

(p.Trp223Arg)

provided′]

NM_000218.2
199472812
KCNQ1

[′Congenital long

(KCNQ1):c.1756A>G

QT syndrome′,

(p.Asn586Asp)

′Long QT syndrome,

LQT1 subtype′]

NM_000218.2
199472817
KCNQ1

[′Sudden infant

(KCNQ1):c.1793A>G

death syndrome′]

(p.Lys598Arg)

NM_000238.3
199472829
KCNH2

[′Congenital long

(KCNH2):c.82A>G

QT syndrome′]

(p.Lys28Glu)

NM_000238.3
199472836
KCNH2

[′Congenital long

(KCNH2):c.128A>G

QT syndrome′,

(p.Tyr43Cys)

′Cardiac arrhythmia′]

NM_000238.3
199472856
KCNH2
[ ]
[ ]
[′Congenital long

(KCNH2):c.301A>G

QT syndrome′,

(p.Lys101Glu)

′Cardiac arrhythmia′]

NM_000238.3
199472869
KCNH2

[′Congenital long

(KCNH2):c.652A>G

QT syndrome′]

(p.Met218Val)

NM_000238.3
199472907
KCNH2

[′Congenital long

(KCNH2):c.1424A>G

QT syndrome′]

(p.Tyr475Cys)

NM_000238.3
199472930
KCNH2

[′Congenital long

(KCNH2):c.1777A>G

QT syndrome′]

(p.Ile593Val)

NM_000238.3
199472932
KCNH2

[′Congenital long

(KCNH2):c.1783A>G

QT syndrome′]

(p.Lys595Glu)

NM_000238.3
199472934
KCNH2

[′Long QT

(KCNH2):c.1790A>G

syndrome′,

(p.Tyr597Cys)

′Congenital long QT

syndrome′]

NM_000238.3
199472940
KCNH2

[′Congenital long

(KCNH2):c.1826A>G

QT syndrome′]

(p.Asp609Gly)

NM_000238.3
199472946
KCNH2

[′Long QT

(KCNH2):c.1847A>G

syndrome′,

(p.Tyr616Cys)

′Congenital long QT

syndrome′, ′Cardiac

arrhythmia′]

NM_000238.3
199472956
KCNH2

[′Congenital long

(KCNH2):c.1885A>G

QT syndrome′,

(p.Asn629Asp)

′Cardiac arrhythmia′]

NM_000238.3
199472960
KCNH2

[′Congenital long

(KCNH2):c.1897A>G

QT syndrome′]

(p.Asn633Asp)

NM_000238.3
199472963
KCNH2

[′Congenital long

(KCNH2):c.1903A>G

QT syndrome′]

(p.Asn635Asp)

NM_000238.3
199472967
KCNH2

[′Congenital long

(KCNH2):c.1910A>G

QT syndrome′]

(p.Glu637Gly)

NM_000238.3
199473004
KCNH2

[′Congenital long

(KCNH2):c.2510A>G

QT syndrome′,

(p.Asp837Gly)

′Cardiac arrhythmia′]

NM_000238.3
199473008
KCNH2

[′Congenital long

(KCNH2):c.2591A>G

QT syndrome′]

(p.Asp864Gly)

NM_000238.3
199473024
KCNH2
[ ]
[′CTGCYCTCCACG
[′Sudden infant

(KCNH2):c.3118A>G

TCGCCCCGGGG′,
death syndrome′]

(p.Ser1040Gly)

′CCTGCYCTCCAC

GTCGCCCCGGG′,

′GCCTGCYCTCCA

CGTCGCCCCGG′]

NM_000238.3
199473029
KCNH2

[′Congenital long

(KCNH2):c.3233A>G

QT syndrome′]

(p.Tyr1078Cys)

NM_000335.4
199473057
SCN5A

[′Congenital long

(SCN5A):c.343A>G

QT syndrome′]

(p.Ser115Gly)

m.827A>G
28358569
MT-RNR1
[ ]
[ ]
[′Aminoglycoside-

induced deafness′,

′Deafness,

nonsyndromic

sensorineural,

mitochondrial′]

NM_000335.4
199473074
SCN5A
[′ATAYAGT
[′ATAYAGTTTTCA
[′Brugada

(SCN5A):c.688A>G

TTTCAGGG
GGGCCCGGAGG′,
syndrome′]

(p.Ile230Val)

CCCGGAGG′,
′CTGATAYAGTTT

′CTGATAY
TCAGGGCCCGG′]

AGTTTTCA

GGGCCCGG′]

NM_000335.4
199473075
SCN5A

[′Congenital long

(SCN5A):c.715A>G

QT syndrome′]

(p.Ile239Val)

NM_000252.2
587783838
MTM1
[ ]
[ ]
[′Severe X-linked

(MTM1):c.575A>G

myotubular

(p.Tyr192Cys)

myopathy′]

NM_004572.3
763639737
PKP2
[ ]
[ ]
[′not provided′]

(PKP2):c.275T>A

(p.Leu92Ter)

NM_000335.4
199473117
SCN5A

[′Brugada

(SCN5A):c.1502A>G

syndrome′]

(p.Asp501Gly)

NM_000335.4
199473152
SCN5A

[′Congenital long

(SCN5A):c.2249A>G

QT syndrome′]

(p.Gln750Arg)

NM_198056.2
199473165
SCN5A

[′Congenital long

(SCN5A):c.2527A>G

QT syndrome′, ′not

(p.Thr843Ala)

provided′]

NM_001165963.1
796052973
SCN1A
[ ]
[ ]
[′not provided′]

(SCN1A):c.1277A>G

(p.Tyr426Cys)

NM_000335.4
199473214
SCN5A

[′Brugada

(SCN5A):c.3755A>G

syndrome′]

(p.Glu1252Gly)

NM_198056.2
199473226
SCN5A
[ ]
[ ]
[′Congenital long

(SCN5A):c.4000A>G

QT syndrome′, ′not

(p.Ile1334Val)

provided′]

NM_000335.4
199473242
SCN5A

[′Brugada

(SCN5A):c.4252A>G

syndrome′]

(p.Lys1418Glu)

NM_000335.4
199473245
SCN5A

[′Brugada

(SCN5A):c.4291A>G

syndrome′]

(p.Arg1431Gly)

NM_000335.4
199473255
SCN5A

[′Congenital long

(SCN5A):c.4412A>G

QT syndrome′]

(p.Asn1471Ser)

NM_198056.2
199473260
SCN5A
[ ]
[ ]
[′Atrial fibrillation′,

(SCN5A):c.4478A>G

′Congenital long QT

(p.Lys1493Arg)

syndrome′, ′not

provided′]

NM_000335.4
199473264
SCN5A

[′Congenital long

(SCN5A):c.4489A>G

QT syndrome′]

(p.Met1497Val)

NM_000335.4
199473270
SCN5A

[′Brugada

(SCN5A):c.4577A>G

syndrome′]

(p.Lys1526Arg)

NM_000335.4
199473299
SCN5A

[′Brugada

(SCN5A):c.5161A>G

syndrome′]

(p.Asn1721Asp)

NM_198056.2
199473311
SCN5A

[′Congenital long

(SCN5A):c.5302A>G

QT syndrome′, ′not

(p.Ile1768Val)

provided′]

NM_000335.4
199473313
SCN5A

[′Brugada

(SCN5A):c.5318A>G

syndrome′]

(p.Asn1773Ser)

NM_000335.4
199473317
SCN5A

[′Congenital long

(SCN5A):c.5366A>G

QT syndrome′]

(p.Asp1789Gly)

NM_000335.4
199473318
SCN5A

[′Congenital long

(SCN5A):c.5402A>G

QT syndrome′]

(p.Asp1801Gly)

NM_000335.4
199473321
SCN5A

[′Congenital long

(SCN5A):c.5513A>G

QT syndrome′]

(p.Asp1838Gly)

NM_198056.2
199473326
SCN5A

[′Congenital long

(SCN5A):c.5726A>G

QT syndrome′, ′not

(p.Gln1909Arg)

provided′]

NM_172201.1
199473366
KCNE2

[′Atrial fibrillation′]

(KCNE2):c.269A>G

(p.Glu90Gly)

NM_000891.2
199473370
KCNJ2

[′Congenital long

(KCNJ2):c.223A>G

QT syndrome′]

(p.Thr75Ala)

NM_000891.2
199473371
KCNJ2

[′Andersen Tawil

(KCNJ2):c.233A>G

syndrome′,

(p.Asp78Gly)

′Congenital long QT

syndrome′]

NM_000891.2
199473382
KCNJ2

[′Congenital long

(KCNJ2):c.574A>G

QT syndrome′]

(p.Thr192Ala)

NM_000218.2
199473396
KCNQ1

[′Congenital long

(KCNQ1):c.548A>G

QT syndrome′]

(p.Lys183Arg)

NM_000218.2
199473404
KCNQ1

[′Congenital long

(KCNQ1):c.1061A>G

QT syndrome′]

(p.Lys354Arg)

NM_000218.2
199473405
KCNQ1

[′Congenital long

(KCNQ1):c.1070A>G

QT syndrome′,

(p.Gln357Arg)

′Cardiac arrhythmia′,

′Long QT syndrome,

LQT1 subtype′]

NM_000218.2
199473406
KCNQ1
[ ]
[ ]
[′Congenital long

(KCNQ1):c.1078A>G

QT syndrome′]

(p.Arg360Gly)

NM_000238.3
199473419
KCNH2

[′Congenital long

(KCNH2):c.209A>G

QT syndrome′,

(p.His70Arg)

′Cardiac arrhythmia′]

NM_000238.3
199473424
KCNH2

[′Congenital long

(KCNH2):c.1724A>G

QT syndrome′]

(p.Glu575Gly)

NM_000238.3
199473427
KCNH2

[′Congenital long

(KCNH2):c.1747A>G

QT syndrome′]

(p.Ile583Val)

NM_000238.3
199473431
KCNH2

[′Congenital long

(KCNH2):c.1762A>G

QT syndrome′]

(p.Asn588Asp)

NM_000218.2
199473451
KCNQ1

[′Congenital long

(KCNQ1):c.430A>G

QT syndrome′]

(p.Thr144Ala)

NM_000218.2
199473469
KCNQ1

[′Congenital long

(KCNQ1):c.931A>G

QT syndrome′]

(p.Thr311Ala)

NM_000238.3
199473496
KCNH2

[′Congenital long

(KCNH2):c.286A>G

QT syndrome′]

(p.Ile96Val)

NM_000238.3
199473506
KCNH2

[′Congenital long

(KCNH2):c.1205A>G

QT syndrome′]

(p.His402Arg)

NM_000238.3
199473507
KCNH2

[′Congenital long

(KCNH2):c.1259A>G

QT syndrome′]

(p.Tyr420Cys)

NM_000238.3
199473513
KCNH2

[′Congenital long

(KCNH2):c.1502A>G

QT syndrome′,

(p.Asp501Gly)

′Cardiac arrhythmia′]

NM_000238.3
199473528
KCNH2

[′Congenital long

(KCNH2):c.1912A>G

QT syndrome′]

(p.Lys638Glu)

NM_000238.3
199473532
KCNH2
[ ]
[ ]
[′Long QT

(KCNH2):c.2131A>G

syndrome′,

(p.Ile711Val)

′Congenital long QT

syndrome′, ′Cardiac

arrhythmia′]

NM_000238.3
199473534
KCNH2

[′Acquired long QT

(KCNH2):c.2266A>G

syndrome′]

(p.Met756Val)

NM_000238.3
199473546
KCNH2

[′Congenital long

(KCNH2):c.3343A>G

QT syndrome′,

(p.Met1115Val)

′Cardiac arrhythmia′]

NM_000335.4
199473551
SCN5A

[′Congenital long

(SCN5A):c.89A>G

QT syndrome′]

(p.Glu30Gly)

NM_000335.4
199473568
SCN5A

[′Brugada

(SCN5A):c.1217A>G

syndrome′]

(p.Asn406Ser)

NM_000249.3
267607794
MLH1
[ ]
[ ]
[′Hereditary

(MLH1):c.791-2A>G

Nonpolyposis

Colorectal

Neoplasms′,

′Hereditary cancer-

predisposing

syndrome′]

NM_000335.4
199473589
SCN5A

[′Brugada

(SCN5A):c.2780A>G

syndrome′]

(p.Asn927Ser)

NM_000335.4
199473593
SCN5A

[′Brugada

(SCN5A):c.3164A>G

syndrome′]

(p.Asp1055Gly)

NM_000335.4
199473610
SCN5A

[′Brugada

(SCN5A):c.4223A>G

syndrome′]

(p.Tyr1408Cys)

NM_198056.2
199473613
SCN5A

[′Brugada

(SCN5A):c.4346A>G

syndrome′, ′not

(p.Tyr1449Cys)

provided′]

NM_198056.2
199473625
SCN5A
[′CGAYGTT
[′CGAYGTTGAAG
[′Brugada

(SCN5A):c.4978A>G

GAAGAGG
AGGGCAGGCAGG′,
syndrome′, ′not

(p.Ile1660Val)

GCAGGCAG
′AGCCCGAYGTTG
provided′]

G′]
AAGAGGGCAGG′]

NM_000335.4
199473628
SCN5A

[′Brugada

(SCN5A):c.5138A>G

syndrome′]

(p.Asp1713Gly)

NM_000335.4
199473632
SCN5A

[′Congenital long

(SCN5A):c.5297A>G

QT syndrome′]

(p.Tyr1766Cys)

NM_000335.4
199473633
SCN5A

[′Congenital long

(SCN5A):c.5317A>G

QT syndrome′]

(p.Asn1773Asp)

NM_000531.5
72556283
OTC
[′TGAGGYA
[′TGAGGYAATCA
[′not provided′]

(OTC):c.527A>G

ATCAGCCA
GCCAGGATCTGG′]

(p.Tyr176Cys)

GGATCTGG′]

NM_001130823.1
199473690
DNMT1

[′Hereditary sensory

(DNMT1):c.1532A>G

neuropathy type IE′]

(p.Tyr511Cys)

NM_000303.2
80338704
PMM2
[ ]
[ ]
[′Carbohydrate-

(PMM2):c.563A>G

deficient

(p.Asp188Gly)

glycoprotein

syndrome type I′,

′not provided′]

NM_000051.3
28942103
—
[ ]
[ ]
[′Ataxia-

(ATM):c.8030A>G

telangiectasia

(p.Tyr2677Cys)

variant′]

NM_175053.3
147962513
KRT74
[ ]
[ ]
[″Ectodermal

(KRT74):c.821T>C

dysplasia, ′pure′

(p.Phe274Ser)

hair-nail type″,

′Ectodermal

dysplasia 7, hair/nail

type′]

NM_000059.3
398122779
BRCA2
[ ]
[ ]
[′Familial cancer of

(BRCA2):c.426-2A>G

breast′, ′Breast-

ovarian cancer,

familial 2′]

NM_133433.3
587783974
NIPBL
[ ]
[ ]
[′Cornelia de Lange

(NIPBL):c.5428-2A>G

syndrome 1′]

NM_000238.3
794728365
KCNH2
[ ]
[′GGACCYGCACC
[′Cardiac

(KCNH2):c.1129-2A>G

CGGGGAAGGCGG′]
arrhythmia′]

NM_000260.3
111033175
MYO7A
[ ]
[ ]
[′Usher syndrome,

(MYO7A):c.6029A>G

type 1′]

(p.Asp2010Gly)

NM_000531.5
72556293
OTC
[ ]
[′AGAGCTAYAGT
[′not provided′]

(OTC):c.548A>G

GTTCCTAAAAGG′]

(p.Tyr183Cys)

NM_000441.1
111033244
SLC26A4
[ ]
[′TGAATYCCTAAG
[′Pendred syndrome′,

(SLC26A4):c.1151A>G

GAAGAGACTGG′]
′Enlarged vestibular

(p.Glu384Gly)

aqueduct syndrome′]

NM_004004.5
111033294
GJB2
[ ]
[ ]
[′Deafness,

(GJB2):c.617A>G

autosomal recessive

(p.Asn206Ser)

1A′, ′Hearing

impairment′]

NM_000441.1
111033313
SLC26A4
[ ]
[ ]
[′Pendred syndrome′,

(SLC26A4):c.919-2A>G

′Enlarged vestibular

aqueduct syndrome′]

NM_001363.4
121912296
DKC1
[ ]
[ ]
[′Dyskeratosis

(DKC1):c.115A>G

congenita X-linked′]

(p.Lys39Glu)

NM_001363.4
121912297
DKC1
[ ]
[ ]
[′Dyskeratosis

(DKC1):c.196A>G

congenita X-linked′]

(p.Thr66Ala)

NM_001363.4
121912305
DKC1
[ ]
[ ]
[′Dyskeratosis

(DKC1):c.361A>G

congenita X-linked′,

(p.Ser121Gly)

′Hoyeraal

Hreidarsson

syndrome′]

NM_178151.2
587783552
DCX
[ ]
[ ]
[′Heterotopia′]

(DCX):c.413A>G

(p.Tyr138Cys)

NM_024675.3
730881879
PALB2
[ ]
[ ]
[′Hereditary cancer-

(PALB2):c.212-2A>G

predisposing

syndrome′]

NM_000260.3
111033415
MYO7A
[ ]
[′AGCYGCAGGGG
[′Usher syndrome,

(MYO7A):c.1344-2A>G

CACAGGGATGGG′,
type 1′]

′AAGCYGCAGGGG

CACAGGGATGG′]

NM_000454.4
121912435
SOD1
[ ]
[ ]
[′Amyotrophic

(SOD1):c.131A>G

lateral sclerosis type

(p.His44Arg)

1′]

NM_000454.4
121912439
SOD1
[ ]
[′AGAATCTYCAAT
[′Amyotrophic

(SOD1):c.302A>G

AGACACATCGG′]
lateral sclerosis type

(p.Glu101Gly)

1′]

NM_000454.4
121912443
SOD1
[ ]
[ ]
[′Amyotrophic

(SOD1):c.140A>G

lateral sclerosis type

(p.His47Arg)

1′]

NM_133433.3
587784042
NIPBL
[ ]
[ ]
[′Cornelia de Lange

(NIPBL):c.737A>G

syndrome 1′]

(p.Asp246Gly)

NM_000454.4(SOD1):
121912458
SOD1
[ ]
[ ]
[′Amyotrophic

c.242A>G

lateral sclerosis type

(p.His81Arg)

1′]

NM_001754.4
121912498
RUNX1
[ ]
[ ]
[′Familial platelet

(RUNX1):c.328A>G

disorder with

(p.Lys110Glu)

associated myeloid

malignancy′]

NM_000238.3
121912505
KCNH2
[ ]
[ ]
[′Long QT syndrome

(KCNH2):c.1408A>G

2′, ′Congenital long

(p.Asn470Asp)

QT syndrome′]

NM_000233.3
121912518
—
[ ]
[ ]
[′Gonadotropin-

(LHCGR):c.1733A>G

independent familial

(p.Asp578Gly)

sexual precocity′]

NM_000493.3
111033554
—
[ ]
[ ]
[′Metaphyseal

(COL10A1):c.1790A>G

chondrodysplasia,

(p.Tyr597Cys)

Schmid type′]

NM_000233.3
121912540
—
[ ]
[ ]
[′Gonadotropin-

(LHCGR):c.1691A>G

independent familial

(p.Asp564Gly)

sexual precocity′]

NM_002769.4
111033567
—
[ ]
[′ATCYTGTCATCA
[′Hereditary

(PRSS1):c.68A>G

TCATCAAAGGG′,
pancreatitis′]

(p.Lys23Arg)

′GATCYTGTCATC

ATCATCAAAGG′]

NM_004999.3
121912560
MYO6
[ ]
[ ]
[′Sensorineural

(MYO6):c.737A>G

deafness with

(p.His246Arg)

hypertrophic

cardiomyopathy′]

NM_000901.4
121912565
NR3C2
[ ]
[′TCATCYGTTTGC
[′Pseudohypoaldosteronism

(NR3C2):c.2327A>G

CTGCTAAGCGG′]
type 1

(p.Gln776Arg)

autosomal

dominant′]

NM_000901.4
121912574
NR3C2
[ ]
[′CCGACYCCACCT
[′Pseudohypo-

(NR3C2):c.2915A>G

TGGGCAGCTGG′]
aldosteronism type 1

(p.Glu972Gly)

autosomal

dominant′]

NM_001173464.1
121912589
KIF21A
[ ]
[′ATTCAYATCTGC
[′Fibrosis of

(KIF21A):c.2839A>G

CTCCATGTTGG′]
extraocular muscles,

(p.Met947Val)

congenital, 1′]

NM_000155.3
111033635
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.67A>G

UDPglucose-

(p.Thr23Ala)

hexose-1-phosphate

uridylyltransferase′]

NM_001041.3
121912612
SI
[ ]
[ ]
[′Sucrase-isomaltase

(SI):c.350A>G

deficiency′]

(p.Gln117Arg)

NM_000155.3
111033639
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.1A>G

UDPglucose-

(p.Met1Val)

hexose-1-phosphate

uridylyltransferase′]

NM_021625.4
121912634
TRPV4
[ ]
[ ]
[′Spondylometaphyseal

(TRPV4):c.998A>G

dysplasia,

(p.Asp333Gly)

Kozlowski type′]

NM_000155.3
111033661
GALT
[ ]
[′ATTCACCYACCG
[′Deficiency of

(GALT):c.253-2A>G

ACAAGGATAGG′]
UDPglucose-

hexose-1-phosphate

uridylyltransferase′,

′not provided′]

NM_000155.3
111033669
GALT
[ ]
[′GAAGTCGYTGTC
[′Deficiency of

(GALT):c.290A>G

AAACAGGAAGG′]
UDPglucose-

(p.Asn97Ser)

hexose-1-phosphate

uridylyltransferase′]

NM_000155.3
111033682
GALT
[ ]
[′TGACCTYACTGG
[′Deficiency of

(GALT):c.379A>G

GTGGTGACGGG′,
UDPglucose-

(p.Lys127Glu)

′ATGACCTYACTG
hexose-1-phosphate

GGTGGTGACGG′]
uridylyltransferase′]

NM_000343.3
121912669
SLC5A1
[ ]
[ ]
[′Congenital

(SLC5A1):c.83A>G

glucose-galactose

(p.Asp28Gly)

malabsorption′]

NM_005159.4
121912674
—
[ ]
[ ]
[′Dilated

(ACTC1):c.1088A>G

cardiomyopathy 1R′]

(p.Glu363Gly)

NM_005159.4
121912677
—
[ ]
[ ]
[′Atrial septal defect

(ACTC1):c.373A>G

5′]

(p.Met125Val)

NM_000155.3
111033731
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.565-2A>G

UDPglucose-

hexose-1-phosphate

uridylyltransferase′]

NM_001681.3
121912732
ATP2A2
[ ]
[ ]
[′Darier disease,

(ATP2A2):c.2300A>G

acral hemorrhagic

(p.Asn767Ser)

type′]

NM_000155.3
111033767
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.821-2A>G

UDPglucose-

hexose-1-phosphate

uridylyltransferase′]

NM_000342.3
121912750
SLC4A1
[ ]
[ ]
[′Spherocytosis type

(SLC4A1):c.2509A>G

4′]

(p.Thr837Ala)

NM_000155.3
111033786
GALT
[ ]
[′CAGCYGCCAAT
[′Deficiency of

(GALT):c.950A>G

GGTTCCAGTTGG′]
UDPglucose-

(p.Gln317Arg)

hexose-1-phosphate

uridylyltransferase′]

NM_001202.3
121912765
BMP4
[ ]
[′CCTCCYCCCCAG
[′Microphthalmia

(BMP4):c.278A>G

ACTGAAGCCGG′]
syndromic 6′]

(p.Glu93Gly)

NM_000155.3
111033809
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.1001A>G

UDPglucose-

(p.Lys334Arg)

hexose-1-phosphate

uridylyltransferase′]

NM_000155.3
111033817
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.1048A>G

UDPglucose-

(p.Thr350Ala)

hexose-1-phosphate

uridylyltransferase′]

NM_000155.3
111033819
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.1132A>G

UDPglucose-

(p.Ile378Val)

hexose-1-phosphate

uridylyltransferase′]

m.3243A>G
199474657
MT-TL1
[ ]
[ ]
[′Leigh disease′,

′Cyclical vomiting

syndrome′, ′Juvenile

myopathy,

encephalopathy,

lactic acidosis AND

stroke′, ′Myoclonus

with epilepsy with

ragged red fibers′,

′Cytochrome-c

oxidase deficiency′,

′Diabetes-deafness

syndrome

maternally

transmitted′, ′3-

Methylglutaconic

aciduria′, ′Age-

related macular

degeneration 2′,

′MERRF/MELAS

overlap syndrome′]

m.3252A>G
199474661
MT-TL1
[ ]
[ ]
[′Mitochondrial

encephalomyopathy′]

m.3251A>G
199474662
MT-TL1
[ ]
[ ]
[ ]

NM_000258.2
199474708
MYL3
[ ]
[ ]
[′Cardiomyopathy′,

(MYL3):c.517A>G

′not specified′, ′not

(p.Met173Val)

provided′]

NM_000094.3
121912856
COL7A1
[ ]
[′CACCYTGGGGA
[′Epidermolysis

(COL7A1):c.425A>G

CACCAGGTCGGG′,
bullosa dystrophica

(p.Lys142Arg)

′TCACCYTGGGGA
inversa, autosomal

CACCAGGTCGG′]
recessive′]

NM_152263.3
199474715
TPM3
[ ]
[′CCAACTYACGA
[′Congenital

(TPM3):c.505A>G

GCCACCTACAGG′]
myopathy with fiber

(p.Lys169Glu)

type disproportion′,

′not provided′]

NM_152263.3
199474718
TPM3
[ ]
[′ATCYCTCAGCAA
[′Congenital

(TPM3):c.733A>G

ACTCAGCACGG′]
myopathy with fiber

(p.Arg245Gly)

type disproportion′,

′not provided′]

NM_001844.4
121912889
COL2A1
[′GCAGTGG
[′GCAGTGGYAGG
[Spondyloperipheral

(COL2A1):c.4172A>G

YAGGTGAT
TGATGTTCTGGG′]
dysplasia′,

(p.Tyr1391Cys)

GTTCTGGG′]

′Platyspondylic

lethal skeletal

dysplasia Torrance

type′]

NM_001844.4
121912895
COL2A1
[ ]
[′CCTCYCTCACCA
[′Spondyloepimeta-

(COL2A1):c.2974A>G

CGTTGCCCAGG′]
physeal dysplasia

(p.Arg992Gly)

Strudwick type′]

NM_001848.2
121912936
COL6A1
[ ]
[ ]
[Ullrich congenital

(COL6A1):c.362A>G

muscular dystrophy′,

(p.Lys121Arg)

′Bethlem myopathy′,

′not provided′]

NM_004004.5
121912968
GJB2
[ ]
[ ]
[′Keratoderma

(GJB2):c.218A>G

palmoplantar

(p.His73Arg)

deafness′]

NM_000941.2
121912975
POR
[ ]
[ ]
[′Antley-Bixler

(POR):c.1733A>G

syndrome with

(p.Tyr578Cys)

genital anomalies

and disordered

steroidogenesis′]

NM_001943.3
121913011
DSG2
[ ]
[ ]
[′Arrhythmogenic

(DSG2):c.797A>G

right ventricular

(p.Asn266Ser)

cardiomyopathy,

type 10′]

NM_000129.3
121913074
F13A1
[ ]
[′ATAGGCAYAGA
[′Factor xiii, a

(F13A1):c.851A>G

TATTGTCCCAGG′]
subunit, deficiency

(p.Tyr284Cys)

of′]

NM_000043.4
121913079
FAS
[ ]
[ ]
[′Autoimmune

(FAS):c.695A>G

lymphoproliferative

(p.Tyr232Cys)

syndrome, type 1a′]

NM_000043.4
121913082
FAS
[ ]
[ ]
[ ]

(FAS):c.763A>G

(p.Asn255Asp)

NM_000043.4
121913083
FAS
[ ]
[ ]
[ ]

(FAS):c.353A>G

(p.Asn118Ser)

NM_206933.2
80338904
USH2A
[ ]
[ ]
[′Retinitis

(USH2A):c.14020A>G

pigmentosa′,

(p.Arg4674Gly)

′Retinitis pigmentosa

39′]

NM_000142.4
121913115
FGFR3
[ ]
[ ]
[′Hypochondroplasia′]

(FGFR3):c.833A>G

(p.Tyr278Cys)

NM_000183.2
121913131
HADHB
[ ]
[ ]
[′Mitochondrial

(HADHB):c.788A>G

trifunctional protein

(p.Asp263Gly)

deficiency′]

NM_001079817.1
121913136
INSR
[ ]
[ ]
[′Leprechaunism

(INSR):c.1459A>G

syndrome′]

(p.Lys487Glu)

NM_000208.2
121913145
INSR
[ ]
[′GCTGYGGCAAC
[′Leprechaunism

(INSR):c.707A>G

AGAGGCCTTCGG′]
syndrome′]

(p.His236Arg)

NM_000208.2
121913147
INSR
[ ]
[ ]
[′Insulin-resistant

(INSR):c.1466A>G

diabetes mellitus

(p.Asn489Ser)

AND acanthosis

nigricans′]

NM_000208.2
121913160
INSR
[ ]
[ ]
[′Leprechaunism

(INSR):c.1372A>G

syndrome′]

(p.Asn458Asp)

NM_000016.5
201375579
ACADM
[ ]
[ ]
[′not provided′]

(ACADM):c.797A>G

(p.Asp266Gly)

NM_024577.3
80338920
SH3TC2
[ ]
[ ]
[′Charcot-Marie-

(SH3TC2):c.530-2A>G

Tooth disease, type

4C′]

NM_001127500.1
121913246
MET
[ ]
[ ]
[′Renal cell

(MET):c.3743A>G

carcinoma,

(p.Tyr1248Cys)

papillary, 1′]

NM_000517.4
63750067
HBA2
[′ACTTYAT
[′CTTYATTCAAAG
[′Hemoglobin H

(HBA2):c.*92A>G

TCAAAGAC
ACCAGGAAGGG′,
disease,

CAGGAAG
′ACTTYATTCAAA
nondeletional′]

G′]
GACCAGGAAGG′]

NM_199440.1
72466451
HSPD1
[ ]
[ ]
[′Leukodystrophy,

(HSPD1):c.86A>G

hypomyelinating, 4′]

(p.Asp29Gly)

NM_000249.3
63750211
MLH1
[ ]
[ ]
[′Hereditary

(MLH1):c.544A>G

Nonpolyposis

(p.Arg182Gly)

Colorectal

Neoplasms′]

NM_025137.3
312262726
SPG11
[ ]
[ ]
[′Spastic paraplegia

(SPG11):c.1457-2A>G

11, autosomal

recessive′]

NM_025137.3
312262745
SPG11
[ ]
[′ACTTAYCCTGGG
[′Spastic paraplegia

(SPG11):c.2608A>G

GAGAAGGATGG′]
11, autosomal

(p.Ile870Val)

recessive′]

NM_025137.3
312262748
SPG11
[ ]
[ ]
[′Spastic paraplegia

(SPG11):c.2833A>G

11, autosomal

(p.Arg945Gly)

recessive′]

NM_003867.3
398123026
FGF17
[′CGTGGYT
[′CGTGGYTGGGG
[′Hypogonadotropic

(FGF17):c.560A>G

GGGGAAG
AAGGGCAGCTGG′]
hypogonadism 20

(p.Asn187Ser)

GGCAGCTG

with or without

G′]

anosmia′]

NM_025137.3
312262780
SPG11
[ ]
[ ]
[′Spastic paraplegia

(SPG11):c.6477+4A>G

11, autosomal

recessive′]

NM_000141.4
121913478
FGFR2
[ ]
[ ]
[′Cutis Gyrata

(FGFR2):c.1124A>G

syndrome of Beare

(p.Tyr375Cys)

and Stevenson′,

′Endometrial

carcinoma′]

NM_000142.4
121913485
FGFR3
[ ]
[ ]
[′Thanatophoric

(FGFR3):c.1118A>G

dysplasia type 1′]

(p.Tyr373Cys)

NM_003611.2
312262820
OFD1
[ ]
[ ]
[′Oral-facial-digital

(OFD1):c.290A>G

syndrome′]

(p.Glu97Gly)

NM_000222.2
121913512
KIT
[′GACTTYG
[′GACTTYGAGTTC
[ ]

(KIT):c.1924A>G

AGTTCAGA
AGACATGAGGG′,

(p.Lys642Glu)

CATGAGGG′]
′GGACTTYGAGTT

CAGACATGAGG′]

NM_003611.2
312262829
OFD1
[ ]
[ ]
[′Oral-facial-digital

(OFD1):c.382-2A>G

syndrome′]

NM_000391.3
119455958
TPP1
[ ]
[ ]
[′Ceroid

(TPP1):c.857A>G

lipofuscinosis,

(p.Asn286Ser)

neuronal, 2′]

NM_005912.2
121913560
MC4R
[ ]
[ ]
[′Obesity′]

(MC4R):c.508A>G

(p.Ile170Val)

NM_005912.2
121913561
MC4R
[ ]
[ ]
[′Obesity′]

(MC4R):c.821A>G

(p.Asn274Ser)

NM_005912.2
121913565
MC4R
[ ]
[ ]
[′Obesity′]

(MC4R):c.289A>G

(p.Asn97Asp)

NM_005912.2
121913566
MC4R
[ ]
[ ]
[′Obesity′]

(MC4R):c.185A>G

(p.Asn62Ser)

NM_000530.6
121913583
MPZ
[ ]
[ ]
[′Charcot-Marie-

(MPZ):c.286A>G

Tooth disease type

(p.Lys96Glu)

1B′]

NM_000095.2
312262901
COMP
[ ]
[ ]
[′Pseudoachondro-

(COMP):c.1760A>G

plastic

(p.His587Arg)

spondyloepiphyseal

dysplasia syndrome′]

NM_000530.6
121913594
MPZ
[′GGCATAG
[′GGCATAGYGGA
[′Charcot-Marie-

(MPZ):c.242A>G

YGGAAGAT
AGATCTATGAGG′]
Tooth disease type

(p.His81Arg)

CTATGAGG′]

1B′]

NM_000484.3
63750399
APP
[ ]
[ ]
[′Alzheimer disease,

(APP):c.2146A>G

type 1′, ′not

(p.Ile716Val)

provided′]

NM_000329.2
62636300
RPE65
[ ]
[ ]
[′Leber congenital

(RPE65):c.1292A>G

amaurosis 2′, ′not

(p.Tyr431Cys)

provided′]

NM_002470.3
121913622
MYH3
[ ]
[ ]
[′Distal

(MYH3):c.1385A>G

arthrogryposis type

(p.Asp462Gly)

2B′]

NM_000257.3
121913634
MYH7
[ ]
[ ]
[′Familial

(MYH7):c.2333A>G

hypertrophic

(p.Asp778Gly)

cardiomyopathy 1′,

′not specified′]

NM_001127500.1
121913677
MET
[ ]
[ ]
[′Childhood

(MET):c.3785A>G

hepatocellular

(p.Lys1262Arg)

carcinoma′]

NM_000222.2
121913682
KIT
[ ]
[′AGAAYCATTCTT
[′Mast cell disease,

(KIT):c.2459A>G

GATGTCTCTGG′]
systemic′]

(p.Asp820Gly)

NM_000222.2
121913684
KIT
[ ]
[ ]
[ ]

(KIT):c.2386A>G

(p.Arg796Gly)

NM_006005.3
398123066
WFS1
[ ]
[ ]
[′Cataract, nuclear

(WFS1):c.1385A>G

total′]

(p.Glu462Gly)

NM_000495.4
587776400
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.3925-2A>G

X-linked recessive′]

NC_012920.1:
587776440
MT-NDS
[ ]
[ ]
[′Leigh disease′]

m.13514A>G

NM_000021.3
63750590
PSEN1
[ ]
[ ]
[′Alzheimer disease,

(PSEN1):c.488A>G

type 3′, ′not

(p.His163Arg)

provided′]

NM_000484.3
63750643
APP
[ ]
[ ]
[′Alzheimer disease,

(APP):c.2140A>G

type 1′, ′not

(p.Thr714Ala)

provided′]

NM_173560.3
587776515
RFX6
[ ]
[ ]
[′Mitchell-Riley

(RFX6):c.224-12A>G

syndrome′]

NM_014043.3
63750818
CHMP2B
[ ]
[ ]
[′Frontotemporal

(CHMP2B):c.85A>G

Dementia,

(p.Ile29Val)

Chromosome 3-

Linked′,

′Amyotrophic lateral

sclerosis 17′, ′not

provided′]

NM_000057.3
367543015
BLM
[ ]
[ ]
[′Bloom syndrome′]

(BLM):c.1088-2A>G

NM_001011658.3
587776753
—
[ ]
[ ]
[′Spondyloepiphyseal

(TRAPPC2):c.238+4T>C

dysplasia tarda′]

NM_000151.3
587776757
G6PC
[ ]
[′GTTCYTACCACT
[′Glycogen storage

(G6PC):c.230+4A>G

TAAAGACGAGG′]
disease type 1A′]

NM_000463.2
587776766
—
[′ACCYGAG
[′ACCYGAGATGC
[′Crigler Najjar

(UGT1A1):c.1085-2A>G

ATGCAAAA
AAAATAGGGAGG′,
syndrome, type 1′]

TAGGGAGG′]
′GTGACCYGAGAT

GCAAAATAGGG′,

′GGTGACCYGAGA

TGCAAAATAGG′]

NM_000330.3
61752063
—
[ ]
[′TTCTTCGYGGAC
[′Juvenile

(RS1):c.286T>C

TGCAAACAAGG′]
retinoschisis′, ′not

(p.Trp96Arg)

provided′]

NM_001024847.2
587776770
TGFBR2
[ ]
[ ]
[′Loeys-Dietz

(TGFBR2):c.1472-2A>G

syndrome 2′]

NM_000257.3
367543053
MYH7
[ ]
[ ]
[′Congenital

(MYH7):c.5807A>G

myopathy with fiber

(p.Ter1936Trp)

type disproportion′]

NM_000321.2
587776791
RB1
[ ]
[ ]
[′Retinoblastoma′]

(RB1):c.2490-1398A>G

NM_024549.5
367543065
TCTN1
[ ]
[′AGCAACYGCAG
[′Joubert syndrome

(TCTN1):c.221-2A>G

AAAAAAGAGGGG′,
13′]

′CAGCAACYGCAG

AAAAAAGAGGG′]

NM_000228.2
587776813
LAMB3
[ ]
[ ]
[′Adult junctional

(LAMB3):c.565-3T>C

epidermolysis

bullosa′]

NM_015884.3
587776867
MBTPS2
[ ]
[ ]
[′Keratosis pilaris

(MBTPS2):c.1523A>G

decalvans′]

(p.Asn508Ser)

NM_000174.4
5030764
GP9
[′GGCTGYT
[′GGCTGYTGTTGG
[′Bernard-Soulier

(GP9):c.182A>G

GTTGGCCA
CCAGCAGAAGG′]
syndrome type C′]

(p.Asn61Ser)

GCAGAAG

G′]

NM_000894.2
5030773
LHB
[ ]
[′CCACCYGAGGC
[′Isolated lutropin

(LHB):c.221A>G

AGGGGCGGCAGG′]
deficiency′]

(p.Gln74Arg)

NM_000264.3
199476092
—
[ ]
[′CGTTACYGAAAC
[′Gorlin syndrome′,

(PTCH1):c.2479A>G

TCCTGTGTAGG′]
′Holoprosencephaly

(p.Ser827Gly)

7′, ′not specified′,

′not provided′]

NM_000021.3
63751037
PSEN1
[ ]
[ ]
[′Alzheimer disease,

(PSEN1):c.415A>G

type 3′, ′not

(p.Met139Val)

provided′]

NM_000484.3
63751039
APP
[ ]
[ ]
[′Alzheimer disease′,

(APP):c.2078A>G

′Alzheimer disease,

(p.Glu693Gly)

type 1′, ′Cerebral

amyloid angiopathy,

APP-related′, ′not

provided′]

NM_000117.2
398123158
EMD
[ ]
[′CGTTCCCYGAGG
[′not provided′]

(EMD):c.450-2A>G

CAAAAGAGGGG′]

RMRP:n.71A>G
199476103
RMRP
[ ]
[′ACTTYCCCCTAG
[′Metaphyseal

GCGGAAAGGGG′,
chondrodysplasia,

′GACTTYCCCCTA
McKusick type′,

GGCGGAAAGGG′,
′Metaphyseal

′GGACTTYCCCCT
dysplasia without

AGGCGGAAAGG′]
hypotrichosis′]

m.14495A>G
199476106
MT-ND6
[ ]
[ ]
[′Leber optic

atrophy′]

m.11084A>G
199476113
MT-ND4
[ ]
[ ]
[′Juvenile myopathy,

encephalopathy,

lactic acidosis AND

stroke′]

NM_000551.3
5030804
VHL
[′TGCGAYT
[′GCGAYTGCAGA
[′Von Hippel-Lindau

(VHL):c.233A>G

GCAGAAG
AGATGACCTGGG′,
syndrome′]

(p.Asn78Ser)

ATGACCTG
′TGCGAYTGCAGA

G′]
AGATGACCTGG′]

m.3397A>G
199476120
MT-ND1
[ ]
[ ]
[′Alzheimer disease′,

′Parkinson disease,

late-onset′]

m.4136A>G
199476121
MT-ND1
[ ]
[ ]
[′Leber optic

atrophy′]

NM_003094.3
587776924
SNRPE
[ ]
[ ]
[′Hypotrichosis 11′]

(SNRPE):c.1A>G

(p.Met1Val)

NM_001310338.1
587776944
MGME1
[ ]
[ ]
[′Mitochondrial

(MGME1):c.743A>G

DNA depletion

(p.Tyr248Cys)

syndrome 11′]

NM_000249.3
63751094
MLH1
[ ]
[ ]
[′Hereditary

(MLH1):c.122A>G

Nonpolyposis

(p.Asp41Gly)

Colorectal

Neoplasms′]

NM_138425.3
587776954
C12orf57
[ ]
[ ]
[′Temtamy

(C12orf57):c.1A>G

syndrome′,

(p.Met1Val)

′Seizures′, ′Corpus

callosum

abnormalities′,

′Colobomatous

microphthalmia′,

′Global

developmental

delay′]

NM_000277.1
5030856
PAH
[ ]
[′CTCYCTGCCACG
[′Phenylketonuria′,

(PAH):c.1169A>G

TAATACAGGGG′,
′Hyperphenylalaninemia,

(p.Glu390Gly)

′ACTCYCTGCCAC
non-pku′, ′not

GTAATACAGGG′,
provided′]

′AACTCYCTGCCA

CGTAATACAGG′]

NM_000277.1
5030860
PAH
[ ]
[′GGGTCGYAGCG
[′Phenylketonuria′,

(PAH):c.1241A>G

AACTGAGAAGGG′,
′Hyperphenylalaninemia,

(p.Tyr414Cys)

′TGGGTCGYAGCG
non-pku′, ′not

AACTGAGAAGG′]
provided′]

NM_000155.3
367543252
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.308A>G

UDPglucose-

(p.Gln103Arg)

hexose-1-phosphate

uridylyltransferase′]

NM_207352.3
199476183
CYP4V2
[ ]
[ ]
[′Bietti crystalline

(CYP4V2):c.1091-2A>G

corneoretinal

dystrophy′]

NM_000518.4
63751128
HBB
[ ]
[ ]
[ ]

(HBB):c.*111A>G

NM_000155.3
367543262
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.857A>G

UDPglucose-

(p.Tyr286Cys)

hexose-1-phosphate

uridylyltransferase′]

NM_000155.3
367543263
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.854A>G

UDPglucose-

(p.Lys285Arg)

hexose-1-phosphate

uridylyltransferase′]

NM_207352.3
199476193
CYP4V2
[ ]
[ ]
[′Bietti crystalline

(CYP4V2):c.761A>G

corneoretinal

(p.His254Arg)

dystrophy′]

NM_000155.3
367543267
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.968A>G

UDPglucose-

(p.Tyr323Cys)

hexose-1-phosphate

uridylyltransferase′]

NM_001142519.1
587777014
FAM111A
[ ]
[ ]
[′Gracile bone

(FAM111A):c.1012A>G

dysplasia′]

(p.Thr338Ala)

NM_000132.3
137852419
F8
[′AACYAGA
[′AACYAGAGTAA
[′Hereditary factor

(F8):c.1660A>G

GTAATAGC
TAGCGGGTCAGG′]
VIII deficiency

(p.Ser554Gly)

GGGTCAGG′]

disease′]

NM_020988.2
587777055
GNAO1
[ ]
[′GGATGYCCTGCT
[′Early infantile

(GNAO1):c.521A>G

CGGTGGGCTGG′]
epileptic

(p.Asp174Gly)

encephalopathy 17′]

NM_000155.3
398123187
GALT
[ ]
[ ]
[′Deficiency of

(GALT):c.905-2A>G

UDPglucose-

hexose-1-phosphate

uridylyltransferase′]

NM_015662.2
587777080
IFT172
[ ]
[ ]
[ ]

(IFT172):c.4607T>C

(p.Leu1536Pro)

NM_014754.2
587777088
PTDSS1
[ ]
[ ]
[Lenz-Majewski

(PTDSS1):c.1058A>G

hyperostosis

(p.Gln353Arg)

syndrome′]

NM_003859.1
587777114
—
[ ]
[ ]
[′Congenital disorder

(DPM1):c.742T>C

of glycosylation type

(p.Ser248Pro)

1E′]

NM_001018005.1
199476319
TPM1
[ ]
[ ]
[′Left ventricular

(TPM1):c.742A>G

noncompaction 9′,

(p.Lys248Glu)

′not provided′]

NM_004826.3
587777129
ECEL1
[ ]
[ ]
[′Arthrogryposis,

(ECEL1):c.2278T>C

distal, type 5d′]

(p.Cys760Arg)

NM_014908.3
587777137
DOLK
[ ]
[ ]
[′Congenital disorder

(DOLK):c.2T>C

of glycosylation type

(p.Met1Thr)

1M′]

NM_000350.2
61752435
ABCA4
[ ]
[ ]
[′Stargardt disease

(ABCA4):c.4540-2A>G

1′, ′not provided′]

NM_001128085.1
63751297
—
[ ]
[ ]
[′Spongy

(ASPA):c.433-2A>G

degeneration of

central nervous

system′]

NM_176787.4
587777186
PIGN
[ ]
[ ]
[′Multiple congenital

(PIGN):c.808T>C

anomalies-

(p.Ser270Pro)

hypotonia-seizures

syndrome 1′]

NM_001165899.1
587777188
PDE4D
[′CTATAYT
[′CTATAYTGTTCA
[′Acrodysostosis 2,

(PDE4D):c.1850T>C

GTTCATCC
TCCCCTCTGGG′,
with or without

(p.Ile617Thr)

CCTCTGGG′,
′ACTATAYTGTTC
hormone resistance′]

′ACTATAYT
ATCCCCTCTGG′]

GTTCATCC

CCTCTGG′]

NM_005017.3
587777195
PCYT1A
[′GCATGYT
[′GCATGYTTGCTC
[′Spondylometaphyseal

(PCYT1A):c.571T>C

TGCTCCAA
CAACACAGAGG′]
dysplasia with

(p.Phe191Leu)

CACAGAGG′]

cone-rod dystrophy′]

NM_024301.4
587777223
FKRP
[ ]
[′CCGCAYGGGGC
[′Congenital

(FKRP):c.1A>G

CGAAGTCTGGGG′,
muscular dystrophy—

(p.Met1Val)

′GCCGCAYGGGGC
dystroglycanopathy

CGAAGTCTGGG′,
with brain and eye

′AGCCGCAYGGGG
anomalies type A5′]

CCGAAGTCTGG′]

NM_198947.3
587777237
FAM111B
[ ]
[ ]
[′Poikiloderma,

(FAM111B):c.1879A>G

hereditary fibrosing,

(p.Arg627Gly)

with tendon

contractures,

myopathy, and

pulmonary fibrosis′]

NM_003638.2
587777279
ITGA8
[ ]
[ ]
[′Renal adysplasia′]

(ITGA8):c.2982+2T>C

NM_199189.2
587777301
MATR3
[′CGGYTGA
[′CGGYTGAACTCT
[′Myopathy, distal,

(MATR3):c.1864A>G

ACTCTCAG
CAGTCTTCTGG′]
2′]

(p.Thr622Ala)

TCTTCTGG′]

NM_001739.1
587777316
CA5A
[ ]
[ ]
[′Carbonic

(CA5A):c.697T>C

anhydrase VA

(p.Ser233Pro)

deficiency,

hyperammonemia

due to′]

NM_005051.2
587777333
QARS
[ ]
[ ]
[′Microcephaly,

(QARS):c.169T>C

progressive, with

(p.Tyr57His)

seizures and cerebral

and cerebellar

atrophy′]

NM_002234.3
587777336
KCNA5
[ ]
[ ]
[′Atrial fibrillation,

(KCNA5):c.143A>G

familial, 7′]

(p.Glu48Gly)

NM_021803.3
587777338
IL21
[ ]
[ ]
[′Common variable

(IL21):c.146T>C

immunodeficiency

(p.Leu49Pro)

11′]

NM_000132.3
137852470
F8
[ ]
[ ]
[′Hereditary factor

(F8):c.6794A>G

VIII deficiency

(p.Gln2265Arg)

disease′]

NM_178014.3
587777355
TUBB
[ ]
[ ]
[′Cortical dysplasia,

(TUBB):c.895A>G

complex, with other

(p.Met299Val)

brain malformations

6′]

NM_005957.4
768434408
MTHFR
[ ]
[ ]
[′Homocysteinemia

(MTHFR):c.1969T>C

due to MTHFR

(p.Ter657Arg)

deficiency′]

NM_005359.5
377767327
SMAD4
[ ]
[ ]
[′Juvenile polyposis

(SMAD4):c.425-6A>G

syndrome′]

NM_022068.3
587777454
PIEZO2
[ ]
[ ]
[′Oculomelic

(PIEZO2):c.8215T>C

amyoplasia′]

(p.Ser2739Pro)

NM_003108.3
587777479
SOX11
[ ]
[′GTACTTGYAGTC
[′Mental retardation,

(SOX11):c.347A>G

GGGGTAGTCGG′]
autosomal dominant

(p.Tyr116Cys)

27′]

NM_021072.3
587777493
HCN1
[ ]
[ ]
[′Epileptic

(HCN1):c.814T>C

encephalopathy,

(p.Ser272Pro)

early infantile, 24′]

NM_020435.3
587777496
GJC2
[ ]
[′TTGYTCCCCCCT
[′Leukodystrophy,

(GJC2):c.-170A>G

CGGCCTCAGGG′,
hypomyelinating, 2′]

′ATTGYTCCCCCCT

CGGCCTCAGG′]

NM_022552.4
587777507
DNMT3A
[ ]
[′CTCCYGGTGCTG
[′Tatton-Brown-

(DNMT3A):c.1943T>C

AAGGACTTGGG′,
rahman syndrome′]

(p.Leu648Pro)

′GCTCCYGGTGCT

GAAGGACTTGG′]

NM_022552.4
587777510
DNMT3A
[ ]
[ ]
[′Tatton-Brown-

(DNMT3A):c.2705T>C

rahman syndrome′]

(p.Phe902Ser)

NM_000223.3
58410481
KRT12
[ ]
[ ]
[′Meesman corneal

(KRT12):c.403A>G

dystrophy′, ′not

(p.Arg135Gly)

provided′]

NM_000232.4
398123262
SGCB
[ ]
[ ]
[′Limb-girdle

(SGCB):c.1A>G

muscular dystrophy,

(p.Met1Val)

type 2E′, ′not

provided′]

NM_020630.4
377767416
RET
[ ]
[ ]
[′MEN2 phenotype:

(RET):c.2342A>G

Unclassified′]

(p.Gln781Arg)

NM_018400.3
587777557
SCN3B
[ ]
[′AATCAYGATGTA
[′Atrial fibrillation,

(SCN3B):c.482T>C

CATCCTTCTGG′]
familial, 16′]

(p.Met161Thr)

NM_001030001.2
587777569
RPS29
[ ]
[′GATAYCGGTTTC
[′Diamond-Blackfan

(RPS29):c.149T>C

ATTAAGGTAGG′]
anemia 13′]

(p.Ile50Thr)

NM_177550.4
587777578
SLC13A5
[ ]
[ ]
[′Epileptic

(SLC13A5):c.1463T>C

encephalopathy,

(p.Leu488Pro)

early infantile, 25′]

NM_002880.3
587777586
RAF1
[ ]
[ ]
[′Cardiomyopathy,

(RAF1):c.1808T>C

dilated, 1NN′]

(p.Leu603Pro)

NM_025150.4
587777594
TARS2
[ ]
[ ]
[′Combined

(TARS2):c.695+3A>G

oxidative

phosphorylation

deficiency 21′]

NM_001759.3
587777618
CCND2
[ ]
[ ]
Negalencephaly-

(CCND2):c.838A>G

polymicrogyria-

(p.Thr280Ala)

polydactyly-

hydrocephalus

syndrome 3′]

NM_153334.6
587777657
SCARF2
[ ]
[′CCACGYGCTGCG
[′Marden Walker

(SCARF2):c.190T>C

CTGGCTGGAGG′]
like syndrome′]

(p.Cys64Arg)

NM_005726.5
587777689
TSFM
[ ]
[′ACTTCYCACCGG
[′Combined

(TSFM):c.57+4A>G

GTAGCTCCCGG′]
oxidative

phosphorylation

deficiency 3′]

NM_000255.3
796052005
MUT
[ ]
[′GCAYACTGGCG
[′not provided′]

(MUT):c.329A>G

GATGGTCCAGGG′,

(p.Tyr110Cys)

′AGCAYACTGGCG

GATGGTCCAGG′]

NM_021870.2
587777720
FGG
[ ]
[ ]
[′Hypodysfibrinogenemia′]

(FGG):c.1210T>C

(p.Ser404Pro)

NM_017617.3
587777736
NOTCH1
[′GGCAAGY
[′GGCAAGYGCAT
[′Adams-Oliver

(NOTCH1):c.1285T>C

GCATCAAC
CAACACGCTGGG′,
syndrome 1′,

(p.Cys429Arg)

ACGCTGGG′]
′GGGCAAGYGCAT
′Adams-Oliver

CAACACGCTGG′]
syndrome 5′]

NM_014946.3
587777752
SPAST
[′TTCYGTA
[′TTCYGTAAAACA
[′Spastic paraplegia

(SPAST):c.1688-2A>G

AAACATAA
TAAAAGTCAGG′]
4, autosomal

AAGTCAGG′]

dominant′]

NM_014946.3
587777755
SPAST
[ ]
[ ]
[′Spastic paraplegia

(SPAST):c.1245+4A>G

4, autosomal

dominant′]

NM_014946.3
587777757
SPAST
[ ]
[ ]
[′Spastic paraplegia

(SPAST):c.1216A>G

4, autosomal

(p.Ile406Val)

dominant′]

NM_144596.3
587777809
TTC8
[ ]
[′GTTCCYGGAAA
[′Retinitis

(TTC8):c.115-2A>G

GCATTAAGAAGG′]
pigmentosa 51′]

NM_170784.2
74315396
MKKS
[ ]
[ ]
[′Bardet-Biedl

(MKKS):c.110A>G

syndrome 6′,

(p.Tyr37Cys)

′McKusick Kaufman

syndrome′]

NM_000252.2
132630302
MTM1
[ ]
[ ]
[′Severe X-linked

(MTM1):c.566A>G

myotubular

(p.Asn189Ser)

myopathy′]

NM_000252.2
132630303
MTM1
[ ]
[ ]
[′Severe X-linked

(MTM1):c.1190A>G

myotubular

(p.Tyr397Cys)

myopathy′]

NM_152384.2(BBS5):
587777828
BBS5
[ ]
[ ]
[′Bardet-Biedl

c.522+3A>G

syndrome 5′]

NM_001205019.1
132630331
GK
[ ]
[ ]
[′Deficiency of

(GK):c.880A>G

glycerol kinase′]

(p.Asn294Asp)

NM_000166.5
587777878
GJB1
[ ]
[′TAGCAYGAAGA
[′X-linked hereditary

(GJB1):c.580A>G

CGGTGAAGACGG′]
motor and sensory

(p.Met194Val)

neuropathy′]

NM_000311.3
74315411
PRNP
[ ]
[ ]
[′Genetic prion

(PRNP):c.547A>G

diseases′,

(p.Thr183Ala)

′Spongiform

encephalopathy with

neuropsychiatric

features′]

NM_144773.2
74315417
PROKR2
[ ]
[ ]
[′Kallmann

(PROKR2):c.629A>G

syndrome 3′]

(p.Gln210Arg)

NM_000531.5
796052013
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.919A>G

(p.Lys307Glu)

NM_001029871.3
74315420
RSPO4
[ ]
[′CGTACYGGCGG
[′Anonychia′]

(RSPO4):c.194A>G

ATGCCTTCCCGG′]

(p.Gln65Arg)

NM_004333.4
180177035
BRAF
[ ]
[ ]
[′Noonan syndrome

(BRAF):c.770A>G

7′,

(p.Gln257Arg)

′Cardiofaciocutaneous

syndrome′,

′Rasopathy′, ′not

provided′]

NM_004333.4
180177037
BRAF
[ ]
[ ]
[′Cardiofaciocutaneous

(BRAF):c.1495A>G

syndrome′,

(p.Lys499Glu)

′Rasopathy′]

NM_198056.2
752476527
SCN5A
[ ]
[ ]
[′not provided′]

(SCN5A):c.5297T>A

(p.Met1766Lys)

NM_000030.2
180177186
AGXT
[ ]
[ ]
[′Primary

(AGXT):c.248A>G

hyperoxaluria, type

(p.His83Arg)

I′]

NM_000030.2
180177219
AGXT
[ ]
[′AGGCCCYGAGG
[′Primary

(AGXT):c.424-2A>G

AAGCAGGGACGG′]
hyperoxaluria, type

(p.Gly_142Gln145del)

I′]

NM_198578.3
35801418
LRRK2
[ ]
[ ]
[′Parkinson disease

(LRRK2):c.5096A>G

8, autosomal

(p.Tyr1699Cys)

dominant′]

NM_002693.2
367610201
POLG
[ ]
[′CTCAYGGCACTT
[′not provided′]

(POLG):c.1808T>C

ACCTGGGATGG′]

(p.Met603Thr)

NM_000030.2
180177245
AGXT
[ ]
[ ]
[′Primary

(AGXT):c.596-2A>G

hyperoxaluria, type

I′]

NM_020223.3
796051853
FAM20C
[ ]
[ ]
[′Raine syndrome′]

(FAM20C):c.1364-2A>G

NM_012203.1
180177319
GRHPR
[ ]
[′TCACAGCYGCG
[′Primary

(GRHPR):c.84-2A>G

GGGAAAGGGAGG′]
hyperoxaluria, type

II′]

NM_006017.2
796051882
PROM1
[ ]
[ ]
[′Cone-rod

(PROM1):c.2077-521A>G

dystrophy 2′]

NM_012203.1
180177324
GRHPR
[′CAAGTYG
[′CAAGTYGTTAGC
[′Primary

(GRHPR):c.934A>G

TTAGCTGC
TGCCAACAAGG′]
hyperoxaluria, type

(p.Asn312Asp)

CAACAAGG′]

II′]

NM_000016.5
796051900
ACADM
[ ]
[ ]
[′not provided′]

(ACADM):c.329A>G

(p.Glu110Gly)

NM_004453.3
796051958
ETFDH
[ ]
[ ]
[′not provided′]

(ETFDH):c.929A>G

(p.Tyr310Cys)

NM_000255.3
796052004
MUT
[ ]
[ ]
[′not provided′]

(MUT):c.1885A>G

(p.Arg629Gly)

NM_012434.4
119491109
SLC17A5
[ ]
[ ]
[′Sialic acid storage

(SLC17A5):c.548A>G

disease, severe

(p.His183Arg)

infantile type′]

NM_000328.2
62638632
RPGR
[ ]
[ ]
[′Retinitis

(RPGR):c.155-2A>G

pigmentosa 15′, ′not

provided′]

NM_005557.3
58608173
KRT16
[ ]
[ ]
[′Pachyonychia

(KRT16):c.373A>G

congenita, type 1′,

(p.Asn125Asp)

′not provided′]

NM_000532.4
796052020
PCCB
[ ]
[ ]
[′not provided′]

(PCCB):c.655-2A>G

NM_000030.2
796052068
AGXT
[ ]
[′GGTACCYGGAA
[′Primary

(AGXT):c.777-2A>G

GACACGAGGGGG′,
hyperoxaluria, type

′TGGTACCYGGAA
I′]

GACACGAGGGG′]

NM_000121.3
62638745
EPOR
[′AGGGYTG
[′AGGGYTGGAGT
[′Acute myeloid

(EPOR):c.1460A>G

GAGTAGGG
AGGGGCCATCGG′]
leukemia, M6 type′,

(p.Asn487Ser)

GCCATCGG′]

′Familial

erythrocytosis, 1′]

NM_000552.3
61754010
VWF
[ ]
[′TGCCAYTGTAAT
[′von Willebrand

(VWF):c.1583A>G

TCCCACACAGG′]
disease, type 2a′, ′not

(p.Asn528Ser)

provided′]

NM_001918.3
796052135
DBT
[ ]
[ ]
[′Intermediate maple

(DBT):

syrup urine disease

c.1017_1018insNC_000001.11:

type 2′]

g.100207187_100207312

NM_001243473.1
143149764
B9D1
[ ]
[ ]
[′Meckel syndrome,

(B9D1):c.400+2T>C

type 9′, ′not

provided′]

NM_001165963.1
764037830
—
[ ]
[ ]
[′Severe myoclonic

(SCN1A):c.4766T>G

epilepsy in infancy′]

(p.Val1589Gly)

NM_000321.2
587778866
RB1
[ ]
[′ATTYCAATGGCT
[′Retinoblastoma′]

(RB1):c.1927A>G

TCTGGGTCTGG′]

(p.Lys643Glu)

NM_006331.7
74435397
EMG1
[ ]
[′ATAYCTGGCCGC
[′Bowen-Conradi

(EMG1):c.257A>G

GCTTCCCCAGG′]
syndrome′]

(p.Asp86Gly)

NM_000249.3
587778888
MLH1
[ ]
[ ]
[′Hereditary

(MLH1):c.113A>G

Nonpolyposis

(p.Asn38Ser)

Colorectal

Neoplasms′]

NM_017777.3
730882120
MKS1
[ ]
[ ]
[′Bardet-Biedl

(MKS1):c.1382A>G

syndrome 13′]

(p.Tyr461Cys)

NM_000261.1
74315335
MYOC
[ ]
[ ]
[′Primary open angle

(MYOC):c.1010A>G

glaucoma juvenile

(p.Gln337Arg)

onset 1′]

NM_152515.4
548949031
CKAP2L
[ ]
[ ]
[′Filippi syndrome′]

(CKAP2L):c.2T>C

(p.Met1Thr)

NM_000156.5
796052527
GAMT
[ ]
[′CGCTCAYGCTGC
[′not provided′]

(GAMT):c.1A>G

AGGCTGGACGG′]

(p.Met1Val)

NM_000833.4
796052544
GRIN2A
[ ]
[ ]
[′not provided′]

(GRIN2A):c.1930A>G

(p.Ser644Gly)

NM_000144.4
140987490
FXN
[ ]
[ ]
[′Friedreich ataxia′]

(FXN):c.385-2A>G

NM_172107.2
796052615
KCNQ2
[ ]
[ ]
[′not provided′]

(KCNQ2):c.297-2A>G

NM_172107.2
796052624
KCNQ2
[ ]
[ ]
[′not provided′]

(KCNQ2):c.611A>G

(p.Gln204Arg)

NM_172107.2
796052637
KCNQ2
[ ]
[′GTACYTGTCCCC
[′not provided′]

(KCNQ2):c.848A>G

GTAGCCAATGG′]

(p.Lys283Arg)

NM_052859.3
772820136
RFT1
[ ]
[ ]
[′Congenital disorder

(RFT1):c.887T>A

of glycosylation type

(p.Ile296Lys)

1N′]

NM_000553.4
775802030
WRN
[ ]
[ ]
[′Werner syndrome′]

(WRN):c.561A>G

(p.Lys187=)

NM_194277.2
786205896
FRMD7
[ ]
[ ]
[′Infantile

(FRMD7):c.556A>G

nystagmus,

(p.Met186Val)

X-linked′]

NM_000535.5
587779347
PMS2
[ ]
[ ]
[′Hereditary

(PMS2):c.989-2A>G

Nonpolyposis

Colorectal

Neoplasms′,

′Hereditary cancer-

predisposing

syndrome′]

NM_000203.4
587779401
IDUA
[ ]
[ ]
[′Hurler syndrome′]

(IDUA):c.1874A>G

(p.Tyr625Cys)

NM_001105243.1
796052839
PCDH19
[ ]
[ ]
[′not provided′]

(PCDH19):c.1019A>G

(p.Asn340Ser)

NM_002693.2
796052891
POLG
[ ]
[ ]
[′not provided′]

(POLG):c.2840A>G

(p.Lys947Arg)

NM_032228.5
724159963
FAR1
[ ]
[′GATAYCATACA
[′Peroxisomal fatty

(FAR1):c.1094A>G

GGAATGCTGGGG′,
acyl-coa reductase 1

(p.Asp365Gly)

′AGATAYCATACA
disorder′]

GGAATGCTGGG′,

′TAGATAYCATAC

AGGAATGCTGG′]

NM_000090.3
587779558
COL3A1
[ ]
[ ]
[′Ehlers-Danlos

(COL3A1):c.2284-2A>G

syndrome, type 4′]

(p.Gly762_Lys779del)

NM_014305.3
724160004
TGDS
[ ]
[ ]
[′Catel Manzke

(TGDS):c.269A>G

syndrome′]

(p.Glu90Gly)

NM_014305.3
724160005
TGDS
[ ]
[ ]
[′Catel Manzke

(TGDS):c.892A>G

syndrome′]

(p.Asn298Asp)

NM_000090.3
587779602
COL3A1
[ ]
[ ]
[′Ehlers-Danlos

(COL3A1):c.997-2A>G

syndrome, type 4′]

(p.Gly333_Lys350del+)

NM_002185.3
1494558
IL7R
[ ]
[ ]
[′Severe combined

(IL7R):c.197T>C

immunodeficiency,

(p.Ile66Thr)

autosomal recessive,

T cell-negative, B

cell-positive, NK

cell-positive′, ′not

specified′]

NM_000277.1
62508578
PAH
[ ]
[ ]
[′Phenylketonuria′,

(PAH):c.974A>G

′not provided′]

(p.Tyr325Cys)

NM_000090.3
587779670
COL3A1
[ ]
[ ]
[′Ehlers-Danlos

(COL3A1):c.997-10A>G

syndrome, type 4′]

(p.Pro332_Gly333insFFQ)

NM_000090.3
587779682
COL3A1
[ ]
[ ]
[′Ehlers-Danlos

(COL3A1):c.3202-2A>G

syndrome, type 4′]

(p.Gly1068_Pro1085de1)

NM_000090.3
587779722
COL3A1
[ ]
[′CACCCYAAAGA
[′Ehlers-Danlos

(COL3A1):c.1762-2A>G

AGAAGTGGTCGG′]
syndrome, type 4′]

(p.Gly588_Gln605del)

NM_021007.2
796053135
SCN2A
[ ]
[ ]
[′not provided′]

(SCN2A):c.4036A>G

(p.Ile1346Val)

m.13637A>G
200855215
MT-ND5
[ ]
[ ]
[′Leber optic

atrophy′]

NM_021007.2
796053169
SCN2A
[′AATAAAG
[′AATAAAGYAGA
[′not provided′]

(SCN2A):c.387-2A>G

YAGAATAT
ATATCGTCAAGG′]

CGTCAAGG′]

NM_021007.2
796053173
SCN2A
[ ]
[ ]
[′not provided′]

(SCN2A):c.851A>G

(p.Asp284Gly)

NM_006516.2
796053251
SLC2A1
[ ]
[ ]
[′not provided′]

(SLC2A1):c.848A>G

(p.Gln283Arg)

NM_006516.2
796053272
SLC2A1
[ ]
[ ]
[′not provided′]

(SLC2A1):c.19-2A>G

NM_000136.2
587779898
FANCC
[ ]
[ ]
[′Hereditary cancer-

(FANCC):c.-78-2A>G

predisposing

syndrome′]

m.8296A>G
118192102
MT-TK
[ ]
[′TTTACAGYGGGC
[′Diabetes-deafness

TCTAGAGGGGG′]
syndrome

maternally

transmitted′]

NM_005360.4
727502767
MAF
[ ]
[ ]
[′Cataracts,

(MAF):c.172A>G

congenital, with

(p.Thr58Ala)

sensorineural

deafness, down

syndrome-like facial

appearance, short

stature, and mental

retardation′]

NM_001145901.1
727502784
SARS2
[ ]
[ ]
[′Hyperuricemia,

(SARS2):c.1175A>G

pulmonary

(p.Asp392Gly)

hypertension, renal

failure, and

alkalosis′]

NM_001077494.3
727502787
NFKB2
[ ]
[′CTGYCTTCCTTC
[′Common variable

(NFKB2):c.2594A>G

ACCTCTGCTGG′]
immunodeficiency

(p.Asp865Gly)

10′]

NM_002238.3
727502819
KCNH1
[ ]
[ ]
[′Zimmermann-

(KCNH1):c.1399A>G

Laband syndrome′,

(p.Ile467Val)

′Temple-Baraitser

syndrome′]

NM_172362.2
727502821
KCNH1
[ ]
[ ]
[′Temple-Baraitser

(KCNH1):c.1508A>G

syndrome′]

(p.Gln503Arg)

NM_000546.5
587780073
TP53
[ ]
[ ]
[′Li-Fraumeni

(TP53):c.701A>G

syndrome′,

(p.Tyr234Cys)

′Hereditary cancer-

predisposing

syndrome′]

NM_003060.3
188698686
SLC22A5
[ ]
[ ]
[′not provided′]

(SLC22A5):c.694A>C

(p.Thr232Pro)

NM_000540.2
118192146
RYR1
[ ]
[ ]
[′Central core

(RYR1):c.14591A>G

disease′, ′not

(p.Tyr4864Cys)

provided′]

NM_058216.2
587780259
RAD51C
[ ]
[ ]
[′Hereditary cancer-

(RAD51C):c.706-2A>G

predisposing

syndrome′]

NM_000501.3
727503027
ELN
[ ]
[ ]
[′Supravalvar aortic

(ELN):c.800-2A>G

stenosis′, ′not

provided′]

NM_000117.2
727503036
EMD
[ ]
[′AGCCYTGGGAA
[Emery-Dreifuss

(EMD):c.266-2A>G

GGGGGGCAGCGG′]
muscular dystrophy

1, X-linked′]

NM_003242.5
104893817
TGFBR2
[ ]
[ ]
[′Loeys-Dietz

(TGFBR2):c.1273A>G

syndrome 2′]

(p.Met425Val)

NM_153638.2
137852965
PANK2
[ ]
[ ]
[ ]

(PANK2):c.700A>G

(p.Thr234Ala)

NM_005861.3
690016544
STUB1
[ ]
[′GGCCCGGYTGGT
[′Spinocerebellar

(STUB1):c.194A>G

GTAATACACGG′]
ataxia, autosomal

(p.Asn65Ser)

recessive 16′]

NM_005360.4
121917736
MAF
[ ]
[ ]
[′Cataract,

(MAF):c.890A>G

pulverulent,

(p.Lys297Arg)

juvenile-onset′]

NM_005211.3
690016554
CSF1R
[ ]
[′GTATCYGGGAG
[′Hereditary diffuse

(CSF1R):c.2655-2A>G

ATAGGACAGAGG′]
leukoencephalopathy

with spheroids′]

NM_003361.3
121917770
UMOD
[′CACAYTG
[′CACAYTGACAC
[′Familial juvenile

(UMOD):c.383A>G

ACACATGT
ATGTGGCCAGGG′,
gout′]

(p.Asn128Ser)

GGCCAGGG′]
′CCACAYTGACAC

ATGTGGCCAGG′]

NM_000256.3
727503190
MYBPC3
[ ]
[ ]
[′Familial

(MYBPC3):c.2234A>G

hypertrophic

(p.Asp745Gly)

cardiomyopathy 4′,

′Familial

hypertrophic

cardiomyopathy 1′,

′not specified′]

NM_172107.2
118192185
KCNQ2
[ ]
[′GCACCAYGGTG
[′Benign familial

(KCNQ2):c.1A>G

CCTGGCGGGAGG′]
neonatal seizures 1′]

(p.Met1Val)

NM_000256.3
727503207
MYBPC3
[ ]
[ ]
[′Cardiomyopathy′,

(MYBPC3):c.1213A>G

′not specified′]

(p.Met405Val)

NM_000021.3
121917809
PSEN1
[ ]
[ ]
[′Primary dilated

(PSEN1):c.998A>G

cardiomyopathy′,

(p.Asp333Gly)

′Cardiomyopathy,

dilated, 1u′, ′Heart

failure′]

NM_021954.3
121917823
GJA3
[ ]
[ ]
[′Zonular

(GJA3):c.188A>G

pulverulent cataract

(p.Asn63Ser)

3′]

NM_000322.4
61755781
PRPH2
[ ]
[ ]
[′Macular dystrophy,

(PRPH2):c.422A>G

vitelliform, adult-

(p.Tyr141Cys)

onset′, ′Patterned

dystrophy of retinal

pigment epithelium′,

′not provided′]

NM_007035.3
121917858
KERA
[ ]
[ ]
[′Cornea plana 2′]

(KERA):c.740A>G

(p.Asn247Ser)

NM_002181.3
121917859
IHH
[ ]
[ ]
[′Brachydactyly type

(IHH):c.284A>G

A1′]

(p.Glu95Gly)

NM_000257.3
727503269
MYH7
[ ]
[ ]
[′Primary familial

(MYH7):c.1157A>G

hypertrophic

(p.Tyr386Cys)

cardiomyopathy′]

NM_000097.5
121917868
CPOX
[ ]
[ ]
[′Harderoporphyria′]

(CPOX):c.1210A>G

(p.Lys404Glu)

NM_012064.3
121917869
MIP
[ ]
[′AGATCYCCACTG
[′Cataract 15,

(MIP):c.401A>G

TGGTTGCCTGG′]
multiple types′]

(p.Glu134Gly)

NM_025243.3
121917884
SLC19A3
[ ]
[ ]
[′Basal ganglia

(SLC19A3):c.1264A>G

disease, biotin-

(p.Thr422Ala)

responsive′]

NM_000373.3
121917890
UMPS
[ ]
[ ]
[′Orotic aciduria′]

(UMPS):c.286A>G

(p.Arg96Gly)

NM_000536.3
121917897
RAG2
[ ]
[ ]
[′Histiocytic

(RAG2):c.115A>G

medullary

(p.Arg39Gly)

reticulosis′]

NM_130838.1
587780579
UBE3A
[ ]
[ ]
[′Angelman

(UBE3A):c.1694-2A>G

syndrome′]

NM_016335.4
2904551
PRODH
[ ]
[ ]
[′Proline

(PRODH):c.1322T>C

dehydrogenase

(p.Leu441Pro)

deficiency′,

′Schizophrenia 4′]

NM_006920.4
121917962
—
[ ]
[ ]
[′Severe myoclonic

(SCN1A):c.4352A>G

epilepsy in infancy′,

(p.Tyr1451Cys)

′not provided′]

NM_006920.4
121917990
SCN1A
[ ]
[ ]
[′Severe myoclonic

(SCN1A):c.1876A>G

epilepsy in infancy′,

(p.Ser626Gly)

′Generalized

epilepsy′]

NM_000478.4
121918014
ALPL
[ ]
[′AGGCCCAYTGCC
[′Infantile

(ALPL):c.1250A>G

ATACAGGATGG′]
hypophosphatasia′]

(p.Asn417Ser)

NM_000174.4
121918036
GP9
[ ]
[′GCAGYCCACCC
[′Bernard-Soulier

(GP9):c.110A>G

ACAGCCCCATGG′]
syndrome type C′]

(p.Asp37Gly)

NM_002693.2
121918050
POLG
[ ]
[ ]
[′Mitochondrial

(POLG):c.2591A>G

DNA depletion

(p.Asn864Ser)

syndrome 4B,

MNGIE type′]

NM_000374.4
121918061
UROD
[ ]
[ ]
[′Hepatoerythropoietic

(UROD):c.932A>G

porphyria′]

(p.Tyr311Cys)

NM_000217.2
121918067
KCNA1
[ ]
[ ]
[ ]

(KCNA1):c.763A>G

(p.Asn255Asp)

NM_000371.3
121918070
TTR
[ ]
[ ]
[′Amyloidogenic

(TTR):c.238A>G

transthyretin

(p.Thr80Ala)

amyloidosis′,

′Cardiomyopathy′]

NM_000371.3
121918075
TTR
[′GGAGYAG
[′GGAGYAGGGGC
[′Amyloidogenic

(TTR):c.401A>G

GGGCTCAG
TCAGCAGGGCGG′,
transthyretin

(p.Tyr134Cys)

CAGGGCGG′,
′ATAGGAGYAGGG
amyloidosis′]

′ATAGGAG
GCTCAGCAGGG′]

YAGGGGCT

CAGCAGGG′]

NM_000371.3
121918081
TTR
[ ]
[ ]
[′Amyloidogenic

(TTR):c.205A>G

transthyretin

(p.Thr69Ala)

amyloidosis′]

NM_000371.3
121918089
TTR
[ ]
[′CGGCAAYGGTG
[′Amyloidogenic

(TTR):c.379A>G

TAGCGGCGGGGG′,
transthyretin

(p.Ile127Val)

′GCGGCAAYGGTG
amyloidosis′]

TAGCGGCGGGG′]

NM_000371.3
121918098
TTR
[ ]
[ ]
[′Amyloidogenic

(TTR):c.113A>G

transthyretin

(p.Asp38Gly)

amyloidosis′,

′AMYLOIDOSIS,

LEPTOMENINGEAL,

TRANSTHYRETIN-

RELATED′]

NM_000823.3
121918121
GHRHR
[ ]
[′CGACTYGGAGA
[′Isolated growth

(GHRHR):c.985A>G

GACGCCTGCAGG′]
hormone deficiency

(p.Lys329Glu)

type 1B′]

NM_000275.2
121918170
OCA2
[′GACATYT
[′GACATYTGGAG
[′Tyrosinase-positive

(OCA2):c.1465A>G

GGAGGGTC
GGTCCCCGATGG′]
oculocutaneous

(p.Asn489Asp)

CCCGATGG′]

albinism′]

NM_000181.3
121918178
GUSB
[ ]
[ ]
[′Mucopolysaccharidosis

(GUSB):c.1484A>G

type VII′]

(p.Tyr495Cys)

NM_018122.4
121918209
DARS2
[ ]
[ ]
[′Leukoencephalopathy

(DARS2):c.133A>G

with Brainstem

(p.Ser45Gly)

and Spinal Cord

Involvement and

Lactate Elevation′]

NM_015697.7
121918230
COQ2
[ ]
[ ]
[′Coenzyme Q10

(COQ2):c.890A>G

deficiency, primary

(p.Tyr297Cys)

1′]

NM_015697.7
121918232
COQ2
[ ]
[ ]
[′Coenzyme Q10

(COQ2):c.683A>G

deficiency, primary

(p.Asn228Ser)

1′]

NM_015384.4
121918265
NIPBL
[ ]
[ ]
[′Cornelia de Lange

(NIPBL):c.7289A>G

syndrome 1′]

(p.Tyr2430Cys)

NM_004183.3
121918291
BEST1
[ ]
[ ]
[′Vitreoretinochoroidopathy

(BEST1):c.707A>G

dominant′]

(p.Tyr236Cys)

NM_014362.3
121918329
HIBCH
[ ]
[ ]
[Beta-

(HIBCH):c.365A>G

hydroxyisobutyryl-

(p.Tyr122Cys)

CoA deacylase

deficiency′]

NM_015335.4
121918333
MED13L
[ ]
[′ATATCAYCTAGA
[′Transposition of

(MED13L):c.6068A>G

GGGAAGGGGGG′,
great arteries′]

(p.Asp2023Gly)

′CATATCAYCTAG

AGGGAAGGGGG′]

NM_015040.3
121918336
PIKFYVE
[ ]
[ ]
[′Fleck corneal

(PIKFYVE):c.3308A>G

dystrophy′]

(p.Lys1103Arg)

NM_006306.3
727503774
SMC1A
[ ]
[ ]
[′Congenital

(SMC1A):c.2974-2A>G

muscular

hypertrophy-cerebral

syndrome′]

NM_002633.2
121918371
PGM1
[ ]
[ ]
[′Congenital disorder

(PGM1):c.343A>G

of glycosylation type

(p.Thr115Ala)

1t′]

NM_000040.1
121918381
APOC3
[′CTGAAGY
[′CTGAAGYTGGTC
[ ]

(APOC3):c.280A>G

TGGTCTGA
TGACCTCAGGG′,

(p.Thr94Ala)

CCTCAGGG′,
′GCTGAAGYTGGT

′GCTGAAG
CTGACCTCAGG′]

YTGGTCTG

ACCTCAGG′]

NM_000040.1
121918382
APOC3
[ ]
[ ]
[′Hyperalphalipo-

(APOC3):c.232A>G

proteinemia 2′]

(p.Lys78Glu)

NM_001146040.1
121918412
GLRA1
[ ]
[ ]
[′Hyperekplexia

(GLRA1):c.910A>G

hereditary′]

(p.Lys304Glu)

NM_000171.3
121918414
GLRA1
[ ]
[ ]
[′Hyperekplexia

(GLRA1):c.523A>G

hereditary′]

(p.Met175Val)

NM_021957.3
121918423
GYS2
[ ]
[ ]
[′Hypoglycemia with

(GYS2):c.116A>G

deficiency of

(p.Asn39Ser)

glycogen synthetase

in the liver′]

NM_002834.3
121918459
PTPN11
[ ]
[ ]
[′Noonan syndrome′,

(PTPN11):c.188A>G

′Noonan syndrome

(p.Tyr63Cys)

1′, ′Rasopathy′, ′not

provided′]

NM_013382.5
727503873
POMT2
[ ]
[ ]
[′not provided′]

(POMT2):c.1726-2A>G

NM_002834.3
121918466
PTPN11
[ ]
[ ]
[′Noonan syndrome′,

(PTPN11):c.236A>G

′Noonan syndrome

(p.Gln79Arg)

1′, ′Rasopathy′, ′not

provided′]

NM_000313.3
121918473
PROS1
[ ]
[ ]
[′Protein S

(PROS1):c.773A>G

deficiency′]

(p.Asn258Ser)

NM_000313.3
121918474
PROS1
[ ]
[ ]
[′Protein S

(PROS1):c.586A>G

deficiency′]

(p.Lys196Glu)

NM_000141.4
121918493
FGFR2
[ ]
[ ]
[′Crouzon

(FGFR2):c.983A>G

syndrome′]

(p.Tyr328Cys)

NM_000141.4
121918500
FGFR2
[′TGCTYGA
[′TGCTYGATCCAC
[′Crouzon

(FGFR2):c.874A>G

TCCACTGG
TGGATGTGGGG′,
syndrome′]

(p.Lys292Glu)

ATGTGGGG′]
′GTGCTYGATCCA

CTGGATGTGGG′,

′CGTGCTYGATCC

ACTGGATGTGG′]

NM_000141.4
121918507
FGFR2
[ ]
[ ]
[′Crouzon

(FGFR2):c.1576A>G

syndrome′,

(p.Lys526Glu)

′Scaphocephaly,

maxillary retrusion,

and mental

retardation′]

NM_002739.3
121918515
PRKCG
[ ]
[ ]
[′Spinocerebellar

(PRKCG):c.380A>G

ataxia 14′]

(p.Gln127Arg)

NM_002739.3
121918517
PRKCG
[ ]
[ ]
[′Spinocerebellar

(PRKCG):c.1081A>G

ataxia 14′]

(p.Ser361Gly)

NM_000098.2
121918528
CPT2
[′GATAGGY
[′GATAGGYACAT
[′Carnitine

(CPT2):c.359A>G

ACATATCA
ATCAAACCAGGG′,
palmitoyltransferase

(p.Tyr120Cys)

AACCAGGG′,
′AGATAGGYACAT
II deficiency,

′AGATAGG
ATCAAACCAGG′]
infantile′]

YACATATC

AAACCAGG′]

NM_005587.2
121918530
MEF2A
[′CCAAGAY
[′AGAYTACCACC
[ ]

(MEF2A):c.788A>G

TACCACCA
ACCTGGTGGAGG′,

(p.Asn263Ser)

CCTGGTGG′]
′CCAAGAYTACCA

CCACCTGGTGG′]

NM_006204.3
121918539
PDE6C
[ ]
[ ]
[′Achromatopsia 5′]

(PDE6C):c.1363A>G

(p.Met455Val)

NM_017654.3
121918554
SAMD9
[ ]
[ ]
[′Tumoral calcinosis,

(SAMD9):c.4483A>G

familial,

(p.Lys1495Glu)

normophosphatemic′]

NM_000191.2
727503963
HMGCL
[ ]
[ ]
[′not provided′]

(HMGCL):c.698A>G

(p.His233Arg)

NM_020166.4
727504006
MCCC1
[ ]
[ ]
[′3 Methylcrotonyl-

(MCCC1):c.137-2A>G

CoA carboxylase 1

deficiency′, ′not

provided′]

NM_001035.2
121918605
RYR2
[ ]
[′CGCCAGCYGCAT
[′Catecholaminergic

(RYR2):c.12602A>G

TTCAAAGATGG′]
polymorphic

(p.Gln4201Arg)

ventricular

tachycardia′]

NM_002764.3
587781262
PRPS1
[ ]
[′TAGCAYATTTGC
[′Charcot-Marie-Tooth disease,

(PRPS1):c.343A>G

AACAAGCTTGG′]
X-linked recessive,

(p.Met115Val)

type 5′, ′Deafness,

high-frequency

sensorineural, X-linked′]

NM_001161766.1
121918608
AHCY
[ ]
[′GCGGGYACTTG
[′Hypermethioninemia

(AHCY):c.344A>G

GTGTGGATGAGG′]
with s-

(p.Tyr115Cys)

adenosylhomocysteine

hydrolase

deficiency′]

NM_000702.3
121918613
ATP1A2
[ ]
[′CTGYCAGGGTCA
[′Familial

(ATP1A2):c.1033A>G

GGCACACCTGG′]
hemiplegic migraine

(p.Thr345Ala)

type 2′]

NM_003126.2
121918644
SPTA1
[ ]
[ ]
[′Hereditary

(SPTA1):c.143A>G

pyropoikilocytosis′]

(p.Lys48Arg)

NM_001024858.2
121918651
SPTB
[ ]
[ ]
[′Elliptocytosis 3′]

(SPTB):c.1A>G

(p.Met1Val)

NM_000899.4
121918653
KITLG
[ ]
[ ]
[′Familial

(KITLG):c.107A>G

progressive

(p.Asn36Ser)

hyperpigmentation

with or without

hypopigmentation′]

NM_198253.2
121918663
TERT
[ ]
[ ]
[′Aplastic anemia′,

(TERT):c.2315A>G

′PULMONARY

(p.Tyr772Cys)

FIBROSIS

AND/OR BONE

MARROW

FAILURE,

TELOMERE-

RELATED, 1′]

NM_001063.3
121918678
TF
[ ]
[ ]
[ ]

(TF):c.1936A>G

(p.Lys646Glu)

NM_000535.5
587781339
PMS2
[ ]
[′GCAGACCYGCA
[′Hereditary cancer-

(PMS2):c.904-2A>G

CAAAATACAAGG′]
predisposing

syndrome′]

NM_001128177.1
121918691
THRB
[ ]
[′CTTCAYGTGCAG
[′Thyroid hormone

(THRB):c.1324A>G

GAAGCGGCTGG′]
resistance,

(p.Met442Val)

generalized,

autosomal

dominant′]

NM_001128177.1
121918692
THRB
[ ]
[′CCACCTYCATGT
[′Thyroid hormone

(THRB):c.1327A>G

GCAGGAAGCGG′]
resistance,

(p.Lys443Glu)

generalized,

autosomal

dominant′]

NM_001128177.1
121918709
THRB
[ ]
[ ]
[′Thyroid hormone

(THRB):c.1009A>G

resistance, selective

(p.Thr337Ala)

pituitary′]

NM_004612.3
121918711
TGFBR1
[′ATAGATG
[′ATAGATGYCAG
[′Loeys-Dietz

(TGFBR1):c.1199A>G

YCAGCACG
CACGTTTGAAGG′]
syndrome 1′]

(p.Asp400Gly)

TTTGAAGG′]

NM_000359.2
121918724
TGM1
[ ]
[ ]
[′Autosomal

(TGM1):c.1469A>G

recessive congenital

(p.Asp490Gly)

ichthyosis 1′]

NM_000257.3
727504238
MYH7
[ ]
[ ]
[′Familial

(MYH7):c.1727A>G

hypertrophic

(p.His576Arg)

cardiomyopathy 1′,

′Cardiomyopathy′,

′not specified′]

NM_000257.3
727504239
MYH7
[ ]
[ ]
[′Primary familial

(MYH7):c.1954A>G

hypertrophic

(p.Arg652Gly)

cardiomyopathy′,

′Familial

hypertrophic

cardiomyopathy 1′]

NM_000257.3
727504270
MYH7
[ ]
[ ]
[′Cardiomyopathy′,

(MYH7):c.1496A>G

′not specified′]

(p.Glu499Gly)

NM_000257.3
727504310
MYH7
[ ]
[ ]
[′Familial

(MYH7):c.2539A>G

hypertrophic

(p.Lys847Glu)

cardiomyopathy 1′,

′Cardiomyopathy′,

′not specified′]

NM_000256.3
727504333
MYBPC3
[ ]
[′CCGTTCYGTGGG
[′Familial

(MYBPC3):c.2906-2A>G

TATAGAGTGGG′,
hypertrophic

′GCCGTTCYGTGG
cardiomyopathy 4′]

GTATAGAGTGG′]

NM_001128425.1
587781628
MUTYH
[′ACCYGAG
[′ACCYGAGAGGG
[′Hereditary cancer-

(MUTYH):c.1187-2A>G

AGGGAGG
AGGGCAGCCAGG′]
predisposing

GCAGCCAG

syndrome′,

G′]

′Carcinoma of

colon′]

NM_005188.3
727504426
CBL
[ ]
[ ]
[′Juvenile

(CBL):c.1228-2A>G

myelomonocytic

leukemia′, ′Noonan

syndrome-like

disorder with or

without juvenile

myelomonocytic

leukemia′,

′Rasopathy′]

NM_000501.3
727504434
ELN
[′GCCYGAA
[′GCCYGAAAACA
[′Supravalvar aortic

(ELN):c.890-2A>G

AACACAGC
CAGCCACAGAGG′]
stenosis′]

CACAGAGG′]

NM_001165963.1
775214722
SCN1A
[ ]
[ ]
[′not provided′]

(SCN1A):c.2877T>A

(p.Cys959Ter)

NM_000833.4
796052551
GRIN2A
[′CCAYGTT
[′CCAYGTTGTCAA
[′not provided′]

(GRIN2A):c.2449A>G

GTCAATGT
TGTCCAGCTGG′]

(p.Met817Val)

CCAGCTGG′]

NM_000314.6
587781784
PTEN
[ ]
[ ]
[′Hereditary cancer-

(PTEN):c.493-2A>G

predisposing

syndrome′]

NM_000498.3
61757294
—
[ ]
[ ]
[′Corticosterone

(CYP11B2):c.1157T>C

methyloxidase type

(p.Val386Ala)

2 deficiency′,

′Corticosterone

methyloxidase type

1 deficiency′]

NM_006204.3
786200910
PDE6C
[ ]
[′CTTTCYGTTGAA
[′Achromatopsia 5′]

(PDE6C):c.1483-2A>G

ATAAGGATGGG′,

′TCTTTCYGTTGAA

ATAAGGATGG′]

NM_003588.3
786200913
CUL4B
[ ]
[ ]
[′Syndromic X-

(CUL4B):c.901-2A>G

linked mental

retardation, Cabezas

type′]

NM_000397.3
137854591
CYBB
[ ]
[ ]
[′Granulomatous

(CYBB):c.302A>G

disease, chronic, X-

(p.His101Arg)

linked, variant′, ′not

provided′]

NM_000311.3
1799990
PRNP
[ ]
[ ]
[′Jakob-Creutzfeldt

(PRNP):c.385A>G

disease′, ′Genetic

(p.Met129Val)

prion diseases′,

′Fatal familial

insomnia′, ′not

specified′]

NM_000051.3
587782276
ATM
[ ]
[ ]
[′Ataxia-

(ATM):c.3994-2A>G

telangiectasia

syndrome′,

′Hereditary cancer-

predisposing

syndrome′]

NM_005211.3
281860267
CSF1R
[ ]
[ ]
[′Hereditary diffuse

(CSF1R):c.1754-2A>G

leukoencephalopathy

with spheroids′]

NM_004646.3
730880174
NPHS1
[ ]
[ ]
[′Finnish congenital

(NPHS1):c.1756A>G

nephrotic

(p.Arg586Gly)

syndrome′]

NM_005211.3
281860272
CSF1R
[′CACYGAG
[′CACYGAGGGAA
[′Hereditary diffuse

(CSF1R):c.2320-2A>G

GGAAAGC
AGCACTGCAGGG′,
leukoencephalopathy

ACTGCAGG
′GCACYGAGGGAA
with spheroids′]

G′]
AGCACTGCAGG′]

NM_000256.3
370890951
MYBPC3
[ ]
[ ]
[′Cardiomyopathy′,

(MYBPC3):c.3392T>C

′Cardiac arrest′, ′not

(p.Ile1131Thr)

specified′]

NM_000551.3
281860296
VHL
[ ]
[′GGTCTTYCTGCA
[′Von Hippel-Lindau

(VHL):c.586A>T

CATTTGGGTGG′]
syndrome′]

(p.Lys196Ter)

NM_005247.2
281860300
FGF3
[′CAGYAGA
[′CAGYAGAGCTT
[′Deafness with

(FGF3):c.146A>G

GCTTGCGG
GCGGCGCCGGGG′,
labyrinthine aplasia

(p.Tyr49Cys)

CGCCGGGG′,
′GCAGYAGAGCTT
microtia and

′GCAGYAG
GCGGCGCCGGG′,
microdontia

AGCTTGCG
′CGCAGYAGAGCT
(LAMM)′]

GCGCCGGG′,
TGCGGCGCCGG′]

′CGCAGYA

GAGCTTGC

GGCGCCGG′]

NM_005247.2
281860306
FGF3
[ ]
[ ]
[′Deafness with

(FGF3):c.317A>G

labyrinthine aplasia

(p.Tyr106Cys)

microtia and

microdontia

(LAMM)′]

NM_000314.6
587782360
PTEN
[ ]
[ ]
[′Hereditary cancer-

(PTEN):c.403A>G

predisposing

(p.Ile135Val)

syndrome′]

NM_004990.3
766466297
MARS
[ ]
[ ]
[′Pulmonary alveolar

(MARS):c.1031A>G

proteinosis′,

(p.Tyr344Cys)

′Interstitial lung and

liver disease′]

NM_006343.2
730880273
MERTK
[ ]
[ ]
[′Retinitis

(MERTK):c.1605-2A>G

pigmentosa 38′]

NM_003611.2
730880283
OFD1
[ ]
[ ]
[′Retinitis

(OFD1):c.935+706A>G

Pigmentosa 23′]

NM_004793.3
730880293
LONP1
[ ]
[ ]
[′CODAS

(LONP1):c.2353A>G

syndrome′]

(p.Arg785Gly)

NM_001698.2
730880311
AUH
[ ]
[ ]
[′3-Methylglutaconic

(AUH):c.263-2A>G

aciduria′]

NM_001698.2
730880312
AUH
[ ]
[ ]
[′3-Methylglutaconic

(AUH):c.943-2A>G

aciduria′]

NM_000169.2
730880444
—
[ ]
[′GTGAACCYGAA
[′not provided′]

(GLA):c.370-2A>G

ATGAGAGGGAGG′]

NM_001110792.1
727505391
MECP2
[ ]
[ ]
[′Rett disorder′]

(MECP2):c.520A>G

(p.Arg174Gly)

NM_030662.3
730880517
MAP2K2
[ ]
[ ]
[′Cardiofaciocutaneous

(MAP2K2):c.181A>G

syndrome′,

(p.Lys61Glu)

′Rasopathy′]

NM_000256.3
730880531
MYBPC3
[ ]
[′GTACCYGGGTG
[′Familial

(MYBPC3):c.1227-2A>G

GGGGCCGCAGGG′,
hypertrophic

′TGTACCYGGGTG
cardiomyopathy 4′,

GGGGCCGCAGG′]
′Cardiomyopathy′]

NM_000642.2
369973784
AGL
[ ]
[ ]
[′Glycogen storage

(AGL):c.4260-12A>G

disease type III′,

′Glycogen storage

disease IIIa′,

′Glycogen storage

disease IIIb′]

NM_000267.3
267606602
NF1
[ ]
[ ]
[′Neurofibromatosis,

(NF1):c.1642-8A>G

type 1′, ′Juvenile

myelomonocytic

leukemia′]

NM_000267.3
267606604
NF1
[ ]
[ ]
[′Neurofibromatosis,

(NF1):c.5944-5A>G

type 1′,

′Neurofibromatosis,

familial spinal′]

m.1555A>G
267606617
MT-
[ ]
[ ]
[′Aminoglycoside-

RNR1

induced deafness′,

′Cardiomyopathy,

restrictive′,

′Deafness,

nonsyndromic

sensorineural,

mitochondrial′]

NM_022458.3
606231150
LMBR1
[ ]
[ ]
[′Triphalangeal

(LMBR1):c.423+5252A>G

thumb′, ′Preaxial

polydactyly 2′]

NM_000642.2
267606639
AGL
[ ]
[ ]
[′Glycogen storage

(AGL):c.3439A>G

disease IIIc′]

(p.Arg1147Gly)

NM_013411.4
267606643
AK2
[ ]
[′TCAYCTTTCATG
[′Reticular

(AK2):c.494A>G

GGCTCTTTTGG′]
dysgenesis′]

(p.Asp165Gly)

NM_001142800.1
183589498
EYS
[ ]
[ ]
[′Retinitis

(EYS):c.9209T>C

pigmentosa′]

(p.Ile3070Thr)

NM_004183.3
267606677
BEST1
[ ]
[ ]
[′Vitelliform

(BEST1):c.680A>G

dystrophy′, ′Retinitis

(p.Tyr227Cys)

pigmentosa,

concentric′, ′not

provided′]

NM_005188.3
267606705
CBL
[ ]
[′TATTTYACATAG
[′Noonan syndrome-

(CBL):c.1144A>G

TTGGAATGTGG′]
like disorder with or

(p.Lys382Glu)

without juvenile

myelomonocytic

leukemia′]

NM_001017361.2
606231235
KHDC3L
[ ]
[ ]
[′Hydatidiform mole,

(KHDC3L):c.1A>G

recurrent, 2′]

(p.Met1Val)

NM_144577.3
606231239
CCDC114
[ ]
[ ]
[′Ciliary dyskinesia,

(CCDC114):c.487-2A>G

primary, 20′]

NM_000277.1
62642934
PAH
[ ]
[′GGCCAAYTTCCT
[′Phenylketonuria′,

(PAH):c.916A>G

GTAATTGGGGG′,
′Hyperphenylalanine

(p.Ile306Val)

′AGGCCAAYTTCC
mia, non-pku′, ′not

TGTAATTGGGG′]
provided′]

NM_000257.3
730880760
MYH7
[ ]
[ ]
[′Cardiomyopathy′]

(MYH7):c.2792A>G

(p.Glu931Gly)

NM_207034.2
267606778
EDN3
[ ]
[ ]
[′Waardenburg

(EDN3):c.335A>G

syndrome type 4B′]

(p.His112Arg)

NM_000117.2
267606782
EMD
[ ]
[′TCCAYGGCGGGT
[′Emery-Dreifuss

(EMD):c.1A>G

GCGGGCTCAGG′]
muscular dystrophy,

(p.Met1Val)

X-linked′]

NM_003937.2
606231307
KYNU
[ ]
[ ]
[′Hydroxykynureninuria′]

(KYNU):c.592A>G

(p.Thr198Ala)

NM_004387.3
587782928
NKX2-5
[ ]
[ ]
[′Atrial septal defect

(NKX2-5):c.461A>G

7 with or without

(p.Glu154Gly)

atrioventricular

conduction defects′]

NM_000142.4
267606808
FGFR3
[ ]
[ ]
[′Thanatophoric

(FGFR3):c.1454A>G

dysplasia type 1′]

(p.Gln485Arg)

NM_014053.3
267606820
FLVCR1
[ ]
[′AGGCGTYGACC
[′Posterior column

(FLVCR1):c.361A>G

AGCGAGTACAGG′]
ataxia with retinitis

(p.Asn121Asp)

pigmentosa′]

NM_000257.3
730880805
—
[ ]
[′GCCCYCCTCGTG
[′Cardiomyopathy′]

(MYH7):c.4664A>G

CTCCAGGGAGG′,

(p.Glu1555Gly)

′CTTGCCCYCCTC

GTGCTCCAGGG′]

NM_138387.3
267606834
G6PC3
[ ]
[′TGATCAYGCAGT
[′Dursun syndrome′]

(G6PC3):c.346A>G

GTCCAGAAGGG′,

(p.Met116Val)

′GTGATCAYGCAG

TGTCCAGAAGG′]

NM_020347.3
515726135
LZTFL1
[ ]
[ ]
[′Bardet-Biedl

(LZTFL1):c.260T>C

syndrome′, ′Bardet-

(p.Leu87Pro)

Biedl syndrome 17′]

NM_000175.3
267606851
GPI
[ ]
[′GTACYGGTCATA
[′Hemolytic anemia,

(GPI):c.1028A>G

GGGCAGCATGG′]
nonspherocytic, due

(p.Gln343Arg)

to glucose phosphate

isomerase

deficiency′]

NM_005859.4
587782994
PURA
[ ]
[ ]
[′Neonatal

(PURA):c.289A>G

hypotonia′,

(p.Lys97Glu)

′Intellectual

disability′, ′Seizures′,

′Delayed speech and

language

development′,

′Global

developmental

delay′, ′Mental

retardation,

autosomal dominant

31′]

NM_005144.4
267606869
HR
[′CTCYAGG
[′CTCYAGGGCCGC
[′Marie Unna

(HR):c.-218A>G

GCCGCAGG
AGGTTGGAGGG′,
hereditary

TTGGAGGG′]
′GCTCYAGGGCCG
hypotrichosis 1′]

CAGGTTGGAGG′,

′GGCGCTCYAGGG

CCGCAGGTTGG′]

NM_000257.3
730880855
MYH7
[ ]
[ ]
[′Cardiomyopathy′]

(MYH7):c.789A>G

(p.Ile263Met)

NM_000060.3
587783004
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.683A>G

deficiency′]

(p.Asp228Gly)

NM_000257.3
730880864
MYH7
[ ]
[ ]
[′Cardiomyopathy′]

(MYH7):c.1051A>G

(p.Lys351Glu)

NM_015713.4
515726182
RRM2B
[ ]
[′TTCCTTCYGGAC
[′RRM2B-related

(RRM2B):c.190T>C

AGCAGAAGAGG′]
mitochondrial

(p.Trp64Arg)

disease′]

NM_005957.4
267606887
MTHFR
[′CGCGGYT
[′CGCGGYTGAGG
[′Homocystinuria

(MTHFR):c.971A>G

GAGGGTGT
GTGTAGAAGTGG′]
due to MTHFR

(p.Asn324Ser)

AGAAGTGG′]

deficiency′]

NM_015713.4
515726187
RRM2B
[ ]
[ ]
[′RRM2B-related

(RRM2B):c.368T>C

mitochondrial

(p.Phe123Ser)

disease′]

m.12770A>G
267606894
MT-ND5
[ ]
[ ]
[′Juvenile myopathy,

encephalopathy,

lactic acidosis AND

stroke′]

NM_000257.3
730880880
MYH7
[ ]
[ ]
[′Cardiomyopathy′]

(MYH7):c.1805A>G

(p.Asn602Ser)

NM_018109.3
267606900
MTPAP
[′AATGGAT
[′AATGGATYCTGA
[′Ataxia, spastic, 4,

(MTPAP):c.1432A>G

YCTGAATG
ATGTACAGAGG′]
autosomal

(p.Asn478Asp)

TACAGAGG′]

recessive′]

NM_000257.3
267606908
MYH7
[ ]
[ ]
[′Primary familial

(MYH7):c.2717A>G

hypertrophic

(p.Asp906Gly)

cardiomyopathy′,

′Familial

hypertrophic

cardiomyopathy 1′,

′Cardiomyopathy′]

NM_003122.4
515726207
SPINK1
[ ]
[ ]
[′Hereditary

(SPINK1):c.160T>C

pancreatitis′]

(p.Tyr54His)

NM_003159.2
587783080
CDKL5
[ ]
[ ]
[′not provided′]

(CDKL5):c.404-2A>G

NM_003159.2
587783083
CDKL5
[′ACAGTYT
[′ACAGTYTTAGGA
[′not provided′]

(CDKL5):c.449A>G

TAGGACAT
CATCATTGTGG′]

(p.Lys150Arg)

CATTGTGG′]

NM_016203.3
267606977
PRKAG2
[ ]
[ ]
[′Familial

(PRKAG2):c.1589A>G

hypertrophic

(p.His530Arg)

cardiomyopathy 6′,

′not provided′]

NM_198965.1
267606987
PTHLH
[ ]
[ ]
[′Brachydactyly type

(PTHLH):c.534A>G

E2′]

(p.Ter178Trp)

NM_000531.5
74518351
OTC
[ ]
[ ]
[′not provided′]

(OTC):c.122A>G

(p.Asp41Gly)

NM_001134363.2
267607005
RBM20
[ ]
[ ]
[′Dilated

(RBM20):c.1909A>G

cardiomyopathy

(p.Ser637Gly)

1DD′]

NM_000553.4
267607008
WRN
[ ]
[ ]
[′Werner syndrome′]

(WRN):c.403A>G

(p.Lys135Glu)

NM_002880.3
730881002
RAF1
[ ]
[′GCTGCYGCCCTC
[′Rasopathy′]

(RAF1):c.1279A>G

GCACCACTGGG′,

(p.Ser427Gly)

′GGCTGCYGCCCT

CGCACCACTGG′]

NM_002977.3
267607030
SCN9A
[ ]
[′AAGCTCYGAGG
[′Primary

(SCN9A):c.29A>G

TCCTGGGGGAGG′]
erythromelalgia′]

(p.Gln10Arg)

NM_016955.3
267607036
SEPSECS
[ ]
[ ]
[′Pontocerebellar

(SEPSECS):c.1001A>G

hypoplasia type 2D′]

(p.Tyr334Cys)

NM_007373.3
267607048
SHOC2
[ ]
[′TACYCATGGTGA
[′Noonan-like

(SHOC2):c.4A>G

CTCAAGCCTGG′]
syndrome with loose

(p.Ser2Gly)

anagen hair′,

′Rasopathy′]

NM_005633.3
730881044
SOS1
[ ]
[ ]
[′Rasopathy′]

(SOS1):c.1430A>G

(p.Gln477Arg)

NM_007375.3
267607102
TARDBP
[ ]
[ ]
[′FRONTOTEMPORAL

(TARDBP):c.787A>G

DEMENTIA

(p.Lys263Glu)

WITH TDP43

INCLUSIONS,

TARDBP-

RELATED′]

NM_003286.2
267607131
—
[ ]
[ ]
[ ]

(TOP1):c.1598A>G

(p.Asp533Gly)

NM_021625.4
267607150
TRPV4
[ ]
[ ]
[′Spondyloepiphyseal

(TRPV4):c.1805A>G

dysplasia

(p.Tyr602Cys)

Maroteaux type′]

NM_000551.3
267607170
VHL
[ ]
[ ]
[′Von Hippel-Lindau

(VHL):c.491A>G

syndrome′]

(p.Gln164Arg)

NM_001006657.1
267607174
WDR35
[ ]
[ ]
[′Cranioectodermal

(WDR35):c.1877A>G

dysplasia 2′]

(p.Glu626Gly)

NM_024884.2
267607206
L2HGDH
[ ]
[ ]
[′L-2-

(L2HGDH):c.293A>G

hydroxyglutaric

(p.His98Arg)

aciduria′]

NM_002437.4
267607256
MPV17
[ ]
[ ]
[′Navajo

(MPV17):c.262A>G

neurohepatopathy′]

(p.Lys88Glu)

NM_006888.4
267607277
CALM1
[ ]
[ ]
[′Catecholaminergic

(CALM1):c.293A>G

polymorphic

(p.Asn98Ser)

ventricular

tachycardia′,

′Ventricular

tachycardia,

catecholaminergic

polymorphic, 4′]

NM_000487.5
6151429
ARSA
[ ]
[ ]
[′Metachromatic

(ARSA):c.*96A>G

leukodystrophy′,

′Arylsulfatase A

pseudodeficiency′,

′not provided′]

NM_003122.4
148954387
SPINK1
[ ]
[ ]
[′Hereditary

(SPINK1):c.194+2T>C

pancreatitis′]

NM_000552.3
267607326
VWF
[ ]
[ ]
[′von Willebrand

(VWF):c.3437A>G

disease type 2′, ′not

(p.Tyr1146Cys)

provided′]

NM_000489.4
122445093
ATRX
[ ]
[ ]
[′ATR-X syndrome′]

(ATRX):c.4826A>G

(p.His1609Arg)

NM_000489.4
122445098
ATRX
[ ]
[ ]
[′ATR-X syndrome′]

(ATRX):c.6488A>G

(p.Tyr2163Cys)

NM_000489.4
122445112
ATRX
[ ]
[ ]
[ ]

(ATRX):c.6811A>G

(p.Arg2271Gly)

NM_004380.2
587783486
CREBBP
[ ]
[′GCAGCCCYAGG
[′Rubinstein-Taybi

(CREBBP):c.3983-2A>G

AAGTCCAGAAGG′]
syndrome′]

NM_004380.2
587783497
CREBBP
[ ]
[ ]
[′Rubinstein-Taybi

(CREBBP):c.4508A>G

syndrome′]

(p.Tyr1503Cys)

NM_000051.3
730881357
ATM
[ ]
[′AGCCYACGGGA
[′Hereditary cancer-

(ATM):c.3154-2A>G

AAAGAACTGTGG′]
predisposing

syndrome′]

NM_178151.2
587783518
DCX
[ ]
[ ]
[′Heterotopia′]

(DCX):c.1027-2A>G

NM_178151.2
587783557
DCX
[ ]
[ ]
[′Heterotopia′]

(DCX):c.520A>G

(p.Lys174Glu)

NM_178151.2
587783560
DCX
[ ]
[ ]
[′Heterotopia′]

(DCX):c.538A>G

(p.Lys180Glu)

NM_178151.2
587783570
DCX
[ ]
[ ]
[′Heterotopia′]

(DCX):c.607A>G

(p.Thr203Ala)

NM_001257235.1
398122394
ALG13
[ ]
[ ]
[′Congenital disorder

(ALG13):c.8A>G

of glycosylation type

(p.Asn3Ser)

1s′]

NM_001256864.1
398122404
DNAJC6
[ ]
[′AGGTATCYGAA
[′Parkinson disease

(DNAJC6):c.801-2A>G

ACAGAAGGTTGG′]
19, juvenile-onset′]

NM_001927.3
267607482
DES
[ ]
[′GAATCGTYCTGC
[′Myofibrillar

(DES):c.1024A>G

AGGAGAGGGGG′]
myopathy 1′, ′not

(p.Asn342Asp)

provided′]

NM_001927.3
267607483
DES
[ ]
[ ]
[′Myofibrillar

(DES):c.735+3A>G

myopathy 1′, ′not

provided′]

NM_001927.3
267607498
DES
[ ]
[ ]
[′not provided′]

(DES):c.1333A>G

(p.Thr445Ala)

NM_005249.4
587783641
FOXG1
[ ]
[ ]
[′Rett syndrome,

(FOXG1):c.757A>G

congenital variant′]

(p.Asn253Asp)

NM_000252.2
587783789
MTM1
[ ]
[ ]
[′Severe X-linked

(MTM1):c.1406A>G

myotubular

(p.His469Arg)

myopathy′]

NM_000391.3
796053439
TPP1
[ ]
[′CAGGTACYGCA
[′not provided′]

(TPP1):c.833A>G

CATCTAGACTGG′]

(p.Gln278Arg)

NM_000252.2
587783818
MTM1
[ ]
[ ]
[′Severe X-linked

(MTM1):c.301A>G

myotubular

(p.Ser101Gly)

myopathy′]

NM_000252.2
587783821
MTM1
[ ]
[ ]
[′Severe X-linked

(MTM1):c.343-2A>G

myotubular

myopathy′]

NM_000252.2
587783831
MTM1
[ ]
[ ]
[′Severe X-linked

(MTM1):c.529-2A>G

myotubular

myopathy′]

NM_000252.2
587783835
MTM1
[ ]
[′GTTATTCYCCAA
[′Severe X-linked

(MTM1):c.550A>G

TGGTGATTGGG′]
myotubular

(p.Arg184Gly)

myopathy′]

NM_000158.3
192044702
GBE1
[ ]
[ ]
[′Glycogen storage

(GBE1):c.691+2T>C

disease, type IV′]

NM_000252.2
587783842
MTM1
[ ]
[′TCATCAYCTGAG
[′Severe X-linked

(MTM1):c.629A>G

GCACGATACGG′]
myotubular

(p.Asp210Gly)

myopathy′]

NM_000249.3
267607760
MLH1
[ ]
[ ]
[′Hereditary

(MLH1):c.545+3A>G

Nonpolyposis

Colorectal

Neoplasms′]

NM_000249.3
267607767
MLH1
[ ]
[ ]
[′Hereditary

(MLH1):c.589-2A>G

Nonpolyposis

Colorectal

Neoplasms′,

′Hereditary cancer-

predisposing

syndrome′]

NM_000249.3
267607777
MLH1
[ ]
[′TGCTACAYTACC
[′Hereditary

(MLH1):c.884+4A>G

TGAGGTACAGG′]
Nonpolyposis

Colorectal

Neoplasms′]

NM_000081.3
80338669
LYST
[ ]
[ ]
[′Ch\xc3\xa9diak-

(LYST):c.10127A>G

Higashi syndrome′]

(p.Asn3376Ser)

NM_000528.3
80338678
MAN2B1
[ ]
[ ]
[′Deficiency of

(MAN2B1):c.1831-2A>G

alpha-mannosidase′]

NM_022132.4
119103225
MCCC2
[ ]
[ ]
[′3-methylcrotonyl

(MCCC2):c.569A>G

CoA carboxylase 2

(p.His190Arg)

deficiency′]

m.3260A>G
199474663
MT-TL1
[′TTAAGTT
[′TTAAGTTYTATG
[′Cardiomyopathy

YTATGCGA
CGATTACCGGG′]
with or without

TTACCGGG′]

skeletal myopathy′]

NM_014874.3
119103264
MFN2
[ ]
[ ]
[′Hereditary motor

(MFN2):c.827A>G

and sensory

(p.Gln276Arg)

neuropathy with

optic atrophy′]

NM_004525.2
80338743
LRP2
[ ]
[ ]
[′Donnai Barrow

(LRP2):c.770-2A>G

syndrome′]

NM_005120.2
80338759
MED12
[ ]
[ ]
[′X-linked mental

(MED12):c.3020A>G

retardation with

(p.Asn1007Ser)

marfanoid habitus

syndrome′]

NM_000834.3
398122824
GRIN2B
[ ]
[ ]
[′Mental retardation,

(GRIN2B):c.2172-2A>G

autosomal dominant

6′]

NM_000249.3
267607883
MLH1
[ ]
[ ]
[′Hereditary

(MLH1):c.1990-2A>G

Nonpolyposis

Colorectal

Neoplasms′, ′not

provided′]

NM_000518.4
33972047
HBB
[ ]
[′CACGYTCACCTT
[′alpha Thalassemia′]

(HBB):c.59A>G

GCCCCACAGGG′,

(p.Asn20Ser)

′CCACGYTCACCT

TGCCCCACAGG′]

NM_003688.3
398122844
CASK
[ ]
[ ]
[′FG syndrome 4′,

(CASK):c.2168A>G

′Mental retardation

(p.Tyr723Cys)

and microcephaly

with pontine and

cerebellar

hypoplasia′]

NM_024675.3
730881897
PALB2
[ ]
[ ]
[′Hereditary cancer-

(PALB2):c.109-2A>G

predisposing

syndrome′]

NM_000251.2
267607962
MSH2
[ ]
[ ]
[′Hereditary

(MSH2):c.1511-2A>G

Nonpolyposis

Colorectal

Neoplasms′]

NM_003124.4
398122922
SPR
[ ]
[ ]
[Sepiapterin

(SPR):c.596-2A>G

reductase

deficiency′]

NM_022455.4
587784120
NSD1
[ ]
[ ]
[′Sotos syndrome 1′]

(NSD1):c.4498-3A>G

NM_000455.4
730881978
STK11
[ ]
[ ]
[′Hereditary cancer-

(STK11):c.889A>G

predisposing

(p.Arg297Gly)

syndrome′]

NM_001927.3
398122940
DES
[ ]
[ ]
[′Muscular

(DES):c.1289-2A>G

dystrophy, limb-

girdle, type 2r′]

NM_000546.5
730882004
TP53
[ ]
[′ACACAYGTAGTT
[′Li-Fraumeni

(TP53):c.709A>G

GTAGTGGATGG′]
syndrome′,

(p.Met237Val)

′Hereditary cancer-

predisposing

syndrome′]

NM_024876.3
398122979
ADCK4
[ ]
[ ]
[′Nephrotic

(ADCK4):c.857A>G

syndrome, type 9′]

(p.Asp286Gly)

NM_022455.4
587784178
NSD1
[ ]
[ ]
[′Sotos syndrome 1′]

(NSD1):c.6059A>G

(p.Asn2020Ser)

NM_022455.4
587784191
NSD1
[ ]
[ ]
[′Sotos syndrome 1′]

(NSD1):c.6356A>G

(p.Asp2119Gly)

NM_007332.2
398123010
—
[ ]
[ ]
[′Familial episodic

(TRPA1):c.2564A>G

pain syndrome 1′]

(p.Asn855Ser)

NM_001231.4
730882052
CASQ1
[ ]
[′GGCTTGYCTGGG
[′Myopathy,

(CASQ1):c.731A>G

ATGGTCACAGG′]
vacuolar, with casq1

(p.Asp244Gly)

aggregates′]

NM_004004.5
80338949
GJB2
[ ]
[ ]
[′Deafness,

(GJB2):c.487A>G

autosomal recessive

(p.Met163Val)

1A′, ′not specified′]

NM_130466.3
398123022
UBE3B
[ ]
[ ]
[′Kaufman

(UBE3B):c.545-2A>G

oculocerebrofacial

syndrome′]

NM_000334.4
80338959
SCN4A
[ ]
[′GATCAYGATGGT
[′Hyperkalemic

(SCN4A):c.4078A>G

GATGTCGAAGG′]
Periodic Paralysis

(p.Met1360Val)

Type 1′]

NM_000334.4
80338960
SCN4A
[ ]
[′CCATCAYGGTGA
[′Hyperkalemic

(SCN4A):c.4108A>G

CCATGTTGAGG′]
Periodic Paralysis

(p.Met1370Val)

Type 1′]

NM_000334.4
80338962
SCN4A
[ ]
[′TGTACAYGTTGA
[′Hyperkalemic

(SCN4A):c.4774A>G

CCACGATGAGG′]
Periodic Paralysis

(p.Met1592Val)

Type 1′, ′Familial

hyperkalemic

periodic paralysis′]

NM_015250.3
398123030
BICD2
[ ]
[ ]
[′Spinal muscular

(BICD2):c.2321A>G

atrophy, lower

(p.Glu774Gly)

extremity

predominant 2,

autosomal

dominant′]

NM_006012.2
398123035
CLPP
[ ]
[ ]
[′Autosomal

(CLPP):c.270+4A>G

recessive hearing

impairment with

normal menstrual

cycles′]

NM_000179.2
267608098
MSH6
[ ]
[ ]
[′Hereditary

(MSH6):c.3439-2A>G

Nonpolyposis

Colorectal

Neoplasms′,

′Hereditary cancer-

predisposing

syndrome′, ′not

provided′]

NM_002246.2
398123043
KCNK3
[ ]
[ ]
[′Primary pulmonary

(KCNK3):c.575A>G

hypertension 4′]

(p.Tyr192Cys)

NM_001070.4
398123046
TUBG1
[ ]
[ ]
[′Cortical dysplasia,

(TUBG1):c.275A>G

complex, with other

(p.Tyr92Cys)

brain malformations

4′]

NM_000383.3
179363882
AIRE
[ ]
[ ]
[′Polyglandular

(AIRE):c.254A>G

autoimmune

(p.Tyr85Cys)

syndrome, type 1′,

′not provided′]

NM_001651.3
398123057
AQP5
[ ]
[ ]
[′Diffuse

(AQP5):c.367A>G

palmoplantar

(p.Asn123Asp)

keratoderma,

Bothnian type′]

NM_012160.4
398123062
FBXL4
[ ]
[′TATGYCCAGCTG
[′Mitochondrial

(FBXL4):c.1694A>G

CTGTAACCTGG′]
DNA depletion

(p.Asp565Gly)

syndrome 13

(encephalomyopathic

type)′]

NM_024531.4
398123068
SLC52A2
[ ]
[ ]
[Brown-Vialetto-

(SLC52A2):c.914A>G

Van Laere syndrome

(p.Tyr305Cys)

2′]

NM_001039550.1
730882140
DNAJB2
[ ]
[′GATCTCGYAGTA
[′Charcot-Marie-

(DNAJB2):c.14A>G

GGATGCCATGG′]
Tooth disease′,

(p.Tyr5Cys)

′Charcot-Marie-

Tooth disease,

axonal, type 2T′]

NM_052859.3
796053522
RFT1
[ ]
[′GCAYCACAAAA
[′Congenital disorder

(RFT1):c.1222A>G

TTGTACCTGGGG′,
of glycosylation type

(p.Met408Val)

′AGCAYCACAAAA
1N′]

TTGTACCTGGG′,

′CAGCAYCACAAA

ATTGTACCTGG′]

NM_007294.3
730882166
BRCA1
[ ]
[ ]
[′Breast-ovarian

(BRCA1):c.5057A>G

cancer, familial 1′]

(p.His1686Arg)

NM_000050.4
398123130
ASS1
[ ]
[ ]
[′Citrullinemia type

(ASS1):c.496-2A>G

I′]

NM_012233.2
730882183
RAB3GAP1
[ ]
[ ]
[′Warburg micro

(RAB3GAP1):c.649-2A>G

syndrome 1′]

NM_000159.3
398123194
GCDH
[ ]
[ ]
[′Glutaric aciduria,

(GCDH):c.542A>G

type 1′, ′not

(p.Glu181Gly)

provided′]

NM_000288.3
267608255
PEX7
[ ]
[ ]
[′Phytanic acid

(PEX7):c.340-10A>G

storage disease′,

′Peroxisome

biogenesis disorder

9B′]

NM_000038.5
786201291
APC
[ ]
[ ]
[′Hereditary cancer-

(APC):c.221-2A>G

predisposing

syndrome′]

NM_000169.2
398123210
—
[ ]
[ ]
[′Fabry disease′]

(GLA):c.509A>G

(p.Asp170Gly)

NM_000169.2
398123211
—
[ ]
[′AACCYGTATGA
[′Fabry disease′]

(GLA):c.548-2A>G

GAAAACAATGGG′,

′TAACCYGTATGA

GAAAACAATGG′]

NM_006888.4
730882252
CALM1
[ ]
[ ]
[′Long QT syndrome

(CALM1):c.389A>G

14′]

(p.Asp130Gly)

NM_000169.2
398123217
—
[ ]
[ ]
[′Fabry disease′]

(GLA):c.647A>G

(p.Tyr216Cys)

NM_006306.3
587784423
SMC1A
[ ]
[′AGCCYGTGCAA
[′Congenital

(SMC1A):c.616-2A>G

ACAGGGGAATGG′]
muscular

hypertrophy-cerebral

syndrome′]

NM_000255.3
398123276
MUT
[ ]
[ ]
[′Methylmalonic

(MUT):c.1445-2A>G

aciduria due to

methylmalonyl-CoA

mutase deficiency′,

′not provided′]

NM_001083962.1
587784470
TCF4
[ ]
[ ]
[′Pitt-Hopkins

(TCF4):c.991-2A>G

syndrome′]

NM_000060.3
201023772
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.1205A>G

deficiency′]

(p.Asn402Ser)

NC_000007.14:
483352872
—
[ ]
[ ]
[′Isolated growth

g.62535490A>G

hormone deficiency

type 1B′]

NM_000271.4
483352887
NPC1
[ ]
[ ]
[′Niemann-Pick

(NPC1):c.1832A>G

disease type C1′]

(p.Asp611Gly)

NM_152419.2
483352896
HGSNAT
[ ]
[ ]
[′Mucopolysaccharidosis,

(HGSNAT):c.372-2A>G

MPS-III-C′]

NM_001199397.1
483352906
NEK1
[ ]
[ ]
[′Short rib-

(NEK1):c.869-2A>G

polydactyly

syndrome, Majewski

type′]

NM_000350.2
398123339
ABCA4
[ ]
[ ]
[′Stargardt disease

(ABCA4):c.67-2A>G

1′]

NM_004992.3
267608412
MECP2
[ ]
[ ]
[′Rett disorder′, ′not

(MECP2):c.27-2A>G

provided′]

NM_003159.2
267608423
CDKL5
[ ]
[ ]
[′Early infantile

(CDKL5):c.100-2A>G

epileptic

encephalopathy 2′,

′not provided′]

NM_003159.2
267608429
CDKL5
[ ]
[ ]
[′Early infantile

(CDKL5):c.125A>G

epileptic

(p.Lys42Arg)

encephalopathy 2′,

′not provided′]

NM_000487.5
398123411
ARSA
[ ]
[′GGCTCYGGGGG
[′Metachromatic

(ARSA):c.1108-2A>G

CAGAGTCAGGGG′,
leukodystrophy′]

′GGGCTCYGGGGG

CAGAGTCAGGG′,

′AGGGCTCYGGGG

GCAGAGTCAGG′]

NM_003159.2
267608468
CDKL5
[ ]
[ ]
[′Atypical Rett

(CDKL5):c.380A>G

syndrome′, ′not

(p.His127Arg)

provided′]

NM_000489.4
398123420
ATRX
[ ]
[ ]
[′not provided′]

(ATRX):c.134-2A>G

NM_003159.2
267608480
CDKL5
[ ]
[ ]
[′Early infantile

(CDKL5):c.464-2A>G

epileptic

encephalopathy 2′,

′not provided′]

NM_000489.4
398123425
ATRX
[ ]
[ ]
[′not provided′]

(ATRX):c.536A>G

(p.Asn179Ser)

NM_000512.4
398123429
GALNS
[ ]
[′CCGCCAYCAGC
[′Mucopolysaccharidosis,

(GALNS):c.1171A>G

GTGTCGCCACGG′]
MPS-IV-A′,

(p.Met391Val)

′not provided′]

NM_003159.2
267608500
CDKL5
[ ]
[′ATGYCCACGGA
[′Early infantile

(CDKL5):c.578A>G

CTTTCCATAGGG′,
epileptic

(p.Asp193Gly)

′CATGYCCACGGA
encephalopathy 2′]

CTTTCCATAGG′]

NM_000521.3
398123446
HEXB
[ ]
[ ]
[′Sandhoff disease′,

(HEXB):c.1243-2A>G

′not provided′]

NM_003159.2
267608553
CDKL5
[ ]
[ ]
[′Early infantile

(CDKL5):c.978-2A>G

epileptic

encephalopathy 2′,

′not provided′]

NM_001164342.2
483353066
ZBTB20
[ ]
[ ]
[′Primrose

(ZBTB20):c.1787A>G

syndrome′]

(p.His596Arg)

NM_000402.4
398123552
—
[ ]
[′ACACACAYATTC
[′Anemia,

(G6PD):c.188T>C

ATCATCATGGG′]
nonspherocytic

(p.Ile63Thr)

hemolytic, due to

G6PD deficiency′,

′not provided′]

NM_001893.4
104894561
CSNK1D
[ ]
[ ]
[′Advanced sleep

(CSNK1D):c.130A>G

phase syndrome,

(p.Thr44Ala)

familial, 2′]

NM_000155.3
75391579
GALT
[ ]
[′TTACCYGGCAGT
[′Deficiency of

(GALT):c.563A>G

GGGGGTGGGGG′,
UDPglucose-

(p.Gln188Arg)

′CTTACCYGGCAG
hexose-1-phosphate

TGGGGGTGGGG′,
uridylyltransferase′,

′CCTTACCYGGCA
′not provided′]

GTGGGGGTGGG′]

NM_007055.3
267608671
POLR3A
[ ]
[ ]
[′Hypomyelinating

(POLR3A):c.2554A>G

leukodystrophy 7′]

(p.Met852Val)

NM_001848.2
398123639
COL6A1
[ ]
[′TTCTCCCYGGAA
[′Ullrich congenital

(COL6A1):c.805-2A>G

CACAAAACAGG′]
muscular dystrophy′,

′Bethlem myopathy′,

′not provided′]

NM_001918.3
398123674
DBT
[ ]
[ ]
[′Maple syrup urine

(DBT):c.773-2A>G

disease′, ′not

provided′]

NM_001999.3
149054177
FBN2
[′GAATGTA
[′GAATGTAYGAT
[′not specified′,

(FBN2):c.3740T>C

YGATAATG
AATGAACGGAGG′]
′Macular

(p.Met1247Thr)

AACGGAG

degeneration, early-

G′]

onset′]

NM_003482.3
398123750
KMT2D
[ ]
[′GCAGTTCYGTGG
[′Kabuki make-up

(KMT2D):c.5645-2A>G

GGGAATGAAGG′]
syndrome′, ′not

provided′]

NM_003494.3
398123769
DYSF
[ ]
[ ]
[′Limb-girdle

(DYSF):c.1398-2A>G

muscular dystrophy,

type 2B′, ′not

provided′]

NM_015560.2
143319805
OPA1
[ ]
[ ]
[′Dominant

(OPA1):c.1146A>G

hereditary optic

(p.Ile382Met)

atrophy′, ′Optic

Atrophy Type 1′,

′not specified′, ′not

provided′]

NM_203447.3
112321280
DOCK8
[ ]
[ ]
[′Hyperimmunoglobulin

(DOCK8):c.1418A>G

E recurrent

(p.Lys473Arg)

infection syndrome,

autosomal

recessive′]

NM_001145.4
121909537
—
[′TGGTTYG
[′TGGTTYGGCATC
[′Amyotrophic

(ANG):c.121A>G

GCATCATA
ATAGTGCTGGG′,
lateral sclerosis type

(p.Lys41Glu)

GTGCTGGG,
′GTGGTTYGGCAT
9′]

′GTGGTTYG
CATAGTGCTGG′]

GCATCATA

GTGCTGG′]

NM_004006.2
398123938
DMD
[ ]
[ ]
[′Dilated

(DMD):c.3432+3A>G

cardiomyopathy 3B′]

NM_006514.3
138404783
SCN10A
[ ]
[ ]
[′Episodic pain

(SCN10A):c.1661T>C

syndrome, familial,

(p.Leu554Pro)

2′]

NM_004006.2
398124033
DMD
[ ]
[ ]
[′Dilated

(DMD):c.6763-2A>G

cardiomyopathy 3B′]

NM_001079802.1
119464998
FKTN
[ ]
[ ]
[ ]

(FKTN):c.1112A>G

(p.Tyr371Cys)

NM_004006.2
398124084
DMD
[ ]
[ ]
[′Dilated

(DMD):c.9224+61934A>G

cardiomyopathy 3B′]

NM_004006.2
398124091
DMD
[ ]
[ ]
[′Duchenne

(DMD):c.9225-647A>G

muscular dystrophy′,

′Becker muscular

dystrophy′, ′Dilated

cardiomyopathy 3B′]

NM_004006.2
398124100
DMD
[ ]
[ ]
[′Duchenne

(DMD):c.9650-2A>G

muscular dystrophy′,

′Becker muscular

dystrophy′, ′Dilated

cardiomyopathy 3B′]

NM_198578.3
35808389
LRRK2
[ ]
[ ]
[′Parkinson disease

(LRRK2):c.3342A>G

8, autosomal

(p.Leu1114=)

dominant′]

NM_031229.2
566912235
RBCK1
[ ]
[ ]
[′Polyglucosan body

(RBCK1):c.1160A>G

myopathy 1 with or

(p.Asn387Ser)

without

immunodeficiency′]

NM_000178.2
28938472
GSS
[ ]
[ ]
[′Glutathione

(GSS):c.656A>G

synthetase

(p.Asp219Gly)

deficiency of

erythrocytes,

hemolytic anemia

due to′]

NM_025132.3
374400438
WDR19
[ ]
[ ]
[SENIOR-LOKEN

(WDR19):c.407-2A>G

SYNDROME 8′]

NM_144997.5
398124528
FLCN
[ ]
[′CCCACYGGGGA
[′Hereditary cancer-

(FLCN):c.1433-2A>G

GAAGGGCAGGGG′,
predisposing

′GCCCACYGGGGA
syndrome′, ′not

GAAGGGCAGGG′,
provided′]

′GGCCCACYGGGG

AGAAGGGCAGG′]

NM_144997.5
398124533
FLCN
[ ]
[ ]
[′not provided′]

(FLCN):c.250-2A>G

NM_000146.3
398124633
FTL
[ ]
[ ]
[Hyperferritinemia

(FTL):c.-160A>G

cataract syndrome′]

NM_003184.3
398124645
TAF2
[ ]
[ ]
[′Mental retardation,

(TAF2):c.1945T>C

autosomal recessive

(p.Trp649Arg)

40′]

NM_013281.3
398124654
—
[ ]
[ ]
[′Hypogonadotropic

(FLRT3):c.1016A>G

hypogonadism 21

(p.Lys339Arg)

with or without

anosmia′]

NM_002834.3
397507523
PTPN11
[ ]
[ ]
[′Noonan syndrome

(PTPN11):c.767A>G

1′, ′Rasopathy′, ′not

(p.Gln256Arg)

provided′]

NM_000054.4
104894749
AVPR2
[′ACAYAGG
[′ACAYAGGTGCG
[′Nephrogenic

(AVPR2):c.614A>G

TGCGACGG
ACGGCCCCAGGG′,
diabetes insipidus′,

(p.Tyr205Cys)

CCCCAGGG,
′GACAYAGGTGCG
′Nephrogenic

′GACAYAG
ACGGCCCCAGG′]
diabetes insipidus,

GTGCGACG

X-linked′]

GCCCCAGG′]

NM_031157.2
397518454
HNRNPA1
[ ]
[ ]
[′Amyotrophic

(HNRNPA1):c.956A>G

lateral sclerosis 20′]

(p.Asn319Ser)

NM_000277.1
62514934
PAH
[ ]
[ ]
[′Phenylketonuria′,

(PAH):c.662A>G

′not provided′]

(p.Glu221Gly)

NM_000219.5
141813529
KCNE1
[ ]
[ ]
[′Congenital long

(KCNE1):c.176T>C

QT syndrome′]

(p.Leu59Pro)

NM_001165963.1
794726713
SCN1A
[ ]
[ ]
[′Severe myoclonic

(SCN1A):c.1076A>G

epilepsy in infancy′]

(p.Asn359Ser)

NM_013339.3
35383149
ALG6
[ ]
[ ]
[′Congenital disorder

(ALG6):c.391T>C

of glycosylation type

(p.Tyr131His)

1C′, ′not specified′]

NM_153767.3
59172778
KCNJ1
[ ]
[ ]
[′Bartter syndrome

(KCNJ1):c.1013T>C

antenatal type 2′]

(p.Met338Thr)

NM_176824.2
119466001
BBS7
[ ]
[ ]
[′Bardet-Biedl

(BBS7):c.968A>G

syndrome 7′]

(p.His323Arg)

NM_000199.3
138504221
SGSH
[ ]
[ ]
[′Mucopolysaccharidosis,

(SGSH):c.892T>C

MPS-III-A′,

(p.Ser298Pro)

′not provided′]

NM_000891.2
199473652
KCNJ2

[′Congenital long

(KCNJ2):c.220A>G

QT syndrome′]

(p.Thr74Ala)

NM_001165963.1
794726768
SCN1A
[′ACAYATA
[′ACAYATATCCCT
[′Severe myoclonic

(SCN1A):c.1048A>G

TCCCTCTG
CTGGACATTGG′]
epilepsy in infancy′]

(p.Met350Val)

GACATTGG′]

NM_002863.4
113993976
PYGL
[ ]
[ ]
[′Glycogen storage

(PYGL):c.1016A>G

disease, type VI′]

(p.Asn339Ser)

NM_001165963.1
794726794
SCN1A
[ ]
[ ]
[′Severe myoclonic

(SCN1A):c.2537A>G

epilepsy in infancy′]

(p.Glu846Gly)

NM_002693.2
113994099
POLG
[ ]
[ ]
[′Autosomal

(POLG):c.2864A>G

dominant

(p.Tyr955Cys)

progressive external

ophthalmoplegia

with mitochondrial

DNA deletions 1′]

NM_000920.3
113994144
PC
[ ]
[ ]
[′Pyruvate

(PC):c.1705A>G

carboxylase

(p.Thr569Ala)

deficiency′]

NM_025265.3
113994149
TSEN2
[ ]
[′CAGAGCAYAGA
[′Pontocerebellar

(TSEN2):c.926A>G

CCAAGAAAAAGG′]
hypoplasia type 2B′]

(p.Tyr309Cys)

NM_001039958.1
113994156
MESP2
[ ]
[ ]
[′Spondylocostal

(MESP2):c.271A>G

dysostosis 2′]

(p.Lys91Glu)

NM_024649.4
113994180
—
[ ]
[ ]
[′Bardet-Biedl

(BBS1):c.1340-2A>G

syndrome′]

NM_033028.4
113994192
BBS4
[ ]
[ ]
[′Bardet-Biedl

(BBS4):c.157-2A>G

syndrome′, ′Bardet-

Biedl syndrome 4′]

NM_212472.2
281864779
PRKAR1A
[ ]
[ ]
[′Carney complex,

(PRKAR1A):c.1A>G

type 1′]

(p.Met1Val)

NM_212472.2
281864796
PRKAR1A
[ ]
[ ]
[′Carney complex,

(PRKAR1A):c.178-2A>G

type 1′]

NM_212472.2
281864799
PRKAR1A
[ ]
[ ]
[′Carney complex,

(PRKAR1A):c.891+3A>G

type 1′]

NM_001165963.1
794726849
SCN1A
[ ]
[ ]
[′Severe myoclonic

(SCN1A):c.433A>G

epilepsy in infancy′]

(p.Met145Val)

NM_005710.2
121917899
PQBP1
[ ]
[ ]
[′Renpenning

(PQBP1):c.194A>G

syndrome 1′]

(p.Tyr65Cys)

NM_000921.4
794726865
PDE3A
[′CGAGGYG
[′CGAGGYGGTGG
[′Brachydactyly with

(PDE3A):c.1333A>G

GTGGTGGT
TGGTCCAAGTGG′]
hypertension′]

(p.Thr445Ala)

CCAAGTGG′]

NM_024312.4
281864974
GNPTAB
[ ]
[ ]
[′Pseudo-Hurler

(GNPTAB):c.1285-2A>G

polydystrophy′]

NM_024312.4
281865003
GNPTAB
[ ]
[ ]
[′I cell disease′]

(GNPTAB):c.2783A>G

(p.Lys928Arg)

NM_024312.4
281865005
GNPTAB
[ ]
[ ]
[′Pseudo-Hurler

(GNPTAB):c.2867A>G

polydystrophy′]

(p.His956Arg)

NM_024312.4
281865007
GNPTAB
[ ]
[ ]
[′I cell disease′]

(GNPTAB):c.3053A>G

(p.Asp1018Gly)

NM_024312.4
281865019
GNPTAB
[ ]
[ ]
[′Pseudo-Hurler

(GNPTAB):c.3458A>G

polydystrophy′]

(p.Asn1153Ser)

NM_024312.4
281865023
GNPTAB
[ ]
[ ]
[′I cell disease′]

(GNPTAB):c.118-2A>G

NM_198578.3
281865052
LRRK2
[ ]
[′TCAACAYAATAT
[′Parkinson disease

(LRRK2):c.5605A>G

TTCTAGGCAGG′]
8, autosomal

(p.Met1869Val)

dominant′]

NM_139241.3
281865065
FGD4
[ ]
[ ]
[′Charcot-Marie-

(FGD4):c.1762-2A>G

Tooth disease, type

4H′]

NM_006121.3
58420087
KRT1
[ ]
[ ]
[′Bullous

(KRT1):c.1445A>G

ichthyosiform

(p.Tyr482Cys)

erythroderma′, ′not

provided′]

NM_000195.4
281865080
HPS1
[ ]
[ ]
[′Hermansky-Pudlak

(HPS1):c.716T>C

syndrome 1′]

(p.Leu239Pro)

NM_000195.4
281865090
HPS1
[ ]
[ ]
[′Hermansky-Pudlak

(HPS1):c.2003T>C

syndrome 1′]

(p.Leu668Pro)

NM_022081.5(HPS4):
281865098
HPS4
[ ]
[ ]
[′Hermansky-Pudlak

c.461A>G

syndrome 4′]

(p.His154Arg)

NM_000277.1
62516141
PAH
[ ]
[ ]
[′Phenylketonuria′,

(PAH):c.1157A>G

′not provided′]

(p.Tyr386Cys)

NM_025114.3
281865192
CEP290
[′GAGATAY
[′GATAYTCACAAT
[′Leber congenital

(CEP290):c.2991+1655A>G

TCACAATT
TACAACTGGGG′,
amaurosis 10′, ′not

ACAACTGG′]
′AGATAYTCACAA
provided′]

TTACAACTGGG′,

′GAGATAYTCACA

ATTACAACTGG′]

NM_018319.3
119467003
TDP1
[ ]
[ ]
[′Spinocerebellar

(TDP1):c.1478A>G

ataxia autosomal

(p.His493Arg)

recessive with

axonal neuropathy′]

NM_000051.3
774925473
ATM
[ ]
[ ]
[′Ataxia-

(ATM):

telangiectasia

c.5762_5763insNG_009830.1:

variant′]

g.91138_91274

NM_004614.4
281865495
TK2
[ ]
[′AAGYCTCAGGA
[′Mitochondrial

(TK2):c.562A>G

TTGGTCCGAAGG′]
DNA depletion

(p.Thr188Ala)

syndrome 2′]

NM_003494.3
756328339
DYSF
[ ]
[′CTAYACTCCCAG
[′Limb-girdle

(DYSF):c.3041A>G

CCTGGGGGAGG′,
muscular dystrophy,

(p.Tyr1014Cys)

′ATGCTAYACTCC
type 2B′]

CAGCCTGGGGG′,

′GATGCTAYACTC

CCAGCCTGGGG′]

NM_000531.5
72558492
OTC
[′AGGTGAG
[′AGGTGAGYAAT
[′not provided′]

(OTC):c.1034A>G

YAATCTGT
CTGTCAGCAGGG′]

(p.Tyr345Cys)

CAGCAGGG′]

NM_000518.4
34165323
HBB
[ ]
[ ]
[′Hemoglobinopathy′]

(HBB):c.199A>G

(p.Lys67Glu)

NM_153427.2
387906810
PITX2
[ ]
[′TCTYGAACCAAA
[′Axenfeld-Rieger

(PITX2):c.262A>G

CCTGGGGGCGG′,
syndrome type 1′]

(p.Lys88Glu)

′GATTCTYGAACC

AAACCTGGGGG′,

′CGATTCTYGAAC

CAAACCTGGGG′]

NM_030964.3
78310959
SPRY4
[ ]
[′AGTGCYTGTCCA
[′Hypogonadotropic

(SPRY4):c.530A>G

GCTCGGGTGGG′,
hypogonadism 17

(p.Lys177Arg)

′AAGTGCYTGTCC
with or without

AGCTCGGGTGG′]
anosmia′]

NM_002834.3
28933386
PTPN11
[ ]
[ ]
[′Noonan syndrome′,

(PTPN11):c.922A>G

′Noonan syndrome

(p.Asn308Asp)

1′, ′Rasopathy′, ′not

provided′]

NM_000518.4
34598529
HBB
[ ]
[ ]
[′alpha Thalassemia′,

(HBB):c.-50-29A>G

′Beta thalassemia

intermedia′]

NM_207352.3
144109267
CYP4V2
[ ]
[′TTCCYGGGGCCA
[′Bietti crystalline

(CYP4V2):c.1393A>G

GCAGAGAAGGG′,
corneoretinal

(p.Arg465Gly)

′GTTCCYGGGGCC
dystrophy′]

AGCAGAGAAGG′]

NM_001360.2
104886033
DHCR7
[ ]
[ ]
[′Smith-Lemli-Opitz

(DHCR7):c.1A>G

syndrome′]

(p.Met1Val)

NM_000495.4
104886050
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.1A>G

X-linked recessive′]

(p.Met1Val)

NM_000495.4
104886192
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.2692A>G

X-linked recessive′]

(p.Met898Val)

NM_000495.4
104886193
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.2746A>G

X-linked recessive′]

(p.Ser916Gly)

NM_004572.3
144601090
PKP2
[ ]
[ ]
[′Arrhythmogenic

(PKP2):c.2062T>C

right ventricular

(p.Ser688Pro)

cardiomyopathy′,

′not specified′, ′not

provided′]

NM_000495.4
104886298
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.4790A>G

X-linked recessive′]

(p.Tyr1597Cys)

NM_000495.4
104886319
COL4A5
[ ]
[′CACCYGAGTAA
[′Alport syndrome,

(COL4A5):c.1340-2A>G

GATAAAGAAAGG′]
X-linked recessive′]

NM_000495.4
104886341
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.2042-18A>G

X-linked recessive′]

NM_000495.4
104886344
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.2147-2A>G

X-linked recessive′]

NM_000495.4
104886358
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.2510-33A>G

X-linked recessive′]

NM_000495.4
104886379
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.3107-2A>G

X-linked recessive′]

NM_000051.3
121434221
ATM
[ ]
[ ]
[′Mantle cell

(ATM):c.7268A>G

lymphoma′]

(p.Glu2423Gly)

NM_000495.4
104886385
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.3605-2A>G

X-linked recessive′]

NM_000096.3
386134137
CP
[ ]
[ ]
[′Deficiency of

(CP):c.1209-2A>G

ferroxidase′]

NM_000348.3
121434251
SRD5A2
[ ]
[ ]
[′3-Oxo-5 alpha-

(SRD5A2):c.692A>G

steroid delta 4-

(p.His231Arg)

dehydrogenase

deficiency′]

NM_002739.3
386134157
PRKCG
[ ]
[ ]
[′Spinocerebellar

(PRKCG):c.76A>G

ataxia 14′]

(p.Arg26Gly)

NM_000383.3
121434255
AIRE
[ ]
[ ]
[′AUTOIMMUNE

(AIRE):c.247A>G

POLYENDOCRIN-

(p.Lys83Glu)

OPATHY

SYNDROME,

TYPE I′]

NM_000495.4
104886416
COL4A5
[ ]
[′ACCCYAAAAGA
[′Alport syndrome,

(COL4A5):c.466-2A>G

AGCCATCAATGG′]
X-linked recessive′]

NM_001127328.2
121434279
ACADM
[ ]
[ ]
[′Medium-chain

(ACADM):c.589A>G

acyl-coenzyme A

(p.Thr197Ala)

dehydrogenase

deficiency′]

NM_000495.4
104886453
COL4A5
[ ]
[ ]
[′Alport syndrome,

(COL4A5):c.892-2A>G

X-linked recessive′]

NM_020533.2
104886461
MCOLN1
[′TACYGTG
[′TACYGTGGGCA
[′Ganglioside

(MCOLN1):c.406-2A>G

GGCAGAG
GAGAAGGGGAGG′,
sialidase deficiency′,

AAGGGGA
′AGGTACYGTGGG
′not provided′]

GG′]
CAGAGAAGGGG′,

′CAGGTACYGTGG

GCAGAGAAGGG′]

NM_018136.4
199422149
ASPM
[ ]
[ ]
[′Primary autosomal

(ASPM):c.2761-25A>G

recessive

microcephaly 5′]

NM_017780.3
121434338
CHD7
[ ]
[ ]
[′CHARGE

(CHD7):c.3082A>G

association′, ′not

(p.Ile1028Val)

provided′]

NM_017780.3
121434345
CHD7
[ ]
[ ]
[′Kallmann

(CHD7):c.164A>G

syndrome 5′]

(p.His55Arg)

NM_152783.4
121434362
D2HGDH
[′GCAGGTY
[′GCAGGTYACCAT
[D-2-

(D2HGDH):c.1315A>G

ACCATCTC
CTCCTGGAGGG′,
hydroxyglutaric

(p.Asn439Asp)

CTGGAGGG′,
′TGCAGGTYACCA
aciduria 1′]

′TGCAGGT
TCTCCTGGAGG′]

YACCATCT

CCTGGAGG′]

NM_005006.6
199422224
NDUFS1
[ ]
[ ]
[′Mitochondrial

(NDUFS1):c.755A>G

complex I

(p.Asp252Gly)

deficiency′, ′not

provided′]

NM_002894.2
121434388
RBBP8
[ ]
[ ]
[′Carcinoma of

(RBBP8):c.1009A>G

pancreas′]

(p.Lys337Glu)

NM_004621.5
121434391
TRPC6
[ ]
[ ]
[′Focal segmental

(TRPC6):c.428A>G

glomerulosclerosis

(p.Asn143Ser)

2′]

NM_003705.4
121434396
SLC25A12
[ ]
[ ]
[′Hypomyelination,

(SLC25A12):c.1769A>G

global cerebral′]

(p.Gln590Arg)

NM_001363.4
199422243
DKC1
[ ]
[ ]
[′Dyskeratosis

(DKC1):c.127A>G

congenita X-linked′]

(p.Lys43Glu)

NM_001084.4
121434414
PLOD3
[ ]
[ ]
[′Bone fragility with

(PLOD3):c.668A>G

contractures, arterial

(p.Asn223Ser)

rupture, and

deafness′]

NM_006702.4
121434415
PNPLA6
[ ]
[ ]
[′Spastic paraplegia

(PNPLA6):c.3034A>G

39′]

(p.Met1012Val)

NR_001566.1
199422262
TERC
[ ]
[ ]
[′Dyskeratosis

(TERC):n.48A>G

congenita autosomal

dominant′]

NM_004984.2
121434441
KIF5A
[ ]
[ ]
[′Spastic paraplegia

(KIF5A):c.767A>G

10′]

(p.Asn256Ser)

NM_004984.2
121434443
KIF5A
[ ]
[′GAACAYAGCTTT
[′Spastic paraplegia

(KIF5A):c.827A>G

TCTGGGGGAGG′]
10′]

(p.Tyr276Cys)

m.10438A>G
121434456
MT-TR
[ ]
[ ]
[′Mitochondrial

encephalomyopathy′]

NM_198253.2
199422302
TERT
[ ]
[ ]
[′Aplastic anemia′]

(TERT):c.2537A>G

(p.Tyr846Cys)

m.12320A>G
121434463
MT-TL2
[′TGGAGTY
[′GAGTYGCACCA
[′Mitochondrial

GCACCAAA
AAATTTTTGGGG′,
myopathy′]

ATTTTTGG′]
′GGAGTYGCACCA

AAATTTTTGGG′,

′TGGAGTYGCACC

AAAATTTTTGG′]

m.4317A>G
121434465
MT-TI
[ ]
[ ]
[ ]

m.4269A>G
121434466
MT-TI
[′ACAYATT
[′ACAYATTTCTTA
[ ]

TCTTAGGT
GGTTTGAGGGG′,

TTGAGGGG′,
′GACAYATTTCTT

′GACAYAT
AGGTTTGAGGG′,

TTCTTAGG
′AGACAYATTTCT

TTTGAGGG′]
TAGGTTTGAGG′]

m.4295A>G
121434467
MT-TI
[ ]
[ ]
[′Primary familial

hypertrophic

cardiomyopathy′,

′Deafness,

nonsyndromic

sensorineural,

mitochondrial′]

m.4300A>G
121434470
MT-TI
[ ]
[ ]
[′Primary familial

hypertrophic

cardiomyopathy′]

NM_001099274.1
199422314
TINF2
[ ]
[′TGACTGYGGGG
[′Dyskeratosis

(TINF2):c.850A>G

CGCTCCTTATGG′]
congenita autosomal

(p.Thr284Ala)

dominant′]

NM_004044.6
121434478
ATIC
[ ]
[′AGTGTACYTGAC
[′AICAR

(ATIC):c.1277A>G

AGCAATGGTGG′]
transformylase/IMP

(p.Lys426Arg)

cyclohydrolase

deficiency′]

NM_001099274.1
199422319
TINF2
[ ]
[ ]
[′Dyskeratosis

(TINF2):c.871A>G

congenita autosomal

(p.Arg291Gly)

dominant′]

NM_015474.3
121434521
SAMHD1
[ ]
[ ]
[′Aicardi Goutieres

(SAMHD1):c.760A>G

syndrome 5′]

(p.Met254Val)

NM_001103.3
121434525
ACTN2
[ ]
[ ]
[′Dilated

(ACTN2):c.26A>G

cardiomyopathy

(p.Gln9Arg)

1AA′,

′Cardiomyopathy′,

′Dilated

cardiomyopathy′,

′not specified′]

NM_000155.3
111033765
GALT
[ ]
[′CGCYCAGCAGG
[′Deficiency of

(GALT):c.812A>G

GGTCAGCTCAGG′]
UDPglucose-

(p.Glu271Gly)

hexose-1-phosphate

uridylyltransferase′,

′not provided′]

NM_000316.2
121434597
PTH1R
[ ]
[ ]
[′Metaphyseal

(PTH1R):c.668A>G

chondrodysplasia,

(p.His223Arg)

Jansen type′]

NM_006006.4
121434606
ZBTB16
[ ]
[′GATCAYGGCCG
[′Skeletal defects,

(ZBTB16):c.1849A>G

AGTAGTCCCGGG′,
genital hypoplasia,

(p.Met617Val)

′TGATCAYGGCCG
and mental

AGTAGTCCCGG′]
retardation′]

NM_014305.3
544436734
TGDS
[ ]
[ ]
[′Catel Manzke

(TGDS):c.700T>C

syndrome′]

(p.Tyr234His)

NM_002835.3
121434623
PTPN12
[ ]
[ ]
[′Carcinoma of

(PTPN12):c.182A>G

colon′]

(p.Lys61Arg)

NM_000035.3
369586696
ALDOB
[ ]
[ ]
[′Hereditary

(ALDOB):c.1027T>C

fructosuria′]

(p.Tyr343His)

NM_006180.4
121434633
NTRK2
[ ]
[ ]
[′Obesity,

(NTRK2):c.2165A>G

hyperphagia, and

(p.Tyr722Cys)

developmental

delay′]

NM_000107.2
121434639
DDB2
[ ]
[ ]
[′Xeroderma

(DDB2):c.730A>G

pigmentosum, group

(p.Lys244Glu)

E′]

NM_000017.3
566325901
ACADS
[ ]
[′AGCCCAYGCCG
[′not provided′]

(ACADS):c.1108A>G

CCCAGGATCTGG′]

(p.Met370Val)

NM_001151.3
28999114
SLC25A4
[ ]
[ ]
[′Autosomal

(SLC25A4):c.311A>G

dominant

(p.Asp104Gly)

progressive external

ophthalmoplegia

with mitochondrial

DNA deletions 2′]

NM_012079.5
148665132
DGAT1
[ ]
[′ACCGCGGYGAG
[′Diarrhea 7′]

(DGAT1):c.751+2T>C

GACCTCTGTGGG′]

NM_002036.3
2814778
ACKR1
[ ]
[ ]
[′White blood cell

(ACKR1):c.-67T>C

count quantitative

trait locus 1′]

NM_000492.3
75789129
CFTR
[ ]
[ ]
[′Cystic fibrosis′, ′not

(CFTR):c.1666A>G

specified′]

(p.Ile556Val)

NM_000155.3
111033830
GALT
[ ]
[′TGCYGGCCCATA
[′Deficiency of

(GALT):c.574A>G

CCTGTCAAGGG′,
UDPglucose-

(p.Ser192Gly)

′CTGCYGGCCCAT
hexose-1-phosphate

ACCTGTCAAGG′]
uridylyltransferase′]

NM_174916.2
119477054
UBR1
[ ]
[ ]
[′Johanson-Blizzard

(UBR1):c.407A>G

syndrome′]

(p.His136Arg)

m.3274A>G
199474666
MT-TL1
[ ]
[ ]
[ ]

NM_000060.3
146011150
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.128A>G

deficiency′]

(p.His43Arg)

NM_172107.2
118192202
KCNQ2
[ ]
[ ]
[′Benign familial

(KCNQ2):c.635A>G

neonatal seizures 1′]

(p.Asp212Gly)

NM_006493.2
148862100
CLN5
[ ]
[ ]
[′Ceroid

(CLN5):c.1121A>G

lipofuscinosis

(p.Tyr374Cys)

neuronal 5′]

NM_000060.3
35976361
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.880A>G

deficiency′]

(p.Ile294Val)

NM_000132.3
28933671
F8
[ ]
[ ]
[′Hereditary factor

(F8):c.1226A>G

VIII deficiency

(p.Glu409Gly)

disease′]

NM_000132.3
28933679
F8
[ ]
[′GAGYGCACATCT
[′Hereditary factor

(F8):c.5600A>G

TTTTCCTAGGG′,
VIII deficiency

(p.His1867Arg)

′TGAGYGCACATC
disease′]

TTTTTCCTAGG′]

NM_000266.3
28933685
NDP
[ ]
[ ]
[′Atrophia bulborum

(NDP):c.1A>G

hereditaria′]

(p.Met1Val)

NM_000133.3
137852230
F9
[ ]
[ ]
[′Hereditary factor

(F9):c.278A>G

IX deficiency

(p.Asp93Gly)

disease′]

NM_000133.3
137852234
F9
[ ]
[ ]
[′Hereditary factor

(F9):c.329A>G

IX deficiency

(p.Asp110Gly)

disease′]

NM_000133.3
137852251
F9
[ ]
[′GCTGCAYTGTAG
[′Hereditary factor

(F9):c.917A>G

TTGTGGTGAGG′]
IX deficiency

(p.Asn306Ser)

disease′]

NM_000133.3
137852262
F9
[ ]
[ ]
[′Hereditary factor

(F9):c.1180A>G

IX deficiency

(p.Met394Val)

disease′]

NM_000133.3
137852277
F9
[ ]
[ ]
[′Hereditary factor

(F9):c.1231A>G

IX deficiency

(p.Ser411Gly)

disease′]

NM_000292.2
137852289
PHKA2
[ ]
[ ]
[′Glycogen storage

(PHKA2):c.896A>G

disease type IXa1′]

(p.Asp299Gly)

NM_000292.2
137852295
PHKA2
[ ]
[ ]
[′Glycogen storage

(PHKA2):c.565A>G

disease IXa2′]

(p.Lys189Glu)

NM_000032.4
137852306
ALAS2
[ ]
[ ]
[′Hereditary

(ALAS2):c.1702A>G

sideroblastic

(p.Ser568Gly)

anemia′]

NM_001287223.1
141686175
SCN11A
[ ]
[′CGTGCGCYGTCC
[′Episodic pain

(SCN11A):c.3473T>C

CAGTTTGAAGG′]
syndrome, familial,

(p.Leu1158Pro)

3′]

NM_000402.4
137852331
G6PD
[ ]
[′ATGCGGTYCCAG
[′Favism,

(G6PD):c.583A>G

CCTCTGCTGGG′]
susceptibility to′,

(p.Asn195Asp)

′Anemia,

nonspherocytic

hemolytic, due to

G6PD deficiency′]

NM_000132.3
137852359
F8
[ ]
[ ]
[′Hereditary factor

(F8):c.872A>G

VIII deficiency

(p.Glu291Gly)

disease′]

NM_018718.2
368178632
CEP41
[ ]
[ ]
[′Joubert syndrome

(CEP41):c.107T>C

9/15, digenic′]

(p.Met36Thr)

NM_000132.3
137852362
F8
[ ]
[ ]
[′Hereditary factor

(F8):c.5183A>G

VIII deficiency

(p.Tyr1728Cys)

disease′]

NM_000132.3
137852369
F8
[ ]
[′TAGCCATYGATT
[′Hereditary factor

(F8):c.5821A>G

GCTGGAGAAGG′]
VIII deficiency

(p.Asn1941Asp)

disease′]

NM_000132.3
137852385
F8
[ ]
[ ]
[′Hereditary factor

(F8):c.328A>G

VIII deficiency

(p.Met110Val)

disease′]

NM_000132.3
137852389
F8
[ ]
[′TCAYATTCAGCT
[′Hereditary factor

(F8):c.398A>G

CCTATAGCAGG′]
VIII deficiency

(p.Tyr133Cys)

disease′]

NM_000132.3
137852390
F8
[ ]
[ ]
[′Hereditary factor

(F8):c.404A>G

VIII deficiency

(p.Asp135Gly)

disease′]

NM_000132.3
137852406
F8
[ ]
[′TGAGCAGYAAG
[′Hereditary factor

(F8):c.940A>G

GAAAGTTATTGG′]
VIII deficiency

(p.Thr314Ala)

disease′]

NM_000041.3
28931576
APOE
[ ]
[′ACAGTGYCTGCA
[ ]

(APOE):c.178A>G

CCCAGCGCAGG′]

(p.Thr60Ala)

NM_000132.3
137852420
F8
[ ]
[ ]
[′Hereditary factor

(F8):c.1682A>G

VIII deficiency

(p.Asp561Gly)

disease′]

NM_000132.3
137852429
F8
[′ATGYTGG
[′ATGYTGGAGGCT
[′Hereditary factor

(F8):c.1892A>G

AGGCTTGG
TGGAACTCTGG′]
VIII deficiency

(p.Asn631Ser)

AACTCTGG′]

disease′]

NM_012082.3
28374544
—
[ ]
[ ]
[′Tetralogy of

(ZFPM2):c.1969A>G

Fallot′]

(p.Ser657Gly)

NM_000098.2
74315300
CPT2
[ ]
[ ]
[′CARNITINE

(CPT2):c.638A>G

PALMITOYL-

(p.Asp213Gly)

TRANSFERASE II

DEFICIENCY,

LATE-ONSET′]

NM_000396.3
74315301
CTSK
[ ]
[′GAGYCACATCTT
[′Pyknodysostosis′]

(CTSK):c.990A>G

GGGGAAGCTGG′]

(p.Ter330Trp)

NM_000132.3
137852454
F8
[ ]
[ ]
[′Hereditary factor

(F8):c.6113A>G

VIII deficiency

(p.Asn2038Ser)

disease′]

NM_000132.3
137852457
F8
[ ]
[ ]
[′Hereditary factor

(F8):c.6278A>G

VIII deficiency

(p.Asp2093Gly)

disease′]

NM_024009.2
74315320
GJB3
[′CAAYGAT
[′CAAYGATGAGC
[′Deafness,

(GJB3):c.421A>G

GAGCTTGA
TTGAAGATGAGG′]
autosomal

(p.Ile141Val)

AGATGAGG′]

recessive′]

NM_000132.3
137852476
F8
[ ]
[ ]
[′Hereditary factor

(F8):c.104A>G

VIII deficiency

(p.Tyr35Cys)

disease′]

NM_000194.2
137852479
HPRT1
[ ]
[ ]
[′Partial

(HPRT1):c.602A>G

hypoxanthine-

(p.Asp201Gly)

guanine

phosphoribosyl-

transferase deficiency′]

NM_000261.1
74315336
MYOC
[ ]
[ ]
[′Primary open angle

(MYOC):c.1267A>G

glaucoma juvenile

(p.Lys423Glu)

onset 1′]

NM_014625.3
74315346
NPHS2
[ ]
[ ]
[′Nephrotic

(NPHS2):c.479A>G

syndrome,

(p.Asp160Gly)

idiopathic, steroid-

resistant′]

NM_000194.2
137852502
HPRT1
[ ]
[ ]
[′Partial

(HPRT1):c.155A>G

hypoxanthine-

(p.Asp52Gly)

guanine

phosphoribosyl-

transferase deficiency′]

NM_002764.3
137852540
PRPS1
[ ]
[′TAGCATAYTTGC
[′Phosphoribosyl-

(PRPS1):c.341A>G

AACAAGCTTGG′]
pyrophosphate

(p.Asn114Ser)

synthetase

superactivity′]

NM_000055.2
1799807
BCHE
[ ]
[ ]
[′Postanesthetic

(BCHE):c.293A>G

apnea′]

(p.Asp98Gly)

NM_170784.2
74315399
MKKS
[ ]
[ ]
[′Bardet-Biedl

(MKKS):c.169A>G

syndrome 6′]

(p.Thr57Ala)

NM_000311.3
74315406
PRNP
[ ]
[ ]
[′Gerstmann-

(PRNP):c.650A>G

Straussler-Scheinker

(p.Gln217Arg)

syndrome′, ′Genetic

prion diseases′]

NM_000311.3
74315413
PRNP
[ ]
[ ]
[′Gerstmann-

(PRNP):c.560A>G

Straussler-Scheinker

(p.His187Arg)

syndrome′, ′Genetic

prion diseases′,

′Spongiform

encephalopathy with

neuropsychiatric

features′]

NM_000044.3
137852567
AR
[ ]
[ ]
[′Reifenstein

(AR):c.2291A>G

syndrome′]

(p.Tyr764Cys)

NM_000044.3
137852570
AR
[ ]
[ ]
[ ]

(AR):c.2362A>G

(p.Met788Val)

NM_000044.3
137852578
AR
[ ]
[ ]
[′Malignant tumor of

(AR):c.2632A>G

prostate′]

(p.Thr878Ala)

NM_020436.3
74315429
SALL4
[ ]
[ ]
[′Duane-radial ray

(SALL4):c.2663A>G

syndrome′]

(p.His888Arg)

NM_000044.3
137852582
AR
[ ]
[ ]
[′Malignant tumor of

(AR):c.2708A>G

prostate′]

(p.Gln903Arg)

NM_000211.4
137852613
ITGB2
[ ]
[ ]
[′Leukocyte

(ITGB2):c.1052A>G

adhesion

(p.Asn351Ser)

deficiency′]

NM_000215.3
137852624
JAK3
[ ]
[′AATCCTGYACAG
[′Severe combined

(JAK3):c.299A>G

CAGGACTTGGG′]
immunodeficiency,

(p.Tyr100Cys)

autosomal recessive,

T cell-negative, B

cell-positive, NK

cell-negative′]

NM_001166107.1
137852640
HMGCS2
[ ]
[′ACCACCGYAGC
[′mitochondrial 3-

(HMGCS2):c.500A>G

AGGCATTGGTGG′]
hydroxy-3-

(p.Tyr167Cys)

methylglutaryl-CoA

synthase deficiency′]

NM_002047.2
137852645
GARS
[ ]
[ ]
[′Charcot-Marie-

(GARS):c.374A>G

Tooth disease type

(p.Glu125Gly)

2D′, ′Distal

hereditary motor

neuronopathy type

5′]

NM_033163.3
137852662
FGF8
[ ]
[ ]
[′Kallmann

(FGF8):c.298A>G

syndrome 6′]

(p.Lys100Glu)

NM_002180.2
137852666
IGHMBP2
[ ]
[ ]
[′Werdnig-Hoffmann

(IGHMBP2):c.638A>G

disease′]

(p.His213Arg)

NM_004387.3
137852683
NKX2-5
[ ]
[ ]
[′Atrial septal defect

(NKX2-5):c.896A>G

7 with or without

(p.Asp299Gly)

atrioventricular

conduction defects′]

NM_004387.3
137852686
NKX2-5
[ ]
[ ]
[ ]

(NKX2-5):c.547A>G

(p.Lys183Glu)

NM_000310.3
137852697
PPT1
[ ]
[ ]
[′Ceroid

(PPT1):c.236A>G

lipofuscinosis

(p.Asp79Gly)

neuronal 1′]

NM_000336.2
137852712
SCNN1B
[ ]
[ ]
[′Bronchiectasis′]

(SCNN1B):c.863A>G

(p.Asn288Ser)

NM_000579.3
1799987
—
[ ]
[ ]
[′Human

(CCR5):c.-301+246A>G

immunodeficiency

virus type 1,

susceptibility to′]

NM_001204.6
137852745
BMPR2
[ ]
[ ]
[′Primary pulmonary

(BMPR2):c.1454A>G

hypertension′]

(p.Asp485Gly)

NM_005591.3
137852760
MRE11A
[ ]
[ ]
[′Hereditary cancer-

(MRE11A):c.350A>G

predisposing

(p.Asn117Ser)

syndrome′, ′Ataxia-

telangiectasia-like

disorder′]

NM_003476.4
137852764
CSRP3
[ ]
[ ]
[′Dilated

(CSRP3):c.206A>G

cardiomyopathy

(p.Lys69Arg)

1M′,

′Cardiomyopathy′,

′Familial

hypertrophic

cardiomyopathy 12′]

NM_000519.3
35518301
HBD
[ ]
[ ]
[ ]

(HBD):c.-81A>G

NM_005633.3
137852814
SOS1
[ ]
[′GCATCCYTTCCA
[′Noonan syndrome′,

(SOS1):c.1654A>G

GTGTACTCCGG′]
′Noonan syndrome

(p.Arg552Gly)

4′, ′Rasopathy′, ′not

provided′]

NM_003688.3
137852818
CASK
[ ]
[ ]
[′FG syndrome 4′]

(CASK):c.2129A>G

(p.Asp710Gly)

NM_031443.3
137852842
CCM2
[ ]
[ ]
[′Cerebral cavernous

(CCM2):c.1A>G

malformations 2′]

(p.Met1Val)

NM_182760.3
137852855
SUMF1
[ ]
[ ]
[′Multiple sulfatase

(SUMF1):c.1A>G

deficiency′]

(p.Met1Val)

NM_001171993.1
137852865
HPD
[ ]
[′CCTCAYATCCAG
[4-

(HPD):c.362A>G

GCAAGAATTGG′]
Hydroxyphenyl-

(p.Tyr121Cys)

pyruvate dioxygenase

deficiency′]

NM_024996.5
119470018
GFM1
[′TTGYTAA
[′TTGYTAATAAAA
[′Combined

(GFM1):c.521A>G

TAAAAGTT
GTTAGAAACGG′]
oxidative

(p.Asn174Ser)

AGAAACG

phosphorylation

G′]

deficiency 1′]

NM_000158.3
137852889
GBE1
[ ]
[ ]
[′Glycogen storage

(GBE1):c.1634A>G

disease, type IV′,

(p.His545Arg)

′GLYCOGEN

STORAGE

DISEASE IV,

FATAL

PERINATAL

NEUROMUSCULAR′]

NM_000158.3
137852891
GBE1
[ ]
[ ]
[′Glycogen storage

(GBE1):c.1883A>G

disease, type IV′,

(p.His628Arg)

′GLYCOGEN

STORAGE

DISEASE IV,

CHILDHOOD

NEUROMUSCULAR]

m.8344A>G
118192098
MT-TK
[ ]
[ ]
[′Parkinson disease,

mitochondrial′,

′Leigh disease′,

′Myoclonus with

epilepsy with ragged

red fibers′]

NM_000540.2
118192126
RYR1
[ ]
[ ]
[′Central core

(RYR1):c.10100A>G

disease′, ′not

(p.Lys3367Arg)

provided′]

NM_000540.2
118192144
RYR1
[ ]
[ ]
[′Central core

(RYR1):c.14572A>G

disease′, ′not

(p.Asn4858Asp)

provided′]

NM_012464.4
137852953
TLL1
[′GGTTAYG
[′GGTTAYGGTGCC
[′Atrial septal defect

(TLL1):c.1885A>G

GTGCCGTT
GTTAAGTTTGG′]
6′]

(p.Ile629Val)

AAGTTTGG′]

NM_025243.3
137852957
SLC19A3
[ ]
[ ]
[′Basal ganglia

(SLC19A3):c.130A>G

disease, biotin-

(p.Lys44Glu)

responsive′]

NM_138691.2
370898981
TMC1
[ ]
[′TGGCCYACCAG
[′Deafness,

(TMC1):c.1763+3A>G

ATCATGCCTTGG′]
autosomal recessive

7′]

NM_000540.2
118192166
RYR1
[ ]
[ ]
[′Central core

(RYR1):c.13909A>G

disease′, ′not

(p.Thr4637Ala)

provided′]

NM_000540.2
118192167
RYR1
[ ]
[′CCATAYACCAGC
[′Malignant

(RYR1):c.14387A>G

CCAGGTACAGG′]
hyperthermia

(p.Tyr4796Cys)

susceptibility type

1′, ′Central core

disease′, ′not

provided′]

NM_032667.6
137852972
—
[ ]
[′CGAGACAYTGG
[′Distal hereditary

(BSCL2):c.263A>G

CAACAGGGAAGG′]
motor neuronopathy

(p.Asn88Ser)

type 5′, ′Silver

spastic paraplegia

syndrome′, ′Charcot-

Marie-Tooth

disease, type 2′]

NM_014795.3
137852983
ZEB2
[ ]
[ ]
[′Mowat-Wilson

(ZEB2):c.3356A>G

syndrome′]

(p.Gln1119Arg)

NM_000540.2
118192184
RYR1
[ ]
[ ]
[′Central core

(RYR1):c.14740A>G

disease′, ′not

(p.Arg4914Gly)

provided′]

NM_172107.2
118192193
KCNQ2
[ ]
[′CTTCYCATACTC
[′Benign familial

(KCNQ2):c.356A>G

CTTGATGGTGG′,
neonatal seizures 1′]

(p.Glu119Gly)

′GCTCTTCYCATA

CTCCTTGATGG′]

NM_172107.2
118192201
KCNQ2
[ ]
[′GGATCAYCCGC
[′Benign familial

(KCNQ2):c.622A>G

AGAATCTGCAGG′]
neonatal seizures 1′]

(p.Met208Val)

NM_172107.2
118192207
KCNQ2
[ ]
[ ]
[′Benign familial

(KCNQ2):c.773A>G

neonatal seizures 1′]

(p.Asn258Ser)

NM_004006.2
1800278
DMD
[ ]
[ ]
[′Duchenne

(DMD):c.8734A>G

muscular dystrophy′,

(p.Asn2912Asp)

′not specified′]

NM_004006.2
1800279
DMD
[ ]
[ ]
[′Becker muscular

(DMD):c.8762A>G

dystrophy′, ′not

(p.His2921Arg)

specified′]

NM_001080463.1
137853026
DYNC2H1
[ ]
[ ]
[′Short-rib thoracic

(DYNC2H1):c.11284A>G

dysplasia 3 with or

(p.Met3762Val)

without

polydactyly′]

NM_001080463.1
137853027
DYNC2H1
[ ]
[′ATAYCTCTAATT
[′Short-rib thoracic

(DYNC2H1):c.9044A>G

ACATCAGGTGG′,
dysplasia 3 with or

(p.Asp3015Gly)

′AGAATAYCTCTA
without

ATTACATCAGG′]
polydactyly′]

NM_001080463.1
137853033
DYNC2H1
[′ACCYGTG
[′ACCYGTGAAGG
[′Short-rib thoracic

(DYNC2H1):c.4610A>G

AAGGGAA
GAACAGAGATGG′]
dysplasia 3 with or

(p.Gln1537Arg)

CAGAGATG

without

G′]

polydactyly′]

NM_001080463.1
137853035
DYNC2H1
[ ]
[ ]
[′Short-rib thoracic

(DYNC2H1):c.5959A>G

dysplasia 3 with or

(p.Thr1987Ala)

without

polydactyly′]

NM_001430.4
137853037
EPAS1
[ ]
[ ]
[′Erythrocytosis,

(EPAS1):c.1603A>G

familial, 4′]

(p.Met535Val)

NM_172107.2
118192238
KCNQ2
[ ]
[ ]
[′Benign familial

(KCNQ2):c.1764-2A>G

neonatal seizures 1′]

NM_004519.3
118192248
KCNQ3
[ ]
[ ]
[′Benign familial

(KCNQ3):c.914A>G

neonatal seizures 2′]

(p.Asp305Gly)

NM_004519.3
118192252
KCNQ3
[′TCTTTAY
[′TCTTTAYTGTTT
[′Benign familial

(KCNQ3):c.1403A>G

TGTTTAAG
AAGCCAACAGG′]
neonatal seizures 2′,

(p.Asn468Ser)

CCAACAGG′]

′not specified′, ′not

provided′]

NM_004519.3
118192254
KCNQ3
[ ]
[ ]
[′Benign familial

(KCNQ3):c.2462A>G

neonatal seizures 2′,

(p.Asn821Ser)

′not specified′, ′not

provided′]

NM_138701.3
137853117
MPLKIP
[ ]
[ ]
[′Trichothiodystrophy,

(MPLKIP):c.430A>G

nonphotosensitive

(p.Met144Val)

1′]

NM_005094.3
137853134
SLC27A4
[ ]
[ ]
[′Ichthyosis

(SLC27A4):c.899A>G

prematurity

(p.Gln300Arg)

syndrome′]

NM_194456.1
137853139
KRIT1
[ ]
[ ]
[′Cerebral cavernous

(KRIT1):c.410A>G

malformations 1′]

(p.Asp137Gly)

NM_000351.4
137853169
STS
[ ]
[ ]
[′X-linked ichthyosis

(STS):c.1331A>G

with steryl-sulfatase

(p.His444Arg)

deficiency′]

NM_152416.3
137853184
NDUFAF6
[ ]
[ ]
[′Leigh syndrome

(NDUFAF6):c.296A>G

due to mitochondrial

(p.Gln99Arg)

complex I

deficiency′]

NM_144573.3
137853197
NEXN
[ ]
[′ATAYACTCTCCT
[′Dilated

(NEXN):c.1955A>G

CCATCTTCTGG′]
cardiomyopathy

(p.Tyr652Cys)

1CC′,

′Cardiomyopathy′,

′not specified′]

NM_000476.2
137853203
AK1
[ ]
[′TTCTCAYAGAAG
[′Adenylate kinase

(AK1):c.491A>G

GCGATGACGGG′,
deficiency,

(p.Tyr164Cys)

′TTTCTCAYAGAA
hemolytic anemia

GGCGATGACGG′]
due to′]

NM_013411.4
137853206
AK2
[ ]
[ ]
[′Reticular

(AK2):c.1A>G

dysgenesis′]

(p.Met1Val)

NM_000308.2
786200859
CTSA
[ ]
[′TCCCAYACCTGT
[′Galactosialidosis,

(CTSA):c.746+3A>G

TCCCCAGAAGG′]
adult′]

NM_002890.2
137853215
RASA1
[ ]
[ ]
[ ]

(RASA1):c.1198A>G

(p.Lys400Glu)

NM_002890.2
137853216
RASA1
[ ]
[ ]
[ ]

(RASA1):c.1201A>G

(p.Ile401Val)

NM_000515.4
137853221
GH1
[ ]
[ ]
[′Kowarski

(GH1):c.413A>G

syndrome′]

(p.Asp138Gly)

NM_017636.3
172151858
TRPM4
[ ]
[ ]
[′Progressive

(TRPM4):c.2741A>G

familial heart block

(p.Lys914Arg)

type 1B′]

NM_000545.6
137853237
HNFlA
[ ]
[ ]
[′Maturity-onset

(HNF1A):c.365A>G

diabetes of the

(p.Tyr122Cys)

young, type 3′]

NM_003494.3
786200897
DYSF
[ ]
[′CAGCYAGAAGA
[′Limb-girdle

(DYSF):c.1285-2A>G

CACAGGGAGGGG′,
muscular dystrophy,

′ACAGCYAGAAGA
type 2B′]

CACAGGGAGGG′,

′CACAGCYAGAAG

ACACAGGGAGG′]

NM_005055.4
786200905
RAPSN
[ ]
[ ]
[′MYASTHENIC

(RAPSN):c.-210A>G

SYNDROME,

CONGENITAL, 11,

ASSOCIATED

WITH

ACETYLCHOLINE

RECEPTOR

DEFICIENCY′]

NM_000276.3
137853262
OCRL
[ ]
[ ]
[′Dent disease 2′]

(OCRL):c.1436A>G

(p.Tyr479Cys)

NM_004463.2
137853267
FGD1
[ ]
[ ]
[′Aarskog

(FGD1):c.1396A>G

syndrome′]

(p.Met466Val)

NM_153252.4
137853272
BRWD3
[ ]
[ ]
[′Mental retardation,

(BRWD3):c.4786A>G

X-linked 93′]

(p.Lys1596Glu)

NM_206933.2
786200928
USH2A
[ ]
[′CTCTTAYCTTGG
[′Usher syndrome,

(USH2A):c.7595-2144A>G

GAAAGGAGAGG′]
type 2A′]

NM_000362.4
137853299
—
[′TGCAGYA
[′TGCAGYAGCCG
[′Sorsby fundus

(TIMP3):c.572A>G

GCCGCCCT
CCCTTCTGCCGG′]
dystrophy′]

(p.Tyr191Cys)

TCTGCCGG′]

NM_006785.3
786200953
MALT1
[′CGCYTTG
[′CGCYTTGAAAA
[′Combined

(MALT1):c.1019-2A>G

AAAAAAA
AAAAAGAAAGGG′,
immunodeficiency′]

AAGAAAG
′TCGCYTTGAAAA

GG′]
AAAAAGAAAGG′]

NM_003639.4
137853321
IKBKG
[ ]
[ ]
[′Incontinentia

(IKBKG):c.1259A>G

pigmenti syndrome′,

(p.Ter420Trp)

′Ectodermal

dysplasia,

anhidrotic, with

immunodeficiency,

osteopetrosis, and

lymphedema′]

NM_003639.4
137853322
IKBKG
[ ]
[′CCAYATCAGGG
[′Incontinentia

(IKBKG):c.1219A>G

GCCTGATACTGG′]
pigmenti syndrome′]

(p.Met407Val)

NM_001014797.2
137853333
KCNMA1
[ ]
[ ]
[′Generalized

(KCNMA1):c.1301A>G

epilepsy and

(p.Asp434Gly)

paroxysmal

dyskinesia′]

NM_016218.2
757103131
POLK
[ ]
[ ]
[′Malignant tumor of

(POLK):c.1679A>T

prostate′]

(p.Glu560Val)

NM_003000.2
786201161
SDHB
[ ]
[ ]
[′Hereditary cancer-

(SDHB):c.541-2A>G

predisposing

syndrome′]

NM_032383.4
397507168
—
[ ]
[ ]
[′Hermansky-Pudlak

(HPS3):c.2482-2A>G

syndrome 3′]

NM_000060.3
397507176
BTD
[ ]
[ ]
[′Biotinidase

(BTD):c.968A>G

deficiency′, ′not

(p.His323Arg)

provided′]

NM_004315.4
137853595
ASAH1
[ ]
[ ]
[′Farber

(ASAH1):c.155A>G

lipogranulomatosis′]

(p.Tyr52Cys)

NM_004315.4
137853596
ASAH1
[ ]
[ ]
[′Farber

(ASAH1):c.1006A>G

lipogranulomatosis′]

(p.Asn336Asp)

NM_000059.3
397507276
BRCA2
[ ]
[ ]
[′Breast-ovarian

(BRCA2):c.1799A>G

cancer, familial 2′]

(p.Tyr600Cys)

NM_022912.2
387906264
REEP1
[ ]
[ ]
[′Spastic paraplegia

(REEP1):c.183-2A>G

31, autosomal

dominant′]

NM_000022.2
387906267
ADA
[ ]
[′CCCCYGGGAAG
[′Severe combined

(ADA):c.219-2A>G

GGAAGAAAGGGG′,
immunodeficiency

′GCCCCYGGGAAG
due to ADA

GGAAGAAAGGG′,
deficiency′]

′AGCCCCYGGGAA

GGGAAGAAAGG′]

NM_018249.5
387906274
CDK5RAP2
[ ]
[ ]
[′Primary autosomal

(CDK5RAP2):c.4005-15A>G

recessive

microcephaly 3′]

NM_032119.3
371981035
ADGRV1
[ ]
[ ]
[′Usher syndrome,

(ADGRV1):c.14973-2A>G

type 2C]

NM_020366.3
17103671
RPGRIP1
[ ]
[ ]
[′Leber congenital

(RPGRIP1):c.3341A>G

amaurosis 6′, ′not

(p.Asp1114Gly)

specified′]

NM_000492.3
387906362
CFTR
[ ]
[′TCAAATCYCACC
[′Cystic fibrosis′]

(CFTR):c.3717+4A>G

CTCTGGCCAGG′]

NM_000492.3
387906374
CFTR
[ ]
[ ]
[′Cystic fibrosis′]

(CFTR):c.273+4A>G

NM_002769.4
397507442
—
[ ]
[′CTTGYCATCATC
[′Hereditary

(PRSS1):c.65A>G

ATCAAAGGGGG′,
pancreatitis′]

(p.Asp22Gly)

′TCTTGYCATCATC

ATCAAAGGGG′,

′ATCTTGYCATCA

TCATCAAAGGG′,

′GATCTTGYCATC

ATCATCAAAGG′]

NM_004006.2
794727575
DMD
[ ]
[ ]
[′Duchenne

(DMD):c.4675-2A>G

muscular dystrophy′,

′Becker muscular

dystrophy′]

NM_000132.3
387906444
F8
[ ]
[ ]
[′Hereditary factor

(F8):c.1418A>G

VIII deficiency

(p.Tyr473Cys)

disease′]

NM_004333.4
397507486
BRAF
[ ]
[ ]
[′Rasopathy′]

(BRAF):c.2126A>G

(p.Gln709Arg)

NM_002834.3
397507501
PTPN11
[ ]
[ ]
[′Noonan syndrome′,

(PTPN11):c.124A>G

′Noonan syndrome

(p.Thr42Ala)

1′, ′Rasopathy′, ′not

provided′]

NM_000834.3
527236034
GRIN2B
[ ]
[ ]
[′Mental retardation,

(GRIN2B):c.1238A>G

autosomal dominant

(p.Glu413Gly)

6′]

NM_004830.3
527236035
MED23
[ ]
[ ]
[′Mental retardation,

(MED23):c.3638A>G

autosomal recessive

(p.His1213Arg)

18′]

NM_002834.3
397507529
PTPN11
[ ]
[ ]
[′Noonan syndrome

(PTPN11):c.844A>G

1′, ′Rasopathy′, ′not

(p.Ile282Val)

provided′]

NM_000406.2
28933074
GNRHR
[ ]
[ ]
[ ]

(GNRHR):c.851A>G

(p.Tyr284Cys)

NM_002834.3
397507547
PTPN11
[ ]
[ ]
[′Noonan syndrome′,

(PTPN11):c.1510A>G

′Noonan syndrome

(p.Met504Val)

1′, ′Rasopathy′, ′not

provided′]

NM_004629.1
397507561
FANCG
[ ]
[ ]
[′Fanconi anemia,

(FANCG):c.925-2A>G

complementation

group G′]

NM_000492.3
76151804
CFTR
[ ]
[ ]
[′Cystic fibrosis′]

(CFTR):c.3140-26A>G

NM_024598.3
137853971
USB1
[ ]
[′CCACCYGGTTTT
[′Poikiloderma with

(USB1):c.502A>G

CTCTTGATTGG′]
neutropenia′]

(p.Arg168Gly)

NM_000067.2
2228063
CA2
[ ]
[′TGTYCTTCAGTG
[ ]

(CA2):c.754A>G

GCTGAGCTGGG′,

(p.Asn252Asp)

′CTGTYCTTCAGT

GGCTGAGCTGG′]

NM_000138.4
387906622
FBN1
[ ]
[ ]
[′Geleophysic

(FBN1):c.5096A>G

dysplasia 2′]

(p.Tyr1699Cys)

NM_001194958.2
527236159
KCNJ18
[ ]
[ ]
[′Thyrotoxic

(KCNJ18):c.1097A>G

periodic paralysis′,

(p.Lys366Arg)

′Thyrotoxic periodic

paralysis 2′]

NM_000138.4
387906625
FBN1
[ ]
[ ]
[′Geleophysic

(FBN1):c.5087A>G

dysplasia 2′]

(p.Tyr1696Cys)

NM_000138.4
387906626
FBN1
[ ]
[ ]
[ ]

(FBN1):c.5099A>G

(p.Tyr1700Cys)

NM_001244710.1
387906638
GFPT1
[ ]
[ ]
[′Congenital

(GFPT1):c.43A>G

myasthenic

(p.Thr15Ala)

syndrome with

tubular aggregates

1′]

NM_002292.3
387906644
LAMB2
[ ]
[ ]
[′Nephrotic

(LAMB2):c.440A>G

syndrome, type 5,

(p.His147Arg)

with or without

ocular

abnormalities′]

NM_005188.3
387906666
CBL
[ ]
[ ]
[ ]

(CBL):c.1112A>G

(p.Tyr371Cys)

NM_000313.3
387906675
PROS1
[′GATTAYA
[′GATTAYATCTGT
[′Thrombophilia due

(PROS1):c.701A>G

TCTGTAGC
AGCCTTCGGGG′,
to protein S

(p.Tyr234Cys)

CTTCGGGG′,
′AGATTAYATCTG
deficiency,

′AGATTAY
TAGCCTTCGGG′,
autosomal

ATCTGTAG
′GAGATTAYATCT
recessive′]

CCTTCGGG′,
GTAGCCTTCGG′]

′GAGATTA

YATCTGTA

GCCTTCGG′]

NM_032018.6
527236213
SPRTN
[ ]
[ ]
[′Ruijs-aalfs

(SPRTN):c.350A>G

syndrome′]

(p.Tyr117Cys)

NM_022464.4
548535414
SIL1
[ ]
[ ]
[′Marinesco-

(SIL1):c.645+2T>C

Sj\xc3\xb6gren

syndrome′]

NM_001040142.1
387906685
SCN2A
[ ]
[ ]
[′Early infantile

(SCN2A):c.4419A>G

epileptic

(p.Ile1473Met)

encephalopathy 11′]

NM_001040142.1
387906687
SCN2A
[ ]
[ ]
[′Benign familial

(SCN2A):c.754A>G

neonatal-infantile

(p.Met252Val)

seizures′]

m.10450A>G
387906731
MT-TR
[ ]
[ ]
[′Mitochondrial

encephalomyopathy′]

m.5816A>G
387906732
MT-TC
[ ]
[ ]
[ ]

m.608A>G
387906735
MT-TF
[′TTCAGYG
[′TTCAGYGTATTG
[ ]

TATTGCTT
CTTTGAGGAGG′]

TGAGGAGG′]

NM_001376.4
387906738
DYNC1H1
[ ]
[ ]
[′Charcot-Marie-

(DYNC1H1):c.917A>G

Tooth disease,

(p.His306Arg)

axonal, type 2O′,

′Charcot-Marie-

Tooth disease′,

′Spinal muscular

atrophy, lower

extremity

predominant 1,

autosomal

dominant′]

NM_001376.4
387906742
DYNC1H1
[ ]
[ ]
[′Spinal muscular

(DYNC1H1):c.2011A>G

atrophy, lower

(p.Lys671Glu)

extremity

predominant 1,

autosomal

dominant′]

NM_001376.4
387906743
DYNC1H1
[ ]
[′ATTCAAGYAGAT
[′Spinal muscular

(DYNC1H1):c.2909A>G

TACCTGATTGG′]
atrophy, lower

(p.Tyr970Cys)

extremity

predominant 1,

autosomal

dominant′]

NM_001354.5
387906750
AKR1C2
[ ]
[ ]
[′46,XY sex reversal

(AKR1C2):c.235A>G

8′]

(p.Ile79Val)

NM_007315.3
387906762
STAT1
[ ]
[ ]
[′Immunodeficiency

(STAT1):c.604A>G

31C′]

(p.Met202Val)

NM_007315.3
387906764
STAT1
[ ]
[ ]
[′Immunodeficiency

(STAT1):c.494A>G

31C′]

(p.Asp165Gly)

NM_007315.3
387906765
STAT1
[ ]
[ ]
[′Immunodeficiency

(STAT1):c.862A>G

31C′]

(p.Thr288Ala)

NM_002052.4
387906772
GATA4
[ ]
[′TCCGCAYTGCAA
[′Atrial septal defect

(GATA4):c.928A>G

GAGGCCTGGGG′,
2′]

(p.Met310Val)

′TTCCGCAYTGCA

AGAGGCCTGGG′]

NM_021615.4
72547544
CHST6
[ ]
[ ]
[′Macular corneal

(CHST6):c.329A>G

dystrophy Type I′]

(p.Tyr110Cys)

NM_000209.3
387906777
PDX1
[ ]
[ ]
[′Pancreatic

(PDX1):c.533A>G

agenesis,

(p.Glu178Gly)

congenital′]

NM_000890.3
387906778
KCNJ5
[ ]
[ ]
[′Andersen Tawil

(KCNJ5):c.472A>G

syndrome′, ′Familial

(p.Thr158Ala)

hyperaldosteronism

type 3′]

NM_001184.3
387906797
ATR
[ ]
[ ]
[′Cutaneous

(ATR):c.6431A>G

telangiectasia and

(p.Gln2144Arg)

cancer syndrome,

familial′]

NM_000382.2
72547575
ALDH3A2
[ ]
[ ]
[′Sj\xc3\xb6gren-

(ALDH3A2):c.1157A>G

Larsson syndrome′]

(p.Asn386Ser)

NM_001005862.2
28933370
ERBB2
[ ]
[ ]
[′Neoplasm of

(ERBB2):c.2480A>G

ovary′]

(p.Asn827Ser)

NM_006194.3
28933373
PAX9
[ ]
[ ]
[′Tooth agenesis,

(PAX9):c.271A>G

selective, 3′]

(p.Lys91Glu)

NM_001083116.1
28933375
PRF1
[ ]
[ ]
[′Hemophagocytic

(PRF1):c.755A>G

lymphohistiocytosis,

(p.Asn252Ser)

familial, 2′,

′Malignant

lymphoma, non-

Hodgkin′]

NM_005257.5
387906817
GATA6
[ ]
[ ]
[′Pancreatic agenesis

(GATA6):c.1354A>G

and congenital heart

(p.Thr452Ala)

disease′]

NM_000414.3
387906825
HSD17B4
[ ]
[′TGCCACAYACTC
[′Gonadal

(HSD17B4):c.650A>G

TGGCTTCAGGG′]
dysgenesis with

(p.Tyr217Cys)

auditory

dysfunction,

autosomal recessive

inheritance′]

NM_004153.3
387906826
ORC1
[ ]
[ ]
[′Meier-Gorlin

(ORC1):c.380A>G

syndrome 1′]

(p.Glu127Gly)

NM_002552.4
387906847
ORC4
[ ]
[ ]
[′Meier-Gorlin

(ORC4):c.521A>G

syndrome 2′]

(p.Tyr174Cys)

NM_004544.3
387906872
NDUFA10
[ ]
[ ]
[′Leigh syndrome

(NDUFA10):c.1A>G

due to mitochondrial

(p.Met1Val)

complex I

deficiency′]

NM_004544.3
387906873
NDUFA10
[ ]
[ ]
[′Leigh syndrome

(NDUFA10):c.425A>G

due to mitochondrial

(p.Gln142Arg)

complex I

deficiency′]

NM_006796.2
387906889
AFG3L2
[′GTAYAGA
[′GTAYAGAGGTA
[′Spastic ataxia 5,

(AFG3L2):c.1847A>G

GGTATTGT
TTGTTCTTTTGG′]
autosomal

(p.Tyr616Cys)

TCTTTTGG′]

recessive′]

NM_006587.3
387906894
CORIN
[ ]
[ ]
[′Preeclampsia/

(CORIN):c.949A>G

eclampsia 5′]

(p.Lys317Glu)

NM_006587.3
387906895
CORIN
[ ]
[′GGATAACYTGTA
[′Preeclampsia/

(CORIN):c.1414A>G

CTGTTGTAGGG′]
eclampsia 5′]

(p.Ser472Gly)

NM_015560.2
387906899
OPA1
[ ]
[ ]
[′Optic Atrophy

(OPA1):c.1294A>G

Type 1′]

(p.Ile432Val)

NM_021625.4
387906903
TRPV4
[ ]
[ ]
[′Metatrophic

(TRPV4):c.590A>G

dysplasia′]

(p.Lys197Arg)

NM_021625.4
387906907
TRPV4
[ ]
[ ]
[′Metatrophic

(TRPV4):c.826A>G

dysplasia′]

(p.Lys276Glu)

NM_024022.2
387906915
TMPRSS3
[ ]
[ ]
[′Deafness,

(TMPRSS3):c.308A>G

autosomal recessive

(p.Asp103Gly)

8′]

NM_019109.4
387906925
ALG1
[ ]
[ ]
[′Congenital disorder

(ALG1):c.1129A>G

of glycosylation type

(p.Met377Val)

1K′]

NM_006886.3
387906929
—
[ ]
[ ]
[′Nuclearly-encoded

(ATP5E):c.35A>G

mitochondrial

(p.Tyr12Cys)

complex V (ATP

synthase) deficiency

3′]

NM_032578.3
140148105
MYPN
[ ]
[ ]
[′Primary dilated

(MYPN):c.59A>G

cardiomyopathy′,

(p.Tyr20Cys)

′Cardiomyopathy′,

′Dilated

cardiomyopathy

1KK′, ′Familial

hypertrophic

cardiomyopathy 22′,

′not provided′]

NM_016013.3
387906957
NDUFAF1
[ ]
[′ACCYTGACCTCC
[′Mitochondrial

(NDUFAF1):c.758A>G

TGCCAGTAGGG′,
complex I

(p.Lys253Arg)

′TACCYTGACCTC
deficiency′]

CTGCCAGTAGG′]

NM_032580.3
387906979
HES7
[ ]
[ ]
[′Spondylocostal

(HES7):c.172A>G

dysostosis 5′]

(p.Ile58Val)

NM_024700.3
387906986
SNIP1
[ ]
[ ]
[′Psychomotor

(SNIP1):c.1097A>G

retardation, epilepsy,

(p.Glu366Gly)

and craniofacial

dysmorphism′]

NM_016952.4
387906997
CDON
[ ]
[ ]
[′Holoprosencephaly

(CDON):c.2368A>G

11′]

(p.Thr790Ala)

NM_031427.3
387907021
DNAL1
[′AGGGAYT
[′AGGGAYTGCCT
[′Kartagener

(DNAL1):c.449A>G

GCCTACAA
ACAAACACCAGG′]
syndrome′, ′Ciliary

(p.Asn150Ser)

ACACCAGG′]

dyskinesia, primary,

16′]

NM_020320.3
387907048
RARS2
[ ]
[ ]
[′Pontocerebellar

(RARS2):c.1024A>G

hypoplasia type 6′]

(p.Met342Val)

NM_000138.4
137854461
FBN1
[ ]
[ ]
[′Marfan syndrome′]

(FBN1):c.6431A>G

(p.Asn2144Ser)

NM_000138.4
137854479
FBN1
[ ]
[ ]
[′Marfan syndrome′]

(FBN1):c.2261A>G

(p.Tyr754Cys)

NM_212482.1
137854488
FN1
[′GAAGTAA
[′GAAGTAAYAGG
[′Glomerulopathy

(FN1):c.2918A>G

YAGGTGAC
TGACCCCAGGGG′]
with fibronectin

(p.Tyr973Cys)

CCCAGGGG′]

deposits 2′]

NM_198994.2
387907098
TGM6
[ ]
[ ]
[′Spinocerebellar

(TGM6):c.980A>G

ataxia 35′]

(p.Asp327Gly)

NM_001363.4
137854492
DKC1
[′GCAGGYA
[′GCAGGYAGAGA
[′Dyskeratosis

(DKC1):c.1069A>G

GAGATGAC
TGACCGCTGTGG′]
congenita X-linked′]

(p.Thr357Ala)

CGCTGTGG′]

NM_052873.2
387907107
IF143
[ ]
[ ]
[′Cranioectodermal

(IFT43):c.1A>G

dysplasia 3′]

(p.Met1Val)

NM_201269.2
387907109
ZNF644
[ ]
[ ]
[′Myopia 21,

(ZNF644):c.2014A>G

autosomal

(p.Ser672Gly)

dominant′]

NM_018699.3
387907111
PRDM5
[ ]
[ ]
[′Brittle cornea

(PRDM5):c.320A>G

syndrome 2′]

(p.Tyr107Cys)

NM_000132.3
28933682
F8
[ ]
[′TAGCCAYTGATT
[′Hereditary factor

(F8):c.5822A>G

GCTGGAGAAGG′]
VIII deficiency

(p.Asn1941Ser)

disease′]

NM_016464.4
387907132
TMEM138
[′GACAYGA
[′GACAYGAAGGG
[′Joubert syndrome

(TMEM138):c.287A>G

AGGGAGAT
AGATGCTGAGGG′,
16′]

(p.His96Arg)

GCTGAGGG′]
′AGACAYGAAGGG

AGATGCTGAGG′]

NM_016464.4
387907135
TMEM138
[ ]
[′CAGYACAACAC
[′Joubert syndrome

(TMEM138):c.389A>G

TGCTGCTGTGGG′,
16′]

(p.Tyr130Cys)

′GCAGYACAACAC

TGCTGCTGTGG′]

NM_177965.3
387907137
C8orf37
[ ]
[ ]
[′Retinitis

(C8orf37):c.545A>G

pigmentosa 64′]

(p.Gln182Arg)

NM_001077488.3
137854530
GNAS
[ ]
[′GCCCAYGGCGG
[′Pseudohypopara-

(GNAS):c.1A>G

CGGCGGCGGCGG′]
thyroidism type 1A′]

(p.Met1Val)

NM_006920.4
727504140
SCN1A
[ ]
[ ]
[′Severe myoclonic

(SCN1A):c.2557-2A>G

epilepsy in infancy′,

′Generalized

epilepsy with febrile

seizures plus, type

2′]

NM_000308.2
137854541
CTSA
[ ]
[ ]
[′Combined

(CTSA):c.200A>G

deficiency of

(p.Gln67Arg)

sialidase AND beta

galactosidase′]

NM_000308.2
137854543
CTSA
[ ]
[ ]
[′Combined

(CTSA):c.1238A>G

deficiency of

(p.Tyr413Cys)

sialidase AND beta

galactosidase′]

NM_000308.2
137854549
CTSA
[ ]
[ ]
[′Galactosialidosis,

(CTSA):c.1411A>G

late infantile′]

(p.Lys471Glu)

NM_000267.3
137854550
NF1
[ ]
[ ]
[′Neurofibromatosis,

(NF1):c.4267A>G

type 1′]

(p.Lys1423Glu)

NM_000267.3
137854557
NF1
[′ACTTAYA
[′ACTTAYAGCTTC
[′Neurofibromatosis,

(NF1):c.1466A>G

GCTTCTTG
TTGTCTCCAGG′]
type 1′]

(p.Tyr489Cys)

TCTCCAGG′]

NM_018105.2
387907176
THAP1
[ ]
[′CCTCACTYGTGG
[′Dystonia 6,

(THAP1):c.70A>G

AAAGAAACGGG′]
torsion′]

(p.Lys24Glu)

NM_000492.3
397508201
CFTR
[ ]
[ ]
[′Cystic fibrosis′]

(CFTR):c.1393-2A>G

NM_001172646.1
387907179
PLCB4
[ ]
[ ]
[′Auriculocondylar

(PLCB4):c.986A>G

syndrome 2′]

(p.Asn329Ser)

NM_005850.4
387907185
SF3B4
[ ]
[ ]
[′Nager syndrome′]

(SF3B4):c.1A>G

(p.Met1Val)

NM_014714.3
387907193
IFT140
[ ]
[ ]
[′Renal dysplasia,

(IFT140):c.932A>G

retinal pigmentary

(p.Tyr311Cys)

dystrophy, cerebellar

ataxia and skeletal

dysplasia′]

NM_005006.6
387907199
NDUFS1
[ ]
[ ]
[′Mitochondrial

(NDUFS1):c.1783A>G

complex I

(p.Thr595Ala)

deficiency′]

NM_000397.3
137854593
CYBB
[ ]
[′TCACAYCTTTCT
[′Chronic

(CYBB):c.1499A>G

CCTCATCATGG′]
granulomatous

(p.Asp500Gly)

disease, X-linked′,

′not provided′]

NM_033360.3
387907206
KRAS
[ ]
[ ]
[′Cardiofaciocutaneous

(KRAS):c.439A>G

syndrome 2′]

(p.Lys147Glu)

NM_000335.4
137854614
SCN5A
[ ]
[ ]
[′Long QT syndrome

(SCN5A):c.5381A>G

3′, ′Congenital long

(p.Tyr1794Cys)

QT syndrome′]

NM_000076.2
387907226
CDKN1C
[ ]
[′CGCTYGGCGAA
[′Intrauterine growth

(CDKN1C):c.832A>G

GAAATCTGCGGG′,
retardation,

(p.Lys278Glu)

′GCGCTYGGCGAA
metaphyseal

GAAATCTGCGG′]
dysplasia, adrenal

hypoplasia

congenita, and

genital anomalies′]

NM_022912.2
387907242
REEP1
[ ]
[′TCCYGTCAAAGG
[′Distal hereditary

(REEP1):c.304-2A>G

AAAAACAGAGG′]
motor neuronopathy

type 5B′]

NM_198253.2
387907250
TERT
[ ]
[ ]
[′PULMONARY

(TERT):c.2705A>G

FIBROSIS

(p.Lys902Arg)

AND/OR BONE

MARROW

FAILURE,

TELOMERE-

RELATED, 1′]

NM_005349.3
387907270
RBPJ
[ ]
[ ]
[′Adams-Oliver

(RBPJ):c.188A>G

syndrome 3′]

(p.Glu63Gly)

NM_005349.3
387907271
RBPJ
[ ]
[ ]
[′Adams-Oliver

(RBPJ):c.505A>G

syndrome 3′]

(p.Lys169Glu)

NM_022787.3
387907291
NMNAT1
[ ]
[′TGTYTCTCTGCA
[′Leber congenital

(NMNAT1):c.817A>G

AAGGGGCCAGG′]
amaurosis 9′]

(p.Asn273Asp)

NM_000492.3
397508328
CFTR
[′TGCAYGG
[′GCAYGGTCTCTC
[′Cystic fibrosis′]

(CFTR):c.1A>G

TCTCTCGG
GGGCGCTGGGG′,

(p.Met1Val)

GCGCTGGG′]
′TGCAYGGTCTCT

CGGGCGCTGGG′,

′CTGCAYGGTCTC

TCGGGCGCTGG′]

NM_020921.3
387907308
NIN
[ ]
[ ]
[′Seckel syndrome

(NIN):c.5126A>G

7′]

(p.Asn1709Ser)

NM_021629.3
387907341
GNB4
[ ]
[ ]
[′Charcot-Marie-

(GNB4):c.265A>G

Tooth disease,

(p.Lys89Glu)

dominant

intermediate F′]

NM_000355.3
372866837
TCN2
[ ]
[ ]
[ ]

(TCN2):c.580+624A>T

NM_032415.5
387907351
CARD11
[ ]
[ ]
[′B-CELL

(CARD11):c.401A>G

EXPANSION

(p.Glu134Gly)

WITH NFKB AND

T-CELL ANERGY′]

NM_005430.3
387907354
WNT1
[ ]
[ ]
[′Osteogenesis

(WNT1):c.624+4A>G

imperfecta type 15′]

NM_207352.3
149684063
CYP4V2
[ ]
[ ]
[′Bietti crystalline

(CYP4V2):c.367A>G

corneoretinal

(p.Met123Val)

dystrophy′, ′not

provided′]

NM_031885.3
137854887
BBS2
[ ]
[ ]
[′Bardet-Biedl

(BBS2):c.472-2A>G

syndrome 2′]

NM_015268.3(DNAJC
387907571
DNAJC13
[ ]
[ ]
[′Parkinson disease,

13):c.2564A>G

late-onset′, ′Essential

(p.Asn855Ser)

tremor′,

′PARKINSON

DISEASE 21′]

NM_001287.5
387907576
CLCN7
[ ]
[′TGTCAYAGTCCA
[′Osteopetrosis

(CLCN7):c.296A>G

AGCTCTGCAGG′]
autosomal dominant

(p.Tyr99Cys)

type 2′,

′Osteopetrosis

autosomal recessive

4′]

REFERENCES

1. Humbert O, Davis L, Maizels N. Targeted gene therapies: tools, applications, optimization. Crit Rev Biochem Mol. 2012; 47(3):264-81. PMID: 22530743.

2. Perez-Pinera P, Ousterout D G, Gersbach C A. Advances in targeted genome editing. Curr Opin Chem Biol. 2012; 16(3-4):268-77. PMID: 22819644.

3. Urnov F D, Rebar E J, Holmes M C, Zhang H S, Gregory P D. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010; 11(9):636-46. PMID: 20717154.

4. Joung J K, Sander J D. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2013; 14(1):49-55. PMID: 23169466.

5. Charpentier E, Doudna J A. Biotechnology: Rewriting a genome. Nature. 2013; 495, (7439):50-1. PMID: 23467164.

6. Pan Y, Xia L, Li A S, Zhang X, Sirois P, Zhang J, Li K. Biological and biomedical applications of engineered nucleases. Mol Biotechnol. 2013; 55(1):54-62. PMID: 23089945.

7. De Souza, N. Primer: genome editing with engineered nucleases. Nat Methods. 2012; 9(1):27. PMID: 22312638.

8. Santiago Y, Chan E, Liu P Q, Orlando S, Zhang L, Urnov F D, Holmes M C, Guschin D, Waite A, Miller J C, Rebar E J, Gregory P D, Klug A, Collingwood T N. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci USA. 2008; 105(15):5809-14. PMID: 18359850.

9. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Lane C R, Lim E P, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley G Q, Lander E S. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999; 22(3):231-8. PMID: 10391209.

10. Jansen R, van Embden J D, Gaastra W, Schouls L M. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002; 43(6):1565-75. PMID: 11952905.

11. Mali P, Esvelt K M, Church G M. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013; 10(10):957-63. PMID: 24076990.

12. Jore M M, Lundgren M, van Duijin E, Bultema J B, Westra E R, Waghmare S P, Wiedenheft B, Pul U, Wurm R, Wagner R, Beijer M R, Barendregt A, Shou K, Snijders A P, Dickman M J, Doudna J A, Boekema E J, Heck A J, van der Oost J, Brouns S J. Structural basis for CRISPR RNA-guided DNA recognition by Cascade. Nat Struct Mol Biol. 2011; 18(5):529-36. PMID: 21460843.

13. Horvath P, Barrangou R. CRISPR/Cas, the immune system of bacteria and archaea. Science. 2010; 327(5962):167-70. PMID: 20056882.

14. Wiedenheft B, Sternberg S H, Doudna J A. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012; 482(7385):331-8. PMID: 22337052.

15. Gasiunas G, Siksnys V. RNA-dependent DNA endonuclease Cas9 of the CRISPR system: Holy Grail of genome editing? Trends Microbiol. 2013; 21(11):562-7. PMID: 24095303.

16. Qi L S, Larson M H, Gilbert L A, Doudna J A, Weissman J S, Arkin A P, Lim W A. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013; 152(5):1173-83. PMID: 23452860.

17. Perez-Pinera P, Kocak D D, Vockley C M, Adler A F, Kabadi A M, Polstein L R, Thakore P I, Glass K A, Ousterout D G, Leong K W, Guilak F, Crawford G E, Reddy T E, Gersbach C A. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods. 2013; 10(10):973-6. PMID: 23892895.

18. Mali P, Aach J, Stranges P B, Esvelt K M, Moosburner M, Kosuri S, Yang L, Church G M. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013; 31(9):833-8. PMID: 23907171.

19. Gilbert L A, Larson M H, Morsut L, Liu Z, Brar G A, Torres S E, Stern-Ginossar N, Brandman O, Whitehead E H, Doudna J A, Lim W A, Weissman J S, Qi L S. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013; 154(2):442-51. PMID: 23849981.

20. Larson M H, Gilbert L A, Wang X, Lim W A, Weissman J S, Qi L S. CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat Protoc. 2013; 8(11):2180-96. PMID: 24136345.

21. Mali P, Yang L, Esvelt K M, Aach J, Guell M, DiCarlo J E, Norville J E, Church G M. RNA-guided human genome engineering via Cas9. Science. 2013; 339(6121):823-6. PMID: 23287722.

22. Cole-Strauss A, Yoon K, Xiang Y, Byrne B C, Rice M C, Gryn J, Holloman W K, Kmiec E B. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science. 1996; 273(5280):1386-9. PMID: 8703073.

23. Tagalakis A D, Owen J S, Simons J P. Lack of RNA-DNA oligonucleotide (chimeraplast) mutagenic activity in mouse embryos. Mol Reprod Dev. 2005; 71(2):140-4. PMID: 15791601.

24. Ray A, Langer M. Homologous recombination: ends as the means. Trends Plant Sci. 2002; 7(10):435-40. PMID 12399177.

25. Britt A B, May G D. Re-engineering plant gene targeting. Trends Plant Sci. 2003; 8(2):90-5. PMID: 12597876.

26. Vagner V, Ehrlich S D. Efficiency of homologous DNA recombination varies along the Bacillus subtilis chromosome. J Bacteriol. 1988; 170(9):3978-82. PMID: 3137211.

27. Saleh-Gohari N, Helleday T. Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res. 2004; 32(12):3683-8. PMID: 15252152.

28. Lombardo A, Genovese P, Beausejour C M, Colleoni S, Lee Y L, Kim K A, Ando D, Urnov F D, Galli C, Gregory P D, Holmes M C, Naldini L. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol. 2007; 25(11):1298-306. PMID: 17965707.

29. Conticello S G. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 2008; 9(6):229. PMID: 18598372.

30. Reynaud C A, Aoufouchi S, Faili A, Weill J C. What role for AID: mutator, or assembler of the immunoglobulin mutasome? Nat Immunol. 2003; 4(7):631-8.

31. Bhagwat A S. DNA-cytosine deaminases: from antibody maturation to antiviral defense. DNA Repair (Amst). 2004; 3(1):85-9. PMID: 14697763.

32. Navaratnam N, Sarwar R. An overview of cytidine deaminases. Int J Hematol. 2006; 83(3):195-200. PMID: 16720547.

33. Holden L G, Prochnow C, Chang Y P, Bransteitter R, Chelico L, Sen U, Stevens R C, Goodman M F, Chen X S. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature. 2008; 456(7218):121-4. PMID: 18849968.

34. Chelico L, Pham P, Petruska J, Goodman M F. Biochemical basis of immunological and retroviral responses to DNA-targeted cytosine deamination by activation-induced cytidine deaminase and APOBEC3G. J Biol Chem. 2009; 284(41). 27761-5. PMID: 19684020.

35. Pham P, Bransteitter R, Goodman M F. Reward versus risk: DNA cytidine deaminases triggering immunity and disease. Biochemistry. 2005; 44(8):2703-15. PMID 15723516.

36. Chen X, Zaro J L, Shen W C. Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013; 65(10):1357-69. PMID: 23026637.

37. Lee J W, Soung Y H, Kim S Y, Lee H W, Park W S, Nam S W, Kim S H, Lee J Y, Yoo N J, Lee S H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005; 24(8):1477-80. PMID: 15608678.

38. Ikediobi O N, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, Santarius T, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Hunter C, Jenkinson A, Jones D, Kosmidou V, Lugg R, Menzies A, Mironenko T, Parker A, Perry J, Raine K, Richardson D, Shepherd R, Small A, Smith R, Solomon H, Stephens P, Teague J, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Reinhold W, Weinstein J N, Stratton M R, Futreal P A, Wooster R. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther. 2006; 5(11):2606-12. PMID: 17088437.

39. Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nature medicine 21, 121-131, doi:10.1038/nm.3793 (2015).

40. Hilton, I. B. & Gersbach, C. A. Enabling functional genomics with genome engineering. Genome research 25, 1442-1455, doi:10.1101/gr.190124.115 (2015).

41. Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nature biotechnology 32, 347-355, doi:10.1038/nbt.2842 (2014).

42. Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nature biotechnology 33, 538-542, doi:10.1038/nbt.3190 (2015).

43. Chu, V. T. et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nature biotechnology 33, 543-548, doi:10.1038/nbt.3198 (2015).

44. Lin, S., Staahl, B. T., Alla, R. K. & Doudna, J. A. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. eLife 3, e04766, doi:10.7554/eLife.04766 (2014).

45. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823, doi:10.1126/science.1231143 (2013).

46. Rong, Z., Zhu, S., Xu, Y. & Fu, X. Homologous recombination in human embryonic stem cells using CRISPR/Cas9 nickase and a long DNA donor template. Protein & cell 5, 258-260, doi:10.1007/s13238-014-0032-5 (2014).

47. Jinek, M. et al. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science 337, 816-821, doi:10.1126/science.1225829 (2012).

48. Harris, R. S., Petersen-Mahrt, S. K. & Neuberger, M. S. RNA Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA Mutators. Molecular Cell 10, 1247-1253 (2002).

49. Jinek, M. et al. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science 343, 1247997, doi:10.1126/science.1247997 (2014).

50. Schellenberger, V. et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nature biotechnology 27, 1186-1190, doi:10.1038/nbt.1588 (2009).

51. Saraconi, G., Severi, F., Sala, C., Mattiuz, G. & Conticello, S. G. The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome biology 15, 417-(2014).

52. Anders, C., Niewoehner, O., Duerst, A. & Jinek, M. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature 513, 569-573, doi:10.1038/nature13579 (2014).

53. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).

54. Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nature biotechnology 33, 187-197, doi:10.1038/nbt.3117 (2015).

55. Kunz, C., Saito, Y. & Schar, P. DNA Repair in mammalian cells: Mismatched repair: variations on a theme. Cellular and molecular life sciences: CMLS 66, 1021-1038, doi:10.1007/s00018-009-8739-9 (2009).

56. D., M. C. et al. Crystal structure of human uracil-DNA glycosylase in complex with a protein inhibitor: protein mimicry of DNA. Cell 82, 701-708 (1995).

57. Caldecott, K. W. Single-strand break repair and genetic disease. Nature reviews. Genetics 9, 619-631, doi:10.1038/nrg2380 (2008).

58. Fukui, K. DNA mismatch repair in eukaryotes and bacteria. Journal of nucleic acids 2010, doi:10.4061/2010/260512 (2010).

59. Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proceedings of the National Academy of Sciences 109, E2579-E2586, doi:10.1073/pnas.1208507109 (2012).

60. Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186-191, doi:10.1038/nature14299 (2015).

61. Kuscu, C., Arslan, S., Singh, R., Thorpe, J. & Adli, M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nature biotechnology 32, 677-683, doi:10.1038/nbt.2916 (2014).

62. Wu, X. et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nature biotechnology 32, 670-676, doi:10.1038/nbt.2889 (2014).

63. Beale, R. C. L. et al. Comparison of the Differential Context-dependence of DNA Deamination by APOBEC Enzymes: Correlation with Mutation Spectra in Vivo. Journal of Molecular Biology 337, 585-596, doi:10.1016/j.jmb.2004.01.046 (2004).

64. Kim, J., Basak, J. M. & Holtzman, D. M. The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303, doi:10.1016/j.neuron.2009.06.026 (2009).

65. Liu, C. C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature reviews. Neurology 9, 106-118, doi:10.1038/nrneuro1.2012.263 (2013).

66. Sjöblom, T. et al. The Consensus Coding Sequences of Human Breast and Colorectal Cancers. Science 314, 268-274, doi:10.1126/science.1133427 (2006).

67. Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404, doi:10.1038/nature11017 (2012).

68. Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Research, doi:10.1093/nar/gkv1222 (2015).

69. Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases with improved specificity. Science, doi:10.1126/science.aad5227 (2015).

70. Davis, K. M., Pattanayak, V., Thompson, D. B., Zuris, J. A. & Liu, D. R. Small molecule-triggered Cas9 protein with improved genome-editing specificity. Nature chemical biology 11, 316-318, doi:10.1038/nchembio.1793 (2015).

71. Zuris, J. A. et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nature biotechnology 33, 73-80, doi:10.1038/nbt.3081 (2015).

72. Kleinstiver, B. P. et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523, 481-485, doi:10.1038/nature14592 (2015).

73. Pattanayak, V. et al. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nature Biotechnology 31, 839-843, doi:10.1038/nbt.2673 (2013).

74. Shcherbakova, D. M. & Verkhusha, V. V. Near-infrared fluorescent proteins for multicolor in vivo imaging. Nature Methods 10, 751-754, doi:10.1038/nmeth.2521 (2013).

75. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protocols 8, 2281-2308, doi:10.1038/nprot.2013.143 (2013).

76. Jiang, F. et al. Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage. Science, doi:10.1126/science.aad8282 (2016).

77. Tsai, S. Q. et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotech 32, 569-576, doi:10.1038/nbt.2908 (2014).

78. Lieber, M. R., Ma, Y., Pannicke, U. & Schwarz, K. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 4, 712-720 (2003).

79. Heller, R. C. & Marians, K. J. Replisome assembly and the direct restart of stalled replication forks. Nat Rev Mol Cell Biol 7, 932-943 (2006).

80. Pluciennik, A. et al. PCNA function in the activation and strand direction of MutLα endonuclease in mismatch repair. Proceedings of the National Academy of Sciences of the United States of America 107, 16066-16071, doi:10.1073/pnas.1010662107 (2010).

81. Seripa, D. et al. The missing ApoE allele. Annals of human genetics 71, 496-500, doi:10.1111/j.1469-1809.2006.00344.x (2007).

82. Kleinstiver, B. P. et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529, 490-495, doi:10.1038/nature16526 (2016).

83. Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L. & Corn, J. E. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotech 34, 339-344, doi:10.1038/nbt.3481 (2016).

84. Simonelli, V., Narciso, L., Dogliotti, E. & Fortini, P. Base excision repair intermediates are mutagenic in mammalian cells. Nucleic acids research 33, 4404-4411, doi:10.1093/nar/gki749 (2005).

85. Barnes, D. E. & Lindahl, T. Repair and Genetic Consequences of Endogenous DNA Base Damage in Mammalian Cells. Annual Review of Genetics 38, 445-476, doi:doi:10.1146/annurev.genet.38.072902.092448 (2004).

EQUIVALENTS AND SCOPE

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the embodiments described herein. The scope of the present disclosure is not intended to be limited to the above description, but rather is as set forth in the appended claims.

Articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between two or more members of a group are considered satisfied if one, more than one, or all of the group members are present, unless indicated to the contrary or otherwise evident from the context. The disclosure of a group that includes “or” between two or more group members provides embodiments in which exactly one member of the group is present, embodiments in which more than one members of the group are present, and embodiments in which all of the group members are present. For purposes of brevity those embodiments have not been individually spelled out herein, but it will be understood that each of these embodiments is provided herein and may be specifically claimed or disclaimed.

It is to be understood that the invention encompasses all variations, combinations, and permutations in which one or more limitation, element, clause, or descriptive term, from one or more of the claims or from one or more relevant portion of the description, is introduced into another claim. For example, a claim that is dependent on another claim can be modified to include one or more of the limitations found in any other claim that is dependent on the same base claim. Furthermore, where the claims recite a composition, it is to be understood that methods of making or using the composition according to any of the methods of making or using disclosed herein or according to methods known in the art, if any, are included, unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.

Where elements are presented as lists, e.g., in Markush group format, it is to be understood that every possible subgroup of the elements is also disclosed, and that any element or subgroup of elements can be removed from the group. It is also noted that the term “comprising” is intended to be open and permits the inclusion of additional elements or steps. It should be understood that, in general, where an embodiment, product, or method is referred to as comprising particular elements, features, or steps, embodiments, products, or methods that consist, or consist essentially of, such elements, features, or steps, are provided as well. For purposes of brevity those embodiments have not been individually spelled out herein, but it will be understood that each of these embodiments is provided herein and may be specifically claimed or disclaimed.

Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value within the stated ranges in some embodiments, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. For purposes of brevity, the values in each range have not been individually spelled out herein, but it will be understood that each of these values is provided herein and may be specifically claimed or disclaimed. It is also to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values expressed as ranges can assume any subrange within the given range, wherein the endpoints of the subrange are expressed to the same degree of accuracy as the tenth of the unit of the lower limit of the range.

In addition, it is to be understood that any particular embodiment of the present invention may be explicitly excluded from any one or more of the claims. Where ranges are given, any value within the range may explicitly be excluded from any one or more of the claims. Any embodiment, element, feature, application, or aspect of the compositions and/or methods of the invention, can be excluded from any one or more claims. For purposes of brevity, all of the embodiments in which one or more elements, features, purposes, or aspects is excluded are not set forth explicitly herein.

Claims

1. A fusion protein comprising: (i) a Cpf1 domain, wherein the Cpf1 domain, when in conjunction with a bound guide RNA (gRNA), specifically binds to a target nucleic acid sequence;(ii) a cytidine deaminase domain, wherein the cytidine deaminase domain deaminates a cytosine base in a single-stranded portion of the target nucleic acid sequence when in conjunction with the Cpf1 domain and the gRNA; and(iii) a uracil glycosylase inhibitor (UGI) domain, wherein the UGI domain inhibits a uracil-DNA glycosylase.
2. The fusion protein of claim 1, wherein at least a portion of the target nucleic acid sequence is double-stranded.
3. The fusion protein of claim 1, wherein the Cpf1 domain is a catalytically inactive Cpf1 (dCpf1) domain.
4. The fusion protein of claim 3, wherein the guide RNA nucleic acid binds the single-stranded portion of the target nucleic acid sequence.
5. The fusion protein of claim 4, wherein the guide RNA nucleic acid is a single-stranded guide RNA.
6. The fusion protein of claim 1, wherein deamination of the cytosine base generates a uracil base.
7. The fusion protein of claim 6, wherein the UGI domain inhibits excision of the uracil base from the target nucleic acid sequence.
8. The fusion protein of claim 1, wherein the cytidine deaminase domain comprises an activation-induced deaminase (AID).
9. The fusion protein of claim 1, wherein the cytidine deaminase domain comprises a deaminase from the apolipoprotein B mRNA-editing complex (APOBEC) family deaminase.
10. The fusion protein of claim 9, wherein the APOBEC family deaminase is selected from the group consisting of apolipoprotein B mRNA-editing complex 1 (APOBEC1), apolipoprotein B mRNA-editing complex 2 (APOBEC2), apolipoprotein B mRNA-editing complex 3 (APOBEC3), apolipoprotein B mRNA-editing complex 3A (APOBEC3A), apolipoprotein B mRNA-editing complex 3B (APOBEC3B), apolipoprotein B mRNA-editing complex 3C (APOBEC3C), apolipoprotein B mRNA-editing complex 3D (APOBEC3D), apolipoprotein B mRNA-editing complex 3E (APOBEC3E), apolipoprotein B mRNA-editing complex 3F (APOBEC3F), apolipoprotein B mRNA-editing complex 3G (APOBEC3G), apolipoprotein B mRNA-editing complex 3H (APOBEC3H), and apolipoprotein B mRNA-editing complex 4 (APOBEC4).
11. A complex comprising the fusion protein of claim 1 and a guide RNA (gRNA).
12. A composition comprising the complex of claim 11 and the target nucleic acid sequence.
13. The composition of claim 12, wherein the target nucleic acid sequence comprises a target DNA sequence.
14. The fusion protein of claim 1, wherein the UGI domain comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 600.
15. The fusion protein of claim 1, wherein the UGI domain comprises the amino acid sequence of SEQ ID NO: 600.
16. The fusion protein of claim 1, wherein the Cpf1 domain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 5807.
17. The fusion protein of claim 1, wherein the Cpf1 domain comprises the amino acid sequence of SEQ ID NO: 5807.
18. A method comprising contacting the fusion protein of claim 1 with a guide RNA and the target nucleic acid sequence.
19. The method of claim 18, wherein the guide RNA comprises a sequence of at least 10 contiguous nucleotides that are complementary to at least 10 contiguous nucleotides of the target nucleic acid sequence.
20. The method of claim 19, wherein the target nucleic acid sequence comprises a point mutation associated with a disease or disorder.
21. The method of claim 18, wherein the target nucleic acid sequence comprises an RNA sequence.
22. The method of claim 18, wherein the target nucleic acid sequence comprises a DNA sequence.
23. The method of claim 18, wherein the guide RNA comprises a sequence of at least 10 contiguous nucleotides that are complementary to at least 18-20 contiguous nucleotides of the target nucleic acid sequence.

RELATED APPLICATIONS

This application is a continuation of and claims priority under 35 U.S.C. § 120 to international PCT Application, PCT/US2016/058344, filed Oct. 22, 2016, and is a continuation of and claims priority under 35 U.S.C. § 120 to U.S. Application, U.S. Ser. No. 15/331,852, filed Oct. 22, 2016, which claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent applications, U.S. Ser. No. 62/245,828 filed Oct. 23, 2015, U.S. Ser. No. 62/279,346 filed Jan. 15, 2016, U.S. Ser. No. 62/311,763 filed Mar. 22, 2016, U.S. Ser. No. 62/322,178 filed Apr. 13, 2016, U.S. Ser. No. 62/357,352 filed Jun. 30, 2016, U.S. Ser. No. 62/370,700 filed Aug. 3, 2016, U.S. Ser. No. 62/398,490 filed Sep. 22, 2016, U.S. Ser. No. 62/408,686 filed Oct. 14, 2016, and U.S. Ser. No. 62/357,332 filed Jun. 30, 2016; each of which is incorporated herein by reference.

GOVERNMENT SUPPORT

This invention was made with government support under grant number R01 EB022376 (formerly R01 GM065400) awarded by the National Institutes of Health, under training grant numbers F32 GM 112366-2 and F32 GM 106601-2 awarded by the National Institutes of Health, and Harvard Biophysics NIH training grant T32 GM008313 awarded by the National Institutes of Health. The government has certain rights in the invention.

US Referenced Citations (448)

Number	Name	Date	Kind
4182449	Kozlow	Jan 1980	A
4186183	Steck et al.	Jan 1980	A
4217344	Vanlerberghe et al.	Aug 1980	A
4235871	Papahadjopoulos et al.	Nov 1980	A
4261975	Fullerton et al.	Apr 1981	A
4485054	Mezei et al.	Nov 1984	A
4501728	Geho et al.	Feb 1985	A
4663290	Weis et al.	May 1987	A
4737323	Martin et al.	Apr 1988	A
4774085	Fidler	Sep 1988	A
4797368	Carter et al.	Jan 1989	A
4837028	Allen	Jun 1989	A
4873316	Meade et al.	Oct 1989	A
4880635	Janoff et al.	Nov 1989	A
4889818	Gelfand et al.	Dec 1989	A
4897355	Eppstein et al.	Jan 1990	A
4906477	Kurono et al.	Mar 1990	A
4911928	Wallach	Mar 1990	A
4917951	Wallach	Apr 1990	A
4920016	Allen et al.	Apr 1990	A
4921757	Wheatley et al.	May 1990	A
4946787	Eppstein et al.	Aug 1990	A
4965185	Grischenko et al.	Oct 1990	A
5017492	Kotewicz et al.	May 1991	A
5047342	Chatterjee	Sep 1991	A
5049386	Eppstein et al.	Sep 1991	A
5079352	Gelfand et al.	Jan 1992	A
5139941	Muzyczka et al.	Aug 1992	A
5173414	Lebkowski et al.	Dec 1992	A
5223409	Ladner et al.	Jun 1993	A
5244797	Kotewicz et al.	Sep 1993	A
5270179	Chatterjee	Dec 1993	A
5374553	Gelfand et al.	Dec 1994	A
5405776	Kotewicz et al.	Apr 1995	A
5436149	Barnes	Jul 1995	A
5449639	Wei et al.	Sep 1995	A
5496714	Comb et al.	Mar 1996	A
5512462	Cheng	Apr 1996	A
5580737	Polisky et al.	Dec 1996	A
5614365	Tabor et al.	Mar 1997	A
5658727	Barbas et al.	Aug 1997	A
5668005	Kotewicz et al.	Sep 1997	A
5677152	Birch et al.	Oct 1997	A
5767099	Harris et al.	Jun 1998	A
5780053	Ashley et al.	Jul 1998	A
5830430	Unger et al.	Nov 1998	A
5834247	Comb et al.	Nov 1998	A
5835699	Kimura	Nov 1998	A
5851548	Dattagupta et al.	Dec 1998	A
5855910	Ashley et al.	Jan 1999	A
5962313	Podsakoff et al.	Oct 1999	A
5981182	Jacobs, Jr. et al.	Nov 1999	A
6057153	George et al.	May 2000	A
6063608	Kotewicz et al.	May 2000	A
6156509	Schellenberger	Dec 2000	A
6183998	Ivanov et al.	Feb 2001	B1
6429298	Ellington et al.	Aug 2002	B1
6453242	Eisenberg et al.	Sep 2002	B1
6479264	Louwrier	Nov 2002	B1
6503717	Case et al.	Jan 2003	B2
6534261	Cox, III et al.	Mar 2003	B1
6589768	Kotewicz et al.	Jul 2003	B1
6599692	Case et al.	Jul 2003	B1
6607882	Cox, III et al.	Aug 2003	B1
6610522	Kotewicz et al.	Aug 2003	B1
6689558	Case	Feb 2004	B2
6824978	Cox, III et al.	Nov 2004	B1
6933113	Case et al.	Aug 2005	B2
6979539	Cox, III et al.	Dec 2005	B2
7013219	Case et al.	Mar 2006	B2
7078208	Smith et al.	Jul 2006	B2
7163824	Cox, III et al.	Jan 2007	B2
7479573	Chu et al.	Jan 2009	B2
7595179	Chen et al.	Sep 2009	B2
7670807	Lampson et al.	Mar 2010	B2
7794931	Breaker et al.	Sep 2010	B2
7919277	Russell et al.	Apr 2011	B2
7993672	Huang et al.	Aug 2011	B2
8067556	Hogrefe et al.	Nov 2011	B2
8361725	Russell et al.	Jan 2013	B2
8394604	Liu et al.	Mar 2013	B2
8440431	Voytas et al.	May 2013	B2
8440432	Voytas et al.	May 2013	B2
8450471	Voytas et al.	May 2013	B2
8492082	De Franciscis et al.	Jul 2013	B2
8546553	Terns et al.	Oct 2013	B2
8569256	Heyes et al.	Oct 2013	B2
8586363	Voytas et al.	Nov 2013	B2
8680069	de Fougerolles et al.	Mar 2014	B2
8691750	Constien et al.	Apr 2014	B2
8697359	Zhang	Apr 2014	B1
8697853	Voytas et al.	Apr 2014	B2
8709466	Coady et al.	Apr 2014	B2
8728526	Heller	May 2014	B2
8748667	Budzik et al.	Jun 2014	B2
8758810	Okada et al.	Jun 2014	B2
8759103	Kim et al.	Jun 2014	B2
8759104	Unciti-Broceta et al.	Jun 2014	B2
8771728	Huang et al.	Jul 2014	B2
8790664	Pitard et al.	Jul 2014	B2
8795965	Zhang	Aug 2014	B2
8822663	Schrum et al.	Sep 2014	B2
8846578	McCray et al.	Sep 2014	B2
8900814	Yasukawa et al.	Dec 2014	B2
8993233	Zhang et al.	Mar 2015	B2
8999641	Zhang et al.	Apr 2015	B2
9023594	Liu et al.	May 2015	B2
9068179	Liu et al.	Jun 2015	B1
9163284	Liu et al.	Oct 2015	B2
9181535	Liu et al.	Nov 2015	B2
9228207	Liu et al.	Jan 2016	B2
9234213	Wu	Jan 2016	B2
9267127	Liu et al.	Feb 2016	B2
9322006	Liu et al.	Apr 2016	B2
9322037	Liu et al.	Apr 2016	B2
9340799	Liu et al.	May 2016	B2
9340800	Liu et al.	May 2016	B2
9359599	Liu et al.	Jun 2016	B2
9388430	Liu et al.	Jul 2016	B2
9394537	Liu et al.	Jul 2016	B2
9458484	Ma et al.	Oct 2016	B2
9512446	Joung et al.	Dec 2016	B1
9526724	Oshiack et al.	Dec 2016	B2
9526784	Liu et al.	Dec 2016	B2
9534210	Park et al.	Jan 2017	B2
9580698	Xu et al.	Feb 2017	B1
9637739	{hacek over (S)}ik{hacek over (s)}nys et al.	May 2017	B2
9737604	Liu et al.	Aug 2017	B2
9738693	Telford et al.	Aug 2017	B2
9771574	Liu et al.	Sep 2017	B2
9783791	Hogrefe et al.	Oct 2017	B2
9816093	Donohoue et al.	Nov 2017	B1
9840538	Telford et al.	Dec 2017	B2
9840690	Karli et al.	Dec 2017	B2
9840699	Liu et al.	Dec 2017	B2
9840702	Collingwood et al.	Dec 2017	B2
9850521	Braman et al.	Dec 2017	B2
9873907	Zeiner et al.	Jan 2018	B2
9879270	Hittinger et al.	Jan 2018	B2
9932567	Xu et al.	Apr 2018	B1
9938288	Kishi et al.	Apr 2018	B1
9944933	Storici et al.	Apr 2018	B2
9982279	Gill et al.	May 2018	B1
9999671	Liu et al.	Jun 2018	B2
10059940	Zhong	Aug 2018	B2
10077453	Liu et al.	Sep 2018	B2
10113163	Liu et al.	Oct 2018	B2
10150955	Lambowitz et al.	Dec 2018	B2
10167457	Liu et al.	Jan 2019	B2
10179911	Liu et al.	Jan 2019	B2
10189831	Arrington et al.	Jan 2019	B2
10202658	Parkin et al.	Feb 2019	B2
10227581	Liu et al.	Mar 2019	B2
10323236	Liu et al.	Jun 2019	B2
10336997	Liu et al.	Jul 2019	B2
10358670	Janulaitis et al.	Jul 2019	B2
10392674	Liu et al.	Aug 2019	B2
10407697	Doudna et al.	Sep 2019	B2
10465176	Liu et al.	Nov 2019	B2
10508298	Liu et al.	Dec 2019	B2
10597679	Liu et al.	Mar 2020	B2
10612011	Liu et al.	Apr 2020	B2
10682410	Liu et al.	Jun 2020	B2
10704062	Liu et al.	Jul 2020	B2
10745677	Maianti et al.	Aug 2020	B2
10858639	Liu et al.	Dec 2020	B2
10912833	Liu et al.	Feb 2021	B2
10947530	Liu et al.	Mar 2021	B2
10954548	Liu et al.	Mar 2021	B2
20030082575	Schultz et al.	May 2003	A1
20030087817	Cox et al.	May 2003	A1
20030096337	Hillman et al.	May 2003	A1
20030108885	Schultz et al.	Jun 2003	A1
20030119764	Loeb et al.	Jun 2003	A1
20030167533	Yadav et al.	Sep 2003	A1
20030203480	Kovesdi et al.	Oct 2003	A1
20040003420	Kuhn et al.	Jan 2004	A1
20040115184	Smith et al.	Jun 2004	A1
20040203109	Lal et al.	Oct 2004	A1
20050136429	Guarente et al.	Jun 2005	A1
20050222030	Allison	Oct 2005	A1
20060088864	Smolke et al.	Apr 2006	A1
20060104984	Littlefield et al.	May 2006	A1
20060246568	Honjo et al.	Nov 2006	A1
20070264692	Liu et al.	Nov 2007	A1
20070269817	Shapero	Nov 2007	A1
20080051317	Church et al.	Feb 2008	A1
20080124725	Barrangou et al.	May 2008	A1
20080182254	Hall et al.	Jul 2008	A1
20080220502	Schellenberger et al.	Sep 2008	A1
20090130718	Short	May 2009	A1
20090215878	Tan et al.	Aug 2009	A1
20090234109	Han et al.	Sep 2009	A1
20100076057	Sontheimer et al.	Mar 2010	A1
20100093617	Barrangou et al.	Apr 2010	A1
20100104690	Barrangou et al.	Apr 2010	A1
20100273857	Thakker et al.	Oct 2010	A1
20100305197	Che	Dec 2010	A1
20100316643	Eckert et al.	Dec 2010	A1
20110016540	Weinstein et al.	Jan 2011	A1
20110059160	Essner et al.	Mar 2011	A1
20110059502	Chalasani	Mar 2011	A1
20110104787	Church et al.	May 2011	A1
20110177495	Liu et al.	Jul 2011	A1
20110189776	Terns et al.	Aug 2011	A1
20110217739	Terns et al.	Sep 2011	A1
20110301073	Gregory et al.	Dec 2011	A1
20120129759	Liu et al.	May 2012	A1
20120141523	Castado et al.	Jun 2012	A1
20120244601	Bertozzi et al.	Sep 2012	A1
20120270273	Zhang et al.	Oct 2012	A1
20130059931	Petersen-Mahrt et al.	Mar 2013	A1
20130117869	Duchateau et al.	May 2013	A1
20130130248	Haurwitz et al.	May 2013	A1
20130158245	Russell et al.	Jun 2013	A1
20130165389	Schellenberger et al.	Jun 2013	A1
20130309720	Schultz et al.	Nov 2013	A1
20130344117	Mirosevich et al.	Dec 2013	A1
20130345064	Liu et al.	Dec 2013	A1
20140004280	Loomis	Jan 2014	A1
20140005269	Ngwuluka et al.	Jan 2014	A1
20140017214	Cost	Jan 2014	A1
20140018404	Chen et al.	Jan 2014	A1
20140044793	Goll et al.	Feb 2014	A1
20140065711	Liu et al.	Mar 2014	A1
20140068797	Doudna et al.	Mar 2014	A1
20140127752	Zhou et al.	May 2014	A1
20140141094	Smyth et al.	May 2014	A1
20140141487	Feldman et al.	May 2014	A1
20140179770	Zhang et al.	Jun 2014	A1
20140186843	Zhang et al.	Jul 2014	A1
20140186958	Zhang et al.	Jul 2014	A1
20140201858	Ostertag et al.	Jul 2014	A1
20140234289	Liu et al.	Aug 2014	A1
20140248702	Zhang et al.	Sep 2014	A1
20140273037	Wu	Sep 2014	A1
20140273226	Wu	Sep 2014	A1
20140273230	Chen et al.	Sep 2014	A1
20140295556	Joung et al.	Oct 2014	A1
20140295557	Joung et al.	Oct 2014	A1
20140342456	Mali et al.	Nov 2014	A1
20140342457	Mali et al.	Nov 2014	A1
20140342458	Mali et al.	Nov 2014	A1
20140349400	Jakimo et al.	Nov 2014	A1
20140356867	Peter et al.	Dec 2014	A1
20140356956	Church et al.	Dec 2014	A1
20140356958	Mali et al.	Dec 2014	A1
20140356959	Church et al.	Dec 2014	A1
20140357523	Zeiner et al.	Dec 2014	A1
20140377868	Joung et al.	Dec 2014	A1
20150010526	Liu et al.	Jan 2015	A1
20150031089	Lindstrom	Jan 2015	A1
20150031132	Church et al.	Jan 2015	A1
20150031133	Church et al.	Jan 2015	A1
20150044191	Liu et al.	Feb 2015	A1
20150044192	Liu et al.	Feb 2015	A1
20150044772	Zhao	Feb 2015	A1
20150050699	Siksnys et al.	Feb 2015	A1
20150056177	Liu et al.	Feb 2015	A1
20150056629	Guthrie-Honea	Feb 2015	A1
20150064138	Lu et al.	Mar 2015	A1
20150064789	Paschon et al.	Mar 2015	A1
20150071898	Liu et al.	Mar 2015	A1
20150071899	Liu et al.	Mar 2015	A1
20150071900	Liu et al.	Mar 2015	A1
20150071901	Liu et al.	Mar 2015	A1
20150071902	Liu et al.	Mar 2015	A1
20150071903	Liu et al.	Mar 2015	A1
20150071906	Liu et al.	Mar 2015	A1
20150079680	Bradley et al.	Mar 2015	A1
20150079681	Zhang	Mar 2015	A1
20150098954	Hyde et al.	Apr 2015	A1
20150118216	Liu et al.	Apr 2015	A1
20150132269	Orkin et al.	May 2015	A1
20150140664	Byrne et al.	May 2015	A1
20150159172	Miller et al.	Jun 2015	A1
20150165054	Liu et al.	Jun 2015	A1
20150166980	Liu et al.	Jun 2015	A1
20150166981	Liu et al.	Jun 2015	A1
20150166982	Liu et al.	Jun 2015	A1
20150166984	Liu et al.	Jun 2015	A1
20150166985	Liu et al.	Jun 2015	A1
20150191744	Wolfe et al.	Jul 2015	A1
20150197759	Xu et al.	Jul 2015	A1
20150211058	Carstens	Jul 2015	A1
20150218573	Loque et al.	Aug 2015	A1
20150225773	Farmer et al.	Aug 2015	A1
20150252358	Maeder et al.	Sep 2015	A1
20150275202	Liu et al.	Oct 2015	A1
20150307889	Petolino et al.	Oct 2015	A1
20150315252	Haugwitz et al.	Nov 2015	A1
20160015682	Cawthorne et al.	Jan 2016	A2
20160017393	Jacobson et al.	Jan 2016	A1
20160017396	Cann et al.	Jan 2016	A1
20160032292	Storici et al.	Feb 2016	A1
20160032353	Braman et al.	Feb 2016	A1
20160040155	Maizels et al.	Feb 2016	A1
20160046952	Hittinger et al.	Feb 2016	A1
20160046961	Jinek et al.	Feb 2016	A1
20160046962	May et al.	Feb 2016	A1
20160053272	Wurtzel et al.	Feb 2016	A1
20160053304	Wurtzel et al.	Feb 2016	A1
20160074535	Ranganathan et al.	Mar 2016	A1
20160076093	Shendure et al.	Mar 2016	A1
20160090603	Carnes et al.	Mar 2016	A1
20160090622	Liu et al.	Mar 2016	A1
20160115488	Zhang et al.	Apr 2016	A1
20160138046	Wu	May 2016	A1
20160186214	Brouns et al.	Jun 2016	A1
20160200779	Liu et al.	Jul 2016	A1
20160201040	Liu et al.	Jul 2016	A1
20160201089	Gersbach et al.	Jul 2016	A1
20160206566	Lu et al.	Jul 2016	A1
20160208243	Zhang et al.	Jul 2016	A1
20160208288	Liu et al.	Jul 2016	A1
20160215275	Zhong	Jul 2016	A1
20160215276	Liu et al.	Jul 2016	A1
20160215300	May et al.	Jul 2016	A1
20160244784	Jacobson et al.	Aug 2016	A1
20160244829	Bang et al.	Aug 2016	A1
20160264934	Giallourakis et al.	Sep 2016	A1
20160272965	Zhang et al.	Sep 2016	A1
20160281072	Zhang	Sep 2016	A1
20160298136	Chen et al.	Oct 2016	A1
20160304846	Liu et al.	Oct 2016	A1
20160304855	Stark et al.	Oct 2016	A1
20160312304	Sorrentino et al.	Oct 2016	A1
20160319262	Doudna et al.	Nov 2016	A1
20160333389	Liu et al.	Nov 2016	A1
20160340622	Abdou	Nov 2016	A1
20160340662	Zhang et al.	Nov 2016	A1
20160345578	Barrangou et al.	Dec 2016	A1
20160346360	Quake et al.	Dec 2016	A1
20160346361	Quake et al.	Dec 2016	A1
20160346362	Quake et al.	Dec 2016	A1
20160348074	Quake et al.	Dec 2016	A1
20160348096	Liu et al.	Dec 2016	A1
20160350476	Quake et al.	Dec 2016	A1
20160355796	Davidson et al.	Dec 2016	A1
20160369262	Reik et al.	Dec 2016	A1
20170009224	Liu et al.	Jan 2017	A1
20170009242	McKinley et al.	Jan 2017	A1
20170014449	Bangera et al.	Jan 2017	A1
20170020922	Wagner et al.	Jan 2017	A1
20170037432	Donohoue et al.	Feb 2017	A1
20170044520	Liu et al.	Feb 2017	A1
20170044592	Peter et al.	Feb 2017	A1
20170053729	Kotani et al.	Feb 2017	A1
20170058271	Joung et al.	Mar 2017	A1
20170058272	Carter et al.	Mar 2017	A1
20170058298	Kennedy et al.	Mar 2017	A1
20170073663	Wang et al.	Mar 2017	A1
20170073670	Nishida et al.	Mar 2017	A1
20170087224	Quake	Mar 2017	A1
20170087225	Quake	Mar 2017	A1
20170088587	Quake	Mar 2017	A1
20170088828	Quake	Mar 2017	A1
20170107536	Zhang et al.	Apr 2017	A1
20170107560	Peter et al.	Apr 2017	A1
20170114367	Hu et al.	Apr 2017	A1
20170121693	Liu et al.	May 2017	A1
20170145394	Yeo et al.	May 2017	A1
20170145405	Tang et al.	May 2017	A1
20170145438	Kantor	May 2017	A1
20170152528	Zhang	Jun 2017	A1
20170152787	Kubo et al.	Jun 2017	A1
20170159033	Kamtekar et al.	Jun 2017	A1
20170166928	Vyas et al.	Jun 2017	A1
20170175104	Doudna et al.	Jun 2017	A1
20170175142	Zhang et al.	Jun 2017	A1
20170191047	Terns et al.	Jul 2017	A1
20170191078	Zhang et al.	Jul 2017	A1
20170198269	Zhang et al.	Jul 2017	A1
20170198277	Kmiec et al.	Jul 2017	A1
20170198302	Feng et al.	Jul 2017	A1
20170226522	Hu et al.	Aug 2017	A1
20170233703	Xie et al.	Aug 2017	A1
20170233756	Begemann et al.	Aug 2017	A1
20170247671	Yung et al.	Aug 2017	A1
20170247703	Sloan et al.	Aug 2017	A1
20170268022	Liu et al.	Sep 2017	A1
20170275665	Silas et al.	Sep 2017	A1
20170283797	Robb et al.	Oct 2017	A1
20170283831	Zhang et al.	Oct 2017	A1
20170314016	Kim et al.	Nov 2017	A1
20170362635	Chamberlain et al.	Dec 2017	A1
20180064077	Dunham et al.	Mar 2018	A1
20180066258	Powell	Mar 2018	A1
20180068062	Zhang et al.	Mar 2018	A1
20180073012	Liu et al.	Mar 2018	A1
20180080051	Sheikh et al.	Mar 2018	A1
20180087046	Badran et al.	Mar 2018	A1
20180100147	Yates et al.	Apr 2018	A1
20180105867	Xiao et al.	Apr 2018	A1
20180119118	Lu et al.	May 2018	A1
20180127780	Liu et al.	May 2018	A1
20180155708	Church et al.	Jun 2018	A1
20180155720	Donohoue et al.	Jun 2018	A1
20180163213	Aneja et al.	Jun 2018	A1
20180170984	Harris et al.	Jun 2018	A1
20180179503	Maianti et al.	Jun 2018	A1
20180179547	Zhang et al.	Jun 2018	A1
20180201921	Malcolm	Jul 2018	A1
20180230464	Zhong	Aug 2018	A1
20180230471	Storici et al.	Aug 2018	A1
20180236081	Liu et al.	Aug 2018	A1
20180237758	Liu et al.	Aug 2018	A1
20180237787	Maianti et al.	Aug 2018	A1
20180245066	Yao et al.	Aug 2018	A1
20180258418	Kim	Sep 2018	A1
20180265864	Li et al.	Sep 2018	A1
20180273939	Yu et al.	Sep 2018	A1
20180282722	Jakimo et al.	Oct 2018	A1
20180298391	Jakimo et al.	Oct 2018	A1
20180305688	Zhong	Oct 2018	A1
20180305704	Zhang	Oct 2018	A1
20180312822	Lee et al.	Nov 2018	A1
20180312825	Liu et al.	Nov 2018	A1
20180312828	Liu et al.	Nov 2018	A1
20180312835	Yao et al.	Nov 2018	A1
20180327756	Zhang et al.	Nov 2018	A1
20190010481	Joung et al.	Jan 2019	A1
20190055543	Tran et al.	Feb 2019	A1
20190093099	Liu et al.	Mar 2019	A1
20190185883	Liu et al.	Jun 2019	A1
20190225955	Liu et al.	Jul 2019	A1
20190233847	Savage et al.	Aug 2019	A1
20190241633	Fotin-Mleczek et al.	Aug 2019	A1
20190256842	Liu et al.	Aug 2019	A1
20190264202	Church et al.	Aug 2019	A1
20190276816	Liu et al.	Sep 2019	A1
20190322992	Liu et al.	Oct 2019	A1
20190352632	Liu et al.	Nov 2019	A1
20190367891	Liu et al.	Dec 2019	A1
20200010818	Liu et al.	Jan 2020	A1
20200010835	Maianti et al.	Jan 2020	A1
20200063127	Lu et al.	Feb 2020	A1
20200071722	Liu et al.	Mar 2020	A1
20200172931	Liu et al.	Jun 2020	A1
20200181619	Tang et al.	Jun 2020	A1
20200190493	Liu et al.	Jun 2020	A1
20200216833	Liu et al.	Jul 2020	A1
20200255868	Liu et al.	Aug 2020	A1
20200277587	Liu et al.	Sep 2020	A1
20200323984	Liu et al.	Oct 2020	A1
20200399619	Maianti et al.	Dec 2020	A1
20200399626	Liu et al.	Dec 2020	A1
20210054416	Liu et al.	Feb 2021	A1

Foreign Referenced Citations (1579)

Number	Date	Country
2012244264	Nov 2012	AU
2012354062	Jul 2014	AU
2015252023	Nov 2015	AU
2015101792	Jan 2016	AU
112015013786	Jul 2017	BR
2894668	Jun 2014	CA
2894681	Jun 2014	CA
2894684	Jun 2014	CA
2 852 593	Nov 2015	CA
1069962	Mar 1993	CN
103224947	Jul 2013	CN
103233028	Aug 2013	CN
103388006	Nov 2013	CN
103614415	Mar 2014	CN
103642836	Mar 2014	CN
103668472	Mar 2014	CN
103820441	May 2014	CN
103820454	May 2014	CN
103911376	Jul 2014	CN
103923911	Jul 2014	CN
103981211	Aug 2014	CN
103981212	Aug 2014	CN
104004778	Aug 2014	CN
104004782	Aug 2014	CN
104017821	Sep 2014	CN
104109687	Oct 2014	CN
104178461	Dec 2014	CN
104342457	Feb 2015	CN
104404036	Mar 2015	CN
104450774	Mar 2015	CN
104480144	Apr 2015	CN
104498493	Apr 2015	CN
104504304	Apr 2015	CN
104531704	Apr 2015	CN
104531705	Apr 2015	CN
104560864	Apr 2015	CN
104561095	Apr 2015	CN
104593418	May 2015	CN
104593422	May 2015	CN
104611370	May 2015	CN
104651392	May 2015	CN
104651398	May 2015	CN
104651399	May 2015	CN
104651401	May 2015	CN
104673816	Jun 2015	CN
104725626	Jun 2015	CN
104726449	Jun 2015	CN
104726494	Jun 2015	CN
104745626	Jul 2015	CN
104762321	Jul 2015	CN
104805078	Jul 2015	CN
104805099	Jul 2015	CN
104805118	Jul 2015	CN
104846010	Aug 2015	CN
104894068	Sep 2015	CN
104894075	Sep 2015	CN
104928321	Sep 2015	CN
105039339	Nov 2015	CN
105039399	Nov 2015	CN
105063061	Nov 2015	CN
105087620	Nov 2015	CN
105112422	Dec 2015	CN
105112445	Dec 2015	CN
105112519	Dec 2015	CN
105121648	Dec 2015	CN
105132427	Dec 2015	CN
105132451	Dec 2015	CN
105177038	Dec 2015	CN
105177126	Dec 2015	CN
105210981	Jan 2016	CN
105219799	Jan 2016	CN
105238806	Jan 2016	CN
105255937	Jan 2016	CN
105274144	Jan 2016	CN
105296518	Feb 2016	CN
105296537	Feb 2016	CN
105316324	Feb 2016	CN
105316327	Feb 2016	CN
105316337	Feb 2016	CN
105331607	Feb 2016	CN
105331608	Feb 2016	CN
105331609	Feb 2016	CN
105331627	Feb 2016	CN
105400773	Mar 2016	CN
105400779	Mar 2016	CN
105400810	Mar 2016	CN
105441451	Mar 2016	CN
105462968	Apr 2016	CN
105463003	Apr 2016	CN
105463027	Apr 2016	CN
105492608	Apr 2016	CN
105492609	Apr 2016	CN
105505976	Apr 2016	CN
105505979	Apr 2016	CN
105518134	Apr 2016	CN
105518135	Apr 2016	CN
105518137	Apr 2016	CN
105518138	Apr 2016	CN
105518139	Apr 2016	CN
105518140	Apr 2016	CN
105543228	May 2016	CN
105543266	May 2016	CN
105543270	May 2016	CN
105567688	May 2016	CN
105567689	May 2016	CN
105567734	May 2016	CN
105567735	May 2016	CN
105567738	May 2016	CN
105593367	May 2016	CN
105594664	May 2016	CN
105602987	May 2016	CN
105624146	Jun 2016	CN
105624187	Jun 2016	CN
105646719	Jun 2016	CN
105647922	Jun 2016	CN
105647962	Jun 2016	CN
105647968	Jun 2016	CN
105647969	Jun 2016	CN
105671070	Jun 2016	CN
105671083	Jun 2016	CN
105695485	Jun 2016	CN
105779448	Jul 2016	CN
105779449	Jul 2016	CN
105802980	Jul 2016	CN
105821039	Aug 2016	CN
105821040	Aug 2016	CN
105821049	Aug 2016	CN
105821072	Aug 2016	CN
105821075	Aug 2016	CN
105821116	Aug 2016	CN
105838733	Aug 2016	CN
105861547	Aug 2016	CN
105861552	Aug 2016	CN
105861554	Aug 2016	CN
105886498	Aug 2016	CN
105886534	Aug 2016	CN
105886616	Aug 2016	CN
105907758	Aug 2016	CN
105907785	Aug 2016	CN
105925608	Sep 2016	CN
105950560	Sep 2016	CN
105950626	Sep 2016	CN
105950633	Sep 2016	CN
105950639	Sep 2016	CN
105985985	Oct 2016	CN
106011104	Oct 2016	CN
106011150	Oct 2016	CN
106011167	Oct 2016	CN
106011171	Oct 2016	CN
106032540	Oct 2016	CN
106047803	Oct 2016	CN
106047877	Oct 2016	CN
106047930	Oct 2016	CN
106086008	Nov 2016	CN
106086028	Nov 2016	CN
106086061	Nov 2016	CN
106086062	Nov 2016	CN
106109417	Nov 2016	CN
106119275	Nov 2016	CN
106119283	Nov 2016	CN
106148286	Nov 2016	CN
106148370	Nov 2016	CN
106148416	Nov 2016	CN
106167525	Nov 2016	CN
106167808	Nov 2016	CN
106167810	Nov 2016	CN
106167821	Nov 2016	CN
106172238	Dec 2016	CN
106190903	Dec 2016	CN
106191057	Dec 2016	CN
106191061	Dec 2016	CN
106191062	Dec 2016	CN
106191064	Dec 2016	CN
106191071	Dec 2016	CN
106191099	Dec 2016	CN
106191107	Dec 2016	CN
106191113	Dec 2016	CN
106191114	Dec 2016	CN
106191116	Dec 2016	CN
106191124	Dec 2016	CN
106222177	Dec 2016	CN
106222193	Dec 2016	CN
106222203	Dec 2016	CN
106244555	Dec 2016	CN
106244591	Dec 2016	CN
106244609	Dec 2016	CN
106282241	Jan 2017	CN
106318934	Jan 2017	CN
106318973	Jan 2017	CN
106350540	Jan 2017	CN
106367435	Feb 2017	CN
106399306	Feb 2017	CN
106399311	Feb 2017	CN
106399360	Feb 2017	CN
106399367	Feb 2017	CN
106399375	Feb 2017	CN
106399377	Feb 2017	CN
106434651	Feb 2017	CN
106434663	Feb 2017	CN
106434688	Feb 2017	CN
106434737	Feb 2017	CN
106434748	Feb 2017	CN
106434752	Feb 2017	CN
106434782	Feb 2017	CN
106446600	Feb 2017	CN
106479985	Mar 2017	CN
106480027	Mar 2017	CN
106480036	Mar 2017	CN
106480067	Mar 2017	CN
106480080	Mar 2017	CN
106480083	Mar 2017	CN
106480097	Mar 2017	CN
106544351	Mar 2017	CN
106544353	Mar 2017	CN
106544357	Mar 2017	CN
106554969	Apr 2017	CN
106566838	Apr 2017	CN
106701763	May 2017	CN
106701808	May 2017	CN
106701818	May 2017	CN
106701823	May 2017	CN
106701830	May 2017	CN
106754912	May 2017	CN
106755026	May 2017	CN
106755077	May 2017	CN
106755088	May 2017	CN
106755091	May 2017	CN
106755097	May 2017	CN
106755424	May 2017	CN
106801056	Jun 2017	CN
106834323	Jun 2017	CN
106834341	Jun 2017	CN
106834347	Jun 2017	CN
106845151	Jun 2017	CN
106868008	Jun 2017	CN
106868031	Jun 2017	CN
106906240	Jun 2017	CN
106906242	Jun 2017	CN
106916820	Jul 2017	CN
106916852	Jul 2017	CN
106939303	Jul 2017	CN
106947750	Jul 2017	CN
106947780	Jul 2017	CN
106957830	Jul 2017	CN
106957831	Jul 2017	CN
106957844	Jul 2017	CN
106957855	Jul 2017	CN
106957858	Jul 2017	CN
106967697	Jul 2017	CN
106967726	Jul 2017	CN
106978428	Jul 2017	CN
106987570	Jul 2017	CN
106987757	Jul 2017	CN
107012164	Aug 2017	CN
107012174	Aug 2017	CN
107012213	Aug 2017	CN
107012250	Aug 2017	CN
107022562	Aug 2017	CN
107034188	Aug 2017	CN
107034218	Aug 2017	CN
107034229	Aug 2017	CN
107043775	Aug 2017	CN
107043779	Aug 2017	CN
107043787	Aug 2017	CN
107058320	Aug 2017	CN
107058328	Aug 2017	CN
107058358	Aug 2017	CN
107058372	Aug 2017	CN
107083392	Aug 2017	CN
107099533	Aug 2017	CN
107099850	Aug 2017	CN
107119053	Sep 2017	CN
107119071	Sep 2017	CN
107129999	Sep 2017	CN
107130000	Sep 2017	CN
107142272	Sep 2017	CN
107142282	Sep 2017	CN
107177591	Sep 2017	CN
107177595	Sep 2017	CN
107177631	Sep 2017	CN
107190006	Sep 2017	CN
107190008	Sep 2017	CN
107217042	Sep 2017	CN
107217075	Sep 2017	CN
107227307	Oct 2017	CN
107227352	Oct 2017	CN
107236737	Oct 2017	CN
107236739	Oct 2017	CN
107236741	Oct 2017	CN
107245502	Oct 2017	CN
107254485	Oct 2017	CN
107266541	Oct 2017	CN
107267515	Oct 2017	CN
107287245	Oct 2017	CN
107298701	Oct 2017	CN
107299114	Oct 2017	CN
107304435	Oct 2017	CN
107312785	Nov 2017	CN
107312793	Nov 2017	CN
107312795	Nov 2017	CN
107312798	Nov 2017	CN
107326042	Nov 2017	CN
107326046	Nov 2017	CN
107354156	Nov 2017	CN
107354173	Nov 2017	CN
107356793	Nov 2017	CN
107362372	Nov 2017	CN
107365786	Nov 2017	CN
107365804	Nov 2017	CN
107384894	Nov 2017	CN
107384922	Nov 2017	CN
107384926	Nov 2017	CN
107400677	Nov 2017	CN
107418974	Dec 2017	CN
107435051	Dec 2017	CN
107435069	Dec 2017	CN
107446922	Dec 2017	CN
107446923	Dec 2017	CN
107446924	Dec 2017	CN
107446932	Dec 2017	CN
107446951	Dec 2017	CN
107446954	Dec 2017	CN
107460196	Dec 2017	CN
107474129	Dec 2017	CN
107475300	Dec 2017	CN
107488649	Dec 2017	CN
107502608	Dec 2017	CN
107502618	Dec 2017	CN
107513531	Dec 2017	CN
107519492	Dec 2017	CN
107523567	Dec 2017	CN
107523583	Dec 2017	CN
107541525	Jan 2018	CN
107557373	Jan 2018	CN
107557378	Jan 2018	CN
107557381	Jan 2018	CN
107557390	Jan 2018	CN
107557393	Jan 2018	CN
107557394	Jan 2018	CN
107557455	Jan 2018	CN
107574179	Jan 2018	CN
107586777	Jan 2018	CN
107586779	Jan 2018	CN
107604003	Jan 2018	CN
107619829	Jan 2018	CN
107619837	Jan 2018	CN
107630006	Jan 2018	CN
107630041	Jan 2018	CN
107630042	Jan 2018	CN
107630043	Jan 2018	CN
107641631	Jan 2018	CN
107653256	Feb 2018	CN
107686848	Feb 2018	CN
206970581	Feb 2018	CN
107760652	Mar 2018	CN
107760663	Mar 2018	CN
107760684	Mar 2018	CN
107760715	Mar 2018	CN
107784200	Mar 2018	CN
107794272	Mar 2018	CN
107794276	Mar 2018	CN
107815463	Mar 2018	CN
107828738	Mar 2018	CN
107828794	Mar 2018	CN
107828826	Mar 2018	CN
107828874	Mar 2018	CN
107858346	Mar 2018	CN
107858373	Mar 2018	CN
107880132	Apr 2018	CN
107881184	Apr 2018	CN
107893074	Apr 2018	CN
107893075	Apr 2018	CN
107893076	Apr 2018	CN
107893080	Apr 2018	CN
107893086	Apr 2018	CN
107904261	Apr 2018	CN
107937427	Apr 2018	CN
107937432	Apr 2018	CN
107937501	Apr 2018	CN
107974466	May 2018	CN
107988229	May 2018	CN
107988246	May 2018	CN
107988256	May 2018	CN
107988268	May 2018	CN
108018316	May 2018	CN
108034656	May 2018	CN
108048466	May 2018	CN
108102940	Jun 2018	CN
108103092	Jun 2018	CN
108103098	Jun 2018	CN
108103586	Jun 2018	CN
108148835	Jun 2018	CN
108148837	Jun 2018	CN
108148873	Jun 2018	CN
108192956	Jun 2018	CN
108251423	Jul 2018	CN
108251451	Jul 2018	CN
108251452	Jul 2018	CN
108342480	Jul 2018	CN
108359691	Aug 2018	CN
108359712	Aug 2018	CN
108384784	Aug 2018	CN
108396027	Aug 2018	CN
108410877	Aug 2018	CN
108410906	Aug 2018	CN
108410907	Aug 2018	CN
108410911	Aug 2018	CN
108424931	Aug 2018	CN
108441519	Aug 2018	CN
108441520	Aug 2018	CN
108486108	Sep 2018	CN
108486111	Sep 2018	CN
108486145	Sep 2018	CN
108486146	Sep 2018	CN
108486154	Sep 2018	CN
108486159	Sep 2018	CN
108486234	Sep 2018	CN
108504657	Sep 2018	CN
108504685	Sep 2018	CN
108504693	Sep 2018	CN
108546712	Sep 2018	CN
108546717	Sep 2018	CN
108546718	Sep 2018	CN
108559730	Sep 2018	CN
108559732	Sep 2018	CN
108559745	Sep 2018	CN
108559760	Sep 2018	CN
108570479	Sep 2018	CN
108588071	Sep 2018	CN
108588123	Sep 2018	CN
108588128	Sep 2018	CN
108588182	Sep 2018	CN
108610399	Oct 2018	CN
108611364	Oct 2018	CN
108624622	Oct 2018	CN
108642053	Oct 2018	CN
108642055	Oct 2018	CN
108642077	Oct 2018	CN
108642078	Oct 2018	CN
108642090	Oct 2018	CN
108690844	Oct 2018	CN
108707604	Oct 2018	CN
108707620	Oct 2018	CN
108707621	Oct 2018	CN
108707628	Oct 2018	CN
108707629	Oct 2018	CN
108715850	Oct 2018	CN
108728476	Nov 2018	CN
108728486	Nov 2018	CN
108753772	Nov 2018	CN
108753783	Nov 2018	CN
108753813	Nov 2018	CN
108753817	Nov 2018	CN
108753832	Nov 2018	CN
108753835	Nov 2018	CN
108753836	Nov 2018	CN
108795902	Nov 2018	CN
108822217	Nov 2018	CN
108823248	Nov 2018	CN
108823249	Nov 2018	CN
108823291	Nov 2018	CN
108841845	Nov 2018	CN
108853133	Nov 2018	CN
108866093	Nov 2018	CN
108893529	Nov 2018	CN
108913664	Nov 2018	CN
108913691	Nov 2018	CN
108913714	Nov 2018	CN
108913717	Nov 2018	CN
109 517 841	Mar 2019	CN
0264166	Apr 1988	EP
2604255	Jun 2013	EP
2840140	Feb 2015	EP
2966170	Jan 2016	EP
3009511	Apr 2016	EP
3031921	Jun 2016	EP
3045537	Jul 2016	EP
3 115 457	Jan 2017	EP
3144390	Mar 2017	EP
3199632	Aug 2017	EP
3216867	Sep 2017	EP
3252160	Dec 2017	EP
3450553	Dec 2019	EP
2740248	Feb 2020	ES
2528177	Jan 2016	GB
2531454	Apr 2016	GB
2542653	Mar 2017	GB
1208045	Feb 2016	HK
2007-501626	Feb 2007	JP
2008-515405	May 2008	JP
2010-539929	Dec 2010	JP
2011-081011	Apr 2011	JP
2011-523353	Aug 2011	JP
2012-525146	Oct 2012	JP
2012-531909	Dec 2012	JP
101584933	Jan 2016	KR
20160133380	Nov 2016	KR
20170037025	Apr 2017	KR
20170037028	Apr 2017	KR
101748575	Jun 2017	KR
2018-0022465	Mar 2018	KR
2016104674	Aug 2017	RU
2634395	Oct 2017	RU
2652899	May 2018	RU
2015128057	Mar 2019	RU
2015128098	Mar 2019	RU
2687451	May 2019	RU
2019112514	Jun 2019	RU
2019127300	Sep 2019	RU
2701850	Oct 2019	RU
1608100	Dec 2017	TW
2018-29773	Aug 2018	TW
WO 9002809	Mar 1990	WO
WO 9116024	Oct 1991	WO
WO 9117271	Nov 1991	WO
WO 9117424	Nov 1991	WO
WO 9206188	Apr 1992	WO
WO 9206200	Apr 1992	WO
WO 9324641	Dec 1993	WO
WO 9418316	Aug 1994	WO
WO 94026877	Nov 1994	WO
WO 9604403	Feb 1996	WO
WO 9610640	Apr 1996	WO
WO 9832845	Jul 1998	WO
WO 2001036452	May 2001	WO
WO 2001038547	May 2001	WO
WO 2002059296	Aug 2002	WO
WO 2002068676	Sep 2002	WO
WO 2002103028	Dec 2002	WO
WO 2004007684	Jan 2004	WO
WO 0514791	Feb 2005	WO
WO 2005014791	Feb 2005	WO
WO 2005019415	Mar 2005	WO
WO 2006002547	Jan 2006	WO
WO 2006042112	Apr 2006	WO
WO 2007025097	Mar 2007	WO
WO 07066923	Jun 2007	WO
WO 2007136815	Nov 2007	WO
WO 2007143574	Dec 2007	WO
WO 08005529	Jan 2008	WO
WO 2008108989	Sep 2008	WO
WO 2009134808	Nov 2009	WO
WO 2010011961	Jan 2010	WO
WO 2010028347	Mar 2010	WO
WO 2010054108	May 2010	WO
WO 2010054154	May 2010	WO
WO 2010068289	Jun 2010	WO
WO 2010075424	Jul 2010	WO
WO 2010102257	Sep 2010	WO
WO 2010129019	Nov 2010	WO
WO 2010129023	Nov 2010	WO
WO 2010132092	Nov 2010	WO
WO 2010144150	Dec 2010	WO
WO 2011002503	Jan 2011	WO
WO 2011017293	Feb 2011	WO
WO 2011053868	May 2011	WO
WO 2011053982	May 2011	WO
WO 2011068810	Jun 2011	WO
WO 2011075627	Jun 2011	WO
WO 2011091311	Jul 2011	WO
WO 2011109031	Sep 2011	WO
WO 2011143124	Nov 2011	WO
WO 2011147590	Dec 2011	WO
WO 2011159369	Dec 2011	WO
WO 2012054726	Apr 2012	WO
WO 2012065043	May 2012	WO
WO 2012088381	Jun 2012	WO
WO 2012125445	Sep 2012	WO
WO 2012138927	Oct 2012	WO
WO 2012149470	Nov 2012	WO
WO 2012158985	Nov 2012	WO
WO 2012158986	Nov 2012	WO
WO 2012164565	Dec 2012	WO
WO 2012170930	Dec 2012	WO
WO 2013012674	Jan 2013	WO
WO 2013013105	Jan 2013	WO
WO 2013013105	Jan 2013	WO
WO 2013039857	Mar 2013	WO
WO 2013039861	Mar 2013	WO
WO 2013045632	Apr 2013	WO
WO 2013047844	Apr 2013	WO
WO 2013066438	May 2013	WO
WO 2013098244	Jul 2013	WO
WO 2013119602	Aug 2013	WO
WO 2013126794	Aug 2013	WO
WO 2013130824	Sep 2013	WO
WO 2013141680	Sep 2013	WO
WO 2013142578	Sep 2013	WO
WO 2013152359	Oct 2013	WO
WO 2013160230	Oct 2013	WO
WO 2013166315	Nov 2013	WO
WO 2013169398	Nov 2013	WO
WO 2013169802	Nov 2013	WO
WO 2013176772	Nov 2013	WO
WO 2013176915	Nov 2013	WO
WO 2013176916	Nov 2013	WO
WO 2013181440	Dec 2013	WO
WO 2013186754	Dec 2013	WO
WO 2013188037	Dec 2013	WO
WO 2013188522	Dec 2013	WO
WO 2013188638	Dec 2013	WO
WO 2013192278	Dec 2013	WO
WO 2013142378	Jan 2014	WO
WO 2014004336	Jan 2014	WO
WO 2014005042	Jan 2014	WO
WO 2014011237	Jan 2014	WO
WO 2014011901	Jan 2014	WO
WO 2014018423	Jan 2014	WO
WO 2014020608	Feb 2014	WO
WO 2014022120	Feb 2014	WO
WO 2014022702	Feb 2014	WO
WO 2014036219	Mar 2014	WO
WO 2014039513	Mar 2014	WO
WO 2014039523	Mar 2014	WO
WO 2014039585	Mar 2014	WO
WO 2014039684	Mar 2014	WO
WO 2014039692	Mar 2014	WO
WO 2014039702	Mar 2014	WO
WO 2014039872	Mar 2014	WO
WO 2014039970	Mar 2014	WO
WO 2014041327	Mar 2014	WO
WO 2014043143	Mar 2014	WO
WO 2014047103	Mar 2014	WO
WO 2014055782	Apr 2014	WO
WO 2014059173	Apr 2014	WO
WO 2014059255	Apr 2014	WO
WO 2014065596	May 2014	WO
WO 2014066505	May 2014	WO
WO 2014068346	May 2014	WO
WO 2014070887	May 2014	WO
WO 2014071006	May 2014	WO
WO 2014071219	May 2014	WO
WO 2014071235	May 2014	WO
WO 2014072941	May 2014	WO
WO 2014081729	May 2014	WO
WO 2014081730	May 2014	WO
WO 2014081855	May 2014	WO
WO 2014082644	Jun 2014	WO
WO 2014085261	Jun 2014	WO
WO 2014085593	Jun 2014	WO
WO 2014085830	Jun 2014	WO
WO 2014089212	Jun 2014	WO
WO 2014089290	Jun 2014	WO
WO 2014089348	Jun 2014	WO
WO 2014089513	Jun 2014	WO
WO 2014089533	Jun 2014	WO
WO 2014089541	Jun 2014	WO
WO 2014093479	Jun 2014	WO
WO 2014093595	Jun 2014	WO
WO 2014093622	Jun 2014	WO
WO 2014093635	Jun 2014	WO
WO 2014093655	Jun 2014	WO
WO 2014093661	Jun 2014	WO
WO 2014093694	Jun 2014	WO
WO 2014093701	Jun 2014	WO
WO 2014093709	Jun 2014	WO
WO 2014093712	Jun 2014	WO
WO 2014093718	Jun 2014	WO
WO 2014093736	Jun 2014	WO
WO 2014093768	Jun 2014	WO
WO 2014093852	Jun 2014	WO
WO 2014096972	Jun 2014	WO
WO 2014099744	Jun 2014	WO
WO 2014099750	Jun 2014	WO
WO 2014104878	Jul 2014	WO
WO 2014110006	Jul 2014	WO
WO 2014110552	Jul 2014	WO
WO 2014113493	Jul 2014	WO
WO 2014123967	Aug 2014	WO
WO 2014124226	Aug 2014	WO
WO 2014125668	Aug 2014	WO
WO 2014127287	Aug 2014	WO
WO 2014128324	Aug 2014	WO
WO 2014128659	Aug 2014	WO
WO 2014130706	Aug 2014	WO
WO 2014130955	Aug 2014	WO
WO 2014131833	Sep 2014	WO
WO 2014138379	Sep 2014	WO
WO 2014143381	Sep 2014	WO
WO 2014144094	Sep 2014	WO
WO 2014144155	Sep 2014	WO
WO 2014144288	Sep 2014	WO
WO 2014144592	Sep 2014	WO
WO 2014144761	Sep 2014	WO
WO 2014144951	Sep 2014	WO
WO 2014145599	Sep 2014	WO
WO 2014145736	Sep 2014	WO
WO 2014150624	Sep 2014	WO
WO 2014152432	Sep 2014	WO
WO 2014152940	Sep 2014	WO
WO 2014153118	Sep 2014	WO
WO 2014153470	Sep 2014	WO
WO 2014158593	Oct 2014	WO
WO 2014161821	Oct 2014	WO
WO 2014164466	Oct 2014	WO
WO 2014165177	Oct 2014	WO
WO 2014165349	Oct 2014	WO
WO 2014165612	Oct 2014	WO
WO 2014165707	Oct 2014	WO
WO 2014165825	Oct 2014	WO
WO 2014172458	Oct 2014	WO
WO 2014172470	Oct 2014	WO
WO 2014172489	Oct 2014	WO
WO 2014173955	Oct 2014	WO
WO 2014182700	Nov 2014	WO
WO 2014183071	Nov 2014	WO
WO 2014184143	Nov 2014	WO
WO 2014184741	Nov 2014	WO
WO 2014184744	Nov 2014	WO
WO 2014186585	Nov 2014	WO
WO 2014186686	Nov 2014	WO
WO 2014190181	Nov 2014	WO
WO 2014191128	Dec 2014	WO
WO 2014191518	Dec 2014	WO
WO 2014191521	Dec 2014	WO
WO 2014191525	Dec 2014	WO
WO 2014191527	Dec 2014	WO
WO 2014193583	Dec 2014	WO
WO 2014194190	Dec 2014	WO
WO 2014197568	Dec 2014	WO
WO 2014197748	Dec 2014	WO
WO 2014199358	Dec 2014	WO
WO 2014200659	Dec 2014	WO
WO 2014201015	Dec 2014	WO
WO 2014204578	Dec 2014	WO
WO 2014204723	Dec 2014	WO
WO 2014204724	Dec 2014	WO
WO 2014204725	Dec 2014	WO
WO 2014204726	Dec 2014	WO
WO 2014204727	Dec 2014	WO
WO 2014204728	Dec 2014	WO
WO 2014204729	Dec 2014	WO
WO 2014205192	Dec 2014	WO
WO 2014207043	Dec 2014	WO
WO 2015002780	Jan 2015	WO
WO 2015004241	Jan 2015	WO
WO 2015006290	Jan 2015	WO
WO 2015006294	Jan 2015	WO
WO 2015006437	Jan 2015	WO
WO 2015006498	Jan 2015	WO
WO 2015006747	Jan 2015	WO
WO 2015007194	Jan 2015	WO
WO 2015010114	Jan 2015	WO
WO 2015011483	Jan 2015	WO
WO 2015013583	Jan 2015	WO
WO 2015017866	Feb 2015	WO
WO 2015018503	Feb 2015	WO
WO 2015021353	Feb 2015	WO
WO 2015021426	Feb 2015	WO
WO 2015021990	Feb 2015	WO
WO 2015024017	Feb 2015	WO
WO 2015024986	Feb 2015	WO
WO 2015026883	Feb 2015	WO
WO 2015026885	Feb 2015	WO
WO 2015026886	Feb 2015	WO
WO 2015026887	Feb 2015	WO
WO 2015027134	Feb 2015	WO
WO 2015028969	Mar 2015	WO
WO 2015030881	Mar 2015	WO
WO 2015031619	Mar 2015	WO
WO 2015031775	Mar 2015	WO
WO 2015032494	Mar 2015	WO
WO 2015033293	Mar 2015	WO
WO 2015034872	Mar 2015	WO
WO 2015034885	Mar 2015	WO
WO 2015035136	Mar 2015	WO
WO 2015035139	Mar 2015	WO
WO 2015035162	Mar 2015	WO
WO 2015040075	Mar 2015	WO
WO 2015040402	Mar 2015	WO
WO 2015042585	Mar 2015	WO
WO 2015048577	Apr 2015	WO
WO 2015048690	Apr 2015	WO
WO 2015048707	Apr 2015	WO
WO 2015048801	Apr 2015	WO
WO 2015049897	Apr 2015	WO
WO 2015051191	Apr 2015	WO
WO 2015052133	Apr 2015	WO
WO 2015052231	Apr 2015	WO
WO 2015052335	Apr 2015	WO
WO 2015053995	Apr 2015	WO
WO 2015054253	Apr 2015	WO
WO 2015054315	Apr 2015	WO
WO 2015057671	Apr 2015	WO
WO 2015057834	Apr 2015	WO
WO 2015057852	Apr 2015	WO
WO 2015057976	Apr 2015	WO
WO 2015057980	Apr 2015	WO
WO 2015059265	Apr 2015	WO
WO 2015065964	May 2015	WO
WO 2015066119	May 2015	WO
WO 2015066634	May 2015	WO
WO 2015066636	May 2015	WO
WO 2015066637	May 2015	WO
WO 2015066638	May 2015	WO
WO 2015066643	May 2015	WO
WO 2015069682	May 2015	WO
WO 2015070083	May 2015	WO
WO 2015070193	May 2015	WO
WO 2015070212	May 2015	WO
WO 2015071474	May 2015	WO
WO 2015073683	May 2015	WO
WO 2015073867	May 2015	WO
WO 2015073990	May 2015	WO
WO 2015075056	May 2015	WO
WO 2015075154	May 2015	WO
WO 2015075175	May 2015	WO
WO 2015075195	May 2015	WO
WO 2015075557	May 2015	WO
WO 2015077058	May 2015	WO
WO 2015077290	May 2015	WO
WO 2015077318	May 2015	WO
WO 2015079056	Jun 2015	WO
WO 2015079057	Jun 2015	WO
WO 2015086795	Jun 2015	WO
WO 2015086798	Jun 2015	WO
WO 2015088643	Jun 2015	WO
WO 2015089046	Jun 2015	WO
WO 2015089077	Jun 2015	WO
WO 2015089277	Jun 2015	WO
WO 2015089351	Jun 2015	WO
WO 2015089354	Jun 2015	WO
WO 2015089364	Jun 2015	WO
WO 2015089406	Jun 2015	WO
WO 2015089419	Jun 2015	WO
WO 2015089427	Jun 2015	WO
WO 2015089462	Jun 2015	WO
WO 2015089465	Jun 2015	WO
WO 2015089473	Jun 2015	WO
WO 2015089486	Jun 2015	WO
WO 2015095804	Jun 2015	WO
WO 2015099850	Jul 2015	WO
WO 2015100929	Jul 2015	WO
WO 2015103057	Jul 2015	WO
WO 2015103153	Jul 2015	WO
WO 2015105928	Jul 2015	WO
WO 2015108993	Jul 2015	WO
WO 2015109752	Jul 2015	WO
WO 2015110474	Jul 2015	WO
WO 2015112790	Jul 2015	WO
WO 2015112896	Jul 2015	WO
WO 2015113063	Jul 2015	WO
WO 2015114365	Aug 2015	WO
WO 2015115903	Aug 2015	WO
WO 2015116686	Aug 2015	WO
WO 2015116969	Aug 2015	WO
WO 2015117021	Aug 2015	WO
WO 2015117041	Aug 2015	WO
WO 2015117081	Aug 2015	WO
WO 2015118156	Aug 2015	WO
WO 2015119941	Aug 2015	WO
WO 2015121454	Aug 2015	WO
WO 2015122967	Aug 2015	WO
WO 2015123339	Aug 2015	WO
WO 2015124715	Aug 2015	WO
WO 2015124718	Aug 2015	WO
WO 2015126927	Aug 2015	WO
WO 2015127428	Aug 2015	WO
WO 2015127439	Aug 2015	WO
WO 2015129686	Sep 2015	WO
WO 2015131101	Sep 2015	WO
WO 2015133554	Sep 2015	WO
WO 2015134121	Sep 2015	WO
WO 2015134812	Sep 2015	WO
WO 2015136001	Sep 2015	WO
WO 2015138510	Sep 2015	WO
WO 2015138739	Sep 2015	WO
WO 2015138855	Sep 2015	WO
WO 2015138870	Sep 2015	WO
WO 2015139008	Sep 2015	WO
WO 2015139139	Sep 2015	WO
WO 2015143046	Sep 2015	WO
WO 2015143177	Sep 2015	WO
WO 2015145417	Oct 2015	WO
WO 2015148431	Oct 2015	WO
WO 2015148670	Oct 2015	WO
WO 2015148680	Oct 2015	WO
WO 2015148761	Oct 2015	WO
WO 2015148860	Oct 2015	WO
WO 2015148863	Oct 2015	WO
WO 2015153760	Oct 2015	WO
WO 2015153780	Oct 2015	WO
WO 2015153789	Oct 2015	WO
WO 2015153791	Oct 2015	WO
WO 2015153889	Oct 2015	WO
WO 2015153940	Oct 2015	WO
WO 2015155341	Oct 2015	WO
WO 2015155686	Oct 2015	WO
WO 2015157070	Oct 2015	WO
WO 2015157534	Oct 2015	WO
WO 2015159068	Oct 2015	WO
WO 2015159086	Oct 2015	WO
WO 2015159087	Oct 2015	WO
WO 2015160683	Oct 2015	WO
WO 2015161276	Oct 2015	WO
WO 2015163733	Oct 2015	WO
WO 2015164740	Oct 2015	WO
WO 2015164748	Oct 2015	WO
WO 2015165274	Nov 2015	WO
WO 2015165275	Nov 2015	WO
WO 2015165276	Nov 2015	WO
WO 2015166272	Nov 2015	WO
WO 2015167766	Nov 2015	WO
WO 2015167956	Nov 2015	WO
WO 2015168125	Nov 2015	WO
WO 2015168158	Nov 2015	WO
WO 2015168404	Nov 2015	WO
WO 2015168547	Nov 2015	WO
WO 2015168800	Nov 2015	WO
WO 2015171603	Nov 2015	WO
WO 2015171894	Nov 2015	WO
WO 2015171932	Nov 2015	WO
WO 2015172128	Nov 2015	WO
WO 2015173436	Nov 2015	WO
WO 2015175642	Nov 2015	WO
WO 2015179540	Nov 2015	WO
WO 2015183025	Dec 2015	WO
WO 2015183026	Dec 2015	WO
WO 2015183885	Dec 2015	WO
WO 2015184259	Dec 2015	WO
WO 2015184262	Dec 2015	WO
WO 2015184268	Dec 2015	WO
WO 2015188056	Dec 2015	WO
WO 2015188065	Dec 2015	WO
WO 2015188094	Dec 2015	WO
WO 2015188109	Dec 2015	WO
WO 2015188132	Dec 2015	WO
WO 2015188135	Dec 2015	WO
WO 2015188191	Dec 2015	WO
WO 2015189693	Dec 2015	WO
WO 2015191693	Dec 2015	WO
WO 2015191899	Dec 2015	WO
WO 2015191911	Dec 2015	WO
WO 2015193858	Dec 2015	WO
WO 2015195547	Dec 2015	WO
WO 2015195621	Dec 2015	WO
WO 2015195798	Dec 2015	WO
WO 2015198020	Dec 2015	WO
WO 2015200334	Dec 2015	WO
WO 2015200378	Dec 2015	WO
WO 2015200555	Dec 2015	WO
WO 2015200805	Dec 2015	WO
WO 2016001978	Jan 2016	WO
WO 2016004010	Jan 2016	WO
WO 2016004318	Jan 2016	WO
WO 2016007347	Jan 2016	WO
WO 2016007604	Jan 2016	WO
WO 2016007948	Jan 2016	WO
WO 2016011080	Jan 2016	WO
WO 2016011210	Jan 2016	WO
WO 2016011428	Jan 2016	WO
WO 2016012544	Jan 2016	WO
WO 2016012552	Jan 2016	WO
WO 2016014409	Jan 2016	WO
WO 2016014565	Jan 2016	WO
WO 2016014794	Jan 2016	WO
WO 2016014837	Jan 2016	WO
WO 2016016119	Feb 2016	WO
WO 2016016358	Feb 2016	WO
WO 2016019144	Feb 2016	WO
WO 2016020399	Feb 2016	WO
WO 2016021972	Feb 2016	WO
WO 2016021973	Feb 2016	WO
WO 2016022363	Feb 2016	WO
WO 2016022866	Feb 2016	WO
WO 2016022931	Feb 2016	WO
WO 2016025131	Feb 2016	WO
WO 2016025469	Feb 2016	WO
WO 2016025759	Feb 2016	WO
WO 2016026444	Feb 2016	WO
WO 2016028682	Feb 2016	WO
WO 2016028843	Feb 2016	WO
WO 2016028887	Feb 2016	WO
WO 2016033088	Mar 2016	WO
WO 2016033230	Mar 2016	WO
WO 2016033246	Mar 2016	WO
WO 2016033298	Mar 2016	WO
WO 2016035044	Mar 2016	WO
WO 2016036754	Mar 2016	WO
WO 2016037157	Mar 2016	WO
WO 2016040030	Mar 2016	WO
WO 2016040594	Mar 2016	WO
WO 2016044182	Mar 2016	WO
WO 2016044416	Mar 2016	WO
WO 2016046635	Mar 2016	WO
WO 2016049024	Mar 2016	WO
WO 2016049163	Mar 2016	WO
WO 2016049230	Mar 2016	WO
WO 2016049251	Mar 2016	WO
WO 2016049258	Mar 2016	WO
WO 2016053397	Apr 2016	WO
WO 2016054326	Apr 2016	WO
WO 2016057061	Apr 2016	WO
WO 2016057821	Apr 2016	WO
WO 2016057835	Apr 2016	WO
WO 2016057850	Apr 2016	WO
WO 2016057951	Apr 2016	WO
WO 2016057961	Apr 2016	WO
WO 2016061073	Apr 2016	WO
WO 2016061374	Apr 2016	WO
WO 2016061481	Apr 2016	WO
WO 2016061523	Apr 2016	WO
WO 2016064894	Apr 2016	WO
WO 2016069282	May 2016	WO
WO 2016069283	May 2016	WO
WO 2016069591	May 2016	WO
WO 2016069774	May 2016	WO
WO 2016069910	May 2016	WO
WO 2016069912	May 2016	WO
WO 2016070037	May 2016	WO
WO 2016070070	May 2016	WO
WO 2016070129	May 2016	WO
WO 2016072399	May 2016	WO
WO 2016072936	May 2016	WO
WO 2016073433	May 2016	WO
WO 2016073559	May 2016	WO
WO 2016073990	May 2016	WO
WO 2016075662	May 2016	WO
WO 2016076672	May 2016	WO
WO 2016077273	May 2016	WO
WO 2016077350	May 2016	WO
WO 2016080097	May 2016	WO
WO 2016080795	May 2016	WO
WO 2016081923	May 2016	WO
WO 2016081924	May 2016	WO
WO 2016082135	Jun 2016	WO
WO 2016083811	Jun 2016	WO
WO 2016084084	Jun 2016	WO
WO 2016084088	Jun 2016	WO
WO 2016086177	Jun 2016	WO
WO 2016089433	Jun 2016	WO
WO 2016089866	Jun 2016	WO
WO 2016089883	Jun 2016	WO
WO 2016090385	Jun 2016	WO
WO 2016094679	Jun 2016	WO
WO 2016094845	Jun 2016	WO
WO 2016094867	Jun 2016	WO
WO 2016094872	Jun 2016	WO
WO 2016094874	Jun 2016	WO
WO 2016094880	Jun 2016	WO
WO 2016094888	Jun 2016	WO
WO 2016097212	Jun 2016	WO
WO 2016097231	Jun 2016	WO
WO 2016097751	Jun 2016	WO
WO 2016099887	Jun 2016	WO
WO 2016100272	Jun 2016	WO
WO 2016100389	Jun 2016	WO
WO 2016100568	Jun 2016	WO
WO 2016100571	Jun 2016	WO
WO 2016100951	Jun 2016	WO
WO 2016100955	Jun 2016	WO
WO 2016100974	Jun 2016	WO
WO 2016103233	Jun 2016	WO
WO 2016104716	Jun 2016	WO
WO 2016106236	Jun 2016	WO
WO 2016106239	Jun 2016	WO
WO 2016106244	Jun 2016	WO
WO 2016106338	Jun 2016	WO
WO 2016108926	Jul 2016	WO
WO 2016109255	Jul 2016	WO
WO 2016109840	Jul 2016	WO
WO 2016110214	Jul 2016	WO
WO 2016110453	Jul 2016	WO
WO 2016110511	Jul 2016	WO
WO 2016110512	Jul 2016	WO
WO 2016111546	Jul 2016	WO
WO 2016112242	Jul 2016	WO
WO 2016112351	Jul 2016	WO
WO 2016112963	Jul 2016	WO
WO 2016114972	Jul 2016	WO
WO 2016115179	Jul 2016	WO
WO 2016115326	Jul 2016	WO
WO 2016115355	Jul 2016	WO
WO 2016116032	Jul 2016	WO
WO 2016120480	Aug 2016	WO
WO 2016123071	Aug 2016	WO
WO 2016123230	Aug 2016	WO
WO 2016123243	Aug 2016	WO
WO 2016123578	Aug 2016	WO
WO 2016126747	Aug 2016	WO
WO 2016130600	Aug 2016	WO
WO 2016130697	Aug 2016	WO
WO 2016131009	Aug 2016	WO
WO 2016132122	Aug 2016	WO
WO 2016133165	Aug 2016	WO
WO 2016135507	Sep 2016	WO
WO 2016135557	Sep 2016	WO
WO 2016135558	Sep 2016	WO
WO 2016135559	Sep 2016	WO
WO 2016137774	Sep 2016	WO
WO 2016137949	Sep 2016	WO
WO 2016141224	Sep 2016	WO
WO 2016141893	Sep 2016	WO
WO 2016142719	Sep 2016	WO
WO 2016145150	Sep 2016	WO
WO 2016148994	Sep 2016	WO
WO 2016149484	Sep 2016	WO
WO 2016149547	Sep 2016	WO
WO 2016150336	Sep 2016	WO
WO 2016150855	Sep 2016	WO
WO 2016154016	Sep 2016	WO
WO 2016154579	Sep 2016	WO
WO 2016154596	Sep 2016	WO
WO 2016155482	Oct 2016	WO
WO 2016161004	Oct 2016	WO
WO 2016161207	Oct 2016	WO
WO 2016161260	Oct 2016	WO
WO 2016161380	Oct 2016	WO
WO 2016161446	Oct 2016	WO
WO 2016164356	Oct 2016	WO
WO 2016164797	Oct 2016	WO
WO 2016166340	Oct 2016	WO
WO 2016167300	Oct 2016	WO
WO 2016168631	Oct 2016	WO
WO 2016170484	Oct 2016	WO
WO 2016172359	Oct 2016	WO
WO 2016172727	Oct 2016	WO
WO 2016174056	Nov 2016	WO
WO 2016174151	Nov 2016	WO
WO 2016174250	Nov 2016	WO
WO 2016176191	Nov 2016	WO
WO 2016176404	Nov 2016	WO
WO 2016176690	Nov 2016	WO
WO 2016177682	Nov 2016	WO
WO 2016178207	Nov 2016	WO
WO 2016179038	Nov 2016	WO
WO 2016179112	Nov 2016	WO
WO 2016181357	Nov 2016	WO
WO 2016182893	Nov 2016	WO
WO 2016182917	Nov 2016	WO
WO 2016182959	Nov 2016	WO
WO 2016183236	Nov 2016	WO
WO 2016183298	Nov 2016	WO
WO 2016183345	Nov 2016	WO
WO 2016183402	Nov 2016	WO
WO 2016183438	Nov 2016	WO
WO 2016183448	Nov 2016	WO
WO 2016184955	Nov 2016	WO
WO 2016184989	Nov 2016	WO
WO 2016185411	Nov 2016	WO
WO 2016186745	Nov 2016	WO
WO 2016186772	Nov 2016	WO
WO 2016186946	Nov 2016	WO
WO 2016186953	Nov 2016	WO
WO 2016187717	Dec 2016	WO
WO 2016187904	Dec 2016	WO
WO 2016191684	Dec 2016	WO
WO 2016191869	Dec 2016	WO
WO 2016196273	Dec 2016	WO
WO 2016196282	Dec 2016	WO
WO 2016196308	Dec 2016	WO
WO 2016196361	Dec 2016	WO
WO 2016196499	Dec 2016	WO
WO 2016196539	Dec 2016	WO
WO 2016196655	Dec 2016	WO
WO 2016196805	Dec 2016	WO
WO 2016196887	Dec 2016	WO
WO 2016197132	Dec 2016	WO
WO 2016197133	Dec 2016	WO
WO 2016197354	Dec 2016	WO
WO 2016197355	Dec 2016	WO
WO 2016197356	Dec 2016	WO
WO 2016197357	Dec 2016	WO
WO 2016197358	Dec 2016	WO
WO 2016197359	Dec 2016	WO
WO 2016197360	Dec 2016	WO
WO 2016197361	Dec 2016	WO
WO 2016197362	Dec 2016	WO
WO 2016198361	Dec 2016	WO
WO 2016198500	Dec 2016	WO
WO 2016200263	Dec 2016	WO
WO 2016201047	Dec 2016	WO
WO 2016201138	Dec 2016	WO
WO 2016201152	Dec 2016	WO
WO 2016201153	Dec 2016	WO
WO 2016201155	Dec 2016	WO
WO 2016205276	Dec 2016	WO
WO 2016205613	Dec 2016	WO
WO 2016205623	Dec 2016	WO
WO 2016205680	Dec 2016	WO
WO 2016205688	Dec 2016	WO
WO 2016205703	Dec 2016	WO
WO 2016205711	Dec 2016	WO
WO 2016205728	Dec 2016	WO
WO 2016205745	Dec 2016	WO
WO 2016205749	Dec 2016	WO
WO 2016205759	Dec 2016	WO
WO 2016205764	Dec 2016	WO
WO 2017001572	Jan 2017	WO
WO 2017001988	Jan 2017	WO
WO 2017004261	Jan 2017	WO
WO 2017004279	Jan 2017	WO
WO 2017004616	Jan 2017	WO
WO 2017005807	Jan 2017	WO
WO 2017009399	Jan 2017	WO
WO 2017010556	Jan 2017	WO
WO 2017011519	Jan 2017	WO
WO 2017011721	Jan 2017	WO
WO 2017011804	Jan 2017	WO
WO 2017015015	Jan 2017	WO
WO 2017015101	Jan 2017	WO
WO 2017015545	Jan 2017	WO
WO 2017015567	Jan 2017	WO
WO 2017015637	Jan 2017	WO
WO 2017017016	Feb 2017	WO
WO 2017019867	Feb 2017	WO
WO 2017019895	Feb 2017	WO
WO 2017023803	Feb 2017	WO
WO 2017023974	Feb 2017	WO
WO 2017024047	Feb 2017	WO
WO 2017024319	Feb 2017	WO
WO 2017024343	Feb 2017	WO
WO 2017024602	Feb 2017	WO
WO 2017025323	Feb 2017	WO
WO 2017027423	Feb 2017	WO
WO 2017028768	Feb 2017	WO
WO 2017029664	Feb 2017	WO
WO 2017031360	Feb 2017	WO
WO 2017031483	Feb 2017	WO
WO 2017035416	Mar 2017	WO
WO 2017040348	Mar 2017	WO
WO 2017040511	Mar 2017	WO
WO 2017040709	Mar 2017	WO
WO 2017040786	Mar 2017	WO
WO 2017040793	Mar 2017	WO
WO 2017040813	Mar 2017	WO
WO 2017043573	Mar 2017	WO
WO 2017043656	Mar 2017	WO
WO 2017044419	Mar 2017	WO
WO 2017044776	Mar 2017	WO
WO 2017044857	Mar 2017	WO
WO 2017048390	Mar 2017	WO
WO 2017049129	Mar 2017	WO
WO 2017050963	Mar 2017	WO
WO 2017053312	Mar 2017	WO
WO 2017053431	Mar 2017	WO
WO 2017053713	Mar 2017	WO
WO 2017053729	Mar 2017	WO
WO 2017053753	Mar 2017	WO
WO 2017053762	Mar 2017	WO
WO 2017053879	Mar 2017	WO
WO 2017054721	Apr 2017	WO
WO 2017058658	Apr 2017	WO
WO 2017059241	Apr 2017	WO
WO 2017062605	Apr 2017	WO
WO 2017062723	Apr 2017	WO
WO 2017062754	Apr 2017	WO
WO 2017062855	Apr 2017	WO
WO 2017062886	Apr 2017	WO
WO 2017062983	Apr 2017	WO
WO 2017064439	Apr 2017	WO
WO 2017064546	Apr 2017	WO
WO 2017064566	Apr 2017	WO
WO 2017066175	Apr 2017	WO
WO 2017066497	Apr 2017	WO
WO 2017066588	Apr 2017	WO
WO 2017066707	Apr 2017	WO
WO 2017066781	Apr 2017	WO
WO 2017068077	Apr 2017	WO
WO 2017068377	Apr 2017	WO
WO 2017069829	Apr 2017	WO
WO 2017070029	Apr 2017	WO
WO 2017070032	Apr 2017	WO
WO 2017070169	Apr 2017	WO
WO 2017070284	Apr 2017	WO
WO 2017070598	Apr 2017	WO
WO 2017070605	Apr 2017	WO
WO 2017070632	Apr 2017	WO
WO 2017070633	Apr 2017	WO
WO 2017072590	May 2017	WO
WO 2017074526	May 2017	WO
WO 2017074962	May 2017	WO
WO 2017075261	May 2017	WO
WO 2017075335	May 2017	WO
WO 2017075475	May 2017	WO
WO 2017077135	May 2017	WO
WO 2017077329	May 2017	WO
WO 2017078751	May 2017	WO
WO 2017079400	May 2017	WO
WO 2017079428	May 2017	WO
WO 2017079673	May 2017	WO
WO 2017079724	May 2017	WO
WO 2017081097	May 2017	WO
WO 2017081288	May 2017	WO
WO 2017083368	May 2017	WO
WO 2017083722	May 2017	WO
WO 2017083766	May 2017	WO
WO 2017087395	May 2017	WO
WO 2017090724	Jun 2017	WO
WO 2017091510	Jun 2017	WO
WO 2017091630	Jun 2017	WO
WO 2017092201	Jun 2017	WO
WO 2017093370	Jun 2017	WO
WO 2017093969	Jun 2017	WO
WO 2017095111	Jun 2017	WO
WO 2017096041	Jun 2017	WO
WO 2017096237	Jun 2017	WO
WO 2017100158	Jun 2017	WO
WO 2017100431	Jun 2017	WO
WO 2017104404	Jun 2017	WO
WO 2017105251	Jun 2017	WO
WO 2017105350	Jun 2017	WO
WO 2017105991	Jun 2017	WO
WO 2017106414	Jun 2017	WO
WO 2017106528	Jun 2017	WO
WO 2017106537	Jun 2017	WO
WO 2017106569	Jun 2017	WO
WO 2017106616	Jun 2017	WO
WO 2017106657	Jun 2017	WO
WO 2017106767	Jun 2017	WO
WO 2017109134	Jun 2017	WO
WO 2017109757	Jun 2017	WO
WO 2017112620	Jun 2017	WO
WO 2017115268	Jul 2017	WO
WO 2017117395	Jul 2017	WO
WO 2017118598	Jul 2017	WO
WO 2017118720	Jul 2017	WO
WO 2017123609	Jul 2017	WO
WO 2017123910	Jul 2017	WO
WO 2017124086	Jul 2017	WO
WO 2017124100	Jul 2017	WO
WO 2017124652	Jul 2017	WO
WO 2017126987	Jul 2017	WO
WO 2017127807	Jul 2017	WO
WO 2017131237	Aug 2017	WO
WO 2017132112	Aug 2017	WO
WO 2017132580	Aug 2017	WO
WO 2017136520	Aug 2017	WO
WO 2017136629	Aug 2017	WO
WO 2017136794	Aug 2017	WO
WO 2017139264	Aug 2017	WO
WO 2017139505	Aug 2017	WO
WO 2017141173	Aug 2017	WO
WO 2017142835	Aug 2017	WO
WO 2017142999	Aug 2017	WO
WO 2017143042	Aug 2017	WO
WO 2017147278	Aug 2017	WO
WO 2017147432	Aug 2017	WO
WO 2017147446	Aug 2017	WO
WO 2017147555	Aug 2017	WO
WO 2017151444	Sep 2017	WO
WO 2017151719	Sep 2017	WO
WO 2017152015	Sep 2017	WO
WO 2017155717	Sep 2017	WO
WO 2017157422	Sep 2017	WO
WO 2017158153	Sep 2017	WO
WO 2017160689	Sep 2017	WO
WO 2017160752	Sep 2017	WO
WO 2017160890	Sep 2017	WO
WO 2017161068	Sep 2017	WO
WO 2017165826	Sep 2017	WO
WO 2017165862	Sep 2017	WO
WO 2017172644	Oct 2017	WO
WO 2017172645	Oct 2017	WO
WO 2017172860	Oct 2017	WO
WO 2017173004	Oct 2017	WO
WO 2017173054	Oct 2017	WO
WO 2017173092	Oct 2017	WO
WO 2017174329	Oct 2017	WO
WO 2017176529	Oct 2017	WO
WO 2017176806	Oct 2017	WO
WO 2017178590	Oct 2017	WO
WO 2017180694	Oct 2017	WO
WO 2017180711	Oct 2017	WO
WO 2017180915	Oct 2017	WO
WO 2017180926	Oct 2017	WO
WO 2017181107	Oct 2017	WO
WO 2017181735	Oct 2017	WO
WO 2017182468	Oct 2017	WO
WO 2017184334	Oct 2017	WO
WO 2017184768	Oct 2017	WO
WO 2017184786	Oct 2017	WO
WO 2017186550	Nov 2017	WO
WO 2017189308	Nov 2017	WO
WO 2017189336	Nov 2017	WO
WO 2017190257	Nov 2017	WO
WO 2017190664	Nov 2017	WO
WO 2017191210	Nov 2017	WO
WO 2017192172	Nov 2017	WO
WO 2017192512	Nov 2017	WO
WO 2017192544	Nov 2017	WO
WO 2017192573	Nov 2017	WO
WO 2017193029	Nov 2017	WO
WO 2017193053	Nov 2017	WO
WO 2017196768	Nov 2017	WO
WO 2017197038	Nov 2017	WO
WO 2017197238	Nov 2017	WO
WO 2017197301	Nov 2017	WO
WO 2017201476	Nov 2017	WO
WO 2017205290	Nov 2017	WO
WO 2017205423	Nov 2017	WO
WO 2017207589	Dec 2017	WO
WO 2017208247	Dec 2017	WO
WO 2017209809	Dec 2017	WO
WO 2017213896	Dec 2017	WO
WO 2017213898	Dec 2017	WO
WO 2017214460	Dec 2017	WO
WO 2017216392	Dec 2017	WO
WO 2017216771	Dec 2017	WO
WO 2017218185	Dec 2017	WO
WO 2017219027	Dec 2017	WO
WO 2017219033	Dec 2017	WO
WO 2017220751	Dec 2017	WO
WO 2017222370	Dec 2017	WO
WO 2017222773	Dec 2017	WO
WO 2017222834	Dec 2017	WO
WO 2017223107	Dec 2017	WO
WO 2017223330	Dec 2017	WO
WO 2018000657	Jan 2018	WO
WO 2018002719	Jan 2018	WO
WO 2018005117	Jan 2018	WO
WO 2018005289	Jan 2018	WO
WO 2018005691	Jan 2018	WO
WO 2018005782	Jan 2018	WO
WO 2018005873	Jan 2018	WO
WO 201806693	Jan 2018	WO
WO 2018009520	Jan 2018	WO
WO 2018009562	Jan 2018	WO
WO 2018009822	Jan 2018	WO
WO 2018013821	Jan 2018	WO
WO 2018013990	Jan 2018	WO
WO 2018014384	Jan 2018	WO
WO 2018015444	Jan 2018	WO
WO 2018015936	Jan 2018	WO
WO 2018017754	Jan 2018	WO
WO 2018018979	Feb 2018	WO
WO 2018020248	Feb 2018	WO
WO 2018021878	Feb 2018	WO
WO 2018022480	Feb 2018	WO
WO 2018022634	Feb 2018	WO
WO 2018025206	Feb 2018	WO
WO 2018026723	Feb 2018	WO
WO 2018026976	Feb 2018	WO
WO 2018027078	Feb 2018	WO
WO 2018030608	Feb 2018	WO
WO 2018031683	Feb 2018	WO
WO 2018035250	Feb 2018	WO
WO 2018035300	Feb 2018	WO
WO 2018035423	Feb 2018	WO
WO 2018035503	Feb 2018	WO
WO 2018039145	Mar 2018	WO
WO 2018039438	Mar 2018	WO
WO 2018039440	Mar 2018	WO
WO 2018039448	Mar 2018	WO
WO 2018045630	Mar 2018	WO
WO 2018048827	Mar 2018	WO
WO 2018049168	Mar 2018	WO
WO 2018051347	Mar 2018	WO
WO 2018058064	Mar 2018	WO
WO 2018062866	Apr 2018	WO
WO 2018064352	Apr 2018	WO
WO 2018064371	Apr 2018	WO
WO 2018064516	Apr 2018	WO
WO 2018067546	Apr 2018	WO
WO 2018067846	Apr 2018	WO
WO 2018068053	Apr 2018	WO
WO 2018069474	Apr 2018	WO
WO 2018071623	Apr 2018	WO
WO 2018071663	Apr 2018	WO
WO 2018071868	Apr 2018	WO
WO 2018071892	Apr 2018	WO
WO 2018074979	Apr 2018	WO
WO 2018079134	May 2018	WO
WO 2018080573	May 2018	WO
WO 2018081504	May 2018	WO
WO 2018081535	May 2018	WO
WO 2018081728	May 2018	WO
WO 2018083128	May 2018	WO
WO 2018083606	May 2018	WO
WO 2018085288	May 2018	WO
WO 2018086623	May 2018	WO
WO 2018089664	May 2018	WO
WO 2018093990	May 2018	WO
WO 2018098383	May 2018	WO
WO 2018098480	May 2018	WO
WO 2018098587	Jun 2018	WO
WO 2018099256	Jun 2018	WO
WO 2018103686	Jun 2018	WO
WO 2018106268	Jun 2018	WO
WO 2018107028	Jun 2018	WO
WO 2018107103	Jun 2018	WO
WO 2018107129	Jun 2018	WO
WO 2018-108272	Jun 2018	WO
WO 2018109101	Jun 2018	WO
WO 2018111946	Jun 2018	WO
WO 2018111947	Jun 2018	WO
WO 2018112336	Jun 2018	WO
WO 2018112446	Jun 2018	WO
WO 2018119354	Jun 2018	WO
WO 2018119359	Jun 2018	WO
WO 2018120283	Jul 2018	WO
WO 2018130830	Jul 2018	WO
WO 2018135838	Jul 2018	WO
WO 2018136396	Jul 2018	WO
WO 2018138385	Aug 2018	WO
WO 2018148246	Aug 2018	WO
WO 2018148256	Aug 2018	WO
WO 2018148647	Aug 2018	WO
WO 2018149418	Aug 2018	WO
WO 2018149888	Aug 2018	WO
WO 2018152197	Aug 2018	WO
WO 2018152418	Aug 2018	WO
WO 2018154380	Aug 2018	WO
WO 2018154387	Aug 2018	WO
WO 2018154412	Aug 2018	WO
WO 2018154413	Aug 2018	WO
WO 2018154418	Aug 2018	WO
WO 2018154439	Aug 2018	WO
WO 2018154459	Aug 2018	WO
WO 2018154462	Aug 2018	WO
WO 2018156372	Aug 2018	WO
WO 2018161009	Sep 2018	WO
WO 2018165504	Sep 2018	WO
WO 2018165629	Sep 2018	WO
WO 2018170015	Sep 2018	WO
WO 2018170340	Sep 2018	WO
WO 2018175502	Sep 2018	WO
WO 2018176009	Sep 2018	WO
WO 2018177351	Oct 2018	WO
WO 2018179578	Oct 2018	WO
WO 2018183403	Oct 2018	WO
WO 2018195402	Oct 2018	WO
WO 2018195545	Oct 2018	WO
WO 2018195555	Oct 2018	WO
WO 2018197020	Nov 2018	WO
WO 2018197495	Nov 2018	WO
WO 2018202800	Nov 2018	WO
WO 2018204493	Nov 2018	WO
WO 2018208755	Nov 2018	WO
WO 2018208998	Nov 2018	WO
WO 2018209158	Nov 2018	WO
WO 2018209320	Nov 2018	WO
WO 2018213708	Nov 2018	WO
WO 2018213726	Nov 2018	WO
WO 2018213771	Nov 2018	WO
WO 2018213791	Nov 2018	WO
WO 2018217852	Nov 2018	WO
WO 2018217981	Nov 2018	WO
WO 2018218166	Nov 2018	WO
WO 2018218188	Nov 2018	WO
WO 2018218206	Nov 2018	WO
WO 2019005886	Jan 2019	WO
WO 2019010384	Jan 2019	WO
WO 2019023680	Jan 2019	WO
WO 2019051097	Mar 2019	WO
WO 2019079347	Apr 2019	WO
WO 2019118949	Jun 2019	WO
WO 2019139645	Jul 2019	WO
WO 2019139951	Jul 2019	WO
WO 2019226953	Nov 2019	WO
WO 2020014261	Jan 2020	WO
WO 2020041751	Feb 2020	WO
WO 2020051360	Mar 2020	WO
WO 2020086908	Apr 2020	WO
WO 2020092453	May 2020	WO
WO 2020102659	May 2020	WO
WO 2020154500	Jul 2020	WO
WO 2020181178	Sep 2020	WO
WO 2020181180	Sep 2020	WO
WO 2020181193	Sep 2020	WO
WO 2020181195	Sep 2020	WO
WO 2020181202	Sep 2020	WO
WO 2020191153	Sep 2020	WO
WO 2020191171	Sep 2020	WO
WO 2020191233	Sep 2020	WO
WO 2020191234	Sep 2020	WO
WO 2020191239	Sep 2020	WO
WO 2020191241	Sep 2020	WO
WO 2020191242	Sep 2020	WO
WO 2020191243	Sep 2020	WO
WO 2020191245	Sep 2020	WO
WO 2020191246	Sep 2020	WO
WO 2020191248	Sep 2020	WO
WO 2020191249	Sep 2020	WO
WO 2020210751	Oct 2020	WO
WO 2020214842	Oct 2020	WO
WO 2020236982	Nov 2020	WO
WO 2021025750	Feb 2021	WO
WO 2021030666	Feb 2021	WO

Non-Patent Literature Citations (1440)

Entry
Wijesinghe et al. (Nucleic Acids Research, 2012, 40:9206-9217) (Year: 2012).
EP 123845790.0, Mar. 18, 2015, Partial Supplementary European Search Report.
EP 123845790.0, Oct. 12, 2015, Supplementary European Search Report.
PCT/US2012/047778, May 30, 2013, International Search Report and Written Opinion.
PCT/US2012/047778, Feb. 6, 2014, International Preliminary Report on Patentability.
PCT/US2014/052231, Dec. 4, 2014, International Search Report and Written Opinion.
PCT/US2014/052231, Jan. 30, 2015, International Search Report and Written Opinion (Corrected Version).
PCT/US2014/052231, Mar. 3, 2016, International Preliminary Report on Patentability.
PCT/US2014/050283, Nov. 6, 2014, International Search Report and Written Opinion.
PCT/US2014/050283, Feb. 18, 2016, International Preliminary Report on Patentability.
PCT/US2014/054247, Mar. 27, 2015, International Search Report and Written Opinion.
PCT/US2014/054247, Mar. 17, 2016, International Preliminary Report on Patentability.
PCT/US2014/054291, Dec. 18, 2014, Invitation to Pay Additional Fees.
PCT/US2014/054291, Mar. 27, 2015, International Search Report and Written Opinion.
PCT/US2014/054291, Mar. 17, 2016, International Preliminary Report on Patentability.
PCT/US2014/054252, Mar. 5, 2015, International Search Report and Written Opinion.
PCT/US2014/054252, Mar. 17, 2016, International Preliminary Report on Patentability.
PCT/US2014/070038, Apr. 14, 2015, International Search Report and Written Opinion.
PCT/US2014/070038, Jun. 23, 2016, International Preliminary Report on Patentability.
EP 15830407.1, Mar. 2, 2018, Extended European Search Report.
PCT/US2015/042770, Feb. 23, 2016, International Search Report and Written Opinion.
PCT/US2015/042770, Dec. 19, 2016, International Preliminary Report on Patentability.
PCT/US2015/058479, Feb. 11, 2016, International Search Report and Written Opinion.
PCT/US2015/058479, May 11, 2017, International Preliminary Report on Patentability.
PCT/US2016/044546, Dec. 28, 2016, International Search Report and Written Opinion.
PCT/US2016/058344, Mar. 1, 2017, Invitation to Pay Additional Fees.
PCT/US2016/058344, Apr. 20, 2017, International Search Report and Written Opinion.
PCT/US2016/058344, May 3, 2018, International Preliminary Report on Patentability.
PCT/US2018/025887, Jun. 21, 2018, International Search Report and Written Opinion.
PCT/US2017/48390, Nov. 7, 2017, Invitation to Pay Additional Fees.
PCT/US2017/48390, Jan. 9, 2018, International Search Report and Written Opinion.
PCT/US2017/068114, Mar. 20, 2018, International Search Report and Written Opinion.
PCT/US2017/068105, Apr. 4, 2018, International Search Report and Written Opinion.
PCT/US2018/021880, Jun. 20, 2018, International Search Report and Written Opinion.
PCT/US2017/046144, Oct. 10, 2017, International Search Report and Written Opinion.
PCT/US2017/045381, Oct. 26, 2017, International Search Report and Written Opinion.
PCT/US2018/021664, Jun. 21, 2018, International Search Report and Written Opinion.
PCT/US2017/056671, Dec. 21, 2017, Invitation to Pay Additional Fees.
PCT/US2017/056671, Feb. 20, 2018, International Search Report and Written Opinion.
PCT/US2018/021878, Jun. 8, 2018, Invitation to Pay Additional Fees.
PCT/US2018/021878, Aug. 20, 2018, International Search Report and Written Opinion.
PCT/US2018/024208, Aug. 23, 2018, International Search Report and Written Opinion.
PCT/US2018/032460, Jul. 11, 2018, International Search Report and Written Opinion.
U.S. Appl. No. 61/838,178, filed Jun. 21, 2013, Joung et al.
U.S. Appl. No. 62/288,661, filed Jan. 29, 2016, Muir et al.
U.S. Appl. No. 62/357,332, filed Jun. 30, 2016, Liu et al.
[No Author Listed] Score result for SEQ 355 to W02017032580. Muir et al. 2016.
Bershtein et al., Advances in laboratory evolution of enzymes. Curr Opin; Chem Biol. Apr. 2008;12(2):151-8. doi: 10.1016/j.cbpa.2008.01.027. Epub Mar. 7, 2008. Review.
Böck et al., Selenocysteine: the 21st amino acid. Mol Microbiol. Mar. 1991;5(3):515-20.
Bogdanove et al., TAL effectors: customizable proteins for DNA targeting. Science. Sep. 30, 2011;333(6051):1843-6. doi: 10.1126/science.1204094.
Bohlke et al., Sense codon emancipation for proteome-wide incorporation of noncanonical amino acids: rare isoleucine codon AUA as a target for genetic code expansion. FEMS Microbiol Lett. Feb. 2014;351(2):133-44. doi: 10.1111/1574-6968.12371. Epub Jan. 27, 2014.
Budisa et al., Residue-specific bioincorporation of non-natural, biologically active amino acids into proteins as possible drug carriers: structure and stability of the per-thiaproline mutant of annexin V. Proc Natl Acad Sci U S A. Jan. 20, 1998;95(2):455-9.
Carroll, Genome engineering with zinc-finger nucleases. Genetics. Aug. 2011;188(4):773-82. doi: 10.1534/genetics.111.131433. Review.
Chavez et al., Precise Cas9 targeting enables genomic mutation prevention. bioRxiv. Jun. 14, 2016; http://dx/doi.oreg/10.1101/058974. 6 pages.
D'Adda di Fagagna et al., The Gam protein of bacteriophage Mu is an orthologue of eukaryotic Ku. EMBO Rep. Jan. 2003;4(1):47-52.
Dumas et al., Designing logical codon reassignment—Expanding the chemistry in biology. Chem Sci. Jan. 1, 2015;6(1):50-69. doi: 10.1039/c4sc01534g. Epub Jul. 14, 2014. Review.
Edwards et al., An Escherichia coli tyrosine transfer RNA is a leucine-specific transfer RNA in the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci U S A. Feb. 15, 1991;88(4):1153-6.
Fagerlund et al., The Cpf1 CRISPR-Cas protein expands genome-editing tools. Genome Biology Nov. 17, 2015;16:251. https://doi.org/10.1186/s13059-015-0824-9.
Farhood et al., Codelivery to mammalian cells of a transcriptional factor with cis-acting element using cationic liposomes. Anal Biochem. Feb. 10, 1995;225(l):89-93.
Hamano-Takaku et al., A mutant Escherichia coli tyrosyl-tRNA synthetase utilizes the unnatural amino acid azatyrosine more efficiently than tyrosine. J Biol Chem. Dec. 22, 2000;275(51):40324-8.
Hayes et al., Stop codons preceded by rare arginine codons are efficient determinants of SsrA tagging in Escherichia coli. Proc Natl Acad Sci U S A. Mar. 19, 2002;99(6):3440-5. Epub Mar. 12, 2002.
Hida et al., Directed evolution for drug and nucleic acid; delivery. Adv Drug Deliv Rev. Dec. 22, 2007;59(15):1562-78. Epub Aug. 28, 2007.; Review.
Hirano et al., Structural Basis for the Altered PAM Specificities of Engineered CRISPR-Cas9. Mol Cell. Mar. 17, 2016;61(6):886-94. doi: 10.1016/j.molcel.2016.02.018.
Husimi, Selection and evolution of bacteriophages in cellstat. Adv Biophys. ; 1989;25:1-43. Review.
Kakiyama et al., A peptide release system using a photo-cleavable linker in a cell array format for cell-toxicity analysis. Polymer J. Feb. 27, 2013;45:535-9.
Kiga et al., An engineered Escherichia coli tyrosyl-tRNA synthetase for site-specific incorporation of an unnatural amino acid into proteins in eukaryotic translation and its application in a wheat germ cell-free system. Proc Natl Acad Sci U S A. Jul. 23, 2002;99(15):9715-20. Epub Jul. 3, 2002.
Köhrer et al., A possible approach to site-specific insertion of two different unnatural amino acids into proteins in mammalian cells via nonsense suppression. Chem Biol. Nov. 2003;10(11):1095-102.
Köhrer et al., Complete set of orthogonal 21st aminoacyl-tRNA synthetase-amber, ochre and opal suppressor tRNA pairs: concomitant suppression of three different termination codons in an mRNA in mammalian cells. Nucleic Acids Res. Dec. 1, 2004;32(21):6200-11. Print 2004.
Kowal et al., Exploiting unassigned codons in Micrococcus luteus for tRNA-based amino acid mutagenesis. Nucleic Acids Res. Nov. 15, 1997;25(22):4685-9.
Link et al., Engineering ligand-responsive gene-control elements: lessons learned from natural riboswitches. Gene Ther. Oct. 2009;16(10):1189-201. doi: 10.1038/gt.2009.81. Epub Jul. 9, 2009. Review.
Liu et al., Engineering a tRNA and aminoacyl-tRNA synthetase for the site-specific incorporation of unnatural amino acids into proteins in vivo. Proc Natl Acad Sci U S A. Sep. 16, 1997;94(19):10092-7.
Liu et al., Fast Colorimetric Sensing of Adenosine and Cocaine Based on a General Sensor Design Involving Aptamers and Nanoparticles. Angew Chem. Dec. 16, 2006;45(1):90-4. DOI: 10.1002/anie.200502589.
Monahan et al., Site-specific incorporation of unnatural amino acids into receptors expressed in Mammalian cells. Chem Biol. Jun. 2003;10(6):573-80.
Nelson et al., Filamentous phage DNA cloning vectors: a noninfective mutant with a nonpolar deletion in gene III. Virology. 1981; 108(2): 338-50.
Oakes et al., Protein engineering of Cas9 for enhanced function. Methods Enzymol. 2014;546:491-511.
Pelletier, CRISPR-Cas systems for the study of the immune function. Nov. 15, 2016. https://doi.org/10.1002/9780470015902.a0026896.
Rakonjac et al., Roles of PIII in filamentous phage assembly. J Mol Biol. 1998; 282(1)25-41.
Riechmann et al.,. The C-terminal domain of TolA is the coreceptor for filamentous phage infection of E. coli. Cell. 1997; 90(2):351-60. PMID:9244308.
Rudolph et al., Synthetic riboswitches for the conditional control of gene expression in Streptomyces coelicolor. Microbiology. Jul. 2013;159(Pt 7):1416-22. doi: 10.1099/mic.0.067322-0. Epub May 15, 2013.
Sharma et al., Efficient introduction of aryl bromide functionality into proteins in vivo. FEBS Lett. Feb. 4, 2000;467(1):37-40.
Smith, Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. Jun. 14, 1985;228(4705):1315-7.
Wals et al., Unnatural amino acid incorporation in E. coli: current and future applications in the design of therapeutic proteins. Front Chem. Apr. 1, 2014;2:15. doi: 10.3389/fchem.2014.00015. eCollection 2014.
Yang et al., APOBEC: From mutator to editor. J Genet Genomics. Sep. 20, 2017;44(9):423-437. doi: 10.1016/j.jgg.2017.04.009. Epub Aug. 7, 2017.
Young et al., Beyond the canonical 20 amino acids: expanding the genetic lexicon. J Biol Chem. Apr. 9, 2010;285(15):11039-44. doi:10.1074/jbc.R109.091306. Epub Feb. 10, 2010.
Yuan et al., Laboratory-directed protein evolution. Microbiol Mol Biol Rev. 2005; 69(3):373-92. PMID: 16148303.
Partial European Search Report for Application No. EP 19187331.4, dated Dec. 19, 2019.
Extended European Search Report for EP 19181479.7, dated Oct. 31, 2019.
International Preliminary Report on Patentability for PCT/US2017/068114, dated Jul. 4, 2019.
International Preliminary Report on Patentability for PCT/US2017/068105, dated Jul. 4, 2019.
International Preliminary Report on Patentability for PCT/US2018/021880, dated Sep. 19, 2019.
International Preliminary Report on Patentability for PCT/US2018/021664, dated Sep. 19, 2019.
International Preliminary Report on Patentability for PCT/US2018/021878, dated Sep. 19, 2019.
International Preliminary Report on Patentability for PCT/US2018/024208, dated Oct. 3, 2019.
International Search Report for PCT/US2018/048969, dated Jul. 31, 2019.
International Prelminary Report on Patentability for PCT/US2018/048969, dated Mar. 12, 2020.
International Preliminary Report on Patentability for PCT/US2018/032460, dated Nov. 21, 2019.
International Search Report and Written Opinion for PCT/US2018/044242, dated Nov. 21, 2019.
International Preliminary Report on Patentability for PCT/US2018/044242, dated Feb. 6, 2020.
U.S. Appl. No. 61/716,256, filed Oct. 19, 2012, Jinek et al.
U.S. Appl. No. 61/717,324, filed Oct. 23, 2012, Cho et al.
U.S. Appl. No. 61/734,256, filed Dec. 6, 2012, Chen et al.
U.S. Appl. No. 61/758,624, filed Jan. 30, 2013, Chen et al.
U.S. Appl. No. 61/761,046, filed Feb. 5, 2013, Knight et al.
U.S. Appl. No. 61/794,422, filed Mar. 15, 2013, Knight et al.
U.S. Appl. No. 61/803,599, filed Mar. 20, 2013, Kim et al.
U.S. Appl. No. 61/837,481, filed Jun. 20, 2013, Cho et al.
U.S. Appl. No. 61/874,682.
U.S. Appl. No. 61/874,746.
[No Author Listed], EMBL Accession No. Q99ZW2. Nov. 2012. 2 pages.
[No Author Listed], Invitrogen Lipofectamine™ 2000 product sheets, 2002. 2 pages.
[No Author Listed], Invitrogen Lipofectamine™ 2000 product sheets, 2005. 3 pages.
[No Author Listed], Invitrogen Lipofectamine™ LTX product sheets, 2011. 4 pages.
[No Author Listed], Thermo Fisher Scientific—How Cationic Lipid Mediated Transfection Works, retrieved from the internet Aug. 27, 2015. 2 pages.
Abudayyeh et al., C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science Aug. 2016;353(6299):aaf5573. DOI: 10.1126/science.aaf5573.
Addgene Plasmid # 44246. pdCas9-humanized, 2017, Stanley Qi.
Addgene Plasmid # 73021. PCMV-BE3, 2017, David Liu.
Addgene Plasmid # 79620. pcDNA3.1_pCMV-nCas-PmCDA1-ugi pH1-gRNA(HPRT), 2017, Akihiko Kondo.
Adrian et al., Targeted SAINT-O-Somes for improved intracellular delivery of siRNA and cytotoxic drugs into endothelial cells. J Control Release. Jun. 15, 2010;144(3):341-9. doi: 10.1016/j.jconrel.2010.03.003. Epub Mar. 11, 2010.
Aguilera et al., Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb). Jun. 2009;1(5-6):371-81. doi: 10.1039/b904878b. Epub May 11, 2009.
Aihara et al., A conformational switch controls the DNA cleavage activity of lambda integrase. Mol Cell. Jul. 2003;12(1):187-98.
Akinc et al., A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. May 2008;26(5):561-9. doi: 10.1038/nbt1402. Epub Apr. 27, 2008.
Akopian et al., Chimeric recombinases with designed DNA sequence recognition. Proc Natl Acad Sci U S A. Jul. 22, 2003;100(15):8688-91. Epub Jul. 1, 2003.
Al-Taei et al., Intracellular traffic and fate of protein transduction domains HIV-1 TAT peptide and octaarginine. Implications for their utilization as drug delivery vectors. Bioconjug Chem. Jan.-Feb. 2006;17(1):90-100.
Alexandrov et al., Signatures of mutational processes in human cancer. Nature. Aug. 22, 2013;500(7463):415-21. doi: 10.1038/nature12477. Epub Aug. 14, 2013.
Ali et al., Novel genetic abnormalities in Bernard-Soulier syndrome in India. Ann Hematol. Mar. 2014;93(3):381-4. doi: 10.1007/s00277-013-1895-x. Epub Sep. 1, 2013.
Allen et al., Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. Jan. 2013;65(1):36-48. doi: 10.1016/j.addr.2012.09.037. Epub Oct. 1, 2012.
Ames et al., A eubacterial riboswitch class that senses the coenzyme tetrahydrofolate. Chem Biol. Jul. 30, 2010;17(7):681-5. doi: 10.1016/j.chembiol.2010.05.020.
Anders et al., Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature. Sep. 25, 2014;513(7519):569-73. doi: 10.1038/nature13579. Epub Jul. 27, 2014.
Arnold et al., Mutants of Tn3 resolvase which do not require accessory binding sites for recombination activity. EMBO J. Mar. 1, 1999;18(5):1407-14.
Badran et al., In vivo continuous directed evolution. Curr Opin Chem Biol. Feb. 2015;24:1-10. doi: 10.1016/j.cbpa.2014.09.040. Epub Nov. 7, 2014.
Bae et al., Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli. Clin Exp Immunol. Jul. 2009;157(1):128-38. doi: 10.1111/j.1365-2249.2009.03943.x.
Barnes et al., Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet. 2004;38:445-76.
Barrangou et al., CRISPR provides acquired resistance against viruses in prokaryotes. Science. Mar. 23, 2007;315(5819):1709-12.
Barrangou, RNA-mediated programmable DNA cleavage. Nat Biotechnol. Sep. 2012;30(9):836-8. doi: 10.1038/nbt.2357.
Basha et al., Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther. Dec. 2011;19(12):2186-200. doi: 10.1038/mt.2011.190. Epub Oct. 4, 2011.
Batey et al., Structure of a natural guanine-responsive riboswitch complexed with the metabolite hypoxanthine. Nature. Nov. 18, 2004;432(7015):411-5.
Beale et al., Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol. Mar. 26, 2004;337(3):585-96.
Bedell et al., In vivo genome editing using a high-efficiency TALEN system. Nature. Nov. 1, 2012;491(7422):114-8. Doi: 10.1038/nature11537. Epub Sep. 23, 2012.
Begley, Scientists unveil the ‘most clever CRISPR gadget’ so far. STAT, Apr. 20, 2016. https://www.statnews.com/2016/04/20/clever-crispr-advance-unveiled/.
Beumer et al., Efficient gene targeting in Drosophila with zinc-ftnger nucleases. Genetics. Apr. 2006;172(4):2391-403. Epub Feb. 1, 2006.
Bhagwat, DNA-cytosine deaminases: from antibody maturation to antiviral defense. DNA Repair (Amst). Jan. 5, 2004;3(1):85-9.
Bibikova et al., Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol Cell Biol. Jan. 2001;21(1):289-97.
Bibikova et al., Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics. Jul. 2002;161(3):1169-75.
Billon et al., CRISPR-Mediated Base Editing Enables Efficient Disruption of Eukaryotic Genes through Induction of STOP Codons. Mol Cell. Sep. 21, 2017;67(6):1068-1079.e4. doi: 10.1016/j.molcel.2017.08.008. Epub Sep. 7, 2017.
Birling et al., Site-specific recombinases for manipulation of the mouse genome. Methods Mol Biol. 2009;561:245-63. doi: 10.1007/978-1-60327-019-9_16.
Bitinaite et al., FokI dimerization is required for DNA cleavage. Proc Natl Acad Sci U S A. Sep. 1, 1998;95(18):10570-5.
Boch et al., Breaking the code of DNA binding specificity of TAL-type III effectors. Science. Dec. 11, 2009;326(5959):1509-12. Doi: 10.1126/science.1178811.
Boch, TALEs of genome targeting. Nat Biotechnol. Feb. 2011;29(2):135-6. Doi: 10.1038/nbt.1767.
Boeckle et al., Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes. J Control Release. May 15, 2006;112(2):240-8. Epub Mar. 20, 2006.
Bolotin et al., Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology. Aug. 2005;151(Pt 8):2551-61.
Borman, Improved route to single-base genome editing. Chemical & Engineering News, Apr. 25, 2016;94(17)p5. http://cen.acs.org/articles/94/i17/Improved-route-single-base-genome.html.
Branden and Tooze, Introduction to Protein Structure. 1999; 2nd edition. Garland Science Publisher: 3-12.
Briner et al., Guide RNA functional modules direct Cas9 activity and orthogonality. Mol Cell. Oct. 23, 2014;56(2):333-339. doi: 10.1016/j.molcel.2014.09.019.
Britt et al., Re-engineering plant gene targeting. Trends Plant Sci. Feb. 2003;8(2):90-5.
Brouns et al., Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. Aug. 15, 2008;321(5891):960-4. doi: 10.1126/science.1159689.
Brown et al., Serine recombinases as tools for genome engineering. Methods. Apr. 2011;53(4):372-9. doi: 10.1016/j.ymeth.2010.12.031. Epub Dec. 30, 2010.
Brusse et al., Spinocerebellar ataxia associated with a mutation in the fibroblast growth factor 14 gene (SCA27): A new phenotype. Mov Disord. Mar. 2006;21(3):396-401.
Buchholz et al., Alteration of Cre recombinase site specificity by substrate-linked protein evolution. Nat Biotechnol. Nov. 2001;19(11):1047-52.
Buchwald et al., Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis. Surgery. Oct. 1980;88(4):507-16.
Bulow et al., Multienzyme systems obtained by gene fusion. Trends Biotechnol. Jul. 1991;9(7):226-31.
Bulyk et al., Exploring the DNA-binding specificities of zinc fingers with DNA microarrays. Proc Natl Acad Sci U S A. Jun. 19, 2001;98(13):7158-63. Epub Jun. 12, 2001.
Burke et al., Activating mutations of Tn3 resolvase marking interfaces important in recombination catalysis and its regulation. Mol Microbiol. Feb. 2004;51(4):937-48.
Burstein et al., New CRISPR-Cas systems from uncultivated microbes. Nature Feb. 2017;542(7640):237-240.
Buskirk et al., Directed evolution of ligand dependence: small-molecule-activated protein splicing. Proc Natl Acad Sci U S A. Jul. 20, 2004;101(29):10505-10. Epub Jul. 9, 2004.
Cade et al., Highly efficient generation of heritable zebrafish gene mutations using homo- and heterodimeric TALENs. Nucleic Acids Res. Sep. 2012;40(16):8001-10. Doi: 10.1093/nar/gks518. Epub Jun. 7, 2012.
Caldecott et al., Single-strand break repair and genetic disease. Nat Rev Genet. Aug. 2008;9(8):619-31. doi: 10.1038/nrg2380.
Cameron, Recent advances in transgenic technology. Mol Biotechnol. Jun. 1997;7(3):253-65.
Cargill et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. Jul. 1999;22(3):231-8.
Caron et al., Intracellular delivery of a Tat-eGFP fusion protein into muscle cells. Mol Ther. Mar. 2001;3(3):310-8.
Carroll et al., Gene targeting in Drosophila and Caenorhabditis elegans with zinc-finger nucleases. Methods Mol Biol. 2008;435:63-77. doi: 10.1007/978-1-59745-232-8_5.
Carroll et al., Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther. Nov. 2008;15(22):1463-8. doi: 10.1038/gt.2008.145. Epub Sep. 11, 2008.
Carroll, A CRISPR approach to gene targeting. Mol Ther. Sep. 2012;20(9):1658-60. doi: 10.1038/mt.2012.171.
Cermak et al., Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. Jul. 2011;39(12):e82. Doi: 10.1093/nar/gkr218. Epub Apr. 14, 2011.
Chadwick et al., In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing. Arterioscler Thromb Vase Biol. Sep. 2017;37(9):1741-1747. doi: 10.1161/ATVBAHA.117.309881. Epub Jul. 27, 2017.
Chaikind et al., A programmable Cas9-serine recombinase fusion protein that operates on DNA sequences in mammalian cells. Nucleic Acids Res. Nov. 16, 2016;44(20):9758-9770. Epub Aug. 11, 2016.
Chang et al., Modification of DNA ends can decrease end joining relative to homologous recombination in mammalian cells. Proc Natl Acad Sci U S A. Jul. 1987;84(14):4959-63.
Charpentier et al., Biotechnology: Rewriting a genome. Nature. Mar. 7, 2013;495(7439):50-1. doi: 10.1038/495050a.
Chavez et al., Highly efficient Cas9-mediated transcriptional programming. Nat Methods. Apr. 2015;12(4):326-8. doi: 10.1038/nmeth.3312. Epub Mar. 2, 2015.
Chavez et al., Precise Cas9 targeting enables genomic mutation prevention. Jun. 14, 2016. doi:https://doi.org/10.1101/058974. [Preprint].
Chavez et al., Precise Cas9 targeting enables genomic mutation prevention. Proc Natl Acad Sci U S A. Apr. 3, 2018;115(14):3669-3673. doi: 10.1073/pnas.1718148115. Epub Mar. 19, 2018.
Chavez et al., Therapeutic applications of the ΦC31 integrase system. Curr Gene Ther. Oct. 2011;11(5):375-81. Review.
Chavez et al., Therapeutic applications of the PhiC31 integrase system. Curr Gene Ther. Oct. 2011;11(5):375-81. Review.
Chelico et al., Biochemical basis of immunological and retroviral responses to DNA-targeted cytosine deamination by activation-induced cytidine deaminase and APOBEC3G. J Biol Chem. Oct. 9, 2009;284(41):27761-5. doi: 10.1074/jbc.R109.052449. Epub Aug. 13, 2009.
Chelico et al., Stochastic properties of processive cytidine DNA deaminases AID and APOBEC3G. Philos Trans R Soc Lond B Biol Sci. Mar. 12, 2009;364(1517):583-93. doi: 10.1098/rstb.2008.0195.
Chen et al., Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. Oct. 2013;65(10):1357-69. doi:10.1016/j.addr.2012.09.039. Epub Sep. 29, 2012.
Chen et al., Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature. Mar. 6, 2008;452(7183):116-9. doi: 10.1038/nature06638. Epub Feb. 20, 2008.
Chesnoy et al., Structure and function of lipid-DNA complexes for gene delivery. Annu Rev Biophys Biomol Struct. 2000;29:27-47.
Chew et al., A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods. Oct. 2016;13(10):868-74. doi: 10.1038/nmeth.3993. Epub Sep. 5, 2016.
Chichili et al., Linkers in the structural biology of protein-protein interactions. Protein Science. 2013;22:153-67.
Chipev et al., A leucine—proline mutation in the H1 subdomain of keratin 1 causes epidermolytic hyperkeratosis. Cell. Sep. 4, 1992;70(5):821-8.
Cho et al., Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. Jan. 2014;24(1):132-41. doi: 10.1101/gr.162339.113. Epub Nov. 19, 2013.
Cho et al., Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. Mar. 2013;31(3):230-2. doi: 10.1038/nbt.2507. Epub Jan. 29, 2013.
Christian et al., Targeting G with TAL effectors: a comparison of activities of TALENs constructed with NN and NK repeat variable di-residues. PLoS One. 2012;7(9):e45383. doi: 10.1371/journal.pone.0045383. Epub Sep. 24, 2012.
Christian et al., Targeting DNA double-strand breaks with TAL effector nucleases. Genetics. Oct. 2010;186(2):757-61. Doi: 10.1534/genetics.110.120717. Epub Jul. 26, 2010.
Chu et al., Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotech. Feb. 13, 2015;33:543-8.
Chung-Il et al., Artificial control of gene expression in mammalian cells by modulating RNA interference through aptamer-small molecule interaction. RNA. May 2006;12(5):710-6. Epub Apr. 10, 2006.
Chylinski et al., The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol. May 2013;10(5):726-37. doi: 10.4161/rna.24321. Epub Apr. 5, 2013.
Cobb et al., Directed evolution as a powerful synthetic biology tool. Methods. Mar. 15, 2013;60(1):81-90. doi: 10.1016/j.ymeth.2012.03.009. Epub Mar. 23, 2012.
Cobb et al., Directed evolution: an evolving and enabling synthetic biology tool. Curr Opin Chem Biol. Aug. 2012;16(3-4):285-91. doi:10.1016/j.cbpa.2012.05.186. Epub Jun. 4, 2012. Review.
Coelho et al., Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. Aug. 29, 2013;369(9):819-29. doi: 10.1056/NEJMoa1208760.
Cole-Strauss et al., Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science. Sep. 6, 1996;273(5280):1386-9.
Colletier et al., Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol. May 10, 2002;2:9.
Cong et al., Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains. Nat Commun. Jul. 24, 2012;3:968. doi: 10.1038/ncomms1962.
Cong et al., Multiplex genome engineering using CRISPR/Cas systems. Science. Feb. 15, 2013;339(6121):819-23. doi: 10.1126/science.1231143. Epub Jan. 3, 2013.
Conticello, The AID/APOBEC family of nucleic acid mutators. Genome Biol. 2008;9(6):229. doi: 10.1186/gb-2008-9-6-229. Epub Jun. 17, 2008.
Cornu et al., DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger nucleases. Mol Ther. Feb. 2008;16(2):352-8. Epub Nov. 20, 2007.
Covino et al., The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy? Current Drug Targets Dec. 2016;17(1):76-110. DOI : 10.2174/138945011701151217110917.
Cox et al., Conditional gene expression in the mouse inner ear using Cre-loxP. J Assoc Res Otolaryngol. Jun. 2012;13(3):295-322. doi: 10.1007/s10162-012-0324-5. Epub Apr. 24, 2012.
Cox et al., Therapeutic genome editing: prospects and challenges. Nat Med. Feb. 2015;21(2):121-31. doi: 10.1038/nm.3793.
Cradick et al., CRISPR/Cas9 systems targeting B-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. Nov. 1, 2013;41(20):9584-92. doi: 10.1093/nar/gkt714. Epub Aug. 11, 2013.
Cradick et al., ZFN-site searches genomes for zinc finger nuclease target sites and off-target sites. BMC Bioinformatics. May 13, 2011;12:152. doi: 10.1186/1471-2105-12-152.
Cradick et al., Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther. May 2010;18(5):947-54. Doi: 10.1038/mt.2010.20. Epub Feb. 16, 2010.
Cronican et al., A class of human proteins that deliver functional proteins into mammalian cells in vitro and in vivo. Chem Biol. Jul. 29, 2011;18(7):833-8. doi: 10.1016/j.chembiol.2011.07.003.
Cronican et al., Potent delivery of functional proteins into mammalian cells in vitro and in vivo using a supercharged protein. ACS Chem Biol. Aug. 20, 2010;5(8):747-52. doi: 10.1021/cb1001153.
Cui et al., Targeted integration in rat and mouse embryos with zinc-finger nucleases. Nat Biotechnol. Jan. 2011;29(1):64-7. Doi: 10.1038/nbt.1731. Epub Dec. 12, 2010.
Cunningham et al., Ensembl 2015. Nucleic Acids Res. Jan. 2015;43(Database issue):D662-9. doi: 10.1093/nar/gku1010. Epub Oct. 28, 2014.
Czerwinski et al., Cytotoxic agents directed to peptide hormone receptors: defining the requirements for a successful drug. Proc Natl Acad Sci U S A. Sep. 29, 1998;95(20):11520-5.
Dahlem et al., Simple methods for generating and detecting locus-specific mutations induced with TALENs in the zebrafish genome. PLoS Genet. 2012;8(8):e1002861. doi: 10.1371/journal.pgen.1002861. Epub Aug. 16, 2012.
Daniels et al., Intrinsically cell-permeable miniature proteins based on a minimal cationic PPII motif. J Am Chem Soc. Nov. 28, 2007;129(47):14578-9. Epub Nov. 6, 2007.
Davis et al., DNA double strand break repair via non-homologous end-joining. Transl Cancer Res. Jun. 2013;2(3):130-143.
Davis et al., Small molecule-triggered Cas9 protein with improved genome-editing specificity. Nat Chem Biol. May 2015;11(5):316-8. doi: 10.1038/nchembio.1793. Epub Apr. 6, 2015.
De Souza, Primer: genome editing with engineered nucleases. Nat Methods. Jan. 2012;9(1):27.
Deltcheva et al., CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. Mar. 31, 2011;471(7340):602-7. doi: 10.1038/nature09886.
Dicarlo et al., Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Research Apr. 2013;41(7):4336-43.
Ding et al., A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell. Feb. 7, 2013;12(2):238-51. Doi: 10.1016/j.stem.2012.11.011. Epub Dec. 13, 2012.
Ding et al., Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. Aug. 15, 2014;115(5):488-92. doi: 10.1161/CIRCRESAHA.115.304351. Epub Jun. 10, 2014.
Dixon et al., Reengineering orthogonally selective riboswitches. Proc Natl Acad Sci U S A. Feb. 16, 2010;107(7):2830-5. doi: 10.1073/pnas.0911209107. Epub Jan. 26, 2010.
Doench et al., Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. Feb. 2016;34(2):184-191. doi: 10.1038/nbt.3437.
Dormiani et al., Long-term and efficient expression of human β-globin gene in a hematopoietic cell line using a new site-specific integrating non-viral system. Gene Ther. Aug. 2015;22(8):663-74. doi: 10.1038/gt.2015.30. Epub Apr. 1, 2015.
Doudna et al., Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. Nov. 28, 2014;346(6213):1258096. doi: 10.1126/science.1258096.
Doyon et al., Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods. Jan. 2011;8(1):74-9. Doi: 10.1038/nmeth.1539. Epub Dec. 5, 2010.
Doyon et al., Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol. Jun. 2008;26(6):702-8. Doi: 10.1038/nbt1409. Epub May 25, 2008.
Dunaime, Breakthrough method means CRISPR just got a lot more relevant to human health. The Verge. Apr. 20, 2016. http://www.theverge.com/2016/4/20/11450262/crispr-base-editing-single-nucleotides-dna-gene-liu-harvard.
During et al., Controlled release of dopamine from a polymeric brain implant: in vivo characterization. Ann Neurol. Apr. 1989;25(4):351-6.
East-Seletsky et al., Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. Nature Oct. 2016;538(7624):270-3.
Edwards et al., Crystal structures of the thi-box riboswitch bound to thiamine pyrophosphate analogs reveal adaptive RNA-small molecule recognition. Structure. Sep. 2006;14(9):1459-68.
Edwards et al., Structural basis for recognition of S-adenosylhomocysteine by riboswitches. RNA. Nov. 2010; 16(11):2144-55. doi:10.1261/rna.2341610. Epub Sep. 23, 2010.
Ellington et al., In vitro selection of RNA molecules that bind specific ligands. Nature. Aug. 30, 1990;346(6287):818-22.
Eltoukhy et al., Nucleic acid-mediated intracellular protein delivery by lipid-like nanoparticles. Biomaterials. Aug. 2014;35(24):6454-61. doi: 10.1016/j.biomaterials.2014.04.014. Epub May 13, 2014.
Esvelt et al., A system for the continuous directed evolution of biomolecules. Nature. Apr. 28, 2011;472(7344):499-503. doi: 10.1038/nature09929. Epub Apr. 10, 2011.
Esvelt et al., Genome-scale engineering for systems and synthetic biology. Mol Syst Biol. 2013;9:641. doi: 10.1038/msb.2012.66.
Esvelt et al., Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods. Nov. 2013;10(11):1116-21. doi: 10.1038/nmeth.2681. Epub Sep. 29, 2013.
Extended European Search Report for EP 15830407.1, dated Mar. 2, 2018.
Fang et al., Synthetic Studies Towards Halichondrins: Synthesis of the Left Halves of Norhalichondrins and Homohalichondrins. Tetrahedron Letters 1992;33(12):1557-1560.
Ferry et al., Rational design of inducible CRISPR guide RNAs for de novo assembly of transcriptional programs. Nat Commun. Mar. 3, 2017;8:14633. doi: 10.1038/ncomms14633.
Fine et al., Trans-spliced Cas9 allows cleavage of HBB and CCR5 genes in human cells using compact expression cassettes. Scientific Reports 2015;5(1):Article No. 10777. doi:10.1038/srep10777. With Supplementary Information.
Fischer et al., Cryptic epitopes induce high-titer humoral immune response in patients with cancer. J Immunol. Sep. 1, 2010;185(5):3095-102. doi: 10.4049/jimmunol.0902166. Epub Jul. 26, 2010.
Fonfara et al., Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. Nucleic Acids Res. Feb. 2014;42(4):2577-90. doi: 10.1093/nar/gktl074. Epub Nov. 22, 2013.
Freshney, Culture of Animal Cells. A Manual of Basic Technique. Alan R. Liss, Inc. New York. 1983;4.
Fu et al., Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. Mar. 2014;32(3):279-84. doi: 10.1038/nbt.2808. Epub Jan. 26, 2014.
Fu et al., High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. Sep. 2013;31(9):822-6. doi: 10.1038/nbt.2623. Epub Jun. 23, 2013.
Fuchs et al., Polyarginine as a multifunctional fusion tag. Protein Sci. Jun. 2005;14(6):1538-44.
Fujisawa et al., Disease-associated mutations in CIAS1 induce cathepsin B-dependent rapid cell death of human THP-1 monocytic cells. Blood. Apr. 1, 2007;109(7):2903-11.
Fukui et al., DNA Mismatch Repair in Eukaryotes and Bacteria. J Nucleic Acids. Jul. 27, 2010;2010. pii: 260512. doi: 10.4061/2010/260512.
Fung et al., Repair at single targeted DNA double-strand breaks in pluripotent and differentiated human cells. PLoS One. 2011;6(5):e20514. doi: 10.1371/journal.pone.0020514. Epub May 25, 2011.
Gabriel et al., An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol. Aug. 7, 2011;29(9):816-23. doi: 10.1038/nbt.1948.
Gaj et al., A comprehensive approach to zinc-finger recombinase customization enables genomic targeting in human cells. Nucleic Acids Res. Feb. 6, 2013;41(6):3937-46.
Gaj et al., Enhancing the specificity of recombinase-mediated genome engineering through dimer interface redesign. J Am Chem Soc. Apr. 2, 2014;136(13):5047-56. doi: 10.1021/ja4130059. Epub Mar. 20, 2014.
Gaj et al., Expanding the scope of site-specific recombinases for genetic and metabolic engineering. Biotechnol Bioeng. Jan. 2014;111(1):1-15. doi: 10.1002/bit.25096. Epub Sep. 13, 2013.
Gaj et al., Structure-guided reprogramming of serine recombinase DNA sequence specificity. Proc Natl Acad Sci U S A. Jan. 11, 2011;108(2):498-503. doi: 10.1073/pnas.1014214108. Epub Dec. 27, 2010.
Gaj et al., ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. Jul. 2013;31(7):397-405. doi: 10.1016/j.tibtech.2013.04.004. Epub May 9, 2013.
Gallo et al., A novel pathogenic PSEN1 mutation in a family with Alzheimer's disease: phenotypical and neuropathological features. J Alzheimers Dis. 2011;25(3):425-31. doi: 10.3233/JAD-2011-110185.
Gao et al., Crystal structure of a TALE protein reveals an extended N-terminal DNA binding region. Cell Res. Dec. 2012;22(12):1716-20. doi: 10.1038/cr.2012.156. Epub Nov. 13, 2012.
Gao et al., DNA-guided genome editing using the Natronobacterium gregoryi Argonaute. Nat Biotechnol. Jul. 2016;34(7):768-73. doi: 10.1038/nbt.3547. Epub May 2, 2016.
Gardlik et al., Vectors and delivery systems in gene therapy. Med Sci Monit. Apr. 2005;11(4):RA110-21. Epub Mar. 24, 2005.
Garneau et al., The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. Nov. 4, 2010;468(7320):67-71. doi: 10.1038/nature09523.
Gasiunas et al., Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A. Sep. 25, 2012;109(39):E2579-86. Epub Sep. 4, 2012. Supplementary materials included.
Gasiunas et al., RNA-dependent DNA endonuclease Cas9 of the CRISPR system: Holy Grail of genome editing? Trends Microbiol. Nov. 2013;21(11):562-7. doi: 10.1016/j.tim.2013.09.001. Epub Oct. 1, 2013.
Genbank Submission; NIH/NCBI, Accession No. J04623. Kita et al., Apr. 26, 1993. 2 pages.
Genbank Submission; NIH/NCBI, Accession No. NC_002737.1. Ferretti et al., Jun. 27, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_015683.1. Trost et al., Jul. 6, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_016782.1. Trost et al., Jun. 11, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_016786.1. Trost et al., Aug. 28, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_017053.1. Fittipaldi et al., Jul. 6, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_017317.1. Trost et al., Jun. 11, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_017861.1. Heidelberg et al., Jun. 11, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_018010.1. Lucas et al., Jun. 11, 2013. 2 pages.
Genbank Submission; NIH/NCBI, Accession No. NC_018721.1. Feng et al., Jun. 11, 2013. 1 pages.
Genbank Submission; NIH/NCBI, Accession No. NC_021284.1. Ku et al., Jul. 12, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_021314.1. Zhang et al., Jul. 15, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_021846.1. Lo et al., Jul. 22, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NP_472073.1. Glaser et al., Jun. 27, 2013. 2 pages.
Genbank Submission; NIH/NCBI, Accession No. P42212. Prasher et al., Mar. 19, 2014. 7 pages.
Genbank Submission; NIH/NCBI, Accession No. YP_002342100.1. Bernardini et al., Jun. 10, 2013. 2 pages.
Genbank Submission; NIH/NCBI, Accession No. YP_002344900.1. Gundogdu et al., Mar. 19, 2014. 2 pages.
Genbank Submission; NIH/NCBI, Accession No. YP_820832.1. Makarova et al., Aug. 27, 2013. 2 pages.
Gerber et al., RNA editing by base deamination: more enzymes, more targets, new mysteries. Trends Biochem Sci. Jun. 2001;26(6):376-84.
Gersbach et al., Directed evolution of recombinase specificity by split gene reassembly. Nucleic Acids Res. Jul. 2010;38(12):4198-206. doi: 10.1093/nar/gkq125. Epub Mar. 1, 2010.
Gersbach et al., Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase. Nucleic Acids Res. Sep. 1, 2011;39(17):7868-78. doi: 10.1093/nar/gkr421. Epub Jun. 7, 2011.
Gilbert et al., CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013 154(2):442-51.
Gilleron et al., Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. Jul. 2013;31(7):638-46. doi: 10.1038/nbt.2612. Epub Jun. 23, 2013.
Gonzalez et al., An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell. Aug. 7, 2014;15(2):215-26. doi: 10.1016/j.stem.2014.05.018. Epub Jun. 12, 2014.
Gordley et al., Evolution of programmable zinc finger-recombinases with activity in human cells. J Mol Biol. Mar. 30, 2007;367(3):802-13. Epub Jan. 12, 2007.
Gordley et al., Synthesis of programmable integrases. Proc Natl Acad Sci U S A. Mar. 31, 2009;106(13):5053-8. doi: 10.1073/pnas.0812502106. Epub Mar. 12, 2009.
Grundy et al., The L box regulon: lysine sensing by leader RNAs of bacterial lysine biosynthesis genes. Proc Natl Acad Sci U S A. Oct. 14, 2003;100(21):12057-62. Epub Oct. 1, 2003.
Guilinger et al., Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat Methods. Apr. 2014;11(4):429-35. doi: 10.1038/nmeth.2845. Epub Feb. 16, 2014.
Guilinger et al., Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol. Jun. 2014;32(6):577-82. doi: 10.1038/nbt.2909. Epub Apr. 25, 2014.
Guo et al., Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. J Mol Biol. Jul. 2, 2010;400(1):96-107. doi: 10.1016/j.jmb.2010.04.060. Epub May 4, 2010.
Guo et al., Protein tolerance to random amino acid change. Proc Natl Acad Sci U S A. Jun. 22, 2004;101(25):9205-10. Epub Jun. 14, 2004.
Guo et al., Structure of Cre recombinase complexed with DNA in a site-specific recombination synapse. Nature. Sep. 4, 1997;389(6646):40-6.
Gupta et al., Zinc finger protein-dependent and -independent contributions to the in vivo off-target activity of zinc finger nucleases. Nucleic Acids Res. Jan. 2011;39(1):381-92. doi: 10.1093/nar/gkq787. Epub Sep. 14, 2010.
Haeussler et al., Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. Jul. 5, 2016;17(1):148. doi: 10.1186/S13059-016-1012-2.
Hale et al., RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. Cell. Nov. 25, 2009;139(5):945-56. doi: 10.1016/j.cell.2009.07.040.
Hampel et al., Evidence for preorganization of the glmS ribozyme ligand binding pocket. Biochemistry. 2006; 45(25):7861-71.
Han, New CRISPR/Cas9-based Tech Edits Single Nucleotides Without Breaking DNA. Genome Web, Apr. 20, 2016. https://www.genomeweb.com/gene-silencinggene-editing/new-crisprcas9-based-tech-edits-single-nucleotides-without-breaking-dna.
Harris et al., RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell. Nov. 2002;10(5): 1247-53.
Hartung et al., Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther. Jun. 2004;9(6):866-75.
Hartung et al., Cre mutants with altered DNA binding properties. J Biol Chem. Sep. 4, 1998;273(36):22884-91.
Hasadsri et al., Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem. Mar. 13, 2009;284(11):6972-81. doi: 10.1074/jbc.M805956200. Epub Jan. 7, 2009.
Heitz et al., Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol. May 2009;157(2):195-206. doi: 10.1111/j.1476-5381.2009.00057.x. Epub Mar. 20, 2009.
Heller et al., Replisome assembly and the direct restart of stalled replication forks. Nat Rev Mol Cell Biol. Dec. 2006;7(12):932-43. Epub Nov. 8, 2006.
Hess et al., Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nat Methods. Dec. 2016;13(12):1036-1042. doi: 10.1038/nmeth.4038. Epub Oct. 31, 2016.
Hickford et al., Antitumour polyether macrolides: four new halichondrins from the New Zealand deep-water marine sponge Lissodendoryx sp. Bioorg Med Chem. Mar. 15, 2009;17(6):2199-203. doi: 10.1016/j.bmc.2008.10.093. Epub Nov. 19, 2008.
Hill et al., Functional analysis of conserved histidines in ADP-glucose pyrophosphorylase from Escherichia coli.Biochem Biophys Res Commun. Mar. 17, 1998;244(2):573-7.
Hilton et al., Enabling functional genomics with genome engineering. Genome Res. Oct. 2015;25(10):1442-55. doi: 10.1101/gr.190124.115.
Hirano et al., Site-specific recombinases as tools for heterologous gene integration. Appl Microbiol Biotechnol. Oct. 2011;92(2):227-39. doi: 10.1007/s00253-011-3519-5. Epub Aug. 7, 2011. Review.
Hockemeyer et al., Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol. Sep. 2009;27(9):851-7. doi: 10.1038/nbt.1562. Epub Aug. 13, 2009.
Hockemeyer et al., Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol. Jul. 7, 2011;29(8):731-4. doi: 10.1038/nbt.1927.
Holden et al., Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature. Nov. 6, 2008;456(7218):121-4. doi: 10.1038/nature07357. Epub Oct. 12, 2008.
Hondares et al., Peroxisome Proliferator-activated Receptor α (PPARα) Induces PPARγ Coactivator 1α (PGC-1α) Gene Expression and Contributes to Thermogenic Activation of Brown Fat. J Biol. Chem Oct. 2011;286(50):43112-22. doi: 10.1074/jbc.M111.252775.
Hope et al., Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review). Mol Membr Biol. Jan.-Mar. 1998;15(1):1-14.
Horvath et al., CRISPR/Cas, the immune system of bacteria and archaea. Science. Jan. 8, 2010;327(5962):167-70. doi: 10.1126/science.1179555.
Hou et al., Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A. Sep. 24, 2013;110(39):15644-9. doi: 10.1073/pnas.1313587110. Epub Aug. 12, 2013.
Houdebine, The methods to generate transgenic animals and to control transgene expression. J Biotechnol. Sep. 25, 2002;98(2-3):145-60.
Howard et al., Intracerebral drug delivery in rats with lesion-induced memory deficits. J Neurosurg. Jul. 1989;71(1):105-12.
Hower et al., Shape-based peak identification for ChIP-Seq. BMC Bioinformatics. Jan. 12, 2011;12:15. doi: 10.1186/1471-2105-12-15.
Hsu et al., DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. Sep. 2013;31(9):827-32. doi: 10.1038/nbt.2647. Epub Jul. 21, 2013.
Hu et al., Chemical Biology Approaches to Genome Editing: Understanding, Controlling, and Delivering Programmable Nucleases. Cell Chem Biol. Jan. 21, 2016;23(1):57-73. doi: 10.1016/j.chembiol.2015.12.009.
Huang et al., Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol. Aug. 5, 2011;29(8):699-700. doi: 10.1038/nbt.1939.
Huang et al., Long-range pseudoknot interactions dictate the regulatory response in the tetrahydrofolate riboswitch. Proc Natl Acad Sci U S A. Sep. 6, 2011;108(36):14801-6. doi: 10.1073/pnas.1111701108. Epub Aug. 22, 2011.
Humbert et al., Targeted gene therapies: tools, applications, optimization. Crit Rev Biochem Mol Biol. May-Jun. 2012;47(3):264-81. doi: 10.3109/10409238.2012.658112.
Hurt et al., Highly specific zinc finger proteins obtained by directed domain shuffling and cellbased selection. Proc Natl Acad Sci U S A. Oct. 14, 2003;100(21):12271-6. Epub Oct. 3, 2003.
Hwang et al., Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. Mar. 2013;31(3):227-9. doi: 10.1038/nbt.2501. Epub Jan. 29, 2013.
Hwang et al., Efficient In Vivo Genome Editing Using RNA-Guided Nucleases. Nat Biotechnol. Mar. 2013;31(3): 227-229. doi: 10.1038/nbt.2501. Epub Jan. 29, 2013.
Händel et al., Expanding or restricting the target site repertoire of zinc-finger nucleases: the inter-domain linker as a major determinant of target site selectivity. Mol Ther. Jan. 2009;17(1):104-11. doi: 10.1038/mt.2008.233. Epub Nov. 11, 2008.
Ikediobi et al., Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther. Nov. 2006;5(11):2606-12. Epub Nov. 6, 2006.
International Preliminary Report on Patentability for PCT/US2016/058344, dated May 3, 2018.
International Preliminary Report on Patentability for PCT/US2012/047778, dated Feb. 6, 2014.
International Preliminary Report on patentability for PCT/US2014/050283, dated Feb. 18, 2016.
International Preliminary Report on Patentability for PCT/US2014/052231, dated Mar. 3, 2016.
International Preliminary Report on Patentability for PCT/US2014/054247, dated Mar. 17, 2016.
International Preliminary Report on Patentability for PCT/US2014/054291, dated Mar. 17, 2016.
International Preliminary Report on Patentability for PCT/US2014/070038, dated Jun. 23, 2016.
International Preliminary Report on Patentability for PCT/US2015/042770, dated Dec. 19, 2016.
International Preliminary Report on Patentability for PCT/US2015/058479, dated May 11, 2017.
International Preliminary Report on Patentability or PCT/US2014/054252, dated Mar. 17, 2016.
International Search Report and Written Opinion for PCT/US2012/047778, dated May 30, 2013.
International Search Report and Written Opinion for PCT/US2014/050283, dated Nov. 6, 2014.
International Search Report and Written Opinion for PCT/US2014/052231, dated Dec. 4, 2014.
International Search Report and Written Opinion for PCT/US2014/052231, dated Jan. 30, 2015 (Corrected Version).
International Search Report and Written Opinion for PCT/US2014/054247, dated Mar. 27, 2015.
International Search Report and Written Opinion for PCT/US2014/054252, dated Mar. 5, 2015.
International Search Report and Written Opinion for PCT/US2014/054291, dated Mar. 27, 2015.
International Search Report and Written Opinion for PCT/US2014/070038, dated Apr. 14, 2015.
International Search Report and Written Opinion for PCT/US2015/042770, dated Feb. 23, 2016.
International Search Report and Written Opinion for PCT/US2015/058479, dated Feb. 11, 2016.
International Search Report and Written Opinion for PCT/US2016/044546, dated Dec. 28, 2016.
International Search Report and Written Opinion for PCT/US2016/058344, dated Apr. 20, 2017.
International Search Report and Written Opinion for PCT/US2017/045381, dated Oct. 26, 2017.
International Search Report and Written Opinion for PCT/US2017/046144, dated Oct. 10, 2017.
International Search Report and Written Opinion for PCT/US2017/056671, dated Feb. 20, 2018.
International Search Report and Written Opinion for PCT/US2017/068105, dated Apr. 4, 2018.
International Search Report and Written Opinion for PCT/US2017/068114, dated Mar. 20, 2018.
International Search Report and Written Opinion for PCT/US2017/48390, dated Jan. 9, 2018.
International Search Report for PCT/US2013/032589, dated Jul. 26, 2013.
International Search Report for PCT/US2018/021664, dated Jun. 21, 2018.
International Search Report for PCT/US2018/021878, dated Aug. 20, 2018.
International Search Report for PCT/US2018/021880, dated Jun. 20, 2018.
International Search Report for PCT/US2018/024208, dated Aug. 23, 2018.
International Search Report for PCT/US2018/025887, dated Jun. 21, 2018.
International Search Report for PCT/US2018/032460, dated Jul. 11, 2018.
Invitation to Pay Additional Fees for PCT/US2014/054291, dated Dec. 18, 2014.
Invitation to Pay Additional Fees for PCT/US2016/058344, dated Mar. 1, 2017.
Invitation to Pay Additional Fees for PCT/US2017/056671, dated Dec. 21, 2017.
Invitation to Pay Additional Fees for PCT/US2017/48390, dated Nov. 7, 2017.
Invitation to Pay Additional Fees for PCT/US2018/021878, dated Jun. 8, 2018.
Irrthum et al., Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet. Aug. 2000;67(2):295-301. Epub Jun. 9, 2000.
Ishino et al., Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. Dec. 1987;169(12):5429-33.
Jamieson et al., Drug discovery with engineered zinc-finger proteins. Nat Rev Drug Discov. May 2003;2(5):361-8.
Jansen et al., Backbone and nucleobase contacts to glucosamine-6-phosphate in the glmS ribozyme. Nat Struct Mol Biol. Jun. 2006;13(6):517-23. Epub May 14, 2006.
Jansen et al., Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. Mar. 2002;43(6): 1565-75.
Jenkins et al., Comparison of a preQ1 riboswitch aptamer in metabolite-bound and free states with implications for gene regulation. J Biol Chem. Jul. 15, 2011;286(28):24626-37. doi: 10.1074/jbc.M111.230375. Epub May 18, 2011.
Jiang et al., RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol. Mar. 2013;31(3):233-9. doi: 10.1038/nbt.2508. Epub Jan. 29, 2013.
Jiang et al., Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage. Science. Feb. 19, 2016;351(6275):867-71. doi: 10.1126/science.aad8282. Epub Jan. 14, 2016.
Jinek et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. Aug. 17, 2012;337(6096):816-21. doi: 10.1126/science.1225829. Epub Jun. 28, 2012.
Jinek et al., RNA-programmed genome editing in human cells. Elife. Jan. 29, 2013;2:e00471. doi: 10.7554/eLife.00471.
Jinek et al., Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science. Mar. 14, 2014;343(6176):1247997. doi: 10.1126/science.1247997. Epub Feb. 6, 2014.
Jore et al., Structural basis for CRISPR RNA-guided DNA recognition by Cascade. Nat Struct Mol Biol. May 2011;18(5):529-36. doi: 10.1038/nsmb.2019. Epub Apr. 3, 2011.
Joung et al.,TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. Jan. 2013;14(1):49-55. doi: 10.1038/nrm3486. Epub Nov. 21, 2012.
Kaiser et al., Gene therapy. Putting the fingers on gene repair. Science. Dec. 23, 2005;310(5756):1894-6.
Kandavelou et al., Targeted manipulation of mammalian genomes using designed zinc finger nucleases. Biochem Biophys Res Commun. Oct. 9, 2009;388(1):56-61. doi: 10.1016/j.bbrc.2009.07.112. Epub Jul. 25, 2009.
Kang et al., Structural Insights into riboswitch control of the biosynthesis of queuosine, a modified nucleotide found in the anticodon of tRNA. Mol Cell. Mar. 27, 2009;33(6):784-90. doi: 10.1016/j.molcel.2009.02.019. Epub Mar. 12, 2009.
Kappel et al., Regulating gene expression in transgenic animals.Curr Opin Biotechnol. Oct. 1992;3(5):548-53.
Karpenshif et al., From yeast to mammals: recent advances in genetic control of homologous recombination. DNA Repair (Amst). Oct. 1, 2012;11(10):781-8. doi: 10.1016/j.dnarep.2012.07.001. Epub Aug. 11, 2012. Review.
Karpinsky et al., Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat Biotechnol. Apr. 2016;34(4):401-9. doi: 10.1038/nbt.3467. Epub Feb. 22, 2016.
Kaya et al., A bacterial Argonaute with noncanonical guide RNA specificity. Proc. Natl. Acad. Sci. USA Apr. 2016;113(15):4057-62.
Kellendonk et al., Regulation of Cre recombinase activity by the synthetic steroid RU 486. Nucleic Acids Res. Apr. 15, 1996;24(8):1404-11.
Kilbride et al., Determinants of product topology in a hybrid Cre-Tn3 resolvase site-specific recombination system. J Mol Biol. Jan. 13, 2006;355(2):185-95. Epub Nov. 9, 2005.
Kim et al., A library of TAL effector nucleases spanning the human genome. Nat Biotechnol. Mar. 2013;31(3):251-8. Doi: 10.1038/nbt.2517. Epub Feb. 17, 2013.
Kim et al., Genome-wide target specificities of CRISPR RNA-guided programmable deaminases. Nat Biotechnol. May 2017;35(5):475-480. doi: 10.1038/nbt.3852. Epub Apr. 10, 2017.
Kim et al., Highly efficient RNA-guided base editing in mouse embryos. Nat Biotechnol. May 2017;35(5):435-437. doi: 10.1038/nbt.3816. Epub Feb. 27, 2017.
Kim et al., Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. Jun. 2014;24(6):1012-9. doi: 10.1101/gr.171322.113. Epub Apr. 2, 2014.
Kim et al., Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A. Feb. 6, 1996;93(3):1156-60.
Kim et al., Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. Nat Biotechnol. Apr. 2017;35(4):371-376. doi: 10.1038/nbt.3803. Epub Feb. 13, 2017.
Kim et al., TALENs and ZFNs are associated with different mutationsignatures. Nat Methods. Mar. 2013;10(3):185. doi: 10.1038/nmeth.2364. Epub Feb. 10, 2013.
Kim et al., Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Res. Jul. 2009;19(7):1279-88. doi: 10.1101/gr.089417.108. Epub May 21, 2009.
Kim et al., The role of apolipoprotein E in Alzheimer's disease. Neuron. Aug. 13, 2009;63(3):287-303. doi: 10.1016/j.neuron.2009.06.026.
Kim et al., Transcriptional repression by zinc finger peptides. Exploring the potential for applications in gene therapy. J Biol Chem. Nov. 21, 1997;272(47):29795-800.
Kitamura et al., Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA. PLoS Pathog. 2013;9(5):e1003361. doi: 10.1371/journal.ppat.1003361. Epub May 16, 2013.
Klauser et al., An engineered small RNA-mediated genetic switch based on a ribozyme expression platform. Nucleic Acids Res. May 1, 2013;41(10):5542-52. doi: 10.1093/nar/gkt253. Epub Apr. 12, 2013.
Klein et al., Cocrystal structure of a class I preQ1 riboswitch reveals a pseudoknot recognizing an essential hypermodified nucleobase. Nat Struct Mol Biol. Mar. 2009;16(3):343-4. doi: 10.1038/nsmb.1563.Epub Feb. 22, 2009.
Kleinstiver et al., Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat Biotechnol. Dec. 2015;33(12):1293-1298. doi: 10.1038/nbt.3404. Epub Nov. 2, 2015.
Kleinstiver et al., Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature. Jul. 23, 2015;523(7561):481-5. doi: 10.1038/nature14592. Epub Jun. 22, 2015.
Kleinstiver et al., High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. Jan. 28, 2016;529(7587):490-5. doi: 10.1038/nature16526. Epub Jan. 6, 2016.
Kleinstiver et al., Monomeric site-specific nucleases for genome editing. Proc Natl Acad Sci U S A. May 22, 2012;109(21):8061-6. doi: 10.1073/pnas.1117984109. Epub May 7, 2012.
Klippel et al., Isolation and characterization of unusual gin mutants. EMBO J. Dec. 1, 1988;7(12):3983-9.
Klippel et al., The DNA invertase Gin of phage Mu: formation of a covalent complex with DNA via a phosphoserine at amino acid position 9. EMBO J. Apr. 1988;7(4):1229-37.
Klug et al., Zinc fingers: a novel protein fold for nucleic acid recognition. Cold Spring Harb Symp Quant Biol. 1987;52:473-82.
Kohli et al., Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J Biol Chem. Dec. 24, 2010;285(52):40956-64. doi: 10.1074/jbc.M110.177402. Epub Oct. 6, 2010.
Komor et al., CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell. Jan. 12, 2017;168(1-2):20-36. doi: 10.1016/j.cell.2016.10.044.
Komor et al., Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci Adv. Aug. 30, 2017;3(8):eaao4774. doi: 10.1126/sciadv.aao4774. eCollection Aug. 2017.
Komor et al., Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. Apr. 20, 2016;533(7603):420-4. doi: 10.1038/nature17946.
Kouzminova et al., Patterns of chromosomal fragmentation due to uracil-DNA incorporation reveal a novel mechanism of replication-dependent double-stranded breaks. Mol Microbiol. Apr. 2008;68(1):202-15. doi: 10.1111/j.1365-2958.2008.06149.x.
Krishna et al., Structural classification of zinc fingers: survey and summary. Nucleic Acids Res. Jan. 15, 2003;31(2):532-50.
Kumar et al., Structural and functional consequences of the mutation of a conserved arginine residue in alphaA and alphaB crystallins. J Biol Chem. Aug. 20, 1999;274(34):24137-41.
Kundu et al., Leucine to proline substitution by SNP at position 197 in Caspase-9 gene expression leads to neuroblastoma: a bioinformatics analysis. 3 Biotech. 2013; 3:225-34.
Kunz et al., DNA Repair in mammalian cells: Mismatched repair: variations on a theme. Cell Mol Life Sci. Mar. 2009;66(6):1021-38. doi: 10.1007/s00018-009-8739-9.
Kury et al., De Novo Disruption of the Proteasome Regulatory Subunit PSMD12 Causes a Syndromic Neurodevelopmental Disorder. Am J Hum Genet. Feb. 2, 2017;100(2):352-363. doi: 10.1016/j.ajhg.2017.01.003. Epub Jan. 26, 2017.
Kuscu et al., CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations. Nat Methods. Jul. 2017;14(7):710-712. doi: 10.1038/nmeth.4327. Epub Jun. 5, 2017.
Kuscu et al., Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol. Jul. 2014;32(7):677-83. doi: 10.1038/nbt.2916. Epub May 18, 2014.
Kwon et al., Chemical basis of glycine riboswitch cooperativity. RNA. Jan. 2008;14(1):25-34. Epub Nov. 27, 2007.
Landrum et al., ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. Jan. 4, 2016;44(D1):D862-8. doi: 10.1093/nar/gkv1222. Epub Nov. 17, 2015.
Langer et al., Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review. Journal of Macromolecular Science, 2006;23(1):61-126. DOI: 10.1080/07366578308079439.
Langer et al., New methods of drug delivery. Science. Sep. 28, 1990;249(4976):1527-33.
Larson et al., CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat Protoc. Nov. 2013;8(11):2180-96. doi: 10.1038/nprot.2013.132. Epub Oct. 17, 2013.
Lau et al., Molecular basis for discriminating between normal and damaged bases by the human alkyladenine glycosylase, AAG. Proc Natl Acad Sci U S A. Dec. 5, 2000;97(25):13573-8.
Lavergne et al., Defects in type IIA von Willebrand disease: a cysteine 509 to arginine substitution in the mature von Willebrand factor disrupts a disulphide loop involved in the interaction with platelet glycoprotein Ib-IX. Br J Haematol. Sep. 1992;82(1):66-72.
Lawrence et al., Supercharging proteins can impart unusual resilience. J Am Chem Soc. Aug. 22, 2007;129(33):10110-2. Epub Aug. 1, 2007.
Lazar et al., Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Mol Cell Biol. Mar. 1988;8(3):1247-52.
Ledford, Gene-editing hack yields pinpoint precision. Nature, Apr. 20, 2016. http://www.nature.com/news/gene-editing-hack-yields-pinpoint-precision-1.19773.
Lee et al., A chimeric thyroid hormone receptor constitutively bound to DNA requires retinoid X receptor for hormone-dependent transcriptional activation in yeast. Mol Endocrinol. Sep. 1994;8(9):1245-52.
Lee et al., An allosteric self-splicing ribozyme triggered by a bacterial second messenger. Science. Aug. 13, 2010;329(5993):845-8. doi: 10.1126/science.1190713.
Lee et al., Failure to detect DNA-guided genome editing using Natronobacterium gregoryi Argonaute. Nat Biotechnol. Nov. 28, 2016;35(1):17-18. doi: 10.1038/nbt.3753.
Lee et al., PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. Feb. 17, 2005;24(8):1477-80.
Lee et al., Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim Biophys Acta. Jan. 31, 1992;1103(2):185-97.
Lee et al., Ribozyme Mediated gRNA Generation for In Vitro and In Vivo CRISPR/Cas9 Mutagenesis. PLoS One. Nov. 10, 2016;11(11):e0166020. doi: 10.1371/journal.pone.0166020. eCollection 2016.
Lei et al., Efficient targeted gene disruption in Xenopus embryos using engineered transcription activator-like effector nucleases (TALENs). Proc Natl Acad Sci U S A. Oct. 23, 2012;109(43):17484-9. Doi: 10.1073/pnas.1215421109. Epub Oct. 8, 2012.
Lenk et al., Pathogenic mechanism of the FIG4 mutation responsible for Charcot-Marie-Tooth disease CMT4J. PLoS Genet. Jun. 2011;7(6):e1002104. doi: 10.1371/journal.pgen.1002104. Epub Jun. 2, 2011.
Levy et al., Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate. Science. Apr. 12, 1985;228(4696):190-2.
Lewis et al., A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci U S A. Apr. 16, 1996;93(8):3176-81.
Lewis et al., Codon 129 polymorphism of the human prion protein influences the kinetics of amyloid formation. J Gen Virol. Aug. 2006;87(Pt 8):2443-9.
Li et al., Base editing with a Cpf1-cytidine deaminase fusion. Nat Biotechnol. Apr. 2018;36(4):324-327. doi: 10.1038/nbt.4102. Epub Mar. 19, 2018.
Li et al., Current approaches for engineering proteins with diverse biological properties. Adv Exp Med Biol. 2007;620:18-33.
Li et al., Generation of Targeted Point Mutations in Rice by a Modified CRISPR/Cas9 System. Mol Plant. Mar. 6, 2017;10(3):526-529. doi: 10.1016/j.molp.2016.12.001. Epub Dec. 8, 2016.
Li et al., Highly efficient and precise base editing in discarded human tripronuclear embryos. Protein Cell. Aug. 19, 2017. doi: 10.1007/s13238-017-0458-7. [Epub ahead of print].
Li et al., Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res. Aug. 2011;39(14):6315-25. doi: 10.1093/nar/gkr188. Epub Mar. 31, 2011.
Li et al., Multiplex and homologous recombination-mediated genome editing in Arabidopsis and Nicotiana benthamiana using guide RNA and Cas9. Nat Biotechnol. Aug. 2013;31(8):688-91. doi: 10.1038/nbt.2654.
Li et al., TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res. Jan. 2011;39(1):359-72. doi: 10.1093/nar/gkq704. Epub Aug. 10, 2010.
Liang et al., Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. Send to; J Biotechnol. Aug. 20, 2015;208:44-53. doi: 10.1016/j.jbiotec.2015.04.024.
Lieber et al., Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol. Sep. 2003;4(9):712-20.
Lin et al., Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife. Dec. 15, 2014;3:e04766. doi: 10.7554/eLife.04766.
Liu et al., C2c1-sgRNA Complex Structure Reveals RNA-Guided DNA Cleavage Mechanism. Molecular Cell Jan. 2017;65(2):310-22.
Liu et al., Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. Feb. 2013;9(2):106-18. doi: 10.1038/nrneurol.2012.263. Epub Jan. 8, 2013.
Liu et al., Balancing AID and DNA repair during somatic hypermutation. Trends Immunol. Apr. 2009;30(4):173-81. doi: 10.1016/j.it.2009.01.007.
Liu et al., Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS One. Jan. 20, 2014;9(1):e85755. doi: 10.1371/journal.pone.0085755. eCollection 2014.
Liu et al., Design of polydactyl zinc-ftnger proteins for unique addressing within complex genomes. Proc Natl Acad Sci U S A. May 27, 1997;94(11):5525-30.
Liu et al., Distance determination by GIY-YIG intron endonucleases: discrimination between repression and cleavage functions. Nucleic Acids Res. Mar. 31, 2006;34(6):1755-64. Print 2006.
Liu et al., Fast Colorimetric Sensing of Adenosine and Cocaine Based on a General Sensor Design Involving Aptamers and Nanoparticles. Angew Chem. 2006;118(1):96-100.
Lombardo et al., Gene editing in human stem cells using zinc finger nucleases and integrasedefective lentiviral vector delivery. Nat Biotechnol. Nov. 2007;25(11):1298-306. Epub Oct. 28, 2007.
Losey et al., Crystal structure of Staphylococcus sureus tRNA adenosine deaminase tadA in complex with RNA. Nature Struct. Mol. Biol. Feb. 2006;13(2):153-9.
Lu et al., Precise Editing of a Target Base in the Rice Genome Using a Modified CRISPR/Cas9 System. Mol Plant. Mar. 6, 2017;10(3):523-525. doi: 10.1016/j.molp.2016.11.013. Epub Dec. 6, 2016.
Lundberg et al., Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. Sep. 2007;21(11):2664-71. Epub Apr. 26, 2007.
Lundquist et al., Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein. Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase. J Biol Chem. Aug. 22, 1997;272(34):21408-19.
Lyons et al., Efficient Recognition of an Unpaired Lesion by a DNA Repair Glycosylase. J. Am. Chem. Soc., 2009;131(49):17742-3. DOI: 10.1021/ja908378y.
Ma et al., Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells. Nature Methods. Oct. 2016;13:1029-35. doi:10.1038/nmeth.4027.
Maeder et al., CRISPR RNA-guided activation of endogenous human genes. Nat Methods. Oct. 2013;10(10):977-9. doi: 10.1038/nmeth.2598. Epub Jul. 25, 2013.
Maeder et al., Rapid “open-source” engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell. Jul. 25, 2008;31(2):294-301. doi:10.1016/j.molcel.2008.06.016.
Maeder et al., Robust, synergistic regulation of human gene expression using TALE activators. Nat Methods. Mar. 2013;10(3):243-5. doi: 10.1038/nmeth.2366. Epub Feb. 10, 2013.
Mahfouz et al., De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks. Proc Natl Acad Sci U S A. Feb. 8, 2011;108(6):2623-8. doi: 10.1073/pnas. 1019533108. Epub Jan. 24, 2011.
Mak et al., The crystal structure of TAL effector PthXo1 bound to its DNA target. Science. Feb. 10, 2012;335(6069):716-9. doi: 10.1126/science.1216211. Epub Jan. 5, 2012.
Makarova et al., Prokaryotic homologs of Argonaute proteins are predicted to function as key components of a novel system of defense against mobile genetic elements. Biology Direct 2009;4:29.
Makarova et al., An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol. Nov. 2015;13(11):722-36. doi: 10.1038/nrmicro3569. Epub Sep. 28, 2015.
Makarova et al., Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol. Jun. 2011;9(6):467-77. doi: 10.1038/nrmicro2577. Epub May 9, 2011.
Mali et al., Cas9 as a versatile tool for engineering biology. Nat Methods. Oct. 2013;10(10):957-63. doi: 10.1038/nmeth.2649.
Mali et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. Sep. 2013;31(9):833-8. doi: 10.1038/nbt.2675. Epub Aug. 1, 2013.
Mali et al., RNA-guided human genome engineering via Cas9. Science. Feb. 15, 2013;339(6121):823-6. doi: 10.1126/science. 1232033. Epub Jan. 3, 2013.
Mandal et al., A glycine-dependent riboswitch that uses cooperative binding to control gene expression. Science. Oct. 8, 2004;306(5694):275-9.
Mandal et al., Adenine riboswitches and gene activation by disruption of a transcription terminator. Nat Struct Mol Biol. Jan. 2004;11(1):29-35. Epub Dec. 29, 2003.
Mani et al., Design, engineering, and characterization of zinc finger nucleases. Biochem Biophys Res Commun. Sep. 23, 2005;335(2):447-57.
Marioni et al., DNA methylation age of blood predicts all-cause mortality in later life. Genome Biol. Jan. 30, 2015;16:25. doi: 10.1186/s13059-015-0584-6.
Marraffini et al., CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science. Dec. 19, 2008;322(5909):1843-5. doi: 10.1126/science.1165771.
Maruyama et al., Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol. May 2015;33(5):538-42. doi: 10.1038/nbt.3190. Epub Mar. 23, 2015.
McNaughton et al., Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins. Proc Natl Acad Sci U S A. Apr. 14, 2009;106(15):6111-6. doi: 10.1073/pnas.0807883106. Epub Mar. 23, 2009.
Meckler et al., Quantitative analysis of TALE-DNA interactions suggests polarity effects. Nucleic Acids Res. Apr. 2013;41(7):4118-28. doi: 10.1093/nar/gkt085. Epub Feb. 13, 2013.
Mei et al., Recent Progress in CRISPR/Cas9 Technology. J Genet Genomics. Feb. 20, 2016;43(2):63-75. doi: 10.1016/j.jgg.2016.01.001. Epub Jan. 18, 2016.
Meng et al., Profiling the DNA-binding specificities of engineered Cys2His2 zinc finger domains using a rapid cell-based method. Nucleic Acids Res. 2007;35(11):e81. Epub May 30, 2007.
Meng et al., Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nat Biotechnol. Jun. 2008;26(6):695-701. doi: 10.1038/nbt1398. Epub May 25, 2008.
Mercer et al., Chimeric TALE recombinases with programmable DNA sequence specificity. Nucleic Acids Res. Nov. 2012;40(21):11163-72. doi: 10.1093/nar/gks875. Epub Sep. 26, 2012.
Meyer et al., Breathing life into polycations: functionalization with pH-responsive endosomolytic peptides and polyethylene glycol enables siRNA delivery. J Am Chem Soc. Mar. 19, 2008;130(11):3272-3. doi: 10.1021/ja710344v. Epub Feb. 21, 2008.
Meyer et al., Confirmation of a second natural preQ1 aptamer class in Streptococcaceae bacteria. RNA. Apr. 2008;14(4):685-95. doi: 10.1261/rna.937308. Epub Feb. 27, 2008.
Midoux et al., Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol. May 2009;157(2):166-78. doi: 10.1111/j.1476-5381.2009.00288.x.
Miller et al., A TALE nuclease architecture for efficient genome editing. Nat Biotechnol. Feb. 2011;29(2):143-8. doi:10.1038/nbt.1755. Epub Dec. 22, 2010.
Miller et al., An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol. Jul. 2007;25(7):778-85. Epub Jul. 1, 2007.
Minoche et al., Evaluation of genomic high-throughput sequencing data generated on Illumina HiSeq and genome analyzer systems. Genome Biol. Nov. 8, 2011;12(11):R112. doi: 10.1186/gb-2011-12-11-r112.
Minoretti et al., A W148R mutation in the human FOXD4 gene segregating with dilated cardiomyopathy, obsessive-compulsive disorder, and suicidality. Int J Mol Med. Mar. 2007;19(3):369-72.
Mojica et al., Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol. Feb. 2005;60(2):174-82.
Mol et al., Crystal structure of human uracil-DNA glycosylase in complex with a protein inhibitor: protein mimicry of DNA. Cell. Sep. 8, 1995;82(5):701-8.
Montange et al., Structure of the S-adenosylmethionine riboswitch regulatory mRNA element. Nature. Jun. 29, 2006;441(7097):1172-5.
Moore et al., Improved somatic mutagenesis in zebrafish using transcription activator-like effector nucleases (TALENs). PloS One. 2012;7(5):e37877. Doi: 10.1371/journal.pone.0037877. Epub May 24, 2012.
Mootz et al., Conditional protein splicing: a new tool to control protein structure and function in vitro and in vivo. J Am Chem Soc. Sep. 3, 2003;125(35):10561-9.
Mootz et al., Protein splicing triggered by a small molecule. J Am Chem Soc. Aug. 7, 2002;124(31):9044-5.
Morbitzer et al., Assembly of custom TALE-type DNA binding domains by modular cloning. Nucleic Acids Res. Jul. 2011;39(13):5790-9. doi: 10.1093/nar/gkr151. Epub Mar. 18, 2011.
Morris et al., A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol. Dec. 2001;19(12):1173-6.
Moscou et al., A simple cipher governs DNA recognition by TAL effectors. Science. Dec. 11, 2009;326(5959):1501. doi: 10.1126/science.1178817.
Mullins et al., Transgenesis in nonmurine species. Hypertension. Oct. 1993;22(4):630-3.
Murphy, Phage recombinases and their applications. Adv Virus Res. 2012;83:367-414. doi: 10.1016/B978-0-12-394438-2.00008-6. Review.
Mussolino et al., A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. Nov. 2011;39(21):9283-93. Doi: 10.1093/nar/gkr597. Epub Aug. 3, 2011.
Mussolino et al., TALE nucleases: tailored genome engineering made easy. Curr Opin Biotechnol. Oct. 2012;23(5):644-50. doi: 10.1016/j.copbio.2012.01.013. Epub Feb. 17, 2012.
Nahvi et al., Coenzyme B12 riboswitches are widespread genetic control elements in prokaryotes. Nucleic Acids Res. Jan. 2, 2004;32(1):143-50.
Narayanan et al., Clamping down on weak terminal base pairs: oligonucleotides with molecular caps as fidelity-enhancing elements at the 5′- and 3′-terminal residues. Nucleic Acids Res. May 20, 2004;32(9):2901-11. Print 2004.
Navaratnam et al., An overview of cytidine deaminases. Int J Hematol. Apr. 2006;83(3):195-200.
NCBI Reference Sequence: NM_002427.3. Wu et al., May 3, 2014. 5 pages.
Neel et al., Riboswitches: Classification, function and in silico approach, International Journal of Pharma Sciences and Research. 2010;1(9):409-420.
Ni et al., Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011;18(27):4206-14. Review.
Nishida et al., Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science. Sep. 16, 2016;353(6305). pii: aaf8729. doi: 10.1126/science.aaf8729. Epub Aug. 4, 2016.
Nishida et al., Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science. Sep. 16, 2016;353(6305):1248. pii: aaf8729. doi: 10.1126/science.aaf8729. Epub Aug. 4, 2016.
Nishimasu et al., Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell. Feb. 27, 2014;156(5):935-49. doi: 10.1016/j.cell.2014.02.001. Epub Feb. 13, 2014.
Nomura et al., Synthetic mammalian riboswitches based on guanine aptazyme. Chem Commun (Camb). Jul. 21, 2012;48(57):7215-7. doi: 10.1039/c2cc33140c. Epub Jun. 13, 2012.
Noris et al., A phenylalanine-55 to serine amino-acid substitution in the human glycoprotein IX leucine-rich repeat is associated with Bernard-Soulier syndrome. Br J Haematol. May 1997;97(2):312-20.
O'Connell et al., Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature. Dec. 11, 2014;516(7530):263-6. doi: 10.1038/nature13769. Epub Sep. 28, 2014.
Offord, Advances in Genome Editing. The Scientist, Apr. 20, 2016. http://www.the-scientist.com/7articles.view/articleNo/45903/title/Advances-in-Genome-Editing/.
Olorunniji et al., Synapsis and catalysis by activated Tn3 resolvase mutants. Nucleic Acids Res. Dec. 2008;36(22):7181-91. doi: 10.1093/nar/gkn885. Epub Nov. 10, 2008.
Osborn et al., TALEN-based gene correction for epidermolysis bullosa. Mol Ther. Jun. 2013;21(6):1151-9. doi: 10.1038/mt.2013.56. Epub Apr. 2, 2013.
Pabo et al., Design and selection of novel Cys2His2 zinc finger proteins. Annu Rev Biochem. 2001;70:313-40.
Pan et al., Biological and biomedical applications of engineered nucleases. Mol Biotechnol. Sep. 2013;55(1):54-62. doi: 10.1007/s12033-012-9613-9.
Parker et al., Admixture mapping identifies a quantitative trait locus associated with FEV1/FVC in the COPDGene Study. Genet Epidemiol. Nov. 2014;38(7):652-9. doi: 10.1002/gepi.21847. Epub Aug. 11, 2014.
Partial Supplementary European Search Report for Application No. EP 12845790.0, dated Mar. 18, 2015.
Pattanayak et al., Determining the specificities of TALENs, Cas9, and other genomeediting enzymes. Methods Enzymol. 2014;546:47-78. doi: 10.1016/B978-0-12-801185-0.00003-9.
Pattanayak et al., High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol. Sep. 2013;31(9):839-43. doi: 10.1038/nbt.2673. Epub Aug. 11, 2013.
Pattanayak et al., Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods. Aug. 7, 2011;8(9):765-70. doi: 10.1038/nmeth.1670.
Pavletich et al., Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A. Science. May 10, 1991;252(5007):809-17.
Pearl, Structure and function in the uracil-DNA glycosylase superfamily. Mutat Res. Aug. 30, 2000;460(3-4):165-81.
Peck et al., Directed evolution of a small-molecule-triggered intein with improved splicing properties in mammalian cells. Chem Biol. May 27, 2011;18(5):619-30. doi: 10.1016/j.chembiol.2011.02.014.
Pennisi et al., The CRISPR craze. Science. Aug. 23, 2013;341(6148):833-6. doi: 10.1126/science.341.6148.833.
Pennisi et al., The tale of the TALEs. Science. Dec. 14, 2012;338(6113):1408-11. doi: 10.1126/science.338.6113.1408.
Perez et al., Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. Jul. 2008;26(7):808-16. Doi: 10.1038/nbt1410. Epub Jun. 29, 2008.
Perez-Pinera et al., Advances in targeted genome editing. Curr Opin Chem Biol. Aug. 2012;16(3-4):268-77. doi: 10.1016/j.cbpa.2012.06.007. Epub Jul. 20, 2012.
Perez-Pinera et al., RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods. Oct. 2013;10(10):973-6. doi: 10.1038/nmeth.2600. Epub Jul. 25, 2013.
Petek et al., Frequent endonuclease cleavage at off-target locations in vivo. Mol Ther. May 2010;18(5):983-6. Doi: 10.1038/mt.2010.35. Epub Mar. 9, 2010.
Petolino et al., Editing Plant Genomes: a new era of crop improvement. Plant Biotechnol J. Feb. 2016;14(2):435-6. doi: 10.1111/pbi.12542.
Pham et al., Reward versus risk: DNA cytidine deaminases triggering immunity and disease. Biochemistry. Mar. 1, 2005;44(8):2703-15.
Phillips, The challenge of gene therapy and DNA delivery. J Pharm Pharmacol. Sep. 2001;53(9):1169-74.
Plasterk et al., DNA inversions in the chromosome of Escherichia coli and in bacteriophage Mu: relationship to other site-specific recombination systems. Proc Natl Acad Sci U S A. Sep. 1983;80(17):5355-8.
Plosky et al., CRISPR-Mediated Base Editing without DNA Double-Strand Breaks. Mol Cell. May 19, 2016;62(4):477-8. doi: 10.1016/j.molcel.2016.05.006.
Pluciennik et al., PCNA function in the activation and strand direction of MutLα endonuclease in mismatch repair. Proc Natl Acad Sci U S A. Sep. 14, 2010;107(37):16066-71. doi: 10.1073/pnas.1010662107. Epub Aug. 16, 2010.
Poller et al., A leucine-to-proline substitution causes a defective alpha 1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics. Sep. 1993;17(3):740-3.
Porteus, Design and testing of zinc finger nucleases for use in mammalian cells. Methods Mol Biol. 2008;435:47-61. doi: 10.1007/978-1-59745-232-8_4.
Pourcel et al., CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology. Mar. 2005;151(Pt 3):653-63.
Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology 2013;31(9):833-8.
Prorocic et al., Zinc-ftnger recombinase activities in vitro. Nucleic Acids Res. Nov. 2011;39(21):9316-28. doi: 10.1093/nar/gkr652. Epub Aug. 17, 2011.
Proudfoot et al., Zinc finger recombinases with adaptable DNA sequence specificity. PLoS One. Apr. 29, 2011;6(4):e19537. doi: 10.1371/journal.pone.0019537.
Prykhozhij et al., CRISPR multitargeter: a web tool to find common and unique CRISPR single guide RNA targets in a set of similar sequences. PLoS One. Mar. 5, 2015;10(3):e0119372. doi: 10.1371/journal.pone.0119372. eCollection 2015.
Putnam et al., Protein mimicry of DNA from crystal structures of the uracil-DNA glycosylase inhibitor protein and its complex with Escherichia coli uracil-DNA glycosylase. J Mol Biol. Mar. 26, 1999;287(2):331-46.
Putney et al., Improving protein therapeutics with sustained-release formulations. Nat Biotechnol. Feb. 1998;16(2):153-7.
Qi et al., Engineering naturally occurring trans-acting non-coding RNAs to sense molecular signals. Nucleic Acids Res. Jul. 2012;40(12):5775-86. doi: 10.1093/nar/gks168. Epub Mar. 1, 2012.
Qi et al., Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. Feb. 28, 2013;152(5):1173-83. doi: 10.1016/j.cell.2013.02.022.
Ramakrishna et al., Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. Jun. 2014;24(6):1020-7. doi: 10.1101/gr.171264.113. Epub Apr. 2, 2014.
Ramirez et al., Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects. Nucleic Acids Res. Jul. 2012;40(12):5560-8. doi: 10.1093/nar/ks179. Epub Feb. 28, 2012.
Ramirez et al., Unexpected failure rates for modular assembly of engineered zinc fingers. Nat Methods. May 2008;5(5):374-5. Doi: 10.1038/nmeth0508-374.
Ran et al., Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. Sep. 12, 2013;154(6):1380-9. doi: 10.1016/j.cell.2013.08.021. Epub Aug. 29, 2013.
Ran et al., Genome engineering using the CRISPR-Cas9 system. Nat Protoc. Nov. 2013;8(11):2281-308. doi: 10.1038/nprot.2013.143. Epub Oct. 24, 2013.
Ran et al., In vivo genome editing using Staphylococcus aureus Cas9. Nature. Apr. 9, 2015;520(7546):186-91. doi: 10.1038/nature14299. Epub Apr. 1, 2015.
Rath et al., Fidelity of end joining in mammalian episomes and the impact of Metnase on joint processing. BMC Mol Biol. Mar. 22, 2014;15:6. doi: 10.1186/1471-2199-15-6.
Ravishankar et al., X-ray analysis of a complex of Escherichia coli uracil DNA glycosylase (EcUDG) with a proteinaceous inhibitor. The structure elucidation of a prokaryotic UDG. Nuclei Acids Res. 26 (21): 4880-4887 (1998).
Ray et al., Homologous recombination: ends as the means. Trends Plant Sci. Oct. 2002;7(10):435-40.
Rebuzzini et al., New mammalian cellular systems to study mutations introduced at the break site by non-homologous end-joining. DNA Repair (Amst). May 2, 2005;4(5):546-55.
Rees et al., Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat Commun. Jun. 6, 2017;8:15790. doi: 10.1038/ncomms15790.
Reynaud et al., What role for AID: mutator, or assembler of the immunoglobulin mutasome? Nat Immunol. Jul. 2003;4(7):631-8.
Richardson et al., Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol. Mar. 2016;34(3):339-44. doi: 10.1038/nbt.3481. Epub Jan. 20, 2016.
Richter et al., Function and regulation of clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR associated (Cas) systems. Viruses. Oct. 19, 2012;4(10):2291-311. doi: 10.3390/v4102291.
Rizk et al., An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells. Proc Natl Acad Sci U S A. Jul. 7, 2009; 106(27):11011-5. doi: 10.1073/pnas.0904907106. Epub Jun. 22, 2009.
Rong et al., Homologous recombination in human embryonic stem cells using CRISPR/Cas9 nickase and a long DNA donor template. Protein Cell. Apr. 2014;5(4):258-60. doi: 10.1007/s13238-014-0032-5.
Rongrong et al., Effect of deletion mutation on the recombination activity of Cre recombinase. Acta Biochim Pol. 2005;52(2):541-4. Epub May 15, 2005.
Roth et al., A riboswitch selective for the queuosine precursor preQ1 contains an unusually small aptamer domain. Nat Struct Mol Biol. Apr. 2007;14(4):308-17. Epub Mar. 25, 2007.
Rowland et al., Regulatory mutations in Sin recombinase support a structure-based model of the synaptosome. Mol Microbiol. Oct. 2009;74(2):282-98. doi: 10.1111/j.1365-2958.2009.06756.x. Epub Jun. 8, 2009.
Sadelain et al., Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer. Dec. 1, 2011;12(1):51-8. doi: 10.1038/nrc3179.
Sage et al., Proliferation of functional hair cells in vivo in the absence of the retinoblastoma protein. Science. Feb. 18, 2005;307(5712):1114-8. Epub Jan. 13, 2005.
Saleh-Gohari et al., Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res. Jul. 13, 2004;32(12):3683-8. Print 2004.
Samal et al., Cationic polymers and their therapeutic potential. Chem Soc Rev. Nov. 7, 2012;41(21):7147-94. doi: 10.1039/c2cs35094g. Epub Aug. 10, 2012.
Sander et al., CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. Apr. 2014;32(4):347-55. doi: 10.1038/nbt.2842. Epub Mar. 2, 2014.
Sander et al., In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites. Nucleic Acids Res. Oct. 2013;41(19):e181. doi: 10.1093/nar/gkt716. Epub Aug. 14, 2013.
Sander et al., Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nat Biotechnol. Aug. 5, 2011;29(8):697-8. doi: 10.1038/nbt.1934.
Sang, Prospects for transgenesis in the chick. Meeh Dev. Sep. 2004;121(9):1179-86.
Sanjana et al., A transcription activator-like effector toolbox for genome engineering. Nat Protoc. Jan. 5, 2012;7(1):171-92. doi: 10.1038/nprot.2011.431.
Santiago et al., Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci U S A. Apr. 15, 2008;105(15):5809-14. doi: 10.1073/pnas.0800940105. Epub Mar. 21, 2008.
Sapranauskas et al., The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res. Nov. 2011;39(21):9275-82. doi: 10.1093/nar/gkr606. Epub Aug. 3, 2011.
Saraconi et al., The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome Biol. Jul. 31, 2014;15(7):417. doi: 10.1186/s13059-014-0417-z.
Sashital et al., Mechanism of foreign DNA selection in a bacterial adaptive immune system. Mol Cell. Jun. 8, 2012;46(5):606-15. doi: 10.1016/j.molcel.2012.03.020. Epub Apr. 19, 2012.
Saudek et al., A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med. Aug. 31, 1989;321(9):574-9.
Schellenberger et al., A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. Dec. 2009;27(12):1186-90. doi: 10.1038/nbt.1588.
Schriefer et al., Low pressure DNA shearing: a method for random DNA sequence analysis. Nucleic Acids Res. Dec. 25, 1990;18(24):7455-6.
Schwank et al., Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. Dec. 5, 2013;13(6):653-8. doi: 10.1016/j.stem.2013.11.002.
Schwartz et al., Post-translational enzyme activation in an animal via optimized conditional protein splicing. Nat Chem Biol. Jan. 2007;3(1):50-4. Epub Nov. 26, 2006.
Schwarze et al., In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. Sep. 3, 1999;285(5433):1569-72.
Sclimenti et al., Directed evolution of a recombinase for improved genomic integration at a native human sequence. Nucleic Acids Res. Dec. 15, 2001;29(24):5044-51.
Sefton et al., Implantable pumps. Crit Rev Biomed Eng. 1987;14(3):201-40.
Segal et al., Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins. Biochemistry. Feb. 25, 2003;42(7):2137-48.
Segal et al., Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5′-GNN-3′ DNA target sequences. Proc Natl Acad Sci U S A. Mar. 16, 1999;96(6):2758-63.
Sells et al., Delivery of protein into cells using polycationic liposomes. Biotechniques. Jul. 1995;19(1):72-6, 78.
Semenova et al., Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc Natl Acad Sci U S A. Jun. 21, 2011;108(25):10098-103. doi: 10.1073/pnas.1104144108. Epub Jun. 6, 2011.
Semple et al., Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. Feb. 2010;28(2):172-6. doi: 10.1038/nbt.1602. Epub Jan. 17, 2010.
Serganov et al., Coenzyme recognition and gene regulation by a flavin mononucleotide riboswitch. Nature. Mar. 12, 2009;458(7235):233-7. doi: 10.1038/nature07642. Epub Jan. 25, 2009.
Serganov et al., Structural basis for discriminative regulation of gene expression by adenine-and guanine-sensing mRNAs. Chem Biol. Dec. 2004;11(12):1729-41.
Serganov et al., Structural basis for gene regulation by a thiamine pyrophosphate-sensing riboswitch. Nature. Jun. 29, 2006;441(7097):1167-71. Epub May 21, 2006.
Seripa et al., The missing ApoE allele. Ann Hum Genet. Jul. 2007;71(Pt 4):496-500. Epub Jan. 22, 2007.
Shah et al., Inteins: nature's gift to protein chemists. Chem Sci. 2014;5(1):446-461.
Shah et al., Kinetic control of one-pot trans-splicing reactions by using a wild-type and designed split intein. Angew Chem Int Ed Engl. Jul. 11, 2011;50(29):6511-5. doi: 10.1002/anie.201102909. Epub Jun. 8, 2011.
Shah et al., Target-specific variants of Flp recombinase mediate genome engineering reactions in mammalian cells. FEBS J. Sep. 2015;282(17):3323-33. doi: 10.1111/febs.13345. Epub Jul. 1, 2015.
Shaikh et al., Chimeras of the Flp and Cre recombinases: tests of the mode of cleavage by Flp and Cre. J Mol Biol. Sep. 8, 2000;302(1):27-48.
Shalem et al., Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. Jan. 3, 2014;343(6166):84-7. doi: 10.1126/science.1247005. Epub Dec. 12, 2013.
Sharbeen et al., Ectopic restriction of DNA repair reveals that UNG2 excises AID-induced uracils predominantly or exclusively during G1 phase. J Exp Med. May 7, 2012;209(5):965-74. doi: 10.1084/jem.20112379. Epub Apr. 23, 2012.
Shcherbakova et al., Near-infrared fluorescent proteins for multicolor in vivo imaging. Nat Methods. Aug. 2013;10(8):751-4. doi: 10.1038/nmeth.2521. Epub Jun. 16, 2013.
Shee et al., Engineered proteins detect spontaneous DNA breakage in human and bacterial cells. Elife. Oct. 29, 2013;2:e01222. doi: 10.7554/eLife.01222.
Sheridan, First CRISPR-Cas patent opens race to stake out intellectual property. Nat Biotechnol. 2014;32(7):599-601.
Sheridan, Gene therapy finds its niche. Nat Biotechnol. Feb. 2011;29(2):121-8. doi: 10.1038/nbt.1769.
Shimantani et al., Targeted base editing in rice and tomato using a CRISPR-Cas9 cytidine deaminase fusion. Nat Biotechnol. May 2017;35(5):441-443. doi: 10.1038/nbt.3833. Epub Mar. 27, 2017.
Shimizu et al., Adding fingers to an engineered zinc finger nuclease can reduce activity. Biochemistry. Jun. 7, 2011;50(22):5033-41. doi: 10.1021/bi200393g. Epub May 11, 2011.
Shimojima et al., Spinocerebellar ataxias type 27 derived from a disruption of the fibroblast growth factor 14 gene with mimicking phenotype of paroxysmal non-kinesigenic dyskinesia. Brain Dev. Mar. 2012;34(3):230-3. doi: 10.1016/j.braindev.2011.04.014. Epub May 19, 2011.
Shmakov et al., Discovery and Functional Characterization of Diverse Class 2 CRISPR Cas Systems. Molecular Cell Nov. 2015;60(3):385-97.
Siebert et al., An improved PCR method for walking in uncloned genomic DNA. Nucleic Acids Res. Mar. 25, 1995;23(6): 1087-8.
Simonelli et al., Base excision repair intermediates are mutagenic in mammalian cells. Nucleic Acids Res. Aug. 2, 2005;33(14):4404-11. Print 2005.
Sirk et al., Expanding the zinc-ftnger recombinase repertoire: directed evolution and mutational analysis of serine recombinase specificity determinants. Nucleic Acids Res. Apr. 2014;42(7):4755-66. doi: 10.1093/nar/gkt1389. Epub Jan. 21, 2014.
Sjoblom et al., The consensus coding sequences of human breast and colorectal cancers. Science. Oct. 13, 2006;314(5797):268-74. Epub Sep. 7, 2006.
Skretas et al., Regulation of protein activity with small-molecule-controlled inteins. Protein Sci. Feb. 2005;14(2):523-32. Epub Jan. 4, 2005.
Slaymaker et al., Rationally engineered Cas9 nucleases with improved specificity. Science. Jan. 1, 2016;351(6268):84-8. doi: 10.1126/science.aad5227. Epub Dec. 1, 2015.
Smith et al., Diversity in the serine recombinases. Mol Microbiol. Apr. 2002;44(2):299-307. Review.
Smith et al., Expression of a dominant negative retinoic acid receptor γ in Xenopus embryos leads to partial resistance to retinoic acid. Roux Arch Dev Biol. Mar. 1994;203(5):254-265. doi: 10.1007/BF00360521.
Song et al., Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. Jun. 2005;23(6):709-17. Epub May 22, 2005.
Stenglein et al., APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol. Feb. 2010;17(2):222-9. doi: 10.1038/nsmb.1744. Epub Jan. 10, 2010.
Stephens et al., The landscape of cancer genes and mutational processes in breast cancer. Nature Jun. 2012;486:400-404. doi:10.1038/nature11017.
Sternberg et al., DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature.Mar. 6, 2014;507(7490):62-7. doi: 10.1038/nature13011. Epub Jan. 29, 2014.
Stevens et al., Design of a Split Intein with Exceptional Protein-Splicing Activity. J Am Chem Soc. Feb. 24, 2016; 138(7):2162-5. doi: 10.1021/jacs.5b13528. Epub Feb. 8, 2016.
Sudarsan et al., An mRNA structure in bacteria that controls gene expression by binding lysine. Genes Dev. Nov. 1, 2003 ;17(21):2688-97.
Sudarsan et al., Riboswitches in eubacteria sense the second messenger cyclic di-GMP. Science. Jul. 18, 2008;321(5887):411-3. doi: 10.1126/science.1159519.
Suess et al., A theophylline responsive riboswitch based on helix slipping controls gene expression in vivo. Nucleic Acids Res. Mar. 5, 2004;32(4):1610-4.
Sun et al., Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease. Mol Biosyst. Apr. 2012;8(4):1255-63. doi: 10.1039/c2mb05461b. Epub Feb. 3, 2012.
Supplementary European Search Report for Application No. EP 12845790.0, dated Oct. 12, 2015.
Swarts et al., Argonaute of the archaeon Pyrococcus furiosus is a DNA-guided nuclease that targets cognate DNA. Nucleic Acids Res. May 26, 2015;43(10):5120-9. doi: 10.1093/nar/gkv415. Epub Apr. 29, 2015.
Swarts et al., DNA-guided DNA interference by a prokaryotic Argonaute. Nature. Mar. 13, 2014;507(7491):258-61. doi: 10.1038/nature12971. Epub Feb. 16, 2014.
Swarts et al., The evolutionary journey of Argonaute proteins. Nat Struct Mol Biol. Sep. 2014;21(9):743-53. doi: 10.1038/nsmb.2879.
Szczepek et al., Structure-based redesign of the dimerization interface reduces the toxicity of zinc-ftnger nucleases. Nat Biotechnol. Jul. 2007;25(7):786-93. Epub Jul. 1, 2007.
Tagalakis et al., Lack of RNA-DNA oligonucleotide (chimeraplast) mutagenic activity in mouse embryos. Mol Reprod Dev. Jun. 2005;71(2):140-4.
Tang et al., Aptazyme-embedded guide RNAs enable ligand-responsive genome editing and transcriptional activation. Nat Commun. Jun. 28, 2017;8:15939. doi: 10.1038/ncomms15939.
Tebas et al., Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. Mar. 6, 2014;370(10):901-10. doi: 10.1056/NEJMoa1300662.
Tessarollo et al., Targeted mutation in the neurotrophin-3 gene results in loss of muscle sensory neurons. Proc Natl Acad Sci U S A. Dec. 6, 1994;91(25):11844-8.
Tesson et al., Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol. Aug. 5, 2011;29(8):695-6. doi: 10.1038/nbt.1940.
Thompson et al., Cellular uptake mechanisms and endosomal trafficking of supercharged proteins. Chem Biol. Jul. 27, 2012;19(7):831-43. doi: 10.1016/j.chembiol.2012.06.014.
Thompson et al., Engineering and identifying supercharged proteins for macromolecule delivery into mammalian cells. Methods Enzymol. 2012;503:293-319. doi: 10.1016/B978-0-12-396962-0.00012-4.
Thorpe et al., Functional correction of episomal mutations with short DNA fragments and RNA-DNA oligonucleotides. J Gene Med. Mar.-Apr. 2002;4(2):195-204.
Thyagarajan et al., Mammalian genomes contain active recombinase recognition sites. Gene. Feb. 22, 2000;244(1-2):47-54.
Thyagarajan et al., Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol Cell Biol. Jun. 2001;21(12):3926-34.
Tirumalai et al., Recognition of core-type DNA sites by lambda integrase. J Mol Biol. Jun. 12, 1998;279(3):513-27.
Trausch et al., The structure of a tetrahydrofolate-sensing riboswitch reveals two ligand binding sites in a single aptamer. Structure. Oct. 12, 2011;19(10):1413-23. doi: 10.1016/j.str.2011.06.019. Epub Sep. 8, 2011.
Truong et al., Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res. Jul. 27, 2015;43(13):6450-8. doi: 10.1093/nar/gkv601. Epub Jun. 16, 2015.
Truong et al., Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res. Jul. 27, 2015;43(13):6450-8. doi: 10.1093/nar/gkv601. Epub Jun. 16, 2015. With Supplementary Data.
Tsai et al., Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol. Jun. 2014;32(6):569-76. doi: 10.1038/nbt.2908. Epub Apr. 25, 2014.
Tsai et al., GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. Feb. 2015;33(2):187-97. doi: 10.1038/nbt.3117. Epub Dec. 16, 2014.
Turan et al., Recombinase-mediated cassette exchange (RMCE)—a rapidly-expanding toolbox for targeted genomic modifications. Gene. Feb. 15, 2013;515(1):1-27. doi: 10.1016/j.gene.2012.11.016. Epub Nov. 29, 2012.
Turan et al., Recombinase-mediated cassette exchange (RMCE): traditional concepts and current challenges. J Mol Biol. Mar. 25, 2011;407(2):193-221. doi: 10.1016/j.jmb.2011.01.004. Epub Jan. 15, 2011.
Turan et al., Site-specific recombinases: from tag-and-target- to tag-and-exchange-based genomic modifications. FASEB J. Dec. 2011;25(12):4088-107. doi: 10.1096/fj.11-186940. Epub Sep. 2, 2011. Review.
Tyszkiewicz et al., Activation of protein splicing with light in yeast. Nat Methods. Apr. 2008;5(4):303-5. doi: 10.1038/nmeth.1189. Epub Feb. 13, 2008.
UniProt Submission; UniProt, Accession No. P01011. Last modified Jun. 11, 2014, version 2. 15 pages.
UniProt Submission; UniProt, Accession No. P01011. Last modified Sep. 18, 2013, version 2. 15 pages.
UniProt Submission; UniProt, Accession No. P04264. Last modified Jun. 11, 2014, version 6. 15 pages.
UniProt Submission; UniProt, Accession No. P04275. Last modified Jul. 9, 2014, version 107. 29 pages.
Urnov et al., Genome editing with engineered zinc finger nucleases. Nat Rev Genet. Sep. 2010;11(9):636-46. doi: 10.1038/nrg2842.
Urnov et al., Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. Jun. 2, 2005;435(7042):646-51. Epub Apr. 3, 2005.
Vagner et al., Efficiency of homologous DNA recombination varies along the Bacillus subtilis chromosome. J Bacteriol. Sep. 1988;170(9):3978-82.
Van Duyne et al., Teaching Cre to follow directions. Proc Natl Acad Sci U S A. Jan. 6, 2009;106(1):4-5. doi: 10.1073/pnas.0811624106. Epub Dec. 31, 2008.
Van Swieten et al., A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia [corrected]. Am J Hum Genet. Jan. 2003;72(1):191-9. Epub Dec. 13, 2002.
Vanamee et al., FokI requires two specific DNA sites for cleavage. J Mol Biol. May 25, 2001;309(1):69-78.
Venken et al., Genome-wide manipulations of Drosophila melanogaster with transposons, Flp recombinase, and ΦC31 integrase. Methods Mol Biol. 2012;859:203-28. doi: 10.1007/978-1-61779-603-6_12.
Vitreschak et al., Regulation of the vitamin B12 metabolism and transport in bacteria by a conserved RNA structural element. RNA. Sep. 2003;9(9):1084-97.
Wacey et al., Disentangling the perturbational effects of amino acid substitutions in the DNA-binding domain of p53. Hum Genet. Jan. 1999;104(1):15-22.
Wadia et al., Modulation of cellular function by TAT mediated transduction of full length proteins. Curr Protein Pept Sci. Apr. 2003;4(2):97-104.
Wadia et al., Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med. Mar. 2004;10(3):310-5. Epub Feb. 8, 2004.
Wah et al., Structure of FokI has implications for DNA cleavage. Proc Natl Acad Sci U S A. Sep. 1, 1998;95(18):10564-9.
Wang et al., CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report. Arterioscler Thromb Vase Biol. May 2016;36(5):783-6. doi: 10.1161/ATVBAHA.116.307227. Epub Mar. 3, 2016.
Wang et al., Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci U S A. Feb. 29, 2016. pii: 201520244. [Epub ahead of print].
Wang et al., Genetic screens in human cells using the CRISPR-Cas9 system. Science. Jan. 3, 2014;343(6166):80-4. doi: 10.1126/science.1246981. Epub Dec. 12, 2013.
Wang et al., Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes. Nature. Oct. 8, 2009;461(7265):754-61. doi: 10.1038/nature08434.
Wang et al., One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. May 9, 2013;153(4):910-8. doi: 10.1016/j.cell.2013.04.025. Epub May 2, 2013.
Wang et al., Recombinase technology: applications and possibilities. Plant Cell Rep. Mar. 2011;30(3):267-85. doi: 10.1007/s00299-010-0938-1. Epub Oct. 24, 2010.
Wang et al., Riboswitches that sense S-adenosylhomocysteine and activate genes involved in coenzyme recycling. Mol Cell. Mar. 28, 2008;29(6):691-702. doi: 10.1016/j.molcel.2008.01.012.
Wang et al., Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme. Genome Res. Jul. 2012;22(7):1316-26. doi: 10.1101/gr.122879.111. Epub Mar. 20, 2012.
Wang et al., Uracil-DNA glycosylase inhibitor gene of bacteriophage PBS2 encodes a binding protein specific for uracil-DNA glycosylase. J Biol Chem. Jan. 15, 1989;264(2):1163-71.
Warren et al., A chimeric Cre recombinase with regulated directionality. Proc Natl Acad Sci U S A. Nov. 25, 2008;105(47):18278-83. doi: 10.1073/pnas.0809949105. Epub Nov. 14, 2008.
Warren et al., Mutations in the amino-terminal domain of lambda-integrase have differential effects on integrative and excisive recombination. Mol Microbiol. Feb. 2005;55(4):1104-12.
Weber et al., Assembly of designer TAL effectors by Golden Gate cloning. PLoS One. 2011;6(5):e19722. doi:10.1371/journal.pone.0019722. Epub May 19, 2011.
Weinberg et al., The aptamer core of SAM-IV riboswitches mimics the ligand-binding site of SAM-I riboswitches. RNA. May 2008;14(5):822-8. doi: 10.1261/rna.988608. Epub Mar. 27, 2008.
Weinberger et al., Disease-causing mutations C277R and C277Y modify gating of human C1C-1 chloride channels in myotonia congenita. J Physiol. Aug. 1, 2012;590(Pt 15):3449-64. doi: 0.1113/jphysiol.2012.232785. Epub May 28, 2012.
Wiedenheft et al., RNA-guided genetic silencing systems in bacteria and archaea. Nature. Feb. 15, 2012;482(7385):331-8. doi: 10.1038/nature10886. Review.
Wijnker et al., Managing meiotic recombination in plant breeding. Trends Plant Sci. Dec. 2008;13(12):640-6. doi: 10.1016/j.tplants.2008.09.004. Epub Oct. 22, 2008.
Winkler et al., An mRNA structure that controls gene expression by binding FMN. Proc Natl Acad Sci U S A. Dec. 10, 2002;99(25):15908-13. Epub Nov. 27, 2002.
Winkler et al., An mRNA structure that controls gene expression by binding S-adenosylmethionine. Nat Struct Biol.Sep. 2003;10(9):701-7. Epub Aug. 10, 2003.
Winkler et al., Control of gene expression by a natural metabolite-responsive ribozyme. Nature. Mar. 18, 2004;428(6980):281-6.
Winkler et al., Thiamine derivatives bind messenger RNAs directly to regulate bacterial gene expression. Nature. Oct. 31, 2002;419(6910):952-6. Epub Oct. 16, 2002.
Wolf et al., tadA, an essential tRNA-specific adenosine deaminase from Escherichia coli. EMBO J. Jul. 15, 2002;21(14):3841-51.
Wolfe et al., Analysis of zinc fingers optimized via phage display: evaluating the utility of a recognition code. J Mol Biol. Feb. 5, 1999;285(5):1917-34.
Wood et al., Targeted genome editing across species using ZFNs and TALENs. Science. Jul. 15, 2011;333(6040):307. doi: 10.1126/science.1207773. Epub Jun. 23, 2011.
Wu et al., Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell. Dec. 5, 2013;13(6):659-62. doi: 10.1016/j.stem.2013.10.016.
Wu et al., Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol. Jul. 2014;32(7):670-6. doi: 10.1038/nbt.2889. Epub Apr. 20, 2014.
Xu et al., Sequence determinants of improved CRISPR sgRNA design. Genome Res. Aug. 2015;25(8):1147-57. doi: 10.1101/gr.191452.115. Epub Jun. 10, 2015.
Yahata et al., Unified, Efficient, and Scalable Synthesis of Halichondrins: Zirconium/Nickel-Mediated One-Pot Ketone Synthesis as the Final Coupling Reaction. Angew Chem Int Ed Engl. Aug. 28, 2017;56(36):10796-10800. doi: 10.1002/anie.201705523. Epub Jul. 28, 2017.
Yamamoto et al., Virological and immunological bases for HIV-1 vaccine design. Uirusu 2007;57(2):133-139. https://doi.org/10.2222/jsv.57.133.
Yamano et al., Crystal Structure of Cpf1 in Complex with Guide RNA and Target DNA. Cell May 2016;165(4)949-62.
Yang et al., Engineering and optimising deaminase fusions for genome editing. Nat Commun. Nov. 2, 2016;7:13330. doi: 10.1038/ncomms13330.
Yang et al., Genome editing with targeted deaminases. BioRxiv. Preprint. First posted online Jul. 28, 2016.
Yang et al., New CRISPR-Cas systems discovered. Cell Res. Mar. 2017;27(3):313-314. doi: 10.1038/cr.2017.21. Epub Feb. 21, 2017.
Yang et al., PAM-dependent Target DNA Recognition and Cleavage by C2C1 CRISPR-Cas endonuclease. Cell Dec. 2016;167(7):1814-28.
Yanover et al., Extensive protein and DNA backbone sampling improves structure-based specificity prediction for C2H2 zinc fingers. Nucleic Acids Res. Jun. 2011;39(11):4564-76. doi: 10.1093/nar/gkr048. Epub Feb. 22, 2011.
Yazaki et al., Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg. Kidney Int. Jul. 2003;64(1):11-6.
Yin et al., Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. Jun. 2014;32(6):551-3. doi: 10.1038/nbt.2884. Epub Mar. 30, 2014.
Yuan et al., Tetrameric structure of a serine integrase catalytic domain. Structure. Aug. 6, 2008;16(8):1275-86. doi: 10.1016/j.str.2008.04.018.
Yuen et al., Control of transcription factor activity and osteoblast differentiation in mammalian cells using an evolved small-molecule-dependent intein. J Am Chem Soc. Jul. 12, 2006;128(27):8939-46.
Zelphati et al., Intracellular delivery of proteins with a new lipid-mediated delivery system. J Biol Chem. Sep. 14, 2001;276(37):35103-10. Epub Jul. 10, 2001.
Zetsche et al., A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat Biotechnol. Feb. 2015;33(2):139-42. doi: 10.1038/nbt.3149.
Zetsche et al., Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. Oct. 22, 2015;163(3):759-71. doi: 10.1016/j.cell.2015.09.038. Epub Sep. 25, 2015.
Zhang et al., Comparison of non-canonical PAMs for CRISPR/Cas9-mediated DNA cleavage in human cells. Sci Rep. Jun. 2014;4:5405.
Zhang et al., Conditional gene manipulation: Cre-ating a new biological era. J Zhejiang Univ Sci B. Jul. 2012;13(7):511-24. doi: 10.1631/jzus.B1200042. Review.
Zhang et al., CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet. Sep. 15, 2014;23(R1):R40-6. doi: 10.1093/hmg/ddu125. Epub Mar. 20, 2014.
Zhang et al., Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol. Feb. 2011;29(2):149-53. doi: 10.1038/nbt.1775. Epub Jan. 19, 2011.
Zhang et al., Programmable base editing of zebrafish genome using a modified CRISPR-Cas9 system. Nat Commun. Jul. 25, 2017;8(1):118. doi: 10.1038/s41467-017-00175-6.
Zhang et al., Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties. Gene Ther. Aug. 1999;6(8):1438-47.
Zheng et al., DNA editing in DNA/RNA hybrids by adenosine deaminases that act on RNA. Nucleic Acids Res. Apr. 7, 2017;45(6):3369-3377. doi: 10.1093/nar/gkx050.
Zimmermann et al., Molecular interactions and metal binding in the theophylline-binding core of an RNA aptamer. RNA. May 2000;6(5):659-67.
Zong et al., Precise base editing in rice, wheat and maize with a Cas9-cytidine deaminase fusion. Nat Biotechnol. May 2017;35(5):438-440. doi: 10.1038/nbt.3811. Epub Feb. 27, 2017.
Zorko et al., Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev. Feb. 28, 2005;57(4):529-45. Epub Jan. 22, 2005.
Zou et al., Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell. Jul. 2, 2009;5(1):97-110. doi: 10.1016/j.stem.2009.05.023. Epub Jun. 18, 2009.
Zuris et al., Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol. 2015;33:73-80.
EP 19181479.7, Oct. 31, 2019, Extended European Search Report.
EP 19187331.4, Dec. 19, 2019, Partial European Search Report.
PCT/US2017/068114, Jul. 4, 2019, International Preliminary Report on Patentability.
PCT/US2017/068105, Jul. 4, 2019, International Preliminary Report on Patentability.
PCT/US2018/021880, Sep. 19, 2019, International Preliminary Report on Patentability.
PCT/US2018/021664, Sep. 19, 2019, International Preliminary Report on Patentability.
PCT/US2018/021878, Sep. 19, 2019, International Preliminary Report on Patentability.
PCT/US2018/024208, Oct. 3, 2019, International Preliminary Report on Patentability.
PCT/US2018/048969, Jul. 31, 2019, International Search Report and Written Opinion.
PCT/US2018/048969, Mar. 12, 2020, International Preliminary Report on Patentability.
PCT/US2018/032460, Nov. 21, 2019, International Preliminary Report on Patentability.
PCT/US2018/044242, Nov. 21, 2019, International Search Report and Written Opinion.
PCT/US2018/044242, Feb. 6, 2020, International Preliminary Report on Patentability.
U.S. Appl. No. 16/374,634, filed Apr. 30, 2019, Liu et al.
U.S. Appl. No. 16/492,548, filed Sep. 9, 2019, Liu et al.
Banerjee et al., Cadmium inhibits mismatch repair by blocking the ATPase activity of the MSH2-MSH6 complex [published correction appears in Nucleic Acids Res. 2005;33(5):1738]. Nucleic Acids Res. 2005;33(4):1410-1419. Published Mar. 3, 2005. doi:10.1093/nar/gki291.
Burke et al., RNA Aptamers to the Adenosine Moiety of S-adenosyl Methionine: Structural Inferences From Variations on a Theme and the Reproducibility of SELEX. Nucleic Acids Res. May 15, 1997;25(10):2020-4. doi: 10.1093/nar/25.10.2020.
Eiler et al., Structural Basis for the Fast Self-Cleavage Reaction Catalyzed by the Twister Ribozyme. Proc Natl Acad Sci U S A. Sep. 9, 2014; 111(36):13028-33. doi: 10.1073/pnas.1414571111. Epub Aug. 25, 2014.
Endo et al., Toward establishing an efficient and versatile gene targeting system in higher plants. Biocatalysis and Agricultural Biotechnology 2014;3,(1):2-6.
Felletti et al., Twister Ribozymes as Highly Versatile Expression Platforms for Artificial Riboswitches. Nat Commun. Sep. 27, 2016;7:12834. doi: 10.1038/ncomms12834.
Genbank Submission; NIH/NCBI, Accession No. NM_174936. Guo et al., Oct. 28, 2015. 6 pages.
Harrington et al., Recent developments and current status of gene therapy using viral vectors in the United Kingdom. BMJ. 2004;329(7470):839?842. doi:10.1136/bmj.329.7470.839.
Horvath et al., Diversity, Activity, and Evolution of CRISPR Loci in Streptococcus thermophilus. J Bacteriol. Feb. 2008;190(4):1401-12. doi: 10.1128/JB.01415-07. Epub Dec. 7, 2007.
Jiang et al., Structural Biology. A Cas9-guide RNA Complex Preorganized for Target DNA Recognition. Science. Jun. 26, 2015;348(6242):1477-81. doi: 10.1126/science.aab1452.
Kobori et al., Deep Sequencing Analysis of Aptazyme Variants Based on a Pistol Ribozyme. ACS Synth Biol. Jul. 21, 2017;6(7):1283-1288. doi: 10.1021/acssynbio.7b00057. Epub Apr. 14, 2017.
Koonin et al., Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol. 2017;37:67?78. doi:10.1016/j.mib.2017.05.008.
Lewis et al., Building the Class 2 CRISPR-Cas Arsenal. Mol Cell 2017;65(3);377-379.
Lilley, D.M. The Varkud Satellite Ribozyme. RNA. Feb. 2004;10(2):151-8.doi: 10.1261/rna.5217104.
Liu et al., Functional Nucleic Acid Sensors. Chem Rev. May 2009;109(5):1948-98. doi: 10.1021/cr030183i.
Ma et al., Single-Stranded DNA Cleavage by Divergent CRISPR-Cas9 Enzymes. Mol Cell. Nov. 5, 2015;60(3):398-407. doi: 10.1016/j.molcel.2015.10.030.
Mandal et al., Riboswitches Control Fundamental Biochemical Pathways in Bacillus Subtilis and Other Bacteria. Cell. May 30, 2003;113(5):577-86. doi: 10.1016/s0092-8674(03)00391-x.
Mir et al., Two Active Site Divalent Ions in the Crystal Structure of the Hammerhead Ribozyme Bound to a Transition State Analogue. Biochemistry. . . Feb. 2, 2016;55(4):633-6. doi: 10.1021/acs.biochem.5b01139. Epub Jan. 19, 2016.
Ni et al., A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res. 2011;52:76-86.
Nishikura, Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem. 2010;79:321-349. doi:10.1146/annurev-biochem-060208-105251.
Nishimasu et al., Crystal Structure of Staphylococcus aureus Cas9. Cell. Aug. 27, 2015;162(5):1113-26. doi: 10.1016/j.cell.2015.08.007.
Nomura et al., Controlling Mammalian Gene Expression by Allosteric Hepatitis Delta Virus Ribozymes. ACS Synth Biol. Dec. 20, 2013;2(12):684-9. doi: 10.1021/sb400037a. Epub May 22, 2013.
Nowak et al., Guide RNA Engineering for Versatile Cas9 Functionality. Nucleic Acids Res. Nov. 16, 2016;44(20):9555-9564. doi: 10.1093/nar/gkw908. Epub Oct. 12, 2016.
Pospsílová et al., Hydrolytic cleavage of N6-substituted adenine derivatives by eukaryotic adenine and adenosine deaminases. Biosci Rep. 2008;28(6):335-347. doi:10.1042/BSR20080081.
Ren et al., In-line Alignment and Mg2? Coordination at the Cleavage Site of the env22 Twister Ribozyme. Nat Commun. Nov. 20, 2014;5:5534. doi: 10.1038/ncomms6534.
Ren et al., Pistol Ribozyme Adopts a Pseudoknot Fold Facilitating Site-Specific In-Line Cleavage. Nat Chem Biol. Sep. 2016;12(9):702-8. doi: 10.1038/nchembio.2125. Epub Jul. 11, 2016.
Sasidharan et al., The selection of acceptable protein mutations. PNAS; Jun. 12, 2007;104(24):10080-5. www.pnas.org/cgi/doi/10.1073.pnas.0703737104.
Tourdot et al., A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol. Dec. 2000;30(12):3411-21.
Wang et al. CRISPR-Cas9 and CRISPR-Assisted Cytidine Deaminase Enable Precise and Efficient Genome Editing in Klebsiella pneumoniae. Appl Environ Microbiol. 2018;84(23):e01834-18. Published Nov. 15, 2018. doi:10.1128/AEM.01834-18.
Wang et al., Enhanced base editing by co-expression of free uracil DNA glycosylase inhibitor. Cell Res. Oct. 2017;27(1): 1289-92. doi: 10.1038/cr.2017.111. Epub Aug. 29, 2017.
Weinberg et al., New Classes of Self-Cleaving Ribozymes Revealed by Comparative Genomics Analysis. Nat Chem Biol. Aug. 2015;11(8):606-10. doi: 10.1038/nchembio.1846. Epub Jul. 13, 2015.
Wijesinghe et al., Efficient deamination of 5-methylcytosines in DNA by human APOBEC3A, but not by AID or APOBEC3G. Nucleic Acids Res. Oct. 2012;40(18):9206-17. doi: 10.1093/nar/gks685. Epub Jul. 13, 2012.
Wilson et al., Assessing annotation transfer for genomics: quantifying the relations between protein sequence, structure and function through traditional and probabilistic scores. J Mol Biol 2000;297:233-49.
Wilson et al., In Vitro Selection of Functional Nucleic Acids. Annu Rev Biochem. 1999;68:611-47. doi: 10.1146/annurev.biochem.68.1.611.
Zhang et al., Ribozymes and Riboswitches: Modulation of RNA Function by Small Molecules. Biochemistry. Nov. 2, 2010;49(43):9123-31. doi: 10.1021/bi1012645.
Zhong et al., Rational Design of Aptazyme Riboswitches for Efficient Control of Gene Expression in Mammalian Cells. Elife. Nov. 2, 2016;5:e18858. doi: 10.7554/eLife.18858.
Rogozin et al., Evolution and diversification of lamprey antigen receptors: evidence for involvement of an AID-APOBEC family cytosine deaminase. Nat Immunol. Jun. 2007;8(6):647-56. doi: 10.1038/ni1463. Epub Apr. 29, 2007.
[No Author Listed] “FokI” from New England Biolabs Inc. Last accessed online via https://www.neb.eom/products/r0109-foki#Product%20Information on Mar. 19, 2021. 1 page.
[No Author Listed] “Nucleic Acids Sizes and Molecular Weights.” Printed Mar. 19, 2021. 2 pages.
[No Author Listed] “Zinc Finger Nuclease” from Wikipedia. Retrieved from https://en.wikipedia.org/w/index.php?title=Zinc_finger_nuclease&oldid= 1007053318. Page last edited Feb. 16, 2021. Printed on Mar. 19, 2021.
[No Author Listed] HyPhy—Hypothesis testing using Phylogenies. Last modified Apr. 21, 2017. Accessed online via http://hyphy.org/w/index.php/Main_Page on Apr. 28, 2021.
[No Author Listed] Theoretical Biochemistry Group. Institute for Theoretical Chemistry. The ViennaRNA Package. Universitat Wien. https://www.tbi.univie.ac.at/RNA/. Last accessed Apr. 28, 2021.
Abremski et al., Bacteriophage P1 site-specific recombination. Purification and properties of the Cre recombinase protein. J Biol Chem. Feb. 10, 1984;259(3):1509-14.
Abudayyeh et al., RNA targeting with CRISPR-Cas13. Nature. Oct. 12, 2017;550(7675):280-284. doi: 10.1038/nature24049. Epub Oct. 4, 2017.
Ada et al., Carbohydrate-protein conjugate vaccines. Clin Microbiol Infect. Feb. 2003;9(2):79-85. doi: 10.1046/j.1469-0691.2003.00530.x.
Adamala et al., Programmable RNA-binding protein composed of repeats of a single modular unit. Proc Natl Acad Sci U S A. May 10, 2016;113(19):E2579-88. doi: 10.1073/pnas.1519368113. Epub Apr. 26, 2016.
Adli, The CRISPR tool kit for genome editing and beyond. Nat Commun. May 15, 2018;9(1):1911. doi: 10.1038/s41467-018-04252-2.
Aguilo et al., Coordination of m(6)A mRNA Methylation and Gene Transcription by ZFP217 Regulates Pluripotency and Reprogramming. Cell Stem Cell. Dec. 3, 2015;17(6):689-704. doi: 10.1016/j.stem.2015.09.005. Epub Oct. 29, 2015.
Ahmad et al., Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Cancer Res. Sep. 1, 1992;52(17):4817-20.
Aik et al., Structure of human RNA N?-methyladenine demethylase ALKBH5 provides insights into its mechanisms of nucleic acid recognition and demethylation. Nucleic Acids Res. Apr. 2014;42(7):4741-54. doi: 10.1093/nar/gku085. Epub Jan. 30, 2014.
Akinsheye et al., Fetal hemoglobin in sickle cell anemia. Blood. Jul. 7, 2011;118(1):19-27. doi: 10.1182/blood-2011-03-325258. Epub Apr. 13, 2011.
Alarcón et al., HNRNPA2B1 Is a Mediator of m(6)A-Dependent Nuclear RNA Processing Events. Cell. Sep. 10, 2015;162(6):1299-308. doi: 10.1016/j.cell.2015.08.011. Epub Aug. 27, 2015.
Alarcón et al., N6-methyladenosine marks primary microRNAs for processing. Nature. Mar. 26, 2015;519(7544):482-5. doi: 10.1038/nature14281. Epub Mar. 18, 2015.
Alexander, HFE-associated hereditary hemochromatosis. Genet Med. May 2009;11(5):307-13. doi: 10.1097/GIM.0b013e31819d30f2.
Altschul et al., Basic local alignment search tool. J Mol Biol. Oct. 5, 1990;215(3):403-10. doi: 10.1016/S0022-2836(05)80360-2.
Amato et al., Interpreting elevated fetal hemoglobin in pathology and health at the basic laboratory level: new and known ?- gene mutations associated with hereditary persistence of fetal hemoglobin. Int J Lab Hematol. Feb. 2014;36(1):13-9. doi: 10.1111/ijlh.12094. Epub Apr. 29, 2013.
Anzalone et al., Reprogramming eukaryotic translation with ligand-responsive synthetic RNA switches. Nat Methods. May 2016;13(5):453-8. doi: 10.1038/nmeth.3807. Epub Mar. 21, 2016.
Anzalone et al., Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. Dec. 2019;576(7785):149-157. doi: 10.1038/s41586-019-1711-4. Epub Oct. 21, 2019.
Aplan, Causes of oncogenic chromosomal translocation. Trends Genet. Jan. 2006;22(1):46-55. doi: 10.1016/j.tig.2005.10.002. Epub Oct. 28, 2005.
Arakawa et al., A method to convert mRNA into a gRNA library for CRISPR/Cas9 editing of any organism. Sci Adv. Aug. 24, 2016;2(8):e1600699. doi: 10.1126/sciadv.1600699.
Araki et al., Comparative analysis of right element mutant lox sites on recombination efficiency in embryonic stem cells. BMC Biotechnol. Mar. 31, 2010;10:29. doi: 10.1186/1472-6750-10-29.
Araki et al., Targeted integration of DNA using mutant lox sites in embryonic stem cells. Nucleic Acids Res. Feb. 15, 1997;25(4):868-72. doi: 10.1093/nar/25.4.868.
Arambula et al., Surface display of a massively variable lipoprotein by a Legionella diversity-generating retroelement. Proc Natl Acad Sci U S A. May 14, 2013;110(20):8212-7. doi: 10.1073/pnas.1301366110. Epub Apr. 30, 2013.
Arazoe et al., Targeted Nucleotide Editing Technologies for Microbial Metabolic Engineering. Biotechnol J. Sep. 2018;13(9):e1700596. doi: 10.1002/biot.201700596. Epub Jun. 19, 2018.
Arbab et al., Cloning-free CRISPR. Stem Cell Reports. Nov. 10, 2015;5(5):908-917. doi: 10.1016/j.stemcr.2015.09.022. Epub Oct. 29, 2015.
Arezi et al., Novel mutations in Moloney Murine Leukemia Virus reverse transcriptase increase thermostability through tighter binding to template-primer. Nucleic Acids Res. Feb. 2009;37(2):473-81. doi: 10.1093/nar/gkn952. Epub Dec. 4, 2008.
Asante et al., A naturally occurring variant of the human prion protein completely prevents prion disease. Nature. Jun. 25, 2015;522(7557):478-81. doi: 10.1038/nature14510. Epub Jun. 10, 2015.
Belshaw et al., Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proc Natl Acad Sci U S A. May 14, 1996;93(10):4604-7. doi: 10.1073/pnas.93.10.4604.
Berkhout et al., Identification of an active reverse transcriptase enzyme encoded by a human endogenous HERV-K retrovirus. J Virol. Mar. 1999;73(3):2365-75. doi: 10.1128/JVI.73.3.2365-2375.1999.
Bernhart et al., Local RNA base pairing probabilities in large sequences. Bioinformatics. Mar. 1, 2006;22(5):614-5. doi: 10.1093/bioinformatics/btk014. Epub Dec. 20, 2005.
Bertolotti et al., Toward genosafe endonuclease-boosted gene targeting using breakthrough CRISP/Cas9 for next generation stem cell gene therapy culminating in efficient ex VIVO in VIVO gene repair/genomic editing. Molecular Therapy. May 2015;23(Suppl1):S139. Abstract 350. 18th Ann Meeting of the American Society of Gene and Cell Therapy. ASGCT 2015. New Orleans, LA. May 13, 2015-May 16, 2015.
Bertrand et al., Localization of ASH1 mRNA particles in living yeast. Mol Cell. Oct. 1998;2(4):437-45. doi: 10.1016/s1097-2765(00)80143-4.
Bi et al., Pseudo attP sites in favor of transgene integration and expression in cultured porcine cells identified by Streptomyces phage phiC31 integrase. BMC Mol Biol. Sep. 8, 2013;14:20. doi: 10.1186/1471-2199-14-20.
Bibb et al., Integration and excision by the large serine recombinase phiRv1 integrase. Mol Microbiol. Mar. 2005;55(6): 1896-910. doi: 10.1111/j.1365-2958.2005.04517.x.
Biehs et al., DNA Double-Strand Break Resection Occurs during Non-homologous End Joining in G1 but Is Distinct from Resection during Homologous Recombination. Mol Cell. Feb. 16, 2017;65(4):671-684.e5. doi: 10.1016/j.molcel.2016.12.016. Epub Jan. 26, 2017.
Biswas et al., A structural basis for allosteric control of DNA recombination by lambda integrase. Nature. Jun. 23, 2005;435(7045):1059-66. doi: 10.1038/nature03657.
Blain et al., Nuclease activities of Moloney murine leukemia virus reverse transcriptase. Mutants with altered substrate specificities. J Biol Chem. Nov. 5, 1993;268(31):23585-92.
Blau et al., A proliferation switch for genetically?modified?cells. PNAS Apr. 1, 1997 94 (7) 3076-3081; https://doi.org/10.1073/pnas.94.7.3076.
Bodi et al., Yeast m6A Methylated mRNAs Are Enriched on Translating Ribosomes during Meiosis, and under Rapamycin Treatment. PLoS One. Jul. 17, 2015;10(7):e0132090. doi: 10.1371/journal.pone.0132090.
Bogdanove et al., Engineering altered protein-DNA recognition specificity. Nucleic Acids Res. Jun. 1, 2018;46(10):4845-4871. doi: 10.1093/nar/gky289.
Borchardt et al., Controlling mRNA stability and translation with the CRISPR endoribonuclease Csy4. RNA. Nov. 2015;21(11):1921-30. doi: 10.1261/rna.051227.115. Epub Sep. 9, 2015.
Boutabout et al., DNA synthesis fidelity by the reverse transcriptase of the yeast retrotransposon Tyl. Nucleic Acids Res. Jun. 1, 2001;29(11):2217-22. doi: 10.1093/nar/29.11.2217.
Box et al., A multi-domain protein system based on the HC fragment of tetanus toxin for targeting DNA to neuronal cells. J Drug Target. Jul. 2003;11(6):333-43. doi: 10.1080/1061186310001634667.
Braun et al., Immunogenic duplex nucleic acids are nuclease resistant. J Immunol. Sep. 15, 1988;141(6):2084-9.
Brown et al., Characterization of the genetic elements required for site-specific integration of plasmid pSE211 in Saccharopolyspora erythraea. J Bacteriol. Apr. 1990;172(4):1877-88. doi: 10.1128/jb.172.4.1877-1888.1990.
Brown et al., Structural insights into the stabilization of MALAT1 noncoding RNA by a bipartite triple helix. Nat Struct Mol Biol. Jul. 2014;21(7):633-40. doi: 10.1038/nsmb.2844. Epub Jun. 22, 2014.
Brzezicha et al., Identification of human tRNA:m5C methyltransferase catalysing intron-dependent m5C formation in the first position of the anticodon of the pre-tRNA Leu (CAA). Nucleic Acids Res. 2006;34(20):6034-43. doi: 10.1093/nar/gkl765. Epub Oct. 27, 2006.
Buchschacher et al., Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol. May 1992;66(5):2731-9. doi: 10.1128/JVI.66.5.2731-2739.1992.
Budker et al., Protein/amphipathic polyamine complexes enable highly efficient transfection with minimal toxicity. Biotechniques. Jul. 1997;23(1):139, 142-7. doi: 10.2144/97231rr02.
Budworth et al., A brief history of triplet repeat diseases. Methods Mol Biol. 2013; 1010:3-17. doi: 10.1007/978-1-62703-411-1_1.
Byrne et al., Multiplex gene regulation: a two-tiered approach to transgene regulation in transgenic mice. Proc Natl Acad Sci U S A. Jul. 1989;86(14):5473-7. doi: 10.1073/pnas.86.14.5473.
Cadwell et al., Randomization of genes by PCR mutagenesis. PCR Methods Appl. Aug. 1992;2(1):28-33. doi: 10.1101/gr.2.1.28.
Cai et al., Reconstruction of ancestral protein sequences and its applications. BMC Evol Biol. Sep. 17, 2004;4:33. doi: 10.1186/1471-2148-4-33.
Camper et al., Postnatal repression of the alpha-fetoprotein gene is enhancer independent. Genes Dev. Apr. 1989;3(4):537-46. doi: 10.1101/gad.3.4.537.
Camps et al., Targeted gene evolution in Escherichia coli using a highly error-prone DNA polymerase I. Proc Natl Acad Sci U S A. Aug. 19, 2003;100(17):9727-32. Epub Aug. 8, 2003.
Canchaya et al., Genome analysis of an inducible prophage and prophage remnants integrated in the Streptococcus pyogenes strain SF370. Virology. Oct. 25, 2002;302(2):245-58. doi: 10.1006/viro.2002.1570.
Canver et al., Customizing the genome as therapy for the ?-hemoglobinopathies. Blood. May 26, 2016;127(21):2536-45. doi: 10.1182/blood-2016-01-678128. Epub Apr. 6, 2016.
Carlson et al., Negative selection and stringency modulation in phage-assisted continuous evolution. Nat Chem Biol. Mar. 2014;10(3):216-22. doi: 10.1038/nchembio.1453. Epub Feb. 2, 2014. With Supplementary Results.
Carvalho et al., Evolution in health and medicine Sackler colloquium: Genomic disorders: a window into human gene and genome evolution. Proc Natl Acad Sci U S A. Jan. 26, 2010;107 Suppl 1(Suppl 1):1765-71. doi: 10.1073/pnas.0906222107. Epub Jan. 13, 2010.
Caspi et al., Distribution of split DnaE inteins in cyanobacteria. Mol Microbiol. Dec. 2003;50(5):1569-77. doi: 10.1046/j.1365-2958.2003.03825.x.
Cattaneo et al., SEL1L affects human pancreatic cancer cell cycle and invasiveness through modulation of PTEN and genes related to cell-matrix interactions. Neoplasia. 2005;7(11):1030-1038.
Ceccaldi et al., Repair Pathway Choices and Consequences at the Double-Strand Break. Trends Cell Biol. Jan. 2016;26(1):52-64. doi: 10.1016/j.tcb.2015.07.009. Epub Oct. 1, 2015.
Chadalavada et al., Wild-type is the optimal sequence of the HDV ribozyme under cotranscriptional conditions. RNA. Dec. 2007;13(12):2189-201. doi: 10.1261/rna.778107. Epub Oct. 23, 2007.
Chalberg et al., phiC31 integrase confers genomic integration and long-term transgene expression in rat retina. Invest Ophthalmol Vis Sci. Jun. 2005;46(6):2140-6. doi: 10.1167/iovs.04-1252.
Chan et al., Molecular recording of mammalian embryogenesis. Nature. Jun. 2019;570(7759):77-82. doi: 10.1038/s41586-019-1184-5. Epub May 13, 2019.
Chapman et al., Playing the end game: DNA double-strand break repair pathway choice. Mol Cell. Aug. 24, 2012;47(4):497-510. doi: 10.1016/j.molcel.2012.07.029.
Chaturvedi et al., Stabilization of triple-stranded oligonucleotide complexes: use of probes containing alternating phosphodiester and stereo-uniform cationic phosphoramidate linkages. Nucleic Acids Res. Jun. 15, 1996;24(12):2318-23.
Chen et al., Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. Nature. Oct. 19, 2017;550(7676):407-410. doi: 10.1038/nature24268. Epub Sep. 20, 2017.
Chen et al., Highly Efficient Mouse Genome Editing by CRISPR Ribonucleoprotein Electroporation of Zygotes. J Biol Chem. Jul. 8, 2016;291(28):14457-67. doi: 10.1074/jbc.M116.733154. Epub May 5, 2016.
Chen et al., m(6)A RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency. Cell Stem Cell. Mar. 5, 2015;16(3):289-301. doi: 10.1016/j.stem.2015.01.016. Epub Feb. 12, 2015.
Chew et al., A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods. Oct. 2016;13(10):868-74. doi: 10.1038/nmeth.3993. Epub Sep. 5, 2016. Supplementary Information.
Chin, Expanding and reprogramming the genetic code of cells and animals. Annu Rev Biochem. 2014;83:379-408. doi: 10.1146/annurev-biochem-060713-035737. Epub Feb. 10, 2014.
Cho et al., Site-specific recombination of bacteriophage P22 does not require integration host factor. J Bacteriol. Jul. 1999;181(14):4245-9. doi: 10.1128/JB.181.14.4245-4249.1999.
Choe et al., Forging Ahead through Darkness: PCNA, Still the Principal Conductor at the Replication Fork. Mol Cell. Feb. 2, 2017;65(3):380-392. doi: 10.1016/j.molcel.2016.12.020.
Choi et al., N(6)-methyladenosine in mRNA disrupts tRNA selection and translation-elongation dynamics. Nat Struct Mol Biol. Feb. 2016;23(2):110-5. doi: 10.1038/nsmb.3148. Epub Jan. 11, 2016.
Chong et al., Modulation of protein splicing of the Saccharomyces cerevisiae vacuolar membrane ATPase intein. J Biol Chem. Apr. 24, 1998;273(17):10567-77. doi: 10.1074/jbc.273.17.10567.
Chong et al., Utilizing the C-terminal cleavage activity of a protein splicing element to purify recombinant proteins in a single chromatographic step. Nucleic Acids Res. Nov. 15, 1998;26(22):5109-15. doi: 10.1093/nar/26.22.5109.
Chong et al., Protein splicing involving the Saccharomyces cerevisiae VMA intein. The steps in the splicing pathway, side reactions leading to protein cleavage, and establishment of an in vitro splicing system. J Biol Chem. Sep. 6, 1996;271(36):22159-68. doi: 10.1074/jbc.271.36.22159.
Chong et al., Protein splicing of the Saccharomyces cerevisiae VMA intein without the endonuclease motifs. J Biol Chem. Jun. 20, 1997;272(25):15587-90. doi: 10.1074/jbc.272.25.15587.
Choudhury et al., Engineering RNA endonucleases with customized sequence specificities. Nat Commun. 2012;3:1147. doi: 10.1038/ncomms2154.
Christiansen et al., Characterization of the lactococcal temperate phage TP901-1 and its site-specific integration. J Bacteriol. Feb. 1994;176(4):1069-76. doi: 10.1128/jb.176.4.1069-1076.1994.
Chuai et al., DeepCRISPR: optimized CRISPR guide RNA design by deep learning. Genome Biol. Jun. 26, 2018;19(1):80. doi: 10.1186/s13059-018-1459-4.
Chuai et al., In Silico Meets In Vivo: Towards Computational CRISPR-Based sgRNA Design. Trends Biotechnol. Jan. 2017;35(1):12-21. doi: 10.1016/j.tibtech.2016.06.008. Epub Jul. 11, 2016.
Chuang et al., Novel Heterotypic Rox Sites for Combinatorial Dre Recombination Strategies. G3 (Bethesda). Dec. 29, 2015;6(3):559-71. doi: 10.1534/g3.115.025841.
Chujo et al., Trmt61B is a methyltransferase responsible for 1-methyladenosine at position 58 of human mitochondrial tRNAs. RNA. Dec. 2012;18(12):2269-76. doi: 10.1261/rna.035600.112. Epub Oct. 24, 2012.
Clackson et al., Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. Sep. 1, 1998;95(18):10437-42. doi: 10.1073/pnas.95.18.10437.
Clement et al., CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol. Mar. 2019;37(3):224-226. doi: 10.1038/s41587-019-0032-3.
Coffey et al., The Economic Impact of BSE on the U.S. Beef Industry: Product Value Losses, Regulatory Costs, and Consumer Reactions. Kansas State University Agricultural Experiment Station and Cooperative Extension Service. MF-2678. May 2005. 68 pages. Accessed via https://bookstore.ksre.ksu.edu/pubs/MF2678.pdf.
Cokol et al., Finding nuclear localization signals. EMBO Rep. Nov. 2000;1(5):411-5. doi: 10.1093/embo-reports/kvd092.
Conrad et al., A Kaposi's sarcoma virus RNA element that increases the nuclear abundance of intronless transcripts. EMBO J. May 18, 2005;24(10):1831-41. doi: 10.1038/sj.emboj.7600662. Epub Apr. 28, 2005.
Cornu et al., Refining strategies to translate genome editing to the clinic. Nat Med. Apr. 3, 2017;23(4):415-423. doi: 10.1038/nm.4313.
Costa et al., Frequent use of the same tertiary motif by self-folding RNAs. EMBO J. Mar. 15, 1995;14(6):1276-85.
Cui et al., Consequences of Cas9 cleavage in the chromosome of Escherichia coli. Nucleic Acids Res. May 19, 2016;44(9):4243-51. doi: 10.1093/nar/gkw223. Epub Apr. 8, 2016.
Cui et al., m6A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells. Cell Rep. Mar. 14, 2017;18(11):2622-2634. doi: 10.1016/j.celrep.2017.02.059.
Cui et al., Review of CRISPR/Cas9 sgRNA Design Tools. Interdiscip Sci. Jun. 2018;10(2):455-465. doi: 10.1007/s12539-018-0298-z. Epub Apr. 11, 2018.
Cupples et al., A set of lacZ mutations in Escherichia coli that allow rapid detection of each of the six base substitutions. Proc Natl Acad Sci U S A. Jul. 1989;86(14):5345-9.
Dahlgren et al., A novel mutation in ribosomal protein S4 that affects the function of a mutated RF1. Biochimie. Aug. 2000;82(8):683-91.
Dahlman et al., Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease. Nat Biotechnol. Nov. 2015;33(11):1159-61. doi: 10.1038/nbt.3390.
Dang et al., Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency. Genome Biol. Dec. 15, 2015;16:280. doi: 10.1186/s13059-015-0846-3.
Das et al.,The crystal structure of the monomeric reverse transcriptase from Moloney murine leukemia virus. Structure. May 2004;12(5):819-29. doi: 10.1016/j.str.2004.02.032.
Dassa et al., Fractured genes: a novel genomic arrangement involving new split inteins and a new homing endonuclease family. Nucleic Acids Res. May 2009;37(8):2560-73. doi: 10.1093/nar/gkp095. Epub Mar. 5, 2009.
Datsenko et al., One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A. Jun. 6, 2000;97(12):6640-5.
De Felipe et al., Co-translational, intraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2A peptide. J Biol Chem. Mar. 28, 2003;278(13):11441-8. doi: 10.1074/jbc.M211644200. Epub Jan. 8, 2003.
De Wit et al., The Human CD4+ T Cell Response against Mumps Virus Targets a Broadly Recognized Nucleoprotein Epitope. J Virol. Mar. 5, 2019;93(6):e01883-18. doi: 10.1128/JVI.01883-18.
Dean et al., Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. Sep. 27, 1996;273(5283):1856-62. doi: 10.1126/science.273.5283.1856.
Deng et al., Widespread occurrence of N6-methyladenosine in bacterial mRNA. Nucleic Acids Res. Jul. 27, 2015;43(13):6557-67. doi: 10.1093/nar/gkv596. Epub Jun. 11, 2015.
Deriano et al., Modernizing the nonhomologous end-joining repertoire: alternative and classical NHEJ share the stage. Annu Rev Genet. 2013;47:433-55. doi: 10.1146/annurev-genet-110711-155540. Epub Sep. 11, 2013.
Deussing, Targeted mutagenesis tools for modelling psychiatric disorders. Cell Tissue Res. Oct. 2013;354(1):9-25. doi: 10.1007/s00441-013-1708-5. Epub Sep. 10, 2013.
Dever et al., CRISPR/Cas9 ?-globin gene targeting in human haematopoietic stem cells. Nature. Nov. 17, 2016;539(7629):384-389. doi: 10.1038/nature20134. Epub Nov. 7, 2016.
Dicarlo et al., Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Res. Apr. 2013;41(7):4336-43. doi: 10.1093/nar/gkt135. Epub Mar. 4, 2013.
Dicarlo et al., Safeguarding CRISPR-Cas9 gene drives in yeast. Nat Biotechnol. Dec. 2015;33(12):1250-1255. doi: 10.1038/nbt.3412. Epub Nov. 16, 2015.
Dickinson et al., Experimental interrogation of the path dependence and stochasticity of protein evolution using phage-assisted continuous evolution. Proc Natl Acad Sci USA. May 2013;110(22):9007-12.
Doman et al., Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat Biotechnol. May 2020;38(5):620-628. doi: 10.1038/s41587-020-0414-6. Epub Feb. 10, 2020.
Dove et al., Conversion of the omega subunit of Escherichia coli RNA polymerase into a transcriptional activator or an activation target. Genes Dev. Mar. 1, 1998;12(5):745-54.
Doyon et al., Directed evolution and substrate specificity profile of homing endonuclease I-SceI. J Am Chem Soc. Feb. 22, 2006;128(7):2477-84.
Drake, A constant rate of spontaneous mutation in DNA-based microbes. Proc Natl Acad Sci U S A. Aug. 15, 1991;88(16):7160-4.
Dubois et al., Retroviral RNA Dimerization: From Structure to Functions. Front Microbiol. Mar. 22, 2018;9:527. doi: 10.3389/fmicb.2018.00527.
Durai et al., A bacterial one-hybrid selection system for interrogating zinc finger-DNA interactions. Comb Chem High Throughput Screen. May 2006;9(4):301-11.
Durai et al., Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res. Oct. 26, 2005;33(18):5978-90. doi: 10.1093/nar/gki912.
Eick et al., Robustness of Reconstructed Ancestral Protein Functions to Statistical Uncertainty. Mol Biol Evol. Feb. 1, 2017;34(2):247-261. doi: 10.1093/molbev/msw223.
Engel et al., The emerging role of mRNA methylation in normal and pathological behavior. Genes Brain Behav. Mar. 2018;17(3):e12428. doi: 10.1111/gbb.12428. Epub Nov. 17, 2017.
Engelward et al., Base excision repair deficient mice lacking the Aag alkyladenine DNA glycosylase. Proc Natl Acad Sci U S A. Nov. 25, 1997;94(24):13087-92.
Enyeart et al., Biotechnological applications of mobile group II introns and their reverse transcriptases: gene targeting, RNA-seq, and non-coding RNA analysis. Mobile DNA 5, 2 (2014). https://doi.org/10.1186/1759-8753-5-2. https://doi.org/10.1186/1759-8753-5-2.
Evans et al., Protein trans-splicing and cyclization by a naturally split intein from the dnaE gene of Synechocystis species PCC6803. J Biol Chem. Mar. 31, 2000;275(13):9091-4. doi: 10.1074/jbc.275.13.9091.
Evans et al., Semisynthesis of cytotoxic proteins using a modified protein splicing element. Protein Sci. Nov. 1998;7(11):2256-64. doi: 10.1002/pro.5560071103.
Evans et al., The cyclization and polymerization of bacterially expressed proteins using modified self-splicing inteins. J Biol Chem. Jun. 25, 1999;274(26):18359-63. doi: 10.1074/jbc.274.26.18359.
Evans et al., The in vitro ligation of bacterially expressed proteins using an intein from Methanobacterium thermoautotrophicum. J Biol Chem. Feb. 12, 1999;274(7):3923-6. doi: 10.1074/jbc.274.7.3923.
Evers et al., CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat Biotechnol. Jun. 2016;34(6):631-3. doi: 10.1038/nbt.3536. Epub Apr. 25, 2016.
Falnes et al., DNA repair by bacterial AlkB proteins. Res Microbiol. Oct. 2003;154(8):531-8. doi: 10.1016/S0923-2508(03)00150-5.
Falnes et al., Repair of methyl lesions in DNA and RNA by oxidative demethylation. Neuroscience. Apr. 14, 2007;145(4):1222-32. doi: 10.1016/j.neuroscience.2006.11.018. Epub Dec. 18, 2006.
Feng et al., Crystal structures of the human RNA demethylase Alkbh5 reveal basis for substrate recognition. J Biol Chem. Apr. 25, 2014;289(17):11571-11583. doi: 10.1074/jbc.M113.546168. Epub Mar. 10, 2014.
Feng et al., Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. Cell. Nov. 29, 1996;87(5):905-16. doi: 10.1016/s0092-8674(00)81997-2.
Feuk, Inversion variants in the human genome: role in disease and genome architecture. Genome Med. Feb. 12, 2010;2(2):11. doi: 10.1186/gm132.
Fitzjohn, Diversitree: comparative phylogenetic analyses of diversification in R. Methods in Evology and Evolution. Dec. 2012;3(6):1084-92 .doi: 10.1111/j.2041-210X.2012.00234.x.
Flajolet et al., Woodchuck hepatitis virus enhancer I and enhancer II are both involved in N-myc2 activation in woodchuck liver tumors. J Virol. Jul. 1998;72(7):6175-80. doi: 10.1128/JVI.72.7.6175-6180.1998.
Flaman et al., A rapid PCR fidelity assay. Nucleic Acids Res. Aug. 11, 1994;22(15):3259-60. doi: 10.1093/nar/22.15.3259.
Fogg et al., New applications for phage integrases. J Mol Biol. Jul. 29, 2014;426(15):2703-16. doi: 10.1016/j.jmb.2014.05.014. Epub May 22, 2014.
Fogg et al., Genome Integration and Excision by a New Streptomyces Bacteriophage, ?Joe. Appl Environ Microbiol. Feb. 15, 2017;83(5):e02767-16. doi: 10.1128/AEM.02767-16.
Fouts et al., Sequencing Bacillus anthracis typing phages gamma and cherry reveals a common ancestry. J Bacteriol. May 2006;188(9):3402-8. doi: 10.1128/JB.188.9.3402-3408.2006.
Freitas et al., Mechanisms and signals for the nuclear import of proteins. Curr Genomics. Dec. 2009;10(8):550-7. doi: 10.2174/138920209789503941.
Fu et al., Promises and Pitfalls of Intracellular Delivery of Proteins. Bioconjugate Chemistry. Aug. 2014;25:1602-8.
Furukawa et al., In vitro selection of allosteric ribozymes that sense the bacterial second messenger c-di-GMP. Methods Mol Biol. 2014;1111:209-20. doi: 10.1007/978-1-62703-755-6_15.
Gajula, Designing an Elusive CoG?GoC CRISPR Base Editor. Trends Biochem Sci. Feb. 2019;44(2):91-94. doi: 10.1016/j.tibs.2018.10.004. Epub Nov. 13, 2018.
Gao et al., Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature. Jan. 11, 2018;553(7687):217-221. doi: 10.1038/nature25164. Epub Dec. 20, 2017.
Garcia et al., Transglycosylation: a mechanism for RNA modification (and editing?). Bioorg Chem. Jun. 2005;33(3):229-51. doi: 10.1016/j.bioorg.2005.01.001. Epub Feb. 23, 2005.
Garibyan et al., Use of the rpoB gene to determine the specificity of base substitution mutations on the Escherichia coli chromosome. DNA Repair (Amst). May 13, 2003;2(5):593-608.
Gaudelli et al., Programmable base editing of AoT to GoC in genomic DNA without DNA cleavage. Nature. Nov. 23, 2017;551(7681):464-471. doi: 10.1038/nature24644. Epub Oct. 25, 2017. Erratum in: Nature. May 2, 2018.
Gehrke et al., An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities. Nat Biotechnol. Nov. 2018;36(10):977-982. doi: 10.1038/nbt.4199. Epub Jul. 30, 2018.
GenBank Accession No. J01600.1. Brooks et al., E.coli dam gene coding for DNA adenine methylase. Apr. 26, 1993.
GenBank Submission; NIH/NCBI Accession No. NM_001319224.2. Umar et al., Apr. 21, 2021. 7 pages.
GenBank Submission; NIH/NCBI Accession No. NM_006027.4. Umar et al., Apr. 10, 2021. 7 pages.
GenBank Submission; NIH/NCBI, Accession No. AAA66622.1. Martinelli et al., May 18, 1995. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. AGT42196. Farzadfar et al., Nov. 2, 2013. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. APG80656.1. Burstein et al., Dec. 10, 2016. 1 pages.
GenBank Submission; NIH/NCBI, Accession No. AYD60528.1. Ram et al., Oct. 2, 2018. 1 page.
GenBank Submission; NIH/NCBI, Accession No. BDB43378. Zhang et al., Aug. 11, 2016. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. KR710351.1. Sahni et al., Jun. 1, 2015. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. NC 002737.2. Nasser et al., Feb. 7, 2021. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. NM_000311.5. Alves et al., Mar. 7, 2021. 5 pages.
GenBank Submission; NIH/NCBI, Accession No. NM_001319224. Umar et al., Apr. 21, 2021. 7 pages.
GenBank Submission; NIH/NCBI, Accession No. NM_003686.4. Umar et al., Apr. 9, 2021. 7 pages.
GenBank Submission; NIH/NCBI, Accession No. NM_006027. Umar et al., Apr. 10, 2021. 7 pages.
GenBank Submission; NIH/NCBI, Accession No. NM_174936.3. Bernardini et al., Oct. 28, 2015. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. NP_000302.1. Alves et al., Mar. 7, 2021. 4 pages.
GenBank Submission; NIH/NCBI, Accession No. NP_955579.1. Chen et al., Aug. 13, 2018. 5 pages.
GenBank Submission; NIH/NCBI, Accession No. QBJ66766. Duan et al. Aug. 12, 2020. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. RFF81513.1. Zhou et al., Aug. 21, 2018. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. SNX31424.1. Weckx, S., Feb. 16, 2018. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. TGH57013. Xu et al., Apr. 9, 2019. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. WP_016631044.1. Haft et al., Sep. 22, 2020. 1 page.
GenBank Submission; NIH/NCBI, Accession No. WP_031386437. No Author Listed., Sep. 23, 2019. 1 page.
GenBank Submission; NIH/NCBI, Accession No. WP_0315 89969.1. Haft et al., Oct. 9, 2019. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. WP_044924278.1. Haft et al., Oct. 9, 2019. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. WP_047338501.1. Haft et al., Oct. 9, 2019. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. WP_060798984.1. Haft et al., Oct. 9, 2019. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. WP_062913273.1. Haft et al., Oct. 9, 2019, 2 pages.
GenBank Submission; NIH/NCBI, Accession No. WP_072754838. No Author Listed., Sep. 23, 2019. 1 page.
GenBank Submission; NIH/NCBI, Accession No. WP_095142515.1. No Author Listed., Sep. 23, 2019. 1 page.
GenBank Submission; NIH/NCBI, Accession No. WP_118538418.1. No Author Listed., Oct. 13, 2019. 1 page.
GenBank Submission; NIH/NCBI, Accession No. WP_119223642.1. No Author Listed., Oct. 13, 2019. 1 page.
GenBank Submission; NIH/NCBI, Accession No. WP_119227726.1. No Author Listed., Oct. 13, 2019. 1 page.
GenBank Submission; NIH/NCBI, Accession No. WP_119623382.1. No Author Listed., Oct. 13, 2019. 1 page.
GenBank Submission; NIH/NCBI, Accession No. WP_132221894.1. No Author Listed., Sep. 23, 2019. 1 page.
GenBank Submission; NIH/NCBI, Accession No. WP_133478044.1. Haft et al., Oct. 9, 2019. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. YP_009283008.1. Bernardini et al., Sep. 23, 2016. 2 pages.
George et al., Adenosine deaminases acting on RNA, RNA editing, and interferon action. J Interferon Cytokine Res. Jan. 2011;31(1):99-117. doi: 10.1089/jir.2010.0097. Epub Dec. 23, 2010. PMID: 21182352; PMCID: PMC3034097.
Gerard et al., Purification and characterization of the DNA polymerase and RNase H activities in Moloney murine sarcoma-leukemia virus. J Virol. Apr. 1975;15(4):785-97. doi: 10.1128/JVI.15.4.785-797.1975.
Gerard et al., The role of template-primer in protection of reverse transcriptase from thermal inactivation. Nucleic Acids Res. Jul. 15, 2002;30(14):3118-29. doi: 10.1093/nar/gkf417.
Gerber et al., An adenosine deaminase that generates inosine at the wobble position of tRNAs. Science. Nov. 5, 1999;286(5442):1146-9. doi: 10.1126/science.286.5442.1146.
Ghahfarokhi et al., Blastocyst Formation Rate and Transgene Expression are Associated with Gene Insertion into Safe and Non-Safe Harbors in the Cattle Genome. Sci Rep. Nov. 13, 2017;7(1):15432. doi: 10.1038/s41598-017-15648-3.
Glasgow et al.,DNA-binding properties of the Hin recombinase. J Biol Chem. Jun. 15, 1989;264(17):10072-82.
Glassner et al., Generation of a strong mutator phenotype in yeast by imbalanced base excision repair. Proc Natl Acad Sci U S A. Aug. 18, 1998;95(17):9997-10002.
Goldberg et al., Epigenetics: a landscape takes shape. Cell. Feb. 23, 2007;128(4):635-8. doi: 10.1016/j.cell.2007.02.006.
Gong et al., Active DNA demethylation by oxidation and repair. Cell Res. Dec. 2011;21(12):1649-51. doi: 10.1038/cr.2011.140. Epub Aug. 23, 2011.
Goodnough et al., Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. FEBS Lett. Feb. 27, 2002;513(2-3):163-8.
Grainge et al., The integrase family of recombinase: organization and function of the active site. Mol Microbiol. Aug. 1999;33(3):449-56.
Gregory et al., Integration site for Streptomyces phage phiBT1 and development of sitespecific integrating vectors. J Bacteriol. Sep. 2003;185(17):5320-3. doi: 10.1128/jb.185.17.5320-5323.2003.
Griffiths, Endogenous retroviruses in the human genome sequence. Genome Biol. 2001;2(6):REVIEWS1017. doi: 10.1186/gb-2001-2-6-reviews1017. Epub Jun. 5, 2001.
Grishok et al., Genes and Mechanisms Related to RNA Interference Regulate Expression of the Small Temporal RNAs that Control C. elegans Developmental Timing. Jul. 13, 2001:106(1):P23-4.
Groth et al., Construction of transgenic Drosophila by using the site-specific integrase from phage phiC31. Genetics. Apr. 2004;166(4):1775-82. doi: 10.1534/genetics.166.4.1775.
Gruber et al., Strategies for measuring evolutionary conservation of RNA secondary structures. BMC Bioinformatics. Feb. 26, 2008;9:122. doi: 10.1186/1471-2105-9-122.
Grunebaum et al., Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. Curr Opin Allergy Clin Immunol. Dec. 2013;13(6):630-8. doi: 10.1097/ACI.0000000000000006.
Grünewald et al., Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature. May 2019;569(7756):433-437. doi: 10.1038/s41586-019-1161-z. Epub Apr. 17, 2019.
Gupta et al., Sequences in attB that affect the ability of phiC31 integrase to synapse and to activate DNA cleavage. Nucleic Acids Res. 2007;35(10):3407-19. doi: 10.1093/nar/gkm206. Epub May 3, 2007.
Guzman et al., Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J Bacteriol. 1995;177(14):4121-4130.
Halmai et al., Targeted CRIPSR/dCas9-mediated reactivation of epigenetically silenced genes suggests limited escape from the inactive X chromosome. 2nd Inti Conf on Epigenetics and Bioengineering. Oct. 4, 2018; Retrieved from the Internet: https://aiche.confex.com/aiche/epibiol8/webprogram/paper544785.html. Retrieved Jun. 29, 2020.
Halperin et al., CRISPR-guided DNA polymerases enable diversification of all nucleotides in a tunable window. Nature. Aug. 2018;560(7717):248-252. doi: 10.1038/s41586-018-0384-8. Epub Aug. 1, 2018.
Halvas et al., Role of murine leukemia virus reverse transcriptase deoxyribonucleoside triphosphate-binding site in retroviral replication and in vivo fidelity. J Virol. Nov. 2000;74(22):10349-58. doi: 10.1128/jvi.74.22.10349-10358.2000.
Handa et al., Template-assisted synthesis of adenine-mutagenized cDNA by a retroelement protein complex. Nucleic Acids Res. Oct. 12, 2018;46(18):9711-9725. doi: 10.1093/nar/gky620.
Hanson et al., Codon optimality, bias and usage in translation and mRNA decay. Nat Rev Mol Cell Biol. Jan. 2018;19(1):20-30. doi: 10.1038/nrm.2017.91. Epub Oct. 11, 2017.
Harms et al., Evolutionary biochemistry: revealing the historical and physical causes of protein properties. Nat Rev Genet. Aug. 2013;14(8):559-71. doi: 10.1038/nrg3540.
Harrington et al., A thermostable Cas9 with increased lifetime in human plasma. Nat Commun. Nov. 10, 2017;8(1):1424. doi: 10.1038/s41467-017-01408-4.
Hasegawa et al., Spontaneous mutagenesis associated with nucleotide excision repair in Escherichia coli. Genes Cells. May 2008;13(5):459-69. doi: 10.1111/j.1365-2443.2008.01185.x.
Heidenreich et al., Non-homologous end joining as an important mutagenic process in cell cycle-arrested cells. EMBO J. May 1, 2003;22(9):2274-83. doi: 10.1093/emboj/cdg203.
Held et al., In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. Mol Ther. Mar. 2005;11(3):399-408. doi: 10.1016/j.ymthe.2004.11.001.
Hermonat et al., Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A. Oct. 1984;81(20):6466-70. doi: 10.1073/pnas.81.20.6466.
Herzig et al., A Novel Leu92 Mutant of HIV-1 Reverse Transcriptase with a Selective Deficiency in Strand Transfer Causes a Loss of Viral Replication. J Virol. Aug. 2015;89(16):8119-29. doi: 10.1128/JVI.00809-15. Epub May 20, 2015.
Hille et al., The Biology of CRISPR-Cas: Backward and Forward. Cell. Mar. 8, 2018;172(6):1239-1259. doi: 10.1016/j.cell.2017.11.032.
Hoang et al., UFBoot2: Improving the Ultrafast Bootstrap Approximation. Mol Biol Evol. Feb. 1, 2018;35(2):518-522. doi: 10.1093/molbev/msx281.
Hoernes et al., Translating the epitranscriptome. Wiley Interdiscip Rev RNA. Jan. 2017;8(1):e1375. doi: 10.1002/wrna.1375. Epub Jun. 27, 2016.
Hollis et al., Phage integrases for the construction and manipulation of transgenic mammals. Reprod Biol Endocrinol. Nov. 7, 2003;1:79. doi: 10.1186/1477-7827-1-79.
Holsinger et al., Signal transduction in T lymphocytes using a conditional allele of Sos. Proc Natl Acad Sci U S A. Oct. 10, 1995;92(21):9810-4. doi: 10.1073/pnas.92.21.9810.
Hoogenboom et al., Natural and designer binding sites made by phage display technology. Immunol Today. Aug. 2000;21(8):371-8.
Hsu et al., DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. Sep. 2013;31(9):827-32. doi: 10.1038/nbt.2647. Epub Jul. 21, 2013. Supplementary Information. 27 pages.
Hu et al., Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. Apr. 5, 2018;556(7699):57-63. doi: 10.1038/nature26155. Epub Feb. 28, 2018.
Huang et al., Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors. Nat Biotechnol. Jun. 2019;37(6):626-631. doi: 10.1038/s41587-019-0134-y. Epub May 20, 2019. Including Supplementary Information.
Hung et al., Protein localization in disease and therapy. J Cell Sci. Oct. 15, 2011;124(Pt 20):3381-92. doi: 10.1242/jcs.089110.
Hwang et al., Web-based design and analysis tools for CRISPR base editing. BMC Bioinformatics. Dec. 27, 2018;19(1):542. doi: 10.1186/s12859-018-2585-4.
Iida et al., A site-specific, conservative recombination system carried by bacteriophage P1. Mapping the recombinase gene cin and the cross-over sites cix for the inversion of the C segment. EMBO J. 1982;1(11):1445-53.
Imburgio et al., Studies of promoter recognition and start site selection by T7 RNA polymerase using a comprehensive collection of promoter variants. Biochemistry. Aug. 29, 2000;39(34):10419-30.
Iwai et al., Circular beta-lactamase: stability enhancement by cyclizing the backbone. FEBS Lett. Oct. 8, 1999;459(2): 166-72. doi: 10.1016/s0014-5793(99)01220-x.
Iwai et al., Highly efficient protein trans-splicing by a naturally split DnaE intein from Nostoc punctiforme. FEBS Lett. Mar. 20, 2006;580(7):1853-8. doi: 10.1016/j.febslet.2006.02.045. Epub Feb. 24, 2006.
Jaffrey et al., Emerging links between m6A and misregulated mRNA methylation in cancer. Genome Med. Jan. 12, 2017;9(1):2. doi: 10.1186/s13073-016-0395-8.
Jasin et al., Repair of strand breaks by homologous recombination. Cold Spring Harb Perspect Biol. Nov. 1, 2013;5(11):a012740. doi: 10.1101/cshperspect.a012740.
Jemielity et al., Novel “anti-reverse” cap analogs with superior translational properties. RNA. Sep. 2003;9(9): 1108-22. doi: 10.1261/rna.5430403.
Jiang et al., CRISPR-Cas9 Structures and Mechanisms. Annu Rev Biophys. May 22, 2017;46:505-529. doi: 10.1146/annurev-biophys-062215-010822. Epub Mar. 30, 2017.
Johann et al., GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus. J Virol. Mar. 1992;66(3):1635-40. doi: 10.1128/JVI.66.3.1635-1640.1992.
Johns et al., The promise and peril of continuous in vitro evolution. J Mol Evol. Aug. 2005;61(2):253-63. Epub Jun. 27, 2005.
Joho et al., Identification of a region of the bacteriophage T3 and T7 RNA polymerases that determines promoter specificity. J Mol Biol. Sep. 5, 1990;215(1):31-9.
Joyce et al., Amplification, mutation and selection of catalytic RNA. Gene. Oct. 15, 1989;82(1):83-7. doi: 10.1016/0378-1119(89)90033-4.
Kaczmarczyk et al., Manipulating the Prion Protein Gene Sequence and Expression Levels with CRISPR/Cas9. PLoS One. Apr. 29, 2016;11(4):e0154604. doi: 10.1371/journal.pone.0154604.
Kadoch et al., Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. Mar. 28, 2013; 153(1):71-85. doi: 10.1016/j.cell.2013.02.036.
Kahmann et al., G inversion in bacteriophage Mu DNA is stimulated by a site within the invertase gene and a host factor. Cell. Jul. 1985;41(3):771-80. doi: 10.1016/s0092-8674(85)80058-1.
Kalyaanamoorthy et al., ModelFinder: fast model selection for accurate phylogenetic estimates. Nat Methods. Jun. 2017;14(6):587-589. doi: 10.1038/nmeth.4285. Epub May 8, 2017.
Karimova et al., Discovery of Nigri/nox and Panto/pox site-specific recombinase systems facilitates advanced genome engineering. Sci Rep. Jul. 22, 2016;6:30130. doi: 10.1038/srep30130.
Karimova et al., Vika/vox, a novel efficient and specific Cre/loxP-like site-specific recombination system. Nucleic Acids Res. Jan. 2013;41(2):e37. doi: 10.1093/nar/gks1037. Epub Nov. 9, 2012.
Kaufman et al., Translational efficiency of polycistronic mRNAs and their utilization to express heterologous genes in mammalian cells. EMBO J. Jan. 1987;6(1):187-93.
Kawarasaki et al., Enhanced crossover SCRATCHY: construction and high-throughput screening of a combinatorial library containing multiple non-homologous crossovers. Nucleic Acids Res. Nov. 1, 2003;31(21):e126.
Keijzers et al., Human exonuclease 1 (EXO1) activity characterization and its function on flap structures. Biosci Rep. Apr. 25, 2015;35(3):e00206. doi: 10.1042/BSR20150058.
Kelman, PCNA: structure, functions and interactions. Oncogene. Feb. 13, 1997;14(6):629-40. doi: 10.1038/sj.onc.1200886.
Kessler et al., Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A. Nov. 26, 1996;93(24):14082-7. doi: 10.1073/pnas.93.24.14082.
Kilcher et al., Brochothrix thermosphacta bacteriophages feature heterogeneous and highly mosaic genomes and utilize unique prophage insertion sites. J Bacteriol. Oct. 2010;192(20):5441-53. doi: 10.1128/JB.00709-10. Epub Aug. 13, 2010.
Kim et al., DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005;7(3):263-273.
Kim et al., High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One. 2011;6(4):e18556. doi: 10.1371/journal.pone.0018556. Epub Apr. 29, 2011.
Kim et al., In vivo high-throughput profiling of CRISPR-Cpf1 activity. Nat Methods. Feb. 2017;14(2):153-159. doi: 10.1038/nmeth.4104. Epub Dec. 19, 2016.
Kim et al., Mycobacteriophage Bxb1 integrates into the Mycobacterium smegmatis groEL1 gene. Mol Microbiol. Oct. 2003;50(2):463-73. doi: 10.1046/j.1365-2958.2003.03723.x.
Kim et al., Rescue of high-specificity Cas9 variants using sgRNAs with matched 5′ nucleotides. Genome Biol. Nov. 15, 2017;18(1):218. doi: 10.1186/s13059-017-1355-3.
Kim et al., Structural and kinetic characterization of Escherichia coli TadA, the wobble-specific tRNA deaminase. Biochemistry. May 23, 2006;45(20):6407-16. doi: 10.1021/bi0522394. PMID: 16700551.
Klapacz et al., Frameshift mutagenesis and micro satellite instability induced by human alkyladenine DNA glycosylase. Mol Cell. Mar. 26, 2010;37(6):843-53. doi: 10.1016/j.molcel.2010.01.038.
Klement et al., Discrimination between bacteriophage T3 and T7 promoters by the T3 and T7 RNA polymerases depends primarily upon a three base-pair region located 10 to 12 base-pairs upstream from the start site. J Mol Biol. Sep. 5, 1990;215(1):21-9.
Knott et al., Guide-bound structures of an RNA-targeting A-cleaving CRISPR-Cas13a enzyme. Nat Struct Mol Biol. Oct. 2017;24(10):825-833. doi: 10.1038/nsmb.3466. Epub Sep. 11, 2017.
Koblan et al., Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat Biotechnol. Oct. 2018;36(9):843-846. doi: 10.1038/nbt.4172. Epub May 29, 2018.
Kohli et al., A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J Biol Chem. Aug. 21, 2009;284(34):22898-904. doi: 10.1074/jbc.M109.025536. Epub Jun. 26, 2009.
Koike-Yusa et al., Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol. Mar. 2014;32(3):267-73. doi: 10.1038/nbt.2800. Epub Dec. 23, 2013.
Komor, Editing the Genome Without Double-Stranded DNA Breaks. ACS Chem Biol. Feb. 16, 2018;13(2):383-388. doi: 10.1021/acschembio.7b00710. Epub Oct. 9, 2017.
Kosicki et al., Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. Sep. 2018;36(8):765-771. doi: 10.1038/nbt.4192. Epub Jul. 16, 2018.
Kotewicz et al., Isolation of cloned Moloney murine leukemia virus reverse transcriptase lacking ribonuclease H activity. Nucleic Acids Res. Jan. 11, 1988;16(1):265-77. doi: 10.1093/nar/16.1.265.
Kowalski et al., Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. Mol Ther. Apr. 10, 2019;27(4):710-728. doi: 10.1016/j.ymthe.2019.02.012. Epub Feb. 19, 2019.
Kozak, An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. Oct. 26, 1987;15(20):8125-48. doi: 10.1093/nar/15.20.8125.
Kraft et al., Deletions, Inversions, Duplications: Engineering of Structural Variants using CRISPR/Cas in Mice. Cell Rep. Feb. 10, 2015;10(5):833-839. doi: 10.1016/j.celrep.2015.01.016. Epub Feb. 7, 2015.
Krokan et al., Base excision repair. Cold Spring Harb Perspect Biol. Apr. 1, 2013;5(4):a012583. doi: 10.1101/cshperspect.a012583.
Krokan et al., Uracil in DNA—occurrence, consequences and repair. Oncogene. Dec. 16, 2002;21(58):8935-48. doi: 10.1038/sj.onc.1205996.
Krzywkowski et al., Limited reverse transcriptase activity of phi29 DNA polymerase. Nucleic Acids Res. Apr. 20, 2018;46(7):3625-3632. doi: 10.1093/nar/gky190.
Kuscu et al., CRISPR-Cas9-AID base editor is a powerful gain-of-function screening tool. Nat Methods. Nov. 29, 2016; 13(12):983-984. doi: 10.1038/nmeth.4076.
Kwart et al., Precise and efficient scarless genome editing in stem cells using CORRECT. Nat Protoc. Feb. 2017;12(2):329-354. doi: 10.1038/nprot.2016.171. Epub Jan. 19, 2017.
Lada et al., Mutator effects and mutation signatures of editing deaminases produced in bacteria and yeast. Biochemistry (Mose). Jan. 2011;76(1):131-46.
Lauer et al., Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors. J Bacteriol. Aug. 2002;184(15):4177-86. doi: 10.1128/jb.184.15.4177-4186.2002.
Lawyer et al., High-level expression, purification, and enzymatic characterization of full-length Thermus aquaticus DNA polymerase and a truncated form deficient in 5′ to 3′ exonuclease activity. PCR Methods Appl. May 1993;2(4):275-87. doi: 10.1101/gr.2.4.275.
Lazarevic et al., Nucleotide sequence of the Bacillus subtilis temperate bacteriophage SPbetac2. Microbiology (Reading). May 1999;145 ( Pt 5):1055-1067. doi: 10.1099/13500872-145-5-1055.
Le Grice et al., Purification and characterization of recombinant equine infectious anemia virus reverse transcriptase. J Virol. Dec. 1991;65(12):7004-7. doi: 10.1128/JVI.65.12.7004-7007.1991.
Leaver-Fay et al., ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 2011;487:545-74. doi: 10.1016/B978-0-12-381270-4.00019-6.
Leconte et al., A population-based experimental model for protein evolution: effects of mutation rate and selection stringency on evolutionary outcomes. Biochemistry. Feb. 26, 2013;52(8):1490-9. doi: 10.1021/bi3016185. Epub Feb. 14, 2013.
Lee et al., Site-specific integration of my cobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guerin. Proc Natl Acad Sci U S A. Apr. 15, 1991;88(8):3111-5. doi: 10.1073/pnas.88.8.3111.
Lee et al., Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering. Elife. May 2, 2017;6:e25312. doi: 10.7554/eLife.25312.
Lee et al., Transcriptional regulation and its misregulation in disease. Cell. Mar. 14, 2013;152(6):1237-51. doi: 10.1016/j.cell.2013.02.014.
Lemos et al., CRISPR/Cas9 cleavages in budding yeast reveal templated insertions and strandspecific insertion/deletion profiles. Proc Natl Acad Sci U S A. Feb. 27, 2018;115(9):E2040-E2047. doi: 10.1073/pnas.1716855115. Epub Feb. 13, 2018.
Levy et al., Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat Biomed Eng. 2020;4(1):97-110. doi:10.1038/s41551-019-0501-5.
Levy et al., Membrane-associated guanylate kinase dynamics reveal regional and developmental specificity of synapse stability. J Physiol. Mar. 1, 2017;595(5):1699-1709. doi: 10.1113/JP273147. Epub Jan. 18, 2017.
Lew et al., Protein splicing in vitro with a semisynthetic two-component minimal intein. J Biol Chem. Jun. 26, 1998;273(26):15887-90. doi: 10.1074/jbc.273.26.15887.
Lewis et al., Cytosine deamination and the precipitous decline of spontaneous mutation during Earth's history. Proc Natl Acad Sci U S A. Jul. 19, 2016;113(29):8194-9. doi: 10.1073/pnas.1607580113. Epub Jul. 5, 2016.
Li et al., A Radioactivity-Based Assay for Screening Human m6A-RNA Methyltransferase, METTL3-METTL14 Complex, and Demethylase ALKBH5. J Biomol Screen. Mar. 2016;21(3):290-7. doi: 10.1177/1087057115623264. Epub Dec. 23, 2015.
Li et al., Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. Jul. 15, 2009;25(14):1754-60. doi: 10.1093/bioinformatics/btp324. Epub May 18, 2009.
Li et al., Lagging strand DNA synthesis at the eukaryotic replication fork involves binding and stimulation of FEN-1 by proliferating cell nuclear antigen. J Biol Chem. Sep. 22, 1995;270(38):22109-12. doi: 10.1074/jbc.270.38.22109.
Li et al., Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum Gene Ther. Sep. 2008;19(9):958-64. doi: 10.1089/hum.2008.009.
Liang et al., Correction of ?-thalassemia mutant by base editor in human embryos. Protein Cell. Nov. 2017;8(11):811-822. doi: 10.1007/s13238-017-0475-6. Epub Sep. 23, 2017.
Lienert et al., Two- and three-input TALE-based and logic computation in embryonic stem cells. Nucleic Acids Res. Nov. 2013;41(21):9967-75. doi: 10.1093/nar/gkt758. Epub Aug. 27, 2013.
Lim et al., Crystal structure of the moloney murine leukemia virus RNase H domain. J Virol. Sep. 2006;80(17):8379-89. doi: 10.1128/JVI.00750-06.
Liu et al., Split dnaE genes encoding multiple novel inteins in Trichodesmium erythraeum. J Biol Chem. Jul. 18, 2003;278(29):26315-8. doi: 10.1074/jbc.C300202200. Epub May 24, 2003.
Liu et al., A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. Feb. 2014;10(2):93-5. doi: 10.1038/nchembio.1432. Epub Dec. 6, 2013.
Liu et al., CasX enzymes comprise a distinct family of RNA-guided genome editors. Nature. Feb. 2019;566(7743):218-223. doi: 10.1038/s41586-019-0908-x. Epub Feb. 4, 2019.
Liu et al., Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch. Cell. Apr. 5, 2018;173(2):430-442.e17. doi: 10.1016/j.cell.2018.03.016. Epub Mar. 29, 2018.
Liu et al., Editing DNA Methylation in the Mammalian Genome. Cell. Sep. 22, 2016;167(1):233-247.e17. doi: 10.1016/j.cell.2016.08.056.
Liu et al., Highly efficient RNA-guided base editing in rabbit. Nat Commun. Jul. 13, 2018;9(1):2717. doi: 10.1038/s41467-018-05232-2.
Liu et al., N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. Feb. 26, 2015;518(7540):560-4. doi: 10.1038/nature14234.
Liu et al., Probing N6-methyladenosine RNA modification status at single nucleotide resolution in mRNA and long noncoding RNA. RNA. Dec. 2013;19(12):1848-56. doi: 10.1261/ma.041178.113. Epub Oct. 18, 2013.
Liu et al., The Molecular Architecture for RNA-Guided RNA Cleavage by Cas13a. Cell. Aug. 10, 2017;170(4):714-726.e10. doi: 10.1016/j.cell.2017.06.050. Epub Jul. 27, 2017.
Loessner et al., Complete nucleotide sequence, molecular analysis and genome structure of bacteriophage A118 of Listeria monocytogenes: implications for phage evolution. Mol Microbiol. Jan. 2000;35(2):324-40. doi: 10.1046/j.1365-2958.2000.01720.x.
Long et al., Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. Jan. 22, 2016;351(6271):400-3. doi: 10.1126/science.aad5725. Epub Dec. 31, 2015.
Lynch, Evolution of the mutation rate. Trends Genet. Aug. 2010;26(8):345-52. doi: 10.1016/j.tig.2010.05.003. Epub Jun. 30, 2010.
Maas et al., Identification and characterization of a human tRNA-specific adenosine deaminase related to the ADAR family of pre-mRNA editing enzymes. Proc Natl Acad Sci U S A. Aug. 3, 1999;96(16):8895-900. doi: 10.1073/pnas.96.16.8895.
Macbeth et al., Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. Science. Sep. 2, 2005;309(5740):1534-9. doi: 10.1126/science.1113150.
Magin et al., Corf, the Rev/Rex homologue of HTDV/HERV-K, encodes an arginine-rich nuclear localization signal that exerts a trans-dominant phenotype when mutated. Virology. Aug. 15, 2000;274(1):11-6. doi: 10.1006/viro.2000.0438.
Makarova et al., Classification and Nomenclature of CRISPR-Cas Systems: Where from Here? CRISPR J. Oct. 2018;1(5):325-336. doi: 10.1089/crispr.2018.0033.
Makeyev et al., Evolutionary potential of an RNA virus. J Virol. Feb. 2004;78(4):2114-20.
Malashkevich et al., Crystal structure of tRNA adenosine deaminase TadA from Escherichia coli. Deposited: Mar. 10, 2005 Released: Feb. 21, 2006 doi:10.2210/pdb1z3a/pdb (2006).
Malito et al., Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc Natl Acad Sci U S A. Apr. 3, 2012;109(14):5229-34. doi: 10.1073/pnas.1201964109. Epub Mar. 19, 2012.
Mandal et al., Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell. Nov. 6, 2014;15(5):643-52. doi: 10.1016/j.stem.2014.10.004. Epub Nov. 6, 2014.
Martinez et al., Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dN'IP concentrations. Proc Natl Acad Sci U S A. Dec. 6, 1994;91(25):11787-91. doi: 10.1073/pnas.91.25.11787.
Mascola et al., HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev. Jul. 2013;254(1):225-44. doi: 10.1111/imr.12075.
Matthews, Structures of human ADAR2 bound to dsRNA reveal base-flipping mechanism and basis for site selectivity. Nat Struct Mol Biol. May 2016;23(5):426-33. doi: 10.1038/nsmb.3203. Epub Apr. 11, 2016.
May et al., Emergent lineages of mumps virus suggest the need for a polyvalent vaccine. Int J Infect Dis. Jan. 2018;66:1-4. doi: 10.1016/j.ijid.2017.09.024. Epub Oct. 4, 2017.
McInerney et al., Error Rate Comparison during Polymerase Chain Reaction by DNA Polymerase. Mol Biol Int. 2014;2014:287430. doi: 10.1155/2014/287430. Epub Aug. 17, 2014.
McKenna et al., Recording development with single cell dynamic lineage tracing. Development. Jun. 27, 2019;146(12):dev169730. doi: 10.1242/dev.169730.
McKenna et al., Whole-organism lineage tracing by combinatorial and cumulative genome editing. Science. Jul. 29, 2016;353(6298):aaf7907. doi: 10.1126/science.aaf7907. Epub May 26, 2016.
McVey et al., MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet. Nov. 2008;24(11):529-38. doi: 10.1016/j.tig.2008.08.007. Epub Sep. 21, 2008.
Menéndez-Arias, Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. Viruses. Dec. 2009;1(3):1137-65. doi: 10.3390/v1031137. Epub Dec. 4, 2009.
Mertens et al., Site-specific recombination in bacteriophage Mu: characterization of binding sites for the DNA invertase Gin. EMBO J. Apr. 1988;7(4):1219-27.
Meyer et al., Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell. Jun. 22, 2012;149(7):1635-46. doi: 10.1016/j.cell.2012.05.003. Epub May 17, 2012.
Meyer et al., Library generation by gene shuffling. Curr Protoc Mol Biol. Jan. 6, 2014;105:Unit 15.12.. doi: 10.1002/0471142727.mb1512s105.
Meyer et al., The dynamic epitranscriptome: N6-methyladenosine and gene expression control. Nat Rev Mol Cell Biol. May 2014;15(5):313-26. doi: 10.1038/nrm3785. Epub Apr. 9, 2014.
Mihai et al., PTEN inhibition improves wound healing in lung epithelia through changes in cellular mechanics that enhance migration. Am J Physiol Lung Cell Mol Physiol. 2012;302(3):L287-L299.
Miller et al., Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol. May 1991;65(5):2220-4. doi: 10.1128/JVI.65.5.2220-2224.1991.
Mishina et al., Conditional gene targeting on the pure C57BL/6 genetic background. Neurosci Res. Jun. 2007;58(2):105-12. doi: 10.1016/j.neures.2007.01.004. Epub Jan. 18, 2007.
Mitton-Fry et al., Poly(A) tail recognition by a viral RNA element through assembly of a triple helix. Science. Nov. 26, 2010;330(6008):1244-7. doi: 10.1126/science.1195858.
Moede et al., Identification of a nuclear localization signal, RRMKWKK, in the homeodomain transcription factor PDX-1. FEBS Lett. Nov. 19, 1999;461(3):229-34. doi: 10.1016/s0014-5793(99)01446-5.
Mohr et al., A Reverse Transcriptase-Cas1 Fusion Protein Contains a Cas6 Domain Required for Both CRISPR RNA Biogenesis and RNA Spacer Acquisition. Mol Cell. Nov. 15, 2018;72(4):700-714.e8. doi: 10.1016/j.molcel.2018.09.013. Epub Oct. 18, 2018.
Mohr et al., Thermostable group II intron reverse transcriptase fusion proteins and their use in cDNA synthesis and next-generation RNA sequencing. RNA. Jul. 2013;19(7):958-70. doi: 10.1261/ma.039743.113. Epub May 22, 2013.
Monot et al., The specificity and flexibility of l1 reverse transcription priming at imperfect T-tracts. PLoS Genet. May 2013;9(5):e1003499. doi: 10.1371/journal.pgen.1003499. Epub May 9, 2013.
Morita et al., The site-specific recombination system of actinophage TGI. FEMS Microbiol Lett. Aug. 2009;297(2):234-40. doi: 10.1111/j.1574-6968.2009.01683.x.
Muller et al., Nucleotide exchange and excision technology (NExT) DNA shuffling: a robust method for DNA fragmentation and directed evolution. Nucleic Acids Res. Aug. 1, 2005;33(13):e117. doi: 10.1093/nar/gni116. PMID: 16061932; PMCID: PMC1182171.
Muzyczka et al., Adeno-associated virus (AAV) vectors: will they work? J Clin Invest. Oct. 1994;94(4):1351. doi: 10.1172/JCI117468.
Myerowiiz et al., The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase. J Biol Chem. Dec. 15, 1988;263(35):18587-9.
Nakade et al., Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9. Nat Commun. Nov. 20, 2014;5:5560. doi: 10.1038/ncomms6560.
Nakamura et al., Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res. Jan. 1, 2000;28(1):292. doi: 10.1093/nar/28.1.292.
Naorem et al., DGR mutagenic transposition occurs via hypermutagenic reverse transcription primed by nicked template RNA. Proc Natl Acad Sci U S A. Nov. 21, 2017;114(47):E10187-E10195. doi: 10.1073/pnas. 1715952114. Epub Nov. 6, 2017.
Nern et al., Multiple new site-specific recombinases for use in manipulating animal genomes. Proc Natl Acad Sci U S A. Aug. 23, 2011;108(34):14198-203. doi: 10.1073/pnas.1111704108. Epub Aug. 9, 2011.
Nguyen et al., Evolutionary drivers of thermoadaptation in enzyme catalysis. Science. Jan. 20, 2017;355(6322):289-294. doi: 10.1126/science.aah3717. Epub Dec. 22, 2016.
Nguyen et al., IQ-TREE: a fast and effective stochastic algorithm for estimating maximumlikelihood phylogenies. Mol Biol Evol. Jan. 2015;32(1):268-74. doi: 10.1093/molbev/msu300. Epub Nov. 3, 2014.
Nishimasu et al., Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science. Sep. 21, 2018;361(6408):1259-1262. doi: 10.1126/science.aas9129. Epub Aug. 30, 2018.
Nottingham et al., RNA-seq of human reference RNA samples using a thermostable group II intron reverse transcriptase. RNA. Apr. 2016;22(4):597-613. doi: 10.1261/ma.055558.115. Epub Jan. 29, 2016.
Nowak et al., Structural analysis of monomeric retroviral reverse transcriptase in complex with an RNA/DNA hybrid. Nucleic Acids Res. Apr. 1, 2013;41(6):3874-87. doi: 10.1093/nar/gkt053. Epub Feb. 4, 2013.
Numrych et al., A comparison of the effects of single-base and triple-base changes in the integrase arm-type binding sites on the site-specific recombination of bacteriophage lambda. Nucleic Acids Res. Jul. 11, 1990;18(13):3953-9. doi: 10.1093/nar/18.13.3953.
Nyerges et al., A highly precise and portable genome engineering method allows comparison of mutational effects across bacterial species. Proc Natl Acad Sci U S A. Mar. 1, 2016;113(9):2502-7. doi: 10.1073/pnas.1520040113. Epub Feb. 16, 2016.
Oakes et al., CRISPR-Cas9 Circular Permutants as Programmable Scaffolds for Genome Modification. Cell. Jan. 10, 2019; 176(1-2):254-267.e16. doi: 10.1016/j.cell.2018.11.052.
Odsbu et al., Specific N-terminal interactions of the Escherichia coli SeqA protein are required to form multimers that restrain negative supercoils and form foci. Genes Cells. Nov. 2005;10(11):1039-49.
Oeemig et al., Solution structure of DnaE intein from Nostoc punctiforme: structural basis for the design of a new split intein suitable for site-specific chemical modification. FEBS Lett. May 6, 2009;583(9):1451-6.
Oh et al., Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder of cytoplasmic organelles. Nat Genet. Nov. 1996;14(3):300-6. doi: 10.1038/ng1196-300.
O'Maille et al., Structure-based combinatorial protein engineering (SCOPE). J Mol Biol. Aug. 23, 2002;321(4):677-91.
Orlando et al., Zinc-finger nuclease-driven targeted integration into mammalian genomes using donors with limited chromosomal homology. Nucleic Acids Res. Aug. 2010;38(15):e152. doi: 10.1093/nar/gkq512. Epub Jun. 8, 2010.
Orthwein et al., A mechanism for the suppression of homologous recombination in G1 cells. Nature. Dec. 17, 2015;528(7582):422-6. doi: 10.1038/nature16142. Epub Dec. 9, 2015.
Ostermeier et al., A combinatorial approach to hybrid enzymes independent of DNA homology. Nat Biotechnol. Dec. 1999;17(12):1205-9.
Otto et al., The probability of fixation in populations of changing size. Genetics. Jun. 1997;146(2):723-33.
Paige et al., RNA mimics of green fluorescent protein. Science. Jul. 29, 2011;333(6042):642-6. doi: 10.1126/science.1207339.
Paquet et al., Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature. May 5, 2016;533(7601):125-9. doi: 10.1038/nature17664. Epub Apr. 27, 2016.
Park et al., Digenome-seq web tool for profiling CRISPR specificity. Nat Methods. May 30, 2017;14(6):548-549. doi: 10.1038/nmeth.4262.
Park et al., Highly efficient editing of the ?-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. Nucleic Acids Res. Sep. 5, 2019;47(15):7955-7972. doi: 10.1093/nar/gkz475.
Park et al., Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing. Mol Ther Methods Clin Dev. Aug. 24, 2016;3:16057. doi: 10.1038/mtm.2016.57.
Patel et al., Flap endonucleases pass 5′-flaps through a flexible arch using a disorder-thread-order mechanism to confer specificity for free 5′-ends. Nucleic Acids Res. May 2012;40(10):4507-19. doi: 10.1093/nar/gks051. Epub Feb. 8, 2012.
Pawson et al., Protein phosphorylation in signaling—50 years and counting. Trends Biochem Sci. Jun. 2005;30(6):286-90. doi: 10.1016/j.tibs.2005.04.013.
Pellenz et al., New human chromosomal safe harbor sites for genome engineering with CRISPR/Cas9, TAL effector and homing endonucleases. Aug. 20, 2018. bioRxiv doi: https://doi.org/10.1101/396390.
Perach et al., Catalytic features of the recombinant reverse transcriptase of bovine leukemia virus expressed in bacteria. Virology. Jun. 20, 1999;259(1):176-89. doi: 10.1006/viro.1999.9761.
Perler et al., Protein splicing elements: inteins and exteins—a definition of terms and recommended nomenclature. Nucleic Acids Res. Apr. 11, 1994;22(7):1125-7. doi: 10.1093/nar/22.7.1125.
Perler, InBase, the New England Biolabs Intein Database. Nucleic Acids Res. Jan. 1, 1999;27(1):346-7. doi: 10.1093/nar/27.1.346.
Perler, Protein splicing of inteins and hedgehog autoproteolysis: structure, function, and evolution. Cell. Jan. 9, 1998;92(1):1-4. doi: 10.1016/s0092-8674(00)80892-2.
Petersen-Mahrt et al., AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature. Jul. 4, 2002;418(6893):99-103.
Peyroties et al., Oligodeoxynucleoside phosphoramidates (P-NH2): synthesis and thermal stability of duplexes with DNA and RNA targets. Nucleic Acids Res. May 15, 1996;24(10):1841-8.
Pfeiffer et al., Mechanisms of DNA double-strand break repair and their potential to induce chromosomal aberrations. Mutagenesis. Jul. 2000;15(4):289-302. doi: 10.1093/mutage/15.4.289.
Pickart et al., Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta. Nov. 29, 2004;1695(1-3):55-72. doi: 10.1016/j.bbamcr.2004.09.019.
Pinkert et al., An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Genes Dev. May 1987;1(3):268-76. doi: 10.1101/gad.1.3.268.
Pirakitikulr et al., PCRless library mutagenesis via oligonucleotide recombination in yeast. Protein Sci. Dec. 2010;19(12):2336-46. doi: 10.1002/pro.513.
Posnick et al., Imbalanced base excision repair increases spontaneous mutation and alkylation sensitivity in Escherichia coli. J Bacteriol. Nov. 1999;181(21):6763-71.
Pu et al., Evolution of a split RNA polymerase as a versatile biosensor platform. Nat Chem Biol. Apr. 2017;13(4):432-438. doi: 10.1038/nchembio.2299. Epub Feb. 13, 2017.
Qu et al., Global mapping of binding sites for phic31 integrase in transgenic maden-darby bovine kidney cells using ChIP-seq. Hereditas. Jan. 14, 2019;156:3. doi: 10.1186/s41065-018-0079-z.
Radany et al., Increased spontaneous mutation frequency in human cells expressing the phage PBS2-encoded inhibitor of uracil-DNA glycosylase. Mutat Res. Sep. 15, 2000;461(1):41-58. doi: 10.1016/s0921-8777(00)00040-9.
Ranzau et al., Genome, Epigenome, and Transcriptome Editing via Chemical Modification of Nucleobases in Living Cells. Biochemistry. Feb. 5, 2019;58(5):330-335. doi: 10.1021/acs.biochem.8b00958. Epub Dec. 12, 2018.
Rasila et al., Critical evaluation of random mutagenesis by error-prone polymerase chain reaction protocols, Escherichia coli mutator strain, and hydroxylamine treatment. Anal Biochem. May 1, 2009;388(1):71-80. doi: 10.1016/j.ab.2009.02.008. Epub Feb. 10, 2009.
Raskin et al., Substitution of a single bacteriophage T3 residue in bacteriophage T7 RNA polymerase at position 748 results in a switch in promoter specificity. J Mol Biol. Nov. 20, 1992;228(2):506-15.
Raskin et al., T7 RNA polymerase mutants with altered promoter specificities. Proc Natl Acad Sci U S A. Apr. 15, 1993;90(8):3147-51.
Rauch et al., Programmable RNA Binding Proteins for Imaging and Therapeutics. Biochemistry. Jan. 30, 2018;57(4):363-364. doi: 10.1021/acs.biochem.7b01101. Epub Nov. 17, 2017.
Ray et al., A compendium of RNA-binding motifs for decoding gene regulation. Nature. Jul. 11, 2013;499(7457):172-7. doi: 10.1038/nature12311.
Rebar et al., Phage display methods for selecting zinc finger proteins with novel DNA-binding specificities. Methods Enzymol. 1996;267:129-49.
Rees et al., Analysis and minimization of cellular RNA editing by DNA adenine base editors. Sci Adv. May 8, 2019;5(5):eaax5717. doi: 10.1126/sciadv.aax5717.
Rees et al., Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet. Dec. 2018;19(12):770-788. doi: 10.1038/s41576-018-0059-1.
Rees et al., Development of hRad51-Cas9 nickase fusions that mediate HDR without doublestranded breaks. Nat Commun. May 17, 2019;10(1):2212. doi: 10.1038/s41467-019-09983-4.
Reyon et al., FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol. May 2012;30(5):460-5. doi: 10.1038/nbt.2170.
Ribeiro et al., Protein Engineering Strategies to Expand CRISPR-Cas9 Applications. Int J Genomics. Aug. 2, 2018;2018:1652567. doi: 10.1155/2018/1652567.
Ringrose et al., The Kw recombinase, an integrase from Kluyveromyces waltii. Eur J Biochem. Sep. 15, 1997;248(3):903-12. doi: 10.1111/j.1432-1033.1997.00903.x.
Roth et al., Purification and characterization of murine retroviral reverse transcriptase expressed in Escherichia coli. J Biol Chem. Aug. 5, 1985;260(16):9326-35.
Rouet et al., Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc Natl Acad Sci U S A. Jun. 21, 1994;91(13):6064-8. doi: 10.1073/pnas.91.13.6064.
Rouet et al., Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Mol Cell Biol. Dec. 1994;14(12):8096-106. doi: 10.1128/mcb.14.12.8096.
Rouet et al., Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing. J Am Chem Soc. May 30, 2018;140(21):6596-6603. doi: 10.1021/jacs.8b01551. Epub May 18, 2018.
Roundtree et al.,YTHDC1 mediates nuclear export of N6-methyladenosine methylated mRNAs. Elife. Oct. 6, 2017;6:e31311. doi: 10.7554/eLife.31311.
Rowland et al., Sin recombinase from Staphylococcus aureus: synaptic complex architecture and transposon targeting. Mol Microbiol. May 2002;44(3):607-19. doi: 10.1046/j.1365-2958.2002.02897.x.
Rubio et al., An adenosine-to-inosine tRNA-editing enzyme that can perform C-to-U deamination of DNA. Proc Natl Acad Sci U S A. May 8, 2007;104(19):7821-6. doi: 10.1073/pnas.0702394104. Epub May 1, 2007. PMID: 17483465; PMCID: PMC1876531.
Rüfer et al., Non-contact positions impose site selectivity on Cre recombinase. Nucleic Acids Res. Jul. 1, 2002;30(13):2764-71. doi: 10.1093/nar/gkf399.
Rutherford et al., Attachment site recognition and regulation of directionality by the serine integrases. Nucleic Acids Res. Sep. 2013;41(17):8341-56. doi: 10.1093/nar/gkt580. Epub Jul. 2, 2013.
Sakuma et al., MMEJ-assisted gene knock-in using TALENs and CRISPR-Cas9 with the PITCh systems. Nat Protoc Jan. 2016;11(1):118-33. doi: 10.1038/nprot.2015.140. Epub Dec. 17, 2015.
Samulski et al., Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol. Sep. 1989;63(9):3822-8. doi: 10.1128/JVI.63.9.3822-3828.1989.
Santoro et al., Directed evolution of the site specificity of Cre recombinase. Proc Natl Acad Sci U S A. Apr. 2, 2002;99(7):4185-90. Epub Mar. 19, 2002.
Saparbaev et al., Excision of hypoxanthine from DNA containing dIMP residues by the Escherichia coli, yeast, rat, and human alkylpurine DNA glycosylases. Proc Natl Acad Sci U S A. Jun. 21, 1994;91(13):5873-7. doi: 10.1073/pnas.91.13.5873.
Satomura et al., Precise genome-wide base editing by the CRISPR Nickase system in yeast. Sci Rep. May 18, 2017;7(1):2095. doi: 10.1038/s41598-017-02013-7.
Sauer et al., DNA recombination with a heterospecific Cre homolog identified from comparison of the pac-c1 regions of P1-related phages. Nucleic Acids Res. Nov. 18, 2004;32(20):6086-95. doi: 10.1093/nar/gkh941.
Schaaper et al., Base selection, proofreading, and mismatch repair during DNA replication in Escherichia coli. J Biol Chem. Nov. 15, 1993;268(32):23762-5.
Schaaper et al., Spectra of spontaneous mutations in Escherichia coli strains defective in mismatch correction: the nature of in vivo DNA replication errors. Proc Natl Acad Sci U S A. Sep. 1987;84(17):6220-4.
Schaefer et al., Understanding RNA modifications: the promises and technological bottlenecks of the ‘epitranscriptome’. Open Biol. May 2017;7(5):170077. doi: 10.1098/rsob.170077.
Schechner et al., Multiplexable, locus-specific targeting of long RNAs with CRISPR-Display. Nat Methods. Jul. 2015;12(7):664-70. doi: 10.1038/nmeth.3433. Epub Jun. 1, 2015.
Schek et al., Definition of the upstream efficiency element of the simian virus 40 late polyadenylation signal by using in vitro analyses. Mol Cell Biol. Dec. 1992;12(12):5386-93. doi: 10.1128/mcb.12.12.5386.
Schenk et al., MPDU1 mutations underlie a novel human congenital disorder of glycosylation, designated type If. J Clin Invest. Dec. 2001;108(11):1687-95. doi: 10.1172/JCI13419.
Schmitz et al., Behavioral abnormalities in prion protein knockout mice and the potential relevance of PrP(C) for the cytoskeleton. Prion. 2014;8(6):381-6. doi: 10.4161/19336896.2014.983746.
Schöller et al., Interactions, localization, and phosphorylation of the m6A generating METTL3-METTL14-WTAP complex. RNA. Apr. 2018;24(4):499-512. doi: 10.1261/ma.064063.117. Epub Jan. 18, 2018.
Schultz et al., Oligo-2′-fluoro-2′-deoxynucleotide N3′—>P5′ phosphoramidates: synthesis and properties. Nucleic Acids Res. Aug. 1, 1996;24(15):2966-73.
Scott et al., Production of cyclic peptides and proteins in vivo. Proc Natl Acad Sci U S A. Nov. 23, 1999;96(24):13638-43. doi: 10.1073/pnas.96.24.13638.
Sebastían-Martín et al., Transcriptional inaccuracy threshold attenuates differences in RNA-dependent DNA synthesis fidelity between retroviral reverse transcriptases. Sci Rep. Jan. 12, 2018;8(1):627. doi: 10.1038/s41598-017-18974-8.
Serrano-Heras et al., Protein p56 from the Bacillus subtilis phage phi29 inhibits DNA-binding ability of uracil-DNA glycosylase. Nucleic Acids Res. 2007;35(16):5393-401. Epub Aug. 13, 2007.
Severinov et al., Expressed protein ligation, a novel method for studying protein-protein interactions in transcription. J Biol Chem. Jun. 26, 1998;273(26):16205-9. doi: 10.1074/jbc.273.26.16205.
Shah et al., Protospacer recognition motifs: mixed identities and functional diversity. RNA Biol. May 2013;10(5):891-9. doi: 10.4161/rna.23764. Epub Feb. 12, 2013.
Shalem et al., High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet. May 2015;16(5):299-311. doi: 10.1038/nrg3899. Epub Apr. 9, 2015.
Sharer et al., The ARF-like 2 (ARL2)-binding protein, BART. Purification, cloning, and initial characterization. J Biol Chem. Sep. 24, 1999;274(39):27553-61. doi: 10.1074/jbc.274.39.27553.
Sharon et al., Functional Genetic Variants Revealed by Massively Parallel Precise Genome Editing. Cell. Oct. 4, 2018;175(2):544-557.e16. doi: 10.1016/j.cell.2018.08.057. Epub Sep. 20, 2018.
Shaw et al., Implications of human genome architecture for rearrangement-based disorders: the genomic basis of disease. Hum Mol Genet. Apr. 1, 2004 ;13 Spec No. 1:R57-64. doi: 10.1093/hmg/ddh073. Epub Feb. 5, 2004.
Shen et al., Predictable and precise template-free CRISPR editing of pathogenic variants. Nature. Nov. 2018;563(7733):646-651. doi: 10.1038/s41586-018-0686-x. Epub Nov. 7, 2018. Erratum in: Nature. Mar. 2019;567(7746):E1-E2.
Sherwood et al., Discovery of directional and nondirectional pioneer transcription factors by modeling DNase profile magnitude and shape. Nat Biotechnol. Feb. 2014;32(2):171-178. doi: 10.1038/nbt.2798. Epub Jan. 19, 2014.
Shi et al., Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. Nat Struct Mol Biol. Feb. 2017;24(2):131-139. doi: 10.1038/nsmb.3344. Epub Dec. 19, 2016.
Shi et al., YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA. Cell Res. Mar. 2017;27(3):315-328. doi: 10.1038/cr.2017.15. Epub Jan. 20, 2017.
Shindo et al., A Comparison of Two Single-Stranded DNA Binding Models by Mutational Analysis of APOBEC3G. Biology (Basel). Aug. 2, 2012;1(2):260-76. doi: 10.3390/biology1020260.
Shmakov et al., Diversity and evolution of class 2 CRISPR-Cas systems. Nat Rev Microbiol. Mar. 2017;15(3):169-182. doi: 10.1038/nrmicro.2016.184. Epub Jan. 23, 2017.
Shultz et al., A genome-wide analysis of FRT-like sequences in the human genome. PLoS One. Mar. 23, 2011;6(3):e18077. doi: 10.1371/journal.pone.0018077.
Silas et al., Direct CRISPR spacer acquisition from RNA by a natural reverse transcriptase-Cas1 fusion protein. Science. Feb. 26, 2016;351(6276):aad4234. doi: 10.1126/science.aad4234.
Silva et al., Selective disruption of the DNA polymerase III α-β complex by the umuD gene products. Nucleic Acids Res. Jul. 2012;40(12):5511-22. doi: 10.1093/nar/gks229. Epub Mar. 9, 2012.
Sivalingam et al., Biosafety assessment of site-directed transgene integration in human umbilical cord-lining cells. Mol Ther. Jul. 2010;18(7):1346-56. doi: 10.1038/mt.2010.61. Epub Apr. 27, 2010.
Sledz et al., Structural insights into the molecular mechanism of the m(6)A writer complex. Elife. Sep. 14, 2016;5:e18434. doi: 10.7554/eLife.18434.
Smargon et al., Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28. Mol Cell. Feb. 16, 2017;65(4):618-630.e7. doi: 10.1016/j.molcel.2016.12.023. Epub Jan. 5, 2017.
Smith et al., Production of human beta interferon in insect cells infected with a baculovirus expression vector. Mol Cell Biol. Dec. 1983;3(12):2156-65. doi: 10.1128/mcb.3.12.2156.
Smith, Phage-encoded Serine Integrases and Other Large Serine Recombinases. Microbiol Spectr. Aug. 2015;3(4). doi: 10.1128/microbiolspec.MDNA3-0059-2014.
Southworth et al., Control of protein splicing by intein fragment reassembly. EMBO J. Feb. 16, 1998;17(4):918-26. doi: 10.1093/emboj/17.4.918.
Southworth et al., Purification of proteins fused to either the amino or carboxy terminus of the Mycobacterium xenopi gyrase A intein. Biotechniques. Jul. 1999;27(1):110-4, 116, 118-20. doi: 10.2144/99271st04.
Spencer et al., A general strategy for producing conditional alleles of Src-like tyrosine kinases. Proc Natl Acad Sci U S A. Oct. 10, 1995;92(21):9805-9. doi: 10.1073/pnas.92.21.9805.
Spencer et al., Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. CurrBiol. Jul. 1, 1996;6(7):839-47. doi: 10.1016/s0960-9822(02)00607-3.
Srivastava et al., An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. Dec. 21, 2012;151(7):1474-87. doi: 10.1016Zj.cell.2012.11.054.
Stamos et al., Structure of a Thermostable Group II Intron Reverse Transcriptase with Template-Primer and Its Functional and Evolutionary Implications. Mol Cell. Dec. 7, 2017;68(5):926-939.e4. doi: 10.1016/j.molcel.2017.10.024. Epub Nov. 16, 2017.
Steele et al., The prion protein knockout mouse: a phenotype under challenge. Prion. Apr.-Jun. 2007;1(2):83-93. doi: 10.4161/pri.1.2.4346. Epub Apr. 25, 2007.
Sterne-Weiler et al., Exon identity crisis: disease-causing mutations that disrupt the splicing code. Genome Biol. Jan. 23, 2014;15(1):201. doi: 10.1186/gb4150.
Stevens et al., A promiscuous split intein with expanded protein engineering applications. Proc Natl Acad Sci U S A. Aug. 8, 2017; 114(32):8538-8543. doi: 10.1073/pnas.1701083114. Epub Jul. 24, 2017.
Stockwell et al., Probing the role of homomeric and heteromeric receptor interactions in TGF-beta signaling using small molecule dimerizers. Curr Biol. Jun. 18, 1998;8(13):761-70. doi: 10.1016/s0960-9822(98)70299-4.
Strecker et al., RNA-guided DNA insertion with CRISPR-associated transposases. Science. Jul. 5, 2019;365(6448):48-53. doi: 10.1126/science.aax9181. Epub Jun. 6, 2019.
Strutt et al., RNA-dependent RNA targeting by CRISPR-Cas9. Elife. Jan. 5, 2018;7:e32724. doi: 10.7554/eLife.32724.
Su et al., Human DNA polymerase ? has reverse transcriptase activity in cellular environments. J Biol Chem. Apr. 12, 2019;294(15):6073-6081. doi: 10.1074/jbc.RA119.007925. Epub Mar. 6, 2019.
Sun et al., The CRISPR/Cas9 system for gene editing and its potential application in pain research. Transl Periop & Pain Med. Aug. 3, 2016;1(3):22-33.
Surun et al., High Efficiency Gene Correction in Hematopoietic Cells by Donor-Template-Free CRISPR/Cas9 Genome Editing. Mol Ther Nucleic Acids. Mar. 2, 2018;10:1-8. doi: 10.1016/j.omtn.2017.11.001. Epub Nov. 10, 2017.
Suzuki et al., In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature. Dec. 1, 2016;540(7631):144-149. doi: 10.1038/nature20565. Epub Nov. 16, 2016.
Suzuki et al., VCre/VloxP and SCre/SloxP: new site-specific recombination systems for genome engineering. Nucleic Acids Res. Apr. 2011;39(8):e49. doi: 10.1093/nar/gkq1280. Epub Feb. 1, 2011.
Tabebordbar et al., In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. Jan. 22, 2016;351(6271):407-411. doi: 10.1126/science.aad5177. Epub Dec. 31, 2015.
Tahara et al., Potent and Selective Inhibitors of 8-Oxoguanine DNA Glycosylase. J Am Chem Soc. Feb. 14, 2018;140(6):2105-2114. doi: 10.1021/jacs.7b09316. Epub Feb. 5, 2018.
Tajiri et al., Functional cooperation of MutT, MutM and MutY proteins in preventing mutations caused by spontaneous oxidation of guanine nucleotide in Escherichia coli. Mutat Res. May 1995;336(3):257-67. doi: 10.1016/0921-8777(94)00062-b.
Tambunan et al., Vaccine Design for H5N1 Based on B- and T-cell Epitope Predictions. Bioinform Biol Insights. Apr. 28, 2016;10:27-35. doi: 10.4137/BBI.S38378.
Tang et al., Evaluation of Bioinformatic Programmes for the Analysis of Variants within Splice Site Consensus Regions. Adv Bioinformatics. 2016;2016:5614058. doi: 10.1155/2016/5614058. Epub May 24, 2016.
Tang et al., Rewritable multi-event analog recording in bacterial and mammalian cells. Science. Apr. 13, 2018;360(6385):eaap8992. doi: 10.1126/science.aap8992. Epub Feb. 15, 2018.
Tassabehji, Williams-Beuren syndrome: a challenge for genotype-phenotype correlations. Hum Mol Genet. Oct. 15, 2003;12 Spec No. 2:R229-37. doi: 10.1093/hmg/ddg299. Epub Sep. 2, 2003.
Taube et al., Reverse transcriptase of mouse mammary tumour virus: expression in bacteria, purification and biochemical characterization. Biochem J. Feb. 1, 1998;329 ( Pt 3)(Pt 3):579-87. doi: 10.1042/bj3290579. Erratum in: Biochem J Jun. 15, 1998;332(Pt 3):808.
Tee et al., Polishing the craft of genetic diversity creation in directed evolution. Biotechnol Adv. Dec. 2013;31(8):1707-21. doi: 10.1016/j.biotechadv.2013.08.021. Epub Sep. 6, 2013.
Telenti et al., The Mycobacterium xenopi GyrA protein splicing element: characterization of a minimal intein. J Bacteriol. Oct. 1997;179(20):6378-82. doi: 10.1128/jb.179.20.6378-6382.1997.
Telesnitsky et al., RNase H domain mutations affect the interaction between Moloney murine leukemia virus reverse transcriptase and its primer-template. Proc Natl Acad Sci U S A. Feb. 15, 1993;90(4): 1276-80. doi: 10.1073/pnas.90.4.1276.
Thuronyi et al., Continuous evolution of base editors with expanded target compatibility and improved activity. Nat Biotechnol. Sep. 2019;37(9):1070-1079. doi: 10.1038/s41587-019-0193-0. Epub Jul. 22, 2019.
Thyagarajan et al., Creation of engineered human embryonic stem cell lines using phiC31 integrase. Stem Cells. Jan. 2008;26(1):119-26. doi: 10.1634/stemcells.2007-0283. Epub Oct. 25, 2007.
Tinland et al., The T-DNA-linked VirD2 protein contains two distinct functional nuclear localization signals. Proc Natl Acad Sci U S A. Aug. 15, 1992;89(16):7442-6. doi: 10.1073/pnas.89.16.7442.
Tom et al., Mechanism whereby proliferating cell nuclear antigen stimulates flap endonuclease 1. J Biol Chem. Apr. 7, 2000;275(14):10498-505. doi: 10.1074/jbc.275.14.10498.
Toor et al., Crystal structure of a self-spliced group II intron. Science. Apr. 4, 2008;320(5872):77-82. doi: 10.1126/science. 1153803.
Torres et al., Non-integrative lentivirus drives high-frequency cre-mediated cassette exchange in human cells. PLoS One. 2011;6(5):e19794. doi: 10.1371/journal.pone.0019794. Epub May 23, 2011.
Townsend et al., Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload. Lancet. Mar. 2, 2002;359(9308):786-90. doi: 10.1016/S0140-6736(02)07885-6. Erratum in: Lancet Jul. 13, 2002;360(9327):176.
Tracewell et al., Directed enzyme evolution: climbing fitness peaks one amino acid at a time. Curr Opin Chem Biol. Feb. 2009;13(1):3-9. doi: 10.1016/j.cbpa.2009.01.017. Epub Feb. 25, 2009.
Tratschin et al., A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol. Oct. 1984;4(10):2072-81. doi: 10.1128/mcb.4.10.2072.
Tratschin et al., Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells. Mol Cell Biol. Nov. 1985;5(11):3251-60. doi: 10.1128/mcb.5.11.3251.
Traxler et al., A genome-editing strategy to treat ?-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med. Sep. 2016;22(9):987-90. doi: 10.1038/nm.4170. Epub Aug. 15, 2016.
Trudeau et al., On the Potential Origins of the High Stability of Reconstructed Ancestral Proteins. Mol Biol Evol. Oct. 2016;33(10):2633-41. doi: 10.1093/molbev/msw138. Epub Jul. 12, 2016.
Tsai et al., CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nat Methods. Jun. 2017;14(6):607-614. doi: 10.1038/nmeth.4278. Epub May 1, 2017.
Tsang et al., Specialization of the DNA-cleaving activity of a group I ribozyme through in vitro evolution. J Mol Biol. Sep. 13, 1996;262(1):31-42. doi: 10.1006/jmbi.1996.0496.
Tsutakawa et al., Human flap endonuclease structures, DNA double-base flipping, and a unified understanding of the FEN1 superfamily. Cell. Apr. 15, 2011;145(2):198-211. doi: 10.1016/j.cell.2011.03.004.
Tycko et al., Pairwise library screen systematically interrogates Staphylococcus aureus Cas9 specificity in human cells. bioRxiv. doi: https://doi.org/10.1101/269399 Posted Feb. 22, 2018.
UniProt Consortium, UniProt: the universal protein knowledgebase. Nucleic Acids Res. Mar. 16, 2018;46(5):2699. doi: 10.1093/nar/gky092.
UniProTKB Submission; Accession No. F0NH53. May 3, 2011. 4 pages.
UniProTKB Submission; Accession No. F0NN87. May 3, 2011. 4 pages.
UniProTKB Submission; Accession No. G3ECR1.2. No Author Listed., Aug. 12, 2020, 8 pages.
UniProTKB Submission; Accession No. P04264. No Author Listed., Apr. 7, 2021. 12 pages.
UniProTKB Submission; Accession No. T0D7A2. Oct. 16, 2013. 10 pages.
UniProTKB Submission; Accession No. U2UMQ6. No Author Listed., Apr. 7, 2021, 11 pages.
Urasaki et al., Functional dissection of the Tol2 transposable element identified the minimal cis-sequence and a highly repetitive sequence in the subterminal region essential for transposition. Genetics. Oct. 2006;174(2):639-49. doi: 10.1534/genetics.106.060244. Epub Sep. 7, 2006.
Van Brunt et al., Molecular Farming: Transgenic Animals as Bioreactors. Biotechnology (N Y). 1988;6(10):1149-1154. doi: 10.1038/nbt1088-1149.
Van Overbeek et al., DNA Repair Profiling Reveals Nonrandom Outcomes at Cas9-Mediated Breaks. Mol Cell. Aug. 18, 2016;63(4):633-646. doi: 10.1016/j.molcel.2016.06.037. Epub Aug. 4, 2016.
Vik et al., Endonuclease V cleaves at inosines in RNA. Nat Commun. 2013;4:2271. doi: 10.1038/ncomms3271.
Voigt et al., Rational evolutionary design: the theory of in vitro protein evolution. Adv Protein Chem. 2000;55:79-160.
Wang et al., AID upmutants isolated using a high-throughput screen highlight the immunity/cancer balance limiting DNA deaminase activity. Nat Struct Mol Biol. Jul. 2009;16(7):769-76. doi: 10.1038/nsmb.1623. Epub Jun. 21, 2009.
Wang et al., Continuous directed evolutions of proteins with improved soluble expression. Nature Chemical Biology. Nat Publishing Group. Aug. 20, 2018; 14(10):972-980.
Wang et al., Evolution of new nonantibody proteins via iterative somatic hypermutation. Proc Natl Acad Sci U S A. Nov. 30, 2004;101(48):16745-9. Epub Nov. 19, 2004.
Wang et al., N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell. Jun. 4, 2015;161(6):1388-99. doi: 10.1016/j.cell.2015.05.014.
Wang et al., Programming cells by multiplex genome engineering and accelerated evolution. Nature. Aug. 13, 2009;460(7257):894-8. Epub Jul. 26, 2009.
Wang et al., Reading RNA methylation codes through methyl-specific binding proteins. RNA Biol. 2014;11(6):669-72. doi: 10.4161/rna.28829. Epub Apr. 24, 2014.
Wang et al., Staphylococcus aureus protein SAUGI acts as a uracil-DNA glycosylase inhibitor. Nucleic Acids Res. Jan. 2014;42(2):1354-64. doi: 10.1093/nar/gkt964. Epub Oct. 22, 2013.
Watowich, The erythropoietin receptor: molecular structure and hematopoietic signaling pathways. J Investig Med. Oct. 2011;59(7):1067-72. doi: 10.2310/JIM.0b013e31820fb28c.
Wharton et al., A new-specificity mutant of 434 repressor that defines an amino acid-base pair contact. Nature. Apr. 30-May 6, 1987;326(6116):888-91.
Wharton et al., Changing the binding specificity of a repressor by redesigning an alpha-helix. Nature. Aug. 15-21, 1985;316(6029):601-5.
Wheeler et al., The thermostability and specificity of ancient proteins. Curr Opin Struct Biol. Jun. 2016;38:37-43. doi: 10.1016/j.sbi.2016.05.015. Epub Jun. 9, 2016.
Wienert et al., KLF1 drives the expression of fetal hemoglobin in British HPFH. Blood. Aug. 10, 2017;130(6):803-807. doi: 10.1182/blood-2017-02-767400. Epub Jun. 28, 2017.
Williams et al., Assessing the accuracy of ancestral protein reconstruction methods. PLoS Comput Biol. Jun. 23, 2006;2(6):e69. doi: 10.1371/journal.pcbi.0020069. Epub Jun. 23, 2006.
Wilson et al., Formation of infectious hybrid virions with gibbon ape leukemia virus and human T-cell leukemia virus retroviral envelope glycoproteins and the gag and pol proteins of Moloney murine leukemia virus. J Virol. May 1989;63(5):2374-8. doi: 10.1128/JVI.63.5.2374-2378.1989.
Wilson et al., Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug's mechanism. Science. Feb. 20, 2015;347(6224):882-6. doi: 10.1126/science.aaa1823.
Winoto et al., A novel, inducible and T cell-specific enhancer located at the 3′ end of the T cell receptor alpha locus. EMBO J. Mar. 1989;8(3):729-33.
Wong et al., A statistical analysis of random mutagenesis methods used for directed protein evolution. J Mol Biol. Jan. 27, 2006;355(4):858-71. Epub Nov. 17, 2005.
Wong et al., The Diversity Challenge in Directed Protein Evolution. Comb Chem High Throughput Screen. May 2006;9(4):271-88.
Wright et al., Continuous in vitro evolution of catalytic function. Science. Apr. 25, 1997;276(5312):614-7.
Wright et al., Rational design of a split-Cas9 enzyme complex. Proc Natl Acad Sci U S A. Mar. 10, 2015;112(10):2984-9. doi: 10.1073/pnas.1501698112. Epub Feb. 23, 2015.
Wu et al., Protein trans-splicing by a split intein encoded in a split DnaE gene of Synechocystis sp. PCC6803. Proc Natl Acad Sci U S A. Aug. 4, 1998;95(16):9226-31. doi: 10.1073/pnas.95.16.9226.
Xiang et al., RNA m6A methylation regulates the ultraviolet-induced DNA damage response. Nature. Mar. 23, 2017;543(7646):573-576. doi: 10.1038/nature21671. Epub Mar. 15, 2017.
Xiao et al., Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing. Mol Cell. Feb. 18, 2016;61(4):507-519. doi: 10.1016/j.molcel.2016.01.012. Epub Feb. 11, 2016.
Xiong et al., Origin and evolution of retroelements based upon their reverse transcriptase sequences. EMBO J. Oct. 1990;9(10):3353-62.
Xu et al., Chemical ligation of folded recombinant proteins: segmental isotopic labeling of domains for NMR studies. Proc Natl Acad Sci U S A. Jan. 19, 1999;96(2):388-93. doi: 10.1073/pnas.96.2.388.
Xu et al., Accuracy and efficiency define Bxb1 integrase as the best of fifteen candidate serine recombinases for the integration of DNA into the human genome. BMC Biotechnol. Oct. 20, 2013;13:87. doi: 10.1186/1472-6750-13-87.
Xu et al., Protein splicing: an analysis of the branched intermediate and its resolution by succinimide formation. EMBO J. Dec. 1, 1994;13(23):5517-22.
Xu et al., Structures of human ALKBH5 demethylase reveal a unique binding mode for specific single-stranded N6-methyladenosine RNA demethylation. J Biol Chem. Jun. 20, 2014;289(25):17299-311. doi: 10.1074/jbc.M114.550350. Epub Apr. 28, 2014.
Xu et al., The mechanism of protein splicing and its modulation by mutation. EMBO J. Oct. 1, 1996;15(19):5146-53.
Yamamoto et al., The ons and offs of inducible transgenic technology: a review. Neurobiol Dis. Dec. 2001;8(6):923-32.
Yan et al., Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein. Mol Cell. Apr. 19, 2018;70(2):327-339.e5. doi: 10.1016/j.molcel.2018.02.028. Epub Mar. 15, 2018.
Yang et al., Construction of an integration-proficient vector based on the site-specific recombination mechanism of enterococcal temperate phage phiFC1. J Bacteriol. Apr. 2002;184(7):1859-64. doi: 10.1128/jb.184.7.1859-1864.2002.
Yang et al., Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants. Protein Cell. Sep. 2018;9(9):814-819. doi: 10.1007/s13238-018-0568-x.
Yang et al., One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell. Sep. 12, 2013;154(6):1370-9. doi: 10.1016/j.cell.2013.08.022. Epub Aug. 29, 2013.
Yang et al., Permanent genetic memory with >1-byte capacity. Nat Methods. Dec. 2014;11(12):1261-6. doi: 10.1038/nmeth.3147. Epub Oct. 26, 2014.
Yang et al., Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment. CurrBiol. Jan. 1, 1998;8(1):11-8. doi: 10.1016/s0960-9822(98)70015-6.
Yang, PAML 4: phylogenetic analysis by maximum likelihood. Mol Biol Evol. Aug. 2007;24(8):1586-91. doi: 10.1093/molbev/msm088. Epub May 4, 2007.
Yang, Phylogenetic Analysis by Maximum Likelihood (PAML). //abacus.gene.ucl.ac.uk/software/paml.html Last accessed Apr. 28, 2021.
Yasui et al., Miscoding Properties of 2′-Deoxyinosine, a Nitric Oxide-Derived DNA Adduct, during Translesion Synthesis Catalyzed by Human DNA Polymerases. J Molec Biol. Apr. 4, 2008;377(4):1015-23.
Yasukawa et al., Characterization of Moloney murine leukaemia virus/avian myeloblastosis virus chimeric reverse transcriptases. J Biochem. Mar. 2009;145(3):315-24. doi: 10.1093/jb/mvn166. Epub Dec. 6, 2008.
Yu et al., Circular permutation: a different way to engineer enzyme structure and function. Trends Biotechnol. Jan. 2011;29(1):18-25. doi: 10.1016/j.tibtech.2010.10.004. Epub Nov. 17, 2010.
Yu et al., Liposome-mediated in vivo E1 A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene. Oct. 5, 1995;11(7):1383-8.
Yu et al., Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell. Feb. 5, 2015;16(2): 142-7. doi: 10.1016/j.stem.2015.01.003.
Yu et al., Synthesis-dependent microhomology-mediated end joining accounts for multiple types of repair junctions. Nucleic Acids Res. Sep. 2010;38(17):5706-17. doi: 10.1093/nar/gkq379. Epub May 11, 2010.
Zakas et al., Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction. Nat Biotechnol. Jan. 2017;35(1):35-37. doi: 10.1038/nbt.3677. Epub Sep. 26, 2016.
Zalatan et al., Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell. Jan. 15, 2015;160(1-2):339-50. doi: 10.1016/j.cell.2014.11.052. Epub Dec. 18, 2014.
Zettler et al., The naturally split Npu DnaE intein exhibits an extraordinarily high rate in the protein trans-splicing reaction. FEBS Lett. Mar. 4, 2009;583(5):909-14. doi: 10.1016/j.febslet.2009.02.003. Epub Feb. 10, 2009.
Zhang et al., Circular intronic long noncoding RNAs. Mol Cell. Sep. 26, 2013;51(6):792-806. doi: 10.1016/j.molcel.2013.08.017. Epub Sep. 12, 2013.
Zhang et al., Copy number variation in human health, disease, and evolution. Annu Rev Genomics Hum Genet. 2009;10:451-81. doi: 10.1146/annurev.genom.9.081307.164217.
Zhang et al., II-Clamp-mediated cysteine conjugation. Nat Chem. Feb. 2016;8(2):120-8. doi: 10.1038/nchem.2413. Epub Dec. 21, 2015.
Zhao et al., An ultraprocessive, accurate reverse transcriptase encoded by a metazoan group II intron. RNA. Feb. 2018;24(2):183-195. doi: 10.1261/ma.063479.117. Epub Nov. 6, 2017.
Zhao et al., Crystal structures of a group II intron maturase reveal a missing link in spliceosome evolution. Nat Struct Mol Biol. Jun. 2016;23(6):558-65. doi: 10.1038/nsmb.3224. Epub May 2, 2016.
Zhao et al., Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. Jan. 2017;18(1):31-42. doi: 10.1038/nrm.2016.132. Epub Nov. 3, 2016.
Zheng et al., ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. Jan. 10, 2013;49(1):18-29. doi: 10.1016/j.molcel.2012.10.015. Epub Nov. 21, 2012.
Zheng et al., Highly efficient base editing in bacteria using a Cas9-cytidine deaminase fusion. CommunBiol. Apr. 19, 2018;1:32. doi: 10.1038/s42003-018-0035-5.
Zhou et al., Dynamic m(6)A mRNA methylation directs translational control of heat shock response. Nature. Oct. 22, 2015;526(7574):591-4. doi: 10.1038/nature15377. Epub Oct. 12, 2015.
Zhou et al., Protective VI27 prion variant prevents prion disease by interrupting the formation of dimer and fibril from molecular dynamics simulations. Sci Rep. Feb. 24, 2016;6:21804. doi: 10.1038/srep21804.
Zimmerly et al., An Unexplored Diversity of Reverse Transcriptases in Bacteria. Microbiol Spectr. Apr. 2015;3(2):MDNA3-0058-2014. doi: 10.1128/microbiolspec.MDNA3-0058-2014.
Zlmmerly et al., Group II intron mobility occurs by target DNA-primed reverse transcription. Cell. Aug. 25, 1995;82(4):545-54. doi: 10.1016/0092-8674(95)90027-6.
Zufferey et al., Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol. Apr. 1999;73(4):2886-92. doi: 10.1128/JVI.73.4.2886-2892.1999.
Zuker et al., Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information. Nucleic Acids Res. Jan. 10, 1981;9(1):133-48. doi: 10.1093/nar/9.1.133.
Zuo et al., Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science. Apr. 19, 2019;364(6437):289-292. doi: 10.1126/science.aav9973. Epub Feb. 28, 2019.
Atkins et al., Ribosomal frameshifting and transcriptional slippage: From genetic steganography and cryptography to adventitious use. Nucleic Acids Res. Sep. 6, 2016;44(15):7007-78. doi: 10.1093/nar/gkw530. Epub Jul. 19, 2016.
Autieri et al., IRT-1, a novel interferon-gamma-responsive transcript encoding a growth-suppressing basic leucine zipper protein. J Biol Chem. Jun. 12, 1998;273(24):14731-7. doi: 10.1074/jbc.273.24.14731.
Avidan et al., The processivity and fidelity of DNA synthesis exhibited by the reverse transcriptase of bovine leukemia virus. Eur J Biochem. Feb. 2002;269(3):859-67. doi: 10.1046/j.0014-2956.2001.02719.x.
Babacic et al., CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: a systematic review. PLoS One. Feb. 22, 2019;14(2):e0212198. doi: 10.1371/journal.pone.0212198.
Badran et al., Continuous evolution of Bacillus thuringiensis toxins overcomes insect resistance. Nature. May 5, 2016;533(7601):58-63. doi: 10.1038/nature17938. Epub Apr. 27, 2016.
Badran et al., Development of potent in vivo mutagenesis plasmids with broad mutational spectra. Nat Commun. Oct. 7, 2015;6:8425. doi: 10.1038/ncomms9425.
Bae et al., Microhomology-based choice of Cas9 nuclease target sites. Nat Methods. Jul. 2014;11(7):705-6. doi: 10.1038/nmeth.3015.
Bagyinszky et al., Characterization of mutations in PRNP (prion) gene and their possible roles in neurodegenerative diseases. Neuropsychiatr Dis Treat. Aug. 14, 2018;14:2067-2085. doi: 10.2147/NDT.S165445.
Balakrishnan et al., Flap endonuclease 1. Annu Rev Biochem. 2013;82:119-38. doi: 10.1146/annurev-biochem-072511-122603. Epub Feb. 28, 2013.
Baranauskas et al., Generation and characterization of new highly thermostable and processive M-MuLV reverse transcriptase variants. Protein Eng Des Sel. Oct. 2012;25(10):657-68. doi: 10.1093/protein/gzs034. Epub Jun. 12, 2012.
Bartlett et al., Efficient expression of protein coding genes from the murine U1 small nuclear RNA promoters. Proc Natl Acad Sci U S A. Aug. 20, 1996;93(17):8852-7. doi: 10.1073/pnas.93.17.8852.
Bartosovic et al., N6-methyladenosine demethylase FTO targets pre-mRNAs and regulates alternative splicing and 3′-end processing. Nucleic Acids Res. Nov. 2, 2017;45(19):11356-11370. doi: 10.1093/nar/gkx778.
Basturea et al., Substrate specificity and properties of the Escherichia coli 16S rRNA methyltransferase, RsmE. RNA. Nov. 2007;13(11):1969-76. doi: 10.1261/rna.700507. Epub Sep. 13, 2007.
Bebenek et al., Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots. J Biol Chem. May 15, 1993;268(14):10324-34.
Belshaw et al., Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. Chem Biol. Sep. 1996;3(9):731-8. doi: 10.1016/s1074-5521(96)90249-5.
U.S. Appl. No. 14/234,031, filed Mar. 24, 2014, Liu et al.
U.S. Appl. No. 14/320,271, filed Jun. 30, 2014, Liu et al.
U.S. Appl. No. 16/441,751, filed Jun. 14, 2019, Liu et al.
U.S. Appl. No. 14/320,519, filed Jun. 30, 2014, Liu et al.
U.S. Appl. No. 14/913,458, filed Feb. 22, 2016, Liu et al.
U.S. Appl. No. 16/266,937, filed Feb. 4, 2019, Liu et al.
U.S. Appl. No. 14/320,370, filed Jun. 30, 2014, Liu et al.
U.S. Appl. No. 14/320,413, filed Jun. 30, 2014, Liu et al.
U.S. Appl. No. 14/874,123, filed Oct. 2, 2015, Liu et al.
U.S. Appl. No. 14/911,117, filed Feb. 9, 2016, Liu et al.
U.S. Appl. No. 17/160,329, filed Jan. 27, 2021, Liu et al.
U.S. Appl. No. 14/462,163, filed Aug. 18, 2014, Liu et al.
U.S. Appl. No. 14/462,189, filed Aug. 18, 2014, Liu et al.
U.S. Appl. No. 14/916,679, filed Mar. 4, 2016, Liu et al.
U.S. Appl. No. 16/860,639, filed Apr. 28, 2020, Liu et al.
U.S. Appl. No. 14/320,498, filed Jun. 30, 2014, Liu et al.
U.S. Appl. No. 14/320,467, filed Jun. 30, 2014, Liu et al.
U.S. Appl. No. 14/916,681, filed Mar. 4, 2016, Liu et al.
U.S. Appl. No. 17/103,233, filed Nov. 24, 2020, Liu et al.
U.S. Appl. No. 14/326,329, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,340, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,361, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/916,683, filed Mar. 4, 2016, Liu et al.
U.S. Appl. No. 16/796,323, filed Feb. 20, 2020, Liu et al.
U.S. Appl. No. 14/325,815, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,109, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,140, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,269, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,290, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,318, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,303, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 15/103,608, filed Jun. 10, 2016, Liu et al.
U.S. Appl. No. 16/374,634, filed Apr. 3, 2019, Liu et al.
U.S. Appl. No. 15/329,925, filed Jan. 27, 2017, Liu et al.
U.S. Appl. No. 16/132,276, filed Sep. 14, 2018, Liu et al.
U.S. Appl. No. 16/888,646, filed May 29, 2020, Liu et al.
U.S. Appl. No. 14/529,010, filed Oct. 30, 2014, Liu et al.
U.S. Appl. No. 15/958,721, filed Apr. 20, 2018, Liu et al.
U.S. Appl. No. 17/130,812, filed Dec. 22, 2020, Liu et al.
U.S. Appl. No. 15/331,852, filed Oct. 22, 2016, Liu et al.
U.S. Appl. No. 15/770,076, filed Apr. 20, 2018, Liu et al.
U.S. Appl. No. 16/327,744, filed Feb. 22, 2019, Maianti et al.
U.S. Appl. No. 15/852,891, filed Dec. 22, 2017, Maianti et al.
U.S. Appl. No. 16/926,436, filed Jul. 10, 2020, Maianti et al.
U.S. Appl. No. 15/852,526, filed Dec. 22, 2017, Maianti et al.
U.S. Appl. No. 16/492,534, filed Sep. 9, 2019, Liu et al.
U.S. Appl. No. 16/324,476, filed Feb. 8, 2019, Liu et al.
U.S. Appl. No. 15/791,085, filed Oct. 23, 2017, Liu et al.
U.S. Appl. No. 16/143,370, filed Sep. 26, 2018, Liu et al.
U.S. Appl. No. 17/148,059, filed Jan. 13, 2021, Liu et al.
U.S. Appl. No. 16/492,548, filed Sep. 9, 2019, Maianti et al.
U.S. Appl. No. 15/784,033, filed Oct. 13, 2017, Liu et al.
U.S. Appl. No. 16/492,553, filed Sep. 9, 2019, Liu et al.
U.S. Appl. No. 15/934,945, filed Mar. 23, 2018, Liu et al.
U.S. Appl. No. 16/643,376, filed Feb. 28, 2020, Liu et al.
U.S. Appl. No. 16/612,988, filed Nov. 12, 2019, Liu et al.
U.S. Appl. No. 16/634,405, filed Jan. 27, 2020, Liu et al.
U.S. Appl. No. 16/976,047, filed Aug. 26, 2020, Liu et al.
U.S. Appl. No. 17/289,665, filed Apr. 28, 2021, Liu et al.
U.S. Appl. No. 16/756,432, filed Apr. 15, 2020, Liu et al.
U.S. Appl. No. 16/772,747, filed Jun. 12, 2020, Shen et al.
U.S. Appl. No. 17/057,398, filed Nov. 20, 2020, Liu et al.
U.S. Appl. No. 17/259,147, filed Jan. 8, 2021, Liu et al.
U.S. Appl. No. 17/270,396, filed Feb. 22, 2021, Liu et al.
U.S. Appl. No. 17/273,688, filed Mar. 4, 2021, Liu et al.
U.S. Appl. No. 17/288,504, filed Apr. 23, 2021, Liu et al.
U.S. Appl. No. 17/219,590, filed Mar. 31, 2021, Liu et al.
U.S. Appl. No. 17/219,635, filed Mar. 31, 2021, Liu et al.
U.S. Appl. No. 17/219,672, filed Mar. 31, 2021, Liu et al.

Related Publications (1)

	Number	Date	Country
	20180312825 A1	Nov 2018	US

Provisional Applications (9)

Number	Date	Country
62408686	Oct 2016	US
62398490	Sep 2016	US
62370700	Aug 2016	US
62357332	Jun 2016	US
62357352	Jun 2016	US
62322178	Apr 2016	US
62311763	Mar 2016	US
62279346	Jan 2016	US
62245828	Oct 2015	US

Continuations (2)

	Number	Date	Country
Parent	PCT/US2016/058344	Oct 2016	US
Child	15960171		US
Parent	15331852	Oct 2016	US
Child	PCT/US2016/058344		US

Nucleobase editors and uses thereof

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

International Classifications

Term Extension

Abstract